Nonylphenol diethoxylate	T131	C1254354
inhibits	T052	C3463820
apoptosis	T043	C0162638
induced	T169	C0205263
PC12 cells	T025	C0085262
Nonylphenol	T131	C1254354
short-chain nonylphenol ethoxylates	T131	C1254354
NP2 EO	T131	C1254354
present	T033	C0150312
aquatic environment	T067	C0563034
wastewater	T069	C3494254
contaminants	T167	C2827365
toxic effects	T037	C0600688
aquatic species	T001	C0596121
Apoptosis	T043	C0162638
induced	T169	C0205263
serum	T031	C0229671
deprivation	T080	C0871712
copper	T121	C0009968
treatment	T169	C1522326
toxicity	T080	C0040539
nonylphenol diethoxylate	T131	C1254354
effects of	T080	C1704420
NP2 EO	T131	C1254354
apoptosis	T043	C0162638
induced	T169	C0205263
serum	T031	C0229671
deprivation	T080	C0871712
copper	T121	C0009968
PC12 cell system	T025	C0085262
Nonylphenol diethoxylate	T131	C1254354
cell viability	T043	C0007620
apoptosis	T043	C0162638
nonylphenol diethoxylate	T131	C1254354
decreased	T081	C0205216
DNA fragmentation	T044	C0376669
apoptosis	T043	C0162638
PC12 cells	T025	C0085262
phenomenon	T067	C1882365
treating	T169	C1522326
apoptotic	T080	C1516044
PC12 cells	T025	C0085262
nonylphenol diethoxylate	T131	C1254354
cytochrome c	T116	C0010749
cytosol	T026	C1383501
decreased	T081	C0205216
apoptotic cells	T025	C0007634
treated	T169	C1522326
nonylphenol diethoxylate	T131	C1254354
Bax	T116	C0219474
contents	T077	C0456205
apoptotic cells	T025	C0007634
reduced	T080	C0392756
exposure to	T080	C0332157
nonylphenol diethoxylate	T131	C1254354
nonylphenol diethoxylate	T131	C1254354
opposite effect	T080	C1280500
apoptosis	T043	C0162638
PC12 cells	T025	C0085262
nonylphenol	T131	C1254354
enhances	T052	C2349975
apoptosis	T043	C0162638
induced	T169	C0205263
serum	T031	C0229671
deprivation	T080	C0871712
difference	T080	C1705242
structure	T082	C0678594
compounds	T103	C0220806
hypothesized	T078	C1512571
phenomenon	T067	C1882365
results	T033	C2825142
nonylphenol diethoxylate	T131	C1254354
capability	T080	C2698977
cell differentiation	T043	C0007589
development	T039	C0243107
potentially	T080	C3245505
harmful effect	T037	C0600688
organisms	T001	C0029235
impact	T080	C4049986
apoptosis	T043	C0162638
EZH2	T028	C1333368
ZFX	T028	C1421578
oncogenes	T028	C0029016
malignant behaviour	T080	C0205282
parathyroid neoplasms	T191	C0030521
studies	T062	C0008972
somatic mutations	T049	C0544886
genes	T028	C0017337
MEN1	T028	C0694884
CTNNB1	T028	C1332803
CDKIs	T028	C0919539
parathyroid adenoma	T191	C0262587
different	T080	C1705242
prevalence	T081	C0220900
activating	T052	C1879547
mutations	T045	C0026882
EZH2	T028	C1333368
ZFX	T028	C1421578
oncogenes	T028	C0029016
benign	T080	C0205183
parathyroid adenoma	T191	C0262587
whole exome sequencing	T063	C3640077
mutations	T045	C0026882
blood	T031	C0005767
ovary	T023	C0029939
malignant tumours	T191	C0006826
hypothesis	T078	C1512571
oncogenes	T028	C0029016
onset	T080	C0332162
parathyroid tumour	T191	C0030521
malignant	T080	C0205282
benign	T080	C0205183
parathyroid neoplasm	T191	C0030521
aim	T078	C1947946
occurrence	T079	C2745955
mutations	T045	C0026882
EZH2	T028	C1333368
ZFX genes	T028	C1421578
Italian	T098	C0337810
cohort	T098	C0599755
sporadic	T079	C0205422
parathyroid carcinomas	T191	C0687150
atypical	T080	C0205182
typical	T080	C3538928
adenomas	T191	C0001430
DNA	T114	C0012854
extracted	T061	C0185115
paraffin-embedded tissues	T024	C1519524
PCR	T063	C0032520
amplified	T067	C1521871
sequenced	T169	C1561491
No	T033	C0205160
mutations	T045	C0026882
detected	T033	C0442726
coding sequence	T114	C0015295
boundaries	T114	C1136191
genes	T028	C0017337
samples	T167	C0370003
polymorphisms	T045	C0678951
EZH2 gene	T028	C1333368
identified	T080	C0205396
different	T080	C1705242
prevalence	T081	C0033105
rs2072407 variant	T028	C0678941
present	T033	C0150312
samples	T167	C0370003
overall	T080	C1561607
frequency	T079	C0439603
larger	T081	C0549177
populations	T081	C0032659
rs78589034 variant	T028	C0678941
5' end	T114	C1254348
exon 16	T114	C0015295
detected	T033	C0442726
proband	T099	C1948021
familial	T169	C0241888
isolated	T169	C0205409
hyperparathyroidism	T047	C0020502
investigated	T169	C1292732
outcome	T169	C1274040
splicing process	T045	C0035687
EZH2	T028	C1333368
ZFX genes	T028	C1421578
impact	T080	C4049986
onset	T080	C0332162
parathyroid tumours	T191	C0030521
benign	T080	C0205183
malignant	T080	C0205282
larger	T081	C0549177
cohorts	T098	C0599755
different	T080	C1705242
ethnicity	T080	C0243103
Patient	T101	C0030705
Physician	T097	C0031831
Discordance	T080	C1705242
Global Assessment	T062	C0281858
Rheumatoid Arthritis	T047	C0003873
Systematic	T169	C0220922
Literature Review	T170	C0282441
Meta-Analysis	T062	C0920317
patient	T101	C0030705
therapeutic	T169	C0302350
decision-making	T041	C0011109
management	T058	C0376636
rheumatoid arthritis	T047	C0003873
RA	T047	C0003873
patient	T101	C0030705
opinion	T041	C0871010
disease	T047	C0012634
status	T080	C0449438
physician's	T097	C0031831
opinion	T041	C0871010
study	T062	C2603343
assess	T052	C1516048
published literature	T170	C0023866
frequency	T079	C0376249
patient	T101	C0030705
physician	T097	C0031831
discordance	T080	C1705242
global assessment	T062	C0281858
RA	T047	C0003873
systematic	T169	C0220922
literature review	T170	C0282441
articles	T170	C1706852
published	T057	C0034037
Medline	T170	C0025141
Embase	T170	C0282574
discordance	T080	C1705242
RA	T047	C0003873
investigators	T097	C0035173
Discordance	T080	C1705242
absolute difference	T080	C1705242
patient global	T170	C4054229
PGA	T170	C4054229
physician global assessments	T062	C0281858
PhGA	T062	C0281858
frequency	T079	C0376249
discordance	T080	C1705242
predictors	T033	C0035648
study	T062	C2603343
Frequencies	T079	C0376249
discordance	T080	C1705242
pooled	T169	C2349200
meta-analysis	T062	C0920317
random	T080	C0439605
effect	T080	C1280500
studies	T062	C2603343
patients	T101	C0030705
weighted mean	T081	C0444504
age	T032	C0001779
years	T079	C0439234
weighted mean	T081	C0444504
disease duration	T079	C0872146
years	T079	C0439234
women	T098	C0043210
value	T081	C1522609
difference	T081	C1705241
PGA	T170	C4054229
PhGA	T062	C0281858
discordance	T080	C1705242
weighted mean value	T081	C0444504
pooled	T169	C2349200
percentage	T081	C0439165
patients	T101	C0030705
discordance	T080	C1705242
confidence interval	T081	C0009667
range	T081	C1514721
PGA	T170	C4054229
higher	T080	C0205250
PhGA	T062	C0281858
PGA	T170	C4054229
pain	T184	C0030193
functional	T169	C0205245
incapacity	T201	C3176592
PhGA	T062	C0281858
joint counts	T170	C0282574
acute-phase reactants	T116	C0001347
Discordance	T080	C1705242
global assessment	T062	C0281858
frequently	T079	C0332183
difference	T080	C1705242
half	T081	C2825407
patients	T101	C0030705
discordant	T080	C1705242
long-term	T079	C0443252
consequences	T169	C0686907
discordance	T080	C1705242
Randomized Controlled Noninferiority Trial	T062	C0206035
Single Dose	T081	C0178602
Oral Dexamethasone	T200	C0360528
Days	T079	C0439228
Oral Prednisone	T200	C3216040
Adult	T100	C0001675
Asthma	T047	C0004096
Oral dexamethasone	T200	C0360528
demonstrates	T052	C3687625
bioavailability	T081	C0005508
similar	T080	C2348205
oral prednisone	T200	C3216040
half-life	T079	C0018517
single dose	T081	C0178602
oral dexamethasone	T200	C0360528
plus	T169	C0332287
days	T079	C0439228
placebo	T122	C1696465
inferior	T082	C0542339
days	T079	C0439228
oral prednisone	T200	C3216040
treatment	T169	C1522326
adults	T100	C0001675
mild	T033	C0581124
moderate	T033	C0581125
asthma exacerbations	T033	C0349790
prevent	T169	C1292733
relapse	T067	C0035020
unscheduled	T079	C3854240
additional treatment	T033	C1706712
persistent	T047	C3266628
worsening	T080	C0332271
asthma	T047	C0004096
days	T079	C0439228
Adult	T100	C0001675
emergency department	T073	C3840745
patients	T101	C0030705
aged	T032	C0001779
years	T079	C0439234
randomized	T062	C0034656
receive	T080	C1514756
single dose	T081	C0178602
oral dexamethasone	T200	C0360528
days	T079	C0439228
placebo	T122	C1696465
day	T079	C0439228
course	T079	C0750729
oral prednisone	T200	C3216040
day	T079	C0439228
Outcomes	T169	C1274040
including	T169	C0332257
relapse	T067	C0035020
assessed	T052	C1516048
follow-up telephone interview	T058	C0178941
weeks	T079	C0439230
hundred seventy-three	T081	C0392762
dexamethasone	T109	C0011777
prednisone	T109	C0032952
subjects	T096	C0681850
completed	T080	C0205197
telephone follow-up	T058	C0178941
dexamethasone	T109	C0011777
group	UnknownType	C0681860
difference	T080	C1705242
groups	UnknownType	C0681860
noninferiority	T080	C0205556
relapse	T067	C0035020
rates	T081	C1521828
days	T079	C0439228
difference	T080	C1705242
confidence interval	T081	C0009667
Subjects	T096	C0681850
groups	UnknownType	C0681860
rates	T081	C1521828
hospitalization	T058	C0019993
relapse	T067	C0035020
visit	T058	C1512346
dexamethasone	T109	C0011777
prednisone	T109	C0032952
difference	T080	C1705242
confidence interval	T081	C0009667
Adverse effect	T080	C1280500
rates	T081	C1521828
groups	UnknownType	C0681860
single dose	T081	C0178602
oral dexamethasone	T200	C0360528
demonstrate	T052	C3687625
noninferiority	T080	C0205556
prednisone	T109	C0032952
days	T079	C0439228
treatment	T169	C1522326
adults	T100	C0001675
mild	T033	C0581124
moderate	T033	C0581125
asthma exacerbations	T033	C0349790
Enhanced	T052	C2349975
compliance	T033	C3714738
convenience	T080	C3831015
use	T169	C0457083
dexamethasone	T109	C0011777
Malignancy	T191	C4282132
associated with	T080	C0332281
microcalcification	T046	C0521174
higher AP/T ratio	T081	C0456603
ultrasonography	T060	C0041618
Hashimoto's thyroiditis	T047	C0677607
histopathology	T059	C0430445
patients	T101	C0030705
thyroid nodules	T191	C0040137
Bethesda Category III	T191	C0040137
AUS	T049	C0522580
FLUS	T033	C1272585
cytology	T059	C1305671
predictors	T170	C0683956
malignancy	T191	C4282132
management	T058	C0376636
nodules	T191	C0040137
atypia of undetermined significance	T049	C0522580
follicular lesion of undetermined significance	T033	C1272585
AUS	T049	C0522580
FLUS	T033	C1272585
ultrasonographical	T170	C0683956
clinical	T170	C0683956
biochemical predictors	T170	C0683956
malignancy	T191	C4282132
patients	T101	C0030705
patients	T101	C0030705
cytologically Bethesda Category III	T191	C0040137
AUS	T049	C0522580
FLUS	T033	C1272585
thyroid nodules	T191	C0040137
retrospective study	T062	C0035363
nodules	T191	C0040137
subgroups	T098	C1257890
histopathology	T059	C0430445
benign	T080	C0205183
malignant	T080	C0205282
preoperative	T079	C0445204
ultrasonographical	T201	C1720195
clinical	T201	C3854293
biochemical findings	T033	C0243095
patients	T101	C0030705
AUS	T049	C0522580
FLUS	T033	C1272585
nodules	T191	C0040137
surgery	T061	C0543467
malignancy	T191	C4282132
malignancy	T191	C4282132
nodules	T191	C0040137
AUS	T049	C0522580
nodules	T191	C0040137
FLUS	T033	C1272585
malignant specimens	T077	C2347026
histopathology	T059	C0430445
papillary thyroid carcinoma	T191	C0238463
PTC	T191	C0238463
Preoperative	T079	C0445204
ultrasonographic features	T201	C1720195
malignant nodules	T191	C0040137
histopathology	T059	C0430445
benign nodules	T191	C0749467
histopathology	T059	C0430445
Anteroposterior/Transverse (AP/T) ratio	T081	C0456603
malignant group	T098	C1257890
benign group	T098	C1257890
multiple logistic analysis	T062	C0936012
higher AP/T ratio	T081	C0456603
microcalcification	T046	C0521174
associated with	T080	C0332281
malignancy	T191	C4282132
malignancy	T191	C4282132
AP/T ratio	T081	C0456603
sensitivity and specificity	T081	C0036668
correlation	T080	C1707520
malignancy	T191	C4282132
Hashimoto's thyroiditis	T047	C0677607
histopathology	T059	C0430445
multivariate analysis	T081	C0026777
Bethesda Category III nodules	T191	C0040137
higher AP/T ratio	T081	C0456603
microcalcification	T046	C0521174
surgery	T061	C0543467
fine-needle aspiration biopsy	T060	C1510483
observation	T062	C0302523
Impact	T080	C4049986
cofactor	T123	C0178555
binding loop	T087	C0682969
mutations	T045	C0026882
thermotolerance	T039	C3544386
activity	T044	C0243102
E. coli	T007	C0014834
transketolase	T116	C0040709
Improvement	T077	C2986411
thermostability	T070	C0597571
engineered enzymes	T116	C0014442
biocatalysis	T070	C2350294
substrates	T167	C3891814
aqueous	T080	C0599956
solubility	T080	C0037628
Denaturation	T044	C0033627
cofactor	T123	C0178555
binding loops	T087	C0682969
Escherichia coli	T007	C0014834
transketolase	T116	C0040709
TK	T116	C0040709
loss	T081	C1517945
enzyme activity	T044	C0243102
conditions	T080	C0348080
high	T080	C0205250
pH	T081	C0020283
urea	T109	C0041942
Incubation	T059	C0022885
temperatures	T081	C0039476
thermal melting transition	T070	C1254365
protein	T116	C0033684
aggregates	T169	C0332621
anneal	T169	C0205245
enzyme	T116	C0014442
increased	T081	C0205217
activity	T044	C0243102
role	T077	C1705810
cofactor	T123	C0178555
binding loop	T087	C0682969
instability	T033	C1444783
cofactor	T123	C0178555
binding loops	T087	C0682969
residues 185-192	T087	C0002518
382-392	T087	C0002518
sequence	T086	C0004793
thermostable	T080	C0205556
Thermus thermophilus	T007	C0085475
TK	T116	C0040709
variants	T028	C0678941
assessed	T052	C1516048
impact	T080	C4049986
thermostability	T070	C0597571
activity	T052	C0441655
Cofactor-binding loop 2	T086	C0004793
variants	T028	C0678941
detrimental effects	T080	C1280500
activity	T052	C0441655
elevated	T080	C3163633
temperatures	T081	C0039476
H192P mutation	T045	C0026882
cofactor-binding loop 1	T086	C0004793
stability	T070	C0597571
inactivation	T169	C0544461
elevated	T080	C3163633
temperatures	T081	C0039476
increased	T081	C0205217
critical onset temperature	T081	C0039476
aggregation	T169	C0332621
activity	T052	C0441655
H192P	T045	C0026882
higher	T080	C0205250
wild-type	T028	C1883559
higher	T080	C0205250
re-cooling	T070	C0678568
pre-incubations	T059	C0022885
H192P	T045	C0026882
active	T169	C0205177
wild-type	T028	C1883559
TK	T116	C0040709
Optimal	T080	C2698651
activity	T052	C0441655
H192P	T045	C0026882
wild type	T028	C1883559
cofactor-binding loop 1	T086	C0004793
role	T077	C1705810
partial	T081	C0728938
denaturation	T044	C0033627
aggregation	T169	C0332621
elevated	T080	C3163633
temperatures	T081	C0039476
single rigidifying mutation	T045	C0026882
loop	T086	C0004793
enzyme specific activity	T044	C0243102
stability	T070	C0597571
thermal	T070	C0018837
denaturation	T044	C0033627
aggregation	T169	C0332621
increased	T081	C0205217
temperature	T081	C0039476
optimum	T080	C2698651
activity	T044	C0243102
Safety	T062	C1705187
transradial diagnostic cardiac catheterization	T060	C2041518
patients	T101	C0030705
oral	T082	C0442027
anticoagulant therapy	T061	C0150457
Cardiac catheterization	T058	C0018795
anticoagulated	UnknownType	C0741134
patients	T101	C0030705
performed	T169	C0884358
anticoagulation	T061	C0003281
withdrawn	T061	C1707825
bridging therapy with heparin	T061	C3873426
observational study	T062	C1518527
patients	T101	C0030705
transradial catheterization	T058	C0018795
patients	T101	C0030705
acenocoumarol	T109	C0000956
group A	T185	C0441835
compared	T052	C1707455
remainder	T080	C1527428
group B	T185	C0441836
complications	T046	C0009566
procedure	T058	C0018795
bleeding	T046	C0019080
vascular access complications	T046	C0920165
Patients	T101	C0030705
group A	T185	C0441835
older	T098	C1518563
indication	T078	C3146298
anticoagulation	T061	C0003281
atrial fibrillation	T047	C0004238
No	T033	C1513916
complications	T046	C0009566
procedures	T058	C0018795
no	T033	C1513916
acute bleedings	T046	C0333276
after	T079	C0687676
bandage	T074	C0004726
removal	T052	C1883720
radial occlusions	T046	C1110554
group A	T185	C0441835
group B	T185	C0441836
recorded	T080	C2355580
Hematomas	T046	C0018944
group A	T185	C0441835
group B	T185	C0441836
1-month	T079	C1442451
follow-up	T058	C1522577
period	T079	C1948053
radial occlusion	T046	C1110554
group	T078	C0441833
recorded	T080	C2355580
mild	T080	C2945599
hematomas	T046	C0018944
group B	T185	C0441836
group A	T185	C0441835
Performing	T169	C0884358
transradial diagnostic cardiac catheterization	T060	C2041518
without	T080	C0332288
removal	T052	C1883720
oral	T082	C0442027
chronic anticoagulation	UnknownType	C0694554
safe	T033	C3266157
patients	T101	C0030705
acenocumarol	T109	C0000956
therapy	T061	C0087111
infrared	T074	C0181645
visualization	T169	C0234621
selection	T052	C1707391
venipuncture	T060	C0600406
sites	T082	C0205145
indwelling	T169	C0439848
needle	T074	C0027551
forearm	T023	C0016536
nursing students	T097	C0038496
effectiveness	T080	C1280519
vein visualization display system	T074	C0025080
near-infrared light	T070	C1289901
Vein Display	T074	C0025080
selection	T052	C1707391
venipuncture	T060	C0600406
sites	T082	C0205145
indwelling	T169	C0439848
needle	T074	C0027551
forearm	T023	C0016536
nursing students	T097	C0038496
indwelling	T169	C0439848
needle	T074	C0027551
Vein	T023	C0042449
Display	T169	C0870432
participants	T098	C0679646
faculty	T097	C0015535
patients	T101	C0030705
venipuncture procedure	T060	C0600406
sites	T082	C0205145
scale	T170	C0349674
authors	T097	C3812881
Time	T079	C0040223
scores	T081	C0449820
patterns	T080	C0332307
puncture	T060	C0600406
site	T082	C0205145
selection	T052	C1707391
tourniquet	T074	C0040519
Vein Display	T074	C0025080
effectiveness	T080	C1280519
Vein	T023	C0042449
Display	T169	C0870432
venipuncture	T060	C0600406
site	T082	C0205145
selection	T052	C1707391
Vein Display	T074	C0025080
administer	T169	C1621583
venipuncture	T060	C0600406
sites	T082	C0205145
venipuncture	T060	C0600406
quality	T080	C0332306
scale	T170	C0349674
Vein Display	T074	C0025080
practical skills	T080	C0008973
venipuncture	T060	C0600406
elderly	T098	C0001792
patients	T101	C0030705
Elective	T061	C0206058
Nephron Sparing Surgery	T061	C0194086
Decreases	T081	C0205216
Other Cause Mortality	T033	C0476465
Relative	T080	C0205345
Radical Nephrectomy	T061	C0401181
Specific	T080	C0205369
Subgroups	T185	C1515021
Patients	T101	C0030705
Renal Cell Carcinoma	T191	C0007134
consensus	T054	C0376298
protective effect	T033	C1545588
mortality	T081	C0205848
cancer	T191	C0006826
patients	T101	C0030705
treated with	T061	C0332293
elective	T061	C0206058
nephron sparing surgery	T061	C0194086
relative	T080	C0205345
radical nephrectomy	T061	C0401181
test	T169	C0039593
protective effect	T033	C1545588
nephron sparing surgery	T061	C0194086
relative	T080	C0205345
radical nephrectomy	T061	C0401181
universal	T080	C0175671
specific	T080	C0205369
subgroups	T185	C1515021
patients	T101	C0030705
collaborative	T081	C0392762
database	T170	C0242356
institutions	T078	C1272753
queried	T170	C1522634
evaluate	T058	C0220825
patients	T101	C0030705
chronic kidney disease	T047	C1561643
diagnosed	T033	C0011900
clinical	T080	C0205210
T1 renal mass	T191	C2217020
treated with	T061	C0332293
nephron sparing surgery	T061	C0194086
radical nephrectomy	T061	C0401181
Multivariable Cox regression analysis	T170	C0034980
assess	T058	C0184514
impact	T080	C4049986
surgery	T061	C0543467
nephron sparing surgery	T061	C0194086
radical nephrectomy	T061	C0401181
other cause mortality	T033	C0476465
patient	T101	C0030705
cancer	T191	C0006826
characteristics	T080	C1521970
Interaction	T169	C1704675
test	T169	C0039593
impact	T080	C4049986
surgery	T061	C0543467
specific	T080	C0205369
subcohorts	T098	C0599755
patients	T101	C0030705
Ten-year	T079	C1254367
other cause mortality	T033	C0476465
survival rates	T081	C0038954
nephron sparing surgery	T061	C0194086
radical nephrectomy	T061	C0401181
overall	T080	C1561607
population	T098	C1257890
radical nephrectomy	T061	C0401181
associated with	T080	C0332281
increased	T081	C0205217
risk	T078	C0035647
other cause mortality	T033	C0476465
multivariable analysis	T081	C0026777
nephron sparing surgery	T061	C0194086
HR	T081	C2985465
CI	T081	C0009667
radical nephrectomy	T061	C0401181
increased	T081	C0205217
risk	T078	C0035647
other cause mortality	T033	C0476465
increasing	T081	C0205217
baseline	T081	C1442488
Charlson comorbidity index	T170	C3714916
interaction	T169	C1704675
test	T169	C0039593
patient	T101	C0030705
Charlson comorbidity index	T170	C3714916
probability	T081	C0033204
10-year	T079	C1254367
other cause mortality	T033	C0476465
survival	T052	C0038952
nephron sparing surgery	T061	C0194086
radical nephrectomy	T061	C0401181
Elective	T061	C0206058
nephron sparing surgery	T061	C0194086
improve	T033	C0184511
survival	T052	C0038952
relative	T080	C0205345
radical nephrectomy	T061	C0401181
patients	T101	C0030705
kidney cancer	T191	C0740457
Patients	T101	C0030705
ill	T184	C0221423
relevant	T080	C2347946
comorbidities	T078	C0009488
benefit	T081	C0814225
nephron sparing surgery	T061	C0194086
other cause mortality	T033	C0476465
dietary	T168	C0012155
Non Enzymatic Antioxidant Capacity	T059	C4049177
risk	T078	C0035647
hip fracture	T037	C0019557
elderly	T098	C0001792
Dietary antioxidants	T168	C0729311
bone loss	T047	C0029453
fractures	T037	C0016658
oxidative stress	T049	C0242606
dietary	T168	C0012155
Non Enzymatic Antioxidant Capacity	T059	C4049177
NEAC	T059	C4049177
risk	T078	C0035647
hip fracture	T037	C0019557
smoking	T055	C0037369
Swedish National March Cohort	T098	C0599755
men	T098	C0025266
women	T098	C0043210
cancer	T191	C0006826
cardiovascular disease	T047	C0007222
hip fracture	T037	C0019557
record-linkages	T062	C0025101
NEAC	T059	C4049177
food frequency questionnaire	T170	C2986698
baseline	T081	C1442488
NEAC	T059	C4049177
sex	T032	C0079399
specific	T080	C0205369
quartiles	T080	C2828255
multivariable adjusted Cox proportional hazards regression models	T081	C0033489
hazard ratios	T081	C2985465
HRs	T081	C2985465
confidence intervals	T081	C0009667
CI	T081	C0009667
follow-up	T058	C1522577
time	T079	C0040223
hip fracture	T037	C0019557
quartile	T080	C2828255
dietary	T168	C0012155
NEAC	T059	C4049177
lower risk	T033	C3843763
hip fracture	T037	C0019557
quartile	T080	C2828255
HR	T081	C2985465
CI	T081	C0009667
quartile	T080	C2828255
risk reduction	T055	C1137094
dietary	T168	C0012155
NEAC	T059	C4049177
dietary	T168	C0012155
NEAC	T059	C4049177
smoking	T055	C0037369
multiplicative	T081	C2911648
additive scale	T081	C0392762
NEAC	T059	C4049177
risk	T078	C0035647
hip fracture	T037	C0019557
Function	T041	C0563143
clinical	T080	C0205210
meaningfulness	T080	C1280519
treatments	T061	C0087111
mild	T080	C2945599
Alzheimer's disease	T047	C0002395
Effectiveness	T080	C1280519
Alzheimer's disease	T047	C0002395
AD	T047	C0002395
treatments	T061	C0087111
coprimary outcomes	T169	C1274040
cognition	T041	C0009240
function	T041	C0563143
clinical	T080	C0205210
meaningfulness	T080	C1280519
cognitive	T041	C0009240
effect	T080	C1280500
reviewed	T080	C1709940
literature	T170	C0023866
functional	T041	C0563143
outcomes	T169	C1274040
mild	T080	C2945599
AD	T047	C0002395
mild cognitive impairment	T048	C1270972
MCI	T048	C1270972
patients	T101	C0030705
mild-moderate	T080	C1299392
severe	T080	C0205082
AD	T047	C0002395
treated with	T061	C0332293
AD	T047	C0002395
drugs	T121	C0013227
Cognitive	T061	C0009244
functional	T041	C0563143
treatment	T061	C0087111
mild	T080	C2945599
AD	T047	C0002395
patients	T101	C0030705
solanezumab	T116	C2935150
EXPEDITION	T052	C0015315
EXPEDITION2	T052	C0015315
studies	T062	C2603343
compared	T052	C1707455
time	T079	C0040223
publications	T073	C0034036
MCI	T048	C1270972
mild	T080	C2945599
AD	T047	C0002395
functional	T041	C0563143
outcomes	T169	C1274040
functional	T041	C0563143
treatment effect	T033	C1518681
Secondary analyses	UnknownType	C0683944
EXPEDITION	T052	C0015315
studies	T062	C2603343
functional	T041	C0563143
effect	T080	C1280500
solanezumab	T116	C2935150
cognition	T041	C0009240
increasing	T169	C0442808
effect	T080	C1280500
solanezumab	T116	C2935150
months	T079	C0439231
cognition	T041	C0009240
function	T041	C0563143
Function	T041	C0563143
measure	T081	C0079809
clinical	T080	C0205210
meaningfulness	T080	C1280519
cognitive	T041	C0009240
effects	T080	C1280500
mild	T080	C2945599
AD	T047	C0002395
limitations	T169	C0449295
disease	T047	C0012634
modifying	T169	C0392747
treatments	T061	C0087111
cognitive	T041	C0009240
functional	T041	C0563143
scales	T170	C0349674
duration of treatment	T079	C0444921
E. coli	T007	C0014834
Compounds	T123	C0574031
Antibiotic	T195	C0003232
Production	T169	C0205245
Streptomyces coelicolor	T007	C0995741
Inter-species Interaction	T054	C0870742
investigate	T169	C1292732
interaction	T169	C1704675
E.coli	T007	C0014834
Streptomyces coelicolor A3 (2)	T007	C1449847
increased	T081	C0205217
production	T169	C0205245
undecylprodigiosin	T109	C0077826
E. coli	T007	C0014834
actives	T169	C0205177
mediating	T054	C0086597
inter-species interaction	T054	C0870742
antibiotics	T195	C0003232
red-pigmented undecylprodigiosin	T109	C0526040
blue-pigmented	T080	C0333610
actinorhodin	T109	C0050663
cultures	T059	C0430402
S. coelicolor	T007	C0995741
medium	T130	C0010454
concentrations	T081	C1264643
actinorhodin	T109	C0050663
compared	T052	C1707455
undecylprodigiosin	T109	C0077826
immunosuppressive	T040	C0021080
antitumor properties	T042	C1516031
increase	T169	C0442805
undecylprodigiosin	T109	C0077826
production	T169	C0205245
live cells	T025	C1441322
heat-killed	T067	C1522240
cells	T025	C0007634
E. coli C600	T007	C0014834
cell-free supernatant	T031	C1550101
E. coli	T007	C0014834
culture	T059	C0430402
S. coelicolor	T007	C0995741
cultures in shake flasks	T059	C3179108
interaction	T169	C1704675
live cells	T025	C1441322
E. coli	T007	C0014834
antibiotic	T195	C0003232
production	T169	C0205245
undecylprodigiosin	T109	C0077826
production	T169	C0205245
enhanced	T052	C2349975
pure cultures	T059	C0430402
S. coelicolor	T007	C0995741
actinorhodin	T109	C0050663
decreased	T081	C0205216
heat-killed	T067	C1522240
cells	T025	C0007634
E. coli	T007	C0014834
no effect	T080	C1301751
antibiotic	T195	C0003232
production	T169	C0205245
growth	T040	C0178747
glucose consumption	T033	C0556133
S. coelicolor	T007	C0995741
same	T080	C0445247
observed	T169	C1441672
pure culture	T059	C0430402
changes	T169	C0392747
antibiotic	T195	C0003232
production	T169	C0205245
nutritional	T040	C1442959
stress	T033	C0038435
Results	T169	C1274040
cell-free supernatant	T031	C1550101
E. coli	T007	C0014834
culture	T059	C0430402
interaction	T169	C1704675
S. coelicolor	T007	C0995741
E. coli	T007	C0014834
mediated	T054	C0086597
diffusible molecule(s)	T123	C0574031
extraction procedures	T059	C0684295
agar-well diffusion bioassays	T059	C0005507
isolated	T169	C0205409
identified	T080	C0205396
class of compounds	T123	C0574031
verification	T169	C1711411
compound	T123	C0574031
chemical structural moiety	T104	C1254350
class of compounds	T123	C0574031
S. coelicolor	T007	C0995741
cultures	T059	C1331092
effects	T080	C1280500
antibiotic	T195	C0003232
production	T169	C0205245
E. coli	T007	C0014834
cells	T025	C0007634
supernatant	T031	C1550101
class of compounds	T123	C0574031
secreted	T043	C1327616
E. coli	T007	C0014834
actives	T169	C0205177
interspecies interaction	T054	C0870742
increase	T169	C0442805
production	T169	C0205245
undecylprodigiosin	T109	C0077826
Group III/IV muscle	T024	C0026845
afferents	T025	C0027883
limit	T169	C0439801
intramuscular	T082	C0442117
metabolic	T169	C0311400
perturbation	T169	C0332453
whole body	T017	C0444584
exercise	T056	C0015259
humans	T016	C0086418
purpose	T169	C1285529
study	T062	C2603343
determine	T059	C1148554
role	T077	C1705810
group III/IV muscle	T024	C0026845
afferents	T025	C0027883
limiting	T169	C0439801
endurance	T033	C0518031
exercise	T056	C0015259
induced	T169	C0205263
metabolic	T169	C0311400
perturbation	T169	C0332453
assayed	T059	C1510438
muscle	T024	C0026845
biopsy samples	T024	C0677862
locomotor	T040	C0023946
muscle	T024	C0026845
Lumbar	T029	C0024090
intrathecal	T030	C1370196
fentanyl	T109	C0015846
attenuate	T052	C0599946
central	T082	C0205099
projection	T082	C0348018
μ-opioid receptor	T116	C0066908
sensitive	T169	C0332324
locomotor	T040	C0023946
muscle	T024	C0026845
afferents	T025	C0027883
cycling	T079	C1511572
time	T079	C0040223
trial	T062	C0008976
findings	T033	C0243095
central	T082	C0205099
projection	T082	C0348018
group III/IV muscle	T024	C0026845
afferent	T025	C0027883
feedback	T039	C0678663
constrains	T077	C1707494
voluntary	T055	C0439656
neural	T169	C3714606
drive	T041	C0013126
working	T169	C0205177
locomotor	T040	C0023946
muscle	T024	C0026845
limits	T169	C0439801
exercise	T056	C0015259
induced	T169	C0205263
intramuscular	T082	C0442117
metabolic	T169	C0311400
perturbation	T169	C0332453
CNS	T022	C3714787
regulate	T038	C1327622
degree	T081	C0449286
metabolic	T169	C0311400
perturbation	T169	C0332453
locomotor	T040	C0023946
muscle	T024	C0026845
limit	T169	C0439801
peripheral	T082	C0205100
fatigue	T184	C0015672
appears	T080	C0700364
group III/IV muscle	T024	C0026845
afferents	T025	C0027883
important	T080	C3898777
neural	T169	C3714606
link	T030	C0178718
regulatory	T038	C1327622
mechanism	T169	C0441712
probably	T078	C0750492
protect	T033	C1545588
locomotor	T040	C0023946
muscle	T024	C0026845
potentially	T080	C3245505
severe	T080	C0205082
functional impairment	T033	C4062321
consequence	T169	C0686907
severe	T080	C0205082
intramuscular	T082	C0442117
metabolic	T169	C0311400
disturbance	T080	C2699787
investigate	T169	C1292732
role	T077	C1705810
metabo	T040	C0025519
mechanosensitive	T080	C1522640
group III/IV muscle	T024	C0026845
afferents	T025	C0027883
limiting	T169	C0439801
intramuscular	T082	C0442117
metabolic	T169	C0311400
perturbation	T169	C0332453
whole body	T017	C0444584
endurance	T033	C0518031
exercise	T056	C0015259
subjects	T096	C0681850
performed	T169	C0884358
cycling	T079	C1511572
time	T079	C0040223
trials	T062	C0008976
under control conditions	T033	C2911690
CTRL	T033	C2911690
lumbar	T029	C0024090
intrathecal	T030	C1370196
fentanyl	T109	C0015846
impairing	T169	C0221099
lower limb	T023	C0023216
muscle	T024	C0026845
afferent	T025	C0027883
feedback	T039	C0678663
FENT	T039	C0678663
Vastus lateralis	T023	C0224444
muscle	T024	C0026845
biopsies	T024	C0677862
obtained	T169	C1301820
before	T079	C0332152
immediately	T079	C0205253
after	T079	C0687676
exercise	T056	C0015259
Motoneuronal	T025	C0026609
output was estimated	T060	C0204709
vastus lateralis surface	T023	C0224444
electromyography	T060	C0013839
EMG	T060	C0013839
Exercise	T056	C0015259
induced	T169	C0205263
changes	T169	C0392747
intramuscular	T082	C0442117
metabolites	T123	C0870883
determine	T059	C1148554
liquid	T167	C0302908
gas chromatography-mass spectrometry	T059	C1720784
Quadriceps	T023	C0224440
fatigue	T184	C0015672
quantified	T081	C1709793
pre	T079	C0332152
post	T079	C0687676
exercise	T056	C0015259
changes	T169	C0392747
potentiated quadriceps twitch torque	T067	C0376590
ΔQTsingle	T067	C0376590
evoked	T080	C1444748
electrical	T169	C0442828
femoral nerve	T023	C0015808
stimulation	T061	C1292856
motoneuronal	T025	C0026609
output	T052	C0441655
higher	T080	C0205250
FENT	T039	C0678663
compared	T052	C1707455
CTRL	T033	C2911690
time	T079	C0040223
complete	T080	C0205197
time	T079	C0040223
trial	T062	C0008976
similar	T080	C2348205
Compared	T052	C1707455
CTRL	T033	C2911690
power output	T070	C0445194
FENT	T039	C0678663
higher	T080	C0205250
first half	T033	C3843058
time	T079	C0040223
trial	T062	C0008976
lower	T080	C0205251
second half	T033	C3843057
exercise	T056	C0015259
induced	T169	C0205263
increase	T169	C0442805
intramuscular	T082	C0442117
inorganic phosphate	T121	C0031603
H(+)	T196	C0033727
adenosine diphosphate	T114	C0001459
lactate	T109	C0022924
phosphocreatine	T116	C0031634
depletion	T169	C0333668
greater	T081	C1704243
FENT	T039	C0678663
CTRL	T033	C2911690
ΔQTsingle	T067	C0376590
greater	T081	C1704243
FENT	T039	C0678663
CTRL	T033	C2911690
difference	T081	C1705241
positively	T033	C1446409
correlated	T080	C1707520
difference	T081	C1705241
inorganic phosphate	T121	C0031603
conclusion	T078	C1707478
whole body	T017	C0444584
exercise	T056	C0015259
group III/IV muscle	T024	C0026845
afferents	T025	C0027883
provide	T052	C1999230
feedback	T039	C0678663
CNS	T022	C3714787
constrains	T077	C1707494
motoneuronal	T025	C0026609
output	T052	C0441655
active	T169	C0205177
skeletal muscle	T024	C0242692
regulatory	T038	C1327622
mechanism	T169	C0441712
limits	T169	C0439801
exercise	T056	C0015259
induced	T169	C0205263
intramuscular	T082	C0442117
metabolic	T169	C0311400
perturbation	T169	C0332453
abnormal homeostatic	T033	C4022950
challenge	T058	C0805586
excessive	T080	C0442802
peripheral	T082	C0205100
fatigue	T184	C0015672
Mitochondrial	T026	C0026237
Ultrastructure	T025	C3825563
Glucose Signaling Pathways	T044	C1622453
Kv1.3 Ion Channel	T116	C0290730
Gene-targeted	T063	C0242613
deletion	T045	C0017260
potassium channel Kv1.3	T116	C0290730
Kv1.3(-∕-)) results i	T034	C0456984
uper-smeller" mice	T015	C0025929
nsory p	T080	C0445254
enotype t	T032	C0031437
increased	T081	C0205217
olfactory	T040	C0439826
ability	T032	C0085732
olfactory	T040	C0439826
circuitry	UnknownType	C0260041
increased	T081	C0205217
abundance	T080	C2346714
olfactory cilia	T026	C0230758
increased	T081	C0205217
expression	T045	C0597360
odorant receptors	T116	C0164313
G-protein, Golf	T116	C0033684
Kv1.3(-∕-) mice a	T015	C0025929
metabolic p	T169	C0311400
enotype i	T032	C0031437
wer b	T081	C1611820
dy weight a	T032	C0005910
creased a	T081	C0205216
iposity,	T032	C1563743
creased total energy expenditure	T033	C0429629
TEE	T033	C0429629
increased	T081	C0205217
locomotor activity	T040	C0023946
resistance	T041	C0237834
diet	T168	C0012155
genetic-induced	T045	C0017391
obesity	T047	C0028754
cellular aspects	T080	C0935919
mechanism	T169	C0441712
loss	T081	C1517945
Kv1.3 channel	T116	C0290730
olfactory bulb	T023	C0028936
OB	T023	C0028936
glucose utilization	T044	C1148560
metabolic rate	T039	C0870882
in situ hybridization	T063	C0162788
Kv1.3	T116	C0290730
insulin	T116	C0021641
dependent	T080	C1701901
glucose transporter type 4	T116	C0166441
GLUT4	T116	C0166441
mitral	T023	C0026264
cell layer	T025	C0007634
OB	T023	C0028936
Disruption	T169	C0332453
Kv1.3	T116	C0290730
conduction	T070	C0457405
pore mutation	T045	C0026882
W386F Kv1.3	T045	C0026882
translocate	T043	C0599893
GLUT4	T116	C0166441
plasma membrane	T026	C0007603
HEK 293 cells	T025	C2936239
olfactory sensory perception	T040	C0037361
maintenance	T052	C0024501
action potential (AP)	T043	C0001272
mitral	T023	C0026264
cells	T025	C0007634
OB	T023	C0028936
Kv1.3	T116	C0290730
mitochondria	T026	C0026237
organelle	T026	C0029219
mitral	T023	C0026264
cells	T025	C0007634
wildtype	T015	C1520150
WT	T015	C1520150
Kv1.3(-∕-) male mice	T015	C0025929
oderately high-fat diet (	T061	C0521974
HF,	T061	C0521974
months	T079	C0439231
OB	T023	C0028936
ultrastructure	T025	C3825563
transmission electron microscopy	T059	C0678118
WT mice	T015	C1520150
mitochondria	T026	C0026237
enlarged	T080	C0442800
diet-induced obesity	T047	C0028754
DIO	T047	C0028754
mitochondria	T026	C0026237
mitophagy	T043	C1820119
mitochondria	T026	C0026237
smaller	T080	C0547044
Kv1.3(-∕-) mice c	T015	C0025929
T mice.	T015	C1520150
etabolic r	T169	C0311400
IO,	T047	C0028754
v1.3(-∕-) mice ha	T015	C0025929
ochondria in	T026	C0026237
s sectional	T082	C0552389
area	T082	C0205146
abundance	T080	C2346714
modified diet	T061	C0521974
disruption	T169	C0332453
Kv1.3 channel	T116	C0290730
OB	T023	C0028936
TEE	T033	C0429629
Kv1.3	T116	C0290730
mitochondrial structure	T026	C0026237
glucose utilization	T044	C1148560
metabolic	T169	C0311400
metabolism	T040	C0025519
OB	T023	C0028936
effects of	T080	C1704420
paternal	T080	C0337493
high-fat diet	T168	C0012155
exposure	T080	C0332157
offspring	T099	C0680063
metabolism	T040	C0025519
epigenetic changes	T045	C1516924
adiponectin	T028	C1540187
leptin	T028	C1416825
gene promoters	T028	C0314621
studies	T062	C2603343
epigenetic changes	T045	C1516924
malnutrition	T047	C0162429
roles	T077	C1705810
transgenerational links	T102	C0871541
metabolic diseases	T047	C0025517
observed	T169	C1441672
exposure	T080	C0332157
high-fat diet	T168	C0012155
HFD	T168	C0012155
in utero	T100	C1708480
caused	T169	C0015127
metabolic	T169	C0311400
syndrome	T047	C0039082
phenomenon	T067	C1882365
through	T169	C0332273
epigenetic modifications	T045	C1516924
adiponectin	T028	C1540187
leptin genes	T028	C1416825
multiple	T081	C0439064
generations	T079	C0079411
etiological	T169	C0015127
studies	T062	C2603343
indicated	T033	C1444656
paternal	T080	C0337493
BMI	T201	C1305855
effects	T080	C1280500
offspring	T099	C0680063
BMI	T201	C1305855
independent of	T169	C0332291
additive	T080	C0442796
maternal	T033	C1858460
BMI	T201	C1305855
effects	T080	C1280500
paternal	T080	C0337493
HFD	T168	C0012155
induced	T169	C0205263
obesity	T047	C0028754
affected	T080	C1280500
metabolic	T169	C0311400
status	T080	C0449438
offspring	T099	C0680063
through	T169	C0332273
epigenetic changes	T045	C1516924
adiponectin	T028	C1540187
leptin genes	T028	C1416825
investigated	T169	C1292732
normal diet	T056	C0184625
during	T079	C0347984
subsequent generations	T078	C1136186
abolished	T052	C1947925
epigenetic changes	T045	C1516924
associated with	T080	C0332281
paternal	T080	C0337493
HFD	T168	C0012155
exposure	T080	C0332157
before	T079	C0332152
conception	T040	C0009637
observed	T169	C1441672
effects of	T080	C1704420
paternal	T080	C0337493
HFD	T168	C0012155
exposure	T080	C0332157
before	T079	C0332152
conception	T040	C0009637
multiple	T081	C0439064
generations	T079	C0079411
offspring	T099	C0680063
metabolic	T169	C0311400
traits	T032	C0599883
including	T169	C0332257
weight	T033	C0043094
fat	T109	C0015677
gain	T081	C1517378
glucose intolerance	T047	C0271650
hypertriglyceridemia	T047	C0020557
abnormal adipocytokine	T116	C1955907
levels	T080	C0441889
hypertension	T047	C0020538
adiponectin	T028	C1540187
leptin gene	T028	C1416825
expression	T045	C0017262
epigenetic changes	T045	C1516924
Normal diet	T056	C0184625
offspring	T099	C0680063
paternal	T080	C0337493
HFD	T168	C0012155
exposure	T080	C0332157
diminished	T081	C0205216
consumption	T052	C2983605
generations	T079	C0079411
abolished	T052	C1947925
effect	T080	C1280500
paternal	T080	C0337493
HFD	T168	C0012155
exposure	T080	C0332157
metabolic	T169	C0311400
traits	T032	C0599883
adipocytokine	T116	C1955907
epigenetic changes	T045	C1516924
offspring	T099	C0680063
effects of	T080	C1704420
paternal	T080	C0337493
HFD	T168	C0012155
exposure	T080	C0332157
offspring	T099	C0680063
weaker	T080	C1762617
following	T079	C0332282
HFD	T168	C0012155
exposure	T080	C0332157
in utero	T100	C1708480
paternal	T080	C0337493
HFD	T168	C0012155
exposure	T080	C0332157
additive	T080	C0442796
metabolic	T169	C0311400
effect	T080	C1280500
generations	T079	C0079411
paternal	T080	C0337493
maternal	T033	C1858460
nutrition	T040	C1442959
affect	T080	C1280500
offspring	T099	C0680063
metabolism	T040	C0025519
through	T169	C0332273
epigenetic modifications	T045	C1516924
adipocytokine genes	T028	C0017337
multiple	T081	C0439064
generations	T079	C0079411
Study	T059	C0947630
Microfocus	T082	C0205234
X-Ray Tube	T074	C0184486
Point-Like Target	T169	C1521840
Micro-Computed Tomography	T060	C2350281
micro-Computed Tomography (Micro-CT) system	T060	C2350281
microfocus	T082	C0205234
X-ray tube	T074	C0184486
essential	T080	C0205224
spatial	T082	C1254362
resolution	T081	C1706463
CT	T060	C0040405
images	T170	C1704254
theory	T078	C0871935
size	T082	C0456389
stability	T080	C0205360
X-ray	T060	C0043299
focal spot	T082	C0205146
microfocus	T082	C0205234
X-ray tube	T074	C0184486
factors	T169	C1521761
voltage	T081	C0598352
fluctuations	T079	C0231241
mechanical	T070	C0376706
vibrations	T070	C0459800
temperature changes	T080	C0450031
cause	T078	C0085978
size	T082	C0456389
stability	T080	C0205360
X-ray	T060	C0043299
focal spot	T082	C0205146
degrade	T067	C1254366
microfocus	T082	C0205234
X-ray tube	T074	C0184486
point-like micro-target	T169	C1521840
X-ray	T060	C0043299
target	T169	C1521840
irradiated	T067	C1254366
electron beam	T073	C0013840
investigated	T169	C1292732
EGS4 Monte Carlo simulation code	T081	C0026507
calculation	T052	C1441506
X-ray	T060	C0043299
intensity	T070	C0596836
point-like micro-target	T169	C1521840
substrate	T167	C3891814
effects of	T080	C1704420
target	T169	C1521840
material	T167	C0520510
target	T169	C1521840
beam	T073	C0013840
size	T082	C0456389
studied	T059	C0947630
simulation	T062	C0679083
results	T169	C1274040
intensity	T070	C0596836
X-rays	T060	C0043299
generated	T080	C2346631
point-like target	T169	C1521840
greater than	T081	C0439093
X-ray	T060	C0043299
intensity	T070	C0596836
substrate	T167	C3891814
X-ray	T060	C0043299
focal spot	T082	C0205146
point-like target	T169	C1521840
electron beam	T073	C0013840
conventional	T080	C0439858
X-ray tube	T074	C0184486
theory	T078	C0871935
reduce	T080	C0392756
effects	T080	C1280500
electron beam trajectory swinging	T033	C0243095
beam	T073	C0013840
size	T082	C0456389
changing	T169	C0392747
microfocus	T082	C0205234
X-ray tube	T074	C0184486
alleviate	T080	C0392756
CT	T060	C0040405
image	T170	C1704254
artifacts	T068	C0085089
caused	T078	C0085978
X-ray	T060	C0043299
focal spot	T082	C0205146
shift	T033	C3845720
size change	T081	C0541591
Early	T079	C1279919
assessment	T058	C0220825
bilateral inguinal hernia repair	T061	C0198737
comparison	T052	C1707455
laparoscopic total extraperitoneal	T061	C0087111
Stoppa approaches	T061	C0087111
present	T079	C0521116
clinical trial	T062	C0008976
compare	T052	C1707455
results	T169	C1274040
bilateral inguinal hernia repair	T061	C0198737
patients	T101	C0030705
conventional	T169	C0443177
Stoppa technique	T061	C0087111
laparoscopic total extraperitoneal repair	T061	C0521293
LTE	T061	C0521293
mesh	T074	C0181805
staple fixation	T061	C1293125
randomised	T062	C0034656
clinical trial	T062	C0008976
General Surgery and Trauma of the Clinics Hospital	T093	C1708333
Medical School	T093	C1708333
University of Sγo Paulo	T093	C1708333
male	T032	C0086582
patients	T101	C0030705
bilateral inguinal hernia	T190	C0267672
years	T079	C0439234
eligible	T080	C1548635
study	T062	C2603343
parameters	T077	C0549193
analysed	T062	C0936012
early	T079	C1279919
post-operative period	T079	C0032790
intensity	T080	C0522510
surgical trauma	T033	C4060629
operation time	T079	C3494201
C-reactive protein	T116	C0006560
CRP	T116	C0006560
levels	T080	C0441889
white blood cell count	T059	C0023508
bleeding	T046	C0019080
pain intensity	T201	C1320357
quality of life	T078	C0034380
assessment	T058	C0220825
post-operative complications	T046	C0032787
LTE procedure	T061	C0521293
longer	T080	C0205166
Stoppa procedure	T061	C0087111
levels	T080	C0441889
CRP	T116	C0006560
higher	T080	C0205250
Stoppa	T061	C0087111
group	T078	C0441833
leucocytes	T025	C0023516
haematocrit	T033	C0518014
haemoglobin	T116	C0019046
similar	T080	C2348205
groups	T078	C0441833
no difference	T033	C3842396
pain	T184	C0030193
post-operative	T033	C0241311
physical functioning	T033	C0516981
physical limitation	T169	C0449295
impact	T080	C4049986
pain	T184	C0030193
daily activities	T056	C0871707
Carolinas Comfort Scale	T170	C0349674
post-operative	T033	C0241311
Complications	T046	C0009566
Stoppa	T061	C0087111
group	T078	C0441833
patients	T101	C0030705
LTE	T061	C0521293
group	T078	C0441833
patients	T101	C0030705
comparative study	T062	C1579762
Stoppa	T061	C0087111
LTE	T061	C0521293
bilateral inguinal hernia repair	T061	C0198737
LTE	T061	C0521293
surgical trauma	T033	C4060629
longer	T080	C0205166
operation time	T079	C3494201
Quality of life	T078	C0034380
early	T079	C1279919
post-operative period	T079	C0032790
similar	T080	C2348205
Complication	T046	C0009566
rates	T081	C1521828
higher	T080	C0205250
Stoppa	T061	C0087111
group	T078	C0441833
Morphological	T082	C0543482
characteristics	T080	C1521970
phallic glans	T023	C0227948
engorgement	T047	C0020452
American alligator	T014	C0327167
distal part	T082	C0205108
crocodilian	T014	C0327160
phallus	T023	C0030851
bulbous glans	T023	C0227948
vascular tissues	T024	C1511228
sexual activity	T053	C0036864
enlarging	T080	C0442800
glans	T023	C1550261
complex	T080	C0439855
functionally	T169	C0205245
undefined	T078	C0750600
copulatory	T054	C1325873
enlarged	T080	C0442800
glans	T023	C1550261
interacts	T169	C1704675
female	T032	C0086287
cloaca	T023	C0008987
change	T169	C0392747
shape	T082	C0332479
her reproductive tract	T022	C0700038
insemination	T042	C0021586
increase	T169	C0442805
probability	T081	C0033204
fertilization	T040	C0015914
cellular-level properties	T043	C0007613
glans	T023	C1550261
inflatable phallic tissues	T024	C0040300
sperm	T025	C0037868
sulcus	T030	C1184482
spermaticus	T023	C0037855
American alligator	T014	C0327167
Alligator mississippiensis	T014	C0327167
histochemical staining	T059	C0200825
collagen	T116	C0009325
elastin fiber	T024	C0230899
densities	T081	C0178587
orientations	T082	C1704322
tissues	T024	C0040300
Extracellular matrix	T024	C0015350
phallic glans	T023	C0227948
affect	T169	C0392760
tissue	T024	C0040300
strength	T081	C0237897
flexibility	T080	C0242808
copulatory	T054	C1325873
forces	T067	C0441722
potential	T080	C3245505
fluids	T167	C0302908
induce	T169	C0205263
alligator	T014	C0002123
phalli	T023	C0030851
serial sectioning	T059	C0022885
three-dimensional reconstruction	T059	C0022885
supracrucal plexus vascular	T023	C0501402
bodies	T026	C1995017
alligator	T014	C0002123
phallus	T023	C0030851
distally adjacent	T082	C1254362
ventro-medial sulcus tissues	T024	C0040300
gross	T080	C0439806
histological examination	T033	C0449575
American alligator	T014	C0327167
phallic glans	T023	C0227948
tissues	T024	C0040300
vascular	T023	C0005847
glans	T023	C1550261
shape	T082	C0332479
potentially	T080	C3245505
secretory products	T026	C0243092
female reproductive tract	T022	C0700038
postcopulatory	T054	C1325873
sexual selection	T054	C1720879
mechanically	T169	C0443254
affecting female reproductive physiology	T039	C1517151
role	T077	C1705810
poly(C) binding proteins	T116	C0242210
programmed ribosomal frameshifting	T045	C0282572
Translational	T045	C1519614
control	T080	C0243148
programmed ribosomal frameshifting	T045	C0282572
PRF	T045	C0282572
viruses	T005	C0042776
cellular	T025	C0007634
genes	T028	C0017337
Frameshifting	T045	C0282572
induced	T169	C0205263
mRNA secondary structures	T114	C0035696
ribosome	T026	C0035553
fidelity	T043	C0007613
decoding	T169	C0205245
heptanucleotide 'slippery' sequence	T086	C0004793
nsp2	T116	C0033684
PRF	T045	C0282572
signal	T044	C0037080
porcine reproductive and respiratory syndrome virus	T005	C0376536
-2	T045	C0282572
-1 PRF	T045	C0282572
requirement	T169	C1514873
trans-acting protein factor	T116	C0033684
viral	T005	C0042776
replicase subunit nsp1β	T116	C0033684
trans-activation	T045	C0040624
frameshifting	T045	C0282572
protein complex	T116	C1180347
nsp1β	T116	C0033684
cellular	T025	C0007634
poly(C) binding protein	T116	C0242210
PCBP	T116	C0242210
in vitro	T080	C1533691
translation	T045	C1519614
electrophoretic mobility shift assays	T059	C0949632
PCBP	T116	C0242210
nsp1β	T116	C0033684
complex	T116	C1180347
C-rich sequence	T086	C0004793
downstream	T082	C0522506
slippery sequence	T086	C0004793
activity	T052	C0441655
mRNA	T114	C0035696
stimulator	T123	C0574031
PRF	T045	C0282572
role	T077	C1705810
trans-acting cellular protein	T116	C0033684
PRF	T045	C0282572
activities	T052	C0441655
associated with	T080	C0332281
poly(C) binding proteins	T116	C0242210
prototypes	T080	C0205556
virus	T005	C0042776
host	T001	C1167395
interactions	T169	C1704675
bioactive	T167	C3714412
conjugated linoleic acid	T109	C1257880
multifunctional	T116	C3658346
enolase	T116	C0031691
Lactobacillus plantarum	T007	C0317608
Lactobacillus plantarum	T007	C0317608
α-enolase	T116	C2364020
multifunctional	T116	C3658346
surface protein	T116	C0025252
enolases	T116	C0031691
glycolytic	T044	C0017952
metabolism	T040	C0025519
characterized	T052	C1880022
intricate metabolism	T040	C0025519
biohydrogenation	T070	C0020286
linoleic acid	T109	C0023749
catalyzing	T070	C0007382
formation	T169	C1522492
bioactive	T167	C3714412
9-cis-11-trans-CLA	T109	C1609806
dehydration	T067	C0598133
isomerization	T044	C0596342
10-hydroxy-12-cis-octadecenoic acid	T109	C0620518
enolase	T116	C0031691
mass spectrometric analysis	T059	C0037813
amino acid sequence	T087	C0002518
molecular mass	T081	C3152252
kDa	T081	C1532717
enolase	T116	C0031691
linoleic acid	T109	C0023749
substrate	T167	C3891814
hydroxyl	T197	C0700307
derivative	T169	C1527240
10-hydroxi-12-cis-octadecenoic acid	T109	C0620518
bioactive	T167	C3714412
conjugated linoleic acid	T109	C0050156
Biochemical	T169	C0205474
optimization	T052	C2698650
studies	T062	C2603343
9-cis-11-trans-CLA	T109	C1609806
stability	T044	C0014439
α-enolase	T116	C2364020
catalyzing	T070	C0007382
reaction	T067	C0596319
structural analysis	T061	C0204514
protein	T116	C0033684
binding sites	T192	C0005456
substrate	T167	C3891814
product	T071	C1514468
molecules	T167	C0567416
characterized	T052	C1880022
hydrophobic	T080	C0598629
enolase	T116	C0031691
channel	T116	C0022009
catalysis	T070	C0007382
dehydration	T067	C0598133
isomerization	T044	C0596342
multifunctional	T116	C3658346
α-enolase	T116	C2364020
cell detoxification	T043	C4235382
polyunsaturated fatty acids	T109	C0032615
linoleic acid	T109	C0023749
linoleate isomerase	T116	C0312354
complex	T104	C1704241
Associations	T080	C0439849
Body Mass Index	T201	C1305855
Physical Activity	T056	C0026606
Sexual Dysfunction	T047	C0549622
Breast Cancer	T191	C0678222
Survivors	T101	C0206194
Sexual dysfunction	T047	C0549622
distressing	T033	C0231303
consequence of	T169	C0686907
breast cancer	T191	C0678222
BC	T191	C0678222
treatment	T061	C0087111
study	T062	C2603343
sexual functioning	T040	C0278092
BC	T191	C0678222
patients	T101	C0030705
association	T041	C0004083
women's	T098	C0043210
personal	T032	C1519021
characteristics	T080	C1521970
cancer treatments	T061	C0920425
cross-sectional study	T062	C0010362
sexual function	T040	C0278092
Female Sexual Function Index	T170	C4289276
FSFI	T170	C4289276
health-related quality of life	T078	C4279947
HRQOL	T078	C4279947
European Organization for Research and Treatment of Cancer	T093	C1516985
EORTC	T093	C1516985
QLQ-C30	T170	C3641780
breast module BR-23	T170	C0282574
participants	T098	C0679646
participants	T098	C0679646
patients	T101	C0030705
no sexual activity	T033	C3840693
month	T079	C0439231
sexual desire	T041	C0023618
domain	T169	C1880389
FSFI	T170	C4289276
patients	T101	C0030705
hypoactive sexual desire disorder	T048	C0020594
HSDD	T048	C0020594
patients	T101	C0030705
sexual activity	T053	C0036864
month	T079	C0439231
sexual dysfunction	T047	C0549622
hierarchical logistic regression	T062	C0206031
body mass index	T201	C1305855
BMI	T201	C1305855
physical activity	T056	C0026606
prediction	T078	C0681842
models	T170	C3161035
sexual dysfunction	T047	C0549622
HSDD	T048	C0020594
Age	T032	C0001779
BMI	T201	C1305855
physical activity	T056	C0026606
sexual dysfunction	T047	C0549622
HSDD	T048	C0020594
BC	T191	C0678222
patients	T101	C0030705
sexual dysfunction	T047	C0549622
lower	T081	C1611820
scores	T081	C0449820
HRQOL	T078	C4279947
functioning	T169	C0205245
fatigue	T184	C0015672
findings	T033	C0243095
BC	T191	C0678222
survivors	T101	C0206194
practice	T041	C0032893
physical activity	T056	C0026606
lose weight	UnknownType	C0418839
sexual dysfunction	T047	C0549622
clinical trials	T062	C0008976
findings	T033	C0243095
Combination	T121	C0013162
telmisartan	T109	C0248719
sildenafil	T109	C0529793
ameliorate	T080	C0205556
progression	T046	C0242656
diabetic nephropathy	T047	C0011881
streptozotocin	T109	C0038432
induced	T169	C0205263
diabetic	T033	C0241863
Diabetic nephropathy	T047	C0011881
DN	T047	C0011881
end-stage renal disease	T047	C0022661
signaling pathways	T044	C0037080
pathogenesis	T046	C0699748
DN	T047	C0011881
elevation	T082	C0702240
angiotensin II	T116	C0003009
formation	T169	C1522492
advanced glycation end products	T109	C0162574
AGE	T109	C0162574
activation	T043	C1819041
protein kinase c	T116	C0033634
PKC	T116	C0033634
lipid accumulation	T033	C0333574
pathways	T044	C0037080
activate	T052	C1879547
oxidative stress	T049	C0242606
expression	T045	C1171362
transforming growth factor beta-1	T116	C1704256
TGF-β 1	T116	C1704256
release	T169	C1283071
interleukins	T116	C0021764
adhesion molecules	T116	C0007578
pathogenic	T033	C3816499
pathway	T077	C1705987
ameliorate	T080	C0205556
progression	T046	C0242656
DN	T047	C0011881
study	T062	C0008972
white male rats	T015	C0684072
rats	T015	C0684072
normal control	T096	C0009932
control vehicle group	T096	C0009932
diabetic	T033	C0241863
intraperitoneal injection	T061	C0021493
Streptozotocin	T109	C0038432
STZ	T109	C0038432
DN	T047	C0011881
rats	T015	C0684072
DN	T047	C0011881
DN	T047	C0011881
Telmisartan	T109	C0248719
Sildenafil	T109	C0529793
Telmisartan	T109	C0248719
Sildenafil	T109	C0529793
combination	T121	C0013162
specified	T080	C0205369
treatment	T169	C0039798
period	T079	C1948053
urine samples	T031	C1610733
collected	T078	C1516695
metabolic cages	T073	C3273359
proteinuria	T033	C0033687
animals	T008	C0003062
euthanized	T054	C0162665
blood	T031	C0178913
tissue samples	T024	C1292533
collected	T078	C1516695
measurement of Blood glucose	T059	C0392201
BUN	T059	C0005845
S.Cr	T059	C0201976
LDL	T059	C0202117
NO	T059	C3810607
TGF-β1	T059	C3889969
IL-1β	T059	C3815172
AGEPs	T059	C0022885
SOD	T059	C0022885
combination therapy	T061	C0013218
BUN	T123	C0600137
S.Cr	T109	C0010294
LDL	T109	C0023823
TGF-β1	T116	C1704256
IL-1β	T116	C0021753
Proteinuria	T033	C0033687
AGEPs	T109	C0162574
SOD	T116	C0038838
NO	T121	C0028128
combination therapy	T061	C0013218
ameliorate	T080	C0205556
DN	T047	C0011881
superior	T080	C0205556
drugs	T121	C0013227
Analysis	T062	C0936012
Low-Biomass	T081	C0005535
Microbial Communities	T001	C0445623
Deep Biosphere	UnknownType	C0681784
few decades	T081	C2981279
subseafloor biosphere	UnknownType	C0681784
scientific ocean drilling	T169	C0205245
depths	T082	C0205125
seafloor	UnknownType	C0681784
organic-rich anaerobic sedimentary habitats	T082	C0871648
ocean margins harbor	T082	C1254362
microbial cells	T001	C0445623
microbial populations	T001	C0445623
ultraoligotrophic aerobic sedimentary habitats	T082	C0871648
ocean gyres	T169	C0205245
magnitude	T081	C1704240
abundant	T080	C2346714
cultivation-independent molecular ecological techniques	T169	C0449851
low-biomass	T081	C0005535
environment	T082	C0014406
technologically challenging	T080	C0332218
deep subseafloor biosphere	UnknownType	C0681784
Reviewing	T080	C1704362
historical background	T170	C1552723
deep-biosphere	UnknownType	C0681784
analytical methods	T170	C0178476
importance	T080	C3898777
clean samples	T167	C0370003
tracing	T033	C0243095
contamination	T078	C2349974
methods	T170	C0025663
detecting	T033	C0243095
microbial	T001	C0599840
life	T078	C0376558
technological aspects	UnknownType	C0681539
molecular microbiology	T091	C0025952
detecting	T033	C0243095
subseafloor	UnknownType	C0681784
metabolic activity	T040	C0025519
sensitivity and specifity	T081	C0036668
DR-70	T123	C0041365
immunoassay	T059	C0020980
tumor marker	T123	C0041365
non-small cell lung cancer	T191	C0007131
Lung cancer	T191	C0242379
cancer related mortality	T081	C1516192
Patients	T101	C0030705
lung cancer	T191	C0242379
diagnosed	T060	C0430022
advanced	T029	C0005898
locally advanced stage	T029	C0005898
early diagnosis	T060	C0596473
lung cancer	T191	C0242379
early detection	T060	C0596473
lung cancer	T191	C0242379
low-dose computed tomography	T060	C0040405
tumor biomarkers	T123	C0041366
evaluate	T058	C0220825
DR-70	T123	C0041365
sensitivity and specificity	T081	C0036668
tumor marker	T123	C0041365
detection	T061	C1511790
non-small cell lung cancers	T191	C0007131
May	T079	C3812381
April	T079	C3715024
serum samples	T031	C1550100
non lung cancer	T191	C0006826
patients	T101	C0030705
patients	T101	C0030705
chronic obstructive pulmonary disesase	T047	C0024117
Blood samples	T031	C0178913
participant	T098	C0679646
analyzed	T062	C0936012
DR-70	T123	C0041365
level	T080	C0441889
patients	T101	C0030705
study	T062	C2603343
male	T098	C0025266
female	T098	C0043210
Histopathologically	T169	C0243140
patients	T101	C0030705
diagnosed	T060	C0430022
squamous cell lung cancer	T191	C0149782
adenocarcinoma	T191	C0001418
non-small cell lung cancer	T191	C0007131
mean serum DR-70	T123	C0041365
levels	T080	C0441889
lung cancer	T191	C0242379
patients	T101	C0030705
significantly higher	T033	C0243095
compared	T052	C1707455
non-cancerous	T033	C0243095
subjects	T098	C2349001
DR-70	T123	C0041365
clinical	T080	C0205210
sensitivity and specificity	T081	C0036668
optimal	T080	C2698651
cut off	T169	C1442160
disease	T047	C0012634
DR-70	T123	C0041365
level	T080	C0441889
DR-70	T123	C0041365
marker	T123	C0041365
measure	T081	C0079809
fibrin degradation products	T116	C0163275
cancers	T191	C0006826
high risk	T033	C0332167
lung cancer	T191	C0242379
patients	T101	C0030705
Catastrophic expenditure	T081	C0015318
impoverishment	T081	C0392762
patients	T101	C0030705
rare diseases	T047	C0678236
China	T083	C0008115
China	T083	C0008115
promoting	T052	C0033414
rare diseases	T047	C0678236
rare disease	T047	C0678236
orphan drugs	T121	C0013232
national planning	UnknownType	C0679910
studies	T062	C2603343
affordability	T081	C0814630
rare disease	T047	C0678236
patients	T101	C0030705
China	T083	C0008115
policy	T170	C0242456
recommendations	T078	C0034866
establishment	T080	C0443211
social security mechanism	T170	C0282574
rare diseases	T047	C0678236
China	T083	C0008115
poverty	T102	C0032854
diseases	T047	C0012634
rare diseases	T047	C0678236
Delphi method	T062	C0011216
Affordability	T081	C0814630
treatment	T061	C0087111
rare diseases	T047	C0678236
assessed	T052	C1516048
annual per capital income	T081	C0021162
catastrophic expenditure	T081	C0015318
impoverishment	T081	C0392762
expenditure	T081	C0015316
urban	T098	C1257890
rural residents	T098	C1257890
China	T083	C0008115
Assessed	T052	C1516048
annual per capital income	T081	C0021162
health expenditure	T081	C0015318
rare diseases	T047	C0678236
health expenditure	T081	C0015318
income	T081	C0021162
years	T079	C0439234
urban resident	T098	C1257890
rural residents	T098	C1257890
catastrophic expenditure	T081	C0015318
assessment	T052	C1516048
proportions	T081	C1709707
population	T098	C1257890
catastrophic expenditure	T081	C0015318
rare diseases	T047	C0678236
ill	T184	C0221423
medications	T170	C4284232
catastrophic health expenditure	T081	C0015318
impoverishment	T081	C0392762
expenditure	T081	C0015316
assessment	T052	C1516048
proportions	T081	C1709707
impoverishment	T081	C0392762
payment	T081	C0680264
urban	T098	C1257890
rural residents	T098	C1257890
rare diseases	T047	C0678236
people	T098	C1257890
poverty	T102	C0032854
affordability	T081	C0814630
treatment	T061	C0087111
rare disease	T047	C0678236
orphan drugs	T121	C0013232
poor	T080	C0542537
Residents	T098	C2347958
income levels	T080	C0870689
treatment	T061	C0087111
rare diseases	T047	C0678236
poverty	T102	C0032854
rare diseases	T047	C0678236
widespread	T082	C0205391
social security mechanism	T170	C0282574
rare disease	T047	C0678236
patients	T101	C0030705
payment	T081	C0680264
orphan drugs	T121	C0013232
Experimental study	T062	C0681814
pulmonary artery	T023	C0034052
sealing	T061	C1963784
vessel-sealing device	T074	C0025080
vessel-sealing devices	T074	C0025080
safety	T068	C0036043
video-assisted thoracoscopic surgery	T061	C0752151
feasibility	T080	C0205556
safety	T068	C0036043
sealing	T061	C1963784
pulmonary arteries	T023	C0034052
Enseal tissue-sealing device	T074	C0025080
Pulmonary arteries	T023	C0034052
beagle dogs	T015	C1296765
groups	T096	C1642385
in-vivo	T082	C1515655
sealing method	T170	C0449371
Enseal	T074	C0025080
ligation	T061	C0189722
proximal	T082	C0205107
ligation	T061	C0189722
distal	T082	C0205108
Enseal	T074	C0025080
pressure	T067	C0033095
tolerance	T080	C1704410
sealed	T169	C0587267
end	T082	C0444930
lobectomy	T061	C0023928
chronic-phase	T079	C0457343
sealed stumps	T074	C0025080
survival model	T008	C0599779
pulmonary arteries	T023	C0034052
dog	T015	C0012984
groups	T096	C1642385
survival	T052	C0038952
period	T079	C1948053
pulmonary arteries	T023	C0034052
Pressure	T067	C0033095
tolerance	T080	C1704410
sealed	T169	C0587267
end	T082	C0444930
pulmonary artery	T023	C0034052
sealed	T169	C0587267
ends	T082	C0444930
pressure	T067	C0033095
tolerance	T080	C1704410
lobectomy	T061	C0023928
dogs	T015	C0012984
pulmonary artery	T023	C0034052
groups	T096	C1642385
No	T033	C1513916
sealing	T061	C1963784
failure	T169	C0231174
pathological	T169	C1521733
findings	T033	C0243095
healing	T040	C0043240
persistent	T079	C0205322
hemostasis	T042	C0019116
sealed	T169	C0587267
ends	T082	C0444930
pulmonary arteries	T023	C0034052
weeks	T079	C0439230
survival	T052	C0038952
period	T079	C1948053
Pulmonary arteries	T023	C0034052
sealed	T169	C0587267
in vivo	T082	C1515655
Enseal device	T074	C0025080
pressure	T067	C0033095
tolerance	T080	C1704410
acute phase	T079	C0439557
persistent	T079	C0205322
hemostasis	T042	C0019116
weeks	T079	C0439230
Pulmonary artery	T023	C0034052
sealing	T061	C1963784
Enseal device	T074	C0025080
feasible	T080	C0205556
safe	T068	C0036043
thoracic surgery	T061	C0524832
Pathophysiology	T169	C0031847
treatment	T061	C0087111
prevention	T061	C0199176
ovarian hyperstimulation syndrome	T047	C0085083
Severe	T080	C0205082
ovarian hyperstimulation syndrome	T047	C0085083
OHSS	T047	C0085083
iatrogenic	T080	C0439669
condition	T080	C0348080
affects	T077	C4054723
women	T098	C0043210
treatment	T061	C0087111
assisted reproductive technology	T061	C0872104
review	T170	C0282443
aims	T078	C1947946
summarize	T170	C1706244
recent	T079	C0332185
evidence	T078	C3887511
pathophysiology	T169	C0031847
treatment	T061	C0087111
prevention	T061	C0199176
OHSS	T047	C0085083
pathophysiology	T169	C0031847
completely	T080	C0205197
understood	T041	C0162340
vascular endothelial growth factor	T116	C0078058
important	T080	C3898777
Human chorionic gonadotropin	T116	C1141639
thought	T041	C0039869
OHSS	T047	C0085083
occur	T052	C1709305
recent case reports	T170	C0007320
proven	T080	C0456369
contribution	T052	C1880177
attenuated	T052	C0599946
anti-Mullerian hormone	T116	C0066928
signalling pathway	T043	C0037083
CD11c	T116	C0023395
HLA-DR	T116	C0019764
dendritic cells	T025	C0011306
associated	T080	C0332281
interleukins	T116	C0021764
recently	T079	C0332185
contributors	T052	C1880177
pathogenesis	T046	C0699748
Treatment	T061	C0087111
supportive	T061	C0344211
based	T078	C1705938
consensus	T054	C0376298
statements	T078	C1710187
evidence	T078	C3887511
important	T080	C3898777
prevent	T169	C1292733
condition	T080	C0348080
identifying	T058	C1269815
women	T098	C0043210
at risk	T080	C1444641
allowing	T054	C0683607
clinician	T097	C0871685
implement	T052	C1708476
preventive strategies	T170	C0679716
including	T169	C0332257
GnRH antagonist	T121	C1268855
cycles	T079	C0001289
agonist	T121	C2987634
research	T062	C0035168
required	T169	C1514873
pathophysiology	T169	C0031847
condition	T080	C0348080
Clinicians	T097	C0871685
employ	T169	C0457083
strategies	T041	C0679199
prevent	T061	C0679698
OHSS	T047	C0085083
Eosinophilic Gastroenteritis	T047	C1262481
Rare	T080	C0522498
Cause	T169	C0015127
Recurrent Epigastric Pain	UnknownType	C0743544
Eosinophilic gastroenteritis	T047	C1262481
EGE	T047	C1262481
inflammatory disorder	T047	C1290884
gastrointestinal tract	T022	C0017189
characterized	T052	C1880022
eosinophilic infiltration	T046	C0333390
bowel wall	T023	C0021853
gastrointestinal disorders	T047	C0017178
wide spectrum of presentations	T033	C0243095
Diagnose	T033	C0011900
excluding	T169	C0332196
other	T080	C0205394
disorders	T047	C0012634
high	T080	C0205250
suspicion	T041	C0242114
report a case	T170	C0007320
year	T079	C0439234
old	T079	C0580836
man	T098	C0025266
history	T033	C0262926
sever epigastric pain	T184	C0232493
nausea	T184	C0027497
vomiting	T184	C0042963
few	T081	C0205388
days	T079	C0439228
before	T079	C0332152
admission	T058	C0030673
diagnosis	T033	C0011900
EGE	T047	C1262481
sonoelastography	T060	C1955929
sonourethrography	T060	C0581495
retrograde urethrography	T060	C0845989
evaluation	T058	C0220825
male	T032	C0086582
anterior urethral strictures	T190	C1720814
Retrograde urethrography	T060	C0845989
RUG	T060	C0845989
imaging modality	T169	C1275506
imaging	T060	C0011923
anterior urethral strictures	T190	C1720814
limitations	T169	C0449295
Sonourethrography	T060	C0581495
SUG	T060	C0581495
overcome	T052	C2983310
limitations	T169	C0449295
RUG	T060	C0845989
accurate results	T080	C0598285
imaging modality	T169	C1275506
planning the treatment	T170	C0599880
recurrence	T067	C0034897
stricture disease	T047	C0041974
spongiofibrosis	T046	C0016059
Sonoelastography	T060	C1955929
SE	T060	C1955929
newer technique	T062	C1519842
pathologies	T091	C0030664
efficacy	T080	C2348251
anterior urethral stricture disease	T190	C1720814
RUG	T060	C0845989
SUG	T060	C0581495
patients	T101	C0030705
anterior urethral stricture disease	T190	C1720814
RUG	T060	C0845989
SUG	T060	C0581495
SE	T060	C1955929
stricture	T047	C1389955
location	T082	C0450429
length	T081	C1444754
depth	T201	C1827571
spongiofibrosis	T046	C0016059
periurethral	T029	C3828581
pathologies	T091	C0030664
histopathological findings	T169	C0243140
diagnostic accuracy	T080	C0598285
SE	T060	C1955929
SUG	T060	C0581495
RGU	T060	C0845989
stricture	T047	C1389955
location	T082	C0450429
length	T081	C1444754
depth	T201	C1827571
spongiofibrosis	T046	C0016059
SE	T060	C1955929
SUG	T060	C0581495
accuracy rates	T080	C0443131
SE	T060	C1955929
intra-operative	T079	C0456904
stricture	T047	C1389955
length	T081	C1444754
SE	T060	C1955929
colour of bladder mucosa	T033	C0475705
cystoscopic examination	T060	C0401483
incision	T061	C0184898
SUG	T060	C0581495
colour of the bladder mucosa	T033	C0475705
incision	T061	C0184898
cystoscopy	T060	C0010702
SE	T060	C1955929
histopathology findings	T169	C0243140
degree of fibrosis	T060	C4285457
Sonoelastography	T060	C1955929
stricture site and length	T082	C1254362
RUG	T060	C0845989
SUG	T060	C0581495
spongiofibrosis	T046	C0016059
prognostic factor	T201	C1514474
stricture recurrence	T067	C0034897
accurately	T080	C0443131
SUG	T060	C0581495
Changes	T169	C0392747
risk factors	T033	C0035648
young	T079	C0332239
male	T032	C0086582
suicide	T033	C0038661
Newcastle upon Tyne	T083	C0017446
Aims	T078	C1947946
method	T170	C0025663
differences	T080	C1705242
patterns of suicide	T033	C0038661
young	T079	C0332239
men	T098	C0025266
decades	T081	C2981279
implications	T080	C0205556
suicide	T033	C0038661
prevention	T080	C2700409
Data	T078	C1511726
suicides	T033	C0038661
open verdicts	T064	C0680738
men	T098	C0025266
coroner's records	T170	C0282574
Newcastle upon Tyne	T083	C0017446
analysed	T062	C0936012
SPSS software	T073	C0037585
Results	T169	C1274040
increase	T169	C0442805
suicide rates	T033	C1822575
decade	T081	C2981279
decade	T081	C2981279
associated with	T080	C0332281
increasing	T169	C0442808
proportion	T081	C1709707
single	T081	C0205171
men	T098	C0025266
living alone	T033	C0260794
unemployment	T033	C0041674
consumption of alcohol	T055	C0001948
hanging	T037	C0544691
previous	T079	C0205156
suicide attempt	T033	C0038663
history of treatment	UnknownType	C0814462
mental illness	T048	C0004936
Clinical	T080	C0205210
implications	T080	C0205556
study	T062	C2603343
interventions	T061	C0184661
focus	T041	C0589098
young	T079	C0332239
males	T032	C0086582
suicide	T033	C0038661
prevention area	T080	C2700409
field of public health	T170	C3244304
reducing	T080	C0392756
access	T082	C0444454
means	T077	C1704970
suicide	T033	C0038661
reducing	T080	C0392756
alcohol use	T055	C0001948
support	T077	C1521721
relationship	T080	C0439849
difficulties	T080	C0332218
engagement	T058	C3508152
mental health services	T058	C0025355
management	T058	C0376636
chronic illness	T047	C0008679
Social cognition	T054	C0871381
schizophrenia	T048	C0036341
Factor structure	T081	C0870541
emotion	T041	C0013987
processing	T041	C0025361
theory of mind	T078	C0935573
Factor analytic studies	T081	C0085801
social cognition	T054	C0871381
schizophrenia	T048	C0036341
results	T169	C1274040
quality of measures	T170	C3242457
Phase 3	T079	C0439561
Social Cognition	T054	C0871381
Psychometric Evaluation (SCOPE) Study	T060	C0033920
psychometrically	T060	C0033920
sound measures	T060	C0430022
social cognition	T054	C0871381
study	T062	C2603343
examine	T033	C0332128
factor structure	T081	C0870541
social cognition	T054	C0871381
schizophrenia	T048	C0036341
psychometrically	T060	C0033920
sound measures	T060	C0430022
examine	T033	C0332128
stability	T080	C0205360
factor structure	T081	C0870541
study	T062	C2603343
factor structure	T081	C0870541
social cognition	T054	C0871381
schizophrenia	T048	C0036341
healthy controls	T080	C2986479
examine	T033	C0332128
factors	T081	C0870541
outcome measures	T081	C0086749
social functioning	T054	C0037395
symptoms	T184	C1457887
Results	T169	C1274040
one-factor model	T170	C0282574
patient	T101	C0030705
healthy control	T080	C2986479
visits	T058	C1512346
visits	T058	C1512346
associated with	T080	C0332281
negative symptoms	T184	C1457887
schizophrenia	T048	C0036341
sample	T167	C0370003
social functioning	T054	C0037395
groups	T098	C1257890
study	T062	C2603343
visits	T058	C1512346
Assessment	T058	C0220825
Residual Disease	T191	C0543478
Molecular Breast Imaging	T060	C2985547
Patients	T101	C0030705
Neoadjuvant Therapy	T061	C0600558
Molecular	T080	C1521991
Subtypes	T185	C0449560
Assessment	T058	C0220825
residual disease	T191	C0543478
neoadjuvant therapy	T061	C0600558
breast cancer	T191	C0006142
breast	T023	C0006141
imaging	T060	C0011923
study	T062	C2603343
evaluates	T058	C0220825
accuracy	T080	C0443131
molecular breast imaging	T060	C2985547
MBI	T060	C2985547
cadmium zinc telluride	T197	C1258740
detectors	T073	C0180392
residual disease	T191	C0543478
neoadjuvant therapy	T061	C0600558
patients	T101	C0030705
breast cancer	T191	C0006142
Clinical data	T170	C1516606
imaging	T060	C0011923
surgical	T169	C0038895
pathological	T169	C1521733
findings	T033	C0243095
women	T098	C0043210
breast cancer	T191	C0006142
neoadjuvant therapy	T061	C0600558
MBI	T060	C2985547
findings	T033	C0243095
correlated	T080	C1707520
surgical pathology results	T170	C1710255
Accuracy	T080	C0443131
MBI	T060	C2985547
complete pathological response	T033	C4050242
size	T082	C0456389
residual disease	T191	C0543478
molecular	T080	C1521991
subtypes	T185	C0449560
size	T082	C0456389
MBI	T060	C2985547
correlated	T080	C1707520
pathology	T169	C0205469
correlation	T080	C1707520
triple negative	T191	C3539878
HER2/neu positive	T201	C2348909
subtypes	T185	C0449560
patients	T101	C0030705
complete pathological response	T033	C4050242
sensitivity	T081	C1511883
specificity	T081	C0037791
MBI	T060	C2985547
residual disease	T191	C0543478
confidence interval	T081	C0009667
CI	T081	C0009667
CI	T081	C0009667
triple negative	T191	C3539878
HER2/neu positive	T201	C2348909
sensitivity	T081	C1511883
specificity	T081	C0037791
CI	T081	C0009667
CI	T081	C0009667
accuracy	T080	C0443131
MBI	T060	C2985547
residual disease	T191	C0543478
neoadjuvant treatment	T061	C0600558
molecular	T080	C1521991
subtype	T185	C0449560
Accuracy	T080	C0443131
triple negative	T191	C3539878
HER2/neu positive	T201	C2348909
subtypes	T185	C0449560
relationship	T080	C0439849
histological	T169	C0205462
prostatitis	T047	C0033581
lower urinary tract symptoms	T184	C0574785
sexual function	T040	C0278092
prospective analysis	T062	C0033522
assessed	T052	C1516048
effect	T080	C1280500
histological	T169	C0205462
prostatitis	T047	C0033581
lower urinary tract	T022	C0729866
functions	T169	C0542341
sexual function	T040	C0278092
patients	T101	C0030705
separated	T080	C0443299
groups	T078	C0441833
histologically	T169	C0205462
observed	T169	C1441672
prostatitis	T047	C0033581
Group A	T078	C0441833
no prostatitis	T033	C0243095
Group B	T078	C0441833
biopsy	T060	C0005558
outcomes	T169	C1274040
International prostate symptom score	T170	C1998280
international index of erectile function-5 scores	T201	C2959364
maximal	T033	C0429784
average flow rate	T033	C0429785
residual urine volumes	T033	C0429774
compared	T052	C1707455
groups	T078	C0441833
significant	T081	C0237881
difference	T080	C1705242
baseline	T081	C1442488
age	T032	C0001779
body mass index value	T201	C1305855
prostate volume	T081	C1441416
prostate-specific antigen levels	T059	C0201544
maximal	T033	C0429784
average flow rate	T033	C0429785
post-void	T079	C1439885
residual urine volume	T033	C0429774
Mean	T081	C0444504
international prostate symptom score	T170	C1998280
patients	T101	C0030705
prostatitis	T047	C0033581
numerically	T081	C0243174
significantly higher	T081	C4055637
without	T080	C0332288
prostatitis	T047	C0033581
Mean	T081	C0444504
international index of erectile function-5 score	T201	C2959364
prostatitis	T047	C0033581
group	T078	C0441833
significantly lower	T081	C4055638
without	T080	C0332288
prostatitis	T047	C0033581
Histological	T169	C0205462
prostatitis	T047	C0033581
affected	T169	C0392760
sexual function	T040	C0278092
patients	T101	C0030705
major	T080	C0205164
risk factor	T033	C0035648
sexual dysfunction	T047	C0549622
effect	T080	C1280500
lower urinary tract symptoms	T184	C0574785
Median	T081	C0876920
Waiting Time	T079	C0814636
Development	T169	C1527148
Validation	T062	C1519941
Risk Model	UnknownType	C0679713
Predict	T078	C0681842
Outcomes	T169	C1274040
Kidney	T023	C0022646
Transplant Waiting List	T170	C3272315
Median	T081	C0876920
historical	T079	C0019659
time	T079	C0040223
kidney transplant	T061	C0022671
risks	T078	C0035647
death	T040	C0011065
removal from the waiting list	T033	C0420299
risk model	UnknownType	C0679713
calculate	T052	C1441506
outcomes	T080	C0085415
kidney transplant	T061	C0022671
candidates	T098	C0524355
information	T078	C1533716
differs	T080	C1705242
median	T081	C0876920
time	T079	C0814636
transplant	T061	C0022671
Data	T078	C1511726
obtained	T169	C1301820
US Scientific Registry	T170	C0034975
Transplant Recipients	T101	C0376387
retrospective cohort	T062	C2985505
adults	T100	C0001675
kidney transplant	T061	C0022671
Predictors	T033	C0035648
age	T032	C0001779
sex	T032	C0079399
blood type	T201	C1383165
calculated	T059	C1443182
panel-reactive antibodies	T059	C1141951
donation	T061	C0411257
service area	T083	C0007403
dialysis	T061	C0011946
duration	T079	C0449238
comorbid conditions	T033	C1275743
body mass index	T201	C1305855
Outcomes	T080	C0085415
living donor	T098	C0348050
transplant	T061	C0022671
death	T040	C0011065
removal from the list	T033	C0420299
due to	T169	C0678226
deteriorating	T080	C0332271
medical	T169	C0205476
condition	T080	C0348080
removal	T033	C0420299
due to	T169	C0678226
other reasons	T033	C3840932
calculated	T169	C0444686
hazards	T080	C0598697
possible	T033	C0332149
outcomes	T080	C0085415
cumulative	T080	C1511559
incidence	T081	C0021149
function	T039	C0031843
candidate	T098	C0524355
risk	T078	C0035647
methodology	T078	C3266812
Discrimination	T041	C0012632
calibration	T081	C0006751
assessed	T052	C1516048
through	T169	C0332273
C statistics	UnknownType	C0681933
calibration	T081	C0006751
plots	T169	C1301732
each	T081	C1457900
cause	T169	C0015127
specific	T080	C0205369
Cox proportional hazard model	T081	C0018623
C statistics	UnknownType	C0681933
Calibration	T081	C0006751
plots	T169	C1301732
good	T080	C0205170
calibration	T081	C0006751
risk model	UnknownType	C0679713
probability	T081	C0033204
possible	T033	C0332149
outcomes	T080	C0085415
12 years	T079	C0439234
candidate's	T098	C0524355
characteristics	T080	C1521970
median	T081	C0876920
waiting time	T079	C0814636
candidate's	T098	C0524355
donation	T061	C0411257
service area	T083	C0007403
risk model	UnknownType	C0679713
relevant	T080	C2347946
information	T078	C1533716
median	T081	C0876920
waiting time	T079	C0814636
given	T077	C1442162
transplant center	T093	C1708333
model	T081	C0033204
updated	T079	C1519814
create	T052	C1706214
recent	T079	C0332185
outcomes	T080	C0085415
changes	T169	C0392747
allocation	T052	C1706778
policy	T170	C0242456
conversations	T054	C0871703
initiated	T169	C1704686
transplant	T061	C0022671
candidates	T098	C0524355
Tead1	T028	C1420679
expression	T045	C0017262
Peripheral Myelin Protein 22	T028	C1418677
Schwann cell development	T043	C1817645
Schwann cells	T025	C0036387
myelinating glia	T025	C0027836
peripheral nervous system	T022	C0206417
myelin sheath	T026	C0026973
peripheral neuropathy	T047	C0031117
copy number variant	T086	C1511518
Peripheral Myelin Protein 22 (PMP22) gene	T028	C1418677
duplication	T045	C0017261
chromosome 17	T026	C0008659
Charcot-Marie-Tooth Disease	T047	C0007959
CMT1A	T047	C0007959
Rodent models	T050	C1519106
CMT1A	T047	C0007959
Pmp22	T028	C1418677
overexpression	T045	C0017262
CMT1A	T047	C0007959
phenotype	T032	C0031437
Mechanistic	T169	C0441712
studies	T062	C2603343
Pmp22	T028	C1418677
regulation	T045	C0017263
enhancers	T114	C0014290
Sox10	T116	C1571654
SRY sex determining region Y-box 10	T116	C1571654
Egr2	T116	C0064419
Krox20	T116	C0064419
Early growth response protein 2	T116	C0064419
transcription factors	T116	C0040648
myelinated nerves	T026	C0027750
transcription factors	T116	C0040648
induce	T169	C0205263
Pmp22	T028	C1418677
expression	T045	C0017262
Schwann cell development	T043	C1817645
myelination	T043	C0596991
Pmp22	T028	C1418677
enhancers	T114	C0014290
cell type-specificity	T044	C1148560
nerve injury	T037	C0161479
development	T169	C1527148
Pmp22	T028	C1418677
enhancers	T114	C0014290
active	T169	C0205177
histone modifications	T044	C1156199
lost	T169	C0745777
injury	T037	C3263723
enhancers	T114	C0014290
development	T169	C1527148
Pmp22	T028	C1418677
upregulation	T044	C0041904
Pmp22	T028	C1418677
enhancers	T114	C0014290
binding motifs	T116	C1956035
TEA domain	T116	C0220134
Tead	T116	C0220134
transcription factors	T116	C0040648
Hippo signaling pathway	T043	C3158583
Tead1	T028	C1420679
Yap	T028	C1424135
Taz	T028	C1336578
Pmp22	T028	C1418677
expression	T045	C0017262
expression	T045	C0017262
Egr2	T028	C1414315
Tead1	T028	C1420679
Pmp22	T028	C1418677
Egr2	T028	C1414315
enhancers	T114	C0014290
development	T169	C1527148
Tead1	T028	C1420679
binding	T044	C1167622
induced	T169	C0205263
myelination	T043	C0596991
Pmp22	T028	C1418677
expression	T045	C0017262
data	T078	C1511726
Tead1	T028	C1420679
regulator	T028	C0017362
Pmp22	T028	C1418677
expression	T045	C0017262
development	T169	C1527148
Sox10	T028	C1420317
Egr2	T028	C1414315
Neutrophil gelatinase-associated lipocalin	T116	C1870887
triphasic	T079	C0205185
rat model	T008	C0599779
adenine	T114	C0001407
induced	T169	C0205263
kidney injury	T037	C0160420
NGAL	T116	C1870887
biomarkers	T201	C0005516
renal tubulointerstitial insult	T047	C0041349
adenine	T114	C0001407
NGAL	T116	C1870887
biomarker	T201	C0005516
acute kidney injury	T037	C2609414
chronic interstitial disease	T047	C0238304
NGAL	T116	C1870887
levels	T080	C0441889
stable	T080	C0205360
through	T169	C0332273
chronic phase	T079	C0457343
adenine model	T008	C0599779
Study group	T098	C2348561
rats	T015	C0034693
adenine	T114	C0001407
diet	T168	C0012155
control group	T096	C0009932
rats	T015	C0034693
regular diet	T056	C0184625
Blood	T031	C0178913
urine samples	T031	C1610733
urea	T109	C0041942
creatinine	T109	C0010294
NGAL	T116	C1870887
rat	T015	C0034693
beginning	T079	C0439659
study	T062	C0008972
Kidney	T023	C0022646
slices	T167	C1519355
rats	T015	C0034693
stained	T059	C0487602
Hematoxylin-eosin	T059	C0523207
HE	T059	C0523207
β-actin	T116	C0005186
stainings	T059	C0487602
Serum urea	T034	C2945624
creatinine	T059	C0201975
NGAL	T116	C1870887
levels	T080	C0441889
urinary NGAL/creatinine ratio	T201	C1316828
baseline	T081	C1442488
control group	T096	C0009932
statistically significant	T081	C0237881
intervals	T079	C1272706
Tubulointerstitial	T047	C0041349
adenine	T114	C0001407
rats	T015	C0034693
rats	T015	C0034693
adenine	T114	C0001407
serum urea	T034	C2945624
creatinine	T059	C1318439
NGAL	T116	C1870887
levels	T080	C0441889
urinary NGAL/creatinine ratio	T201	C1316828
triphasic pattern	T033	C1336825
kidney injury	T037	C0160420
acute phase	T079	C0439557
adenine	T114	C0001407
diet	T168	C0012155
partial	T081	C0728938
recovery	T040	C2004454
phase	T079	C0205390
regular diet	T056	C0184625
chronic kidney disease	T047	C1561643
phase	T079	C0205390
renal function	T042	C0232804
NGAL	T116	C1870887
biomarker	T201	C0005516
acute kidney injury	T037	C2609414
chronic kidney disease	T047	C1561643
tubulointerstitial	T047	C0041349
rat model	T008	C0599779
Talking	T056	C0234856
Keeping Silent	T080	C0443304
Parental	T099	C0030551
Mental Health Problems	T033	C1446377
Grounded Theory	T170	C1510611
Parents	T099	C0030551
Decision Making	T041	C0011109
Experiences	T041	C0596545
Children	T100	C0008059
grounded theory	T170	C1510611
study	T062	C2603343
parents	T099	C0030551
experiences	T041	C0596545
children's	T100	C0008059
parental	T099	C0030551
mental health	T041	C0025353
concerns	T078	C2699424
parents	T099	C0030551
severe	T080	C0205082
mental health difficulties	T033	C1446377
study	T062	C2603343
findings	T033	C0243095
social processes	T068	C0871384
parents	T099	C0030551
talk	T056	C0234856
children	T100	C0008059
parental	T099	C0030551
mental health issues	T033	C1446377
Protecting	T041	C3146231
being protected	T041	C3146231
Responding	T032	C0871261
children's	T100	C0008059
search	T052	C1706202
understanding	T041	C0162340
Prioritizing	T079	C0549179
family life	T054	C0015608
Relating to others	T053	C0004927
findings	T033	C0243095
clinical practice	T058	C1254363
research	T062	C0035168
family-orientated services	T058	C1254363
parents	T099	C0030551
experience	T041	C0596545
parental	T099	C0030551
mental health problems	T033	C1446377
case	T077	C1706256
bilateral	T082	C0238767
pneumothoraces	T047	C0032326
tracheostomy	T061	C0040590
advanced	UnknownType	C0679246
laryngeal cancer	T191	C0007107
Pneumothorax	T047	C0032326
complication	T046	C0009566
tracheostomy	T061	C0040590
report	T058	C0700287
bilateral	T082	C0238767
pneumothoraces	T047	C0032326
tracheostomy	T061	C0040590
advanced	UnknownType	C0679246
laryngeal cancer	T191	C0007107
patient	T101	C0030705
man	T032	C0086582
clinic	T073	C0442592
evaluation	T058	C0220825
treatment	T061	C0087111
laryngeal tumor	T191	C0023055
Laryngeal endoscopy	T060	C0023072
limited movement	T033	C0243095
bilateral vocal cords	T023	C0459363
computed tomography	T060	C0040405
tumor	T191	C0027651
lesion	T033	C0221198
vocal cords	T023	C0042930
subglottic area	T023	C0456475
days	T079	C0439228
first visit	T033	C4287881
patient	T101	C0030705
respiratory difficulty	T184	C0013404
emergency tracheostomy	T061	C0498305
airway management	T061	C0150126
procedure	T061	C0543467
hyperventilating	T033	C0020578
respiratory discomfort	T033	C4062414
chest pain	T184	C0008031
mediastinal	T029	C0025066
air leak	T047	C2242512
suspected	T080	C0332147
pneumothorax	T047	C0032326
tracheostomy	T061	C0040590
Chest X-ray	T060	C0039985
bilateral	T082	C0238767
pneumothoraces	T047	C0032326
inserted	T058	C0441587
bilateral	T082	C0238767
chest	T029	C0817096
drainage tubes	T074	C0184114
stabilized	T033	C0184512
respiratory condition	T033	C4062804
pathogenesis	T046	C0699748
bilateral	T082	C0238767
pneumothoraces	T047	C0032326
weakened	T080	C1762617
alveolar walls	T023	C0225695
long-term	T079	C0443252
smoking	T055	C0037369
rise	T169	C0442805
airway pressure	T201	C0428719
airway constriction	T184	C0231818
neck-extended position	T082	C0577754
hyperventilation	T033	C0020578
tracheostomy	T061	C0040590
Arsenic Triglutathione	T116	C0596621
As(GS)3	T116	C0596621
Transport	T043	C0005528
Multidrug Resistance Protein 1	T116	C1451297
MRP1	T116	C1451297
ABCC1	T116	C1451297
Modified	T169	C0392747
Phosphorylation	T044	C1158886
Tyr920/Ser921	T087	C0002518
Glycosylation	T044	C0376322
Asn19/Asn23	T087	C0002518
ATP-binding cassette (ABC) transporter	T116	C0242738
multidrug resistance protein 1	T116	C1451297
MRP1	T116	C1451297
ABCC1	T116	C1451297
cellular	T025	C0007634
export	T067	C0699789
diverse	T080	C1880371
array	T082	C1510941
xenobiotics	T123	C0043335
endogenous	T169	C0205227
compounds	T167	C0439861
Arsenic	T121	C0003818
human	T016	C0086418
carcinogen	T131	C0007090
high-affinity	T080	C0205556
MRP1	T116	C1451297
substrate	T167	C3891814
arsenic triglutathione	T116	C0596621
As(GS)3	T116	C0596621
As(GS)3	T116	C0596621
transport	T043	C0005528
kinetics	T090	C2825046
MRP1	T116	C1451297
membrane	T026	C0596901
vesicles	T026	C1622418
prepared	T052	C1521827
human	T016	C0086418
embryonic	T018	C0013935
kidney	T023	C0022646
293 (HEK)	T025	C2936239
Km	T081	C1706312
Vmax	T067	C1710637
HeLa	T025	C0018873
Km	T081	C1706312
Vmax	T067	C1710637
cells	T025	C0007634
Mutant	T116	C1564139
MRP1	T116	C1451297
glycosylation	T044	C0376322
Asn19/23/1006Gln	T087	C0002518
(SF)-MRP1	T116	C1451297
expressed	T045	C1171362
HEK293	T025	C2936239
HeLa cells	T025	C0018873
Km	T081	C1706312
Vmax	T067	C1710637
As(GS)3	T116	C0596621
similar	T080	C2348205
HeLa wild-type	T025	C0018873
MRP1	T116	C1451297
prepared	T052	C1521827
presence	T033	C0150312
phosphatase inhibitors	T121	C0597217
WT-	T116	C1451297
SF-MRP1	T116	C1451297
membrane	T026	C0596901
vesicles	T026	C1622418
Km	T081	C1706312
As(GS)3	T116	C0596621
cell line	T025	C0682523
Kinetic parameters	T033	C0449381
As(GS)3	T116	C0596621
HEK	T025	C2936239
Asn19/23Gln-MRP1	T116	C1451297
similar	T080	C2348205
HeLa	T025	C0018873
HEK	T025	C2936239
SF-MRP1	T116	C1451297
HeLa-WT	T025	C0018873
MRP1	T116	C1451297
single	T081	C0205171
glycosylation	T044	C0376322
mutants	T116	C1564139
HEK-WT	T025	C2936239
Mutation	T045	C0026882
potential	T080	C3245505
phosphorylation	T044	C1158886
sites	T082	C0205145
HEK	T025	C2936239
Tyr920Phe/Ser921Ala-MRP1	T116	C1451297
transported	T043	C0005528
As(GS)3	T116	C0596621
HeLa-WT	T025	C0018873
MRP1	T116	C1451297
HEK	T025	C2936239
Tyr920Phe-	T116	C1451297
Ser921Ala-MRP1	T116	C1451297
mutants	T116	C1564139
similar	T080	C2348205
HEK-WT	T025	C2936239
MRP1	T116	C1451297
results	T033	C0683954
Asn19/Asn23	T087	C0002518
glycosylation	T044	C0376322
Tyr920/Ser921	T087	C0002518
phosphorylation	T044	C1158886
altering	T169	C0392747
kinetics	T090	C2825046
MRP1	T116	C1451297
As(GS)3	T116	C0596621
transport	T043	C0005528
kinetics	T090	C2825046
As(GS)3	T116	C0596621
transport	T043	C0005528
HEK	T025	C2936239
Asn19/23Gln/Tyr920Glu/Ser921Glu	T087	C0002518
similar	T080	C2348205
HEK-WT	T025	C2936239
MRP1	T116	C1451297
phosphorylation	T044	C1158886
influence	T077	C4054723
Asn19/23Gln	T087	C0002518
glycosylation	T044	C0376322
MRP1	T116	C1451297
glycosylation	T044	C0376322
phosphorylation	T044	C1158886
phosphorylation	T044	C1158886
Tyr920	T087	C0002518
Ser921	T087	C0002518
MRP1	T116	C1451297
lower-affinity	T080	C0205556
higher-capacity	T080	C0205556
As(GS)3	T116	C0596621
transporter	T116	C0596902
arsenic	T121	C0003818
detoxification	T043	C4235382
broad	T082	C0332464
concentration	T081	C1446561
range	T081	C1514721
Naphthohydroquinones	T121	C1254351
naphthoquinones	T109	C0027388
anthraquinones	T109	C0003174
naphthohydroquinone	T121	C1254351
dimer	T104	C0596448
isolated	T169	C0205409
aerial parts	T002	C1136056
Morinda parvifolia	T002	C1474894
cytotoxic effects	T049	C0596402
up-regulation	T045	C0162493
p53	T028	C0079419
unknown	T080	C0439673
compounds	T121	C1254351
morindaparvins C-G	T121	C1254351
naphthohydroquinones	T121	C1254351
naphthoquinone	T109	C0027388
anthraquinone	T109	C0003174
naphthohydroquinone	T121	C1254351
dimer	T104	C0596448
quinones	T109	C0034435
compounds	T121	C1254351
isolated	T169	C0205409
aerial parts	T002	C1136056
Morinda parvifolia	T002	C1474894
morindaparvins C	T121	C1254351
D	T121	C1254351
E	T121	C1254351
F	T121	C1254351
G	T121	C1254351
spectroscopic	T059	C0037812
X-ray diffraction analysis	T059	C0599643
methyl 4-hydroxy-1,6-dimethoxy-naphthalene-2-carboxylate	T121	C1254351
methyl 4,8-dihydroxy-1-methoxy-naphthalene-2-carboxylate	T121	C1254351
3-amino-6-methoxy-2-methoxycarbonyl-1,4-naphthoquinone	T121	C1254351
1,4-dihydroxy-7-hydroxymethyl-anthraquinone	T121	C1254351
dimethyl 1,1'-dihydroxy-4,4',7,7'-tetramethoxy-2,2'-binaphthalene-3,3'-dicarboxylate	T121	C1254351
Naphthoquinones	T109	C0027388
naphthohydroquinone	T121	C1254351
dimers	T104	C0596448
unknown	T080	C0439673
genus	T185	C1708235
Morinda	T002	C1010821
compounds	T121	C1254351
tested	T169	C0039593
cytotoxicity	T049	C0596402
human	T016	C0086418
cancer cell lines	T025	C0085983
HeLa	T025	C0018873
A2780	T025	C0085983
Ketr3	T025	C0085983
MCF-7	T025	C0596890
effects	T080	C1280500
p53	T028	C0079419
activated	T052	C1879547
transcription	T045	C0040649
naphthoquinones	T109	C0027388
moderate	T080	C1881878
cytotoxic effects	T049	C0596402
IC50	T081	C0600495
ranging	T081	C1514721
up-regulation	T045	C0162493
p53	T028	C0079419
transcriptional activity	T045	C0162493
Identification	T041	C0020792
SAR	T080	C0038477
Evaluation	T058	C0220825
Hemozoin	T109	C0062496
Inhibiting	T052	C3463820
Benzamides	T109	C0005029
Active	T169	C0205177
Plasmodium falciparum	T204	C0032150
Quinoline	T109	C0034423
antimalarials	T121	C0003374
target	T169	C1521840
hemozoin	T109	C0062496
formation	T169	C1522492
cytotoxic	T169	C1511636
accumulation	T033	C4055506
ferriprotoporphyrin IX	T109	C0015877
Fe(III)PPIX	T109	C0015877
SAR	T080	C0038477
models	T170	C3161035
β-hematin	T109	C0062496
inhibition	T052	C3463820
parasite	T204	C0030498
activity	T052	C0441655
cellular mechanisms	T044	C1148560
compound class	T170	C0456387
investigations	T033	C0243095
hemozoin	T109	C0062496
inhibiting	T052	C3463820
chemotypes	T121	C1254351
benzamide	T109	C0053139
analogues	T104	C0002776
HTS	T059	C2718003
purchased	T052	C0870238
synthesized	T052	C1883254
derivatives containing an electron deficient aromatic ring	T104	C0243072
flat conformations	T082	C0026377
π-π interactions	T169	C1704675
Fe(III)PPIX	T109	C0015877
inhibited	T080	C0311403
β-hematin	T109	C0062496
formation	T169	C1522492
analogues	T104	C0002776
nanomolar	T081	C0439282
parasite	T204	C0030498
activity	T052	C0441655
CQ	T109	C0008269
cross-resistance	T046	C2363980
cytotoxicity	T049	C0596402
in vitro	T080	C1533691
microsomal	T080	C1979928
stability	T080	C0205360
analogues	T104	C0002776
inhibited	T080	C0311403
hemozoin	T109	C0062496
formation	T169	C1522492
Plasmodium falciparum	T204	C0032150
levels	T080	C0441889
heme	T109	C0018966
quinolines	T109	C0034424
introduction	T169	C0579004
amine side chains	T104	C1254350
benzamide	T109	C0053139
accumulation	T033	C4055506
parasite	T204	C0030498
data	T078	C1511726
relationships	T080	C0439849
heme binding	T044	C1148616
heme	T109	C0018966
levels	T080	C0441889
cellular accumulation	T043	C0007613
in vitro	T080	C1533691
activity	T052	C0441655
novel	T080	C0205314
antimalarials	T121	C0003374
Shear modulus	T081	C0392762
structured	T082	C0678594
electrorheological fluid	T167	C1704353
mixtures	T167	C0439962
immiscible blends	T167	C0439861
electric field	T070	C0337037
periodic	T079	C0332182
structures	T082	C0678594
electrodes	T074	C0013812
shear	T070	C3825679
structures	T082	C0678594
tilt	T080	C1711426
elastic	T169	C0681018
electric energy	T070	C0013790
two-dimensional	T081	C0439534
stripe structure	T082	C0678594
Maxwell stress	T070	C0038442
expression	T078	C2911684
shear modulus	T081	C0392762
electric field	T070	C0337037
composition	T070	C1882370
dielectric properties	T081	C0596437
blend	T167	C0439861
interfacial tension	T070	C2713544
effect of	T080	C1704420
electric field	T070	C0337037
derivation	T080	C1441547
scaling law	T170	C1947938
wavelength	T081	C0449819
structure	T082	C0678594
electric field	T070	C0337037
Sequence-specific DNA binding	T045	C1624609
long hairpin	T104	C1254350
pyrrole-imidazole polyamides	T109	C0029224
8-amino-3,6-dioxaoctanoic acid	T109	C0029224
aqueous solubility	T081	C0597682
designed	T052	C1707689
synthesized	T052	C1883254
N-methylpyrrole (Py)-N-methylimidazole (Im) polyamides	T109	C0029224
9-bp sequences	T086	C0004793
DNA-binding	T045	C1148673
affinities	T070	C1510827
sequence	T086	C0004793
specificities	T081	C0037791
SPR	T063	C0597731
Bind-n-Seq analyses	T062	C0936012
design	T052	C1707689
polyamide 1	T109	C0029224
model	T170	C3161035
Py	T109	C0383659
Im	T109	C0044472
β-alanine	T116	C0000392
twist	T082	C0231467
DNA	T114	C0012854
helices	T082	C1254362
Polyamides 2 and 3	T109	C0029224
8-amino-3,6-dioxaoctanoic acid	T109	C0029224
AO	T109	C0029224
linker	T109	C0029224
Py-Im polyamides	T109	C0029224
Py	T109	C0383659
Py - Im hairpin motifs	T104	C1254350
Im	T109	C0044472
tandem hairpin	T104	C1254350
AO	T109	C0029224
linker element	T109	C0029224
2-bp	T086	C0004793
hairpin motifs	T104	C1254350
AO	T109	C0029224
fail	T169	C0231175
bind	T052	C1145667
sequence	T086	C0004793
polyamide 4	T109	C0029224
AO	T109	C0029224
hairpin form	T082	C1254362
motif	T082	C1254362
KD value	T081	C0392762
Polyamide 5	T109	C0029224
β-alanine-β-alanine	T116	C0000392
AO	T109	C0029224
polyamide 2	T109	C0029224
synthesized	T052	C1883254
comparison	T052	C1707455
aqueous solubilities	T081	C0597682
nuclear localization	T038	C1659087
polyamides	T109	C0029224
results	T169	C1274040
AO	T109	C0029224
core	T082	C0444669
Py-Im polyamide compounds	T109	C0029224
Causes of Death	T033	C0007465
Children	T100	C0008059
Aged	T032	C0001779
Years	T079	C1510829
Old	T079	C0580836
Ethiopia	T083	C0015024
mortality among children	T081	C0008083
trend	T079	C1521798
improvements	T077	C2986411
living standard	T081	C0080190
challenges	T058	C0805586
children	T100	C0008059
African countries	T083	C0454695
Sub-Saharan Africa	T083	C0001738
global	T080	C2348867
child mortality	T081	C0008083
objective	T170	C0018017
magnitude	T081	C1704240
distribution	T169	C1704711
causes of death	T033	C0007465
children	T100	C0008059
aged	T032	C0001779
population	T098	C1257890
verbal	T080	C0439824
autopsy	T060	C0004398
period	T079	C1948053
September	T079	C3828193
rural	T082	C0178837
urban	T082	C0178876
kebeles	T098	C1257890
kebeles	T098	C1257890
district	T083	C0001567
data	T078	C1511726
Kersa HDSS database	T170	C0282574
study	T062	C2603343
population	T098	C1257890
children	T100	C0008059
aged	T032	C0001779
period	T079	C1948053
age	T032	C0001779
questionnaires	T170	C0034394
Data	T078	C1511726
SPSS database	T170	C0282574
STATA	T170	C0282574
deaths	T033	C1306577
period	T079	C1948053
death rate	T081	C0205848
population	T098	C1257890
age group	T100	C0027362
study	T062	C2603343
period	T079	C1948053
death rate	T081	C0205848
populations	T098	C1257890
females	T032	C0086287
males	T032	C0086582
deaths	T033	C1306577
study	T062	C2603343
malnutrition	T047	C0162429
intestinal infectious diseases	T047	C0178238
acute lower respiratory infections	T047	C0238990
causes of death	T033	C0007465
causes of death	T033	C0007465
classification	T185	C0008902
injuries	T037	C0043251
cause of death	T033	C0007465
communicable diseases	T047	C0009450
deaths	T033	C1306577
causes of death	T033	C0007465
classification	T185	C0008902
malnutrition	T047	C0162429
intestinal infectious diseases	T047	C0178238
acute lower respiratory infections	T047	C0238990
causes of death	T033	C0007465
causes of death	T033	C0007465
communicable diseases	T047	C0009450
injuries	T037	C0043251
causes of death	T033	C0007465
mortality	T081	C0008083
causes of death	T033	C0007465
inferential analysis	T062	C0936012
prevention	T061	C0033144
management	T058	C0376636
infectious diseases	T047	C0009450
Naïve	T025	C3641721
CD8(+) T cell	T025	C0242629
tumor	T191	C0027651
specific	T080	C0205369
cytotoxic effectors	T025	C3641722
remedy	T077	C1880198
TGF-β	T116	C0040690
immunosuppression	T047	C4048329
tumor microenvironment	T070	C2936626
cancer immunotherapy	T061	C0278348
conventional	T080	C0439858
approaches	T169	C1292724
in vitro	T080	C1533691
expanded	T082	C0205229
CD8(+) T cells	T025	C0242629
suboptimal	T080	C2984009
outcomes	T080	C0085415
loss	T081	C1517945
functionality	T169	C0542341
cellular	T025	C0007634
exhaustion	UnknownType	C0678684
phenotypic	T032	C0031437
functional	T169	C0205245
differences	T080	C1705242
in vitro	T080	C1533691
activated	T052	C1879547
CD8(+) T cells	T025	C0242629
sources	T033	C0449416
naïve	T025	C3641721
NTeff	T025	C3641721
memory	T025	C0682639
MTeff	T025	C0682639
tumor-infiltrating lymphocytes	T025	C0079722
TILeff	T025	C0079722
human	T016	C0086418
mice	T015	C0025929
mechanisms	T169	C0441712
effector	T025	C3641722
functions	T169	C0542341
limitations	T169	C0449295
proliferation	T043	C0596873
activity	T052	C0441655
telomere	T026	C0085187
lengths	T081	C1444754
NTeff populations	T025	C3641721
cells	T025	C0007634
naïve origin	T079	C0439659
T cell	T025	C0039194
exhaustion	UnknownType	C0678684
markers	T201	C0005516
MTeff	T025	C0682639
TILeff	T025	C0079722
expression patterns	T045	C1171362
memory-promoting transcription factors	T116	C0040648
T-bet	T116	C0913648
Eomes	T116	C1454790
induced	T169	C0205263
rapid	T080	C0456962
sustainable	T169	C0443318
manner	T169	C0205245
NTeff cells	T025	C3641721
expression	T045	C1171362
Foxp1	T116	C3273485
apoptosis	T043	C0162638
TGF-β	T116	C0040690
conditioning	T169	C0205245
survival	T043	C0007620
potential	T080	C3245505
resistance	T169	C4281815
tumor	T191	C0027651
induced	T169	C0205263
immune suppression	T047	C4048329
CD8(+) T cell	T025	C0242629
activated	T052	C1879547
tumor	T191	C0027651
specific	T080	C0205369
CTLs	T025	C0039195
naïve cell	T025	C3641721
generated	T052	C3146294
effectors	T025	C3641722
cytotoxic activity	T033	C0243095
design	T052	C1707689
adoptive immunotherapy	T061	C0079613
Antiadipogenic Activity	T033	C0243095
γ-Oryzanol	T109	C0061081
Stability	T080	C0205360
Pigmented	T080	C0333610
Rice	T168	C0035567
γ-Oryzanol	T109	C0061081
pigmented	T080	C0333610
rice	T168	C0035567
varieties	T080	C0332307
obesity-associated metabolic disorders	T047	C1285391
Antiadipogenic activities	T033	C0243095
γ-oryzanol	T109	C0061081
human	T016	C0086418
adipose	T024	C0001527
derived	T078	C1550535
mesenchymal stem cells	T025	C1257975
mouse	T015	C1522424
derived	T078	C1550535
3T3-L1 cells	T025	C1257743
γ-Oryzanol	T109	C0061081
decreased	T081	C0205216
lipid accumulation	T033	C3810056
reduced	T080	C0392756
glycerol-3-phosphate dehydrogenase activities	T044	C1151278
adipocytes	T025	C0206131
γ-oryzanol	T109	C0061081
pigmented	T080	C0333610
rice	T168	C0035567
varieties	T080	C0332307
black with giant embryo	T168	C0035567
brown	T168	C0452710
sugary brown	T168	C0035567
red	T168	C0452711
stable	T080	C0205360
stored	T169	C1698986
room temperature	T080	C2348236
bioactives	T167	C3714412
lutein	T109	C0043328
β-carotene	T109	C0053396
stable	T080	C0205360
yield	T081	C1265611
γ-oryzanol	T109	C0061081
rice	T168	C0035567
varieties	T080	C0332307
steaming	T067	C1522240
roasting processes	T067	C1522240
γ-oryzanol	T109	C0061081
antiadipogenic activity	T033	C0243095
suppressing	T169	C1260953
adipocyte differentiations	T043	C1159884
stable	T080	C0205360
pigmented	T080	C0333610
rice	T168	C0035567
extended	T169	C0231448
period of time	T079	C1948053
storage	T169	C1698986
after	T079	C0687676
cooking	T056	C0335326
intake	T169	C1512806
pigmented	T080	C0333610
rice	T168	C0035567
preventing	T169	C1292733
obesity	T047	C0028754
Impact	T080	C4049986
Chemotherapy	T061	C3665472
Diet	T168	C0012155
Nutritional Status	T033	C0392209
Women	T098	C0043210
Breast Cancer	T191	C0006142
Prospective Study	T062	C0033522
food groups	T168	C0016452
rejected	T080	C1548437
chemotherapy	T061	C3665472
CT	T061	C3665472
side effects of treatment	T046	C0879626
interfere with	T169	C0521102
adequate diet	UnknownType	C0547809
nutritional status	T033	C0392209
study	T062	C2603343
evaluate	T058	C0220825
treatment	T169	C0039798
impact	T080	C4049986
diet	T168	C0012155
nutritional status	T033	C0392209
women	T098	C0043210
breast cancer	T191	C0006142
BC	T191	C0006142
prospective longitudinal study	T062	C0033522
women	T098	C0043210
BC	T191	C0006142
age	T032	C0001779
years	T079	C0439234
data	T078	C1511726
Anthropometric	T081	C0815129
dietary assessments	T060	C0814244
dietary recall	T061	C0566508
Brazilian Healthy Eating Index Revised	T170	C0282574
BHEI-R	T170	C0282574
calculating	T052	C1441506
prevalence	T081	C0220900
inadequacy	T080	C0205412
EAR cut-off point method	T170	C0282574
BHEI-R	T170	C0282574
analysis	T062	C0936012
women	T098	C0043210
diet	T168	C0012155
modification	T033	C3840684
beginning	T079	C0439659
during treatment	T079	C2709058
CT	T061	C3665472
greater percentage	T081	C0439165
patients	T101	C0030705
inadequate diet	T033	C0522060
Total	T080	C0439810
Fruit	T168	C0016767
consumption	T052	C0441655
Dark Green	T168	C2348898
Orange Vegetable	T168	C0016452
Legume	T002	C0023263
consumption	T052	C0441655
decreased significantly	T081	C0205216
during treatment	T079	C2709058
significant reduction	T080	C0392756
intake	T169	C1512806
macro	T077	C2346926
micronutrients	T123	C0282575
prevalence	T081	C0220900
inadequacy	T080	C0205412
calcium	T197	C0006726
iron	T197	C0376520
phosphorus	T196	C0080014
magnesium	T196	C2348270
niacin	T109	C0027996
riboflavin	T109	C0035527
thiamin	T109	C0039840
vitamin B6	T109	C0087162
vitamin C	T109	C0003968
zinc	T196	C2348288
Assessment	T060	C0028708
nutritional status	T033	C0392209
patients	T101	C0030705
overweight	T184	C0497406
Weight	T032	C0005910
BMI	T201	C1305855
Waist Circumference	T201	C0455829
increased significantly	T081	C0205217
worse	T033	C1457868
nutritional status	T033	C0392209
correlation	T080	C1707520
poor diet quality	T080	C0332306
higher values	T080	C0042295
BMI	T201	C1305855
Waist-Hip Ratio	T032	C0205682
Waist-to-Height Ratio	T033	C1821269
Chemotherapy	T061	C3665472
interferes	T169	C0521102
patients	T101	C0030705
diet	T168	C0012155
negative impact	T080	C4049986
quality	T080	C0332306
intake	T169	C1512806
micro	T123	C0282575
macronutrients	T077	C2346926
impact	T080	C4049986
nutritional status	T033	C0392209
anthropometric measurements	T081	C0815129
risk	T058	C0035649
total hip arthroplasty	T061	C0040508
direct anterior approach	T082	C0205511
dual mobility cup	T074	C0025080
risks	T058	C0035649
dual mobility cup	T074	C0025080
DMC	T074	C0025080
THA	T061	C0040508
direct anterior approach	T082	C0205511
DAA	T082	C0205511
study	T062	C2603343
safety	T062	C1705187
postoperative complication	T046	C0032787
DAA	T082	C0205511
DMC	T074	C0025080
THA	T061	C0040508
DAA	T082	C0205511
single standard cup	T074	C0025080
DMC	T074	C0025080
intra	T079	C0456904
perioperative	T079	C1518988
outcomes	T169	C1274040
hips	T023	C0019552
treated	T061	C0087111
DAA	T082	C0205511
group	T078	C0441833
hips	T023	C0019552
treated	T061	C0087111
DAA	T082	C0205511
group	T078	C0441833
primary	T080	C0205225
secondary	T081	C0205436
outcome	T169	C1274040
intra	T046	C0021890
perioperative	T079	C1518988
complication	T046	C0009566
months	T079	C0439231
operative time	T079	C3494201
months	T079	C0439231
postoperatively	T079	C0032790
DMC	T074	C0025080
intra	T079	C0456904
perioperative	T079	C1518988
outcomes	T169	C1274040
No	T033	C1513916
intraoperative complications	T046	C0021890
group	T078	C0441833
anterior dislocation	T037	C1265658
periprosthetic hip fracture	T037	C4040051
DAA	T082	C0205511
group	T078	C0441833
surgical times	T079	C3494201
DAA	T082	C0205511
DAA	T082	C0205511
groups	T078	C0441833
month	T079	C0439231
postoperative	T079	C0032790
hip function scores	T081	C0449820
groups	T078	C0441833
DMC	T074	C0025080
intra	T079	C0456904
perioperative	T079	C1518988
outcomes	T169	C1274040
safety	T062	C1705187
DMC	T074	C0025080
DAA	T082	C0205511
standard single mobility cup	T074	C0025080
Diffuse traumatic brain injury	T037	C2832047
chronic	T079	C0205191
corticosterone	T109	C0010124
function	T169	C0542341
rat	T015	C0034721
patients	T101	C0030705
history	T033	C0332119
traumatic brain injury	T037	C0876926
TBI	T037	C0876926
chronic	T079	C0205191
endocrine dysfunction	T047	C1397856
impaired quality of life	T054	C4049260
impaired	T169	C0221099
rehabilitation	T169	C0034992
efforts	T051	C1516084
lowered life expectancy	T033	C1504437
Endocrine dysfunction	T047	C1397856
TBI	T037	C0876926
result	T169	C1274040
acceleration	T067	C0000894
deceleration	T070	C0011100
forces	T067	C0441722
brain	T023	C0006104
skull	T023	C2951888
hypothalamic	T023	C0020663
pituitary	T023	C0032005
neuropathology	T046	C1540677
hypothalamic	T023	C0020663
hypothalamic -pituitary endocrine	T022	C0014136
HPE	T022	C0014136
dysfunction	T046	C0277785
experiments	T062	C0681814
hypothesis	T078	C1512571
diffuse TBI	T037	C2832047
results	T169	C1274040
chronic	T079	C0205191
dysfunction	T046	C0277785
corticosterone	T109	C0010124
CORT	T109	C0010124
glucocorticoid	T109	C0017710
released	T169	C0391871
stress	T046	C0449430
testosterone	T109	C0039601
rodent model	T050	C1519106
diffuse TBI	T037	C2832047
midline fluid percussion injury	T037	C3714660
mFPI	T037	C3714660
months	T079	C0439231
postinjury	T079	C1254367
compared	T052	C1707455
uninjured control animals	T008	C1511501
circulating	T169	C0175630
levels	T080	C0441889
CORT	T109	C0010124
at rest	T169	C0443144
restraint stress	T046	C0449430
dexamethasone	T109	C0011777
synthetic glucocorticoid	T109	C0017711
HPE	T022	C0014136
axis	T082	C1522496
regulation	T038	C1327622
Testosterone	T109	C0039601
evaluated	T169	C1292732
at rest	T169	C0443144
changes	T169	C0392747
injury	T037	C3714660
induced	T169	C0205263
neuron	T025	C0027882
morphology	T080	C0332437
Golgi stain	T059	C0487602
neuropathology	T046	C1540677
silver stain	T059	C0487602
activated	T043	C1326120
astrocytes	T025	C0004112
GFAP	T059	C0487602
paraventricular nucleus	T023	C0030532
PVN	T023	C0030532
hypothalamus	T023	C0020663
plasma	T031	C0032105
CORT	T109	C0010124
levels	T080	C0441889
decreased	T081	C0205216
months	T079	C0439231
postinjury	T079	C1254367
CORT	T109	C0010124
increase	T081	C0205217
restraint induced stress	T046	C0449430
No changes	T033	C0442739
testosterone	T109	C0039601
measured	T080	C0444706
changes	T169	C0392747
CORT	T109	C0010124
concomitantly	T079	C0521115
altered	T169	C0392747
complexity	T080	C0439855
neuron	T025	C0027882
processes	T043	C0007613
PVN	T023	C0030532
time	T079	C0040223
neuropathology	T046	C1540677
astrocytosis	T046	C3887640
Results	T169	C1274040
diffuse TBI	T037	C2832047
changes	T169	C0392747
CORT	T109	C0010124
function	T169	C0542341
persistence of symptoms	T033	C0518691
endocrine dysfunction	T047	C1397856
experiments	T062	C0681814
evaluate	T169	C1292732
HP-related hormones	T125	C0019932
endocrine	T022	C0014136
circuit pathology	T169	C0205469
diffuse TBI	T037	C2832047
Methamphetamine	T109	C0025611
3,4-methylenedioxymethamphetamine	T109	C0115471
MDMA	T109	C0115471
3,4-methylenedioxypyrovalerone	T109	C2974592
MDPV	T109	C2974592
induce	T169	C0205263
differential	T080	C0443199
cytotoxic effects	T049	C0596402
bovine	T015	C0007452
brain	T023	C0006104
microvessel	T023	C2350570
endothelial cells	T025	C0225336
Designer drugs	T131	C0011684
synthetic psychostimulants	T121	C0304403
problem	T033	C0033213
drug abuse	T048	C0013146
addiction	T048	C1510472
methamphetamine	T109	C0025611
METH	T109	C0025611
drugs	T131	C0011684
3,4-methylenedioxy-methamphetamine	T109	C0115471
MDMA	T109	C0115471
commercial	T170	C0680536
preparations	T052	C1521827
synthetic cathinones	T109	C0054876
3,4-methylenedioxypyrovalerone	T109	C2974592
MDPV	T109	C2974592
bath salts	T109	C0771243
psychostimulants	T121	C0304403
neurotoxic effects	T037	C0235032
altering	T078	C1515926
monoamine systems	UnknownType	C0815020
brain	T023	C0006104
METH	T109	C0025611
MDMA	T109	C0115471
adversely affect	T046	C0879626
integrity	T080	C1947912
blood-brain barrier	T023	C0005854
BBB	T023	C0005854
reports	T170	C0684224
effects of	T080	C1704420
MDPV	T109	C2974592
BBB	T023	C0005854
study	T062	C2603343
compare	T052	C1707455
effects of	T080	C1704420
METH	T109	C0025611
MDMA	T109	C0115471
MDPV	T109	C2974592
bovine	T015	C0007452
brain	T023	C0006104
microvessel	T023	C2350570
endothelial cells	T025	C0225336
bBMVECs	T025	C0225336
in vitro model	T062	C1515654
BBB	T023	C0005854
Confluent	T080	C0205200
bBMVEC	T025	C0225336
monolayers	T023	C0934502
treated	T169	C1522326
METH	T109	C0025611
MDMA	T109	C0115471
MDPV	T109	C2974592
METH	T109	C0025611
MDMA	T109	C0115471
increased	T081	C0205217
lactate dehydrogenase	T116	C0022917
release	T169	C1283071
highest	T080	C1522410
concentration	T081	C1446561
MDPV	T109	C2974592
induced	T169	C0205263
cytotoxicity	T049	C0596402
concentration	T081	C1446561
MDMA	T109	C0115471
METH	T109	C0025611
decreased	T081	C0205216
cellular proliferation	T043	C0596290
effects	T080	C1280500
MDPV	T109	C2974592
exposures	T080	C0332157
MDPV	T109	C2974592
increased	T081	C0205217
reactive oxygen species	T123	C0162772
production	T052	C1883254
concentrations	T081	C1446561
tested	T169	C0039593
drugs	T131	C0011684
increased	T081	C0205217
nitric oxide	T121	C0028128
production	T052	C1883254
Morphological analysis	T062	C0936012
different	T080	C1705242
compound	T103	C1706082
induced	T169	C0205263
cell damage	T049	C0599732
METH	T109	C0025611
induced	T169	C0205263
vacuole	T026	C0042219
formatio	T169	C1522492
disruption	T169	C0332453
monolayer	T023	C0934502
MDMA	T109	C0115471
induced	T169	C0205263
disruption	T169	C0332453
endothelial	T025	C0225336
monolayer	T023	C0934502
vacuolization	T033	C0010840
MDPV	T109	C2974592
induced	T169	C0205263
monolayer	T023	C0934502
disruption	T169	C0332453
doses	T081	C0178602
vacuole	T026	C0042219
formation	T169	C1522492
cells	T025	C0007634
endothelial morphology	T080	C0332437
data	T078	C1511726
synthetic psychostimulants	T121	C0304403
monoaminergic systems	UnknownType	C0815020
induce	T169	C0205263
BBB	T023	C0005854
toxicity	T037	C0013221
different	T080	C1705242
mechanisms	T169	C0441712
MDPV	T109	C2974592
toxic	T080	C1407029
Alleviation	T080	C0392756
hepatic	T029	C0205054
fat accumulation	T033	C0333574
betaine	T109	C0005304
reduction	T080	C0392756
homocysteine	T116	C0019878
up-regulation	T044	C0041904
betaine-homocysteine methyltransferase	T116	C0053518
BHMT	T116	C0053518
investigated	T169	C1292732
anti-lipogenic effect	T169	C0205245
betaine	T109	C0005304
rats	T015	C0086893
methionine	T116	C0025646
choline	T109	C0008405
deficient	T080	C0332268
diet	T168	C0012155
MCD	T168	C0012155
MCD	T168	C0012155
significant	T078	C0750502
accumulation	T033	C0333574
hepatic	T029	C0205054
lipids	T109	C0023779
prevented	T080	C2700409
betaine	T109	C0005304
supplementation	T061	C0242297
drinking water	T167	C0599638
Phosphorylation	T044	C1158886
AMP-activated protein kinase	T116	C2350345
AMPK	T116	C2350345
acetyl-CoA carboxylase	T116	C0001022
ACC	T116	C0001022
sterol regulatory element-binding protein 1c	T116	C0537474
SREBP-1c	T116	C0537474
liver kinase B1	T116	C1431123
LKB1	T116	C1431123
inhibited	T080	C0311403
MCD	T168	C0012155
intake	T169	C1512806
inhibited	T080	C0311403
betaine	T109	C0005304
feeding	T058	C3714845
betaine	T109	C0005304
supplementation	T061	C0242297
reversed	T169	C1555029
reduction	T080	C0392756
methionine and S-adenosylmethionine	T044	C1325080
SAM	T044	C1325080
elevation	T080	C3163633
homocysteine levels	T059	C2242817
liver,	T023	C0023884
induction	T045	C0014431
betaine-homocysteine methyltransfease	T116	C0053518
BHMT	T116	C0053518
methionine adenosyltransferase	T116	C0025647
MAT	T116	C0025647
Different	T080	C1705242
cell lines	T025	C0007634
homocysteine	T116	C0019878
activation	T044	C0014429
AMPK	T116	C2350345
pathway	T044	C0598390
Homocysteine	T116	C0019878
treatment	T169	C1522326
decreased	T081	C0205216
pAMPK	T116	C2350345
pACC	T116	C0001022
pSREBP-1c	T116	C0537474
pLKB1	T116	C1431123
HepG2 cells	T025	C2717940
Metformin	T109	C0025598
induced	T169	C0205263
activation	T044	C0014429
AMPK	T116	C2350345
inhibited	T080	C0311403
homocysteine	T116	C0019878
Treatment	T169	C1522326
hydroxylamine	T197	C0020362
cystathionine β-synthase	T116	C0010641
inhibitor	T121	C0014432
reduction	T080	C0392756
pAMPK	T116	C2350345
pACC	T116	C0001022
pSREBP-1c	T116	C0537474
elevation	T080	C3163633
intracellular	T082	C0178719
homocysteine	T116	C0019878
Betaine	T109	C0005304
treatment	T061	C0087111
prevented	T080	C2700409
homocysteine	T116	C0019878
induced	T169	C0205263
reduction	T080	C0392756
pAMPK	T116	C2350345
pACC	T116	C0001022
pSREBP-1c	T116	C0537474
pLKB1	T116	C1431123
H4IIE cells	T025	C0007634
HepG2 cells	T025	C2717940
elevation	T080	C3163633
homocysteine	T116	C0019878
inhibition	T052	C3463820
protein expression	T045	C1171362
BHMT	T116	C0053518
prevented	T080	C2700409
betaine	T109	C0005304
H4IIE cells	T025	C0007634
express	T045	C1171362
BHMT	T116	C0053518
betaine	T109	C0005304
hepatic	T029	C0205054
lipid	T109	C0023779
accumulation	T033	C0333574
attributed	T078	C0449234
depletion	T169	C0333668
homocysteine	T116	C0019878
up-regulation	T044	C0041904
BHMT	T116	C0053518
hepatocytes	T025	C0227525
Dual-color STED microscopy	T059	C0026018
sandwich structure	T082	C0678594
Bassoon	T116	C1454967
Piccolo	T116	C1452991
active zones	T026	C3541837
adult	T100	C0001675
aged	T032	C0001779
mice	T015	C0025929
Presynaptic active zones	T026	C3541837
synaptic vesicle	T026	C0039065
release sites	T029	C0005898
synaptic transmission	T043	C0027793
molecular architecture	T082	C1254362
active zones	T026	C3541837
mammalian	T015	C0024660
neuromuscular junctions	T026	C0027869
NMJs	T026	C0027869
sub-diffraction limited resolution	T077	C2699488
Bassoon	T116	C1454967
Piccolo	T116	C1452991
active zone	T026	C3541837
cytosolic	T026	C1383501
proteins	T116	C0033684
active zone assembly	T043	C3896009
NMJs	T026	C0027869
ribbon synapses	T030	C1179874
brain	T023	C0006104
synapses	T030	C0039062
proteins	T116	C0033684
colocalize	T082	C0392752
active zones	T026	C3541837
non-overlapping localization	T043	C0597704
proteins	T116	C0033684
mouse	T015	C0025929
NMJs	T026	C0027869
dual-color stimulated emission depletion	T070	C1254365
STED	T070	C1254365
super resolution microscopy	T059	C0026018
Piccolo	T116	C1452991
puncta	T033	C0243095
Bassoon	T116	C1454967
puncta	T033	C0243095
aligned	T081	C1706765
Piccolo	T116	C1452991
Bassoon	T116	C1454967
Piccolo	T116	C1452991
structure	T082	C0678594
adult	T100	C0001675
NMJs	T026	C0027869
P/Q-type voltage-gated calcium channel	T116	C0814022
VGCC	T116	C0814022
puncta	T033	C0243095
colocalized	T082	C0392752
Bassoon	T116	C1454967
puncta	T033	C0243095
P/Q-type VGCC	T116	C0814022
Bassoon	T116	C1454967
protein levels	T034	C0428479
decreased	T081	C0205216
NMJs	T026	C0027869
aged	T032	C0001779
mouse	T015	C0025929
Piccolo	T116	C1452991
levels	T034	C0428479
NMJs	T026	C0027869
aged	T032	C0001779
mice	T015	C0025929
levels	T034	C0428479
adult	T100	C0001675
mice	T015	C0025929
molecular architecture	T082	C1254362
active zones	T026	C3541837
mouse	T015	C0025929
NMJs	T026	C0027869
sub-diffraction limited resolution	T077	C2699488
selective degeneration mechanism	T043	C0007613
active zone	T026	C3541837
proteins	T116	C0033684
NMJs	T026	C0027869
aged	T032	C0001779
mice	T015	C0025929
localization pattern	T043	C0597704
active zone	T026	C3541837
proteins	T116	C0033684
active zone	T026	C3541837
structures	T082	C0678594
electron microscope tomography	T059	C2350255
Molecular	T080	C1521991
serum	T031	C0229671
signature	T201	C0005516
treatment resistant depression	T048	C2063866
major depressive disorder	T048	C1269683
MDD	T048	C1269683
multiple	T081	C0439064
trials	T062	C0008976
anti-depressants	T121	C0003289
chronic	T079	C0205191
course of disease	T046	C0242656
treatment	T061	C0087111
resistant	T039	C1514892
molecular	T080	C1521991
changes	T169	C0392747
treatment-resistant depression	T048	C2063866
TRD	T048	C2063866
genes	T028	C0017337
biomarkers	T201	C0005516
TRD	T048	C2063866
high-throughput proteomic platforms	T091	C0872252
peripheral	T082	C0205100
biomarkers	T201	C0005516
TRD	T048	C2063866
staging models	T170	C0449394
Thase and Rush staging model	T170	C0449394
TRM	T170	C0449394
Maudsley Staging Model	T170	C0449394
MSM	T170	C0449394
Serum	T031	C0229671
inpatient	T101	C0021562
individuals	T098	C0027361
MDD	T048	C1269683
mass spectrometric-based platforms	T059	C0037813
label-free liquid chromatography mass spectrometry	T059	C0872318
LC-MS(E)	T059	C0872318
selective reaction monitoring	T169	C2826902
SRM	T169	C2826902
multiplex bead based assay	T059	C0020980
LC-MS(E) analysis	T059	C0872318
proteins	T116	C0033684
acute phase response	T046	C0001349
complement activation	T044	C0009528
coagulation	T039	C1328723
staging groups	T170	C0449394
models	T170	C0449394
multiplex bead-based assay	T059	C0020980
TNF-α levels	T059	C1168005
log(odds)	T081	C0023956
significantly	T081	C0237881
different	T080	C1705242
TRM	T170	C0449394
comparison	T052	C1707455
SRM	T169	C2826902
significant	T081	C0237881
changes	T169	C0392747
apolipoproteins A-I	T116	C0085201
M	T116	C1438565
F	T116	C0052208
TRM	T170	C0449394
MSM	T170	C0449394
findings	T033	C0243095
proteins	T116	C0033684
immune	T043	C1155000
complement activation	T044	C0009528
biomarkers	T201	C0005516
clinicians	T097	C0871685
high-risk	T033	C0332167
patients	T101	C0030705
molecular	T080	C1521991
changes	T169	C0392747
staging groups	T170	C0449394
interpreted	T169	C1285553
study	T062	C2603343
fine-mode aerosol	T073	C0001712
big urban area	UnknownType	C0814837
relevant doses	T081	C0178602
deposited	T169	C0333562
human	T016	C0086418
respiratory tract	T023	C0282335
health	T078	C0018684
effects	T080	C1280500
PM	T131	C1510837
particle size	T081	C0030608
UltraFine Particles	T104	C0597177
UFPs	T104	C0597177
fraction of	T081	C1264633
atmospheric	T070	C0004178
aerosol	T073	C0001712
Rome	T083	C0035831
levels	T080	C0441889
PM2.5	T131	C1510837
PM10	T131	C1510837
PM2.5	T131	C1510837
submicron particles	T104	C0597177
great urban area	UnknownType	C0814837
daytime	T079	C0332169
nighttime	T079	C3844540
work-	T079	C0680192
weekdays	T079	C0680189
cold	T070	C0009264
hot	T070	C2350229
seasonal trends	T079	C0036497
submicron particles	T104	C0597177
NOx	T197	C0028167
PAH	T109	C0032458
UFPs	T104	C0597177
combustion processes	T067	C1522240
dose	T081	C0178602
submicron particles	T104	C0597177
deposited	T169	C0333562
respiratory system	T022	C0035237
head	T029	C0018670
tracheobronchial	T023	C0458580
alveolar regions	T023	C1440080
lung lobes	T023	C0225752
Dosimeter	T074	C0180488
estimates	T081	C0750572
Multiple-Path Particle Dosimetry model	T170	C3161035
MPPD v.2.1	T170	C3161035
aerosol	T073	C0001712
doses	T081	C0178602
deposited	T169	C0333562
respiratory system	T022	C0035237
individuals	T098	C0237401
exposed	T080	C0332157
traffic	T033	C3840880
traffic	T033	C3840880
hours	T079	C0439227
particles	T104	C0597177
deposited	T169	C0333562
respiratory system	T022	C0035237
dose	T081	C0178602
UFPs	T104	C0597177
dose	T081	C0178602
estimated	T081	C0750572
right lung lobes	T023	C0446959
susceptible	T169	C0231204
respiratory	T169	C0521346
pathologies	T046	C0677042
left lobes	T023	C0446960
International Liver Transplant Society Practice Guidelines	T170	C0162791
Diagnosis	T033	C0011900
Management	T058	C0376636
Hepatopulmonary Syndrome	T047	C0600452
Portopulmonary Hypertension	T047	C1868851
pulmonary vascular disorders	T047	C0854416
hepatopulmonary syndrome	T047	C0600452
HPS	T047	C0600452
portopulmonary hypertension	T047	C1868851
POPH	T047	C1868851
consequence of	T169	C0686907
hepatic parenchymal	T023	C0736268
vascular abnormalities	T033	C0241657
HPS	T047	C0600452
POPH	T047	C1868851
clinical	T080	C0205210
implications	T033	C0243095
liver transplantation	T061	C0023911
European Respiratory Society Task Force	T064	C0162458
Pulmonary-Hepatic Disorders	T047	C0012634
diagnosis	T033	C0011900
guide management	T170	C0162791
disorders	T047	C0012634
International Liver Transplant Society diagnostic and management guidelines	T170	C0162791
task force	T064	C0162458
clinical	T080	C0205210
HPS	T047	C0600452
POPH	T047	C1868851
MEDLINE search	T170	C0242356
clinical guidelines	T170	C0282451
selected single care reports	T058	C0700287
small series	T081	C0205549
registries	T170	C0034975
databases	T170	C0242356
expert opinion	T077	C0600219
randomized, controlled trials	T062	C0206035
disorders	T047	C0012634
Guidelines	T170	C0282451
Definitions	T170	C0679227
Diagnostic criteria	T170	C0679228
Hepatopulmonary syndrome	T047	C0600452
Portopulmonary hypertension	T047	C1868851
Implications	T033	C0243095
liver transplantation	T061	C0023911
Suggestions	T078	C1705535
clinical research	T062	C0008972
Uveitis	T047	C0042164
children	T100	C0008059
novel	T080	C0205314
risk markers	T080	C1519104
development	T169	C1527148
pediatric	T080	C1521725
inflammatory uveitis	T047	C0042164
severe disease course	T046	C0242656
treatment	T061	C0087111
refractory disease	T033	C1514815
measurement	T169	C0242485
visual outcomes	T169	C1274040
genetic markers	T045	C0017393
biomarkers	T201	C0005516
clinical	T080	C0205210
factors	T169	C1521761
child's	T100	C0008059
uveitis	T047	C0042164
disease course	T046	C0242656
children	T100	C0008059
risk	T078	C0035647
poor visual outcomes	T169	C1274040
refractory	T169	C0332325
traditional therapy	T061	C3650840
Racial disparities	T033	C0243095
reported	T170	C0684224
agents	T120	C0450442
potential benefit	T081	C0814225
patient reported outcomes	T170	C2987124
population	T101	C0030705
Uveitis	T047	C0042164
vision-threatening complications	T046	C0009566
Timely and aggressive treatment	T061	C0087111
children	T100	C0008059
risk	T078	C0035647
severe uveitis course	T046	C0242656
improved outcomes	T169	C1274040
Utility	T169	C0457083
mHealth App	T170	C3658310
Self-Management	T058	C0086969
Education	T065	C0013621
Cardiac Diseases	T047	C0018799
Spanish	T083	C0037747
Urban and Rural Areas	T083	C0017446
Analyze	T062	C0936012
utility	T169	C0457083
mobile health app	T170	C3658310
HeartKeeper	T170	C3827995
several groups of population	T098	C1257890
obtain	T169	C1301820
conclusions	T078	C1707703
applied	T169	C4048755
other similar apps	T170	C3658310
questionnaire	T170	C0034394
designed	T052	C1707689
usage	T169	C0457083
utility	T169	C0457083
HeartKeeper app	T170	C3658310
questionnaire	T170	C0034394
information	T078	C1533716
collected	T169	C1516698
cardiologists	T097	C0175906
patients	T101	C0030705
before and after	UnknownType	C0150091
used	T169	C0457083
app	T170	C3658310
Patients	T101	C0030705
randomly selected	T062	C0150105
quotas	T062	C2347740
interest groups	T098	C1705429
men	T098	C0025266
women	T098	C0043210
patients	T101	C0030705
older	T098	C0001792
younger	T079	C0332239
years old	T079	C0439234
patients	T101	C0030705
urban or rural areas	T083	C0017446
equally represented	T052	C1882932
statistical techniques	T062	C1710191
HeartKeeper app	T170	C3658310
patients	T101	C0030705
qualify	T080	C1548635
overall opinion	T033	C3272903
app	T170	C3658310
remember	T041	C0034770
pills	T122	C0994475
improvement	T077	C2986411
global improvement	T077	C2986411
observe	T169	C1441672
improvements	T077	C2986411
area (urban or rural)	T083	C0017446
patient	T101	C0030705
sex	T032	C0079399
older patients	T098	C1518563
needed	T080	C0027552
use	T169	C0457083
app	T170	C3658310
used	T169	C0457083
less frequently	T079	C0205213
improvements	T077	C2986411
several measures	T081	C0079809
remembering	T041	C0034770
pills	T122	C0994475
breathing problems	T184	C0497337
trouble developing activities	T184	C0858854
older patients	T098	C1518563
higher	T080	C0205250
improvements	T077	C2986411
younger ones	T100	C0238598
results	T169	C1274040
sample	T081	C0079809
patients	T101	C0030705
research	T062	C0035168
utility	T169	C0457083
HeartKeeper app	T170	C3658310
utility	T169	C0457083
urban and rural areas	T083	C0017446
patients	T101	C0030705
both sexes	T032	C0079399
to some extent	T080	C1555600
age	T100	C0027362
patient	T101	C0030705
older patients	T098	C1518563
slightly lower frequency	T079	C0205213
use	T169	C0457083
higher	T080	C0205250
health improvements	T077	C2986411
younger ones	T100	C0238598
holistic approach	T078	C0683249
age	T032	C0001779
estimation	T041	C0680844
refugee	T098	C0034961
children	T100	C0008059
refugee	T098	C0034961
children	T100	C0008059
Australia	T083	C0004340
inaccurately	T080	C0443236
documented	T058	C1301725
date of birth	T170	C2348576
DOB	T170	C2348576
medical assessment	T058	C0582103
child's age	T032	C0001779
concern	T078	C2699424
documented	T058	C1301725
DOB	T170	C2348576
incorrect	T080	C3827420
assess	T058	C0184514
accuracy	T080	C0443131
holistic age assessment tool	T170	C0037589
AAT	T170	C0037589
estimating	T041	C0680844
age	T032	C0001779
refugee	T098	C0034961
children	T100	C0008059
Australia	T083	C0004340
holistic AAT	T170	C0037589
medical	UnknownType	C0679624
non-medical approaches	T078	C1254370
estimate	T041	C0680844
ages	T032	C0001779
refugee	T098	C0034961
children	T100	C0008059
DOB	T170	C2348576
tool	T170	C0037589
components	T077	C1705248
assess	T058	C0184514
age	T032	C0001779
oral	T082	C0442027
narrative	T054	C1135957
developmental	T080	C0458003
assessment	T058	C0220825
anthropometric measures	T170	C2598146
pubertal	T033	C1627769
assessment	T058	C0220825
Assessors	T097	C0401803
blinded	T062	C0150108
true	T080	C0205238
age	T032	C0001779
child	T100	C0008059
Correlation coefficients	T081	C0392762
actual	T080	C0237400
estimated	T041	C0680844
age	T032	C0001779
calculated	T052	C1441506
tool	T170	C0037589
overall and individual components	T077	C1705248
correlation coefficient	T081	C0392762
actual	T080	C0237400
estimated	T041	C0680844
age	T032	C0001779
AAT	T170	C0037589
boys	T100	C0870221
girls	T100	C0870604
oral	T082	C0442027
narrative	T054	C1135957
component	T077	C1705248
tool	T170	C0037589
age	T032	C0001779
estimates	T041	C0680844
year	T079	C0439234
true	T080	C0205238
age	T032	C0001779
years	T079	C0439234
standard deviation	T081	C0871420
years	T079	C0439234
months	T079	C0439231
AAT	T170	C0037589
holistic	T078	C1254370
simple	T080	C0205352
safe	UnknownType	C0814103
estimate	T041	C0680844
age	T032	C0001779
refugee	T098	C0034961
children	T100	C0008059
radiological methods	T091	C0039431
CAGEd-oPOSSUM	T170	C0037589
motif enrichment analysis	T062	C0936012
CAGE	T170	C0150098
TSSs	T114	C0949639
large-scale Cap Analysis of Gene Expression (CAGE) datasets	T170	C0150098
individual labs	T073	C0022877
FANTOM consortium	T077	C1709701
cis-regulatory regions	T114	C0034987
gene transcription	T045	C0040649
unprecedented level of refinement	T080	C0205556
transcription factor binding site	T044	C3158211
TFBS	T044	C3158211
enrichment analysis	T062	C0936012
CAGE	T170	C0150098
genomic regions	T028	C0598659
CAGEd-oPOSSUM	T170	C0037589
identify	T080	C0205396
TFs	T116	C0040648
key	T077	C1706198
regulators	T077	C1704735
genes	T028	C0017337
specific	T080	C0205369
mammalian cell	T025	C1512977
tissue types	T024	C2713035
webtool	T170	C0037589
analysis	T062	C0936012
CAGE	T170	C0150098
transcription start sites	T114	C0949639
TSSs	T114	C0949639
user	T098	C1706077
mammalian	T015	C0024660
samples	T167	C0370003
FANTOM5 project	T077	C1709701
pre-computed	T052	C1880157
TFBS	T044	C3158211
JASPAR TF binding profiles	T170	C0242356
tool	T170	C0242356
insights	T041	C0233820
regulation of genes	T045	C0017263
study	T062	C2603343
specific	T080	C0205369
usage	T169	C0457083
TSSs	T114	C0949639
specific	T080	C0205369
cell types	T170	C0449475
specific conditions	T080	C0348080
CAGEd-oPOSUM web tool	T170	C0037589
Perl	T170	C0037589
MySQL	T170	C1710218
Apache	T170	C0243030
http://cagedop.cmmt.ubc.ca/CAGEd_oPOSSUM	T170	C2349146
anthony.mathelier@ncmm.uio.no	T170	C1705961
wyeth@cmmt.ubc.ca	T170	C1705961
Supplementary information	T170	C2936424
Supplementary data	T170	C2936424
Bioinformatics	T170	C0282420
online	T073	C0029038
Self-assembled	T044	C0872376
polymeric	T104	C0032521
vectors	T074	C0085104
mixtures	T167	C0439962
characterization	T052	C1880022
polymorphism	T080	C1882417
synergistic	T080	C2986495
effects	T080	C1280500
photodynamic therapy	T061	C0031740
purity	T081	C1882508
polymeric	T104	C0032521
self-assemblies	T044	C0872376
vectors	T074	C0085104
solution	T167	C0037633
photodynamic therapeutic	T061	C0031740
efficiency	T081	C0013682
amphiphilic	T121	C0002671
block copolymers	T104	C0596383
poly(ethyleneoxide-b-ε-caprolactone)	T109	C1258138
self-assemblies	T044	C0872376
morphologies	T080	C0332437
micelles	T109	C0025938
worm-like micelles	T109	C0025938
vesicles	T080	C0332437
controlled mixtures	T167	C0439962
micelles	T109	C0025938
vesicles	T080	C0332437
dynamic light scattering	T059	C1882368
asymmetrical flow field flow fractionation	T059	C1135847
AsFlFFF	T059	C1135847
custom-made	T052	C1880202
program	T073	C0037585
STORMS	T073	C0037585
DLS	T059	C1882368
data	T078	C1511726
parameters	T077	C0549193
DLS	T059	C1882368
larger	T081	C0549177
vesicles	T080	C0332437
micelles	T109	C0025938
vesicles	T080	C0332437
ratio	T081	C0456603
AsFlFFF	T059	C1135847
detection	T033	C0442726
micelles	T109	C0025938
ratio	T081	C0456603
photodynamic therapy	T061	C0031740
efficiency	T081	C0013682
controlled mixtures	T167	C0439962
spheroids	T033	C1844596
photosensitizer	T121	C0162713
pheophorbide a	T109	C0070716
encapsulated	T080	C0205223
polymer	T104	C0032521
self-assemblies	T044	C0872376
efficient	T080	C0442799
monomorphous systems	T033	C0700329
mixtures	T167	C0439962
PDT	T061	C0031740
efficiency	T081	C0013682
nano	T081	C1553036
objects	T072	C0347997
synergistic	T080	C2986495
effect	T080	C1280500
delivery	T070	C3850077
photosensitizer	T121	C0162713
Polymorphous	T080	C1882417
vectors	T074	C0085104
therapeutic applications	T169	C0039798
Fuzheng Qingjie Granules	T123	C0574031
Inhibit	T052	C3463820
Growth	T039	C0220844
Hepatoma Cells	T025	C0677626
Inducing	T169	C0205263
Mitochondria	T026	C0026237
Apoptosis	T043	C0162638
Enhancing	T052	C2349975
Immune Function	T042	C1817756
Fuzheng Qingjie	T123	C0574031
(FZQJ) granules	T123	C0574031
compound	T103	C1706082
Chinese medicine	T091	C0025123
adjuvant therapy	T061	C0677850
alimentary tract	T022	C0017189
cancers	T191	C0006826
anticancer	T033	C0243095
mechanisms	T169	C0441712
present	T079	C0521116
study	T062	C2603343
HepG2 cells	T025	C2717940
treated	T169	C1522326
FZQJ	T123	C0574031
containing	T052	C2700400
serum	T031	C0229671
Cell proliferation	T043	C0596290
evaluated	T058	C0220825
MTT assay	T062	C2986858
Apoptosis	T043	C0162638
analyzed	T062	C0936012
flow cytometer	T074	C0180279
Cell ultrastructure	T025	C3825563
observed	T169	C1441672
transmission electron microscope	T074	C0262880
mitochondrial membrane potential	T043	C1720920
Δψ	T043	C1720920
examined	T033	C0332128
JC-1 dye	T130	C0013343
H22 tumor-bearing mice	T191	C1512411
CD4(+) T cells	T025	C0039215
CD8(+) T cells	T025	C0242629
CD3(+) T cells	T025	C1267816
natural killer cells	T025	C0022688
NK	T025	C0022688
peripheral blood	T031	C0229664
cytometrically	T074	C0180279
Interleukin (IL)-2	T116	C0021756
tumor necrosis factor	T116	C0041368
(TNF)-α	T116	C0041368
levels	T080	C0441889
measured	T080	C0444706
radioimmunoassay	T059	C0034580
mRNA	T114	C0035696
levels	T080	C0441889
Bax	T028	C0812198
Bcl-2	T028	C0376515
examined	T033	C0332128
reverse transcription-polymerase chain reaction	T063	C0599161
protein	T116	C0033684
levels	T080	C0441889
Bax	T116	C0219474
Bcl-2	T116	C0210955
cytochrome C	T116	C0010749
caspase 3	T116	C0291573
9	T116	C0910167
PARP	T116	C0032405
CD69	T116	C0108800
examined	T033	C0332128
Western blotting	T059	C0005863
apoptotic	T080	C1516044
cells	T025	C0007634
tissues	T024	C0040300
observed	T169	C1441672
TUNEL method	T063	C0872284
Alanine transaminase	T116	C0001899
ALT	T116	C0001899
aspartate transaminase	T116	C0004002
AST	T116	C0004002
blood urea nitrogen	T123	C0600137
BUN	T123	C0600137
creatinine	T109	C0010294
CRE	T109	C0010294
detected	T033	C0442726
automatic	T169	C0205554
biochemical	T169	C0205474
analyzer	T074	C0179038
results	T169	C1274040
FZQJ	T123	C0574031
containing	T052	C2700400
serum	T031	C0229671
inhibited	T052	C3463820
proliferation	T043	C0596290
HepG2 cells	T025	C2717940
dose	T081	C1512045
time	T079	C0040223
dependent	T080	C0851827
induced	T169	C0205263
HepG2 cell	T025	C2717940
apoptosis	T043	C0162638
decrease	T081	C0547047
Δψ	T043	C1720920
Analysis	T062	C0936012
tumor tissue	T024	C0475358
FZQJ	T123	C0574031
induced	T169	C0205263
apoptosis	T043	C0162638
downregulation	T044	C0013081
Bcl-2	T116	C0210955
upregulation	T044	C0041904
Bax	T116	C0219474
release	T169	C1283071
cytochrome c	T116	C0010749
activation	T044	C0014429
caspase 3	T116	C0291573
9	T116	C0910167
cleavage	T044	C0597304
PARP	T116	C0032405
FZQJ	T123	C0574031
increased	T081	C0205217
percentages	T081	C0439165
CD4(+) T	T025	C0039215
NK cells	T025	C0022688
ratio	T081	C0456603
CD4(+)	T025	C0039215
CD8(+) T cells	T025	C0242629
levels	T080	C0441889
serum	T031	C0229671
TNF-α	T116	C0041368
FZQJ	T123	C0574031
increased	T081	C0205217
CD69	T116	C0108800
expression	T045	C1171362
tumor tissue	T024	C0475358
No hepatorenal toxicity	T033	C0243095
observed	T169	C1441672
H22 tumor-bearing mice	T191	C1512411
results	T169	C1274040
indicated	T033	C1444656
FZQJ	T123	C0574031
inhibit	T052	C3463820
growth	T039	C0220844
hepatoma cells	T025	C0677626
immune function	T042	C1817756
inducing	T169	C0205263
mitochondria	T026	C0026237
apoptosis	T043	C0162638
Professional reinventions	T170	C0282574
Swedish	T098	C1710263
psychologists	T097	C0033908
20th century	T079	C0681748
Swedish	T098	C1710263
psychology profession	T091	C0033909
changes	T169	C0392747
essential tasks	T052	C0441655
epistemological foundations	T170	C0376553
social roles	T054	C0035820
changes	T169	C0392747
occurred	T052	C1709305
Swedish	T098	C1710263
society	T092	C0037455
profession	T090	C0028811
society's	T092	C0037455
concerns	T078	C2699424
problems	T033	C0033213
profession's	T090	C0028811
goals	T170	C0018017
aims	T078	C1947946
history	T169	C0019665
profession	T090	C0028811
changing	T169	C0392747
definitions	T170	C1704788
contours	T082	C0876954
psychology profession	T091	C0033909
organization	T169	C1300196
society	T092	C0037455
article	T170	C1706852
history	T169	C0019665
Swedish	T098	C1710263
psychology profession	T091	C0033909
analysis	T062	C0936012
discussions	T054	C2584313
debates	T052	C0870392
Swedish	T098	C1710263
Psychological Association's journal	T073	C0162443
analytical framework	T077	C1254372
actor-network theory	T170	C0683613
science studies	T062	C0242481
profession's	T090	C0028811
institutional connections	T080	C0439849
tasks	T052	C0441655
epistemological	T170	C0376553
underpinnings	T078	C1254370
social position	UnknownType	C0680375
changed	T169	C0392747
decades	T081	C2981279
insecurity	T041	C0233497
profession	T090	C0028811
legitimize	T169	C1552821
politicians	T097	C0682232
media	T170	C0009458
patients	T101	C0030705
customers	T077	C2981734
economized	T169	C0013557
vocabulary	T170	C0042926
novel	T080	C0205314
empirical research	T062	C0376367
changes	T169	C0392747
socialized	T054	C2371613
profession	T090	C0028811
actors	T097	C0335083
Swedish	T098	C1710263
society	T092	C0037455
conflicts	T080	C1705242
profession	T090	C0028811
control	T080	C0243148
loss of autonomy	T033	C4061233
PsycINFO Database Record	T170	C0242356
Personally Meaningful Rituals	T053	C2945764
Increase	T169	C0442805
Compassion	T054	C0242270
Decrease	T081	C0547047
Burnout	T033	C0476644
Hospice	T058	C0085555
Staff	T097	C0851286
Volunteers	T098	C3661466
Rituals	T053	C2945764
increase	T169	C0442805
sense of connectedness	UnknownType	C0814552
meaning	T078	C0876919
support	T054	C0037438
death	T040	C0011065
Hospice	T058	C0085555
staff	T097	C1547600
personal rituals	T053	C2945764
cope with	T055	C0009967
frequent deaths	T081	C0205848
patients	T101	C0030705
compassionate care	T052	C1947933
burnout	T033	C0476644
personally meaningful rituals	T053	C2945764
increasing	T169	C0442805
compassion	T054	C0242270
decreasing	T080	C0392756
burnout	T033	C0476644
hospice	T058	C0085555
staff	T097	C1547600
volunteers	T098	C3661466
online survey	T170	C0038951
National Hospice and Palliative Care Organization	T073	C4035207
Hospice	T058	C0085555
NHPCO	T073	C4035207
personal ritual	T053	C2945764
Professional Quality of Life (ProQOL) scale	T170	C0451401
ProQOL	T170	C0451401
Compassion	T054	C0242270
Satisfaction	T041	C0242428
Burnout	T033	C0476644
Secondary Traumatic Stress	T048	C4042834
hospice	T058	C0085555
staff	T097	C1547600
volunteers	T098	C3661466
states	T083	C1301808
online survey	T170	C0038951
participants	T098	C0679646
Caucasian	T098	C0043157
female	T032	C0086287
hospice	T058	C0085555
hospice and palliative care	T073	C4035207
hospice	T058	C0085555
staff	T097	C1547600
volunteers	T098	C3661466
rituals	T053	C2945764
death	T040	C0011065
patients	T101	C0030705
cope	T055	C0009967
rituals	T053	C2945764
Compassion	T054	C0242270
Satisfaction	T041	C0242428
Burnout	T033	C0476644
ProQOL	T170	C0451401
professional support	T033	C1822039
social support	T054	C0037438
age	T032	C0001779
significant roles	T033	C0243095
Rituals	T053	C2945764
increase	T169	C0442805
compassion	T054	C0242270
decrease	T081	C0547047
burnout	T033	C0476644
hospice	T058	C0085555
staff	T097	C1547600
volunteers	T098	C3661466
Organizations	T073	C4035207
training and support	T065	C0040607
personalized rituals	T053	C2945764
new staff	T097	C1547600
at greater risk	T080	C1444641
burnout	T033	C0476644
Activation	T052	C1879547
orphan receptor GPR55	T116	C2002138
lysophosphatidylinositol	T109	C0065391
promotes	T052	C0033414
metastasis	T191	C0027627
triple-negative breast cancer	T191	C3539878
orphan G protein-coupled receptor	T116	C0682972
GPR55	T116	C2002138
directly	T080	C1947931
indirectly	T080	C0439852
related	T080	C0439849
alterations	T078	C1515926
malignant	T080	C0205282
growth	T040	C0018270
uncontrolled	T080	C0205318
cell proliferation	T043	C0596290
sustained angiogenesis	T042	C0302600
cell adhesion	T043	C0007577
migration	T067	C1254366
little	T081	C0700321
known	T080	C0205309
involvement	T169	C1314939
receptor	T116	C0597357
metastasis	T191	C0027627
elevated	T080	C3163633
GPR55 expression	T045	C0597360
human	T016	C0086418
tumors	T191	C0027651
associated with	T080	C0332281
aggressive basal	T191	C0027671
triple-negative breast cancer	T191	C3539878
population	T098	C1257890
higher probability	T081	C0033204
metastases	T191	C0027627
poor	T080	C2700379
patient	T101	C0030705
prognosis	T058	C0033325
Activation	T052	C1879547
GPR55	T116	C2002138
endogenous	T169	C0205227
ligand	T103	C0023688
lysophosphatidylinositol	T109	C0065391
pro-invasive	T080	C0205281
features	T080	C2348519
breast cancer cells	T025	C1512505
in vitro	T080	C1533691
in vivo	T082	C1515655
effect	T080	C1280500
elicited by	T080	C0449265
coupling	T169	C1948027
Gq/11 heterotrimeric proteins	T116	C2975447
subsequent	T079	C0332282
activation	T052	C1879547
ERK	T116	C0600388
transcription factor ETV4	T116	C1333479
PEA3	T116	C0084827
Together	T080	C1883357
data	T078	C1511726
GPR55	T116	C2002138
promotes	T052	C0033414
breast cancer	T191	C0678222
metastasis	T191	C0027627
supports	T077	C1521721
orphan receptor	T116	C0597357
new	T080	C0205314
therapeutic	T169	C0302350
target	T169	C1521840
potential	T080	C3245505
biomarker	T201	C0005516
aggressive triple-negative subtype	T185	C1519691
Effect	T080	C1280500
ultrasonic	T169	C0220934
processing	T052	C1709694
activity	T044	C1537044
aggregation	T169	C0332621
secondary	T082	C0162807
tertiary structure	T082	C0162808
polyphenol oxidase	T116	C0012524
oriental	T083	C0017446
sweet melon	T168	C0440285
Cucumis melo var. makuwa Makino	T002	C0947370
Polyphenol oxidase	T116	C0012524
PPO	T116	C0012524
contributes	T052	C1880177
browning reaction	T070	C0085927
fruits	T168	C0016767
vegetables	T168	C0042440
serious	T080	C0205404
damage	T169	C1883709
quality	T080	C0332306
sweet melon	T168	C0440285
products	T071	C1514468
traditional	T169	C0443324
methods	T169	C0449851
inactivate	T169	C0544461
browning	T070	C0085927
induce	T169	C0205263
unexpected	T170	C4055646
risks	T078	C0035647
ultrasonic	T169	C0220934
processing	T052	C1709694
reports	T170	C0684224
effect	T080	C1280500
ultrasound	T070	C1456803
PPO	T116	C0012524
purified	T169	C1998793
sweet melon	T168	C0440285
PPO	T116	C0012524
original	T078	C0205313
juice	T168	C1268568
inactivated	T169	C0544461
purified	T169	C1998793
treated with	T061	C0332293
ultrasound	T070	C1456803
purified	T169	C1998793
PPO	T116	C0012524
thermal treatment	T061	C0454527
heat	T070	C0018837
inactivate	T169	C0544461
PPO	T116	C0012524
ultrasonic	T169	C0220934
treatment	T061	C0087111
intensity lower	T033	C2173560
ultrasound	T070	C1456803
significantly	T078	C0750502
structure	T082	C0678594
activity	T078	C1561536
PPO	T116	C0012524
latent	T080	C0205275
PPO	T116	C0012524
activated	T052	C1879547
intensity higher	T033	C2173560
ultrasound	T070	C1456803
inactivated	T169	C0544461
PPO	T116	C0012524
induced	T169	C0205263
aggregation	T169	C0332621
dissociation	T044	C0301643
PPO	T116	C0012524
particles	T104	C0597177
significantly decreased	T081	C4055638
α-helix structure	T082	C0162805
Low-frequency	T079	C0205213
high-intensity	T185	C4081854
ultrasound	T070	C1456803
inactivation	T169	C0544461
effect	T080	C1280500
conformational changes	T044	C0301641
purified	T169	C1998793
PPO	T116	C0012524
oriental	T083	C0017446
sweet melons	T168	C0440285
Changes	T169	C0392747
PPO	T116	C0012524
structure	T082	C0678594
induced	T169	C0205263
ultrasound	T070	C1456803
inactivated	T169	C0544461
enzyme	T116	C0014442
Ultrasound	T070	C1456803
potential	T080	C3245505
method	T169	C0449851
inactivate	T169	C0544461
PPO	T116	C0012524
oriental	T083	C0017446
sweet melons	T168	C0440285
Phylogeography	T090	C2936603
Spanish	T098	C0086409
Moon Moth	T204	C0026593
Graellsia isabellae	T204	C1024524
Lepidoptera	T204	C0023338
Saturniidae	T204	C3102349
Geographic	T077	C0017444
demographic factors	T078	C0011292
specialisation	T090	C0037776
host-plant	UnknownType	C0868970
host	UnknownType	C0868970
associated	T080	C0332281
differentiation	T169	C2945687
plant	T002	C0032098
insects	T204	C0021585
phylogeography	T090	C2936603
protected	T169	C0205245
moth	T204	C0026593
Graellsia isabellae	T204	C1024524
host-plant	UnknownType	C0868970
species	T185	C1705920
Pinus sylvestris	T002	C0996613
P. nigra	T002	C1670069
evolutionary history	T169	C0019665
lepidopteran	T204	C0023338
DNA	T114	C0012854
variation	T070	C0042333
mitochondrial	T026	C0026237
marker	T086	C0012872
nuclear	T026	C0007610
microsatellite loci	T028	C0678933
phylogeographic pattern	T033	C0243095
G. isabellae	T204	C1024524
Spain	T083	C0037747
France	T083	C0016674
groups	T078	C0441833
distributed	T169	C1704711
different	T080	C1705242
mountain ranges	T083	C0442533
Reanalysis	T062	C0936012
chloroplast	T026	C0008266
microsatellite dataset	T170	C0150098
revealed	T080	C0443289
group structure	T102	C0018266
Spanish	T098	C0086409
P. sylvestris	T002	C0996613
P. nigra	T002	C1670069
protected	T169	C0205245
moth	T204	C0026593
match	T080	C1708943
P. sylvestris	T002	C0996613
P. nigra	T002	C1670069
no evidence of	T080	C0332125
host	UnknownType	C0868970
associated	T080	C0332281
differentiation	T169	C2945687
P. sylvestris	T002	C0996613
inhabiting	T169	C0205245
P. nigra	T002	C1670069
major	T080	C0205164
mitochondrial	T026	C0026237
clades	T078	C0441833
G. isabellae	T204	C1024524
Last Glacial Maximum	T079	C1254367
geographically	T082	C1517526
separated	T080	C0443299
species	T185	C1705920
southern	T082	C1710133
Central and Southern Iberian clusters	T081	C1704332
northern	T082	C1709269
lineage	T077	C1881379
Eastern Iberian	T081	C1704332
Pyrenean	T081	C1704332
French Alpine clusters	T081	C1704332
Eastern Iberian System	T081	C1704332
insect	T204	C0021585
host-plants	UnknownType	C0868970
highest	T080	C1522410
level	T080	C0441889
genetic	T169	C0314603
diversity	T080	C1880371
group	T078	C0441833
colonised	T033	C4289767
West	T082	C1705493
East parts	T082	C1707877
Pyrenees	UnknownType	C0681784
native	T169	C0302891
origin	T079	C0439659
French populations	T081	C0032659
occurring	T079	C2745955
Alps	T083	C0442533
genetically	T169	C0314603
Eastern Iberian	UnknownType	C0681784
Pyrenean sites	UnknownType	C0681784
Central Iberian group	T078	C0441833
Southern Iberian	UnknownType	C0681784
ancestors	T099	C0870134
Secondary	T081	C0205436
contacts	T080	C0205556
Southern/Central Iberian populations	T081	C0032659
Eastern Iberian cluster	T081	C1704332
Pyrenean ones	T081	C1704332
mito-nuclear discordance	T081	C0392762
Eastern Iberian cluster	T081	C1704332
congruent	T080	C0439853
secondary	T081	C0205436
contact	T080	C0205556
evolution	T045	C0015219
mito-nuclear incompatibilities	T080	C0205556
geographically isolated areas	UnknownType	C0681784
Prevalence	T081	C0220900
Physical Activity	T056	C0026606
Sitting	T039	C2584297
Time	T079	C0040223
South Korean	T098	C1556095
Adolescents	T100	C0205653
Results	T033	C0683954
Korean	T098	C1556095
National Health and Nutrition Examination Survey	T062	C0376344
physical activity	T056	C0026606
PA	T056	C0026606
sitting	T039	C2584297
time	T079	C0040223
associations	T080	C0439849
sociodemographic factors	T078	C0011292
weight	T032	C0005910
status	T080	C0449438
PA	T056	C0026606
sitting	T039	C2584297
time	T079	C0040223
South Korean	T098	C1556095
adolescents	T100	C0205653
years	T079	C1510829
Findings	T169	C2607943
self-report data	T062	C2700446
participants	T098	C0679646
Korea	T083	C0022771
National Health and Nutrition Examination Survey	T062	C0376344
adolescents	T100	C0205653
minutes	T079	C0439232
moderate-to-vigorous PA	T056	C0026606
daily	T079	C0332173
Adolescents	T100	C0205653
mins/d	T079	C0556973
sitting	T039	C2584297
age	T032	C0001779
sex	T032	C0079399
individuals	T098	C0027361
higher income groups	T098	C0019532
compared	T052	C1707455
lowest income group	T098	C0024045
living	T052	C2982691
nonmetro	T082	C1254362
Seoul	T083	C3850150
compared	T052	C1707455
metro	T082	C0599587
Seoul	T083	C3850150
overweight	T184	C0497406
compared	T052	C1707455
nonoverweight	T032	C0005910
PA	T056	C0026606
guidelines	T170	C0162791
Participants	T098	C0679646
highest income group	T098	C0019532
compared	T052	C1707455
lowest income group	T098	C0024045
residing	T052	C2982691
nonmetro	T082	C1254362
Seoul	T083	C3850150
compared	T052	C1707455
metro	T082	C0599587
Seoul	T083	C3850150
sitting	T039	C2584297
time	T079	C0040223
group	T078	C0441833
min/d	T079	C0556973
Increasing	T169	C0442808
PA	T056	C0026606
reducing	T080	C0392756
sitting	T039	C2584297
public health	T170	C3244304
priority	T079	C0549179
South Korea	T083	C0022773
Graphene	T196	C2936695
Nafion	T109	C0068361
composite film	T167	C1561572
glassy	T080	C0522500
carbon electrode	T074	C3874229
simultaneous	T079	C0521115
determination	T059	C1148554
paracetamol	T109	C0000970
aspirin	T109	C0004057
caffeine	T109	C0006644
pharmaceutical formulations	T077	C1705957
graphene	T196	C2936695
Nafion	T109	C0068361
composite film	T167	C1561572
fabricated	T057	C0870840
glassy	T080	C0522500
carbon electrode	T074	C3874229
GR-NF/GCE	T074	C3874229
simultaneous	T079	C0521115
determination	T059	C1148554
paracetamol	T109	C0000970
PAR	T109	C0000970
aspirin	T109	C0004057
ASA	T109	C0004057
caffeine	T109	C0006644
CAF	T109	C0006644
electrochemical behaviors	T080	C0205556
PAR	T109	C0000970
ASA	T109	C0004057
CAF	T109	C0006644
investigated	T169	C1292732
cyclic voltammetry	UnknownType	C0683134
square-wave adsorptive anodic stripping voltammetry	T059	C0201748
stripping	T059	C0201748
simultaneous	T079	C0521115
determination	T059	C1148554
PAR	T109	C0000970
ASA	T109	C0004057
CAF	T109	C0006644
electrochemical oxidation peaks	T080	C0444505
appeared	T080	C0700364
good	T080	C0205170
linear current responses	T080	C0205556
obtained	T169	C1301820
detection limits	T081	C2718050
proposed	T078	C1705535
electrochemical sensor	T073	C0183210
successfully	T080	C1272703
applied	T169	C4048755
quantifying	T081	C1709793
PAR	T109	C0000970
ASA	T109	C0004057
CAF	T109	C0006644
commercial	T170	C0680536
tablet formulations	T077	C1705957
Long-term	T079	C0443252
antibiofilm activity	T052	C0441655
carboxymethyl chitosan	T109	C1744331
mixed biofilm	T007	C0081786
silicone	T109	C0037114
Silicone	T109	C0037114
voice prostheses	T074	C0087165
frequently	T079	C0332183
voice rehabilitation	T061	C0199531
laryngectomized	T061	C0023065
patients	T101	C0030705
functional device	T033	C1385354
lifetimes	T079	C4071830
limited	T169	C0439801
due to	T169	C0678226
formation	T169	C1522492
mixed biofilms	T007	C0081786
in vitro models	T062	C1515654
biofilm formation	T043	C1325881
restricted	T169	C0443288
short-term	T079	C0443303
periods	T079	C1948053
goal	T170	C0018017
study	T062	C2603343
effect	T080	C1280500
carboxymethyl chitosan	T109	C1744331
mixed biofilm formation	T043	C1325881
fungi	T004	C0016832
bacteria	T007	C0004611
silicone	T109	C0037114
long-term	T079	C0443252
period	T079	C1948053
species	T185	C1705920
biofilms	T007	C0081786
Candida albicans	T004	C0006837
Candida tropicalis	T004	C0319882
Lactobacillus gasseri	T007	C0317620
Streptococcus salivarius	T007	C0318179
Rothia dentocariosa	T007	C0318071
Staphylococcus epidermidis	T007	C0038174
cultivated	T067	C1254366
surfaces	T082	C0205148
medical-grade silicone	T109	C0037114
carboxymethyl chitosan	T109	C1744331
Biofilm kinetics	T070	C0022702
designed image analysis software	T170	C3203922
calculate	T052	C1441506
percentual surface covering	T169	C0205245
platelet	T025	C0005821
Biofilm architecture	T082	C1254362
investigated	T169	C1292732
scanning electron microscopy	T059	C0026020
cover	T169	C1999244
living	T078	C0376558
mixed biofilm	T007	C0081786
days	T079	C0439228
silicone	T109	C0037114
maximum	T081	C0806909
biofilm	T007	C0081786
surface covering	T169	C0205245
day	T079	C0439228
less than	T081	C0439092
surface coverage	T169	C1999244
observed	T169	C1441672
carboxymethyl chitosan	T109	C1744331
treated	T169	C1522326
testing	T169	C0039593
period	T079	C1948053
Scanning electron microscopy	T059	C0026020
confirms	T033	C0750484
surfaces	T082	C0205148
treated	T169	C1522326
carboxymethyl chitosan	T109	C1744331
biofilm	T007	C0081786
less	T080	C0547044
dense	T080	C0439794
fewer	T081	C0205388
cells	T025	C0007634
profuse cellular debris	T033	C4055264
together	T080	C1883357
morphologically altered	T190	C1260954
yeast	T004	C0043393
yeast cells	T025	C0007634
Carboxymethyl chitosan	T109	C1744331
possible	T033	C0332149
antibiofilm agent	T167	C0439861
biofilm formation	T043	C1325881
voice prostheses	T074	C0087165
Laryngoscope	T074	C0180453
Spectral fingerprints	T059	C0037812
cortical	T023	C0007776
dynamics	T070	C3826426
during	T079	C0347984
ambiguous	T080	C0237467
motion perception	T041	C0026598
Ambiguous	T169	C1274012
stimuli	T067	C0234402
neuronal	T025	C0027882
correlates	T080	C1707520
consciousness	T041	C0234421
conscious	T041	C0234421
perception	T041	C0030971
dynamic	T169	C0729333
cortical areas	T023	C0007776
phase coupling	T042	C4042905
correlate	T080	C1707520
cortical	T023	C0007776
coupling modes	T042	C4042905
cortical functions	T042	C0234393
coupling modes	T042	C4042905
phase and envelope coupling	T042	C4042905
dynamics	T070	C3826426
EEG	T060	C0013819
participants	T098	C0679646
bistable motion task	T060	C0025365
connectivity	T169	C1707489
analysis	T062	C0936012
techniques	T169	C0449851
functional relevance	T077	C2700217
coupling modes	T042	C4042905
cortical	T023	C0007776
gamma-band phase coupling	T042	C4042905
extrastriate	T029	C3498366
visual cortex	T023	C0042817
visual tokens	T060	C0031734
moving	T040	C0560560
stimulus	T067	C0234402
ambiguous	T080	C0237467
visual stimulation	T060	C0031734
envelope coupling	T042	C4042905
ambiguous	T080	C0237467
motion perception	T041	C0026598
local parieto-occipital	T023	C1518897
alpha-band phase coupling	T042	C4042905
hemispheric	T082	C0205139
information transfer	T169	C0205245
correlative	T080	C1707520
evidence	T078	C3887511
synchronized	T079	C0439580
brain activity	T039	C0443158
processing of sensory	T042	C1327511
information integration	T040	C0679019
spatiotemporal scales	T062	C3494293
distinct coupling modes	T081	C0392762
cortical	T023	C0007776
computations	T052	C1880157
spatiotemporal correlation	T062	C3494293
structure of the brain	T023	C0006104
functional	T169	C0205245
cortical	T023	C0007776
Beneficial effects	UnknownType	C0683156
voglibose	T109	C0532578
administration	T061	C1533734
body weight	T032	C0005910
lipid metabolism	T044	C0598783
gastrointestinal	T022	C0012240
bile acid	T109	C0005390
modification	UnknownType	C0579005
study	T062	C0008972
goal	T170	C0018017
effects	T169	C0728866
voglibose	T109	C0532578
administration	T061	C1533734
body weight	T032	C0005910
lipid metabolism	T044	C0598783
mechanism	T169	C0441712
high fat diet	T061	C0521974
obese mice	T015	C0025933
Male	T032	C0086582
C57BL/6 mice	T015	C1521751
groups	T096	C1642385
control diet	T096	C0009932
CTL	T096	C0009932
high-fat diet	T096	C1642385
HF	T096	C1642385
high-fat diet supplemented with voglibose	T096	C1642385
VO	T096	C1642385
high fat diet pair-fed group	T096	C1642385
PF	T096	C1642385
weeks	T079	C0439230
characteristics	T080	C1521970
serum lipid	T059	C0428462
glucose levels	T034	C0583332
expression levels	T081	C3244092
genes	T028	C0017337
lipid	T044	C0598783
bile acid metabolism	T044	C0678714
pyrosequencing	T059	C2732543
composition	T201	C0486616
gut microbiota	T001	C2985398
feces	T031	C0015733
Total body weight gain	T033	C0043094
significantly lower	T081	C4055638
VO group	T096	C1642385
CTL	T096	C0009932
HF	T096	C1642385
PF groups	T096	C1642385
VO group	T096	C1642385
metabolic profiles	T039	C3853758
blood glucose	T059	C0392201
triglyceride	T034	C0428475
total cholesterol levels	T034	C0428466
week	T079	C0439230
voglibose	T109	C0532578
administration	T061	C1533734
Firmicutes	T007	C1254144
Bacteroidetes	T007	C0995456
feces	T031	C0015733
levels	T080	C0441889
taurocholic	T109	C0039358
cholic acid	T109	C0055568
significantly higher	T081	C4055637
VO group	T096	C1642385
HF	T096	C1642385
CTL groups	T096	C0009932
Deoxycholic acid	T109	C0011479
levels	T080	C0441889
VO group	T096	C1642385
HF group	T096	C1642385
Voglibose	T109	C0532578
administration	T061	C1533734
downregulated	T044	C0013081
expression levels	T081	C3244092
CYP8B1	T028	C1413895
HNF4α genes	T028	C1415629
upregulated	T044	C0041904
PGC1α	T028	C1418779
FXRα	T028	C1417825
Voglibose	T109	C0532578
administration	T061	C1533734
composition	T201	C0486616
intestinal microbiota	T001	C2985398
circulating metabolites	T123	C0870883
systemic effects	UnknownType	C0678788
body weight	T032	C0005910
lipid metabolism	T044	C0598783
mice	T015	C0025929
Supramolecular Recognition	T044	C0599844
Amino Acids	T116	C0002520
Twisted Cucurbit[14]uril	T109	C1737934
Binding	T044	C1167622
interactions	T169	C1704675
between	T082	C0205103
twisted cucurbit[14]uril	T109	C1737934
(tQ[14])	T109	C1737934
standard	T080	C1442989
amino acids	T116	C0002520
(AAs)	T116	C0002520
investigated	T169	C1292732
NMR spectroscopy	T060	C0877853
isothermal titration calorimetry	T059	C0006779
(ITC)	T059	C0006779
aqueous	T121	C0043047
HCl solutions	T130	C0020259
DMSO	T109	C0012403
results	T169	C1274040
tQ[14]	T109	C1737934
displays	T169	C0870432
binding	T044	C1167622
affinity	T070	C1510827
AAs	T116	C0002520
positively charged side chain	T104	C1254350
containing	T169	C0332256
aromatic ring	T109	C0020245
weaker	T080	C1762617
binding	T044	C1167622
affinity	T070	C1510827
AAs	T116	C0002520
hydrophobic	T120	C1254355
polar side chains	T120	C1254355
binding	T044	C1167622
mode	T169	C1513371
side chain	T104	C1254350
AAs	T116	C0002520
Comparison	T052	C1707455
alkaline phosphatase activity	T044	C1149888
MC3T3-E1 cells	T025	C0007600
Ti	T196	C0040302
surfaces	T082	C0205148
sandblasted	T067	C1254366
grit	T104	C0440273
acid-etched	T067	C1254366
MSLA	T196	C0040302
laser-treated	T067	C1254366
laser and acid-treated	T067	C1254366
Ti	T196	C0040302
surfaces	T082	C0205148
study	T062	C2603343
study	T062	C2603343
evaluate	T058	C0220825
surface	T082	C0205148
cell differentiation	T043	C0007589
osteoblast cells	T025	C0029418
surfaces	T082	C0205148
grit	T104	C0440273
NaCl	T121	C0037494
laser treatment	T067	C1254366
LT	T067	C1254366
laser treatment	T067	C1254366
titanium	T196	C0040302
surface	T082	C0205148
laser and acid-treated	T067	C1254366
laser treatment, acid-etched	T067	C1254366
titanium	T196	C0040302
surface	T082	C0205148
MSLA	T196	C0040302
surfaces	T082	C0205148
control group	T096	C0009932
LT	T196	C0040302
LAT	T196	C0040302
surfaces	T082	C0205148
test groups	T078	C0441833
Alkaline phosphatase	T116	C0002059
expression	T045	C1171362
ALP	T116	C0002059
osteoblastic differentiation	T043	C1159974
MC3T3-E1 cell	T025	C0007600
Surface	T082	C0205148
roughness	T080	C0205556
evaluated	T058	C0220825
contact profilometer	T074	C0025080
Japan	T083	C0022341
mean roughness	T080	C0205556
Ra	T080	C0205556
maximum peak-to-valley height	T081	C0392762
Rt	T081	C0392762
Scanning electron microscope	T074	C0262878
control group	T096	C0009932
surface	T082	C0205148
rough	T080	C0205556
LT	T196	C0040302
LAT	T196	C0040302
surface	T082	C0205148
test groups	T078	C0441833
Alkaline phosphatase	T116	C0002059
expression	T045	C1171362
osteoblastic differentiation	T043	C1159974
ALP	T116	C0002059
expression	T045	C1171362
surface-adherent cells	T025	C0007634
days	T079	C0439228
surfaces	T082	C0205148
ALP	T116	C0002059
expression	T045	C1171362
levels	T080	C0441889
MSLA	T196	C0040302
LAT	T196	C0040302
surfaces	T082	C0205148
expression	T045	C1171362
levels	T080	C0441889
LT	T196	C0040302
surface-adherent cells	T025	C0007634
days	T079	C0439228
ALP	T116	C0002059
expression	T045	C1171362
levels	T080	C0441889
MSLA	T196	C0040302
LAT	T196	C0040302
surface	T082	C0205148
days	T079	C0439228
study	T062	C2603343
MSLA	T196	C0040302
LAT	T196	C0040302
surfaces	T082	C0205148
favorable	T080	C3640814
environment	T082	C0014406
osteoblast differentiation	T043	C1159974
LT	T196	C0040302
surface	T082	C0205148
implant	T074	C0021102
surface	T082	C0205148
modification	T169	C0392747
studies	T062	C2603343
Overcoming	T052	C2983310
structural	T082	C0678594
inequalities	T080	C0242503
oral health	T058	C0029162
dental	T058	C0011365
curricula	T170	C0010478
health professional schools	T073	C0036376
oral health	T058	C0029162
inequalities	T080	C0242503
attempts	T051	C1516084
focused	T169	C1285542
systemic	T169	C0205373
reform	T078	C0870472
societal obligations	T078	C0028761
Professionalism	T078	C4046065
competency	T080	C0086035
dental schools	T073	C0036376
range	T081	C1514721
Professionalism	T078	C4046065
competency	T080	C0086035
debate	T052	C0870392
shifting phenomenon	T169	C0392747
professionalism	T078	C4046065
dental	T058	C0011365
curricula	T170	C0010478
social accountability	T078	C0037394
Social accountability	T078	C0037394
oral health	T058	C0029162
professional curricula	T170	C0010478
education	T185	C0013622
research	T062	C0035168
service activities	T058	C1254363
priority	T079	C0549179
health	T078	C0018684
concerns	T078	C2699424
community	T096	C0009462
oral health	T058	C0029162
inequalities	T080	C0242503
dental schools	T073	C0036376
socially accountable	T078	C0037394
address	T170	C0376649
oral health	T058	C0029162
inequalities	T080	C0242503
dental	T058	C0011365
curricula	T170	C0010478
political	T068	C0032380
structural	T082	C0678594
social	T102	C0337460
ethical	T078	C0026531
factors	T169	C1521761
influence	T077	C4054723
institutions	T093	C2607850
graduates	T098	C0588053
Function	T169	C0542341
analysis	T062	C0936012
Mef2c	T028	C1417102
promoter	T114	C0086860
muscle differentiation	T043	C1326080
Regeneration of adult skeletal muscle	T042	C2752380
injury	T037	C3263722
activation	T043	C1326120
satellite cells	T025	C0599856
proliferates	T043	C0596290
differentiates	T043	C0007589
fuses	T043	C1261468
injured	T169	C0332664
myofibers	T023	C3899956
Myocyte enhancer factor 2 (MEF2) proteins	T116	C3658245
adult	T100	C0001675
muscle regeneration	T033	C1850849
Mef2c gene	T028	C1417102
promoter	T114	C0086860
pig	T015	C0039005
Mef2c gene	T028	C1417102
Quantitative real-time PCR	T063	C3179034
qRT-PCR	T063	C3179034
expression	T045	C0017262
Mef2c gene	T028	C1417102
muscle	T024	C0026845
tissues	T024	C0040300
Mef2c	T028	C1417102
promoter	T114	C0086860
transcriptional activity	T045	C0040649
differentiated	T043	C0007589
C2C12 cells	T025	C0007634
proliferating	T043	C0596290
C2C12 cells	T025	C0007634
up-regulation	T045	C0162493
mRNA expression	T045	C1515670
Mef2c gene	T028	C1417102
Function	T169	C0542341
deletion	T045	C0017260
mutation	T045	C0026882
analyses	T062	C0936012
MyoD	T116	C0165230
MEF2	T116	C3658245
binding sites	T087	C1514535
Mef2c	T028	C1417102
promoter	T114	C0086860
regulation	T045	C1158770
Mef2c	T028	C1417102
transcription	T045	C0040649
MEF2C	T028	C1417102
up-regulate the transcriptional activities	T045	C0162493
Mef2c	T028	C1417102
promoter constructs	T114	C0086860
3'-end nucleotide sequence	T086	C0314659
p300	T116	C1530358
binding site	T086	C0004793
Electrophoretic mobility shift assays	T059	C0949632
EMSA	T059	C0949632
chromatin immunoprecipitation (ChIP) assays	T059	C1328856
MyoD	T116	C0165230
binding site	T087	C1514535
Mef2c	T028	C1417102
promoter	T114	C0086860
promoter	T114	C0086860
pig	T015	C0039005
Mef2c gene	T028	C1417102
Mef2c	T028	C1417102
promoter	T114	C0086860
regulation mechanisms	T045	C1158770
Mef2c	T028	C1417102
muscle differentiation	T043	C1326080
muscle repair	T061	C0185414
regeneration	T033	C1850849
diabetic	T033	C0241863
bladder disorder	T047	C0005686
metabolomic analysis	T091	C1328813
rat	T015	C0034721
diabetic	T033	C0241863
detrusor	T023	C1180419
urothelial layer	T024	C0227692
changes	T169	C0392747
bladder	T023	C0005682
metabolism	T040	C0025519
diabetes	T047	C0011847
diabetic	T033	C0241863
bladder disorder (DBD)	T047	C0005686
metabolome	T070	C2350399
detrusor	T023	C1180419
urothelial layer	T024	C0227692
streptozotocin	T109	C0038432
rat	T015	C0034721
model	T050	C0012644
type 1 diabetes	T047	C0011854
nondiabetic controls	T096	C0009932
diabetes	T047	C0011847
changes	T169	C0392747
detrusor	T023	C1180419
urothelial layer's	T024	C0227692
metabolome	T070	C2350399
Diabetes	T047	C0011847
changes	T169	C0392747
diabetic	T047	C0011847
markers	T201	C0005516
tissues	T024	C0040300
glucose	T109	C0017725
lactate	T109	C0064582
2-hydroxybutyrate	T109	C0046188
branched-chain amino acid degradation products	T116	C3494275
bile acids	T109	C0005390
1,5-anhydroglucitol	T109	C0044029
markers	T201	C0005516
oxidative stress	T049	C0242606
detrusor	T023	C1180419
urothelial layer	T024	C0227692
diabetes	T047	C0011847
pentose-phosphate	T109	C0030893
polyol	T109	C0071629
pathways	T044	C1704259
TCA cycle	T044	C1516586
β-oxidation	T044	C1158368
Changes	T169	C0392747
detrusor	T023	C1180419
energy-generating pathways	T044	C1158271
sorbitol	T109	C0037688
advanced glycation end products	T109	C0162574
DBD	T047	C0005686
diabetic	T033	C0241863
urothelial layer	T024	C0227692
flux	T070	C2348693
glucose	T109	C0017725
glycolysis	T044	C0017952
changes	T169	C0392747
changes	T169	C0392747
lipid metabolism	T044	C0598783
prostaglandin	T109	C0033554
synthesis	T052	C1883254
detrusor	T023	C1180419
dysfunction	T046	C0277785
Proximal Soil Sensing	T059	C0022885
Contribution	T052	C1880177
Species	T185	C1705920
Habitat	T082	C0871648
Distribution	T169	C1704711
Modelling	T062	C0870071
Earthworms	T204	C0086194
Agricultural	T082	C0562975
Soils	T167	C0037592
Earthworms	T204	C0086194
soil	T167	C0037592
ecosystem	T070	C0162358
functioning	T169	C0542341
indicators	T130	C0021212
soil	T167	C0037592
fertility	T080	C0205556
earthworms	T204	C0086194
time-consuming	T080	C3827829
assessment	T052	C1516048
earthworm	T204	C0086194
abundances	T080	C2346714
sampling	T078	C0870078
density	T081	C0178587
fields	T082	C0562975
mobile terrestrial sensor platforms	T073	C0183210
proximal soil sensing	T059	C0022885
PSS	T059	C0022885
tools	T073	C0336791
information	T078	C1533716
soils	T167	C0037592
sensing principles	T170	C0282574
PSS	T059	C0022885
assessing	T052	C1516048
earthworm	T204	C0086194
habitats	T082	C0871648
study	T062	C2603343
investigates	T169	C1292732
PSS	T059	C0022885
data	T078	C1511726
prediction	T078	C0681842
earthworm	T204	C0086194
abundances	T080	C2346714
species	T185	C1705920
distribution	T169	C1704711
models	T170	C3161035
agricultural	T082	C0562975
soils	T167	C0037592
Proximal soil sensing	T059	C0022885
data	T078	C1511726
soil	T167	C0037592
electrical conductivity	T081	C0013777
EC	T081	C0013777
pH	T081	C0020283
near infrared absorbance	T059	C0376519
NIR	T059	C0376519
collected	T078	C1516695
real-time	T079	C1550177
field	T082	C0562975
management strategies	T170	C0680830
reduced	T080	C0392756
tillage	T067	C1254366
tillage	T067	C1254366
sandy	T167	C0037592
loam soils	T167	C0037592
PSS	T059	C0022885
observations	T062	C0302523
long-term	T079	C0443252
years	T079	C0439234
earthworm	T204	C0086194
observation study	T033	C0552617
plots	T082	C0562975
Earthworms	T204	C0086194
sampled	T078	C0870078
soil	T167	C0037592
identified	T080	C0205396
species	T185	C1705920
level	T080	C0441889
Sensor	T075	C0600364
data	T078	C1511726
earthworm	T204	C0086194
abundances	T080	C2346714
observed	T169	C1441672
reduced	T080	C0392756
tillage	T067	C1254366
correlated	T080	C1707520
earthworm	T204	C0086194
abundances	T080	C2346714
observed	T169	C1441672
conventional tillage	T067	C1254366
management	T057	C1273870
influences	T077	C4054723
sensor	T075	C0600364
earthworm	T204	C0086194
models	T170	C3161035
state-space models	T170	C3161035
modelling	T062	C0870071
data	T078	C1511726
EC	T081	C0013777
pH	T081	C0020283
NIR	T059	C0376519
sensors	T075	C0600364
results	T033	C0683954
modelling	T062	C0870071
sensor	T075	C0600364
data	T078	C1511726
data	T078	C1511726
sensor	T075	C0600364
earthworm	T204	C0086194
species	T185	C1705920
sensor	T075	C0600364
habitat	T082	C0871648
requirements	T169	C1514873
earthworms	T204	C0086194
Earthworm	T204	C0086194
species	T185	C1705920
soil	T167	C0037592
habitat	T082	C0871648
preferences	T078	C0558295
accuracy	T080	C0443131
PSS	T059	C0022885
ubiquitous	T080	C2348867
species	T185	C1705920
findings	T033	C0243095
PSS	T059	C0022885
modelling	T062	C0870071
earthworm	T204	C0086194
abundances	T080	C2346714
field scale	UnknownType	C0814860
species	T185	C1705920
distribution	T169	C1704711
modelling	T062	C0870071
soil	T167	C0037592
earthworm	T204	C0086194
agroecosystems	T070	C0162358
Size	T081	C0870226
Brain volume	T081	C1113695
correlates	T080	C1707520
intrinsic	T082	C0205102
brain activity	T039	C0443158
healthy	T080	C3898900
individuals	T098	C0027361
neuroscience	T091	C0027910
structural	T082	C0678594
substrates	T169	C1521761
Intrinsic	T082	C0205102
brain activity	T039	C0443158
cognitive functions	T041	C0392335
cognitive functions	T041	C0392335
brain volume	T081	C1113695
size	T081	C0870226
association	T080	C0439849
intrinsic	T082	C0205102
brain activities	T039	C0443158
brain volume	T081	C1113695
size	T081	C0870226
brain volume	T081	C1113695
size	T081	C0870226
impact	T080	C4049986
intrinsic	T082	C0205102
brain activity	T039	C0443158
human	T016	C0086418
brains	T023	C0006104
study	T062	C2603343
investigate	T169	C1292732
brain structure	T023	C0006104
function	T039	C0031843
relationship	T080	C0439849
cohorts	T098	C0599755
young adults	T100	C0238598
Structural	T082	C0678594
MRI	T060	C0024485
performed	T169	C0884358
estimate	T081	C0750572
brain volume	T081	C1113695
resting-state functional-MRI	T060	C4288291
amplitude of low-frequency fluctuations	T081	C0392762
ALFF	T081	C0392762
intrinsic	T082	C0205102
brain activity	T039	C0443158
linear	T082	C0205132
correlation	T080	C1707520
whole-brain size	T081	C0870226
ALFF	T081	C0392762
specific	T080	C0205369
brain lobes	T023	C0228179
regions	T029	C1273723
frontal lobe	T023	C0016733
left middle frontal gyrus	T023	C2338540
anterior cingulate gyrus	T023	C0175190
Rolandic operculum	T023	C0228265
insula	T023	C0021640
reliable	T080	C0205556
positive	T033	C1446409
volume	T081	C1113695
ALFF	T081	C0392762
correlation	T080	C1707520
cohorts	T098	C0599755
direct	T080	C1947931
empirical	T080	C1880496
evidence of	T169	C0332120
strong	T080	C0442821
association	T080	C0439849
brain size	T081	C0870226
volume	T081	C1113695
intrinsic	T082	C0205102
brain activity	T039	C0443158
structural	T082	C0678594
substrates	T169	C1521761
intrinsic	T082	C0205102
brain activity	T039	C0443158
human	T016	C0086418
brain	T023	C0006104
Control	T169	C2587213
Social	T169	C0728831
Approach-Avoidance Behavior	T033	C0562433
Neural	T169	C3714606
Endocrine	T169	C0521425
Mechanisms	T169	C0441712
ability	T032	C0085732
control	T169	C2587213
automatic	T169	C0205554
action	T052	C3266814
tendencies	T078	C0750492
crucial	T080	C1511545
adequate	T080	C0205411
social interactions	T033	C0037420
Emotional	T033	C0849912
events	T051	C0441471
trigger	T080	C1444748
automatic	T169	C0205554
approach and avoidance	T033	C0562433
tendencies	T078	C0750492
actions	T052	C3266814
adaptive	T169	C0231193
capacity	T081	C1516240
override	T052	C1547671
emotional reactions	T033	C0221736
key	T077	C1706198
flexible	T080	C0443220
behavior	T053	C0004927
social interaction	T033	C0037420
present	T079	C0521116
chapter	T078	C1552857
provides	T052	C1999230
review	T078	C1552617
neuroendocrine	T022	C0027912
mechanisms	T169	C0441712
ability	T032	C0085732
relation	T080	C0439849
social	T169	C0728831
psychopathologies	T091	C0033927
Aberrant	T080	C0443127
social behavior	T054	C0037397
observed	T169	C1441672
social anxiety	T048	C4237417
psychopathy	T048	C0031212
marked	T080	C1706089
abnormalities	T033	C1704258
approach-avoidance	T033	C0562433
tendencies	T078	C0750492
ability	T032	C0085732
control	T169	C2587213
Key	T077	C1706198
neural	T169	C3714606
regions	T082	C0205147
involved	T169	C1314939
regulation	T038	C1327622
approach-avoidance behavior	T033	C0562433
amygdala	T023	C0002708
implicated	T080	C4049986
automatic	T169	C0205554
emotional	T033	C0849912
processing	T041	C0025361
anterior	T082	C0205094
prefrontal cortex	T023	C0162783
exerts	T040	C0015264
control	T169	C2587213
amygdala	T023	C0002708
Hormones	T125	C0019932
testosterone	T109	C0039601
cortisol	T109	C0020268
affect	T041	C0001721
approach-avoidance behavior	T033	C0562433
associated	T080	C0332281
neural	T169	C3714606
mechanisms	T169	C0441712
present	T079	C0521116
chapter	T078	C1552857
directly	T080	C1947931
influence	T077	C4054723
social	T169	C0728831
approach and avoidance behavior	T033	C0562433
research	T062	C0035168
agenda	T170	C0681473
advance	T169	C1527148
important	T080	C3898777
research field	T062	C0035168
Control	T169	C2587213
approach-avoidance	T033	C0562433
tendencies	T078	C0750492
exemplar	T170	C3161035
emotional	T033	C0849912
action	T052	C3266814
regulation	T038	C1327622
great	T081	C1704243
value	T080	C3827682
understanding	T041	C0162340
mechanisms	T169	C0441712
development	T169	C1527148
affective disorders	T048	C0001723
Non-Clear Cell Renal Cell Carcinoma	T191	C0007134
Oman	T083	C0028971
renal cell carcinoma	T191	C0007134
RCC	T191	C0007134
older patients	T101	C0030705
clear cell type	T191	C0279702
histology	T091	C0019638
ethnic variations	T080	C0205419
study	T062	C2603343
epidemiological pattern	UnknownType	C0681682
RCC	T191	C0007134
Oman	T083	C0028971
RCC	T191	C0007134
patients	T101	C0030705
presented	T078	C0449450
tertiary care center	T073	C0587437
Sultanate of Oman	T083	C0017446
studied	T062	C2603343
main findings	T033	C0243095
median age	T032	C0001779
presentation	T078	C0449450
low	T080	C0205251
patients	T101	C0030705
presented	T078	C0449450
localized	T082	C0392752
stage	T079	C1306673
non-clear	T191	C0007134
papillary	T191	C1306837
histology	T091	C0019638
Data	T078	C1511726
Gulf countries	T083	C0454664
Patient Mobility	T061	C2094221
Elective	UnknownType	C0814500
Secondary Health Care Services	T058	C0018747
Response	T041	C2911692
Patient Choice Policies	T089	C0600591
Systematic Review	T170	C1955832
empirical	T080	C1880496
evidence	T078	C3887511
patient mobility	T061	C2094221
elective secondary care services	T058	C3494402
countries	T083	C0454664
patients	T101	C0030705
health care provider	T097	C1999121
PubMed	T170	C1138432
Embase	T170	C0282574
articles	T170	C1706852
titles	T170	C1705823
abstracts	T170	C0600678
reviewed	T080	C1709940
studies	T062	C0008972
studies	T062	C0008972
methodological	T057	C0025662
models	T170	C3161035
mobility	T033	C0425245
Variation	T080	C0205419
patient mobility	T061	C2094221
Mobility	T033	C0425245
associated with	T080	C0332281
lower waiting times	T079	C0814636
indicators	T169	C1522602
better service quality	T058	C0034379
advanced technology	T092	C1510819
advanced age	T098	C0001792
socioeconomic	T077	C0748878
policy	T170	C0242456
perspective	T170	C0032670
proportion	T081	C1709707
patients	T101	C0030705
travel	T056	C0040802
provider	T097	C1999121
elective services	UnknownType	C0814500
providers	T097	C1999121
winners	T058	C0511302
losers	T033	C0243095
decreased	T081	C0205216
provider	T097	C1999121
capacity	T081	C1516240
inefficient	T169	C0231185
services	T058	C0018747
Equity	T080	C4042901
New	T080	C0205314
Breast Pain	T184	C0024902
Chart	T074	C0007963
Objective Record	T170	C0034869
Mastalgia	T184	C0024902
Mastalgia	T184	C0024902
commonest	T081	C0205214
affliction	T041	C0018235
mammary gland	T023	C0929301
ladies	T098	C0043210
reproductive	T079	C0035156
age group	T100	C0027362
etiopathogenesis	T169	C1510540
therapy	T061	C0087111
different	T080	C1705242
cyclical	T184	C0405472
noncyclical pain	T184	C0405473
breast clinics	T073	C3810844
patient	T101	C0030705
pain diary	T170	C0451366
period	T079	C1948053
months	T079	C0439231
menstrual cycles	T040	C0025329
Cardiff pain chart records	T074	C0007963
severity	T080	C0439793
pain	T184	C0030193
triangle	T077	C0205119
mild	T080	C2945599
moderate pain	T184	C0278139
square	T082	C0205120
severe pain	T033	C0278140
Cardiff pain chart	T074	C0007963
patient	T101	C0030705
record	T080	C2355580
severity	T080	C0439793
pain	T184	C0030193
days	T079	C0439228
menses	T040	C0025344
problems	T033	C0033213
resolved	T077	C2699488
new	T080	C0205314
breast pain	T184	C0024902
chart	T074	C0007963
new	T080	C0205314
pain chart	T074	C0007963
lady	T098	C0043210
records	T080	C2355580
pain	T184	C0030193
severity	T080	C0439793
visual linear analogue scale score	T201	C2960751
every day	T079	C0332173
menstrual cycle	T040	C0025329
menstrual	T040	C0025329
experience	T041	C0596545
chart	T074	C0007963
visualize	T082	C0449911
month's	T079	C0439231
pain	T184	C0030193
severity	T080	C0439793
Cigarettes	T073	C0677453
Tanzania	T083	C0039298
Implications	UnknownType	C0814846
Tobacco	T109	C0040329
Taxation Policy	UnknownType	C0681007
study	T062	C2603343
cigarettes	T073	C0677453
Tanzania	T083	C0039298
simulation	T062	C0679083
results	T169	C1274040
effect	T080	C1280500
cigarette	T073	C0677453
excise tax	UnknownType	C0681045
smoking	T055	C0037369
participation	T169	C0679823
government revenue	UnknownType	C0681043
magnitude	T081	C1704240
cigarette consumption	T033	C0459840
country	T083	C0454664
African	T083	C0454695
countries	T083	C0454664
Tanzanian	T083	C0039298
household budget	T170	C0006347
survey	T170	C0038951
cigarettes	T073	C0677453
Tanzania	T083	C0039298
smoking	T055	C0037369
Tanzania	T083	C0039298
expenditure (income) groups	UnknownType	C0681860
Smoking	T055	C0037369
per capita consumption	UnknownType	C0681013
cigarettes	T073	C0677453
cigarettes	T073	C0677453
two-part demand equation model	T170	C3161035
elasticities	UnknownType	C0680960
equation	T077	C0552449
price elasticities	UnknownType	C0814751
smoking	T055	C0037369
participation	T169	C0679823
smoking	T055	C0037369
elasticity	UnknownType	C0680960
developing countries	T080	C0011750
expenditure (income) groups	UnknownType	C0681860
magnitude	T081	C1704240
elasticity	UnknownType	C0680960
high expenditure groups	UnknownType	C0681860
low expenditure groups	UnknownType	C0681860
simulation	T062	C0679083
effect	T080	C1280500
excise	UnknownType	C0681045
rates	T081	C1521828
smoking	T055	C0037369
participation rate	T081	C1521828
cigarette consumption	T033	C0459840
tax revenue	UnknownType	C0681043
effect	T080	C1280500
increase	T169	C0442805
cigarette	T073	C0677453
excise tax	UnknownType	C0681045
expenditure groups	UnknownType	C0681860
results	T169	C1274040
increase	T169	C0442805
excise tax	UnknownType	C0681045
cigarettes	T073	C0677453
Tanzania	T083	C0039298
cigarette consumption	T033	C0459840
increase	T169	C0442805
government tax revenue	UnknownType	C0681043
Physicians'	T097	C0031831
work-related	T047	C0871617
chronic obstructive pulmonary disease	T047	C0024117
Chronic obstructive pulmonary disease	T047	C0024117
COPD	T047	C0024117
work environment	T082	C0162579
conditions	T080	C0348080
estimates	T081	C0750572
COPD	T047	C0024117
cases	T169	C0868928
associated with	T080	C0332281
occupational exposure	T037	C0028798
dusts	T167	C0013330
irritant	T131	C0022108
gases	T104	C0017110
cases	T169	C0868928
work-related	T047	C0871617
COPD	T047	C0024117
Poland	T083	C0032356
study	T062	C2603343
analyze	T062	C0936012
low	T080	C0205251
incidence	T081	C0021149
work-related	T047	C0871617
COPD	T047	C0024117
context	T078	C0449255
pulmonologists	T097	C0586859
occupational	T169	C0521127
risk factors	T033	C0035648
procedures	T169	C2700391
reporting	T058	C0700287
suspected	T047	C0277540
occupational diseases	T047	C0028797
survey	T170	C0038951
pulmonologists	T097	C0586859
randomly	T080	C0439605
specialists	T097	C0920580
Local Physicians Chamber	T093	C1708333
Łódź	UnknownType	C0681784
study	T062	C2603343
performed	T169	C0884358
anonymously	T080	C2346787
questionnaire	T170	C0034394
surveyed	T170	C0038951
pulmonologists	T097	C0586859
identified	T080	C0205396
environmental	T082	C0014406
risk factors	T033	C0035648
COPD	T047	C0024117
identified	T080	C0205396
occupational	T169	C0521127
risk factors	T033	C0035648
cause	T078	C0085978
COPD	T047	C0024117
pulmonologists	T097	C0586859
patients	T101	C0030705
suffering	T033	C0231303
COPD	T047	C0024117
job	T090	C0028811
profession	T090	C0028811
procedures	T169	C2700391
reporting	T058	C0700287
suspected	T047	C0277540
occupational diseases	T047	C0028797
physicians	T097	C0031831
rarely	T080	C0522498
patients	T101	C0030705
suffering	T033	C0231303
COPD	T047	C0024117
job	T090	C0028811
profession	T090	C0028811
relationship	T080	C0439849
ailments	T184	C0221423
occupational exposure	T037	C0028798
legal regulations	T089	C0680575
referral of a patient	T058	C0034927
suspected	T047	C0277540
case	T169	C0868928
occupational disease	T047	C0028797
results	T169	C1274040
study	T062	C2603343
indicate	T078	C3146298
increasing	T169	C0442808
pulmonologists	T097	C0586859
work-related	T047	C0871617
COPD	T047	C0024117
Case Report	T170	C0085973
Necrotizing Fasciitis	T047	C0238124
Associated with	T080	C0332281
Streptococcus pneumoniae	T007	C0038410
Necrotizing fasciitis	T047	C0238124
Streptococcus pneumoniae	T007	C0038410
extremely rare	T080	C0522498
life-threatening	T033	C2826244
bacterial	T007	C0004611
soft tissue infection	T047	C0149778
report	T058	C0700287
case	T169	C0868928
necrotizing fasciitis	T047	C0238124
associated with	T080	C0332281
Streptococcus pneumoniae	T007	C0038410
infection	T046	C3714514
year	T079	C0439234
man	T098	C0025266
immunocompromised	T033	C0085393
mixed connective tissue disease	T047	C0026272
patient	T101	C0030705
acute	T079	C0205178
painful	T184	C0030193
erythematous	T169	C0332476
edematous skin	T046	C0521464
lesions	T033	C0221198
right lower back	T029	C0817923
progressed	T169	C1280477
right knee	T023	C0230431
patient	T101	C0030705
surgical exploration	T060	C0184899
diagnosis	T033	C0011900
necrotizing fasciitis	T047	C0238124
pathological	T169	C1521733
evidence	T078	C3887511
necrosis	T042	C0027540
fascia	T024	C0015641
neutrophil infiltration	T039	C0751982
tissue biopsies	T060	C3864006
Cultures	T059	C3826495
fascial	T029	C0015450
tissue biopsies	T060	C3864006
blood samples	T031	C0178913
positive	T033	C1446409
Streptococcus pneumoniae	T007	C0038410
report	T058	C0700287
necrotizing fasciitis	T047	C0238124
Streptococcus pneumoniae	T007	C0038410
diagnosed	T033	C0011900
phase	T079	C0205390
patient recovered	T032	C1115804
surgical debridement	T061	C0455097
Comparative Study	T062	C1579762
Efficacy	T080	C1280519
IV	T082	C0348016
Dexketoprofen	T109	C0772505
Lornoxicam	T109	C0055477
Diclophenac Sodium	T121	C1254351
Postoperative Analgesia	T061	C0853389
Tramadol	T109	C0040610
Consumption	UnknownType	C0678263
Patients	T101	C0030705
Patient-Controlled	T061	C0078944
Tramadol	T109	C0040610
study	T062	C2603343
designed	T052	C1707689
compare	T052	C1707455
effects of	T080	C1704420
dexketoprofen	T109	C0772505
lornoxicam	T109	C0055477
diclophenac sodium	T121	C1254351
postoperative analgesia	T061	C0853389
tramadol	T109	C0040610
consumption	UnknownType	C0678263
patients	T101	C0030705
postoperative	T079	C0032790
patient-controlled	T061	C0078944
tramadol	T109	C0040610
major	T080	C0205164
abdominal surgery	T061	C0198482
patients	T101	C0030705
randomized	T033	C3815594
study	T062	C2603343
drugs	T121	C1254351
Patients	T101	C0030705
group	T078	C0441833
dexketoprofen	T109	C0772505
DT	T109	C0772505
IV	T082	C0348016
dexketoprofen	T109	C0772505
group	T078	C0441833
lornoxicam	T109	C0055477
LR	T109	C0055477
IV	T082	C0348016
lornoxicam	T109	C0055477
group	T078	C0441833
diclophenac sodium	T121	C1254351
DS	T121	C1254351
IV	T082	C0348016
diclophenac sodium	T121	C1254351
group	T078	C0441833
saline	T167	C0036082
S	T167	C0036082
saline	T167	C0036082
syringes	T074	C0039142
min	T079	C0439232
anaesthesia	T061	C0002903
standardized	T080	C1442989
dose	T081	C0178602
tramadol	T109	C0040610
routinely	T080	C0205547
administered	T169	C1621583
patients	T101	C0030705
loading dose	T081	C3714444
surgery	T061	C0543467
Postoperatively	T079	C0032790
patients	T101	C0030705
tramadol	T109	C0040610
patient-controlled analgesia device	T033	C3266095
bolus dose	T061	C1511237
tramadol	T109	C0040610
Pain	T184	C0030193
discomfort	T184	C0231218
sedation	T033	C0235195
scores	T081	C0449820
cumulative	T080	C1511559
tramadol	T109	C0040610
consumption	UnknownType	C0678263
supplemental	T169	C2348609
meperidine	T109	C0025376
requirement	T169	C1514873
side effects	T046	C0879626
Visual rating scale	T081	C0681889
patient	T101	C0030705
discomfort	T184	C0231218
scores	T081	C0449820
significantly	T078	C0750502
lower	T052	C2003888
DT	T109	C0772505
LR	T109	C0055477
DS	T121	C1254351
groups	T078	C0441833
group	T078	C0441833
S	T167	C0036082
Cumulative	T080	C1511559
tramadol	T109	C0040610
consumption	UnknownType	C0678263
significantly	T078	C0750502
lower	T052	C2003888
non-steroidal anti-inflammatory drug	T121	C3536840
NSAID	T121	C3536840
treated	T169	C1522326
groups	T078	C0441833
study period	T062	C2347804
postoperative	T079	C0032790
hour	T079	C0439227
group	T078	C0441833
S	T167	C0036082
Supplemental	T169	C2348609
meperidine	T109	C0025376
requirement	T169	C1514873
significantly	T078	C0750502
group	T078	C0441833
S	T167	C0036082
study period	T062	C2347804
postoperative	T079	C0032790
min	T079	C0439232
NSAID	T121	C3536840
treated	T169	C1522326
groups	T078	C0441833
major	T080	C0205164
abdominal surgery	T061	C0198482
IV	T082	C0348016
diclophenac	T109	C0012091
lornoxicam	T109	C0055477
dexketoprofen	T109	C0772505
patient-controlled	T061	C0078944
tramadol	T109	C0040610
lower	T052	C2003888
pain	T184	C0030193
scores	T081	C0449820
smaller	T080	C0547044
tramadol	T109	C0040610
consumption	UnknownType	C0678263
supplemental	T169	C2348609
analgesic	T109	C0002771
requirement	T169	C1514873
side effects	T046	C0879626
tramadol	T109	C0040610
group	T078	C0441833
Perioperative Management	T058	C0150706
Severe Hypertension	T033	C4013784
Laparoscopic Surgery	T061	C0751429
Pheochromocytoma	T191	C0031511
Phaeochromocytoma	T191	C0031511
catecholamine-secreting	T043	C1325901
vascular tumour	T191	C0282607
chromaffin cell	T025	C0376604
Lethal	T033	C3151529
cardiovascular complications	T046	C0161816
hypertension	T047	C0020538
myocardial infarction	T047	C0027051
aortic dissection	T047	C0340643
uncontrolled catecholamine release	T191	C0271748
stage	T079	C0205390
anaesthesia management	T061	C1300200
destructive catecholamine secretion	T191	C0271748
induction	T061	C0857127
perioperative stage	T079	C1518988
surgical manipulation	T061	C0185111
preoperative preparation	T058	C0150706
severe, persistent hypertension attack management	T058	C1254363
α-adrenergic blockade	T121	C3536752
β-adrenergic blockade	T121	C3536830
sodium nitroprusside	T109	C0037533
remifentanil	T109	C0246631
patient	T101	C0030705
laparoscopic surgery	T061	C0751429
phaeochromocytoma	T191	C0031511
case	T169	C0868928
reflection	T033	C0243095
communicating end	T169	C0205196
life	T078	C0376558
information	T078	C1533716
non-English speaking	T033	C1546417
patients	T101	C0030705
year old	T079	C1510829
Chinese	T098	C0152035
man	T098	C0025266
non-English speaking	T033	C1546417
emergency department	T073	C0562508
non-specific	T080	C0205370
symptoms	T184	C1457887
diagnosed	T033	C0011900
advanced cancer of the pancreas	T191	C0235974
aggressive	T191	C2945759
treatment resistant cancer	T047	C0871547
poor prognosis	T033	C0278252
diagnosis	T033	C0011900
family	T099	C0015576
team	T058	C0086390
medical	T169	C0205476
issues	T033	C0033213
diagnosis	T033	C0011900
support	T077	C1521721
family	T099	C0015576
diagnosis	T033	C0011900
collective will	UnknownType	C0680341
information	T078	C1533716
medical	T169	C0205476
discussion	T061	C0557061
doctor in charge	T097	C0031831
diagnosis	T033	C0011900
interpreter	T097	C0150646
family	T099	C0015576
bed	T073	C0004916
case	T169	C0868928
respecting patients' and families' preferences	T061	C1279750
medical treatment and care	T058	C0237726
Difference-in-Differences Method	T062	C1710191
Comparative Effectiveness Research	T062	C2718022
Unbalanced Groups	UnknownType	C0681860
Comparative effectiveness research	T062	C2718022
CER	T062	C2718022
observational studies	T170	C3658316
administrative data	T033	C1320722
CER	T062	C2718022
group	UnknownType	C0681860
differences	T080	C1705242
difference-in-differences (DiD) estimation	T062	C1710191
DiD	T062	C1710191
method	T170	C0025663
treatment outcomes	T080	C0085415
CER	T062	C2718022
MarketScan® Databases	T170	C0242356
multiple sclerosis	T047	C0026769
MS	T047	C0026769
patients	T101	C0030705
therapies	T061	C0087111
patients	T101	C0030705
Test Cohort	T098	C2348484
glatiramer acetate	T116	C0289884
GA	T116	C0289884
switched	T058	C2936279
fingolimod	T109	C1699926
FTY	T109	C1699926
Control Cohort	T096	C0009932
GA	T116	C0289884
no switch	T033	C0243095
US administrative claims database	T170	C0242356
trend analysis	UnknownType	C0681702
regression	T170	C0034980
mean	T081	C0444504
relapse	T067	C0035020
treatment cohorts	T098	C2348484
DiD analysis	T062	C1710191
comparisons	T052	C1707455
Test	T098	C2348484
Control Cohorts	T096	C0009932
Logistic regression	T062	C0206031
probability	T081	C0033204
relapse	T067	C0035020
switching	T058	C2936279
GA	T116	C0289884
FTY	T109	C1699926
compare	T052	C1707455
group	UnknownType	C0681860
differences	T080	C1705242
pre	T079	C0332152
post	T079	C0687676
index periods	T079	C1948053
DiD analysis	T062	C1710191
pre	T079	C0332152
index period	T079	C1948053
patients	T101	C0030705
Test Cohort	T098	C2348484
MS	T047	C0026769
relapse	T067	C0035020
mean number	T081	C0444504
relapses	T067	C0035020
Control Cohort	T096	C0009932
pre	T079	C0332152
index period	T079	C1948053
numeric	T080	C1704455
MS	T047	C0026769
relapses	T067	C0035020
patients	T101	C0030705
Test Cohort	T098	C2348484
Control Cohort	T096	C0009932
no significant	T033	C1273937
group	UnknownType	C0681860
differences	T080	C1705242
post	T079	C0687676
index period	T079	C1948053
linear modeling	T081	C0023732
DiD	T062	C1710191
regression estimation	UnknownType	C0681925
MS	T047	C0026769
relapses	T067	C0035020
post	T079	C0687676
index period	T079	C1948053
patients	T101	C0030705
Test Cohort	T098	C2348484
patients	T101	C0030705
Control Cohort	T096	C0009932
MS	T047	C0026769
population	T098	C1257890
DiD	T062	C1710191
treatment effects	T033	C1518681
heterogeneous	T080	C0019409
population	T098	C1257890
Test	T098	C2348484
Control Cohorts	T096	C0009932
DiD	T062	C1710191
comparing	T052	C1707455
diverse	T080	C1880371
cohorts	T098	C0599755
risk-adjustment methods	T081	C0600568
Metabolomic	T091	C1328813
analysis	T169	C1524024
glycerophospholipid	T109	C0162448
inflammation	T046	C0021368
treated with	T061	C0332293
non-steroidal anti-inflammatory drugs	T121	C0003211
RAW264.7 cells	T025	C0024432
(1)H NMR	T060	C0877853
U-HPLC	T059	C0008562
Q-TOF-MS	T059	C0599827
Non-destructive proton nuclear magnetic resonance ((1)H NMR) spectroscopy	T060	C0877853
highly sensitive	T080	C0439822
ultra-performance liquid chromatography	T059	C0008562
quadrupole time-of-flight mass spectrometry	T059	C0599827
U-HPLC	T059	C0008562
Q-TOF-MS	T059	C0599827
data processing	T066	C0868941
methods	T170	C0025663
metabolic profiling	T091	C1328813
glycerophospholipids	T109	C0162448
GPLs	T109	C0162448
RAW264.7 cells	T025	C0024432
inflammation	T046	C0021368
prognosis	T058	C0033325
Analysis	T062	C0936012
(1)H NMR	T060	C0877853
models	T170	C3161035
grouped	T169	C1522242
differences	T080	C1705242
highly simple	T080	C0205352
accurate	T080	C0443131
(1)H NMR	T060	C0877853
anti-inflammatory drugs	T121	C0003209
metabolic profiling	T091	C1328813
GPLs	T109	C0162448
GPLs	T109	C0162448
identified	T080	C0205396
U-HPLC	T059	C0008562
Q-TOF-MS	T059	C0599827
identified	T080	C0205396
study	T062	C2603343
potential	T080	C3245505
biomarkers	T201	C0005516
phosphatidylcholine	T109	C1959616
PC	T109	C1959616
changed	T081	C0443172
drug-induced	T169	C0458082
groups	T078	C0441833
biomarkers	T201	C0005516
(1)H NMR	T060	C0877853
U-HPLC	T059	C0008562
Q-TOF-MS	T059	C0599827
higher	T080	C0205250
sensitivity and specificity	T081	C0036668
determination	T059	C1148554
biomarkers	T201	C0005516
deficiency	T080	C2987487
time-consuming	T080	C3827829
sample preparation steps	T059	C1720914
metabolite	T123	C0870883
identification	T080	C0205396
changes	T081	C1705241
GPLs	T109	C0162448
inflammation	T046	C0021368
(1)H NMR spectroscopy	T060	C0877853
U-HPLC	T059	C0008562
Q-TOF-MS	T059	C0599827
metabolic profiling	T091	C1328813
GPLs	T109	C0162448
evidence	T078	C3887511
inflammation	T046	C0021368
diagnosis	T033	C0011900
prognosis	T058	C0033325
mechanisms	T169	C0441712
inflammation	T046	C0021368
progression	T046	C0242656
Characterization	T052	C1880022
novel	T080	C0205314
DeoR-family	T116	C0035147
member	T096	C1551024
Streptomyces ahygroscopicus	T007	C1937901
strain CK-15	T001	C1518614
repressor	T116	C1336789
morphological	T082	C0543482
development	T169	C1527148
Wuyiencin	T131	C0031253
produced	T052	C0441655
Streptomyces ahygroscopicus var. wuyiensis	T007	C1937901
China	T083	C0008115
industrially	T092	C0007983
produced	T057	C0033268
biopesticide	T131	C0031253
control	T080	C0243148
fungal diseases	T047	C0026946
mechanism	T169	C0441712
action	T052	C3266814
breeding	T040	C0006159
fermentation	T044	C0015852
characterized	T052	C1880022
regulatory functions	T044	C1817179
biosynthesis	T169	C0005572
morphological	T082	C0543482
development	T169	C1527148
wysR3 gene	T028	C0017337
S. ahygroscopicus	T007	C1937901
strain CK-15	T001	C1518614
novel	T080	C0205314
member	T096	C1551024
DeoR family	T116	C0035147
regulatory genes	T028	C0017362
assessed	T052	C1516048
function	T169	C0542341
gene knockdown	T063	C2350567
DeoR family proteins	T116	C0035147
source	T033	C0449416
single	T081	C0205171
branch	T082	C1253959
phylogenetic tree	T080	C0205556
wysR3	T028	C0017337
repressor	T116	C1336789
morphological	T082	C0543482
development	T169	C1527148
wuyiencin	T131	C0031253
production	T052	C0441655
ΔwysR3	T028	C0017337
strain	T001	C1518614
plateau	T081	C2964353
stage	T079	C1306673
biomass	T081	C0005535
faster	T080	C0456962
wild-type	T028	C1883559
strain	T001	C1518614
industrial	T092	C0007983
fermentation	T044	C0015852
production	T057	C0033268
process	T067	C1522240
ΔwysR3	T028	C0017337
strain	T001	C1518614
reduce	T080	C0392756
consumption	T052	C0009830
time	T079	C0040223
money	T073	C0870909
Targeting	T169	C1521840
ecology	T090	C0013546
role	T077	C1705810
gut-brain axis	T082	C1522496
human	T016	C0086418
microbiota	T001	C3887843
drug addiction	T048	C1510472
major advances	T079	C3854260
understanding	T041	C0162340
brain	T023	C0006104
using	T169	C1524063
traditional neuroscience	T091	C0027910
reliable	T170	C3858758
efficacious	T080	C1704419
treatments	T061	C0087111
drug addiction	T048	C1510472
remained elusive	T033	C0243095
time	T079	C0040223
utilize	T169	C0042153
novel	T080	C0205314
approaches	T082	C0449445
drawing	T080	C0205556
contemporary	T079	C1254367
advances	T079	C3854260
fields	T077	C1521738
established	T080	C0443211
neuroscienc	T091	C0027910
psychiatry	T091	C0033873
time	T079	C0040223
paradigm shift	T062	C0681797
addiction	T048	C0085281
sciences	T090	C0036397
Apropos	T080	C1548787
revolution	T169	C0205245
area	T082	C0205146
human	T016	C0086418
health	T078	C0018684
underway	T169	C1272688
occurring	T052	C1709305
nexus	T080	C0205556
enteric	T082	C1304890
microbiology	T091	C0025952
neuroscience	T091	C0027910
increasingly	T169	C0442805
clear	T080	C2963144
human	T016	C0086418
microbiota	T001	C3887843
ecology	T090	C0013546
bacteria	T007	C0004611
residing	T052	C2982691
human	T016	C0086418
organism	T001	C0029235
important	T080	C3898777
role	T077	C1705810
health	T078	C0018684
disease	T047	C0012634
estimated	T081	C0750572
bacteria	T007	C0004611
living	T052	C2982691
human body	T016	C0242821
approximately	T080	C0332232
mass	T081	C1306372
equivalent	T080	C0205163
human	T016	C0086418
brain	T023	C0006104
human cells	T034	C0427861
understanding	T041	C0162340
role	T077	C1705810
microbiota	T001	C3887843
areas	T082	C0205146
human	T016	C0086418
health	T078	C0018684
yielded	T081	C0392762
intriguing	T080	C0205556
results	T169	C1274040
Clostridium difficile	T047	C1411966
irritable bowel syndrome	T047	C0022104
autism	T048	C0004352
date	T079	C0011008
systematic	T169	C0220922
programs	T169	C3484370
research	T062	C0035168
examined	T033	C0332128
role	T077	C1705810
microbiota	T001	C3887843
drug addiction	T048	C1510472
current	T079	C0521116
hypothesis	T078	C1512571
gut dysbiosis	T184	C4287543
role	T077	C1705810
addictive	T048	C0085281
disorders	T047	C0012634
context	T078	C0449255
hypothesis	T078	C1512571
paper	T170	C0282420
provides	T052	C1999230
rationale	T078	C2699007
future	T079	C0016884
research	T062	C0035168
target	T169	C1521840
gut	T023	C0699819
brain	T023	C0006104
axis	T082	C1522496
addiction	T048	C0085281
background	T077	C1706907
gut	T023	C0699819
brain	T023	C0006104
axis	T082	C1522496
provided	T052	C1999230
series	T081	C0205549
hypothesis-driven	T078	C1512571
ideas	T078	C1947946
potential	T080	C3245505
treatments	T061	C0087111
addiction	T048	C0085281
manipulations	T033	C0243095
ecology	T090	C0013546
Homogeneous	T080	C1881065
synthesis	T052	C1883254
Ag nanoparticles	T073	C1721060
water-soluble cellulose acetate	T109	C0050505
versatile	T080	C0205556
applications	T169	C4048755
report	T170	C0684224
facile	T080	C0205352
efficient	T080	C0442799
approach	T082	C0449445
synthesis	T052	C1883254
well-dispersed	T082	C0332624
stable	T080	C0205360
silver nanoparticles	T073	C1721060
Ag NPs	T073	C1721060
water-soluble cellulose acetate	T109	C0050505
CA	T109	C0050505
reductant	T130	C0376446
stabilizer	T167	C1550603
Partially	T081	C0728938
CA	T109	C0050505
highly	T080	C0205250
active	T169	C0205177
hydroxyl groups	T197	C0700307
excellent	T080	C1961136
water-solubility	T081	C0597682
able	T033	C1299581
reduce	T070	C0301630
silver ions	T196	C0022023
homogeneous	T080	C1881065
aqueous	T080	C0599956
medium	T167	C1705217
effectively	T080	C1704419
synthesized	T052	C1883254
Ag NPs	T073	C1721060
characterized	T052	C1880022
UV-vis spectroscopy	T059	C0037812
X-ray diffraction	T059	C0043301
X-ray photoelectron spectroscopy	T059	C2700282
transmission electron microscopy	T059	C0678118
energy dispersive X-ray spectroscope	T059	C2699997
analysis	T059	C0002778
prepared	T033	C4082130
Ag NPs	T073	C1721060
well-dispersed	T082	C0332624
surface plasmon resonance	T063	C0597731
peak	T080	C0444505
nm	T081	C0439202
Ag NPs	T073	C1721060
CA	T109	C0050505
nanohybrids	T073	C1721059
high	T080	C0205250
catalytic activity	T169	C1264638
reduction	T070	C0301630
4-nitrophenol	T109	C0048581
4-aminophenol	T109	C0048047
NaBH4	T130	C0074728
nanohybrids	T073	C1721059
effective	T080	C1704419
inhibiting	T052	C3463820
growth	T040	C0018270
bacterial	T007	C0004611
environmentally friendly method	T057	C2350566
promotes	T052	C0033414
use of	T169	C1524063
renewable natural resources	T078	C0027492
prepare	T052	C1521827
variety	T077	C2346866
inorganic-organic materials	T167	C0520510
catalysis	T070	C0007382
antibacterial	T195	C0279516
sensors	T073	C0183210
applications	T169	C4048755
ISX-9	T109	C0022266
cell proliferation	T043	C0596290
neuronal	T025	C0027882
commitment	T043	C1160036
rat	T015	C0086893
dentate gyrus	T023	C0152314
Adult	T100	C0001675
hippocampal	T023	C0019564
neurogenesis	T040	C0814002
modulated	T082	C0443264
physiological	T039	C1254359
pathological conditions	T046	C0752135
stress	T033	C0038435
affective disorders	T048	C0525045
neurological	T080	C0205494
conditions	T080	C0348080
structural plasticity	T042	C1254358
functioning	T039	C0031843
hippocampus	T023	C0019564
learning	T041	C0023185
memory	T041	C0025260
affective	T078	C0243150
behaviors	T053	C0004927
alterations	T078	C1515926
hippocampal	T023	C0019564
neurogenesis	T040	C0814002
behavioral	T053	C0004927
deficits	T080	C2987487
associated with	T080	C0332281
psychiatric	T169	C0205487
neurological	T080	C0205494
conditions	T080	C0348080
search	T052	C1706202
compounds	T121	C1254351
reverse	T169	C1555029
deficits	T080	C2987487
minimal	T080	C0547040
side effects	T046	C0879626
study	T062	C0008972
tested	T169	C0039593
pro-neurogenic	T080	C0205494
effects	T080	C1280500
isoxazole 9	T109	C0022266
Isx-9	T109	C0022266
synthetic	T052	C1883254
molecule	T167	C0567416
identified	T080	C0205396
screening of chemical libraries	T059	C0373483
stem cell-based assays	T059	C0009385
administration	T061	C1533734
Isx-9	T109	C0022266
cell proliferation	T043	C0596290
increase	T169	C0442805
number	T081	C0237753
immature	T080	C0205252
neurons	T025	C0027882
hippocampal	T023	C0019564
DG	T023	C0152314
adult	T100	C0001675
rats	T015	C0086893
In addition	T169	C0332287
Isx-9	T109	C0022266
treatment	T061	C0087111
completely	T080	C0205197
reverse	T169	C1555029
marked	T080	C1706089
reduction	T080	C0392756
initial	T079	C0205265
stages	T079	C0205390
neurogenic process	T042	C1518289
observed	T169	C1441672
vehicle	T122	C0042444
treated	T169	C1522326
animals	T008	C0003062
repeated	T169	C0205341
handling	T059	C0037793
exposure to	T080	C0332157
daily	T079	C0332173
intraperitoneal injections	T061	C0021493
results	T034	C1254595
neurogenesis	T040	C0814002
studies	T062	C0008972
repeated	T169	C0205341
handling	T059	C0037793
manipulation	T061	C0947647
animals	T008	C0003062
control	T080	C0243148
baseline	T081	C1442488
levels	T080	C0441889
hippocampal	T023	C0019564
cell proliferation	T043	C0596290
neuronal	T025	C0027882
differentiation	T043	C0007589
findings	T033	C2825141
Isx-9	T109	C0022266
synthetic	T052	C1883254
compound	T121	C1254351
mitigation	T067	C1553901
stress	T033	C0038435
induced	T169	C0205263
deficits	T080	C2987487
adult	T100	C0001675
hippocampal	T023	C0019564
neurogenesis	T040	C0814002
studies	T062	C0008972
evaluate	T058	C0220825
pro-neurogenic	T080	C0205494
properties	T080	C0871161
Isx-9	T109	C0022266
animal models	T008	C0599779
affective	T048	C0525045
neurological disorders	T047	C0027765
associated with	T080	C0332281
impaired	T169	C0221099
hippocampal	T023	C0019564
structural plasticity	T042	C1254358
Changes	T169	C0392747
parenting	T054	C0085092
strategies	T041	C0679199
young	T079	C0332239
person's	T098	C0027361
self-harm	T037	C0424366
qualitative study	T062	C0949415
discovery	T052	C1880355
child's	T100	C0008059
self-harm	T037	C0424366
mothers	T099	C0026591
fathers	T099	C0015671
re-evaluate	T058	C0220825
parenting	T054	C0085092
strategies	T041	C0679199
changes	T169	C0392747
support	T054	C0037438
child	T100	C0008059
changes	T169	C0392747
degree	T081	C0449286
control	T080	C0243148
monitor	T052	C0441655
child	T100	C0008059
in-depth qualitative study	T062	C0949415
parents	T099	C0030551
young	T079	C0332239
people	T098	C0027361
self-harmed	T037	C0424366
parenting	T054	C0085092
changed	T169	C0392747
discovery	T052	C1880355
self-harm	T037	C0424366
Early	T079	C1279919
parents	T099	C0030551
upset	T041	C3887804
child	T100	C0008059
control	T080	C0243148
Parents	T099	C0030551
reactions	T169	C0443286
self-harm	T037	C0424366
adolescence	T079	C0001578
mental health issue	T048	C4061796
naughty behaviour	T053	C0004927
Parenting	T054	C0085092
children	T100	C0008059
family	T099	C0015576
parents	T099	C0030551
time	T079	C0040223
siblings	T099	C0037047
parents	T099	C0030551
strategies	T041	C0679199
parents	T099	C0030551
learning	T041	C0023185
blaming	T041	C0870209
child	T100	C0008059
self-harm	T037	C0424366
communicate	T033	C0566001
child	T100	C0008059
Parents	T099	C0030551
knowledge	T170	C0376554
people	T098	C0027361
situation	T169	C0868928
Parents	T099	C0030551
changes	T169	C0392747
parenting	T054	C0085092
behaviours	T053	C0004927
discovery	T052	C1880355
child	T100	C0008059
self-harm	T037	C0424366
Professionals	T097	C0679924
care	T052	C1947933
young	T079	C0332239
people	T098	C0027361
self-harm	T037	C0424366
information	T078	C1533716
supporting	T077	C1521721
advising	T052	C1828381
parents	T099	C0030551
Optimizing	T052	C2698650
Survival	T169	C0220921
Patients	T101	C0030705
Marginally Operable	T080	C0205188
Stage IIIA Non-Small-Cell Lung Cancer	T191	C0278983
Chemoradiotherapy	T061	C0436307
With	T169	C0038895
Without	T080	C0332288
Surgery	T169	C0038895
marginally operable	T080	C0205188
stage IIIA non-small-cell lung cancer	T191	C0278983
NSCLC	T191	C0278983
surgery	T169	C0038895
neoadjuvant	T061	C0600558
concurrent chemoradiotherapy	T061	C3178775
CCRT	T061	C3178775
unresectable	T201	C1519810
medically inoperable	T080	C0205187
conditions	T080	C0348080
patient refusal	T055	C0040809
study	T062	C2603343
investigate	T169	C1292732
outcomes	T169	C1274040
phased CCRT protocol	T061	C0040808
operability	T169	C0205245
marginally operable	T080	C0205188
stage IIIA NSCLC	T191	C0278983
reassessed	T052	C1516048
inoperable patients	T101	C0030705
continuous-course definitive CCRT	T061	C3178775
patients	T101	C0030705
marginally operable	T080	C0205188
stage IIIA NSCLC	T191	C0278983
CCRT	T061	C3178775
patients	T101	C0030705
treated	T169	C1522326
phased CCRT protocol	T061	C0040808
neoadjuvant	T061	C0600558
CCRT	T061	C3178775
surgery	T169	C0038895
group A	T078	C0441833
reassessed	T052	C1516048
inoperable patients	T101	C0030705
patients	T101	C0030705
maintenance chemotherapy	T033	C0481504
split-course CCRT	T061	C3178775
boost	T169	C1511253
group B	T078	C0441833
treated	T169	C1522326
continuous-course definitive CCRT	T061	C3178775
group C	T078	C0441833
Overall survival	T081	C4086681
OS	T081	C4086681
progression-free survival	T081	C0242792
PFS	T081	C0242792
analyzed	T062	C0936012
median	T081	C0876920
OS	T081	C4086681
PFS	T081	C0242792
months	T079	C0439231
median	T081	C0876920
follow-up	T058	C1522577
months	T079	C0439231
median	T081	C0876920
OS	T081	C4086681
group A	T078	C0441833
group B	T078	C0441833
months	T079	C0439231
group C	T078	C0441833
months	T079	C0439231
multivariate analysis	T081	C0026777
performance status	T201	C1518965
hazard ratio	T081	C2985465
HR	T081	C2985465
adenocarcinoma	T191	C0001418
HR	T081	C2985465
group A	T078	C0441833
HR	T081	C2985465
independent prognostic factors	T201	C1514474
OS	T081	C4086681
group B	T078	C0441833
HR	T081	C2985465
confidence interval	T081	C0009667
statistically different	T080	C1705242
group C	T078	C0441833
marginally operable	T080	C0205188
stage IIIA NSCLC	T191	C0278983
phased CCRT strategy	T061	C0040808
optimize	T052	C2698650
survival	T169	C0220921
operability	T169	C0205245
survival	T169	C0220921
reassessed	T052	C1516048
inoperable patients	T101	C0030705
split-course CCRT	T061	C3178775
boost	T169	C1511253
maintenance chemotherapy	T033	C0481504
Three	T081	C0205449
Protein-Extraction Methods	T059	C3827821
Proteome	T116	C0751973
Analysis	T059	C0002778
Maize	T002	C0010028
Leaf	T002	C0242724
Midrib	T185	C2698828
Compound Tissue	T025	C1514137
Sclerenchyma Cells	T025	C1514137
Leaf	T002	C0242724
morphology	T080	C0332437
growth and development	T040	C0018271
maize (Zea mays L.) plants	T002	C0010028
kernel	T168	C0043137
maize	T002	C0010028
leaf	T002	C0242724
midrib	T185	C2698828
leaf	T002	C0242724
aerial position	T002	C1136056
sunlight	T070	C0038817
Leaf	T002	C0242724
midrib	T185	C2698828
adult	T079	C0205286
plants	T002	C0010028
sclerenchyma cells	T025	C1514137
heavily thickened	T080	C1280412
lignified	T109	C0023705
secondary walls	T026	C0918262
phenolics	T109	C0359916
protein extraction	T059	C3827821
proteome	T116	C0751973
analysis	T059	C0002778
leaf	T002	C0242724
midrib	T185	C2698828
protein-extraction methods	T059	C3827821
plant	T002	C0032098
proteomics	T091	C0872252
phenol	T109	C0070570
extraction	T059	C0684295
TCA	T109	C0040900
acetone	T109	C0001002
extraction	T059	C0684295
TCA	T109	C0040900
acetone	T109	C0001002
phenol	T109	C0070570
extraction	T059	C0684295
qualitatively	T080	C0034375
quantitatively evaluated	T081	C0034384
MS/MS analysis	T059	C0037813
midribs	T185	C2698828
leaves	T002	C0242724
maize plants	T002	C0010028
Microscopy	T059	C0026018
sclerenchyma	T025	C1514137
maize	T002	C0010028
midrib	T185	C2698828
epidermises	T002	C0376608
abaxial	T082	C1254362
epidermises	T002	C0376608
2DE mapping	T059	C0013860
phenol	T109	C0070570
extraction	T059	C0684295
TCA	T109	C0040900
acetone	T109	C0001002
extraction	T059	C0684295
TCA	T109	C0040900
acetone	T109	C0001002
phenol	T109	C0070570
extraction	T059	C0684295
MS/MS analysis	T059	C0037813
spots	T077	C1705203
three	T081	C0205449
phenol	T109	C0070570
extraction	T059	C0684295
control	T096	C0009932
proteins	T116	C0032089
hydrophilic	T080	C0475370
GRAVY values	T081	C0392762
three	T081	C0205449
protein	T116	C0032089
2DE maps	T059	C0013860
maize	T002	C0010028
leaf	T002	C0242724
midrib	T185	C2698828
phenol	T109	C0070570
extraction	T059	C0684295
2DE map	T059	C0013860
resolution	T077	C2699488
spots	T077	C1705203
TCA	T109	C0040900
acetone	T109	C0001002
extraction	T059	C0684295
protein	T116	C0032089
yields	T081	C0392762
differential	T080	C0443199
protein extraction	T059	C3827821
three	T081	C0205449
protein extraction	T059	C3827821
proteome	T116	C0751973
analysis	T059	C0002778
plant tissues	T025	C1514137
sclerenchyma cells	T025	C1514137
Dominant	T033	C0429283
Dominant	T033	C0429283
Frequency	T079	C0376249
Evoked	T080	C1444748
Ventricular Fibrillation	T047	C0042510
Dogs	T015	C0012984
Myocardial Ischemia	T047	C0151744
electrically provoked	T061	C3517066
ventricular fibrillation	T047	C0042510
dogs	T015	C0012984
ischemic heart disease	T047	C0151744
characterized	T052	C1880022
organized	T169	C1300196
myocardial activity	T042	C1254358
dominant ECG frequency	T033	C0429283
ventricular fibrillation	T047	C0042510
low-frequency oscillations	T080	C0205556
fibrillation	T047	C0042510
dominant frequencies	T033	C0429283
low	T080	C0205251
medium	T081	C0439536
fibrillation	T047	C0042510
oscillations	T061	C0695434
dominant	T033	C0429283
ischemic myocardium	T033	C2919051
maintains	T052	C0024501
organized structure	T079	C0449236
ventricular fibrillation	T047	C0042510
development	T169	C1527148
automatic diagnostics	T060	C0011905
abnormal cardiac activity	T033	C4062482
humans	T016	C0086418
Adverse events	T046	C0877248
risk	T078	C0035647
associated with	T080	C0332281
angiogenesis inhibitors	T121	C0596087
therapy	T061	C0087111
ovarian cancer	T191	C0029925
meta-analysis	T062	C0920317
randomized controlled trials	T062	C0206035
Inhibition of angiogenesis	T043	C1510884
treatment strategy	T061	C0087111
advanced	T191	C0029925
recurrent ovarian cancer	T191	C0278689
meta-analysis	T062	C0920317
investigate	T169	C1292732
risk	T078	C0035647
adverse events	T046	C0877248
angiogenesis inhibitors	T121	C0596087
AIs	T121	C0596087
ovarian cancer	T191	C0029925
Databases	T170	C0242356
PubMed	T170	C1138432
Web of Science	T170	C0282574
Cochrane library	T073	C0023621
relevant	T080	C2347946
studies	T062	C2603343
studies	T062	C2603343
prospective randomized controlled phase II/III clinical trials	T062	C0206035
evaluating	T058	C0557980
therapy	T061	C0087111
AIs	T121	C0596087
ovarian cancer	T191	C0029925
relative risk	T081	C0242492
RR	T081	C0242492
confidence intervals	T081	C0009667
CIs	T081	C0009667
calculated	T052	C1441506
random-effects	T080	C0205556
fixed-effects	T080	C0205556
heterogeneity	T080	C0019409
trials	T062	C0008976
patients	T101	C0030705
clinical trials	T062	C0008976
meta-analysis	T062	C0920317
Pooled	T169	C2349200
RR	T081	C0242492
use of	T169	C1524063
AIs	T121	C0596087
associated with	T080	C0332281
increased	T081	C0205217
risk	T078	C0035647
adverse	T169	C0001688
outcomes	T080	C0085415
arterial thromboembolic	T046	C3544094
events	T051	C0441471
RR	T081	C0242492
gastrointestinal (GI) perforation	T047	C0151664
RR	T081	C0242492
proteinuria	T033	C0033687
RR	T081	C0242492
hypertension	T047	C0020538
RR	T081	C0242492
No statistically significant	T033	C3694175
differences	T080	C1705242
hemorrhagic	T046	C0019080
events	T051	C0441471
venous thromboembolic	T047	C1861172
events	T051	C0441471
fatal	T080	C1302234
adverse events	T046	C0877248
AIs	T121	C0596087
therapy	T061	C0087111
ovarian cancer	T191	C0029925
increase	T169	C0442805
risk	T078	C0035647
arterial thromboembolic	T046	C3544094
events	T051	C0441471
GI perforation	T047	C0151664
proteinuria	T033	C0033687
hypertension	T047	C0020538
venous thromboembolic	T047	C1861172
events	T051	C0441471
hemorrhagic	T046	C0019080
events	T051	C0441471
fatal	T080	C1302234
adverse events	T046	C0877248
Relationship	T080	C0439849
LRRK2	T028	C1425650
R1628P polymorphism	T086	C0752046
Parkinson's disease	T047	C0030567
Asian populations	T098	C0078988
leucine-rich repeat kinase 2	T028	C1425650
LRRK2	T028	C1425650
R1628P polymorphism	T086	C0752046
associated with	T080	C0332281
risk	T078	C0035647
Parkinson's disease	T047	C0030567
PD	T047	C0030567
Taiwan	T083	C0039260
China	T083	C0008115
Singapore	T083	C0037173
relationship	T080	C0439849
meta-analysis	T062	C0920317
associations	T080	C0439849
LRRK2	T028	C1425650
R1628P polymorphism	T086	C0752046
rs33949390	T086	C0752046
PD	T047	C0030567
Asian populations	T098	C0078988
studies	T062	C2603343
PubMed	T170	C1138432
Embase	T170	C0079198
SinoMed	T170	C0079198
China Knowledge Resource Integrated Database	T170	C0242356
confidence intervals	T081	C0009667
association	T080	C0439849
R1628P polymorphism	T086	C0752046
PD	T047	C0030567
meta-analysis	T062	C0920317
studies	T062	C2603343
PD	T047	C0030567
patients	T101	C0030705
controls	T096	C0009932
R1628P polymorphism	T086	C0752046
associated with	T080	C0332281
risk	T078	C0035647
PD	T047	C0030567
Asian populations	T098	C0078988
stratification analyses	T062	C1514983
R1628P polymorphism	T086	C0752046
associated with	T080	C0332281
risk	T078	C0035647
PD	T047	C0030567
Chinese	T098	C0152035
non-Chinese Asian populations	T098	C0078988
risk	T078	C0035647
PD	T047	C0030567
Chinese patients	T101	C0030705
China	T083	C0008115
Taiwan	T083	C0039260
Singapore	T083	C0037173
stratified analysis	T062	C1514983
age	T032	C0001779
associations	T080	C0439849
PD	T047	C0030567
PD	T047	C0030567
R1628P polymorphism	T086	C0752046
LRRK2 gene	T028	C1425650
PD	T047	C0030567
susceptibility	T201	C0012655
Asian	T098	C0078988
Chinese	T098	C0152035
populations	T098	C1257890
Efficacy	T080	C1280519
safety	T080	C0678800
cisplatin	T121	C0008838
dexamethasone	T109	C0011777
gemcitabine	T114	C0045093
pegaspargase	T116	C0071568
DDGP	T121	C1254351
regimen	T061	C0040808
newly diagnosed	T080	C1518321
advanced-stage	T080	C0205179
extranodal natural killer/T-cell lymphoma	T191	C1955906
interim	T079	C2827738
analysis	T062	C0936012
phase 4	T079	C0439562
study	T062	C2603343
effective	T080	C1704419
treatment	T169	C0039798
newly diagnosed	T080	C1518321
advanced-stage	T080	C0205179
extranodal natural killer/T-cell lymphoma, nasal type	T191	C0392788
ENKTL	T191	C0392788
phase 4	T079	C0439562
study	T062	C2603343
cisplatin	T121	C0008838
dexamethasone	T109	C0011777
gemcitabine	T114	C0045093
pegaspargase	T116	C0071568
DDGP	T121	C1254351
regimen	T061	C0040808
end point	T080	C2349179
progression-free survival	T081	C0242792
PFS	T081	C0242792
protocol treatment	T061	C0040808
endpoints	T080	C2349179
response rate	T079	C0237629
RR	T079	C0237629
overall survival	T081	C4086681
OS	T081	C4086681
median survival time	T079	C2986586
MST	T079	C2986586
interim	T079	C2827738
analysis	T062	C0936012
data	T078	C1511726
received	T080	C1514756
DDGP	T121	C1254351
chemotherapy	T061	C3665472
eligible	T080	C1548635
patients	T101	C0030705
patients	T101	C0030705
complete response	T033	C1275810
CR	T033	C1275810
partial response	T033	C1521726
PR	T033	C1521726
progressive disease	T047	C1335499
PD	T047	C1335499
RR	T079	C0237629
treatment	T169	C0039798
median	T081	C0876920
follow-up	T058	C1522577
duration	T079	C0449238
months	T079	C0439231
months	T079	C0439231
PFS	T081	C0242792
OS rate	T081	C0038954
CI	T081	C0009667
CI	T081	C0009667
MST	T079	C2986586
months	T079	C0439231
CI	T081	C0009667
months	T079	C0439231
months	T079	C0439231
Grade	T185	C0441800
leukopenia	T047	C0023530
occurred	T079	C2745955
patients	T101	C0030705
grade	T185	C0441800
thrombocytopenia	T047	C0040034
occurred	T079	C2745955
patients	T101	C0030705
patients	T101	C0030705
Activated Partial Phromboplastin Ptime	T059	C0030605
APTT	T059	C0030605
elongation	T033	C0240671
patients	T101	C0030705
hypofibrinogenemia	T047	C0553681
DDGP	T121	C1254351
regimen	T061	C0040808
effective	T080	C1704419
tolerated	T033	C0013220
treatment	T169	C0039798
newly diagnosed	T080	C1518321
advanced-stage	T080	C0205179
ENKTL	T191	C0392788
trial	T062	C0008976
registered	T058	C1514821
www.ClinicalTrials.gov	T170	C2349146
Effect	T080	C1280500
Hepatitis C Virus Coinfection	T047	C1698259
CD4(+) and CD8(+)	T025	C0483191
T Cell	T025	C0039194
Subpopulations	T185	C0079720
HIV	T005	C0019682
Infected	T033	C0439663
Patients	T101	C0030705
Receiving	T080	C1514756
Antiretroviral Therapy	T061	C1963724
effect	T080	C1280500
hepatitis C virus coinfection	T047	C1698259
T cell	T025	C0039194
subpopulations	T185	C0079720
HIV	T005	C0019682
infected	T033	C0439663
patients	T101	C0030705
antiretroviral therapy	T061	C1963724
Coinfection	T047	C0275524
hepatitis C virus	T005	C0220847
decrease	T081	C0547047
naive CD4(+) T cells	T025	C3273372
increase	T169	C0442805
count	T081	C0750480
CD8(+) memory T cells	T025	C0242629
patients	T101	C0030705
Hepatitis C virus	T005	C0220847
no effect	T080	C1301751
CD4(+) memory T cells	T025	C3273371
HIV	T005	C0019682
negative	T033	C0205160
effect	T080	C1280500
hepatitis C virus	T005	C0220847
course	T079	C0750729
HIV	T005	C0019682
infection	T046	C3714514
Examining	T169	C1292732
contribution	T052	C1880177
motor movement	T169	C1513492
language	T171	C0023008
dominance	T078	C0870441
increased	T081	C0205217
left	T082	C0205091
lateralization	T042	C0013010
sign	T171	C0037078
generation	T052	C3146294
native	T169	C0302891
signers	T098	C1257890
neural systems	T022	C0027763
speech	T040	C0037817
sign	T078	C1547188
processing	T041	C0025361
similar	T080	C2348205
fTCD study	T062	C2603343
hearing	T041	C0025361
native	T169	C0302891
signers	T098	C1257890
left	T082	C0205091
lateralization	T042	C0013010
sign	T078	C1547188
speech	T040	C0037817
increased	T081	C0205217
lateralization	T042	C0013010
hand	T023	C0018563
movement	T040	C0026649
motor movement	T169	C1513492
linguistic	T171	C0023008
processes	T041	C0025361
strength	T078	C0808080
hemispheric	T082	C0205139
lateralization	T042	C0013010
sign	T078	C1547188
production	T041	C0025361
contrast	T080	C1979874
lateralization	T042	C0013010
strength	T078	C0808080
covert	T078	C0871315
overt	T080	C2963144
signing	T078	C1547188
phonological	T169	C0542341
semantic	T078	C0036612
fluency	T080	C0870569
tasks	T169	C0542341
hearing	T041	C0025361
native	T169	C0302891
signers	T098	C1257890
elevated	T080	C3163633
lateralization indices	T081	C0392762
LIs	T081	C0392762
task	T169	C0542341
dominant	T169	C1527180
language	T171	C0023008
deaf	T101	C0525064
native	T169	C0302891
signers	T098	C1257890
dominant	T169	C1527180
language	T171	C0023008
British Sign Language	T171	C3874914
BSL	T171	C3874914
Signers	T098	C1257890
left	T082	C0205091
lateralized	T042	C0013010
overt	T080	C2963144
covert	T078	C0871315
sign	T078	C1547188
strength	T078	C0808080
lateralization	T042	C0013010
correlated	T080	C1707520
movements	T040	C0026649
right hand	T023	C0230370
Comparisons	T052	C1707455
data	T078	C1511726
hearing	T041	C0025361
native	T169	C0302891
English	T171	C0376245
speakers	T098	C1257890
laterality indices	T081	C0392762
sign	T078	C1547188
speech	T040	C0037817
covert	T078	C0871315
overt	T080	C2963144
tasks	T169	C0542341
increased	T081	C0205217
left	T082	C0205091
lateralization	T042	C0013010
properties	T080	C0871161
sign	T078	C1547188
production	T041	C0025361
increased	T081	C0205217
use	T169	C0457083
self-monitoring	T055	C0237864
mechanisms	T169	C0441712
nature	T078	C0349590
phonological encoding	T041	C0679058
signs	T078	C1547188
Hard ticks	T204	C0598741
Acari: Ixodidae	T204	C0598741
livestock	T008	C2936506
Nicaragua	T083	C0028002
notes	T170	C1317574
distribution	T169	C1704711
document	T170	C0920316
species	T185	C1705920
ticks	T204	C0040203
parasitize	T047	C1384353
livestock	T008	C2936506
Nicaragua	T083	C0028002
study	T062	C2603343
tick	T204	C0040203
collection	T169	C1516698
cattle	T015	C0007452
horses	T015	C0019944
farms	T082	C0557759
departments	T092	C1704729
animals	T008	C0003062
cows	T015	C0007452
horses	T015	C0019944
parasitized	T047	C1384353
bovines	T015	C3667982
equines	T015	C0019944
study	T062	C2603343
cows	T015	C0007452
horses	T015	C0019944
parasitized	T047	C1384353
species	T185	C1705920
specimens	T167	C0370003
entomological	T090	C0014386
museum	T073	C0026863
León	T083	C3814077
ticks	T204	C0040203
cattle	T015	C0007452
Rhipicephalus microplus	T204	C0323515
ticks	T204	C0040203
collected	T169	C1516698
Amblyomma mixtum	T204	C3989620
A. parvum	T204	C1667898
A. tenellum	T204	C1690769
A. maculatum	T204	C0323501
ticks	T204	C0040203
collected	T169	C1516698
horses	T015	C0019944
Dermacentor nitens	T204	C0323524
A. mixtum	T204	C3989620
R. microplus	T204	C0323515
A. parvum	T204	C1667898
A. tenellum	T204	C1690769
D. dissimilis	T204	C0011595
A. maculatum	T204	C0323501
Assessment	T058	C0220825
Exposure	T080	C0332157
Level	T080	C0441889
Rare Earth Elements	T196	C0025556
Workers	T098	C1527116
Producing	T057	C0033268
Cerium	T109	C0007828
Lanthanum Oxide	T197	C0534702
Ultrafine	T109	C0077801
Nanoparticles	T073	C1450054
assess	T058	C0184514
occupational	T169	C0521127
exposure	T080	C0332157
level	T080	C0441889
rare earth elements	T196	C0025556
REEs	T196	C0025556
identify	T080	C0205396
associated	T080	C0332281
influence	T077	C4054723
inductively coupled plasma mass spectrometry	T059	C1553183
ICP-MS	T059	C1553183
based	T169	C1527178
closed	T169	C0587267
vessel	T073	C3273359
microwave	T070	C0026051
assisted	T080	C1269765
wet digestion procedure	T169	C2700391
determinate	T059	C1148554
concentration	T081	C1446561
Y	T196	C0043432
La	T197	C0534702
Ce	T109	C0007828
Pr	T196	C0032904
Nd	T196	C0027599
Sm	T121	C0036147
Eu	T196	C0015180
Gd	T130	C0016911
Tb	T196	C0039541
Dy	T196	C0013407
Ho	T196	C0019846
Er	T196	C0014688
Tm	T196	C0040066
Yb	T121	C0043431
Lu	T196	C0024170
urinary samples	T031	C1610733
obtained	T169	C1301820
workers	T098	C1527116
producing	T057	C0033268
ultrafine	T109	C0077801
nanoparticles	T073	C1450054
cerium	T109	C0007828
lanthanum oxide	T197	C0534702
results	T034	C1254595
suggest	T078	C1705535
La	T197	C0534702
Ce	T109	C0007828
primary	T080	C0205225
component	T077	C1705248
accounting	UnknownType	C0680857
REEs	T196	C0025556
workers	T098	C1527116
urinary	T031	C1610733
levels	T080	C0441889
La	T197	C0534702
Ce	T109	C0007828
workers	T098	C1527116
creatinine	T109	C0010294
significantly	T078	C0750502
enriched	T080	C0205556
compared	T052	C1707455
levels	T080	C0441889
measured	T080	C0444706
control	T096	C0009932
subjects	T096	C0681850
creatinine	T109	C0010294
study	T062	C2603343
simultaneously	T079	C0521115
identified	T080	C0205396
associated	T080	C0332281
individual	T098	C0237401
factors	T169	C1521761
results	T034	C1254595
indicate	T078	C3146298
concentrations	T081	C1446561
group	T078	C0441833
La	T197	C0534702
Ce	T109	C0007828
significantly	T078	C0750502
elevated	T080	C3163633
compared	T052	C1707455
group	T078	C0441833
La	T197	C0534702
Ce	T109	C0007828
Compared	T052	C1707455
urinary	T031	C1610733
levels	T080	C0441889
La	T197	C0534702
Ce	T109	C0007828
separation	T169	C0445406
packaging	T068	C0030176
locations	T082	C0450429
La	T197	C0534702
Ce	T109	C0007828
locations	T082	C0450429
La	T197	C0534702
Ce	T109	C0007828
results	T034	C1254595
urinary	T031	C1610733
concentrations	T081	C1446561
significantly	T078	C0750502
higher	T080	C0205250
workers	T098	C1527116
separation	T169	C0445406
packaging	T068	C0030176
locations	T082	C0450429
Inter	T079	C1548610
individual	T098	C0237401
variation	T080	C0205419
levels	T080	C0441889
La	T197	C0534702
Ce	T109	C0007828
urine	T031	C0042036
result	T169	C1274040
multi-factorial	T081	C0015483
comprehensive	T080	C1880156
action	T052	C3266814
researches	T097	C0035173
focus	T169	C1285542
multiple	T081	C0439064
factors	T169	C1521761
contributing	T052	C1880177
REEs	T196	C0025556
levels	T080	C0441889
occupationally	T169	C0521127
exposed	T080	C0332157
workers	T098	C1527116
known	T080	C0205309
new	T080	C0205314
species	T185	C1705920
Draconematidae	T204	C2992016
Epsilonematida	T204	C2287919
Nematoda	T204	C0027581
Desmodorida	T204	C1030325
White Sea	T083	C0036493
North Russia	T083	C0035970
Morphological	T082	C0543482
descriptions	T170	C0678257
walking nematode	T204	C1704319
species	T185	C1705920
White Sea	T083	C0036493
Draconema ophicephalum	T204	C4111696
Claparède	T170	C0805191
Draconematidae	T204	C2992016
Epsilonema steineri	T204	C4093458
Chitwood	T170	C0805191
Epsilonematidae	T204	C2287919
insufficient	T080	C0231180
females	T032	C0086287
problems	T033	C0033213
taxonomic	T169	C0008903
identification	T080	C0205396
species	T185	C1705920
compositions	T201	C0486616
genera	T185	C1708235
new	T080	C0205314
species	T185	C1705920
Prochaetosoma marisalbi sp	T204	C2992020
Draconematidae	T204	C2992016
Prochaetosoma species	T204	C2992020
P. longicapitatum	T204	C2992020
Allgén	T170	C0805191
pharyngeal	T023	C0031354
bulb	T017	C1947952
lumen	T030	C0524461
not cuticularised	T033	C0243095
P. longicapitatum	T204	C2992020
shape of body	T017	C1268086
rostrum	T026	C0243092
greater	T081	C1704243
cephalic	T082	C0205096
adhesive tubes	T026	C0243092
P. maertensi	T204	C2992020
Decraemer	T170	C0805191
longer	T080	C0205166
tail	T023	C0039259
anterior	T082	C0205094
adhesive tubes	T026	C0243092
longer	T080	C0205166
spicules	T077	C2826618
cuticular thickening	T042	C1160234
pharyngeal	T023	C0031354
bulb	T017	C1947952
Draconema hoonsooi	T204	C2992018
D. youngeouni	T204	C2992018
P.rochaetosoma beomseomense	T204	C2992020
P. brevicaudatum	T204	C2992020
P. byungilli	T204	C2992020
P. cracense	T204	C2992020
P. saheungi	T204	C2992020
P. sujungi	T204	C2992020
P. supseomense	T204	C2992020
erected	T080	C0443211
Rho	T170	C0805191
Min	T170	C0805191
invalid	T080	C3245471
species	T185	C1705920
Prochaetosoma arcticum	T204	C2992020
P. lugubre	T204	C2992020
Epsilonema cygnoides	T204	C2287919
species inquirenda	T185	C1705920
phylogenetic tree	T062	C1519068
18S rRNA gene	T028	C0035899
White Sea	T083	C0036493
species	T185	C1705920
adjoin	T082	C0205107
unidentified	T080	C0205427
species	T185	C1705920
genera	T185	C1708235
Differential	T080	C0443199
effects of	T080	C1704420
crude oil	T109	C0031264
denitrification	T067	C0598972
anammox	T044	C1158281
impact	T080	C4049986
N2O	T121	C0028215
production	T070	C1254365
Denitrification	T067	C0598972
anammox	T044	C1158281
processes	T067	C1522240
reducing	T080	C0392756
external	T082	C0205101
nitrogen	T123	C0028158
delivered	T169	C1705822
coastal	T082	C0557760
ecosystems	T070	C0162358
processes	T067	C1522240
affected	T169	C0392760
pollutants	T131	C0599786
study	T062	C2603343
investigated	T169	C1292732
effect of	T080	C1704420
crude oil	T109	C0031264
denitrification	T067	C0598972
anammox	T044	C1158281
Controlled laboratory experiments	T062	C0681814
sediment	T167	C1550099
slurries	T167	C1550099
Lima	T083	C0017446
Estuary	T070	C3494468
NW	T082	C1254362
Portugal	T083	C0032729
Anammox	T044	C1158281
denitrification	T067	C0598972
rates	T081	C0392762
(15)N-labeled	T196	C0028162
NO3(-)	T197	C0699857
production	T070	C1254365
(29)N2	T123	C0028158
(30)N2	T123	C0028158
membrane inlet mass spectrometry	T059	C0037813
denitrification	T067	C0598972
rates	T081	C0392762
crude oil	T109	C0031264
amendment	T170	C0680532
anammox	T044	C1158281
activity	T052	C0441655
completely	T080	C0205197
inhibited	T080	C0311403
addition	T169	C1883712
crude oil	T109	C0031264
rates	T081	C0392762
unamended controls	T077	C1882979
estuarine	T082	C1254362
sediment	T167	C1550099
types	T080	C0332307
physical-chemical characteristics	T080	C1521970
N2O	T121	C0028215
production	T070	C1254365
reduced	T080	C0392756
crude oil	T109	C0031264
addition	T169	C1883712
mechanism(s)	T169	C0441712
observed	T169	C1441672
reduction	T080	C0392756
N2O	T121	C0028215
production	T070	C1254365
study	T062	C2603343
contributions	T052	C1880177
impact	T080	C4049986
crude oil	T109	C0031264
pollution	T069	C0392355
denitrification	T067	C0598972
anammox	T044	C1158281
management	T057	C1273870
aquatic	T067	C0563034
ecosystems	T070	C0162358
eutrophication	T067	C0015191
N-removal	T052	C1883720
medical	T169	C0205476
leadership	T054	C0023181
qualitative study	T062	C0949415
Australia	T083	C0004340
aims	T078	C1947946
beliefs	T078	C0004951
doctors	T097	C0031831
leadership	T054	C0023181
concept	T078	C0178566
data	T078	C1511726
interviews	T052	C0021822
doctors	T097	C0031831
medical	T169	C0205476
leadership	T054	C0023181
Australia	T083	C0004340
beliefs	T078	C0004951
perspectives	T078	C1254370
doctors	T097	C0031831
leadership	T054	C0023181
barriers	T033	C4063003
doctors	T097	C0031831
leadership	T054	C0023181
Australian	T098	C0238711
health system	T064	C1456613
research	T062	C0035168
beliefs	T078	C0004951
medical	T169	C0205476
leaders	T097	C0557558
themes	UnknownType	C0869035
dimensions	T081	C0439534
data	T078	C1511726
qualitative studies	T062	C0949415
medical	T169	C0205476
leadership	T054	C0023181
Australia	T083	C0004340
collaboration	T054	C0282116
researchers	T097	C0035173
semi-structured interviews	UnknownType	C0681913
medical	T169	C0205476
leaders	T097	C0557558
leadership	T054	C0023181
Australia	T083	C0004340
health services	T058	C0018747
private	T073	C0033173
public hospitals	T073	C0020022
professional associations	T094	C0680403
health departments	T093	C1514958
data	T078	C1511726
approaches	T082	C0449445
coding	T057	C0009219
interview	T052	C0021822
data	T078	C1511726
literature review	T170	C0282441
coded	T057	C0009219
data	T078	C1511726
grouped	T078	C0441833
themes	UnknownType	C0869035
Medical	T169	C0205476
leaders	T097	C0557558
beliefs	T078	C0004951
eyes	T023	C0015392
clinical experience	T080	C0008973
clinical	T080	C0205210
colleagues	T098	C0681088
beliefs	T078	C0004951
dimensions	T081	C0439534
belief	T078	C0004951
managerial	T090	C0402281
clinical	T080	C0205210
credibility	T080	C0870373
conflict	T078	C0079152
clinicians	T097	C0871685
clinical	T080	C0205210
colleagues	T098	C0681088
medical	T169	C0205476
leadership	T054	C0023181
doctors	T097	C0031831
clinical practice	T080	C0008973
medical	T169	C0205476
leadership	T054	C0023181
research	T062	C0035168
Western	T082	C1705493
developed-nation	T080	C0282613
Australia	T083	C0004340
interviews	T052	C0021822
doctors	T097	C0031831
medical	T169	C0205476
leadership	T054	C0023181
doctors	T097	C0031831
beliefs	T078	C0004951
research	T062	C0035168
doctors	T097	C0031831
transition	T052	C2700061
leadership	T054	C0023181
health practitioners	T097	C1552267
perspective	T078	C1254370
research	T062	C0035168
descriptive	T033	C0437940
qualitative methods	T062	C0681940
quantitative research	T062	C1510569
research	T062	C0035168
statistical generalisation	T062	C0871424
health organisations	T073	C0018720
medical	T169	C0205476
employers	T097	C1274022
health departments	T093	C1514958
study	T062	C2603343
concept	T078	C0178566
medical	T169	C0205476
leadership	T054	C0023181
evidence	T078	C3887511
researched	T062	C0035168
data	T078	C1511726
studies	T062	C2603343
analysis	T062	C0936012
coding	T057	C0009219
concept	T078	C0178566
Erlotinib	T109	C1135135
gemcitabine	T114	C0045093
gemcitabine	T114	C0045093
pancreatic cancer	T191	C0235974
real	T080	C0237400
world	T098	C2700280
analysis	T062	C0936012
Korean	T083	C0022771
national	T092	C0015737
database	T170	C0242356
randomized clinical trial	T062	C0206034
addition	T067	C0596304
erlotinib	T109	C1135135
gemcitabine	T114	C0045093
GEM	T114	C0045093
E	T109	C1135135
pancreatic cancer	T191	C0235974
modest	T080	C0205081
increase	T169	C0442805
survival	T052	C0038952
aim	T078	C1947946
national	T082	C0681788
population	T098	C1257890
based	T169	C1527178
retrospective study	T062	C0035363
compare	T052	C1707455
effectiveness	T080	C1280519
GEM	T114	C0045093
E	T109	C1135135
GEM	T114	C0045093
pancreatic cancer	T191	C0235974
patients	T101	C0030705
real clinical practice	T057	C0205897
Patients	T101	C0030705
pancreatic cancer	T191	C0235974
(ICD-10	T170	C1137110
prescription	T170	C1521941
gemcitabine	T114	C0045093
erlotinib	T109	C1135135
retrospectively	T080	C1514923
identified	T080	C0205396
Korean	T083	C0022771
Health Insurance	T058	C0027452
database	T170	C0242356
study	T062	C2603343
population	T098	C1257890
patients	T101	C0030705
required	T169	C1514873
histological	UnknownType	C0679557
cytological diagnosis	T033	C1298647
chemotherapy	T061	C3665472
Patients	T101	C0030705
treated with	T033	C0332154
radiotherapy	T061	C1522449
surgery	T058	C2081627
chemotherapy	T061	C3665472
excluded	T078	C1554077
reduce	T061	C0441610
heterogeneity	T080	C0019409
survival	T052	C0038952
initiation	T169	C1704686
therapy	T061	C0087111
medical costs	T081	C0086600
GEM	T114	C0045093
E	T109	C1135135
GEM	T114	C0045093
compared	T052	C1707455
patients	T101	C0030705
analysis	T062	C0936012
survival	T052	C0038952
significantly	T078	C0750502
longer	T080	C0205166
patients	T101	C0030705
treated	T033	C0332154
GEM	T114	C0045093
E	T109	C1135135
median	T081	C0876920
GEM	T114	C0045093
E	T109	C1135135
GEM	T114	C0045093
no significant	T033	C3694175
difference	T081	C1705241
survival rates	T081	C0038954
Multivariate analysis	T081	C0026777
age	T032	C0001779
gender	T032	C0079399
comorbidities	T078	C0009488
covariates	UnknownType	C0814913
reveal	T080	C0443289
significant	T078	C0750502
differences	T081	C1705241
survival	T052	C0038952
Based	T169	C1527178
relative effectiveness	T081	C0035023
incremental	T081	C1705117
cost	T081	C0010186
life	T078	C0376558
year	T079	C0439234
gained	T081	C1517378
GEM	T114	C0045093
estimated	T081	C0750572
USD	T081	C1555442
GEM	T114	C0045093
E	T109	C1135135
GEM	T114	C0045093
E	T109	C1135135
pancreatic cancer	T191	C0235974
effective	T080	C1704419
GEM	T114	C0045093
real	T080	C0237400
world	T098	C2700280
setting	T078	C1552652
provide	T052	C1999230
reasonable	T033	C0566251
cost-effectiveness	T081	C0010181
GEM	T114	C0045093
Quantitative Structure-Activity Relationship	T081	C0887819
Model	T170	C3161035
Pulmonary Absorption	T042	C3852990
Isolated	T169	C0205409
Perfused	T169	C1549542
Respiring	T039	C0035203
Rat Lung	T023	C1882727
Model	T170	C3161035
Quantitative Structure-Activity Relationship	T081	C0887819
QSAR	T081	C0887819
model	T170	C3161035
physicochemical	T070	C2350461
pulmonary absorption	T042	C3852990
compound design	T090	C0013171
prediction	T078	C0681842
absorption	T067	C2347023
model	T170	C3161035
compounds	T121	C0013227
Pulmonary absorption	T042	C3852990
isolated	T169	C0205409
perfused	T169	C1549542
respiring	T039	C0035203
rat lung	T023	C1882727
IPRLu	T023	C1882727
model	T170	C3161035
drug discovery	T062	C0920472
compounds	T121	C0013227
marketed drugs	T121	C1254351
QSAR	T081	C0887819
model	T170	C3161035
physicochemical properties	T070	C2350461
compounds	T121	C0013227
model's	T170	C3161035
capability	T080	C2698977
QSAR	T081	C0887819
model	T170	C3161035
compounds	T121	C0013227
Test set	T170	C0150098
correlation	T081	C0010100
compounds	T121	C0013227
permeability	T070	C0031164
hydrophobicity	T080	C0598629
pulmonary absorption	T042	C3852990
charge	T080	C0205556
ionisation	T067	C0596801
size	T082	C0456389
QSAR	T081	C0887819
model	T170	C3161035
IPRLu	T023	C1882727
model	T170	C3161035
ranking	T170	C0699794
classifying	T185	C0008902
compounds	T121	C0013227
synthesis	T052	C1883254
inhaled drug discovery	T062	C0920472
physicochemical	T070	C2350461
pulmonary absorption	T042	C3852990
compound	T121	C0013227
dataset	T170	C0150098
EpiDerm™	T170	C0282574
3D human reconstructed skin micronucleus (RSMN) assay	T059	C1511123
Historical control	T062	C3850080
data	T078	C1511726
proof	T033	C0565962
principle studies	T062	C2603343
mechanistic assay	T059	C1510438
in vitro human reconstructed skin micronucleus (RSMN) assay	T059	C1511123
EpiDerm™	T170	C0282574
animal alternative	T062	C0003059
genotoxicity	T049	C0598309
topically applied	T061	C0683174
chemicals	T103	C0220806
assessing	T058	C0184514
cosmetic ingredients	T120	C0456611
tested	T169	C0039593
in vivo	T082	C1515655
assays	T059	C1510438
test	T170	C0392366
regulatory	T089	C0220905
decision-making	T041	C0011109
RSMN assay	T059	C1511123
laboratory	T073	C0022877
Good Laboratory Practice	T185	C2983608
OECD	T093	C3850013
test guideline 487	T170	C0162791
in vitro	T080	C1533691
mammalian cell	T025	C1512977
micronucleus test	T059	C0026006
assay	T059	C1510438
direct-acting genotoxins	T131	C0026879
genotoxins	T131	C0026879
metabolism	T040	C0025519
non-genotoxic	T033	C0243095
non-carcinogenic	T033	C0243095
chemicals	T103	C0220806
report	T170	C0684224
analysis	T062	C0936012
historical control	T062	C3850080
data	T078	C1511726
positive control	T077	C1883676
values	T081	C0392762
micronuclei	T026	C4048301
binucleated cells	T049	C0333909
Technical issues	T067	C1710348
solvents	T130	C0037638
treatment regimens	T061	C0040808
investigated	T169	C1292732
mechanistic studies	T089	C2698671
CREST analysis	T062	C0242481
RSMN assay	T059	C1510438
aneugens	T120	C0949641
clastogens	T131	C0008904
assay	T059	C1510438
cytokines	T116	C0079189
markers	T080	C0162489
proliferative	T046	C0334094
toxic effects	T037	C0600688
chemicals	T103	C0220806
Wnt-5a	T116	C4255015
Frizzled9	T116	C1438694
receptor signaling	T044	C1514762
Gαo	T116	C3884317
Gβγ complex	T116	C0596637
regulates	T038	C1327622
dendritic spine	T026	C0872341
formation	T043	C0007613
Wnt ligands	T116	C0033684
development	T042	C1254358
regulation of synapse structure and function	T042	C1325905
Wnt-5a	T116	C4255015
secreted growth factor	T116	C0018284
regulates	T038	C1327622
dendritic spine	T026	C0872341
formation	T043	C0007613
rodent	T015	C0035804
hippocampal	T023	C0019564
neurons	T025	C0027882
postsynaptic	T026	C1167384
development	T042	C1254358
clustering of the postsynaptic density protein-95 (PSD-95)	T043	C3269066
early	T079	C1279919
events	T051	C0441471
interaction	T044	C0872079
Wnt-5a	T116	C4255015
Frizzled receptor	T116	C1564903
neuronal	T025	C0027882
cell surface	T026	C0699040
role	T077	C1705810
heterotrimeric G proteins	T116	C0752348
Wnt-5a	T116	C4255015
synaptic	T026	C0039063
development	T042	C1254358
Frizzled9	T116	C1438694
FZD9	T116	C1438694
Wnt	T116	C4255015
receptor	T116	C1564903
Williams' syndrome	T047	C0175702
postsynaptic region	UnknownType	C0682686
interacts	T044	C0872079
Wnt-5a	T116	C4255015
FZD9	T116	C1438694
Wnt-5a	T116	C4255015
increase	T169	C0442805
dendritic spine density	T026	C0872341
FZD9	T116	C1438694
pre-coupled complex	T026	C3893600
Gαo	T116	C3884317
basal conditions	T070	C1254365
dissociates	T044	C0301643
Wnt-5a	T116	C4255015
stimulation	T044	C1148560
G-protein inhibition abrogates	T043	C0007613
Wnt-5a	T116	C4255015
pathway	T044	C1704259
hippocampal	T023	C0019564
neurons	T025	C0027882
activation	T052	C1879547
Gαo	T116	C3884317
controlling	T067	C2239193
Wnt-5a	T116	C4255015
induced	T169	C0205263
dendritic spine density	T026	C0872341
Gβγ	T116	C0596637
Wnt-5a	T116	C4255015
increase	T169	C0442805
cytosolic	T026	C1383501
calcium	T121	C0006675
levels	T080	C0441889
spinogenesis	T043	C0007613
findings	T169	C2607943
FZD9	T116	C1438694
heterotrimeric G proteins	T116	C0752348
regulate	T038	C1327622
Wnt-5a	T116	C4255015
signaling	T044	C0037080
dendritic spines	T026	C0872341
cultured	T025	C0007635
hippocampal	T023	C0019564
neurons	T025	C0027882
Delayed	T079	C0205421
Diagnosis	T033	C0011900
Chronic Mesenteric Ischaemia	T047	C0311262
Clinicians	T097	C0871685
Cognitive	T169	C1516691
Errors	T080	C0743559
Chronic	T079	C0205191
diarrhoeal illnesses	T047	C1290807
nausea	T184	C0027497
weight loss	T033	C1262477
common	T081	C0205214
indication	T078	C3146298
gastroenterology	T091	C0017163
review	T078	C1552617
intra-luminal	T082	C0442115
aetiologies	T169	C1314792
inflammatory bowel disease	T047	C0021390
coeliac disease	T047	C0007570
malabsorptive conditions	T033	C3280502
functional	T169	C0205245
gut	T023	C0699819
disorders	T047	C0012634
systemic	T169	C0205373
malignancy	T191	C4282132
clinicians	T097	C0871685
vascular disorders	T047	C0042373
patient	T101	C0030705
delayed	T079	C0205421
diagnosis	T033	C0011900
chronic mesenteric ischaemia	T047	C0311262
months	T079	C0439231
gastrointestinal symptoms	T184	C0426576
alternative	T077	C1523987
diagnosis	T033	C0011900
inflammatory bowel disease	T047	C0021390
atypical	T080	C0205182
predominance	T169	C1527180
nausea	T184	C0027497
diarrhoea	T184	C0011991
pain	T184	C0030193
review	T078	C1552617
literature	T170	C0023866
treatment	T169	C1522326
condition	T047	C0012634
sequence	T169	C1519249
cognitive	T169	C1516691
errors	T080	C0743559
clinicians	T097	C0871685
diagnostic	T033	C0011900
delay	T079	C0205421
errors	T080	C0743559
minimised	T080	C0392756
practice	T057	C0205897
Evaluation	T058	C0220825
Choroidal	T023	C0008520
Thickness	T080	C1280412
Patients	T101	C0030705
Pseudoexfoliation Syndrome	T047	C0206368
Pseudoexfoliation Glaucoma	T047	C0206368
Purpose	T169	C1285529
compare	T052	C1707455
macular	T082	C0332574
peripapillary	T082	C0442163
choroidal	T023	C0008520
thickness	T080	C1280412
eyes	T023	C0015392
pseudoexfoliation (PEX) syndrome	T047	C0206368
PEX glaucoma	T047	C0206368
normal	T080	C0205307
eyes	T023	C0015392
healthy	T080	C3898900
controls	T096	C0009932
prospective study	T062	C0033522
eyes	T023	C0015392
patients	T101	C0030705
PEX syndrome	T047	C0206368
eyes	T023	C0015392
patients	T101	C0030705
PEX glaucoma	T047	C0206368
eyes	T023	C0015392
age	T032	C0001779
healthy	T080	C3898900
subjects	T096	C0681850
Choroidal	T023	C0008520
thicknesses	T080	C1280412
macular	T082	C0332574
peripapillary	T082	C0442163
areas	T082	C0205146
measured	T080	C0444706
spectral domain optical coherence tomography	T074	C3876157
Gender	T032	C0079399
age	T032	C0001779
axial length	T081	C2936396
not significantly	T033	C1273937
groups	UnknownType	C0681860
mean values	T081	C0444504
choroidal	T023	C0008520
thickness	T080	C1280412
macular	T082	C0332574
peripapillary	T082	C0442163
areas	T082	C0205146
except	T169	C0332300
superior	T082	C1282910
quadrant	T082	C1631280
patients	T101	C0030705
PEX syndrome	T047	C0206368
PEX glaucoma	T047	C0206368
lower	T052	C2003888
compared	T052	C1707455
controls	T096	C0009932
mean values	T081	C0444504
macular	T082	C0332574
peripapillary	T082	C0442163
choroidal	T023	C0008520
thickness	T080	C1280412
PEX glaucoma	T047	C0206368
group	UnknownType	C0681860
lower	T052	C2003888
compared	T052	C1707455
PEX syndrome	T047	C0206368
group	UnknownType	C0681860
difference	T080	C1705242
not significant	T033	C1273937
findings	T033	C0243095
study	T062	C2603343
revealed	T080	C0443289
macular	T082	C0332574
peripapillary	T082	C0442163
choroidal	T023	C0008520
thicknesses	T080	C1280412
decreased	T081	C0205216
PEX syndrome	T047	C0206368
PEX glaucoma	T047	C0206368
cases	T169	C0868928
choroid	T023	C0008520
development	T169	C1527148
glaucomatous	T047	C0017601
damage	T169	C1883709
patients	T101	C0030705
PEX syndrome	T047	C0206368
unclear	T033	C3845108
Clinical Features	T184	C0037088
Complications	T046	C0009566
HLA-B27	T116	C0019740
Acute Anterior Uveitis	T047	C0701807
Metanalysis	T062	C0920317
article	T170	C1706852
literature-based	T170	C0023866
metanalysis	T062	C0920317
clinical features	T184	C0037088
HLA-B27	T116	C0019740
Acute Anterior Uveitis	T047	C0701807
AAU	T047	C0701807
examined	T033	C0332128
observational studies	T062	C1518527
participants	T098	C0679646
Acute Anterior Uveitis	T047	C0701807
HLA B27+	T034	C0239961
HLA B27-	T034	C0587081
articles	T170	C1706852
HLA B27 uveitis	T047	C0042164
articles	T170	C1706852
review	T078	C1552617
articles	T170	C1706852
analyzed	T062	C0936012
clinical characteristics	T201	C0683325
metanalysis	T062	C0920317
systemic disease	T047	C0442893
sex distribution	T081	C0036878
laterality	T032	C0023114
visual acuity	T201	C0042812
hypopion	T047	C0020641
anterior chamber's fibrin	T116	C0015982
elevated intraocular pressure	T033	C0234708
IOP	T042	C0021888
inflammation	T046	C0021368
glaucoma	T047	C0017601
posterior synechiae	T047	C0152253
cataract	T020	C0086543
cystoid macular edema	T047	C0024440
papillitis	T047	C0030353
relative risk	T081	C0242492
RR	T081	C0242492
outcome measured	T081	C0086749
results	T169	C1274040
HLA B27	T116	C0019740
Acute Anterior Uveitis	T047	C0701807
association with	T080	C0332281
ankylosing spondylitis	T047	C0038013
RR	T081	C0242492
systemic diseases	T047	C0442893
RR	T081	C0242492
male	T032	C0086582
prevalence	T081	C0220900
RR	T081	C0242492
unilateral	T082	C0205092
RR	T081	C0242492
bilateral	T082	C0238767
RR	T081	C0242492
involvement	T169	C1314939
hypopion	T047	C0020641
RR	T081	C0242492
fibrinous	T116	C0033684
reaction	T169	C0443286
papillitis	T047	C0030353
bilateral	T082	C0238767
RR	T081	C0242492
AAU	T047	C0701807
frequent	T079	C0332183
HLA-B27	T116	C0019740
negative	T033	C0205160
risk	T078	C0035647
elevated IOP	T033	C0234708
glaucoma	T047	C0017601
RR	T081	C0242492
B27- Acute Anterior Uveitis	T047	C0701807
HLA B 27 positive	T033	C4285788
negative	T033	C0205160
AAU	T047	C0701807
observed	T169	C1441672
visual acuity	T201	C0042812
complications	T046	C0009566
posterior synechiae	T047	C0152253
cataract	T020	C0086543
maculare edema	T047	C0024440
clinical evaluation	T058	C4084924
therapeutic	T169	C0302350
decision	T041	C0679006
ophthalmologic	T169	C0205481
condition	T080	C0348080
Splenic Infarct	T047	C0037998
Diagnosed	T033	C0011900
Primary Bone Marrow	T024	C0005953
CD5 Positive	T025	C0882892
DLBCL	T191	C0079744
Clinicopathological Correlation	T080	C1707520
De novo	T078	C1515568
CD5+	T025	C0882892
Diffuse large B cell lymphoma	T033	C0011900
DLBCL	T191	C0079744
rare	T080	C0522498
aggressive subtype	T033	C0243095
DLBCL	T191	C0079744
clinicopathologic	T033	C0243095
entity	T071	C1551338
complex molecular profile	T169	C1704864
poor prognosis	T033	C0278252
year	T079	C0439234
female	T032	C0086287
presented with	T033	C0150312
pyrexia of unknown origin	T184	C0015970
month	T079	C0439231
examination	T058	C0031809
severe pallor	T033	C0030232
hepatosplenomegaly	T184	C0019214
no palpable	T080	C0522499
lymphadenopathy	T047	C0497156
Complete blood count	T059	C0009555
revealed	T080	C0443289
bicytopenia	T034	C1142446
normal total leucocyte count	T033	C0438221
Liver	T059	C0023901
renal function tests	T059	C0022662
normal	T080	C0205307
Ultrasonography abdomen	T060	C0203464
revealed	T080	C0443289
splenic enlargement	T033	C0038002
two focal lesions	T033	C0243095
splenic abscess	T047	C0272412
infarcts	T047	C0037998
Patient	T101	C0030705
splenic infarct	T047	C0037998
bicytopenia	T034	C1142446
investigation	T058	C0220825
elevated serum ferritin	T033	C0241013
triglycerides	T033	C0813230
LDH	T034	C1275604
clinical	T080	C0205210
suspicion	T041	C0242114
infection	T046	C3714514
haemophagocytic lymphohistiocytosis	T047	C0024291
bone marrow aspiration	T060	C0398523
bone marrow aspiration (BMA) and biopsy (BMBx)	T060	C0005954
BMA	T060	C0398523
biopsy	T060	C0005558
extensive	T080	C0205231
haemophagocytosis	T047	C0876991
large lymphoma-like cells	T191	C0027671
PET-CT	T060	C1699633
enlarged spleen	T033	C0038002
diffuse uptake	T033	C0301639
BMBx	T060	C0005954
nodular	T020	C0028259
intrasinusoidal	T082	C0442041
abnormal lymphoid cells	T025	C0086574
immunohistochemistry	T060	C0021044
cells	T025	C0086574
positive for CD20	T034	C4289894
CD5	T116	C0054964
MUM1	T116	C0299544
BCL-2	T129	C1317122
BCL-6	T129	C1829684
negative	T033	C0205160
CD3	T116	C0108779
CD10	T116	C0025250
CD23	T116	C0123242
CD34	T116	C0054953
focal	T082	C0205234
intrasinusoidal	T082	C0442041
pattern	T082	C0449774
clinicopathological profile	T058	C1254363
diagnosis	T033	C0011900
de novo	T078	C1515568
CD5+	T025	C0882892
DLBCL	T191	C0079744
primary hepatosplenic	T047	C0012634
pattern	T082	C0449774
CD5+	T025	C0882892
DLBCL	T191	C0079744
splenic infarct	T047	C0037998
very rare	T033	C1855575
unusual	T080	C2700116
diagnosis	T033	C0011900
primary aggressive lymphoma	T191	C1332225
haemophagocytosis	T047	C0876991
established	T080	C0443211
patient	T101	C0030705
fever	T184	C0015967
splenic infarct	T047	C0037998
lymphadenopathy	T047	C0497156
morphological	T082	C0543482
assessment	T052	C1516048
bone marrow aspirate	T031	C0857285
biopsy	T060	C0005558
correct diagnosis	T033	C0011900
cost-effectiveness	T081	C0010181
family	T099	C0015576
family-based therapy	T061	C0087111
treatment	T169	C1522326
externalizing disorders	T048	C0004936
substance use disorders	T048	C0038586
delinquency	T048	C0522174
review	T170	C0282443
Family therapy	T061	C0087111
family-based treatment	T169	C1522326
children	T100	C0008059
adolescents	T100	C0205653
mental health care	T061	C0184643
economic evaluations	T057	C0150099
interventions	T061	C0184661
review	T170	C0282443
evaluate	T058	C0220825
cost-effectiveness	T081	C0010181
family	T099	C0015576
family-based therapy	T061	C0087111
externalizing disorders	T048	C0004936
substance use disorders	T048	C0038586
delinquency	T048	C0522174
PubMed	T170	C1138432
Education Resource information Centre	T073	C1449627
ERIC	T073	C1449627
Psycinfo	T170	C1140129
Cochrane	T170	C0242356
reviews	T170	C0282443
studies	T059	C0947630
economic evaluations	T057	C0150099
family	T099	C0015576
family-based interventions	T061	C0184661
adolescents	T100	C0205653
years	T079	C0439234
treated	T169	C1522326
substance use disorders	T048	C0038586
delinquency	T048	C0522174
externalizing disorders	T048	C0004936
articles	T170	C1706852
studies	T059	C0947630
studies	T059	C0947630
quality	T080	C0332306
studies	T059	C0947630
assessed	T052	C1516048
studies	T059	C0947630
family	T099	C0015576
family-based interventions	T061	C0184661
disorders	T047	C0012634
outcomes	T057	C0085565
quality	T080	C0332306
economic evaluations	T057	C0150099
study	T059	C0947630
meta-analysis	T062	C0920317
quality	T080	C0332306
economic evaluations	T057	C0150099
family	T099	C0015576
family-based therapy	T061	C0087111
treatment	T169	C1522326
externalizing disorders	T048	C0004936
adolescent	T100	C0205653
substance use disorders	T048	C0038586
delinquency	T048	C0522174
cost-effectiveness	T081	C0010181
family	T099	C0015576
family-based therapy	T061	C0087111
quality	T080	C0332306
Regulation	T045	C0017263
ABCA1	T028	C1412058
ABCG1	T028	C1412096
gene expression	T045	C0017262
intraabdominal adipose tissue	T024	C1563739
Tissue specific expression of genes	T045	C1519516
encoding	T052	C2700640
cholesterol	T109	C0008377
transporters	T116	C0007292
ABCA1	T116	C3711161
ABCG1	T116	C0963751
genes	T028	C0017337
encoding	T052	C2700640
transcriptional	T045	C0040649
regulators	T116	C0815047
adipogenesis	T044	C0596843
LXRa	T116	C0297439
LXRb	T116	C0754148
PPARg	T116	C3887582
RORa	T116	C0284080
investigated	T169	C1292732
intraabdominal adipose tissue	T024	C1563739
IAT	T024	C1563739
samples	T167	C0370003
correlation	T080	C1707520
ABCA1	T116	C3711161
ABCG1 proteins	T116	C0963751
RORa protein	T116	C0284080
level	T080	C0441889
suggests	T078	C1705535
transcription factor	T116	C0040648
RORa	T116	C0284080
regulation	T038	C1327622
IAT	T024	C1563739
ABCA1	T116	C3711161
ABCG1 protein	T116	C0963751
levels	T080	C0441889
ABCA1	T028	C1412058
ABCG1	T028	C1412096
gene expression	T045	C0017262
correlated	T080	C1707520
obesity	T047	C0028754
indicators	T130	C0021212
body mass index	T201	C1305855
BMI	T201	C1305855
waist circumference	T201	C0455829
development	T169	C1527148
obesity	T047	C0028754
associated with	T080	C0332281
decreased	T081	C0205216
IAT	T024	C1563739
levels	T080	C0441889
RORa	T028	C1335634
LXRb	T028	C1417823
mRNA	T114	C0035696
data	T078	C1511726
suggest	T078	C1705535
nuclear factor RORa	T116	C0284080
significant	T078	C0750502
regulation	T038	C1327622
cholesterol metabolism	T044	C1156530
control	T080	C0243148
IAT	T024	C1563739
expression	T045	C1171362
ABCA1	T116	C3711161
ABCG1	T116	C0963751
level	T080	C0441889
IAT	T024	C1563739
LXRb	T028	C1417823
gene expression	T045	C0017262
associated with	T080	C0332281
development	T169	C1527148
obesity	T047	C0028754
Triterpenoids	T109	C1519655
stems	T002	C0242767
Tripterygium regelii	T002	C1059497
triterpenoids	T109	C1519655
triregelolides	T109	C1519655
triregeloic acid	T109	C1519655
isolated	T169	C0205409
stems	T002	C0242767
Tripterygium regelii	T002	C1059497
triterpene	T109	C0041113
analogues	T104	C0002776
compounds	T109	C0041113
NMR spectroscopic	T060	C0877853
HRESIMS	T059	C0596495
Compounds	T109	C0041113
4	T109	C0041113
7	T109	C0041113
8	T109	C0041113
10	T109	C0041113
13	T109	C0041113
14	T109	C0041113
17	T109	C0041113
21-23	T109	C0041113
isolated	T169	C0205409
T. regelii	T002	C1059497
Compounds	T109	C1519655
3	T109	C1519655
5	T109	C0041113
6	T109	C0041113
8	T109	C0041113
9	T109	C0041113
10	T109	C0041113
14	T109	C0041113
16	T109	C0041113
inhibitory effects on the proliferation	T043	C1156236
human breast cancer cells	T025	C1512505
MCF-7	T025	C0596890
concentration	T081	C0392762
Biochemical	T169	C0205474
mitochondrial	T026	C0026237
genetic	T169	C0314603
modifier	T028	C3178895
phenotypic	T032	C0031437
manifestation	T169	C0205319
Leber's hereditary optic neuropathy	T047	C0917796
mitochondrial DNA mutation	T019	C0948444
Leber's hereditary optic neuropathy	T047	C0917796
LHON	T047	C0917796
mitochondrial disease	T047	C0751651
Mitochondrial	T026	C0026237
modifiers	T028	C3178895
phenotypic expression	T032	C0031437
LHON	T047	C0917796
mitochondrial DNA	T114	C0012929
mtDNA	T114	C0012929
mutations	T019	C0948444
study	T062	C2603343
LHON	T047	C0917796
susceptibility	T201	C0012655
allele	T028	C0002085
m.14502T > C	T028	C0002085
p. 58I > V	T028	C0002085
ND6 gene	T028	C1537995
modulated	T082	C0443264
phenotypic expression	T032	C0031437
LHON	T047	C0917796
m.11778G > A mutation	T045	C0026882
Han Chinese	UnknownType	C0814942
pedigrees	T170	C0030761
m.14502T > C	T045	C0026882
m.11778G > A mutations	T045	C0026882
penetrance	T081	C0524899
optic neuropathy	T047	C3887709
m.11778G > A mutation	T045	C0026882
functional	T169	C0205245
assays	T059	C0005507
cybrid cell models	T025	C0007600
mtDNA-less ρ(o) cells	T025	C0007634
enucleated cells	T025	C0007634
LHON	T047	C0917796
patients	T101	C0030705
m.11778G > A	T045	C0026882
m.14502T > C mutations	T045	C0026882
m.14502T > C	T045	C0026882
m.11778G > A mutation	T045	C0026882
mtDNA	T114	C0012929
haplogroup	T032	C0018591
cybrids cell lines	T025	C0007600
m.14502T > C mutation	T045	C0026882
effects	T080	C1280500
mitochondrial	T026	C0026237
functions	T169	C0542341
m.11778G > A mutation	T045	C0026882
mitochondrial	T026	C0026237
dysfunctions	T077	C3887504
cell lines	T025	C0007600
m.14502T > C	T045	C0026882
m.11778G > A mutations	T045	C0026882
m.11778G > A	T045	C0026882
m.14502T > C mutation	T045	C0026882
m.14502T > C mutation	T045	C0026882
complex I	T116	C0171406
respiratory	T169	C0521346
phenotypes	T032	C0031437
m.11778G > A mutation	T045	C0026882
defective	T169	C0332452
complex I	T116	C0171406
mitochondrial	T026	C0026237
ATP	T114	C0001480
reactive oxygen species	T123	C0162772
mutant	T049	C0596988
cells	T025	C0007634
m.14502T > C	T045	C0026882
m.11778G > A mutation	T045	C0026882
11778G > A mutation	T045	C0026882
pathophysiology	T169	C0031847
LHON	T047	C0917796
manifested by	T080	C1280444
mtDNA	T114	C0012929
mutations	T019	C0948444
Improving	T080	C1272745
Care Transitions	T058	C4019079
Healthcare	T058	C0086388
Settings	T082	C1254362
Human Factors	T033	C4035944
decades	T081	C2981279
research	T062	C0035168
care transition	T058	C4019079
improvement	T077	C2986411
intervention	T061	C0184661
development	T169	C1527148
unfavorable outcome	T033	C1519790
measures	T169	C1879489
associated with	T080	C0332281
care transitions	T058	C4019079
healthcare	T058	C0086388
settings	T082	C1254362
Readmissions	UnknownType	C0745042
rates	T081	C1264674
outcome	T169	C1274040
target	T169	C1521840
intervention	T061	C0184661
adverse events	T046	C0877248
associated with	T080	C0332281
care transitions	T058	C4019079
issue	T033	C0033213
patients	T101	C0030705
dissatisfied	T041	C0870433
quality	T080	C0332306
care	T052	C1947933
interventions	T061	C0184661
care transitions	T058	C4019079
disease	T047	C0012634
specific	T080	C0205369
substantial	T080	C0205556
financial investments	T058	C3826621
training	T065	C0220931
allied healthcare professionals	T097	C0002122
hospital-based discharge planning	T058	C1563179
complex situation	T080	C0205556
method of evaluation	T062	C2911685
comprehensive	T080	C1880156
in-depth	T082	C0205125
context-driven	T078	C1254370
investigation	T058	C0220825
potential risks	T033	C0035648
care transitions	T058	C4019079
healthcare	T058	C0086388
settings	T082	C1254362
creation	T052	C1706214
effective	T080	C1704419
usable	T080	C0205556
sustainable	T169	C0443318
interventions	T061	C0184661
Human Factors and Ergonomics	T090	C0020120
HFE	T090	C0020120
evaluates	T170	C1550545
factors	T169	C1521761
human performance	T052	C0020115
article	T170	C1706852
HFE	T090	C0020120
improve	T080	C1272745
care transitions	T058	C4019079
Adenosine	T114	C0001443
adenosine A2A receptor agonist	T121	C2936552
CGS21680	T109	C0055233
upregulate	T044	C0949479
CD39	T129	C0108783
CD73	T116	C0000530
expression	T045	C0597360
E2F-1	T116	C1384539
CREB	T116	C0056695
regulatory T cells	T025	C0039198
isolated	T169	C0205409
septic	T169	C0333534
mice	T015	C0025929
regulatory T cells	T025	C0039198
Treg cells	T025	C0039198
expression	T045	C0597360
ectonucleoside triphosphate diphosphohydrolase 1	T129	C0108783
ENTPD1	T129	C0108783
CD39	T129	C0108783
5'-ectonucleotidase	T116	C0000530
NT5E	T116	C0000530
CD73	T116	C0000530
Treg cell	T025	C0039198
surface	T082	C0205148
increased	T081	C0205217
sepsis	T047	C0243026
factors	T123	C0005515
high	T080	C0205250
expression	T045	C0597360
CD39	T129	C0108783
CD73	T116	C0000530
regulation of	T038	C1327622
CD39	T129	C0108783
CD73	T116	C0000530
adenosine	T114	C0001443
pathway	T077	C1705987
Treg cells	T025	C0039198
septic	T169	C0333534
mouse model	T050	C2986594
sepsis	T047	C0243026
Treg cells	T025	C0039198
flow cytometer	T074	C0180279
Treg cells	T025	C0039198
isolated	T169	C0205409
peritoneal lavage	T058	C0031148
splenocytes	T025	C1519477
mice	T015	C0025929
treated with	T061	C0332293
adenosine	T114	C0001443
adenosine A2A receptor agonist	T121	C2936552
CGS21680	T109	C0055233
transfected	T063	C0040669
siRNA	T114	C1099354
targeting	T169	C1521840
E2F transcription factor 1	T116	C1384539
E2F-1	T116	C1384539
cyclic adenosine monophosphate (cAMP) response element-binding protein	T116	C0056695
CREB	T116	C0056695
transcription regulatory factors	T116	C0040648
CD39	T129	C0108783
CD73	T116	C0000530
regulatory	T038	C1327622
factors	T123	C0005515
western blot analysis	T059	C0949466
dual-luciferase reporter assay	T059	C0022885
changes	T169	C0392747
adenosine metabolism	T044	C1158592
treated	T169	C1522326
cells	T025	C0007634
adenosine	T114	C0001443
CGS21680	T109	C0055233
upregulated	T044	C0949479
CD39	T129	C0108783
CD73	T116	C0000530
expression	T045	C0597360
E2F-1	T116	C1384539
CREB	T116	C0056695
CD39	T129	C0108783
CD73	T116	C0000530
expression	T045	C0597360
upregulated	T044	C0949479
adenosine	T114	C0001443
CGS21680	T109	C0055233
Adenosine triphosphate (ATP) hydrolysis	T044	C1510699
adenosine	T114	C0001443
generation	T052	C3146294
inhibited	T052	C3463820
knockdown	T080	C0849355
E2F-1	T116	C1384539
CREB	T116	C0056695
accelerated	T169	C0521110
CGS21680	T109	C0055233
adenosine	T114	C0001443
adenosine A2A receptor agonist	T121	C2936552
E2F-1	T116	C1384539
CREB	T116	C0056695
factors	T123	C0005515
high	T080	C0205250
expression	T045	C0597360
CD39	T129	C0108783
CD73	T116	C0000530
Treg cell	T025	C0039198
surface	T082	C0205148
sepsis	T047	C0243026
Adenosine	T114	C0001443
A2A receptor agonist	T121	C2936552
signal transducer	T044	C1152628
factors	T123	C0005515
CD39	T129	C0108783
CD73	T116	C0000530
adenosine	T114	C0001443
pathway	T077	C1705987
accelerating	T169	C0521110
adenosine	T114	C0001443
generation	T052	C3146294
research	T062	C0035168
adenosine metabolism	T044	C1158592
treatment	T061	C0087111
sepsis	T047	C0243026
Consumer	T098	C1707496
Patient	T101	C0030705
Knowledge	T170	C0376554
Behavior	T053	C0004927
Attitude	T041	C0004271
Toward	T078	C3875150
Medicinal	T121	C0013227
Lifestyle Products	T073	C3273359
Purchased	T052	C0870238
Internet	T073	C0282111
Web	T073	C0282111
Based	T169	C1527178
Survey	T170	C0038951
lifestyle products	T073	C3273359
improve	T033	C0184511
people's	T098	C0027361
physical	T032	C2607857
mental	T041	C0025361
performance	T055	C0597198
Internet	T073	C0282111
major	T080	C0205164
role	T077	C1705810
spread	T080	C0332261
products	T071	C1514468
literature	T170	C0023866
authenticity	T080	C0205556
medicines	T121	C0013227
purchased	T052	C0870238
Internet	T073	C0282111
impact	T080	C4049986
counterfeit medicines	T131	C2936336
public	T092	C0678367
health	T078	C0018684
no data are available	T080	C1546437
authenticity	T080	C0205556
lifestyle products	T073	C3273359
toxicity	T080	C0040539
associated with	T080	C0332281
use	T169	C1524063
misuse	T033	C0549649
investigate	T169	C1292732
consumer	T080	C0680971
patient attitudes	T041	C0870289
toward	T078	C3875150
purchase	T052	C0870238
lifestyle products	T073	C3273359
Internet	T073	C0282111
knowledge	T170	C0376554
product	T071	C1514468
authenticity	T080	C0205556
toxicity	T080	C0040539
experiences	T041	C0596545
counterfeit	T080	C0205556
lifestyle products	T073	C3273359
Web	T073	C0282111
based	T169	C1527178
study	T062	C2603343
performed	T169	C0884358
Uniform	T080	C0205375
collection of data	T062	C0010995
performed	T169	C0884358
through	T169	C0332273
anonymous	T080	C2346787
online	T073	C0029038
questionnaire	T170	C0034394
Participants	T098	C0679646
worldwide	T082	C0332464
email	T170	C0013849
social media	T170	C3179065
personal communication	T054	C0086792
complete	T080	C0205197
online	T073	C0029038
questionnaire	T170	C0034394
total	T080	C0439810
participants	T098	C0679646
completed	T080	C0205197
questionnaire	T170	C0034394
results	T169	C1274040
questionnaire	T170	C0034394
participants	T098	C0679646
purchased	T052	C0870238
lifestyle products	T073	C3273359
Internet	T073	C0282111
mainly	T080	C1542147
due to	T169	C0678226
convenience	T080	C3831015
reduced	T080	C0392756
cost	T081	C0010186
More than	T081	C0439093
half	T081	C2825407
participants	T098	C0679646
purchased	T052	C0870238
cosmetic products	T073	C0010164
minority	T080	C0205165
purchased	T052	C0870238
medicinal products	T121	C0013227
participants	T098	C0679646
aware	T041	C0004448
presence	T033	C0150312
counterfeit	T080	C0205556
lifestyle products	T073	C3273359
Internet	T073	C0282111
experienced	T041	C0596545
counterfeit	T080	C0205556
products	T071	C1514468
cases	T169	C0868928
counterfeit	T080	C0205556
lifestyle products	T073	C3273359
reported	T058	C0700287
authorities	T093	C1708333
participants	T098	C0679646
experienced	T041	C0596545
adverse effects	T046	C0879626
counterfeit	T080	C0205556
lifestyle products	T073	C3273359
patients	T101	C0030705
experienced	T041	C0596545
counterfeit	T080	C0205556
lifestyle products	T073	C3273359
resulted in	T169	C0332294
adverse effects	T046	C0879626
health	T078	C0018684
adverse effects	T046	C0879626
reported	T058	C0700287
study	T062	C2603343
counterfeit	T080	C0205556
products	T071	C1514468
underreported	T058	C0700287
authorities	T093	C1708333
public awareness campaigns	UnknownType	C0679750
patient education	T065	C0030688
needed	T080	C0027552
Prune Belly Syndrome	T047	C0033770
Associated with VACTERL	T019	C1735591
Prune belly syndrome	T047	C0033770
rare	T080	C0522498
abnormality	T033	C1704258
association with VACTERL	T019	C1735591
rarer	T080	C0522498
association	T019	C1735591
reported	T058	C0700287
literature	T170	C0023866
reported	T058	C0700287
majority	T054	C0680220
stillbirths or died shortly after birth	T033	C1850556
case	T077	C1706256
Prune belly syndrome	T047	C0033770
associated with VACTERL	T019	C1735591
Changes	T169	C0392747
Cardiovascular	T029	C3887460
Health Status	T080	C0018759
Risk of	T078	C0035647
New-Onset Hypertension	UnknownType	C0745129
Kailuan	T098	C1257890
Cohort Study	T081	C0009247
American Heart Association	T093	C0002458
cardiovascular	T029	C3887460
health metrics	T170	C0282574
cardiovascular diseases	T047	C0007222
key	T080	C3898777
risk factor	T033	C0035648
high	T080	C0205250
morbidity	T081	C0026538
mortality	T081	C0681679
cardiovascular diseases	T047	C0007222
hypertension	T047	C0020538
relationship	T080	C0439849
health status	T080	C0018759
attention	T041	C0004268
influence	T077	C4054723
individual	T098	C0027361
health status	T080	C0018759
changes	T169	C0392747
risk of	T078	C0035647
new-onset hypertension	UnknownType	C0745129
assess	T058	C0184514
changes	T169	C0392747
cardiovascular	T029	C3887460
health status	T080	C0018759
morbidity	T081	C0026538
hypertension	T047	C0020538
Kailuan	T098	C1257890
cohort study	T081	C0009247
north	T082	C1709269
China	T083	C0008115
Cardiovascular	T029	C3887460
Health Score	T081	C0449820
CHS	T081	C0449820
evaluated	T058	C0220825
follow-ups	T058	C3274571
study population	T098	C2348561
divided	T169	C0332849
groups	T078	C0441833
changes	T169	C0392747
CHS score	T081	C0449820
follow-ups	T058	C3274571
morbidity	T081	C0026538
hypertension	T047	C0020538
collected	T169	C1516698
during	T079	C0347984
follow-ups	T058	C3274571
Data analysis	T057	C0010992
during	T079	C0347984
median	T081	C0876920
follow-up	T058	C3274571
morbidity	T081	C0026538
hypertension	T047	C0020538
relationship	T080	C0439849
standardized	T058	C1255664
morbidity	T081	C0026538
hypertension	T047	C0020538
participants	T098	C0679646
increased	T081	C0205217
decrease	T081	C0547047
future	T079	C0016884
risk of	T078	C0035647
new-onset hypertension	UnknownType	C0745129
CI	T081	C0009667
relationship	T080	C0439849
new-onset hypertension	UnknownType	C0745129
elevation	T080	C3163633
cardiovascular	T029	C3887460
health metrics	T170	C0282574
Population	T098	C1257890
prevention	T080	C2700409
promotion	T058	C0018738
lifestyle	T054	C0023676
improvements	T077	C2986411
critical	T080	C1511545
reducing	T080	C0392756
morbidity	T081	C0026538
new-onset hypertension	UnknownType	C0745129
HIV	T005	C0019682
tailored	T058	C2986593
quit	T052	C1947925
smoking	T055	C0037369
counselling	T058	C0010210
pilot	T062	C0031928
intervention	T061	C0184661
targeting	T169	C1521840
depressive symptoms	T184	C0086132
Nicotine Replacement Therapy	T061	C1278444
Cardiovascular disease	T047	C0007222
CVD	T047	C0007222
rates	T081	C0026538
people	T098	C0027361
living with HIV/AIDS	T101	C2963182
PHAs	T101	C2963182
high	T080	C0205250
Rates	T081	C1521828
cigarette smoking	T055	C0700219
leading	T169	C1522538
contributor	T052	C1880177
CVD	T047	C0007222
PHAs	T101	C2963182
higher	T080	C0205250
general population	T098	C0683971
PHAs	T101	C2963182
high	T080	C0205250
rates	T081	C1521828
depression	T048	C0011570
risk factor	T033	C0035648
smoking	T055	C0037369
cessation	T052	C1880019
relapse	T067	C0035020
pilot study	T062	C0031928
examined	T033	C0332128
effectiveness	T080	C1280519
tailored	T058	C2986593
session	T051	C1883016
smoking	T055	C0037369
cessation	T052	C1880019
counselling programme	T058	C0010210
PHAs	T101	C2963182
depression	T048	C0011570
Nicotine Replacement Therapy	T061	C1278444
NRT	T061	C1278444
cohort	T098	C0599755
PHA	T101	C2963182
smokers	T033	C0337664
month	T079	C0439231
follow-up	T058	C1522577
participants	T098	C0679646
biochemically	T169	C0205474
verified	T169	C1711411
abstinence	T061	C3843422
smoking	T055	C0037369
result	T033	C2825142
compares	T052	C1707455
quit	T052	C1947925
smoking	T055	C0037369
intervention	T061	C0184661
studies	T062	C0008972
high	T080	C0205250
percentage	T081	C0439165
HIV+	T034	C0019699
smokers	T033	C0337664
depression	T048	C0011570
study	T062	C0008972
baseline	T081	C1442488
HIV+	T034	C0019699
smokers	T033	C0337664
clinical	T080	C0205210
cut-off	T169	C1442160
depression	T048	C0011570
Centre for Epidemiological Studies - Depression (CES-D) scale	T170	C0679604
HIV+	T034	C0019699
smokers	T033	C0337664
depression	T048	C0011570
study	T062	C0008972
baseline	T081	C1442488
quantitatively	T081	C0392762
lower	T052	C2003888
depression	T048	C0011570
month	T079	C0439231
follow-up	T058	C1522577
large	T081	C0549177
effect size	T081	C0814843
statistical significance	T081	C0237881
depression	T048	C0011570
relapse	T067	C0035020
depression	T048	C0011570
counselling programme	T058	C0010210
adequately	T080	C0205411
significant	T078	C0750502
barrier	T080	C0679881
smoking	T055	C0037369
cessation	T052	C1880019
PHAs	T101	C2963182
pilot study	T062	C0031928
importance	T080	C3898777
tailored programmes	T058	C2986593
PHAs	T101	C2963182
quit	T052	C1947925
smoking	T055	C0037369
significance	T078	C0750502
depressive symptoms	T184	C0086132
tailored counselling programmes	T058	C2986593
enhance	T052	C2349975
quit	T052	C1947925
rates	T081	C1521828
PHAs	T101	C2963182
Effects of	T080	C1704420
complex	T080	C0439855
life cycles	T079	C0023675
genetic diversity	T070	C0042333
cyclical parthenogenesis	T040	C0030596
population	T098	C1257890
genetic diversity	T070	C0042333
species	T185	C1705920
complex	T080	C0439855
life cycles	T079	C0023675
anticipate	T078	C0681842
Cyclical parthenogenesis	T040	C0030596
CP	T040	C0030596
organisms	T001	C0029235
clonal	T024	C1522642
reproduction	T040	C0035150
sexual event	T053	C0036864
life cycle	T079	C0023675
species	T185	C1705920
crop	T002	C0242775
pests	T008	C0869004
aphids	T204	C0003562
human parasites	T204	C0585165
trematodes	T204	C3889286
models	T170	C3161035
evolutionary science	T091	C0017398
Daphnia	T204	C0010979
cyclical parthenogens	T001	C0029235
life cycle	T079	C0023675
genetic diversity	T070	C0042333
distributions	T169	C1704711
genetic diversity	T070	C0042333
conditions	T080	C0348080
CP	T040	C0030596
clonal	T024	C1522642
phase	T079	C0205390
lengths	T081	C1444754
Markov chain model	T081	C0024828
CP	T040	C0030596
single	T081	C0205171
locus	T082	C1708726
simulations	T062	C0679083
two	T081	C0205448
loci	T082	C1708726
departures	T052	C1706081
sexuality	T053	C0036915
generations	T079	C0079411
clonality	T080	C1704387
convergence	T052	C2700387
predictions	T078	C0681842
clonality	T080	C1704387
clonal	T024	C1522642
phase	T079	C0205390
mutations	T045	C0026882
genetic drift	T045	C0917892
sexual event	T053	C0036864
CP	T040	C0030596
genetic diversity	T070	C0042333
single	T081	C0205171
locus	T082	C1708726
predictions	T078	C0681842
sexuality	T053	C0036915
recombination	T045	C0034865
gametic phases	T043	C0007613
full-sexuality	T053	C0036915
predictions	T078	C0681842
clonality	T080	C1704387
CP	T040	C0030596
partial	T081	C0728938
clonality	T080	C1704387
individuals	T098	C0237401
clonally	T080	C1704387
generation	T079	C0079411
distribution	T169	C1704711
genetic diversity	T070	C0042333
predictions	T078	C0681842
genetic diversity	T070	C0042333
null model	T170	C3161035
evolutionary	T045	C0015219
demographic	T090	C0011298
processes	T067	C1522240
cyclical parthenogens	T001	C0029235
Recent	T079	C0332185
advances	T078	C1519201
chitosan	T109	C0162969
nanoparticulate	T073	C1450054
pulmonary	T023	C0024109
drug delivery	T074	C0085104
biodegradable polymer	T109	C0597998
encapsulated	T080	C0205223
drug	T121	C1254351
nanoparticles	T073	C1450054
pulmonary	T023	C0024109
route of administration	T169	C0013153
drug delivery	T074	C0085104
research	T062	C0035168
Chitosan	T109	C0162969
natural	T169	C0205296
biodegradable	T109	C0597998
biocompatible	T122	C0005479
polysaccharide	T109	C0032594
received	T080	C1514756
carrier	T122	C0013161
drug delivery	T074	C0085104
nanoparticles	T073	C1450054
chitosan	T109	C0162969
CS	T109	C0162969
synthetic derivatives	T109	C0162969
investigated	T169	C1292732
encapsulation	T067	C2348438
delivery	T169	C0205245
drugs	T121	C1254351
improved	T033	C0184511
targeting	T169	C1521840
controlled release	T079	C0868939
recent	T079	C0332185
advances	T078	C1519201
preparation	T052	C1521827
use of	T169	C1524063
micro-	T026	C4085688
nanoparticles	T073	C1450054
chitosan	T109	C0162969
derivatives	T109	C0162969
pulmonary	T023	C0024109
delivery	T169	C0205245
therapeutic agents	T073	C0304231
drugs	T121	C1254351
genes	T028	C0017337
vaccines	T121	C0042210
reviewed	T080	C1709940
chitosan	T109	C0162969
applications	T169	C0205245
formulations	T062	C0524527
routes of drug delivery	T169	C0013153
review	T170	C0282443
pulmonary	T023	C0024109
delivery of drug-encapsulated nanoparticles	T058	C1881966
chitosan	T109	C0162969
derivatives	T109	C0162969
controversial	T078	C1254370
toxicological effects	T037	C0600688
chitosan	T109	C0162969
nanoparticles	T073	C1450054
lung	T023	C0024109
delivery	T169	C0205245
Form	T080	C0348078
function	T169	C0542341
gene regulatory networks	T044	C1720950
structure	T082	C0678594
network motifs	T080	C0205556
fundamental properties	T080	C0871161
dynamical state space	T082	C1254362
Network motifs	T080	C0205556
motifs	T080	C0205556
feed-forward loop	T080	C0205556
regulatory networks	T044	C1720950
Recent	T079	C0332185
studies	T062	C2603343
Boolean	T170	C1552663
network	T169	C1882071
motifs	T080	C0205556
form	T080	C0348078
function	T169	C0542341
gene regulatory networks	T044	C1720950
structure	T082	C0678594
motif	T080	C0205556
function	T169	C0542341
gene expression	T045	C0017262
patterns	T082	C0449774
motif	T080	C0205556
higher	T080	C0205250
level	T080	C0441889
definition	T170	C1704788
function	T169	C0542341
motif	T080	C0205556
fundamental properties	T080	C0871161
dynamical state space	T082	C1254362
Boolean	T170	C1552663
network	T169	C1882071
basin entropy	T081	C4068571
complexity	T169	C0237523
measure	T081	C0079809
dynamics	T070	C3826426
Boolean	T170	C1552663
networks	T169	C1882071
diversity	T080	C1880371
cyclic attractor lengths	T081	C1444754
motif	T080	C0205556
measures	T081	C0079809
three-node	T077	C2697524
motifs	T080	C0205556
structural	T082	C0678594
properties	T080	C0871161
motif	T080	C0205556
feedback loops	T080	C0205556
feed-forward loops	T080	C0205556
fundamental characteristics	T080	C1521970
dynamical state space	T082	C1254362
functional versatility	T169	C0205245
higher	T080	C0205250
level	T080	C0441889
properties	T080	C0871161
regulatory networks	T044	C1720950
basin entropy	T081	C4068571
cycle length	T081	C1444754
diversity	T080	C1880371
prevalence	T081	C0220900
neural	T040	C0598941
genetic regulatory networks	T044	C1720950
motifs	T080	C0205556
self-interactions	T169	C1704675
literature	T170	C0023866
Jak1	T116	C0169658
STAT3	T116	C0253050
Signals	T043	C0037083
Essential	T080	C0205224
Effectors	T116	C0599560
USP6	T116	C1175888
TRE17 Oncogene	T116	C1175888
Tumorigenesis	T191	C0596263
Bone	T191	C0005967
soft tissue tumors	T191	C0037579
BSTT	T191	C0027651
development	T169	C1527148
effective	T080	C1704419
therapies	T061	C0087111
report	T170	C0684224
ubiquitin-specific protease 6	T116	C1175888
USP6	T116	C1175888
TRE17 oncogene	T116	C1175888
overexpressed	T045	C1514559
chromosome translocation	T049	C0040715
human	T016	C0086418
tumors	T191	C0027651
aneurysmal bone cyst	T047	C0152244
ABC	T047	C0152244
benign	T080	C0205183
lesion	T033	C0221198
nodular fasciitis	T047	C0410005
Ectopic expression	T045	C1512167
USP6	T116	C1175888
formation	T169	C1522492
tumors	T191	C0027651
key features	T080	C2348519
ABC	T047	C0152244
nodular fasciitis	T047	C0410005
identity	T078	C0017390
USP6's	T116	C1175888
substrates	T120	C0178623
report	T170	C0684224
Jak1	T116	C0169658
STAT3	T116	C0253050
signaling pathway	T044	C0037080
essential	T080	C0205224
effector	T116	C0599560
USP6	T116	C1175888
BSTT	T191	C0027651
formation	T169	C1522492
USP6	T116	C1175888
deubiquitinated	T044	C1157996
Jak1	T116	C0169658
leading	T169	C1522538
stabilization	T033	C0184512
activation	T045	C0599177
STAT3	T116	C0253050
tumorigenic	T191	C0007621
potential	T080	C3245505
USP6	T116	C1175888
attenuated significantly by	T080	C0332161
CRISPR	T114	C3658200
deletion	T045	C0017260
Jak1	T028	C1334290
STAT3	T028	C1367307
administration	T169	C1621583
Jak family	T116	C0597721
inhibitor	T080	C1999216
Analysis	T062	C0936012
primary clinical samples	T077	C2347026
nodular fasciitis	T047	C0410005
confirmed	T033	C0750484
activation	T045	C0599177
Jak1	T116	C0169658
STAT3	T116	C0253050
gene signature	T169	C1708225
in vivo	T062	C0681829
studies	T059	C0947630
Jak1	T116	C0169658
substrate	T120	C0178623
USP6	T116	C1175888
mechanistic rationale	T078	C2699007
clinical investigation	T058	C1261322
Jak	T116	C0597721
STAT3	T116	C0253050
inhibitors	T080	C1999216
therapeutics	T169	C0302350
treatment	T061	C0087111
bone	T191	C0005967
soft tissue tumors	T191	C0037579
neoplasms	T191	C0027651
USP6	T116	C1175888
overexpression	T045	C1514559
Evidence	T078	C3887511
Integrating	T052	C1881786
Palliative Care	T091	C0030231
Oncology	T191	C0027651
Practice	T057	C0033284
Palliative care services	T093	C0587605
provided	T052	C1999230
traditional	T169	C0443324
oncology care	T058	C3244201
beneficial	T080	C0205556
patients	T101	C0030705
families	T099	C0015576
article	T170	C1706852
brief	T079	C1879313
history	T090	C0019664
palliative care	T091	C0030231
implementing	T052	C1705848
services	T057	C0557854
currently	T079	C0521116
established	T080	C0443211
oncology programs	T058	C1516732
discussion	T054	C2584313
common barriers	T080	C4045969
Secondary Ossification Center	T023	C1184751
Appearance	T080	C0700364
Closure in the Pelvis	T061	C1293215
Proximal Femur	T029	C0448190
ossification	T042	C0029433
patterns	T082	C0449774
pelvis	T023	C0030797
skeletally	T022	C0037253
immature	T080	C0205252
patients	T101	C0030705
pelvic	T023	C0030797
radiographs	T060	C1306645
sex	T032	C1522384
comparisons	T052	C1707455
secondary ossification centers	T023	C1184751
evaluates	T058	C0220825
chronology	T170	C0008717
sex differences	T032	C0036866
appearance	T080	C0700364
closure of pelvic	T061	C1293215
proximal femoral	T029	C0448190
secondary ossification centers	T023	C1184751
computed tomography	T060	C0040405
CT	T060	C0040405
Patients	T101	C0030705
abdominal	T060	C0412620
pelvic CT scans	T060	C3842376
trauma centers	T073	C0040786
retrospectively	T080	C1514923
reviewed	T080	C1709940
Patients	T101	C0030705
ages	T032	C0001779
imaging	T060	C0011923
pelvis	T023	C0030797
proximal femurs	T029	C0448190
Patients	T101	C0030705
orthopaedic trauma	T091	C1274117
pathology	T091	C0030664
affecting	T169	C0392760
ossification	T042	C0029433
CT scans	T060	C0040405
assessed	T052	C1516048
appearance	T080	C0700364
closure	T061	C0185003
secondary ossification centers	T023	C1184751
anterior inferior iliac spine	T023	C0223645
AIIS	T023	C0223645
anterior superior iliac spine	T023	C0223644
ASIS	T023	C0223644
femoral head	T023	C0015813
FH	T023	C0015813
greater trochanter	T023	C0223865
GT	T023	C0223865
iliac crest	T023	C0223651
IC	T023	C0223651
ischial tuberosity	T023	C0223656
IT	T023	C0223656
lesser trochanter	T023	C0223866
LT	T023	C0223866
posterior superior iliac spine	T023	C0223646
PSIS	T023	C0223646
symphysis pubis	T030	C0034015
SP	T030	C0034015
triradiate cartilage	T024	C0007301
TRC	T024	C0007301
CT scans	T060	C0040405
inclusion criteria	T080	C1512693
males	T032	C0086582
females	T032	C0086287
appearance	T080	C0700364
secondary ossification centers	T023	C1184751
male	T032	C0086582
GT	T023	C0223865
LT	T023	C0223866
AIIS	T023	C0223645
IT	T023	C0223656
ASIS	T023	C0223644
PSIS	T023	C0223646
IC	T023	C0223651
SP	T030	C0034015
female	T032	C0086287
GT	T023	C0223865
LT	T023	C0223866
IT	T023	C0223656
AIIS	T023	C0223645
PSIS	T023	C0223646
IC	T023	C0223651
ASIS	T023	C0223644
SP	T030	C0034015
closure	T061	C0185003
male	T032	C0086582
TRC	T024	C0007301
LT	T023	C0223866
FH	T023	C0015813
AIIS	T023	C0223645
GT	T023	C0223865
ASIS	T023	C0223644
PSIS	T023	C0223646
IT	T023	C0223656
IC	T023	C0223651
SP	T030	C0034015
female	T032	C0086287
LT	T023	C0223866
TRC	T024	C0007301
AIIS	T023	C0223645
FH	T023	C0015813
GT	T023	C0223865
ASIS	T023	C0223644
PSIS	T023	C0223646
IT	T023	C0223656
IC	T023	C0223651
SP	T030	C0034015
Female	T032	C0086287
ossification centers	T023	C1184744
males	T032	C0086582
locations	T029	C1515974
Female	T032	C0086287
ossification centers	T023	C1184744
males	T032	C0086582
locations	T029	C1515974
TRC	T024	C0007301
IC	T023	C0223651
SP	T030	C0034015
appearance	T080	C0700364
closure of the pelvis	T061	C1293215
proximal femur	T029	C0448190
secondary ossification centers	T023	C1184751
females	T032	C0086287
males	T032	C0086582
ages of developmen	T033	C1821962
sex differences	T032	C0036866
skeletal development	T040	C1160401
secondary ossification centers	T023	C1184751
evaluate	T058	C0220825
skeletal maturity	T060	C3825673
pediatric	T091	C0030755
pathology	T091	C0030664
surgical management	T058	C1515089
Pediatric	T100	C0008059
Orthopaedic	T022	C0037253
Trauma	T037	C3714660
Associated Injuries	T037	C3263723
Snowmobile	T033	C2063141
ATV	T067	C0683911
Dirtbike Accidents	T067	C0683911
19-Year	T079	C0439234
Pediatric	T100	C0008059
Trauma Center	T073	C0040786
study	T062	C2603343
type	T080	C0332307
severity	T080	C0439793
orthopaedic	T037	C0597457
associated injuries	UnknownType	C0412812
snowmobile	T033	C2063141
All-terrain vehicles	T067	C0683911
ATV	T067	C0683911
motorized dirtbike accidents	T067	C0683911
pediatric	T100	C0008059
patient population	T101	C0030705
patients	T101	C0030705
snowmobile	T037	C3714660
ATV-related	T037	C3714660
dirtbike (n=363)-related trauma	T037	C3714660
institution	T093	C2607850
reviewed	T080	C1709940
axial	T037	C0016658
appendicular fractures	T037	C0016658
procedures	T169	C2700391
Snowmobile	T033	C2063141
dirtbike accidents	T067	C0683911
associated with	T080	C0332281
fractures	T037	C0016658
ATV group	T098	C1257890
Snowmobile injuries	UnknownType	C0412812
spinal	T037	C0080179
lower extremity fractures	T037	C1542178
Snowmobile	T098	C0599755
dirtbike cohorts	T098	C0599755
femur fractures	T037	C0015802
ATV cohort	T098	C0599755
upper extremity	T023	C1140618
hand	T023	C0018563
scapula	T023	C0036277
open fractures	T037	C0016662
Head trauma	T037	C0018674
associated injury	UnknownType	C0412812
patients	T101	C0030705
ATV group	T098	C1257890
Snowmobile	T101	C0030705
ATV patients	T101	C0030705
Injury Severity Score	T170	C0021504
dirtbike patients	T101	C0030705
ATV patients	T101	C0030705
younger	T079	C0332239
snowmobile	T101	C0030705
dirtbike	T101	C0030705
Pediatric	T100	C0008059
snowmobile	T033	C2063141
ATV	T067	C0683911
dirtbike accidents	T067	C0683911
severe	T080	C0205082
orthopaedic	T037	C0597457
associated injuries	UnknownType	C0412812
vehicle	T073	C0348005
injury	T037	C3263723
patterns	T082	C0449774
Injury prevention	T061	C0150638
safety mechanisms	T058	C0150755
protective gear	T073	C3840637
off-road vehicle	T073	C0028892
strict laws	T089	C0023150
age	T032	C0001779
Hospitalist	T097	C0600620
Co-management	T057	C1273870
Pediatric	T080	C1521725
Orthopaedic	T061	C0524852
Surgical Patients	T101	C0871463
Community Hospital	T073	C0020003
hospitalist	T097	C0600620
co-management	T057	C1273870
pediatric	T080	C1521725
surgical patients	T101	C0871463
bettering	T080	C0332272
patient safety	T058	C1113679
decreasing	T033	C0442797
negative	T080	C3853545
patient outcomes	T078	C1547647
comprehensive medical care	T058	C0009586
dedicated resource	T078	C0035201
patients	T101	C0030705
postoperative care	T058	C0032786
study	T062	C2603343
characterize	T052	C1880022
nature	T078	C0349590
patients	T101	C0030705
pediatric	T080	C1521725
hospitalist	T097	C0600620
authors	T097	C3812881
hypothesize	T078	C1512571
hospitalist	T097	C0600620
co-management	T057	C1273870
safe	T033	C3266157
efficacious	T080	C1280519
pediatric	T080	C1521725
orthopaedic	T061	C0524852
surgical patients	T101	C0871463
admitted	T058	C0184666
community hospital	T073	C0020003
retrospective review	T062	C0035363
pediatric	T080	C1521725
orthopaedic	T061	C0524852
surgical patients	T101	C0871463
admitted	T058	C0184666
community hospital	T073	C0020003
pediatric	T080	C1521725
hospitalist	T097	C0600620
hospitalization	T058	C0019993
pain control	T061	C1304888
antibiotic infusion	T061	C0199779
neurovascular monitoring	T058	C1828265
Parameters	T077	C0549193
postoperative care	T058	C0032786
co-management	T057	C1273870
assessed	T052	C1516048
presence	T033	C0150312
complications	T078	C2362589
medication introduction	T061	C1293116
hospitalist	T097	C0600620
follow-up	T058	C1522577
adherence	T169	C1510802
readmission	T058	C0030700
complication	T078	C2362589
rates	T081	C1521828
discharge	T058	C0030685
patients	T101	C0030705
assessed	T052	C1516048
average age	T032	C0001779
years	T079	C0439234
percent	T081	C0439165
patients	T101	C0030705
associated comorbidity	T078	C0009488
asthma	T047	C0004096
attention deficit disorder	T048	C0041671
autism	T048	C0004352
pediatric	T080	C1521725
hospitalist	T097	C0600620
pain medication	T061	C0508321
postoperative orders	T058	C0032786
orthopaedics team	T097	C0334954
percent	T081	C0439165
patients	T101	C0030705
breakthrough pain	T184	C1135120
percent	T081	C0439165
patients	T101	C0030705
pain medication	T061	C0508321
dosing	T081	C0178602
schedule	T058	C0030703
hospitalist	T097	C0600620
team	T096	C0871489
surgeon	T097	C0582175
patients	T101	C0030705
percent	T081	C0439165
surgeon	T097	C0582175
pain medication	T061	C0508321
patient	T101	C0030705
anesthesia	T061	C0002903
surgeon	T097	C0582175
patients	T101	C0030705
hospitalists	T097	C0600620
discharged patients	T058	C0030685
patients	T101	C0030705
follow-up appointment and schedule	UnknownType	C0184760
hospitalist	T097	C0600620
every patient	T101	C0030705
followed up	T058	C1522577
days	T079	C0439228
discharge	T058	C0030685
complications	T078	C2362589
hospital readmissions	T058	C0600290
days	T079	C0439228
discharge	T058	C0030685
Hospitalist	T097	C0600620
co-management	T057	C1273870
pediatric	T080	C1521725
orthopaedic	T061	C0524852
surgical patients	T101	C0871463
patients	T101	C0030705
community hospital	T073	C0020003
medical comorbidity	T078	C0009488
medication management	T058	C0150270
Hospitalist	T097	C0600620
inpatient stay	T169	C0420512
help	T080	C1269765
streamline communication	T054	C0009452
providers	T097	C0018724
patients	T101	C0030705
surgeon	T097	C0582175
Co-management	T057	C1273870
safe	T033	C3266157
efficacious	T080	C1280519
pediatric	T080	C1521725
orthopaedic	T061	C0524852
surgical patients	T101	C0871463
patients	T101	C0030705
admitted	T058	C0184666
community hospital	T073	C0020003
carbohydrate binding module	T116	C0108401
contributes	T052	C1880177
processivity	T080	C0205556
catalytic activity	T044	C0243102
non-modular hydrolase	T116	C0020289
5 endoglucanase	T116	C0384886
Fomitiporia mediterranea MF3/22	T004	C1225186
FmEG	T116	C0384886
Fomitiporia mediterranea	T004	C1225186
non-modular endoglucanase	T116	C0384886
24-amino acids	T116	C0002520
extension	T169	C0231448
13-amino acids	T116	C0002520
linker-like peptide	T116	C0030956
N-terminus	T087	C1514562
312-amino acids	T116	C0002520
GH5 catalytic domain	T087	C0600499
CD	T087	C0600499
C-terminus	T087	C1514562
FmEG	T116	C0384886
deletion	T052	C1880274
N-terminal fragments	T116	C0030935
fusion	T116	C0162768
family 1 carbohydrate-binding module	T116	C0108401
CBM1	T116	C0108401
contribution	T052	C1880177
CBM1	T116	C0108401
FmEG	T116	C0384886
processivity	T080	C0205556
catalytic activity	T044	C0243102
FmEG	T116	C0384886
processivity	T080	C0205556
cellobiose	T109	C0007630
G2	T109	C0007630
cellotriose	T109	C1690565
G3	T109	C1690565
main end products	T071	C1514468
cellotriose	T109	C1690565
G4	T109	C1690565
minor end product	T071	C1514468
filter paper	T074	C0180859
FP	T074	C0180859
G4	T109	C1690565
regenerated amorphous cellulose	T109	C0007648
RAC	T109	C0007648
derivatives	T109	C1690565
carboxymethylcellulose	T109	C0007068
CMC	T109	C0007068
same optimal	T080	C2698651
pH	T081	C0020283
temperature	T081	C0039476
CBM1	T116	C0108401
FmEG△24	T116	C0384886
FmEG△37	T116	C0384886
flexible peptide	T116	C0030956
processivity	T080	C0205556
catalytic activity	T169	C1264638
FP	T074	C0180859
RAC	T109	C0007648
soluble	T080	C1948047
ratio	T081	C0456603
FP	T074	C0180859
RAC	T109	C0007648
FmEG△24	T116	C0384886
CBM1	T116	C0108401
FmEG△24	T116	C0384886
CBM1	T116	C0108401
FmEG△24	T116	C0384886
2.67-fold more activity	T033	C0243095
RAC	T109	C0007648
FP	T074	C0180859
CBM1	T116	C0108401
FmEG△37	T116	C0384886
FmEG△37	T116	C0384886
CBM1	T116	C0108401
FmEG	T116	C0384886
alteration	T078	C1515926
cleavage pattern	T067	C0596311
insoluble celluloses	T109	C0007648
processivity	T080	C0205556
catalytic activity	T169	C1264638
CBM1	T116	C0108401
binding affinity	T044	C0033618
N-terminal 24- or 37-amino acids	T116	C0002520
spatial separation	T082	C1254362
two domains	T087	C1514562
processivity	T080	C0205556
catalytic activity	T169	C1264638
deletion	T052	C1880274
N-terminal 24- or 37-amino acids	T116	C0002520
significant reduction	T080	C0392756
thermostability	T070	C0597571
enzymatic activity	T044	C0243102
Overnight	T079	C0439583
switching	T058	C2936279
oxcarbazepine	T109	C0069751
eslicarbazepine acetate	T109	C2725262
observational study	T062	C1518527
clinical situations	T067	C0013956
appropriate	T080	C1548787
switch	T058	C2936279
patients	T101	C0030705
immediate-release	T122	C1708470
oxcarbazepine	T109	C0069751
OXC	T109	C0069751
eslicarbazepine acetate	T109	C2725262
ESL	T109	C2725262
investigated	T169	C1292732
effects of	T080	C1704420
patients	T101	C0030705
overnight	T079	C0439583
OXC	T109	C0069751
ESL	T109	C2725262
retrospective	T062	C0035363
single-center study	T062	C2603343
patients	T101	C0030705
drug-resistant	T038	C0013203
focal epilepsy	T047	C0014547
dose	T081	C0678766
immediate-release	T122	C1708470
OXC	T109	C0069751
4 weeks	T079	C1442465
switched	T058	C2936279
overnight	T079	C0439583
ESL	T109	C2725262
Patients	T101	C0030705
switched	T058	C2936279
persistent	T079	C0205322
seizures	T184	C0036572
OXC	T109	C0069751
unable	T033	C1299582
tolerate	T080	C4053931
OXC	T109	C0069751
dosing	T081	C0678766
adverse events	T046	C0041755
Tolerability	T080	C4053931
assessed	T052	C1516048
Adverse Events Profile	T170	C0282574
AEP	T170	C0282574
quality of life	T078	C0034380
assessed	T052	C1516048
Quality of Life in Epilepsy Inventory 10	T170	C0282574
QOLIE-10	T170	C0282574
alertness	T041	C1443086
assessed	T052	C1516048
reaction time	T079	C0034746
Test Battery for Attention Performance version 2.3	T073	C0037585
Assessments	T058	C1261322
performed	T169	C0884358
immediately	T079	C0205548
prior to	T079	C0332152
5 days	T079	C1442466
switching	T058	C2936279
OXC	T109	C0069751
ESL	T109	C2725262
days	T079	C0439228
analysis	T062	C0936012
patients	T101	C0030705
women	T098	C0043210
men	T098	C0025266
mean age 36 years	T033	C0243095
switching	T058	C2936279
OXC	T109	C0069751
ESL	T109	C2725262
improvements	T077	C2986411
mean scores	T081	C0449820
AEP	T170	C0282574
QOLIE-10	T170	C0282574
alertness	T041	C1443086
Adverse Events Profile	T170	C0282574
total scores	T081	C0449820
improved	T033	C0184511
patients	T101	C0030705
QOLIE-10	T170	C0282574
total scores	T081	C0449820
improved	T033	C0184511
patients	T101	C0030705
alertness	T041	C1443086
scores	T081	C0449820
improved	T033	C0184511
patients	T101	C0030705
short-term	T079	C0443303
single-center study	T062	C2603343
overnight	T079	C0439583
switch	T058	C2936279
twice-daily	T079	C0585361
OXC	T109	C0069751
once-daily	T079	C0556983
ESL	T109	C2725262
patients	T101	C0030705
drug-resistant	T038	C0013203
focal epilepsies	T047	C0014547
resulted	T033	C2825142
improvements	T077	C2986411
side effects	T046	C0041755
quality of life	T078	C0034380
alertness	T041	C1443086
Complete	T080	C0205197
Genome	T028	C0017428
Sequences	T086	C0162326
Outbreak	T067	C0012652
Legionella pneumophila	T007	C0023238
Isolates	T123	C1764827
complete	T080	C0205197
genome	T028	C0017428
sequences	T086	C0162326
Legionella pneumophila	T007	C0023238
isolates	T123	C1764827
associated with	T080	C0332281
Legionnaires' disease	T047	C0023241
outbreak	T067	C0012652
New York	T083	C0027976
clinical	T080	C0205210
isolates	T123	C1764827
D7630	T007	C0023238
D7632	T007	C0023238
environmental	T082	C0014406
isolate	T123	C1764827
D7631	T007	C0023238
recovered	T080	C0521108
outbreak	T067	C0012652
isolate-specific	T123	C1764827
virulence	T038	C0042765
gene	T028	C0017337
D7632	T007	C0023238
isolates	T123	C1764827
evaluating	T058	C0220825
genomic	T028	C0017428
resolution	T077	C2699488
bioinformatics	T091	C1140694
approaches	T169	C1292724
L. pneumophila	T007	C0023238
serogroup 1	T170	C0449543
isolates	T123	C1764827
Genome Sequence Analysis	T059	C3854164
Infectious Bursal Disease Virus	T005	C0021338
India	T083	C0021201
infectious bursal disease virus	T005	C0021338
IBDV	T005	C0021338
isolate	T123	C3494870
BGE14/ABT1/MVC/India	T005	C0021338
virulent	T080	C1520022
IBDV	T005	C0021338
isolated	T123	C3494870
broiler flocks	T012	C0005595
India	T083	C0021201
India	T083	C0021201
genome sequence	T028	C0017428
BGE14/ABT1/MVC/India	T005	C0021338
strain	T001	C1518614
segments A and B	T028	C0017428
virulent	T080	C1520022
IBDV	T005	C0021338
strain	T001	C1518614
attenuated	T052	C0599946
IBDV	T005	C0021338
genetic exchange	T045	C1749881
attenuated	T052	C0599946
virulent	T080	C1520022
strains	T001	C1518614
IBDV	T005	C0021338
circulating	T169	C0175630
in the field	T082	C3539073
Patient Satisfaction	T080	C0030702
Postpartum	T079	C0086839
Teaching	T065	C0220924
Methods	T170	C0025663
Postpartum	T079	C0086839
discharge instructions	T170	C4282220
mother's	T099	C0026591
birth	T040	C0005615
experience	T041	C0596545
Finding	T033	C0243095
method	T170	C0025663
discharge instructions	T170	C4282220
increases	T169	C0442805
mother's	T099	C0026591
satisfaction	T041	C0242428
hospital	T073	C0019994
experience	T041	C0596545
quasi-experimental study	T062	C2985410
examined	T033	C0332128
relationship	T080	C0439849
new	T080	C0205314
mothers'	T099	C0026591
interaction	T033	C0037420
nurses	T097	C0028661
postpartum	T079	C0086839
instructions	T170	C1442085
traditional	T169	C0443324
methods	T170	C0025663
satisfaction	T041	C0242428
discharge teaching	T065	C0514209
new	T080	C0205314
mothers	T099	C0026591
satisfied	T041	C0242428
methods	T170	C0025663
discharge teaching	T065	C0514209
agreement	T054	C0680240
satisfaction	T041	C0242428
traditional	T169	C0443324
method	T170	C0025663
discharge teaching	T065	C0514209
attending	T169	C1999232
discharge class	T065	C0514209
Splicing	T045	C0035687
ADAR2	T116	C0001457
ADAR2	T116	C0001457
RNA editing	T045	C0162782
glioma	T191	C0017638
alternative splicing	T045	C0002345
RNA editing	T045	C0162782
gene regulation	T045	C0017263
transcriptome	T086	C3178810
Adenosine deaminases	T116	C0001457
RNA	T114	C0035668
ADARs	T116	C0001457
adenosine-to-inosine (A-to-I) editing	T045	C1158747
RNA editing	T045	C0162782
alternative splicing	T045	C0002345
self-editing	T045	C0162782
ADAR2	T116	C0001457
pre-mRNA	T114	C0026661
alternative splicing	T045	C0002345
Alternative splicing	T045	C0002345
splicing	T045	C0035687
ADAR2	T116	C0001457
pre-mRNA	T114	C0026661
alternative splicing	T045	C0002345
catalytic activities	T044	C0243102
A-to-I RNA editing	T045	C1158747
physiological processes	T039	C0031845
humans	T016	C0086418
diseases	T047	C0012634
amyotrophic lateral sclerosis	T047	C0002736
mood disorders	T048	C0525045
epilepsy	T047	C0014544
glioma	T191	C0017638
editing	T045	C0162782
glutamine	T116	C0017797
arginine	T116	C0003765
AMPA receptor subunit GluA2	T116	C0536483
glioma	T191	C0017638
ADAR2	T116	C0001457
expression	T045	C1171362
alteration	T078	C1515926
catalytic activity	T044	C0243102
ADAR2	T116	C0001457
review	T170	C0282443
literature	T170	C0023866
experimental results	T033	C2825142
ADAR2	T116	C0001457
alternative splicing	T045	C0002345
review	T170	C0282443
splicing	T045	C0035687
ADAR2	T116	C0001457
ADAR2	T116	C0001457
editing	T045	C0162782
glioma	T191	C0017638
expression	T045	C1171362
ADAR2	T116	C0001457
splicing	T045	C0035687
enzyme activity	T044	C0243102
RNA editing	T045	C0162782
GluA2 subunit	T116	C0536483
glutamine	T116	C0017797
arginine	T116	C0003765
glioma	T191	C0017638
Heat-shock protein 60	T116	C0109272
Porphyromonas gingivalis	T007	C0085478
dysfunction	T077	C3887504
human umbilical endothelial cells	T025	C3179121
regulation	T038	C1327622
endothelial-nitric oxide synthase	T116	C0669365
vascular endothelial-cadherin	T116	C0300423
periodontitis	T047	C0031099
risk factor	T033	C0035648
coronary heart disease	T047	C0010068
CAD	T047	C0010068
Porphyromonus gingivalis	T007	C0085478
P. gingivalis	T007	C0085478
periodontal	T080	C0332275
pathogen	T001	C0450254
inflammatory response	T046	C1155266
CAD	T047	C0010068
in vivo	T082	C1515655
study	T062	C2603343
P. gingivalis	T007	C0085478
heat-shock protein 60	T116	C0109272
HSP60	T116	C0109272
dysfunction	T077	C3887504
human umbilical vein endothelial cells	T025	C3179121
HUVECs	T025	C3179121
in vitro	T080	C1533691
HUVECs	T025	C3179121
stimulated	T070	C1948023
P. gingivalis	T007	C0085478
HSP60	T116	C0109272
concentrations	T081	C0392762
time-points	T079	C2348792
levels	T080	C0441889
vascular endothelial (VE)-cadherin	T116	C0300423
endothelial nitric oxide synthase	T116	C0669365
eNOS	T116	C0669365
cysteinyl aspartate-specific protease-3	T116	C0291573
caspase-3	T116	C0291573
western blot	T059	C0949466
analysis	T062	C0936012
apoptotic	T043	C0162638
rate	T081	C1521828
HUVECs	T025	C3179121
flow cytometry	T059	C0016263
P. gingivalis	T007	C0085478
HSP60	T116	C0109272
concentration	T081	C0392762
expression	T045	C1171362
levels	T080	C0441889
VE-cadherin	T116	C0300423
eNOS protein	T116	C0669365
h	T079	C0439227
stimulation	T070	C1948023
proteins	T116	C0033684
low dose	T081	C0445550
P. gingivalis	T007	C0085478
HSP60	T116	C0109272
P. gingivalis	T007	C0085478
HSP60	T116	C0109272
downregulated	T044	C0013081
expression	T045	C1171362
levels	T080	C0441889
VE-cadherin	T116	C0300423
eNOS protein	T116	C0669365
HUVECs	T025	C3179121
cleavage	T067	C0596311
caspase-3	T116	C0291573
concentrations	T081	C0392762
P. gingivalis	T007	C0085478
HSP60	T116	C0109272
apoptosis	T043	C0162638
HUVECs	T025	C3179121
concentration	T081	C0392762
dependent	T169	C3244310
results	T169	C1274040
P. gingivalis	T007	C0085478
HSP60	T116	C0109272
dysfunction	T077	C3887504
apoptosis	T043	C0162638
HUVECs	T025	C3179121
downregulating	T044	C0013081
expression	T045	C1171362
levels	T080	C0441889
VE-cadherin	T116	C0300423
eNOS	T116	C0669365
cleavage	T067	C0596311
caspase-3	T116	C0291573
Estradiol	T109	C0014912
prodrugs	T120	C0033262
EP	T120	C0033262
oral	T061	C0001563
estrogen treatment	T169	C3173348
estrogen	T109	C0014939
liver functions	T042	C0232741
Oral	T061	C0001563
parenteral	T061	C0259961
estrogen administration	T169	C3173348
systemic	T169	C0205373
hepatic	T029	C0205054
estrogenic effects	T033	C0877035
lipids	T109	C0023779
hemostatic factors	T042	C0019116
GH	T116	C0037663
IGF I	T116	C0021665
angiotensinogen	T116	C0003017
metabolic effects	T039	C2945675
oral treatment	T061	C0001563
estradiol	T109	C0014912
E2	T109	C0014912
prodrugs	T120	C0033262
EP	T120	C0033262
liver tissue	T023	C0736268
Carbone17-OH sulfonamide [-O2-NH2] substituted esters	T104	C1254350
E2	T109	C0014912
EC508	T109	C0014912
carbonic anhydrase II	T116	C0007034
CA-II	T116	C0007034
binding	T044	C1149286
CA II	T116	C0007034
erythrocytes	T025	C0014792
EP	T120	C0033262
portal vein blood	T024	C2324289
liver	T023	C0023884
passage	T082	C0439799
Ovariectomized	T033	C3687559
OVX	T033	C3687559
rats	T015	C0034721
orally treated	T061	C0001563
Uteri	T023	C0042149
dissected	T169	C0205239
weighed	T059	C3827964
Cholesterol fractions	T059	C0201950
angiotensinogen	T059	C0523500
plasma	T031	C0032105
Oral E2	T200	C0360514
ethinyl estradiol	T109	C0015011
EE	T109	C0015011
uterine	T023	C0042149
growth	T040	C0018270
hepatic	T029	C0205054
estrogenic effects	T033	C0877035
EP	T120	C0033262
uterine growth	T042	C1326619
plasma	T031	C0032105
cholesterol	T109	C0008377
angiotensinogen	T116	C0003017
pharmacokinetic studies	T062	C0201734
EC508	T109	C0014912
intravenous	T082	C0013125
oral administration	T061	C0001563
male	T032	C0086582
rats	T015	C0034721
oral	T061	C0001563
bioavailability	T081	C0005508
blood	T031	C0005767
plasma	T031	C0032105
erythrocyte	T025	C0014792
binding	T052	C1145667
EC508	T109	C0014912
in vivo	T082	C1515655
liver	T023	C0023884
passage	T082	C0439799
systemic	T169	C0205373
estrogenicity	T109	C0014939
hepatic	T029	C0205054
estrogenic effects	T033	C0877035
systemic	T169	C0205373
E2	T109	C0014912
sulfonamide EP	T120	C0033262
oral	T061	C0001563
EP	T120	C0033262
liver	T023	C0023884
erythrocytes	T025	C0014792
systemic	T169	C0205373
estradiol	T109	C0014912
hydrolysis	T070	C0020291
hepatic	T029	C0205054
estrogenic	UnknownType	C0720298
oral	T061	C0001563
estrogen therapy	T061	C0279494
Differences	T080	C1705242
pain	T184	C0030193
experience	T041	C0596545
cooperation	T055	C1321605
consecutive surgeries	T061	C0543467
patients	T101	C0030705
phacoemulsification	T061	C0282545
study	T062	C2603343
pain	T184	C0030193
experience	T041	C0596545
cooperation	T055	C1321605
consecutive surgeries	T061	C0543467
patients	T101	C0030705
phacoemulsification	T061	C0282545
eyes	T023	C0015392
sub-Tenon's local anesthesia	T061	C0002921
sedation	T061	C0344106
study	T062	C2603343
patients	T101	C0030705
bilateral senile cataracts	T047	C3864031
operations	T061	C0543467
sedation	T061	C0344106
corneal	T023	C0010031
phacoemulsification technique	T061	C0282545
sub-Tenon's local anesthesia	T061	C0002921
surgeons	T097	C0582175
surgery	T061	C0543467
eye	T023	C0015392
cataract	T020	C0086543
eye	T023	C0015392
operated	T052	C3241922
3 months	T079	C1442461
surgeon	T097	C0582175
months	T079	C0439231
patients	T101	C0030705
pain	T184	C0030193
experience	T041	C0596545
induction	T061	C0857127
maintenance	T052	C0024501
anesthesia	T061	C0002903
phacoemulsification surgery	T061	C0282545
visual analogue scale	T060	C0042815
VAS	T060	C0042815
no pain	T033	C3891813
unbearable pain	T184	C3640014
surgery	T061	C0543467
cooperation	T055	C1321605
patient	T101	C0030705
markedeye	T039	C0015413
head movement	T040	C0376591
lid squeezing	T184	C0850674
surgeon	T097	C0582175
VAS scores	T081	C2732809
cooperation	T055	C1321605
scores	T081	C0449820
patients	T101	C0030705
outcome measurements	T081	C0086749
mean pain score	T033	C0582148
eye	T023	C0015392
eye	T023	C0015392
administration	T061	C1533734
sub-Tenon's anesthesia	T061	C0002921
eye	T023	C0015392
eye	T023	C0015392
phacoemulsification surgery	T061	C0282545
patient cooperation	T055	C1321605
score	T081	C0449820
surgery	T061	C0543467
surgery	T061	C0543467
differences	T080	C1705242
surgeries	T061	C0543467
outcome measures	T081	C0086749
Patients	T101	C0030705
phaco surgery	T061	C0282545
eye	T023	C0015392
pain	T184	C0030193
worse	T033	C1457868
cooperation	T055	C1321605
phaco surgery	T061	C0282545
eye	T023	C0015392
surgeries	T061	C0543467
months	T079	C0439231
surgeon	T097	C0582175
difficulty	T080	C0332218
operation	T061	C0543467
patient's cooperation	T055	C1321605
surgeon	T097	C0582175
contralateral eye surgery	T061	C0038901
sedation	T061	C0344106
analgesia	T061	C3202977
surgery	T061	C0543467
influence	T077	C4054723
recent memory	T041	C0233792
patient's	T101	C0030705
pain	T184	C0030193
experience	T041	C0596545
Co-ChIP	T059	C1328856
genome-wide mapping	T062	C0079435
histone mark	T087	C1257775
co-occurrence	T079	C2745955
single-molecule resolution	T077	C2699488
Histone modifications	T044	C1156199
important	T080	C3898777
role	T077	C1705810
chromatin organization	T045	C1156187
transcriptional regulation	T045	C1158770
large amount	T081	C3869890
genome-wide	T028	C0017428
histone modification	T044	C1156199
data	T078	C1511726
collected	T078	C1516695
different	T080	C1705242
cells	T025	C0007634
tissues	T024	C0040300
co-occurrence	T079	C2745955
modifications	T044	C1156199
nucleosome	T116	C0028623
present	T078	C0449450
genome-wide quantitative method	T062	C1510568
combinatorial indexed	T170	C0918012
chromatin immunoprecipitation	T059	C1328856
co-ChIP	T059	C1328856
co-occurrence	T079	C2745955
histone modifications	T044	C1156199
nucleosomes	T116	C0028623
co-ChIP	T059	C1328856
study	T062	C0681814
genome-wide	T028	C0017428
co-occurrence	T079	C2745955
chromatin marks	T087	C1257775
pairwise combinations	T080	C0205195
co-occurrence	T079	C2745955
patterns	T082	C0449774
co-occurrence	T079	C2745955
H3K9me1	T028	C0314621
H3K27ac	T028	C0314621
super-enhancers	T086	C0004793
apply	T169	C4048755
co-ChIP	T059	C1328856
measure	T081	C0079809
distribution	T169	C1704711
bivalent	T081	C0392762
H3K4me3	T028	C0314621
H3K27me3	T028	C0314621
domains	T087	C1514562
mouse embryonic stem cell	T025	C4042879
mESC	T025	C4042879
adult tissues	T024	C0040300
observe	T169	C1441672
dynamic	T169	C0729333
changes	T081	C0443172
discover	T052	C1880355
loss	T081	C1517945
de novo	T078	C1515568
gain	T081	C1517378
bivalency	T081	C0392762
tissue-specific	T024	C1955394
regulatory genes	T028	C0017362
suggesting	T078	C1705535
functional role	T077	C1705810
bivalent	T081	C0392762
domains	T087	C1514562
stages	T079	C1306673
development	T169	C1527148
results	T033	C0683954
co-ChIP	T059	C1328856
reveal	T080	C0443289
complex interactions	T169	C1704675
histone modifications	T044	C1156199
Hand-Assisted Laparoscopic	T061	C2936499
Standard Laparoscopic Colectomy	T061	C1517722
Outcomes	T080	C0085415
Operative Time	T079	C3494201
HAL	T061	C2936499
colectomy	T061	C0009274
technique	T169	C0449851
laparoscopic surgery	T061	C0751429
operative time	T079	C3494201
data	T078	C1511726
single-institution studies	T062	C2603343
National Surgical Quality Improvement Program Participant Data Use File	T170	C0242193
patients	T101	C0030705
SL	T061	C1517722
HAL	T061	C2936499
colectomy	T061	C0009274
Patients	T101	C0030705
outcomes	T080	C0085415
subgroup analysis	T062	C0936012
patients	T101	C0030705
segmental	T082	C0205122
resections	T061	C0015252
patients	T101	C0030705
HAL	T061	C2936499
colectomy	T061	C0009274
Patients	T101	C0030705
HAL	T061	C2936499
SL colectomy	T061	C1517722
rates	T081	C1521828
postoperative ileus	T047	C0400877
wound complication	T037	C1096106
day	T079	C0439228
readmission	T058	C0030700
operative time	T079	C3494201
segmental	T082	C0205122
colectomies	T061	C0009274
HAL	T061	C2936499
rates	T081	C1521828
wound complications	T037	C1096106
postoperative ileus	T047	C0400877
day	T079	C0439228
readmission	T058	C0030700
operative time	T079	C3494201
HAL	T061	C2936499
HAL	T061	C2936499
colectomy	T061	C0009274
risk	T058	C0086930
wound complications	T037	C1096106
postoperative ileus	T047	C0400877
readmissions	T058	C0030700
technique	T169	C0449851
operative time	T079	C3494201
Safety	T068	C0036043
immunogenecity	T062	C4054739
attenuated	T121	C0042211
Rift Valley fever vaccine	T121	C1548485
CL13T	T121	C1548485
camels	T015	C0006801
Rift Valley fever	T047	C0035613
zoonotic	T001	C1628327
viral disease	T047	C0042769
enzootic	T047	C0277551
endemic	T047	C0277550
Africa	T083	C0001737
Arabian Peninsula	T083	C0003671
significant	T078	C0750502
threat	T078	C0749385
human	T016	C0086418
animal	T008	C0003062
health	T047	C3534575
disease	T047	C0035613
severe	T080	C0205082
ruminants	T015	C0035950
causing	T169	C0678227
abortions	T046	C0149814
pregnant	T040	C0032961
animals	T008	C0003062
sheep animals	T015	C0036945
mortality	T081	C0205848
young	T079	C0332239
populations	T098	C1257890
mortality rates	T081	C0205848
severe	T080	C0205082
clinical	T080	C0205210
manifestation	T080	C1280464
reported	T170	C0684224
camel	T015	C0006801
populations	T098	C1257890
Africa	T083	C0001737
currently	T079	C0521116
available	T169	C0470187
live vaccines	T121	C0042211
RVF	T047	C0035613
tested	T169	C0039593
safety	T068	C0036043
efficacy	T080	C1280519
species	T185	C1705920
study	T062	C2603343
safety	T068	C0036043
efficacy	T080	C1280519
neutralizing antibody	T116	C0475463
response	T032	C0871261
thermostable live attenuated	T121	C0042211
RVF CL13T vaccine	T121	C1548485
evaluated	T058	C0220825
camels	T015	C0006801
different	T080	C1705242
preliminary	T079	C0439611
experiments	T062	C0681814
camels	T015	C0006801
camels	T015	C0006801
pregnant	T040	C0032961
camels	T015	C0006801
study	T062	C2603343
revealed	T080	C0443289
CL13T vaccine	T121	C1548485
safe	T068	C0036043
use	T169	C0457083
camels	T015	C0006801
abortions	T046	C0149814
teratogenic effects	T046	C0232910
observed	T169	C1441672
dose	T081	C0178602
vaccine	T121	C0042211
strong	T080	C0442821
neutralizing antibody	T116	C0475463
response	T032	C0871261
months	T079	C0439231
presence	T033	C0150312
neutralization antibodies	T116	C0475463
correlate with	T080	C0332281
protection	T033	C1545588
protection	T033	C1545588
confirmed by	T080	C0521093
experiments	T062	C0681814
virulent	T080	C1520022
RVF virus	T005	C0035614
Autoantibodies	T116	C0004358
MOG	T116	C0069428
subgroup	T185	C1515021
adult	T100	C0001675
multiple sclerosis	T047	C0026769
evaluate	T058	C0220825
antibodies	T116	C0003241
conformation	T082	C0033625
myelin oligodendrocyte glycoprotein	T116	C0069428
MOG	T116	C0069428
subgroup	T185	C1515021
adult	T100	C0001675
patients	T101	C0030705
clinically	T080	C0205210
multiple sclerosis	T047	C0026769
MS	T047	C0026769
clinical	T080	C0205210
phenotype	T032	C0031437
severe	T080	C0205082
spinal cord	T023	C0037925
optic nerve	T023	C0029130
brainstem	T023	C0006121
Antibodies	T116	C0003241
MOG	T116	C0069428
investigated	T169	C1292732
cell-based assay	T059	C0005507
groups	T098	C1257890
patients	T101	C0030705
patients	T101	C0030705
MS	T047	C0026769
group 1	T098	C1257890
age	T032	C0001779
sex	T032	C0079399
patients	T101	C0030705
MS	T047	C0026769
group 2	T098	C1257890
brain-biopsied	T060	C0740294
patients	T101	C0030705
demyelinating diseases	T047	C0011303
CNS	T022	C3714787
MS	T047	C0026769
classified	T185	C0008902
MS type II	T047	C0026769
group 3	T098	C1257890
epitopes	T129	C0003316
mutated	T045	C0596611
variants	T028	C0678941
MOG	T028	C1417228
Antibodies	T116	C0003241
MOG	T116	C0069428
adult	T100	C0001675
patients	T101	C0030705
MS	T047	C0026769
groups 2	T098	C1257890
3	T098	C1257890
patients	T101	C0030705
tested	T169	C0039593
MOG	T116	C0069428
antibodies	T116	C0003241
Patients	T101	C0030705
MS	T047	C0026769
antibodies	T116	C0003241
MOG	T116	C0069428
manifested	T169	C0205319
concomitant	T079	C0521115
severe	T080	C0205082
brainstem	T023	C0006121
spinal cord	T023	C0037925
severe	T080	C0205082
disease course	T046	C0242656
relapse	T067	C0035020
rates	T081	C1521828
failure	T033	C0162643
disease-modifying therapies	T061	C0087111
treated with	T061	C0332293
plasma exchange	T061	C0032113
favorable response	UnknownType	C0221607
anti-MOG	T129	C1291777
patients	T101	C0030705
MS	T047	C0026769
MS	T047	C0026769
lesions	T033	C0221198
brain MRI	T060	C0412675
Longitudinal analysis	UnknownType	C0815265
years	T079	C0439234
fluctuations	T184	C0231239
anti-MOG reactivity	T044	C1621287
Epitope mapping	T059	C0242831
interindividual heterogeneity	T080	C0019409
intraindividual stability	T080	C0205360
antibody response	T038	C0003261
Antibodies	T116	C0003241
MOG	T116	C0069428
subgroup	T185	C1515021
adult	T100	C0001675
MS	T047	C0026769
clinical	T080	C0205210
phenotype	T032	C0031437
disease	T047	C0012634
heterogeneity	T080	C0019409
Acute Ph-negative lymphoblastic leukemias	T191	C4289946
adults	T100	C0001675
Risk factors	T033	C0035648
ALL-2009 protocol	T170	C2348563
risk factors	T033	C0035648
RFs	T033	C0035648
age	T032	C0001779
immunophenotype	T059	C0079611
baseline	T081	C1442488
leukocytosis	T046	C0023518
enhanced	T052	C2349975
lactate dehydrogenase	T116	C0022917
LDH	T116	C0022917
activity	T044	C0243102
remission	T033	C0544452
risk group	T098	C0684030
cytogenetic abnormalities	T049	C0008625
patients	T101	C0030705
acute lymphoblastic leukemia	T191	C0023449
ALL	T191	C0023449
ALL-2009 protocol	T170	C2348563
protocol	T170	C2348563
patients	T101	C0030705
women	T098	C0043210
including	T169	C0332257
pregnant women	T098	C0033011
men	T098	C0025266
Ph-negative ALL	T191	C4289946
phenotype	T032	C0031437
patients	T101	C0030705
patients	T101	C0030705
B-cell ALL	T191	C0279593
pre-B ALL	T191	C0279593
ALL	T191	C0023449
pre-B ALL	T191	C0279593
patients	T101	C0030705
T-cell ALL	T191	C0279592
T-ALL	T191	C0279592
thymic	T023	C0040113
T-ALL	T191	C0279592
mature	T079	C0205286
T-ALL	T191	C0279592
baseline	T081	C1442488
clinical	T080	C0205210
laboratory	T073	C0022877
parameters	T033	C0449381
leukocytosis	T046	C0023518
B-ALL	T191	C0279593
T-ALL	T191	C0279592
phenotype	T032	C0031437
B-ALL	T191	C0279593
phenotype	T032	C0031437
T-ALL	T191	C0279592
LDH	T116	C0022917
activity	T044	C0243102
presence	T033	C0150312
translocation t(4;11)	T049	C0040715
high-risk group	T098	C0684030
included	T169	C0332257
patients	T101	C0030705
B-ALL	T191	C0279593
T-ALL	T191	C0279592
patients	T101	C0030705
T-ALL	T191	C0279592
autologous bone marrow transplantation	T061	C0194037
BMT	T061	C0005961
Allogeneic BMT	T061	C0149615
performed	T169	C0884358
patients	T101	C0030705
induction phase	T062	C4049995
overall survival	T081	C4086681
patients	T101	C0030705
included	T169	C0332257
investigation	T058	C0220825
relapse-free	T061	C0679867
patients	T101	C0030705
B-ALL	T191	C0279593
T-ALL	T191	C0279592
overall survival rates	T081	C0038954
Multivariate analysis	T081	C0026777
including	T169	C0332257
RFs	T033	C0035648
T-ALL	T191	C0279592
patient's	T101	C0030705
age	T032	C0001779
B-ALL	T191	C0279593
chemotherapeutic	T121	C0729502
allogeneic BMTs	T061	C0149615
treatment	T061	C0087111
results	T034	C0456984
adult	T100	C0001675
patients	T101	C0030705
ALL	T191	C0023449
cytostatic	T121	C0010858
effects	T080	C1280500
preserving	T169	C0728887
cytostatic	T121	C0010858
loading dose	T081	C3714444
results	T034	C0456984
Russian	T083	C0035970
investigation	T058	C0220825
allogeneic BMTs	T061	C0149615
adult	T100	C0001675
patients	T101	C0030705
ALL	T191	C0023449
Multidetector CT	T060	C3179130
expected	T170	C1517001
findings	T033	C0243095
complications	T046	C0009566
contemporary	T079	C1254367
inguinal hernia repair	T061	C0021446
surgery	T061	C0543467
Inguinal hernia repair	T061	C0021446
IHR	T061	C0021446
prosthetic	T074	C0175649
mesh	T074	C0181805
implantation	T061	C0021107
procedure	T061	C0087111
general surgery	T061	C2242991
performed	T169	C0884358
open	T082	C0348025
laparoscopic approach	T082	C0393360
paper	T073	C0030351
overview	T170	C0814812
contemporary	T079	C1254367
IHR	T061	C0021446
techniques	T169	C0449851
materials	T167	C0520510
expected	T170	C1517001
postoperative	T033	C0231287
imaging findings	T034	C1287399
iatrogenic injuries	T037	C0854404
multidetector CT	T060	C3179130
ideal	T080	C1512612
modality	T078	C0695347
operated	T169	C0205245
groin region	T029	C1279151
deeper	T082	C0205125
intra-abdominal structures	T023	C0588044
CT	T060	C0040405
seroma	T046	C0262627
mesh infections	T046	C3888473
hemorrhages	T046	C0019080
bowel	T023	C0021853
complications	T046	C0009566
urinary bladder	T023	C0005682
injuries	T037	C0403677
consistent	T078	C0332290
therapeutic	T169	C0302350
choice	T052	C1707391
radiologists	T097	C0334907
increasingly	T169	C0442808
investigate	T169	C1292732
suspected	T078	C0750491
iatrogenic	T080	C0439669
complications	T046	C0009566
paper	T073	C0030351
increased	T081	C0205217
familiarity	T041	C0600269
early	T079	C1279919
CT	T060	C0040405
studies	T060	C1881134
IHR	T061	C0021446
complications	T046	C0009566
normal	T080	C0205307
postoperative	T033	C0231287
appearances	T080	C0700364
focal	T082	C0205234
pseudolesions	T046	C1261287
avoid misinterpretation	T058	C1254363
inappropriate	T080	C1548788
management	T058	C0376636
transcription factors	T116	C0040648
MS188	T116	C4277090
AMS	T116	C1434242
complex	T080	C0439855
activate	T169	C1515877
expression	T045	C1171362
CYP703A2	T116	C2000791
sporopollenin biosynthesis	T044	C2755351
Arabidopsis thaliana	T002	C0162740
sexine layer	T026	C1820011
pollen grain	T002	C0032385
sporopollenins	T109	C0075041
sporophytic secretory tapetum	T025	C2717770
required	T169	C1514873
biosynthesis of sporopollenin	T044	C2755351
enzymes	T116	C0014442
involved	T169	C1314939
sporopollenin biosynthesis	T044	C2755351
regulatory mechanism	T044	C1152521
enzymes	T116	C0014442
tapetal layer	T025	C2717770
ABORTED MICROSPORES	T116	C1434242
AMS	T116	C1434242
MALE STERILE 188	T116	C4277090
MYB103	T116	C0769095
MYB80	T116	C0769095
MS188	T116	C4277090
MYB103	T116	C0769095
MYB80	T116	C0769095
tapetal cell	T025	C2717770
transcription factors	T116	C0040648
required	T169	C1514873
pollen wall formation	T042	C1326804
AMS	T116	C1434242
functions	T169	C0542341
upstream	T082	C0522505
MS188	T116	C4277090
AMS	T116	C1434242
MS188	T116	C4277090
target	T169	C1521840
CYP703A2 gene	T028	C1333195
involved	T169	C1314939
sporopollenin biosynthesis	T044	C2755351
AMS	T116	C1434242
MS188	T116	C4277090
localized	T082	C0392752
tapetum	T025	C2717770
CYP703A2	T116	C2000791
localized	T082	C0392752
tapetum	T025	C2717770
locule	T002	C1136229
Chromatin immunoprecipitation	T059	C1328856
ChIP	T059	C1328856
MS188	T116	C4277090
bound	T052	C1145667
promoter	T114	C0086860
CYP703A2	T028	C1333195
luciferase-inducible	T116	C0024075
assay	T059	C1510438
MS188	T116	C4277090
activated	T052	C1879547
expression	T045	C1171362
CYP703A2	T116	C2000791
Yeast two-hybrid	T063	C1961118
electrophoretic mobility shift assays	T059	C0949632
EMSAs	T059	C0949632
MS188	T116	C4277090
complexed	T080	C0439855
AMS	T116	C1434242
expression	T045	C1171362
CYP703A2	T028	C1333195
elevated levels	T080	C3163633
MS188	T116	C4277090
ams	T116	C1434242
mutant	T049	C0596988
data	T078	C1511726
reveal	T080	C0443289
MS188	T116	C4277090
coordinates	T169	C0700114
AMS	T116	C1434242
activate	T169	C1515877
CYP703A2	T116	C2000791
sporopollenin biosynthesis	T044	C2755351
plant	T002	C0032098
tapetum	T025	C2717770
Activation	T052	C1879547
ephrinB-EphB receptor signalling	T169	C2984386
rat spinal cord	T023	C1882864
maintenance	T052	C0024501
diabetic	T033	C0241863
neuropathic pain	T033	C3714625
Diabetic	T033	C0241863
neuropathic pain	T033	C3714625
DNP	T033	C3714625
severe	T080	C0205082
intractable	T169	C0205269
clinic	T073	C0442592
specific	T080	C0205369
cellular	T043	C0007613
molecular	T044	C1148560
mechanisms	T169	C0441712
DNP	T033	C3714625
treatment	T169	C0039798
limited	T169	C0439801
investigated	T169	C1292732
roles	T077	C1705810
EphB1 receptor	T116	C0907648
DNP	T033	C3714625
Diabetic	T033	C0241863
neuropathic pain	T033	C3714625
male	T032	C0086582
adult	T100	C0001675
Sprague-Dawley rats	T015	C0034715
streptozotocin	T109	C0038432
STZ	T109	C0038432
alloxan	T109	C0002151
Western blot analysis	T059	C0949466
immunohistochemistry	T060	C0021044
expression	T045	C1171362
EphB1 receptor	T116	C0907648
activation	T052	C1879547
glial cells	T025	C0027836
pro-inflammatory cytokines	T116	C0079189
spinal cord	T023	C0037925
DNP	T033	C3714625
manifested	T169	C0205319
mechanical allodynia	T184	C2936719
measuring	T080	C0444706
incidence	T081	C0021149
foot	T023	C0016504
withdrawal	T052	C0441655
response	T032	C0871261
mechanical indentation	T082	C0332467
hind	T082	C2983612
paw	T023	C0687080
electro von Frey filament	T073	C3273359
Diabetic	T033	C0241863
neuropathic pain	T033	C3714625
high blood glucose	T033	C2919432
simultaneously	T079	C0521115
animals	T008	C0003062
STZ	T109	C0038432
alloxan	T109	C0002151
Phosphorylation	T044	C0031715
EphB1	T116	C0907648
activation	T052	C1879547
astrocytes	T025	C0004112
microglial cells	T025	C0206116
level	T080	C0441889
tumour necrosis factor	T116	C1456820
(TNF)-α	T116	C1456820
interleukin (IL)-1β	T116	C0021753
spinal cord	T023	C0037925
rats	T015	C0034721
DNP	T033	C3714625
Spinal	T082	C0521329
blocking	T169	C0332206
EphB1 receptor	T116	C0907648
activation	T052	C1879547
STZ	T109	C0038432
injection	T061	C1533685
suppressed	T169	C1260953
mechanical allodynia	T184	C2936719
activation	T052	C1879547
astrocytes	T025	C0004112
microglial cells	T025	C0206116
activity	T052	C0441655
TNF-α	T116	C1456820
IL-1β	T116	C0021753
spinal	T082	C0521329
treatment	T169	C0039798
EphB1	T116	C0907648
Fc	T116	C0034805
early phase	UnknownType	C0814494
STZ	T109	C0038432
injection	T061	C1533685
induction	T169	C0205263
DNP	T033	C3714625
EphB1 receptor	T116	C0907648
activation	T052	C1879547
spinal cord	T023	C0037925
critical	T080	C1511545
maintenance	T052	C0024501
induction	T169	C0205263
diabetic	T033	C0241863
pain	T184	C0030193
EphB1 receptor	T116	C0907648
potential	T080	C3245505
target	T169	C1521840
relieving	T061	C0002766
diabetic	T033	C0241863
pain	T184	C0030193
Activation	T052	C1879547
EphB1 receptor	T116	C0907648
spinal cord	T023	C0037925
critical	T080	C1511545
maintaining	T169	C1314677
diabetic	T033	C0241863
neuropathic pain	T033	C3714625
diabetic	T033	C0241863
pain	T184	C0030193
induction	T169	C0205263
Spinal	T082	C0521329
blocking	T169	C0332206
EphB1 receptor	T116	C0907648
activation	T052	C1879547
suppresses	T169	C1260953
diabetic	T033	C0241863
neuropathic pain	T033	C3714625
Conservation	T080	C2347858
Red Kite	T012	C0325557
Milvus milvus	T012	C0325557
Aves	T012	C0005595
Accipitriformes	T012	C3669511
Affected	T169	C0392760
Hybrid	T001	C0020205
Zone	T082	C1710706
Black Kite	T012	C1016933
Milvus migrans migrans	T012	C1016933
Central Europe	T083	C0682369
Accipitriformes	T012	C3669511
species	T185	C1705920
reported	T170	C0684224
hybrid	T001	C0020205
zones	T082	C1710706
red kite	T012	C0325557
Milvus milvus	T012	C0325557
black kite	T012	C1016933
Milvus migrans migrans	T012	C1016933
M. milvus	T012	C0325557
endemic	T169	C0302891
western Palearctic	UnknownType	C0681784
population	T081	C0032659
breeding	T040	C0006159
pairs	T080	C1709450
species	T185	C1705920
persecution	T054	C0871062
ingestion	T038	C0232478
rodenticide-treated baits	T131	C0035805
illegal	T078	C3242151
poisoning	T037	C0032343
agricultural practices	T090	C0001829
core	T082	C0444669
range	T081	C1514721
F1	T099	C0314650
M. milvus	T012	C0325557
M. migr. migrans	T012	C1016933
hybrid	T001	C0020205
offspring	T099	C0680063
F2	T099	C0314651
F3	T099	C0680063
hybrids	T001	C0020205
reported	T170	C0684224
nesting	T054	C0027776
success	T054	C0597535
rates	T081	C1521828
F1	T099	C0314650
hybrids	T001	C0020205
partial	T081	C0728938
hybrid	T001	C0020205
analyzed	T062	C0936012
mitochondrial	T026	C0026237
CO1	T028	C1537985
CytB	T028	C1537988
nuclear	T026	C0007610
Myc	T028	C0086661
DNA	T114	C0012854
loci	T082	C1708726
M. milvus	T012	C0325557
M. migr. migrans	T012	C1016933
F1	T099	C0314650
hybrid	T001	C0020205
central Europe	T083	C0682369
agreement	T170	C4255373
studies	T062	C2603343
heterozygosity	T032	C0019425
M. milvus	T012	C0325557
locus	T082	C1708726
populations	T081	C0032659
examined	T033	C0332128
species	T185	C1705920
characterized	T052	C1880022
gene flow	T045	C1565556
populations	T081	C0032659
haplotypes	T032	C0018591
examined	T033	C0332128
area	T083	C0017446
haplotypes	T032	C0018591
statistically significant	T081	C0237881
aggregation	T169	C0332621
region	T083	C0017446
mitochondrial DNA	T114	C0012929
species	T185	C1705920
plumage	T023	C0015731
species	T185	C1705920
F1	T099	C0314650
hybrids	T001	C0020205
Haldane´s Rule	T170	C0870077
investigated	T169	C1292732
genomic	T028	C0017428
methods	T169	C0025664
gene flow	T045	C1565556
paternal	T080	C0337493
examined	T033	C0332128
Myc gene	T028	C0086661
divergence	T082	C0443204
M. milvus	T012	C0325557
M. migr. migrans	T012	C1016933
central Europe	T083	C0682369
population	T081	C0032659
M. milvus	T012	C0325557
gene flow	T045	C1565556
origin	T079	C0439659
M. milvus	T012	C0325557
Extracellular	T026	C0521119
Potassium	T123	C0032821
Seizures	T184	C0036572
Excitation	T052	C0549255
Inhibition	T052	C3463820
Ih	T116	C1956068
Seizure activity	T184	C0036572
extracellular	T026	C0521119
potassium	T123	C0032821
concentration	T081	C1264643
K	T121	C0597277
neuronal	T025	C0027882
passive	T080	C3686820
active	T169	C0205177
membrane	T026	C3161472
population	T098	C1257890
activities	T052	C0441655
study	T062	C2603343
extracellular	T026	C0521119
potassium	T123	C0032821
seizure activities	T184	C0036572
4-AP	T109	C0000477
seizure	T184	C0036572
model	T170	C3161035
neocortex	T023	C0175173
in vivo	T082	C1515655
in vitro	T080	C1533691
K	T121	C0597277
prolonged	T079	C0439590
seizure	T184	C0036572
durations	T079	C0449238
shortened interictal intervals	T079	C1254367
depolarized	T046	C1395184
neuronal	T025	C0027882
resting membrane potential	T043	C0025251
RMP	T043	C0025251
K	T121	C0597277
seizure like events	T184	C0036572
SLEs	T184	C0036572
blocked	T169	C0332206
neurons	T025	C0027882
depolarization	T046	C1395184
blocked	T169	C0332206
Spreading	T080	C0332261
depression	T048	C0011570
ictal events	T184	C0036572
K	T121	C0597277
concentration	T081	C1264643
K	T121	C0597277
in vivo	T082	C1515655
in vitro	T080	C1533691
mouse brain preparations	T024	C1521713
human	T016	C0086418
neocortical	T023	C0175173
tissue	T024	C0040300
epilepsy	T047	C0014544
surgery	T061	C0543467
Blocking	T169	C0332206
hyperpolarization-activated cyclic nucleotide-gated (HCN) channels	T116	C1956068
K	T121	C0597277
influence	T077	C4054723
SLEs	T184	C0036572
K	T121	C0597277
inhibitory actions	T052	C3463820
K	T121	C0597277
neuronal	T025	C0027882
excitability	T184	C0235169
seizure activity	T184	C0036572
Activation	T044	C0014429
general control nonderepressible 2 kinase	T116	C2354171
protects	T033	C1545588
human	T016	C0086418
glomerular endothelial cells	T025	C1182791
high-glucose	T033	C0860803
induced	T169	C0205263
molecular pathways	T044	C1704259
protein	T116	C0033684
restriction	T169	C0443288
diabetic nephropathy	T047	C0011881
DN	T047	C0011881
renal	T023	C0022646
endothelium	T024	C0014257
pathogenesis	T046	C0699748
evaluated	T058	C0220825
general control nonderepressible 2 (GCN2) kinase	T116	C2354171
activation	T044	C0014429
sensor	T075	C0600364
amino acid	T116	C0002520
deprivation	T080	C0871712
molecular pathways	T044	C1704259
human	T016	C0086418
glomerular endothelial cells	T025	C1182791
GEnC	T025	C1182791
GEnC	T025	C1182791
cultured	T059	C0430400
high	T080	C0205250
high -glucose conditions	T047	C0020456
GCN2 kinase	T116	C2354171
activator	T044	C2247123
tryptophanol	T116	C0526839
Glucose transporter 1	T116	C0168458
GLUT1	T116	C0168458
expression	T045	C1171362
assessed	T052	C1516048
western blotting	T059	C0005863
reactive oxygen species	T123	C0162772
ROS	T123	C0162772
fluorogenic probe	T130	C0016321
Activities	T044	C0243102
glyceraldehyde 3-phosphate dehydrogenase	T116	C3536868
GAPDH	T116	C3536868
protein kinase C	T116	C0033634
PKC	T116	C0033634
assessed	T052	C1516048
commercial activity assays	T059	C0005507
sorbitol	T109	C0037688
colorimetrically	T059	C1531834
methylglyoxal	T109	C0034338
ELISA	T059	C0014441
O-linked β-N-acetyl glucosamine (O-GlcNAc)-modified proteins	T116	C0671368
western blotting	T059	C0005863
High glucose	T033	C0860803
induced	T169	C0205263
GLUT1	T116	C0168458
expression	T045	C1171362
increased	T081	C0205217
ROS	T123	C0162772
inhibited	T080	C0311403
GAPDH	T116	C3536868
increased	T081	C0205217
polyol	T109	C0071629
pathway	T044	C1704259
sorbitol	T109	C0037688
PKC	T116	C0033634
activity	T044	C0243102
O-GlcNAc-modified proteins	T116	C0671368
hexosamine	T109	C0019477
pathway	T044	C1704259
advanced glycation endproducts'	T109	C0162574
precursor	T078	C1709634
methylglyoxal	T109	C0034338
Co-treatment	T058	C0814472
GEnC	T025	C1182791
tryptophanol	T116	C0526839
high-glucose	T033	C0860803
induced	T169	C0205263
Activation	T044	C0014429
GCN2 kinase	T116	C2354171
GEnC	T025	C1182791
high-glucose	T033	C0860803
induced	T169	C0205263
molecular pathways	T044	C1704259
concurrently	T079	C0205420
pathways	T044	C1704259
DN	T047	C0011881
pathogenesis	T046	C0699748
GCN2 kinase	T116	C2354171
pharmaceutical	T091	C0031336
target	T169	C1521840
treatment	T061	C0087111
DN	T047	C0011881
Juicer	T170	C0037589
Provides	T052	C1999230
Analyzing	T062	C0936012
Loop-Resolution Hi-C Experiments	T059	C0200892
Hi-C experiments	T059	C0200892
3D structure	T082	C0026377
genome	T028	C0017428
generating	T052	C3146294
terabases of data	T170	C0150098
high-resolution	T059	C1719039
contact maps	T170	C0814036
Juicer	T170	C0037589
open-source tool	T170	C0037589
terabase-scale	T081	C0392762
Hi-C datasets	T170	C0150098
Juicer	T170	C0037589
users	T098	C1706077
without	T080	C0332288
computational	T052	C1880157
background	T077	C1706907
transform	T062	C1705163
raw sequence data	T170	C0026382
contact maps	T170	C0814036
Juicer	T170	C0037589
hic file	T170	C0242193
compressed	T169	C0332260
contact matrices	T082	C1704640
resolutions	T081	C1706463
visualization	T041	C0175631
analysis	T062	C0936012
multiple scales	T081	C0392762
Structural features	T082	C0026377
loops	T026	C1516509
domains	T044	C0599845
automatically	T066	C0004374
annotated	T080	C1552720
Juicer	T170	C0037589
open	T080	C1996904
source	T081	C0011001
software	T073	C0037585
BJN Awards	T073	C0004446
IV therapy	T061	C0455142
Professor	T097	C0015535
Nursing	T097	C0028661
Centre of Research Excellence	T097	C1516383
Nursing	T097	C0028661
awarded	T073	C0004446
BJN Awards	T073	C0004446
IV Therapy	T061	C0455142
Nurse	T097	C0028661
Year	T079	C0439234
field	T058	C1254363
Stressful	T169	C0231297
life events	T032	C0557155
leucocyte telomere length	T047	C1836777
lifestyle factors	T201	C1517875
somatic	T080	C2986476
mental health	T041	C0025353
low grade inflammation	T046	C0021368
relationship	T080	C0439849
cohort	T098	C0599755
Danish men	T098	C0025266
born	T040	C0005615
Exposure to	T080	C0332157
psychosocial	T169	C0542298
stress	T033	C0038435
associated with	T080	C0332281
risk	T078	C0035647
somatic	T080	C2986476
mental disorders	T048	C0004936
relation	T080	C0439849
relation	T080	C0439849
immune system	T022	C0020962
functioning	T169	C0542341
stressful events	T051	C0038444
life	T078	C0376558
associated with	T080	C0332281
leucocyte telomere length	T047	C1836777
TL	T047	C1836777
accumulated	T033	C4055506
inflammation	T046	C0021368
oxidative stress	T049	C0242606
life course	T079	C1510618
address	T078	C1547607
childhood	T079	C0231335
sensitive period	T079	C1948053
relation	T080	C0439849
stressful	T169	C0231297
TL	T047	C1836777
somatic	T080	C2986476
mental health	T041	C0025353
lifestyle	T054	C0023676
markers	T201	C0005516
low-grade inflammation	T046	C0021368
cohort	T098	C0599755
Danish men	T098	C0025266
born	T040	C0005615
birth	T040	C0005615
Metropolit Cohort	T098	C0599755
men	T098	C0025266
health examination	T058	C0420151
blood sampling	T060	C0005834
quantitative PCR-based measurement	T059	C2733022
TL	T047	C1836777
relation	T080	C0439849
stressful	T169	C0231297
life events	T032	C0557155
TL	T047	C1836777
structural equation modelling	T062	C0681947
estimate	T081	C0750572
proportion	T081	C1709707
effect	T080	C1280500
somatic	T080	C2986476
mental health	T041	C0025353
cardiovascular disease	T047	C0007222
body mass	T033	C0518010
depressive mood	T033	C0344315
lifestyle factors	T201	C1517875
low grade inflammation	T046	C0021368
C-reactive protein	T116	C0006560
CRP	T116	C0006560
interleukin (IL)-6	T116	C0021760
IL-10	T116	C0085295
Total number	T081	C4288115
stressful events	T051	C0038444
experienced	T067	C0023672
during	T079	C0347984
life course	T079	C1510618
associated with	T080	C0332281
TL	T047	C1836777
sensitive periods	T079	C1948053
number	T081	C0237753
stressful events	T051	C0038444
childhood	T079	C0231335
associated with	T080	C0332281
shorter TL	T047	C1836777
stressful events	T051	C0038444
childhood	T079	C0231335
relation	T080	C0439849
home	T082	C0442519
effect	T080	C1280500
stressful events	T051	C0038444
childhood	T079	C0231335
TL	T047	C1836777
variables	T081	C1705098
proportion	T081	C1709707
depressive mood	T033	C0344315
CRP	T116	C0006560
stressful events	T051	C0038444
childhood	T079	C0231335
associated with	T080	C0332281
shorter TL	T047	C1836777
middle-aged men	T100	C3825963
relation	T080	C0439849
depressive mood	T048	C0852545
low grade inflammation	T046	C0021368
Description	T170	C0678257
Ancylomarina subtilis gen. nov., sp. nov.	T007	C0004611
isolated	T169	C0205409
coastal sediment	T082	C0557760
proposal	T078	C1555306
Marinilabiliales ord. nov.	T007	C0004611
transfer	T078	C3244299
Marinilabiliaceae	T007	C3557298
Prolixibacteraceae	T007	C3800560
Marinifilaceae	T007	C3986640
order	T185	C1705177
Marinilabiliales	T007	C0004611
Gram-stain-negative	T007	C0018150
facultatively anaerobic	T007	C1532741
moderately halophilic	T194	C0599691
filamentous	T080	C1979891
non-motile bacterium	T007	C1301466
designated	T169	C1524084
FA102T	T007	C0018149
isolated	T169	C0205409
marine sediment	T070	C0282589
coast	T082	C0442544
Weihai, China	T083	C0008115
Phylogenetic analysis	T062	C1519068
based	T169	C1527178
16S rRNA gene sequences	T114	C3537372
showed	T169	C0870432
strain	T080	C0456178
FA102T	T007	C0018149
distinct	T080	C2963144
evolutionary	T045	C0015219
lineage	T077	C1881379
family	T077	C1704727
Marinifilaceae	T007	C3986640
closest relative	T033	C1821461
Marinifilum fragile JCM 15579T	T007	C2990363
sequence similarity	T081	C1710052
DNA	T114	C0012854
G+C content	T081	C1135899
novel	T080	C0205314
strain	T080	C0456178
predominant	T080	C1542147
cellular	T025	C0007634
fatty acids	T109	C0015684
respiratory	T169	C0521346
quinone	T109	C0034435
iso-C15:0	T109	C0044840
iso-C15:0 3-OH	T116	C0754432
MK-7	T109	C0078382
respectively	T080	C1548787
basis	T169	C1527178
phylogenetic	UnknownType	C0683236
phenotypic	T032	C0031437
physiological	T169	C0205463
data	T078	C1511726
strain	T080	C0456178
FA102T	T007	C0018149
represents	T052	C1882932
novel	T080	C0205314
genus	T185	C1708235
species	T185	C1705920
Ancylomarina subtilis gen. nov., sp. nov.	T007	C0004611
proposed	T080	C1553874
type	T080	C0332307
strain	T080	C0456178
Ancylomarina subtilis	T007	C0018149
FA102T	T007	C0018149
KCTC 42257T	T007	C0004611
DSM 28825T	T007	C0004611
CICC 10902T	T007	C0004611
new	T080	C0205314
order	T185	C1705177
Marinilabiliales	T007	C0004611
proposed	T080	C1553874
accommodate	T033	C1832072
families	T077	C1704727
previously	T079	C0205156
classified	T185	C0008902
order	T185	C1705177
Bacteroidales	T007	C1080663
Marinilabiliales ord. nov.	T007	C0004611
families	T077	C1704727
Marinilabiliaceae	T007	C3557298
Prolixibacteraceae	T007	C3800560
Marinifilaceae	T007	C3986640
Treatment	T061	C0087111
Rheumatoid Arthritis	T047	C0003873
Risk	T033	C1281905
Alzheimer's Disease	T047	C0002395
Nested Case-Control Analysis	T062	C0027775
increasingly	T169	C0442808
accepted	T080	C1272684
inflammation	T046	C0021368
pathogenesis	T046	C0699748
Alzheimer's disease	T047	C0002395
AD	T047	C0002395
several	T081	C0443302
immune	T022	C0020962
genes	T028	C0017337
associated with	T080	C0332281
AD	T047	C0002395
tumor necrosis factor (TNF)-α	T116	C1456820
proinflammatory cytokine	T116	C0079189
autoimmune disorders	T047	C0004364
rheumatoid arthritis	T047	C0003873
RA	T047	C0003873
AD	T047	C0002395
RA	T047	C0003873
similar	T080	C2348205
pathological mechanisms	T046	C0030660
production	T038	C0003261
TNF-α,	T116	C1456820
relationship	T080	C0439849
AD	T047	C0002395
RA	T047	C0003873
unknown	T080	C0439673
relative risk	T081	C0242492
AD	T047	C0002395
RA	T047	C0003873
patients	T101	C0030705
RA	T047	C0003873
patients	T101	C0030705
anti-TNF therapy	T061	C0281481
RA	T047	C0003873
associated with	T080	C0332281
lower	T080	C0205251
risk	T033	C1281905
AD	T047	C0002395
RA	T047	C0003873
patients	T101	C0030705
nested case-control study	T062	C0027775
insured	T170	C1548605
adults	T100	C0001675
US states	T083	C0041703
Puerto Rico	T083	C0034044
US Virgin Islands	T083	C0042752
Verisk Health claims database	T170	C0242356
sub-cohort	T098	C0599755
diagnosis	T033	C0011900
RA	T047	C0003873
controls	T096	C0009932
RA	T047	C0003873
AD	T047	C0002395
cases	T077	C1706256
matching	T062	C0150103
cases	T077	C1706256
age	T032	C0001779
sex	T032	C0079399
exposure assessment period	T058	C1545382
methotrexate treatment	T061	C0746573
assessed relative risk	T058	C0086930
AD	T047	C0002395
exposure to	T080	C0332157
standard	T080	C1442989
RA	T047	C0003873
therapies	T061	C0087111
anti-TNF agents	T121	C1562242
infliximab	T116	C0666743
adalimumab	T116	C1122087
etanercept	T116	C0717758
methotrexate	T109	C0025677
prednisone	T109	C0032952
sulfasalazine	T109	C0036078
rituximab	T116	C0393022
Odds ratios	T081	C0028873
comorbidities	T078	C0009488
coronary artery disease	T047	C0010068
diabetes mellitus	T047	C0011849
peripheral vascular disease	T047	C0085096
AD	T047	C0002395
prevalent	T080	C1542147
RA	T047	C0003873
patients	T101	C0030705
without	T080	C0332288
RA	T047	C0003873
Chronic conditions	T033	C4315615
coronary artery disease	T047	C0010068
odds ratio	T081	C0028873
OR	T081	C0028873
confidence interval	T081	C0009667
CI	T081	C0009667
diabetes	T047	C0011847
OR	T081	C0028873
CI	T081	C0009667
peripheral vascular disease	T047	C0085096
OR	T081	C0028873
CI	T081	C0009667
relative risk	T081	C0242492
AD	T047	C0002395
RA	T047	C0003873
patients	T101	C0030705
Exposure to	T080	C0332157
anti-TNF agents	T121	C1562242
class	T081	C1547013
immunosuppressive drugs	T121	C0021081
associated with	T080	C0332281
lowered	T081	C1272755
risk	T033	C1281905
AD	T047	C0002395
RA	T047	C0003873
patients	T101	C0030705
OR	T081	C0028873
CI	T081	C0009667
OR	T081	C0028873
CI	T081	C0009667
Sub-group analysis	T081	C2347789
anti-TNF agents	T121	C1562242
etanercept	T116	C0717758
OR	T081	C0028873
CI	T081	C0009667
OR	T081	C0028873
CI	T081	C0009667
associated with	T080	C0332281
decreased	T081	C0205216
risk	T033	C1281905
AD	T047	C0002395
RA	T047	C0003873
patients	T101	C0030705
increased	T081	C0205217
risk	T033	C1281905
AD	T047	C0002395
RA	T047	C0003873
population	T081	C0032659
relative risk	T081	C0242492
AD	T047	C0002395
RA	T047	C0003873
lowered	T081	C1272755
exposed to	T080	C0332157
etanercept	T116	C0717758
Anti-TNF therapy	T061	C0281481
etanercept	T116	C0717758
promise	T078	C1555307
potential	T080	C3245505
treatment	T061	C0087111
AD	T047	C0002395
Dimerization	T067	C2350408
EGFR	T116	C0034802
HER2	T116	C0069515
breast cancer	T191	C0006142
cell motility	T040	C0007608
STAT1	T116	C0287920
ACTA2	T116	C2716282
induction	T169	C0205263
dimerization	T067	C2350408
EGFR	T116	C0034802
HER2	T116	C0069515
prognosis	T058	C0033325
induction	T169	C0205263
tumor growth	T191	C0598934
cell invasion	T046	C2699153
compared	T052	C1707455
EGFR	T116	C0034802
homodimer	T104	C0596448
mechanism	T169	C0441712
dimerization	T067	C2350408
breast cancer	T191	C0006142
models	T075	C0026336
expressions	T045	C1171362
alpha-smooth muscle actin	T116	C2716282
ACTA2	T116	C2716282
signal transducer and activator of transcription 1	T116	C0287920
STAT1	T116	C0287920
increased	T081	C0205217
overexpression	T045	C1514559
HER2	T116	C0069515
EGFR	T116	C0034802
positive	T033	C1446409
breast cancer	T191	C0006142
cells	T025	C0007634
ACTA2	T116	C2716282
STAT1	T116	C0287920
expression	T045	C1171362
increased	T081	C0205217
HER2	T116	C0069515
positive	T033	C1446409
breast cancer	T191	C0006142
patients	T101	C0030705
ACTA2	T116	C2716282
expression	T045	C1171362
decreased	T081	C0205216
HER2 siRNA	T114	C1099354
STAT1	T116	C0287920
ACTA2	T116	C2716282
expression	T045	C1171362
ACTA2	T116	C2716282
expression	T045	C1171362
decreased	T081	C0205216
treatment	T061	C0087111
STAT1 inhibitor	T121	C1254351
fludarabine	T114	C0059985
JAK2 inhibitor	T121	C1254351
AG490	T109	C0381241
ACTA2	T116	C2716282
expression	T045	C1171362
increased	T081	C0205217
STAT1	T116	C0287920
overexpression	T045	C1514559
ACTA2	T116	C2716282
STAT1	T116	C0287920
HER2	T116	C0069515
increased	T081	C0205217
free survival	T081	C0242793
decreased	T081	C0205216
high-risk	T033	C0332167
breast cancer	T191	C0006142
patients	T101	C0030705
investigated	T169	C1292732
ACTA2	T116	C2716282
cell motility	T040	C0007608
suppressed	T169	C1260953
ACTA2 shRNA	T114	C2930586
overexpression	T045	C1514559
MDA-MB231	T025	C1512505
HER2	T116	C0069515
4T1 mammary carcinoma cells	T025	C1512505
lung metastatic nodules	T033	C0034079
decreased	T081	C0205216
ACTA2	T116	C2716282
knockdown mice	T015	C0206745
induction	T169	C0205263
ACTA2	T116	C2716282
EGFR	T116	C0034802
HER2	T116	C0069515
dimerization	T067	C2350408
JAK2	T116	C0169661
STAT1	T116	C0287920
signaling pathway	T044	C0037080
ACTA2	T116	C2716282
expression	T045	C1171362
expression	T045	C1171362
invasiveness	T046	C0027626
metastasis	T191	C0027627
breast cancer	T191	C0006142
cells	T025	C0007634
social	T169	C0728831
cognitive treatment	T061	C0009244
treatment	T169	C1522326
participation	T169	C0679823
partners	T098	C3887537
persons	T098	C0027361
relapsing remitting multiple sclerosis	T047	C0751967
observation	T058	C0700325
improved	T033	C0184511
self-efficacy	T041	C0600564
quality of life	T078	C0034380
anxiety	T033	C0003467
depression	T048	C0011570
year	T079	C0439234
persons	T098	C0027361
multiple sclerosis	T047	C0026769
MS	T047	C0026769
self-efficacy	T041	C0600564
positively	T033	C1446409
health-related quality of life	T078	C4279947
HRQoL	T078	C4279947
physical activity	T056	C0026606
observed	T169	C1441672
months	T079	C0439231
day	T079	C0439228
social	T169	C0728831
cognitive treatment	T061	C0009244
treatment	T169	C1522326
participation	T169	C0679823
partners	T098	C3887537
self-efficacy	T041	C0600564
HRQoL	T078	C4279947
improved	T033	C0184511
persons	T098	C0027361
relapsing remitting MS	T047	C0751967
RRMS	T047	C0751967
chronic	T079	C0205191
nature of the disease	T080	C0449786
beneficial	T081	C0814225
changes	T169	C0392747
treatment	T169	C1522326
persons	T098	C0027361
MS	T047	C0026769
partners	T098	C3887537
baseline	T081	C1442488
months	T079	C0439231
treatment	T061	C0087111
self-efficacy	T041	C0600564
control	T169	C2587213
self-efficacy	T041	C0600564
function	T169	C0542341
physical	T169	C0205485
mental	T041	C0025353
HRQoL	T078	C4279947
anxiety	T033	C0003467
depression	T048	C0011570
fatigue	T184	C0015672
assessed	T052	C1516048
self-report	T062	C2700446
questionnaires	T170	C0034394
Differences	T080	C1705242
tested	T169	C0039593
paired t test	T170	C1709451
persons	T098	C0027361
MS	T047	C0026769
completed	T080	C0205197
baseline	T081	C1442488
assessment	T052	C1516048
day	T079	C0439228
treatment	T169	C1522326
month	T079	C0439231
questionnaires	T170	C0034394
response	T033	C1704632
rate	T081	C1521828
RRMS	T047	C0751967
progressive	T169	C0205329
MS	T047	C0026769
RR	T047	C0751967
group	T078	C0441833
self-efficacy	T041	C0600564
control	T169	C2587213
increased	T081	C0205217
physical	T169	C0205485
HRQoL	T078	C4279947
depression	T048	C0011570
anxiety	T033	C0003467
decreased	T081	C0205216
changes	T169	C0392747
mental	T041	C0025353
HRQoL	T078	C4279947
fatigue	T184	C0015672
failed	T169	C0231175
statistically significant	T081	C0237881
progressive	T169	C0205329
group	T078	C0441833
changes	T169	C0392747
suggestive of	T169	C0332299
improvement	T077	C2986411
findings	T169	C2607943
suggest	T078	C1705535
day	T079	C0439228
social	T169	C0728831
cognitive treatment	T061	C0009244
treatment	T169	C1522326
participation	T169	C0679823
partners	T098	C3887537
long lasting	T079	C1254367
beneficial	T081	C0814225
effects	T080	C1280500
self-efficacy	T041	C0600564
HRQoL	T078	C4279947
persons	T098	C0027361
RRMS	T047	C0751967
improvements	T077	C2986411
anxiety	T033	C0003467
depression	T048	C0011570
month	T079	C0439231
develop	T169	C1527148
months	T079	C0439231
Perineal injuries	T037	C3544174
birth positions	T033	C0243095
women	T098	C0043210
low risk pregnancy	T033	C0404841
homebirth	T033	C0419367
birth positions	T033	C0243095
associated with	T080	C0332281
perineal injuries	T037	C3544174
severe perineal trauma	UnknownType	C0559034
SPT	UnknownType	C0559034
unclear	T033	C3845108
objective	T170	C0018017
study	T062	C2603343
prevalence	T081	C0220900
perineal injuries	T037	C3544174
severity	T080	C0439793
low-risk	T081	C3538919
population	T098	C1257890
women	T098	C0043210
birth at home	T033	C0419367
prevalence	T081	C0220900
perineal injuries	T037	C3544174
SPT	UnknownType	C0559034
episiotomy	T061	C0014586
birth positions	T033	C0243095
Nordic countries	T083	C0036273
population	T098	C1257890
prospective cohort study	T062	C1709709
home births	T033	C0419367
Nordic countries	T083	C0036273
assess medical outcomes	T057	C3824997
questionnaire	T170	C0034394
birth	T040	C0005615
midwife	T097	C0026083
Descriptive statistics	T062	C1710191
bivariate analysis	UnknownType	C0681927
logistic regression	T062	C0206031
data	T078	C1511726
women	T098	C0043210
home births	T033	C0419367
home	T082	C0442519
transfer to hospital	T058	C0184736
prevalence	T081	C0220900
SPT	UnknownType	C0559034
prevalence	T081	C0220900
episiotomy	T061	C0014586
maternal	T033	C1858460
characteristics	T080	C1521970
flexible	T080	C0443220
sacrum	T029	C3669209
positions	T082	C0733755
sutured	T169	C0205368
perineal injuries	T037	C3544174
OR	T081	C0028873
CI	T081	C0009667
SPT	UnknownType	C0559034
OR	T081	C0028873
CI	T081	C0009667
Flexible	T080	C0443220
sacrum	T029	C3669209
positions	T082	C0733755
associated with	T080	C0332281
episiotomies	T061	C0014586
OR	T081	C0028873
CI	T081	C0009667
prevalence	T081	C0220900
SPT	UnknownType	C0559034
episiotomy	T061	C0014586
women	T098	C0043210
home birth	T033	C0419367
Nordic countries	T083	C0036273
Women	T098	C0043210
birth positions	T033	C0243095
birth	T040	C0005615
flexible	T080	C0443220
sacrum	T029	C3669209
positions	T082	C0733755
flexible	T080	C0443220
sacrum	T029	C3669209
positions	T082	C0733755
SPT	UnknownType	C0559034
Flexible	T080	C0443220
sacrum	T029	C3669209
positions	T082	C0733755
associated with	T080	C0332281
episiotomies	T061	C0014586
Parallel-processing	T066	C0597171
continuous-flow device	T074	C0179969
optimization	T052	C2698650
free	T169	C0332296
polymerase chain reaction	T063	C0032520
parallel-processing	T066	C0597171
four-station polymerase chain reaction	T063	C0032520
PCR	T063	C0032520
device	T073	C0699733
performs	T169	C0884358
continuous-flow	T070	C0806140
PCR	T063	C0032520
optimization	T052	C2698650
annealing	T045	C0920681
temperature	T081	C0039476
annealing	T045	C0920681
temperature	T081	C0039476
station	T073	C1883167
controlled	T169	C2587213
independently	T169	C0332291
device	T073	C0699733
covers	T169	C1999244
annealing	T045	C0920681
temperature	T081	C0039476
range	T081	C1514721
wide	T082	C0332464
perform	T169	C0884358
PCR	T063	C0032520
DNA fragment	UnknownType	C0684192
optimum	T080	C2698651
annealing	T045	C0920681
condition	T080	C0348080
arrangement	T169	C0870432
continuously	T078	C0549178
obtain	T169	C1301820
amplified	T067	C1521871
amount	T081	C1265611
DNA fragment	UnknownType	C0684192
stations	T073	C1883167
device	T073	C0699733
identical	T080	C0205280
cylindrical	T082	C0205114
stations	T073	C1883167
diameter	T081	C1301886
height	T032	C0489786
polytetrafluoroethylene	T109	C0032611
capillary reactor	T074	C0376432
length	T081	C1444754
wound helically	T082	C0231467
up	T082	C1282911
around	T078	C0750503
station	T073	C1883167
assembly	T052	C1706853
designed	T052	C1707689
minimize	T080	C1524031
number	T081	C0237753
heating blocks	T074	C0181153
providing	T052	C1999230
temperatures	T081	C0039476
denaturation	T044	C0301642
annealing	T045	C0920681
extension	T169	C0231448
shape	T082	C0332479
compact	T033	C1333134
cube	T082	C1880194
height	T032	C0489786
base	T081	C1626935
reproducibility	T080	C1514863
continuous-flow	T070	C0806140
PCR	T063	C0032520
high	T080	C0205250
run	T169	C1704688
run	T169	C1704688
station	T073	C1883167
station	T073	C1883167
standard deviation	T081	C0871420
amplification	T045	C0683230
Performance	T052	C1882330
optimization	T052	C2698650
free	T169	C0332296
DNA amplification	T045	C0683230
evaluated	T058	C0220825
DNA samples	T026	C0444245
different	T080	C1705242
annealing	T045	C0920681
conditions	T080	C0348080
product	T071	C1514468
sizes	T082	C0456389
demonstrated	T080	C0443289
cases	T169	C0868928
PCR	T063	C0032520
successful	T080	C1272703
station	T073	C1883167
addition	T169	C0332287
DNA fragment	UnknownType	C0684192
different	T080	C1705242
lengths	T081	C1444754
successfully	T080	C1272703
amplified	T067	C1521871
segmented	T082	C0442059
flow	T070	C0806140
mode	T169	C1513371
contamination	T078	C2349974
segments	T082	C0442059
result	T169	C1274040
device	T073	C0699733
PCR	T063	C0032520
module	T077	C1709061
continuous-flow	T070	C0806140
high-throughput on-line total DNA analysis	T060	C0872186
system	T169	C0449913
integrating	T080	C0205195
modules	T077	C1709061
cell	T025	C0007634
lysis	T046	C0024348
DNA extraction	T063	C3839098
PCR	T063	C0032520
product	T071	C1514468
analysis	T062	C0936012
Assessing	T052	C1516048
sex-differences	T032	C0036866
effect	T080	C1280500
timing	T079	C0449243
vaccination	T061	C0042196
immunogenicity	T038	C4277607
reactogenicity	T033	C1691781
efficacy of vaccines	T033	C3242199
young	T079	C0332239
children	T100	C0008059
study protocol	T170	C2348563
individual	T098	C0237401
participant	T098	C0679646
data	T078	C1511726
meta-analysis	T062	C0920317
randomised controlled trials	T062	C0206035
Disease	T047	C0012634
incidence	T081	C0021149
males	T032	C0086582
females	T032	C0086287
infectious	T047	C0009450
inflammatory diseases	T047	C1290884
Sex-differences	T032	C0036866
immune responses	T042	C0301872
vaccines	T121	C0042210
viral vaccines	T121	C0042742
adults	T100	C0001675
evidence	T078	C3887511
available	T169	C0470187
sex-differences	T032	C0036866
response	T033	C1704632
immunisation	T061	C0020971
infancy	T079	C0231330
age group	T100	C0027362
vaccines	T121	C0042210
administered	T169	C1521801
Factors	T169	C1521761
sex	T032	C1522384
timing	T079	C0449243
coadministration	T061	C1533734
vaccines	T121	C0042210
influence	T077	C4054723
immune response	T042	C0301872
vaccination	T061	C0042196
Individual	T098	C0237401
participant	T098	C0679646
data	T078	C1511726
meta-analysis	T062	C0920317
randomised controlled trials	T062	C0206035
vaccines	T121	C0042210
infants	T100	C0021270
young	T079	C0332239
children	T100	C0008059
data	T078	C1511726
randomised controlled trials	T062	C0206035
accines	T121	C0042210
diphtheria	T047	C0012546
tetanus	T047	C0039614
Bordetella pertussis	T007	C0006017
polio	T047	C0032371
Haemophilus influenzae type B	T007	C0121772
hepatitis B	T047	C0019163
Streptococcus pneumoniae	T007	C0038410
Neisseria meningitidis	T007	C0027575
measles	T047	C0025007
mumps	T047	C0026780
rubella	T047	C0035920
varicella	T047	C0008049
rotavirus	T005	C0035870
analysis	T062	C0936012
Outcomes	T169	C1274040
measures	T169	C1879489
immunogenicity	T038	C4277607
immunoglobulins	T116	C0021027
reactogenicity	T033	C1691781
safety	T068	C0036043
disease	T047	C0012634
clinical efficacy	T080	C3850123
Data	T078	C1511726
trials	T062	C0008976
vaccines	T121	C0042210
components	T073	C0449432
hierarchical	T169	C0699032
models	T170	C3161035
effect	T080	C1280500
sex	T032	C1522384
timing	T079	C0449243
vaccinations	T061	C0042196
outcome	T169	C1274040
Systematic reviews	T170	C1955832
published	T057	C0034037
sex-differences	T032	C0036866
answer questions	T061	C0508431
field	T077	C1521738
comparisons	T052	C1707455
purpose	T169	C1285529
clinical trial	T062	C0008976
large	T081	C0549177
degree	T081	C0449286
reporting	T058	C0700287
bias	T078	C0242568
exists	T077	C2987476
published	T057	C0034037
literature	T170	C0023866
improvements	T077	C2986411
widespread	T082	C0205391
availability of	T169	C0470187
individual	T098	C0237401
participant	T098	C0679646
data	T078	C1511726
randomised controlled trials	T062	C0206035
extensive	T080	C0205231
individual	T098	C0237401
participant	T098	C0679646
data	T078	C1511726
meta-analyses	T062	C0920317
previously	T079	C0205156
impossible	T033	C0243095
reducing	T080	C0392756
effect	T080	C1280500
publication	T073	C0034036
reporting	T058	C0700287
bias	T078	C0242568
understanding	T041	C0162340
infant	T100	C0021270
immune response	T042	C0301872
Preliminary results	T078	C1548161
available	T169	C0470187
results	T169	C1274040
available	T169	C0470187
No	T169	C0332197
ethics	T078	C0015000
review	T170	C0282443
secondary analyses	UnknownType	C0683944
data	T078	C1511726
ultrasensitive	T169	C0332324
electrochemiluminescence	T059	C3830326
sensor	T073	C0183210
reduced graphene oxide	T196	C2936695
copper sulfide	T197	C0389357
composite	T080	C0205199
capillary electrophoresis	T059	C0201699
determination	T059	C1148554
amlodipine besylate	T109	C0354468
mice	T015	C0025929
plasma	T031	C0032105
electrochemiluminescence	T059	C3830326
ECL	T059	C3830326
sensor	T073	C0183210
reduced graphene oxide	T196	C2936695
copper sulfide	T197	C0389357
rGO	T196	C2936695
CuS	T197	C0389357
composite	T080	C0205199
capillary electrophoresis	T059	C0201699
CE	T059	C0201699
ultrasensitive	T169	C0332324
detection	T061	C1511790
amlodipine besylate	T109	C0354468
AML	T109	C0354468
rGO	T196	C2936695
CuS	T197	C0389357
composite	T080	C0205199
hydrothermal method	T169	C0449851
electrode	T074	C0013812
modification	T033	C3840684
electrochemical	T059	C2350499
ECL	T059	C3830326
sensor	T073	C0183210
investigated	T169	C1292732
enhance	T052	C2349975
ECL	T059	C3830326
intensity	T081	C0871362
observed	T169	C1441672
rGO	T196	C2936695
CuS	T197	C0389357
composite	T080	C0205199
results	T034	C0456984
presence	T080	C3854307
rGO	T196	C2936695
CuS	T197	C0389357
composite	T080	C0205199
electrode	T074	C0013812
surface	T082	C0205148
electron transfer rate	T081	C1521828
electroactive	T169	C0205177
center	T082	C0205099
Ru(bpy)3(2+)	T104	C1704241
electrode	T074	C0013812
ECL	T059	C3830326
sensor	T073	C0183210
coupled	T169	C1948027
CE	T059	C0201699
selectivity	T034	C1254595
CE	T059	C0201699
ECL	T059	C3830326
parameters	T033	C0449381
separation	UnknownType	C0678621
detection	T061	C1511790
optimum	T080	C2698651
linear ranges	T081	C1514721
AML	T109	C0354468
detection limit	T081	C2718050
method	T059	C0871511
high sensitivity	T067	C2346484
good selectivity	T034	C1254595
linear range	T081	C1514721
detection limit	T081	C2718050
fine reproducibility	T080	C1514863
AML	T109	C0354468
mice	T015	C0025929
plasma	T031	C0032105
result	T034	C0456984
potential	T080	C3245505
pharmaceutical analysis	T062	C0936012
Estrogen	T109	C0014939
Progesterone	T109	C0033308
hormone	T125	C0019932
receptor expression	T045	C0597360
oral cavity cancer	T191	C0151546
increase	T169	C0442805
incidence	T081	C0021149
oral squamous cell carcinoma	T191	C0585362
OSCC	T191	C0585362
younger	T079	C0332239
patients	T101	C0030705
hypothesis	T078	C1512571
tumors	T191	C0027651
hormonally	T125	C0019932
induced	T169	C0205263
pregnancy	T040	C0032961
young	T079	C0332239
female	T032	C0086287
patients	T101	C0030705
risk factors	T033	C0035648
alcohol	T048	C0085762
tobacco abuse	T048	C0040336
Estrogen Receptor alpha	T116	C0665341
ERα	T116	C0665341
Progesterone Receptor	T116	C0034833
PR	T116	C0034833
expression	T045	C0597360
analyzed	T062	C0936012
oral mucosa	T023	C0026639
oral precursor lesions	T033	C0221198
simple hyperplasia	T047	C0456483
squamous intraepithelial neoplasia	T191	C1302751
SIN I-III	T191	C1302751
OSCC	T191	C0585362
specimen	T167	C0370003
OSCCs	T191	C0585362
stratified	T080	C0205363
young	T079	C0332239
female	T032	C0086287
cohort	T098	C0599755
older	T098	C3826770
patients	T101	C0030705
young	T079	C0332239
female	T032	C0086287
cohort	T098	C0599755
patients	T101	C0030705
OSCC	T191	C0585362
pregnancy	T040	C0032961
Breast cancer	T191	C0678222
tissues	T024	C0040300
positive control	T077	C1883676
ERα	T116	C0665341
PR	T116	C0034833
expression	T045	C0597360
ERα	T116	C0665341
expression	T045	C0597360
oral precursor lesions	T033	C0221198
squamous intraepithelial neoplasia	T191	C1302751
SIN I-III	T191	C1302751
OSCC	T191	C0585362
specimen	T167	C0370003
ERα	T116	C0665341
positive	T033	C1446409
OSCC	T191	C0585362
samples	T167	C0370003
older	T098	C3826770
male	T032	C0086582
patients	T101	C0030705
patients	T101	C0030705
young	T079	C0332239
female	T032	C0086287
cohort	T098	C0599755
negatively	T033	C0205160
ERα	T116	C0665341
PR	T116	C0034833
ER	T116	C0034804
expression	T045	C0597360
seldom	T080	C0522498
risk factor	T033	C0035648
OSCC	T191	C0585362
PR	T116	C0034833
expression	T045	C0597360
relevant	T080	C2347946
development	T169	C1527148
OSCC	T191	C0585362
Studying	T062	C0681814
neuroprotective effect	T169	C0815279
Atorvastatin	T109	C0286651
small molecule	T109	C1328819
drug	T121	C1254351
high glucose	T033	C0860803
induced	T169	C0205263
neurotoxicity	T037	C0235032
undifferentiated	T080	C0205618
PC12 cells	T025	C0085262
role	T077	C1705810
NADPH oxidase	T116	C0068355
Overproduction	T080	C0205556
reactive oxygen species	T123	C0162772
ROS	T123	C0162772
NADPH oxidase	T116	C0068355
NOX	T116	C0068355
activation	T044	C0014429
considered	T078	C0750591
essential	T080	C0205224
mechanism	T169	C0441712
induced	T169	C0205263
hyperglycemia	T047	C0020456
tissues	T024	C0040300
no comprehensive	T080	C0205556
study	T062	C0681814
role	T077	C1705810
NOXs	T116	C0068355
high glucose	T033	C0860803
HG	T033	C0860803
induced	T169	C0205263
toxic effect	T037	C0600688
neural tissues	T024	C0027757
therapeutic	T169	C0302350
strategy	T041	C0679199
oxidative	T169	C0311404
related	T080	C0439849
pathologies	T091	C0030664
introduced	T169	C1292748
blocking	T169	C0332206
undesirable actions	T052	C3266814
NOX enzymes	T116	C0068355
small molecules	T109	C1328819
protective	T033	C1545588
roles	T077	C1705810
Statins	T109	C0360714
ameliorating	T080	C0205556
oxidative stress	T049	C0242606
NOX	T116	C0068355
inhibition	T039	C1524081
tissues	T024	C0040300
neural	T024	C0027757
hypothesized	T078	C1512571
different	T080	C1705242
NOXs	T116	C0068355
role	T077	C1705810
HG	T033	C0860803
induced	T169	C0205263
neural cell injury	T049	C0599732
postulate	T078	C1705535
Atorvastatin	T109	C0286651
small molecule	T109	C1328819
modulate	T082	C0443264
NOXs activity	T044	C1151146
protect	T033	C1545588
neural cells	T025	C0027882
Undifferentiated	T080	C0205618
PC12 cells	T025	C0085262
treated with	T061	C0332293
HG	T033	C0860803
24 h	T079	C0456696
presence	T033	C0150312
absence	T169	C0332197
Atorvastatin	T109	C0286651
96 h	T079	C0439227
cell viability	T043	C0007620
measured	T080	C0444706
MTT assay	T062	C2986858
gene	T081	C1956267
protein expressions profile	T034	C3463810
NOX	T116	C0068355
determined by	T080	C0521095
RT-PCR	T063	C0599161
western blotting	T059	C0005863
Levels	T080	C0441889
ROS	T123	C0162772
malondialdehyde	T109	C0024643
MDA	T109	C0024643
evaluated	T052	C1516048
Gene	T045	C0017262
protein expression	T045	C1171362
levels	T080	C0441889
NOX	T116	C0068355
consequently	T033	C3845876
ROS	T123	C0162772
MDA	T109	C0024643
levels	T080	C0441889
elevated	T080	C3163633
HG	T033	C0860803
treated	T169	C1522326
PC12 cells	T025	C0085262
Atorvastatin	T109	C0286651
significantly	T078	C0750502
decrease	T081	C0547047
HG	T033	C0860803
induced	T169	C0205263
NOXs	T116	C0068355
ROS	T123	C0162772
MDA	T109	C0024643
elevation	T082	C0702240
improve	T033	C0184511
impaired	T169	C0221099
cell viability	T043	C0007620
concluded	T078	C1707478
HG	T033	C0860803
elevate	T080	C3163633
NOXs activity	T044	C1151146
ROS	T123	C0162772
MDA	T109	C0024643
levels	T080	C0441889
neural tissues	T024	C0027757
Atorvastatin	T109	C0286651
small molecule	T109	C1328819
NOX inhibitor drug	T121	C1254351
prevent	T080	C2700409
delay	T079	C0205421
diabetic complications	T047	C0342257
neuropathy	T047	C0442874
Intravascular	T082	C0442123
Inflammation	T046	C0021368
Triggers	T080	C1444748
Intracerebral	T082	C0442111
Activated	T052	C1879547
Microglia	T025	C0206116
Secondary Brain Injury	T037	C0270611
Experimental	T080	C1517586
Subarachnoid Hemorrhage	T047	C0038525
eSAH	T047	C0038525
Activation	T052	C1879547
innate immunity	T032	C0020969
secondary brain injury	T037	C0270611
experimental	T080	C1517586
subarachnoid hemorrhage	T047	C0038525
eSAH	T047	C0038525
Microglia	T025	C0206116
accumulation	T033	C4055506
activation	T052	C1879547
brain	T023	C0006104
neuronal cell death	T043	C2754100
eSAH	T047	C0038525
isolated	T169	C0205409
mouse	T015	C0025929
brain	T023	C0006104
capillaries	T023	C0935624
eSAH	T047	C0038525
gene expression	T045	C0017262
intercellular adhesion molecule-1	T028	C1334074
ICAM-1	T028	C1334074
P-selectin	T028	C1335809
hypothesized	T078	C1512571
extracerebral	T082	C1254362
intravascular	T082	C0442123
inflammatory processes	T046	C1155266
reported	T058	C0700287
microglia	T025	C0206116
accumulation	T033	C4055506
brain tissue	T023	C0459385
eSAH	T047	C0038525
knockout mice	T015	C0206745
ICAM-1	T028	C1334074
ICAM-1(-/-)	T028	C1334074
P-selectin glycoprotein ligand-1	T028	C1419941
PSGL-1(-/-)	T028	C1419941
neutrophil	T025	C0027950
endothelial	T025	C0225336
interaction	T043	C0007582
bleeding	T046	C0019080
chronic	T079	C0205191
cranial	T082	C3163632
window model	T075	C0026339
inhibition	T052	C3463820
neutrophil recruitment	T039	C0751982
endothelium	T025	C0225336
ameliorated	T033	C0243095
microglia	T025	C0206116
accumulation	T033	C4055506
neuronal cell death	T043	C2754100
knockout animals	T008	C1171353
activation	T052	C1879547
CNS innate	T022	C3714787
immune system	T022	C0020962
vessel	T029	C0042591
brain	T023	C0006104
eSAH	T047	C0038525
Microglia	T025	C0206116
cells	T025	C0007634
brain's	T023	C0006104
innate immune system	T032	C0020969
triggered	T080	C1444748
inflammatory reaction	T046	C0021368
microvasculature	T042	C0243079
eSAH	T047	C0038525
neuronal cell death	T043	C2754100
research	T062	C0035168
targets	T169	C1521840
therapy	T169	C0039798
patients	T101	C0030705
eSAH	T047	C0038525
Amphetamine Withdrawal	T048	C0236665
Expression	T045	C1171362
Organic Cation Transporter 3	T116	C1453697
Serotonin Transporter	T116	C0170657
Limbic	T022	C0023715
Brain Regions	T023	C0006104
Amphetamine withdrawal	T048	C0236665
anxiety	T033	C0003467
stress	T033	C0038435
blunted	T080	C1997138
ventral	T082	C1704448
hippocampus	T023	C0019564
vHipp	T023	C0019564
central nucleus of the amygdala	T023	C0175219
CeA	T023	C0175219
serotonin	T109	C0036751
responses	T032	C0871261
Extracellular	T026	C0521119
serotonin	T109	C0036751
levels	T080	C0441889
serotonin transporter	T116	C0170657
SERT	T116	C0170657
organic cation transporter 3	T116	C1453697
OCT3	T116	C1453697
vHipp	T023	C0019564
OCT3	T116	C1453697
expression	T045	C1171362
24 hours	T079	C1442770
amphetamine withdrawal	T048	C0236665
SERT	T116	C0170657
expression	T045	C1171362
OCT3	T116	C1453697
SERT	T116	C0170657
expression	T045	C1171362
CeA	T023	C0175219
withdrawal	T048	C2825032
limbic	T022	C0023715
serotonergic neurotransmission	T043	C2262837
two weeks	T079	C4082118
withdrawal	T048	C2825032
transporter	T116	C0596902
expression	T045	C1171362
Male	T032	C0086582
rats	T015	C0004728
amphetamine	T109	C0002658
saline	T167	C0036082
two weeks	T079	C4082118
24 hours	T079	C1442770
two weeks	T079	C4082118
withdrawal	T048	C2825032
transporter	T116	C0596902
expression	T045	C1171362
Western immunoblot	T059	C0949466
OCT3	T116	C1453697
SERT	T116	C0170657
expression	T045	C1171362
CeA	T023	C0175219
withdrawal	T048	C2825032
vHipp	T023	C0019564
OCT3	T116	C1453697
expression	T045	C1171362
24 hours	T079	C1442770
withdrawal	T048	C2825032
dorsomedial hypothalamus	T023	C0013055
No changes	T033	C0442739
regions	T029	C0005898
limbic	T022	C0023715
OCT3	T116	C1453697
SERT	T116	C0170657
expression	T045	C1171362
serotonergic	T109	C0036751
imbalance	T184	C1397014
negative affect	T033	C1513916
amphetamine withdrawal	T048	C0236665
Nutritional aspects	T169	C0868998
night	T079	C0240526
eating	T040	C0013470
association with	T080	C0332281
weight	T032	C0005910
status	T080	C0449438
Korean	T098	C1556095
adolescents	T100	C0205653
growing	T169	C0205245
research	T062	C0035168
night	T079	C0240526
eating	T040	C0013470
associated with	T080	C0332281
poor diet	T033	C0588012
quality	T080	C0332306
negative	T033	C0205160
health outcomes	T170	C1550208
study	T170	C0085973
nutritional aspects	T169	C0868998
night	T079	C0240526
eating	T040	C0013470
factors	T169	C1521761
association	T080	C0439849
night	T079	C0240526
eating	T040	C0013470
body weight	T032	C0005910
Korean	T098	C1556095
adolescents	T100	C0205653
study	T170	C0085973
data	T078	C1511726
day	T079	C0439228
dietary recall	T062	C0242481
demographic survey	T062	C0011296
Korean	T098	C1556095
adolescents	T100	C0205653
years	T079	C0439234
Korea	T083	C0022771
National Health and Nutrition Examination Survey	T062	C0376344
Night	T079	C0240526
eating	T040	C0013470
daily energy intake	T081	C0564415
Subjects	T098	C0080105
condition	T080	C0348080
night	T079	C0240526
eaters	T098	C1257890
non-night eaters	T098	C1257890
Logistic regression analysis	UnknownType	C0681925
factors	T169	C1521761
night	T079	C0240526
eating	T040	C0013470
Multiple linear regression analyses	T081	C0023733
relationship	T080	C0439849
night	T079	C0240526
eating	T040	C0013470
BMI	T201	C1305855
z-scores	T081	C0871421
multinomial logistic regression analysis	UnknownType	C0681925
relationship	T080	C0439849
night	T079	C0240526
eating	T040	C0013470
weight	T032	C0005910
status	T080	C0449438
Korean	T098	C1556095
adolescents	T100	C0205653
night	T079	C0240526
eaters	T098	C1257890
Night	T079	C0240526
eaters	T098	C1257890
increased	T081	C0205217
breakfast	T056	C2698559
skipping	T033	C0560435
energy intake	T081	C0006777
snacks	T168	C0453863
proportion of energy intake from fat	T081	C0564429
lower Dietary Diversity Scores	T081	C0449820
non-night eaters	T098	C1257890
Male	T032	C0086582
adolescents	T100	C0205653
times	T081	C1632851
night	T079	C0240526
eaters	T098	C1257890
females	T032	C0086287
Adolescents	T100	C0205653
parents	T099	C0030551
night	T079	C0240526
eaters	T098	C1257890
times	T081	C1632851
night	T079	C0240526
eaters	T098	C1257890
parents	T099	C0030551
Female	T032	C0086287
adolescents	T100	C0205653
relationship	T080	C0439849
night	T079	C0240526
eating	T040	C0013470
BMI	T201	C1305855
z-scores	T081	C0871421
night	T079	C0240526
eating	T040	C0013470
increase	T169	C0442805
overweight	T184	C0497406
obese	T047	C0028754
adolescents	T100	C0205653
Night	T079	C0240526
eating	T040	C0013470
Korean	T098	C1556095
adolescents	T100	C0205653
undesirable dietary behaviours	T033	C4019289
low diet quality	T033	C2136285
BMI	T201	C1305855
z-scores	T081	C0871421
females	T032	C0086287
Male	T032	C0086582
gender	T032	C0079399
parental	T099	C0030551
night	T079	C0240526
eating	T040	C0013470
factors	T169	C1521761
increased	T081	C0205217
night	T079	C0240526
eating	T040	C0013470
night	T079	C0240526
eating	T040	C0013470
nutrition education	T065	C0204934
intervention programs	T061	C0599917
adolescents	T100	C0205653
randomized trial	T062	C0206034
Plasma-Lyte A	T121	C0071213
0.9 % sodium chloride	T121	C1725399
acute pediatric gastroenteritis	T047	C0267446
efficacy	T080	C1280519
Plasma-Lyte A	T121	C0071213
PLA	T121	C0071213
0.9 % sodium chloride	T121	C1725399
NaCl	T121	C1725399
intravenous (IV) fluid replacement	T061	C0559692
children	T100	C0008059
severe dehydration	T047	C3472181
acute gastroenteritis	T047	C0267446
AGE	T047	C0267446
Prospective	T062	C0033522
randomized	T062	C0034656
double-blind study	T062	C0013072
pediatric	T080	C1521725
emergency departments	T073	C0562508
EDs	T073	C0562508
US	T083	C0041703
Canada	T083	C0006823
primary outcome measure	T080	C3274433
serum bicarbonate level	T034	C1261426
Secondary outcomes	T080	C3274440
tolerability	T062	C3274448
hypothesis	T078	C1512571
PLA	T121	C0071213
0.9 % NaCl	T121	C1725399
improvement of 4-h bicarbonate	T059	C0202059
Patients	T101	C0030705
AGE	T047	C0267446
severe dehydration	T047	C3472181
Patients	T101	C0030705
baseline	T081	C1442488
bicarbonate level	T034	C0428196
formed	T169	C0205431
modified	T169	C0392747
intent to treat	T169	C1292734
mITT	T169	C1292734
group	T098	C1257890
baseline	T081	C1442488
treatment	T061	C0087111
groups	T098	C1257890
PLA	T121	C0071213
group	T098	C1257890
PLA	T121	C0071213
group	T098	C1257890
increases in serum bicarbonate	T033	C0858078
baseline	T081	C1442488
0.9 % NaCl	T121	C1725399
group	T098	C1257890
baseline	T081	C1442488
treatment	T061	C0087111
groups	T098	C1257890
fluid volumes	T081	C0449971
PLA	T121	C0071213
group	T098	C1257890
abdominal pain	T184	C0000737
dehydration	T047	C0011175
patient	T101	C0030705
clinically relevant worsening	T078	C1546960
laboratory findings	T034	C0587081
physical examination	T058	C0031809
hospital admission rates	T081	C0598610
similar	T080	C2348205
patient	T101	C0030705
treatment	T061	C0087111
group	T098	C1257890
hyponatremia	T047	C0020625
patients	T101	C0030705
hyperkalemia	T033	C0020461
PLA	T121	C0071213
0.9 % NaCl	T121	C1725399
comparison	T052	C1707455
0.9 % NaCl	T121	C1725399
PLA	T121	C0071213
rehydration	T061	C0034997
children	T100	C0008059
AGE	T047	C0267446
improvement in serum bicarbonate	T059	C0428301
dehydration	T047	C0011175
relationships	T080	C0439849
symptoms	T184	C1457887
quality of life	T078	C0034380
course	T079	C0750729
cognitive-behavioral therapy	T061	C0009244
panic disorder	T048	C0030319
Japan	T083	C0022341
study	T062	C2603343
examined	T033	C0332128
relationships	T080	C0439849
changes	T169	C0392747
symptoms	T184	C1457887
changes	T169	C0392747
quality of life	T078	C0034380
QOL	T078	C0034380
cognitive-behavioral therapy	T061	C0009244
CBT	T061	C0009244
panic disorder	T048	C0030319
PD	T048	C0030319
treated	T169	C1522326
PD	T048	C0030319
patients	T101	C0030705
CBT	T061	C0009244
Japan	T083	C0022341
multiple regression analysis	T170	C0034980
examined	T033	C0332128
associations	T080	C0439849
changes	T169	C0392747
QOL	T078	C0034380
changes	T169	C0392747
PD	T048	C0030319
symptoms	T184	C1457887
comorbid psychological symptoms	T184	C0233397
CBT	T061	C0009244
Changes	T169	C0392747
anticipatory anxiety	T033	C0231397
agoraphobic fear	T048	C0233702
avoidance	T041	C0870186
somatization	T048	C0149779
predictors	T078	C2698872
changes	T169	C0392747
QOL	T078	C0034380
somatization	T048	C0149779
anticipatory anxiety	T033	C0231397
agoraphobic fear	T048	C0233702
QOL	T078	C0034380
CBT	T061	C0009244
PD	T048	C0030319
Coupling	T169	C1948027
TRPV6	T116	C1452353
TMEM16A	T116	C2976269
epithelial principal cells	T025	C0014597
rat epididymis	T023	C1882657
epididymis	T023	C0014533
congenial	T080	C1524057
environment	T082	C0014406
sperm maturation	T042	C0037846
protection	T033	C1545588
fluid	T031	C0005889
acidic	T081	C0920750
calcium	T121	C0006675
concentration	T081	C1446561
low	T080	C0205251
length	T081	C1444754
epididymal tubule	T023	C0014533
ionic currents	T043	C0162585
mechanisms	T169	C0441712
calcium homeostasis	T043	C1156269
rat epididymal	T023	C1882657
epithelial cells	T025	C0014597
study	T062	C2603343
calcium regulation	T043	C1156269
epididymis	T023	C0014533
patch-clamp method	T062	C0242625
rat	T015	C0034693
cauda epididymal	T023	C0228024
principal cells	T025	C0007634
detect	T033	C0442726
active	T169	C0205177
Ca(2+)	T121	C0596235
current	T043	C0162585
characteristics	T080	C1521970
epithelial	T024	C0014609
calcium channel	T116	C0006685
TRPV6	T116	C1452353
Electrophysiological	T060	C0850293
pharmacological data	T060	C1831759
active calcium-activated chloride conductance	T116	C1956140
CaCC	T116	C1956140
extracellular	T026	C0521119
calcium	T121	C0006675
attenuates	T052	C0599946
TRPV6	T116	C1452353
conductance	UnknownType	C0678840
CaCC	T116	C1956140
Lanthanide	T196	C0205838
block	T169	C0332206
time	T079	C0040223
dependent	T080	C0851827
TRPV6	T116	C1452353
inhibited	T043	C1516145
CaCC	T116	C1956140
CaCC	T116	C1956140
blocker	T121	C0870261
niflumic acid	T109	C0028067
inhibits	T043	C1516145
whole-cell	T025	C0007634
currents	T043	C0162585
La(3+)	T197	C0534702
whole-cell	T025	C0007634
currents	T043	C0162585
principal cells	T025	C0007634
Membrane potential	T043	C0025251
measurements	T169	C0242485
La(3+)	T197	C0534702
sensitive ion channels	T116	C0022009
sensitive	T169	C0332324
specific	T170	C1552740
TMEM16A	T116	C2976269
inhibitor	T120	C0243077
tannic acid	T109	C0039294
In vivo	T082	C1515655
perfusion	T061	C0031001
cauda epididymal tubule	T023	C0228024
Ca(2+)	T121	C0596235
reabsorption	T039	C3852988
luminal side	T082	C0524462
suppressed	T169	C1260953
ruthenium red	T130	C0035975
blocker	T121	C0870261
epithelial	T024	C0014609
Ca(2+) channels	T116	C0006685
CaCC	T116	C1956140
messenger RNA	T114	C0035696
TRPV6	T116	C1452353
TMEM16A	T116	C2976269
rat epididymis	T023	C1882657
proteins	T116	C0033684
colocalize	T082	C0392752
apical membrane	T026	C0596119
principal cells	T025	C0007634
data	T078	C1511726
evidence	T078	C3887511
coupling	T169	C1948027
mechanism	T169	C0441712
TRPV6	T116	C1452353
TMEM16A	T116	C2976269
principal cells	T025	C0007634
regulation of calcium homeostasis	T043	C1156269
epididymis	T023	C0014533
Conversation	T054	C0871703
Allen J. Wilcox	T016	C0086418
Allen James Wilcox	T016	C0086418
Columbus, OH	T083	C3831044
medicine	T091	C0025118
University of Michigan	T073	C0041740
internship	T065	C0237690
completed a master's degree	T033	C2030948
maternal and child health	T091	C4035700
PhD	T170	C1512022
epidemiology	T091	C0014507
University of North Carolina	T073	C0041740
Chapel Hill	T083	C0017446
graduation	T065	C1711333
work	T057	C0043227
National Institute of Environmental Health Sciences	T093	C1955979
NIEHS	T093	C1955979
US National Institutes of Health	T093	C0027468
Durham, NC	T083	C3830368
career	T057	C0178534
research program	T062	C0683935
perinatal epidemiology	T091	C1518977
early pregnancy	T047	C0747845
documented	T058	C1301725
subclinical	T080	C0205211
pregnancy loss	T046	C0687675
humans	T016	C0086418
established	T080	C0443211
fertile days	T079	C0015894
woman's	T098	C0043210
menstrual cycle	T040	C0025329
Chief of	T097	C1706996
Epidemiology	T091	C0014507
Branch	T097	C1706131
Editor-in-Chief	T097	C1522486
journal	T073	C0162443
EPIDEMIOLOGY	T091	C0014507
textbook	T073	C0039712
Fertility and Pregnancy-An Epidemiologic Perspective	T073	C0039712
published	T057	C0034037
Oxford University Press	T170	C1552679
elected	UnknownType	C0682233
American Epidemiological Society	T093	C1708333
president	T090	C0028811
president	T090	C0028811
Society of Pediatric and Perinatal Epidemiological Research	T093	C1708333
president	T090	C0028811
Society of Epidemiological Research	T093	C1708333
teaching	T065	C0220924
appointments	T079	C0003629
University of North Carolina	T073	C0041740
Harvard University	T073	C0041740
University of Bergen	T073	C0041740
Norway	T083	C0028423
awarded	T073	C0004446
honorary	T080	C2985253
doctoral degree	T170	C1512027
Evaluation	T058	C0220825
Spontaneous	T169	C0205359
Bone Regeneration	T042	C0005972
Enucleation	T061	C0014392
Large	T081	C0549177
Cysts	T047	C0010709
Jaws	T023	C0022359
Radiographic	T070	C0444708
Computed	T059	C1441526
Software	T073	C0037585
Spontaneous	T169	C0205359
regeneration of bone	T042	C0005972
commonly	T081	C0205214
small	T081	C0700321
surgical	T061	C0543467
defects	T169	C1457869
enucleation	T061	C0014392
cysts	T047	C0010709
large	T081	C0549177
surgical	T061	C0543467
defects	T169	C1457869
enucleation	T061	C0014392
spontaneous	T169	C0205359
regeneration of bone	T042	C0005972
rare	T080	C0522498
phenomenon	T067	C1882365
depends	T080	C1701901
factors	T169	C1521761
age	T032	C0001779
patient	T101	C0030705
intact	T080	C0205266
periosteum	T024	C0031110
stabilization	T061	C1293130
study	T062	C2603343
included	T169	C0332257
patients	T101	C0030705
reported	T058	C0700287
department of oral and maxillofacial surgery	T073	C0019961
complaint	T047	C0012634
pain	T184	C0030193
swelling	T033	C0038999
jaws	T023	C0022359
diagnosed	T033	C0011900
cyst	T047	C0010709
sample	T077	C2347026
included	T169	C0332257
numbers	T081	C0237753
male	T032	C0086582
female	T032	C0086287
subjects	T096	C0681850
aged	T032	C0001779
Panoramic radiographs	T060	C0034579
pre-	T079	C0445204
postoperatively	T079	C0032790
enucleation	T061	C0014392
dimensions	T081	C0439534
cyst	T047	C0010709
evaluated	T058	C0220825
radiograph	T060	C1306645
proforma	T169	C0205245
Subsequent	T079	C0332282
radiographs	T060	C1306645
regular	T080	C0205272
intervals	T079	C1272706
standard	T081	C0034925
parameters	T077	C0549193
analyzed	T062	C0936012
MCID™ analysis	T170	C3203917
software	T073	C0037585
imaging research	T060	C1881134
Mean	T081	C0444504
reduction	T061	C0441610
cystic	T080	C0205207
cavity	T190	C1510420
size	T082	C0456389
increase	T169	C0442805
mean	T081	C0444504
density	T081	C0178587
intervals	T079	C1272706
Spontaneous	T169	C0205359
bone regeneration	T042	C0005972
primary	T080	C0205225
closure	T061	C0185003
large	T081	C0549177
cystic	T080	C0205207
defect	T169	C1457869
need	T080	C0027552
placement	T058	C0441587
foreign substances	T167	C0729652
grafts	T122	C0181074
eliminated	T080	C0849355
complications	T046	C0009566
resulting from	T169	C0678226
placement	T058	C0441587
foreign substance	T167	C0729652
studies	T062	C2603343
required	T169	C1514873
larger	T081	C0549177
sample	T077	C2347026
longer	T080	C0205166
follow-up	T058	C1522577
durations	T079	C0449238
confirm	T080	C1456348
outcome of the present work	T080	C0085415
benefit	T081	C0814225
patients	T101	C0030705
present	T079	C0521116
study	T062	C2603343
spontaneous	T169	C0205359
bone regeneration	T042	C0005972
accepted	T080	C1272684
results	T033	C0808233
simple	T080	C0205352
enucleation	T061	C0014392
jaw	T023	C0022359
cyst	T047	C0010709
aid	T080	C1269765
graft material	T122	C0181074
simple	T080	C0205352
enucleation	T061	C0014392
considered	T078	C0750591
first line of treatment	T061	C1708063
modality	T078	C0695347
cystic	T080	C0205207
lesion	T033	C0221198
jaws	T023	C0022359
surgical procedure	T061	C0543467
decreases	T081	C0547047
economic	T169	C0013557
biologic	T080	C0205460
costs	T081	C0010186
reduces	T061	C0441610
risk	T078	C0035647
postoperative complications	T046	C0032787
Follow-up	T058	C1522577
patient's	T101	C0030705
compliance	T055	C1321605
success of treatment	T080	C0679864
Membrane Protein Solubilization	T044	C1621323
Composition	T070	C0243176
Protein	T116	C0033684
Detergent	T120	C0011740
Complexes	T104	C1704241
Membrane proteins	T116	C0025252
typically expressed	T045	C1171362
heterologous	T080	C0439860
systems	T169	C0449913
in vitro	T062	C0681828
characterization	T052	C1880022
critical step	T077	C1261552
preparation	T052	C1521827
membrane proteins	T116	C0025252
expression	T045	C1171362
system	T169	C0449913
solubilization of the protein	T044	C1621323
aqueous solution	T121	C3255993
detergents	T120	C0011740
lipids	T109	C0023779
protein	T116	C0033684
suitable	T080	C3900053
purification	T169	C0243114
structural	T061	C0204514
functional	T169	C0205245
analysis	T062	C0936012
process	T067	C1522240
protein	T116	C0033684
unnatural	T080	C0522502
environment	T082	C0014406
protein	T116	C0033684
detergent	T120	C0011740
complex	T104	C1704241
natural	T169	C0205296
lipid	T109	C0023779
minimum	T080	C1524031
destabilization	T043	C1622120
modification	T033	C3840684
structure	T082	C0678594
process	T067	C1522240
difficult	T080	C0332218
increasing	T169	C0442808
membrane proteins	T116	C0025252
successfully isolated	T169	C0205409
expression	T045	C1171362
systems	T169	C0449913
general protocol	T170	C2348563
protein	T116	C0033684
detergent	T120	C0011740
complexes	T104	C1704241
critical steps	T077	C1261552
analyze	T062	C0936012
composition	T070	C0243176
protein	T116	C0033684
detergent	T120	C0011740
complexes	T104	C1704241
analysis	T062	C0936012
compositional	T070	C0243176
variation	T080	C0205419
Predict	T078	C0681842
Burnout	T048	C0006433
Student Nurses	T097	C0038496
ICWR-1 Model	T170	C0026347
Individual	T098	C0237401
Psychological Resilience	T055	C0683253
nursing work	T091	C0028677
demanding	T061	C0441516
stressful	T169	C0231297
high	T080	C0205250
rate	T081	C1521828
burnout	T048	C0006433
employed	T033	C0557351
nurses	T097	C0028661
resilience	T055	C0683253
psychological adjustment	T055	C0683269
employed	T033	C0557351
nurses	T097	C0028661
theoretical model	T170	C0026350
resilience	T055	C0683253
includes	T169	C0332257
several	T081	C0443302
constructs	T185	C2827421
literature	T170	C0023866
resilience	T055	C0683253
psychological functioning	T041	C0233398
nursing students	T097	C0038496
future	T079	C0016884
nursing	T091	C0028677
workforce	T097	C2700616
important	T080	C3898777
advance	T079	C3854260
determinants	T169	C1521761
resilience	T055	C0683253
population	T098	C1257890
Student nurses	T097	C0038496
completed	T078	C1556116
final	T079	C3853528
practicum	T065	C0032929
online survey	T170	C0038951
measuring	T080	C0444706
constructs	T185	C2827421
ICWR-1 model	T170	C0026347
students	T097	C0038496
Australia	T083	C0004340
Canada	T083	C0006823
completed	T078	C1556116
survey	T170	C0038951
several	T081	C0443302
demographics	T078	C1704791
trait negative affect	T033	C0233849
mindfulness	T041	C3542996
self-efficacy	T041	C0600564
coping	T055	C0009967
resilience	T055	C0683253
burnout	T048	C0006433
measured	T080	C0444706
structural equation modeling	T062	C0681947
major	T080	C0205164
pathways	T077	C1705987
model	T170	C0026347
resilience	T055	C0683253
significant	T078	C0750502
influence	T077	C4054723
relationship	T080	C0439849
mindfulness	T041	C3542996
self-efficacy	T041	C0600564
coping	T055	C0009967
psychological adjustment	T055	C0683269
burnout	T048	C0006433
scores	T081	C0449820
predicted	T078	C0681842
Neuroticism	T048	C1842981
relationship	T080	C0439849
coping	T055	C0009967
burnout	T048	C0006433
potential	T080	C3245505
approaches	T169	C1292724
nursing students	T097	C0038496
at risk	T080	C1444641
burnout	T048	C0006433
Medication Intervention	T061	C2735670
Chronic Kidney Disease	T047	C1561643
Patients	T101	C0030705
Transitioning	T052	C2700061
Hospital	T073	C0019994
Home	T082	C0442519
Study Design	T062	C0035171
Baseline	T081	C1442488
Characteristics	T080	C1521970
hospital readmission	T058	C0600290
rate	T081	C1521828
population	T098	C1257890
chronic kidney disease	T047	C1561643
CKD	T047	C1561643
risk	T078	C0035647
needed	T080	C0027552
CKD	T047	C1561643
Medication Intervention Trial	T061	C2735670
CKD	T047	C1561643
MIT	T061	C2735670
www.clinicaltrials.gov; NCTO1459770	T170	C4287891
single-blind	T062	C0037181
investigators	T097	C0008961
randomized	T062	C0034656
clinical trial	T062	C0008976
Providence Health Care	T058	C0086388
Spokane, Washington	T083	C3827207
Study participants	T096	C0681850
hospitalized patients	T101	C0870668
CKD	T047	C1561643
stages	T079	C1306673
treated with	T061	C0332293
kidney replacement therapy	T061	C0206074
acute illness	T046	C4061114
study intervention	T170	C1096775
pharmacist-led	T097	C1449564
home-based	T058	C0338059
medication management	T058	C0150270
intervention	T061	C0184661
delivered	T169	C1705822
days	T079	C0439228
hospital discharge	T058	C0586003
primary outcome	T169	C1274040
hospital readmissions	T058	C0600290
emergency departments	T073	C0562508
urgent care centers	T073	C1710587
days	T079	C0439228
hospital discharge	T058	C0586003
Secondary outcomes	T169	C1274040
achievements	UnknownType	C0683272
guideline-based	T170	C0162791
targets	T169	C1521840
CKD	T047	C1561643
risk factors	T033	C0035648
complications	T046	C0009566
Enrollment	T058	C1516879
February	T080	C3830166
May	T079	C3812381
baseline	T081	C1442488
age	T032	C0001779
participants	T098	C0679646
years	T079	C0439234
women	T098	C0043210
hypertension	T047	C0020538
diabetes	T047	C0011847
baseline	T081	C1442488
estimated glomerular filtration	T059	C3811844
rate	T081	C1521828
urine albumin-to-creatinine ratio	T059	C0455271
interquartile range	T081	C1711350
diagnosis category	T185	C1550395
hospital admission	T058	C0184666
cardiovascular diseases	T047	C0007222
single diagnosis	T033	C0011900
admission	T058	C0030673
community-acquired	T080	C0456394
acute kidney injury	T047	C0022660
Participants	T098	C0679646
CKD	T047	C1561643
MIT	T061	C2735670
acutely ill	T046	C4061114
hospitalized patients	T101	C0870668
CKD	T047	C1561643
medication management	T058	C0150270
intervention	T061	C0184661
hospital discharge	T058	C0586003
study	T062	C2603343
reduce	T080	C0392756
post	T079	C0687676
hospitalization	T058	C0019993
acute care	T058	C0679878
utilization	T169	C0042153
CKD	T047	C1561643
management	T058	C0376636
Direct	T080	C1947931
Repair	T058	C1705181
Lumbar Pars Interarticularis	T023	C3874316
Defects	T169	C1457869
Utilizing	T169	C0042153
Intraoperative O-Arm-Based Navigation	T074	C0392304
Microendoscopic Techniques	T060	C0014245
retrospective analysis	T062	C0035363
clinical outcomes	T033	C2985631
patients	T101	C0030705
lumbar pars interarticulars	T023	C3874316
defects	T169	C1457869
treated	T033	C0332154
direct	T080	C1947931
repair	T058	C1705181
aid	T080	C1269765
intraoperative O-arm based navigation	T074	C0392304
microendoscopic techniques	T060	C0014245
aim	T078	C1947946
study	T062	C2603343
investigate	T169	C1292732
efficacy	T080	C1280519
safety	T068	C0036043
direct	T080	C1947931
screw	T074	C0301559
repair	T058	C1705181
using	T169	C0457083
minimally invasive surgery	T061	C0282624
lumbar pars interarticulars	T023	C3874316
defects	T169	C1457869
pilot study	T062	C2603343
Direct	T080	C1947931
repair	T058	C1705181
pars interarticulars	T023	C3874316
defects	T169	C1457869
used	T169	C0457083
treat	T061	C0087111
young adult	T100	C0238598
patients	T101	C0030705
Reports	T170	C0684224
concerning	T078	C2699424
direct	T080	C1947931
repair	T058	C1705181
minimally invasive techniques	T061	C0282624
pars interarticulars	T023	C3874316
defects	T169	C1457869
rare	T080	C0522498
Review	T078	C1552617
medical records	T170	C0025102
identified	T080	C0205396
consecutive	T080	C1707491
patients	T101	C0030705
treated	T033	C0332154
intraoperative O-arm based navigation	T074	C0392304
microendoscopic techniques	T060	C0014245
Debridement	T061	C0011079
autograft	T061	C0040736
pars interarticularis	T023	C3874316
defects	T169	C1457869
performed	T169	C0884358
microendoscopic procedure	T060	C0014245
percutaneous	T082	C0522523
bilateral	T082	C0238767
intralaminar	T082	C0205274
screws	T074	C0301559
inserted	T058	C0441587
utilizing	T169	C0042153
intraoperative navigation	T074	C0392304
clinical	T170	C1516606
radiological	T091	C0039431
data	T078	C1511726
collected	T078	C1516695
analyzed	T062	C0936012
retrospectively	T080	C1514923
patients	T101	C0030705
mean	T081	C0444504
age	T032	C0001779
younger	T079	C0332239
time	T079	C0040223
treatment	T061	C0087111
Symptoms	T184	C1457887
included	T052	C2700399
axial	T082	C0205131
back pain	T184	C0004604
patients	T101	C0030705
concomitant	T079	C0521115
radiculopathy	T047	C0700594
Autograft	T061	C0040736
used	T169	C0457083
cases	T077	C1706256
average	T081	C1510992
follow-up	T058	C1522577
duration	T079	C0449238
range	T081	C1514721
Symptoms	T184	C1457887
resolved	T033	C3714811
completely	T080	C0205197
partially	T081	C0728938
patients	T101	C0030705
Low back pain	T184	C0024031
visual analog scores	T201	C2960751
decrease	T081	C0547047
preoperative	T079	C0445204
postoperative	T079	C0032790
cases	T077	C1706256
pars	T023	C0229962
defects	T169	C1457869
healing	T040	C2004454
observed	T169	C1441672
radiological	T091	C0039431
follow-up	T058	C1522577
patient	T101	C0030705
bilateral fusion failure	T019	C0332917
refused	T052	C1705116
revision surgery	T061	C0035110
mild complaint	T033	C0436343
No complications	T033	C4032686
dural tear	T037	C1504340
nerve root injury	T037	C0854396
infection	T046	C3714514
occurred	T052	C1709305
Minimally invasive	T061	C0282624
direct	T080	C1947931
repair	T058	C1705181
pars interarticularis	T023	C3874316
defects	T169	C1457869
intralaminar	T082	C0205274
screws	T074	C0301559
using	T169	C0457083
microendoscopic system	T060	C0014245
navigation procedure	T074	C0392304
provide	T052	C1999230
effective	T080	C1704419
treatment	T061	C0087111
spondylolysis	T047	C0038018
satisfactory	T080	C0205410
clinical	T080	C0205210
radiological	T091	C0039431
outcomes	T169	C1274040
need	T080	C0027552
special tools	T074	C0025080
steep	T080	C0332218
learning curve	T041	C0023185
Evidence	T078	C3887511
Review	T170	C0282443
Survey	T170	C0038951
Expert Opinion	T077	C0600219
Reconstruction	T061	C0524865
Metastatic Spine Tumors	T191	C0684550
Systematic	T169	C0220922
review	T170	C0282443
consensus	T054	C0376298
expert opinion	T077	C0600219
surgeons	T097	C0582175
health care professionals	T097	C0018724
guidelines	T170	C0162791
surgical reconstruction	T061	C0524865
metastatic	T191	C0027627
spine disease	T047	C0037933
evidence	T078	C3887511
expert opinion	T077	C0600219
surgical treatment	T061	C0543467
spinal metastases	T191	C0684550
surgical reconstruction	T061	C0524865
bone graft	T061	C0005976
during	T079	C0347984
surgery	T061	C0543467
metastatic spine tumors	T191	C0684550
design	T052	C1707689
reconstruction	T061	C0524865
construct	T122	C0005479
stabilize	T033	C0184512
systematic	T169	C0220922
review	T170	C0282443
available	T169	C0470187
medical	T169	C0205476
literature	T170	C0023866
combined	T080	C0205195
consensus	T054	C0376298
expert opinion	T077	C0600219
survey	T170	C0038951
spine	T023	C0037949
surgeons	T097	C0582175
treat	T061	C0087111
metastatic spine tumors	T191	C0684550
evidence	T078	C3887511
literature	T170	C0023866
guidance	T058	C0150600
use of	T169	C1524063
bone graft	T061	C0005976
metastatic tumor	T191	C0027627
reconstruction	T061	C0524865
evidence	T078	C3887511
literature	T170	C0023866
use of	T169	C1524063
graft type	T170	C0449494
respondents	T098	C0282122
bone graft	T061	C0005976
bone graft	T061	C0005976
substitutes	T122	C0243003
fusion	T061	C1293131
studies	T062	C0008972
use of	T169	C1524063
prefabricated prosthetic	T074	C0175649
studies	T062	C0008972
use of	T169	C1524063
polymethyl methacrylate	T109	C0005533
PMMA	T109	C0005533
bone cement	T122	C0005934
studies	T062	C0008972
use of	T169	C1524063
bone graft	T061	C0005976
anterior	T082	C0205094
column	T023	C0037949
reconstruction	T061	C0524865
use of	T169	C1524063
structural allograft	T061	C2367546
experts	T097	C0009817
anterior	T082	C0205094
reconstruction	T061	C0524865
followed by	T079	C0332283
cage	T074	C0441239
reconstruction	T061	C0524865
PMMA	T109	C0005533
bone cement	T122	C0005934
bony union	T030	C0391889
importance	T080	C3898777
maintenance	T052	C0024501
spinal	T023	C0037949
stability	T080	C0205360
long term	T079	C0443252
reconstruction	T061	C0524865
bony union	T030	C0391889
required	T169	C1514873
patients	T101	C0030705
shorter	T081	C1806781
life expectancies	T102	C0023671
literature	T170	C0023866
use of	T169	C1524063
anterior	T082	C0205094
reconstruction	T061	C0524865
prefabricated prosthetic	T074	C0175649
PMMA	T109	C0005533
bone cement	T122	C0005934
use of	T169	C1524063
anterior	T082	C0205094
construct	T122	C0005479
bilateral	T082	C0238767
posterior	T082	C0205095
instrumentation	T080	C0021632
performing	T061	C0450010
three-column reconstruction	T061	C0524865
transesophageal echocardiography	T060	C0206054
embolic strokes of undetermined source	T047	C3888970
diagnostic yield	T060	C0011933
transesophageal echocardiography	T060	C0206054
TEE	T060	C0206054
patients	T101	C0030705
ischemic stroke	T047	C0948008
IS	T047	C0948008
diagnostic criteria	T170	C0679228
embolic strokes of undetermined source	T047	C3888970
ESUS	T047	C3888970
patients	T101	C0030705
IS	T047	C0948008
ESUS	T047	C3888970
hospital	T073	C0019994
TEE examination	T060	C0206054
tertiary care stroke centers	T073	C0587437
during a 12-month period	T079	C1254367
systematic review	T170	C1955832
meta-analysis estimating	T062	C0920317
TEE	T060	C0206054
findings	T033	C0243095
therapeutic management	T169	C0039798
secondary stroke prevention	T061	C1277289
IS	T047	C0948008
patients	T101	C0030705
ESUS	T047	C3888970
underwent investigation	T058	C1261322
TEE	T060	C0206054
men	T098	C0025266
NIH Stroke Scale score	T170	C4028214
interquartile range	T081	C1711350
TEE	T060	C0206054
findings	T033	C0243095
confidence interval	T081	C0009667
CI	T081	C0009667
study population	T098	C2348561
TEE	T060	C0206054
findings	T033	C0243095
initiation	T169	C1704686
anticoagulation therapy	T061	C0003281
administration	T061	C1533734
IV antibiotic therapy	T061	C0338237
patent foramen ovale closure	T061	C0189967
CI	T081	C0009667
patients	T101	C0030705
pooled rate	T081	C1521828
anticoagulation therapy	T061	C0003281
abnormal	T033	C0205161
TEE	T060	C0206054
findings	T033	C0243095
IS	T047	C0948008
patients	T101	C0030705
meta-analysis	T062	C0920317
CI	T081	C0009667
subgroup analysis	T062	C0936012
initiation	T169	C1704686
anticoagulation therapy	T061	C0003281
TEE	T060	C0206054
patients	T101	C0030705
cryptogenic stroke	T169	C0332240
CI	T081	C0009667
ESUS	T047	C3888970
CI	T081	C0009667
IS	T047	C0948008
CI	T081	C0009667
TEE	T060	C0206054
findings	T033	C0243095
appropriate	T080	C1548787
therapeutic strategy	T061	C0087111
patients	T101	C0030705
ESUS	T047	C3888970
Simultaneous	T079	C0521115
thrombosis	T046	C0040053
multiple coronary arteries	T023	C0205042
patient	T101	C0030705
rheumatoid arthritis	T047	C0003873
case	T169	C0868928
simultaneous	T079	C0521115
coronary thrombosis of the left main	T047	C0264689
left anterior descending artery	T023	C0226032
right coronary artery	T023	C0226042
patient	T101	C0030705
diagnosed	T060	C0430022
rheumatoid arthritis	T047	C0003873
Unintentional Injuries	T037	C0151736
Children	T100	C0008059
Years	T079	C1510829
Age	T032	C0001779
Parental	T099	C0030551
Knowledge	T170	C0376554
Attitudes	T041	C0004271
Behaviors	T053	C0004927
Italy	T083	C0022277
risk factors	T033	C0035648
associated with	T080	C0332281
unintentional injuries	T037	C0151736
children	T100	C0008059
years	T079	C1510829
parents	T099	C0030551
knowledge	T170	C0376554
attitudes	T041	C0004271
behaviors	T053	C0004927
pediatric	T080	C1521725
injuries	T037	C3263723
preventive measures	UnknownType	C0814446
cross-sectional survey	T062	C0010362
May	T079	C3812381
July	T080	C3829447
random sample	T062	C0150105
parents	T099	C0030551
children	T100	C0008059
self-administered	T169	C1519231
anonymous questionnaire	T170	C0034394
parents	T099	C0030551
children	T100	C0008059
unintentional injury	T037	C0151736
months	T079	C0439231
children	T100	C0008059
boys	T100	C0870221
leading cause	T033	C0552510
falls	T037	C0000921
injuries	T037	C3263723
home	T082	C0442519
emergency department	T073	C0562508
Parents	T099	C0030551
unintentional injuries	T037	C0151736
child	T100	C0008059
injured	T169	C0332664
respondents	T098	C0282122
aware	T041	C0004448
security measures	T089	C0036547
pediatric	T080	C1521725
injuries	T037	C3263723
knowledge	T170	C0376554
parents	T099	C0030551
college level of education	T065	C0013652
middle school education	T065	C0870891
perceived	T041	C0030971
education	T065	C0013621
preventive measures	UnknownType	C0814446
pediatric	T080	C1521725
injuries	T037	C3263723
mean value	T081	C0444504
Likert scale	T170	C0451267
mothers	T099	C0026591
public health	T058	C0699943
educational programs	T065	C0150562
parents	T099	C0030551
prevention	UnknownType	C0814446
unintentional injuries	T037	C0151736
children	T100	C0008059
safety	T068	C0036043
injury prevention	T061	C0150638
reduce	T081	C0547047
risks	T078	C0035647
injuries	T037	C3263723
home	T082	C0442519
Truncated Bovine	T015	C0007452
Integrin Alpha-v/Beta-6	T116	C0166814
Universal Capture Ligand	T044	C1749457
FMD	T047	C0016514
Diagnosis	T033	C0011900
Foot-and-mouth disease	T047	C0016514
FMD	T047	C0016514
endemic	T047	C0277550
regions	T082	C0205147
world	T098	C2700280
epizootic	T067	C0598393
animal diseases	T047	C0003047
FMD	T047	C0016514
livestock	T008	C2936506
cattle	T015	C0007452
sheep	T015	C0036945
goats	T015	C1510458
pigs	T015	C0039005
enormous economic losses	T081	C0681022
productivity	T081	C0033269
trade restrictions	T169	C0443288
Preparedness	T033	C1318963
early diagnosis	T060	C0596473
essential	T080	C0205224
effective control	T058	C0085557
FMD	T047	C0016514
diagnostic assays	T059	C1510438
dependent	T080	C0851827
high-affinity	T080	C0205556
anti-FMD virus	T005	C0949945
FMDV	T005	C0949945
serotype-specific antibodies	T116	C0443640
animals	T008	C0003062
rabbits	T015	C3887509
guinea pigs	T015	C0085979
virus	T005	C0042776
soluble	T080	C1948047
truncated forms	T080	C0348078
bovine	T015	C0007452
αvβ6	T116	C0166814
bind	T044	C1167622
FMDV	T005	C0949945
RGD	T116	C0052350
divalent cation dependent interaction	T044	C1372999
trapping reagent	T130	C0034760
FMDV	T005	C0949945
sandwich ELISA	T059	C0014441
inclusion	T080	C1512693
FLAG	T116	C0251594
His tags	T116	C0019602
purification	T059	C0597301
loss	T081	C1517945
virus binding	T038	C1721019
evidence	T078	C3887511
combined	T080	C0205195
guinea pig	T015	C0085979
polyclonal serum	T031	C0229671
serotype-specific monoclonal antibodies	T116	C0003250
integrin	T116	C0021701
detect	T033	C0442726
viruses	T005	C0042776
FMDV serotypes	T005	C0884162
recombinant FMDV	T005	C0597363
empty capsids	T017	C0006933
stabilising disulphide bonds	T070	C0596391
antigen	T129	C0003320
ELISA	T059	C0014441
inactivated virus antigen	T129	C0003320
positive control	T077	C1883676
assay	T059	C1510438
results	T034	C0456984
potential	T080	C3245505
bovine	T015	C0007452
αvβ6	T116	C0166814
FMDV	T005	C0949945
empty capsids	T017	C0006933
FMD	T047	C0016514
diagnostic assays	T059	C1510438
Stress	T048	C0038443
binge drinking	T055	C0556346
toxic	T037	C0600688
teenage	T079	C0001578
brain	T023	C0006104
Young adult	T100	C0238598
university students	T080	C0597615
binge	T055	C0556346
alcohol	T055	C0001948
high	T080	C0205250
stress levels	T033	C1319127
rodents	T015	C0035804
heavy current alcohol use	T033	C2030272
elevated	T080	C3163633
stress	T048	C0038443
depression scores	T033	C3483981
associated with	T080	C0332281
deficits	T080	C2987487
high	T080	C0205250
interference	T169	C0521102
memory	T041	C0025260
tasks	T057	C3540678
early onset	T033	C1833334
binge	T055	C0556346
patterns	T055	C0556328
cognitive deficits	T048	C0009241
associative encoding	T041	C0679058
executive functions	T041	C0935584
Concentration	T041	C0086045
Memory	T041	C0025260
Task	T057	C3540678
computerized version	T066	C0009609
Concentration	T041	C0086045
card game	T073	C0870328
high	T080	C0205250
interference	T169	C0521102
young adults	T100	C0238598
elevated	T080	C3163633
stress	T033	C4296662
depression	T033	C3483981
alcohol consumption scores	T081	C0449820
impaired	T169	C0221099
Concentration	T041	C0086045
Memory	T041	C0025260
Task	T057	C3540678
analyzed data	T057	C0010992
higher	T080	C0205250
alcohol consumption scores	T081	C0449820
associated with	T080	C0332281
impaired	T169	C0221099
performance	T055	C0597198
high	T080	C0205250
interference	T169	C0521102
memory	T041	C0025260
task	T057	C3540678
Kirwan and Stark's Mnemonic Similarity Test	T170	C0392366
adolescent	T100	C0205653
onset	T081	C0206132
binge drinking	T055	C0556346
poorer	T080	C2700379
performance	T055	C0597198
memory	T041	C0025260
tests	T170	C0392366
systematic test of spatial recognition memory	T170	C0451414
associative learning	T041	C0023185
task	T057	C3540678
results	T033	C0683954
consistent with	T078	C0332290
rodents	T015	C0035804
acute alcohol	T051	C4038778
stress	T048	C0038443
suppress	T169	C1260953
neurogenesis	T040	C0814002
adult	T100	C0001675
hippocampus	T023	C0019564
impairs	T169	C0221099
performance	T055	C0597198
high	T080	C0205250
interference	T169	C0521102
memory	T041	C0025260
tasks	T057	C3540678
adolescent	T100	C0205653
onset	T081	C0206132
binge drinking	T055	C0556346
extensive	T080	C0205231
brain damage	T037	C0270611
cognitive deficits	T048	C0009241
Kindlins	T116	C0033684
Cancer	T191	C0006826
Kindlins	T116	C0033684
4.1-ezrin-ridixin-moesin (FERM) domain	T087	C1514562
proteins	T116	C0033684
kindlins	T116	C0033684
mammals	T015	C0024660
high	T080	C0205250
sequence	T087	C0002518
Kindlin-1	T116	C0033684
expressed	T045	C1171362
epithelial cells	T025	C0014597
kindlin-2	T116	C0033684
distributed	T169	C1704711
abundant	T080	C2346714
adherent cells	T025	C0007634
kindlin-3	T116	C0033684
expressed	T045	C1171362
hematopoietic cells	T025	C2323499
distributions	T169	C1704711
exclusive	T078	C1548966
cells	T025	C0007634
express	T045	C1171362
multiple	T081	C0439064
kindlins	T116	C0033684
transformed cells	T025	C0007634
often	T079	C0332183
aberrant	T080	C0443127
expression	T045	C1171362
isoforms	T116	C0597298
levels	T080	C0441889
kindlins	T116	C0033684
kindlins	T116	C0033684
major	T080	C0205164
roles	T077	C1705810
controlling	T067	C2239193
integrin	T116	C0021701
function	T044	C1527118
In vitro studies	T062	C0681828
in vivo studies	T062	C0681829
mice	T015	C0025929
deficient	T169	C0011155
kindlins	T116	C0033684
studies	T062	C0681814
patients	T101	C0030705
genetic	T169	C0314603
deficiencies	T169	C0011155
kindlins	T116	C0033684
established	T080	C0443211
capacity	T081	C1516240
integrins	T116	C0021701
mediate	T080	C0205556
functions	T169	C0542341
Kindlins	T116	C0033684
adaptor proteins	T116	C0033684
function	T169	C0542341
emanate	T080	C0700364
interaction	T169	C1704675
binding	T044	C1167622
cytoplasmic tails	T026	C0521449
integrins	T116	C0021701
actin cytoskeleton	T026	C0025979
purpose	T169	C1285529
review	T170	C0282443
brief	T079	C1879313
overview	T170	C0814812
kindlin	T116	C0033684
structure	T116	C1510464
function	T044	C1527118
consideration	T033	C0518609
binding	T044	C1167622
relationship	T080	C0439849
kindlin	T116	C0033684
family	T116	C1335532
member	T096	C1551024
cancer	T191	C0006826
view	T082	C0449911
correlations	T080	C1707520
kindlin	T116	C0033684
expression	T045	C1171362
levels	T080	C0441889
neoplasia	T191	C0027651
association	T080	C0439849
integrins	T116	C0021701
tumor progression	T191	C0178874
metastasis	T191	C0027627
consider	T078	C0750591
kindlins	T116	C0033684
function	T169	C0542341
attractive	T080	C2346874
targets	T169	C1521840
treatment of cancer	T061	C0920425
Preclinical	T080	C1709630
fibrinolysis	T039	C0016017
patients	T101	C0030705
ST-segment elevation myocardial infarction	T047	C1536220
rural region	T082	C0178837
current guidelines	T170	C4291682
treatment	T061	C0087111
patients	T101	C0030705
ST-segment elevation myocardial infarction	T047	C1536220
STEMI	T047	C1536220
recommends	T078	C0034866
preclinical	T080	C1709630
fibrinolysis	T039	C0016017
reperfusion therapy	T061	C0035124
transportation	T078	C1554194
times	T079	C0040223
cardiac catheterisation	T058	C0018795
available	T169	C0470187
min	T079	C0439232
remaining	T080	C1527428
expertise	T080	C0870520
method	T169	C0449851
fibrinolysis	T039	C0016017
presently	T078	C0750528
rarely	T080	C0522498
indicated	T033	C1444656
rural area	T082	C0178837
southwestern	T082	C1710136
Germany	T083	C0017480
emergency primary percutaneous coronary intervention	T061	C1532297
routinely	T080	C0205547
available	T169	C0470187
min	T079	C0439232
STEMI	T047	C1536220
patients	T101	C0030705
fibrinolysis	T039	C0016017
plasminogen activator reteplase	T116	C0256103
performed by	T080	C1550369
emergency	T067	C0013956
physicians	T097	C0031831
practicality	T080	C0205556
treatment	T061	C0087111
complications	T046	C0009566
mortality	T081	C0205848
patients	T101	C0030705
preclinical	T080	C1709630
phase	T079	C0205390
arrival	T052	C1706079
hospital	T073	C0019994
retrospectively studied	T062	C0035363
mean time	T079	C0040223
onset of	T080	C0332162
symptoms	T184	C1457887
medical contact	T058	C0582446
min	T079	C0439232
mean interval	T079	C1272706
start	T079	C0439659
fibrinolysis	T039	C0016017
min	T079	C0439232
min	T079	C0439232
mandated	T089	C0520248
Patients	T101	C0030705
inferior STEMI	T047	C2882099
represented	T052	C1882932
largest	T081	C0443228
subgroup	T185	C1515021
cases	T096	C0681850
complications	T046	C0009566
infarction	T046	C0021308
common	T081	C0205214
prehospital	T058	C2735050
phase	T079	C0205390
cases	T096	C0681850
cardiogenic shock	T046	C0036980
cases	T096	C0681850
complications	T046	C0009566
manageable	T033	C0243095
patient	T101	C0030705
died	T033	C1306577
arrival	T052	C1706079
hospital	T073	C0019994
lysis	T046	C0024348
associated	T080	C0332281
adverse effects	T046	C0879626
uncomplicated	T080	C0443334
mucosal haemorrhages	T184	C0854375
mild allergic skin reactions	T047	C0863090
seen	T080	C0205397
emergency situations	T067	C0013956
transportation	T078	C1554194
times	T079	C0040223
suitable	T080	C3900053
cardiac catheterisation	T058	C0018795
laboratory	T073	C0022877
preclinical	T080	C1709630
fibrinolysis	T039	C0016017
STEMI	T047	C1536220
workable method	T169	C0449851
Success	T054	C0597535
strategy	T041	C0679199
strong training	T065	C0220931
emergency	T067	C0013956
physicians	T097	C0031831
ECG	T060	C1623258
lysis	T046	C0024348
therapy	T061	C0087111
co-operation	T054	C0392337
cardiac centres	T073	C0475309
method	T169	C0449851
providing	T052	C1999230
formative feedback	T057	C4042837
large	T081	C0549177
cohort	T098	C0599755
first-year	T079	C1254367
physiology	T091	C0031842
anatomy	T091	C0002808
students	T098	C0038492
evidence	T078	C3887511
demonstrates	T052	C3687625
critical	T080	C1511545
effective	T080	C1704419
meaningful	T080	C0205556
feedback	T041	C2911691
enhance	T052	C2349975
student	T098	C0038492
learning	T041	C0023185
Effective	T080	C1704419
feedback	T041	C2911691
part of	T082	C1292711
learning	T041	C0023185
cycle	T079	C1511572
learning	T041	C0023185
opportunity	T062	C0683937
student	T098	C0038492
inform	T057	C1552002
teacher	T097	C0221457
ongoing	T078	C0549178
curriculum development	T065	C0681362
Feedback	T041	C2911691
considered	T078	C0750591
important	T080	C3898777
during	T079	C0347984
first year	T079	C1254367
university	T073	C0041740
retention	T169	C0333117
attenuate	T052	C0599946
student	T098	C0038492
performance anxieties	T048	C0458631
solidify	T080	C0205556
perceptions	T041	C0030971
academic support	T065	C0000875
individualized	T080	C1881197
timely	T080	C3827828
feedback	T041	C2911691
first-year	T079	C1254367
courses	UnknownType	C0681364
large	T081	C0549177
diverse	T080	C1880371
cohort	T098	C0599755
classes	T170	C0456387
time	T079	C0040223
logistics	T057	C0242415
feedback	T041	C2911691
provide	T052	C1999230
rapid	T080	C0456962
cost-effect	T081	C0010181
feedback	T041	C2911691
large	T081	C0549177
cohorts	T098	C0599755
limited	T169	C0439801
benefit	T081	C0814225
students	T098	C0038492
weaknesses	T033	C0243095
knowledge	T170	C0376554
present	T033	C0150312
study	T062	C2603343
describes	T078	C1552738
method	T169	C0449851
provide	T052	C1999230
formative task-related feedback	T057	C4042837
large	T081	C0549177
cohort	T098	C0599755
first-year	T079	C1254367
physiology	T091	C0031842
anatomy	T091	C0002808
students	T098	C0038492
student	T098	C0038492
evaluations	T058	C0220825
presented	T078	C0449450
study	T062	C2603343
method	T169	C0449851
provided	T052	C1999230
feedback	T041	C2911691
students	T098	C0038492
uncovered	T169	C0439845
underlying misconceptions	T033	C0243095
peer	T098	C0679739
discussion	T054	C2584313
provided	T052	C1999230
new	T080	C0205314
instruction	T065	C0039401
allowing	T054	C0683607
lecturer	T097	C0920339
recognize	T041	C0524637
common	T081	C0205214
gaps	T082	C3887622
knowledge	T170	C0376554
ongoing	T078	C0549178
curriculum development	T065	C0681362
SIRT2	T116	C2720168
Deacetylates	T044	C2246982
Inhibits the Peroxidase Activity	T044	C3893923
Peroxiredoxin-1	T116	C0672553
Sensitize Breast Cancer Cells	T025	C1512505
Oxidant Stress	T049	C0242606
Inducing	T169	C0205263
SIRT2	T116	C2720168
protein deacetylase	T044	C2246982
tumor suppressor activity	T043	C1325410
breast	T191	C0006142
liver tumors	T191	C0345904
mutated	T049	C1705285
substrates	T167	C3891814
antitumor activity	T033	C0243095
SIRT2	T116	C2720168
binds	T044	C1149286
deacetylates	T044	C1511737
inhibits the peroxidase activity	T044	C3893923
antioxidant protein peroxiredoxin	T116	C0672553
Prdx-1	T116	C0672553
breast cancer cells	T025	C1512505
Ectopic	T082	C0574895
overexpression	T045	C0017262
SIRT2	T116	C2720168
catalytically dead mutant	T049	C0596988
increased	T081	C0205217
intracellular levels	T082	C0178719
reactive oxygen species	T123	C0162772
ROS	T123	C0162772
induced by hydrogen peroxide,	T121	C0020281
increased	T081	C0205217
levels	T080	C0441889
overoxidized and multimeric form of Prdx-1	T116	C0672553
activity as a molecular chaperone	T116	C0243041
Elevated	T080	C3163633
levels	T080	C0441889
SIRT2	T028	C1420071
sensitized breast cancer cells	T025	C1512505
intracellular DNA damage	T049	C0012860
cell death induced by oxidative stress	T043	C3894015
increased	T081	C0205217
levels	T080	C0441889
nuclear FOXO3A	T116	C1333633
proapoptotic BIM protein	T116	C4282114
elevated	T080	C3163633
levels	T080	C0441889
SIRT2	T116	C2720168
sensitized breast cancer cells	T025	C1512505
arsenic trioxide	T121	C0052416
therapeutic agent	T073	C0304231
intracellular ROS	T123	C0162772
inducing agents	T121	C1254351
antisense RNA	T114	C0080124
mediated attenuation	T052	C0599946
SIRT2	T116	C2720168
reversed	T169	C1555029
ROS	T123	C0162772
induced toxicity	T037	C1516457
zebrafish	T013	C0043457
embryo model system	T018	C0013935
tumor suppressor activity	T043	C1325410
SIRT2	T116	C2720168
restrict	T169	C0443288
antioxidant activity	T044	C1148564
Prdx-1	T116	C0672553
sensitizing breast cancer cells	T025	C1512505
ROS	T123	C0162772
induced DNA damage	T049	C0012860
cell cytotoxicity	T049	C0596402
development	T169	C1527148
conjunctival hyperemia	T047	C1761613
computer-assisted diagnosis tools	T060	C0011905
feature	T080	C2348519
selection	T052	C1707391
class imbalance	T170	C0282574
blood flow	T039	C0232338
bulbar conjunctiva	T023	C0229275
hyperemia	T047	C0020452
red hue	T070	C0678581
variable	T080	C0439828
intensity	T080	C0205556
hyperemia	T047	C0020452
grading scale	T170	C0282574
time consuming	T080	C3827829
automatisation	T066	C0004376
straightforward	T080	C1272701
class imbalance	T170	C0282574
correlated	T080	C1707520
features	T080	C2348519
features	T080	C2348519
hyperemia	T047	C0020452
automatic framework	T170	C0282574
hyperemia	T047	C0020452
grading	T033	C0243095
Oversampling	T170	C0282574
undersampling	T170	C0282574
SMOTE approaches	T170	C0282574
class imbalance	T170	C0282574
regression methods	T170	C0034980
grading scale	T170	C0282574
features	T080	C2348519
experts' values	T033	C0243095
feature	T080	C2348519
selection	T052	C1707391
lowest mean square error	T081	C0392762
MSE	T081	C0392762
regression systems	T170	C0034980
Multi-layer perceptron	T170	C0870951
MLP	T170	C0870951
random forest (RF) method	T170	C0282574
MLP	T170	C0870951
Correlation based feature selection	T170	C0282574
CFS	T170	C0282574
MSE	T081	C0392762
MSE	T081	C0392762
class imbalance problem	T170	C0282574
SMOTE approach	T170	C0282574
MSE	T081	C0392762
Machine learning	T066	C0376284
hyperemia	T047	C0020452
grading	T033	C0243095
intra- and inter-expert subjectivity	T080	C0205556
computation	T052	C1880157
time	T079	C0040223
SMOTE	T170	C0282574
oversampling approaches	T170	C0282574
class imbalance problem	T170	C0282574
feature	T080	C2348519
selection	T052	C1707391
features	T080	C2348519
MSE	T081	C0392762
system	T073	C0015324
human expert	T097	C0031831
experts	T097	C0031831
system	T073	C0015324
expert	T097	C0031831
Medication	T058	C2081612
rehabilitation	T169	C0034992
health care consumption	T055	C0814514
adults	T100	C0001675
cerebral palsy	T047	C0007789
population based study	T062	C1709599
medication	T058	C2081612
rehabilitation	T169	C0034992
healthcare consumption	T055	C0814514
adults	T100	C0001675
CP	T047	C0007789
function	T169	C0542341
Gross Motor Function Classification System	T170	C3873236
GMFCS	T170	C3873236
Questionnaire	T170	C0034394
cross-sectional study	T062	C0010362
Brittany	T083	C0017446
French county	T083	C0079170
Adults	T100	C0001675
cerebral palsy	T047	C0007789
Questionnaires	T170	C0034394
drugs	T121	C0013227
orthotic devices	T074	C0029365
mobility aids	T074	C3495449
rehabilitation	T169	C0034992
medical input	T033	C0496675
sent	T169	C1519246
members	T098	C0680022
unique	T080	C1710548
regional French	T083	C0017446
network	T169	C1882071
adults	T100	C0001675
cerebral palsy	T047	C0007789
questionnaire	T170	C0034394
completed	T080	C0205197
participant	T098	C0679646
helper	UnknownType	C0682221
responders	T033	C0919876
GMFCS level	T170	C3873236
Participants	T098	C0679646
large amount of healthcare	T055	C0814514
Almost three-quarters	T081	C2825406
orally administered drugs	T121	C0013227
antispastic	T121	C4020576
antiepileptic drugs	T121	C0003299
most frequent	T079	C0332183
patients	T101	C0030705
rehabilitation	T169	C0034992
physiotherapy	T061	C0949766
mobility aid	T074	C3495449
orthotic device	T074	C0029365
frequency	T079	C0439603
GMFCS level	T170	C3873236
Specificities	T081	C0037791
found	T033	C0150312
GMFCS level	T170	C3873236
participants	T098	C0679646
GMFCS level	T170	C3873236
high level	T080	C0441889
medical input	T033	C0496675
greater use of	T169	C1524063
trunk-supporting devices	T074	C0025080
antireflux	T061	C0399651
laxative	T121	C0282090
Profiles	T081	C0237801
GMFCS levels	T170	C3873236
Adults	T100	C0001675
cerebral palsy	T047	C0007789
large amount	T081	C3869890
drugs	T121	C0013227
mobility aids	T074	C3495449
orthotic devices	T074	C0029365
rehabilitation	T169	C0034992
medical input	T033	C0496675
Healthcare	T058	C0086388
targeted	T169	C1521840
cerebral palsy	T047	C0007789
cerebral palsy -related issues	T033	C0033213
GMFCS	T170	C3873236
determinant	T169	C1521761
healthcare consumption	T055	C0814514
clinical practice	T057	C0205897
target	T169	C1521840
care	T052	C1947933
appropriately	T080	C1548787
Transcriptome sequencing	T059	C4086963
de novo	T078	C1515568
characterization	T052	C1880022
Korean	T083	C0022771
land snail	T204	C0037378
Koreanohadra kurodana	T204	C0037378
transcripts	T114	C1519595
SSR	T114	C1519302
markers	T045	C0017393
Korean	T083	C0022771
land snail	T204	C0037378
Koreanohadra kurodana	T204	C0037378
Gastropoda	T204	C0324023
Bradybaenidae	T204	C1040093
humid areas	T067	C0563027
broadleaf forests	T070	C0086312
shrubs	T002	C0446286
individuals	T098	C0237401
years	T079	C0439234
species	T204	C0684063
genomic level	T028	C0017428
functions	T169	C0542341
molecular	T080	C1521991
genetics level	T169	C0314603
study	T062	C2603343
de novo	T078	C1515568
transcriptome sequencing	T059	C4086963
transcript	T114	C1519595
dataset	T170	C0150098
visceral mass tissue	T024	C0040300
K. kurodana	T204	C0037378
Illumina paired-end sequencing technology	T063	C1513384
contigs	T082	C1511491
unigenes	T170	C1710539
N50	T114	C0028630
length	T081	C1444754
unigenes	T170	C1710539
protein	T087	C0002518
nucleotide sequences	T086	C0004793
public databases	T170	C0242356
direction	T082	C0449738
unigenes	T170	C1710539
COG	T170	C0242356
GO	T170	C1138831
KEGG	T170	C0242356
InterProScan	T170	C2826595
protein domain	T087	C1514562
search	T052	C1706202
GO	T170	C1138831
analysis	T062	C0936012
unigenes	T170	C1710539
functional groups	T120	C0598132
KEGG annotation	T170	C0242356
metabolism pathway	T169	C1291081
genes	T028	C0017337
protein motifs	T087	C1514562
zinc finger	T087	C0080347
ribonuclease H	T116	C0085431
reverse transcriptase	T116	C0035379
ankyrin repeat domains	T044	C1956127
simple sequence repeats	T114	C1519302
SSRs	T114	C1519302
length	T081	C1444754
unigenes	T170	C1710539
dinucleotide repeat motifs	T114	C0282524
tri-	T114	C0282537
tetranucleotide motifs	T114	C0282521
unigenes	T170	C1710539
adaptation	T038	C0392673
defense mechanisms	T041	C0011142
heat shock proteins 70	T116	C0243043
Toll-like receptor 4	T116	C1411976
AMP-activated protein kinase	T116	C2350345
aquaporin-2	T116	C0213238
identification	T080	C0205396
characterization	T052	C1880022
genes	T028	C0017337
polymorphic	T080	C1882417
SSR	T114	C1519302
markers	T045	C0017393
K. kurodana	T204	C0037378
transcriptome	T086	C3178810
http://bioinfo.sch.ac.kr/submission/	T170	C0872179
phylogenetics study	T062	C1519068
genetic diversity	T070	C0042333
assessment	T052	C1516048
Prediction	T078	C0681842
Estrogenic	T109	C0014939
Bioactivity	T052	C0441655
Environmental Chemical	T103	C0220806
Metabolites	T123	C0870883
US Environmental Protection Agency's	T092	C0041712
EPA	T092	C0041712
Endocrine Disruptor Screening Program	T058	C1254363
EDSP	T058	C1254363
in vitro data	T078	C1511726
ToxCast	T170	C0282574
Tox21	T170	C0282574
high-throughput screening assays	T059	C2718002
endocrine	T022	C0014136
activity	T052	C0441655
environmental chemicals	T103	C0220806
in vitro assays	T059	C3850137
metabolic capacity	T169	C0025520
inactive chemicals	T103	C0220806
biotransformed	T040	C0005576
metabolites	T123	C0870883
endocrine	T022	C0014136
bioactivity	T052	C0441655
screening	T169	C1305399
testing	T169	C0039593
metabolism	T040	C0025519
endocrine	T022	C0014136
activity	T052	C0441655
parent chemicals	T103	C0220806
metabolites	T123	C0870883
software	T073	C0037585
metabolites	T123	C0870883
parent compounds	T103	C1706082
chemicals	T103	C0220806
estrogenic	T109	C0014939
metabolites	T123	C0870883
compounds	T103	C1706082
metabolites	T123	C0870883
estrogenic	T109	C0014939
activity	T052	C0441655
ER	T116	C0034804
QSAR	T081	C0887819
models	T170	C3161035
estrogen	T109	C0014939
bioactivity	T052	C0441655
parent compounds	T103	C1706082
metabolites	T123	C0870883
models	T170	C3161035
chemicals	T103	C0220806
estrogenicity	T169	C0205245
parent chemical	T103	C0220806
metabolites	T123	C0870883
metabolite prediction software	T073	C0037585
estrogenic	T109	C0014939
metabolites	T123	C0870883
parent chemicals	T103	C0220806
metabolite	T123	C0870883
estrogenic	T109	C0014939
metabolites	T123	C0870883
biotransformation	T040	C0005576
products	T121	C0005522
parent chemical	T103	C0220806
QSAR	T081	C0887819
models	T170	C3161035
estrogenic	T109	C0014939
activity	T052	C0441655
estrogenic	T109	C0014939
metabolites	T123	C0870883
parent chemicals	T103	C0220806
models	T170	C3161035
parent compounds	T103	C1706082
chemicals	T103	C0220806
estrogenicity	T169	C0205245
metabolites	T123	C0870883
in silico	T066	C3489666
detection	T033	C0442726
chemicals	T103	C0220806
estrogenic	T109	C0014939
metabolites	T123	C0870883
false negative	T034	C0205558
in vitro assays	T059	C3850137
Effects of	T080	C1704420
Application	T169	C4048755
Social Marketing	T057	C0037424
Theory	T078	C0871935
Health Belief Model	T058	C3714363
Promoting	T052	C0033414
Cervical Cancer Screening	T061	C0281187
Targeted	T169	C1521840
Women	T098	C0043210
Sisaket Province	T083	C1514578
Thailand	T083	C0039725
Cervical cancer	T191	C4048328
major	T080	C0205164
public health problem	T033	C0033213
Thailand	T083	C0039725
ranked	T170	C0699794
breast cancer	T191	C0678222
Thai	T098	C0337910
women	T098	C0043210
reported	T058	C0700287
low	T080	C0205251
rate	T081	C1521828
cervical cancer screening	T061	C0281187
goal	T170	C0018017
WHO	T093	C0043237
aimed	T078	C1947946
apply	T169	C4048755
social marketing	T057	C0037424
theory	T078	C0871935
health belief model	T058	C3714363
promoting	T052	C0033414
cervical cancer screening	T061	C0281187
Kanthararom District	T083	C0017446
Sisaket Province	T083	C1514578
total	T080	C0439810
targeted	T169	C1521840
women	T098	C0043210
aged	T032	C0001779
years	T079	C0439234
randomly	T062	C0034656
divided	T169	C0332849
groups	T078	C0441833
experimental group	T098	C1257890
application	T169	C4048755
social marketing	T057	C0037424
theory	T078	C0871935
health belief model	T058	C3714363
program	T169	C3484370
promoting	T052	C0033414
cervical cancer screening	T061	C0281187
control group	T096	C0009932
received	T080	C1514756
normal services	T058	C1254363
research tools	T170	C1516602
application	T169	C4048755
social marketing	T057	C0037424
theory	T078	C0871935
health belief model	T058	C3714363
program	T169	C3484370
questionnaire	T170	C0034394
evaluate	T052	C1516048
perceptions	T041	C0030971
cervical cancer	T191	C4048328
Descriptive	T170	C0678257
inferential statistics	T081	C0002780
including	T169	C0332257
paired	T080	C1709450
sample ttest	T170	C0392366
independent	T169	C0332291
ttest	T170	C0392366
analyze the data	T057	C0010992
program	T169	C3484370
mean score	T033	C3533236
perception	T041	C0030971
cervical cancer	T191	C4048328
experimental group	T098	C1257890
higher	T080	C0205250
level	T080	C0441889
S.D.	T081	C0871420
control group	T096	C0009932
S.D.	T081	C0871420
statistical significance	T081	C0237881
research	T062	C0035168
appropriate	T080	C1548787
communication	T054	C0009452
process	T067	C1522240
behavioral	T053	C0004927
modification	T169	C0392747
cervical cancer	T191	C4048328
recommended	T078	C0034866
program	T169	C3484370
featuring	T080	C2348519
social marketing	T057	C0037424
health belief model	T058	C3714363
promote	T052	C0033414
cervical cancer screening	T061	C0281187
targeted	T169	C1521840
women	T098	C0043210
promoted	T052	C0033414
guideline	T170	C0162791
health services	T058	C0018747
health promotion	T058	C0018738
disease prevention	T061	C0679698
Visualization	T060	C0011923
Intimal Flap	T023	C0038925
Intracranial Arterial Dissection	T190	C3665731
High-Resolution	T059	C1719039
3T MRI	T060	C0024485
Presence	T033	C0150312
intimal flap	T023	C0038925
critical	T080	C1511545
imaging finding	T034	C1287399
diagnosing	T033	C0011900
intracranial artery dissection	T190	C3665731
ICAD	T190	C3665731
reports	T170	C0684224
high-resolution	T059	C1719039
magnetic resonance imaging	T060	C0024485
MRI	T060	C0024485
better	T080	C0332272
intimal flaps	T023	C0038925
compared	T052	C1707455
MRI techniques	T060	C0024485
clinical settings	T082	C3176918
sequence	T169	C1519249
high-resolution	T059	C1719039
MRI	T060	C0024485
gadolinium	T130	C0016911
enhancement	T052	C2349975
images	T078	C1551337
quality	T080	C0332306
scanning	T060	C0441633
times	T079	C0040223
evaluated	T058	C0220825
nonenhanced high-resolution fast spin echo (HR-FSE) MRI	T060	C0024485
sequence	T169	C1519249
intimal flaps	T023	C0038925
patients	T101	C0030705
ICAD	T190	C3665731
patients	T101	C0030705
ICAD	T190	C3665731
MRI	T060	C0024485
2-dimensional	T082	C1705052
T2-weighted FSE imaging	T060	C0011923
sequence	T169	C1519249
3T system	T169	C0449913
scanning	T060	C0441633
conventional	T080	C0439858
modalities	T078	C0695347
CT angiography	T060	C1536105
magnetic resonance angiography	T060	C0243032
digital subtraction angiography	T060	C0002979
assessed	T052	C1516048
imaging methods	T169	C1275506
intimal flap	T023	C0038925
double lumen sign	T033	C0243095
participants	T098	C0679646
compared	T052	C1707455
results	T033	C0683954
HR-FSE	T060	C0024485
modalities	T078	C0695347
HR-FSE	T060	C0024485
images	T078	C1551337
intimal flaps	T023	C0038925
double lumen signs	T033	C0243095
patients	T101	C0030705
conventional	T080	C0439858
modalities	T078	C0695347
identified	T080	C0205396
double lumen sign	T033	C0243095
patients	T101	C0030705
HR-FSE imaging	T060	C0024485
3T system	T169	C0449913
improved	T033	C0184511
visualization	T060	C0011923
intimal flaps	T023	C0038925
assessing	T052	C1516048
patients	T101	C0030705
suspected	T078	C0750491
ICAD	T190	C3665731
diagnosed	T033	C0011900
conventional	T080	C0439858
imaging modalities	T169	C1275506
Quantification	T081	C1709793
intact	T080	C0205266
plasma	T031	C0032105
AGT	T116	C0003017
reduced conformations	T082	C0033625
ELISA	T059	C0014441
pleiotropic actions	T052	C3266814
renin-angiotensin system	T022	C0035096
RAS	T022	C0035096
availability of	T169	C0470187
angiotensinogen	T116	C0003017
AGT	T116	C0003017
generates	T052	C3146294
angiotensin I	T116	C0003006
ANG I	T116	C0003006
cleaved	T082	C0205242
renin	T116	C0035094
quantification	T081	C1709793
intact	T080	C0205266
AGT	T116	C0003017
iAGT	T116	C0003017
concentrations	T081	C1264643
important	T080	C3898777
actual	T080	C0237400
renin substrate	T116	C0003017
available	T169	C0470187
iAGT	T116	C0003017
conformation	T082	C0033625
oxidized AGT	T116	C0003017
oxi-AGT	T116	C0003017
reduced AGT	T116	C0003017
red-AGT	T116	C0003017
disulfide bond	T087	C1511997
oxi-AGT	T116	C0003017
higher	T080	C0205250
affinity	T070	C1510827
renin	T116	C0035094
RAS	T022	C0035096
associated diseases	T046	C0243083
determined	T080	C0521095
iAGT	T116	C0003017
oxi-AGT	T116	C0003017
red-AGT	T116	C0003017
levels	T080	C0441889
plasma	T031	C0032105
rats	T015	C0034693
mice	T015	C0025929
Blood samples	T031	C0178913
obtained	T169	C1301820
cardiac puncture	T059	C0022885
immediately	T079	C0205253
mixed	T169	C0205430
inhibitor	T120	C0243077
solution	T167	C0037633
containing	T169	C0332256
renin inhibitor	T121	C1960108
Total	T080	C0439810
AGT	T116	C0003017
tAGT	T116	C0003017
levels	T080	C0441889
measured	T080	C0444706
tAGT	T116	C0003017
ELISA	T059	C0014441
detects	T033	C0442726
cleaved	T082	C0205242
iAGT	T116	C0003017
iAGT	T116	C0003017
levels	T080	C0441889
determined by	T080	C0521095
iAGT	T116	C0003017
ELISA	T059	C0014441
detect	T033	C0442726
red-AGT	T116	C0003017
samples	T031	C0178913
dithiothreitol	T109	C0012789
reducing agent	T130	C0376446
quantify	T081	C1709793
total	T080	C0439810
iAGT	T116	C0003017
concentration	T081	C1264643
tAGT	T116	C0003017
levels	T080	C0441889
rat	T015	C0034693
mouse	T015	C0025929
plasma	T031	C0032105
iAGT	T116	C0003017
levels	T080	C0441889
tAGT	T116	C0003017
rat	T015	C0034693
plasma	T031	C0032105
mouse	T015	C0025929
plasma	T031	C0032105
greater	T081	C1704243
plasma	T031	C0032105
renin	T116	C0035094
activity	T044	C0243102
mice	T015	C0025929
ratios	T081	C0456603
oxi-AGT	T116	C0003017
red-AGT	T116	C0003017
rat	T015	C0034693
mouse	T015	C0025929
Plasma	T031	C0032105
iAGT	T116	C0003017
oxi-AGT	T116	C0003017
red-AGT	T116	C0003017
suggesting	T078	C1705535
oxidative stress	T049	C0242606
influence	T077	C4054723
ANG I	T116	C0003006
generation	T052	C3146294
AGT	T116	C0003017
conformation	T082	C0033625
lower	T052	C2003888
availability of	T169	C0470187
plasma	T031	C0032105
iAGT	T116	C0003017
mice	T015	C0025929
suggests	T078	C1705535
limiting	T169	C0439801
factor	T169	C1521761
ANG I	T116	C0003006
formation	T169	C1522492
species	T185	C1705920
Carbon Monoxide	T131	C0007018
Improves	T033	C0184511
Efficacy	T080	C1280519
Mesenchymal Stromal Cells	T025	C3178844
During	T079	C0347984
Sepsis	T047	C0243026
Specialized	T077	C1704211
Proresolving	T033	C0243095
Lipid Mediators	T123	C0599745
Mesenchymal stromal cells	T025	C3178844
investigated	T169	C1292732
cell-based therapy	T061	C3658313
disease processes	T046	C0030660
results	T033	C2825142
animal models	T008	C0599779
systemic inflammation	T047	C3646020
sepsis	T047	C0243026
Studies	T062	C2603343
improve	T033	C0184511
therapeutic	T169	C0302350
potential	T080	C3245505
mesenchymal stromal cells	T025	C3178844
gas	T104	C0017110
molecule	T167	C0567416
improves	T033	C0184511
outcome	T169	C1274040
experimental	T080	C1517586
sepsis	T047	C0243026
carbon monoxide	T131	C0007018
preconditioning	T169	C0205245
mesenchymal stromal cells	T025	C3178844
carbon monoxide	T131	C0007018
ex vivo	T169	C2348480
promote	T052	C0033414
therapeutic	T169	C0302350
benefit	T081	C0814225
cells	T025	C0007634
administered	T169	C1521801
in vivo	T082	C1515655
onset of	T080	C0332162
polymicrobial	T047	C0275524
sepsis	T047	C0243026
mice	T015	C0025929
Animal study	T008	C0683949
primary cell culture	T059	C1449562
Laboratory	T073	C0022877
investigation	T058	C0220825
BALB/c mice	T015	C0025919
Polymicrobial	T047	C0275524
sepsis	T047	C0243026
induced	T169	C0205263
cecal	T023	C0007531
ligation	T061	C0023690
puncture	T058	C0034117
Mesenchymal stromal cells	T025	C3178844
mesenchymal stromal cells	T025	C3178844
conditioned	T080	C0205556
carbon monoxide	T131	C0007018
fibroblasts	T025	C0016030
fibroblasts	T025	C0016030
conditioned	T080	C0205556
carbon monoxide	T131	C0007018
delivered	T169	C1705822
tail vein	T023	C2985205
injections	T061	C1533685
septic	T169	C0333534
mice	T015	C0025929
mice	T015	C0025929
assessed	T052	C1516048
survival	T052	C0038952
bacterial	T080	C0521009
clearance	T080	C0449297
inflammatory response	T046	C1155266
during	T079	C0347984
sepsis	T047	C0243026
groups	T078	C0441833
Mesenchymal stromal cells	T025	C3178844
assessed	T052	C1516048
ability	T032	C0085732
promote	T052	C0033414
bacterial	T080	C0521009
phagocytosis	T043	C0031308
neutrophils	T025	C0027950
specialized	T077	C1704211
proresolving	T033	C0243095
lipid mediators	T123	C0599745
mesenchymal stromal cells	T025	C3178844
function	T039	C0031843
gene silencing	T045	C0598496
Ex vivo	T169	C2348480
preconditioning	T169	C0205245
carbon monoxide	T131	C0007018
mesenchymal stromal cells	T025	C3178844
administered	T169	C1521801
onset of	T080	C0332162
sepsis	T047	C0243026
therapeutic effect	T201	C1527144
increased	T081	C0205217
survival	T052	C0038952
Carbon monoxide	T131	C0007018
preconditioned	T081	C0205217
mesenchymal stromal cells	T025	C3178844
organ injury	T037	C0332675
improve	T033	C0184511
bacterial	T080	C0521009
clearance	T080	C0449297
promote	T052	C0033414
resolution	T046	C1514893
inflammation	T046	C0021368
Mesenchymal stromal cells	T025	C3178844
exposed to	T080	C0332157
carbon monoxide	T131	C0007018
docosahexaenoic acid	T109	C0556150
substrate	T167	C3891814
specialized	T077	C1704211
proresolving	T033	C0243095
lipid mediators	T123	C0599745
D-series	T080	C0205556
resolvins	T109	C4288292
promoted	T052	C0033414
survival	T052	C0038952
Silencing	T045	C0598496
lipoxygenase pathways	T044	C1157322
5-lipoxygenase	T044	C1151570
12	T044	C1151569
15-lipoxygenase	T044	C1324412
important	T080	C3898777
enzymes	T116	C0014442
specialized	T077	C1704211
proresolving	T033	C0243095
lipid mediator	T123	C0599745
biosynthesis	T169	C0005572
resulted	T169	C1274040
therapeutic	T169	C0302350
benefit	T081	C0814225
mesenchymal stromal cells	T025	C3178844
carbon monoxide	T131	C0007018
data	T078	C1511726
specialized	T077	C1704211
proresolving	T033	C0243095
lipid mediators	T123	C0599745
contribute	T052	C1880177
improved	T033	C0184511
mesenchymal stromal cell	T025	C3178844
efficacy	T080	C1280519
exposed to	T080	C0332157
carbon monoxide	T131	C0007018
improved	T033	C0184511
therapeutic response	T201	C0521982
during	T079	C0347984
sepsis	T047	C0243026
Effect	T080	C1280500
primary health care	T058	C0033137
reforms	T077	C2986411
Turkey	T083	C0041400
health service utilization	T058	C0030672
user satisfaction	T033	C3650764
Strengthening	T080	C1704419
primary health care	T058	C0033137
PHC	T058	C0033137
efficient	T080	C0442799
responsive	T169	C0205342
health systems	T093	C0018696
empirical	T080	C1880496
evidence	T078	C3887511
income	T081	C0021162
countries	T083	C0454664
limited	T169	C0439801
stepwise introduction	T061	C1293116
family medicine	T091	C0015607
provinces	T083	C1514578
Turkey	T083	C0041400
middle-income	T080	C0870890
country	T083	C0454664
PHC	T058	C0033137
strengthening	T080	C1704419
natural experiment	T062	C0681814
assessing	T052	C1516048
effect	T080	C1280500
family medicine	T091	C0015607
health service utilization	T058	C0030672
user satisfaction	T033	C3650764
effect	T080	C1280500
health system	T093	C0018696
reforms	T077	C2986411
family medicine	T091	C0015607
utilization	T169	C0042153
assessed	T052	C1516048
longitudinal	T062	C0023981
province-level data	T062	C0035168
years	T079	C0439234
multivariate regression models	T075	C0026336
supply-side variables	T080	C0439828
demographics	UnknownType	C0681669
socio-economic development	T080	C0086996
yearly	T079	C0439234
trends	T079	C0040833
User satisfaction	T033	C3650764
primary	T058	C0033137
secondary care	T058	C3494402
services	T058	C0018747
data	T078	C1511726
annual Life Satisfaction Surveys	T170	C0038951
Trends	T079	C0040833
contact	T169	C0332158
primary	T058	C0033137
secondary	T058	C3494402
public	T073	C0020022
private	T073	C0033173
reason for choice	T055	C0008300
health services	T058	C0018747
issues	UnknownType	C0744349
described	T078	C1552738
stratified	T080	C0205363
patient characteristics	T201	C0815172
provider type	T201	C2706153
rural/urban settings	T083	C0017446
average number	T081	C0449788
PHC	T058	C0033137
consultations	T058	C0009818
increased	T081	C0205217
person	T098	C0027361
year	T079	C0439234
multivariate models	T075	C0026336
family medicine	T091	C0015607
introduction	T061	C1293116
associated with	T080	C0332281
increase	T169	C0442805
PHC	T058	C0033137
consultations	T058	C0009818
person	T098	C0027361
slower	T080	C0439834
annual growth	T067	C2911660
PHC	T058	C0033137
secondary care	T058	C3494402
consultations	T058	C0009818
family medicine	T091	C0015607
introduction	T061	C1293116
growth	T067	C2911660
PHC	T058	C0033137
secondary care	T058	C3494402
consultations	T058	C0009818
person	T098	C0027361
year	T079	C0439234
PHC	T058	C0033137
increased	T081	C0205217
provider	T201	C2706153
years	T079	C0439234
proximity	T082	C1514583
service satisfaction	T033	C3650764
increased	T081	C0205217
Reporting	T058	C0700287
poor facility hygiene	T033	C0745076
difficulty getting an appointment	T033	C1822076
poor	T080	C2700379
physician	T097	C0031831
behaviour	T053	C0004927
high	T080	C0205250
costs of health care	T081	C0085552
declined	T080	C1511741
PHC	T058	C0033137
settings	T083	C0017446
higher	T080	C0205250
urban	T080	C2700386
low-income	T033	C1331016
working-age	T032	C0001779
populations	T098	C1257890
Laparoscopic	T060	C0031150
radical lymph node dissection	T061	C0193854
advanced colon cancer	T191	C4016406
hepatic flexure	T029	C0227385
Complete mesocolic excision	T061	C0728940
standard procedure	T061	C0184661
colon cancer	T191	C0699790
Gastroepiploic	T023	C0447070
infrapyloric	T023	C0229779
superficial pancreatic head lymph node	T023	C0229783
metastases	T191	C0024232
gastrocolic ligament	T023	C0230229
colon cancer	T191	C0699790
hepatic flexure	T029	C0227385
metastases	T191	C0024232
gastrocolic ligament	T023	C0230229
colon cancer	T191	C0699790
hepatic flexure	T029	C0227385
single-center retrospective study	T062	C0035363
patients	T101	C0030705
T2	T033	C0475373
invasive	T080	C0205281
colon cancer	T191	C0699790
tumor location	T082	C3897292
laparoscopic right hemicolectomy	T061	C0585464
extended right hemicolectomy	T061	C0400043
institution	T073	C0018704
April	T079	C3715024
March	T079	C3829202
Lymph node dissection	T061	C0242382
gastrocolic ligament	T023	C0230229
Complications	T046	C0009566
patients	T101	C0030705
Clavien-Dindo classification	T185	C4055231
Lymph node metastases	T191	C0024232
gastrocolic ligament	T023	C0230229
patients	T101	C0030705
metastasis	T191	C0024232
mm	T081	C0439200
Metastases	T191	C0024232
gastrocolic ligament	T023	C0230229
patients	T101	C0030705
T2	T033	C0475373
invasive	T080	C0205281
colon cancer	T191	C0699790
hepatic flexure	T029	C0227385
Laparoscopy	T061	C1883297
gastrocolic ligament resection	T061	C0728940
study	T062	C2603343
sample	T167	C0370003
extended	T082	C0231449
follow-up	T058	C1522577
studies	T062	C2603343
clinical relevance	T080	C2347946
finding	T033	C0243095
recurrence	T067	C0034897
long-term	T079	C0443252
survival	T052	C0038952
Smartphone	T073	C3204335
Psychotherapeutic	T061	C0033968
Micro-Interventions	T061	C0184661
Mood	T041	C0026516
Real-World Setting	T079	C1254367
mobile	T073	C1136360
communication technology	UnknownType	C0681426
approach	T082	C0449445
treat	T061	C0087111
mental disorders	T048	C0004936
quality of life	T078	C0034380
Knowledge	T170	C0376554
intervention	T061	C0184661
components	T073	C0449432
psychopathological	T091	C0033927
processes	T067	C1522240
psychotherapy	T061	C0033968
approaches	T082	C0449445
smartphone	T073	C3204335
micro-interventions	T061	C0184661
psychotherapeutic techniques	T170	C0237915
video-clips	T170	C3463807
mood changes	T048	C0085633
neurofeedback	T061	C2713543
study	T062	C2603343
subjects	T098	C0080105
neurofeedback	T061	C2713543
condition	T080	C0348080
daily	T079	C0332173
smartphone	T073	C3204335
micro-interventions	T061	C0184661
days	T079	C0439228
techniques	T169	C0449851
viscerosensory	T080	C0445254
attention	T041	C0004268
emotional	T033	C0849912
imagery	T041	C0175631
facial expression	T033	C0015457
contemplative	T080	C1277196
repetition	T169	C0205341
Changes	T169	C0392747
mood	T041	C0026516
Multidimensional Mood State Questionnaire	T170	C0451394
good	T080	C0205170
bad	T080	C0205169
awake	T033	C0234422
tired	T184	C0557875
calm	T041	C0522165
nervous	T184	C0027769
men	T098	C0025266
days	T079	C0439228
analyses	T062	C0936012
micro-intervention sessions	UnknownType	C0679644
viscerosensory	T080	C0445254
attention	T041	C0004268
sessions	UnknownType	C0679644
contemplative	T080	C1277196
repetition	T169	C0205341
sessions	UnknownType	C0679644
techniques	T169	C0449851
models	T170	C3161035
subjects	T098	C0080105
mood	T041	C0026516
confidence interval	T081	C0009667
CI	T081	C0009667
awake	T033	C0234422
CI	T081	C0009667
calmer	T041	C0522165
CI	T081	C0009667
pre	T079	C1254367
post-micro-intervention	T079	C1254367
mood	T041	C0026516
improvements	T077	C2986411
pre	T079	C1254367
post-micro-intervention	T079	C1254367
changes in mood	T048	C0085633
day	T079	C0439228
day	T079	C0439228
GB mood	T041	C0026516
CI	T081	C0009667
AT mood	T041	C0026516
CI	T081	C0009667
CN mood	T041	C0026516
CI	T081	C0009667
findings	T033	C0243095
smartphone	T073	C3204335
micro-interventions	T061	C0184661
short-term	T079	C0443303
mood changes	T048	C0085633
techniques	T169	C0449851
psychotherapeutic	T061	C0033968
approaches	T082	C0449445
mindfulness	T041	C3542996
psychotherapy	T061	C0033968
transcendental meditation	T041	C0150814
contemplative	T080	C1277196
therapies	T061	C0087111
techniques	T169	C0449851
capability	T080	C2698977
mood	T041	C0026516
controlled studies	T062	C0681867
patients	T101	C0030705
Smartphone	T073	C3204335
micro-interventions	T061	C0184661
mood	T041	C0026516
real-world settings	T079	C1254367
psychotherapeutic interventions	T061	C0582386
precision	T079	C1547902
medicine approach	UnknownType	C0679624
data	T078	C1511726
randomized trial	T062	C0206034
Primary	T080	C0205225
pituitary	T023	C0032005
diffuse large B-cell lymphoma	T191	C0079744
somatotroph hyperplasia	T190	C0342369
acromegaly	T047	C0001206
case report	T170	C0085973
Diffuse large B-cell lymphoma	T191	C0079744
DLBCL	T191	C0079744
common	T081	C0205214
type	T080	C0332307
non-Hodgkin lymphoma	T191	C0024305
lymphomas	T191	C0024299
Patients	T101	C0030705
present	T033	C0150312
nonpainful	T169	C0234226
mass	T033	C0577559
neck	T029	C0027530
groin	T029	C0018246
abdomen	T029	C0000726
associated with	T080	C0332281
constitutional symptoms	T184	C0009812
report	T170	C0684224
authors	T097	C3812881
rare	T080	C0522498
case	T169	C0868928
year	T079	C1510829
woman	T098	C0043210
hyperprolactinemia	T047	C0020514
hypothyroidism	T047	C0020676
acromegaly	T047	C0001206
elevation	T080	C0205250
insulin-like growth factor-1	T116	C0021665
IGF-1	T116	C0021665
elevated	T080	C0205250
growth hormone-releasing hormone	T116	C0037668
GHRH	T116	C0037668
MRI	T060	C0024485
demonstrated	T080	C0443289
diffuse enlargement of the pituitary gland	T184	C0877018
medical treatment	T061	C0418981
patient	T101	C0030705
persistent	T079	C0205322
elevation	T080	C0205250
IGF-1	T116	C0021665
transsphenoidal biopsy	T060	C0176118
yielded	T052	C1999230
diagnosis	T033	C0011900
DLBCL	T191	C0079744
activated	T052	C1879547
B-cell	T025	C0004561
immunophenotype	T059	C0079611
somatotroph hyperplasia	T190	C0342369
stereo-tactic radiation therapy	T061	C3896609
combination	T080	C0205195
chemotherapy	T061	C3665472
currently	T079	C0521116
remission	T191	C0687702
lymphoma	T191	C0024299
normalized	T062	C1882115
IGF-1	T116	C0021665
levels	T080	C0441889
medical therapy	T061	C0418981
months	T079	C0439231
histopathological	T169	C0243140
diagnosis	T033	C0011900
reported	T170	C0684224
case	T169	C0868928
differential diagnosis	T060	C0011906
multidisciplinary evaluation	T060	C0729737
critical	T080	C1511545
intraoperative	T079	C0456904
decision-making	T041	C0011109
treating	T169	C1522326
sellar	T023	C0036609
lesions	T033	C0221198
Doctor	T097	C0031831
Competence	T080	C0086035
Demand	T061	C0441516
Healthcare	T058	C0086388
Evidence	T078	C3887511
Rural China	T083	C0008115
agency	T092	C0237463
problem	T033	C0033213
patients	T101	C0030705
doctors	T097	C0031831
health economics literature	T170	C0023866
empirical	T080	C1880496
evidence	T078	C3887511
patients	T101	C0030705
evaluate	T052	C1516048
better	T080	C0332272
quality care	T058	C0034379
mixed	T169	C0205430
inconclusive	T080	C1629507
household	T099	C0020052
data	T078	C1511726
assessment	T052	C1516048
village	T083	C0562518
doctors'	T097	C0031831
clinical competence	T080	C0008956
rural China	T083	C0008115
no correlation	T080	C0205556
doctor	T097	C0031831
competence	T080	C0086035
patients'	T101	C0030705
healthcare	T058	C0086388
utilisation	T169	C0042153
confidence intervals	T081	C0009667
Household	T099	C0020052
perceptions	T041	C0030971
quality	T080	C0332306
important	T080	C3898777
determinant	T169	C1521761
care-seeking behaviour	T055	C0018695
patients	T101	C0030705
appear	T080	C0700364
unable	T033	C1299582
recognise	T080	C0205396
competent	T080	C0086035
doctors	T097	C0031831
relationship	T080	C0439849
doctor	T097	C0031831
competence	T080	C0086035
perceptions	T041	C0030971
quality	T080	C0332306
Unintentional	T169	C1283932
insecticide poisoning	T037	C0413048
age	T032	C0001779
analysis	T062	C0936012
calls	T058	C0302186
Data	T078	C1511726
assessed	T052	C1516048
determine	T078	C0205258
mechanisms	T169	C0441712
insecticide poisoning	T037	C0413048
young children	T100	C0728836
<5 years	T079	C0439234
age	T032	C0001779
affects	T041	C0001721
insecticide-poisoning	T037	C0413048
patterns	T082	C0449774
Records	T170	C0034869
insecticide-related calls	T058	C0302186
obtained	T169	C1301820
stratified	T080	C0205363
analysis	T062	C0936012
call	T058	C0302186
patterns	T082	C0449774
age	T032	C0001779
conducted	T169	C0205245
insecticide-related calls	T058	C0302186
received by	T080	C1709850
young children	T100	C0728836
calls	T058	C0302186
peaked	T080	C0444505
children	T100	C0008059
aged one	T079	C4082117
Ant	T204	C0003455
cockroach	T204	C0009208
baits	T131	C1254354
accounted	T081	C0392762
calls	T058	C0302186
Sprays	T122	C1154182
found	T033	C0150312
pyrethroids	T109	C0597329
pyrethrins	T109	C0034245
piperonly butoxide	T109	C0031962
organophosphate diazinon	T109	C0012013
accounted	T081	C0392762
calls	T058	C0302186
Mouthing	T040	C2584309
ingesting	T038	C0232478
pest-control product	T131	C0031253
consuming	T052	C0441655
treatment	T169	C0039798
mechanisms	T169	C0441712
children	T100	C0008059
age of two	T079	C0439234
Topical	T082	C0332237
exposure to	T080	C0332157
sprays	T122	C1154182
direct	T080	C1947931
application	T169	C1524063
child	T100	C0008059
older sibling	T099	C0337511
peaked	T080	C0444505
children	T100	C0008059
aged two	T079	C0439234
calls	T058	C0302186
medical attention	T058	C0948564
child	T100	C0008059
sought	UnknownType	C0743213
advised by	T058	C0418832
Normal behaviours	T053	C0004927
associated with	T080	C0332281
child development	T040	C0008071
mouthing	T040	C2584309
behaviours	T053	C0004927
peak of exposure	T080	C0332157
one-year	T079	C4082117
olds	T100	C0008059
finding	T033	C0243095
strategies	T041	C0679199
minimise	T080	C1524031
poisonings	T037	C0032343
vulnerable population	T098	C0949366
Synthetic	T114	C0597550
Oligonucleotide	T114	C0028953
Mir31	T114	C2607480
Duchenne Muscular Dystrophy	T047	C0013264
Exon-skipping	T045	C0035687
synthetic	T114	C0597550
antisense oligonucleotides	T114	C0079925
therapies	T061	C0087111
Duchenne muscular dystrophy	T047	C0013264
DMD	T047	C0013264
sequence-specific	T045	C1624609
oligonucleotide	T114	C0028953
patients	T101	C0030705
discovery	T052	C1880355
dystrophin	T116	C0079259
mRNA	T114	C0035696
translational suppression	T045	C1519619
microRNA	T114	C1101610
miR31	T114	C2607480
miR31	T114	C2607480
muscle	T024	C0026845
DMD	T047	C0013264
patients	T101	C0030705
oligonucleotide	T114	C0028953
exon skipping	T045	C0035687
translational block	T045	C1519619
synergistically	T080	C2986495
exon skipping	T045	C0035687
3'UTR	T086	C0600600
DMD	T047	C0013264
patients	T101	C0030705
in-frame	T086	C0080089
transcript	T114	C1519595
investigations	T058	C1261322
exon skipping	T045	C0035687
miR31	T114	C2607480
modulation	UnknownType	C0678672
in vitro	T059	C3850137
models	T075	C0026339
mdx mouse	T015	C0206535
animal model	T008	C0599779
DMD	T047	C0013264
monitoring	T058	C1283169
effects	T080	C1280500
dystrophin	T116	C0079259
transcriptional	T045	C0040649
translational	T045	C1519614
cell culture	T059	C0007585
model	T075	C0026339
in vivo	T082	C1515655
data	T078	C1511726
enhancement	T052	C2349975
dystrophin	T116	C0079259
translation	T045	C1519614
miR31	T114	C2607480
modulation	UnknownType	C0678672
oligonucleotide	T114	C0028953
outcome	T080	C0085415
investigations	T058	C1261322
Undisclosed	T080	C0439673
HIV infection	T047	C0019693
art	T061	C1963724
use	T169	C0457083
kenya AIDS indicator survey 2012	T170	C0038951
relevance	T080	C2347946
targets	T169	C1521840
HIV diagnosis	T060	C0920550
treatment	T061	C0087111
kenya	T083	C0022558
assess	T058	C0184514
impact	T080	C4049986
undisclosed	T080	C0439673
HIV infection	T047	C0019693
antiretroviral (ARV) therapy	T061	C1963724
ART	T061	C1963724
national	T082	C0681788
estimates	T081	C0750572
diagnosed HIV	T033	C2186509
ART	T061	C1963724
coverage	T169	C1999244
Kenya	T083	C0022558
HIV-positive	T033	C2186509
dried blood spot samples	T031	C0178913
Kenya's second AIDS Indicator Survey	T170	C0038951
tested	T169	C0039593
ARV	T121	C1979629
biomarker	T201	C0005516
liquid chromatography-tandem mass spectrometry	T059	C4049918
Estimates	T081	C0750572
diagnosed HIV	T033	C2186509
ART	T061	C1963724
use	T169	C0457083
self-report	T062	C2700446
compared	T052	C1707455
undisclosed	T080	C0439673
HIV infection	T047	C0019693
ART	T061	C1963724
use	T169	C0457083
ARV	T121	C1979629
Multivariate analysis	T081	C0026777
determined	T080	C0521095
factors	T169	C1521761
associated with	T080	C0332281
undisclosed	T080	C0439673
HIV infection	T047	C0019693
ART	T061	C1963724
use	T169	C0457083
persons	T098	C0027361
ART	T061	C1963724
HIV-positive	T033	C2186509
samples	T031	C0178913
ARV	T121	C1979629
biomarker	T201	C0005516
detected	T033	C0442726
ARV drugs	T121	C0599685
reporting HIV-positive	T033	C2186509
receiving	T080	C1514756
ART	T061	C1963724
reporting HIV-positive	T033	C2186509
ART	T061	C1963724
use	T169	C0457083
reporting	T058	C0700287
HIV-negative status	T034	C0854048
reporting	T058	C0700287
no	T033	C1513916
previous	T079	C0205156
HIV test	T059	C1321876
undisclosed	T080	C0439673
HIV infection	T047	C0019693
ART	T061	C1963724
use	T169	C0457083
diagnosed HIV	T033	C2186509
increased	T081	C0205217
ART	T061	C1963724
coverage	T169	C1999244
increased	T081	C0205217
Undisclosed	T080	C0439673
HIV infection	T047	C0019693
ART	T061	C1963724
associated with	T080	C0332281
aged	T098	C0001792
health provider	T097	C0018724
younger age	T033	C4061789
higher wealth	T080	C0699759
associated with	T080	C0332281
undisclosed	T080	C0439673
ART	T061	C1963724
use	T169	C0457083
Substantial	T078	C0750502
levels	T080	C0441889
undisclosed	T080	C0439673
HIV infection	T047	C0019693
ART	T061	C1963724
use	T169	C0457083
ART	T061	C1963724
observed	T169	C1441672
resulting in	T169	C0332294
diagnosed HIV	T033	C2186509
persons	T098	C0027361
ART	T061	C1963724
coverage	T169	C1999244
persons	T098	C0027361
self-reported	T062	C2700446
ART	T061	C1963724
status	T080	C0449438
objective measures	T170	C0870410
ART	T061	C1963724
use	T169	C0457083
national	T082	C0681788
population	T098	C1257890
sero-surveys	T058	C0019700
improve	T033	C0184511
monitoring	T058	C1283169
treatment	T061	C0087111
targets	T169	C1521840
countries	T083	C0454664
control	T080	C0243148
function	T169	C0542341
Arabidopsis	T002	C0162741
ProDH1	T028	C1418945
ProDH2 genes	T028	C1424903
infection	T046	C3714514
biotrophic	T033	C0243095
necrotrophic	T033	C0243095
pathogens	T001	C0450254
Arabidopsis	T002	C0162741
proline dehydrogenase (ProDH) genes	T028	C1418945
ProDH1	T028	C1418945
ProDH2	T028	C1424903
encoding	T052	C2700640
homologous	T116	C1512488
functional	T169	C0205245
isoenzymes	T116	C0022173
ProDH1	T028	C1418945
abiotic stress	T046	C0449430
ProDH2	T028	C1424903
years	T079	C0439234
genes	T028	C0017337
expression	T045	C0017262
patterns	T082	C0449774
weak	T080	C1762617
transcriptional co-regulation	T045	C1158770
activated	T052	C1879547
pathogen	T001	C0450254
infected	T033	C0439663
tissues	T024	C0040300
Arabidopsis plants	T002	C0162741
silenced	T045	C0598496
ProDH1	T028	C1418945
2	T028	C1424903
expression	T045	C0017262
fail	T169	C0231175
defences	T040	C1154988
hemibiotrophic	T033	C0243095
bacterial	T007	C0004611
pathogen	T001	C0450254
Pseudomonas syringae pv. tomato AvrRpm1	T007	C0317966
Pst-AvrRpm1	T007	C0317966
ProDH1	T028	C1418945
ProDH2	T028	C1424903
regulated	T064	C0851285
salicylic acid	T109	C0036079
SA	T109	C0036079
prodh1	T002	C0162741
prodh2	T002	C0162741
mutant	T049	C0596988
plants	T002	C0032098
gene	T028	C0017337
resistance	T169	C4281815
Pst-AvrRpm1	T007	C0317966
necrotrophic	T033	C0243095
fungal pathogen	T004	C3826297
Botrytis cinerea	T004	C0579190
sensitivity	T169	C0332324
ProDH1	T028	C1418945
ProDH2	T028	C1424903
jasmonic acid	T109	C0064138
JA	T109	C0064138
defence	T040	C1154988
pathway	T044	C1704259
ProDH1	T116	C3657000
ProDH2	T116	C3657000
resistance	T169	C4281815
Pst-AvrRpm1	T007	C0317966
B. cinerea	T004	C0579190
ProDH2	T116	C3657000
restriction	T169	C0443288
B. cinerea	T004	C0579190
growth	T040	C0018270
ProDH1	T028	C1418945
up-regulated	T044	C0041904
SA	T109	C0036079
JA	T109	C0064138
ProDH2	T028	C1424903
activated	T052	C1879547
JA	T109	C0064138
genes	T028	C0017337
transcriptional inter-regulation	T045	C1158770
basal	T082	C0205112
infection	T046	C3714514
conditions	T080	C0348080
ProDH2	T028	C1424903
disease resistance	T040	C1136180
regulation	T064	C0851285
complementary function	T169	C0542341
enzyme isoforms	T116	C0022173
infected	T033	C0439663
tissues	T024	C0040300
ProDH	T028	C1418945
biotrophic	T033	C0243095
necrotrophic	T033	C0243095
pathogens	T001	C0450254
Effect	T080	C1280500
Protein	T116	C0033684
Repetitiveness	T169	C0205341
Protein-Protein Interaction	T044	C0872079
Prediction	T078	C0681842
Results	T169	C1274040
Support Vector Machines	T081	C2699740
computational approaches	T062	C1516769
protein-protein interactions	T044	C0872079
support vector machines	T081	C2699740
SVMs	T081	C2699740
methods	T170	C0025663
repetitiveness	T169	C0205341
datasets	T170	C0150098
study	T062	C2603343
repetitiveness	T169	C0205341
datasets	T170	C0150098
predicting	T078	C0681842
results	T169	C1274040
methods	T170	C0025663
positive	T033	C1446409
datasets	T170	C0150098
proteins	T116	C0033684
graph	T170	C0681493
protein-protein interaction	T044	C0872079
datasets	T170	C0150098
negative	T033	C0205160
datasets	T170	C0150098
proteins	T116	C0033684
repetitiveness	T169	C0205341
graph	T170	C0681493
adjacency matrix	T082	C1879629
relationship	T080	C0439849
SVM	T081	C2699740
prediction	T078	C0681842
results	T169	C1274040
repeated	T169	C0205341
proteins	T116	C0033684
distributions	T169	C1704711
repeated	T169	C0205341
proteins	T116	C0033684
datasets	T170	C0150098
Protein	T116	C0033684
repetitiveness	T169	C0205341
positive	T033	C1446409
negative	T033	C0205160
datasets	T170	C0150098
prediction	T078	C0681842
result	T169	C1274040
protein	T116	C0033684
repetitiveness	T169	C0205341
positive	T033	C1446409
negative	T033	C0205160
datasets	T170	C0150098
result	T169	C1274040
repetitiveness	T169	C0205341
datasets	T170	C0150098
protein-protein interactions	T044	C0872079
prediction	T078	C0681842
SVMs	T081	C2699740
data	T078	C1511726
repeat	T169	C0205341
proteins	T116	C0033684
sense of number	T041	C0596887
sense of	T041	C0424215
magnitude	T081	C1704240
continuous	T078	C0549178
magnitudes	T081	C1704240
numerical	T081	C0237753
cognition	T041	C0009240
pitting	T169	C0205323
theories	T078	C0871935
theory	T078	C0871935
number sense	T041	C0596887
theory	T078	C0871935
sense of number	T041	C0596887
innate	T055	C0021619
non-symbolic numerosity	T041	C0871836
continuous	T078	C0549178
magnitudes	T081	C1704240
size	T082	C0456389
area	T082	C0205146
density	T081	C0178587
theory	T078	C0871935
numerosities	T041	C0871836
continuous	T078	C0549178
magnitudes	T081	C1704240
numerosities	T041	C0871836
sense of number	T041	C0596887
innate	T055	C0021619
number sense	T041	C0596887
theory	T078	C0871935
correlation	T080	C1707520
numerosities	T041	C0871836
continuous	T078	C0549178
magnitudes	T081	C1704240
non-symbolic numerosity processing	T041	C0871836
continuous	T078	C0549178
magnitudes	T081	C1704240
behavioral	T062	C0004939
imaging studies	T060	C1881134
infants	T100	C0021270
adults	T100	C0001675
animals	T008	C0003062
continuous	T078	C0549178
magnitudes	T081	C1704240
sense of	T041	C0424215
magnitude	T081	C1704240
theory	T078	C0871935
theory	T078	C0871935
continuous	T078	C0549178
magnitudes	T081	C1704240
numerosities	T041	C0871836
number sense	T041	C0596887
theory	T078	C0871935
theory	T078	C0871935
number sense	T041	C0596887
innate	T055	C0021619
hypothesis	T078	C1512571
correlation	T080	C1707520
numerosity	T041	C0871836
continuous	T078	C0549178
magnitudes	T081	C1704240
Integrated Management Strategies	T059	C0022885
Promote	T052	C0033414
Protein	T116	C0033684
Quality	T080	C0332306
Cotton Embryos	T002	C0010197
High	T080	C0205250
Levels	T080	C0441889
Soil	T167	C0037592
Available	T169	C0470187
N	T123	C0028158
N	T123	C0028158
Assimilation	T070	C1254365
Protein	T116	C0033684
Accumulation	T033	C4055506
Rate	T081	C1521828
Cottonseed	T002	C0010197
source	T033	C0449416
ruminant	T015	C0035950
feed	T168	C0003050
industrial	T057	C0021267
purposes	T169	C1285529
improve	T033	C0184511
nutritional value	T080	C0028722
cotton embryos	T002	C0010197
study	T062	C2603343
conventional management	T059	C0022885
CM	T059	C0022885
cotton	T002	C0010197
management strategies	T059	C0022885
IMS1	T059	C0022885
IMS2	T059	C0022885
performed	T169	C0884358
soil	T167	C0037592
fertility	T033	C0243095
levels	T080	C0441889
study	T062	C2603343
relationships	T080	C0439849
soil	T167	C0037592
N	T123	C0028158
N	T123	C0028158
assimilation	T070	C1254365
embryonic	T002	C0036563
protein	T116	C0033684
accumulation	T033	C4055506
protein	T116	C0033684
quality	T080	C0332306
levels of proteins	T059	C0202202
essential amino acids	T059	C0201874
semi-essential amino acids	T059	C0201874
glutamate	T059	C0523665
lysine	T059	C0523760
methionine	T059	C0428210
higher	T080	C0205250
IMS1	T059	C0022885
IMS2	T059	C0022885
embryos	T002	C0036563
CM	T059	C0022885
embryos	T002	C0036563
changes	T169	C0392747
positively	T033	C1446409
correlated	T080	C1707520
soil	T167	C0037592
available	T169	C0470187
N content	T059	C0523793
glutamine synthetase activity	T044	C1150667
peak	T080	C0444505
protein	T116	C0033684
accumulation	T033	C4055506
rate	T081	C1521828
negatively	T033	C1513916
correlated	T080	C1707520
free	T080	C1996904
amino acid level	T059	C1328436
results	T033	C0683954
integrated management strategies	T059	C0022885
rates	T081	C1521828
timing	T079	C0449243
N	T123	C0028158
application	T169	C4048755
raise	T169	C0442805
level	T080	C0441889
soil	T167	C0037592
available	T169	C0470187
N	T123	C0028158
N	T123	C0028158
assimilation	T070	C1254365
cotton embryos	T002	C0010197
protein content	T059	C0202202
limited	T169	C0439801
rate	T081	C1521828
protein	T116	C0033684
accumulation	T033	C4055506
free	T080	C1996904
amino acid content	T059	C0201874
combination	T080	C0205195
target yield	T081	C0392762
fertilization	T070	C1254365
growth	T040	C0597252
N	T123	C0028158
application	T169	C4048755
high	T080	C0205250
plant	T002	C0032098
density	T081	C0178587
seedling	T002	C0242437
bio-organic fertilizer	T167	C1289928
improve	T033	C0184511
protein	T116	C0033684
quality	T080	C0332306
cotton embryos	T002	C0010197
soil	T167	C0037592
soil	T167	C0037592
organic matter	T109	C0029224
total	T080	C0439810
nitrogen	T123	C0028158
HIV	T005	C0019682
epidemic	T067	C0014499
public consultation	T061	C0886172
HIV prevention	T061	C0150413
tool	T170	C0282574
PrEP	T061	C3850098
pre-exposure prophylaxis	T061	C3850098
HIV	T005	C0019682
epidemic	T067	C0014499
NHS England consultation	T058	C1254363
September	T079	C3828193
Osseointegration	T042	C0079949
novel	T080	C0205314
Ti-Nb-Zr-Ta-Si alloy	T122	C0011323
dental implants	T074	C0011373
in vivo	T082	C1515655
study	T062	C2603343
evaluate	T058	C0220825
effects of	T080	C1704420
Ti-Nb-Zr-Ta-Si alloy	T122	C0011323
implants	T074	C0011373
mineral apposition rate	T081	C1521828
BIC contact	T081	C0392762
rabbits	T015	C3887509
Ti-Nb-Zr-Ta-Si alloy	T122	C0011323
implants	T074	C0011373
fabricated	T169	C0205245
placed	T058	C1533810
right	T082	C0444532
femur	T023	C0015811
sites	T029	C1515974
rabbits	T015	C3887509
titanium	T196	C0040302
implants	T074	C0011373
controls	T096	C0009932
left	T082	C0443246
femur	T023	C0015811
Tetracycline	T109	C0039644
alizarin red	T109	C0051165
weeks	T079	C0439230
week	T079	C0439230
euthanization	T058	C1136183
weeks	T079	C0439230
weeks	T079	C0439230
implantation	T061	C0011370
animals	T008	C0003062
euthanized	T058	C3686530
Surface	T082	C0205148
characterization	T052	C1880022
implant-bone contact	T081	C0392762
surface	T082	C0205148
analysis	T062	C0936012
performed	T169	C0884358
scanning electron microscope	T074	C0262878
energy dispersive X-ray detector	T074	C0025080
Mineral apposition rate	T081	C1521828
evaluated	T058	C0220825
confocal laser scanning microscope	T059	C0242841
Toluidine blue staining	T059	C0523203
performed	T169	C0884358
undecalcified	T033	C0243095
sections	T167	C1522472
histology	T091	C0019638
histomorphology	T080	C0332437
Scanning electron microscope	T074	C0262878
histomorphology	T080	C0332437
observation	T078	C1554188
revealed	T080	C0443289
direct contact	T169	C0332158
implants	T074	C0011373
bone	T023	C0262950
groups	T078	C0441833
healing	T040	C0043240
period	T079	C1948053
weeks	T079	C0439230
Ti-Nb-Zr-Ta-Si alloy	T122	C0011323
implants	T074	C0011373
mineral apposition rate	T081	C1521828
titanium	T196	C0040302
implants	T074	C0011373
no significant	T033	C1273937
Ti-Nb-Zr-Ta-Si alloy	T122	C0011323
implants	T074	C0011373
titanium	T196	C0040302
implants	T074	C0011373
weeks	T079	C0439230
No significant	T033	C1273937
bone-to-implant contact	T081	C0392762
observed	T169	C1441672
Ti-Nb-Zr-Ta-Si alloy	T122	C0011323
implants	T074	C0011373
titanium	T196	C0040302
implants	T074	C0011373
implants	T074	C0011373
healing	T040	C0043240
period	T079	C1948053
weeks	T079	C0439230
weeks	T079	C0439230
Ti-Nb-Zr-Ta-Si alloy	T122	C0011323
implants	T074	C0011373
close direct contact	T169	C0332158
titanium	T196	C0040302
implants	T074	C0011373
implants	T074	C0011373
improved	T033	C0184511
mineral matrix apposition rate	T081	C1521828
alternative	T077	C1523987
material	T167	C0520510
dental implants	T074	C0011373
Simultaneous	T079	C0521115
edited	T077	C1711200
MRS	T060	C0024487
GABA	T116	C0016904
glutathione	T116	C0017817
Edited	T077	C1711200
MRS	T060	C0024487
detection	T061	C1511790
low	T080	C0205251
concentration	T081	C1446561
metabolites	T123	C0870883
signals	T067	C1710082
not	T169	C1518422
resolved	T077	C2699488
MR spectrum	T060	C0024487
Tailored acquisitions	T052	C1706701
designed	T090	C0920454
detect	T061	C1511790
example	T077	C1707959
inhibitory	T052	C3463820
neurotransmitter	T123	C0027908
γ-aminobutyric acid	T116	C0016904
GABA	T116	C0016904
reduction-oxidation	T044	C0030012
redox	T044	C0030012
glutathione	T116	C0017817
GSH	T116	C0017817
single	T081	C0205171
voxel	T077	C2700259
edited	T077	C1711200
experiments	T062	C0681814
rate	T081	C1521828
one	T081	C0205447
metabolite	T123	C0870883
per-experiment	T062	C0681814
simultaneous	T079	C0521115
detection	T061	C1511790
overlapping	T079	C1948020
signals	T067	C1710082
GABA	T116	C0016904
GSH	T116	C0017817
using	T169	C1524063
Hadamard Encoding and Reconstruction of Mega-Edited Spectroscopy	T059	C0022885
HERMES	T059	C0022885
HERMES	T059	C0022885
applies	T169	C4048755
orthogonal editing encoding	T052	C2700640
following	T079	C0332282
Hadamard scheme	T170	C1519193
GSH-	T116	C0017817
GABA	T116	C0016904
edited	T077	C1711200
difference	T080	C1705242
spectra	T077	C2827424
single multiplexed experiment	T062	C0681814
TE	T079	C2826100
editing	T077	C1711200
pulses	T067	C1947910
applied	T169	C4048755
GSH	T116	C0017817
GABA	T116	C0016904
both	T080	C1706086
offsets	T081	C1711330
dual-lobe cosine-modulated pulse	T067	C1947910
Hadamard combinations	T170	C0282574
sub-experiments	T062	C0681814
GABA	T116	C0016904
GSH	T116	C0017817
difference	T080	C1705242
spectra	T077	C2827424
HERMES	T059	C0022885
excellent	T080	C1961136
separation	T080	C0443299
edited	T077	C1711200
GABA	T116	C0016904
GSH	T116	C0017817
signals	T067	C1710082
phantoms	T073	C0282611
edited	T077	C1711200
lineshapes	T080	C0348078
agree	T033	C3641827
well	T080	C0205170
separate	T080	C0443299
Mescher-Garwood Point-resolved Spectroscopy	T059	C0022885
MEGA-PRESS	T059	C0022885
acquisitions	T052	C1706701
In vivo	T082	C1515655
quality	T080	C0332306
signal-to-noise ratio	T081	C2986823
SNR	T081	C2986823
HERMES	T059	C0022885
spectra	T077	C2827424
similar	T080	C2348205
sequentially	T080	C1705294
acquired	T080	C0439661
MEGA-PRESS	T059	C0022885
spectra	T077	C2827424
benefit	T081	C0814225
acquisition	T052	C1706701
time	T079	C0040223
Chitosan	T109	C0162969
poly(2-hydroxyethyl methacrylate)	T109	C0032509
core-shell microgels	T122	C0013161
drug delivery carriers	T074	C0085104
salicylic acid	T109	C0036079
loading and release	T169	C0205245
chitosan	T109	C0162969
poly(2-hydroxyethyl methacrylate)	T109	C0032509
CS	T109	C0162969
PHEMA	T109	C0032509
core-shell microgels	T122	C0013161
drug delivery carriers	T074	C0085104
CS	T109	C0162969
PHEMA	T109	C0032509
microgels	T122	C0013161
emulsifier-free emulsion polymerisation	T067	C0314672
N,N '-methylenebisacrylamide	T109	C0067314
MBA	T109	C0067314
crosslinker	T109	C0029224
study on drug loading	T062	C0013175
salicylic acid	T109	C0036079
SA	T109	C0036079
model drug	T121	C1254351
encapsulation efficiency	T067	C2348438
EE	T067	C2348438
drug	T121	C1254351
ratio	T081	C0456603
EE	T067	C2348438
crosslinking	T067	C1254366
MBA	T109	C0067314
EE	T067	C2348438
pH	T081	C0020283
release of SA	T070	C3850077
pH	T081	C0020283
pH	T081	C0020283
release of SA	T070	C3850077
NaCl	T121	C0037494
pH	T081	C0020283
ionic-sensitivity	T080	C0205556
CS	T109	C0162969
PHEMA	T109	C0032509
sustained release delivery device	T121	C1135768
oral delivery	T074	C0302620
Breast Augmentation	T061	C0191925
Conservation Surgery	T061	C0917927
Radiation Therapy	T061	C1522449
patients	T101	C0030705
breast augmentation	T061	C0191925
implants	T074	C0021102
breast conservation surgery	T061	C0917927
BCS	T061	C0917927
radiotherapy	T061	C1522449
retrospective study	T062	C0035363
patients	T101	C0030705
breast implant	T074	C0179412
augmentation	T061	C0191925
BCS	T061	C0917927
radiotherapy	T061	C1522449
women	T098	C0043210
prosthetic	T074	C0179412
breast reconstruction	T061	C0085076
patients	T101	C0030705
augmentation	T061	C0191925
BCS	T061	C0917927
radiotherapy	T061	C1522449
mean	T081	C0444504
age	T032	C0001779
years	T079	C1510829
range	T081	C1514721
years	T079	C1510829
patients	T101	C0030705
one-stage implant	T061	C0021107
breast augmentation	T061	C0191925
patients	T101	C0030705
two-stage expander	T061	C0021107
implant augmentation	T061	C0191925
surgeries	T061	C0543467
breast implant	T074	C0179412
patients	T101	C0030705
contralateral	T082	C0441988
augmentation	T061	C0191925
patient	T101	C0030705
oral	T169	C1527415
antibiotics	T195	C0003232
wound infection	T046	C0043241
Patients	T101	C0030705
cosmetic	T033	C1390444
result	T169	C1274040
breasts	T023	C0006141
patients	T101	C0030705
breast cancer	T191	C0006142
BCS	T061	C0917927
radiotherapy	T061	C1522449
augmented	T081	C0205217
breast implants	T074	C0179412
Mitochondrial pyruvate dehydrogenase phosphatase 1	T028	C1418818
differentiation of cardiomyocytes	T043	C1817118
mouse embryonic stem cells	T025	C4042879
Mitochondria	T026	C0026237
embryonic stem cells	T025	C0596508
ESCs	T025	C0596508
differentiation	T043	C0007589
cell lineages	T078	C0282637
cardiomyocytes	T025	C0225828
mitochondrial regulators	T123	C0574031
rate of differentiation	T081	C1521828
cell fate	T043	C1540661
mitochondrial factor	T116	C0033684
differentiation of ESCs	T043	C1514964
cardiac myocytes	T025	C0225828
cardiomyocyte differentiation	T043	C1817118
mouse ESCs	T025	C4042879
mESCs	T025	C4042879
microarray assays	T059	C1449575
messenger RNA	T114	C0035696
mRNA	T114	C0035696
expression	T045	C0040649
differentiation day 8	T033	C0243095
D8	T033	C0243095
undifferentiated	T080	C0205618
mESCs	T025	C4042879
expressed genes	T028	C0017337
Pdp1	T028	C1418818
expression	T045	C0017262
D8	T033	C0243095
D0	T080	C0205618
suppressed	T169	C1260953
mitochondrial	T026	C0026237
indices	T170	C0918012
ATP	T114	C0001480
membrane potential	T043	C1156295
ROS	T044	C3894464
mitochondrial Ca(2+)	T043	C1658623
Pdp1	T028	C1418818
overexpression	T045	C0017262
mitochondrial	T026	C0026237
indices	T170	C0918012
pyruvate dehydrogenase activity	T044	C1151688
expression	T045	C0040649
cardiac differentiation	T043	C2247990
marker mRNA	T045	C0872263
cardiac differentiation	T043	C2247990
rate	T081	C1521828
knockdown	T063	C2350567
Pdp1 gene	T028	C1418818
expression	T045	C0040649
cardiac differentiation	T043	C2247990
marker mRNA	T045	C0872263
cardiac differentiation	T043	C2247990
rate	T081	C1521828
mitochondrial PDP1	T028	C1418818
cardiac differentiation	T043	C2247990
differentiation stage	T079	C1254367
ESCs	T025	C0596508
Thermo-reversible capture and release	T067	C1254366
DNA	T114	C0012854
zwitterionic surfactants	T120	C0038891
thermo-reversible capture and release	T067	C1254366
DNA	T114	C0012854
protonation	T067	C0178812
deprotonation	T067	C0599225
alkyldimethylamine oxide	T109	C0029224
CnDMAO	T109	C0029224
Tris-HCl	T130	C1254353
buffer solution	T130	C3190981
DNA	T114	C0012854
C14DMAO	T109	C0029224
Tris-HCl	T130	C1254353
buffer solution	T130	C3190981
pH	T081	C0020283
transparent	T080	C0522503
DNA	T114	C0012854
molecules	T167	C0567416
individuals	T098	C0237401
binding	T044	C1167622
C14DMAO	T109	C0029224
weak	T080	C1762617
increase	T169	C0442805
temperature	T081	C0039476
pH	T081	C0020283
buffer solution	T130	C3190981
decreases	T081	C0547047
protonation	T067	C0178812
C14DMAO	T109	C0029224
C14DMAO	T109	C0029224
H(+)	T196	C0033727
C14DMAOH(+)	T109	C0029224
increase of the turbidity	T033	C0301634
samples	T167	C0439861
binding	T044	C1167622
protonated	T067	C0178812
C14DMAOH(+)	T109	C0029224
DNA	T114	C0012854
formation	T169	C1522492
DNA	T114	C0012854
C14DMAOH(+)	T109	C0029224
complexes	T104	C1704241
DNA	T114	C0012854
molecules	T167	C0567416
compacted	T033	C1333134
UV-vis	T070	C1883416
UV-vis absorptions	T059	C0022885
circular dichroism	T059	C0008813
CD	T059	C0008813
measurements	T169	C0242485
atomic force microscopy	T059	C0242849
AFM	T059	C0242849
observations	T062	C0302523
dynamic light scattering	T059	C1882368
DLS	T059	C1882368
measurements	T169	C0242485
agarose gel electrophoresis	T059	C0013856
AGE	T059	C0013856
temperature	T081	C0039476
compacted	T033	C1333134
DNA	T114	C0012854
molecules	T167	C0567416
cycle	T079	C1511572
loss	T081	C1517945
efficiency	T081	C0013682
effect of	T080	C1704420
chain length	T081	C0596310
CnDMAO	T109	C0029224
C14DMAO	T109	C0029224
C12DMAO	T109	C0029224
phenomena	T067	C1882365
higher	T080	C0205250
critical	T080	C1511545
surfactant	T120	C0038891
concentration	T081	C1446561
DNA	T114	C0012854
compaction	T033	C1333134
lower	T080	C0205251
pH	T081	C0020283
Tris-HCl	T130	C1254353
buffer solution	T130	C3190981
pH	T081	C0020283
DNA	T114	C0012854
C10DMAO	T109	C0029224
DNA	T114	C0012854
compaction	T033	C1333134
Tris-HCl	T130	C1254353
buffer solution	T130	C3190981
lower	T080	C0205251
pH	T081	C0020283
higher	T080	C0205250
C10DMAO	T109	C0029224
concentration	T081	C1446561
negative charges	T080	C2825491
DNA	T114	C0012854
molecules	T167	C0567416
positive charges	T080	C2825490
cationic CnDMAOH(+)	T109	C0029224
micelles	T109	C0025938
DNA	T114	C0012854
compacted	T033	C1333134
DNA	T114	C0012854
CnDMAOH(+)	T109	C0029224
complexes	T104	C1704241
higher	T080	C0205250
critical	T080	C1511545
micelle	T109	C0025938
concentration	T081	C1264643
cmc	T081	C1264643
chain length	T081	C0596310
C10DMAOH(+)	T109	C0029224
cationic C10DMAOH(+)	T109	C0029224
micelles	T109	C0025938
compact	T033	C1333134
DNA	T114	C0012854
efficient	T080	C0442799
alternative approach	T061	C0679761
stimuli-responsive gene therapy	T061	C0017296
drug release	T070	C3850077
Collaborating	T054	C0282116
Systems	T169	C0449913
Change	T169	C0392747
Social Science Framework	T170	C0596159
Academic Roles	UnknownType	C0683838
Community Partnerships	T054	C0680453
Environmental health	T091	C0014413
researchers	T097	C0035173
government agencies	T092	C0018105
community groups	UnknownType	C0683986
community	T096	C0009462
academic	UnknownType	C0683838
partnerships	T092	C1711206
effective strategy	T041	C0679199
support	T077	C1521721
science	T090	C0036397
improvements	T077	C2986411
environmental health	T091	C0014413
Social sciences	T090	C0037434
concepts	T078	C0178566
approaches	T078	C1254370
methods	T170	C0025663
translational partnerships	T092	C1711206
appropriate	T080	C1548787
roles	T078	C0086939
academic	UnknownType	C0683838
partners	T098	C3887537
process	T067	C1522240
changing	T169	C0392747
systems	T169	C0449913
policies	T170	C0242456
practices	T057	C0033284
programs	T169	C3484370
planning	T170	C0086960
evaluating	T078	C1550157
sustaining	T169	C0443318
partnerships	T092	C1711206
conceptual framework	T078	C1254370
academic	UnknownType	C0683838
partners	T098	C3887537
different stages	T079	C1306673
systems	T169	C0449913
change	T169	C0392747
framework	T078	C1254370
academic	UnknownType	C0683838
community	T096	C0009462
partnerships	T092	C1711206
National Institute of Environmental Health Sciences	T093	C1955979
Community Outreach and Engagement Cores	T097	C1522486
framework	T078	C1254370
academic	UnknownType	C0683838
partners	T098	C3887537
appropriate	T080	C1548787
expertise	T080	C0870520
community	T096	C0009462
improve	T033	C0184511
environmental health	T091	C0014413
novel	T080	C0205314
mechanical simulator	T074	C0183309
cannulation	T061	C0917707
sphincterotomy	T061	C0748895
Billroth II	T061	C0192444
Roux-en-Y reconstruction	T061	C0372024
patients	T101	C0030705
Billroth II	T061	C0192444
B II	T061	C0192444
Roux-en-Y	T061	C0372024
anatomy	T017	C0700276
endoscopic retrograde cholangiopancreatography	T060	C0008310
ERCP	T060	C0008310
novel	T080	C0205314
simulator	T074	C0183309
simulated	T062	C0679083
fluoroscopy	T060	C0016356
cannulation	T061	C0917707
sphincterotomy	T061	C0748895
training	T065	C0220931
simulation system	T074	C4075558
built	T052	C1706853
common	T081	C0205214
chassis	T073	C1707356
series	T081	C0205549
previously	T079	C0205156
ERCP	T060	C0008310
simulators	T074	C0183309
papilla	T023	C3714556
organic	T080	C0747055
material	T167	C0520510
cut	T067	C1883724
high frequency	T079	C0205212
current	T070	C1705970
advancement	T169	C1280477
guidewires	T073	C1708264
instruments	T074	C0348000
transparent	T080	C0522503
bile ducts	T023	C0005400
window	T073	C1704674
simulator	T074	C0183309
fluoroscopy	T060	C0016356
ERCP	T060	C0008310
B II	T061	C0192444
Roux-en-Y	T061	C0372024
simulation system	T074	C4075558
evaluated	T058	C0220825
ERCP	T060	C0008310
course	T079	C0750729
technical problems	T067	C1710348
novel	T080	C0205314
simulator	T074	C0183309
course	T079	C0750729
sphincterotomy	T061	C0748895
organic	T080	C0747055
papillae	T023	C3714556
exchanged	T169	C0205245
seconds	T079	C0457385
novel	T080	C0205314
B II	T061	C0192444
Roux-en-Y	T061	C0372024
simulator	T074	C0183309
favorable	T080	C3640814
results	T169	C1274040
trainees	T097	C1522486
expert	T097	C1611835
endoscopists	T097	C1522486
categories	T170	C0683312
assessed	T052	C1516048
B II	T061	C0192444
Roux-en-Y	T061	C0372024
mechanical simulator	T074	C0183309
simple	T080	C0205352
practicable	T080	C0205556
evaluation	T058	C0220825
ERCP	T060	C0008310
course	T079	C0750729
results	T169	C1274040
thermophilic	T001	C0597570
ene-reductase	T116	C0030016
acidophilic	T169	C0333931
iron oxidizer	T007	C0004611
Ene-reductases	T116	C0030016
extremophiles	T001	C4277715
biocatalysis	T070	C2350294
higher	T080	C0205250
stability	T080	C0205360
properties	T080	C0871161
genome	T028	C0017428
acidophilic	T169	C0333931
iron-oxidizing bacterium	T007	C0004611
Ferrovum" sp. JA12	T007	C3908921
thermophilic	T001	C0597570
ene-reductase	T116	C0030016
FOYE-1	T116	C0030016
foye-1 gene	T028	C0017337
pET16bp	T114	C0032136
expression	T045	C0017262
vector system	T114	C0017397
enzyme	T116	C0014442
Escherichia coli	T007	C0014834
BL21 (DE3; pLysS) cells	T025	C0007634
FOYE-1	T116	C0030016
activity	T044	C0243102
rates	T081	C1521828
N-phenylmaleimide	T109	C0068268
N-phenyl-2-methylmaleimide	T109	C0029224
conversion	T169	C0439836
nicotinamide cofactors	T109	C0009235
NADPH	T114	C0027303
NADH	T114	C0027289
catalytic	T070	C0007382
efficiency	T081	C0013682
NADPH	T114	C0027303
higher	T080	C0205250
NADH	T114	C0027289
temperature	T081	C0039476
maximum	T081	C0806909
pH optimum	T081	C0020283
activity	T044	C0243102
doubled	T052	C1705764
findings	T033	C0243095
FOYE-1	T116	C0030016
biocatalyst	T067	C0175921
synthesis	T052	C1883254
succinimides	T109	C0038623
thermophilic	T001	C0597570
ene-reductase	T116	C0030016
acidic habitat	T082	C0871648
genomic	T028	C0017428
neighborhood	T082	C0014406
encoding	T052	C2700640
gene	T028	C0017337
FOYE-1	T116	C0030016
quorum-sensing	T043	C1154599
tanshinone I	T109	C0075810
derivative	T169	C1527240
activities	T038	C3714634
antibiotics	T195	C0003232
Staphylococcus aureus	T007	C0038172
in vitro	T080	C1533691
in vivo	T082	C1515655
Infections	T046	C3714514
Staphylococcus aureus	T007	C0038172
discovery	T052	C1880355
antibiotics	T195	C0003232
resistant bacteria	T007	C1444090
health	T078	C0018684
problem	T033	C0033213
hospital	T073	C0019994
community settings	T093	C1274109
antibiotic	T195	C0003232
antibiotics	T195	C0003232
study	T062	C2603343
16-aldehyde tanshinone I	T121	C1254351
ALT	T121	C1254351
synthesized	T052	C1883254
bacteriostatic activity	T038	C3714634
synergistic	T080	C2986495
additive	T080	C0442796
activity	T038	C3714634
ALT	T121	C1254351
aminoglycoside antibiotics	T109	C0003233
β-lactam antibiotics	T109	C0026458
in vitro	T080	C1533691
ALT	T121	C1254351
streptomycin	T109	C0038425
STR	T109	C0038425
ampicillin	T109	C0002680
AMP	T109	C0002680
S. aureus	T007	C0038172
murine infection model	T050	C2986594
mechanistic insight	T044	C0678659
ALT	T121	C1254351
damage	T169	C1883709
bacterial	T007	C0004611
cell membrane	T026	C3161472
accumulation	T033	C4055506
antibiotics	T195	C0003232
bacterial cells	T007	C0563199
treating	T169	C1522326
infections	T046	C3714514
S. aureus	T007	C0038172
application	T169	C4048755
tanshinones	T109	C0075810
argyrophilic	T025	C0682551
nucleolar organizing region	T026	C0028609
Ischemia/reperfusion (I/R) injury	T037	C0035126
complex event	T051	C0441471
observed	T169	C1441672
vascular surgery	T061	C0042381
functional	T043	C0007613
structural	T026	C0243092
cell damage	T049	C0599732
Nucleolar-organizing regions	T026	C0028609
NORs	T026	C0028609
sites	T082	C0205145
ribosomal genes	T028	C0035899
chromosomes	T026	C0008633
stained	T059	C0487602
silver	T196	C0037125
active	T169	C0205177
proteins	T116	C0033684
argyrophilic-NOR (AgNOR)-associated proteins	T116	C1571148
effects of	T080	C1704420
renal	T023	C0022646
I/R injury	T037	C0035126
NOR protein	T116	C1571149
synthesis	T044	C0597295
AgNOR proteins	T116	C1571148
amount	T081	C1265611
histopathological injuring score	T033	C2825141
female	T032	C0086287
wistar-albino rats	T015	C0086893
animals	T008	C0003062
randomly	T080	C0439605
divided	T169	C0332849
groups	T078	C0441833
Control Group	T096	C0009932
I/R	T037	C0035126
Group	T078	C0441833
I/R	T037	C0035126
group	T078	C0441833
rats	T015	C0086893
renal pedicle	T023	C0733948
occlusion	T046	C0028778
reperfusion	T038	C0684253
control group	T096	C0009932
drug injections	T061	C0392877
ischemia reperfusion	T037	C0035126
performed	T169	C0884358
animals	T008	C0003062
histopathological injury score	T033	C2825141
mean AgNOR number	T033	C0243095
total AgNOR area	T033	C0243095
nuclear area	T033	C0243095
TAA	T033	C0243095
NA	T033	C0243095
detected	T033	C0442726
rat	T015	C0086893
control	T096	C0009932
I/R	T037	C0035126
groups	T078	C0441833
significant	T078	C0750502
histopathological injury scores	T033	C2825141
control group	T096	C0009932
I/R	T037	C0035126
group	T078	C0441833
significant	T078	C0750502
mean AgNOR number	T033	C0243095
TAA/NA ratio	T081	C0456603
positive correlation	T080	C1707520
TAA/NA ratio	T081	C0456603
histopathological injury score	T033	C2825141
mean AgNOR number	T033	C0243095
histopathological injury score	T033	C2825141
detection	T061	C1511790
AgNOR proteins	T116	C1571148
amount	T081	C1265611
indicator	T169	C1522602
information	T078	C1533716
cellular behaviour	T043	C0007613
self-protective	T039	C0524828
tubular epithelial cells	T025	C1266872
I/R injury	T037	C0035126
cellular damage	T049	C0599732
levels	T080	C0441889
emotion	T041	C0013987
expression	T033	C0015457
social costs	UnknownType	C0814661
Parkinson's disease	T047	C0030567
Patients	T101	C0030705
Parkinson's disease	T047	C0030567
PD	T047	C0030567
perceived	T041	C0030971
negatively	T033	C0205160
healthy	T080	C3898900
peers	T098	C0679739
factors	T169	C1521761
contribute	T052	C1880177
negative	T033	C0205160
social perception	T041	C0037427
cohort	T098	C0599755
PD	T047	C0030567
patients	T101	C0030705
healthy controls	T080	C2986479
assessed	T052	C1516048
emotion	T041	C0013987
emotional	T033	C0849912
intensity	T080	C0522510
displayed	T169	C0870432
dynamic	T169	C0729333
facial expressions	T033	C0015457
adults	T100	C0001675
PD	T047	C0030567
watched	T041	C2371283
emotionally	T041	C0013987
films	T170	C4019020
Experiment	T062	C0681814
age	T032	C0001779
peers	T098	C0679739
patients	T101	C0030705
disease	T047	C0012634
social desirability	T054	C0037408
dimensions	T081	C0439534
audiovisual	T170	C2936644
stimuli	T067	C0234402
interview excerpts	T097	C0021821
films	T170	C4019020
Experiment	T062	C0681814
Experiment	T062	C0681814
participants	T098	C0679646
PD	T047	C0030567
rated	T052	C0871208
significantly more	T081	C4055637
facially expressive	T033	C0015457
healthy controls	T080	C2986479
ratings	T052	C0871208
PD	T047	C0030567
patients	T101	C0030705
experiencing	T041	C0596545
negative	T033	C0205160
emotion	T041	C0013987
controls	T080	C0243148
rated	T052	C0871208
displaying	T169	C0870432
positive	T033	C1446409
emotion	T041	C0013987
reported	T058	C0700287
feeling	T041	C1527305
Experiment	T062	C0681814
results	T034	C0456984
age-peers	T098	C0679739
rated	T052	C0871208
PD	T047	C0030567
patients	T101	C0030705
significantly less	T081	C4055638
socially desirable	T054	C0037408
control	T080	C0243148
participants	T098	C0679646
PD	T047	C0030567
patients	T101	C0030705
rated	T052	C0871208
involved	T169	C1314939
interested	T041	C0543488
friendly	T080	C2700214
optimistic	T033	C0564470
physically attractive	T080	C2346874
healthy controls	T080	C2986479
results	T034	C0456984
PD	T047	C0030567
patients	T101	C0030705
report	T058	C0700287
feeling	T041	C1527305
attributions	T041	C0596130
emotions	T041	C0013987
social characteristics	T055	C0037401
significant	T078	C0750502
social challenges	T080	C0699806
disease	T047	C0012634
changes	T169	C0392747
ability	T032	C0085732
modulate	T082	C0443264
expression	T033	C0015457
negative	T033	C0205160
emotions	T041	C0013987
contribute	T052	C1880177
negative	T033	C0205160
social	T169	C0728831
impressions	T055	C0596764
PD	T047	C0030567
patients	T101	C0030705
hospital	T073	C0019994
geriatrics services	T093	C4041524
Africa	T083	C0001737
University of Benin Teaching Hospital	T073	C0019994
geriatrics	T091	C0017469
project	T077	C1709701
healthcare	T058	C0086388
needs	T080	C0027552
elderly	T098	C0001792
resource	T078	C0035201
constraints	T169	C0443288
Nigerian	T083	C0028075
hospitals	T073	C0019994
human	T081	C0700103
infrastructural resources	T081	C0392762
older adults	T098	C0001792
healthcare	T058	C0086388
needs	T080	C0027552
health services	T093	C0557829
elderly	T098	C0001792
Africa	T083	C0001737
Nigeria	T083	C0028075
population	T098	C1257890
healthcare facility	T073	C0018704
services	T058	C1704289
elderly	T098	C0001792
University of Benin Teaching Hospital	T073	C0019994
UBTH	T073	C0019994
Nigeria	T083	C0028075
geriatrics	T091	C0017469
trained interdisciplinary teams	T058	C0086390
healthcare services	T093	C0557829
elderly	T098	C0001792
UBTH	T073	C0019994
geriatrics	T091	C0017469
project	T077	C1709701
interdisciplinary	T058	C0597720
health services	T058	C0018747
older adults	T098	C0001792
training	T065	C0220931
professional development	T057	C0871147
geriatrics	T091	C0017469
healthcare staff	T097	C0557570
inpatient	T101	C0021562
services	T058	C1704289
acute care for elders	T058	C0683810
ACE	T058	C0683810
model	T170	C0596657
ACE units	T170	C0596657
resources	T078	C0035201
geriatrics unit	T091	C0017469
interdisciplinary team	T058	C0086390
Family	T099	C0015576
participation	T169	C0679823
practice	T091	C0086343
residents	T098	C2347958
house officers	T097	C0401975
internal medicine	T121	C0013227
weekly	T079	C0332174
rotations	T169	C0035868
academic program	T033	C3844065
weekly	T079	C0332174
geriatric	T080	C1704440
pharmacotherapy	T061	C0013216
seminars	T058	C2029815
weekly	T079	C0332174
seminars	T058	C2029815
weekly	T079	C0332174
journal club meetings	T052	C0556656
seminars	T058	C2029815
geriatric assessment tools	T170	C2585718
geriatric services	T093	C4041524
practices	T091	C0086343
human resources	T081	C0700103
infrastructure	T185	C1514880
services	T093	C0557829
Africa	T083	C0001737
Engaging	T033	C2937292
adolescent girls	T100	C0001588
transactional sex	T054	C0033595
through	T169	C0332273
compensated	T080	C0205432
dating	T054	C0237553
Transactional sex	T054	C0033595
through	T169	C0332273
compensated	T080	C0205432
dating	T054	C0237553
adolescent girls	T100	C0001588
problem	T033	C0033213
need	T080	C0027552
public	T092	C0678367
concern	T078	C2699424
Compensated	T080	C0205432
dating	T054	C0237553
use of	T169	C1524063
information communication technology	T170	C0683867
advertise	T057	C0001690
search	T052	C1706202
bargain	T054	C0871661
transactional sex	T054	C0033595
technology	T170	C0683867
enables	T041	C1171285
sexual partners	T098	C0036911
maintain	T052	C0024501
privacy	T078	C0080048
secrecy	T078	C0871315
transactional sex	T054	C0033595
secrecy	T078	C0871315
necessitates	T080	C0027552
girls	T098	C0043210
disclosure	T055	C0012625
life experiences	T067	C0023672
order	T080	C1705176
concern	T078	C2699424
disclosure	T055	C0012625
focus	T169	C1285542
qualitative study	T062	C0949415
girls	T098	C0043210
practicing	T041	C0237607
dating	T054	C0237553
Hong Kong	T083	C0019907
China	T083	C0008115
Based	T169	C1527178
disclosure	T055	C0012625
study	T062	C2603343
grounded theory	T170	C1510611
engagement	T033	C2937292
compensated	T080	C0205432
dating	T054	C0237553
referential choice	T055	C0008300
referential choice theory	T078	C0871935
choice	T055	C0008300
reference	T169	C0205543
family	T099	C0015576
push	T067	C0441722
social norms	T078	C0237750
sustains	T169	C0443318
engagement	T033	C2937292
choice	T055	C0008300
expectancy	T078	C0679138
reinforcement	T169	C0442805
experiential learning	T065	C0243012
compensated	T080	C0205432
dating	T054	C0237553
theory	T078	C0871935
engagement	T033	C2937292
through	T169	C0332273
diverting	T080	C0743226
referential choice	T055	C0008300
dating	T054	C0237553
Numerical simulation	T062	C0679083
emitted particle	T104	C0597177
characteristics	T080	C1521970
airway	T023	C0458827
deposition	T169	C0333562
distribution	T039	C1378698
Symbicort(®) Turbuhaler(®)	T109	C1735945
dry powder	T122	C0032861
combination	T121	C0013162
aerosol drug	T122	C1112870
dry powder	T122	C0032861
combinations	T121	C0013162
asthma	T047	C0004096
chronic obstructive pulmonary disease	T047	C0024117
COPD	T047	C0024117
management	T058	C0376636
Symbicort(®) Turbuhaler(®)	T109	C1735945
study	T062	C2603343
simulate	T062	C0679083
deposition	T169	C0333562
distribution	T039	C1378698
components	T185	C0184498
drug	T121	C1254351
airways	T023	C0458827
airflow measurements	T060	C0678216
Breathing	T040	C0004048
parameters	T077	C0549193
healthy adults	T033	C0686750
females	T032	C0086287
males	T032	C0086582
acquired	T080	C0439661
inhaling	T040	C0004048
Turbuhaler(®)	T074	C1553479
Individual	T098	C0027361
emitted doses	T081	C0178602
particle size	T081	C0030608
distributions	T039	C1378698
Symbicort(®) Turbuhaler(®)	T109	C1735945
determined	T080	C0521095
particle	T104	C0597177
deposition	T169	C0333562
model	T170	C3161035
adapted	T169	C0205245
validated	T169	C0205245
simulate	T062	C0679083
deposition	T169	C0333562
budesonide	T109	C0054201
inhaled corticosteroid	T109	C1629043
ICS	T109	C1629043
formoterol	T109	C0060657
long acting β2 agonist	T121	C2987634
LABA	T121	C2987634
upper airways	T030	C0225377
lungs	T023	C0024109
healthy volunteers	T098	C1708335
current	T079	C0521116
simulations	T062	C0679083
emitted doses	T081	C0178602
dose	T081	C0178602
ICS	T109	C1629043
LABA	T121	C2987634
component	T185	C0184498
individual	T098	C0027361
inhalation flow rate	T201	C0231832
variability	T077	C2827666
induced	T169	C0205263
individual	T098	C0027361
spread	T080	C0332261
deposited	T169	C0333562
lung	T023	C0024109
doses	T081	C0178602
range	T081	C1514721
budesonide	T109	C0054201
range	T081	C1514721
formoterol	T109	C0060657
Significant	T078	C0750502
inter-gender	T032	C0079399
differences	T080	C1705242
observed	T169	C1441672
lung	T023	C0024109
dose	T081	C0178602
budesonide	T109	C0054201
dose	T081	C0178602
females	T032	C0086287
males	T032	C0086582
formoterol	T109	C0060657
deposited	T169	C0333562
efficiency	T081	C0013682
females	T032	C0086287
males	T032	C0086582
results	T169	C1274040
importance	T080	C3898777
breath-holding	T033	C0235744
inhalation	T040	C0004048
drug	T121	C1254351
lung	T023	C0024109
deposition	T169	C0333562
occurred	T052	C1709305
breath-hold	T033	C0235744
breath-hold	T033	C0235744
time	T079	C0040223
depositions	T169	C0333562
confirmed	T080	C0521093
appropriate	T080	C1548787
lung	T023	C0024109
deposition	T169	C0333562
Symbicort(®) Turbuhaler(®)	T109	C1735945
genders	T032	C0079399
optimal inhalation technique	T061	C1998547
advised	T078	C0034866
persons	T098	C0027361
low vital capacity	T033	C0476408
study	T062	C2603343
personalized	T080	C1709510
prediction	T078	C0681842
airway	T023	C0458827
deposition	T169	C0333562
aerosol drugs	T122	C1112870
numerical simulations	T062	C0679083
methodology	T078	C3266812
study	T062	C2603343
applicable	T080	C1706839
marketed	T080	C3640197
drugs	T121	C1254351
future	T079	C0016884
Nutrient intake	T058	C0558027
infants	T100	C0021270
toddlers	T100	C0682053
United Arab Emirates	T083	C0041698
Infants	T100	C0021270
Toddlers	T100	C0682053
nutrient adequacy	T081	C0006777
diet	T168	C0012155
infants	T100	C0021270
toddlers	T100	C0682053
United Arab Emirates	T083	C0041698
infants	T100	C0021270
toddlers	T100	C0682053
Al Ain	T083	C0041698
Dubai	T083	C0041698
March	T079	C3829202
February	T080	C3830166
nutrient intake	T058	C0558027
infants	T100	C0021270
toddlers	T100	C0682053
breastfeeding	T040	C0006147
energy intake	T081	C0006777
infant girls	T100	C0870604
Al Ain	T083	C0041698
Dubai	T083	C0041698
kcal	T081	C0439259
kcal	T081	C0439259
kcal	T081	C0439259
kcal	T081	C0439259
boys	T100	C0870221
toddlers	T100	C0682053
energy intake	T081	C0006777
girls	T100	C0870604
kcal	T081	C0439259
kcal	T081	C0439259
kcal	T081	C0439259
kcal	T081	C0439259
boys	T100	C0870221
Iron intake	T033	C0518043
low	T080	C0205251
body mass index	T201	C1305855
body weight	T032	C0005910
height	T032	C0005890
World Health Organization	T093	C0043237
infants	T100	C0021270
toddlers	T100	C0682053
over	T184	C0497406
underweight	T033	C0041667
macronutrient	T077	C2346926
intakes	T058	C0558027
RDA	T170	C0524787
over	T047	C1257763
underfed	T047	C0162429
HIV-1	T005	C0019704
backward	T082	C0439784
mutation rate	T080	C3178846
transmitted drug-resistant	T038	C0013203
strains	T001	C1518614
threats	T078	C0749385
antiretroviral therapy	T061	C1963724
human immunodeficiency virus	T005	C0019704
HIV-1	T005	C0019704
infected	T047	C2363741
patients	T101	C0030705
increasing prevalence	T081	C1512456
transmitted drug resistance	T038	C0013203
HIV-1	T005	C0019704
drug-resistant	T038	C0013203
strains	T001	C1518614
wild-type	T028	C1883559
strains	T001	C1518614
drug-resistant	T038	C0013203
strains	T001	C1518614
primary	T080	C0205225
phase	T079	C0205390
HIV-1 infection	T047	C2363741
replaced	T169	C0559956
wild-type	T028	C1883559
strains	T001	C1518614
replacement	T169	C0559956
HIV-1 resistant	T033	C1836231
mutations	T045	C0026882
wild-type	T028	C1883559
strains	T001	C1518614
process	T067	C1522240
backward	T082	C0439784
mutation	T045	C0026882
replacement	T169	C0559956
dependent	T169	C3244310
HIV-1	T005	C0019704
mutation	T045	C0026882
group	T078	C0441833
backward	T082	C0439784
mutation rates	T080	C3178846
mutational	T045	C0026882
groups	T078	C0441833
HIV-1	T005	C0019704
drug resistance	T038	C0013203
stochastic model	T062	C0871922
data	T078	C1511726
individuals	T098	C0237401
infected	T033	C0439663
HIV-1	T005	C0019704
strain	T001	C1518614
drug resistance	T038	C0013203
mutations	T045	C0026882
period of time	T201	C3259132
resistant	T169	C0332325
strain	T001	C1518614
replaced	T169	C0559956
distribution	T169	C1704711
simulations	T062	C0679083
stochastic model	T062	C0871922
observed	T169	C1441672
clinical data	T170	C1516606
replacement	T169	C0559956
times	T081	C1632851
mutation	T045	C0026882
Lamivudine/Emtricitabine	T109	C1977395
mutations	T045	C0026882
backward	T082	C0439784
mutation rate	T080	C3178846
relative	T080	C0205345
fitness	T056	C1456706
classes	T170	C0456387
protease inhibitors	T121	C0033607
mutations	T045	C0026882
backward	T082	C0439784
mutation rate	T080	C3178846
relative	T080	C0205345
fitness	T056	C1456706
mutation	T045	C0026882
classes	T170	C0456387
estimates	T081	C0750572
Modeling	T062	C0870071
hospital	T073	C0019994
safety	T068	C0036043
partnership	T058	C3826012
preferences of patients	T080	C0376409
families	T099	C0015576
discrete	T080	C0443299
choice	T055	C0008300
conjoint experiment	T062	C0681814
Patients	T101	C0030705
families	T099	C0015576
role	T077	C1705810
improve	T077	C2986411
health service	T058	C0018747
safety	T068	C0036043
objective	T170	C0018017
study	T062	C2603343
safety	T068	C0036043
partnership	T058	C3826012
preferences of patients	T080	C0376409
families	T099	C0015576
discrete	T080	C0443299
choice	T055	C0008300
conjoint experiment	T062	C0681814
safety	T068	C0036043
partnership	T058	C3826012
preferences	T080	C0376409
patients	T101	C0030705
parents	T099	C0030551
Participants	T098	C0679646
choices	T055	C0008300
safety	T068	C0036043
partnerships	T058	C3826012
partnership	T058	C3826012
design	T052	C1707689
attributes	T055	C0037401
Participants	T098	C0679646
preferred	T078	C0558295
approach	T082	C0449445
safety	T068	C0036043
partnerships	T058	C3826012
patients	T101	C0030705
staff	T097	C0025106
responsibility	T055	C0678341
safety	T068	C0036043
hospital staff	T097	C0025109
opportunity to participate	UnknownType	C0814559
safety	T068	C0036043
partnerships	T058	C3826012
medication double checks	T058	C1254363
immediate	T079	C0205253
risk reduction	T055	C1137094
analysis	T062	C0936012
Actively engaged participants	T098	C0679646
outpatients	T101	C0029921
higher education	T065	C2584301
anticipated	T033	C3840775
benefits	T081	C0814225
safety	T068	C0036043
partnerships	T058	C3826012
more confident	T033	C3840600
ability	T032	C0085732
contribute	T052	C1880177
intent	T080	C1283828
participating	T169	C0679823
prefer	T080	C0376409
engagement	T058	C3508152
strategy	T041	C0679199
scientific evidence	T078	C3887511
preferred	T078	C0558295
approach	T082	C0449445
safety education	T065	C1272340
disclosure of errors	T080	C4046003
anticipated	T033	C3840775
fewer	T081	C0205388
benefits	T081	C0814225
confident	T055	C0558095
ability	T032	C0085732
contribute	T052	C1880177
participating	T169	C0679823
engagement	T058	C3508152
strategy	T041	C0679199
signage	T073	C4054026
preferred	T078	C0558295
staff	T097	C0025106
patients	T101	C0030705
care	T058	C0086388
errors	T080	C0376531
Inpatients	T101	C0021562
immigrant backgrounds	T033	C2242882
less education	T033	C0013658
Health services	T058	C0018747
information	T078	C1533716
risks	T078	C0035647
partnership	T058	C3826012
preferences	T080	C0376409
opportunities	UnknownType	C0814559
individual differences	T054	C0021228
positive response	T033	C1514241
patients	T101	C0030705
safety	T068	C0036043
concerns	T078	C2699424
ozone	T103	C0030106
paracetic acid	T109	C0030968
disinfection	T061	C0012683
adhesion of	T070	C0175633
resilient liners	T122	C0440188
acrylic resin	T122	C0001222
paracetic acid	T109	C0030968
PAA	T109	C0030968
ozone	T103	C0030106
disinfection	T061	C0012683
tensile bond strength	T081	C0039526
TBS	T081	C0039526
silicone-based	T109	C0037114
resilient liners	T122	C0440188
acrylic resins	T122	C0001222
dumbbell shaped	T082	C0686912
heat-polymerized	T067	C0314672
acrylic resins	T122	C0001222
specimens	T167	C0370003
acrylic	T122	C0001222
resilient liners	T122	C0440188
specimens	T167	C0370003
2 control	T167	C0370003
control1	T167	C0370003
control7	T167	C0370003
PAA	T109	C0030968
ozone	T103	C0030106
disinfection	T061	C0012683
PAA1	T109	C0030968
PAA7	T109	C0030968
ozone1	T103	C0030106
ozone7	T103	C0030106
distilled water	T121	C0790233
control1	T167	C0370003
control7	T167	C0370003
PAA	T109	C0030968
ozone	T103	C0030106
water	T121	C0043047
PAA	T109	C0030968
ozone	T103	C0030106
tensile	T081	C0039526
tests	T059	C0022885
TBS	T081	C0039526
ANOVA	T081	C0002780
Tukey's HSD test	T059	C0022885
Adhesive	T073	C0001516
strength	T078	C0808080
Mollosil	T109	C1436546
ozone	T103	C0030106
disinfection	T061	C0012683
PAA	T109	C0030968
disinfection	T061	C0012683
TBS	T081	C0039526
Mollosil	T109	C1436546
Molloplast B	T109	C0128823
acrylic resin	T122	C0001222
ozone	T103	C0030106
disinfection	T061	C0012683
TBS	T081	C0039526
Molloplast B	T109	C0128823
prolonged	T079	C0439590
exposure to ozone	T033	C0240618
adhesive	T073	C0001516
strength	T078	C0808080
adhesion	T070	C0175633
resilient liners	T122	C0440188
PAA	T109	C0030968
disinfection	T061	C0012683
ozonated	T052	C3640178
water	T121	C0043047
TBS	T081	C0039526
Mollosil	T109	C1436546
ozone	T103	C0030106
adhesion	T070	C0175633
Molloplast B	T109	C0128823
denture base materials	T074	C3504513
construction	T052	C1521827
three-dimensional	T082	C0450363
composite	T122	C0009570
fibrous	T080	C0439709
macrostructures	T082	C0678594
with nanotextures	T080	C0449582
biomedical	T091	C1879848
applications	T169	C4048755
biomedical	T091	C1879848
nanotechnology	T090	C0872323
three-dimensional	T082	C0450363
macrostructures	T082	C0678594
with nanotextures	T080	C0449582
applications	T169	C4048755
biological systems	T022	C0460002
restoration	UnknownType	C0678689
regeneration	T040	C0815081
body tissues	T024	C0040300
organs	T023	C0178784
conductive polymers	T104	C0032521
electrical	T169	C0442828
cues	T078	C0010439
cells	T025	C0007634
three-dimensional	T082	C0450363
composite	T122	C0009570
nanofibre	T073	C1881960
macrostructures	T082	C0678594
polycaprolactone	T109	C0137734
PCL	T109	C0137734
concentrations	T081	C1446561
polyaniline	T109	C0962453
PANi	T109	C0962453
electrospinning technology	T169	C0449851
3D	T082	C0450363
structures	T082	C0678594
cap-like macrostructures	T082	C0678594
centimetre-scale	T081	C0475210
thickness	T080	C1280412
pore nanotextures	T080	C0449582
nanometre-scale	T081	C0439202
nanofibres	T073	C1881960
biocompatibility	T044	C0596177
3D	T082	C0450363
PCL	T109	C0137734
PANi	T109	C0962453
composite	T122	C0009570
nanofibre	T073	C1881960
macrostructures	T082	C0678594
mouse	T015	C0025929
myoblasts	T025	C0596995
C2C12 cells	T025	C0596995
model	T050	C2986594
cells	T025	C0007634
C2C12 cells	T025	C0596995
3D	T082	C0450363
PCL	T109	C0137734
PANi	T109	C0962453
composite	T122	C0009570
macrostructures	T082	C0678594
PCL	T109	C0137734
cells	T025	C0007634
myoblast-like morphologies	T080	C0332437
pseudopodia	T026	C0033827
PANi	T109	C0962453
cell proliferation	T043	C0596290
PANi	T109	C0962453
cell affinity	T038	C3714634
conductive	T080	C0205556
PANi	T109	C0962453
3D	T082	C0450363
composite	T122	C0009570
nanofibre	T073	C1881960
macrostructures	T082	C0678594
myoblast differentiation	T043	C1159966
myotube maturation	T043	C2265916
electrospun	T080	C0205556
3D	T082	C0450363
PCL	T109	C0137734
PANi	T109	C0962453
composite	T122	C0009570
nanofibre	T073	C1881960
macrostructures	T082	C0678594
macrostructures	T082	C0678594
applications	T169	C4048755
tissue engineering	T061	C0596171
Mechanisms	T169	C0441712
replacement	T169	C0559956
circulating	T169	C0175630
viruses	T005	C0042776
seasonal	T047	C4304723
pandemic influenza A viruses	T005	C0029347
Seasonal influenza	T047	C4304723
epidemics	T067	C0014499
accumulation	T033	C4055506
antigenic changes	T044	C0003319
Pandemic influenza	T047	C4304383
antigenic change	T044	C0003319
influenza A virus	T005	C0029347
originate	T079	C0439659
hosts	T001	C1167395
antigenic variants	T044	C0003319
influenza A virus	T005	C0029347
circulating	T169	C0175630
seasonal	T005	C0042776
pandemic viruses	T005	C0042776
replacement	T169	C0559956
mechanisms	T169	C0441712
stochastic individual-based SEIR (susceptible-exposed-infectious-recovered) model	T170	C0282574
viral strains	T001	C1518614
circulating	T169	C0175630
old strain	T001	C1518614
newly emerged strain	T001	C1518614
simulations	T062	C0679083
replacement	T169	C0559956
mechanisms	T169	C0441712
Factors	T169	C1521761
conditions	T080	C0348080
virus	T005	C0042776
host	T001	C1167395
replacement	T169	C0559956
tropical regions	T083	C0017446
temperate regions	T083	C0017446
magnitude	T081	C1704240
epidemic	T067	C0014499
old strain	T001	C1518614
herd immunity	T039	C1135927
old strain	T001	C1518614
timing	T079	C0449243
appearance	T080	C0700364
new strain	T001	C1518614
replacement	T169	C0559956
replacement	T169	C0559956
pandemic virus	T005	C0042776
seasonal virus	T005	C0042776
susceptibility	T169	C1264642
reproductive	T040	C0035150
pandemic virus	T005	C0042776
replacement	T169	C0559956
mechanisms	T169	C0441712
virus transmission	T043	C1160716
dynamics	T070	C3826426
effective	T080	C1704419
mitigate	T067	C1553901
seasonal	T047	C4304723
pandemic influenza	T047	C4304383
Request	T052	C1272683
fulfillment	T169	C3242069
postpartum	T079	C0086839
tubal ligation	T061	C0520483
patients	T101	C0030705
high-risk pregnancy	T046	C0242786
Female sterilization	T061	C0015787
methods	T170	C0025663
contraception	T061	C0700589
United States	T083	C0041703
studies	T062	C2603343
postpartum	T079	C0086839
tubal ligation	T061	C0520483
PPTL	T061	C0520483
requests	T052	C1272683
unfulfilled	T169	C0205245
study	T062	C2603343
obstetric	T169	C0205484
medical risk	T078	C0035647
status	T080	C0449438
patients	T101	C0030705
request	T052	C1272683
completion	T080	C0205197
PPTL	T061	C0520483
study	T062	C2603343
retrospective cohort study	T062	C2985505
women	T098	C0043210
delivering	T040	C0005615
university hospital	T073	C0020028
prenatal care	T058	C0033052
faculty	T097	C0015535
resident clinics	T073	C0442592
High-risk	T033	C0332167
status	T080	C0449438
Society for Maternal-Fetal Medicine guidelines	T170	C2945690
Documentation	T170	C0920316
contraceptive plan	T170	C0599880
administration	T061	C1533734
contraceptive methods	T061	C0700589
abstracted	T079	C3259344
patient records	T170	C0025102
pregnancies	T040	C0032961
abstracted	T079	C3259344
participants	T098	C0679646
low risk	T081	C3538919
high risk	T033	C0332167
requested	T052	C1272683
PPTL	T061	C0520483
high-risk	T033	C0332167
patients	T101	C0030705
low-risk	T081	C3538919
patients	T101	C0030705
public insurance	T078	C0021672
unintended index pregnancy	T033	C0041747
patients	T101	C0030705
requesting	T052	C1272683
PPTL	T061	C0520483
procedure	T061	C0087111
postpartum	T079	C0086839
Completion	T080	C0205197
high-risk	T033	C0332167
status	T080	C0449438
race	T098	C0034510
insurance status	T078	C0376629
parity	T033	C0030563
women	T098	C0043210
unfulfilled	T169	C0205245
PPTL	T061	C0520483
request	T052	C1272683
pregnancies	T040	C0032961
months	T079	C0439231
follow-up	T058	C1522577
women	T098	C0043210
high-risk pregnancies	T046	C0242786
request	T052	C1272683
PPTL	T061	C0520483
complete	T080	C0205197
procedure	T061	C0087111
high-risk	T033	C0332167
patients	T101	C0030705
requests	T052	C1272683
unfulfilled	T169	C0205245
women	T098	C0043210
high-risk pregnancies	T046	C0242786
request	T052	C1272683
PPTL	T061	C0520483
complete	T080	C0205197
procedure	T061	C0087111
procedures	T061	C0087111
urgent	T079	C0439609
high-risk	T033	C0332167
women	T098	C0043210
patients	T101	C0030705
procedure	T061	C0087111
Gut microbiota	T001	C2985398
Roux-en-Y gastric bypass	T061	C0585179
sleeve gastrectomy	T061	C3160799
diabetic	T047	C0011847
rat	T015	C0034721
model	T050	C0012644
diversity	T080	C1880371
discriminant	T080	C0205235
genera	T185	C1708235
metabolic	T040	C0025519
changes	T169	C0392747
gut microbiota	T001	C2985398
bariatric surgery	T061	C1456587
gut microbiota	T001	C2985398
host	T001	C1167395
metabolism	T040	C0025519
Roux-en-Y gastric bypass	T061	C0585179
RYGB	T061	C0585179
sleeve gastrectomy	T061	C3160799
SG	T061	C3160799
gut microbiota	T001	C2985398
food	T168	C0016452
intake	T169	C1512806
weight	T032	C0005910
loss	T081	C1517945
loss	T081	C1517945
host	T001	C1167395
metabolism	T040	C0025519
diabetic	T047	C0011847
fatty rats	T015	C0034721
groups	T078	C0441833
RYGB	T061	C0585179
sham-operated	T061	C0032042
RYGB	T061	C0585179
sham-operated	T061	C0032042
SG	T061	C3160799
metabolic effects	T039	C2945675
gut microbiota	T001	C2985398
profile	T169	C2003903
analyzed	T062	C0936012
weeks	T079	C0439230
discriminating	T080	C0205235
genera	T185	C1708235
metabolic markers	T123	C1513159
RYGB	T061	C0585179
procedures	T061	C0087111
glucose	T109	C0017725
improvement	T077	C2986411
flora	T001	C2985398
diversity	T080	C1880371
weeks	T079	C0439230
compared	T052	C1707455
sham-operated	T061	C0032042
RYGB	T061	C0585179
Proteobacteria	T007	C0751985
Gammaproteobacteria	T007	C0751988
Betaproteobacteria	T007	C0751987
Fusobacteria	T007	C1222477
Clostridium	T007	C0009054
SG	T061	C3160799
Actinobacteria	T007	C0600148
compared	T052	C1707455
discriminant	T080	C0205235
genera	T185	C1708235
correlated	T080	C1707520
changes	T169	C0392747
metabolic	T040	C0025519
phenotype	T032	C0031437
correlations	T080	C1707520
weight	T032	C0005910
discriminant	T080	C0205235
genera	T185	C1708235
correlated	T080	C1707520
serum insulin level	T034	C1261415
food	T168	C0016452
intake	T169	C1512806
weight	T032	C0005910
loss	T081	C1517945
RYGB	T061	C0585179
data	T078	C1511726
RYGB	T061	C0585179
SG	T061	C3160799
surgery	T169	C0038895
diversity	T080	C1880371
microbiota	T001	C2985398
diabetic	T047	C0011847
fatty rats	T015	C0034721
functions	T040	C0025519
discriminate	T080	C0205235
microbiota	T001	C2985398
mechanisms	T169	C0441712
postsurgical	T079	C1254367
modulation	T082	C0443264
gut microbiota	T001	C2985398
improvements	T077	C2986411
insulin resistance	T046	C0021655
Ocular toxicity	T037	C1262036
AUY922	T109	C2348996
pigmented	T015	C0034700
albino rats	T015	C0684072
AUY922	T109	C2348996
heat shock protein 90	T116	C0243044
inhibitor	T080	C1999216
ocular	T023	C0015392
adverse events	T046	C0877248
AEs	T046	C0877248
ocular	T023	C0015392
AEs	T046	C0877248
patients	T101	C0030705
investigative studies	T062	C2603343
step-wise approach	T082	C0449445
retinal structure	T023	C0035298
pigmented	T015	C0034700
Brown Norway	T015	C0034700
albino (Wistar) rats	T015	C0684072
Wistar	T015	C0034716
rats	T015	C0034721
administered	T169	C1521801
AUY922	T109	C2348996
AUC	T081	C0376690
h	T079	C0439227
Cmax	T081	C2347813
patients	T101	C0030705
AUY922	T109	C2348996
rats	T015	C0034721
morbidity	T081	C0026538
mortality	T081	C0596099
weekly	T079	C0332174
treatment	T061	C0087111
Electroretinography	T060	C0013867
ERG	T060	C0013867
changes	T169	C0392747
doses	T081	C0178602
ERG	T060	C0013867
changes	T169	C0392747
dose dependent	T081	C1512045
consistent	T078	C0332290
photoreceptors	T025	C0031760
reversible	T169	C0205343
ERG	T060	C0013867
Cmax	T081	C2347813
AUC	T081	C0376690
Histopathological	T169	C0243140
changes	T169	C0392747
rats	T015	C0034721
administered	T169	C1521801
AUY922	T109	C2348996
hour	T079	C0439227
infusion	T061	C0574032
AUY922	T109	C2348996
disorganization	T033	C4061689
outer segment photoreceptor	T026	C1325525
morphology	T080	C0332437
male	T032	C0086582
Brown Norway rats	T015	C0034700
disorganization	T033	C4061689
administrations	T061	C1533734
reversible	T169	C0205343
week	T079	C0439230
posttreatment period	T079	C2709088
ocular	T023	C0015392
response	T032	C0871261
Brown Norway	T015	C0034700
Wistar rats	T015	C0034716
serum iron levels	T034	C0036810
rhodopsin	T116	C0035499
PDE6α	T116	C1567350
β-transducin	T116	C0040665
concentrations	T081	C0392762
retinal pigment epithelium-specific protein RPE65	T116	C1571376
expression	T045	C0017262
infusions	T061	C0574032
AUY922	T109	C2348996
vehicle-treated controls	T096	C0009932
AUY922	T109	C2348996
retinal toxicity	T190	C0877104
rats	T015	C0034721
patients	T101	C0030705
reversible	T169	C0205343
molecular mechanism	T044	C1258062
Assessment	T058	C0220825
cerebral	T023	C0006104
blood perfusion	T042	C0599705
acetazolamide	T109	C0000981
3D spiral ASL MRI	T060	C3891302
pediatric	T080	C1521725
patients	T101	C0030705
clinical feasibility	T062	C0015730
non-Cartesian cylindrically-distributed spiral 3D pseudo-continuous arterial spin labeling (pCASL) magnetic resonance imaging (MRI)	T060	C3891302
pulse sequence	T082	C3828438
pediatric	T080	C1521725
patients	T101	C0030705
quantifying	T081	C1709793
cerebral blood flow	T033	C0428714
CBF	T033	C0428714
acetazolamide (ACZ) vasodilator	T121	C0042402
MRI exams	T060	C0024485
3 Tesla Philips Ingenia systems using 32 channel head coil arrays	T073	C3273359
institutional review board approval	T170	C2346499
3D spiral-based pCASL technique	T060	C3891302
brain MRI exam	T060	C0412675
pediatric	T080	C1521725
patients	T101	C0030705
patients	T101	C0030705
administered	T058	C3469597
ACZ	T109	C0000981
clinically indicated	T033	C2985739
whole-brain CBF measurements	T060	C0005776
pre	T079	C0332152
post	T079	C0687676
ACZ	T109	C0000981
cerebrovascular reserve	T042	C0007818
3D spiral pCASL	T060	C3891302
data	T078	C1511726
cases	T062	C0150093
patients	T101	C0030705
CBF	T033	C0428714
administration of	T058	C3469597
ACZ	T109	C0000981
patients	T101	C0030705
CBF	T033	C0428714
ACZ	T109	C0000981
CBF	T033	C0428714
ACZ	T109	C0000981
statistically significant	T081	C0237881
patients	T101	C0030705
t-test analysis	T170	C0871472
CBF	T033	C0428714
perfusion	T042	C0599705
MR angiography	T060	C1636167
clinical findings	T170	C0455712
3D cylindrically-distributed spiral pCASL MRI	T060	C3891302
assess	T058	C0184514
cerebral blood flow	T033	C0428714
pediatric	T080	C1521725
patients	T101	C0030705
Assessing	T058	C0184514
learning	T041	C0023185
potential	T080	C3245505
interactive	T065	C0815244
digital game	T073	C0870328
interactive-style	T065	C0815244
didactic	T080	C0205556
lecture	T170	C0376683
didactic	T080	C0205556
teaching	T065	C0039401
medical student	T097	C0038495
education	T065	C0013621
Games	T056	C0150593
educational	T065	C0013621
possible	T033	C0332149
interactive	T065	C0815244
increasing	T081	C0205217
learner	T098	C1257890
satisfaction	T041	C0242428
two-armed experiment	T062	C0681814
evaluate	T058	C0220825
student	T098	C0038492
satisfaction	T041	C0242428
content	T077	C0456205
mastery	T041	C0870851
pediatric radiology	T091	C1518934
topic	T170	C1555712
taught	T080	C0348054
interactive	T065	C0815244
digital game	T073	C0870328
traditional	T169	C0443324
didactic	T080	C0205556
lecture	T170	C0376683
Medical students	T097	C0038495
participating	T169	C0679823
radiology	T091	C0034599
elective	T079	C0439608
participate	T169	C0679823
Student	T098	C0038492
cohorts	T098	C0599755
alternatively	T077	C1523987
faculty	T097	C0015535
supervised	T065	C0039401
session	T077	C1883017
playing	T056	C0032214
interactive	T065	C0815244
digital	T080	C1883674
Tic-tac-toe	T056	C0150593
quiz module	T077	C1709061
pediatric gastrointestinal radiology	T060	C0203054
didactic	T080	C0205556
lecture	T170	C0376683
topic	T170	C1555712
Survey	T170	C0038951
questions	T170	C1522634
assessed	T052	C1516048
learners'	T098	C1257890
perceived	T041	C0030971
ability to recall	T201	C1718058
material	T167	C0520510
satisfaction	T041	C0242428
educational	T065	C0013621
experience	T041	C0596545
end-of-rotation	T079	C1254367
exam	T169	C4284036
reviewed	T080	C1709940
evaluate	T058	C0220825
quantitative measure	T081	C0034384
learning	T041	C0023185
groups	T078	C0441833
Survey	T170	C0038951
responses	T041	C2911692
analyzed	T062	C0936012
chi-squared test	T170	C0008041
Exam	T169	C4284036
groups	T078	C0441833
analyzed	T062	C0936012
Student's t-test	T081	C0871453
Students	T098	C0038492
lecture	T170	C0376683
group	T078	C0441833
higher	T080	C0205250
test scores	T080	C0237855
compared	T052	C1707455
students	T098	C0038492
game	T056	C0150593
group	T078	C0441833
Students	T098	C0038492
lecture	T170	C0376683
group	T078	C0441833
reported	T058	C0700287
greater	T081	C1704243
understanding	T041	C0162340
recall	T041	C0034770
material	T167	C0520510
students	T098	C0038492
game	T056	C0150593
group	T078	C0441833
Students	T098	C0038492
lecture	T170	C0376683
group	T078	C0441833
perceived	T041	C0030971
lecture	T170	C0376683
enjoyable	T033	C3843343
time	T079	C0040223
compared	T052	C1707455
game	T056	C0150593
group	T078	C0441833
statistically significant	T081	C0237881
difference	T033	C3842396
lecture	T170	C0376683
game	T056	C0150593
group	T078	C0441833
ability	T032	C0085732
interest	T054	C0162400
pre-survey	T079	C1254367
statistically significant	T081	C0237881
decrease	T081	C0547047
interest	T054	C0162400
digital	T080	C1883674
interactive	T065	C0815244
materials	T167	C0520510
reported	T058	C0700287
students	T098	C0038492
game	T056	C0150593
group	T078	C0441833
experience	T041	C0596545
traditional	T169	C0443324
lecture	T170	C0376683
digital game	T073	C0870328
affected	T169	C0392760
specific	T080	C0205369
lecture	T170	C0376683
digital	T080	C1883674
content	T077	C0456205
comparison	T052	C1707455
digital	T080	C1883674
module	T077	C1709061
Predictors	T078	C2698872
day	T079	C0439228
mortality	T081	C0205848
patients	T101	C0030705
spontaneous	T169	C0205359
primary	T080	C0205225
intracerebral hemorrhage	T033	C2937358
Intracerebral hemorrhage	T033	C2937358
ICH	T033	C2937358
life threatening	T033	C2826244
early outcome assessment	T058	C0029909
therapeutic efforts	T061	C0087111
retrospectively	T080	C1514923
analyzed	T062	C0936012
data	T078	C1511726
patients	T101	C0030705
spontaneous	T169	C0205359
primary	T080	C0205225
ICH	T033	C2937358
predictors	T078	C2698872
day	T079	C0439228
mortality	T081	C0205848
clinical	T080	C0205210
radiological	T169	C0205483
therapeutical	T169	C0302350
parameters	T077	C0549193
outcome grading scoring systems	T170	C0282574
ICH score	T081	C0449820
FUNC score	T081	C0449820
intracerebral hemorrhage grading scale	T170	C0349674
ICH-GS	T170	C0349674
population	T098	C1257890
correlation	T080	C1707520
scores	T081	C0449820
day	T079	C0439228
mortality	T081	C0205848
study	T062	C2603343
outcome grading scoring systems	T170	C0282574
ICH score	T081	C0449820
FUNC score	T081	C0449820
intracerebral hemorrhage grading scale	T170	C0349674
ICH-GS	T170	C0349674
population	T098	C1257890
correlation	T080	C1707520
scores	T081	C0449820
day	T079	C0439228
mortality	T081	C0205848
study	T062	C2603343
patients	T101	C0030705
age	T032	C0001779
years	T079	C0439234
Glasgow Coma Scale	T170	C0017594
GCS	T170	C0017594
admission	T058	C0184666
ICH	T033	C2937358
volume	T081	C0449468
hematoma	T046	C0018944
location	T029	C1515974
basal ganglia	T023	C0004781
surgical	T061	C0543467
conservative treatment	T061	C0459914
day	T079	C0439228
mortality	T081	C0205848
multivariate analysis	T081	C0026777
GCS	T170	C0017594
Odds ratio	T081	C0028873
OR	T081	C0028873
confidence interval	T081	C0009667
CI	T081	C0009667
bleeding	T046	C0019080
volume	T081	C0449468
OR	T081	C0028873
CI	T081	C0009667
infratentorial	T082	C0441939
hematoma	T046	C0018944
location	T029	C1515974
OR	T081	C0028873
CI	T081	C0009667
predictors	T078	C2698872
day	T079	C0439228
mortality	T081	C0205848
receiver operating characteristics	T081	C0034772
analysis	T062	C0936012
high-risk group	T098	C0684030
short-term	T079	C0443303
outcome	T169	C1274040
GCS	T170	C0017594
ICH	T033	C2937358
volume	T081	C0449468
supratentorially	T082	C0441938
infratentorially	T082	C0441939
Pearson correlation	T170	C1709490
correlation	T080	C1707520
ICH score	T081	C0449820
day	T079	C0439228
mortality	T081	C0205848
FUNC score	T081	C0449820
day	T079	C0439228
mortality	T081	C0205848
ICH-GS	T170	C0349674
day	T079	C0439228
mortality	T081	C0205848
GCS	T170	C0017594
score	T081	C0449820
admission	T058	C0184666
baseline	T081	C1442488
volume	T081	C0449468
localization	T169	C0475264
hemorrhage	T046	C0019080
predictors	T078	C2698872
day	T079	C0439228
mortality	T081	C0205848
patients	T101	C0030705
spontaneous	T169	C0205359
primary	T080	C0205225
intracerebral hemorrhage	T033	C2937358
high-risk	T033	C0332167
patients	T101	C0030705
short-term	T079	C0443303
outcome	T169	C1274040
ICH score	T081	C0449820
ICH-GS	T170	C0349674
accurately	T080	C0443131
predict	T078	C2698872
day	T079	C0439228
mortality	T081	C0205848
Gga-miR-21	T114	C1101610
inhibits	T080	C0311403
chicken	T012	C0008051
pre-adipocyte	T025	C0206131
proliferation	T043	C0596290
down-regulating	T044	C0013081
Kruppel-like factor 5	T028	C1416661
Gga-miR-21	T114	C1101610
expressed	T045	C0017262
chicken	T012	C0008051
pre-adipocytes	T025	C0206131
investigated	T169	C1292732
gga-miR-21	T114	C1101610
chicken	T012	C0008051
pre-adipocyte	T025	C0206131
proliferation	T043	C0596290
Cell proliferation assay	T062	C3899698
gene expression analysis	T063	C1880945
proliferating cell nuclear antigen	T028	C1366837
PCNA	T028	C1366837
gga-miR-21	T114	C1101610
mimic	T052	C0441655
inhibited	T080	C0311403
pre-adipocyte	T025	C0206131
proliferation	T043	C0596290
gga-miR-21	T114	C1101610
inhibitor	T080	C1999216
enhanced	T052	C2349975
pre-adipocyte	T025	C0206131
proliferation	T043	C0596290
investigation	T169	C1292732
Kruppel-like factor 5	T028	C1416661
KLF5	T028	C1416661
mRNA	T114	C0035696
target	T169	C1521840
gga-miR-21	T114	C1101610
gga-miR-21	T114	C1101610
mimic	T052	C0441655
inhibited	T080	C0311403
KLF5	T028	C1416661
3(')UTR	T086	C0600600
reporter	T028	C0206414
activity	T052	C0441655
decreased	T081	C0205216
endogenous	T169	C0205227
KLF5	T028	C1416661
expression	T045	C0017262
primary	T080	C0205225
pre-adipocytes	T025	C0206131
KLF5	T028	C1416661
knockdown	T063	C2350567
RNAi	T045	C1136031
effect	T080	C1280500
gga-miR-21	T114	C1101610
mimic	T052	C0441655
cell proliferation	T043	C0596290
promoting	T052	C0033414
effect	T080	C1280500
gga-miR-21	T114	C1101610
inhibitor	T080	C1999216
pre-adipocyte	T025	C0206131
proliferation	T043	C0596290
attenuated	T080	C0332161
KLF5	T028	C1416661
knockdown	T063	C2350567
miR-21	T114	C1101610
chicken	T012	C0008051
pre-adipocyte	T025	C0206131
proliferation	T043	C0596290
targeting	T063	C0242613
KLF5	T028	C1416661
application	T169	C4048755
heterogeneous cluster grouping	T081	C1704332
reflective writing	T090	C0043266
medical humanities	T090	C0020157
literature study	T062	C2603343
enhance	T052	C2349975
students'	T098	C0038492
empathy	T055	C0013989
critical thinking	T041	C4279941
reflective writing	T090	C0043266
interdisciplinary collaboration	T058	C0597720
connections	T082	C0449379
patients'	T101	C0030705
diseases	T047	C0012634
social	T169	C0728831
cultural contexts	T169	C0220814
study	T062	C2603343
examined	T033	C0332128
heterogeneous cluster grouping	T081	C1704332
reflective writing	T090	C0043266
medical humanities	T090	C0020157
acquisition	T052	C1706701
positive effects	T080	C1280500
medical university	T073	C0000872
students	T098	C0038492
empathy	T055	C0013989
critical thinking	T041	C4279941
reflective writing	T090	C0043266
15-week	T079	C0439230
quasi-experimental design	UnknownType	C0815255
investigate	T169	C1292732
learning outcomes	T169	C1274040
cluster algorithms	T170	C0002045
heterogeneous learning clusters	T081	C1704332
experimental group	UnknownType	C0681860
non-heterogeneous learning clusters	T081	C1704332
control group	T096	C0009932
medical humanities	T090	C0020157
literature study	T062	C2603343
intervention	T061	C0184661
Empathy Scale	T170	C0349674
Patient Care	T058	C0017313
ES	T170	C0349674
PC	T058	C0017313
critical thinking disposition assessment	T058	C0220825
CTDA-R	T058	C0220825
reflective writing test	T058	C1254363
administered	T169	C1521801
groups	T078	C0441833
empathy scale	T170	C0349674
behavioral empathy	T055	C0013989
affective empathy	T055	C0013989
post-test mean scores	T033	C3533236
experimental group	UnknownType	C0681860
control group	T096	C0009932
intelligent empathy	T055	C0013989
critical thinking	T041	C4279941
systematicity	T169	C0220922
analyticity	T062	C0936012
skepticism	T041	C1510638
well-informed	T058	C1254363
maturity	T080	C0449989
skepticism	T041	C1510638
reflective writing	T090	C0043266
ideas	T078	C1254370
voice	T040	C0042939
point of view	T078	C1254370
critical thinking	T041	C4279941
representation	T052	C1882932
depth of reflection	T041	C0025361
personal growth	T055	C0871850
focus	T169	C1285542
context structure	T078	C0449255
language	T171	C0023008
conventions	T068	C0086047
study	T062	C2603343
heterogeneous cluster grouping	T081	C1704332
reflective writing	T090	C0043266
medical humanities	T090	C0020157
interdisciplinary cooperation	T054	C0392337
medical care	T033	C0496675
Employing	T033	C0557351
Electronic Traction Table	T074	C0183817
Flexibility	T080	C0242808
Adolescent Idiopathic Scoliosis	T190	C0410702
study	T062	C2603343
develop	T169	C1527148
equipment	T073	C0014672
assessment	T058	C0220825
flexibility	T080	C0242808
spine	T023	C0037949
forces	T067	C0441722
system	T169	C0449913
adolescent idiopathic scoliosis	T190	C0410702
AIS	T190	C0410702
selection	T052	C1707391
fusion levels	T080	C0441889
surgical	T061	C0543467
success	T080	C0679864
patients	T101	C0030705
AIS	T190	C0410702
posterior	T082	C0205095
instrumented spinal fusion	T061	C0919636
clinic	T073	C0442592
study	T062	C2603343
Electronic Traction Table	T074	C0183817
ETT	T074	C0183817
clinic	T073	C0442592
radiogical	T077	C0549193
clinical	T080	C0205210
parameters	T077	C0549193
spine	T023	C0037949
prescriptive angle	T080	C0205556
Cobb angles	T033	C0563192
postoperative angles	T080	C0205556
longitudinal	T082	C0205127
traction	T061	C0040597
lateral pushing Cobb angles	T033	C0563192
Longitudinal	T082	C0205127
traction	T061	C0040597
lateral pushing angles	T033	C0563192
correction ratios	T081	C0456603
significant	T078	C0750502
longitudinal	T082	C0205127
traction	T061	C0040597
Cobb angle	T033	C0563192
longitudinal	T082	C0205127
traction	T061	C0040597
lateral pushing minor Cobb angle	T033	C0563192
postoperative minor Cobb angles	T033	C0563192
deformity	T190	C0302142
tractional	T061	C0040597
rotational	T169	C0035868
rotational forces	T067	C0441722
technique	T169	C0449851
flexibility	T080	C0242808
operation	T061	C0543467
Electronic traction table	T074	C0183817
device	T074	C0025080
preoperative flexibility	T080	C0242808
longitudinal	T082	C0205127
traction	T061	C0040597
lateral pushing radiographs	T060	C1306645
choosing	T052	C1707391
fusion levels	T080	C0441889
proximal	T082	C0205107
distal	T082	C0205108
vertebral column	T023	C0037949
MEssaging for Diabetes	T058	C1254363
Intervention	T061	C0184661
Barriers	T080	C0679881
Medication Adherence	T033	C2364172
Low-Income	T033	C1331016
Adults	T100	C0001675
Type 2	T047	C0011860
Nonadherence	T033	C0746935
diabetes	T047	C0011847
medication	T058	C2081612
MEssaging for Diabetes	T058	C1254363
MED	T058	C1254363
mobile health	T058	C2718080
mHealth	T058	C2718080
intervention	T061	C0184661
user	T098	C1706077
barriers	T080	C0679881
medication adherence	T033	C2364172
MED	T058	C1254363
users	T098	C1706077
barriers	T080	C0679881
barrier	T080	C0679881
within-participant	T098	C0679646
adherence	T169	C1510802
glycemic control	T080	C0205556
HbA1c	T116	C0019018
Adults	T100	C0001675
type 2 diabetes	T047	C0011860
barriers	T080	C0679881
adherence	T169	C1510802
monthly	T079	C0332177
months	T079	C0439231
assessment	T058	C0220825
barriers	T080	C0679881
user	T098	C1706077
month	T079	C0439231
users	T098	C1706077
text messages	T170	C3178910
barriers	T080	C0679881
barriers	T080	C0679881
participant	T098	C0679646
monthly	T079	C0332177
t-tests	T170	C0871472
within-participant	T098	C0679646
barriers	T080	C0679881
month	T079	C0439231
regression models	T170	C3161035
participant's	T098	C0679646
adherence	T169	C1510802
HbA1c	T116	C0019018
Participants	T098	C0679646
HbA1c	T116	C0019018
month	T079	C0439231
months	T079	C0439231
months	T079	C0439231
barriers	T080	C0679881
cost	T081	C0010186
medications	T058	C2081612
medications	T058	C2081612
medications	T058	C2081612
Participants	T098	C0679646
barrier	T080	C0679881
month	T079	C0439231
barrier	T080	C0679881
adherence	T169	C1510802
adherence	T169	C1510802
text messages	T170	C3178910
participants	T098	C0679646
month	T079	C0439231
barrier	T080	C0679881
months	T079	C0439231
HbA1c	T116	C0019018
users	T098	C1706077
barriers	T080	C0679881
adherence	T169	C1510802
mHealth	T058	C2718080
interventions	T061	C0184661
low-income	T033	C1331016
patients	T101	C0030705
Macular	T082	C0332574
Ganglion Cell	T025	C0228071
Inner Plexiform Layer	T023	C1512785
Thickness	T080	C1280412
Associated with	T080	C0332281
Clinical Progression	T046	C0242656
Mild Cognitive Impairment	T047	C1719378
Alzheimers Disease	T047	C0002395
macular	T082	C0332574
ganglion cell	T025	C0228071
inner plexiform layer	T023	C1512785
GCIPL	T023	C1512785
peripapillary retinal nerve fiber layer	T023	C1517753
RNFL	T023	C1517753
thicknesses	T080	C1280412
disease progression	T046	C0242656
mild cognitive impairment	T047	C1719378
MCI	T047	C1719378
Alzheimer's disease	T047	C0002395
AD	T047	C0002395
patients	T101	C0030705
AD	T047	C0002395
MCI	T047	C1719378
elderly controls	T096	C0009932
thicknesses	T080	C1280412
RNFL	T023	C1517753
GCIPL	T023	C1512785
spectral-domain optic coherent tomography	T074	C3876157
participants	T098	C0679646
baseline	T081	C1442488
patients	T101	C0030705
MCI	T047	C1719378
AD	T047	C0002395
clinical	T080	C0205210
neuropsychological tests	T060	C0027902
baseline	T081	C1442488
once every year thereafter for 2 years	T079	C1254367
Clinical Dementia Rating scale-Sum of Boxes	T170	C3827230
CDR-SB	T170	C3827230
score	T081	C0449820
negative	T033	C0205160
relationships	T080	C0439849
average GCIPL	T023	C1512785
thickness	T080	C1280412
GCIPL	T023	C1512785
thickness	T080	C1280412
superotemporal	T029	C1275875
superonasal	T029	C1275872
inferonasal sectors	T029	C1275873
composite memory score	T081	C0449820
positive	T033	C1446409
associations	T080	C0439849
average GCIPL	T023	C1512785
thickness	T080	C1280412
GCIPL	T023	C1512785
thickness	T080	C1280412
superotemporal	T029	C1275875
inferonasal	T029	C1275873
inferotemporal sectors	T029	C1275868
temporal RNFL	T023	C1517753
thickness	T080	C1280412
GCIPL	T023	C1512785
thicknesses	T080	C1280412
GCIPL	T023	C1512785
thickness	T080	C1280412
inferonasal	T029	C1275873
inferior	T029	C0005898
inferotemporal sectors	T029	C1275868
baseline	T081	C1442488
reduced	T080	C0392756
MCI	T047	C1719378
patients	T101	C0030705
AD	T047	C0002395
MCI	T047	C1719378
patients	T101	C0030705
CDR-SB	T170	C3827230
baseline	T081	C1442488
years	T079	C0439234
negative	T033	C0205160
associations	T080	C0439849
minimum GCIPL	T023	C1512785
thicknesses	T080	C1280412
GCIPL	T023	C1512785
thickness	T080	C1280412
superotemporal	T029	C1275875
superior	T029	C0005898
superonasal	T029	C1275872
inferonasal sectors	T029	C1275873
baseline	T081	C1442488
GCIPL	T023	C1512785
thickness	T080	C1280412
biomarker	T201	C0005516
progression	T046	C0242656
MCI	T047	C1719378
AD	T047	C0002395
Green	T057	C2350565
rapid	T080	C0456962
synthesis	T052	C1883254
silver	T196	C0037125
nanoparticles	T073	C1721060
Borago officinalis	T002	C0522465
leaf	T002	C0242724
extract	T123	C0032081
anticancer	T033	C0243095
antibacterial activities	T033	C0243095
cost	T081	C0010186
effective	T080	C1704419
ecofriendly	T057	C2350565
synthesis	T052	C1883254
silver	T196	C0037125
nanoparticles	T073	C1721060
AgNPs	T073	C1721060
Borago officinalis	T002	C0522465
leaves	T002	C0242724
extract	T123	C0032081
efficiently	T080	C0442799
biosynthesis	T052	C1883254
AgNPs	T073	C1721060
verified	T078	C1547321
UV-Vis spectrum	T070	C1883416
surface plasmon resonance	T063	C0597731
SPR	T063	C0597731
Transmission electron microscope (TEM) analysis	T059	C0678118
particles	T073	C1721060
spherical	T082	C0332501
hexagonal	T082	C1708361
irregular	T080	C0205271
shape	T082	C0332479
size	T081	C0030608
ranging	T081	C1514721
energy dispersive X-ray spectroscopy	T059	C2699997
EDX	T059	C2699997
elemental mapping	T059	C0022885
purity	T081	C1882508
maximum	T081	C0806909
distribution	T169	C1704711
silver	T196	C0037125
AgNPs	T196	C0037125
crystalline	T104	C0444626
AgNPs	T196	C0037125
identified	T080	C0205396
X-ray diffraction	T059	C0043301
XRD	T059	C0043301
selected area diffraction pattern	T059	C0022885
particle size	T081	C0030608
analysis	T169	C1524024
Z-average	T081	C1510992
diameter	T081	C1301886
AgNPs	T196	C0037125
polydispersity index	T077	C1882415
PDI	T077	C1882415
Zeta potential	T067	C0597697
analysis	T169	C1524024
colloidal stability	T080	C0205556
AgNPs	T196	C0037125
efficacy	T080	C1280519
AgNPs	T073	C1721060
lung	T023	C0024109
cancer cell lines	T025	C0085983
A549	T025	C4277577
cervical	T023	C0007874
cancer cell line	T025	C0085983
HeLa	T025	C0018873
in vitro	T080	C1533691
AgNPs	T073	C1721060
cytotoxicity	T049	C0596402
A549	T025	C4277577
HeLa	T025	C0018873
cancer cell line	T025	C0085983
concentrations	T081	C1446561
AgNPs	T196	C0037125
antibacterial activity	T033	C0243095
biofilm	T007	C0081786
inhibition	T052	C3463820
pathogenic	T033	C3816499
bacteria	T007	C0004611
B. officinalis	T002	C0522465
leaves	T002	C0242724
extract	T123	C0032081
efficiently	T080	C0442799
synthesis	T052	C1883254
AgNPs	T196	C0037125
AgNPs	T196	C0037125
potentials	T080	C3245505
anticancer	T109	C0003392
antibacterial agents	T195	C0279516
development	T169	C1527148
anticancer	T109	C0003392
antimicrobial agents	T121	C1136254
Genotyping	T059	C3178894
Staphylococcus aureus	T007	C0038172
bovine mastitis	T047	C0024895
phenotypic	T032	C0031437
characteristics	T080	C1521970
mastitis	T047	C0024895
Staphylococcus aureus	T007	C0038172
S. aureus	T007	C0038172
animal	T008	C0003062
health	T078	C0018684
farmers	T097	C0221460
acute mastitis	T047	C0024895
risk	T078	C0035647
persistent	T079	C0205322
mastitis	T047	C0024895
genetic variants	T028	C0678941
strain	T001	C1518614
infection	T046	C3714514
study	T062	C2603343
microarrays	T073	C1709016
virulence	T038	C0042765
genes	T028	C0017337
S. aureus	T007	C0038172
dairy cows	T015	C0175925
acute clinical mastitis	T047	C0024895
findings	T033	C0243095
genotypic	T032	C0017431
phenotypic	T032	C0031437
characteristics	T080	C1521970
virulence factors	T109	C1136170
genes	T028	C0017337
encoding	T052	C2700640
hemolysin	T123	C0019053
types	T080	C0332307
leukocidins D	T116	C0023504
lukM	T116	C0293523
lukF-P83	T116	C0033684
clumping factors A	T116	C1871029
B	T116	C0969304
fibrinogen binding protein	T116	C1437844
fibronectin-binding protein A	T116	C2976610
virulence factors	T109	C1136170
fibronectin-binding protein B	T116	C2976609
Staphylococcus aureus	T007	C0038172
surface protein G	T116	C0025252
Genes	T028	C0017337
staphylococcal enterotoxins	T123	C0597508
toxic shock syndrome toxin-1	T116	C1617068
TSST-1	T116	C1617068
pulsotype	T001	C1518614
No	T033	C1513916
beta-lactamase genes	T028	C0017337
pulsotype	T001	C1518614
pulsotypes	T001	C1518614
human origin	T077	C4287933
TSST-1	T116	C1617068
enterotoxins	T116	C0014372
hemolysins	T123	C0019053
beta-lactamase	T116	C0597979
genes	T028	C0017337
study	T062	C2603343
genotypic	T032	C0017431
differences	T080	C1705242
similarities	T080	C2348205
pulsotypes	T001	C1518614
S. aureus	T007	C0038172
mastitis	T047	C0024895
Sweden	T083	C0038995
diagnostic tools	T063	C0949688
udder	T023	C0242386
health	T078	C0018684
S. aureus	T007	C0038172
genotype	T032	C0017431
Uveitis	T047	C0042164
spondyloarthritis	T047	C0949690
patients	T101	C0030705
association with	T080	C0332281
HLA-B27 histocompatibility antigen	T116	C0019740
prospective study	T062	C0033522
prospective study	T062	C0033522
clinical presentation	T170	C2708283
course	T079	C0750729
uveitis	T047	C0042164
spondyloarthritis	T047	C0949690
SpA	T047	C0949690
patients	T101	C0030705
association with	T080	C0332281
HLA-B27 histocompatibility antigen	T116	C0019740
study	T062	C2603343
patients	T101	C0030705
uveitis	T047	C0042164
tested	T169	C0039593
HLA-B27 antigen	T116	C0019740
infections	T046	C3714514
viral	T047	C0042769
bacterial	T047	C0004623
parasitic	T047	C0747256
examined	T033	C0332128
locomotive system	T022	C0026860
involvement	T169	C1314939
presence	T033	C0150312
HLA-B27 antigen	T116	C0019740
determined	T080	C0521095
patients	T101	C0030705
diagnosed	T033	C0011900
entity	T071	C1551338
SpA	T047	C0949690
group	T078	C0441833
remaining	T080	C1527428
patients	T101	C0030705
HLA-B27	T116	C0019740
negative	T033	C0205160
diagnosed	T033	C0011900
entity	T071	C1551338
SpA	T047	C0949690
group	T078	C0441833
patients	T101	C0030705
diseases	T047	C0012634
SpA	T047	C0949690
group	T078	C0441833
comparing	T052	C1707455
groups	T078	C0441833
HLA-B27-positive	T034	C0239961
negative	T033	C0205160
patients	T101	C0030705
SpA	T047	C0949690
uveitis	T047	C0042164
statistically significant	T081	C0237881
difference	T080	C1705242
age of onset	T081	C0206132
site	T029	C1515974
frequency of attacks	T079	C0439603
uni	T082	C0205092
bilateral	T082	C0238767
involvement	T169	C1314939
performed	T169	C0884358
comparison	T052	C1707455
HLA-B27-positive	T034	C0239961
negative	T033	C0205160
patients	T101	C0030705
SpA	T047	C0949690
status	T080	C0449438
revealed	T080	C0443289
higher	T080	C0205250
complication	T046	C0009566
rate	T081	C1521828
negative	T033	C0205160
HLA-B27	T116	C0019740
negative	T033	C0205160
patients	T101	C0030705
autoimmune	T047	C3888523
infectious uveitis	T047	C0042164
different	T080	C1705242
long	T080	C0205166
short	T081	C1806781
remissions	T033	C0544452
Assessing	T058	C0184514
site	T029	C1515974
course	T079	C0750729
uveitis	T047	C0042164
HLA-B27	T116	C0019740
testing	T169	C0039593
uveitis	T047	C0042164
patients	T101	C0030705
important	T080	C3898777
etiological	T169	C1314792
diagnosis	T033	C0011900
Diseases	T047	C0012634
SpA	T047	C0949690
group	T078	C0441833
times	T081	C1632851
HLA-B27-positive	T034	C0239961
patients	T101	C0030705
compared	T052	C1707455
HLA-B27	T116	C0019740
negative	T033	C0205160
Clinical presentation	T170	C2708283
uveitis	T047	C0042164
presence	T033	C0150312
SpA	T047	C0949690
HLA-B27-positive	T034	C0239961
negative	T033	C0205160
patients	T101	C0030705
idiopathic uveitis	T047	C0042164
HLA-B27	T116	C0019740
associated	T080	C0332281
syndrome	T047	C0039082
entities	T071	C1551338
SpA	T047	C0949690
group	T078	C0441833
severe	T080	C0205082
clinical presentation	T170	C2708283
course	T079	C0750729
uveitis	T047	C0042164
associated with	T080	C0332281
worse prognosis	T033	C0278252
Complications	T046	C0009566
uveitis	T047	C0042164
non-SpA	T033	C0243095
HLA-B27	T116	C0019740
negative	T033	C0205160
patients	T101	C0030705
Human	T016	C0086418
brucellosis	T047	C0006309
South Africa	T083	C0037712
Public health	T170	C3244304
diagnostic pitfalls	UnknownType	C0679836
Human	T016	C0086418
brucellosis	T047	C0006309
South Africa	T083	C0037712
SA	T083	C0037712
under-diagnosed	UnknownType	C0679837
under-reported	T033	C0243095
clinicians	T097	C0871685
affected patients	T080	C0522476
nonspecific	T078	C0750540
insidious	T080	C1288298
nature of the disease	T080	C0449786
case	T169	C0868928
human	T016	C0086418
brucellosis	T047	C0006309
Brucella melitensis	T007	C0006305
patient	T101	C0030705
Western Cape Province	UnknownType	C0681784
SA	T083	C0037712
described	T078	C1552738
resulting	T169	C0332294
staff members	T097	C1552089
medical microbiology laboratories	T073	C0022877
public health investigation	T058	C1827659
article	T170	C0282420
aims	T078	C1947946
integration	T169	C0243126
public health	T170	C3244304
medical	T058	C0199168
veterinary	T091	C0042615
services	T057	C0557854
exposing deficiencies	T169	C0011155
public health	T170	C3244304
veterinary	T091	C0042615
laboratory	T073	C0022877
Survey	T170	C0038951
Trichinella infection	T047	C0856687
domestic pigs	T015	C1136016
historical	T033	C2004062
endemic areas	T082	C0205146
Henan province	T083	C1514578
central China	T083	C0008115
aim	T078	C1947946
work	T057	C0043227
investigate	T169	C1292732
current situation	T033	C0150312
Trichinella infection	T047	C0856687
domestic pigs	T015	C1136016
historical	T033	C2004062
endemic areas	T082	C0205146
Henan province	T083	C1514578
central China	T083	C0008115
diaphragm samples	T031	C3687538
indoor-raised pigs	T015	C1136016
collected	T169	C1516698
five	T081	C0205451
cities	T083	C0008848
Henan	T083	C1514578
examined	T033	C0332128
artificial digestion method	T169	C0025664
overall prevalence	T081	C1707459
Trichinella infection	T047	C0856687
pigs	T015	C0039005
Trichinella larvae	T204	C0546803
detected	T033	C0442726
pigs	T015	C0039005
Nanyang city	T083	C0008848
Henan	T083	C1514578
larval	T204	C0023047
burden	T078	C2828008
infected animals	T033	C0237158
larvae	T204	C0023047
muscles	T024	C0026845
range	T081	C1514721
larvae	T204	C0546803
identified	T080	C0205396
Trichinella spiralis	T204	C0040892
multiple PCR	T063	C3179032
study	T062	C2603343
confirms	T080	C0521093
existence	T077	C2987476
swine	T015	C0039005
trichinellosis	T047	C0040896
Henan	T083	C1514578
infection	T046	C3714514
level	T080	C0441889
minimum level	T080	C0441889
infectious sources	T001	C0314732
humans	T016	C0086418
prevalence	T081	C0220900
swine	T015	C0039005
Trichinella infection	T047	C0856687
Henan	T083	C1514578
evaluated	T058	C0220825
large scale	T081	C0549177
pork samples	T167	C3687765
meat	T168	C0025017
food safety	T057	C1456535
Voriconazole	T109	C0393080
metabolism	T044	C0683140
influenced	T077	C4054723
severe	T080	C0205082
inflammation	T046	C0021368
prospective study	T062	C0033522
infection	T046	C3714514
inflammation	T046	C0021368
several	T081	C0443302
drug	T121	C1254351
metabolizing	T044	C0683140
enzymes	T116	C0014442
liver	T023	C0023884
down-regulated	T044	C1327624
cytochrome P450 iso-enzymes	T116	C0010762
voriconazole	T109	C0393080
extensively	T080	C0205231
metabolized	T044	C0683140
cytochrome P450 iso-enzymes	T116	C0010762
metabolism	T044	C0683140
voriconazole	T109	C0393080
influenced	T077	C4054723
inflammation	T046	C0021368
reduced	T080	C0392756
clearance of the drug	T039	C0683151
higher	T080	C0205250
voriconazole	T109	C0393080
trough concentrations	T081	C3640757
influence	T077	C4054723
inflammation	T046	C0021368
voriconazole	T109	C0393080
metabolism	T044	C0683140
voriconazole	T109	C0393080
trough concent ratio ns	T081	C3640757
ratio	T081	C0456603
prospective observational study	T062	C0033522
University Medical Center	T073	C0000872
Groningen	T083	C0017446
Patients	T101	C0030705
eligible	T080	C1548635
inclusion	T080	C1512693
treated with	T061	C0332293
voriconazole	T109	C0393080
Voriconazole	T109	C0393080
voriconazole-N-oxide	T109	C4263709
concentrations	T081	C1446561
blood samples	T031	C0178913
degree	T081	C0449286
inflammation	T046	C0021368
C-reactive protein (CRP) concentrations	T059	C0201657
longitudinal data analysis	T062	C0023981
assess	T058	C0184514
effect	T080	C1280500
inflammation	T046	C0021368
metabolic	T044	C0683140
ratio	T081	C0456603
voriconazole	T109	C0393080
trough concentration	T081	C3640757
patients	T101	C0030705
voriconazole	T109	C0393080
trough concentrations	T081	C3640757
longitudinal data analysis	T062	C0023981
analysis	T062	C0023981
inflammation	T046	C0021368
CRP concentrations	T059	C0201657
influence	T077	C4054723
metabolic	T044	C0683140
ratio	T081	C0456603
voriconazole	T109	C0393080
trough concentration	T081	C3640757
voriconazole-N-oxide	T109	C4263709
concentration	T081	C1446561
factors	T169	C1521761
influence	T077	C4054723
voriconazole	T109	C0393080
metabolism	T044	C0683140
metabolic	T044	C0683140
ratio	T081	C0456603
decreased	T081	C0205216
voriconazole-N-oxide	T109	C4263709
concentration	T081	C1446561
voriconazole	T109	C0393080
trough concentration	T081	C3640757
increased	T081	C0205217
CRP	T116	C0006560
voriconazole	T109	C0393080
metabolism	T044	C0683140
decreased	T081	C0205216
inflammation	T046	C0021368
higher	T080	C0205250
voriconazole	T109	C0393080
trough concentration	T081	C3640757
frequent	T079	C0332183
monitoring	T058	C1283169
voriconazole	T109	C0393080
serum concentrations	T081	C0683149
severe	T080	C0205082
inflammation	T046	C0021368
Neoadjuvant Chemotherapy	T061	C4272610
Ovarian Cancer	T191	C0029925
Tumor-Infiltrating Lymphocyte	T025	C0079722
Response	T039	C0301909
Immunotherapy	T061	C0278348
chemotherapy	T061	C0392920
antitumor	T080	C2986475
immunity	T039	C0020964
immunogenic	T169	C0872192
cell death	T043	C0007587
T-cell activation	T043	C1155065
tumor infiltration	T191	C4060690
tumors	T191	C0027651
immunotherapies	T061	C0278348
checkpoint blockade	T043	C1155873
platinum	T196	C0032207
taxane	T109	C0215136
chemotherapy	T061	C0392920
ovarian cancer	T191	C0029925
immunologic	T169	C0205470
Experimental Design	T062	C0015320
pre	T079	C0332152
post	T079	C0687676
neoadjuvant chemotherapy	T061	C4272610
tumor samples	T024	C0475358
high-grade serous carcinoma	T191	C3839280
HGSC	T191	C3839280
immunohistochemistry	T060	C0021044
IHC	T060	C0021044
immune cells	T025	C0312740
post	T079	C0687676
chemotherapy	T061	C0392920
TIL	T025	C0079722
cohort	T098	C0599755
Neoadjuvant chemotherapy	T061	C4272610
CD3	T116	C0108779
CD8	T129	C0085358
CD8	T129	C0085358
TIA-1	T116	C1429678
PD-1	T116	C2986635
CD20	T116	C0054946
TIL	T025	C0079722
CD79a	T116	C0286618
CD138	T116	C1609943
plasma cells	T025	C0032112
CD68	T116	C0108799
macrophages	T025	C0024432
MHC class I	T116	C0019629
tumor cells	T025	C0597032
Immunosuppressive	T047	C4048329
cell	T025	C0007634
FoxP3	T116	C4282118
PD-1	T116	C2986635
cells	T025	C0039198
regulatory T cells	T025	C0039198
IDO-1	T116	C3529891
PD-L1	T129	C4300350
macrophages	T025	C0024432
tumor cells	T025	C0597032
Hierarchical clustering	T062	C1881045
TIL	T025	C0079722
tumors	T191	C0027651
immune markers	T080	C0162489
chemotherapy	T061	C4272610
TIL	T025	C0079722
TIL	T025	C0079722
negative	T033	C0205160
negative	T033	C0205160
chemotherapy	T061	C0392920
TIL	T025	C0079722
Chemotherapy	T061	C4272610
TIL	T025	C0079722
responses	T039	C0301909
immune-suppressive mechanisms	T047	C1840264
immunotherapy	T061	C0278348
tumor microenvironment	T070	C2936626
adder	T014	C0206298
Vipera berus	T014	C0206298
Southern Altay Mountains	T083	C0442533
population characteristics	T102	C0032661
distribution	T082	C0037775
morphology	T080	C0332437
phylogenetic position	T080	C1519069
distributed	T082	C0037775
snake	T014	C0037382
Eurasia	T083	C0017446
adder	T014	C0206298
Vipera berus	T014	C0206298
extensively	T080	C0205231
investigated	T169	C1292732
Europe	T083	C0015176
Asia	T083	C0003980
Southern Altay Mountains	T083	C0442533
adder's	T014	C0206298
southern	T082	C1710133
distribution	T082	C0037775
limit	T169	C0439801
Central Asia	T083	C0003982
population status	T081	C0032671
assessed	T052	C1516048
field surveys	T062	C1517184
adder	T014	C0206298
areas	T082	C0205146
Southern Altay Mountains	T083	C0442533
combination	T080	C0205195
line transects	T062	C0242481
random	T080	C0439605
searches	T052	C1706202
morphological characteristics	T080	C0332437
collected specimens	T059	C0200345
analyses	T062	C0936012
external	T082	C0205101
morphology	T080	C0332437
molecular phylogeny	T078	C0031797
results	T033	C0683954
adder	T014	C0206298
distributed	T082	C0037775
survey	T062	C0011296
sites	T082	C0205145
recorded	T170	C0034869
sightings	T053	C1947978
Kanas river valley	T082	C0563004
estimated	T081	C0750572
encounter	T053	C1947978
rate	T081	C1521828
transects	T062	C0242481
sightings	T053	C1947978
occurrence	T079	C2745955
melanism	T047	C0025209
small size	T033	C0748864
typical	T080	C3538928
adders	T014	C0206298
Southern Altay Mountains	T083	C0442533
geographic populations	T081	C0032659
nominate	T052	C1707391
subspecies	T185	C1883207
phylogenetic tree	T080	C1519069
obtained	T169	C1301820
Bayesian Inference	T081	C0242196
DNA sequences	T086	C0162326
mitochondrial cytochrome b	T116	C0010744
grouped	T082	C0439745
Northern clade	T081	C0032659
species	T185	C1705920
separate	T080	C0443299
subspecies	T185	C1883207
V. b. sachalinensis	T014	C0206298
discovery	T052	C1880355
distribution	T082	C0037775
range	T081	C1514721
V. berus	T014	C0206298
basis	T169	C1527178
researches	T062	C0035168
hypothesis	T078	C1512571
adder	T014	C0206298
expands	T082	C0205229
distribution	T082	C0037775
border	T185	C2828371
southwest	T082	C1710136
mountains	T083	C0442533
elevation	T082	C0702240
gradient	T081	C0812409
population	T098	C1257890
abundance	T080	C2346714
declines	T081	C0547047
gradually	T080	C0439833
drying climate	T070	C0681771
Binding	T052	C1145667
Pollutants	T131	C0599786
Biomolecules	T123	C0574031
Simulation Study	T062	C0679083
cases	T169	C0868928
world	T098	C2700280
animals	T008	C0003062
found dead	T033	C0476463
dying	T040	C0184532
symptoms	T184	C1457887
thiamine	T047	C0039841
(vitamin B) deficiency	T047	C0042850
pollutants	T131	C0599786
investigate	T058	C0220825
biomolecules	T123	C0574031
thiamin binding	T044	C1523455
transport	T043	C1159805
blocked	T169	C0332206
pollutants	T131	C0599786
in silico	T066	C3489666
docking	T044	C1522290
compound	T123	C0574031
classes	T170	C0456387
compounds	T123	C0574031
prion protein	T116	C4082486
ECF-type ABC transporter	T026	C3158987
thi-box riboswitch receptor	T114	C2936590
thiamin pyrophosphokinase	T116	C0039850
YKoF protein	T116	C0033684
molecular dynamics (MD) simulations	T066	C2717775
stability	T080	C0205360
complexes	T104	C1704241
compound	T123	C0574031
classes	T170	C0456387
thiamin	T109	C0039840
analogues	T104	C0002776
control	T167	C1550141
pesticides	T131	C0031253
veterinary	T080	C0042614
medicines	T121	C0013227
polychlorinated biphenyls	T109	C0032447
dioxins	T109	C0012503
prevalent	T081	C0220900
environment	T082	C0014406
compounds	T123	C0574031
bind	T044	C1167622
ECF-type ABC transporter	T026	C3158987
none binds stably	T033	C0243095
prion protein	T116	C4082486
riboswitch	T114	C2936590
compounds	T123	C0574031
binding pockets	T120	C1254355
MD simulation	T066	C2717775
RNA	T114	C0035668
binding site	T192	C0005456
YKoF	T116	C0033684
thiamin pyrophosphokinase	T116	C0039850
TPK	T116	C0039850
compounds	T123	C0574031
tightly bound	T052	C1145667
TPK	T116	C0039850
biomolecules	T123	C0574031
pollutant	T131	C0599786
induced	T169	C0205263
conformational changes	T044	C0301641
compounds	T123	C0574031
quantitative methods	T062	C1510568
free energy perturbation	UnknownType	C0678592
calculations	T052	C1441506
conclusions	T078	C1707478
study	T062	C2603343
quantitative	T081	C0034384
computational screening	T059	C4297010
interactions	T169	C1704675
biological entities	T123	C0574031
pollutant molecules	T131	C0599786
Characterisation	T052	C1880022
methicillin-resistant Staphylococcus aureus	T007	C1265292
clinical	T080	C0205210
isolates	T123	C1764827
animals	T008	C0003062
New Zealand	T083	C0027978
subclinical	T080	C0205211
colonisation	T033	C2242741
dogs	T015	C0012984
cats	T015	C0007450
Auckland	UnknownType	C0681784
characterise	T052	C1880022
methicillin-resistant Staphylococcus aureus	T007	C1265292
MRSA	T007	C1265292
isolates	T123	C1764827
infection sites	T047	C0578491
animals	T008	C0003062
New Zealand	T083	C0027978
prevalence	T081	C0220900
subclinical	T080	C0205211
MRSA colonisation	T033	C2242741
dogs	T015	C0012984
cats	T015	C0007450
veterinary clinics	T073	C2936717
Auckland	UnknownType	C0681784
MRSA	T007	C1265292
isolates	T123	C1764827
clinical	T080	C0205210
specimens	T167	C0370003
New Zealand	T083	C0027978
veterinary diagnostic laboratories	T073	C0022877
June	T079	C3829443
June	T079	C3829443
genotypically characterised	T052	C1880022
DNA microarray hybridisation analysis	T063	C1522053
spa	T116	C0038164
typing	T059	C0087124
nasal	T023	C0222095
perineal skin	T023	C0222176
swabs	T167	C0183753
cross-sectional sample	T167	C0370003
dogs	T015	C0012984
cats	T015	C0007450
veterinary clinics	T073	C2936717
Auckland	UnknownType	C0681784
period	T079	C1948053
analysed	T062	C0936012
MRSA	T007	C1265292
culture	T059	C2242979
MRSA	T007	C1265292
clinical	T080	C0205210
isolates	T123	C1764827
characterisation	T052	C1880022
laboratories	T073	C0022877
isolates	T123	C1764827
dogs	T015	C0012984
isolates	T123	C1764827
dog	T015	C0012984
foal	T015	C3669731
isolate	T123	C1764827
source	T033	C0449416
strain	T001	C1518614
types	T080	C0332307
identified	T080	C0205396
AK3 (ST-5 SCCmecIV	T007	C1265292
USA500 (ST8 SCCmecIV	T007	C1265292
WSPP (ST30 SCCmecIV	T007	C1265292
Rhine Hesse (ST5 SCCmecII	T007	C1265292
EMRSA-15 (ST22 SCCmecIV	T007	C1265292
MRSA	T007	C1265292
isolated	T169	C0205409
cultured swabs	T167	C0183753
Methicillin-susceptible S. aureus	T007	C1265292
detected	T033	C0442726
swabs	T167	C0183753
non-aureus staphylococci	T007	C0038170
swabs	T167	C0183753
MRSA	T007	C1265292
subclinical	T080	C0205211
colonisation	T033	C2242741
prevalence	T081	C0220900
CI	T081	C0009667
cats	T015	C0007450
dogs	T015	C0012984
modest number	T081	C0237753
MRSA	T007	C1265292
isolates	T123	C1764827
study	T170	C0085973
laboratories	T073	C0022877
clinical	T080	C0205210
MRSA infection	T047	C0343401
animals	T008	C0003062
New Zealand	T083	C0027978
sporadic	T079	C0205422
strain	T001	C1518614
types	T080	C0332307
strain	T001	C1518614
type	T080	C0332307
diversity	T080	C1880371
humans	T016	C0086418
bias	T078	C0242568
non-random sampling	T062	C0150105
dogs	T015	C0012984
cats	T015	C0007450
colonisation	T033	C4289767
prevalence	T081	C0220900
consistent with	T078	C0332290
prevalence	T081	C0220900
subclinical	T080	C0205211
colonisation	T033	C2242741
humans	T016	C0086418
New Zealand	T083	C0027978
similarities	T080	C2348205
epidemiology	T091	C0014507
animal	T008	C0003062
human	T016	C0086418
MRSA infections	T047	C0343401
decade	T081	C2981279
prevalence	T081	C0220900
human	T016	C0086418
MRSA infections	T047	C0343401
New Zealand	T083	C0027978
increased	T081	C0205217
study	T170	C0085973
MRSA	T007	C1265292
animals	T008	C0003062
New Zealand	T083	C0027978
clinical	T080	C0205210
MRSA infection	T047	C0343401
animals	T008	C0003062
sporadic	T079	C0205422
diversification	T057	C0680948
strain	T001	C1518614
types	T080	C0332307
therapeutic	T169	C0302350
veterinarians	T097	C0242856
resistome	T028	C2945710
Cloud-based MOTIFSIM	T170	C0037589
Detecting	T033	C0442726
Similarity	T080	C2348205
DNA Motif	T086	C3178798
Data Sets	T170	C0150098
cloud-based MOTIFSIM	T170	C0037589
Amazon Web Services	T066	C1710664
AWS	T066	C1710664
cloud	T066	C4042841
tool	T170	C0037589
version	T170	C0333052
web-based tool version 2.0	T170	C0037589
algorithm	T170	C0002045
detecting	T033	C0442726
similarity	T080	C2348205
DNA motif	T086	C3178798
data sets	T170	C0150098
cloud	T066	C4042841
version	T170	C0333052
researchers	T097	C0035173
computing resources	T078	C0035201
AWS	T066	C1710664
detect	T033	C0442726
similarity	T080	C2348205
DNA motif	T086	C3178798
data sets	T170	C0150098
next-generation sequencing technology	T063	C2936622
tool	T170	C0037589
AWS	T066	C1710664
Utilization	T169	C0042153
Outcomes	T062	C0086750
Sentinel Lymph Node Biopsy	T060	C0796693
Vulvar Cancer	T191	C0375071
sentinel node biopsy	T060	C0796693
women	T098	C0043210
vulvar cancer	T191	C0375071
Perspective database	T170	C0242356
all-payer database	T170	C0242356
collects data	T062	C0010995
hospitals	T073	C0019994
retrospective cohort study	T062	C2985505
women	T098	C0043210
vulvar cancer	T191	C0375071
vulvectomy	T061	C0195066
lymph node assessment	T060	C0193842
Multivariable models	T075	C0026336
factors	T169	C0679238
sentinel node biopsy	T060	C0796693
Length of stay	T079	C0023303
cost	T081	C0087112
women	T098	C0043210
sentinel node biopsy	T060	C0796693
lymphadenectomy	T061	C0024203
women	T098	C0043210
sentinel node biopsy	T060	C0796693
inguinofemoral lymphadenectomy	T061	C0398408
sentinel node biopsy	T060	C0796693
confidence interval	T081	C0009667
CI	T081	C0009667
CI	T081	C0009667
multivariable model	T075	C0026336
women	T098	C0043210
treated	T169	C1522326
sentinel node biopsy	T060	C0796693
women	T098	C0043210
comorbidities	T078	C0009488
treated	T169	C1522326
rural hospitals	T093	C0020023
procedure	T060	C0796693
median	T082	C2939193
length of stay	T079	C0023303
sentinel node biopsy	T060	C0796693
median	T082	C2939193
interquartile range	T081	C1711350
women	T098	C0043210
inguinofemoral lymphadenectomy	T061	C0398408
interquartile range	T081	C1711350
sentinel node biopsy	T060	C0796693
interquartile range	T081	C1711350
interquartile range	T081	C1711350
lymphadenectomy	T061	C0024203
sentinel node biopsy	T060	C0796693
vulvar cancer	T191	C0375071
Sentinel lymph node biopsy	T060	C0796693
shorter hospital stay	T079	C3489408
decreased cost	T081	C0010187
inguinofemoral lymphadenectomy	T061	C0398408
Condition	T080	C0348080
dependent	T080	C0851827
co-regulation	T038	C1327622
genomic clusters	T028	C0017258
virulence factors	T109	C1136170
grapevine trunk	T047	C0012634
pathogen	T001	C0450254
Neofusicoccum parvum	T004	C2269732
ascomycete	T004	C0003965
Neofusicoccum parvum	T004	C2269732
causal agents	T033	C0449411
Botryosphaeria dieback	T004	C1011772
wood	T167	C0043217
infecting	T033	C0439663
fungus	T004	C0016832
threat	T078	C0749385
grape	T168	C0018208
worldwide	T098	C2700280
capability	T080	C2698977
colonizing	T033	C4289767
woody tissue	T025	C1514137
combined	T080	C0205195
secretion	T038	C0036536
phytotoxic	T080	C1407029
compounds	T103	C1706082
pathogenicity	T032	C1136169
virulence	T038	C0042765
virulence factors	T109	C1136170
transcriptional	T045	C0040649
dynamics	T070	C3826426
fungus	T004	C0016832
feeds	T168	C0016452
substrates	T167	C3891814
colonizes	T033	C4289767
woody stem	T002	C2699642
assembled	T052	C1706853
annotated	T080	C1552720
highly	T080	C0205250
contiguous	T082	C0205283
genome	T028	C0017428
single molecule real-time DNA sequencing	UnknownType	C0687728
Transcriptome profiling	T059	C0752248
RNA-sequencing	T059	C0917793
genome	T028	C0017428
patterns	T082	C0449774
expression	T045	C0017262
virulence factors	T109	C1136170
in vitro	T062	C0681828
potato	T168	C0032846
dextrose agar	T130	C3266617
medium	T130	C0010454
amended	T080	C1691222
grape	T168	C0018208
wood	T167	C0043217
substrate	T167	C3891814
planta	T002	C0032098
Pairwise statistical testing	T170	C0237913
differential	T080	C1705242
expression	T045	C0017262
co-expression network analysis	T063	C1880945
physically	T169	C0205485
clustered genes	T028	C0017258
coding	T085	C0017380
virulence	T038	C0042765
functions	T169	C0542341
substrate	T167	C3891814
stage	T079	C1306673
plant	T002	C0032098
infection	T046	C3714514
Co-expressed	T045	C0017262
gene clusters	T028	C0017258
genes	T028	C0017337
associated with	T080	C0332281
secondary metabolism	T044	C0260000
cell wall degradation	T043	C1157855
dynamic	T169	C0729333
co-regulation	T038	C1327622
transcriptional networks	T044	C1720950
N. parvum	T004	C2269732
virulence	T038	C0042765
co-expressed	T045	C0017262
clusters	T028	C0017258
genes	T028	C0017337
promoter region	T114	C0033413
co-regulation	T038	C1327622
transcription factor	T116	C0040648
Co-expression analysis	T063	C1880945
chromatin	T116	C0008546
regulators	T077	C1704735
correlated	T080	C1707520
expression	T045	C0017262
inducible	T169	C0205263
clusters	T028	C0017258
virulence factors	T109	C1136170
regulation	T038	C1327622
virulence	T038	C0042765
N. parvum	T004	C2269732
Congenital anomalies	T019	C0000768
isotretinoin	T109	C0022265
legal aspects	T064	C0022433
neonate	T100	C0021289
severe	T080	C0205082
multiple abnormalities	T019	C0000772
isotretinoin	T109	C0022265
mother	T099	C0026591
knowledge	T170	C0376554
drug complications	T046	C1393201
physical examination	T058	C0031809
delivery	T061	C0011209
congenital absence	T019	C0332907
both eyes	T023	C0229118
auricles	T023	C0928075
anal atresia	T019	C0003466
cleft palate	T019	C0008925
severe	T080	C0205082
respiratory distress	T184	C0476273
atresia	T019	C0243066
anus	T023	C0003461
neonate	T100	C0021289
neonatal	T100	C0021289
intensive care unit	T073	C0021708
reconstructive surgery	T061	C0524865
drug	T121	C1254351
pregnancy	T040	C0032961
drug	T121	C1254351
pregnancy	T040	C0032961
side effects	T046	C0041755
legal	T169	C1301860
consequences	T169	C0686907
Functional adaptation	T038	C0392673
crustacean	T204	C1704306
exoskeletal	T023	C0596796
elements	T196	C0013879
structural	T082	C0678594
compositional	T032	C0005885
diversity	T080	C0282469
combined	T080	C0205195
experimental	T062	C0681814
theoretical study	T062	C0039778
crustacean	T204	C1704306
cuticle	T002	C2699479
composite	T080	C0205199
material	T167	C0520510
animal	T008	C0003062
continuous exoskeleton	T023	C0596796
Nano-fibers	T073	C1881960
chitin	T109	C0008141
protein molecules	T116	C0033684
organic	T080	C0747055
matrix	T109	C4050026
cuticle	T002	C2699479
macroscale	T081	C0392762
hierarchical	T169	C0699032
levels	T080	C0441889
exo-	T002	C2699479
endocuticle	T002	C2699479
mineral phase	T197	C0026162
Mg	T123	C0024467
calcite	T197	C0205686
amorphous	T080	C1979848
calcium carbonate	T121	C0006681
phosphate	T121	C0031603
hierarchical	T169	C0699032
levels	T080	C0441889
compositional	T032	C0005885
diversity	T080	C0282469
degree of freedom	T080	C0205556
varying	T169	C0392747
physical	T201	C1998468
mechanical	T169	C0205245
properties	T080	C0871161
material	T167	C0520510
cuticle	T002	C2699479
versatile material	T167	C0520510
skeletal	T082	C0521324
elements	T196	C0013879
adapted	T038	C0392673
functions	T169	C0542341
eco-physiological strains	T001	C1518614
individual species	T185	C1705920
review	T170	C0282443
analytical	T170	C0178476
experimental	T062	C0681814
theoretical studies	T062	C0039778
cuticle	T002	C2699479
hierarchical	T169	C0699032
levels	T080	C0441889
structure	T082	C0678594
composition	T032	C0005885
physical properties	T201	C1998468
multi-scale hierarchical modeling approach	T075	C0026336
results	T169	C1274040
studies	T062	C2603343
systematically	T169	C0220922
predicting	T078	C0681842
structure	T082	C0678594
composition	T032	C0005885
property	T080	C0871161
relations	T080	C0439849
cuticle	T002	C2699479
composites	T080	C0205199
molecular	T080	C1521991
level	T080	C0441889
macro-scale	T081	C0392762
modeling approach	T075	C0026336
development	T169	C1527148
biomimetic materials	T073	C1136386
knowledge-based design approach	T075	C0026336
Draft Genome Sequences	T085	C2348746
Isolates	T123	C3494793
Listeria monocytogenes Serotype 1/2a	T007	C3472320
Subgroup	T185	C1515021
ST204	T001	C1518614
Listeria monocytogenes	T007	C0023861
sequence type 204 (ST204) strains	T001	C1518614
isolated	T169	C0205409
range of food	T168	C0016452
environmental	T082	C0014406
clinical	T080	C0205210
sources	T033	C0449416
Australia	T083	C0004340
draft genome sequences	T085	C2348746
meat	T168	C0025017
dairy associated sources	T168	C0010947
Transferability	T080	C0205556
Homoeolog-Specific Markers	T045	C0017393
Bread	T168	C0006138
Wheat	T168	C0043137
Synthesized	T052	C1883254
Hexaploid Wheat Lines	T168	C0043137
Bread	T168	C0006138
wheat	T168	C0043137
Triticum aestivum	T002	C1123020
allohexaploid genome	T028	C0017428
differentiate	T169	C2945687
homoeologous sequences	T085	C0162774
chromosome A	T026	C0008633
B	T026	C0008633
D	T026	C0008633
subgenomes	T028	C0017428
chromosome	T026	C0008633
genome	T028	C0017428
sequence	T086	C0004793
Chinese Spring	T168	C0043137
wheat cultivar	T168	C0043137
development	T169	C1527148
polymerase chain reaction	T063	C0032520
PCR	T063	C0032520
markers	T045	C0017393
Chinese Spring	T168	C0043137
genes	T028	C0017337
homoeolog-specific markers	T045	C0017393
chromosomes 4B	T026	C0008633
7B	T026	C0008633
markers	T045	C0017393
PCR assays	T063	C0032520
4B	T026	C0008633
7B	T026	C0008633
synthetic hexaploid wheat (SHW) line	T168	C0043137
hybridization	T070	C0376343
Triticum turgidum	T002	C0997189
diploid species	T025	C1257909
Aegilops tauschii	T002	C1007013
markers	T045	C0017393
chromosomes 4B	T026	C0008633
7B	T026	C0008633
SHW	T168	C0043137
markers	T045	C0017393
Chinese Spring	T168	C0043137
bread	T168	C0006138
wheat	T168	C0043137
SHW lines	T168	C0043137
Homoeolog-specific markers	T045	C0017393
genes	T028	C0017337
genetic investigations	T059	C0796344
chromosome	T026	C0008633
expression	T045	C0017262
Participation	T169	C0679823
adherence	T169	C1510802
physical exercise	T056	C0015259
completion	T080	C0205197
primary cancer	T191	C1306459
treatment	T061	C0087111
purpose	T169	C1285529
study	T062	C2603343
identify	T041	C0020792
demographic	T078	C0011292
clinical	T080	C0205210
psychosocial	T169	C0542298
physical	T169	C0205485
environmental	T082	C0014406
factors	T169	C1521761
associated with	T080	C0332281
participation	T169	C0679823
adherence	T169	C1510802
combined	T080	C0205195
resistance	T169	C4281815
endurance exercise	T061	C0419120
program	T169	C3484370
cancer survivors	T101	C1516231
completion	T080	C0205197
primary cancer	T191	C1306459
treatment	T061	C0087111
Data	T078	C1511726
randomized	T033	C3815594
controlled	T169	C2587213
Resistance and Endurance exercise After ChemoTherapy	T170	C0282574
REACT	T170	C0282574
study	T062	C2603343
study	T062	C2603343
participants	T098	C0679646
REACT	T170	C0282574
study	T062	C2603343
randomly	T080	C0439605
allocated	T052	C1706778
high intensity	T185	C4081854
HI	T185	C4081854
low	T080	C0205251
moderate intensity	T185	C4081855
LMI	T080	C0522510
exercise	T056	C0015259
program	T169	C3484370
Patients	T101	C0030705
participation	T169	C0679823
rate	T081	C1521828
cancer survivors	T101	C1516231
participate	T169	C0679823
REACT	T170	C0282574
study	T062	C2603343
Exercise	T056	C0015259
adherence	T169	C1510802
reflected	T041	C0558058
participants	T098	C0679646
attendance	T052	C2827364
scheduled	T080	C0205539
exercise	T056	C0015259
sessions	T051	C1883016
compliance	T055	C1321605
prescribed	T058	C0278329
exercises	T056	C0015259
High	T080	C0205250
session	T051	C1883016
attendance	T052	C2827364
rates	T081	C1521828
attending	T169	C1999232
sessions	T051	C1883016
High	T080	C0205250
compliance	T055	C1321605
rates	T081	C1521828
performing	T169	C0884358
prescribed	T058	C0278329
exercise	T056	C0015259
sessions	T051	C1883016
Correlates	T080	C1707520
exercise	T056	C0015259
adherence	T169	C1510802
studied	T062	C2603343
separately	T080	C0443299
HI	T185	C4081854
LMI	T080	C0522510
exercise	T056	C0015259
Demographic	T078	C0011292
clinical	T080	C0205210
physical	T169	C0205485
factors	T169	C1521761
assessed	T052	C1516048
self-reported	T062	C0681906
questionnaires	T170	C0034394
Relevant	T080	C2347946
clinical information	T170	C2708733
extracted	T169	C1301820
medical records	T170	C0025102
Multivariable logistic regression analyses	UnknownType	C0681925
applied	T169	C4048755
identify	T041	C0020792
correlates	T080	C1707520
significantly	T078	C0750502
associated with	T080	C0332281
participation	T169	C0679823
high	T080	C0205250
session	T051	C1883016
attendance	T052	C2827364
high	T080	C0205250
compliance	T055	C1321605
resistance	T169	C4281815
high	T080	C0205250
compliance	T055	C1321605
endurance exercises	T061	C0419120
Participants	T098	C0679646
more likely	T033	C3840799
higher education	T170	C0424933
non-smokers	T033	C0337672
lower	T080	C0205251
psychological distress	T048	C0815107
higher	T080	C0205250
outcome	T080	C0085415
expectations	T078	C0679138
perceive	T041	C0030971
more	T081	C0205172
exercise	T056	C0015259
barriers	T080	C0679881
non-participants	T098	C1257890
HI	T185	C4081854
exercise	T056	C0015259
higher	T080	C0205250
self-efficacy	T041	C0600564
significantly	T078	C0750502
associated with	T080	C0332281
high	T080	C0205250
session	T051	C1883016
attendance	T052	C2827364
high	T080	C0205250
compliance	T055	C1321605
endurance exercises	T061	C0419120
lower	T080	C0205251
psychological distress	T048	C0815107
significantly	T078	C0750502
associated with	T080	C0332281
high	T080	C0205250
compliance	T055	C1321605
resistance	T169	C4281815
exercise	T056	C0015259
LMI	T080	C0522510
exercise	T056	C0015259
non-smoker	T033	C0337672
significantly	T078	C0750502
associated with	T080	C0332281
high	T080	C0205250
compliance	T055	C1321605
resistance	T169	C4281815
exercises	T056	C0015259
higher	T080	C0205250
BMI	T201	C1305855
significantly	T078	C0750502
associated with	T080	C0332281
high	T080	C0205250
compliance	T055	C1321605
resistance	T169	C4281815
endurance exercises	T061	C0419120
breast cancer survivors	T101	C1516231
less	T081	C0439092
likely	T078	C0750492
report	T058	C0700287
high	T080	C0205250
compliance	T055	C1321605
resistance	T169	C4281815
endurance exercises	T061	C0419120
LMI	T080	C0522510
exercise	T056	C0015259
compared	T052	C1707455
survivors	T101	C0206194
cancer	T191	C0006826
discriminative	T041	C0012632
ability	T032	C0085732
multivariable	T080	C0439828
models	T170	C3161035
ranged	T081	C1514721
demographic	T078	C0011292
clinical	T080	C0205210
psychosocial	T169	C0542298
factors	T169	C1521761
associated with	T080	C0332281
participation	T169	C0679823
adherence	T169	C1510802
exercise	T056	C0015259
cancer survivors	T101	C1516231
Psychosocial	T169	C0542298
factors	T169	C1521761
more	T081	C0205172
strongly	T080	C0442821
associated with	T080	C0332281
adherence	T169	C1510802
HI	T185	C4081854
LMI	T080	C0522510
exercise	T056	C0015259
study	T062	C2603343
registered	T170	C0684224
Netherlands Trial Register	T170	C0034975
NTR2153	T170	C0034975
In situ	T082	C0444498
stabilization	T080	C0205360
heavy metals	T196	C0347988
metal	T197	C0025552
contaminated	T169	C0205279
paddy	T002	C1083174
soil	T167	C0037592
steel	T122	C0038239
slag	T197	C0885779
silicon	T196	C0037107
fertilizer	T073	C0015919
Steel	T122	C0038239
slag	T197	C0885779
silicon	T196	C0037107
fertilizer	T073	C0015919
mobility	T033	C0425245
bioavailability	T081	C0005508
heavy metals	T196	C0347988
soil	T167	C0037592
objective	T170	C0018017
study	T062	C2603343
evaluate	T058	C0220825
influence	T077	C4054723
particle size	T081	C0030608
composition	T070	C0243176
slag	T197	C0885779
metal	T197	C0025552
immobilization	T169	C0205245
acidic	T103	C0001128
soil	T167	C0037592
metals	T197	C0025552
uptake	T039	C0243144
rice	T002	C1140671
rice	T002	C1140671
growth	T039	C0220844
slag	T197	C0885779
soil	T167	C0037592
pH	T081	C0020283
plant	T002	C0032098
silicon	T196	C0037107
concentrations	T081	C1446561
soil	T167	C0037592
decreased	T081	C0205216
bioavailability	T081	C0005508
metals	T197	C0025552
control treatment	T080	C0243148
pulverous slag	T197	C0885779
S1	T197	C0885779
more effective	T080	C1704419
granular	T080	C0205248
slag	T197	C0885779
acid	T103	C0001128
extractable fraction of	T081	C1264633
Cd	T131	C0006632
soil	T167	C0037592
decreased	T081	C0205216
S1	T197	C0885779
Cu	T121	C0009968
Zn	T121	C0043481
decreased	T081	C0205216
treated	T169	C1522326
S1	T197	C0885779
significantly lower	T081	C4055638
Cd	T131	C0006632
Cu	T121	C0009968
Zn	T121	C0043481
concentrations	T081	C1446561
rice	T002	C1140671
tissues	T025	C1514137
controls	T096	C0009932
pulverous slag	T197	C0885779
promotes	T052	C0033414
rice	T002	C1140671
growth	T039	C0220844
rice	T002	C1140671
growth	T039	C0220844
treated	T169	C1522326
reduced	T080	C0392756
particle size	T081	C0030608
slag	T197	C0885779
rice	T002	C1140671
growth	T039	C0220844
metals	T197	C0025552
stabilization	T080	C0205360
Plasmodium falciparum	T204	C0032150
Choline Kinase	T116	C0008415
Inhibition	T052	C3463820
Decrease	T081	C0547047
Phosphatidylethanolamine	T109	C1450468
Parasite	T204	C0030498
Death	T040	C0011065
Malaria	T047	C0024530
life-threatening	T033	C2826244
disease	T047	C0012634
species	T185	C1705920
protozoan parasite	T204	C0585171
Plasmodium	T204	C0032148
P. falciparum	T204	C0032150
Increasing	T169	C0442808
parasitic	T169	C0521066
resistance	T169	C4281815
antimalarials	T121	C0003374
novel	T080	C0205314
treat	T061	C0087111
disease	T047	C0012634
enzymes	T116	C0014442
synthesis	T052	C1883254
phosphatidylcholine	T109	C1959616
phosphatidylethanolamine	T109	C1450468
drug targets	T169	C1521840
treat	T061	C0087111
malaria	T047	C0024530
inhibition	T052	C3463820
parasite's	T204	C0030498
growth	T040	C0018270
cures	T033	C0679252
malaria	T047	C0024530
mouse model	T050	C2986594
study	T062	C2603343
mode of action	T169	C1524059
P. falciparum	T204	C0032150
choline kinase	T116	C0008415
inhibitors	T120	C0243077
in vitro	T080	C1533691
in vivo	T082	C1515655
compounds	T080	C0205198
binding	T044	C1167622
choline	T109	C0008405
ethanolamine	T109	C0059696
binding site	T192	C0005456
P. falciparum	T204	C0032150
choline kinase	T116	C0008415
inhibition	T052	C3463820
compounds	T080	C0205198
ethanolamine kinase activity	T044	C1150468
P. falciparum	T204	C0032150
choline kinase	T116	C0008415
decrease	T081	C0547047
phosphatidylethanolamine	T109	C1450468
levels	T080	C0441889
P. falciparum	T204	C0032150
growth phenotype	T032	C0031437
parasites	T204	C0030498
death	T040	C0011065
mode of action	T169	C1524059
antimalarial development	T039	C0243107
P. falciparum	T204	C0032150
choline kinase	T116	C0008415
Anti-CD45RB	T116	C0003250
donor-specific spleen cells transfusion	T169	C0199960
inhibition	T052	C3463820
allograft skin rejection	T046	C2891288
memory T cells	T025	C0682639
memory T (Tm)cells	T025	C0682639
rejection	T042	C0018129
transplanted organs	T023	C0524930
anti-CD45RB monoclonal antibody (α-CD45RB)	T116	C0003250
donor	T098	C0013018
specific	T080	C0205369
tolerance	T040	C0887937
study	T062	C2603343
pre-sensitization	T079	C1254367
female	T032	C0086287
C57BL/6 mice	T015	C1521751
skin	T022	C1123023
female	T032	C0086287
BLAB/c mice	T015	C0026809
Tm cells	T025	C0682639
rejection	T042	C0018129
secondly	T081	C0205436
transplanted	T169	C0700106
allografts	T122	C0450127
α-CD45RB	T116	C0003250
tolerance	T040	C0887937
skin allograft	T122	C0440814
primarily	T080	C0205225
transplanted	T169	C0700106
tolerance	T040	C0887937
pre-sensitized mice	T015	C0026809
Donor-specific spleen cell transfusion	T169	C0199960
DST	T169	C0199960
tolerance	T040	C0887937
pre-sensitized	T079	C1254367
recipients	T101	C0376387
α-CD45RB	T116	C0003250
DST	T169	C0199960
rejection	T042	C0018129
memory T cells	T025	C0682639
pre-sensitized mice	T015	C0026809
CD25+ T-cell	T025	C0039194
depletion	T061	C0677960
α-CD45RB	T116	C0003250
DST	T169	C0199960
therapy	T061	C0087111
recipients	T101	C0376387
skin allograft	T122	C0440814
tolerance	T040	C0887937
adoptive transfer	T061	C0376518
donor	T098	C0013018
memory T cells	T025	C0682639
tolerant	T040	C0887937
recipients	T101	C0376387
tolerance	T040	C0887937
findings	T033	C0243095
α-CD45RB	T116	C0003250
DST	T169	C0199960
rejection	T042	C0018129
memory T cells	T025	C0682639
skin allograft	T122	C0440814
acceptance	T039	C0301944
mice	T015	C0026809
Recruitment	T052	C2949735
Minority	T098	C0026192
Adolescents	T100	C0205653
Young Adults	T100	C0238598
Randomised Clinical Trials	T062	C0206035
Testing	T169	C0039593
Design	T052	C1707689
Technology Enhanced Community Health Nursing	T058	C0886296
TECH-N	T058	C0886296
Pelvic Inflammatory Disease	T047	C0242172
Pelvic inflammatory disease	T047	C0242172
PID	T047	C0242172
disproportionately	T080	C0205350
adolescent	T100	C0205653
young adult	T100	C0238598
AYA	T100	C0027362
women	T098	C0043210
influence	T077	C4054723
reproductive health	T091	C0242667
randomized controlled trials	T062	C0206035
RCTs	T062	C0206035
improve	T033	C0184511
outpatient	T101	C0029921
adherence	T169	C1510802
reduce	T080	C0392756
reproductive	T040	C0035150
morbidity	T081	C0026538
population	T098	C1257890
research methods	T062	C0086912
preliminary	T079	C0439611
effectiveness	T080	C1280519
recruitment	T052	C2949735
retention	UnknownType	C0679857
intervention	T058	C0886296
RCT	T062	C0206035
technology-enhanced community-health nursing	T058	C0886296
TECH-N	T058	C0886296
intervention	T058	C0886296
AYA	T100	C0027362
PID	T047	C0242172
AYA	T100	C0027362
women	T098	C0043210
aged	T032	C0001779
years	T079	C1510829
recruited	T052	C2949735
acute PID	T047	C0149959
visits	T058	C1512346
outpatient clinics	T073	C0002424
emergency departments	T073	C0562508
ED	T073	C0562508
participate	T058	C0030699
IRB-approved	T170	C2346499
Participants	T098	C0679646
completed	T080	C0205197
audio-computerized self-interview	T052	C0021822
ACASI	T052	C0021822
vaginal specimens	T024	C0586773
randomized	T062	C0034656
standard	T080	C1442989
treatment	T061	C0087111
intervention	T058	C0886296
Intervention	T058	C0886296
participants	T098	C0679646
received	T080	C1514756
text-messaging	T052	C3178908
support	T077	C1521721
days	T079	C0439228
community health nurse (CHN) interventionist	T097	C1522710
performed	T169	C0884358
home visit with clinical assessment	T058	C2046813
days	T079	C0439228
enrollment	T058	C1516879
patients	T101	C0030705
course	T079	C0750729
medications	T058	C1254363
completed	T080	C0205197
visits	T058	C0848616
days	T079	C0439228
adherence	T169	C1510802
days	T079	C0439228
days	T079	C0439228
outreach worker	T097	C0586969
STI	T047	C0036916
testing	T169	C0039593
performed	T169	C0884358
day	T079	C0439228
visits	T058	C1512346
Exploratory analyses	T062	C0936012
descriptive statistics	T062	C1710191
recruitment	T052	C2949735
retention	UnknownType	C0679857
follow-up	T058	C1522577
data	T078	C1511726
design	T052	C1707689
intervention	T058	C0886296
months	T079	C0439231
patients	T101	C0030705
eligible	T080	C1548635
eligible	T080	C1548635
patients	T101	C0030705
recruited	T052	C2949735
eligible	T080	C1548635
patients	T101	C0030705
enrolled	T058	C1516879
participants	T098	C0679646
African American	T098	C0085756
mean	T081	C0444504
age	T032	C0001779
individuals	T098	C0027361
TECH-N intervention	T058	C0886296
completed	T080	C0205197
nursing visits	T058	C0848616
completed	T080	C0205197
visits	T058	C0848616
day	T079	C0439228
window	T079	C1272706
patients	T101	C0030705
retained	T169	C0333118
month	T079	C0439231
follow-up	T058	C1522577
period	T079	C1948053
Biological	T080	C0205460
data	T078	C1511726
shift in the biological milieu	T070	C0001398
Chlamydia trachomatis	T047	C0518948
Mycoplasma genitalium	T047	C3854370
Trichomonas vaginalis infections	T047	C0040923
Preliminary	T079	C0439611
data	T078	C1511726
TECH-N	T058	C0886296
urban	T083	C0442529
low-income	T033	C1331016
minority	T098	C0026192
AYA	T100	C0027362
PID	T047	C0242172
recruited	T052	C2949735
retained	T169	C0333118
participate	T058	C0030699
sexual	T032	C2362326
reproductive health	T091	C0242667
RCTs	T062	C0206035
sufficient	T080	C0205410
investment	T073	C0021953
design	T052	C1707689
infrastructure of the study	T185	C1514880
Community	T096	C0009462
sexual health	T032	C2362326
interventions	T061	C0184661
feasible	T080	C0205556
acceptable	T080	C1879533
population	T098	C1257890
Prostate Health Index	T059	C4084801
[-2]pro-prostate-specific antigen	T116	C3710767
Chinese	T098	C0152035
men	T098	C0025266
prostate specific antigen	T116	C0138741
normal	T080	C0205307
digital rectal examination	T060	C1384593
Prostate Health Index	T059	C4084801
PHI	T059	C4084801
[-2]pro-prostate-specific antigen	T116	C3710767
%p2PSA	T116	C3710767
Chinese	T098	C0152035
men	T098	C0025266
prostate-specific antigen	T116	C0138741
PSA	T116	C0138741
normal	T080	C0205307
digital rectal examination	T060	C1384593
DRE	T060	C1384593
Chinese	T098	C0152035
men	T098	C0025266
PSA	T116	C0138741
normal	T080	C0205307
DRE	T060	C1384593
transrectal ultrasound	T060	C0373345
TRUS	T060	C0373345
prostate biopsy	T060	C0194804
Blood samples	T031	C0178913
TRUS	T060	C0373345
prostate biopsy	T060	C0194804
total PSA	T059	C2986589
tPSA	T059	C2986589
free-to-total PSA	T059	C2207083
fPSA	T059	C2207083
%p2PSA	T116	C3710767
PHI	T059	C4084801
logistic regression	T062	C0206031
receiver operating characteristic	T081	C0034772
decision curve analyses	T062	C0936012
DCA	T062	C0936012
Chinese	T098	C0152035
men	T098	C0025266
men	T098	C0025266
diagnosed	T033	C0011900
prostate cancer	T191	C0376358
biopsy	T060	C0005558
men	T098	C0025266
positive biopsies	T033	C1514241
biopsies	T060	C0005558
PHI	T059	C4084801
PHI	T059	C4084801
PHI	T059	C4084801
chi-square test	T170	C0008041
area under curves	T081	C0376690
AUC	T081	C0376690
base model	T170	C3161035
age	T032	C0001779
tPSA	T059	C2986589
biopsy	T060	C0005558
%p2PSA	T116	C3710767
PHI	T059	C4084801
base model	T170	C3161035
improved	T033	C0184511
AUC	T081	C0376690
DCA	T062	C0936012
positive biopsy	T033	C1514241
biopsy	T060	C0005558
Gleason 7 or above	T185	C0332326
prostate cancers	T191	C0376358
PHI	T059	C4084801
PHI	T059	C4084801
PHI	T059	C4084801
chi-square test	T170	C0008041
PHI	T059	C4084801
men	T098	C0025266
PSA	T116	C0138741
normal	T080	C0205307
DRE	T060	C1384593
biopsies	T060	C0005558
avoided	T078	C1554079
PHI	T059	C4084801
%p2PSA	T116	C3710767
prostate cancer	T191	C0376358
high grade prostate cancer	T191	C0376358
PHI	T059	C4084801
%p2PSA	T116	C3710767
Chinese	T098	C0152035
men	T098	C0025266
normal	T080	C0205307
DRE	T060	C1384593
pilot study	T062	C0031928
relationship	T080	C0439849
self	T078	C0036588
compassion	T054	C0242270
self	T078	C0036588
judgement	T041	C0022423
self	T078	C0036588
kindness	T041	C0871641
compassion	T054	C0242270
professional quality of life	T078	C0034380
wellbeing	T033	C0031206
UK	T083	C0041700
community nurses	T097	C0557521
Compassion fatigue	T048	C4042834
burnout	T048	C0006433
impact	T080	C4049986
performance	T052	C1882330
nurses	T097	C0557521
relationship	T080	C0439849
self	T078	C0036588
compassion	T054	C0242270
self	T078	C0036588
judgement	T041	C0022423
self	T078	C0036588
kindness	T041	C0871641
compassion	T054	C0242270
professional quality of life	T078	C0034380
wellbeing	T033	C0031206
community nurses	T097	C0557521
measure	T081	C0079809
associations	T080	C0332281
self	T078	C0036588
compassion	T054	C0242270
compassion fatigue	T048	C4042834
wellbeing	T033	C0031206
burnout	T048	C0006433
community nurses	T097	C0557521
Quantitative	T081	C0392762
data	T078	C1511726
collected	T169	C1516698
standardised	T080	C1442989
psychometric questionnaires	T170	C0034394
Professional Quality of Life Scale	T170	C0451401
Self-Compassion Scale	T081	C0392762
short Warwick Edinburgh Mental Wellbeing Scale	T170	C4075266
Compassion For Others Scale	T081	C0392762
measure	T081	C0079809
relationships	T080	C0439849
self	T078	C0036588
compassion	T054	C0242270
compassion fatigue	T048	C4042834
wellbeing	T033	C0031206
burnout	T048	C0006433
cross sectional	T062	C0010362
registered community nurses	T097	C0687673
postgraduate	T077	C2983146
diploma	T033	C4035742
University	T073	C0041740
North of England	T083	C0014282
study	T062	C0031928
Results	T169	C1274040
community nurses	T097	C0557521
score	T081	C0449820
high	T080	C0205250
measures	T081	C0079809
self	T078	C0036588
compassion	T054	C0242270
wellbeing	T033	C0031206
less	T080	C0547044
burnout	T048	C0006433
Greater	T081	C1704243
compassion	T054	C0242270
satisfaction	T041	C0242428
positively	T033	C1446409
associated with	T080	C0332281
compassion	T054	C0242270
wellbeing	T033	C0031206
negatively	T033	C0205160
correlated	T080	C1707520
burnout	T048	C0006433
High	T080	C0205250
levels	T080	C0441889
self	T078	C0036588
compassion	T054	C0242270
lower	T052	C2003888
levels	T080	C0441889
burnout	T048	C0006433
community nurses	T097	C0557521
greater	T081	C1704243
compassion	T054	C0242270
satisfaction	T041	C0242428
compassion	T054	C0242270
increased	T081	C0205217
wellbeing	T033	C0031206
less	T080	C0547044
burnout	T048	C0006433
implications	T169	C0205245
suggestions	T078	C1705535
promotion	T052	C0033414
greater	T081	C1704243
compassion	T054	C0242270
CD169	T116	C1608815
identifies	T033	C0243095
activated	T025	C1515879
CD8(+) T cell	T025	C0242629
subset	T185	C0079720
regional lymph nodes	T023	C1179441
predicts	T078	C0681842
favorable	T080	C3640814
prognosis	T058	C0033325
colorectal cancer	T191	C1527249
patients	T101	C0030705
CD169	T116	C1608815
macrophages	T025	C0024432
Mϕ	T025	C0024432
antigen presentation	T043	C0206431
CD169 expression	T045	C0017262
CD8(+) T lymphocytes	T025	C0242629
regional lymph nodes	T023	C1179441
LNs	T023	C1179441
investigated	T169	C1292732
function	T039	C0031843
clinical relevance	T033	C0243095
CD169(+)CD8(+) T cells	T025	C0039194
tumor-draining LNs	T023	C0024204
colorectal cancer	T191	C1527249
CRC	T191	C1527249
patients	T101	C0030705
Fresh tumor-draining LN tissues	T024	C0440747
randomly	T080	C0439605
enrolled patients	T033	C4316108
assessed	T052	C1516048
flow cytometry	T059	C0016263
activation	T025	C1440937
differentiation	T043	C0007589
CD169(+)CD8(+) T cells	T025	C0039194
T cell-mediated killing of tumor cells	T043	C1523368
tumor-draining LN	T023	C0024204
CRC	T191	C1527249
patients	T101	C0030705
multiple-color immunofluorescence	T059	C0016318
CD169(+)CD8(+) T cell	T025	C0039194
distribution	T169	C1704711
prognostic	T170	C0220901
significance	T080	C0205556
CD169(+)CD8(+) T cells	T025	C0039194
evaluated	T058	C0220825
Kaplan-Meier analysis	T081	C1720943
fraction of	T081	C1264633
CD8(+) T cells	T025	C0242629
regional LNs	T023	C1179441
peripheral blood	T031	C0229664
tonsils	T023	C0836921
tumors	T191	C0027651
expressed surface CD169	T116	C1608815
In situ	T082	C0444498
detection	T061	C1511790
draining LNs	T023	C0024204
revealed	T080	C0443289
localization	T169	C0475264
CD169(+)CD8(+) T cells	T025	C0039194
subcapsular sinus	T024	C1518052
interfollicular regions	T029	C1512836
associated with	T080	C0332281
CD169(+) Mϕ	T025	C0024432
CD169(+)CD8(+) T cell	T025	C0039194
ratios	T081	C0456603
peri-tumor	T082	C1254362
LNs	T023	C0024204
distant-tumor	T082	C1254362
LNs	T023	C0024204
CD169(+)CD8(+) T cells	T025	C0039194
predominantly	T080	C0205556
activation markers	T201	C0005516
CD69	T116	C0108800
HLA-DR	T116	C0019764
PD-1	T116	C0135710
CD45RA	T116	C0108789
CD62L	T116	C0125090
levels	T080	C0441889
high	T080	C0205250
granzyme B	T116	C0061878
perforin	T116	C0070410
TNF-α	T116	C1456820
IFNγ	T116	C3539881
levels	T080	C0441889
tumor-killing efficiency	T061	C1446301
ex vitro	T082	C1254362
CD169(+)CD8(+) T cells	T025	C0039194
infiltrating	T046	C0332448
tumor-draining LNs	T023	C0024204
decreased	T081	C0205216
disease progression	T046	C0242656
associated with	T080	C0332281
CRC	T191	C1527249
patient	T101	C0030705
survival	T052	C0038952
identified	T080	C0205396
activated	T025	C1440937
cytolytic CD169(+)CD8(+) T cells	T025	C0039195
regional LNs	T023	C1179441
prognostic factor	T201	C1514474
indicator	T169	C1522602
selecting	T052	C1707391
patients	T101	C0030705
immunotherapy	T061	C0021083
Appearance	T080	C0700364
Differences	T080	C1705242
Lots	T170	C3272563
Brands	T170	C0592503
Shade	T080	C0009393
Designations	T170	C0600091
Dental Composite Resins	T109	C0891703
purposes	T169	C1285529
study	T062	C2603343
investigate	T169	C1292732
differences	T080	C1705242
inherent	T080	C2347662
appearance	T080	C0700364
characteristics	T080	C1521970
lots	T170	C3272563
enamel dental composite resin	T109	C0891703
shade	T080	C0009393
brand	T170	C0592503
compare	T052	C1707455
differences	T080	C1705242
shade	T080	C0009393
designation	T170	C0600091
different	T080	C1705242
brand	T170	C0592503
dental composite resins	T109	C0891703
Appearance	T080	C0700364
analyses	T062	C0936012
proceeded	T079	C0439659
lots	T170	C3272563
shades	T080	C0009393
A1	T185	C0008902
B2	T185	C0008902
D3	T185	C0008902
manufactured	T057	C0870840
company	T073	C0683757
lot	T170	C3272563
shade	T080	C0009393
EA1	T185	C0008902
manufactured	T057	C0870840
Samples	T167	C0370003
measured	T080	C0444706
black	T080	C0439541
white	T080	C0220938
gray	T080	C1269776
backings	T077	C1706907
spectroradiometry	T059	C0034603
Kubelka-Munk theory	T078	C0871935
reflectivity	T081	C4054089
lot	T170	C3272563
studied	T062	C2603343
CIELAB values	T080	C0042295
color	T080	C0009393
differences	T080	C1705242
shades	T080	C0009393
lots	T170	C3272563
analyzed	T062	C0936012
Translucency	T080	C0522503
indicators	T130	C0021212
compared	T052	C1707455
lots	T170	C3272563
thicknesses	T080	C1280412
Differences	T080	C1705242
inherent	T080	C2347662
color	T080	C0009393
lots	T170	C3272563
shade	T080	C0009393
designations	T170	C0600091
brand	T170	C0592503
acceptability	T080	C0814633
threshold	T080	C0449864
Color	T080	C0009393
difference	T080	C1705242
enamel composite resin	T109	C0891703
shade	T080	C0009393
A1	T185	C0008902
composite resin	T109	C0891703
shade	T080	C0009393
EA1	T185	C0008902
acceptability	T080	C0814633
threshold	T080	C0449864
Statistically significant	T081	C0237881
differences	T080	C1705242
translucency	T080	C0522503
lots	T170	C3272563
shade	T080	C0009393
range	T081	C1514721
thicknesses	T080	C1280412
studied	T062	C2603343
Appearance	T080	C0700364
analyses	T062	C0936012
indicate	T078	C3146298
variation	T080	C0205419
lots	T170	C3272563
shade	T080	C0009393
designations	T170	C0600091
brands	T170	C0592503
shade	T080	C0009393
designations	T170	C0600091
Optical	T090	C0029144
applied	T169	C4048755
important	T080	C3898777
clinical	T080	C0205210
appearance	T080	C0700364
characterize	T052	C1880022
inherent	T080	C2347662
appearance	T080	C0700364
aid	T080	C1269765
appearance	T080	C0700364
matching	T080	C1708943
process	T067	C1522240
dental composite resins	T109	C0891703
restorative	T061	C0204217
operative dental procedures	T061	C0543467
Patient Preferences	T080	C0376409
Treatment	T061	C0087111
Choices	T052	C1707391
Early-Stage	T079	C2363430
Lung Cancer	T191	C0242379
Decision-making	T041	C0011109
lung cancer	T191	C0242379
treatment	T061	C0087111
complex	T080	C0439855
provider	T097	C0031831
recommendations	T078	C0034866
patient's	T101	C0030705
clinical	T080	C0205210
condition	T080	C0348080
patient preferences	T080	C0376409
study	T062	C2603343
considerations	T033	C0518609
lung cancer	T191	C0242379
treatment	T061	C0087111
patient's	T101	C0030705
perspective	T041	C0871010
conjoint preference experiment	T062	C0681814
respondents	T098	C0282122
diagnosed	T033	C0011900
lung cancer	T191	C0242379
Respondents	T098	C0282122
chose	T052	C1707391
procedures	T061	C0087111
treatment	T061	C0087111
modalities	T077	C3889585
treatment	T061	C0087111
complications	T046	C0009566
likelihood	T081	C0033204
recurrence	T067	C0034897
provider	T097	C0031831
case	T169	C0868928
volume	T081	C0449468
distance	T081	C0012751
needed	T169	C1514873
travel	T056	C0040802
treatment	T061	C0087111
Conjoint analysis	T062	C0681814
attributes	T080	C1521970
responses	T170	C1706817
analyzed	T062	C0936012
Respondents	T098	C0282122
minimally	T080	C0547040
invasive operations	T061	C4048276
treatment	T061	C0087111
lung cancer	T191	C0242379
stereotactic body radiation therapy	T061	C3896609
SBRT	T061	C3896609
thoracotomy	T061	C0039991
Treatment	T061	C0087111
risk of recurrence	T081	C2986492
attributes	T080	C1521970
conjoint experiment	T062	C0681814
provider	T097	C0031831
volume	T081	C0449468
risk	T078	C0035647
complications	T046	C0009566
distance	T081	C0012751
needed	T169	C1514873
travel	T056	C0040802
treatment	T061	C0087111
Procedural	T061	C0087111
treatment	T061	C0087111
preferences	T078	C0558295
demographics	T080	C1521970
self-reported	T062	C2700446
health status	T080	C0018759
familiarity	T041	C0600269
procedures	T061	C0087111
Survey	T170	C0038951
respondents	T098	C0282122
minimally	T080	C0547040
invasive operations	T061	C4048276
SBRT	T061	C3896609
thoracotomy	T061	C0039991
treatment	T061	C0087111
early-stage	T079	C2363430
non-small cell lung cancer	T191	C0007131
Treatment	T061	C0087111
modality	T077	C3889585
risk	T078	C0035647
cancer recurrence	T191	C0920420
treatment	T061	C0087111
preferences	T078	C0558295
Provider	T097	C0031831
experience	T041	C0596545
need	T169	C1514873
travel	T056	C0040802
lung cancer	T191	C0242379
treatment	T061	C0087111
Suppressed	T169	C1260953
translation	T044	C0597295
ULK1	T116	C1313678
degradation	T044	C0597297
potential	T080	C3245505
mechanisms	T169	C0441712
autophagy	T043	C0004391
prolonged	T079	C0439590
starvation	T033	C0038187
Macroautophagy	T043	C1155604
autophagy	T043	C0004391
intracellular degradation	T043	C1523935
activated	T052	C1879547
starvation	T033	C0038187
data	T078	C1511726
transcriptional	T045	C0040649
upregulation	T044	C0041904
autophagy	T043	C0004391
genes	T028	C0017337
mechanism	T169	C0441712
controls	T169	C2587213
autophagy	T043	C0004391
starvation	T033	C0038187
upregulation	T044	C0041904
mRNA	T114	C0035696
autophagy	T043	C0004391
initiation gene	T028	C0017337
ULK1	T028	C1421350
protein	T116	C1313678
level	T080	C0441889
reduced	T080	C0392756
starvation	T033	C0038187
autophagic	T043	C0004391
proteasomal systems	T116	C0033684
degradation	T044	C0597297
ULK1	T116	C1313678
prolonged	T079	C0439590
nitrogen	T123	C0028158
deprivation	T080	C0871712
level	T080	C0441889
reduced	T080	C0392756
ATG7	T028	C1825498
knockout cells	T025	C0007634
cells	T025	C0007634
treated	T169	C1522326
lysosomal	T026	C0024369
proteasomal inhibitors	T121	C1443643
starvation	T033	C0038187
protein translation	T044	C0597295
diminished	T081	C0205216
treatments	T061	C0087111
proteosynthesis inhibitors	T121	C0033671
cycloheximide	T109	C0010572
anisomycin	T109	C0003082
reduction	T080	C0392756
ULK1	T116	C1313678
inhibition	T052	C3463820
mitochondrial	T026	C0026237
respiratory complexes	T026	C4235129
mitochondrial	T026	C0026237
ATP synthase function	T044	C2250396
absence	T169	C0332197
substrates	T167	C3891814
upregulation	T044	C0041904
ULK1 mRNA	T114	C0035696
protein expression	T045	C1171362
AMPK	T116	C2350345
dependent	T169	C3244310
U1810 lung cancer cells	T025	C0597032
culture medium	T130	C0010454
inhibitors	T080	C1999216
increase	T169	C0442805
ULK1 protein	T116	C1313678
U1810 cells	T025	C0597032
ATG13	T028	C3146638
ULK1	T116	C1313678
expression	T045	C1171362
diminished	T081	C0205216
upregulation	T044	C0041904
ULK1 protein	T116	C1313678
starvation	T033	C0038187
translation	T044	C0597295
transcriptional	T045	C0040649
upregulation	T044	C0041904
ULK1 protein	T116	C1313678
diminished	T081	C0205216
model	T075	C0026336
inhibition	T052	C3463820
protein translation	T044	C0597295
degradation	T044	C0597297
autophagy	T043	C0004391
starvation	T033	C0038187
Neuroprotective Role	T169	C0815279
MicroRNA-22	T028	C1537720
6-Hydroxydopamine	T109	C0085196
Induced	T169	C0205263
Cell	T025	C0007634
Model	T050	C0684309
Parkinson's Disease	T047	C0030567
Regulation	T045	C0017263
Target	T169	C1521840
Gene	T028	C0017337
TRPM7	T028	C1425224
Parkinson's disease	T047	C0030567
PD	T047	C0030567
prevalent	T082	C0205391
neurodegenerative disorder	T047	C0524851
symptomatic	T169	C0231220
treatment	T061	C0087111
available	T169	C0470187
characterized	T052	C1880022
progressive	T169	C0205329
loss	T081	C1517945
dopaminergic neurons	T025	C1512035
midbrain	T023	C0025462
microRNAs	T114	C1101610
miRs	T114	C1101610
regulate post-transcriptional	T045	C1514248
gene expression	T045	C0017262
neuronal disease	T047	C0027765
study	T062	C2603343
effects	T080	C1280500
mechanism	T169	C0441712
miR-22	T028	C1537720
PC12 pheochromocytoma cells	T025	C0085262
treated	T169	C1522326
6-hydroxydopamine	T109	C0085196
6-OHDA	T109	C0085196
PD	T047	C0030567
RT-PCR	T063	C0599161
results	T169	C1274040
expression	T045	C0017262
miR-22	T028	C1537720
downregulated	T044	C0013081
6-OHDA	T109	C0085196
treated	T169	C1522326
PC12 cells	T025	C0085262
overexpression	T045	C0017262
miR-22	T028	C1537720
promoted	T052	C0033414
survival	T043	C0007620
proliferation	T043	C0596290
6-OHDA	T109	C0085196
induced	T169	C0205263
PC12 cells	T025	C0085262
miR-22	T028	C1537720
inhibitor	T080	C1999216
reversed	T169	C1555029
effects	T080	C1280500
PC12 cells	T025	C0085262
treated	T169	C1522326
miR-22 mimics	T028	C1537720
inhibitor	T080	C1999216
following	T079	C0332282
6-OHDA	T109	C0085196
administration	T061	C1533734
ROS	T123	C0162772
production	T044	C1148560
upregulation	T044	C0041904
downregulation	T044	C0013081
caspase-3 activity	T044	C1150132
luciferase	T116	C0024075
assay	T059	C2717977
revealed	T080	C0443289
transient receptor potential melastatin 7	T028	C1425224
TRPM7	T028	C1425224
direct	T080	C1947931
target	T169	C1521840
gene	T028	C0017337
miR-22	T028	C1537720
miR-22	T028	C1537720
overexpression	T045	C0017262
downregulated	T044	C0013081
level	T080	C0441889
TRPM7	T028	C1425224
analysis	T062	C0936012
miR-22	T028	C1537720
6-OHDA	T109	C0085196
induced	T169	C0205263
PC12	T025	C0085262
cell survival	T043	C0007620
proliferation	T043	C0596290
targeting	T169	C1521840
TRPM7	T028	C1425224
study	T062	C2603343
miR-22	T028	C1537720
overexpression	T045	C0017262
neuroprotective	T169	C0815279
reversal	T169	C1555029
effects	T080	C1280500
6-OHDA	T109	C0085196
induced	T169	C0205263
PC12	T025	C0085262
cell growth	T043	C0007595
apoptosis	T043	C0162638
targeting	T169	C1521840
TRPM7	T028	C1425224
Obstacle course runs	T056	C0038039
review	T170	C0282443
injuries	T037	C3263723
illnesses	T184	C0221423
series	T081	C0205549
Canadian	T033	C0238884
events	T051	C0441471
RACE	T056	C0038039
obstacle course runs	T056	C0038039
OCRs	T056	C0038039
significant	T078	C0750502
concerns	T078	C2699424
safety	T068	C0036043
injuries	T037	C3263723
illnesses	T184	C0221423
rural areas	T082	C0178837
OCRs	T056	C0038039
emergency medical services	T058	C0013961
EMS	T058	C0013961
Literature	T170	C0023866
concerning	T078	C2699424
safety	T068	C0036043
events	T051	C0441471
minimal	T080	C0547040
media	T170	C0009458
reports	T170	C0684224
characterise	T052	C1880022
injury	T037	C3263723
illness	T184	C0221423
OCRs	T056	C0038039
level	T080	C0441889
medical care	T061	C0237078
study	T062	C2603343
analysed	T062	C0936012
OCR	T056	C0038039
events	T051	C0441471
Canada	T083	C0006823
participants	T098	C0679646
Data	T078	C1511726
extracted	UnknownType	C0677145
event	T051	C0441471
medical charts	T074	C0007963
patients	T101	C0030705
onsite	T082	C0450429
medical team	T058	C0086390
injury	T037	C3263723
illness	T184	C0221423
treatment	T061	C0087111
disposition	T078	C0743223
race participants	T098	C0679646
treated	T169	C1522326
OCR	T056	C0038039
events	T051	C0441471
participants	T098	C0679646
medical complaints	T170	C0025102
injuries	T037	C3263723
musculoskeletal	T169	C0497254
event	T051	C0441471
medical care	T061	C0237078
treatments	T061	C0087111
first aid	T061	C0016143
medical equipment	T074	C0025080
patients	T101	C0030705
patients	T101	C0030705
hospital	T073	C0019994
EMS	T058	C0013961
fracture	T037	C0016658
dislocation	T037	C0012691
head injury	T037	C0018674
chest pain	T184	C0008031
fall from height	T067	C1997329
abdominal pain	T184	C0000737
race participants	T098	C0679646
medical services	T058	C0199168
minor	T037	C0332673
musculoskeletal	T037	C0272448
treated	T169	C1522326
hospital	T073	C0019994
EMS	T058	C0013961
consistent with	T078	C0332290
mass gathering	T033	C3841750
events	T051	C0441471
Modern	T079	C0242324
Medical Management	T058	C1444483
Changing	T169	C0392747
Patient Outcomes	T078	C1547647
Inflammatory Bowel Disease	T047	C0021390
impact	T080	C4049986
modern	T079	C0242324
medical management	T058	C1444483
inflammatory bowel disease	T047	C0021390
IBD	T047	C0021390
surgical necessity	T058	C0587668
outcomes	T169	C1274040
unclear	T033	C3845108
surgery	T061	C0543467
rates	T081	C1521828
decreased	T081	C0205216
outcomes	T169	C1274040
worsened	T033	C1457868
operating	T061	C0543467
sicker	T184	C0221423
patients	T101	C0030705
introduction	T169	C0579004
biologic medications	T061	C1531518
Inpatient	T101	C0021562
Sample	T167	C0370003
ICD-9-CM codes	T170	C1137112
inpatient	T101	C0021562
admissions	T058	C0184666
Crohn's disease	T047	C0010346
ulcerative colitis	T047	C0009324
Trends	T079	C1521798
IBD	T047	C0021390
nutrition	T033	C0392209
surgeries	T061	C0543467
postoperative complications	T046	C0032787
admissions	T058	C0184666
IBD	T047	C0021390
study	T062	C2603343
period	T079	C1948053
Surgery	T061	C0543467
rates	T081	C1521828
unchanged	T033	C0442739
study	T062	C2603343
period	T079	C1948053
admissions	T058	C0184666
Crohn's disease	T047	C0010346
ulcerative colitis	T047	C0009324
rate	T081	C1521828
poor nutrition	T047	C0162429
increased	T081	C0205217
ulcerative colitis	T047	C0009324
Crohn's disease	T047	C0010346
Rates	T081	C1521828
postoperative	T079	C0032790
anastomotic leak	T046	C0919691
unchanged	T033	C0442739
Postoperative infection	T046	C0392618
rates	T081	C1521828
decreased	T081	C0205216
Crohn's disease	T047	C0010346
trend	T033	C1545470
ulcerative colitis	T047	C0009324
Rates	T081	C1521828
IBD	T047	C0021390
surgery	T091	C0038894
stable	T080	C0205360
postoperative infectious complications	T046	C0032787
stable	T080	C0205360
decreased	T081	C0205216
implementation	T058	C0018726
biologic therapies	T061	C1531518
increase	T169	C0442805
poor nutrition	T047	C0162429
surgical patients	T101	C0871463
Clinical	T080	C0205210
Experience	T067	C0023672
Subcutaneous Implantable Cardioverter-Defibrillator	T074	C3694431
Adults	T100	C0001675
Congenital Heart Disease	T019	C0152021
Sudden cardiac death	T046	C0085298
mortality	T081	C0205848
adults	T100	C0001675
congenital heart disease	T019	C0152021
subcutaneous	T082	C0443315
implantable cardioverter-defibrillator	T074	C0162589
ICD	T074	C0162589
novel	T080	C0205314
tool	T073	C0336791
prevention	T080	C2700409
sudden cardiac death	T046	C0085298
clinical performance	T033	C3266594
data	T078	C1511726
adults	T100	C0001675
congenital heart disease	T019	C0152021
retrospective study	T062	C0035363
year	T079	C0439234
period	T079	C1948053
performed	T169	C0884358
patients	T101	C0030705
median	T081	C2347635
years	T079	C0439234
diagnosis	T033	C0011900
single ventricle	T019	C0152424
physiology	T039	C0031843
palliated	T061	C1274136
Fontan operation	T061	C0190010
aortopulmonary shunts	T061	C0397538
d-transposition of the great arteries	T019	C1275836
Mustard	T061	C1306542
Senning	T061	C0339890
tetralogy of Fallot	T019	C0039685
aortic valve disease	T047	C1260873
biventricular	T082	C0699808
surgery	T061	C0543467
cardiac device	T074	C0018825
implanted	T061	C0948629
ICD	T074	C0162589
indication	T078	C3146298
primary prevention	T061	C0033144
secondary	T061	C0679699
patient s	T101	C0030705
subcutaneous	T082	C0443315
ICD	T074	C0162589
placement	T058	C0441587
transvenous access	T082	C0522521
ventricular lead	T074	C2825199
placement	T058	C0441587
intracardiac right-to-left shunt	T033	C0489644
Ventricular arrhythmia	T047	C0085612
induced	T169	C0205263
Joules	T081	C0439256
implant complication related to infection	T046	C0085073
not	T080	C0332288
device removal	T061	C0752250
median	T081	C2347635
follow-up	T058	C1522577
months	T079	C0439231
patients	T101	C0030705
inappropriate	T047	C0340944
patient	T101	C0030705
appropriate shocks	T046	C0036984
arrhythmic death	T033	C3844298
asystole	T047	C0018790
single ventricle	T019	C0152424
patient	T101	C0030705
Subcutaneous	T082	C0443315
ICD	T074	C0162589
implantation	T061	C0021107
adults	T100	C0001675
congenital heart disease	T019	C0152021
patients	T101	C0030705
candidates	T101	C0030705
single ventricle	T019	C0152424
heart disease	T047	C0018799
transvenous options	T082	C0522521
ICD	T074	C0162589
placement	T058	C0441587
variable	T080	C0439828
anatomy	T080	C1384516
study	T062	C2603343
successful	T080	C1272703
conversion	T169	C0439836
induced	T169	C0205263
ventricular arrhythmia	T047	C0085612
reasonable	T033	C0184784
rhythm	T042	C0232187
discrimination	T042	C0234412
follow-up	T058	C1522577
Interaction	T169	C1704675
multiple	T081	C0439064
gene variants	T028	C0678941
effects	T080	C1280500
schizophrenia	T048	C0036341
phenotypes	T032	C0031437
Schizophrenia	T048	C0036341
clinically	T080	C0205210
heterogeneous disorder	T033	C1858576
genetic architecture	T169	C0314603
schizophrenia	T048	C0036341
susceptibility	T201	C0012655
genes	T028	C0017337
identified	T080	C0205396
inconsistent	T080	C0442809
contradictory	T080	C0205556
genetic association studies	T063	C2717878
symptoms	T184	C1457887
interaction	T169	C1704675
genes	T028	C0017337
interacting	T169	C1704675
genes	T028	C0017337
associated with	T080	C0332281
specific	T080	C0205369
sub-phenotypes	T032	C0031437
schizophrenia	T048	C0036341
schizophrenia	T048	C0036341
investigates	T169	C1292732
relationship	T080	C0439849
schizophrenia	T048	C0036341
susceptibility	T201	C0012655
genes	T028	C0017337
schizophrenia	T048	C0036341
sub-phenotypes	T032	C0031437
identifying	T080	C0205396
multiple	T081	C0439064
gene variant	T028	C0678941
interactions	T169	C1704675
SNPs	T086	C0752046
genes	T028	C0017337
genotyped	T059	C3178894
Australian	T098	C0238711
participants	T098	C0679646
schizophrenia	T048	C0036341
screened	T058	C0220908
phenotypes	T032	C0031437
Schizophrenia	T048	C0036341
participants	T098	C0679646
relevant	T080	C2347946
phenotype	T032	C0031437
clusters	T081	C1704332
cluster analysis	T062	C0009085
normalized	T062	C1882115
phenotype	T032	C0031437
cluster	T081	C1704332
scores	T081	C0449820
patient	T101	C0030705
relationship	T080	C0439849
genotypes	T032	C0017431
normalized	T062	C1882115
phenotype	T032	C0031437
cluster	T081	C1704332
scores	T081	C0449820
linear regression analysis	T170	C0034980
phenotype	T032	C0031437
clusters	T081	C1704332
identified	T080	C0205396
symptoms	T184	C1457887
phenotype	T032	C0031437
clusters	T081	C1704332
depression	T048	C0011570
cluster 1	T081	C1704332
speech disorder	T047	C0037822
behavior symptoms	T184	C2039359
cluster 2	T081	C1704332
hallucination	T048	C0018524
symptoms	T184	C1457887
cluster 3	T081	C1704332
delusion	T048	C0011253
symptoms	T184	C1457887
Interaction	T169	C1704675
SNPs	T086	C0752046
cluster 1	T081	C1704332
symptoms	T184	C1457887
SNPs	T086	C0752046
cluster 2	T081	C1704332
symptoms	T184	C1457887
SNPs	T086	C0752046
cluster 3	T081	C1704332
symptoms	T184	C1457887
interaction	T169	C1704675
specific	T080	C0205369
susceptibility	T201	C0012655
genes	T028	C0017337
specific	T080	C0205369
clinical	T080	C0205210
sub-phenotypes	T032	C0031437
schizophrenia	T048	C0036341
patient	T101	C0030705
cohorts	T098	C0599755
clinical	T080	C0205210
data	T078	C1511726
detection	T033	C0442726
gene interactions	T045	C0596610
schizophrenia	T048	C0036341
clinical	T080	C0205210
phenotypes	T032	C0031437
DNMT1	T028	C1414121
gene expression profile	T081	C1956267
methylation	T044	C0025723
promoter region	T114	C0033413
patients	T101	C0030705
ankylosing spondylitis	T047	C0038013
Ankylosing spondylitis	T047	C0038013
AS	T047	C0038013
autoimmune disease	T047	C0004364
chronic inflammatory arthritis	T047	C0003864
methylation	T044	C0025723
biology	T091	C0005532
immunocytes	T025	C0312737
surveyed	T170	C0038951
disease	T047	C0012634
etiology	T169	C1314792
DNA methyltransferase 1	T116	C1621352
DNMT1	T116	C1621352
enzyme	T116	C0014442
regulates	T038	C1327622
patterns	T082	C0449774
methylated cytosine	T109	C0010843
aim	T078	C1947946
investigation	T058	C0220825
methylation	T044	C0025723
CpG	T114	C0056912
sites	T082	C0205145
DNMT1	T028	C1414121
promoter	T114	C0086860
mRNA expression	T045	C1515670
level	T080	C0441889
gene	T028	C0017337
peripheral blood mononuclear cells	T025	C1321301
PBMCs	T025	C1321301
AS	T047	C0038013
patients	T101	C0030705
PBMCs	T025	C1321301
whole blood	T031	C0370231
AS	T047	C0038013
patients	T101	C0030705
healthy	T080	C3898900
individuals	T098	C0027361
RNA	T114	C0035668
DNA	T114	C0012854
leukocytes	T025	C0023516
extracted	T061	C0185115
quantitative analysis	T081	C0034384
real-time PCR	T063	C1709846
SYBR Green PCR Master Mix	T170	C0282574
methylation	T044	C0025723
level	T080	C0441889
PCR	T063	C0032520
products	T114	C0012854
bisulfite-treated DNA	T114	C0012854
patients	T101	C0030705
controls	T096	C0009932
sequenced	T059	C1294197
healthy	T080	C3898900
controls	T096	C0009932
expression level	T045	C0017262
DNMT1	T028	C1414121
AS	T047	C0038013
patients	T101	C0030705
downregulated	T044	C0013081
Methylation	T044	C0025723
DNMT1	T028	C1414121
promoter	T114	C0086860
AS	T047	C0038013
patients	T101	C0030705
controls	T096	C0009932
negative	T033	C0205160
correlation	T080	C1707520
methylation	T044	C0025723
expression level	T045	C0017262
DNMT1	T028	C1414121
AS	T047	C0038013
patients	T101	C0030705
methylation	T044	C0025723
expression level	T045	C0017262
DNMT1	T028	C1414121
correlate	T080	C1707520
clinical	T080	C0205210
manifestations	T169	C0205319
decreased	T081	C0205216
expression level	T045	C0017262
DNMT1	T028	C1414121
hypermethylation	T045	C1512554
DNMT1	T028	C1414121
promoter	T114	C0086860
PBMCs	T025	C1321301
AS	T047	C0038013
patients	T101	C0030705
survey	T170	C0038951
DNMT1	T028	C1414121
expression	T045	C0017262
altered	T169	C0392747
methylation	T044	C0025723
level	T080	C0441889
target	T169	C1521840
genes	T028	C0017337
AS	T047	C0038013
Antibacterial	T195	C0279516
Activity	T052	C0441655
Polyaniline	T109	C0962453
Coated	T080	C1522408
Silver	T196	C0037125
Nanoparticles	T073	C1721060
Synthesized	T052	C1883254
Piper Betle Leaves Extract	T109	C3643364
Plants	T002	C0032098
natural resources	T078	C0027492
alternative	T077	C1523987
method	T169	C0449851
nanoparticles	T073	C1450054
synthesis	T052	C1883254
study	T062	C2603343
polyaniline	T109	C0962453
coated	T080	C1522408
silver	T196	C0037125
nanoparticles	T073	C1721060
AgNPs	T073	C1721060
synthesized	T052	C1883254
Piper betle leaves extract	T109	C3643364
antibacterial	T195	C0279516
activity	T052	C0441655
activity	T052	C0441655
Silver	T196	C0037125
nanoparticles	T073	C1721060
reduction	T080	C0392756
silver nitrate	T121	C0037129
NaBH4	T130	C0074728
reducing agent	T130	C0376446
Silver	T196	C0037125
nanoparticles	T073	C1721060
extracts	T123	C0032081
coated	T080	C1522408
polyaniline	T109	C0962453
nanoparticles	T073	C1721060
characterized	T052	C1880022
Visual inspection	T169	C2984756
Ultraviolet-visible spectroscopy	T059	C0037812
UV	T059	C0037812
Fourier transform infrared Spectroscopy	T062	C0206055
FT-IR	T062	C0206055
Transmission Electron Microscopy (TEM) techniques	T059	C0678118
Antibacterial	T195	C0279516
activities	T052	C0441655
synthesized	T052	C1883254
silver	T196	C0037125
nanoparticles	T073	C1721060
tested	T169	C0039593
Staphylococcus aureus ATCC 25923	T007	C0038172
Salmonella typhi ATCC 14028	T007	C0036125
Escherichia coli ATCC 25922	T007	C0014834
Pseudomonas aeruginosa ATCC 27853	T007	C0033809
UV-Vis spectrum	T059	C0037812
reaction mixture	T167	C0439962
strong absorption peak	T080	C0444505
FT-IR	T062	C0206055
results	T034	C0587081
Ag-NPs	T073	C1721060
synthesized	T052	C1883254
capped with bio-compounds	T080	C0205556
P. betle	T109	C3643364
TEM	T059	C0678118
Ag-NPs	T073	C1721060
dispersed	T082	C0332624
spherical structures	T082	C0332501
particle size	T081	C0030608
result	T169	C1274040
revealed	T080	C0443289
Ag-Extract NPs	T073	C1450054
inhibition	T052	C3463820
S. aureus	T007	C0038172
norfloxacin	T109	C0028365
positive control	T077	C1883676
inhibition	T052	C3463820
S. aureus	T007	C0038172
maximum zone	T082	C1710706
inhibition	T052	C3463820
S. typhi	T007	C0036125
E. coli	T007	C0014834
P. aeruginosa	T007	C0033809
results	T169	C1274040
study	T062	C2603343
extrapolated	T081	C3176113
human	T016	C0086418
further studies	T062	C0008972
antimicrobial	T121	C1136254
activity	T052	C0441655
Ag-Extract NPs	T073	C1450054
drug development program	T091	C0872152
Clinical Pearls	T170	C2708733
Tremor	T184	C0040822
Hyperkinetic Movement	T048	C0424295
Disorders	T048	C0004936
Hyperkinetic movements	T048	C0424295
tremor	T184	C0040822
myoclonus	T184	C0027066
chorea	T047	C0008489
dystonia	T184	C0013421
neurologic	T047	C0524851
medical conditions	T047	C0012634
clinical evaluation	T058	C4084924
diagnosis	T062	C1704656
treatment	T061	C0087111
patients	T101	C0030705
abnormal movements	T047	C0013384
children	T100	C0008059
acute lymphoblastic leukemia	T191	C0023449
abandoned	T080	C1272694
therapy	T061	C0087111
Experience	T041	C0596545
challenges	T058	C0805586
parental	T099	C0030551
perspectives	T082	C0449911
treatment	T061	C0087111
subsidies	T058	C0038574
intensified counseling	T058	C0010210
Refusal for treatment	T055	C0040809
therapy	T061	C0087111
abandonment	T033	C0452129
childhood	T079	C0231335
acute lymphoblastic leukemia	T191	C0023449
ALL	T191	C0023449
resource	T078	C0018741
countries	T083	C0454664
study	T062	C2603343
children	T100	C0008059
ALL	T191	C0023449
treatment	T061	C0087111
abandoned	T080	C1272694
children	T100	C0008059
outcome	T169	C1274040
therapy	T061	C0087111
abandonment	T033	C0452129
refusal	T055	C0040809
outcome	T169	C1274040
ALL	T191	C0023449
abandonment	T033	C0452129
treatment	T061	C0087111
subsidies	T058	C0038574
intensified multistage counseling	T058	C0010210
children	T100	C0008059
therapy	T061	C0087111
refused upfront	T052	C1705116
abandoned	T080	C1272694
chemotherapy	T061	C3665472
families	T099	C0015576
Financial problems	T033	C0549106
dependents	T098	C1962923
home	T082	C0442519
perceptions	T041	C0030971
cancer	T191	C0006826
abandonment	T033	C0452129
Children abandoning treatment	T033	C0243095
induction	T061	C0857127
survival	T052	C0038952
abandoned	T080	C1272694
post induction	T079	C1254367
Intensified preabandonment counseling	T058	C0010210
treatment	T061	C0087111
reduction	T080	C0392756
abandonment rates	T081	C1521828
Effect	T080	C1280500
New-Onset	T033	C0746890
Left Bundle Branch Block	T047	C0023211
Transcatheter Aortic Valve Implantation	T061	C3509486
CoreValve	T074	C0184252
Mortality	T081	C0205848
Frequency	T079	C0439603
Re-Hospitalization	T058	C0019993
Pacemaker	T074	C0030163
New-onset	T033	C0746890
conduction disturbances	T046	C0232219
transcatheter aortic valve implantation	T061	C3509486
TAVI	T061	C3509486
complication	T046	C0009566
left bundle branch block	T047	C0023211
LBBB	T047	C0023211
clinical	T080	C0205210
impact	T080	C4049986
new-onset	T033	C0746890
LBBB	T047	C0023211
TAVI	T061	C3509486
controversial	T054	C0680243
clinical	T080	C0205210
impact	T080	C4049986
new-onset	T033	C0746890
LBBB	T047	C0023211
mortality	T081	C0205848
morbidity	T081	C0178685
pacemakers	T074	C0030163
admissions	T058	C0030673
heart failure	T047	C0018801
long-term follow-up	T058	C1517942
patients	T101	C0030705
aortic stenosis	T047	C0003507
treated with	T061	C0332293
implantation	T061	C0021107
CoreValve prosthesis	T074	C0184252
patients	T101	C0030705
analysis	T062	C0936012
patients	T101	C0030705
pre-existing	T080	C2347662
LBBB	T047	C0023211
permanent pacemaker	T074	C0281945
implanted	T074	C0021102
hours	T079	C0439227
implantation	T061	C0021107
patients	T101	C0030705
groups	T078	C0441833
group	T078	C0441833
persistent	T079	C0205322
new-onset	T033	C0746890
LBBB	T047	C0023211
group	T078	C0441833
conduction disturbances	T046	C0232219
treatment	T061	C0087111
groups	T078	C0441833
followed up	T058	C1522577
month	T079	C0439231
months	T079	C0439231
months	T079	C0439231
yearly	T079	C0332181
Persistent	T079	C0205322
new-onset	T033	C0746890
LBBB	T047	C0023211
patients	T101	C0030705
TAVI	T061	C3509486
patients	T101	C0030705
conduction disturbances	T046	C0232219
follow-up	T058	C1522577
time	T079	C0040223
groups	T078	C0441833
months	T079	C0439231
months	T079	C0439231
time	T079	C0040223
groups	T078	C0441833
mortality	T081	C0205848
groups	T078	C0441833
groups	T078	C0441833
re-hospitalizations	T058	C0019993
heart failure	T047	C0018801
Group	T078	C0441833
pacemaker implantation	T061	C0189842
follow-up	T058	C1522577
group	T078	C0441833
new-onset	T033	C0746890
LBBB	T047	C0023211
associated with	T080	C0332281
higher	T080	C0205250
incidence	T081	C0021149
permanent pacemaker	T074	C0281945
CoreValve	T074	C0184252
implantation	T061	C0021107
associated with	T080	C0332281
mortality	T081	C0205848
re-hospitalization	T058	C0019993
relationship	T080	C0439849
polymorphisms	T045	C0032529
BDNFOS	T028	C1538322
BDNF genes	T028	C1332408
heroin addiction	T048	C0019337
Han Chinese population	UnknownType	C0814942
heroin	T109	C0011892
addicts	T101	C0858354
increasing	T169	C0442808
world	T098	C2700280
environmental	T080	C0686732
genetic factors	T080	C0814299
critical	T080	C1511545
process	T067	C1522240
heroin addiction	T048	C0019337
aimed	T078	C1947946
investigate	T169	C1292732
associations	T080	C0439849
single nucleotide polymorphisms	T086	C0752046
SNPs	T086	C0752046
LIN7C	T028	C1425077
BDNFOS	T028	C1538322
BDNF genes	T028	C1332408
drug addiction	T048	C1510472
Han Chinese population	UnknownType	C0814942
case-control study	T062	C0007328
cases	T169	C0868928
healthy controls	T080	C2986479
Xi'an	UnknownType	C0681784
China	T083	C0008115
SNPs	T086	C0752046
selected	T052	C1707391
genotyped	T059	C1285573
MassARRAY technology	T170	C0282574
Sequenom	T073	C0683757
San Diego, CA	T083	C3828258
USA	T083	C0041703
Odds ratios	T081	C0028873
OR	T081	C0028873
confidence intervals	T081	C0009667
CIs	T081	C0009667
calculated	T052	C1441506
unconditional logistic regression	T062	C0206031
age	T032	C0001779
sex	T032	C0079399
chi-squared test	T170	C0008041
rs7481311	T028	C0678941
OR	T081	C0028873
CI	T081	C0009667
rs11030096	T028	C0678941
OR	T081	C0028873
CI	T081	C0009667
BNDFOS	T028	C1538322
associated with	T080	C0332281
increased	T081	C0205217
risk	T078	C0035647
heroin addiction	T048	C0019337
rs988712	T028	C0678941
BDNFOS	T028	C1538322
decreased	T081	C0205216
risk	T078	C0035647
heroin addiction	T048	C0019337
OR	T081	C0028873
CI	T081	C0009667
genetic model	T170	C0026343
analysis	T062	C0936012
'T' allele	T028	C0002085
rs988712	T028	C0678941
BDNFOS	T028	C1538322
heroin addiction	T048	C0019337
additive model	T170	C0026343
dominant model	T170	C0026343
allele 'T'	T028	C0002085
rs7481311	T028	C0678941
BDNFOS	T028	C1538322
elevated	T080	C3163633
risk	T078	C0035647
heroin addiction	T048	C0019337
additive model	T170	C0026343
recessive model	T170	C0026343
dominant model	T170	C0026343
allele 'C	T028	C0002085
rs11030096	T028	C0678941
associated with	T080	C0332281
increased	T081	C0205217
risk	T078	C0035647
addiction	T048	C0019337
dominant model	T170	C0026343
additive model	T170	C0026343
rs6265	T028	C0678941
rs11030104	T028	C0678941
rs10767664	T028	C0678941
BDNF	T028	C1332408
associated with	T080	C0332281
decreased	T081	C0205216
risk	T078	C0035647
heroin addiction	T048	C0019337
rs7481311	T028	C0678941
BDNFOS	T028	C1538322
significant	T078	C0750502
Bonferroni correction	T081	C2347434
results	T033	C2825142
polymorphisms	T045	C0032529
BDNFOS	T028	C1538322
important	T080	C3898777
heroin addiction	T048	C0019337
susceptibility	T169	C1264642
Chinese Han population	UnknownType	C0814942
Risk and protective factors	T201	C0814287
associated with	T080	C0332281
adolescent girls'	T100	C0001588
substance use	T048	C0237123
Data	T078	C1511726
Facebook	T170	C3179065
reductions	T081	C0547047
teenage	T079	C0001578
substance use	T048	C0237123
adolescent girls	T100	C0001588
rates	T081	C1521828
substance use	T048	C0237123
unacceptably high	T080	C1299351
article	T170	C1706852
girls	T098	C0043210
substance use	T048	C0237123
associated with	T080	C0332281
risk and protective factors	T201	C0814287
goal setting	T041	C0025361
problem solving	T041	C0033211
refusal skills	T055	C0683255
peer use	T054	C0683549
self-efficacy	T041	C0600564
gender	T032	C0079399
specific	T080	C0205369
risk and protective factors	T201	C0814287
communication style	T054	C0178556
coping skills	T055	C0086059
self-esteem	T041	C0036597
body image	T041	C0005891
perceived stress	T048	C0038443
anxiety	T048	C0003469
depression	T048	C0011570
Cross-sectional data	T062	C0010362
online surveys	T062	C0178803
adolescent girls	T100	C0001588
Facebook	T170	C3179065
multivariate analyses	T081	C0026777
correlates	T041	C0871178
adolescent	T100	C0205653
substance use	T048	C0237123
gender	T032	C0079399
specific	T080	C0205369
risk and protective factors	T201	C0814287
associated with	T080	C0332281
alcohol	T055	C0001948
cigarette	T055	C0694535
drug use	T048	C0242510
past-month marijuana use	T048	C0871810
associated with	T080	C0332281
factors	T169	C1521761
Refusal skill	T055	C0683255
peer use	T054	C0683549
coping	T055	C0009967
depressive mood	T033	C0344315
associated with	T080	C0332281
substance use	T048	C0237123
Substance abuse prevention	T058	C1171221
programs	T058	C0043113
adolescent girls	T100	C0001588
risk and protective factors	T201	C0814287
problem solving	T041	C0033211
refusal skill	T055	C0683255
peer influences	T054	C0683549
self-efficacy	T041	C0600564
gender	T032	C0079399
specific	T080	C0205369
risk and protective factors	T201	C0814287
communication style	T054	C0178556
coping	T055	C0009967
self-esteem	T041	C0036597
body image	T041	C0005891
perceived stress	T048	C0038443
mood management	T061	C0262715
Ethics	T078	C0015000
Hype	T080	C0683753
concern	T078	C2699424
phenomenon	T067	C1882365
science	T090	C0036397
hype	T080	C0683753
exaggerate	T080	C0442801
near	T080	C1706276
future	T079	C0016884
application	T169	C4048755
research results	T033	C0683954
problem	T033	C0033213
area of biomedicine	T091	C1879848
topic	T170	C1555712
genetics	T091	C0017398
enthusiastic	T041	C0558083
predictions	T078	C0681842
world	T098	C2700280
decades	T079	C1254367
media	T170	C0009458
researchers	T097	C0035173
politicians	T097	C0682232
biotech	T091	C0005574
industry	T057	C0021267
genome	T028	C0017428
health care	T058	C0086388
revolution	T068	C0441716
revolution	T068	C0441716
rhetoric	T169	C0814791
genohype	T080	C0683753
adverse	T033	C0243095
social consequences	T054	C0037397
public	T098	C0162592
hurting	T184	C3640015
long-term	T079	C0443252
legitimacy	T089	C0023262
field	T077	C1521738
data	T078	C1511726
nature	T078	C0349590
magnitude	T081	C1704240
harms	UnknownType	C0680558
proposition	T170	C0035174
sustained	T169	C0443318
science	T090	C0036397
hype	T080	C0683753
benefit	T081	C0814225
robust	T080	C2986815
science	T090	C0036397
accurate	T080	C0443131
public	T098	C0162592
representations	T052	C1882932
biomedical research	T062	C0005540
consideration	T033	C0518609
degree	T081	C0449286
scholarship	T078	C0036365
ethical	T078	C0086264
legal	T089	C0680513
social issues	T054	C0683653
conclusions	T078	C1707478
ELSI scholarship	T078	C0036365
exaggerated	T080	C0442801
Lubiprostone	T109	C1684405
Accelerates	T169	C0521110
Intestinal Transit	T042	C0232484
Alleviates	T169	C0205245
Small Intestinal Bacterial Overgrowth	T047	C3160854
Patients	T101	C0030705
Chronic Constipation	T184	C0401149
Lubiprostone	T109	C1684405
effective	T080	C1704419
treatment	T169	C1522326
chronic constipation	T184	C0401149
CC	T184	C0401149
mechanism of action	T169	C1524059
lubiprostone	T109	C1684405
increasing	T169	C0442808
fluid secretion	T043	C2263233
lubrication	T067	C0024069
intestinal lumen	T030	C0545876
effects	T080	C1280500
lubiprostone	T109	C1684405
gastrointestinal transit	T042	C0232484
small intestinal bacterial overgrowth	T047	C3160854
SIBO	T047	C3160854
study	T062	C2603343
investigate	T169	C1292732
lubiprostone	T109	C1684405
gastrointestinal transit	T042	C0232484
SIBO	T047	C3160854
patients	T101	C0030705
constipation	T184	C0009806
female patients	T032	C0150905
mean age	T032	C0001779
years	T079	C0439234
range	T081	C1514721
CC	T184	C0401149
received	T080	C1514756
weeks	T079	C0439230
lubiprostone	T109	C1684405
Stool consistency	T033	C0426740
Bristol stool scale	T170	C4084861
frequency of bowel movements	T033	C0426642
BMs	T040	C0011135
Gastric emptying time	T079	C1954153
small bowel transit time	T042	C1254358
colon	T023	C0009368
transit time	T042	C1254358
CTT	T042	C1254358
small and large bowel transit time	T042	C0232688
SLBTT	T042	C0232688
gut	T023	C0699819
transit time	T042	C1254358
measured	T080	C0444706
wireless motility capsule	T060	C0430022
SIBO	T047	C3160854
status	T080	C0449438
lactulose breath test	T060	C0344439
Data	T078	C1511726
analyzed	T062	C0936012
Wilcoxon rank	T081	C0242931
Mann-Whitney U	T081	C0242927
Spearman׳s rank correlation	T081	C0242929
Chi-square tests	T170	C0008041
Lubiprostone	T109	C1684405
softened	T067	C0870079
stool	T031	C0015733
increased	T081	C0205217
frequency of BM	T033	C0426642
median	T081	C0876920
times	T081	C1632851
week	T079	C0439230
CTT	T042	C1254358
SLBTT	T042	C0232688
shorter	T080	C1282927
responders	T098	C1257890
lubiprostone	T109	C1684405
times	T081	C1632851
increase	T169	C0442805
number	T081	C0237753
weekly	T079	C0332174
BM	T040	C0011135
compared	T052	C1707455
nonresponders	T098	C1257890
higher	T080	C0205250
frequency of BM	T033	C0426642
treatment	T169	C1522326
correlated	T080	C1707520
acceleration	T067	C0000894
CTT	T042	C1254358
SLBTT	T042	C0232688
gut	T023	C0699819
transit time	T042	C1254358
patients	T101	C0030705
tested	T169	C0039593
SIBO	T047	C3160854
baseline	T081	C1442488
positive	T033	C1446409
SIBO	T047	C3160854
positive	T033	C1446409
patients	T101	C0030705
SIBO	T047	C3160854
negative	T033	C0205160
lubiprostone	T109	C1684405
treatment	T169	C1522326
CC	T184	C0401149
lubiprostone	T109	C1684405
frequency of BMs	T033	C0426642
softens	T067	C0870079
stool	T031	C0015733
accelerates	T169	C0521110
intestinal transit	T042	C0232484
decreases	T081	C0547047
SIBO	T047	C3160854
improvement	T077	C2986411
SIBO	T047	C3160854
cleansing	T052	C1947930
effect	T080	C1280500
increased	T081	C0205217
intestinal fluid	T042	C0232671
mucus	T031	C0026727
enhanced	T052	C2349975
intestinal motility	T042	C0021838
lubiprostone	T109	C1684405
Minimally invasive treatment	T061	C0282624
bleeding	T046	C0019080
lesions	T033	C0221198
small bowel	T023	C0021852
Bleeding	T046	C0019080
lesions	T033	C0221198
small bowel	T023	C0021852
identify	T080	C0205396
obscure	T033	C3844685
symptomatology	T184	C1457887
Localizing	T082	C0392752
lesions	T033	C0221198
specific	T080	C0205369
techniques	T169	C0449851
Double-balloon enteroscopy	T060	C2936452
DBE	T060	C2936452
localize	T082	C0392752
lesions	T033	C0221198
minimally invasive surgical treatment	T061	C0282624
robot	T073	C0336537
assisted	T080	C1269765
small bowel procedures	T061	C3865550
combination	T080	C0205195
DBE	T060	C2936452
localization	T082	C0392752
robotic resection	T061	C4038855
jejunal resections	T061	C3837064
ileal resections	T061	C3837066
age	T032	C0001779
years	T079	C0439234
operative time	T079	C3494201
minutes	T079	C0439232
blood loss	T033	C3163616
conversion-to-open	T061	C3494226
post-operative	T079	C0032790
complications	T046	C0009566
day	T079	C0439228
mortality	T081	C0205848
length of stay	T079	C0023303
days	T079	C0439228
pathology	T170	C0807321
consistent with	T078	C0332290
malignancy	T191	C4282132
cases	T169	C0868928
combination	T080	C0205195
double-balloon enteroscopy	T060	C2936452
robotic technology	T061	C4038855
accurate	T080	C0443131
identification	T080	C0205396
treatment	T169	C1522326
lesions	T033	C0221198
treat	T169	C1522326
minimally invasive fashion	T061	C0282624
Kinematic	T091	C0600169
EMG	T060	C0013839
Responses	T032	C0871261
Pelvis	T023	C0030797
Leg	T023	C1140621
Assistance	T077	C1521721
Force	T070	C0336996
Treadmill Walking	T056	C2712999
Children	T100	C0008059
Cerebral Palsy	T047	C0007789
Treadmill training	T061	C2107089
locomotor function	T040	C0023946
children	T100	C0008059
cerebral palsy	T047	C0007789
CP	T047	C0007789
paradigms	T062	C0681797
kinematic	T091	C0600169
EMG	T060	C0013839
responses	T032	C0871261
force	T070	C0336996
body	T017	C1268086
treadmill walking	T056	C2712999
paradigms	T062	C0681797
objective	T170	C0018017
study	T062	C2603343
kinematic	T091	C0600169
EMG	T060	C0013839
responses	T032	C0871261
pelvis	T023	C0030797
leg	T023	C1140621
assistance	T077	C1521721
force	T070	C0336996
children	T100	C0008059
spastic CP	T019	C0338596
participate	T058	C0030699
study	T062	C2603343
assistance	T077	C1521721
force	T070	C0336996
pelvis	T023	C0030797
legs	T023	C1140621
stance	T033	C2019827
swing phase of gait	T033	C2039052
robotic system	T170	C1738367
walking	T056	C0080331
Muscle	T024	C0026845
activities	T052	C0441655
spatial	T082	C1254362
temporal	T079	C2362314
gait parameters	T033	C0016928
loading conditions	T032	C4279935
walking	T056	C0080331
spatial-temporal gait parameters	T033	C0016928
walking	T056	C0080331
treadmill training	T061	C2107089
pelvis	T023	C0030797
assistance	T077	C1521721
improved	T033	C0184511
step height	T033	C0427127
leg	T023	C1140621
assistance	T077	C1521721
improved	T033	C0184511
step length	T033	C0427126
walking	T056	C0080331
leg	T023	C1140621
assistance	T077	C1521721
reduced	T080	C0392756
muscle	T024	C0026845
activation	T052	C1879547
ankle flexor	T023	C0581542
swing phase of gait	T033	C2039052
step length	T033	C0427126
walking speed	T032	C2009910
improved	T033	C0184511
session	T051	C1883016
treadmill training	T061	C2107089
pelvis	T023	C0030797
leg	T023	C1140621
assistance	T077	C1521721
Population "at Risk"	T098	C0242444
Parkinson's Disease	T047	C0030567
Evidence	T078	C3887511
Case-Control Study	T062	C0007328
multifactorial pathogenesis	T046	C0699748
Parkinson's Disease	T047	C0030567
PD	T047	C0030567
populations "at risk"	T098	C0242444
disease	T047	C0030567
case-control study	T062	C0007328
analyzed	T062	C0936012
Italian	T083	C0022277
population	T098	C1257890
general criteria	T078	C0243161
population "at risk"	T098	C0242444
PD	T047	C0030567
PD	T047	C0030567
patients	T101	C0030705
controls	T096	C0009932
gender	T032	C0079399
age	T032	C0001779
matched	T096	C0024908
urban	T080	C2700386
geographical area	UnknownType	C0681784
subjects	T098	C0080105
interviewed	T052	C0021822
demographics	T090	C0011298
family history	T033	C0241889
PD	T047	C0030567
occupational and environmental toxicants exposure	T033	C0149685
smoking status	T201	C1519386
alcohol consumption	T055	C0001948
patients	T101	C0030705
controls	T096	C0009932
serum	T031	C1550100
dosing	T081	C0178602
iron	T059	C0337439
copper	T059	C0373587
mercury	T059	C0428257
manganese	T059	C0373677
Inductively Coupled-Plasma-Mass-Spectrometry	T059	C1553183
ICP-MS	T059	C1553183
Positive	T033	C1446409
family history	T033	C0241889
toxicants exposure	T033	C0040537
non-current-smoker	T033	C3496610
alcohol nonconsumer status	T033	C0425322
risk factors	T033	C0035648
population	T098	C1257890
concurring risk factors	T033	C0035648
overlapping	T079	C1948020
same subject	T098	C0080105
increased	T081	C0205217
overall risk	T080	C1444641
No significant differences	T033	C3842396
measured	T080	C0444706
metal	T197	C0025552
serum	T031	C1550100
levels	T080	C0441889
findings	T033	C0243095
concurrent	T079	C0205420
PD	T047	C0030567
risk factors	T033	C0035648
at risk	T080	C1444641
PD	T047	C0030567
stratification	T062	C1514983
questionnaires	T170	C0034394
identifying subjects	T062	C0949543
neuroprotective strategies	T041	C0679199
Work	T057	C0043227
process	T067	C1522240
performance	T033	C1286385
professional profile	T097	C0679924
Hearing Health Network	T058	C0018747
reference	T170	C1561577
satisfaction	T041	C0242428
analyze	T062	C0936012
correlation	T080	C1707520
satisfaction	T041	C0022397
professionals	T097	C0679924
Hearing Health Care network	T058	C0018747
micro	T077	C3811161
regions	T082	C0205147
Minas Gerais state	UnknownType	C0681784
sociodemographic profile	T169	C2003903
work	T057	C0043227
process	T067	C1522240
work performance	T033	C1286385
health service	T058	C0018747
cross-sectional	T062	C0010362
observational	T062	C1518527
analytic study	T081	C0009247
non-probabilistic sample	T062	C4288587
professionals	T097	C0679924
Hearing Health Care services	T058	C0018747
Data collection	T062	C0010995
individual	T098	C0237401
interviews	T052	C0021822
municipality	T083	C0600182
professional practice	T057	C0033284
Associations	T080	C0439849
Professional Satisfaction	T041	C0022397
variable	T080	C0439828
explanatory	T170	C0681841
variables	T080	C0439828
Sociodemographic Data	T078	C1511726
Work Routine	T080	C0205547
Developed	T169	C0332253
Actions	T052	C3266814
Professionals	T097	C0679924
graduate studies	T065	C0013630
satisfied	T170	C4084799
human resources policy	T170	C0162791
activities	T052	C0441655
developed	T169	C0332253
health	T058	C0086388
civil servants	T097	C0401892
satisfaction	T041	C0242428
wage	T081	C0036064
policy	T170	C0242456
work schedule	T079	C0237852
correlation analysis	T062	C0010101
work	T057	C0043227
process	T067	C1522240
satisfaction	T041	C0022397
revealed	T080	C0443289
moderate	T081	C1510992
positive	T033	C1514241
correlation	T080	C1707520
Health Promotion	T058	C0018738
Actions	T052	C3266814
Satisfaction	T041	C0022397
Diagnostic Equipment	T074	C0524922
Satisfaction	T041	C0022397
Maintenance Equipment	T033	C4035913
study	T062	C2603343
higher	T080	C0205250
level	T080	C0441889
satisfaction	T041	C0022397
professionals	T090	C2698884
graduate studies	T065	C0013630
human resources policy	T170	C0162791
activities	T052	C0441655
developed	T169	C0332253
civil servants	T097	C0401892
wage	T081	C0036064
policy	T170	C0242456
work schedule	T079	C0237852
relevance	T080	C2347946
study	T062	C2603343
health professionals	T097	C1704312
Health Care Network	T058	C0018747
study	T062	C2603343
satisfaction	T041	C0022397
level	T080	C0441889
improvements	T077	C2986411
satisfied	T170	C4084799
professionals	T090	C2698884
improve	T033	C0184511
service quality	T080	C0871201
show greater creativity	T033	C0517173
commitment	T041	C0870312
performance	T033	C1286385
Application	T058	C0185125
Laparoscopic	T060	C0031150
Lumbar Discectomy	T061	C0408632
Artificial Disc Replacement	T061	C2144940
Follow-Up	T058	C1522577
prospective	T062	C0033522
observational study	T062	C1518527
patients	T101	C0030705
diagnosed	T033	C0011900
symptomatic	T169	C0231220
degenerative disc disease	T047	C0158266
artificial disc replacement	T061	C2144940
ADR	T061	C2144940
laparoscopic	T060	C0031150
technique	T169	C0449851
study	T062	C2603343
aimed	T078	C1947946
assess	T052	C1516048
safety	T068	C0036043
efficacy	T080	C1280519
ADR	T061	C2144940
laparoscopic	T060	C0031150
technique	T169	C0449851
lumbar disc herniation	T020	C0281899
Symptomatic	T169	C0231220
degenerative disc disease	T047	C0158266
low back pain	T184	C0024031
lumbar	T029	C0024090
segmental	T082	C0205122
instability	T033	C1444783
ADR	T061	C2144940
increased	T081	C0205217
popularity	T054	C0679970
alternative treatment	UnknownType	C0683466
lumbar disc herniation	T020	C0281899
traditional	T169	C0443324
approach	T082	C0449445
spinal surgery	T061	C0920347
risk	T078	C0035647
catastrophic	T047	C0007397
bleeding	T046	C0019080
injury	T037	C3263723
vessels	T023	C0005847
iatrogenic	T080	C0439669
injury	T037	C3263723
viscera	T023	C0042779
associated structures	T023	C1285145
laparoscopic	T060	C0031150
lumbar discectomy	T061	C0408632
ADR	T061	C2144940
represent	T052	C1882932
alternative	T077	C1523987
patients	T101	C0030705
males	T032	C0086582
females	T032	C0086287
diagnosed	T033	C0011900
symptomatic	T169	C0231220
degenerative disc disease	T047	C0158266
study	T062	C2603343
cases	T169	C0868928
cases	T169	C0868928
patients	T101	C0030705
ineffective	T078	C3242229
conservative treatments	T061	C0459914
patients	T101	C0030705
surgery	T061	C0543467
operation	T061	C0543467
consent	T169	C1511481
Three-dimensional	T082	C0450363
computed tomographic angiography	T060	C1536105
3D	T082	C0450363
CTA	T060	C1536105
iliac	T023	C0020889
blood vessels	T023	C0005847
completed	T080	C0205197
surgery	T061	C0543467
surgical procedures	T061	C0543467
laparoscope	T074	C0023036
patients	T101	C0030705
followed up	T058	C1522577
surgeries	T061	C0543467
successfully	T080	C1272703
completed	T080	C0205197
average	T081	C1510992
operation	T061	C0543467
time	T079	C0040223
range	T081	C1514721
average	T081	C1510992
hemorrhage	T046	C0019080
range	T081	C1514721
cases	T169	C0868928
X-rays	T060	C0043299
postoperative	T058	C0032786
follow-up	T058	C1522577
outcome	T169	C1274040
mobilization	T169	C0300926
displacement	T067	C2347509
subsidence	T067	C3805266
patients	T101	C0030705
exception	T077	C1705847
case	T169	C0868928
prosthesis migration	T067	C2930543
follow-up	T058	C1522577
range	T081	C1514721
mean	T081	C0444504
visual analog scale	T201	C2960751
VAS	T201	C2960751
Oswestry scores	T033	C2960603
decreased	T081	C0205216
postoperatively	T079	C0032790
mean	T081	C0444504
improvement	T077	C2986411
rate	T081	C1521828
VAS score	T201	C2960751
Lumbar	T029	C0024090
ADR	T061	C2144940
laparoscope	T074	C0023036
minimally invasive	T169	C2711297
treatment	T169	C0039798
symptomatic	T169	C0231220
degenerative disc disease	T047	C0158266
severe	T080	C0205082
lumbar discogenic pain	T047	C3662826
Low literacy	T033	C1401894
written drug information	T170	C0033081
information-seeking	T033	C0392349
leaflet	T170	C3273178
evaluation	T078	C1550157
preferences	T078	C0558295
images	T170	C1704922
Low-literate	T098	C1518028
patients	T101	C0030705
risk	T078	C0035647
written drug information	T170	C0033081
patient information	T170	C1955348
group	T098	C1257890
communication barriers	T078	C0009454
information	T078	C1533716
people	T098	C0027361
low literacy	T033	C1401894
written drug information	T170	C0033081
patient	T101	C0030705
leaflet	T170	C3273178
images	T170	C1704922
Food banks	T092	C1561598
education institution	T073	C0036375
Dutch language	T171	C0376241
training	T065	C0220931
Netherlands	T083	C0027778
focus groups	T096	C0016400
individual	T098	C0237401
interviews	T052	C0021822
low-literate participants	T098	C1518028
thematic framework approach	T077	C1254372
data	T078	C1511726
outcome	T169	C1274040
Low-literate people's	T098	C1518028
experience	T078	C1533716
patient information	T170	C1955348
leaflets	T170	C3273178
ideas	T078	C1254370
improvements	T077	C2986411
perceptions	T041	C0030971
visuals	T169	C0234621
Patient information	T170	C1955348
leaflets	T170	C3273178
information	T078	C1533716
understand	T041	C0162340
information sources	T033	C0683836
leaflet	T170	C3273178
organisation	T169	C1300196
legibility	T033	C0870803
readability	T080	C0871211
Participants	T098	C0679646
images	T170	C1704922
leaflet's	T170	C3273178
questions	T170	C1522634
overview	T170	C0814812
textual	T170	C1527021
information	T078	C1533716
recall	T041	C0034770
confidence	T041	C1704726
empowerment	T054	C0679959
safety	T068	C0036043
leaflet	T170	C3273178
low-literate patients	T098	C1518028
experience	T041	C0596545
barriers in the communication	T078	C0009454
written drug information	T170	C0033081
visual	T169	C0234621
textual	T170	C1527021
explanations	T170	C0681841
leaflet	T170	C3273178
improve	T033	C0184511
understanding	T041	C0162340
low-literate target group	T098	C1518028
flow cytometry	T059	C0016263
method	T170	C0025663
detecting	T033	C0442726
histone acetylation	T044	C1156200
levels	T080	C0441889
Histone deacetylase inhibitors	T116	C1512474
AIDS	T047	C0001175
diseases	T047	C0012634
anticancer drugs	T109	C0003392
lack	T080	C0332268
unified	T080	C1706076
reliable	T170	C3858758
method	T170	C0025663
detecting	T033	C0442726
histone acetylation	T044	C1156200
levels	T080	C0441889
basic	T062	C0681833
clinical research	T062	C0008972
study	T062	C2603343
flow cytometry	T059	C0016263
method	T170	C0025663
detect	T061	C1511790
detect	T033	C0442726
histone acetylation	T044	C1156200
levels	T080	C0441889
comparing	T052	C1707455
sample	T167	C0370003
processing	T052	C1709694
temperature	T081	C0039476
ice	T197	C0020746
room temperature	T033	C1822393
room temperature	T033	C1822393
permeabilization	T043	C0007605
method	T170	C0025663
intracellular	T026	C0021868
nuclear	T026	C0028584
antibody	T116	C0003241
dose	T081	C0178602
antibody titration	T059	C0522986
antibody	T116	C0003241
incubation time	T079	C0040223
time gradient	T081	C0812409
whole blood	T031	C0370231
peripheral blood mononuclear cells	T025	C1321301
optimized	T052	C2698650
method	T170	C0025663
in vitro	T080	C1533691
experiment	T062	C0681814
clinical trial	T062	C0008976
Chidamide	T109	C2932486
China	T083	C0008115
FDA approved HDACi	T170	C2700205
result	T169	C1274040
confirmed	T033	C0750484
flow cytometry	T059	C0016263
method	T170	C0025663
detecting	T033	C0442726
histone acetylation	T044	C1156200
levels	T080	C0441889
reliable	T170	C3858758
fast	T080	C0456962
convenient	T080	C3831015
method	T170	C0025663
basic	T062	C0681833
clinical research	T062	C0008972
Performance	T052	C1882330
safety	T080	C0086139
collagenated xenogeneic bone block	T122	C0181075
lateral alveolar ridge augmentation	T061	C0002387
staged implant placement	T061	C0021107
monocenter, prospective single-arm clinical study	T062	C2826346
assess	T058	C0184514
clinical safety	T080	C2826199
performance	T052	C1882330
collagenated xenogeneic bone block	T122	C0181075
CXBB	T122	C0181075
lateral alveolar ridge augmentation	T061	C0002387
two-stage	T079	C0574055
implant placement	T061	C0021107
patients	T101	C0030705
exhibiting	T078	C0449450
single	T081	C0205171
tooth	T023	C0040426
gap	T082	C3887622
surgical procedure	T061	C0543467
included	T052	C2700399
preparation	T052	C1521827
mucoperiosteal flaps	T017	C1881914
rigid fixation	T061	C0185023
CXBB	T122	C0181075
Geistlich Bio-Graft(®)	T170	C0282574
osteosynthesis screw	T074	C0005975
contour	T082	C0876954
augmentation	T061	C1293122
submerged healing	T040	C0043240
primary endpoint	T130	C2986535
final	T079	C3853528
ridge	T029	C0447361
width	T081	C0487742
sufficient	T080	C0205410
adequately	T080	C0205410
dimensioned	T081	C0439534
titanium implant	T061	C2165380
sites	T082	C0205145
Secondary outcomes	T080	C3274440
included	T052	C2700399
gain	T081	C1517378
ridge	T029	C0447361
width	T081	C0487742
Clinical parameters	T062	C2347800
bleeding on probing	T033	C2698524
BOP	T033	C2698524
probing depth	T081	C1317646
PD	T081	C1317646
mucosal recession	T190	C0333047
MR	T190	C0333047
assessed	T052	C1516048
cementation of the crown	T061	C0458893
final visit	T061	C0204309
implant placement	T061	C0021107
achieved	T052	C1706701
patients	T101	C0030705
exhibiting	T078	C0449450
mean	T081	C0444504
gain	T081	C1517378
ridge	T029	C0447361
width	T081	C0487742
mean	T081	C0444504
SD	T081	C0871420
Histological	T080	C0002809
analysis	T062	C0936012
homogeneous	T082	C0439713
osseous	T023	C0262950
organization	T169	C1300196
CXBB	T122	C0181075
changes	T169	C0392747
mean	T081	C0444504
BOP	T033	C2698524
PD	T081	C1317646
MR	T190	C0333047
values	T081	C1522609
final visit	T061	C0204309
amounted	T081	C1265611
CXBB	T122	C0181075
successfully	T080	C0679864
support	T077	C1521721
lateral alveolar ridge augmentation	T061	C0002387
two-stage	T079	C0574055
implant placement	T061	C0021107
self-perceptions	T041	C0242498
aging	T040	C0001811
cancer	T191	C0006826
physical	T169	C0205485
mental health	T041	C0025353
older people	T098	C3826770
cancer	T191	C0006826
A cross-sectional study	T062	C0010362
Older people	T098	C3826770
stigmas	T048	C0011570
cancer	T191	C0006826
aging	T040	C0001811
studies	T062	C2603343
negative	T033	C0205160
view	T082	C0449911
cancer	T191	C0006826
level of depression	T033	C1319226
studied	T062	C2603343
elderly population	T098	C0001792
negative	T033	C0205160
self-perception	T041	C0242498
aging	T040	C0001811
consequences	T169	C0686907
mental	T041	C0025353
physical health	T033	C4060919
aging	T040	C0001811
pathological	T169	C1521733
contexts	T078	C0449255
oncology	T191	C0027651
analyze	T062	C0936012
stigmas	T048	C0011570
health	T078	C0018684
elderly	T098	C0001792
oncology	T191	C0027651
patients	T101	C0030705
patients	T101	C0030705
cancer	T191	C0006826
breast	T191	C0006142
gynecological	T047	C0017411
lung	T191	C0242379
hematological	T047	C0018939
diagnosis	T033	C0011900
self-perception	T041	C0242498
age	T032	C0001779
cancer	T191	C0006826
health	T078	C0018684
physical	T033	C4060919
mental	T041	C0025353
regressions	T041	C0684321
patients	T101	C0030705
negative	T033	C0205160
self-perception	T041	C0242498
aging	T040	C0001811
negative	T033	C0205160
cancer	T191	C0006826
poorer	T080	C2700379
global health	T091	C1456573
negative	T033	C0205160
self-perception	T041	C0242498
aging	T040	C0001811
associated with	T080	C0332281
physical	T033	C4060919
mental health	T041	C0025353
negative	T033	C0205160
cancer	T191	C0006826
mental health	T041	C0025353
stigmas	T048	C0011570
independent	T078	C0085862
patients	T101	C0030705
cancer	T191	C0006826
stigmatization	T078	C0038330
negative	T033	C0205160
self-perception	T041	C0242498
aging	T040	C0001811
cancer	T191	C0006826
stigmas	T048	C0011570
mental health	T041	C0025353
Self-perception	T041	C0242498
aging	T040	C0001811
physical health	T033	C4060919
Longitudinal studies	T062	C0023981
analyze	T062	C0936012
stigmatization	T078	C0038330
health	T078	C0018684
Aortic Root	T029	C0549113
Natural History	T090	C0175860
Root-Sparing Ascending Replacement	T061	C0729662
Nonsyndromic	T033	C2677304
Aneurysmal Patients	T101	C0030705
native	T169	C0302891
aortic tissue	T024	C0040300
in situ	T082	C0444498
root-sparing ascending aortic replacement	T061	C0729662
concern	T078	C2699424
potential	T080	C3245505
later	T079	C0205087
need	T080	C0027552
root	T029	C0549113
reoperation	T061	C0035110
potential	T080	C3245505
occurrence	T079	C2745955
localized	T082	C0392752
dissections	T047	C0340643
rupture	T037	C3203359
residual	T080	C1609982
root	T029	C0549113
purpose of this study	UnknownType	C0681832
evaluate	T058	C0184514
natural growth	T040	C0018270
aortic root	T029	C0549113
root-sparing aortic replacement	T061	C0729662
consecutive	T080	C1707491
patients	T101	C0030705
mean	T081	C0444504
age	T032	C0001779
years	T079	C0439234
male	T098	C0025266
root-sparing aortic replacement	T061	C0729662
sufficient	T080	C0205410
retrievable information	T078	C1533716
aortic root	T029	C0549113
diameter	T081	C1301886
postoperative	T079	C0032790
baseline	T081	C1442488
follow-up	T058	C1522577
imaging	T060	C0079595
computed tomography	T060	C0040405
echocardiography	T060	C0013516
annual	T079	C0332181
growth rate	T079	C0449249
evaluated	T052	C1516048
compared	T052	C1707455
influence	T077	C4054723
valve morphology	T080	C0332437
concomitant	T079	C0521115
aortic valve replacement	T061	C0003506
years	T079	C0439234
natural history	T090	C0175860
require	T169	C1514873
root	T029	C0549113
enlargement	T190	C2711450
mm	T081	C0439200
threshold	T080	C0449864
root	T029	C0549113
diameter	T081	C1301886
calculated	T052	C1441506
estimated	T081	C0750572
growth rate	T079	C0449249
aortic root	T029	C0549113
root-sparing aortic replacement	T061	C0729662
mm	T081	C0439200
per year	T079	C0439508
mean	T081	C0444504
mm	T081	C0439200
underlying diameter	T081	C1301886
less than	T081	C0439092
aortic regions	T029	C0225914
root aneurysm	T047	C1298820
reoperation	T061	C0035110
expected	T170	C1517001
years	T079	C0439234
average	T081	C1510992
patients	T101	C0030705
diameter	T081	C1301886
mm	T081	C0439200
at risk	T080	C1444641
reoperation	T061	C0035110
until	T170	C1720302
after	T079	C0687676
years	T079	C0439234
have passed	T033	C2828386
Neither	T080	C4284892
valve morphology	T080	C0332437
concomitant	T079	C0521115
aortic valve replacement	T061	C0003506
influenced	T077	C4054723
rate	T081	C1521828
root dilation	T047	C1866956
nonsyndromic	T033	C2677304
patients	T101	C0030705
aortic root	T029	C0549113
slowest	T080	C0439834
growing	T040	C0018270
portion	T082	C0449719
thoracic aorta	T023	C1522460
native	T169	C0302891
root	T029	C0549113
root-sparing ascending aortic replacement	T061	C0729662
safe approach	T082	C0449445
secondary root	T029	C0549113
intervention	T061	C0184661
aortic root	T029	C0549113
diameters	T081	C1301886
mm	T081	C0439200
Physical Exercise	T056	C0015259
Late-Life	T079	C2362314
Depression	T048	C0011581
Effects	T080	C1280500
Heart Rate	T201	C0018810
Variability	T077	C2827666
Late-life	T079	C2362314
major depression	T048	C1269683
associated with	T080	C0332281
increased	T081	C0205217
cardiovascular risk	T033	C1113685
impaired autonomic control of the heart	T047	C0018799
reduced	T080	C0392756
heart rate	T201	C0018810
variability	T077	C2827666
HRV	T077	C2827666
antidepressant drug	T121	C0003289
therapy	T061	C0087111
associated with	T080	C0332281
reductions	T080	C0392756
HRV	T077	C2827666
SEEDS study	T062	C2603343
sertraline	T109	C0074393
associated with	T080	C0332281
physical exercise	T056	C0015259
improvements	T077	C2986411
HRV	T077	C2827666
antidepressant drug	T121	C0003289
therapy	T061	C0087111
Single-blind	T062	C0037181
randomized controlled trial	T062	C0206035
Psychiatric consultation	T073	C1548378
primary care	T058	C0033137
Patients	T101	C0030705
major depression	T048	C1269683
primary care	T058	C0033137
Sertraline	T109	C0074393
tailored group	UnknownType	C0681860
physical exercise	T056	C0015259
S + EX	UnknownType	C0681860
sertraline	T109	C0074393
weeks	T079	C0439230
HRV	T077	C2827666
indices	T170	C0918012
percentage of NN intervals greater than 50 msec	T081	C0392762
pNN50	T081	C0392762
square root of the mean squared differences of successive NN intervals	T081	C0392762
RMSSD	T081	C0392762
standard deviation	T081	C0871420
heart rate	T201	C0018810
SDHR	T081	C0871420
standard deviation of the NN interval	T081	C0871420
SDNN	T081	C0871420
high-frequency band	T081	C0392762
HF	T081	C0392762
low-frequency band	T081	C0392762
LF	T081	C0392762
ratio	T081	C0456603
LF/HF	T081	C0456603
measured	T080	C0444706
baseline	T081	C1442488
week	T079	C0439230
week	T079	C0439230
Psychiatric	T060	C0846574
medical assessments	T058	C0582103
Participants	T098	C0679646
improvements	T077	C2986411
HRV	T077	C2827666
indices	T170	C0918012
pNN50	T081	C0392762
RMSSD	T081	C0392762
SDHR	T081	C0871420
SDNN	T081	C0871420
HF	T081	C0392762
LF	T081	C0392762
LF/HF	T081	C0456603
patients	T101	C0030705
S + EX group	UnknownType	C0681860
increases	T169	C0442805
HRV	T077	C2827666
indices	T170	C0918012
RR	T081	C0392762
pNN50	T081	C0392762
RMSSD	T081	C0392762
SDHR	T081	C0871420
SDNN	T081	C0871420
HF	T081	C0392762
LF	T081	C0392762
S group	UnknownType	C0681860
combination	T080	C0205195
physical exercise	T056	C0015259
sertraline	T109	C0074393
positive	T033	C1446409
effects	T080	C1280500
autonomic control of the heart	T042	C0232164
patients	T101	C0030705
major depression	T048	C1269683
Genome-Wide SNP Linkage Mapping	T059	C0008630
QTL	T028	C0597336
Analysis	T059	C0796344
Fiber	T002	C1260603
Quality	T080	C0332306
Yield	T081	C0392762
Traits	T032	C0599883
Upland Cotton	T002	C0010196
Recombinant Inbred Lines	T008	C1514783
genes	T028	C0017337
fiber	T002	C1260603
quality	T080	C0332306
yield	T081	C0392762
traits	T032	C0599883
markers	T045	C0017393
marker-assisted selection	T062	C0017395
MAS	T062	C0017395
cotton	T002	C0010196
breeding	T040	C4042898
188 F8	T002	C0010196
recombinant inbred lines	T008	C1514783
RILs	T008	C1514783
intraspecific	T080	C0205369
cross	T040	C4042898
HS46	T002	C0010196
MARCABUCAG8US-1-88	T002	C0010196
genotyped	T032	C0017431
cotton	T002	C0010196
single nucleotide polymorphism (SNP) assay	T059	C3536614
Field trials	T062	C0868962
Sanya, Hainan Province	UnknownType	C0681784
cropping	T090	C4042899
seasons	T079	C0036497
standard	T080	C1442989
conditions	T080	C0348080
significant	T081	C0237881
differences	T080	C1705242
RILs	T008	C1514783
environments	T082	C0014406
replications	T080	C1883725
fiber	T002	C1260603
quality	T080	C0332306
yield	T081	C0392762
traits	T032	C0599883
heritabilities	T169	C0439660
traits	T032	C0599883
fiber	T002	C1260603
length	T081	C1444754
fiber	T002	C1260603
uniformity	T080	C0205375
micronaire	T080	C0205556
fiber	T002	C1260603
elongation	T040	C0018270
fiber	T002	C1260603
strength	T081	C0039526
boll	T002	C0010197
weight	T081	C0043100
lint	T167	C4019096
percentage	T081	C0439165
cM	T081	C0582522
centimorgans	T081	C0582522
linkage map	T059	C0008630
polymorphic	T080	C1882417
SNP	T086	C0752046
markers	T045	C0017393
cM	T081	C0582522
marker	T045	C0017393
quantitative trait locus	T028	C0597336
QTLs	T028	C0597336
fiber	T002	C1260603
quality	T080	C0332306
yield	T081	C0392762
traits	T032	C0599883
chromosomes	T026	C1135923
phenotypic	T032	C0031437
variance	T080	C1711260
stable	T080	C0205360
QTLs	T028	C0597336
environments	T082	C0014406
regions	T026	C1953345
hotspot	T086	C2986491
cluster	T028	C0017258
traits	T032	C0599883
Chr05	T026	C1135923
Chr09	T026	C1135923
Chr10	T026	C1135923
Chr14	T026	C1135923
Chr19	T026	C1135923
Chr20	T026	C1135923
epistatic	T028	C0017344
QTLs	T028	C0597336
e-QTLs	T028	C0597336
additive	T080	C0442796
QTLs	T028	C0597336
additive	T080	C0442796
QTLs	T028	C0597336
e-QTLs	T028	C0597336
QTL	T028	C0597336
clusters	T028	C0017258
SNP	T086	C0752046
markers	T045	C0017393
target	T169	C1521840
regions	T026	C1953345
map-based cloning	T059	C0598888
gene discovery	T063	C2717881
MAS	T062	C0017395
cotton	T002	C0010196
breeding	T040	C4042898
Effects	T080	C1280500
intervention	T061	C0184661
human	T016	C0086418
amniotic	T018	C0002630
epithelial cells	T025	C0014597
COPD	T047	C0024117
rat	T015	C0034716
model	T075	C0026336
study	T062	C2603343
investigate	T169	C1292732
effect	T080	C1280500
intervention	T061	C0184661
human	T016	C0086418
amniotic	T018	C0002630
epithelial cell	T025	C0014597
hAEC	T025	C0014597
rat	T015	C0034716
model	T075	C0026336
chronic obstructive pulmonary disease	T047	C0024117
COPD	T047	C0024117
specific pathogen-free	T001	C0162470
Wistar rats	T015	C0034716
randomized	T062	C0206034
control	T096	C0009932
COPD	T047	C0024117
COPD	T047	C0024117
hAEC	T025	C0014597
groups	T078	C0441833
COPD	T047	C0024117
intratracheal	T169	C1555389
LPS	T109	C0023810
smoke	T131	C0037366
fumigation	T068	C0016804
days	T079	C0439228
day	T079	C0439228
model	T075	C0026336
rats	T015	C0034716
AEC	T025	C0014597
group	T078	C0441833
intratracheal instillation	T169	C1555389
hAECs	T025	C0014597
placenta	T018	C0032043
healthy	T080	C3898900
donors	T098	C0013018
mean linear intercept	T081	C1444754
MLI	T081	C1444754
mean alveolar number	T081	C0237753
MAN	T081	C0237753
lung emphysema	T047	C0034067
IL-8	T116	C0079633
radioimmunoassay	T059	C0034580
surfactant protein D	T116	C0084692
SP-D	T116	C0084692
ELISA	T059	C0014441
matrix metalloproteinase (MMP)2	T116	C0172537
MMP8	T116	C0172956
expression	T045	C1171362
PCR	T063	C0032520
Smoke	T131	C0037366
fumigation	T068	C0016804
LPS	T109	C0023810
COPD	T047	C0024117
rat	T015	C0034716
model	T075	C0026336
emphysema	T047	C0034067
airway inflammation	T046	C0021368
elevated	T080	C3163633
MLI	T081	C1444754
MAN	T081	C0237753
elevated	T080	C3163633
systemic	T169	C0205373
lung	T023	C0024109
tissue	T024	C0040300
levels	T080	C0441889
IL-8	T116	C0079633
SP-D	T116	C0084692
expression	T045	C1171362
MMP2	T116	C0172537
MMP8	T116	C0172956
Rats	T015	C0034716
COPD	T047	C0024117
hAEC	T025	C0014597
group	T078	C0441833
alleviated	T080	C0392756
lung	T023	C0024109
damage	T037	C0010957
MLI	T081	C1444754
MAN	T081	C0237753
reduced	T080	C0392756
systemic	T169	C0205373
lung	T023	C0024109
tissue	T024	C0040300
levels	T080	C0441889
IL-8	T116	C0079633
SP-D	T116	C0084692
MMP2	T116	C0172537
MMP8	T116	C0172956
expression	T045	C1171362
intervention	T061	C0184661
hAECs	T025	C0014597
disease progression	T046	C0242656
rats	T015	C0034716
COPD	T047	C0024117
Systematic	T169	C0220922
Identification	T041	C0020792
Pharmacological	T038	C0007992
Targets	T169	C1521840
Small-Molecule	T109	C1328819
Phenotypic Screens	T059	C0373483
Phenotypic	T032	C0031437
drug discovery	T062	C0920472
advantages	UnknownType	C0681074
target	T169	C1521840
based	T169	C1527178
methods	T170	C0025663
drug leads	T121	C0013227
tested	T169	C0039593
systems	T169	C0449913
more	T081	C0205172
closely	T033	C3810854
model	T075	C0026339
distinct	T080	C2963144
disease states	T033	C0231294
potential	T080	C3245505
disadvantage	T080	C0205556
difficulty	T080	C0332218
linking	T052	C2986575
observed	T169	C1441672
phenotype	T032	C0031437
specific	T080	C0205369
cellular	T025	C0007634
target	T169	C1521840
problem	T033	C0033213
developed	T169	C1527148
DePick	T170	C0037589
computational	T052	C1880157
de-convolution	T066	C1707643
tool	T073	C2827396
determine	T059	C1148554
targets	T169	C1521840
specifically	T080	C0205369
linked	T052	C2986575
small-molecule	T109	C1328819
phenotypic screens	T059	C0373483
applied	T169	C1632850
DePick	T170	C0037589
publicly	T092	C0678367
screens	T074	C0302765
predicted	T078	C0681842
drug	T121	C0013227
target	T169	C1521840
phenotype	T032	C0031437
associations	T080	C0439849
literature	T170	C0023866
based	T169	C1527178
evidence	T078	C3887511
predictions	T078	C0681842
provide	T052	C1999230
experimental	T080	C1517586
support	T077	C1521721
predicted	T078	C0681842
associations	T080	C0439849
Interestingly	T041	C0543488
analysis	T062	C0936012
discovery	T052	C1880355
previously	T079	C0205156
unrecognized	T080	C4288068
connection	T082	C0449379
Wnt signaling pathway	T044	C1520113
aromatase	T116	C0003805
CYP19A1	T116	C3254086
results	T033	C0683954
demonstrate	T080	C0443289
DePick	T170	C0037589
accelerate	T169	C0521110
target	T169	C1521840
de-convolution	T066	C1707643
aid	T080	C1269765
discovery	T052	C1880355
functionally	T169	C0205245
relevant	T080	C2347946
biological	T080	C0205460
relationships	T080	C0439849
Yarn	T058	C1512347
clinical yarning	T058	C1512347
clinician	T097	C0871685
patient	T101	C0030705
communication	T054	C0009452
Aboriginal	T098	C0935542
health care	T058	C0086388
communication	T054	C0009452
clinical consultation	T058	C0009818
communication	T054	C0009452
Aboriginal	T098	C0935542
patients	T101	C0030705
practitioners	T097	C0017319
doctors	T097	C0031831
nurses	T097	C0028661
allied health professionals	T097	C0002122
problematic	T033	C0033213
health care	T058	C0086388
Aboriginal people	T098	C0935542
overarching framework	T170	C0282574
practitioners	T097	C0017319
communication	T054	C0009452
Aboriginal	T098	C0935542
patients	T101	C0030705
clinical yarning	T058	C1512347
Clinical yarning	T058	C1512347
patient	T101	C0030705
Aboriginal	T098	C0935542
cultural communication	T054	C0009452
biomedical	T091	C1879848
health and disease	T070	C0679215
Clinical yarning	T058	C1512347
social	T169	C0728831
yarn	T058	C1512347
practitioner	T097	C0017319
interpersonal relationship	T054	C0021797
diagnostic	T169	C0348026
yarn	T058	C1512347
practitioner	T097	C0017319
patient's	T101	C0030705
health story	T078	C1254370
biomedical	T091	C1879848
scientific lens	T059	C0947630
yarn	T058	C1512347
employs stories	T078	C1254370
metaphors	T078	C0302829
patients	T101	C0030705
health issue	T033	C0243095
collaborative management approach	T062	C0681804
cultural	T169	C0220814
research	T062	C0242481
evidence	T078	C3887511
Clinical yarning	T058	C1512347
outcomes	T169	C1274040
patients	T101	C0030705
practitioners	T097	C0017319
single-dose	T201	C1960417
carbapenem	T109	C0006968
exposure	T033	C0743284
transcriptional expression	T045	C0017262
blaNDM-1	T028	C3699343
mexA	T028	C0376623
Pseudomonas aeruginosa	T007	C0033809
therapeutic option	T169	C0302350
carbapenem antibiotic	T109	C0006968
Pseudomonas aeruginosa	T007	C0033809
acquired	T040	C1155281
intrinsic resistance	T032	C0949669
New Delhi metallo-β-lactamase	T116	C2973511
carbapenem resistance determinant	T032	C0949285
P. aeruginosa	T007	C0033809
strain	T001	C1518614
blaNDM-1	T028	C3699343
overexpressed	T045	C0017262
MexAB-OprM	T028	C0029073
carbapenem	T109	C0006968
therapy	T061	C0338237
clinical isolates	T123	C1764827
P. aeruginosa	T007	C0033809
meropenem	T109	C0066005
strains	T001	C1518614
strain overexpressing	T045	C0017262
MexAB-OprM	T028	C0029073
no	T169	C0332197
blaNDM-1	T028	C3699343
blaNDM-1	T028	C3699343
expressing	T045	C0017262
MexAB-OprM	T028	C0029073
strain	T001	C1518614
blaNDM-1	T028	C3699343
overexpressing	T045	C0017262
MexAB-OprM	T028	C0029073
P. aeruginosa PAO1	T007	C4164297
P. aeruginosa K2733-PAO1	T007	C4164297
ΔMexAB-OprM	T028	C0029073
ΔMexCD-OprJ	T028	C0029073
ΔMexEF-OprN	T028	C0029073
ΔMexXY-OprM	T028	C0029073
blaNDM-1	T028	C3699343
cloned	T059	C0598888
Strains	T001	C1518614
Luria-Bertani broth	T130	C2919900
meropenem	T109	C0066005
Total RNA	T059	C4086963
reverse transcribed	T045	C0035380
cDNA	T114	C0006556
Quantitative real-time PCR	T063	C3179034
resistance mechanisms	T062	C1517585
Meropenem	T109	C0066005
exposure	T033	C0743284
elevate transcription	T045	C0040649
blaNDM-1	T028	C3699343
mexA gene	T028	C0376623
single-dose	T201	C1960417
exposure to carbapenem	T033	C0743284
efflux pump system	T024	C3824504
role in bacterial survival	T169	C0220921
NDM-1	T116	C2973511
bacterial response to carbapenem antibiotic	T040	C0683154
resistance mechanisms	T062	C1517585
antimicrobials	T121	C1136254
Inducible	T169	C0205263
Expression	T045	C0017262
ermB	T028	C0017337
ermT	T028	C0017337
High	T080	C0205250
Macrolide Resistance	T033	C3160879
Streptococcus gallolyticus subsp. pasteurianus	T007	C1459658
Isolates	T001	C1518614
China	T083	C0008115
Streptococcus gallolyticus subsp. pasteurianus	T007	C1459658
pathogen	T001	C0450254
zoonotic agent	T007	C1690490
opportunistic infections	T047	C0029118
humans	T016	C0086418
recognition	T080	C0205396
subspecies	T007	C1459658
human	T016	C0086418
infectious diseases	T047	C0004623
antibiotic resistance	T032	C0949669
mechanism	T169	C0441712
study	T062	C2603343
molecular mechanism	T044	C1148560
macrolide resistance	T033	C3160879
S. gallolyticus subsp. pasteurianus	T007	C1459658
isolates	T001	C1518614
dead	T033	C1306577
ducklings	T012	C0013268
China	T083	C0008115
isolates	T001	C1518614
multi-drug resistance	T032	C0242640
macrolide resistance	T033	C3160879
MIC	T034	C1304747
MIC	T034	C1304747
erythromycin	T109	C0014806
clarithromycin	T109	C0055856
Efflux-encoding mefA	T028	C0017337
mefE genes	T028	C0017337
isolates	T001	C1518614
23S rRNA	T114	C0035704
mutations	T045	C0026882
isolates	T001	C1518614
macrolide	T109	C0282563
MIC	T034	C1304747
nucleotide	T114	C0028630
substitutions	T052	C1706204
genes	T028	C0017337
ribosomal proteins L4	T116	C0073302
L22	T116	C0035552
ermB	T028	C0017337
ermT genes	T028	C0017337
genomes	T028	C0017428
isolates	T001	C1518614
genes	T028	C0017337
independently	T169	C0332291
virulent isolate AL101002	T001	C1518614
Tn916	T001	C1518614
IS1216	T001	C1518614
expression	T045	C0017262
ermB	T028	C0017337
ermT	T028	C0017337
isolates	T001	C1518614
erythromycin	T109	C0014806
inducible	T169	C0205263
macrolide	T109	C0282563
MICs	T034	C1304747
isolates	T001	C1518614
inducible	T169	C0205263
expression	T045	C0017262
ermB	T028	C0017337
ermT	T028	C0017337
macrolide resistance	T033	C3160879
S. gallolyticus subsp. pasterianus	T007	C1459658
isolates	T001	C1518614
findings	T033	C0243095
macrolide resistance	T033	C3160879
S. gallolyticus subsp. pasteurianus	T007	C1459658
ermB	T028	C0017337
ermT	T028	C0017337
Bilateral	T082	C0238767
C1 laminar hooks	T074	C0025080
C2 pedicle screw	T074	C1961768
fixation	T061	C0185023
treatment	T061	C0087111
atlantoaxial subluxation	T037	C0263905
Grisel syndrome	T047	C0263885
etiologies	T169	C0015127
atlantoaxial subluxaion	T037	C0263905
Grisel syndrome	T047	C0263885
GS	T047	C0263885
subluxation	T037	C0263905
spontaneously	T169	C0205359
inflammatory	T169	C0333348
processes	T067	C1522240
head	T029	C0018670
neck	T029	C0027530
Diagnosis	T033	C0011900
clinical history	T033	C0262926
suspicion	T041	C0242114
syndrome	T047	C0039082
Nonsurgical treatment	T061	C0087111
resolves	T077	C2699488
symptoms	T184	C1457887
cases	T169	C0868928
surgical treatment	T061	C0543467
repair	T061	C0374711
subluxation	T037	C0263905
surgical techniques	T060	C0011918
instrumentation systems	T074	C0348000
treat	T061	C0087111
atlantoaxial subluxation	T037	C0263905
consensus	T054	C0376298
treatment method	T061	C0087111
pediatric	T080	C1521725
population	T098	C1257890
case	T169	C0868928
atlantoaxial subluxation	T037	C0263905
child	T100	C0008059
GS	T047	C0263885
treated	T033	C0332154
surgically	T061	C0543467
alternative	T077	C1523987
construct	T074	C0025080
case report	T170	C0085973
literature review	T170	C0282441
case study	T170	C0085973
year	T079	C0439234
girl	T100	C0870604
month	T079	C0439231
history	T033	C0332119
unresolved	T080	C0443342
Fielding type II atlantoaxial subluxation	T037	C0263905
GS	T047	C0263885
conservative treatment	T061	C0459914
patient's	T101	C0030705
symptoms	T184	C1457887
continued	T078	C0549178
progress	T169	C1280477
failed	T169	C0231175
closed reduction	T061	C0441610
attempts	T051	C1516084
open reduction	T061	C2370853
C1-C2 fusion	T061	C0037935
performed	T169	C0884358
atlas laminar hook	T074	C0181209
axis pedicle polyaxial screws	T074	C0301559
literature review	T170	C0282441
surgical treatment	T061	C0543467
GS	T047	C0263885
performed	T169	C0884358
surgery	T169	C0038895
patient	T101	C0030705
clinical	T080	C0205210
functional recovery	T184	C0599766
complete resolution	T077	C2699488
symptoms	T184	C1457887
month	T079	C0439231
follow-up	T058	C1522577
examination	T058	C0582103
continual	T079	C0439598
evidence	T078	C3887511
satisfactory	T033	C0438110
reduction	T061	C0441610
fusion	T061	C1293131
complications	T046	C0009566
observed	T169	C1441672
completion	T080	C0205197
literature review	T170	C0282441
GS	T047	C0263885
cases	T169	C0868928
treated	T169	C1522326
surgically	T061	C0543467
patient	T101	C0030705
age	T032	C0001779
years	T079	C0439234
Conservative management	T061	C0459914
GS	T047	C0263885
common	T081	C0205214
effective	T080	C1704419
treatment	T061	C0087111
surgical cases	T169	C0868928
reported	T058	C0700287
literature	T170	C0023866
results	T169	C1274040
Satisfactory	T033	C0438110
clinical results	T033	C2985631
fusion	T061	C1293131
months	T079	C0439231
post surgery	T033	C0241311
pediatric	T080	C1521725
patient	T101	C0030705
atlantoaxial subluxation	T037	C0263905
instability	T033	C1444783
atlas laminar hook	T074	C0181209
axis pedicle polyaxial screws	T074	C0301559
Caries	T047	C0333519
Dental Fluorosis	T047	C0026618
Oral Health Behaviour	T201	C1830927
12-Year	T079	C0439234
School Children	T100	C0260267
Moderate-Fluoride Drinking Water Community	T096	C0009462
Quetta	T083	C0017446
Pakistan	T083	C0030211
prevalence	T081	C0033105
dental caries	T047	C0011334
relationship	T080	C0439849
dental fluorosis	T047	C0026618
oral health behaviour	T201	C1830927
dietary behaviour	T033	C4019289
12-year	T079	C0439234
school children	T100	C0260267
moderate-fluoride drinking water community	T096	C0009462
Quetta	T083	C0017446
Pakistan	T083	C0030211
Cross-sectional study	T062	C0010362
Government	T073	C0036375
private schools	T073	C0036375
Quetta	T083	C0017446
November	T079	C3828767
February	T080	C3830166
children	T100	C0008059
12-year	T079	C0439234
schools	T073	C0036375
data collection	T062	C0010995
questionnaire	T170	C0034394
children	T100	C0008059
Dental caries	T047	C0011334
status	T080	C0449438
status	T080	C0449438
examined	T033	C0332128
WHO	T093	C0043237
Dental caries	T047	C0011334
children	T100	C0008059
DMFT	T081	C0012845
Boys	T100	C0870221
dental caries	T047	C0011334
girls	T100	C0870604
Dental fluorosis	T047	C0026618
children	T100	C0008059
moderate	T080	C0205081
Dental fluorosis	T047	C0026618
status	T080	C0449438
associated with	T080	C0332281
dental caries	T047	C0011334
status	T080	C0449438
children	T100	C0008059
children	T100	C0008059
mild	T080	C2945599
moderate	T080	C0205081
severe	T080	C0205082
fluorosis	T047	C0026618
develop	T169	C1527148
caries	T047	C0333519
fluorosis	T047	C0026618
association	T080	C0439849
children's	T100	C0008059
caries	T047	C0333519
status	T080	C0449438
paste	T122	C0040462
brushing habit	T061	C0040461
miswak	T122	C0011379
visit	T053	C0545082
dentist	T097	C0011441
pastries	T168	C0016452
juices	T168	C1268568
children's	T100	C0008059
dental caries	T047	C0011334
status	T080	C0449438
Dental caries	T047	C0011334
children	T100	C0008059
Quetta	T083	C0017446
fluoride	T121	C0016327
deficient	T169	C0011155
countries	T083	C0454664
prevalence	T081	C0033105
dental fluorosis	T047	C0026618
consumption	T052	C2983605
pastries	T168	C0016452
juices	T168	C1268568
dental caries	T047	C0011334
Proteomics	T116	C0751973
analysis	T059	C0002778
endogenous	T169	C0205227
leaf	T002	C0242724
SUMOylome	T044	C0872079
SUMOylation	T044	C1157990
post-translational modification	T044	C0033666
regulates	T038	C1327622
critical	T080	C1511545
biological processes	T038	C3714634
mammals	T015	C0024660
yeast	T004	C0043393
plants	T002	C0032098
understand	T041	C0162340
functional effects	T033	C0935657
SUMOylation	T044	C1157990
essential	T080	C0205224
identification	T041	C0020792
endogenous	T169	C0205227
targets	T169	C1521840
SUMOylation	T044	C1157990
report	T170	C0684224
results	T169	C1274040
proteomic approach	T091	C0872252
3D	T082	C0450363
gels	T122	C0017243
endogenous	T169	C0205227
SUMO	T116	C0911575
targets	T169	C1521840
leaves	T002	C0242724
Solanum tuberosum	T002	C1145678
3D	T082	C0450363
gels	T122	C0017243
co-migration	T067	C1254366
proteins	T116	C0033684
major	T080	C0205164
limitation	T169	C0449295
2D	T082	C1705052
gels	T122	C0017243
highly sensitive	T080	C0439822
CyDye DIGE fluor saturation dyes	T130	C0016320
identified	T080	C0205396
individual proteins	T116	C0033684
probable	T081	C0033204
SUMO	T116	C0911575
targets	T169	C1521840
leaves	T002	C0242724
Solanum tuberosum	T002	C1145678
method	T059	C0871511
approaches	T169	C1292724
possible	T033	C0332149
future	T079	C0016884
developments	T169	C1527148
authors	T097	C3812881
conflicts of interest	T078	C0079152
authors	T097	C3812881
approved	T080	C0205540
manuscript	T073	C0600659
agree	T033	C3641827
submission	T169	C1515022
Journal of Proteomics	T073	C0162443
Antenatal	T079	C2828394
consultation	T058	C0009818
following	T079	C0332282
limb malformation	T019	C0206762
discovery	T052	C1880355
ultrasound scan	T060	C0041618
unit	T073	C0019988
providing	T052	C1999230
antenatal	T079	C2828394
consultations	T058	C0009818
following	T079	C0332282
discovery	T052	C1880355
limb malformation	T019	C0206762
fetus	T018	C0015965
consultations	T058	C0009818
specific	T080	C0205369
carried out	T058	C2733037
multi-professional team	T058	C0086390
requires	T169	C1514873
rehabilitation	T091	C1306847
doctor	T097	C0031831
orthopedic surgeon	T097	C0334891
occupational therapist	T097	C0028807
upper limb malformation	T019	C1404175
physiotherapist	T097	C2362565
lower malformation	T019	C1404177
psychologist	T097	C0033908
multidisciplinary	T057	C0242479
consultation	T058	C0009818
unique	T080	C1710548
pregnancy	T040	C0032961
patient	T101	C0030705
life story	T170	C0681455
sonologist	T097	C1522486
diagnosis	T033	C0011900
couples	T099	C0010222
shocked	T033	C0436570
prenatal diagnosis	T060	C0033053
acceptance	T055	C0000899
child	T100	C0008059
imaginary	T041	C0025361
child	T100	C0008059
Medical information	T058	C0850397
perceived	T041	C0030971
surfeit	T080	C0205556
information	T078	C1533716
difficult	T080	C0332218
couple	T099	C0010222
stunned	T033	C4061448
overwhelming	T080	C0205556
diagnosis	T033	C0011900
critical	T080	C1511545
medical description	T033	C0517733
malformations	T019	C0000768
potential treatments	T061	C0087111
psychological support	T058	C0600015
parents	T099	C0030551
personal	T032	C1519021
life story	T170	C0681455
self-defense mechanism	T041	C0011142
guilt feeling	T041	C0018379
ethical aspect	T078	C1136353
consultation	T058	C0009818
important	T080	C3898777
Team	T058	C0086390
members	T098	C0680022
neutral	T170	C4050008
possible	T033	C0332149
assessments	T058	C0220825
couple	T099	C0010222
decision	T041	C0679006
continuation	T033	C0805733
pregnancy	T040	C0032961
request	T052	C1272683
voluntary	T055	C0439656
termination of pregnancy	T061	C0392535
prenatal	T100	C0678804
consultations	T058	C0009818
importance	T080	C0205556
multidisciplinary	T080	C0205556
global	T080	C2348867
care	T058	C0086388
Bending rules	T170	C0870077
shape	T082	C0332479
perceptual	T041	C0030971
generalisation	T041	C0017324
gradient	T081	C0812409
sensitive	T169	C0332324
inference rules	T170	C0870077
Generalising	T041	C0017326
learned	T041	C0023185
stimulus	T067	C0234402
perceptually	T041	C0030971
stimuli	T067	C0234402
behavioural	T053	C0004927
phenomenon	T067	C1882365
evaluated	T058	C0220825
rule	T170	C0870077
learning	T041	C0023185
mechanism	T169	C0441712
generalisation	T041	C0017324
assessed	T052	C1516048
inference rules	T170	C0870077
communicated	T033	C0566001
verbal instructions	T058	C1254363
generalisation	T041	C0017324
Expectancy	T078	C0679138
ratings	T052	C0871208
ratings	T052	C0871208
sensitive	T169	C0332324
manipulation	T053	C0018578
role	T170	C1704326
inference rules	T170	C0870077
generalisation	T041	C0017324
study	T062	C2603343
clinical	T080	C0205210
implications	T169	C0205245
targeting	T169	C1521840
inference rules	T170	C0870077
strategy	T041	C0679199
excessive	T080	C0442802
generalisation	T041	C0017324
psychopathology	T091	C0033927
Neuroticism	T048	C1842981
Fatigue	T184	C0015672
3 Months	T079	C1442461
Ischemic Stroke	T047	C0948008
Cross-Sectional Study	T062	C0010362
examine	T033	C0332128
neuroticism	T048	C1842981
fatigue	T184	C0015672
Chinese	T083	C0008115
patients	T101	C0030705
stroke	T047	C0038454
Cross-sectional study	T062	C0010362
Acute	T079	C0205178
stroke unit	T093	C0587502
Survivors	T101	C0206194
ischemic stroke	T047	C0948008
acute	T079	C0205178
stroke unit	T093	C0587502
personality trait	T033	C0233849
neuroticism	T048	C1842981
measured	T080	C0444706
neuroticism	T048	C1842981
subscale	T081	C0459443
Chinese	T083	C0008115
version	T170	C0333052
NEO Five-Factor Inventory	T060	C0031213
level	T080	C0441889
fatigue	T184	C0015672
measured	T080	C0444706
Fatigue Assessment Scale	T170	C2733557
National Institutes of Health Stroke Scale	T170	C3472496
Geriatric Depression Scale	T170	C0451184
Barthel Index	T170	C0451019
Mini-Mental State Examination	T060	C0451306
administered	T169	C1521801
demographic	T090	C0011298
clinical information	T170	C2708733
Fatigue severity	T170	C3813323
3 months	T079	C1442461
stroke	T047	C0038454
correlated	T080	C1707520
Geriatric Depression Scale	T170	C0451184
NEO Five-Factor Inventory	T060	C0031213
neuroticism	T048	C1842981
scores	T081	C0449820
negatively	T033	C0205160
correlated	T080	C1707520
Barthel Index score	T081	C1642833
Neuroticism	T048	C1842981
independent	T033	C1299583
depressive symptoms	T184	C0086132
fatigue severity	T170	C3813323
3 months	T079	C1442461
stroke	T047	C0038454
psychological	T169	C0205486
screening programs	T169	C3484370
detection	T061	C1511790
patients	T101	C0030705
high risk of	T033	C0332167
poststroke depression	T047	C2938940
Hematological	T033	C0243095
biochemical	T033	C0243095
toxicopathic effects	T033	C0243095
subchronic	T080	C4053983
acetamiprid	T109	C1142891
toxicity	T037	C0600688
Wistar rats	T015	C0034716
Acetamiprid	T109	C1142891
neonicotinoids	T131	C1997222
investigates	T169	C1292732
toxic effects	T037	C0600688
oral administration	T169	C1527415
doses	T081	C0178602
acetamiprid	T109	C1142891
LD50	T081	C0023378
days	T079	C0439228
male	T032	C0086582
Wistar rats	T015	C0034716
groups	T078	C0441833
Hematological	T033	C0243095
biochemical	T033	C0243095
toxicopathic effects	T033	C0243095
acetamiprid	T109	C1142891
evaluated	T058	C0220825
decrease	T081	C0547047
body weight gain	T033	C0043094
dose	T081	C0178602
LD50	T081	C0023378
acetamiprid	T109	C1142891
increase	T169	C0442805
liver	T023	C0023884
weight	T081	C0043100
dose	T081	C0178602
level	T080	C0441889
hematological constituents	T167	C0729650
decrease	T081	C0547047
RBC	T025	C0014792
HGB	T116	C0019046
HCT	T033	C0518014
rats	T015	C0034716
treated	T169	C1522326
doses	T081	C0178602
acetamiprid	T109	C1142891
LD50	T081	C0023378
increase	T169	C0442805
WBC	T025	C0023516
PLT	T025	C0005821
doses	T081	C0178602
acetamiprid	T109	C1142891
induced liver toxicity	T047	C4279912
increased	T081	C0205217
activities	T044	C0243102
aspartate aminotransferase	T116	C0004002
AST	T116	C0004002
alanine aminotransferase	T116	C0001899
ALT	T116	C0001899
alkaline phosphates	T116	C0002059
ALPs	T116	C0002059
lactate dehydrogenase	T116	C0022917
LDH	T116	C0022917
loss	T081	C1517945
hepatic membrane architecture	T026	C2331083
hepatocellular damage	T046	C0151763
exposure to	T080	C0332157
acetamiprid	T109	C1142891
decrease	T081	C0547047
levels	T080	C0441889
superoxide dismutase	T116	C0038838
catalase	T116	C0007367
activities	T044	C0243102
concomitant	T079	C0521115
increase	T169	C0442805
lipid peroxidation	T044	C0023775
rat	T015	C0034716
liver	T023	C0023884
findings	T033	C0243095
subchronic	T080	C4053983
hepatotoxicity	T037	C0235378
acetamiprid	T109	C1142891
Sustained delivery	T122	C1710261
vincristine	T109	C0042679
orthotopic	T082	C0574893
mouse sarcoma	T191	C1522023
decreases	T081	C0547047
tumor growth	T191	C0598934
Sarcoma	T191	C1261473
solid tumors	T191	C0280100
children	T100	C0008059
Surgery	T061	C0543467
morbidity	T081	C0026538
chemotherapy	T061	C3665472
tumors	T191	C0027651
sustained release	T122	C1710261
silk	T116	C0074529
tumor growth	T191	C0598934
Human	T016	C0086418
Ewing sarcoma	T191	C0553580
cells A673	T025	C0334227
cultured	T059	C0430400
vincristine	T109	C0042679
doxorubicin	T109	C0013089
half maximal inhibitory concentration	T081	C0600495
IC50	T081	C0600495
Cells	T025	C0334227
mouse	T015	C0025929
hind leg	T023	C1522391
orthotopic	T082	C0574893
tumors	T191	C0027651
Tumor volumes	T081	C0475276
ultrasound	T060	C0041618
interventions	T061	C0184661
implantation	T061	C0021107
drug-free	UnknownType	C0683584
silk	T116	C0074529
Control	T096	C0009932
doxorubicin	T109	C0013089
(Dox400	T109	C0013089
vincristine	T109	C0042679
Vin50	T109	C0042679
drug-free	UnknownType	C0683584
silk	T116	C0074529
gel	T167	C1382104
Control	T096	C0009932
vincristine	T109	C0042679
gel	T167	C1382104
Vin50	T109	C0042679
intravenous	T082	C0348016
vincristine	T109	C0042679
Vin50	T109	C0042679
End-point	T080	C2349179
Kaplan Meier	T081	C1720943
ANOVA	T081	C0002780
IC50	T081	C0600495
vincristine	T109	C0042679
doxorubicin	T109	C0013089
Dox400	T109	C0013089
1days	T079	C0439228
end point	T080	C2349179
DTEP	T080	C2349179
Control	T096	C0009932
DTEP	T080	C2349179
Vin50	T109	C0042679
DTEP	T080	C2349179
slower growth	T033	C4086857
Control	T096	C0009932
Vin50	T109	C0042679
Vin50	T109	C0042679
DTEP	T080	C2349179
Growth was slowest	T033	C4086857
Vin50	T109	C0042679
DTEP	T080	C2349179
Sustained delivery	T122	C1710261
vincristine	T109	C0042679
sarcoma	T191	C1261473
tumor	T191	C0027651
silk	T116	C0074529
gel	T167	C1382104
decreased	T081	C0547047
tumor growth	T191	C0598934
intratumoral treatment	T061	C1831733
decrease	T081	C0547047
surgical excision	T061	C0728940
Spinal	T023	C0037949
load	T032	C1318107
nurses	T097	C0028661
emergency	T067	C0013956
lifting	T052	C0206244
obese	T047	C0028754
patients	T101	C0030705
preliminary results	T078	C1548161
Nurses	T097	C0028661
risk	T078	C0035647
injury	T037	C3263722
handling	T033	C1832073
patients	T101	C0030705
obese	T047	C0028754
patients	T101	C0030705
goal	T170	C0018017
estimate	T081	C0750572
spinal	T023	C0037949
loads	T032	C1318107
risk	T078	C0035647
injury	T037	C3263722
nurses	T097	C0028661
lifting	T052	C0206244
obese	T047	C0028754
patients	T101	C0030705
floor	T073	C0016249
bariatric sheet	T074	C0183235
hospital	T073	C0019994
emergency	T067	C0013956
male	T032	C0086582
nurses	T097	C0028661
study	T062	C2603343
biomechanical analysis	T060	C0430022
lifting	T052	C0206244
obese	T047	C0028754
in-patients	T101	C0021562
experimental study	T062	C0681814
groups	T078	C0441833
Body Mass Index	T201	C1305855
BMI	T201	C1305855
Three-dimensional motion analysis	T060	C0430022
optoelectronic system	T074	C0025080
trunk	T029	C0460005
kinematics	T091	C0600169
loading	T032	C1318107
spines	T023	C0037949
nurses	T097	C0028661
computed	T059	C1441526
data	T078	C1511726
nurse	T097	C0028661
trunk	T029	C0460005
flexed	T042	C0231452
lift	T052	C0206244
reduced	T080	C0392756
range of motion	T201	C2607871
values	T081	C1522609
higher	T080	C0205250
nurse	T097	C0028661
patients	T101	C0030705
higher	T080	C0205250
BMIs	T201	C1305855
kinetic parameters	T081	C1706312
tension	T042	C0026841
lumbar muscles	T023	C0224323
movement	T040	C0026649
lower	T080	C0205251
values	T081	C1522609
nurse	T097	C0028661
patient's	T101	C0030705
head	T029	C0018670
feet	T023	C0016504
patient groups	T101	C0030705
data	T078	C1511726
load	T032	C1318107
spine	T023	C0037949
nurse	T097	C0028661
patient's	T101	C0030705
recommended	T078	C0034866
safety	T068	C0036043
limits	T169	C0439801
Expectations	T078	C0679138
methodology	T078	C3266812
translation	T062	C0242481
animal research	T062	C0003048
survey	T170	C0038951
general public	T098	C0683971
medical students	T097	C0038495
animal	T008	C0003062
researchers	T097	C0035173
North America	T083	C0028405
acceptable	T080	C1879533
standards	T170	C0038137
animal research	T062	C0003048
AR	T062	C0003048
methodology	T078	C3266812
translation rate	T081	C1521828
humans	T016	C0086418
survey	T170	C0038951
general public	T098	C0683971
Sampling Survey International	T170	C1552679
SSI	T170	C1552679
Canada	T083	C0006823
Amazon Mechanical Turk	T170	C1552679
AMT	T170	C1552679
USA	T083	C0041703
Canadian city	T083	C0006823
festival	T052	C0015922
CF	T052	C0015922
Canadian	T083	C0006823
children's hospital	T093	C0020017
CH	T093	C0020017
medical students	T097	C0038495
scientists	T097	C0402112
authors	T097	C3812881
academic	T092	C1510747
paediatricians	T097	C0237433
responses	T032	C0871261
general public	T098	C0683971
SSI	T170	C1552679
AMT	T170	C1552679
CF	T052	C0015922
CH	T093	C0020017
medical student	T097	C0038495
responses	T032	C0871261
scientist	T097	C0402112
responses	T032	C0871261
methodological quality	UnknownType	C0815254
general public	T098	C0683971
medical student	T097	C0038495
respondents	T098	C0282122
AR	T062	C0003048
high quality	T080	C0332306
anaesthesia	T061	C0002903
analgesia	T061	C0002766
euthanasia	T058	C0015187
optimal	T080	C2698651
statistical design	UnknownType	C0681864
comprehensive	T080	C1880156
literature review	T170	C0282441
randomisation	T062	C0034656
blinding	T062	C0150108
costs	T081	C0010186
acceptable	T080	C1879533
justifications	T078	C0392360
lower quality	T080	C0332306
costs	T081	C0010186
consultation	T058	C0009818
laboratory staff	T097	C0025106
expectations	T078	C0679138
translation	T062	C0242481
humans	T016	C0086418
toxicity	T037	C0600688
carcinogenicity	T191	C0858970
teratogenicity	T046	C0232910
treatment	T169	C0039798
findings	T169	C2607943
translation	T062	C0242481
translation	T062	C0242481
minority	T098	C0026192
AR	T062	C0003048
Medical students	T097	C0038495
supportive	T077	C1521721
AR	T062	C0003048
translation	T062	C0242481
Expectations	T078	C0679138
AR	T062	C0003048
empirical data	T078	C1511726
Predicting	T078	C0681842
violence	T048	C0042693
recidivism	T055	C0680458
males	T032	C0086582
probation	T089	C0687758
parole	T089	C0814701
study	T062	C2603343
evaluated	T078	C1550157
Iowa	T083	C0022037
Violence	T048	C0042693
Victimization	T068	C0376695
Instrument	T170	C0038951
males	T032	C0086582
Iowa	T083	C0022037
probation	T089	C0687758
released from prison	T033	C0425147
parole	T089	C0814701
supervision	T057	C1273870
study	T062	C2603343
potential	T080	C3245505
Iowa	T083	C0022037
Violence	T048	C0042693
Victimization	T068	C0376695
Instrument	T170	C0038951
predict	T078	C0681842
criminal offenses	UnknownType	C0680468
males	T032	C0086582
months	T079	C0439231
admission	T079	C0457453
probation	T089	C0687758
parole	T089	C0814701
AUC	T081	C0376690
analyses	T062	C0936012
predictive	T080	C0681890
Iowa	T083	C0022037
Violence	T048	C0042693
Victimization	T068	C0376695
Instrument	T170	C0038951
violence	T048	C0042693
victimization	T068	C0376695
predictive	T080	C0681890
drug offenses	UnknownType	C0680484
instrument	T170	C0038951
month	T079	C0439231
follow-up	T058	C1522577
Iowa	T083	C0022037
Violence	T048	C0042693
Victimization	T068	C0376695
Instrument	T170	C0038951
predicted	T078	C0681842
violence	T048	C0042693
Violence	T048	C0042693
current	T079	C0521116
findings	T169	C2607943
potential	T080	C3245505
expand	T082	C0205229
jurisdictions	T170	C0680647
populations	T098	C1257890
Prognostic significance	T201	C1514474
non-HPV16 genotypes	T032	C0017431
oropharyngeal squamous cell carcinoma	T191	C0280313
oropharyngeal squamous cell carcinoma	T191	C0280313
OPSCC	T191	C0280313
positive	T034	C4288937
HPV16 genotype	T114	C3872681
better	T080	C0332272
overall survival	T081	C4086681
compared	T052	C1707455
HPV genotypes	T114	C0807283
replicate	T080	C1883725
modified by	T080	C0205349
expression	T045	C1171362
p16 tumor suppressor protein	T116	C0249880
OPSCC	T191	C0280313
Carolina Head and Neck Cancer Study	T062	C1516225
CHANCE	T062	C1516225
population based case-control study	T062	C1709599
Tumors	T191	C0027651
positive solely	T034	C4288937
HPV16 genotype	T114	C3872681
genotypes	T032	C0017431
PCR	T063	C0032520
classified	T185	C0008902
HPV16-positive	T034	C4288937
Tumors	T191	C0027651
positive for	T034	C4288937
high-risk	T033	C0332167
HPV genotype	T114	C3872595
classified	T185	C0008902
non-HPV16-positive	T034	C4288937
Expression	T045	C1171362
p16	T116	C0249880
tumor	T191	C0027651
determined	T080	C0521095
immunohistochemistry	T060	C0021044
date of diagnosis	T079	C2316983
date of death	T079	C1148348
Overall survival	T081	C4086681
Kaplan-Meier curves	T081	C1720944
log-rank test	T081	C0242928
Hazard ratios	T081	C2985465
HR	T081	C2985465
smoking	T055	C0037369
alcohol use	T055	C0001948
sex	T032	C0079399
race	T098	C0034510
age	T032	C0001779
Cox proportional hazard regression	T081	C0010235
HPV16-positive	T034	C4288937
OPSCC	T191	C0280313
better	T080	C0332272
overall survival	T081	C4086681
non-HPV16-positive	T034	C4288937
OPSCC	T191	C0280313
OPSCC	T191	C0280313
positive	T033	C1446409
p16 expression	T045	C1171362
trend	T079	C1521798
non-HPV16-positive	T034	C4288937
OPSCC	T191	C0280313
greater risk of	T033	C0332167
death	T033	C1306577
HPV16-positive	T034	C4288937
tumors	T191	C0027651
HR	T081	C2985465
finding	T033	C0243095
indicates	T033	C1444656
HPV	T005	C0021344
genotyping	T059	C2368152
valuable prognostic significance	T201	C1514474
p16	T116	C0249880
status	T080	C0449438
OPSCC	T191	C0280313
HPV genotypes	T114	C0807283
Randomized Trials	T062	C0206034
Teen	T100	C0205653
Outreach Program	T095	C0871024
Louisiana	T083	C0024024
Rochester	T083	C0017446
New York	T083	C0027976
evaluate	T058	C0220825
Teen	T100	C0205653
Outreach Program	T095	C0871024
pregnancy prevention	T061	C0679784
program	T170	C0679717
community	T096	C0009462
evaluated	T058	C0220825
Teen	T100	C0205653
Outreach Program	T095	C0871024
positive youth development program	T077	C1709697
cohorts	T098	C0599755
youths	T100	C0087178
states	T083	C1301808
Louisiana	T083	C0024024
agencies	T092	C0237463
individualized	T080	C1881197
randomized controlled trial	T062	C0206035
youths	T100	C0087178
treatment	T061	C0087111
control condition	T096	C0009932
agencies	T092	C0237463
Rochester	T083	C0017446
New York	T083	C0027976
cluster	T081	C1704332
randomized controlled trial	T062	C0206035
no differences	T033	C3842396
intervention	T061	C0184661
control youths	T096	C0009932
delay	T079	C0205421
sexual	T053	C0036864
onset	T080	C0332162
Louisiana	T083	C0024024
adjusted odds ratio	T081	C0028873
AOR	T081	C0028873
confidence interval	T081	C0009667
CI	T081	C0009667
Rochester	T083	C0017446
New York	T083	C0027976
AOR	T081	C0028873
CI	T081	C0009667
sex	T040	C0009253
birth control	T121	C0009871
Louisiana	T083	C0024024
AOR	T081	C0028873
CI	T081	C0009667
Rochester	T083	C0017446
AOR	T081	C0028873
CI	T081	C0009667
controlling	T067	C2239193
covariates	T081	C1705098
no	T033	C1513916
short-term	T079	C0443303
effects	T080	C1280500
intervention	T061	C0184661
Research	T062	C0035168
long-term	T067	C0023983
intermediate impacts	T080	C1280500
youth development programs	T077	C1709697
adolescent	T100	C0205653
risk behaviors	T055	C0086931
single session	T051	C1883016
exhaustive exercise	T056	C0015259
decreases	T081	C0547047
circulating	T169	C0175630
guanidinoacetic acid	T109	C0061626
healthy	T080	C3898900
men	T098	C0025266
women	T098	C0043210
evaluated	T058	C0220825
effects of	T080	C1704420
exercise	T056	C0015259
circulating	T169	C0175630
concentrations	T081	C0457929
guanidinoacetic acid	T109	C0061626
GAA	T109	C0061626
creatine	T116	C0010286
healthy volunteers	T098	C3661466
running	T056	C0035953
exhaustion	T184	C0392674
free-weight bench-press	T056	C0015259
volitional failure	T056	C0026606
Blood	T031	C0005767
exercise	T056	C0015259
session	T051	C1883016
Running	T056	C0035953
induced	T169	C0205263
decrease	T081	C0547047
serum	T031	C0229671
GAA	T109	C0061626
free-weight exercise	T056	C0015259
reduced	T080	C0392756
GAA	T109	C0061626
serum	T031	C0229671
GAA	T109	C0061626
biomarker	T201	C0005516
exhaustion	T184	C0392674
Anti-helminthic	T121	C0003158
activity	T169	C0205177
Momordica charantia L	T002	C0330482
Fasciola hepatica eggs	T204	C3662687
days	T079	C0439228
incubation	T059	C1439852
in vitro	T080	C1533691
Fasciolosis	T047	C0015652
parasitic disease	T047	C0030499
trematode	T204	C0040818
Fasciola hepatica	T204	C0015648
human	T016	C0086418
animal population	T008	C1318101
world	T098	C2700280
synthetic drugs	T121	C0259849
treat	T061	C0087111
condition	T047	C0012634
natural selection	T070	C0086685
resistant	T169	C0332325
strains	T001	C1518614
parasite	T204	C0030498
anti-helminthic	T121	C0003158
properties	T169	C1292721
medicinal plants	T002	C0032100
phytopharmaceuticals	T109	C0577749
study	T062	C2603343
anti-fasciolicide	T169	C0205245
action	T052	C3266814
Momordica charantia	T002	C0330482
leaf	T002	C0242724
extracts	T123	C0032081
fractions	T081	C1264633
eggs of F. hepatica parasites	T204	C3662687
lyophilized	T080	C0205222
crude extract	T103	C1258023
CE	T103	C1258023
M. charantia leaves	T002	C0330482
sub-fractions	T081	C1264633
liquid-liquid partitioning	T059	C3178840
organic solvents	T109	C0360100
analysed	T062	C0936012
High Performance Liquid Chromatography	T059	C0008562
HPLC	T059	C0008562
suspended	T078	C1553389
DMSO	T109	C0012403
in vitro	T080	C1533691
tests	T059	C0022885
Quadruplicates	T081	C0205175
F. hepatica eggs	T204	C3662687
incubated	T059	C1439852
M. charantia	T002	C0330482
leaf	T002	C0242724
CE	T103	C1258023
concentrations	T081	C1446561
days	T079	C0439228
larvae	T204	C0023047
eggs	T204	C3662687
incubated	T059	C1439852
CE	T103	C1258023
concentrations	T081	C1446561
Eggs	T204	C3662687
incubated	T059	C1439852
CE	T103	C1258023
sub-fractions	T081	C1264633
concentrations	T081	C1446561
affected	T169	C0392760
embryonic development	T042	C0013936
n-butanol	T109	C0089147
inhibition	T052	C3463820
miracidia	T204	C0023047
formation	T169	C1522492
miracidia	T204	C0023047
hatched	T040	C0598016
control experiments	T096	C0009932
DMSO	T109	C0012403
embryogenesis	T042	C0013936
abolished	T079	C2746065
concentration	T081	C1446561
albendazole sulphoxide	T109	C0051091
ABZ(SO)	T109	C0051091
Chemical analysis	T059	C3495389
CE	T103	C1258023
sub-fractions	T081	C1264633
flavonoids	T109	C0596577
HPLC-MS	T059	C3641325
Quercetin	T109	C0034392
flavonoids	T109	C0596577
CE	T103	C1258023
n-butanol	T109	C0089147
subfraction	T081	C1264633
study	T062	C2603343
analyse	T062	C0936012
anti-fasciolicide	T169	C0205245
action	T052	C3266814
M. charantia	T002	C0330482
leaf	T002	C0242724
CE	T103	C1258023
subfractions	T081	C1264633
Dabigatran	T109	C2348066
oral anticoagulant	T109	C0354604
Guidelines	T170	C0162791
oral surgery procedures	T061	C0524861
review of the literature	T170	C0282441
Dabigatran	T109	C2348066
drug	T121	C1254351
anticoagulants	T121	C0003280
venous thromboembolism	T047	C1861172
stroke	T047	C0038454
systemic arterial valve embolism	UnknownType	C0149876
thrombin	T116	C0040018
patients	T101	C0030705
increases	T169	C0442805
risk of bleeding	T033	C3251812
dental treatment	T061	C0011331
bibliographic search	UnknownType	C0260071
PubMed	T170	C1138432
Medline	T170	C0025141
Cochrane Library	T073	C0023625
anticoagulants	T121	C0003280
dabigatran	T109	C2348066
surgical treatments	T061	C0543467
anatomical locations	T029	C0923870
oral cavity	T030	C0226896
randomized clinical trial	T062	C0206034
narrative literature reviews	UnknownType	C0815257
case series	T062	C0150093
clinical cases	T077	C1706256
expert opinion	T077	C0600219
clinical trials	T062	C0008976
meta-analysis	T062	C0920317
consensus	T054	C0376298
procedure	T061	C0543467
patients	T101	C0030705
dabigatran	T109	C2348066
risk	T078	C0035647
embolism	T046	C0013922
postoperative bleeding	T046	C0032788
renal function	T042	C0232804
invasive interventions	T061	C4048276
anti-hemolytic measures	T061	C0199176
FIDELIS	T170	C0282574
projects	T077	C1709701
contribute	T052	C1880177
detection	T033	C0442726
smear	T059	C2019329
positive	T033	C1514241
pulmonary tuberculosis	T047	C0041327
China	T083	C0008115
first phase of the Fund for Innovative DOTS Expansion through Local Initiatives to Stop TB	T170	C0282574
FIDELIS	T170	C0282574
projects	T077	C1709701
China	T083	C0008115
FIDELIS	T170	C0282574
projects	T077	C1709701
contribute	T052	C1880177
increased	T081	C0205217
case	T169	C0868928
detection	T033	C0442726
rate	T081	C1521828
smear	T059	C2019329
positive	T033	C1514241
pulmonary tuberculosis	T047	C0041327
PTB	T047	C0041327
China	T083	C0008115
compared	T052	C1707455
case notification rates	T081	C1521828
CNRs	T081	C1521828
intervention year	T079	C0439234
previous	T079	C0205156
year	T079	C0439234
FIDELIS	T170	C0282574
areas	T083	C0017446
compared	T052	C1707455
difference	T080	C1705242
CNRs	T081	C1521828
intervention year	T079	C0439234
previous	T079	C0205156
year	T079	C0439234
FIDELIS	T170	C0282574
areas	T083	C0017446
non-FI-DELIS	T033	C0243095
areas	T083	C0017446
province	T083	C1514578
increase	T169	C0442805
CNR	T081	C1521828
intervention year	T079	C0439234
compared	T052	C1707455
previous	T079	C0205156
year	T079	C0439234
project	T077	C1709701
differences	T080	C1705242
CNR	T081	C1521828
intervention year	T079	C0439234
previous	T079	C0205156
year	T079	C0439234
ranged	T081	C1514721
population	T098	C1257890
FIDELIS	T170	C0282574
areas	T083	C0017446
non-FIDELIS	T033	C0243095
areas	T083	C0017446
Differences	T080	C1705242
differences	T080	C1705242
analysis	T062	C0936012
differences	T080	C1705242
CNRs	T081	C1521828
FIDELIS	T170	C0282574
areas	T083	C0017446
statistically significantly	T081	C0237881
different	T080	C1705242
FIDELIS	T170	C0282574
areas	T083	C0017446
FIDELIS	T170	C0282574
projects	T077	C1709701
contributed	T052	C1880177
increase	T169	C0442805
case	T169	C0868928
detection	T033	C0442726
smear	T059	C2019329
positive	T033	C1514241
PTB	T047	C0041327
China	T083	C0008115
level	T080	C0441889
evidence	T078	C3887511
low	T080	C0205251
Liver Fatty Acid Binding Protein	T116	C0163315
Deficiency	T169	C0011155
Oxidative Stress	T049	C0242606
Inflammation	T046	C0021368
Apoptosis	T043	C0162638
Hepatotoxicity	T037	C0235378
Induced	T169	C0205263
Pyrazinamide	T109	C0034239
Zebrafish	T013	C0043457
Larvae	T204	C0023047
Pyrazinamide	T109	C0034239
PZA	T109	C0034239
essential	T080	C0205224
antitubercular drug	T121	C0003448
hepatotoxicity	T037	C0235378
potential	T080	C3245505
effects of	T080	C1704420
PZA	T109	C0034239
exposure	T080	C0332157
zebrafish	T013	C0043457
Danio rerio	T013	C0043457
larvae	T204	C0023047
hepatotoxicity	T037	C0235378
transgenic line	T028	C0282641
zebrafish	T013	C0043457
larvae	T204	C0023047
expressed	T045	C1171362
enhanced green fluorescent protein	T116	C1258415
EGFP	T116	C1258415
liver	T023	C0023884
incubated	T059	C1439852
PZA	T109	C0034239
postfertilization	T040	C0015914
endpoints	T080	C2349179
mortality	T081	C0205848
morphology	T033	C0700329
changes	T169	C0392747
size	T032	C1450569
shape	T082	C0332479
liver	T023	C0023884
histological	T091	C0019638
changes	T169	C0392747
transaminase analysis	T059	C0919834
apoptosis	T043	C0162638
markers	T201	C0005516
oxidative	T049	C0242606
genetic damage	T049	C0012860
expression	T045	C0017262
genes	T028	C0017337
evaluate	T058	C0220825
PZA	T109	C0034239
induced	T169	C0205263
hepatotoxicity	T037	C0235378
confirm	T033	C0750484
PZA	T109	C0034239
dose-dependent	T081	C1512045
hepatotoxicity	T037	C0235378
PZA	T109	C0034239
induce	T169	C0205263
marked	T080	C1706089
injury	T037	C3263723
zebrafish	T013	C0043457
larvae	T204	C0023047
liver atrophy	T047	C0391996
elevations of transaminase levels	T033	C0438717
oxidative stress	T049	C0242606
hepatocyte apoptosis	T043	C3269241
PZA	T109	C0034239
induced	T169	C0205263
hepatotoxicity	T037	C0235378
changes	T169	C0392747
gene expression levels	T081	C3244092
zebrafish	T013	C0043457
larvae	T204	C0023047
exposed to	T080	C0332157
PZA	T109	C0034239
postexposure	T080	C0332157
PZA	T109	C0034239
decreased	T081	C0205216
expression levels	T081	C3244092
liver fatty acid binding protein	T116	C0163315
L-FABP	T116	C0163315
target gene	T028	C1332838
peroxisome proliferator-activated receptor α	T116	C0166415
PPAR-α	T116	C0166415
severe	T080	C0205082
oxidative stress	T049	C0242606
hepatitis	T047	C0019158
upregulation	T044	C0041904
inflammatory cytokines	T043	C0010813
tumor necrosis factor alpha	T116	C1456820
TNF-α	T116	C1456820
transforming growth factor β	T116	C0040690
TGF-β	T116	C0040690
L-FABP	T116	C0163315
PPAR-α	T116	C0166415
downregulation	T044	C0949469
hepatotoxic response	T043	C3549372
zebrafish	T013	C0043457
larva	T204	C0023047
liver cell	T025	C0227525
apoptosis	T043	C0162638
L-FABP	T116	C0163315
biomarker	T201	C0005516
early detection	T060	C0596473
PZA	T109	C0034239
induced	T169	C0205263
liver damage	T046	C0151763
zebrafish	T013	C0043457
larvae	T204	C0023047
Smooth	T080	C0205357
Textured	T080	C0205556
Surfaces	T082	C0205148
Feature	T080	C2348519
Category	T170	C0683312
Selectivity	T052	C1707391
Human	T016	C0086418
Visual Cortex	T023	C0042817
fMRI studies	T060	C0376335
human	T016	C0086418
lateral occipital (LO) cortex	T023	C0028785
images	T170	C1704922
objects	T072	C0347997
compared	T052	C1707455
nonobjects	T071	C1551338
unresolved	T080	C0443342
objects	T072	C0347997
equivalent	T080	C0205163
levels	T080	C0441889
activity	T052	C0441655
LO	T023	C0028785
image features	T080	C2346469
stronger	T080	C0442821
activation	T052	C1879547
unbiased parametric texture model	T170	C3161035
predict	T078	C0681842
preferred	T067	C0234402
nonpreferred stimuli	T067	C0234402
LO	T023	C0028785
Observation	T062	C0302523
psychophysical results	T169	C1274040
predicted	T078	C0681842
preferred	T078	C0558295
stimuli	T067	C0234402
objects	T072	C0347997
nonobjects	T071	C1551338
smooth	T080	C0205357
textured	T080	C0205556
surfaces	T082	C0205148
predictions	T078	C0681842
confirmed	T080	C0521093
fMRI	T060	C0376335
objects	T072	C0347997
nonobjects	T071	C1551338
preferences	T078	C0558295
fusiform face area	T022	C3536733
FFA	T022	C3536733
Consistent with	T078	C0332290
FFA	T022	C3536733
LO	T023	C0028785
nonfreckled	T080	C0205556
smooth	T080	C0205357
faces	T082	C0205148
compared	T052	C1707455
freckled	T033	C0016689
textured	T080	C0205556
faces	T082	C0205148
functional	T169	C0205245
connections	T082	C0449379
LO	T023	C0028785
FFA	T022	C3536733
LO	T023	C0028785
FFA	T022	C3536733
information	T078	C1533716
processing	T052	C1709694
feature	T080	C2348519
category	T170	C0683312
selectivity	T052	C1707391
smooth	T080	C0205357
textured	T080	C0205556
High-fructose diet	T061	C1445913
high-fat diet	T061	C0521974
induction	T061	C0857127
insulin resistance	T046	C0021655
diabetes	T047	C0011847
hepatic	T029	C0205054
pancreatic	T023	C0030274
endoplasmic reticulum (ER) stress	T049	C3178870
context	T078	C0449255
high	T080	C0205250
human	T016	C0086418
consumption	T169	C0457083
fructose	T109	C0016745
diets	T168	C0012155
need	T080	C0027552
understand	T041	C0162340
dietary	T169	C2699635
fructose intake	T033	C0556134
influence	T077	C4054723
cellular	T025	C0007634
molecular	T080	C1521991
mechanisms	T169	C0441712
affect	T080	C1280500
β-cell dysfunction	T033	C1969875
insulin resistance	T046	C0021655
evidence	T078	C3887511
exists	T077	C2987476
relationship	T080	C0439849
high	T080	C0205250
fat	T109	C0015677
induced	T169	C0205263
insulin resistance	T046	C0021655
metabolic disorders	T047	C0025517
lack of	T080	C0332268
studies	T062	C2603343
high-fructose diet	T061	C1445913
study	T062	C2603343
effect	T080	C1280500
different	T080	C1705242
diets	T168	C0012155
high-fat diet	T061	C0521974
HFD	T061	C0521974
high-fructose diet	T061	C1445913
HFS	T061	C1445913
combination	T080	C0205195
HFS	T061	C1445913
HFD	T061	C0521974
diet	T168	C0012155
glucose homeostasis	T039	C1326961
insulin sensitivity	T046	C0920563
male	T032	C0086582
Wistar rats	T015	C0034716
compared	T052	C1707455
control animals	T008	C1511501
fed	T052	C2987508
normal	T080	C0205307
pellet	T081	C1998480
diet	T168	C0012155
Investigations	T169	C1292732
oral glucose tolerance test	T060	C0029161
insulin tolerance test	T059	C0236287
histopathology	T059	C0430445
H&E	T059	C0523207
Masson's trichrome staining	T059	C1294297
mRNA expression	T045	C1515670
real-time PCR	T063	C1709846
protein expression	T059	C1882495
Western blot	T059	C0949466
caspase-3 activity	T044	C1150132
colorimetry	T059	C0009407
Rats	T015	C0034721
high-fat	T061	C0521974
fructose diets	T061	C1445913
glucose	T109	C0017725
intolerant	T169	C0231200
insulin-resistant	T046	C0021655
dyslipidemic	T033	C0243095
Compared	T052	C1707455
control animals	T008	C1511501
rats	T015	C0034721
different	T080	C1705242
combination	T080	C0205195
fat	T061	C0521974
fructose diets	T061	C1445913
increased	T081	C0205217
mRNA	T045	C1515670
protein expression	T045	C1171362
ER stress	T049	C3178870
markers	T080	C0008963
pancreas	T023	C0030274
liver	T023	C0023884
Transcription factors	T116	C0040648
β-cell function	T043	C0007613
INSIG1	T116	C1447572
SREBP1c	T116	C0537474
PDX1	T116	C1528563
hepatic	T029	C0205054
gluconeogenesis	T044	C0017715
FOXO1	T116	C0250455
PEPCK	T116	C4042244
adversely affected	T046	C0879626
diet	T168	C0012155
induced	T169	C0205263
insulin-resistant	T046	C0021655
rats	T015	C0034721
convergence	T052	C2700387
chronic	T079	C0205191
ER stress	T049	C3178870
apoptosis	T043	C0162638
pancreas	T023	C0030274
liver	T023	C0023884
indicated	T033	C1444656
increased	T081	C0205217
levels	T080	C0441889
CHOP mRNA	T114	C0035696
increased	T081	C0205217
JNK	T044	C1150587
Caspase-3	T044	C1150132
rats	T015	C0034721
high-fat	T061	C0521974
fructose diets	T061	C1445913
study	T062	C2603343
experimental	T080	C1517586
support	T077	C1521721
high-fructose diet	T061	C1445913
equally	T080	C0205163
causing	T169	C0678227
metabolic disorders	T047	C0025517
Immature	T080	C0205252
stages	T079	C1306673
larval	T204	C0562676
chaetotaxy	T090	C1515222
Notofairchildia stenygros	T204	C1082670
Diptera	T204	C0012578
Psychodidae	T204	C0033888
Bruchomyiinae	T204	C1082670
Bruchomyiinae	T204	C1082670
plesiomorphic subfamily	T185	C1711207
Psychodidae	T204	C0033888
members	T071	C1551338
primitive	T080	C0205225
living	T078	C0376558
Diptera	T204	C0012578
Bruchomyiinae	T204	C1082670
no	T033	C1513916
medical	T169	C0205476
importance	T080	C3898777
evolutionary	T045	C0015219
significance	T078	C0750502
sister group	T169	C0008903
Phlebotominae	T204	C1123010
species	T185	C1705920
subfamily	T185	C1711207
natural environment	T082	C0557745
adults	T204	C0563200
immature	T080	C0205252
stages	T079	C1306673
flies	T204	C0012578
egg	T204	C0562677
larvae	T204	C0562676
pupae	T204	C0034120
Notofairchildia stenygros	T204	C1082670
nomenclatural notes	T170	C0600281
larval	T204	C0562676
chaetotaxy	T090	C1515222
scanning electron microscopy	T059	C0026020
SEM	T059	C0026020
optic microscopy	T059	C0596569
morphology	T080	C0332437
immature	T080	C0205252
Nt. stenygros	T204	C1082670
Bruchomyiinae	T204	C1082670
Psychodidae	T204	C0033888
species	T185	C1705920
species	T185	C1705920
Phlebotominae	T204	C1123010
similar	T080	C2348205
Bruchomyiinae	T204	C1082670
Results	T033	C0683954
study	T062	C2603343
morphological	T082	C0543482
differences	T080	C1705242
immature	T080	C0205252
stages	T079	C1306673
Bruchomyiinae	T204	C1082670
Phlebotominae	T204	C1123010
abdominal	T029	C0000726
pseudopods	T026	C0033827
microtrichia	T023	C0018494
cephalic	T082	C0205096
integument	T022	C0037267
larvae	T204	C0562676
Phlebotominae	T204	C1123010
morphological	T082	C0543482
differences	T080	C1705242
immature	T080	C0205252
stages	T079	C1306673
members	T071	C1551338
subfamilies	T185	C1711207
findings	T033	C0243095
molecular studies	T059	C2236970
Bruchomyiinae	T204	C1082670
Phlebtominae	T204	C1704307
evolutionarily	T045	C0015219
not closely related	T078	C1546988
Notofairchildia stenygros	T204	C1082670
fourth	T081	C0205438
species	T185	C1705920
Bruchomyiinae	T204	C1082670
immature	T080	C0205252
stages	T079	C1306673
clinical results	T034	C0456984
ThermoCool® SmartTouch® Surround Flow catheter	T074	C0490683
Biosense Webster ThermoCool(®) SmartTouch(®) Surround Flow (STSF) catheter	T074	C0490683
ablation	T061	C0547070
catheter	T074	C0085590
Surround Flow	T042	C0232177
SF	T042	C0232177
technology	T090	C0039421
quantify	T081	C1709793
tissue	T024	C0040300
contact	T169	C0332158
ThermoCool(®) SF catheter	T074	C0490683
Procedure	T061	C0087111
data	T078	C1511726
ablation procedures	T061	C0547070
STSF catheter	T074	C0490683
database	T170	C0242356
procedures	T061	C0087111
SF catheter	T074	C0490683
STSF procedure	T061	C0087111
procedure type	T185	C0455713
operator	T098	C1705274
experience	T041	C0596545
patient age	T032	C0001779
gender	T032	C0079399
groups	UnknownType	C0681860
patient age	T032	C0001779
gender	T032	C0079399
procedure type	T185	C0455713
Procedure duration	T079	C1442476
groups	UnknownType	C0681860
IQR	T081	C1711350
fluoroscopy duration	T079	C4029016
shorter	T081	C1806781
STSF group	UnknownType	C0681860
IQR	T081	C1711350
No complication	T033	C4032686
STSF group	UnknownType	C0681860
Complications	T046	C0009566
cases	T077	C1706256
SF group	UnknownType	C0681860
pericardial effusion	T047	C0031039
drainage	T061	C0013103
permanent	T079	C0205355
pacing	T061	C0199640
Complete procedural success	T033	C3897822
cases	T077	C1706256
STSF group	UnknownType	C0681860
cases	T077	C1706256
SF group	UnknownType	C0681860
failure	T066	C0086138
acute	T079	C0205178
complication	T046	C0009566
STSF group	UnknownType	C0681860
STSF catheter	T074	C0490683
effective	T080	C1704419
treating	T169	C1522326
arrhythmias	T033	C0003811
SF catheter	T074	C0490683
safety	T068	C0036043
efficacy	T080	C1280519
Low birth weight	T033	C0024032
features	T080	C2348519
neuroticism	T048	C1842981
mood disorder	T048	C0525045
participants	T098	C0679646
UK	T083	C0041700
Biobank	T093	C0206512
cohort	T098	C0599755
Low birth weight	T033	C0024032
risk	T078	C0035647
affective disorders	T048	C0001723
major depressive disorder	T048	C1269683
MDD	T048	C1269683
studies	T062	C2603343
investigating	T169	C1292732
associations	T080	C0439849
birth weight	T032	C0005612
bipolar disorder	T048	C0005586
BD	T048	C0005586
personality traits	T033	C0233849
predispose	T032	C0220898
affective disorders	T048	C0001723
neuroticism	T048	C1842981
cohorts	T098	C0599755
assess	T052	C1516048
very low birth weight	T184	C0282666
low birth weight	T033	C0024032
associated with	T080	C0332281
higher neuroticism	T033	C0564512
scores	T081	C0449820
assessed	T052	C1516048
middle age	T079	C0026062
lifetime history	T032	C0598779
MDD	T048	C1269683
BD	T048	C0005586
confounding factors	T169	C0009673
Retrospective	T080	C1514923
cohort study	T081	C0009247
baseline	T081	C1442488
data	T078	C1511726
UK	T083	C0041700
Biobank	T093	C0206512
participants	T098	C0679646
mental health	T041	C0025353
birth weight	T032	C0005612
data	T078	C1511726
outcomes	T169	C1274040
MDD	T048	C1269683
BD	T048	C0005586
neuroticism	T048	C1842981
assessed	T052	C1516048
Eysenck Personality Inventory Neuroticism scale - Revised	T170	C0034394
EPIN-R	T170	C0034394
normal birth weight	T033	C0456136
very low	T184	C0282666
low birth weight	T033	C0024032
higher neuroticism	T033	C0564512
scores	T081	C0449820
increased	T081	C0205217
MDD	T048	C1269683
BD	T048	C0005586
associations	T080	C0439849
birth weight	T032	C0005612
category	T170	C0683312
MDD	T048	C1269683
higher neuroticism	T033	C0564512
findings	T033	C0683954
intrauterine	T029	C0694756
programming	T038	C1720850
role	T077	C1705810
lifetime	T079	C4071830
vulnerability	T033	C1821973
affective disorders	T048	C0001723
DNA annealing	T045	C0920681
Redβ	T116	C0766456
homologous recombination	T045	C0599773
intra- and inter-molecular interactions	UnknownType	C0678593
Single strand annealing proteins	T116	C0033684
SSAPs	T116	C0033684
Redβ	T116	C0766456
homologous recombination	T045	C0599773
annealing complementary DNA strands	T114	C0006556
C-terminally truncated	T044	C1514568
Redβ	T116	C0766456
annealing	T045	C0920681
nucleoprotein filament formation	T045	C1158503
homologous recombination	T045	C0599773
Mutations	T045	C0026882
C-terminal domain	T087	C1514562
single	T114	C0012935
double stranded	T114	C0311474
ss	T114	C0012935
ds	T114	C0311474
recombination	T045	C0034865
assays	T059	C0005507
Mutations	T059	C0012878
critical amino acids	T116	C0002520
dsDNA	T114	C0311474
recombination	T043	C1158522
ssDNA	T114	C0012935
dsDNA recombination	T043	C1158522
dsDNA recombination	T043	C1158522
recombination	T043	C1158522
co-immunoprecipitation experiments	T059	C1449705
dsDNA recombination function	T043	C1158522
Redα	T116	C0033684
Redβ	T116	C0766456
protein-protein interaction	T044	C0872079
C-terminal domain	T087	C1514562
N-terminus	T087	C1514562
nucleoprotein filament formed	T045	C1158503
C-terminally truncated	T044	C1514568
Redβ	T116	C0766456
C-terminal function	T044	C1149341
interaction	T045	C1511658
functional	T169	C0205245
filaments	T026	C0025979
C-terminal function	T044	C1149341
Redβ	T116	C0766456
host factor interaction	T043	C1659605
Red recombination	T045	C0599773
Redβ	T116	C0766456
RAD52	T116	C0663124
SSAPs	T116	C0033684
Multi-drug-resistant	T032	C0242640
Acinetobacter calcoaceticus-Acinetobacter baumannii complex	T007	C2828037
infection	T046	C3714514
outbreak	T067	C0012652
dogs	T015	C0012984
cats	T015	C0007450
veterinary hospital	T073	C0019996
Acinetobacter calcoaceticus-Acinetobacter baumannii complex	T007	C2828037
severe	T080	C0205082
outbreaks	T067	C0012652
humans	T016	C0086418
increasingly	T169	C0442805
reported	T058	C0700287
animals	T008	C0003062
retrospective study	T062	C0035363
severe	T080	C0205082
outbreak	T067	C0012652
dogs	T015	C0012984
cats	T015	C0007450
multidrug resistant member	T007	C4076168
Acinetobacter calcoaceticus-Acinetobacter baumannii complex	T007	C2828037
veterinary hospital	T073	C0019996
study	T062	C2603343
included	T169	C0332257
dogs	T015	C0012984
cats	T015	C0007450
Acinetobacter calcoaceticus-Acinetobacter baumannii complex bacteria	T007	C2828037
isolated	T169	C0205409
urine	T031	C0042036
animals	T008	C0003062
respiratory tract	T022	C0035237
tissues	T024	C0040300
blood	T031	C0005767
most	T081	C0205393
common	T081	C0205214
infection	T046	C3714514
associated findings	T033	C0449380
included	T169	C0332257
fever	T184	C0015967
purulent discharge	T184	C0333274
endotracheal tubes	T074	C0336630
hypotension	T033	C0020649
neutropaenia	T047	C0221023
Infection	T046	C3714514
pneumonia	T047	C0032285
urinary tract infection	T047	C0042029
cellulitis	T046	C0007642
sepsis	T047	C0243026
Infection	T046	C3714514
transmitted	T046	C0242781
intensive care unit	T073	C0021708
animals	T008	C0003062
initially	T079	C0205265
hospitalised	T058	C0184666
mortality rate	T081	C0205848
animals	T008	C0003062
higher	T080	C0205250
respiratory infection	T047	C0035243
compared	T052	C1707455
infections	T046	C3714514
environmental	T082	C0014406
cleaning	T052	C1947930
disinfection	T061	C0012683
staff education	T065	C0588974
personal hygiene	T056	C0564673
antisepsis	T061	C0003424
decreased	T081	C0205216
infection	T046	C3714514
incidence	T081	C0021149
Health care	T078	C0018684
associated	T080	C0332281
outbreaks	T067	C0012652
multidrug resistant	T032	C0242640
Acinetobacter calcoaceticus-Acinetobacter baumannii complex	T007	C2828037
dogs	T015	C0012984
cats	T015	C0007450
highly	T080	C0205250
fatal	T080	C1302234
difficult	T080	C0332218
eradicate	T061	C2728502
monitoring	T058	C1283169
antiseptic	T121	C3536839
techniques	T169	C0449851
antibiotic	T195	C0003232
use	T169	C0457083
crystal form	T104	C0444626
unexpectedly results	T033	C0243095
interwoven packing networks	T116	C1510464
pseudo-translational symmetry	T082	C1254362
Nonribosomal peptide synthetases	T116	C0535847
NRPSs	T116	C0535847
multimodular enzymes	T116	C0014442
synthesize	T052	C1883254
myriad	T081	C0439064
diverse molecules	T167	C0567416
Tailoring domains	T087	C1514562
NRPSs	T116	C0535847
nonribosomal peptide products	T116	C0030956
Linear gramicidin synthetase	T116	C0018160
contains	T052	C2700400
formylation	T044	C1159286
tailoring domain	T087	C1514562
initiation module	T077	C1709061
F-A	T044	C1159286
PCP	T087	C1514562
F-A	T044	C1159286
di-domain	T087	C1514562
crystal form	T104	C0444626
solvent	T130	C0037638
channels	T082	C0439799
no density	T081	C0178587
Asub subdomain	T087	C1514562
packing	T052	C2828395
removing	T052	C1883720
Asub subdomain	T087	C1514562
F-A	T044	C1159286
sub	T087	C1514562
crystal	T104	C0444626
PCP domain	T087	C1514562
crystal	T104	C0444626
original packing network	T116	C1510464
second network	T116	C1510464
packing	T052	C2828395
original network	T116	C1510464
solvent	T130	C0037638
channels	T082	C0439799
space group of the crystal	T104	C0444626
Folate	T109	C0178638
single cell screening	T059	C0597452
surface enhanced Raman microimaging	T059	C0037815
nanotechnology	T090	C0872323
biomedical settings	T062	C0005540
early cancer diagnosis	T060	C2350269
cancer cells	T025	C0334227
expression	T045	C0597360
plasma membrane	T026	C0007603
molecular receptors	T091	C1513401
assessing the stage of development of the disease	T058	C3650728
single cell screening	T059	C0597452
Surface Enhanced Raman Scattering (SERS) microimaging	T059	C0037815
SERS	T059	C0037815
SERS-labelled	T059	C0037815
nanovector	T090	C0872323
biofunctionalization	T078	C0870589
gold nanoparticles	T073	C1721060
folic acid	T109	C0016410
treating the cells	T025	C0007634
nanovector	T090	C0872323
distinguish three different cell populations	T059	C0596289
different cell lines	T025	C0007600
cancer HeLa	T025	C0018873
PC-3	T050	C3890720
normal HaCaT lines	T025	C0022567
expressions	T045	C0597360
folate binding proteins	T116	C2955669
nanovector	T090	C0872323
binds much more efficiently	T052	C1145667
cancer cell lines	T025	C0334227
SERS	T059	C0037815
cancer cells	T025	C0334227
single cell diagnostics	T059	C0597452
potentially	T080	C3245505
theranostics	T091	C4046052
Self-reported	T062	C2700446
occupational injuries	T037	C0521168
industrial	T057	C0021267
beef	T015	C0175923
slaughterhouse	T073	C0000715
workers	T098	C1527116
Midwestern United States	T083	C0026081
workers	T098	C1527116
meatpacking facilities	T092	C0025019
United States	T083	C0041703
high rates	T081	C1521828
occupational injury	T037	C0521168
injury	T037	C3263723
research	T062	C0035168
research indicates	T062	C0242481
underreporting	T058	C0700287
injury rates	T033	C1822478
industry	T057	C0021267
injury rates	T033	C1822478
occupational injury	T037	C0521168
meatpacking	T092	C0025019
workers	T098	C1527116
cross-sectional study	T062	C0010362
workers	T098	C1527116
industrial beefpacking plant	T092	C0025019
Nebraska	T083	C0027523
United States	T083	C0041703
workers	T098	C1527116
injury	T037	C3263723
self-reported	T062	C2700446
injury	T037	C3263723
annual incidence rates	T081	C1708485
self-reported	T062	C2700446
injuries	T037	C3263723
OSHA	T093	C0041731
formula	T170	C0489829
industry-wide data	T078	C1511726
psychological distress	T048	C0815107
Kessler-6 scale	T170	C4300240
distress	T033	C0231303
associated with	T080	C0332281
occupational injury	T037	C0521168
injury	T037	C3263723
workers	T098	C1527116
occupational injuries	T037	C0521168
job transfer	UnknownType	C0681128
restriction during	T079	C0347984
annual incidence rate	T081	C1708485
injuries	T037	C3263723
workers	T098	C1527116
injuries	T037	C3263723
plant	T073	C0000715
injuries	T037	C3263723
injuries	T037	C3263723
metal mesh	T074	C0181807
sleeves	T074	C0183336
metal mesh	T074	C0181807
gloves	T073	C0441051
associated with	T080	C0332281
injury	T037	C3263723
carbon	T196	C0007009
steel	T122	C0038239
knife	T073	C1706313
associated with	T080	C0332281
moderate and severe	T080	C0205556
injury	T037	C3263723
self-reported	T062	C2700446
occupational injury	T037	C0521168
psychological distress	T048	C0815107
Self-reported	T062	C2700446
incidence rate	T081	C1708485
severe	T080	C0205082
injury	T037	C3263723
industry estimates	T081	C0750572
self-reports	T062	C2700446
injury prevention	T061	C0150638
Effect	T080	C1280500
l-Arginine	T116	C0003765
Dural Healing	T040	C0043240
Induced	T169	C0205263
Dural	T023	C0013313
Defect	T169	C1457869
Rat	T015	C0034693
Model	T075	C0026339
Incomplete	T080	C0205257
repair	T040	C0043240
dura mater	T023	C0013313
result	T169	C1274040
numerous	T081	C0439064
complications	T046	C0009566
cerebrospinal fluid leakage	T047	C0023182
meningitis	T047	C0025289
accurate	T080	C0443131
repair	T040	C0043240
dura mater	T023	C0013313
essential	T080	C0205224
effect	T080	C1280500
systemic	T169	C0205373
local	T082	C0205276
supplementation	T169	C2348609
l-arginine	T116	C0003765
dural healing	T040	C0043240
male	T032	C0086582
Wistar rats	T015	C0034716
divided	T169	C0332849
control	T096	C0009932
local	T082	C0205276
systemic	T169	C0205373
l-arginine	T116	C0003765
groups	T078	C0441833
rats	T015	C0034716
group	T078	C0441833
experimental incision	T061	C0184898
lumbar segment of the dura mater	T029	C2330954
cerebrospinal fluid leakage	T047	C0023182
induced	T169	C0205263
group	T078	C0441833
divided	T169	C0332849
subgroups	T185	C1515021
weeks	T079	C0439230
rats	T015	C0034716
killed	T058	C0015187
damaged	T169	C1883709
segments	T082	C0441635
dura	T023	C0013313
separated	T080	C0443299
histologically	T169	C0205462
dural healing	T040	C0043240
indicators	T169	C1522602
cell types	T025	C0007634
granulation tissue	T024	C0018180
formation	T169	C1522492
collagen	T116	C0009325
deposit	T169	C0333562
vascularization	T169	C0042382
compared	T052	C1707455
groups	T078	C0441833
systematic	T169	C0220922
supplementation	T169	C2348609
l-arginine	T116	C0003765
significant	T078	C0750502
effect	T080	C1280500
dural healing	T040	C0043240
compared	T052	C1707455
control group	T096	C0009932
week	T079	C0439230
granulation	T024	C0018180
formation	T169	C1522492
increased	T081	C0205217
weeks	T079	C0439230
collagen	T116	C0009325
deposition	T169	C0333562
neovascularization	T046	C0027686
different	T080	C1705242
compared	T052	C1707455
control group	T096	C0009932
comparison	T052	C1707455
different	T080	C1705242
groups	T078	C0441833
weeks	T079	C0439230
maximum	T081	C0806909
changes	T169	C0392747
healing	T040	C0043240
indicators	T169	C1522602
observed	T169	C1441672
systemic	T169	C0205373
group	T078	C0441833
variations	T080	C0205419
control group	T096	C0009932
systemic	T169	C0205373
supplementation	T169	C2348609
l-arginine	T116	C0003765
accelerate	T169	C0521110
dural healing	T040	C0043240
increasing	T169	C0442808
level	T080	C0441889
granulation tissue	T024	C0018180
formation	T169	C1522492
collagen	T116	C0009325
deposition	T169	C0333562
vascularization	T169	C0042382
Birth Preparedness and Complication Readiness Practice	T058	C1254363
Associated	T080	C0439849
Factors	T169	C1521761
Pregnant Women	T098	C0033011
Northwest Ethiopia	T083	C0015024
birth preparedness and complication readiness	T058	C1254363
BPCR	T058	C1254363
plan	T169	C1301732
maternal mortality	T081	C0024923
study	T062	C2603343
assess	T058	C0184514
status	T080	C0449438
BPCR	T058	C1254363
associated	T080	C0439849
factors	T169	C1521761
pregnant women	T098	C0033011
South Wollo	T083	C0015024
Northwest Ethiopia	T083	C0015024
pregnant women	T098	C0033011
Data	T078	C1511726
interviewer	T097	C0021821
administered questionnaire	T170	C0034394
analyzed	T062	C0936012
computer program	T073	C0037585
SPSS version 20.00	T170	C0333052
Results	T169	C1274040
Pregnant women	T098	C0033011
prepared	T033	C4082130
elements	T077	C3812827
BPCR	T058	C1254363
Pregnant women	T098	C0033011
danger signs	T184	C0037088
pregnancy	T040	C0032961
delivery	T040	C0005615
postnatal period	T079	C0871109
Women	T098	C0043210
secondary education	T170	C0683860
CI	T081	C0009667
prepared	T033	C4082130
illiterates	T033	C0020899
Women	T098	C0043210
lifetime history	T032	C0598779
stillbirth	T033	C0595939
attending	T169	C1999232
ANC	T058	C0033052
child	T100	C0008059
pregnancy	T040	C0032961
participating	T169	C0679823
community	T096	C0009462
BPCR	T058	C1254363
group discussion	T054	C0237576
male	T032	C0086582
partner	T099	C0682323
BPCR	T058	C1254363
counseling	T058	C0010210
ANC	T058	C0033052
follow-up	T058	C1522577
prepared	T033	C4082130
Conclusions	T078	C1707478
BPCR	T058	C1254363
health communication	T058	C1512347
partner	T099	C0682323
BPCR	T058	C1254363
counseling	T058	C0010210
Fluoranthene	T109	C0060514
degradation	T070	C0005482
binding	T044	C1167622
mechanism	T169	C0441712
study	T062	C2603343
active-site	T169	C0205681
structure	T082	C0678594
ring-hydroxylating dioxygenase	T116	C0599874
Microbacterium paraoxydans JPM1	T007	C4153571
study	T062	C2603343
gram-positive fluoranthene-degrading bacterial	T007	C0018154
strain	T001	C1518614
isolated	T169	C0205409
crude oil	T109	C0031264
Dagang Oilfield	T070	C3179127
identified	T080	C0205396
Microbacterium paraoxydans JPM1	T007	C4153571
analysis	T062	C0936012
16S rDNA	T114	C3537372
sequence	T086	C0004793
days	T079	C0439228
incubation	T059	C1439852
strain	T001	C1518614
JPM1	T007	C4153571
initial	T079	C0205265
amount	T081	C1265611
fluoranthene	T109	C0060514
metabolites	T123	C0870883
9-fluorenone-1-carboxylic acid	T123	C0574031
9-fluorenone	T109	C0050227
phthalic acid	T109	C0070968
benzoic acid	T109	C0053225
culture solution	T130	C0010454
gene sequence	T086	C0004793
encoding	T052	C2700640
aromatic-ring-hydroxylating dioxygenase	T116	C0599874
amplified	T045	C0017256
strain	T001	C1518614
JPM1	T007	C4153571
PCR	T063	C0032520
protein sequence	T087	C0002518
homology modeling method	T063	C1512489
crystal structure	T104	C0444626
dioxygenase	T116	C0599874
interaction	T169	C1704675
mechanism	T169	C0441712
fluoranthene	T109	C0060514
active site	T169	C0205681
dioxygenase	T116	C0599874
simulated	T062	C0679083
analyzed	T062	C0936012
molecular docking	T063	C3494273
degrading	T070	C0005482
pathway	T044	C1704259
fluoranthene	T109	C0060514
strain	T001	C1518614
JPM1	T007	C4153571
metabolites	T123	C0870883
interaction analyses	T081	C0237688
thermodynamic analysis	T062	C0936012
strain	T001	C1518614
JPM1	T007	C4153571
high	T080	C0205250
tolerance	T080	C1704410
fluoranthene	T109	C0060514
influence	T077	C4054723
fluoranthene	T109	C0060514
bacterial	T007	C0004611
growth	T040	C0018270
negligible	T080	C0332269
concentrations	T081	C1446561
study	T062	C2603343
strain	T001	C1518614
JPM1	T007	C4153571
potential	T080	C3245505
study	T062	C2603343
bioremediation	T069	C0598015
polycyclic aromatic hydrocarbon	T109	C0032458
PAH	T109	C0032458
contaminated	T169	C0205279
sites	T082	C0205145
Ultrasonography	T060	C0041618
acute appendicitis	T047	C0003615
physical examination	T058	C0031809
laboratory support	T059	C0022885
diagnosis	T033	C0011900
acute appendicitis	T047	C0003615
clinical practice	T057	C0205897
negative appendectomy	T061	C0003611
rate	T081	C1521828
ultrasonography	T060	C0041618
US	T060	C0041618
reliable	T170	C3858758
diagnostic method	T060	C0086143
atypical	T080	C0205182
presentation	T078	C0449450
rule out	T169	C0332196
differential diagnoses	T060	C0011906
publications	T073	C0034036
multidetector computed tomography	T060	C3179130
CT	T060	C3179130
false negative findings	T034	C0205558
operation	T061	C0543467
Extensive	T080	C0205231
uncritical application	T061	C0441485
children	T100	C0008059
radiation exposure	T037	C0418228
inadequate	T080	C0205412
performance	T052	C1882330
US	T060	C0041618
egocentric	T033	C0564559
economic	T169	C0013557
preponderance	T081	C0220900
US	T060	C0041618
CT	T060	C3179130
acute appendicitis	T047	C0003615
US with graded compression	T060	C0041618
diagnosing	T033	C0011900
acute appendicitis	T047	C0003615
visual	T169	C0234621
arousal	T041	C0003808
fostering	T056	C0242298
clinical medicine	T091	C0008964
Mesenchymal stem cells	T025	C1257975
enhance	T052	C2349975
oncolytic	T080	C1518581
effect	T080	C1280500
Newcastle disease virus	T005	C0027984
glioma	T191	C0017638
cells	T025	C0007634
glioma	T191	C0017638
stem cells	T025	C0038250
secretion	T038	C0036536
TRAIL	T116	C0385242
Newcastle disease virus	T005	C0027984
NDV	T005	C0027984
avian paramyxovirus	T005	C0206540
exerts	T040	C0015264
oncolytic	T080	C1518581
effects	T080	C1280500
cancer cells	T025	C0334227
Mesenchymal stem cells	T025	C1257975
MSCs	T025	C1257975
tumor growth	T191	C0598934
deliver	T169	C1705822
anti-tumor agents	T109	C0003392
experimental	T080	C1517586
glioblastoma	T191	C0017636
GBM	T191	C0017636
effects of	T080	C1704420
NDV	T005	C0027984
infected	T033	C0439663
MSCs	T025	C1257975
sources	T033	C0449416
glioma	T191	C0017638
cells	T025	C0007634
glioma	T191	C0017638
stem cells	T025	C0038250
GSCs	T025	C0038250
mechanisms	T169	C0441712
effects	T080	C1280500
glioma	T191	C0017638
cell lines	T025	C0085983
A172	T025	C0085983
U87	T025	C0085983
primary	T080	C0205225
GSCs	T025	C0038250
generated	T052	C3146294
GBM	T191	C0017636
tumors	T191	C0027651
study	T062	C0681814
MSCs	T025	C1257975
derived	T080	C1441547
bone marrow	T024	C0005953
adipose tissue	T024	C0001527
umbilical cord	T018	C0041633
infected	T033	C0439663
NDV	T005	C0027984
MTH-68/H	T061	C0965740
ability	T032	C0085732
cells	T025	C0007634
deliver	T169	C1705822
virus	T005	C0042776
glioma	T191	C0017638
cell lines	T025	C0085983
GSCs	T025	C0038250
effects of	T080	C1704420
NDV	T005	C0027984
infected	T033	C0439663
MSCs	T025	C1257975
cell death	T043	C0007587
stemness	T080	C0205556
self-renewal	T043	C1155711
GSCs	T025	C0038250
examined	T033	C0332128
mechanisms	T169	C0441712
involved	T169	C1314939
cytotoxic	T169	C1511636
effects of	T080	C1704420
NDV	T005	C0027984
infected	T033	C0439663
MSCs	T025	C1257975
influence	T077	C4054723
radiation sensitivity	T032	C0034537
GSCs	T025	C0038250
examined	T033	C0332128
NDV	T005	C0027984
induced	T169	C0205263
dose-dependent	T081	C1512045
cell death	T043	C0007587
glioma	T191	C0017638
cells	T025	C0007634
low	T080	C0205251
level	T080	C0441889
apoptosis	T043	C0162638
inhibition	T052	C3463820
self-renewal	T043	C1155711
GSCs	T025	C0038250
MSCs	T025	C1257975
derived	T080	C1441547
bone marrow	T024	C0005953
adipose	T024	C0001527
umbilical cord	T018	C0041633
infected	T033	C0439663
NDV	T005	C0027984
delivered	T169	C1705822
virus	T005	C0042776
co-cultured	T059	C0282547
glioma	T191	C0017638
cells	T025	C0007634
GSCs	T025	C0038250
Conditioned medium	T130	C0162518
NDV	T005	C0027984
infected	T033	C0439663
MSCs	T025	C1257975
induced	T169	C0205263
higher	T080	C0205250
level	T080	C0441889
apoptosis	T043	C0162638
tumor cells	T025	C0597032
compared	T052	C1707455
apoptosis	T043	C0162638
induced	T169	C0205263
direct infection	T047	C1707758
similar	T080	C2348205
virus titers	T081	C2713348
results	T033	C0683954
suggest	T078	C1705535
factor(s)	T169	C1521761
secreted	T043	C1327616
infected	T033	C0439663
MSCs	T025	C1257975
sensitized	T025	C0312864
glioma	T191	C0017638
cells	T025	C0007634
cytotoxic	T169	C1511636
effects of	T080	C1704420
NDV	T005	C0027984
identified	T080	C0205396
TRAIL	T116	C0385242
mediator	T080	C0205556
cytotoxic	T169	C1511636
effects of	T080	C1704420
infected	T033	C0439663
MSCs	T025	C1257975
demonstrated	T080	C0205556
TRAIL	T116	C0385242
NDV	T005	C0027984
induction	T169	C0205263
cell death	T043	C0007587
glioma	T191	C0017638
cells	T025	C0007634
GSCs	T025	C0038250
conditioned	T080	C0348080
medium	T081	C0439536
infected	T033	C0439663
MSCs	T025	C1257975
enhanced	T052	C2349975
GSCs	T025	C0038250
γ-radiation	T070	C0017011
NDV	T005	C0027984
infected	T033	C0439663
umbilical cord	T018	C0041633
derived	T080	C1441547
MSCs	T025	C1257975
novel	T080	C0205314
effective	T080	C1704419
therapeutic	T169	C0302350
approach	T082	C0449445
targeting	T169	C1521840
GSCs	T025	C0038250
GBM	T191	C0017636
tumors	T191	C0027651
γ-radiation	T070	C0017011
Importance	T080	C3898777
Ecological Factors	T077	C0870460
Colony	T078	C0441833
Handling	T033	C1832073
Optimizing	T052	C2698650
Health Status	T080	C0018759
Apiaries	T073	C3273359
Mediterranean	T098	C0240321
Ecosystems	T070	C0162358
analyzed	T062	C0936012
apiaries	T073	C3273359
natural environments	T082	C0557745
Mediterranean	T098	C0240321
ecosystem	T070	C0162358
Madrid	T083	C0037747
central Spain	T083	C0037747
understand	T041	C0162340
landscape	T082	C0870781
management	T170	C0680830
characteristics	T080	C1521970
influence	T077	C4054723
apiary	T073	C3273359
health	T078	C0018684
bee	T204	C0004923
long term	T079	C0443252
focused	T169	C1285542
criteria	T078	C0243161
habitat	T082	C0871648
quality	T080	C0332306
landscape	T082	C0870781
heterogeneity	T080	C0019409
climate	T070	C0008946
management	T170	C0680830
health	T078	C0018684
subcriteria	T078	C0243161
analytic hierarchy process	T062	C0035177
AHP	T062	C0035177
rank	T170	C0699794
relevance	T080	C2347946
Habitat	T082	C0871648
quality	T080	C0332306
relevance	T080	C2347946
beehive	T073	C3273359
management	T170	C0680830
habitat	T082	C0871648
quality	T080	C0332306
subcriteria	T078	C0243161
relevant	T080	C2347946
orographic diversity	T080	C1880371
elevation	T082	C0702240
range	T081	C1514721
important	T080	C3898777
plant	T002	C0032098
species	T185	C1705920
located	T082	C0332285
apiary	T073	C3273359
important	T080	C3898777
subcriteria	T078	C0243161
beehive	T073	C3273359
management	T170	C0680830
honey	T168	C0019906
production	T057	C0033268
apiary	T073	C3273359
location	T082	C0450429
altitude	T081	C0002349
wax	T122	C0004924
renewal	T169	C0205245
Temperature	T081	C0039476
subcriterion	T078	C0243161
climate	T070	C0008946
pathogen	T001	C0450254
Varroa	T204	C0323623
loads	T033	C0243095
significant	T078	C0750502
health	T078	C0018684
apiaries	T073	C3273359
best values	T081	C1299381
AHP	T062	C0035177
analysis	T062	C0936012
annual	T079	C0332181
honey	T168	C0019906
production	T057	C0033268
colony	T078	C0441833
productivity	T081	C0033269
elevation	T082	C0702240
range	T081	C1514721
orographic diversity	T080	C1880371
habitat	T082	C0871648
quality	T080	C0332306
apiaries	T073	C3273359
best value	T081	C1299381
beehive	T073	C3273359
management	T170	C0680830
best value	T081	C1299381
health	T078	C0018684
low	T080	C0205251
pathogen	T001	C0450254
load	T033	C0243095
low	T080	C0205251
average	T081	C1510992
number	T081	C0237753
viruses	T005	C0042776
results	T169	C1274040
importance	T080	C3898777
environmental factors	T077	C0870460
sanitary practices	T169	C0205245
apiary	T073	C3273359
health	T078	C0018684
honey	T168	C0019906
productivity	T081	C0033269
Chordoma dedifferentiation	T191	C1266174
proton beam therapy	T061	C2169187
case report	T170	C0007320
review of the literature	T170	C0282441
Chordoma	T191	C0008487
rare	T080	C0522498
invasive	T080	C0205281
bone tumor	T191	C0005967
neuraxis	T082	C1522496
primary	T080	C0205225
histological varieties	T191	C0027652
identified	T080	C0205396
conventional	T191	C0008487
chondroid	T191	C1266173
dedifferentiated	T191	C1266174
report	T170	C0684224
case	T077	C1706256
white	T098	C0007457
girl	T100	C0870604
conventional chordoma	T191	C0008487
treated	T033	C0332154
surgical resection	T061	C0015252
mixed	T169	C0205430
proton	T070	C0729603
photon beam therapy	T061	C3539769
recurrence	T067	C0034897
resection cavity	T020	C1515091
dedifferentiated morphology	T191	C1266174
recurrent tumor	T191	C0521158
express	T045	C1171362
brachyury	T116	C0170844
recently	T079	C0332185
identified	T080	C0205396
protein	T116	C0033684
specific	T080	C0205369
tissue	T024	C0040300
notochordal	T018	C0028439
origin	T079	C0439659
short	T081	C1806781
time period	T079	C1948053
radiation therapy	T061	C2169187
dedifferentiation	T043	C2248595
low dose	T081	C0445550
photons	T167	C0086805
rarity	T080	C0522498
dedifferentiated skull base chordomas	T191	C2164487
pediatric	T080	C1521725
patients	T101	C0030705
alert	T169	C3665546
clinicians	T097	C0871685
possibility	T033	C0332149
chordoma dedifferentiation	T191	C1266174
proton beam therapy	T061	C2169187
Volumetric absorptive microsampling	T060	C0430022
home	T082	C0442519
alternative	T077	C1523987
tool	T073	C0336791
monitoring	T058	C1283169
HbA1c	T116	C0019018
diabetes	T047	C0011847
patients	T101	C0030705
Microsampling techniques	T169	C0449851
blood collection	T060	C0005834
Dried blood spot (DBS) sampling	T059	C3178862
blood collection	T060	C0005834
heparinized capillaries	T074	C0184108
standard	T080	C1442989
techniques	T059	C0022885
Volumetric absorptive microsampling	T060	C0430022
VAMS	T060	C0430022
technique	T059	C0022885
volume	T081	C0449468
blood	T031	C0005767
tip	T080	C3282898
blood drop	T031	C0005767
study	T062	C2603343
HbA1c	T116	C0019018
monitoring	T058	C1283169
VAMS sampling	T060	C0430022
home	T082	C0442519
analysis	T062	C0936012
laboratory	T073	C0022877
Diabetic	T047	C0011847
patients	T101	C0030705
study	T062	C2603343
consultation	T058	C0009818
endocrinologist	T097	C0259863
venous	T031	C0444255
adults	T100	C0001675
capillary (children) sample	T031	C0444254
HbA1c	T116	C0019018
analysis	T062	C0936012
DBS	T059	C3178862
dried VAMS	T060	C0430022
home	T082	C0442519
laboratory	T073	C0022877
pediatric	T080	C1521725
patients	T101	C0030705
VAMS	T060	C0430022
consultation	T058	C0009818
analysis	T062	C0936012
wet VAMS	T060	C0430022
HbA1c	T116	C0019018
analyses	T062	C0936012
Tosoh HLC-723 G8 high-performance liquid chromatography (HPLC) analyzer	T074	C0179038
sampling	T060	C0430022
home	T082	C0442519
analysis	T062	C0936012
days	T079	C0439228
Results	T169	C1274040
HbA1c	T116	C0019018
VAMS	T060	C0430022
venous	T031	C0444255
capillary blood	T031	C0444254
hospital	T073	C0019994
concordance correlation coefficient	T081	C1707429
CCC	T081	C1707429
standard	T080	C1442989
DBS	T059	C3178862
HbA1c	T116	C0019018
results	T169	C1274040
wet VAMS	T060	C0430022
CCC	T081	C1707429
standard	T080	C1442989
blood samples	T031	C0178913
Patients	T101	C0030705
VAMS	T060	C0430022
DBS	T059	C3178862
easy	T033	C0332219
convenient	T080	C3831015
use	T169	C0457083
equipment	T073	C0014672
standard	T080	C1442989
clinical	T080	C0205210
laboratory	T073	C0022877
home	T082	C0442519
dried VAMS	T060	C0430022
DBS	T059	C3178862
monitoring	T058	C1283169
HbA1c	T116	C0019018
HbA1c	T116	C0019018
wet VAMS	T060	C0430022
capillary microsamples	T031	C0444254
Eyes	T023	C0015392
Mirror	T070	C0870904
Soul	T078	C1510643
Eye	T023	C0015392
Wrinkles	T190	C2729169
Reveal	T080	C0443289
Horse's	T015	C0019944
Emotional State	T041	C0935620
valid	T080	C2349099
indicators	T169	C1522602
emotional states	T041	C0935620
animal welfare science	T052	C0003061
investigated	T169	C1292732
horses	T015	C0019944
variation	T080	C0205419
expression	T080	C0700364
eye	T023	C0015392
wrinkles	T190	C2729169
contraction	T046	C1140999
inner eyebrow	T023	C0015420
reflects	T041	C0558058
emotional valence	T033	C0849912
horses	T015	C0019944
positive	T033	C1446409
negative	T033	C0205160
conditions	T080	C0348080
induce	T169	C0205263
positive	T033	C1446409
negative	T033	C0205160
emotional states	T041	C0935620
hypothesising	T078	C1512571
positive	T033	C1446409
emotions	T041	C0013987
reduce	T080	C0392756
negative	T033	C0205160
emotions	T041	C0013987
increase	T169	C0442805
eye	T023	C0015392
wrinkle	T190	C2729169
expression	T080	C0700364
horses	T015	C0019944
exposed	T080	C0332157
balanced	T169	C0205415
positive	T033	C1446409
grooming	T055	C0018249
food anticipation	T041	C0679106
negative	T033	C0205160
condition	T080	C0348080
food	T168	C0016452
competition	T054	C0679932
waving	T052	C0441655
plastic bag	T073	C3273359
condition	T080	C0348080
seconds	T079	C0457385
second	T079	C0457385
control phase	T079	C0205390
phases	T079	C0205390
pictures	T073	C0441468
eyes	T023	C0015392
horse	T015	C0019944
pictures	T073	C0441468
condition	T080	C0348080
phase	T079	C0205390
randomly selected	T052	C1707391
Pictures	T073	C0441468
random order	T080	C1705176
experimenters	T097	C0870526
blind	T062	C0150108
condition	T080	C0348080
phase	T079	C0205390
outcome measures	T081	C0086749
qualitative	T080	C0205556
impression	T080	C1998467
eyelid	T023	C0015426
shape	T082	C0332479
markedness	T080	C1706089
wrinkles	T190	C2729169
presence	T033	C0150312
eye white	T023	C0036410
number	T081	C0237753
wrinkles	T190	C2729169
angle	T082	C0205143
eyeball	T023	C0015392
highest	T080	C1522410
wrinkle	T190	C2729169
angle	T082	C0205143
decreased	T081	C0205216
grooming	T055	C0018249
increased	T081	C0205217
food	T168	C0016452
competition	T054	C0679932
compared	T052	C1707455
control phase	T079	C0205390
phases	T079	C0205390
food anticipation	T041	C0679106
plastic bag	T073	C3273359
condition	T080	C0348080
No effects	T080	C1301751
outcome measures	T081	C0086749
detected	T033	C0442726
measures	T081	C0079809
assess	T052	C1516048
eye	T023	C0015392
wrinkle	T190	C2729169
expression	T080	C0700364
measure	T081	C0079809
affected	T169	C0392760
conditions	T080	C0348080
horses	T015	C0019944
exposed to	T080	C0332157
Variation	T080	C0205419
eye	T023	C0015392
wrinkle	T190	C2729169
expression	T080	C0700364
provide	T168	C0359589
information	T078	C1533716
horse	T015	C0019944
welfare	T052	C0003061
validation	T062	C1519941
specific	T080	C0205369
measures	T081	C0079809
different	T080	C1705242
conditions	T080	C0348080
Effective	T080	C1704419
mercury(II)	T131	C0025424
bioremoval	T052	C1883720
aqueous solution	T121	C3255993
electrochemical determination	UnknownType	C0259857
mercury	T131	C0025424
elimination	T052	C1883720
agricultural	T090	C0001829
waste	T167	C0043045
Allium Cepa L	T002	C1262904
biomass	T081	C0005535
removed	T080	C0849355
mercury	T131	C0025424
pseudo-second order kinetics	T070	C0022702
Langmuir model	T170	C0876936
adequately	T080	C0205411
adsorption isotherm	T067	C1254366
maximum	T081	C0806909
mercury	T131	C0025424
adsorption	T059	C0001674
capacity	T081	C1516240
biomass	T081	C0005535
high	T080	C0205250
density	T081	C0178587
strong	T080	C0442821
mercury	T131	C0025424
chelating groups	T121	C0007974
economically	T169	C0013557
attractive	T080	C2346874
implementation	T052	C1708476
mercury	T131	C0025424
selective electrode	T059	C0201747
continuous	T078	C0549178
determination	T059	C1148554
real time	T079	C1550177
proposed	T080	C1553874
electrode	T073	C1705652
replaces	T078	C1550539
techniques	T169	C0449851
atomic absorption spectroscopy	T059	C0037806
real time	T079	C1550177
studies	T062	C2603343
perspective	T169	C0449851
removing	T052	C1883720
mercury(II)	T131	C0025424
contaminated water	T069	C0043056
environmental remediation	T069	C3853059
Modeling	T062	C0870071
nurse-patient assignments	T057	C0578393
patient acuity	T080	C3494263
travel	T056	C0040802
distance	T081	C0012751
metrics	T169	C0242485
Balancing	T169	C0205415
workload	T081	C0085122
nurses	T097	C0028661
hospital unit	T073	C0019988
satisfaction	T041	C0242428
safety	T068	C0036043
nurses	T097	C0028661
patients	T101	C0030705
balance	T169	C0205415
nurse	T097	C0028661
workloads	T081	C0085122
direct	T080	C1947931
patient care activities	T058	C0017313
indirect	T080	C0439852
patient care activities	T058	C0017313
non-patient care activities	T058	C1254363
shift	T169	C0333051
hospital unit	T073	C0019988
location	T082	C0450429
nurse's	T097	C0028661
assigned	T169	C1516050
patients	T101	C0030705
relative	T080	C0205345
resources	T078	C0035201
unit	T073	C0019988
important factors	T169	C1521761
achieving	T033	C1272277
workload	T081	C0085122
balance	T169	C0205415
hospitals	T073	C0019994
nurse	T097	C0028661
responsible	T033	C1273518
shift	T169	C0333051
assignment	T169	C1516050
patients	T101	C0030705
nurses	T097	C0028661
experience	T041	C0596545
past practices	T041	C0237607
nurse-patient assignment	T057	C0578393
process	T067	C1522240
manual process	T067	C1522240
nurse	T097	C0028661
sort	T052	C1947906
multiple decision criteria	T078	C0243161
time	T079	C0040223
methodology	T078	C3266812
balanced	T169	C0205415
nurse-patient workload assignments	T057	C0578393
proposed	T080	C1553874
methodology	T078	C3266812
scoring	T081	C0449820
metrics	T169	C0242485
developed	T169	C1527148
measures	T081	C0079809
available	T169	C0470187
hospital unit	T073	C0019988
demonstrated	T169	C0205245
complex scheduling	T080	C0205539
problem	T033	C0033213
methodology	T078	C3266812
scheduling	T080	C0205539
problem	T033	C0033213
hospital unit	T073	C0019988
approach	T082	C0449445
workforce	T169	C0024752
scheduling	T080	C0205539
problems	T033	C0033213
measures	T081	C0079809
workload	T081	C0085122
required	T169	C1514873
elements	T077	C1254372
work environment	T082	C0162579
variability	T077	C2827666
required	T169	C1514873
tasks	T057	C3540678
measurable	T169	C1513040
perception	T041	C0030971
relative	T080	C0205345
intensity	T080	C0522510
work elements	T077	C1254372
Effect of	T080	C1704420
alpha lipoic acid	T109	C0023791
in vitro	T080	C1533691
development	T040	C0678723
bovine	T015	C3667982
secondary preantral follicles	T023	C0737234
study	T062	C2603343
evaluate	T058	C0220825
in vitro	T080	C1533691
effect of	T080	C1704420
alpha lipoic acid	T109	C0023791
ALA	T109	C0023791
culture medium	T130	C0010454
development	T040	C0678723
bovine	T015	C3667982
secondary preantral follicles	T023	C0737234
Bovine	T015	C3667982
secondary preantral follicles	T023	C0737234
collected	T169	C1516698
divided	T169	C0332849
groups	T078	C0441833
size	T082	C0456389
in vitro	T080	C1533691
media	T130	C0010454
doses	T081	C0178602
ALA	T109	C0023791
genes expression	T045	C0017262
levels	T080	C0441889
follicle-stimulating hormone beta-subunit	T028	C1414828
FSHR	T028	C1414828
insulin-like growth factor	T028	C1334089
IGF-1	T028	C1334089
Activin	T028	C0017337
luteinizing hormone/choriogonadotropin receptor	T028	C1416843
bone morphogenetic protein receptor type IA	T028	C1332430
transforming growth factor beta receptor 1	T028	C1424583
growth differentiation factor 9	T028	C1333668
BCL2-associated X protein	T028	C0812198
BAX	T028	C0812198
C-Myc	T028	C0079068
real-time polymerase chain reaction	T063	C1709846
protein expression	T045	C1171362
levels	T080	C0441889
FSHR	T116	C0034806
IGF-1	T116	C0021665
BAX	T116	C0219474
Western blot analysis	T059	C0949466
results	T034	C1254595
in vitro	T080	C1533691
ALA	T109	C0023791
induced	T169	C0205263
significant	T078	C0750502
increase in the growth	T042	C1155901
development	T040	C0678723
secondary preantral follicles	T023	C0737234
culture	T059	C0430400
period	T079	C1948053
compared	T052	C1707455
control	T096	C0009932
FSHR	T028	C1414828
IGF-1	T028	C1334089
luteinizing hormone/choriogonadotropin receptor	T028	C1416843
bone morphogenetic protein receptor type IA	T028	C1332430
transforming growth factor beta receptor 1	T028	C1424583
growth differentiation factor 9	T028	C1333668
Activin A genes	T028	C0017337
upregulated	T044	C0041904
ALA	T109	C0023791
treated	T169	C1522326
follicles	T023	C0737234
compared	T052	C1707455
control	T096	C0009932
preapoptotic genes	T028	C0017337
BAX	T028	C0812198
C-Myc	T028	C0079068
downregulated	T044	C0013081
treated	T169	C1522326
follicles	T023	C0737234
compared	T052	C1707455
control	T096	C0009932
protein levels	T034	C0428479
FSHR	T116	C0034806
IGF-1	T116	C0021665
expressed	T045	C1171362
treated	T169	C1522326
follicles	T023	C0737234
compared	T052	C1707455
control	T096	C0009932
BAX protein	T116	C0219474
downregulated	T044	C0013081
treated	T169	C1522326
follicles	T023	C0737234
groups	T078	C0441833
ALA	T109	C0023791
culture medium	T130	C0010454
enhances	T052	C2349975
secondary preantral follicles	T023	C0737234
development	T040	C0678723
growth	T042	C1155901
proxies	T169	C1521761
cognitive reserve	T041	C2936352
evaluated	T058	C0220825
population	T098	C1257890
healthy	T080	C3898900
older adults	T098	C0001792
tools	T170	C1516602
estimate	T081	C0750572
individual's	T098	C0027361
cognitive reserve	T041	C2936352
CR	T041	C2936352
assessed	T052	C1516048
adequacy	T080	C0205410
CR	T041	C2936352
proxy	T169	C1521761
appropriate	T080	C1548787
estimate	T081	C0750572
CR	T041	C2936352
common	T081	C0205214
assessment	T058	C0220825
CR	T041	C2936352
proxies	T169	C1521761
literature	T170	C0023866
years of education	T081	C4054327
calculation	T052	C1441506
comprehensive	T080	C1880156
index	T170	C0918012
most significant	T080	C1299394
parameters	T033	C0449381
estimation	T041	C0680844
CR	T041	C2936352
CR	T041	C2936352
proxies	T169	C1521761
education	T065	C0013621
occupation	T090	C0028811
leisure activities	T056	C0023292
older adults	T098	C0001792
Regression analyses	T170	C0034980
indices	T170	C0918012
CR	T041	C2936352
ICR-standard	T170	C0918012
ICR-detailed	T170	C0918012
index	T170	C0918012
CR	T041	C2936352
ICR-standard	T170	C0918012
calculated	T052	C1441506
combination	T080	C0205195
common	T081	C0205214
measures	T081	C0079809
reserve	T041	C2936352
literature	T170	C0023866
number of schooling years	T081	C4054327
complexity	T080	C0439855
occupation	T090	C0028811
current	T079	C0521116
participation	T169	C0679823
stimulating	T070	C1948023
activities	T052	C0441655
ICR-detailed	T170	C0918012
calculated	T052	C1441506
most significant	T080	C1299394
parameters	T033	C0449381
initial	T079	C0205265
analyses	T062	C0936012
CR	T041	C2936352
highest level of education	T033	C4264309
combined	T080	C0205195
training courses	T065	C0040607
last	T080	C1517741
occupation	T090	C0028811
amount	T081	C1265611
participation	T169	C0679823
social	T054	C2371613
intellectual activities	T065	C0013652
comparison	T052	C1707455
indices	T170	C0918012
ICR-standard	T170	C0918012
ICR-detailed	T170	C0918012
associated with	T080	C0332281
greater	T081	C1704243
minimization	T080	C0392756
effects of	T080	C1704420
age	T032	C0001779
cognition	T041	C0009240
ICR-detailed	T170	C0918012
associated	T080	C0332281
minimization	T080	C0392756
ICR-standard	T170	C0918012
ICR-detailed	T170	C0918012
CR	T041	C2936352
great	T081	C0549177
importance	T080	C3898777
measuring	T080	C0444706
CR	T041	C2936352
proxies	T169	C1521761
clinical tool	T170	C1516602
comprehensive	T080	C1880156
accurate	T080	C0443131
estimation	T041	C0680844
CR	T041	C2936352
Discordance	T077	C3639994
pathology report	T170	C0807321
central pathology review	T060	C2347585
breast cancer	T191	C0006142
adjuvant treatment	T061	C0677850
Pathological	T169	C1521733
predictive factors	T170	C0683956
markers	T201	C0005516
breast cancer	T191	C0006142
adjuvant therapy	T061	C0677850
randomized clinical trials	T062	C0206034
variability	T077	C2827666
pathology report	T170	C0807321
central pathology review	T060	C2347585
discordance	T077	C3639994
rate	T081	C1521828
DR	T081	C1521828
inter-rater agreement	T081	C0870740
local	T082	C0205276
central	T082	C0205099
histopathological report	T170	C0684224
clinical	T080	C0205210
treatment decision	T033	C4061230
retrospective analysis	T062	C0035363
breast cancer tumors	T191	C1458155
local pathologists	T097	C0334866
reviewed	T080	C1709940
Pathology Division	T093	C0587487
European Institute of Oncology	T093	C1708333
inter-rater agreement	T081	C0870740
central pathology	T091	C0030664
Ki-67	T116	C0208804
grading	T170	C0441799
hormone receptors	T116	C0019929
ER	T116	C0034804
PgR	T116	C0034833
HER2/neu	T201	C1512413
Bland-Altman plots	T062	C0242481
Ki-67	T116	C0208804
ER	T116	C0034804
PgR	T116	C0034833
DR	T081	C1521828
ER	T116	C0034804
PgR	T116	C0034833
HER2	T116	C0069515
pathology specimens	T031	C0444061
Cancer Centers	T093	C1513817
reviewed	T080	C1709940
ER	T116	C0034804
CI	T081	C0009667
PgR	T116	C0034833
CI	T081	C0009667
Ki-67	T116	C0208804
CI	T081	C0009667
grading	T170	C0441799
CI	T081	C0009667
HER2	T116	C0069515
CI	T081	C0009667
DR	T081	C1521828
HER2	T116	C0069515
ER	T116	C0034804
PgR	T116	C0034833
Her2	T116	C0069515
ER	T116	C0034804
PgR	T116	C0034833
systemic	T169	C0205373
prescription	T058	C0033080
retrospective analysis	T062	C0035363
central pathological review	T060	C2347585
decision-making process	T058	C2364257
breast cancer	T191	C0006142
clinical trials	T062	C0008976
Implementing	T052	C1708476
Non-Invasive	T169	C0205303
Prenatal Diagnosis	T060	C0033053
NIPD	T060	C0033053
National Health Service Laboratory	T073	C0022877
Dominant	T169	C1527180
Recessive	T045	C0678943
Disorders	T047	C0012634
UK National Health Service regional genetics laboratory	T073	C0022877
NIPD	T060	C0033053
autosomal dominant	T045	C0443147
de novo	T078	C1515568
conditions	T080	C0348080
achondroplasia	T019	C0001080
thanataphoric dysplasia	T019	C0039743
Apert syndrome	T019	C0001193
paternal	T080	C0337493
mutation	T045	C0026882
exclusion	T169	C0680251
cystic fibrosis	T047	C0010674
bespoke tests	T060	C0683443
NIPD	T060	C0033053
risks	T033	C0035648
associated with	T080	C0332281
invasive testing	T060	C0430022
prenatal diagnosis	T060	C0033053
more	T081	C0205172
families	T099	C0015576
high	T080	C0205250
genetic risk	T081	C1517512
definitive	T079	C0443196
diagnosis	T033	C0011900
autosomal recessive diseases	T047	C0265388
complicated	T169	C0231242
predominance	T080	C0332251
maternal	T099	C0026591
mutant	T049	C0596988
allele	T028	C0002085
cell-free DNA	T114	C4289789
sample	T077	C2347026
variety	T077	C2346866
different	T080	C1705242
approaches	T082	C0449445
Validation	T062	C1519941
diagnostic	T169	C0348026
implementation	T052	C1708476
NIPD	T060	C0033053
congenital adrenal hyperplasia	T047	C0001627
CAH	T047	C0001627
complicated	T169	C0231242
presence	T033	C0150312
pseudogene	T028	C0033799
different	T080	C1705242
approach	T082	C0449445
assay	T059	C0005507
targeting	T169	C1521840
approximately	T080	C0332232
heterozygous	T032	C0019425
SNPs	T086	C0752046
CAH gene	T028	C1413861
CYP21A2	T028	C1413861
high-risk	T033	C0332167
parental	T099	C0030551
haplotypes	T032	C0018591
approach	T082	C0449445
inheritance	T081	C0242538
parental	T099	C0030551
alleles	T028	C0002085
identified	T080	C0205396
NIPD	T060	C0033053
measures	T081	C0079809
fetal	T018	C0015965
inheritance	T081	C0242538
parental	T099	C0030551
mutations	T045	C0026882
utility	T080	C3827682
NIPD	T060	C0033053
multi-disorder panel	T059	C0022885
autosomal recessive disease	T047	C0265388
testing	T169	C0039593
applicable	T080	C1706839
families	T099	C0015576
serious	T080	C0205404
genetic conditions	T047	C0019247
Silk fibroin	T121	C4050636
carrier system	T122	C0013161
delivery	T169	C1705822
fibrinogen	T116	C0016006
thrombin	T116	C0040018
coagulant	T121	C0009117
supplements	T169	C2348609
control	T169	C2587213
bleeding	T046	C0019080
interventions	T061	C0184661
traumatic injury	T037	C3263723
Hemostatic devices	T121	C0019120
delivering	UnknownType	C0677249
blood clotting	T046	C0302148
agents	T121	C0009117
fibrinogen	T116	C0016006
increasingly	T169	C0442808
efficacy	T080	C1280519
application	T058	C0185125
method	T170	C0025663
incorporate	T169	C0243126
coagulant	T121	C0009117
supplements	T169	C2348609
fibrinogen	T116	C0016006
thrombin	T116	C0040018
silk protein	T121	C4050636
sponges	T074	C0441126
coagulants	T121	C0009117
aqueous	T121	C0043047
silk	T116	C0074529
molding	T059	C0022885
freeze-drying	T059	C0016698
water annealing	T059	C0022885
combination	T080	C0205195
system	T169	C0449913
delivery	T169	C1705822
fibrinogen	T116	C0016006
hemostatic potential	T042	C0019116
Concentration ratios	T081	C1264681
silk	T116	C0074529
fibrinogen	T116	C0016006
thrombin	T116	C0040018
fibrin	T116	C0015982
polymeric	T104	C0032521
network	T169	C1882071
silk	T116	C0074529
spongy structure	T082	C0678594
interconnected	UnknownType	C0683595
silk	T116	C0074529
intact	T080	C0205266
network	T169	C1882071
mechanical characterization	T052	C1880022
fibrinogen-releasing	T169	C1283071
silk	T116	C0074529
sponges	T074	C0441126
induction	T169	C0205263
fibrinogen	T116	C0016006
polymerization	T067	C0314672
fibrin	T116	C0015982
network	T169	C1882071
reduced	T080	C0392756
permanent	T079	C0205355
deformation	T169	C0333067
fibrinogen	T116	C0016006
silk	T116	C0074529
sponges	T074	C0441126
fibrin	T116	C0015982
formation	T169	C1522492
linear	T082	C0205132
elastic behavior	T070	C0013764
Calcein-AM	T109	C0252016
PI	T109	C0033470
stainings	T130	C0038128
MTT assay	T062	C2986858
uniform	T080	C0205375
cell adhesion	T043	C0007577
surface	T082	C0205148
cytocompatibility	T080	C1524057
silk	T116	C0074529
fibrin	T116	C0015982
sponges	T074	C0441126
co-delivery	T169	C1705822
thrombin	T116	C0040018
fibrinogen	T116	C0016006
silk	T116	C0074529
carrier material	T122	C0013161
mechanically	T169	C0443254
robust	T080	C2986815
durable system	T080	C0205556
preserving	T169	C0728887
hemostatic features	T042	C0019116
coagulant substances	T121	C0009117
generation	T052	C3146294
hemostatic devices	T121	C0019120
natural killer cells	T025	C0022688
antitumor activity	T033	C0243095
epigenetic imprinting	T045	C0242614
CD4(+) T cell	T025	C0039215
Natural killer (NK) cell	T025	C0022688
infusions	T061	C0574032
patients	T101	C0030705
cancer	T191	C0006826
NK cell	T025	C0022688
activation	T043	C1326120
infusion	T061	C0574032
NK cells	T025	C0022688
cytokines	T116	C0079189
IL-12	T116	C0123759
15	T116	C0254610
18	T116	C0383327
NK cell	T025	C0022688
antitumor activity	T033	C0243095
NK cells	T025	C0022688
in vitro	T059	C3850137
IL-12	T116	C0123759
15	T116	C0254610
18	T116	C0383327
IL-15	T116	C0254610
antitumor activity	T033	C0243095
1 mo	T079	C1254367
lymphopenic	T047	C0024312
RAG-2(-/-)	T028	C1419248
mice	T015	C0026809
NK cell	T025	C0022688
IFNγ	T116	C0021745
non-coding sequence	T114	C0021920
CNS	T114	C0021920
Ifng	T028	C1334085
locus	T082	C1708726
transcription	T045	C0040649
Ifng	T028	C1334085
xenograft melanoma mouse model	T050	C0012644
human	T016	C0086418
IL-12	T116	C0123759
15	T116	C0254610
18	T116	C0383327
NK cells	T025	C0022688
tumors	T191	C0027651
RAG-2(-/-)	T028	C1419248
mice	T015	C0026809
CD4(+) T cells	T025	C0039215
NK cells	T025	C0022688
IFNγ	T116	C0021745
IL-2	T116	C0021756
CD4(+) T cell	T025	C0039215
activation	T043	C1326120
homeostatic proliferation	T043	C1326161
macrophages	T025	C0024432
NK cell	T025	C0022688
antitumor activity	T033	C0243095
NK cells	T025	C0022688
cytokines	T116	C0079189
epigenetic imprinting	T045	C0242614
IFNγ	T116	C0021745
phenotype	T032	C0031437
cytokine	T116	C0079189
NK cells	T025	C0022688
CD4(+) T cell	T025	C0039215
activation	T043	C1326120
lymphopenic	T047	C0024312
NK cell	T025	C0022688
cancer immunotherapy	T061	C0278348
Survey	T062	C0018762
Neonatal Intensive Care Unit	T073	C0021709
Nurse	T097	C0028661
Attitudes	T041	C0004271
Therapeutic Hypothermia Treatment	T061	C0020674
traumatic	T169	C0332663
parent	T099	C0030551
babies	T100	C0021270
treated with	T061	C0332293
therapeutic hypothermia	T061	C0020674
TH	T061	C0020674
research	T062	C0035168
assessed	T052	C1516048
neonatal intensive care unit	T073	C0021709
NICU	T073	C0021709
nurse	T097	C0028661
hypothermic	T033	C0020672
babies	T100	C0021270
parents	T099	C0030551
NICU	T073	C0021709
nurse	T097	C0028661
attitudes	T041	C0004271
TH	T061	C0020674
perceptions	T041	C0030971
baby	T100	C0021270
pain	T184	C0030193
sedation	T061	C0344106
nurse	T097	C0028661
parent	T099	C0030551
education	T065	C0013621
decision making	T041	C0011109
initiation	T169	C1704686
TH	T061	C0020674
survey	T062	C0018762
nurses	T097	C0028661
NICUs	T073	C0021709
responses	T170	C1706817
nurses	T097	C0028661
responses	T170	C1706817
response	T170	C1706817
Overwhelming	T080	C0522501
urban	T093	C0020029
rural institutions	T093	C0020023
NICU	T073	C0021709
nurses	T097	C0028661
TH	T061	C0020674
TH	T061	C0020674
long-term	T079	C0443252
outcomes	T080	C0085415
TH	T061	C0020674
Nurses	T097	C0028661
urban institution	T093	C0020029
treatment	T061	C0087111
baby	T100	C0021270
pain	T184	C0030193
sedation	T061	C0344106
nurses	T097	C0028661
institutions	UnknownType	C0337951
nurse	T097	C0028661
parent	T099	C0030551
education	T065	C0013621
TH	T061	C0020674
decision making	T041	C0011109
initiation	T169	C1704686
TH	T061	C0020674
NICU	T073	C0021709
nurses	T097	C0028661
outcomes	T080	C0085415
babies	T100	C0021270
treatment	T061	C0087111
TH	T061	C0020674
parents	T099	C0030551
education	T065	C0013621
TH	T061	C0020674
Research	T062	C0035168
TH treatment	T061	C0020674
parent	T099	C0030551
baby	T100	C0021270
Pharmacological Venous Thromboembolism Prophylaxis	T061	C0199242
Meningioma	T191	C0025286
Patients	T101	C0030705
Clinical Practice	T061	C0695275
report	T170	C2936319
Turkish Neurosurgery	T073	C1552762
retrospective study	T062	C0035363
intracranial meningioma	T191	C0349604
patients	T101	C0030705
open surgery	T061	C4283938
venous thromboembolism	T047	C1861172
VTE	T047	C1861172
patients	T101	C0030705
VTE	T047	C1861172
deep vein thrombosis	T047	C0149871
DVT	T047	C0149871
pulmonary embolism	T047	C0034065
PE	T047	C0034065
complication	T046	C0009566
meningioma surgery	T061	C1096493
patients	T101	C0030705
prophylaxis	T061	C0199176
VTE	T047	C1861172
pharmacological prophylaxis	T061	C0420172
clinical extrapolation	T169	C0205245
BEST	T170	C0282574
Next-Generation	T079	C1254367
Biomedical Entity Search Tool	T170	C0282574
Knowledge	T170	C0376554
Discovery	T052	C1880355
Biomedical Literature	T078	C0025120
volume	T080	C1690016
publications	T073	C0034036
rapidly	T080	C0456962
increases	T081	C0205217
searching	T052	C1706202
relevant	T080	C2347946
information	T078	C1533716
literature	T170	C0023866
challenging	T033	C0243095
standard	T080	C1442989
search engines	T170	C2348167
PubMed	T170	C1138432
desirable	T080	C0205556
advanced search tool	T170	C2348167
directly	T080	C1947931
returns	T080	C0332156
relevant	T080	C2347946
biomedical	T080	C0205556
entities	T071	C1551338
targets	T074	C0085104
drugs	T121	C0013227
mutations	T045	C0026882
existing	T033	C0243095
tools	T170	C0037589
submit	T169	C1515023
query	T170	C1522634
PubMed	T170	C1138432
process	T067	C1522240
abstracts	T170	C0600678
information	T078	C1533716
query	T170	C1522634
time	T079	C0040223
resulting	T169	C1274040
slow	T080	C0439834
time	T079	C0040223
limited	T169	C0439801
coverage	T169	C1999244
fraction of	T081	C1264633
PubMed corpus	T170	C1138432
tools	T170	C0037589
preprocess	T066	C1882455
PubMed corpus	T170	C1138432
time	T079	C0040223
constantly	T080	C1948059
updated	T079	C1519814
produce	T169	C0678227
outdated	T170	C3645590
results	T169	C1274040
tools	T170	C0037589
process	T067	C1522240
sophisticated	T080	C0205556
queries	T170	C1522634
searches	T052	C1706202
mutations	T045	C0026882
co-occur	T052	C1709305
query	T170	C1522634
literature	T170	C0023866
problems	T033	C0033213
introduce	T169	C1292748
BEST	T170	C0282574
biomedical entity search tool	T170	C0282574
BEST	T170	C0282574
returns	T080	C0332156
result	T169	C1274040
different	T080	C1705242
biomedical	T080	C0205556
entities	T071	C1551338
including	T169	C0332257
genes	T028	C0017337
diseases	T047	C0012634
drugs	T121	C0013227
targets	T074	C0085104
transcription factors	T116	C0040648
miRNAs	T114	C1101610
mutations	T045	C0026882
relevant	T080	C2347946
query	T170	C1522634
knowledge	T170	C0376554
BEST	T170	C0282574
system	T169	C0449913
processes	T067	C1522240
text	T170	C1527021
queries	T170	C1522634
returns	T080	C0332156
up-to-date	T033	C0243095
results	T169	C1274040
real time	T079	C1550177
including	T169	C0332257
mutation	T045	C0026882
information	T078	C1533716
results	T169	C1274040
BEST	T170	C0282574
Alanine	T116	C0001898
Serine	T116	C0036720
Variant	T080	C0205419
Calcium Sensing Receptor	T116	C0249742
Colorectal Cancer	T191	C1527249
Risk	T078	C0035647
effect	T080	C1280500
calcium	T121	C0006675
colorectal cancer	T191	C1527249
CRC	T191	C1527249
role	T077	C1705810
calcium sensing receptor	T116	C0249742
CaSR	T116	C0249742
calcium homeostasis	T121	C3653518
investigated	T169	C1292732
CaSR gene	T028	C1413136
rs1801725	T028	C0678941
A986S variant	T028	C0678941
associated with	T080	C0332281
susceptibility	T169	C1264642
CRC	T191	C1527249
risk	T078	C0035647
case-control study	T062	C0007328
cases	T169	C0868928
CRC	T191	C1527249
controls	T096	C0009932
subjects	T096	C0681850
genotyped	T032	C0017431
CaSR gene	T028	C1413136
A986S variant	T028	C0678941
PCR	T063	C0032520
RFLP method	T059	C3714764
No significant	T033	C1273937
difference	T080	C1705242
observed	T169	C1441672
A986S variant	T028	C0678941
CaSR gene	T028	C1413136
genotype	T032	C0017431
allele frequencies	T081	C0017270
cases	T169	C0868928
controls	T096	C0009932
lack	T080	C0332268
difference	T080	C1705242
adjustment	T169	C0456081
age	T032	C0001779
BMI	T201	C1305855
sex	T032	C1522384
smoking status	T201	C1519386
family history	T033	C0241889
CRC	T191	C1527249
No evidence	T080	C0332125
effect	T080	C1280500
modification	T033	C3840684
association	T080	C0439849
A986S variant	T028	C0678941
CRC	T191	C1527249
BMI	T201	C1305855
sex	T032	C1522384
tumor site	T082	C0475445
observed	T169	C1441672
risk	T078	C0035647
obesity	T047	C0028754
relation	T080	C0439849
A986S variant	T028	C0678941
controls	T096	C0009932
cases	T169	C0868928
analyzed	T062	C0936012
no significant difference	T033	C3842396
normal weight	T033	C2712185
BMI	T201	C1305855
overweight	T184	C0497406
obese	T047	C0028754
BMI	T201	C1305855
subjects	T096	C0681850
findings	T033	C0243095
effect	T080	C1280500
CaSR gene	T028	C1413136
A986S variant	T028	C0678941
CRC	T191	C1527249
risk	T078	C0035647
finding	T033	C0243095
confirmation	T033	C0750484
role	T077	C1705810
gene variant	T028	C0678941
carcinogenesis	T191	C0596263
investigated	T169	C1292732
Treatment	T061	C0087111
erythematotelangiectatic rosacea	T047	C1449852
fractionation	T061	C3161031
high-fluence	T079	C0205212
pulsed dye laser	T074	C1289859
lasers	T073	C0023089
treatment	T061	C0087111
erythematotelangiectatic rosacea	T047	C1449852
ETR	T047	C1449852
systemic	T061	C1515119
topical therapy	T061	C0150349
pulsed dye lasers	T074	C1289859
PDLs	T074	C1289859
ETR	T047	C1449852
purpuragenic	T047	C0034150
fluence	T079	C0376249
purpura	T047	C0034150
postinflammatory hyperpigmentation	T046	C0333616
PIH	T046	C0333616
patients	T101	C0030705
nonpurpuragenic	T033	C0243095
fluence	T079	C0376249
high fluence	T079	C0205212
PDL	T074	C1289859
purpura	T047	C0034150
fractionation	T061	C3161031
high fluence	T079	C0205212
PDL	T074	C1289859
patients	T101	C0030705
ETR	T047	C1449852
patients	T101	C0030705
PDL	T074	C1289859
Erythema	T047	C0041834
telangiectasia	T047	C0039446
physicians	T097	C0031831
digital photographs	T170	C3899375
patients	T101	C0030705
erythema	T047	C0041834
telangiectasia	T047	C0039446
Purpura	T047	C0034150
PIH	T046	C0333616
patients	T101	C0030705
fractionation	T061	C3161031
high-fluence	T079	C0205212
PDL	T074	C1289859
treatment	T061	C0087111
ETR	T047	C1449852
Propulsion strategy	T041	C0679199
gait	T033	C0016928
primary school	T073	C0033145
children	T100	C0008059
effect	T080	C1280500
age	T032	C0001779
speed	T081	C0678536
strategy	T041	C0679199
generate	T052	C3146294
power	T081	C3854080
propulsion	T040	C0026649
walking	T056	C0080331
running	T056	C0035953
marker	T201	C0005516
gait	T033	C0016928
maturation	T040	C0678723
elastic energy	T081	C1442080
recycling	T169	C0334213
study	T062	C2603343
investigated	T058	C0220825
ankle	T029	C0003086
hip	T023	C0019552
power	T081	C3854080
generation	T052	C3146294
propulsion strategy	T041	C0679199
PS	T041	C0679199
late stance	T033	C2019827
early swing phases	T033	C2039052
walking	T056	C0080331
running	T056	C0035953
typically developing	T067	C0870861
TD	T067	C0870861
children	T100	C0008059
years	T079	C0439234
years	T079	C0439234
three-dimensional	T082	C0450363
gait analysis	T060	C0558820
Peak	T080	C0444505
ankle	T029	C0003086
power	T081	C3854080
generation	T052	C3146294
push-off	T080	C0444505
peakA2	T080	C0444505
peak	T080	C0444505
hip	T023	C0019552
power	T081	C3854080
generation	T052	C3146294
early swing	T033	C2039052
peakH3	T080	C0444505
propulsion strategy	T041	C0679199
(PS)	T041	C0679199
peakA2	T080	C0444505
(peakA2+peakH3	T080	C0444505
calculated	T169	C0444686
ankle	T029	C0003086
power	T081	C3854080
propulsion	T040	C0026649
Mean	T081	C0444504
PS	T041	C0679199
values	T080	C0042295
decreased	T081	C0205216
speed	T081	C0678536
increased	T081	C0205217
comfortable walking	T056	C0080331
fast	T080	C0456962
walking	T056	C0080331
fast	T080	C0456962
running	T056	C0035953
jogging	T056	C0022400
PS	T041	C0679199
age	T032	C0001779
fast	T080	C0456962
walking	T056	C0080331
speed	T081	C0678536
fast	T080	C0456962
walking	T056	C0080331
older children	T100	C1455726
generated	T052	C3146294
peakA2	T080	C0444505
peakH3	T080	C0444505
younger children	T100	C0728836
kinetics	T070	C0022702
running	T056	C0035953
propulsion	T040	C0026649
age	T032	C0001779
years	T079	C0439234
skills	T055	C0678856
fast	T080	C0456962
walking	T056	C0080331
neuromuscular	T080	C1979768
maturity	UnknownType	C0678732
findings	T033	C0243095
running	T056	C0035953
skill	T055	C0678856
matures	T040	C0678723
early	T079	C1279919
TD	T067	C0870861
children	T100	C0008059
relationship	T080	C0439849
anthropometry	T062	C0003188
body composition	T032	C0005885
computed tomography	T060	C0040405
Atherosclerosis	T047	C0004153
South Asians	T098	C1519427
Living	T078	C0376558
America	T083	C0002454
relationships	T080	C0439849
anthropometry	T062	C0003188
body composition	T032	C0005885
sex	T032	C1522384
relationships	T080	C0439849
South Asians	T098	C1519427
US	T083	C0041703
cross-sectional study	T062	C0010362
participants	T098	C0679646
Atherosclerosis	T047	C0004153
South Asians	T098	C1519427
Living	T078	C0376558
America	T083	C0002454
(MASALA) Study	T062	C2603343
BMI	T201	C1305855
abdominal CT scans	T060	C0412620
measurement	T169	C0242485
visceral	T024	C1563740
subcutaneous fat	T024	C0222331
Linear regression	T081	C0023733
model	T170	C3161035
anthropometric measures	T170	C2598146
body composition	T032	C0005885
anthropometry	T062	C0003188
height	T032	C0005890
associated with	T080	C0332281
visceral fat	T024	C1563740
significant	T078	C0750502
visceral fat	T024	C1563740
significant	T078	C0750502
heterogeneity	T080	C0019409
sex	T032	C1522384
waist circumference	T201	C0455829
visceral fat	T024	C1563740
women	T098	C0043210
men	T098	C0025266
waist-to-hip ratio	T032	C0205682
women	T098	C0043210
men	T098	C0025266
height	T032	C0005890
anthropometry	T062	C0003188
associated with	T080	C0332281
subcutaneous fat	T024	C0222331
significant	T078	C0750502
significant	T078	C0750502
heterogeneity	T080	C0019409
sex	T032	C1522384
weight	T032	C0005910
women	T098	C0043210
men	T098	C0025266
BMI	T201	C1305855
waist circumference	T201	C0455829
hip circumference	T201	C0562350
participants	T098	C0679646
relationships	T080	C0439849
anthropometric measures	T170	C2598146
visceral	T024	C1563740
subcutaneous fat	T024	C0222331
race	T098	C0034510
ethnic groups	T098	C0015031
weaker	T080	C1762617
heterogeneity	T080	C0019409
sex	T032	C1522384
researchers	T097	C0035173
sex	T032	C1522384
South Asians	T098	C1519427
subcutaneous fat	T024	C0222331
waist circumference	T201	C0455829
visceral fat	T024	C1563740
Active	T169	C0205177
packaging	T068	C0030176
chicken meats	T168	C0677521
modified	T169	C0392747
atmosphere	T070	C0935443
oxygen	T121	C0030054
scavengers	T120	C1254355
effects of	T080	C1704420
modified	T169	C0392747
atmosphere	T070	C0935443
packaging	T068	C0030176
MAP	T070	C0935443
CO2	T123	C0007012
N2	T123	C0028158
iron	T121	C0302583
oxygen	T121	C0030054
scavengers	T120	C1254355
OS	T120	C1254355
packaging system	T073	C0178791
microbiological	T170	C0025953
oxidative	T169	C0311404
changes	T169	C0392747
chicken thigh meats	T168	C0677521
refrigerated storage	T169	C1698986
day	T079	C0439228
intervals	T079	C1272706
Total aerobic mesophilic bacteria counts	T081	C0392762
acceptability limit	T081	C0392762
control group	T096	C0009932
MAP	T070	C0935443
AIR	T167	C0001861
MAP	T070	C0935443
OS	T120	C1254355
samples	T167	C0370003
OS	T120	C1254355
utilization	T169	C0042153
reductions	T080	C0392756
Pseudomonas spp.	T007	C0033808
counts	T081	C0439157
storage	T169	C1698986
AIR	T167	C0001861
MAP	T070	C0935443
groups	T078	C0441833
MAP	T070	C0935443
OS	T120	C1254355
groups	T078	C0441833
coliform counts	T081	C0805715
AIR	T167	C0001861
group	T078	C0441833
reduction	T080	C0392756
cases	T169	C0868928
OS	T120	C1254355
utilization	T169	C0042153
TBARS	T109	C0162781
values	T081	C1522609
carbonyl	T077	C0456205
sulphydryl contents	T077	C0456205
stages	T079	C1306673
refrigerated storage	T169	C1698986
AIR	T167	C0001861
MAP	T070	C0935443
groups	T078	C0441833
effects	T080	C1280500
MAP	T070	C0935443
suppressed	T169	C1260953
microbiological growth	T067	C2911660
lipid	T044	C2612546
protein oxidation	T044	C1159301
chicken thigh meats	T168	C0677521
day	T079	C0439228
shelf-life	T070	C4279909
effects of	T080	C1704420
OS	T120	C1254355
Multidrug Resistance	T032	C0242640
Acinetobacter Baumannii	T007	C0314787
Ladoke Akintola University Teaching Hospital	T073	C0019994
Osogbo, Nigeria	T083	C0028075
Acinetobacter baumannii	T007	C0314787
pathogen	T001	C0450254
healthcare-associated infections	T046	C0010356
Ladoke Akintola University Teaching Hospital	T073	C0019994
Isolates	T123	C3494793
assayed	T059	C1510438
standard protocol	T170	C0442711
isolates	T123	C3494793
molecular techniques	T063	C1513384
blaOXA, blaTEM, blaCTX-M, and blaSHV genes	T028	C1442492
strains	T007	C0314787
A. baumannii	T007	C0314787
isolates	T123	C3494793
A. baumannii	T007	C0314787
patients	T101	C0030705
age group	T100	C0027362
male	T032	C0086582
patients	T101	C0030705
infected	T033	C0439663
female	T032	C0086287
Patients	T101	C0030705
intensive care unit	T073	C0021708
ICU	T073	C0021708
infected	T033	C0439663
organism	T001	C0029235
isolates	T123	C3494793
resistance	T169	C4281815
amikacin	T109	C0002499
ciprofloxacin	T109	C0008809
ceftriaxone	T109	C0007561
ceftazidime	T109	C0007559
resistance	T169	C4281815
antibiotics	T195	C0003232
study	T062	C2603343
piperacillin	T109	C0031955
imipenem	T109	C0066005
gentamycin	T109	C3854019
meropenem	T109	C0066005
isolates	T123	C3494793
resistant	T169	C4281815
colistin	T109	C0002499
PCR	T063	C0032520
results	T034	C0456984
blaOXA, blaTEM, and blaCTX-M genes	T028	C1442492
positive	T033	C1446409
isolates	T123	C3494793
blaSHV	T028	C1442492
not detected	T033	C0442737
isolates	T123	C3494793
study	T062	C2603343
revealed	T080	C0443289
strains	T007	C0314787
A. baumannii	T007	C0314787
isolated	T169	C0205409
multiple drug resistant	T032	C0242640
monitoring	T058	C1283169
prescription	T058	C0033080
detection	T061	C1511790
resistance	T169	C4281815
antibiotics	T195	C0003232
organism	T001	C0029235
Dataset	T170	C0150098
molecular dynamics simulations	T066	C2717775
bilayers	T080	C0205556
amyloidogenic peptide	T116	C0030956
VDSWNVLVAG	T087	C0002518
Bgl2p-glucantransferase	T116	C0014442
S. cerevisiae	T004	C0036025
cell wall	T026	C0007623
amyloidogenic peptide	T116	C0030956
VDSWNVLVAG	T087	C0002518
Bgl2p-glucantransferase	T116	C0014442
Saccharomyces cerevisiae	T004	C0036025
cell wall	T026	C0007623
analog	T104	C0243071
VESWNVLVAG	T087	C0002518
four	T081	C0205450
bilayers	T080	C0205556
orientation	T082	C1704322
peptides	T116	C0030956
layers	T080	C0205556
layers	T080	C0205556
bilayers	T080	C0205556
models	T170	C3161035
molecular dynamics	T044	C0596957
MD	T044	C0596957
changes	T169	C0392747
secondary structure	T082	C0162807
simulations	T062	C0679083
data	T078	C1511726
article	T170	C1706852
information	T078	C1533716
models	T170	C3161035
β-strands	T082	C0600383
organization	T169	C1300196
oligomer	T087	C0599219
structure	T082	C0678594
results	T169	C1274040
research article	T170	C1706852
Structural model	T073	C0026349
amyloid fibrils	T116	C1449651
amyloidogenic peptide	T116	C0030956
Bgl2p-glucantransferase	T116	C0014442
S. cerevisiae	T004	C0036025
cell wall	T026	C0007623
analog	T104	C0243071
morphology	T080	C0332437
amyloid fibrils	T116	C1449651
Straight configuration saphenous vein	T023	C0036186
transposition	T061	C1293442
popliteal artery	T023	C0032649
vascular access	T074	C0750138
saphenous vein	T023	C0036186
vascular graft	T023	C0740038
peripheral artery	T023	C0489868
surgery	T061	C0543467
rarely	T080	C0522498
vascular access	T074	C0750138
literature	T170	C0023866
straight configuration saphenous vein	T023	C0036186
transposition	T061	C1293442
popliteal artery	T023	C0032649
scarce	T080	C0522498
straight configuration saphenous vein	T023	C0036186
transposition	T061	C1293442
popliteal artery	T023	C0032649
vascular access	T074	C0750138
surgical technique	T060	C0011918
follow-up	T058	C1522577
young	T100	C0238598
men	T098	C0025266
years	T079	C0439234
lower-limb vascular access	T061	C0457913
hemodialysis	T061	C0019004
patient	T101	C0030705
paraplegic	T047	C0030486
upper extremity vascular access	UnknownType	C0749854
patient	T101	C0030705
infected	T033	C0439663
upper extremity arteriovenous graft	UnknownType	C0749781
(AVG	UnknownType	C0749781
closed	T169	C0587267
AVFs	T190	C0003855
arm veins	T023	C0042449
patients	T101	C0030705
received	T080	C1514756
autologous	T080	C0439859
lower extremity	T023	C4266545
straight configuration saphenous vein	T023	C0036186
transpositions	T061	C1293442
popliteal artery	T023	C0032649
spinal anesthesia	T061	C0002928
Cannulation	T061	C0917707
fistula	T190	C0080304
month	T079	C0439231
no early complications	T184	C0231243
Slight swelling	T033	C0038999
leg	T023	C1140621
appeared	T080	C0700364
patients	T101	C0030705
fistulas	T190	C0080304
functional	T169	C0205245
months	T079	C0439231
straight configuration saphenous vein	T023	C0036186
transposition	T061	C1293442
popliteal artery	T023	C0032649
long and straight segment	T082	C0441635
cannulation	T061	C0917707
autologous	T080	C0439859
vascular access	T074	C0750138
patients	T101	C0030705
Inhibited	T080	C0311403
Temperament	T041	C0039474
Hippocampal	T023	C0019564
Volume	T081	C1113695
Offspring	T099	C0680063
Parents	T099	C0030551
Bipolar Disorder	T048	C0005586
suggested	T078	C1705535
inhibited	T080	C0311403
temperament	T041	C0039474
associated with	T080	C0332281
increased	T081	C0205217
risk	T078	C0035647
anxiety	T048	C0003469
mood disorder	T048	C0525045
bipolar disorder	T048	C0005586
increased	T081	C0205217
risk	T078	C0035647
unknown	T080	C0439673
examine	T033	C0332128
temperament	T041	C0039474
symptomatic	T169	C0231220
asymptomatic	T033	C0231221
child	T100	C0008059
offspring	T099	C0680063
parents	T099	C0030551
bipolar disorder	T048	C0005586
OBD	T048	C0005586
investigate	T169	C1292732
inhibited	T080	C0311403
inhibited	T080	C0311403
temperament	T041	C0039474
associated with	T080	C0332281
aberrant	T080	C0443127
hippocampal	T023	C0019564
volumes	T081	C1113695
compared	T052	C1707455
healthy control	T080	C2986479
HC	T080	C2986479
youth	T100	C0087178
OBD	T048	C0005586
group	UnknownType	C0681860
youth	T100	C0087178
current	T079	C0521116
psychiatric symptoms	T184	C0233401
(OBD(+)s)	T048	C0005586
without	T080	C0332288
psychiatric symptoms	T184	C0233401
compared	T052	C1707455
HC	T080	C2986479
youth	T100	C0087178
Temperament	T041	C0039474
characteristics	T080	C1521970
measured	T080	C0444706
Revised Dimensions of Temperament Survey	T060	C0430022
Magnetic resonance imaging	T060	C0024485
measure	T081	C0079809
hippocampal	T023	C0019564
volumes	T081	C1113695
association	T080	C0439849
temperament	T041	C0039474
hippocampal	T023	C0019564
volumes	T081	C1113695
tested	T169	C0039593
multiple regression analysis	T080	C0681923
Compared	T052	C1707455
OBD(-)s group	UnknownType	C0681860
OBD(+)s	T048	C0005586
group	UnknownType	C0681860
significantly more	T081	C4055637
inhibited	T080	C0311403
inhibited	T080	C0311403
temperament	T041	C0039474
traits	T032	C0599883
less	T080	C0547044
flexibility	T080	C0443220
more	T081	C0205172
negative	T033	C0205160
mood	T041	C0026516
less	T080	C0547044
regular	T080	C0205272
rhythm	T033	C0871269
daily	T079	C0332173
routines	T080	C0205547
OBD(-)s group	UnknownType	C0681860
novel	T080	C0205314
situations	T080	C0348080
compared	T052	C1707455
OBD(+)s	T048	C0005586
HC	T080	C2986479
groups	UnknownType	C0681860
OBD(+)s	T048	C0005586
group	UnknownType	C0681860
inhibited	T080	C0311403
inhibited	T080	C0311403
temperament	T041	C0039474
associated with	T080	C0332281
right	T082	C0444532
hippocampal	T023	C0019564
volumes	T081	C1113695
symptomatic	T169	C0231220
OBD	T048	C0005586
characterized	T052	C1880022
inhibited	T080	C0311403
inhibited	T080	C0311403
temperament	T041	C0039474
inversely	T080	C0439850
correlated	T080	C1707520
hippocampal	T023	C0019564
volume	T081	C1113695
longitudinal studies	T062	C0023981
needed	T080	C0027552
inverse	T080	C0439850
correlations	T080	C1707520
hippocampal	T023	C0019564
volume	T081	C1113695
inhibited	T080	C0311403
inhibited	T080	C0311403
temperament	T041	C0039474
markers	T201	C0005516
risk	T078	C0035647
bipolar disorder	T048	C0005586
Dynamic	T169	C0729333
disorder	T080	C0205556
non-exponential	T081	C0392762
kinetics	T070	C0022702
protein mechanical unfolding	T043	C1655065
Protein unfolding	T043	C1655065
single molecule force spectroscopy	T059	C4279975
studies	T059	C0947630
stretched exponential	T080	C0205556
kinetics	T070	C0022702
protein unfolding	T043	C1655065
constant pulling force	T067	C0441722
molecular	T080	C1521991
origin	T079	C0439659
mechanical unfolding	T043	C1655065
ubiquitin	T116	C0041538
NuG2	T116	C0033684
Molecular Dynamics (MD) simulations	T066	C2717775
proteins	T116	C0033684
kinetics	T070	C0022702
stretched exponentials	T080	C0205556
stretching exponents	T081	C1711342
experiments	T062	C0681814
absent	T169	C0332197
MD simulations	T066	C2717775
non-exponential	T081	C0392762
kinetics	T070	C0022702
dynamic	T169	C0729333
disorder	T080	C0205556
conformational	T082	C0026377
fluctuations	T079	C0231241
nanosecond timescale	T079	C1254367
study	T062	C2603343
dynamic	T169	C0729333
disorder	T080	C0205556
protein kinetics	T070	C0022702
time scales	T079	C1254367
MD simulations	T066	C2717775
GTPV	T005	C0206574
bidirectional	T080	C1706937
promoter region	T114	C0033413
goat pox chick embryo-attenuated virus	T005	C0206574
GTPV	T005	C0206574
vaccine	T121	C0042210
immune responses	T042	C0301872
genome	T028	C0017428
express	T045	C0017262
exogenous	T169	C0205228
genes	T028	C0017337
virus	T005	C0206574
ideal	T080	C1512612
vector	T114	C0599566
recombinant live vaccines	T116	C0034862
infectious diseases	T047	C0009450
ruminant animals	T015	C0035950
bidirectional	T080	C1706937
promoter region	T114	C0033413
GTPV	T005	C0206574
PbVV(±)	T114	C0086860
PbVV(±)	T114	C0086860
ETF-l	T116	C0082367
VITF-3	T116	C0040648
transcribed	T045	C0040649
opposite	T082	C1521805
directions	T082	C0449738
recombinant goat pox virus	T005	C0206574
rGTPV	T005	C0206574
PbVV(+)	T114	C0086860
promoter	T114	C0086860
enhance	T052	C2349975
Brucella OMP31	T116	C1621913
expression	T045	C1171362
PbVV	T114	C0086860
promoter element	T114	C0086860
enhanced green fluorescent protein	T116	C1258415
EGFP	T116	C1258415
PbVV(-) promoter	T114	C0086860
P7.5 promoter	T114	C0086860
vaccinia virus	T005	C0042216
EGFP	T116	C1258415
expression	T045	C1171362
fluorescence intensity	T059	C0026022
EGFP	T116	C1258415
expressed	T045	C1171362
cells	T025	C0007634
fluorescence microscopy	T059	C0026022
flow cytometry	T059	C0016263
PbVV(+) promoter	T114	C0086860
Brucella OMP31	T116	C1621913
expression	T045	C1171362
anti-Brucella-OMP31 monoclonal antibody	T116	C0003250
western blotting	T059	C0005863
OMP31	T116	C1621913
mRNA expression	T045	C1515670
qRT-PCR	T063	C1514628
effective	T080	C1704419
multivalent vaccines	T121	C1514218
rGTPV	T005	C0206574
expression	T045	C1171362
exogenous	T169	C0205228
genes	T028	C0017337
Psychometric analysis	T060	C0033920
Patient Health Questionnaire	T170	C1879301
Danish	T083	C0011318
patients	T101	C0030705
implantable cardioverter defibrillator	T074	C0162589
DEFIB-WOMEN study	T062	C0681876
psychometric properties	T060	C0033920
Patient Health Questionnaire	T170	C4083201
PHQ-9	T170	C4083201
measure	T081	C0079809
depressive symptoms	T184	C0086132
large	T081	C0549177
Danish	T083	C0011318
national cohort	T098	C0599755
patients	T101	C0030705
heart disease	T047	C0018799
implanted	T061	C0021107
implantable cardioverter defibrillator	T074	C0162589
ICD	T074	C0162589
item response theory	T062	C0870753
prospective cohort	T098	C0599755
patients	T101	C0030705
implanted	T061	C0021107
ICD	T074	C0162589
men	T098	C0025266
PHQ-9	T170	C4083201
implant	T061	C0021107
Data	T078	C1511726
analyzed	T062	C0936012
item response theory models	T062	C0870753
partial credit model	T081	C0026348
generalized partial credit model	T081	C0026348
analysis	T062	C0936012
disordered response	T170	C1706817
thresholds	T080	C0449864
items	T080	C0871791
partial credit model	T081	C0026348
items	T080	C0871791
generalized partial credit model	T081	C0026348
respondents	T098	C0282122
difficulty	T080	C0332218
discriminating	T041	C0012632
response	T170	C1706817
response	T170	C1706817
options	T169	C1518601
rescored	T081	C0449820
PHQ-9	T170	C4083201
models	T081	C0026348
unidimensionality	T080	C0205556
precision	T080	C1706245
rescored	T081	C0449820
PHQ-9	T170	C4083201
Items	T062	C0871509
differential functioning	T169	C0205245
DIF	T169	C0205245
educational level	T033	C0013658
age	T032	C0001779
indication	T078	C3146298
ICD	T074	C0162589
implantation	T061	C0021107
severity	T080	C0439793
heart failure	T047	C0018801
influence	T077	C4054723
depression	T048	C0011570
outcomes	T169	C1274040
patients	T101	C0030705
ICD	T074	C0162589
DIF	T169	C0205245
gender	T032	C0079399
items	T062	C0871509
partial credit model	T081	C0026348
generalized partial credit model	T081	C0026348
item set	T062	C0871509
unidimensionality	T080	C0205556
reliability	T081	C2347947
Danish version	T171	C0010969
PHQ-9	T170	C4083201
confirmed	T033	C0750484
associated	T080	C0332281
consequences	T169	C0686907
response	T170	C1706817
options	T169	C1518601
Likert scale	T170	C0451267
examined	T033	C0332128
PHQ-9	T170	C4083201
screening	T058	C1710032
tool	T170	C0037589
outcome measure	T081	C0086749
Geographical variations	T033	C0935553
incidence	T081	C0021149
management	T058	C0376636
survival	T081	C0038954
hepatocellular carcinoma	T191	C2239176
Western country	T083	C0454664
Information	T078	C1533716
incidence	T081	C0021149
management	T058	C0376636
prognosis	T058	C0033325
hepatocellular carcinoma	T191	C2239176
HCC	T191	C2239176
population samples	T098	C2348150
regional	T082	C0205147
data	T078	C1511726
registries	T170	C0034975
Comprehensive	T080	C1880156
national	T092	C1555720
evaluations	T058	C0220825
country	T083	C0454664
lacking	T080	C0332268
study	T062	C2603343
investigate	T169	C1292732
regional	T082	C0205147
variations	T080	C0205419
HCC	T191	C2239176
care	T052	C1947933
France	T083	C0016674
observational study	T062	C1518527
data	T078	C1511726
French	T098	C1556084
administrative databases	T170	C0242356
patients	T101	C0030705
HCC	T191	C2239176
diagnosed	T033	C0011900
incidence	T081	C0021149
HCC	T191	C2239176
access	T082	C0444454
surgery	T061	C0543467
survival	T081	C0038954
national level	T082	C0681788
geographical levels	UnknownType	C0681784
French regions	T083	C0454828
French	T098	C1556084
departments	T092	C1704729
France	T083	C0016674
divided administratively	T092	C2919030
influence	T077	C4054723
outcome	T169	C1274040
hospital	T073	C0019994
HCC	T191	C2239176
managed	T057	C1273870
assessed	T052	C1516048
national level	T082	C0681788
median survival	T079	C2986586
months	T079	C0439231
patients	T101	C0030705
curative treatment	T033	C1273390
regions	T083	C0017446
departments	T092	C1704729
incidence	T081	C0021149
access	T082	C0444454
curative treatment	T033	C1273390
median survival	T079	C2986586
range	T081	C1514721
months	T079	C0439231
administrative type	T057	C0001554
annual	T079	C0332181
HCC	T191	C2239176
caseload	T081	C0814777
hospital	T073	C0019994
patients	T101	C0030705
admitted	T058	C0184666
independent	T078	C0085862
influence	T077	C4054723
treatment	T061	C0087111
survival	T081	C0038954
insurance coverage	T078	C0376629
citizens	T098	C0682134
national	T092	C1555720
measures	T081	C0079809
reduce inequities	T080	C0242503
management	T058	C0376636
cancer patients	T101	C1516213
recommendations	T078	C0034866
HCC	T191	C2239176
surveillance	T061	C0038842
management	T058	C0376636
percentage	T081	C0439165
patients	T101	C0030705
curative treatment	T033	C1273390
survival	T081	C0038954
postcode	T033	C0421454
hospital	T073	C0019994
patients	T101	C0030705
managed	T057	C1273870
influence	T077	C4054723
accessibility	T080	C0814423
good care	T052	C1947933
survival	T081	C0038954
Population-based studies	T062	C1709599
countries	T083	C0454664
survival	T081	C0038954
patients	T101	C0030705
malignancy	T191	C4282132
effectiveness	T080	C1280519
health systems	T064	C1456613
incidence	T081	C0021149
cancer	T191	C0006826
quality	T080	C0332306
registration	T058	C1514821
country	T083	C0454664
minimal	T080	C0547040
countries	T083	C0454664
study	T062	C2603343
country	T083	C0454664
incidence	T081	C0021149
curative treatment	T033	C1273390
rate	T081	C1521828
survival	T081	C0038954
patients	T101	C0030705
HCC	T191	C2239176
Evidence	T078	C3887511
care	T052	C1947933
survival	T081	C0038954
country	T083	C0454664
strengthen the impetus	T080	C0205556
government	T092	C0018104
clinicians	T097	C0871685
disparities	T080	C1955989
Identification	T080	C0205396
predictive	T080	C0681890
markers	T080	C0008963
dexamethasone	T109	C0011777
resistance	T038	C0013203
childhood	T079	C0231335
acute lymphoblastic leukemia	T191	C0023449
Response	T040	C0683154
dexamethasone	T109	C0011777
DEXA	T109	C0011777
hallmark drug	T121	C1254351
treatment	T169	C0039798
childhood	T079	C0231335
acute lymphoblastic leukemia	T191	C0023449
ALL	T191	C0023449
prognostic factors	T201	C1514474
prediction of outcome	T058	C0033325
ALL	T191	C0023449
Identification	T080	C0205396
predictive	T080	C0681890
markers	T080	C0008963
chemoresistance	T038	C0013203
therapeutic protocol	T061	C0040808
effect adverse	T046	C0879626
drug targets	T074	C0085104
2DE	T059	C0013860
MS	T059	C0037813
proteomics study	T059	C0022885
DEXA	T109	C0011777
resistant cell line	T025	C0007600
REH	T025	C0007600
model	T075	C0026336
DEXA	T109	C0011777
patients	T101	C0030705
drug treatment	T061	C0013216
proteomic methods	T059	C0022885
expressed	T045	C1171362
proteins	T116	C0033684
detected	T033	C0442726
voltage dependent anion channel 1	T116	C0753015
VDAC1	T116	C0753015
sorting Nexin 3	T116	C1741224
SNX3	T116	C1741224
prefoldin subunit 6	T116	C1743484
PFDN6	T116	C1743484
expression	T045	C1171362
proteins	T116	C0033684
DEXA	T109	C0011777
treatment	T169	C0039798
REH cells	T025	C0007600
expression	T045	C1171362
proteins	T116	C0033684
mRNA	T114	C0035696
level	T080	C0441889
quantitative PCR method	T059	C2733022
proteins	T116	C0033684
proteins	T116	C0033684
roles	T077	C1705810
drug resistance	T038	C0013203
regulation of apoptosis	T043	C1148568
VDAC1	T116	C0753015
protein trafficking	T043	C0599895
SNX3	T116	C1741224
protein folding	T044	C0162847
PFDN6	T116	C1743484
mRNA	T114	C0035696
expression level	T081	C3244092
proteins	T116	C0033684
assessed	T052	C1516048
bone marrow samples	T031	C0438737
children	T100	C0008059
newly diagnosed	T080	C1518321
ALL	T191	C0023449
non-cancerous samples	T167	C0370003
controls	T096	C0009932
molecular subtypes	T185	C0449560
leukemia	T191	C0023418
mRNA	T114	C0035696
expression	T045	C1171362
VDAC1	T116	C0753015
SNX3	T116	C1741224
PFDN6	T116	C1743484
ALL	T191	C0023449
samples	T167	C0370003
non-cancerous samples	T167	C0370003
VDAC1	T116	C0753015
mRNA	T114	C0035696
expression	T045	C1171362
proteins	T116	C0033684
high-risk	T033	C0332167
samples	T167	C0370003
standard	T080	C1442989
risk	T078	C0035647
cases	T169	C0868928
diagnostic	T169	C0348026
prognostic	T170	C0220901
value	T080	C0042295
proteins	T116	C0033684
childhood	T079	C0231335
ALL	T191	C0023449
investigation	T058	C0220825
protein-protein interaction	T044	C0872079
STRING	T170	C1547402
database	T170	C0242356
proteins	T116	C0033684
signaling pathway	T044	C0037080
NR3C1	T116	C1370369
dexamethasone	T109	C0011777
target	T033	C0243095
proteomic study	T059	C0022885
DEXA	T109	C0011777
resistant	T038	C0013203
leukemic cells	T025	C1517806
VDAC1	T116	C0753015
SNX3	T116	C1741224
PFDN6	T116	C1743484
proteins	T116	C0033684
biomarkers	T201	C0005516
prognosis	T058	C0033325
chemotherapy	T061	C3665472
childhood	T079	C0231335
ALL	T191	C0023449
Benthic injury dose-response models	T170	C0282574
polychlorinated biphenyl	T109	C0032447
contaminated	T169	C0205279
sediment	T167	C1550099
equilibrium partitioning	T170	C0282574
study	T062	C2603343
sediment	T167	C1550099
polychlorinated biphenyl	T109	C0032447
PCB	T109	C0032447
dose-response model	T170	C0282574
benthic invertebrate	T001	C0599636
PCBs	T109	C0032447
equilibrium partitioning (EqP) approach	T170	C0282574
PCB	T109	C0032447
sediment	T167	C1550099
concentrations	T081	C0457929
Aroclor 1254	T109	C0052391
gradient	T081	C0812409
toxic effects	T037	C0600688
benthic organisms	T001	C0599636
aquatic	T067	C0563034
toxicity	T037	C0600688
studies	T062	C2603343
study	T062	C2603343
EqP	T170	C0282574
sediment	T167	C1550099
dose-response	T038	C0678790
gradient	T081	C0812409
PCBs	T109	C0032447
chronic	T079	C0205191
aquatic	T067	C0563034
toxicity	T037	C0600688
literature	T170	C0023866
aqueous	T080	C0599956
PCB	T109	C0032447
concentrations	T081	C0457929
benthic invertebrate	T001	C0599636
aquatic	T067	C0563034
toxic effect	T037	C0600688
data	T078	C1511726
studies	T062	C2603343
common metric	T081	C0025867
percent injury	T081	C0392762
organic carbon	T109	C0007011
sediment	T167	C1550099
PCB	T109	C0032447
concentrations	T081	C0457929
organic carbon	T109	C0007011
aqueous	T080	C0599956
PCB	T109	C0032447
toxicity	T037	C0600688
data set	T170	C0150098
EqP	T170	C0282574
US Environmental Protection Agency's	T092	C0041712
EPIWEB 4.1	T073	C0037585
water-organic carbon partition coefficient	T081	C1518903
KOC	T081	C1518903
dose-response numerical model	T170	C0282574
sediment	T167	C1550099
PCB	T109	C0032447
concentrations	T081	C0457929
biological effects	T070	C1511145
median effective concentration	T081	C1446561
models	T170	C0282574
tables	T170	C1706074
percent injury	T081	C0392762
benthic biota	T070	C1253910
Aroclor	T109	C0052391
sediment	T167	C1550099
concentrations	T081	C0457929
model	T170	C0282574
EPIWEB	T073	C0037585
KOC	T081	C1518903
mean benthic injury	T081	C0392762
sediment	T167	C1550099
concentrations	T081	C0457929
Aroclor 1254	T109	C0052391
organic carbon	T109	C0007011
model	T170	C0282574
site-specific	T082	C0449604
KOC	T081	C1518903
tables	T170	C1706074
equations	T077	C0552449
dose-response	T038	C0678790
sediment	T167	C1550099
concentration	T081	C0457929
Extract of Caulis Spatholobi	T123	C0032081
Caulis Spatholobi	T002	C0242767
blocker	T121	C1254351
tumor cell	T025	C0597032
tumor cell ‑induced platelet aggregation	T043	C0032176
breast cancer	T191	C0006142
metastasis	T191	C0027627
Metastasis	T191	C0027627
breast cancer	T191	C0006142
malignant progression	T191	C0948048
hematogenous metastasis	T191	C0027627
cancer cells	T025	C0334227
platelet	T025	C0005821
hypercoagulable state	T047	C0398623
factor	T169	C1521761
coagulation	T042	C0005778
system	T169	C0449913
metastasis	T191	C0027627
platelet	T025	C0005821
tumor cell	T025	C0597032
tumor cell	T025	C0597032
metastasis	T191	C0027627
tumor cell	T025	C0597032
tumor cell ‑induced platelet aggregation	T043	C0032176
TCIPA	T043	C0032176
suppression	T044	C1519692
tumor metastasis	T191	C0027627
aspirin	T109	C0004057
ASA	T109	C0004057
tumor‑platelet (T‑P) complex,	T026	C0243092
ethanol	T109	C0001962
extracts of Caulis Spatholobi	T123	C0032081
Caulis Spatholobi	T002	C0242767
SET	T123	C0032081
hypercoagulation state	T047	C0398623
tumor metastasis	T191	C0027627
survival	T052	C0038952
breast	T023	C0006141
cancer cell	T025	C0334227
model	T075	C0026336
MTT	T059	C0201596
anti‑aggregation assay stimulated by ADP	T059	C0005507
optimum treatment time	T079	C0040223
optimum dose	T081	C0178602
SET	T123	C0032081
confocal microscopy	T059	C0242842
SET	T123	C0032081
formation	T169	C1522492
T‑P complex	T026	C0243092
n vitro	T080	C1533691
FACS analysis	T059	C0079366
fluorescent value	T081	C0392762
T‑P complex	T026	C0243092
drug‑treated groups.	T078	C0441833
In vivo	T082	C1515655
4T1 cells	T025	C0597032
injected	T061	C1533685
mouse	T015	C0025929
tail vein	T023	C2985205
dynamic visualization	T060	C0430022
small animal imaging system	T073	C2697665
metastatic intensity	T081	C0392762
survival curve	T081	C0392762
analyzed	T062	C0936012
hematoxylin and eosin (H&E) staining	T059	C0523207
lung	T023	C0024109
tissue	T024	C0040300
SET	T123	C0032081
inhibition	T052	C3463820
metastasis	T191	C0027627
survival rate	T081	C0038954
mice	T015	C0025929
molecular mechanism	T044	C1148560
study	T062	C2603343
anti‑TCIPA	T059	C0005507
zymography	T062	C1517469
T‑PCR assay	T063	C0599161
molecular mechanism	T044	C1148560
SET	T123	C0032081
‑T interaction	T043	C0007582
drug efficacy	T080	C0598333
pharmacological	T169	C0205464
breast	T023	C0006141
metastasis	T191	C0027627
TCIPA	T043	C0032176
clinical	T080	C0205210
cancer treatment	T061	C0920425
Generalized Epilepsy	T047	C0014548
Myoclonic Seizures	T047	C0014550
22q11.2 Deletion Syndrome	T047	C0012236
juvenile myoclonic epilepsy	T047	C0270853
JME	T047	C0270853
22q11.2 deletion syndrome	T047	C0012236
22q11DS	T047	C0012236
recurrent copy number variants	T086	C1511518
genetic	T169	C0017399
generalized epilepsy	T047	C0014548
GGE	T047	C0014548
correlation	T080	C1707520
22q11DS	T047	C0012236
GGE	T047	C0014548
myoclonic seizures	T047	C0014550
routine diagnostics	T060	C0086143
individuals	T098	C0027361
uncommon	T080	C0522498
combination	T080	C0205195
22q11DS	T047	C0012236
JME	T047	C0270853
screened	T058	C0220908
literature	T170	C0023866
reports	T170	C0684224
epilepsy phenotype	T032	C0031437
22q11DS	T047	C0012236
screened	T058	C0220908
database	T170	C0242356
22q11DS	T047	C0012236
patients	T101	C0030705
individual	T098	C0027361
JME	T047	C0270853
cases	T169	C0868928
GGE	T047	C0014548
novel	T080	C0205314
published	T057	C0034037
cases	T169	C0868928
co-occurrence	T033	C0243095
22q11DS	T047	C0012236
GGE	T047	C0014548
patients	T101	C0030705
GGE	T047	C0014548
associated with	T080	C0332281
myoclonic seizures	T047	C0014550
diagnosis	T033	C0011900
JME	T047	C0270853
individuals	T098	C0027361
22q11DS	T047	C0012236
cases	T169	C0868928
diagnosis	T033	C0011900
focal	T047	C0014547
generalized epilepsy	T047	C0014548
cases	T169	C0868928
focal epilepsy	T047	C0014547
syndrome-associated hypocalcaemia	T047	C0020598
cerebral bleeds	T033	C2937358
structural brain anomalies	T033	C3280971
GGE	T047	C0014548
study	T062	C2603343
individuals	T098	C0027361
22q11DS	T047	C0012236
GGE	T047	C0014548
JME	T047	C0270853
disorders	T047	C0012634
frequently co-occur	T033	C0243095
reported prevalence	T081	C0220900
case series	T062	C0150093
22q11DS	T047	C0012236
individuals	T098	C0027361
epilepsy	T047	C0014544
GGE	T047	C0014548
22q11.2	T026	C1521104
GGE	T047	C0014548
candidate genes	T028	C1332838
aetiological	T169	C0015127
correlation	T080	C1707520
GABAB receptor	T116	C0052887
Normal Levels	T080	C0441889
Urinary	T031	C0042036
CC16 Protein	T116	C1505089
Comments on Beamer et al. Association	T170	C0282574
Children's	T100	C0008059
Urinary	T031	C0042036
CC16	T116	C1505089
Levels	T059	C0262923
Arsenic Concentrations	T059	C0373548
Multiple Environmental Media	T077	C1254372
Max Clara	T016	C0086418
cell	T025	C0007634
human	T016	C0086418
lung	T023	C0024109
exocrine secretory cell type containing granules	T026	C0230676
proteins	T116	C0033684
Colletotrichum species	T004	C0320203
anthracnose	T047	C0032080
tea plants	T002	C0032098
Camellia sinensis (L.) O. Kuntze	T002	C0949852
China	T083	C0008115
Anthracnose	T047	C0032080
Colletotrichum	T004	C0320203
diseases	T047	C0032080
Camellia sinensis	T002	C0949852
research	T062	C0035168
diversity	T080	C1880371
geographical distribution	T079	C0681686
Colletotrichum	T004	C0320203
China	T083	C0008115
study	T062	C0681814
Colletotrichum	T004	C0320203
isolates	T123	C1764827
collected	T169	C1516698
diseased	T047	C0032080
leaves	T002	C0242724
Ca. sinensis	T002	C0949852
tea production	T090	C1518533
provinces	T083	C1514578
China	T083	C0008115
Multi-locus phylogenetic analysis	T062	C1519068
morphological identification	T059	C1294314
collected	T169	C1516698
isolates	T123	C1764827
species	T185	C1705920
species	T185	C1705920
C. camelliae	T004	C2642537
C. cliviae	T004	C2803492
C. fioriniae	T004	C2813833
C. fructicola	T004	C2804746
C. karstii	T004	C3397324
C. siamense	T004	C2804749
record species	T185	C1705920
C. aenigma	T004	C3584139
C. endophytica	T004	C3746379
C. truncatum	T004	C2790917
species	T185	C1705920
C. wuxiense	T004	C0016832
strain	T001	C1518614
Colletotrichum sp.	T004	C0320203
species	T185	C1705920
C. camelliae	T004	C2642537
C. fructicola	T004	C2804746
species	T185	C1705920
anthracnose	T047	C0032080
Ca. sinensis	T002	C0949852
study	T062	C0681814
evidence	T078	C3887511
phylogenetic analysis	T062	C1519068
ApMat and GS sequences	T086	C0162326
taxonomic	T169	C0008903
relationships	T080	C0439849
C. gloeosporioides	T004	C1531932
species complex	T185	C1705920
pathogenicity	T032	C1136169
tests	T059	C0022885
C. camelliae	T004	C2642537
C. aenigma	T004	C3584139
C. endophytica	T004	C3746379
invasive	T080	C0205281
species	T185	C1705920
inoculation	T061	C2987620
leaves	T002	C0242724
Ca. sinensis	T002	C0949852
ATP	T114	C0001480
release	T169	C1283071
bladder urothelium	T024	C0227692
serosa	T024	C0036760
model	T050	C0012644
partial bladder outlet obstruction	T047	C0005694
Overactive bladder	T047	C0878773
health problem	T033	C0243095
elderly people	T098	C0001792
Adenosine triphosphate	T114	C0001480
ATP	T114	C0001480
released	T169	C1283071
urinary bladder cells	T025	C0227599
smooth muscle contraction	T042	C1155937
sensory signal	T041	C0597440
micturition	T040	C0042034
ATP	T114	C0001480
pathophysiology	T046	C0277785
overactive bladder	T047	C0878773
ATP	T114	C0001480
overactive bladder	T047	C0878773
partial bladder outlet obstruction	T047	C0005694
pBOO	T047	C0005694
model	T050	C0012644
rats	T015	C0034693
bladder	T023	C0005682
pBOO	T047	C0005694
increase	T169	C0442805
bladder	T023	C0005682
weight	T081	C0043100
hypertrophy	T046	C0020564
sub-urothelium	T024	C0227598
sub-serosal area	T024	C0036760
non	T169	C1518422
voiding bladder contraction	T042	C0232850
urine	T031	C0042036
Basal	T082	C0205112
ATP	T114	C0001480
urothelium	T024	C0227692
serosa	T024	C0036760
pBOO	T047	C0005694
rats	T015	C0034693
rats	T015	C0034693
Distention	T033	C0005687
ATP	T114	C0001480
release	T169	C1283071
urothelium	T024	C0227692
pBOO	T047	C0005694
rats	T015	C0034693
distention	T033	C0005687
induced	T169	C0205263
ATP	T114	C0001480
release	T169	C1283071
serosa	T024	C0036760
pBOO	T047	C0005694
rats	T015	C0034693
ATP	T114	C0001480
released	T169	C1283071
serosa	T024	C0036760
non	T169	C1518422
voiding contractions	T042	C0232850
overactive bladder	T047	C0878773
symptoms	T184	C1457887
putative vectors	T008	C0012656
Bogia Coconut Syndrome	T047	C0032080
phytoplasma	T007	C1004784
loop-mediated isothermal amplification	T059	C3539922
single-insect feeding media	T168	C0016452
Phytoplasmas	T007	C1004784
insect vectored mollicutes	T007	C3179193
disease	T047	C0012634
crops	T002	C0032098
insect species	T204	C0021585
vectors	T008	C0012656
phytoplasma	T007	C1004784
disease	T047	C0012634
disease-free plants	T002	C0032098
insects	T204	C0021585
months	T079	C0439231
transmission	T070	C1521797
molecular testing	T059	C0752096
phytoplasma	T007	C1004784
DNA	T114	C0012854
sucrose	T109	C0376597
solution	T167	C0037633
insects	T204	C0021585
fed	T052	C2987508
study	T062	C2603343
feeding medium method	T059	C0022885
loop-mediated isothermal amplification (LAMP) assay	T059	C3539922
insect	T204	C0021585
specimens	T077	C2347026
Hemiptera taxa	T204	C0018992
Papua New Guinea	T083	C0030375
Bogia coconut syndrome	T047	C0032080
BCS	T047	C0032080
LAMP assay	T059	C3539922
phytoplasma	T007	C1004784
DNA	T114	C0012854
feeding solution	T168	C0016452
head	T029	C0018670
tissue	T024	C0040300
insects	T204	C0021585
taxa	T077	C1515221
Derbidae	T204	C1063109
Lophopidae	T204	C1063149
Flatidae	T204	C1003013
Ricaniidae	T204	C1063157
taxa	T077	C1515221
heads	T029	C0018670
single-insect feeding medium tests	T059	C0022885
LAMP assays	T059	C3539922
putative vectors	T008	C0012656
transmission	T070	C1521797
tests	T169	C0039593
phytoplasma	T007	C1004784
pathosystems	T091	C0030664
Non-toxigenic	T169	C0445099
environmental	T082	C0014406
Vibrio cholerae O1	T007	C0318248
strain	T001	C1518614
Haiti	T083	C0018510
provides	T052	C1999230
evidence	T078	C3887511
pre-pandemic	T067	C1615608
cholera	T047	C0008354
Hispaniola	T083	C0454978
Vibrio cholerae	T007	C0042629
ubiquitous	T080	C2348867
aquatic environments	T067	C0563034
environmental	T082	C0014406
toxigenic	T170	C0445332
V. cholerae O1	T007	C0318248
strains	T001	C1518614
serving	T081	C1519269
source	T033	C0449416
recurrent	T079	C2945760
cholera epidemics	T047	C0008354
pandemic	T067	C1615608
disease	T047	C0012634
long-term	T079	C0443252
survival	T169	C0220921
V. cholerae	T007	C0042629
strains	T001	C1518614
aquatic environmental	T067	C0563034
reservoirs	T083	C0442537
monitoring	T057	C0014416
Haitian	T083	C0018510
aquatic environment	T067	C0563034
cholera epidemic	T047	C0008354
isolated	T169	C0205409
two	T081	C0205448
novel	T080	C0205314
non-toxigenic	T169	C0445099
ctxA/B	T028	C0017337
negative	T033	C0205160
Vibrio cholerae O1	T007	C0318248
two	T081	C0205448
isolates	T123	C1764827
whole-genome sequencing	T063	C3640076
investigated	T169	C1292732
through	T169	C0332273
comparative	T052	C1707455
genomics	T091	C0887950
Bayesian coalescent analysis	T081	C0242196
isolates	T123	C1764827
tree	T002	C0040811
strains	T001	C1518614
clinical	T080	C0205210
cholera	T047	C0008354
possessing	T078	C3154893
genomic components	T028	C0017428
pandemic	T067	C1615608
lineages	T077	C1881379
diverge	T080	C0443299
modern	T079	C0521116
cholera	T047	C0008354
strains	T001	C1518614
Vibrio Pathogenicity Island	T028	C0017258
(VPI)-1	T028	C0017258
present	T033	C0150312
SXT/R391-family ICE	T028	C0017258
VPI-2	T028	C0017258
absent	T169	C0332197
Rugose phenotype	T032	C0031437
conversion	T169	C0439836
vibriophage	T005	C0042776
resistance	T169	C4281815
evidenced	T169	C0332120
persistence	T041	C0546816
aquatic environments	T067	C0563034
identification	T080	C0205396
V. cholerae O1	T007	C0318248
strains	T001	C1518614
Haitian	T083	C0018510
environment	T067	C0563034
reported	T062	C0011000
cholera	T047	C0008354
pandemic	T067	C1615608
understanding	T041	C0162340
history	T169	C0019665
pandemics	T067	C1615608
similar	T080	C2348205
environmental	T067	C0563034
strains	T001	C1518614
acquire	T052	C1706701
virulence	T080	C0220936
genes	T028	C0017337
Haitian	T083	C0018510
epidemic	T067	C0014499
clone	T024	C1522642
cholera toxin	T116	C0008356
producing	T169	C0678227
CTXϕ	T116	C0008356
Pre-Eclampsia	T046	C0032914
Ontology	T077	C1707788
Disease Ontology	T077	C1707788
Pre-Eclampsia	T046	C0032914
Pre-eclampsia	T046	C0032914
PE	T046	C0032914
clinical syndrome	T185	C0221444
new-onset hypertension	UnknownType	C0745129
proteinuria	T033	C0033687
≥20 weeks of gestation	T033	C1998040
cause	T169	C0015127
maternal	T033	C3656218
perinatal morbidity	T046	C0848215
mortality	T081	C0205848
abundant	T080	C2346714
data	T078	C1511726
PE	T046	C0032914
risk factors	T033	C0035648
pathological findings	T169	C0205469
data	T078	C1511726
Clinical data	T170	C1516606
PE	T046	C0032914
patients	T101	C0030705
semantic	T078	C0036612
heterogeneity	T080	C0019409
disparate terminology	T170	C0028275
phenomena	T067	C1882365
clinical studies	T062	C0008972
heterogenic	T078	C1512426
clinical data	T170	C1516606
situations	T169	C0868928
situation	T169	C0868928
semantic	T078	C0036612
framework	T077	C1254372
research	T062	C0035168
pathology	T169	C0205469
PE	T046	C0032914
heterogenic	T078	C1512426
clinical data	T170	C1516606
PE	T046	C0032914
patients	T101	C0030705
ontology	T077	C1707788
clinical features	T201	C0683325
treatments	T061	C0087111
genetic factors	T080	C0814299
environmental factors	T080	C0686732
aspects	T080	C1879746
PE	T046	C0032914
pre-eclampsia	T046	C0032914
ontology	T077	C1707788
PEO	T077	C1707788
ontologies	T077	C1707788
PEO	T077	C1707788
Basic Formal Ontology	T090	C1518584
BFO	T090	C1518584
PEO	T077	C1707788
concepts	T078	C0178566
terms	T079	C1515273
PE	T046	C0032914
clinical	T062	C0008972
biomedical research	T062	C0005540
PE	T046	C0032914
PEO	T077	C1707788
enhance	T052	C2349975
PE	T046	C0032914
information retrieval	T057	C0079623
clinical	T062	C0008972
biomedical research	T062	C0005540
fields	UnknownType	C0683945
Predictors	T078	C2698872
Moderators	T080	C1881878
Spontaneous	T169	C0205359
Pretend Play	T041	C2371970
Children	T100	C0008059
Autism Spectrum Disorder	T048	C1510586
pretend play	T041	C2371970
children's	T100	C0008059
normative	T080	C0205307
cognitive development	T041	C0679035
inconsistent	T080	C0442809
findings	T033	C0243095
examining	T169	C1292732
relation	T080	C0439849
Spontaneous	T169	C0205359
pretend play	T041	C2371970
atypical	T080	C0205182
development	T039	C0243107
autism spectrum disorder	T048	C1510586
ASD	T048	C1510586
ASD	T048	C1510586
traits	T032	C0599883
continuum	T082	C0595960
general population	T098	C0683971
investigating	T169	C1292732
pretend play	T041	C2371970
ASD	T048	C1510586
symptoms	T184	C1457887
variations	T080	C0205419
ASD	T048	C1510586
traits	T032	C0599883
ASD	T048	C1510586
populations	T098	C1257890
ASD	T048	C1510586
symptoms	T184	C1457887
relation	T080	C0439849
pretend play	T041	C2371970
cognitive development	T041	C0679035
study	T062	C2603343
rigorous observational methods	T062	C0870991
spontaneous	T169	C0205359
pretend play	T041	C2371970
min	T079	C0439232
free-play sessions	T058	C1254363
discrete	T080	C0443299
toy	T073	C0040565
blinded coders	T073	C1707428
pretense development	T041	C0025361
attribution of pretend properties	T080	C0871161
APP	T080	C0871161
object substitution	T052	C1706204
OS	T052	C1706204
imaginary objects	T041	C0025361
examined	T169	C1292732
pretend play	T041	C2371970
production	T041	C0025361
analyzed	T062	C0936012
relation	T080	C0439849
ASD	T048	C1510586
symptoms	T184	C1457887
theory of mind	T078	C0935573
ToM	T078	C0935573
verbal ability	T041	C1145677
familiarity	T041	C0600269
interest	T041	C0543488
specific	T080	C0205369
toys	T073	C0040565
children	T100	C0008059
males	T032	C0086582
threshold	T080	C0449864
ASD	T048	C1510586
diagnosis	T033	C0011900
parent	T099	C0030551
ASD	T048	C1510586
symptoms	T184	C1457887
play sessions	T058	C1254363
measures	T081	C0079809
verbal IQ	T032	C0582577
ToM	T078	C0935573
measure	T081	C0079809
child	T100	C0008059
ASD	T048	C1510586
symptoms	T184	C1457887
parents	T099	C0030551
survey	T170	C0038951
child's	T100	C0008059
interest	T041	C0543488
familiarity	T041	C0600269
play session	T058	C1254363
toys	T073	C0040565
ToM	T078	C0935573
predicted	T078	C0681842
APP	T080	C0871161
interest	T041	C0543488
toys	T073	C0040565
predicted	T078	C0681842
OS	T052	C1706204
pretend play	T041	C2371970
production	T041	C0025361
children	T100	C0008059
ASD	T048	C1510586
symptoms	T184	C1457887
verbal ability	T041	C1145677
predicted	T078	C0681842
pretend play	T041	C2371970
production	T041	C0025361
children	T100	C0008059
ASD	T048	C1510586
symptoms	T184	C1457887
ToM	T078	C0935573
predicted	T078	C0681842
pretend play	T041	C2371970
production	T041	C0025361
ASD	T048	C1510586
symptoms	T184	C1457887
pretend play	T041	C2371970
ToM	T078	C0935573
verbal ability	T041	C1145677
pretend play	T041	C2371970
children	T100	C0008059
ASD	T048	C1510586
symptoms	T184	C1457887
treatment	T061	C0087111
pretend ability	T032	C0085732
children	T100	C0008059
ASD	T048	C1510586
symptoms	T184	C1457887
Allelic	T028	C0002085
diversity	T080	C1880371
NLR gene	T028	C0017337
BPH9	T028	C0017337
rice	T002	C1140671
planthopper	T204	C0600234
variation	T070	C0042333
Brown planthopper	T204	C0600234
BPH	T204	C0600234
Nilaparvata lugens Stål	T204	C1051066
insect	T204	C0021585
pests	T008	C0869004
rice	T002	C1140671
Oryza sativa L.	T002	C1140671
BPH	T204	C0600234
resistance genes	T028	C2945710
chromosome regions	T026	C1953345
molecular cloning	T059	C0009017
characterization	T052	C1880022
BPH	T204	C0600234
resistance gene	T028	C2945710
BPH9	T028	C0017337
long arm of rice chromosome 12	T026	C1276871
BPH9	T028	C0017337
nucleotide-binding	T044	C1148916
leucine-rich repeat	T087	C1517773
NLR	T087	C1517773
protein	T116	C0033684
endomembrane system	T026	C1167315
cell death	T043	C0007587
phenotype	T032	C0031437
BPH9	T028	C0017337
salicylic acid	T109	C0036079
jasmonic acid	T109	C0064138
signaling pathways	T044	C0037080
rice	T002	C1140671
plants	T002	C0032098
antixenosis	T070	C1254365
antibiosis	T070	C0003219
BPH	T204	C0600234
BPH	T204	C0600234
resistance genes	T028	C2945710
chromosome 12L	T026	C0008633
BPH1	T028	C0017337
literature	T170	C0023866
locus	T082	C1708726
BPH1/9	T028	C0017337
genes	T028	C0017337
allelotypes	T028	C0002085
BPH1/9-1	T028	C0017337
-2	T028	C0017337
-7	T028	C0017337
-9	T028	C0017337
allelotypes	T028	C0002085
levels	T080	C0441889
resistance	T039	C1514892
biotypes	T170	C0449562
BPH	T204	C0600234
coding region	T028	C0079941
BPH1/9	T028	C0017337
diversity	T080	C1880371
rice germplasm	T002	C1140671
nucleotide-binding	T044	C1148916
NB	T044	C1148916
leucine-rich repeat	T087	C1517773
LRR	T087	C1517773
domains	T087	C1514562
repository	T073	C3847505
allele	T028	C0002085
diversity	T080	C1880371
rice	T002	C1140671
plant	T002	C0032098
genetic information	T169	C0017399
insect	T204	C0021585
herbivores	T008	C0562691
allelic variation	T070	C0042333
artificial shuffling	T062	C0242481
gene	T028	C0017337
breeding	T040	C0006159
biotypes	T170	C0449562
BPH	T204	C0600234
Nontoxic	T080	C1518413
Formulations	T167	C0439962
Scintillation	T070	C0678573
Nanocrystals	T073	C1721058
X-ray Computed Tomography	T060	C0040405
Contrast Agents	T130	C0009924
X-ray computed tomography	T060	C0040405
CT	T060	C0040405
noninvasive	T185	C2986496
clinical	T080	C0205210
in vivo	T082	C1515655
imaging techniques	T060	C0079595
X-ray device	T074	C0183263
contrast	T080	C1979874
enhancement technologies	T061	C0969683
study	T062	C2603343
metal tungstates	T130	C0077513
CaWO4	T130	C0054486
contrast agents	T130	C0009924
X-ray	T060	C0043299
radiation	T070	C0851346
CT imaging	T060	C0040405
X-ray	T060	C0043299
mass attenuation	T052	C0599946
tungsten	T196	C0041383
W	T196	C0041383
formulation	T167	C0439962
CaWO4	T130	C0054486
CWO	T130	C0054486
nanoparticles	T073	C1450054
NPs	T073	C1450054
encapsulated	T080	C0205223
poly(ethylene glycol-b-d,l-lactic acid) (PEG-PLA) block copolymer (BCP) capsule	T109	C0257395
PEG-PLA	T109	C0257395
encapsulated	T080	C0205223
CWO NPs	T073	C1450054
CT	T060	C0040405
contrast	T080	C1979874
iodine	T121	C0021968
radiocontrast agents	T130	C0009924
Iohexol	T109	C0022005
W	T196	C0041383
I	T121	C0021968
atoms	T196	C0567415
PEG-PLA	T109	C0257395
coated	T080	C1522408
CWO NPs	T073	C1450054
nontoxic	T080	C1518413
maximum tolerated dose	T081	C0752079
MTD	T081	C0752079
material	T167	C0520510
mice	T015	C0026809
body weight	T032	C0005910
intravenous (IV) administration	T082	C0013125
dextran	T109	C0086140
coated	T080	C1522408
iron oxide	T121	C0060240
nanoparticles	T073	C1450054
clinically	T080	C0205210
MRI	T060	C0024485
contrast agents	T130	C0009924
MTD	T081	C0752079
mice	T015	C0026809
dose	T081	C0178602
injected	T169	C0449894
PEG-PLA	T109	C0257395
CWO NPs	T073	C1450054
no	T033	C1513916
histopathologic	T091	C0677043
damage	T169	C1883709
excretory organs	T023	C0178784
heart	T023	C0018787
liver	T023	C0023884
lungs	T023	C0024109
spleen	T023	C0037993
kidney	T023	C0022646
dose	T081	C0178602
mice	T015	C0026809
blood circulation	T039	C0005775
half-life	T079	C0018517
NPs	T073	C1450054
mice	T015	C0026809
renal	T023	C0022646
hepatobiliary systems	T022	C1711359
intratumorally administered	T169	C1517565
PEG-PLA	T109	C0257395
coated	T080	C1522408
CWO NPs	T073	C1450054
tumor-bearing mouse model	T050	C2986594
week	T079	C0439230
PEG-PLA	T109	C0257395
coated	T080	C1522408
CWO NPs	T073	C1450054
materials	T167	C0520510
CT	T060	C0040405
contrast	T080	C1979874
Albumin	T116	C0001924
Gd	T130	C0016911
CuS	T197	C0056599
Nanotheranostic Agent	T073	C0304231
In Vivo	T082	C1515655
Photoacoustic	T060	C3897929
Photoacoustic / Magnetic Resonance Imaging -Guided Tumor -Targeted Photothermal Therapy	T061	C0087111
Magnetic Resonance Imaging	T060	C0024485
Tumor	T191	C0027651
Photothermal therapy	T061	C0087111
PTT	T061	C0087111
skin	T022	C1123023
skin cancer therapy	T061	C0920425
clinic	T073	C0442592
noninvasiveness	T080	C0205556
low systemic adverse effects	T046	C0261794
biocompatible PTT agents	T073	C0304231
accurate	T080	C0443131
imaging	T060	C0011923
monitoring	T058	C1283169
diagnosis	T033	C0011900
biocompatible Gd -integrated CuS nanotheranostic agent	T073	C0304231
Gd	T130	C0016911
CuS	T197	C0056599
Gd	T130	C0016911
CuS	T197	C0056599
BSA	T116	C0036774
synthesized	T052	C1883254
biomimetic strategy	T041	C0679199
bovine serum albumin	T116	C0036774
BSA	T116	C0036774
biotemplate	T078	C1705542
physiological temperature	T081	C0039476
Gd	T130	C0016911
CuS	T197	C0056599
BSA	T116	C0036774
nanoparticles	T073	C1450054
NPs	T073	C1450054
ultrasmall sizes	T033	C0748864
photothermal conversion efficiency	T033	C0243095
photostability	T033	C0243095
near-infrared (NIR) laser	T070	C1289901
irradiation	T070	C0851346
doped Gd species	T130	C0016911
tunable NIR absorbance	T080	C0205556
Gd	T130	C0016911
CuS	T197	C0056599
BSA	T116	C0036774
NPs	T073	C1450054
tumor-contrasted imaging	T060	C0011923
photoacoustic	T060	C3897929
photoacoustic and magnetic resonance imaging modalities	T169	C1275506
magnetic resonance imaging	T060	C0024485
Gd	T130	C0016911
Gd: CuS @ BSA -mediated PTT	T061	C0087111
CuS	T197	C0056599
BSA	T116	C0036774
therapy efficacy	T033	C0243095
NIR absorption	T033	C0243095
photothermal conversion efficiency	T033	C0243095
immune response	T042	C0301872
triggered by	T080	C1444748
Gd	T130	C0016911
Gd: CuS @ BSA -mediated PTT	T061	C0087111
CuS	T197	C0056599
BSA	T116	C0036774
toxicity studies	T060	C0242890
in vitro	T080	C1533691
in vivo	T082	C1515655
Gd	T130	C0016911
CuS	T197	C0056599
BSA	T116	C0036774
NPs	T073	C1450054
biocompatible agents	T073	C3273359
biodistribution study	T062	C0242481
NPs	T073	C1450054
hepatic clearance	UnknownType	C0678764
body	T016	C0242821
practicality	T080	C0205556
versatility	T080	C0205556
albumin	T116	C0001924
albumin -mediated biomimetic mineralization	T067	C1254366
nanotheranostic agent	T073	C0304231
Gd	T130	C0016911
CuS	T197	C0056599
BSA	T116	C0036774
NPs	T073	C1450054
imaging guidance	T061	C0442972
tumor ablation properties	T061	C0087111
spatial resolution	T080	C0205556
deep tissue penetration	T080	C0205556
tissue	T024	C0040300
Family	T099	C0015576
healthcare professionals	T097	C1704312
perceptions	T041	C0030971
hospice	T058	C0085555
home	T082	C0442519
programme	T058	C0679897
children	T100	C0008059
study	T062	C2603343
Parents	T099	C0030551
improvement	T077	C2986411
quality of life	T078	C0034380
provision	T058	C1283218
hospice	T058	C0085555
supportive care	T061	C0344211
service	T058	C0018747
home	T082	C0442519
study	T062	C2603343
families	T099	C0015576
nurse	T097	C0028661
hospice	T058	C0085555
home	T082	C0442519
programme	T058	C0679897
experiences	T041	C0596545
healthcare professionals	T097	C1704312
programme	T058	C0679897
study	T062	C2603343
telephone interviews	T062	C0021823
parents	T099	C0030551
focus groups	T096	C0016400
individual	T098	C0237401
interviews	T052	C0021822
healthcare professionals	T097	C1704312
parents	T099	C0030551
families	T099	C0015576
programme	T058	C0679897
care	T058	C0086388
healthcare professionals	T097	C1704312
programme	T058	C0679897
parents	T099	C0030551
telephone interviews	T062	C0021823
focus groups	T096	C0016400
external stakeholders	T098	C1257890
participants	T098	C0679646
in-patient	T101	C0030705
hospice staff	T097	C0025106
participants	T098	C0679646
hospice	T058	C0085555
participants	T098	C0679646
interviews	T052	C0021822
individual	T098	C0237401
stakeholders	T098	C1257890
focus group	T096	C0016400
interviews	T052	C0021822
parents	T099	C0030551
care	T058	C0086388
healthcare professionals	T097	C1704312
communication	T054	C0009452
services	T058	C0018747
education and training	T065	C0582584
lone working	T057	C0043227
hospice	T058	C0085555
home	T082	C0442519
programme	T058	C0679897
study	T062	C2603343
programme	T058	C0679897
clarification	T052	C2986669
services	T058	C0018747
communication	T054	C0009452
services	T058	C0018747
families	T099	C0015576
Functional	T169	C0205245
1,3a,6a-triazapentalene	T109	C3253155
scaffold	T104	C1254350
Design	T052	C1707689
fluorescent probes	T130	C0016321
kinesin spindle protein	T116	C1173400
KSP	T116	C1173400
1,3a,6a-Triazapentalene	T109	C3253155
fluorescent	T130	C0016321
chromophore	T120	C0596335
study	T062	C2603343
triazapentalene	T109	C3253155
biphenyl-type	T109	C0005580
inhibitors	T121	C0033671
kinesin spindle protein	T116	C1173400
KSP	T116	C1173400
fluorescent probes	T130	C0016321
intracellular	T082	C0178719
visualization	T169	C0234621
protein	T116	C0033684
Microscopic	T080	C0205288
studies	T062	C2603343
novel	T080	C0205314
triazapentalene	T109	C3253155
labeled	T080	C1708632
compounds	T103	C1706082
inhibitory	T052	C3463820
activity	T169	C0205177
KSP	T116	C1173400
cultured cells	T025	C0007635
information	T078	C1533716
intracellular	T082	C0178719
distribution	T169	C1704711
C4b binding protein	T116	C0056193
negatively regulates	T044	C0013081
TLR1	T116	C0971363
2	T116	C0754728
response	T032	C0871261
TLR2	T116	C0754728
associates with	T080	C0332281
TLR1	T116	C0971363
microbial	T001	C0599840
lipoproteins	T116	C0023820
Pam3CSK4	T116	C1698795
triacylated lipoprotein	T116	C0023820
anchored	T044	C1624581
extracellular domain	T082	C1517050
TLR1	T116	C0971363
TLR2	T116	C0754728
induces	T169	C0205263
pro-inflammatory	T046	C0021368
signals	T038	C3537152
C4b binding protein	T116	C0056193
C4BP	T116	C0056193
complement pathway	T044	C1305430
inhibitor	T080	C1999216
TLR2	T116	C0754728
Immunoprecipitation assay	T059	C0021069
anti-TLR2 mAb	T129	C0021054
C4BP	T116	C0056193
binds to	T044	C1167622
TLR2	T116	C0754728
C4BP-deficient	T028	C1413001
mice	T015	C0206745
Pam3CSK4	T116	C1698795
induced	T169	C0205263
IL-6	T116	C0021760
levels	T080	C0441889
increased	T081	C0205217
compared	T052	C1707455
wild type mice	T015	C0025929
C4BP	T116	C0056193
expressing	T045	C1171362
cells	T025	C0007634
Pam3CSK4	T116	C1698795
induced	T169	C0205263
IL-8 production	T040	C1819461
reduced	T080	C0392756
C4BP	T116	C0056193
expression levels	T081	C3244092
reveal	T080	C0443289
C4BP	T116	C0056193
negative regulation	T044	C0013081
TLR1	T116	C0971363
2	T116	C0754728
dependent	T116	C0079189
pro-inflammatory	T046	C0021368
cytokine production	T040	C1327413
fluorescent conjugated	T130	C0016321
Pam3CSK4	T116	C1698795
C4BP	T116	C0056193
blocks	T169	C0332206
binding of	T044	C1167622
Pam3CSK4	T116	C1698795
TLR1	T116	C0971363
2	T116	C0754728
exogenous	T169	C0205228
C4BP	T116	C0056193
inhibits	T052	C3463820
Pam3CSK4	T116	C1698795
induced signaling	T044	C1511122
IL-8 production	T040	C1819461
C4BP	T116	C0056193
binding to	T044	C1167622
TLR2	T116	C0754728
consequent	T033	C3845876
neutralization	T169	C2987668
activity	T044	C1152633
pro-inflammatory	T046	C0021368
cytokine production	T040	C1327413
C4BP	T116	C0056193
negative regulator	T044	C0013081
TLR1	T116	C0971363
2	T116	C0754728
activity	T044	C1152633
Effect	T080	C1280500
emodin	T109	C0013982
mobility signal transduction system	T043	C0037083
gallbladder	T023	C0016976
smooth muscle	T024	C1267092
Guinea pig	T015	C0085979
cholelithiasis	T047	C0008350
study	T062	C2603343
effect	T080	C1280500
emodin	T109	C0013982
protein	T045	C1171362
gene expressions	T045	C0017262
massagers	UnknownType	C0815029
mobility signal transduction system	T043	C0037083
cholecyst	T023	C0016976
smooth muscle cells	T025	C0596981
guinea pig	T015	C0085979
cholesterol calculus	T031	C0333018
guinea pigs	T015	C0085979
groups	T078	C0441833
control group	T096	C0009932
gall-stone	T047	C1392480
GS	T047	C1392480
group	T078	C0441833
emodin	T109	C0013982
group	T078	C0441833
ursodeoxycholic acid	T109	C0042105
UA	T109	C0042105
group	T078	C0441833
Cholesterol calculus	T031	C0333018
models	T075	C0026336
guinea pigs	T015	C0085979
GS	T047	C1392480
emodin	T109	C0013982
UA	T109	C0042105
groups	T078	C0441833
lithogenic diet	T168	C0012155
emodin	T109	C0013982
UA	T109	C0042105
group	T078	C0441833
weeks	T079	C0439230
histomorphological	T080	C0332437
ultrastructure	T078	C0041623
change	T169	C0392747
gallbladder	T023	C0016976
detected	T033	C0442726
microscope	T074	C0181839
electron microscope	T074	C0181845
plasma	T031	C0032105
cholecystokinin	T116	C0008328
CCK	T116	C0008328
[Ca(2+)]i	T121	C0596235
analyzed	T062	C0936012
radioimmunoassay	T059	C0034580
flow cytometry	T059	C0016263
protein	T116	C0033684
mRNA	T114	C0035696
Gsα	T116	C0086903
Giα	T116	C0086706
Cap	T116	C0073423
cholecyst	T023	C0016976
cells	T025	C0596981
determined by	T080	C0521095
western blotting	T059	C0005863
real time polymerase chain reaction	T063	C1709846
RT-PCR	T063	C1709846
Emodin	T109	C0013982
UA	T109	C0042105
pathogenic	T033	C3816499
changes	T169	C0392747
epithelial cells	T025	C0014597
muscle cells	T025	C0596981
gallbladder	T023	C0016976
guinea pig	T015	C0085979
cholesterol calculus	T031	C0333018
microscope	T074	C0181839
transmission electron microscope	T074	C0262880
cholecyst	T023	C0016976
cells	T025	C0596981
GS	T047	C1392480
group	T078	C0441833
CCK	T116	C0008328
levels	T080	C0441889
plasma	T031	C0032105
[Ca(2+)]i	T121	C0596235
decreased	T081	C0205216
protein	T116	C0033684
mRNA	T114	C0035696
GS	T047	C1392480
down-regulated	T044	C0013081
protein	T116	C0033684
mRNA	T114	C0035696
Gi	T116	C0086706
Cap	T116	C0073423
up-regulated	T044	C0041904
Emodin	T109	C0013982
significantly	T078	C0750502
decreased	T081	C0205216
formative	T169	C1522492
rate	T081	C1521828
gallstone	T047	C1392480
pathogenic	T033	C3816499
change	T169	C0392747
epithelial cells	T025	C0014597
muscle cells	T025	C0596981
CCK	T116	C0008328
levels	T080	C0441889
plasma	T031	C0032105
[Ca(2+)]i	T121	C0596235
cholecyst	T023	C0016976
cells	T025	C0596981
protein	T116	C0033684
mRNA	T114	C0035696
Gs	T116	C0086903
cholecyst	T023	C0016976
cells	T025	C0596981
reduced	T080	C0392756
protein	T116	C0033684
mRNA	T114	C0035696
Gi	T116	C0086706
Cap	T116	C0073423
cholecyst	T023	C0016976
cells	T025	C0596981
guinea pig	T015	C0085979
cholesterol calculus	T031	C0333018
dysfunction	T077	C3887504
gallbladder contraction	T042	C0232772
disorders	T047	C0012634
mobility signal transduction system	T043	C0037083
cholecyst	T023	C0016976
smooth muscle cells	T025	C0596981
including	T169	C0332257
plasma	T031	C0032105
CCK	T116	C0008328
[Ca(2+)]i	T121	C0596235
cholecyst	T023	C0016976
cells	T025	C0596981
abnormal protein	T116	C0311448
mRNA	T114	C0035696
Gs	T116	C0086903
Gi	T116	C0086706
Cap	T116	C0073423
Emodin	T109	C0013982
enhance	T052	C2349975
contractibility of gallbladder	T042	C0232772
alleviate	T081	C0547047
cholestasis	T047	C0008370
regulating	T038	C1327622
plasma	T031	C0032105
CCK	T116	C0008328
levels	T080	C0441889
[Ca(2+)]i	T121	C0596235
cholecyst	T023	C0016976
cells	T025	C0596981
protein	T116	C0033684
mRNA	T114	C0035696
Gs	T116	C0086903
Gi	T116	C0086706
Cap	T116	C0073423
Quantification	T081	C1709793
urinary	T080	C1524119
mono-hydroxylated metabolites	T123	C0870883
polycyclic aromatic hydrocarbons	T109	C0032458
on-line solid phase extraction	T059	C1720880
high performance liquid chromatography-tandem mass spectrometry	T059	C4054772
Human	T016	C0086418
exposure to	T080	C0332157
polycyclic aromatic hydrocarbons	T109	C0032458
PAHs	T109	C0032458
assessed	T052	C1516048
monitoring	T058	C1283169
urinary	T080	C1524119
mono-hydroxylated PAHs	T109	C0032458
OH-PAHs	T109	C0032458
Gas chromatography	T059	C0008555
GC	T059	C0008555
separate	T080	C0443299
OH-PAHs	T109	C0032458
quantification	T081	C1709793
mass spectrometry	T059	C0037813
biomonitoring	T057	C0005517
studies	T062	C2603343
GC	T059	C0008555
derivatization	T169	C0449851
time consuming	T080	C3827829
developed	T169	C1527148
on-line solid phase extraction	T059	C1720880
coupled	T169	C1948027
isotope	T196	C0022262
dilution	T169	C1948037
high performance liquid chromatography-tandem mass spectrometry	T059	C4054772
on-line-SPE	T059	C1720880
HPLC-MS	T059	C4054772
MS	T059	C0037813
method	T170	C0025663
quantification	T081	C1709793
urine	T031	C0042036
1-OH-naphthalene	T109	C0027375
2-OH-naphthalene	T109	C0027375
2-OH-fluorene	T109	C0060517
3-OH-fluorene	T109	C0060517
1-OH-phenanthrene	T109	C0031367
2-OH	T109	C0031367
3-OH-phenanthrene	T109	C0031367
4-OH-phenanthrene	T109	C0031367
1-OH-pyrene	T109	C0072667
method	T170	C0025663
employed	T033	C0557351
well plate platform	T082	C4283957
on-line SPE	T059	C1720880
good sensitivity	T067	C2346484
limits	T169	C0439801
detection	T061	C1511790
ranged	T081	C1514721
urine	T031	C0042036
Accuracy	T080	C0443131
calculated	T059	C1443182
recovery	T052	C0237820
percentage	T081	C0439165
spiking	T082	C0348018
levels	T080	C0441889
varied	T080	C0205419
depending	T080	C1701901
analyte	T167	C0443354
inter	T079	C1548610
intra	T079	C0347985
day precision	T078	C1561539
calculated	T059	C1443182
repeated	T169	C0205341
measurements	T169	C0242485
quality control	T169	C0034378
materials	T167	C0520510
varied	T080	C0205419
Adequate	T080	C0205411
method	T170	C0025663
performance	T052	C1882330
confirmed by	T080	C0521093
acceptable	T080	C1879533
recovery	T052	C0237820
NIST	T092	C0021622
standard reference	T081	C0034925
materials	T167	C0520510
high-throughput	T170	C0872047
on-line-SPE	T059	C1720880
HPLC-MS	T059	C4054772
MS	T059	C0037813
method	T170	C0025663
large	T081	C0549177
scale	T077	C1522412
epidemiological studies	T062	C0002783
Graphical abstract	T170	C0870616
LC-MS chromatogram	T169	C1883002
urinary	T080	C1524119
mono-hydroxylated PAH	T109	C0032458
metabolites	T123	C0870883
Utility	T169	C0205245
applicability	T169	C0205245
"Childhood Obesity Risk Evaluation" (CORE)-index	T170	C0282574
obesity	T047	C0028754
childhood	T079	C0231335
adolescence	T079	C0001578
Greece	T083	C0018226
early	T079	C1279919
life	T078	C0376558
Early	T079	C1279919
identification	T058	C0150323
infants	T100	C0021270
high risk	T033	C0332167
obese	T047	C0028754
later	T079	C0205087
childhood	T079	C0231335
adolescence	T079	C0001578
obesity	T047	C0028754
prevention	T080	C2700409
initiative	T033	C1287154
utility	T169	C0205245
applicability	T169	C0205245
"Childhood Obesity Risk Evaluation (CORE)" index	T170	C0282574
screening	T058	C1710032
tool	T073	C0336791
early	T079	C1279919
prediction	T078	C0681842
obesity	T047	C0028754
childhood	T079	C0231335
adolescence	T079	C0001578
Anthropometric	T078	C1511726
socio-demographic data	T078	C1511726
collected	T078	C1516695
cross-sectionally	T080	C0205556
retrospectively	T080	C1514923
sample	T167	C0370003
children	T100	C0008059
adolescents	T100	C0205653
calculating	T052	C1441506
CORE-index score	T170	C0282574
Logistic regression analyses	UnknownType	C0681925
associations	T080	C0439849
CORE-index score	T170	C0282574
obesity	T047	C0028754
gender	T032	C0079399
age group	T100	C0027362
cut-off point analysis	T062	C0242481
optimal	T080	C2698651
value	T081	C1522609
CORE-index score	T170	C0282574
differentiates	T080	C0205615
obese	T047	C0028754
non-obese children	T100	C0008059
Mean CORE-index score	T170	C0282574
total	T080	C0439810
sample	T167	C0370003
sd	T081	C0871420
increase	T169	C0442805
CORE-index score	T170	C0282574
associated with	T080	C0332281
C.I.	T081	C0009667
increased	T081	C0205217
likelihood	T081	C0033204
obesity	T047	C0028754
childhood	T079	C0231335
adolescence	T079	C0001578
optimal	T080	C2698651
cut-off value	T081	C0392762
CORE-index score	T170	C0282574
predicted	T078	C0681842
obesity	T047	C0028754
highest	T080	C1522410
sensitivity and specificity	T081	C0036668
utility	T169	C0205245
applicability	T169	C0205245
CORE-index	T170	C0282574
screening	T058	C1710032
tool	T073	C0336791
early	T079	C1279919
identification	T058	C0150323
infants	T100	C0021270
higher risk	T033	C0332167
obese	T047	C0028754
childhood	T079	C0231335
adolescence	T079	C0001578
tool	T073	C0336791
health professionals	T097	C1704312
infants	T100	C0021270
high risk	T033	C0332167
counselling	T058	C0010210
parents	T099	C0030551
caregivers	T097	C0085537
effectiveness	T080	C1280519
early	T079	C1279919
obesity	T047	C0028754
prevention	T080	C2700409
initiatives	T033	C1287154
Childhood	T079	C0231335
obesity	T047	C0028754
epidemic proportions	T081	C1709707
perinatal	T033	C0243095
socio-demographic indices	T033	C0243095
identified	T080	C0205396
childhood	T079	C0231335
obesity	T047	C0028754
children	T100	C0008059
CORE-index	T170	C0282574
screening	T058	C1710032
tool	T073	C0336791
obesity	T047	C0028754
risk	T078	C0035647
year-old	T079	C1510829
children	T100	C0008059
utility	T169	C0205245
applicability	T169	C0205245
CORE-index	T170	C0282574
screening	T058	C1710032
tool	T073	C0336791
age	T032	C0001779
years	T079	C1510829
CORE-index	T170	C0282574
cost-effective	T080	C0205556
screening	T058	C1710032
tool	T073	C0336791
health professionals	T097	C1704312
obesity	T047	C0028754
preventive measures	T170	C0033107
early	T079	C1279919
life	T078	C0376558
Methodology	T078	C3266812
development	T169	C1527148
aquatic environmental	T067	C0563034
assessment	T058	C0220825
Water Framework Directive	T170	C0282574
aims	T078	C1947946
ecological	T070	C0162358
status	T080	C0449438
surface	T082	C0205148
ground water bodies	T082	C0596631
quality	T080	C0332306
evaluation	T058	C0220825
waters	T121	C0043047
special	T080	C0205555
water	T121	C0043047
chemistry	T169	C0079107
parameters	T077	C0549193
Water Framework Directive	T170	C0282574
legal regulations	T089	C0680575
purpose	T169	C1285529
quantitative	T081	C0392762
water	T121	C0043047
quality	T080	C0332306
assessment	T058	C0220825
method	T170	C0025663
provide	T052	C1999230
rapid	T080	C0456962
accurate	T080	C0443131
reliable	T170	C3858758
information	T078	C1533716
quality	T080	C0332306
surface	T082	C0205148
waters	T121	C0043047
water	T121	C0043047
chemistry	T169	C0079107
parameters	T077	C0549193
Quality	T080	C0332306
classes	T170	C0456387
defined	T080	C0442825
water	T121	C0043047
chemistry	T169	C0079107
parameter	T077	C0549193
legal limit values	T089	C0752073
water	T121	C0043047
parameters	T077	C0549193
weight indices	T081	C0392762
calculated	T059	C1443182
outcome	T169	C1274040
paired comparison	T081	C0086766
water	T121	C0043047
chemistry	T169	C0079107
parameters	T077	C0549193
normalized	T062	C1882115
matrix	T082	C1704640
parametric level analysis	UnknownType	C0681933
water	T121	C0043047
chemistry	T169	C0079107
parameters	T077	C0549193
aquatic environment index	T170	C0282574
AEI	T170	C0282574
calculated	T059	C1443182
provided	T052	C1999230
general information	T185	C0332118
quality	T080	C0332306
water	T121	C0043047
water	T121	C0043047
chemistry	T169	C0079107
parameters	T077	C0549193
method	T170	C0025663
Lake	T083	C0337049
Balaton	T083	C0017446
Hungary	T083	C0020174
water	T121	C0043047
samples	T167	C0370003
Balatonfüred City	T083	C0017446
lake	T083	C0337049
area	T083	C0017446
analyzed	T062	C0936012
evaluated	T058	C0220825
method	T170	C0025663
WDR26	T116	C4307325
promotes	T052	C0033414
mitophagy	T043	C1820119
cardiomyocytes	T025	C0225828
induced	T169	C0205263
hypoxia	T046	C0242184
Parkin	T116	C1570554
translocation	T043	C0599893
Myocardial ischemia	T047	C0151744
heart	T023	C0018787
condition	T080	C0348080
reduction	T080	C0392756
blood flow	T039	C0232338
heart	T023	C0018787
heart	T023	C0018787
receiving	T080	C1514756
oxygen	T121	C0030054
Myocardial ischemia	T047	C0151744
cause of death	T033	C0007465
globally	T082	C0205246
Heart	T023	C0018787
ischemic preconditioning	T061	C0376466
IPC	T061	C0376466
protective effect	T080	C1280500
myocardial cell	T025	C0225828
death	T043	C0007587
induced	T169	C0205263
ischemia	T046	C0022116
ischemia-reperfusion injury	T037	C0035126
WDR26	T116	C4307325
identified	T080	C0205396
protein	T116	C0033684
increased	T081	C0205217
rat	T015	C0034693
cardiac	T023	C0018787
IPC	T061	C0376466
WDR26	T116	C4307325
promote	T052	C0033414
proliferation	T043	C0596290
H9c2 cells	T025	C0007634
cardiomyocytes	T025	C0225828
oxidative stress	T049	C0242606
inhibiting	T052	C3463820
apoptosis	T043	C0162638
role	T077	C1705810
myocardial ischemia	T047	C0151744
study	T062	C2603343
WDR26	T116	C4307325
myocardial ischemia	T047	C0151744
H9c2 cell	T025	C0007634
hypoxia	T046	C0242184
results	T169	C1274040
WDR26	T116	C4307325
induced	T169	C0205263
myocardial ischemia	T047	C0151744
H9c2 cell	T025	C0007634
hypoxia	T046	C0242184
WDR26	T116	C4307325
H9c2 cells	T025	C0007634
hypoxia	T046	C0242184
injury	T037	C3263722
inhibiting	T052	C3463820
LDH	T116	C0022917
cell viability	T043	C0007620
WDR26	T116	C4307325
promotes	T052	C0033414
hypoxia	T046	C0242184
induced	T169	C0205263
autophagy	T043	C0004391
hypoxia	T046	C0242184
H9c2 cells	T025	C0007634
H9c2 cell	T025	C0007634
hypoxia	T046	C0242184
WDR26	T116	C4307325
increases	T169	C0442805
mitochondrial membrane potential	T043	C1720920
increases	T169	C0442805
Parkin	T116	C1570554
translocation	T043	C0599893
mitochondria	T026	C0026237
Parkin	T116	C1570554
translocated	T043	C0599893
mitochondria	T026	C0026237
WDR26	T116	C4307325
increase	T169	C0442805
mitochondria	T026	C0026237
protein ubiquitination	T044	C1816438
hypoxia	T046	C0242184
H9c2 cells	T025	C0007634
WDR26	T116	C4307325
hypoxia	T046	C0242184
WDR26	T116	C4307325
hypoxia	T046	C0242184
autophagy	T043	C0004391
mitophagy	T043	C1820119
study	T062	C2603343
novel	T080	C0205314
WDR26	T116	C4307325
cardiomyocyte	T025	C0225828
injury	T037	C3263722
hypoxia	T046	C0242184
WDR26	T116	C4307325
target	T169	C1521840
treatment	T061	C0087111
myocardial ischemia	T047	C0151744
Impact	T080	C4049986
antibiotic	T195	C0003232
de-escalation	T061	C3651014
clinical outcomes	T169	C1274040
community-acquired	T080	C0456394
pneumococcal pneumonia	T047	C0032300
antibiotic	T195	C0003232
de-escalation	T061	C3651014
reduces	T080	C0392756
adverse drug effects	T046	C0041755
costs	T081	C0085123
evidence	T078	C3887511
community-acquired pneumococcal pneumonia	T047	C0032300
CAPP	T047	C0032300
lacking	T080	C0332268
retrospective	T080	C1514923
analysis	T062	C0936012
data	T078	C1511726
cohort	T098	C0599755
hospitalized adults	T101	C0001585
CAPP	T047	C0032300
Pneumococcal	T047	C0032300
aetiology	T169	C1314792
established	T080	C0443211
patients	T101	C0030705
positive cultures	T033	C0159125
Streptococcus pneumoniae	T007	C0038410
blood	T031	C0005767
sterile fluids	T031	C0005889
sputum	T031	C0038056
positive	T033	C1446409
urinary antigen test	T059	C1319561
De-escalation therapy	T061	C3651014
antibiotic therapy	T061	C0338237
penicillin	T109	C0220892
amoxicillin	T109	C0002645
amoxicillin/clavulanate	T121	C0054066
admission	T058	C0184666
outcomes	T169	C1274040
day	T079	C0439228
mortality	T081	C0205848
length of hospital stay	T079	C3826195
LOS	T079	C3826195
Adjustment	T169	C0456081
performed	T169	C0884358
multivariate	T081	C0026777
propensity score	T081	C2718044
analyses	T062	C0936012
CAPP	T047	C0032300
antibiotic	T195	C0003232
de-escalation	T061	C3651014
admission	T058	C0184666
performed	T169	C0884358
cases	T169	C0868928
adjustment	T169	C0456081
antibiotic	T195	C0003232
de-escalation	T061	C3651014
associated with	T080	C0332281
risk	T078	C0035647
mortality	T081	C0205848
OR	T081	C0028873
CI	T081	C0009667
protective factor	T055	C0679688
prolonged	T079	C0439590
LOS	T079	C3826195
median	T081	C0876920
OR	T081	C0028873
CI	T081	C0009667
results	T169	C1274040
patients	T101	C0030705
high-risk	T033	C0332167
pneumonia	T047	C0032285
clinical instability	T033	C1444783
bacteraemia	T047	C0004610
No significant differences	T033	C3842396
documented	T058	C1301725
adverse drug reactions	T046	C0041755
readmission	T058	C0184666
days	T079	C0439228
Antibiotic	T195	C0003232
de-escalation	T061	C3651014
effective	T080	C1704419
reducing	T080	C0392756
duration	T079	C0449238
LOS	T079	C3826195
adversely affect	T046	C0879626
outcomes	T169	C1274040
patients	T101	C0030705
CAPP	T047	C0032300
bacteraemia	T047	C0004610
severe disease	T047	C0012634
clinically unstable	T033	C0443343
Radiation	T070	C0851346
induced	T169	C0205263
Parotid Gland Atrophy	T046	C0341045
Patients	T101	C0030705
Head and Neck Cancer	T191	C0278996
Carbon-ion Radiotherapy	T061	C3494442
study	T062	C0008972
clarify	T052	C2986669
relationship	T080	C0439849
dosimetric	T059	C0034603
factors	T169	C1521761
parotid gland (PG) atrophy	T046	C0341045
carbon ion radiotherapy	T061	C3494442
C-ion RT	T061	C3494442
patients	T101	C0030705
head and neck tumours	T191	C0018671
PGs	T023	C0030580
patients	T101	C0030705
treated with	T061	C0332293
total doses	T081	C0034620
relative biological effectiveness	T081	C3825732
RBE	T081	C3825732
PG	T023	C0030580
volumes	T081	C0449468
measured	T059	C2700258
computed tomographic images	T078	C1551337
C-ion RT	T061	C3494442
months	T079	C0439231
median	T081	C0876920
follow-up	T058	C1522577
period	T079	C1948053
months	T079	C0439231
range	T081	C1514721
months	T079	C0439231
Univariate analysis	T062	C0683962
PG	T023	C0030580
volumes	T081	C0449468
RBE	T081	C3825732
V5	T081	C0449468
V10	T081	C0449468
V15	T081	C0449468
V20	T081	C0449468
mean	T081	C0444504
dose	T081	C0034620
maximum	T081	C0806909
dose	T081	C0034620
associated with	T080	C0332281
PG atrophy	T046	C0341045
Multivariate analysis	T081	C0026777
V5	T081	C0449468
associated with	T080	C0332281
atrophy	T046	C0341045
Increasing	T169	C0442808
V5	T081	C0449468
risk factor	T033	C0035648
PG atrophy	T046	C0341045
C-ion RT	T061	C3494442
IL-27	T116	C1706289
Suppression	T061	C0021079
Experimental	T080	C1517586
Allergic Asthma	T047	C0155877
TLR7	T116	C1579758
8	T116	C1579755
Agonist	T121	C2987634
R848	T109	C3642356
Resiquimod	T109	C0965594
models of experimental	T050	C0684309
allergic asthma	T047	C0155877
TLR7	T116	C1579758
8	T116	C1579755
agonist	T121	C2987634
resiquimod	T109	C0965594
R848	T109	C3642356
inhibitor	T080	C1999216
type 2 helper cell	T025	C0242633
inflammatory responses	T046	C1155266
therapeutic effects	T201	C1527144
model of experimental	T050	C0684309
allergic asthma	T047	C0155877
induction	T061	C0857127
IL-27	T116	C1706289
R848	T109	C3642356
ameliorative	T080	C0332272
R848	T109	C3642356
inhibited	T080	C0311403
hallmarks	T025	C1512330
experimental	T080	C1517586
allergic asthma	T047	C0155877
airway hyperreactivity	T047	C0004096
eosinophilic	T169	C0333930
airway	T023	C0458827
inflammation	T046	C0021368
mucus hypersecretion	T047	C0155872
Ag	T129	C0003320
specific Ig	T116	C0358334
production	T038	C0003261
R848	T109	C3642356
IL-5	T116	C0021759
IL-13	T116	C0214743
IL-17	T116	C0384648
IFN-γ	T116	C3539881
IL-27	T116	C1706289
Neutralization	T169	C2987668
IL-27	T116	C1706289
therapeutic effect	T201	C1527144
R848	T109	C3642356
experimental	T080	C1517586
asthma	T047	C0004096
model	T050	C0684309
R848	T109	C3642356
suppression	T061	C0021079
IL-27	T116	C1706289
In vitro	T080	C1533691
R848	T109	C3642356
induced	T061	C0857127
IL-27	T116	C1706289
murine	T015	C0026809
alveolar macrophages	T025	C0085236
dendritic cells	T025	C0011306
enhanced	T052	C2349975
expression	T045	C1171362
programmed death-ligand 1	T129	C4300350
expression	T045	C1171362
monocytes	T025	C0085236
dendritic cells	T025	C0011306
regulate	T038	C1327622
peripheral tolerance	T042	C3179073
murine	T015	C0026809
human	T016	C0086418
in vitro	T080	C1533691
IL-27	T116	C1706289
enhanced	T052	C2349975
secretion	T043	C1327616
IFN-γ	T116	C3539881
inhibited	T080	C0311403
IL-5	T116	C0021759
IL-13	T116	C0214743
Th2	T025	C0242633
R848	T109	C3642356
suppression	T061	C0021079
experimental	T080	C1517586
asthma	T047	C0004096
IL-27	T116	C1706289
IL-27	T116	C1706289
Th2	T025	C0242633
allergic diseases	T047	C1504369
functional	T169	C0205245
patients	T101	C0030705
revision arthroscopic repair	T061	C1997575
rotator cuff tears	T047	C0263912
without	T080	C0332288
arthroscopic	T082	C0443142
suprascapular nerve release	T061	C3515385
functional	T169	C0205245
patients	T101	C0030705
revision repair	T061	C1997575
rotator cuff tears	T047	C0263912
retracted medial	T082	C1254362
glenoid	T030	C1261046
Goutallier Grade 4 atrophy	T046	C0026846
release of the suprascapular nerve	T061	C3515385
patients	T101	C0030705
Grade 3 atrophy	T046	C0026846
revision rotator cuff repair	T061	C1997575
RTCR	T061	C1997575
nerve release	T061	C3515385
patients	T101	C0030705
nerve release	T061	C3515385
functional	T169	C0205245
University of California	T092	C1883464
Los Angeles	T083	C0024015
shoulder rating scale	T081	C0681889
UCLA	T081	C0681889
patients	T101	C0030705
revision repair	T061	C1997575
rotator cuff tears	T047	C0263912
release of the suprascapular nerve	T061	C3515385
suprascapular notch	T029	C0816410
preoperative	T079	C0445204
postoperative	T079	C0032790
UCLA score	T080	C0237855
patients	T101	C0030705
group	T098	C1257890
patients	T101	C0030705
revision RTCR	T061	C1997575
without	T080	C0332288
suprascapular nerve release	T061	C3515385
groups	T098	C1257890
preoperatively	T079	C0445204
follow-up	T058	C1522577
preoperative	T079	C0445204
UCLA score	T080	C0237855
nerve-release group	T098	C1257890
follow-up	T058	C1522577
group	T098	C1257890
preoperative	T079	C0445204
UCLA score	T080	C0237855
follow-up	T058	C1522577
preoperative	T079	C0445204
UCLA score	T080	C0237855
nerve-release group	T098	C1257890
postoperative	T079	C0032790
UCLA score	T080	C0237855
groups	T098	C1257890
nerve-release group	T098	C1257890
flexion	T042	C0231452
strength	T042	C0517349
pain relief	T061	C0451615
Patients	T101	C0030705
release of the suprascapular nerve	T061	C3515385
revision RTCR	T061	C1997575
pain relief	T061	C0451615
active forward flexion	T042	C0231452
strength	T042	C0517349
group	T098	C1257890
without	T080	C0332288
nerve release	T061	C3515385
Fading	T081	C0205216
With Time	T079	C0332311
PD-L1	T129	C4300350
Immunoreactivity	T044	C0597879
Non-Small Cells Lung Cancer	T191	C0007131
Tissues	T024	C0040300
Methodological Study	T057	C0025662
Blockade	T169	C0332206
inhibitory immune checkpoints	T043	C1155874
immunologic	T169	C0205470
option	T169	C1518601
tumor therapy	T061	C0920425
Inhibition	T052	C3463820
programmed cell death protein 1	T116	C2986635
ligand	T103	C0023688
programmed death-ligand 1	T129	C4300350
PD-L1	T129	C4300350
clinical trials	T062	C0008976
advanced	T080	C0205179
melanoma	T191	C0025202
non-small cell lung cancer	T191	C0007131
NSCLC	T191	C0007131
bladder	T191	C0005695
kidney cancer	T191	C1378703
immunohistochemical	T059	C1441616
IHC	T059	C1441616
expression	T045	C1171362
PD-L1	T129	C4300350
reagents	T130	C0034760
clones	T024	C1522642
cell	T025	C0007634
expression	T045	C1171362
subjective	T080	C0439655
interpretation	T033	C0438231
PD-L1	T129	C4300350
immunoreactivity	T044	C0597879
epithelial cells	T025	C0014597
lymphocytes	T025	C0024264
issue	T033	C0033213
NSCLC	T191	C0007131
surgical specimens	T024	C1292533
pathologic examination	T060	C4086729
January	T080	C3829466
July	T080	C3829447
microarray approach	T059	C1449575
IHC expression	T059	C1441616
PD-L1	T129	C4300350
tumor-infiltrating lymphocytes	T025	C0079722
tumor cells	T025	C0597032
TCs	T025	C0597032
ICH staining	T059	C1441616
tumor histology	T091	C1516204
grade	T185	C0919553
tissue blocks	T024	C0040300
finding	T033	C0243095
fading	T081	C0205216
PD-L1	T129	C4300350
IHC expression	T059	C1441616
TCs	T025	C0597032
tissues	T024	C0040300
PD-L1	T129	C4300350
expression	T045	C0017262
tumor-infiltrating lymphocytes	T025	C0079722
years	T079	C0439234
similar	T080	C2348205
significant higher	T080	C1299395
immunoreactivity	T044	C0597879
TCs	T025	C0597032
high grade	T080	C0205082
NSCLC	T191	C0007131
squamous carcinoma	T191	C0007137
histotype	T201	C0449574
low grade	T080	C1282907
tumors	T091	C0019638
adenocarcinoma	T191	C0001418
histology	T091	C0019638
IHC evaluation	T059	C1441616
PD-L1	T129	C4300350
NSCLC	T191	C0007131
archival tissues	T024	C0040300
pathology setting	T091	C0030664
tissue blocks	T024	C0040300
year	T079	C0439234
Differential	T080	C1705242
transcriptome	T086	C3178810
expression	T045	C0017262
human	T016	C0086418
nucleus accumbens	T023	C0028633
loneliness	T033	C0023974
Loneliness	T033	C0023974
associated with	T080	C0332281
impaired	T046	C0684336
mental	T041	C0025353
physical health	T078	C0018684
lonely individuals	T098	C0237401
differential expression	T045	C1519516
inflammatory	T169	C0333348
genes	T028	C0017337
peripheral	T082	C0205100
leukocytes	T025	C0023516
diminished	T081	C0205216
activation	T045	C0017255
brain	T023	C0006104
reward regions	T029	C1273723
nucleus accumbens	T023	C0028633
gene expression	T045	C0017262
human	T016	C0086418
brain	T023	C0006104
genome-wide RNA expression	T045	C0017262
post-mortem	T060	C0004398
nucleus accumbens	T023	C0028633
donors	T098	C0013018
loneliness	T033	C0023974
measures	T081	C0079809
Loneliness	T033	C0023974
associated with	T080	C0332281
differentially expressed transcripts	T114	C1519595
genes	T028	C0017337
genes	T028	C0017337
DEGs	T028	C0017337
false discovery rate	T081	C1880720
associated with	T080	C0332281
behavioral processes	T053	C0004927
neurological disease	T047	C0027765
psychological disorders	T048	C0004936
cancer	T191	C0006826
organismal	T001	C0029235
injury	T037	C0178314
skeletal	T047	C0263661
muscular disorders	T047	C0026848
networks	T169	C1882071
upstream	T082	C0522505
RNA regulators	T028	C0017362
DEGs	T028	C0017337
associated with	T080	C0332281
Alzheimer's disease	T047	C0002395
AD	T047	C0002395
genes	T028	C0017337
correlated	T080	C1707520
loneliness	T033	C0023974
sample	T167	C0370003
gene expression analyses	T063	C1880945
AD	T047	C0002395
diagnosis	T033	C0011900
targets	T169	C1521840
mechanistic studies	T062	C0242481
gene	T028	C0017337
nucleus accumbens	T023	C0028633
gene regulatory mechanisms	T045	C0017263
diseases	T047	C0012634
loneliness	T033	C0023974
Molecular Psychiatry advance online publication	T073	C0034036
November	T079	C3828767
Quality Properties	T080	C0871161
Kiwifruit	T168	C0440282
Treated by	T061	C0332293
Cinnamaldehyde	T109	C0055754
Citral	T109	C0055809
Microbial	T001	C0599840
Antioxidant Capacity	T044	C1148564
Cold Storage	T059	C0010405
evaluate	T058	C0220825
microbiological	T170	C0025953
characteristics	T080	C1521970
antioxidant	T044	C1148564
physiological activities	T039	C0031843
kiwifruits	T168	C0440282
Actinida deliciosa	T002	C0971874
cinnamaldehyde	T109	C0055754
citral	T109	C0055809
fumigation	T068	C0016804
treatments	T169	C1522326
storage	T169	C1698986
Essential oils	T109	C0028908
EOs	T109	C0028908
treatment	T169	C1522326
viable counts	T081	C0750480
yeast	T004	C0043393
mold	T004	C0369241
EOs	T109	C0028908
antioxidant activities	T044	C1148564
kiwifruit	T168	C0440282
enhanced	T052	C2349975
phenolics	T109	C0359916
flavonoids	T109	C0596577
fruit	T168	C0016767
tissue	T025	C1514137
ascorbic acid	T109	C0003968
treated	T169	C1522326
groups	T078	C0441833
rate	T081	C1521828
MDA	T109	C0024643
malondialdehyde	T109	C0024643
H2 O2	T121	C0020281
hydrogen peroxide	T121	C0020281
O2(-)	T196	C0038836
superoxide anion	T196	C0038836
effectively	T080	C1704419
decreased	T081	C0205216
Physicochemical characteristics	T080	C1521970
kiwifruits	T168	C0440282
treated	T169	C1522326
group	T078	C0441833
flesh luminosity	T080	C0009393
firmness	T080	C1545487
EOs	T109	C0028908
decreased	T081	C0205216
reducing sugar	T109	C0026492
increased	T081	C0205217
soluble protein	T116	C0033684
amino acid	T116	C0002520
EOs	T109	C0028908
treatment	T169	C1522326
positive effects	T080	C1280500
senescence	T038	C3546449
enhancing	T052	C2349975
antioxidant capacities	T044	C1148564
kiwifruit	T168	C0440282
Anti-inflammatory effect	T080	C1515999
Yu-Ping-Feng-San	T109	C1676720
TGF-β1	T116	C1704256
signaling suppression	T038	C3158357
rat	T015	C0034721
model	T050	C0012644
COPD	T047	C0024117
Yu-Ping-Feng-San	T109	C1676720
YPFS	T109	C1676720
Chinese medicine	T121	C0013227
treatment	T169	C1522326
diseases	T047	C0012634
respiratory systems	T022	C0035237
chronic obstructive pulmonary disease	T047	C0024117
COPD	T047	C0024117
chronic inflammatory disease	T047	C1290886
molecular mechanism	T044	C3537153
transforming growth factor beta 1	T116	C1704256
TGF-β1	T116	C1704256
Smad2	T116	C1566792
signaling pathway	T044	C0037080
inflammatory cytokines	T116	C0079189
YPFS	T109	C1676720
attenuate	T052	C0599946
inflammatory response	T046	C1155266
TGF-β1	T116	C1704256
Smad2	T116	C1566792
signaling	T038	C3537152
COPD	T047	C0024117
rats	T015	C0034721
cigarette smoke extract	T131	C0239059
CSE	T131	C0239059
treated	T169	C1522326
human	T016	C0086418
bronchial epithelial (Beas-2B) cells	T025	C1711178
COPD	T047	C0024117
rat	T015	C0034721
model	T050	C0012644
exposure	T080	C0332157
cigarette smoke	T131	C0239059
intratracheal instillation	T169	C1555389
lipopolysaccharide	T109	C0023810
YPFS	T109	C1676720
animals	T008	C0003062
efficacy	T080	C1280519
YPFS	T109	C1676720
severity	T080	C0439793
pulmonary pathological damage	T046	C0030660
pro-inflammation cytokines	T116	C0079189
collagen related genes	T028	C0017337
activation	T052	C1879547
TGF-β1	T116	C1704256
Smad2	T116	C1566792
signaling pathway	T044	C0037080
CSE	T131	C0239059
treated	T169	C1522326
cells	T025	C0007634
effect	T080	C1280500
YPFS	T109	C1676720
TGF-β1	T116	C1704256
Smad2	T116	C1566792
signaling	T038	C3537152
knockdown	T063	C2350567
Smad2	T028	C1334468
Si-RNA	T114	C1099354
pretreatment	T052	C3539076
inhibitor	T080	C1999216
TGF-β1	T116	C1704256
YPFS	T109	C1676720
injury of lung	T037	C0273115
suppressed	T169	C1260953
pro-inflammatory cytokines	T116	C0079189
collagen deposition	T046	C0333584
COPD	T047	C0024117
animals	T008	C0003062
exogenous TGF-β1	T116	C1704256
IL-1β	T116	C0021753
IL-6	T116	C0021760
TNFα	T116	C1456820
YPFS	T109	C1676720
inflammatory response	T046	C1155266
down-regulated	T044	C0013081
TGF-β1	T116	C1704256
Smad2	T116	C1566792
signaling	T038	C3537152
in vivo	T082	C1515655
in vitro	T080	C1533691
knockdown	T063	C2350567
Smad2	T028	C1334468
inhibition	T052	C3463820
TGF-β1	T116	C1704256
anti-inflammatory effect	T080	C1515999
YPFS	T109	C1676720
CSE	T131	C0239059
treated	T169	C1522326
cells	T025	C0007634
YPFS	T109	C1676720
anti-inflammatory effects	T080	C1515999
suppressing	T169	C1260953
phosphorylation	T044	C0031715
Smad2	T116	C1566792
TGF-β1	T116	C1704256
Smad2	T116	C1566792
signaling pathway	T044	C0037080
YPFS	T109	C1676720
anti-inflammation	T080	C1515999
COPD	T047	C0024117
rats	T015	C0034721
CSE	T131	C0239059
treated	T169	C1522326
Beas-2B cells	T025	C1711178
association	T080	C0439849
maternal	T033	C1858460
hydronephrosis	T047	C0020295
acute	T079	C0205178
flank pain	T184	C0016199
pregnancy	T040	C0032961
prospective	T062	C0033522
pilot-study	T062	C0031928
Maternal	T033	C1858460
hydronephrosis	T047	C0020295
flank pain	T184	C0016199
pregnancy	T040	C0032961
aimed	T078	C1947946
investigate	T169	C1292732
maternal	T033	C1858460
hydronephrosis	T047	C0020295
flank pain	T184	C0016199
intensity	T201	C1320357
consecutive	T080	C1707491
women	T098	C0043210
singleton pregnancies	T040	C0032961
acute	T079	C0205178
flank pain	T184	C0016199
prospectively	T062	C0033522
evaluated	T058	C0220825
renal	T023	C0022646
ultrasonography	T060	C0041618
pain	T184	C0030193
questionnaires	T170	C0034394
visual analogue scale	T060	C0042815
pain intensity	T201	C1320357
study	T062	C2603343
significant	T078	C0750502
correlation	T080	C1707520
hydronephrosis	T047	C0020295
flank pain	T184	C0016199
Spearman's test	T170	C1710141
consecutive	T080	C1707491
women	T098	C0043210
left-sided	T082	C0443246
right-sided	T082	C0444532
bilateral	T082	C0238767
pain	T184	C0030193
mean	T081	C0444504
gestational age	T032	C0017504
women	T098	C0043210
pain	T184	C0030193
weeks	T079	C0439230
consultation	T058	C0009818
mean	T081	C0444504
VAS score	T201	C1508029
women	T098	C0043210
hydronephrosis	T047	C0020295
renal	T023	C0022646
correlation	T080	C1707520
hydronephrosis	T047	C0020295
pain intensity	T201	C1320357
Women	T098	C0043210
mean	T081	C0444504
gestational age	T032	C0017504
weeks	T079	C0439230
infants	T100	C0021270
mean	T081	C0444504
birthweight	T032	C0005612
Hydronephrosis	T047	C0020295
finding	T033	C0243095
pregnant women	T098	C0033011
acute	T079	C0205178
flank pain	T184	C0016199
hydronephrosis	T047	C0020295
pain intensity	T201	C1320357
study	T062	C2603343
normal pregnancy	T033	C0232989
outcomes	T033	C0032972
women	T098	C0043210
Simulating	T062	C0679083
potential	T080	C3245505
role	T077	C1705810
media coverage	T057	C0681284
infected	T033	C0439663
bats	T015	C0008139
Ebola	T047	C0282687
outbreak	T067	C0012652
epidemiological	T169	C1516907
models	T075	C0026336
developed	T169	C1527148
transmission dynamics	T078	C0040722
Ebola virus (EBOV) disease	T047	C0282687
West Africa	T083	C0001747
severity	T080	C0392364
epidemic	T067	C0014499
compartmental model	T170	C2986731
media impact	T080	C4049986
effect	T080	C1280500
infected	T033	C0439663
bats	T015	C0008139
calibrated	T081	C0006751
data	T078	C1511726
cumulative	T080	C1511559
number of deaths	T081	C0205848
confirmed	T033	C0750484
cases	T077	C1706256
estimated	T081	C0750572
CI	T081	C0009667
CI	T081	C0009667
epidemic	T067	C0014499
estimated	T081	C0750572
similar	T080	C2348205
data	T078	C1511726
reported	T058	C0700287
World Health Organization	T093	C0043237
sensitivity analysis	T062	C0936012
indicated	T033	C1444656
increase	T169	C0442805
media impact	T080	C4049986
number	T081	C0237753
infectious	T080	C1550587
bats	T015	C0008139
daily	T079	C0332173
increase	T169	C0442805
cumulative	T080	C1511559
number	T081	C0237753
confirmed	T033	C0750484
cases	T077	C1706256
deaths	T081	C0205848
epidemiological parameters	T169	C1516907
media coverage	T057	C0681284
peak time	T033	C3840073
value	T081	C1522609
cumulative	T080	C1511559
confirmed	T033	C0750484
cases	T077	C1706256
deaths	T081	C0205848
cumulative	T080	C1511559
confirmed	T033	C0750484
cases	T077	C1706256
deaths	T081	C0205848
media	T170	C0009458
mechanism	T169	C0441712
media impact	T080	C4049986
control	T080	C0243148
Ebola	T047	C0282687
outbreak	T067	C0012652
infectious	T080	C1550587
bats	T015	C0008139
potential	T080	C3245505
source	T033	C0449416
epidemic	T067	C0014499
Body	T016	C0242821
Diffusion Weighted Imaging	T060	C0598801
Non-CPMG Fast Spin Echo	T060	C0079595
SS-FSE	T060	C0079595
fast	T080	C0456962
technique	T060	C0079595
off-resonance	T033	C2828093
distortions	T080	C2919017
EPI	T060	C0162734
EPI	T060	C0162734
SS-FSE	T060	C0079595
diffusion weighted imaging	T060	C0598801
DWI	T060	C0598801
Carr-Purcell-Meiboom-Geill (CPMG) condition	T033	C0243095
Non-CPMG	T033	C0243095
phase	T079	C0205390
cycling	T079	C1511572
SS-FSE	T060	C0079595
DWI	T060	C0598801
places	T082	C0442504
constraints	T169	C0443288
reconstruction	T169	C0205245
resolved	T033	C3714811
parallel imaging	T060	C0079595
improved	T033	C0184511
echo stability	T080	C0205360
short duration	T080	C0439593
DIVERSE	T080	C1880371
radiofrequency	T070	C2347883
pulses	T067	C1710082
signal-to-noise ratio	T081	C2986823
SNR	T081	C2986823
EPI	T060	C0162734
nCPMG	T033	C0243095
SS-FSE	T060	C0079595
acquisitions	T066	C1708464
reconstruction techniques	T169	C0449851
similar	T080	C2348205
values	T080	C0042295
Diffusion imaging	T060	C0598801
nCPMG	T033	C0243095
SS-FSE	T060	C0079595
similar	T080	C2348205
SNR	T081	C2986823
EPI	T060	C0162734
acquisition	T066	C1708464
apparent diffusion coefficient	T077	C3890194
values	T080	C0042295
higher	T080	C0205250
EPI	T060	C0162734
In vivo	T082	C1515655
images	T170	C1704922
image quality	T080	C0806487
distortion	T080	C2919017
distortion	T080	C2919017
free	T169	C0332296
DWI	T060	C0598801
images	T170	C1704922
areas	T082	C0205146
significant	T078	C0750502
off-resonance	T033	C2828093
SNR	T081	C2986823
Parallel imaging	T060	C0079595
DIVERSE	T080	C1880371
RF	T070	C2347883
pulses	T066	C1708464
shorter ETL	T079	C1254367
implementations	T052	C1708476
reduces	T080	C0392756
phase	T079	C0205390
encode	T052	C2700640
direction	T082	C0449738
blur	T080	C1511231
SAR	T040	C1155281
accumulation	T033	C4055506
Modification	T169	C0392747
Mechanical Properties	T080	C0871161
Polymerization	T067	C0314672
Temperature	T081	C0039476
Handling Time	T079	C0040223
Polymethylmethacrylate	T109	C0005533
Cement	T122	C0005934
Applicability	T169	C4048755
Vertebroplasty	T061	C1303192
Polymethylmethacrylate	T109	C0005533
PMMA	T109	C0005533
bone cement	T122	C0005934
bone	T023	C0262950
void	T030	C0229984
filler	T122	C0005934
vertebroplasty	T061	C1303192
PMMA	T109	C0005533
material's	T122	C0005479
stiffness	T080	C0018599
exothermic polymerization	T067	C0314672
short	T081	C1806781
handling time	T079	C0040223
study	T062	C2603343
modified	T169	C0392747
bone cement	T122	C0005934
problems	T033	C0033213
Modified	T169	C0392747
bone cements	T122	C0005934
prepared	T052	C1521827
PMMA	T109	C0005533
volume fractions	T081	C0560268
castor oil	T109	C0007343
peak	T080	C0444505
polymerization	T067	C0314672
temperatures	T081	C0039476
peak	T080	C0444505
polymerization	T067	C0314672
temperature	T081	C0039476
porosities	T080	C0080037
densities	T081	C0178587
modulus	T081	C2350289
maximum	T081	C0806909
compression strengths	T081	C0376507
standard	T080	C1442989
castor oil	T109	C0007343
modified	T169	C0392747
cements	T122	C0005934
investigated	T169	C1292732
ambient temperature	T070	C0428692
precooling	T070	C0678568
conditions	T080	C0348080
specimens	T167	C0370003
parameters	T077	C0549193
Increasing	T081	C0205217
castor oil	T109	C0007343
precooling	T070	C0678568
treatment	T169	C1522326
decreased	T081	C0205216
peak	T080	C0444505
polymerization	T067	C0314672
temperatures	T081	C0039476
increased	T081	C0205217
duration	T079	C0449238
peak	T080	C0444505
polymerization	T067	C0314672
temperature	T081	C0039476
mechanical properties	T080	C0871161
material	T122	C0005479
density	T081	C0178587
modulus	T081	C2350289
maximum	T081	C0806909
compression strength	T081	C0376507
decreased	T081	C0205216
increasing	T081	C0205217
castor oil	T109	C0007343
content	T077	C0456205
preparation	T052	C1521827
temperature	T081	C0039476
room temperature	T070	C0428692
precooling	T070	C0678568
mechanical properties	T080	C0871161
castor oil	T109	C0007343
PMMA	T109	C0005533
precooling	T070	C0678568
modified	T169	C0392747
bone cement	T122	C0005934
modulus	T081	C2350289
polymerization	T067	C0314672
temperature	T081	C0039476
handling time	T079	C0040223
applicability	T169	C4048755
safety	T068	C0036043
vertebroplasty	T061	C1303192
case	T169	C0868928
retrograde intussusception	T020	C0400855
Roux-en-Y anastomosis	T061	C0002804
total gastrectomy	T061	C0017118
review of the literature	T170	C0282441
old man	T032	C0086582
total gastrectomy	T061	C0017118
Roux-en-Y reconstruction	T061	C0372024
gastric cancer	T191	C0699791
admitted	T058	C0184666
hospital	T073	C0019994
complaints	T184	C0871764
abdominal pain	T184	C0000737
palpable	T080	C0522499
abdominal tumor	T191	C0000735
hematemesis	T033	C0018926
On admission	T058	C0809949
abdominal tenderness	T184	C0232498
improving	T080	C1272745
abdominal tumor	T191	C0000735
palpable	T080	C0522499
Mild inflammatory	T046	C0021368
anemia	T047	C0002871
blood examination	T059	C3826648
Abdominal	T029	C0000726
computed tomography	T060	C0040405
tumor	T191	C0027651
layered structure	T080	C0205556
left abdomen	T029	C0000726
patient	T101	C0030705
diagnosed	T033	C0011900
intestinal obstruction	T047	C0021843
intussusception	T047	C0021933
surgery	T061	C0543467
performed	T169	C0884358
Retrograde intussusception	T020	C0400855
Y anastomosis	T061	C0002805
manual reduction	T061	C0185114
Hutchinson procedure	T061	C0087111
intestinal	T023	C0021853
color	T080	C0009393
reduction	T061	C0441610
intestinal resection	T061	C1096244
required	T169	C1514873
Postoperative recovery	T033	C4304804
patient	T101	C0030705
discharged	T058	C0030685
surgery	T061	C0543467
Reports	T170	C0684224
jejunal	T023	C0022378
intussusception	T047	C0021933
total gastrectomy	T061	C0017118
Roux-en-Y reconstruction	T061	C0372024
jejunal	T023	C0022378
intussusception	T047	C0021933
total gastrectomy	T061	C0017118
Roux-en-Y reconstruction	T061	C0372024
Brassinosteroid	T109	C0038317
induced	T169	C0205263
changes	T169	C0392747
lipid	T109	C0023779
composition	T070	C0243176
leaves	T002	C0242724
Pisum sativum L.	T002	C1262903
senescence	T040	C1326530
effect of	T080	C1704420
steroid	T109	C0038317
phytohormone	T116	C0032082
24-epibrassinolide	T109	C0243833
EBR	T109	C0243833
composition	T070	C0243176
lipid	T109	C0023779
classes	T170	C0456387
free fatty acids	T109	C0015688
triacylglycerols	T109	C0041004
galactolipids	T109	C0060960
detached	T169	C0687118
pea	T002	C1262903
leaves	T002	C0242724
EBR	T109	C0243833
senescence	T040	C1326530
increased	T081	C0205217
content	T077	C0456205
free fatty acids	T109	C0015688
triacylglycerols	T109	C0041004
detached	T169	C0687118
leaves	T002	C0242724
mock-treated leaves	T002	C0242724
content	T077	C0456205
identified	T080	C0205396
fatty acids	T109	C0015684
galactolipids	T109	C0060960
decreased	T081	C0205216
detached	T169	C0687118
leaves	T002	C0242724
treated	T169	C1522326
EBR	T109	C0243833
mock-treated leaves	T002	C0242724
findings	T169	C2607943
free fatty acids	T109	C0015688
polar	T081	C0813983
lipids	T109	C0023779
esterification	T044	C2612539
neutral lipids	T109	C0023779
detached	T169	C0687118
leaves	T002	C0242724
EBR	T109	C0243833
treatment	T169	C1522326
steroid	T109	C0038317
phytohormones	T116	C0032082
regulation	T038	C1327622
leaf	T002	C0242724
senescence	T040	C1326530
alteration	T078	C1515926
cell	T025	C0007634
lipid	T109	C0023779
composition	T070	C0243176
Posterior dislocation	T037	C1265659
sternoclavicular joint	T030	C0038291
report	T170	C0684224
cases	T169	C0868928
report	T170	C0684224
cases	T169	C0868928
young	T079	C0332239
patients	T101	C0030705
sporting accident	T037	C0337205
posterior traumatic dislocation	T037	C1265659
sternoclavicular joint	T030	C0038291
patients	T101	C0030705
closed reduction	T061	C0185500
limb	T023	C0015385
sling	T074	C0183346
patient	T101	C0030705
reduction	T061	C1293152
recurrence	T067	C0034897
dislocation	T037	C1265659
surgical treatment	T061	C0543467
relevance	T080	C2347946
computed tomography	T060	C0040405
diagnosing	T062	C1704656
reduction procedure	T061	C1293152
study	T062	C2603343
treatment	T061	C0087111
rare	T080	C0522498
injury	T037	C3263722
posterior dislocation	T037	C1265659
sternoclavicular joint	T030	C0038291
graphical risk tool	T058	C1254363
willingness to take	T033	C0243095
migraine	T047	C0149931
prophylactic	T061	C0199176
medications	T121	C0013227
migraine	T047	C0149931
sufferers	T101	C0030705
daily	T079	C0332173
prophylactic therapy	T061	C0199176
frequency	T079	C0439603
headache	T184	C0018681
Food and Drug Administration	T093	C0041714
approved	T080	C0205540
several	T081	C0439064
medications	T121	C0013227
migraine	T047	C0149931
prophylaxis	T061	C0199176
sufferers	T101	C0030705
treatments	T061	C0087111
clinically significant	T078	C0750502
benefits	T081	C0814225
side effect	T046	C0879626
profiles	T059	C1979963
headache	T184	C0018681
sufferers	T101	C0030705
community	T096	C0009462
local	T082	C0205276
headache	T184	C0018681
clinics	T073	C0442592
print	T057	C0033161
television	T073	C0039461
advertising	T057	C0001690
Participants	T098	C0679646
headache	T184	C0018681
median	T081	C0876920
frequency	T079	C0439603
headache	T184	C0018681
days per month	T079	C0556971
sufferers	T101	C0030705
cross-sectional, single-site, study	T062	C0010362
Participants	T098	C0679646
probability	T081	C0033204
side effects	T046	C0879626
several	T081	C0439064
blinded	T062	C0150108
medication	T121	C0013227
profiles	T059	C1979963
divalproex sodium	T109	C0886883
venlafaxine	T109	C0078569
gabapentin	T109	C0060926
propranolol	T109	C0033497
topiramate	T109	C0076829
likelihood	T081	C0033204
side effect	T046	C0879626
profiles	T059	C1979963
medication	T121	C0013227
participants	T098	C0679646
willing to take	T033	C0243095
medication	T121	C0013227
headache	T184	C0018681
reduction	T080	C0392756
level	T080	C0441889
days per month	T079	C0556971
side effect	T046	C0879626
profile	T059	C1979963
divalproex sodium	T109	C0886883
associated with	T080	C0332281
smallest willingness to take	T033	C0243095
gabapentin	T109	C0060926
propranolol	T109	C0033497
topiramate	T109	C0076829
participants	T098	C0679646
willingness to take	T033	C0243095
medications	T121	C0013227
reduction	T080	C0392756
headache	T184	C0018681
frequency	T079	C0439603
Several	T081	C0439064
predictors	T078	C2698872
willingness to take	T033	C0243095
high	T080	C0205250
headache	T184	C0018681
disability	T033	C0231170
depressive symptoms	T184	C0086132
pain medication	T109	C0002771
concerns	T078	C2699424
fear	T041	C0015726
tolerance	T041	C0220929
findings	T033	C0243095
informed	T080	C1522154
side effect	T046	C0879626
profiles	T059	C1979963
medications	T121	C0013227
patients	T101	C0030705
treatments	T061	C0087111
Genome-Wide Detection	T063	C2350277
Selective Signatures	T045	C0017393
Chicken	T012	C0008051
High Density SNPs	T086	C0752046
Chicken	T012	C0008051
model	T075	C0026339
genetic	T169	C0314603
mechanism	T169	C0441712
phenotypic	T032	C0031437
genomic	T028	C0017428
evolution	T045	C0015219
population size	T081	C0032683
human	T016	C0086418
selection	T052	C1707391
Extended Haplotype Homozygosity	UnknownType	C0545278
EHH	UnknownType	C0545278
core regions	T086	C0004793
SNP	T086	C0752046
Chicken	T012	C0008051
chip	T063	C3897601
F2 population	T078	C0441833
hens	T012	C0005595
reciprocal crosses	T059	C0010364
White Leghorn	T012	C0008051
Dongxiang chicken	T012	C0008051
core regions	T086	C0004793
length	T081	C1444754
identified	T080	C0205396
genome	T028	C0017428
autosomes	T026	C0596142
core regions	T086	C0004793
Genes	T028	C0017337
candidate regions	T086	C0004793
positive selection	T059	C2347644
economic traits	T080	C0205556
panel	T078	C0441833
genes	T028	C0017337
AASDHPPT	T028	C1422497
GDPD5	T028	C1539559
PAR3	T028	C1414507
SOX6	T028	C1424266
GPC1	T028	C1415193
signal pathway	T044	C0037080
AKT1	T028	C0812228
detected	T033	C0442726
P-values	T081	C1709380
enrichment analyses	T062	C0936012
genes	T028	C0017337
associated with	T080	C0332281
immune function	T042	C1817756
sensory organ development	T042	C1160370
neurogenesis	T040	C0814002
positive selection	T059	C2347644
chicken	T012	C0008051
core regions	T086	C0004793
genes	T028	C0017337
GWAS	T063	C2350277
genes	T028	C0017337
positive selection	T059	C2347644
egg	T168	C0013710
production	T052	C0441655
Findings	T169	C2607943
genome-wide map	T062	C0079435
selection signature	T045	C0017393
chicken	T012	C0008051
genome	T028	C0017428
genetic	T169	C0314603
mechanisms	T169	C0441712
phenotypic	T032	C0031437
diversity	T080	C1880371
poultry	T012	C0032850
breeding	T040	C0006159
Genotyping	T059	C3178894
TaqMan Allelic Discrimination	T059	C3178894
Allele-Specific Genotyping Assays	T059	C3178894
Real-time PCR	T063	C1709846
genotyping methods	T059	C3178894
TaqMan allelic discrimination assays	T059	C3178894
allele-specific genotyping	T059	C3178894
useful	T080	C3827682
screening	T060	C0813145
single nucleotide polymorphisms	T086	C0752046
samples	T167	C0370003
different	T080	C1705242
individuals	T098	C0027361
tissues	T024	C0040300
pre	T079	C0332152
amplified DNA	T045	C0683230
real-time PCR	T063	C1709846
based	T169	C1527178
methods	T170	C0025663
TaqMan	T059	C3178894
well-established	T080	C0443211
alternative	T077	C1523987
methods	T170	C0025663
allele-specific genotyping	T059	C3178894
alternatives	T077	C1523987
genotyping	T059	C3178894
short tandem repeat	T114	C1519302
(STR)	T114	C1519302
length	T081	C1444754
polymorphisms	T045	C0032529
relevant	T080	C2347946
aspects	T080	C1521970
developing	T169	C1527148
assay	T059	C1510438
SNP	T086	C0752046
STR	T114	C1519302
TaqMan	T059	C3178894
allele-specific genotyping	T059	C3178894
primer	T114	C0206416
probe	T114	C0012893
optimization	T052	C2698650
reaction	T169	C0443286
conditions	T080	C0348080
experimental procedure for typing	T059	C3178894
samples	T167	C0370003
data	T078	C1511726
evaluation	T058	C0220825
goal	T170	C0018017
provide	T052	C1999230
guideline	T170	C0162791
developing	T169	C1527148
genotyping assays	T059	C3178894
approaches	T169	C1292724
reproducible	T080	C1514863
genotype calls	T059	C3178894
involving	T169	C1314939
minimal	T080	C0547040
optimization	T052	C2698650
P2X7 receptors	T116	C0386482
rodent	T015	C0035804
PCP	T109	C0031381
induced	T169	C0205263
schizophrenia	T048	C0036341
model	T050	C0012644
P2X7 receptors	T116	C0386482
P2X7Rs	T116	C0386482
ligand-gated ion channels	T116	C0815090
sensitive	T169	C0332324
extracellular	T026	C0521119
ATP	T114	C0001480
examined	T033	C0332128
P2X7R	T116	C0386482
animal model	T008	C0599779
schizophrenia	T048	C0036341
PCP	T109	C0031381
induced	T169	C0205263
schizophrenia	T048	C0036341
model	T050	C0012644
genetic deletion	T045	C1511760
pharmacological	T169	C0205464
inhibition	T052	C3463820
P2X7Rs	T116	C0386482
alleviate	T169	C1301676
schizophrenia-like	T033	C0243095
behavioral	T053	C0004927
alterations	T078	C1515926
P2rx7+/+	T028	C1418215
mice	T015	C0025929
PCP	T109	C0031381
induced	T169	C0205263
hyperlocomotion	T033	C3540840
stereotype behavior	T048	C0038271
ataxia	T184	C0004134
social withdrawal	T033	C0424095
P2X7 receptor	T028	C1418215
deficient	T169	C0011155
mice	T015	C0206745
P2rx7-/-	T028	C1418215
social interactions	T033	C0037420
increased	T081	C0205217
PCP	T109	C0031381
induced	T169	C0205263
hyperlocomotion	T033	C3540840
stereotype behavior	T048	C0038271
alleviated	T169	C1301676
P2X7 receptor antagonist	T121	C2936582
JNJ-47965567	T121	C2936582
effect of	T080	C1280500
gene deficiency	T045	C1511760
PCP	T109	C0031381
induced	T169	C0205263
behavioral changes	T055	C0542299
PCP	T109	C0031381
induced	T169	C0205263
social withdrawal	T033	C0424095
PCP	T109	C0031381
treatment	T169	C1522326
upregulates	T044	C0041904
increases	T169	C0442805
functional	T169	C0205245
responsiveness	T169	C0205342
P2X7Rs	T116	C0386482
prefrontal cortex	T023	C0162783
young adult	T100	C0238598
animals	T008	C0003062
amplitude	UnknownType	C0678555
NMDA	T116	C0080093
evoked	T080	C1444748
currents	T070	C1705970
layer V pyramidal neurons	T025	C0206441
cortical	T023	C0007776
decreased	T081	C0205216
genetic deletion	T045	C1511760
P2rx7	T028	C1418215
JNJ-47965567	T121	C2936582
PCP	T109	C0031381
induced	T169	C0205263
alterations	T078	C1515926
mRNA expression	T045	C1515670
schizophrenia-related	T048	C0036341
genes	T028	C0017337
NR2A	T028	C1415299
NR2B	T028	C1415300
neuregulin 1	T116	C0626201
NR1	T192	C0914905
GABA α1	T116	C1565610
absent	T169	C0332197
young adult	T100	C0238598
P2rx7-/-	T028	C1418215
animals	T050	C1517490
findings	T033	C0243095
P2X7R	T116	C0386482
potential	T080	C3245505
therapeutic	T169	C0302350
target	T169	C1521840
schizophrenia	T048	C0036341
flavor	T168	C0982164
nutritional	T080	C1521739
characteristic	T080	C1521970
strawberry	T168	C0457802
varieties	T077	C1883525
cultured	T090	C0001829
soilless system	T167	C0439861
Strawberry fruits	T168	C0457802
cv. Benihoppe	T168	C0457802
Tochiotome	T168	C0457802
Sachinoka	T168	C0457802
Guimeiren	T168	C0457802
flavor	T168	C0982164
nutritional	T080	C1521739
parameters	T077	C0549193
principal component analysis	T081	C0429865
hierarchical clustering analysis	T062	C1881045
volatile compounds	T109	C2350439
composition	T070	C0243176
sugar	T109	C0242209
acid	T109	C0369760
concentration	T081	C1446561
sweetness	T080	C0678582
total soluble sugars	T109	C0242209
total organic acids	T109	C0369760
varieties	T077	C1883525
volatile compounds	T109	C2350439
identified	T080	C0205396
determined	T080	C0521095
cv. Benihoppe	T168	C0457802
Tochiotome	T168	C0457802
Sachinoka	T168	C0457802
Guimeiren strawberry fruits	T168	C0457802
extracted	T061	C0185115
head-space solid-phase microextraction	T059	C1720881
HS-SPME	T059	C1720881
Esters	T109	C0014898
chemical composition	T070	C0243176
varieties	T077	C1883525
Furaneol	T109	C0378287
cultivars	T002	C0032098
Sachinoka	T168	C0457802
Guimeiren	T168	C0457802
mesifuran	T168	C0457802
cv. Tochiotome	T168	C0457802
Tochiotome	T168	C0457802
Sachinoka	T168	C0457802
content	T081	C1446561
linalool	T109	C0064997
(E)-nerolidol	T109	C0955941
Sachinoka	T168	C0457802
highest	T080	C0205250
content	T081	C1446561
total sugars	T109	C0242209
total acids	T109	C0369760
Guimeiren	T168	C0457802
sweetness	T080	C0678582
index	T170	C0918012
cultivars	T002	C0032098
Firmness	T080	C1545487
Tochiotome	T168	C0457802
highest	T080	C0205250
varieties	T077	C1883525
highest	T080	C0205250
total soluble solids TSS value	T081	C0392762
cv. Sachinoka	T168	C0457802
Guimeiren	T168	C0457802
Tochiotome	T168	C0457802
varieties	T077	C1883525
Sachinoka	T168	C0457802
highest	T080	C0205250
titratable acidity TA value	T034	C0368606
content	T081	C1446561
ascorbic acid	T109	C0003968
AsA	T109	C0003968
cv. Tochiotome	T168	C0457802
higher	T080	C0205250
no significant	T033	C1273937
difference	T081	C1705241
cultivars	T002	C0032098
Benihoppe	T168	C0457802
Tochiotome	T168	C0457802
Sachinoka	T168	C0457802
Fructose	T109	C0016745
glucose	T109	C0017725
sugars	T109	C0242209
cultivars	T002	C0032098
Citric acid	T109	C0055819
organic acid	T109	C0369760
cv. Tochiotome	T168	C0457802
cv. Sachinoka	T168	C0457802
cv. Guimeiren	T168	C0457802
Tochiotome	T168	C0457802
higher	T080	C0205250
ratios	T081	C0456603
TSS	T109	C1635078
TA	T034	C0368606
total sugars	T109	C0242209
total organic acids	T109	C0369760
acid	T109	C0369760
content	T081	C1446561
comprehensive evaluation score	T081	C0449820
Sachinoka	T168	C0457802
Guimeiren	T168	C0457802
Tochiotome	T168	C0457802
Benihoppe	T168	C0457802
Prognostic value	T081	C0449821
GLUT-1	T116	C0168458
expression	T045	C1171362
oral squamous cell carcinoma	T191	C0585362
prisma-compliant meta-analysis	T170	C0282574
studies	T062	C2603343
evaluated	T058	C0220825
correlation	T080	C1707520
glucose transporter-1	T116	C0168458
GLUT-1	T116	C0168458
expression	T045	C1171362
prognosis	T058	C0033325
oral squamous cell carcinoma	T191	C0585362
OSCC	T191	C0585362
results	T169	C1274040
inconsistent	T080	C0442809
inconclusive	T080	C1629507
meta-analysis	T062	C0920317
assess	T058	C0184514
prognostic	T170	C0220901
significance	T078	C0750502
GLUT-1	T116	C0168458
OSCC	T191	C0585362
Electronic databases	T170	C3841595
PubMed	T170	C1138432
Embase	T170	C0282574
Web of Science	T170	C0282574
relevant studies	T062	C2603343
July	T080	C3829447
Odds ratio	T081	C0028873
OR	T081	C0028873
confidence interval	T081	C0009667
CI	T081	C0009667
evaluate	T058	C0220825
relationship	T078	C1705630
GLUT-1	T116	C0168458
clinical features	T033	C3810252
hazard ratio	T081	C2985465
HR	T081	C2985465
CI	T081	C0009667
measure	T081	C0079809
effect	T080	C1280500
GLUT-1	T116	C0168458
overall survival	T081	C4086681
OS	T081	C4086681
statistically significant	T081	C0237881
studies	T062	C2603343
subjects	T098	C0080105
meta-analysis	T062	C0920317
pooled data	T078	C1511726
GLUT-1	T116	C0168458
expression	T045	C1171362
associated with	T080	C0332281
advanced tumor stages	T201	C1300072
OR	T081	C0028873
CI	T081	C0009667
higher tumor grade	T185	C0441800
OR	T081	C0028873
CI	T081	C0009667
tumor size	T082	C0475440
OR	T081	C0028873
CI	T081	C0009667
lymph node metastasis	T033	C0332397
OR	T081	C0028873
CI	T081	C0009667
tobacco use	T055	C0543414
OR	T081	C0028873
CI	T081	C0009667
distant metastasis	T201	C1302548
OR	T081	C0028873
CI	T081	C0009667
increased	T081	C0205217
GLUT-1	T116	C0168458
expression	T045	C1171362
correlated	T080	C1707520
shorter OS	T081	C4086681
HR	T081	C2985465
CI	T081	C0009667
significant publication bias	T080	C0206086
detected	T033	C0442726
meta-analysis	T062	C0920317
GLUT-1	T116	C0168458
overexpression	T045	C1514559
aggressive clinical features	T033	C3810252
worse OS	T081	C4086681
OSCC	T191	C0585362
studies	T062	C2603343
GLUT-1	T116	C0168458
prognostic	T170	C0220901
biomarker	T201	C0005516
OSCC	T191	C0585362
Biogeography	T090	C2936603
Evolution	T038	C0282688
Ciliate	T204	C0008781
Genus	T185	C1708235
Euplotes	T204	C0085343
Spirotrichea	T204	C1004715
Euplotia	T204	C0085343
Description	T170	C0678257
Euplotes curdsi sp. nov	T204	C0085343
Ciliates	T204	C0008781
diverse	T080	C1880371
ecologically	T077	C0870460
important	T080	C3898777
phylum	T185	C1709533
unicellular protists	T001	C0597305
genera	T185	C1708235
Euplotes	T204	C0085343
morphospecies	T185	C1705920
molecularly tested	T169	C0039593
Euplotes	T204	C0085343
taxa	T077	C1515221
characterizations	T052	C1880022
morphological	T082	C0543482
observations	T062	C0302523
sequencing	T169	C1561491
molecular markers	T201	C0005516
comparison	T052	C1707455
literature	T170	C0023866
Euplotes curdsi sp. nov	T204	C0085343
distinguishable	T080	C0205615
combination	T080	C0205195
features	T080	C2348519
length	T081	C1444754
oval or elongated shape	T080	C0332437
narrow peristome	T080	C0332437
adoral membranelles	T080	C0332437
conspicuous paroral membrane	T026	C0596901
double-eurystomus dorsal argyrome type	T080	C0332437
dorsolateral kineties	T080	C0332437
frontoventral cirri	T080	C0332437
populations	T081	C0032659
species	T185	C1705920
brackish	T131	C0337056
marine samples	T083	C0017446
Mediterranean	T083	C0025138
White Sea	T083	C0017446
SSU rRNA gene	T028	C0017337
sequences	T028	C1517495
populations	T081	C0032659
phylogeny	T078	C0031797
genus	T185	C1708235
Euplotes	T204	C0085343
molecular	T080	C1521991
phylogenetic tree	T080	C0205556
aspects	T080	C1879746
biogeographical history	T169	C0019665
genus	T185	C1708235
evolution	T038	C0282688
taxonomic	T169	C0008903
characters	T080	C1521970
descriptions	T170	C0678257
data	T078	C1511726
recurrent	T079	C2945760
trends	T079	C1521798
freshwater	T167	C0016710
morphological	T082	C0543482
evolution	T038	C0282688
Euplotes	T204	C0085343
Comparative Effectiveness	T062	C2718022
Treatments	T061	C0087111
Chronic Low Back Pain	T047	C0457949
Multiple Treatment Comparison Analysis	T062	C4277638
systematic review	T170	C1955832
network meta-analysis	T062	C4277638
current treatment options	T061	C2827774
chronic low back pain	T047	C0457949
LBP	T047	C0457949
randomized controlled trials	T062	C0206035
RCTs	T062	C0206035
compare	T052	C1707455
effectiveness	T080	C1280519
treatments	T061	C0087111
mixed-treatment comparison	T062	C4277638
MTC	T062	C4277638
evidence-based	T078	C3887511
assessment	T058	C0220825
treatment options	T061	C0683525
LBP	T047	C0457949
systematic search	T062	C0035168
RCTs	T062	C0206035
MEDLINE	T170	C0025141
Cochrane Collaboration Library	T073	C0023621
selected studies	T062	C2603343
preoperative	T079	C0445204
postoperative	T079	C0032790
ODI	T033	C2960603
VAS back pain scores	T081	C2732809
additional surgeries	T058	C2081627
complications	T046	C0009566
Standard and network meta-analytic techniques	T062	C4277638
RCTs	T062	C0206035
analysis	T062	C0936012
total disk replacement	T061	C2144940
TDR	T061	C2144940
fusion	T061	C0186045
TDR	T061	C2144940
exercise	T061	C1522704
cognitive behavioral therapy	T061	C0009244
CBT	T061	C0009244
fusion	T061	C0186045
exercise	T061	C1522704
CBT	T061	C0009244
fusion	T061	C0186045
physical therapy	T061	C0949766
PT	T061	C0949766
MTC	T062	C4277638
ODI change scores	T033	C2960603
pooled mean difference	T081	C1705241
fusion	T061	C0186045
exercise	T061	C1522704
CBT	T061	C0009244
pooled mean difference	T081	C1705241
TDR	T061	C2144940
exercise	T061	C1522704
CBT	T061	C0009244
pooled mean difference	T081	C1705241
fusion	T061	C0186045
PT	T061	C0949766
pooled mean differences	T081	C1705241
TDR	T061	C2144940
fusion	T061	C0186045
PT	T061	C0949766
structured exercise	T061	C1522704
CBT	T061	C0009244
pooled mean difference	T081	C1705241
exercise	T061	C1522704
CBT	T061	C0009244
PT	T061	C0949766
TDR	T061	C2144940
PT	T061	C0949766
pooled mean difference	T081	C1705241
TDR	T061	C2144940
PT	T061	C0949766
surgery rates	T081	C1521828
treatment options	T061	C0683525
treatments	T061	C0087111
benefit	T081	C0814225
patients	T101	C0030705
chronic LBP	T047	C0457949
MTC analysis	T062	C4277638
TDR	T061	C2144940
most effective	T080	C1704419
treatment	T061	C0087111
PT	T061	C0949766
least effective	T080	C1704419
treatment	T061	C0087111
chronic LBP	T047	C0457949
review	T170	C0282443
limited number	T081	C0449788
RCT studies	T062	C0206035
treatment	T061	C0087111
modality	T078	C0695347
patients	T101	C0030705
Inhibitor	T121	C0014432
Delta-5 Desaturase	T116	C0057338
Insulin Resistance	T046	C0021655
Reduces Body Weight	T033	C1262477
Diet	T168	C0012155
Obese	T047	C0028754
C57BL/6J Mice	T015	C1521751
Obesity	T047	C0028754
inflammation	T046	C0021368
metabolic	T169	C0311400
inflammation	T046	C0021368
Delta-5 desaturase	T116	C0057338
D5D	T116	C0057338
enzyme	T116	C0014442
dihomo-γ-linolenic acid	T109	C0000658
DGLA	T109	C0000658
arachidonic acid	T109	C0003695
AA	T109	C0003695
D5D	T116	C0057338
inhibition	T039	C1524081
DGLA	T109	C0000658
anti-inflammatory	T080	C1515999
eicosanoids	T109	C0013725
AA	T109	C0003695
eicosanoids	T109	C0013725
synergistic	T080	C2986495
improvement	T077	C2986411
reduced	T080	C0392756
insulin resistance	T046	C0021655
anti-obesity	T121	C0376607
D5D	T116	C0057338
compound-326	T121	C1254351
orally	T082	C0442027
small-molecule	T109	C1328819
high-fat diet	T168	C0453819
obese (DIO) mouse	T015	C0025933
model	T050	C0012644
D5D	T116	C0057338
inhibition	T039	C1524081
blood	T031	C0005767
AA	T109	C0003695
DGLA	T109	C0000658
profiles	T059	C2022317
DIO mice	T015	C0025933
compound-326	T121	C1254351
insulin resistance	T046	C0021655
body weight loss	T033	C1262477
calorie intake	T081	C4281687
macrophage infiltration into adipose tissue	T033	C4014887
mRNA analysis	T059	C0872262
energy expenditure	T039	C0014272
administration	T061	C1533734
compound-326	T121	C1254351
body weight loss	T033	C1262477
D5D	T116	C0057338
inhibitor	T121	C0014432
compound-326	T121	C1254351
obese	T047	C0028754
diabetic	T047	C0011847
patients	T101	C0030705
Blood Collection Tubes	T074	C0184104
Storage Temperature	T080	C3640194
Siemens ADVIA Centaur XP	T073	C3831595
Measuring 25-Hydroxyvitamin D	T059	C2984945
Siemens ADVIA Centaur XP	T073	C3831595
measurement of 25-hydroxyvitamin D	T059	C2984945
25OHD	T109	C0535968
VACUETTE® tubes with Serum Clot Activator and Gel	T074	C0184104
tubes	T074	C0184104
temperatures	T081	C0039476
25OHD results	T059	C2984945
Siemens ADVIA Centaur XP	T073	C3831595
Serum	T031	C0229671
vacuum blood collection tubes	T074	C0184104
25OHD was analyzed	T059	C2984945
Siemens ADVIA Centaur XP	T073	C3831595
liquid chromatography tandem mass spectrometry	T059	C4049918
LC-MS/MS	T059	C4049918
Significantly higher	T081	C4055638
25OHD values	T059	C2984945
Siemens ADVIA Centaur XP	T073	C3831595
VACUETTE® tubes with serum clot activator and gel	T074	C0184104
VACUETTE® tubes with clot activator	T074	C0184104
VACUETTE® tubes	T074	C0184104
25OHD values	T059	C2984945
LC-MS/MS	T059	C4049918
IMPROVEVACUTER® tubes with serum clot activator and ge	T074	C0184104
significantly increased	T081	C4055637
Siemens ADVIA Centaur XP	T073	C3831595
VACUETTE® tubes	T074	C0184104
25OHD results	T059	C2984945
Siemens ADVIA Centaur XP	T073	C3831595
serum	T031	C0229671
IMPROVEVACUTER® tubes	T074	C0184104
freezing	T070	C0016701
25OHD	T109	C0535968
assay platform	T073	C3273359
Evolution	T045	C0015219
Fitness	T045	C3824713
Cost-Neutral	T033	C0243095
Mutant	T049	C0596988
PfCRT	T116	C0962247
P. falciparum	T204	C0032150
4-Aminoquinoline	T109	C0048060
Drug Resistance	T038	C0013203
Altered	T169	C0392747
Parasite	T204	C0030498
Metabolism	T040	C0025519
Digestive Vacuole	T026	C1167024
Physiology	T091	C0031842
Southeast Asia	T083	C0003983
multidrug-resistant	T032	C0242640
Plasmodium falciparum strains	T204	C0032150
allelic	T028	C0002085
variants	T028	C0678941
parasite	T204	C0030498
drug resistance	T038	C0013203
genes	T028	C0017337
P. falciparum chloroquine resistance transporter	T028	C0017337
pfcrt	T028	C0017337
reductions	T061	C0441610
deployment	T052	C2825812
4-aminoquinoline	T109	C0048060
drug	T121	C1254351
chloroquine	T109	C0008269
CQ	T109	C0008269
mutant	T028	C0678941
pfcrt	T028	C0017337
alleles	T028	C0002085
CQ	T109	C0008269
efficacy	T080	C1280519
parasite	T204	C0030498
pfcrt	T028	C0017337
locus	T082	C1708726
highly	T080	C0205250
mutated	T045	C0026882
allele	T028	C0002085
Cam734 pfcrt	T028	C0017337
parasite	T204	C0030498
CQ	T109	C0008269
resistance	T038	C0013203
fitness	T045	C3824713
cost	T080	C4049986
pfcrt	T028	C0017337
zinc-finger nucleases	T116	C0597094
genetically dissect	T169	C0205239
allele	T028	C0002085
pathogenic	T033	C3816499
asexual blood-stage infection	T046	C3714514
Comparative analysis	T062	C0683941
drug resistance	T038	C0013203
growth	T040	C0018270
recombinant parasites	T204	C0030498
express	T045	C0017262
Cam734	T028	C0017337
variants	T028	C0678941
Dd2	T028	C0017337
Southeast Asian	T083	C0003983
variant	T028	C0678941
wild-type	T028	C1883559
pfcrt	T028	C0017337
PfCRT	T116	C0962247
mutations	T045	C0026882
parasite	T204	C0030498
antimalarial agents	T121	C0003374
GC03	T028	C0017337
strain	T001	C1518614
pfcrt	T028	C0017337
studies	T062	C2603343
allele	T028	C0002085
Cam734	T028	C0017337
CQ	T109	C0008269
resistance	T038	C0013203
A144F	T045	C0026882
mutation	T045	C0026882
Southeast Asia	T083	C0003983
impacts	T080	C4049986
Cam734	T028	C0017337
mutations	T045	C0026882
CQ	T109	C0008269
resistance	T038	C0013203
parasite	T204	C0030498
growth rates	T079	C0449249
Biochemical assays	T059	C0005507
impact	T080	C4049986
mutant	T049	C0596988
PfCRT	T116	C0962247
isoforms	T116	C0597298
parasite	T204	C0030498
metabolism	T040	C0025519
nucleoside triphosphate	T114	C0597106
levels	T080	C0441889
hemoglobin catabolism	T044	C1157963
heme	T109	C0018966
digestive vacuole	T026	C1167024
volume	T081	C0449468
pH	T081	C0020283
complex molecular basis	T170	C4246449
physiological	T169	C0205463
impact	T080	C4049986
PfCRT	T116	C0962247
antimalarial	T121	C0003374
drug resistance	T038	C0013203
pfcrt	T028	C0017337
alleles	T028	C0002085
efficacy	T080	C1280519
antimalarial drug	T121	C0003374
regimens	T061	C0040808
Effect	T080	C1280500
nutritionally induced	T033	C0392209
hyperlipidaemia	T047	C0020473
in vitro	T080	C1533691
bovine	T015	C3667982
embryo	T018	C0013935
fatty acid	T109	C0015684
diet	T168	C0012155
study	T062	C2603343
examined	T033	C0332128
effects of	T080	C1704420
dietary	T168	C0012155
hyperlipidaemia	T047	C0020473
preimplantation embryo development	T039	C1446949
fatty acid	T109	C0015684
FA	T109	C0015684
diet	T168	C0012155
in vivo	T082	C1515655
in vitro	T080	C1533691
bovine	T015	C3667982
model	T008	C0599779
cows	T015	C0007452
fed	T052	C3853577
diets	T168	C0012155
feeding	T052	C2987508
maintenance control diet	T168	C0012155
CONT	T168	C0012155
high	T080	C0205250
starch	T168	C0311120
diet	T168	C0012155
saturated fat	T168	C0597423
SAT	T168	C0597423
high	T080	C0205250
starch	T168	C0311120
diet	T168	C0012155
omega-3	T109	C0015689
unsaturated fat	T109	C0012172
UNSAT	T109	C0012172
feeding	T052	C2987508
sequences	T169	C1519249
fed	T052	C3853577
CONT	T168	C0012155
SAT1	T168	C0597423
UNSAT2	T109	C0012172
fed	T052	C3853577
CONT	T168	C0012155
UNSAT1	T109	C0012172
SAT2	T168	C0597423
Serum	T031	C0229671
dietary	T168	C0012155
period	T079	C1948053
analysed	T062	C0936012
tested	T169	C0039593
bovine	T015	C3667982
in vitro	T080	C1533691
embryo culture	T059	C0920489
SAT	T168	C0597423
UNSAT	T109	C0012172
diets	T168	C0012155
hyperlipidaemia	T047	C0020473
hypercholesterolaemia	T047	C0020443
free FAs	T109	C0015688
insulin sensitivity	T046	C0920563
serum	T031	C0229671
metabolites	T123	C0870883
FA profile	T059	C0202009
diet	T168	C0012155
feeding	T052	C2987508
sequence	T169	C1519249
SAT1	T168	C0597423
SAT2	T168	C0597423
serum	T031	C0229671
blastocyst	T018	C1281743
blastocyst	T018	C1281743
mRNA expression	T045	C1515670
apoptosis	T043	C0162638
oxidative stress	T049	C0242606
UNSAT1	T109	C0012172
UNSAT2	T109	C0012172
serum	T031	C0229671
embryo	T018	C0013935
quality	T080	C0332306
in vitro	T080	C1533691
sequence	T169	C1519249
feeding	T052	C2987508
substitution	T052	C1706204
saturated fat	T168	C0597423
omega-3 fat	T109	C0015689
high-caloric diet	T061	C0301590
hyperlipidaemia	T047	C0020473
FA profile	T059	C0202009
blastocysts	T018	C1281743
normolipidaemic controls	T096	C0009932
Draft Genome Sequence	T085	C2348746
Soil	T167	C0037592
Isolate	T123	C1764827
Lysinibacillus fusiformis M5	T007	C1095838
Potential	T080	C3245505
Hypoxanthine	T109	C0020684
Lysinibacillus fusiformis strain M5	T007	C1095838
potential	T080	C3245505
hypoxanthine	T109	C0020684
isolated	T123	C1764827
clay	T197	C0055863
soil	T167	C0037592
draft genome sequence	T085	C2348746
annotated	T063	C2936606
studies	T062	C2603343
L. fusiformis M5.	T007	C1095838
Impact	T080	C4049986
Clinical Trial	T062	C0008976
Results	T034	C0456984
Temporal	T079	C2362314
Trends	T079	C0040833
Carotid Endarterectomy	T061	C0014099
Stenting	T061	C2348535
Randomized trials	T062	C0206034
conflicting	T080	C1705242
data	T078	C1511726
efficacy	T080	C1280519
carotid-artery stenting	T061	C2348535
endarterectomy	T061	C0014098
impact	T080	C4049986
conflicting	T080	C1705242
clinical trial publications	T170	C1096775
utilization	UnknownType	C0815187
utilization rates	T081	C1521828
carotid revascularization procedures	T061	C3495793
population-level time-series analysis	T062	C0681939
individuals	T098	C0237401
carotid endarterectomy	T061	C0014099
stenting	T061	C2348535
Ontario	T083	C0029040
Canada	T083	C0006823
primary analysis	T062	C0936012
temporal	T079	C2362314
changes	T081	C1705241
rates	T081	C1521828
carotid revascularization procedures	T061	C3495793
publications	T073	C0034036
randomized trials	T062	C0206034
Secondary analyses	UnknownType	C0683944
changes	T081	C1705241
overall	T080	C1561607
age	T032	C0001779
sex	T032	C0079399
carotid-artery symptom	T184	C1457887
operator specialty-specific procedure rates	T081	C1521828
patients	T101	C0030705
endarterectomy	T061	C0014098
stenting	T061	C2348535
carotid revascularization	T061	C3495793
procedures	T061	C0184661
individuals	T098	C0237401
procedures	T061	C0184661
rate	T081	C1521828
endarterectomy	T061	C0014098
decreased	T081	C0205216
rate	T081	C1521828
carotid-artery stenting	T061	C2348535
increased	T081	C0205217
marked increase	T169	C0442805
stenting	T061	C2348535
publication	T073	C0034036
SAPPHIRE trial	T062	C0242481
Stenting and Angioplasty With Protection in Patients at High Risk for Endarterectomy	T062	C0242481
stenting	T061	C2348535
unchanged	T033	C0442739
randomized trials	T062	C0206034
endarterectomy	T061	C0014098
decreased	T081	C0205216
trials	T062	C0681815
overall rates	T081	C1521828
carotid revascularization	T061	C3495793
endarterectomy	T061	C0014098
rate	T081	C1521828
carotid-artery stenting	T061	C2348535
risen	T081	C0205217
publication	T073	C0034036
stenting	T061	C2348535
SAPPHIRE trial	T062	C0242481
conflicting	T080	C1705242
randomized trials	T062	C0206034
associated with	T080	C0332281
decreasing rate	T033	C0442797
carotid endarterectomy	T061	C0014099
Electronic tongues	T073	C4279906
wine	T168	C0043188
sensory	T080	C0445254
descriptors	T170	C0282354
work	T057	C0043227
reports	T170	C0684224
application	T169	C4048755
electronic tongue	T073	C4279906
tool	T073	C0336791
analysis	T062	C0936012
wine	T168	C0043188
discrimination	T078	C0242568
maturing	T079	C0205286
barrels	T073	C3273359
prediction	T078	C0681842
global	T080	C2348867
scores	T081	C0449820
sensory panel	T097	C0027363
red wine	T168	C0349371
samples	T167	C0370003
analysed	T062	C0936012
voltammetric sensor array	T073	C0183210
sample	T167	C0370003
pretreatment	T052	C3539076
responses	T169	C0443286
preprocessed	T067	C1522240
fast Fourier transform	T170	C0002045
FFT	T170	C0002045
compression	T070	C0728907
reduction	T080	C0392756
signal	T067	C1710082
complexity	T080	C0439855
coefficients	T081	C1707429
inputs	T077	C1708517
qualitative	T080	C0205556
quantitative	T081	C0392762
models	T075	C0026336
linear discriminant analysis	T062	C0012630
LDA	T062	C0012630
partial least squares regression	T170	C0034980
PLS	T170	C0034980
results	T033	C0683954
classification	T185	C0008902
rate	T081	C1521828
discrimination	T078	C0242568
barrel	T073	C3273359
wine	T168	C0043188
maturing	T079	C0205286
normalized NRMSE	T081	C0079809
ageing	T040	C0001811
time	T079	C0040223
months	T079	C0439231
prediction	T078	C0681842
scores	T081	C0449820
trained sensory panel	T097	C0027363
test	T169	C0039593
subset	T185	C1515021
optimizing	T052	C2698650
dental implant	T074	C0392413
Surface	T082	C0205148
characterization	T052	C1880022
Ti	T196	C0040302
TiZr	T197	C4041873
implant materials	T122	C0440216
Targeting	T169	C1521840
enhanced	T052	C2349975
osseointegration	T042	C0079949
kinetics	T070	C0022702
goal	T170	C0018017
study	T062	C2603343
characterize	T052	C1880022
surface	T082	C0205148
morphology	T080	C0332437
composition	T201	C0486616
Ti	T196	C0040302
TiZr	T197	C4041873
dental implant	T074	C0392413
substrates	T167	C3891814
surface	T082	C0205148
treatments	T169	C1522326
treatments	T169	C1522326
SLA	T074	C0392413
SLActive	T074	C0392413
rapid	T080	C0456962
osseointegration	T042	C0079949
techniques	T169	C0449851
applied	T169	C4048755
characterize	T052	C1880022
different	T080	C1705242
substrate	T082	C0205148
surface	T082	C0205148
treatment	T169	C1522326
combinations	T080	C0205195
TiSLA	T074	C0392413
TiSLActive	T074	C0392413
TiZrSLA	T074	C0392413
TiZrSLActive	T074	C0392413
Contact	T169	C0332158
angle	T082	C0205143
measurements	T169	C0242485
hydrophilic	T080	C0475370
hydrophobic	T080	C0598629
Surface	T082	C0205148
morphology	T080	C0332437
scanning electron microscopy	T059	C0026020
X-ray diffraction	T059	C0043301
Raman μ-spectroscopy	T059	C0037815
X-ray photoelectron spectroscopy	T059	C2700282
composition	T201	C0486616
surface	T082	C0205148
Consistent with	T078	C0332290
previous	T079	C0205156
surface	T082	C0205148
morphology	T080	C0332437
differ	T080	C1705242
nanoscale	T081	C1553036
SLActive	T074	C0392413
substrates	T167	C3891814
displaying	T169	C0870432
nano	T081	C1553036
protrusions	T190	C0333056
Spectroscopic	T059	C0037812
data	T078	C1511726
substrates	T167	C3891814
surface	T082	C0205148
films	T080	C1522408
titanium oxide	T121	C0145999
TiO2	T121	C0145999
stoichiometry	T081	C0597526
Raman μ-spectroscopy	T059	C0037815
reveals	T080	C0443289
amorphous	T080	C1979848
TiO2	T121	C0145999
phase	T079	C0205390
present	T033	C0150312
TiSLA	T074	C0392413
rutile	T121	C0141060
TiO2	T121	C0145999
evidenced	T078	C3887511
TiSLActive	T074	C0392413
TiZrSLA	T074	C0392413
TiZrSLActive	T074	C0392413
TiZr	T197	C4041873
alloy	T122	C0002154
substrates	T167	C3891814
evidence	T078	C3887511
discrete	T080	C0443299
phases	T079	C0205390
oxidized	T044	C0030011
Zr	T196	C0043506
X-ray photoelectron spectra	T059	C2700282
samples	T167	C0370003
terminated	T078	C1692758
adventitious	T080	C1517294
carbon	T196	C0007009
thicker	T080	C1280412
TiSLA	T074	C0392413
TiZrSLA	T074	C0392413
previous	T079	C0205156
in vivo studies	T062	C0681829
acquired	T080	C0439661
data	T078	C1511726
nanoscale	T081	C1553036
protrusions	T190	C0333056
thinner	T080	C0205168
layer	T080	C1522408
adventitious	T080	C1517294
carbon	T196	C0007009
contribute	T052	C1880177
rapid	T080	C0456962
osseointegration	T042	C0079949
SLActive	T074	C0392413
dental implants	T074	C0392413
Composition	T201	C0486616
surface	T082	C0205148
oxide	T197	C0030015
layer	T080	C1522408
less	T080	C0547044
important	T080	C3898777
osseointegration	T042	C0079949
kinetics	T070	C0022702
Cocaine	T109	C0009170
Use	T169	C1524063
Reverses	T169	C1555029
Striatal Plasticity	T042	C0027880
Produced	T169	C0678227
During	T079	C0347984
Cocaine	T109	C0009170
Relapse	T067	C0035020
two	T081	C0205448
component	T077	C1705248
process	T067	C1522240
highly	T080	C0205250
motivated	T041	C0026605
phase	T079	C0205390
followed by	T079	C0332283
drug-using	T048	C0242510
phase	T079	C0205390
resulting in	T169	C0332294
temporary	T079	C0205374
satiation	T041	C0036239
rodents	T015	C0035804
requires	T169	C1514873
transient synaptic potentiation	T042	C0206249
t-SP	T042	C0206249
cortical glutamatergic synapses	T030	C0039062
nucleus accumbens	T023	C0028633
core	T082	C0444669
medium spiny neurons	T025	C0682698
unknown	T080	C0439673
drug use	T048	C0242510
affects	T041	C0001721
plasticity	T042	C0027880
modeled	T077	C3714583
phases	T079	C0205390
relapse	T067	C0035020
extinction	T041	C0015347
cocaine	T109	C0009170
self-administration	T061	C0036589
assess	T052	C1516048
cocaine	T109	C0009170
affects	T041	C0001721
t-SP	T042	C0206249
associated with	T080	C0332281
Rats	T015	C0034721
self-administer	T061	C0036589
cocaine	T109	C0009170
yoked	T073	C1710702
saline	T167	C0036082
control animals	T008	C1511501
extinction	T041	C0015347
reinstatement	T079	C0678335
initiated	T169	C1704686
minutes	T079	C0439232
followed by	T079	C0332283
minutes	T079	C0439232
contingent	T080	C1701901
cocaine	T109	C0009170
access	T169	C1554204
cocaine	T109	C0009170
discontinued	T033	C1444662
unreinforced lever pressing ensued	T033	C0243095
Three	T081	C0205449
measures	T081	C0079809
t-SP	T042	C0206249
assayed	T059	C1510438
during	T079	C0347984
reinstatement	T079	C0678335
dendritic spine	T026	C0872341
morphology	T080	C0332437
alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid	T109	C0051318
AMPA	T109	C0051318
N-methyl-D-aspartate	T116	C0079883
NMDA	T116	C0079883
ratios	T081	C0456603
matrix metalloproteinase	T116	C0025543
activity	T044	C0243102
found	T033	C0243095
cocaine	T109	C0009170
minutes	T079	C0439232
collapsed	T169	C0392748
three	T081	C0205449
measures	T081	C0079809
t-SP	T042	C0206249
baseline	T081	C1442488
cocaine	T109	C0009170
discontinued	T033	C1444662
minutes	T079	C0439232
dendritic spine	T026	C0872341
morphology	T080	C0332437
AMPA	T109	C0051318
NMDA	T116	C0079883
ratios	T081	C0456603
animals	T008	C0003062
motivated	T041	C0026605
lever pressing	T033	C0243095
positively	T033	C1446409
correlated	T080	C1707520
changes	T169	C0392747
spine	T026	C2752558
morphology	T080	C0332437
cocaine	T109	C0009170
access	T169	C1554204
reversed	T169	C1555029
relationship	T080	C0439849
novel	T080	C0205314
modification	T169	C0392747
reinstatement	T079	C0678335
paradigm	T062	C0681797
cocaine	T109	C0009170
reversed	T169	C1555029
synaptic plasticity	T042	C1254358
motivation	T041	C0026605
drug	T121	C1254351
Delicaflavone	T121	C1254351
induces	T169	C0205263
autophagic cell death	T043	C1326207
lung cancer	T191	C0684249
Akt	T044	C1515844
mTOR	T044	C1515673
p70S6K	T116	C0073337
signaling pathway	T044	C0037080
potential	T080	C3245505
anticancer agents	T109	C0003392
natural sources	T033	C0449416
effective	T080	C1704419
novel	T080	C0205314
chemotherapeutic agents	T121	C0729502
study	T062	C2603343
data	T078	C1511726
in vitro	T080	C1533691
in vivo	T082	C1515655
anticancer effects	T033	C0243095
delicaflavone	T121	C1254351
biflavonoid	T109	C0596577
Selaginella doederleinii	T002	C1210298
Delicaflavone	T121	C1254351
favorable	T080	C3640814
anticancer	T033	C0243095
properties	T070	C0243178
MTT assay	T062	C2986858
xenograft model	T050	C1520166
human	T016	C0086418
non-small cell lung cancer	T191	C0007131
male	T032	C0086582
BALB/c nude mice	T015	C0025929
adverse effect	T046	C0559546
transmission electron microscopy	T059	C0678118
acridine orange	T109	C0001185
Cyto-ID®Autophagy	T043	C0004391
dyes	T130	C0013343
Western blot	T059	C0949466
analysis	T062	C0936012
RT-PCR assay	T063	C1709846
delicaflavone	T121	C1254351
induces	T169	C0205263
autophagic cell death	T043	C1326207
increasing	T169	C0442808
LC3-II	T116	C3711208
LC3-I	T116	C3714087
autophagy-related proteins	T116	C4277731
promoting	T052	C0033414
generation	T052	C3146294
acidic vesicular organelles	T026	C0029219
autolysosomes	T026	C0230822
cytoplasm	T026	C0010834
lung cancer	T191	C0684249
A549	T025	C4277577
PC-9 cells	T025	C0007634
time	T079	C0040223
dose-dependent	T081	C1512045
Delicaflavone	T121	C1254351
downregulated	T044	C0013081
expression of phospho-Akt	T033	C2697945
phospho-mTOR	T116	C0033684
phospho-p70S6K	T116	C0033684
time	T079	C0040223
dose-dependent	T081	C1512045
suggesting	T078	C1705535
induced	T169	C0205263
autophagy	T043	C0004391
inhibiting	T052	C3463820
Akt	T044	C1515844
mTOR	T044	C1515673
p70S6K	T116	C0073337
pathway	T044	C0037080
A549	T025	C4277577
PC-9 cells	T025	C0007634
Delicaflavone	T121	C1254351
potential	T080	C3245505
anticancer agent	T109	C0003392
induce	T169	C0205263
autophagic cell death	T043	C1326207
human	T016	C0086418
non-small cell lung cancer	T191	C0007131
Akt	T044	C1515844
mTOR	T044	C1515673
p70S6K	T116	C0073337
signaling pathway	T044	C0037080
Delicaflavone	T121	C1254351
anti-lung cancer effects	T033	C0243095
in vitro	T080	C1533691
in vivo	T082	C1515655
Delicaflavone	T121	C1254351
induced	T169	C0205263
autophagic cell death	T043	C1326207
Akt	T044	C1515844
mTOR	T044	C1515673
p70S6K	T116	C0073337
signaling pathway	T044	C0037080
Delicaflavone	T121	C1254351
side effects	T046	C0879626
xenograft mouse model	T050	C1520166
Delicaflavone	T121	C1254351
potential	T080	C3245505
therapeutic agent	T073	C0304231
lung cancer	T191	C0684249
Delicaflavone	T121	C1254351
anti-lung cancer effects	T033	C0243095
in vitro	T080	C1533691
in vivo	T082	C1515655
Delicaflavone	T121	C1254351
autophagic cell death	T043	C1326207
Akt	T044	C1515844
mTOR	T044	C1515673
p70S6K	T116	C0073337
signaling pathway	T044	C0037080
Delicaflavone	T121	C1254351
side effects	T046	C0879626
xenograft mouse model	T050	C1520166
Delicaflavone	T121	C1254351
potential	T080	C3245505
therapeutic agent	T073	C0304231
lung cancer	T191	C0684249
Determinants	T169	C1521761
On-Road	T073	C0442650
Driving	T056	C0004379
Multiple Sclerosis	T047	C0026769
investigate	T169	C1292732
cognitive	T169	C1516691
visual	T169	C0234621
motor deficits	T033	C0521654
dimensions	T033	C0233849
on-road	T073	C0442650
driving	T056	C0004379
individuals	T098	C0237401
multiple sclerosis	T047	C0026769
MS	T047	C0026769
cross-sectional study	T062	C0010362
MS clinic	T073	C3839267
driving	T056	C0004379
simulator	T062	C0679083
lab	T073	C0022877
Active drivers	T098	C0684312
MS	T047	C0026769
Off-road	T073	C0442650
cognitive	T169	C1516691
visual	T169	C0234621
motor functions	T038	C0234130
specific	T080	C0205369
driving skills	UnknownType	C0683900
skills	UnknownType	C0683900
categorized	T052	C0871968
hierarchic clusters	T062	C0009085
operational	T052	C3241922
tactical	UnknownType	C0683900
visuo-integrative	T169	C0234621
mixed driving	UnknownType	C0683900
Stepwise regression analysis	T170	C0034980
off-road	T073	C0442650
on-road	T073	C0442650
test	T169	C0039593
cluster	T081	C1704332
Visuospatial function	T041	C0814069
inhibition	T041	C0021467
binocular acuity	T033	C0429540
vertical visual field	T060	C1301505
stereopsis	T041	C0011586
variance	T080	C1711260
on-road	T073	C0442650
score	T081	C0449820
Attentional shift	T033	C4274597
stereopsis	T041	C0011586
glare recovery	T060	C1321305
assistive devices	T074	C0036605
operational cluster	T062	C0009085
Visuospatial function	T041	C0814069
inhibition	T041	C0021467
reasoning	T041	C0684328
binocular acuity	T033	C0429540
stereopsis	T041	C0011586
tactical cluster	T062	C0009085
visuo-integrative mode	T170	C0026347
binocular acuity	T033	C0429540
stereopsis	T041	C0011586
Inhibition	T041	C0021467
binocular acuity	T033	C0429540
model	T081	C0026348
mixed cluster	T062	C0009085
impairments	T169	C0221099
on-road	T073	C0442650
driving	T056	C0004379
targeted	T169	C1521840
driving	T056	C0004379
intervention programs	T061	C0599917
MS	T047	C0026769
Netarsudil	T121	C1254351
Increases	T169	C0442805
Outflow Facility	T060	C0430894
Human	T016	C0086418
Eyes	T023	C0015392
Multiple	T081	C0439064
Mechanisms	T169	C0441712
Netarsudil	T121	C1254351
Rho kinase/norepinephrine transporter inhibitor	T121	C0033671
phase 3 clinical development	T062	C0282461
glaucoma	T047	C0017601
treatment	T061	C0087111
metabolite	T123	C0870883
netarsudil-M1	T121	C1254351
outflow facility	T060	C0430894
C	T060	C0430894
outflow	T039	C1254359
hydrodynamics	T070	C2936194
morphology	T080	C0332437
conventional	T080	C0439858
outflow pathway	T077	C1705987
enucleated human eyes	T037	C1396718
Paired	T080	C1709450
human	T016	C0086418
eyes	T023	C0015392
perfused	T061	C0031001
netarsudil-M1	T121	C1254351
vehicle solution	T122	C0042444
constant pressure	T067	C0033095
hours	T079	C0439227
fluorescent microspheres	T074	C0026032
perfusion	T061	C0031001
media	T130	C0009924
trace	T081	C1552622
outflow patterns	T039	C1254359
perfusion	T061	C0031001
fixation	T061	C0185023
percentage effective filtration length	T081	C1444754
PEFL	T081	C1444754
measured	T080	C0444706
lengths	T081	C1444754
tracer	T130	C1522485
distribution	T169	C1704711
trabecular meshwork	T023	C0040573
TM	T023	C0040573
episcleral veins	T023	C0226616
ESVs	T023	C0226616
inner wall	T082	C1254362
IW	T082	C1254362
Schlemm's canal	T030	C0229108
global	T080	C2348867
confocal imaging	T059	C0242842
Morphologic changes	T190	C1260954
trabecular	T023	C0040573
outflow pathway	T077	C1705987
confocal	T059	C0242842
light	T059	C0430389
electron microscopy	T059	C0026019
Perfusion	T061	C0031001
netarsudil-M1	T121	C1254351
significantly	T078	C0750502
increased	T081	C0205217
C	T060	C0430894
paired	T080	C1709450
significantly	T078	C0750502
increased	T081	C0205217
PEFL	T081	C1444754
IW	T082	C1254362
ESVs	T023	C0226616
eyes	T023	C0015392
PEFL	T081	C1444754
significantly	T078	C0750502
ESVs	T023	C0226616
IW	T082	C1254362
associated with	T080	C0332281
increased	T081	C0205217
cross-sectional area	T082	C0205146
ESVs	T023	C0226616
Percentage effective filtration length	T081	C1444754
ESVs	T023	C0226616
C	T060	C0430894
significant	T078	C0750502
increase	T169	C0442805
juxtacanalicular connective tissue	T024	C0009780
JCT	T024	C0009780
thickness	T080	C1280412
eyes	T023	C0015392
Netarsudil	T121	C1254351
acutely	T079	C0205178
increased	T081	C0205217
C	T060	C0430894
JCT	T024	C0009780
ESVs	T023	C0226616
redistribution	T169	C0332620
outflow	T039	C1254359
larger area	T082	C0205146
IW	T082	C1254362
ESVs	T023	C0226616
Geographical	UnknownType	C0681784
Factors	T169	C1521761
Associated With	T080	C0332281
Health Disparities	T033	C1171307
Prostate Cancer	T191	C0376358
Treatment	T061	C0087111
variation	T080	C1705242
prostate cancer	T191	C0376358
clinical	T080	C0205210
clinician	T097	C0871685
factors	T169	C1521761
patient preferences	T080	C0376409
availability of	T169	C0470187
resources	T078	C0018741
access	T082	C0444454
physicians	T097	C0031831
treating facilities	T073	C0018704
research	T062	C0035168
treatment	T061	C0087111
disparities	T080	C1705242
men	T098	C0025266
prostate cancer	T191	C0376358
race	T098	C0034510
socioeconomic factors	T102	C0037464
geography	T077	C0017444
disparities	T080	C1705242
racial	T033	C0682075
socioeconomic differences	T033	C0682194
patients	T080	C0376409
live	T052	C2982691
barriers	T080	C4045969
care	T058	C0086388
areas	UnknownType	C0681784
access	T082	C0444454
care	T058	C0086388
health resources	T078	C0018741
Research	T062	C0035168
treatment	T061	C0087111
patterns	T082	C0449774
disparities	T080	C1705242
prostate cancer	T191	C0376358
Geographical Information System	T170	C0815319
GIS	T170	C0815319
searched	T052	C1706202
Studies	T062	C2603343
English-language	T171	C0376245
articles	T170	C1706852
research	T062	C0035168
US	T083	C0041703
populations	T098	C1257890
articles	T170	C1706852
information	T078	C1533716
spatial	T082	C0037775
geographical	UnknownType	C0681784
analyses	T062	C0936012
assess	T052	C1516048
differences	T080	C1705242
disparities	T080	C1705242
prostate cancer	T191	C0376358
treatment	T061	C0087111
GIS	T170	C0815319
research	T062	C0035168
geographical	UnknownType	C0681784
spatial determinants	T169	C1521761
prostate cancer	T191	C0376358
disparities	T080	C1705242
reviewed	T080	C1709940
geographical	UnknownType	C0681784
analyses	T062	C0936012
state level	UnknownType	C0683927
Florida	T083	C0016253
geographical	UnknownType	C0681784
disparities	T080	C1705242
men	T098	C0025266
prostate cancer	T191	C0376358
reviewed	T080	C1709940
evidence	T078	C3887511
geographical	UnknownType	C0681784
factors	T169	C1521761
disparities	T080	C1705242
prostate cancer	T191	C0376358
Disparities	T080	C1705242
prostate cancer	T191	C0376358
common	T081	C0205214
persistent	T079	C0205322
treatment	T061	C0087111
Geographical	UnknownType	C0681784
analysis	T062	C0936012
information	T078	C1533716
disparate	T080	C1705242
groups	T098	C1257890
live	T052	C2982691
map	T073	C0024779
access	T082	C0444454
care	T058	C0086388
information	T078	C1533716
public health officials	T097	C2826212
health-systems administrators	T097	C0018707
clinicians	T097	C0871685
policymakers	T097	C0242170
geographical	UnknownType	C0681784
barriers	T080	C4045969
disparities in care	T080	C1955989
miR-9600	T114	C1101610
Suppresses	T169	C1260953
Tumor Progression	T191	C0178874
Paclitaxel	T109	C0144576
Sensitivity	T080	C0205556
Non-small-cell Lung Cancer	T191	C0007131
Altering	T078	C1515926
STAT3	T028	C1367307
Expression	T045	C0017262
MicroRNAs	T114	C1101610
identified	T080	C0205396
center stage	T201	C1300072
cancer biology	T091	C1516164
cell proliferation	T043	C0596290
migration	T043	C1622501
negatively	T033	C0205160
regulate gene expression	T045	C0017263
translation	UnknownType	C0678935
targeted mRNAs	T114	C0035696
degradation	T169	C0243125
characterized	T052	C1880022
identified	T080	C0205396
miR-9600	T114	C1101610
target	T169	C1521840
human	T016	C0086418
non-small-cell lung cancer	T191	C0007131
NSCLC	T191	C0007131
miR-9600	T114	C1101610
downregulated	T044	C0013081
NSCLC	T191	C0007131
tissues	T024	C0040300
cells	T025	C0007634
signal transducer and activator of transcription 3	T028	C1367307
STAT3	T028	C1367307
putative target gene	T028	C0017337
inhibited	T080	C0311403
miR-9600	T114	C1101610
miR-9600	T114	C1101610
suppressed	T169	C1260953
protein expression	T045	C1171362
STAT3	T028	C1367307
no significant	T033	C3694175
influence	T077	C4054723
mRNA	T114	C0035696
levels	T080	C0441889
miR-9600	T114	C1101610
STAT3	T028	C1367307
miR-9600	T114	C1101610
inhibited	T080	C0311403
cell growth	T043	C0007595
expression	T045	C1171362
cell cycle	T043	C0007586
proteins	T116	C0033684
inhibited	T080	C0311403
cell migration	T043	C1622501
invasion	T046	C2699153
human	T016	C0086418
NSCLC	T191	C0007131
cell lines	T025	C0085983
miR-9600	T114	C1101610
suppressed	T169	C1260953
tumor growth	T191	C0598934
nude mice	T015	C0025932
miR-9600	T114	C1101610
tumorigenesis	T191	C0007621
metastasis	T046	C4255448
targeting	T044	C1148560
STAT3	T028	C1367307
identified	T080	C0205396
miR-9600	T114	C1101610
paclitaxel	T109	C0144576
cisplatin	T121	C0008838
sensitivity	T080	C0205556
downregulating	T044	C0013081
STAT3	T028	C1367307
chemotherapy	T061	C3665472
induced	T169	C0205263
apoptosis	T043	C0162638
miR-9600	T114	C1101610
therapeutic	T169	C0302350
target	T169	C1521840
NSCLC	T191	C0007131
Beneficial effects	UnknownType	C0683156
natural eggshell membrane	T109	C3651790
NEM	T109	C3651790
arthritis	T047	C0003864
collagen-induced arthritic	T050	C0971858
rats	T015	C0034721
study	T062	C2603343
evaluate	T058	C0220825
potential efficacy	T080	C1280519
natural eggshell membrane	T109	C3651790
NEM	T109	C3651790
collagen-induced arthritic	T050	C0971858
rats	T015	C0034721
rodent model of inflammation	T050	C1519106
rheumatoid arthritis	T047	C0003873
Rats	T015	C0034721
type II collagen-induced arthritis	T050	C0971858
CIA	T050	C0971858
daily	T079	C0332173
oral gavage	T169	C2698653
study days	T079	C2826182
vehicle	T122	C0042444
NEM	T109	C3651790
body weight	T032	C0005910
Rats	T015	C0034721
euthanized	T062	C2983562
study day	T079	C2826182
Efficacy	T080	C1280519
assessed	T052	C1516048
daily	T079	C0332173
ankle	T029	C0003086
caliper	T074	C0175720
measurements	T169	C0242485
measurements	T169	C0242485
ankle	T029	C0003086
diameter	T081	C1301886
area under the curve	T081	C0376690
AUCd0-17	T081	C0376690
histopathologic evaluation	T091	C0677043
ankles	T029	C0003086
knees	T023	C0022742
Serum	T031	C0229671
biomarkers	T201	C0005516
cartilage function	T042	C0231581
inflammation	T046	C0021368
collagen type II C-telopeptide	T059	C2825914
CTXII	T059	C2825914
cartilage oligomeric matrix protein	T059	C3715143
COMP	T059	C3715143
alpha-2-macroglobulin	T059	C0523483
A2M	T059	C0523483
measured	T080	C0444706
ELISA	T059	C0014441
Treatment	T169	C0039798
NEM	T109	C3651790
significant beneficial effects	UnknownType	C0683156
daily	T079	C0332173
ankle	T029	C0003086
diameter	T081	C1301886
measurements	T169	C0242485
ankle	T029	C0003086
diameter	T081	C1301886
AUC	T081	C0376690
Ankle	T029	C0003086
knee	T023	C0022742
histopathology scores	T034	C0428093
significantly reduced	T080	C0392756
reduction	T080	C0392756
histopathology scores	T034	C0428093
ankle	T029	C0003086
knee	T023	C0022742
rats	T015	C0034721
NEM	T109	C3651790
serum	T031	C0229671
CTXII	T059	C2825914
COMP	T059	C3715143
A2M	T059	C0523483
NEM	T109	C3651790
treated	T169	C1522326
rats	T015	C0034721
NEM	T109	C3651790
inflammatory arthritis	T047	C0003864
inflammation	T046	C0021368
pannus	T046	C0333350
cartilage damage	T037	C0549421
bone resorption	T042	C0005974
periosteal bone formation	T042	C0231565
study	T062	C2603343
CTXII	T116	C0631180
COMP	T116	C0601900
A2M	T116	C0002198
biomarkers	T201	C0005516
NEM	T109	C3651790
cell membrane	T026	C3161472
bio-inspired	T090	C0872312
simultaneous	T079	C0521115
monovalent	UnknownType	C0678553
anion	T196	C0003075
selectivity	T052	C1707391
antifouling properties	T070	C0243178
anion	T196	C0003075
membrane	T074	C0025256
bio-inspired method	T090	C0872312
simultaneously	T079	C0521115
monovalent	UnknownType	C0678553
anion	T196	C0003075
selectivity	T052	C1707391
antifouling properties	T070	C0243178
anion	T196	C0003075
membranes	T074	C0025256
polydopamine	T109	C3252413
PDA	T109	C3252413
N-O-sulfonic acid benzyl chitosan	T109	C0162969
NSBC	T109	C0162969
innermost	T082	C0205102
outermost	T082	C0205101
layers	T167	C1561572
PDA	T109	C3252413
middle	T082	C0444598
layer	T167	C1561572
NSBC	T109	C0162969
Fourier transform infrared spectroscopy	T062	C0206055
scanning electron microscopy	T059	C0026020
PDA	T109	C3252413
NSBC	T109	C0162969
membranes	T074	C0025256
hydrophilicity	T080	C0475370
membranes	T074	C0025256
electrodialysis experiments	UnknownType	C0683122
Cl(-)	T196	C0596019
SO4(2-)	T196	C3536965
monovalent	UnknownType	C0678553
anion	T196	C0003075
selectivity	T052	C1707391
Cl(-)	T196	C0596019
SO4(2-)	T196	C3536965
permselectivity	T070	C0031164
membranes	T074	C0025256
commercial membrane	T074	C0025256
electrodialysis	UnknownType	C0683122
ED	UnknownType	C0683122
membranes	T074	C0025256
antifouling properties	T070	C0243178
Sodium dodecyl benzene sulfonate	T109	C0142877
SDBS	T109	C0142877
fouling	T070	C3826310
ED	UnknownType	C0683122
membrane	T074	C0025256
modified membrane	T074	C0025256
Loop 2 Region	T087	C1514562
Ribosomal Protein uS5	T116	C0073335
Spectinomycin	T109	C0001268
Sensitivity	T033	C0427965
Translational Fidelity	T044	C3824282
Ribosome Biogenesis	T043	C1156140
Ribosomal protein uS5	T116	C0073335
essential component	T077	C1705248
small ribosomal subunit	T026	C1167012
subunit assembly	T043	C1156143
maintenance of translational fidelity	T044	C3824282
ribosome's	T026	C0035553
response	T032	C0871261
antibiotic spectinomycin	T109	C0001268
uS5 mutations	T045	C0026882
decoding	T044	C1148560
interface	T044	C1148560
uS4	T116	C0073333
residues	T077	C1709915
uS4-uS5 interface	T044	C1148560
decoding process	T067	C1522240
interface-remote area	T082	C1254362
loop 2 region	T087	C1514562
residues	T077	C1709915
mutagenesis	T044	C0079866
Escherichia. coli	T007	C0014834
unique mutants	T049	C0596988
loop 2	T087	C1514562
resistance	T169	C4281815
spectinomycin	T109	C0001268
fidelity of translation	T044	C3824282
rRNA	T114	C0035701
ribosome biogenesis	T043	C1156140
defects	T169	C1457869
Multiplex	T080	C0205556
social	T169	C0728831
ecological	T082	C0565987
network analysis	T062	C0242481
reveals	T080	C0443289
social changes	T054	C0037400
affect	T169	C0392760
community	T096	C0009462
robustness	T080	C2986815
resource	T081	C0178640
depletion	T080	C0392756
Network analysis	T062	C0242481
provides	T052	C1999230
complex	T080	C0439855
influences	T077	C4054723
social	T102	C0680343
ecological structures	T082	C0565987
community	T096	C0009462
household	T099	C0020052
network studies	T062	C0242481
social	T169	C0728831
ecological systems	T070	C0162358
simple	T080	C0205352
unweighted networks	T169	C1882071
multiplex	T080	C0205556
directed	T082	C0449738
weighted networks	T169	C1882071
subsistence	T052	C0024501
food	T168	C0016452
collected	T078	C1516695
indigenous	T102	C1512704
communities	T096	C0009462
Arctic	T083	C0003740
Alaska	T083	C0001905
economic	T169	C0013557
ecological	T082	C0565987
changes	T169	C0392747
future	T079	C0016884
scenarios	T169	C0683579
changes	T169	C0392747
social	T169	C0728831
relations	T080	C0439849
households	T099	C0020052
effects	T080	C1280500
community	T096	C0009462
robustness	T080	C2986815
changes	T169	C0392747
specific	T080	C0205369
wild food resources	T081	C0178640
Heavy Resistance Training	T061	C0872279
Hypoxia	T046	C0242184
Enhances	T052	C2349975
1RM	T081	C4054321
Squat	T033	C0241236
Performance	T055	C0597198
heavy resistance training	T061	C0872279
hypoxia	T046	C0242184
IHRT	T061	C0872279
effective	T080	C1704419
improving	T080	C1272745
strength	T081	C0237897
power	T033	C0424581
increasing	T169	C0442808
lean mass	T201	C0424678
training	T080	C2673163
pair-matched	T080	C0085145
placebo-controlled study	T062	C0599724
design	T052	C1707689
resistance-trained	T061	C0872279
participants	T098	C0679646
IHRT	T061	C0872279
FIO2	T061	C2370852
placebo	T096	C0009932
FIO2	T061	C2370852
group	UnknownType	C0681860
Participants	T098	C0679646
matched	T080	C1708943
strength	T081	C0237897
training	T061	C0872279
Both	T080	C1706086
groups	UnknownType	C0681860
performed	T169	C0884358
sessions	T051	C1883016
weeks	T079	C0439230
IHRT	T061	C0872279
placebo	T096	C0009932
participants	T098	C0679646
tested	T169	C0039593
1RM	T081	C4054321
20-m	T081	C3842775
sprint	T061	C0454374
body composition	T032	C0005885
countermovement jump	T056	C0221189
pre	T079	C0332152
mid	T079	C1254367
post	T079	C0687676
training	T061	C0872279
compared	T052	C1707455
magnitude	T081	C1704240
based	T169	C1527178
inferences	T041	C0679201
Groups	UnknownType	C0681860
not clearly	T033	C3845108
different	T080	C1705242
test	T169	C0039593
baseline	T081	C1442488
Training	T061	C0872279
improved	T033	C0184511
both	T080	C1706086
absolute	T080	C0205344
IHRT	T061	C0872279
effect size	T081	C0814843
ES	T081	C0814843
placebo	T096	C0009932
ES	T081	C0814843
relative	T080	C0205345
1RM	T081	C4054321
IHRT	T061	C0872279
ES	T081	C0814843
placebo	T096	C0009932
ES	T081	C0814843
post	T079	C0687676
both	T080	C1706086
groups	UnknownType	C0681860
increased	T081	C0205217
absolute	T080	C0205344
IHRT	T061	C0872279
ES	T081	C0814843
placebo	T096	C0009932
ES	T081	C0814843
relative	T080	C0205345
1RM	T081	C4054321
IHRT	T061	C0872279
ES	T081	C0814843
placebo	T096	C0009932
ES	T081	C0814843
change	T169	C0392747
IHRT	T061	C0872279
greater	T081	C1704243
placebo	T096	C0009932
both	T080	C1706086
absolute	T080	C0205344
greater	T081	C1704243
change	T169	C0392747
Confidence Interval	T081	C0009667
CI	T081	C0009667
ES	T081	C0814843
relative	T080	C0205345
strength	T081	C0237897
greater	T081	C1704243
change	T169	C0392747
CI	T081	C0009667
ES	T081	C0814843
relative	T080	C0205345
greater	T081	C1704243
change	T169	C0392747
IHRT	T061	C0872279
both	T080	C1706086
absolute	T080	C0205344
greater	T081	C1704243
change	T169	C0392747
CI	T081	C0009667
ES	T081	C0814843
relative	T080	C0205345
1RM	T081	C4054321
greater	T081	C1704243
change	T169	C0392747
CI	T081	C0009667
ES	T081	C0814843
IHRT	T061	C0872279
increased	T081	C0205217
countermovement jump	T056	C0221189
peak	T080	C0444505
power	T033	C0424581
Post	T079	C0687676
ES	T081	C0814843
difference	T080	C1705242
IHRT	T061	C0872279
placebo	T096	C0009932
unclear	T033	C3845108
CI	T081	C0009667
ES	T081	C0814843
no clear	T033	C3845108
differences	T080	C1705242
speed	T081	C0678536
body composition	T032	C0005885
Heavy resistance training	T061	C0872279
hypoxia	T046	C0242184
effective	T080	C1704419
placebo	T096	C0009932
improving	T080	C1272745
absolute	T080	C0205344
relative	T080	C0205345
strength	T081	C0237897
Ultrasonography	T060	C0041618
magnetic resonance imaging	T060	C0024485
evaluation	T058	C0220825
pediatric	T080	C1521725
spinal anomalies	T019	C0266498
Spinal dysraphisms	T019	C0080178
congenital abnormalities	T019	C0000768
spine	T023	C0037949
fusion	T169	C0332466
midline	T082	C0549183
mesenchymal	T080	C1513143
bony	T169	C0443157
neural	T169	C3714606
structures	T082	C0678594
Imaging	T060	C0011923
evaluation	T058	C0220825
patients	T101	C0030705
concurrent	T079	C0205420
anomalies	T019	C0000768
corrected	T080	C0205202
simultaneously	T079	C0521115
repeat surgeries	T061	C0035110
study	T062	C2603343
evaluate	T058	C0220825
Spinal dysraphisms	T019	C0080178
USG	T060	C0041618
MRI	T060	C0024485
correlate	T080	C1707520
imaging	T060	C0011923
findings	T169	C2607943
operative	T079	C1882154
findings	T169	C2607943
patients	T101	C0030705
surgery	T061	C0543467
Hospital	T073	C0019994
observational study	T062	C1518527
period	T079	C1948053
year	T079	C0439234
cases	T077	C1706256
sexes	T032	C1522384
years	T079	C0439234
age	T032	C0001779
spinal dysraphism	T019	C0080178
USG	T060	C0041618
cases	T077	C1706256
acoustic window	T082	C1254362
evaluation	T058	C0220825
MRI	T060	C0024485
cases	T077	C1706256
USG	T060	C0041618
findings	T169	C2607943
MRI	T060	C0024485
findings	T169	C2607943
operative	T079	C1882154
follow up	T058	C3274571
cases	T077	C1706256
operative management	T058	C0150270
analysed	T062	C0936012
percentage	T081	C0439165
arithmetic mean	T081	C0392762
cases	T077	C1706256
male	T032	C0086582
cases	T077	C1706256
female	T032	C0086287
Neonatal period	T079	C0935562
age group	T100	C0027362
Closed	T169	C0587267
spinal dysraphism	T019	C0080178
open	T082	C0175566
cases	T077	C1706256
spinal	T082	C0521329
USG	T060	C0041618
MRI	T060	C0024485
examinations	T058	C0582103
operative	T079	C1882154
correlation	T080	C1707520
USG	T060	C0041618
findings	T169	C2607943
confirmatory	T033	C0750484
cases	T077	C1706256
MRI	T060	C0024485
findings	T169	C2607943
confirmatory	T033	C0750484
cases	T077	C1706256
USG	T060	C0041618
modality	T169	C1275506
evaluation	T058	C0220825
spinal dysraphism	T019	C0080178
screening	T058	C1710032
suspected	T078	C0750491
cases	T077	C1706256
MRI	T060	C0024485
abnormal	T033	C0205161
USG	T060	C0041618
findings	T169	C2607943
concurrent	T079	C0205420
abnormalities	T019	C0000768
anatomical	T080	C0220784
details	T080	C1522508
surgical planning	T170	C0599880
BORA	T028	C1824391
PLK1	T116	C1579259
regulation	T043	C1158894
cancer therapy	T061	C0920425
mitotic kinase polo like kinase 1	T116	C1579259
PLK1	T116	C1579259
overexpressed	T045	C1514559
cancers and its inhibition	T043	C1512773
slows down proliferation	T043	C1156236
increases apoptosis	T043	C2248382
cancer cell lines	T025	C0334227
PLK1 is activated	T043	C1819041
PLK1 inhibitors	T116	C1449702
anticancer properties	T109	C0003392
regulatory loop	UnknownType	C0678662
PLK1 activation	T043	C1819041
cyclin-dependent kinase 1	T116	C2353787
CDK1	T116	C2353787
Activation of transcription	T045	C0162493
nuclear bodies	T026	C0230595
zebrafish	T013	C0043457
embryos	T018	C0013935
Nuclear bodies	T026	C0230595
cellular compartments	T030	C2335889
lack	T080	C0332268
lipid bilayers	T026	C0023768
specific	T080	C0205369
RNAs	T114	C0035668
proteins	T116	C0033684
nuclear bodies	T026	C0230595
nuclear bodies	T026	C0230595
investigate	T169	C1292732
Cajal bodies	T026	C0751972
CBs	T026	C0751972
histone locus bodies	T026	C2752281
HLBs	T026	C2752281
nucleoli	T026	C0007609
splicing machinery	T045	C0314666
histone mRNA 3' end processing	T045	C1158725
rRNA processing	T045	C1156152
embryos	T018	C0013935
zebrafish	T013	C0043457
Danio rerio	T013	C0043457
embryo	T018	C0013935
nuclear body	T026	C0230595
zygotic	T018	C0043544
transcription	T045	C0040649
activated	T052	C1879547
CBs	T026	C0751972
fertilization	T040	C0015914
HLB	T026	C2752281
nucleolar	T026	C0007609
components	T026	C0243092
foci	T082	C0205234
histone	T116	C0019652
genes	T028	C0017337
rDNA	T114	C0012933
active	T169	C0205177
HLB	T026	C2752281
blocked	T169	C0332206
transcription inhibition	T045	C1514673
nascent histone transcripts	T114	C1519595
HLB	T026	C2752281
components	T026	C0243092
U7 snRNP	T114	C0162464
base-pairing	T044	C0600436
nascent histone transcripts	T114	C1519595
localization	T043	C1158693
HLBs	T026	C2752281
HLBs	T026	C2752281
CBs	T026	C0751972
snRNAs	T114	C0035709
CBs	T026	C0751972
HLBs	T026	C2752281
contribution	T052	C1880177
protein	T116	C0033684
constituents	T167	C0729650
nuclear bodies	T026	C0230595
nucleolar	T026	C0007609
HLB	T026	C2752281
CB	T026	C0751972
components	T026	C0243092
early	T079	C1279919
embryogenesis	T042	C0013936
transcription	T045	C0040649
transcription	T045	C0040649
specific	T080	C0205369
gene loci	T082	C1708726
nuclear body	T026	C0230595
components	T026	C0243092
specificity	T081	C0037791
regulatory	T077	C1704735
functions	T039	C0031843
Variation in the age	T100	C0699810
first reproduction	T040	C0035150
different strategies	T080	C0205556
individual quality	T080	C0332306
age	T032	C0001779
first reproduction	T040	C0035150
demographic parameter	T078	C0011292
high selective pressure	T033	C0460139
variable	T080	C0439828
variability	T077	C2827666
hypotheses	T078	C1512571
variability	T077	C2827666
expression	T055	C0565975
individual strategies	T080	C0205556
allocation strategies	T052	C1706778
fitness components	T078	C0031812
individual difference	T054	C0021228
intrinsic quality	T082	C0205102
individuals	T098	C0237401
fitness components	T078	C0031812
tested	T169	C0039593
hypotheses	T078	C1512571
Wandering Albatross	T012	C0325368
relationships	T080	C0439849
age	T032	C0001779
first reproduction	T040	C0035150
adult	T100	C0001675
demographic	T090	C0011298
traits	T032	C0599883
finite mixture capture recapture modeling	T062	C0870071
age	T032	C0001779
first reproduction	T040	C0035150
negatively	T033	C1513916
reproductive	T040	C0035150
performances	T055	C0597198
adult	T100	C0001675
survival	T052	C0038952
individual quality	T080	C0332306
variation	T077	C2827666
age	T032	C0001779
first reproduction	T040	C0035150
age	T032	C0001779
first breeding	T040	C0006159
predictor	T078	C2698872
quality	T080	C0332306
seabird species	T012	C0325368
Heterogeneity	T080	C0019409
colorectal cancer	T191	C1527249
risk	T078	C0035647
tumour	T191	C0027651
characteristics	T080	C1521970
prospective study	T062	C0033522
UK	T083	C0041700
women	T098	C0043210
Associations	T080	C0439849
behavioural	T053	C0004927
personal	T032	C1519021
factors	T169	C1521761
colorectal cancer	T191	C1527249
risk	T078	C0035647
tumour	T191	C0027651
characteristics	T080	C1521970
UK	T083	C0041700
prospective study	T062	C0033522
risk factors	T033	C0035648
colorectal cancer	T191	C1527249
risk	T078	C0035647
anatomical sites	T029	C0005898
morphological	T082	C0543482
subtypes	T185	C0449560
women	T098	C0043210
colorectal cancers	T191	C1527249
follow-up	T058	C1522577
national cancer registry	T170	C0805443
data	T078	C1511726
Cox regression	T081	C0010235
relative risks	T081	C0242492
Statistical significance	T081	C0237881
colorectal cancer	T191	C1527249
risk	T078	C0035647
associated with	T080	C0332281
height	T032	C0005890
body mass index	T201	C1305855
BMI	T201	C1305855
smoking	T055	C0037369
alcohol intake	T055	C0001948
physical activity	T056	C0026606
parity	T033	C0030563
menopausal hormone therapy	T061	C0282402
smoking	T055	C0037369
heterogeneity	T080	C0019409
morphological	T082	C0543482
types	T080	C0332307
relative risks	T081	C0242492
smokers	T033	C0337664
signet ring cell	T025	C0333727
neuroendocrine tumours	T191	C0206754
Obese	T047	C0028754
women	T098	C0043210
at higher risk	T033	C3843761
signet ring cell	T025	C0333727
tumours	T191	C0027651
adenocarcinomas	T191	C0001418
colorectal cancers	T191	C1527249
cohort	T098	C0599755
risk factor	T033	C0035648
associations	T080	C0439849
heterogeneity	T080	C0019409
risk	T078	C0035647
tumours	T191	C0027651
right colon	T023	C1305188
left colon	T023	C0227388
rectum	T023	C0034896
factors	T033	C0035648
epidemiological	T091	C0014507
findings	T033	C0243095
molecular studies	T063	C0946228
developmental	T080	C0458003
pathways	T077	C1705987
tumour	T191	C0027651
types	T080	C0332307
Impact	T080	C4049986
alcohol use	T055	C0001948
EEG dynamics	T060	C0013819
response inhibition	T041	C1510574
cotwin control analysis	T062	C0242481
alcohol misuse	UnknownType	C0678254
associated with	T080	C0332281
behavioral disinhibition	T048	C0424296
neurophysiological mechanisms	T040	C1327471
relationship	T080	C0439849
inhibition	T041	C1510574
cognitive control	T041	C0392335
electrophysiological theta-band dynamics	T060	C0850293
medial frontal cortex	T024	C2951740
MFC	T024	C2951740
power enhancement	T042	C1254358
functional connectivity	T042	C1254358
MFC	T024	C2951740
dorsal prefrontal cortex	T023	C4019080
dPFC	T023	C4019080
alcohol misuse	UnknownType	C0678254
men	T098	C0025266
women	T098	C0043210
risk	T078	C0035647
physical	T039	C0871083
neurocognitive correlates	T041	C0871178
drinking	T055	C0001948
study	T062	C2603343
alcohol misuse	UnknownType	C0678254
deleterious effect	T046	C0879626
theta-band	T061	C0204631
response inhibition	T041	C1510574
EEG dynamics	T060	C0013819
sample	T098	C1257890
twins	T099	C0041427
cotwin control (CTC) design	T062	C0035171
risk	T078	C0035647
alcohol use	T055	C0001948
causal effects	T080	C1280500
alcohol exposure	T051	C4038778
Drinking	T055	C0001948
associated with	T080	C0332281
theta-band	T061	C0204631
MFC power	T042	C1254358
MFC	T024	C2951740
dPFC	T023	C4019080
connectivity	T030	C0229984
response inhibition	T041	C1510574
effect	T080	C1280500
women	T098	C0043210
CTC analysis	T062	C0242481
women	T098	C0043210
theta-band	T061	C0204631
MFC power	T042	C1254358
MFC	T024	C2951740
dPFC	T023	C4019080
connectivity	T030	C0229984
deleterious causal effects	T046	C0879626
alcohol exposure	T051	C4038778
diminished	T081	C0205216
theta-band	T061	C0204631
MFC power	T042	C1254358
MFC	T024	C2951740
dPFC	T023	C4019080
connectivity	T030	C0229984
neurophysiological mechanisms	T040	C1327471
alcohol-related disinhibition	T048	C0424296
normative levels	T033	C0243095
alcohol use	T055	C0001948
adulthood	T079	C0700597
causal effects	T080	C1280500
response inhibition	T041	C1510574
EEG dynamics	T060	C0013819
Neutrophil	T025	C0027950
Monocyte	T025	C0026473
Function	T043	C0007613
Patients	T101	C0030705
Chronic Hepatitis C	T047	C0524910
Antiviral Therapy	T061	C0280274
Regimens	T061	C0040808
Protease Inhibitors	T121	C0033607
Interferon	T116	C0021747
Real-life data	T078	C1511726
increased	T081	C0205217
incidence	T081	C0021149
bacterial infections	T047	C0004623
patients	T101	C0030705
liver disease	T047	C0023895
receiving	T080	C1514756
protease inhibitor	T121	C0033607
PI	T121	C0033607
antiviral regimen	T061	C0040808
hepatitis C	T005	C0220847
HCV	T005	C0220847
PIs	T121	C0033607
innate immune responses	T032	C0020969
inhibition of proteases	T039	C1524081
anti-bacterial functions	T039	C0544570
neutrophils	T025	C0027950
monocytes	T025	C0026473
study	T077	C1706256
assess	T058	C0184514
phagocytic and oxidative burst	T043	C0085416
capacity	T081	C1516240
neutrophils	T025	C0027950
monocytes	T025	C0026473
patients	T101	C0030705
receiving	T080	C1514756
PI	T121	C0033607
antiviral regimen	T061	C0040808
cytokine secretion	T043	C1327414
neutrophil	T025	C0027950
stimulation	T043	C0007613
flagellin	T116	C0016194
patients	T101	C0030705
chronic HCV	T047	C0524910
cirrhosis	T047	C0023890
study	T077	C1706256
received	T080	C1514756
triple therapy	T061	C0087111
Group A	T185	C0441835
pegylated-interferon	T116	C0021747
ribavirin	T114	C0035525
weeks	T079	C0439230
PI	T121	C0033607
telaprevir	T116	C1876229
boceprevir	T116	C1738934
simeprevir	T109	C2605855
patients	T101	C0030705
received	T080	C1514756
interferon	T116	C0021747
interferon -free regimen	T061	C0040808
Group B	T185	C0008902
simeprevir	T109	C2605855
sofosbuvir	T114	C2976303
Phagocytosis and oxidative burst	T043	C0085416
capacity	T081	C1516240
flow cytometry	T059	C0016263
baseline	T081	C1442488
week	T079	C0439230
week	T079	C0439230
therapy	T061	C0087111
neutrophils	T025	C0027950
Group A	T185	C0441835
patients	T101	C0030705
oxidative burst	T043	C0085416
rate	T081	C1521828
oxidative	T169	C0311404
enzymatic activity per cell	T044	C2267219
decreased	T081	C0205216
study period	T079	C1254367
Pairwise comparisons	T081	C0086766
decrease	T081	C0547047
baseline	T081	C1442488
week	T079	C0439230
therapy	T061	C0087111
introduction	T061	C1293116
PI	T121	C0033607
oxidative	T169	C0311404
enzymatic activity per cell	T044	C2267219
monocytes	T025	C0026473
decrease	T081	C0547047
study period	T079	C1254367
decrease	T081	C0547047
baseline	T081	C1442488
week	T079	C0439230
therapy	T061	C0087111
patients	T101	C0030705
Group A	T185	C0441835
findings	T169	C2607943
Group B	T185	C0008902
patients	T101	C0030705
Cytokine secretion	T043	C1327414
study	T077	C1706256
groups	T078	C0441833
data	T078	C1511726
interferon	T116	C0021747
PI	T121	C0033607
deleterious effect	T080	C1280500
neutrophil	T025	C0027950
monocyte	T025	C0026473
phagocytic and oxidative burst	T043	C0085416
capacity	T081	C1516240
cohort	T098	C0599755
patients	T101	C0030705
HCV	T005	C0220847
advanced liver fibrosis	T047	C0239946
Child death	T033	C0524343
maternal	T033	C1858460
psychosis-like experiences	T048	C0033975
low-	T098	C0024045
middle-income	T080	C0870890
countries	T083	C0454664
depression	T048	C0011570
child death	T033	C0524343
mental wellbeing	T041	C0025353
women	T098	C0043210
low-	T098	C0024045
middle-income	T080	C0870890
countries	T083	C0454664
LMICs	T083	C0454664
child mortality	T081	C0008083
association	T080	C0439849
child death	T033	C0524343
psychosis-like experiences	T048	C0033975
PLEs	T048	C0033975
depression	T048	C0011570
association	T080	C0439849
Data	T081	C0010100
LMICs	T083	C0454664
World Health Survey	T062	C0018762
WHS	T062	C0018762
women	T098	C0043210
birth	T040	C0005615
years	T079	C0439234
self-reported	T062	C0681906
lifetime	T079	C4071830
psychosis diagnosis	T060	C0596905
World Mental Health Survey	T170	C3481515
Composite International Diagnostic Interview	T170	C0451085
CIDI	T170	C0451085
diagnosis	T062	C1704656
month	T079	C0439231
DSM-IV	T170	C0220952
depression	T048	C0011570
positive psychotic symptoms	T184	C0871189
Depression	T048	C0011570
self-reported	T062	C0681906
lifetime	T079	C4071830
depression diagnosis	T060	C0596905
month	T079	C0439231
depression	T048	C0011570
logistic regression analyses	UnknownType	C0681925
potential confounders	T169	C0009673
women	T098	C0043210
child death	T033	C0524343
PLEs	T048	C0033975
depression	T048	C0011570
OR	T081	C0028873
depression	T048	C0011570
OR	T081	C0028873
CI	T081	C0009667
depression	T048	C0011570
delusion of control	T048	C0233685
associated with	T080	C0332281
child death	T033	C0524343
OR	T081	C0028873
CI	T081	C0009667
Child death	T033	C0524343
mental wellbeing	T041	C0025353
women	T098	C0043210
LMICs	T083	C0454664
adverse health outcomes	T057	C3858647
associated with	T080	C0332281
PLEs	T048	C0033975
depression	T048	C0011570
symptoms	T184	C1457887
mental health care	T061	C0184643
mothers	T099	C0026591
child loss	T033	C0848031
LMICs	T083	C0454664
Prednisolone	T109	C0032950
associated with	T080	C0332281
worse lipid profile	T033	C0740400
hydrocortisone	T109	C0020268
patients	T101	C0030705
adrenal insufficiency	T047	C0001623
Prednisolone	T109	C0032950
glucocorticoid	T109	C0017710
replacement therapy	T061	C0279033
adrenal insufficiency	T047	C0001623
AI	T047	C0001623
data	T078	C1511726
AI	T047	C0001623
associated with	T080	C0332281
bone mineral density	T201	C0005938
Data	T078	C1511726
risk factors	T033	C0035648
cardiovascular disease	T047	C0007222
patients	T101	C0030705
AI	T047	C0001623
treated	T169	C1522326
prednisolone	T109	C0032950
cause	T033	C0007465
mortality	T081	C0205848
data	T078	C1511726
European Adrenal Insufficiency Registry	T170	C0282574
EU-AIR	T170	C0282574
EU-AIR	T170	C0282574
centres	T073	C0475309
Germany	T083	C0017480
Netherlands	T083	C0027778
Sweden	T083	C0038995
UK	T083	C0041700
patients	T101	C0030705
AI	T047	C0001623
Patients	T101	C0030705
prednisolone	T109	C0032950
hydrocortisone	T109	C0020268
identified	T080	C0205396
grouped	T082	C0439745
prednisolone	T109	C0032950
hydrocortisone	T109	C0020268
gender	T032	C0079399
age	T032	C0001779
duration	T079	C0449238
type of disease	T170	C0457464
Data	T078	C1511726
baseline	T081	C1442488
follow-up	T058	C1522577
visits	T058	C1512346
Data	T078	C1511726
patients	T101	C0030705
congenital adrenal hyperplasia	T047	C0001627
excluded	T052	C2828389
mean ± s.d. total	T081	C0392762
low-density lipoprotein (LDL) cholesterol	T109	C0023824
LDL	T109	C0023823
levels	T080	C0441889
identified	T080	C0205396
patients	T101	C0030705
prednisolone	T109	C0032950
hydrocortisone	T109	C0020268
baseline	T081	C1442488
follow-up	T058	C1522577
HbA1c	T116	C0019018
high-density lipoprotein	T116	C0023821
triglyceride levels	T034	C0428475
body mass index	T201	C1305855
systolic	T047	C0221155
diastolic blood pressure	T047	C0235222
waist circumference	T201	C0455829
matched	T080	C1708943
analysis	T062	C0936012
LDL levels	T034	C0428473
patients	T101	C0030705
prednisolone	T109	C0032950
hydrocortisone	T109	C0020268
risk	T078	C0035647
cardiovascular disease	T047	C0007222
group	T078	C0441833
Oxytocin	T116	C0030095
Reduces	T080	C0392756
Face	T029	C0015450
Processing	T052	C1709694
Time	T079	C0040223
Leaves	T080	C0205556
Recognition	T041	C0524637
Accuracy	T080	C0443131
Eye	T023	C0015392
Gaze	T033	C0553544
Unaffected	T077	C2986417
Previous	T079	C0205156
studies	T062	C0681814
oxytocin	T116	C0030095
OXT	T116	C0030095
improve	T033	C0184511
recognition	T041	C0524637
emotional	T033	C0849912
facial expressions	T033	C0015457
proposed	T080	C1553874
effect	T080	C1280500
mediated	T054	C0086597
increase	T169	C0442805
attention	T041	C0004268
eye-region	T029	C0446453
faces	T029	C0015450
evidence	T078	C3887511
inconsistent	T080	C0442809
few	T081	C0205388
studies	T062	C0681814
directly	T080	C1947931
tested	T169	C0039593
effect	T080	C1280500
oxytocin	T116	C0030095
emotion	T041	C0013987
recognition	T041	C0524637
altered	T169	C0392747
eye	T023	C0015392
gaze	T033	C0553544
Methods	T170	C0025663
double-blind	T062	C0013072
within	T082	C0332285
subjects	T098	C0080105
randomized control experiment	T062	C0681814
healthy	T080	C3898900
male participants	T098	C0025266
received	T080	C1514756
IU	T081	C0439453
intranasal	T061	C0001560
OXT	T116	C0030095
placebo	T122	C1696465
identical	T080	C0205280
experimental	T080	C1517586
sessions	T051	C1883016
separated	T080	C0443299
week	T079	C0439230
interval	T079	C1272706
Visual attention	T041	C0589102
eye-region	T029	C0446453
assessed	T052	C1516048
participants	T098	C0679646
completed	T080	C0205197
static	T080	C0441463
facial	T029	C0015450
emotion	T041	C0013987
recognition	T041	C0524637
task	T057	C3540678
medium intensity	T080	C0522510
facial expressions	T033	C0015457
OXT	T116	C0030095
no effect	T080	C1301751
emotion	T041	C0013987
recognition	T041	C0524637
accuracy	T080	C0443131
recognition	T041	C0524637
performance	T052	C1882330
improved	T033	C0184511
face	T029	C0015450
processing	T052	C1709694
faster	T080	C0456962
emotions	T041	C0013987
influence	T077	C4054723
OXT	T116	C0030095
effect	T080	C1280500
marginally	T080	C1947914
significant	T078	C0750502
Consistent with	T078	C0332290
previous	T079	C0205156
study	T062	C0681814
dynamic stimuli	T067	C0234402
OXT	T116	C0030095
no effect	T080	C1301751
eye	T023	C0015392
gaze	T033	C0553544
patterns	T082	C0449774
viewing	T082	C0449911
static	T080	C0441463
emotional	T033	C0849912
faces	T029	C0015450
recognition	T041	C0524637
accuracy	T080	C0443131
face	T029	C0015450
processing	T052	C1709694
time	T079	C0040223
findings	T033	C0243095
suggest	T078	C1705535
OXT	T116	C0030095
induced	T169	C0205263
enhanced	T052	C2349975
facial	T029	C0015450
emotion	T041	C0013987
recognition	T041	C0524637
mediated	T054	C0086597
increase	T169	C0442805
attention	T041	C0004268
eye-region	T029	C0446453
faces	T029	C0015450
previously	T079	C0205156
assumed	T170	C3242379
several	T081	C0443302
methodological	T078	C3266812
issues	T033	C0033213
discrepant findings	T033	C0243095
suggest	T078	C1705535
effect	T080	C1280500
OXT	T116	C0030095
visual attention	T041	C0589102
task	T057	C3540678
requirements	T169	C1514873
psychiatric rehabilitation	T061	C0204512
USA	T083	C0041703
American	T098	C0596070
researchers	T097	C0035173
world	T098	C2700280
developing	T169	C1527148
evaluating	T058	C0220825
disseminating	T082	C0205221
evidence	T078	C3887511
psychiatric rehabilitation	T061	C0204512
practices	T169	C1510541
people	T098	C0027361
serious	T080	C0205404
mental illness	T048	C0004936
USA	T083	C0041703
industrialized nations	T080	C0282613
access	T080	C0018748
high-quality	T058	C0034379
mental health	T058	C0025355
psychiatric services	T058	C3526598
essay	T170	C0684224
evidence-based practices	T169	C1510541
USA	T083	C0041703
practices	T058	C0034024
barriers	T033	C3260965
availability	T080	C0018748
people	T098	C0027361
benefit	T081	C0086387
services	T058	C0025355
overcoming	T052	C2983310
barriers	T033	C3260965
Factors	T169	C1521761
sustainment	T052	C0024501
effective	T080	C1704419
client	T096	C0008942
practices	T058	C0034024
availability	T169	C0470187
adequate and stable funding	T081	C0243098
committed leadership	T054	C0023181
influence	T077	C4054723
promoting	T052	C0033414
spread	T080	C0332261
sustainment	T052	C0024501
well-implemented evidence-based practices	T169	C1510541
adoption	T052	C1708476
fidelity scales	T054	C0680011
learning	T041	C0023185
communities	T096	C0009462
Modifiable	T169	C0392747
Healthy Lifestyle Behaviors	T055	C4277664
Health Outcomes	T170	C1550208
Health Promotion Program	T058	C0018738
impact of	T080	C4049986
healthy lifestyle choices	T055	C4277664
health-related outcomes	T170	C1550208
fragmented	T080	C1708096
cross-sectional nature	T062	C0010362
assessing the relative impact	T058	C1160858
modifiable	T169	C0392747
behaviors	T053	C0004927
long-term	T079	C0443252
outcomes	T170	C1550208
working adult population	T098	C1527116
remains challenging	T080	C0205556
self-reported	T062	C2700446
healthy lifestyle behaviors	T055	C4277664
health outcomes	T170	C1550208
cohort	T098	C0599755
participants	T098	C0679646
voluntary	T055	C0439656
workplace	T082	C0162579
wellness program	T058	C0043113
Cox proportional-hazards models	T081	C0010235
computed hazard ratios	T081	C2985465
HRs	T081	C2985465
lifestyle characteristics	T054	C0023676
time	T079	C0040223
self-reported	T062	C2700446
chronic diseases	T047	C0008679
death	T040	C0011065
Data were collected	T033	C4019276
Behaviors	T053	C0004927
future outcomes	T081	C0086749
low-fat diet	T061	C0242970
aerobic exercise	T061	C0001701
nonsmoking	T058	C0812017
adequate sleep	T033	C2364286
dose-response effect	T062	C4284887
dietary fat intake	T033	C0425440
hypertension	T047	C0020538
obesity	T047	C0028754
diabetes	T047	C0011847
heart disease	T047	C0018799
hypercholesterolemia	T047	C0020443
dietary fat intake	T033	C0425440
aerobic exercise	T061	C0001701
behavior	T053	C0004927
development of outcomes	T062	C0086750
sedentary	T080	C0205254
participants	T098	C0679646
exercised	T056	C0015259
new-onset diabetes	UnknownType	C0743128
HR	T081	C2985465
CI	T081	C0009667
heart disease	T047	C0018799
HR	T081	C2985465
CI	T081	C0009667
hypercholesterolemia	T047	C0020443
HR	T081	C2985465
CI	T081	C0009667
Low-fat diet	T061	C0242970
adequate sleep	T033	C2364286
healthy behaviors	T055	C4277664
eating a daily breakfast	T055	C0814440
Modifiable	T169	C0392747
lifestyle behaviors	T054	C0023676
health promotion programs	T058	C0018738
evidence-based manner	T169	C1510541
workplace	T082	C0162579
health promotion	T058	C0018738
low-fat diet	T061	C0242970
aerobic exercise	T061	C0001701
nonsmoking	T058	C0812017
adequate sleep	T033	C2364286
Diazoxide	T109	C0012022
prevents	T169	C1292733
reactive oxygen species	T123	C0162772
mitochondrial damage	T046	C1096176
anti-hypertrophic effects	T033	C0243095
Pathological	T169	C0205469
cardiac hypertrophy	T046	C1383860
characterized	T052	C1880022
wall	T023	C0446987
thickening	T033	C0205400
chamber	T023	C0729936
enlargement	T046	C0020564
heart	T023	C0018787
pressure	T081	C4284008
volume	T081	C0449468
condition	T080	C0348080
improve	T033	C0184511
organ	T023	C0178784
contractile function	T042	C1258017
sustained	T169	C0443318
dysfunctional	T077	C3887504
mitochondria	T026	C0026237
oxidative stress	T049	C0242606
Mitochondrial ATP-sensitive K(+) channels	T116	C0764439
mitoKATP	T116	C0764439
modulate	T082	C0443264
redox status	T044	C0030012
cell	T025	C0007634
protect	T033	C1545588
cardiac	T023	C0018787
insults	T169	C1883709
hypothesis	T078	C1512571
mitoKATP	T116	C0764439
opening	T082	C1882151
diazoxide	T109	C0012022
isoproterenol	T109	C0022245
induced	T169	C0205263
cardiac hypertrophy	T046	C1383860
in vivo	T082	C1515655
reactive oxygen species	T123	C0162772
(ROS	T123	C0162772
mitochondrial	T026	C0026237
Ca(2+)	T121	C0596235
induced	T169	C0205263
swelling	T033	C0038999
induce	T169	C0205263
cardiac hypertrophy	T046	C1383860
Swiss mice	T015	C0162416
treated	T169	C1522326
intraperitoneally	T082	C0442120
isoproterenol	T109	C0022245
day	T079	C0439228
days	T079	C0439228
Diazoxide	T109	C0012022
day	T079	C0439228
mitoKATP	T116	C0764439
5-hydroxydecanoate	T109	C0098450
day	T079	C0439228
mitoKATP	T116	C0764439
blocker	T121	C0870261
Isoproterenol	T109	C0022245
treated	T169	C1522326
mice	T015	C0025929
elevated	T080	C3163633
heart	T023	C0018787
weight	T081	C0043100
tibia	T023	C1279118
length	T081	C1444754
ratios	T081	C0456603
increased	T081	C0205217
myocyte	T025	C0225828
cross-sectional areas	T033	C0243095
hypertrophic	T169	C0333959
hearts	T023	C0018787
higher	T080	C0205250
levels	T080	C0441889
H2O2	T121	C0020281
glutathione peroxidase activity	T044	C1151528
mitoKATP	T116	C0764439
opening	T082	C1882151
diazoxide	T109	C0012022
blocked	T169	C0332206
isoproterenol	T109	C0022245
effects	T080	C1280500
reversed	T169	C1555029
5-hydroxydecanoate	T109	C0098450
Isolated	T169	C0205409
mitochondria	T026	C0026237
Isoproterenol	T109	C0022245
induced	T169	C0205263
hypertrophic	T169	C0333959
hearts	T023	C0018787
increased	T081	C0205217
susceptibility	T169	C0231204
Ca(2+)	T121	C0596235
induced	T169	C0205263
swelling	T033	C0038999
mitochondrial permeability transition pore	T116	C0908146
opening	T082	C1882151
MitokATP	T116	C0764439
opening	T082	C1882151
Ca(2+)	T121	C0596235
induced	T169	C0205263
mitochondrial swelling	T049	C0026244
effect	T080	C1280500
blocked	T169	C0332206
5-hydroxydecanoate	T109	C0098450
mitoKATP	T116	C0764439
opening	T082	C1882151
negatively	T033	C0205160
regulates	T038	C1327622
cardiac hypertrophy	T046	C1383860
oxidative	T169	C0311404
impairment	T169	C0221099
mitochondrial damage	T046	C1096176
Anticholinergic	T121	C0242896
premedication	T061	C0033045
bradycardia	T046	C0428977
spinal anesthesia	T061	C0002928
dexmedetomidine	T109	C0113293
sedation	T061	C0344106
randomized	T062	C0206034
double-blind	T062	C0013072
placebo-controlled study	T062	C0599724
dexmedetomidine	T109	C0113293
patients	T101	C0030705
spinal anesthesia	T061	C0002928
incidence	T169	C0220856
bradycardia	T046	C0428977
parasympathetic	T022	C0030510
activation	T052	C1879547
effectiveness	T080	C1280519
atropine	T109	C0004259
premedication	T061	C0033045
preventing	T169	C1292733
incidence	T169	C0220856
bradycardia	T046	C0428977
hemodynamic effect	T042	C0019010
patients	T101	C0030705
spinal anesthesia	T061	C0002928
sedation	T061	C0344106
dexmedetomidine	T109	C0113293
Randomized	T062	C0206034
double-blind	T062	C0013072
placebo-controlled study	T062	C0599724
Operating room	T073	C0029064
patients	T109	C0113293
years	T079	C1510829
American Society of Anesthesiology class I-II	T094	C0037459
study	T062	C2603343
spinal anesthesia	T061	C0002928
patients	T109	C0113293
groups	UnknownType	C0681860
group A	UnknownType	C0681860
group C	UnknownType	C0681860
spinal anesthesia	T061	C0002928
dexmedetomidine	T109	C0113293
infused	T061	C0574032
loading dose	UnknownType	C0678767
minutes	T079	C0439232
infusion	T061	C0574032
loading dose	UnknownType	C0678767
dexmedetomidine	T109	C0113293
patients	T109	C0113293
group A	UnknownType	C0681860
intravenous bolus	T169	C1522229
atropine	T109	C0004259
patients	T109	C0113293
group C	UnknownType	C0681860
intravenous normal saline	T061	C2064712
bolus	T061	C1511237
Data	T078	C1511726
administration	T061	C1533734
atropine	T109	C0004259
ephedrine	T109	C0014479
Hemodynamic	T059	C4281788
data	T078	C1511726
heart rate	T201	C0018810
systolic blood pressure	T201	C0871470
diastolic blood pressure	T201	C0428883
DBP	T201	C0428883
mean blood pressure	T033	C0428886
MBP	T033	C0428886
incidence	T169	C0220856
bradycardia	T046	C0428977
atropine	T109	C0004259
treatment	T061	C0087111
significantly higher	T081	C4055637
group C	UnknownType	C0681860
group A	UnknownType	C0681860
incidence	T169	C0220856
hypotension	T033	C0020649
ephedrine	T109	C0014479
treatment	T061	C0087111
no significant difference	T033	C3842396
groups	UnknownType	C0681860
Systolic blood pressure	T201	C0871470
heart rate	T201	C0018810
no significant differences	T033	C3842396
groups	UnknownType	C0681860
group A	UnknownType	C0681860
increases	T081	C0205217
DBP	T201	C0428883
MBP	T033	C0428886
group C	UnknownType	C0681860
Prophylactic	T061	C0199176
atropine	T109	C0004259
incidence	T169	C0220856
bradycardia	T046	C0428977
patients	T109	C0113293
spinal anesthesia	T061	C0002928
dexmedetomidine	T109	C0113293
sedation	T061	C0344106
DBP	T201	C0428883
MBP	T033	C0428886
increases	T081	C0205217
patients	T109	C0113293
prophylactic	T061	C0199176
atropine	T109	C0004259
administrated	T061	C1533734
atropine	T109	C0004259
premedication	T061	C0033045
administered	T061	C1533734
Downregulation	T044	C0013081
Endothelial Transient Receptor Potential Vanilloid Type 4 Channel	T116	C1563722
Small-Conductance of Ca2+-Activated K+ Channels	T116	C1571638
Impaired	T169	C0221099
Endothelium-Dependent Hyperpolarization	T123	C0082428
Hypertension	T047	C0020538
Endothelium-dependent hyperpolarization	T123	C0082428
EDH	T123	C0082428
responses	T033	C1704632
impaired	T169	C0221099
hypertension	T047	C0020538
mechanisms	T169	C0441712
activation	T052	C1879547
small-	T116	C1571638
intermediate-conductance of Ca(2+)-activated K(+) channels	T116	C1571649
SKCa	T116	C1571638
IKCa	T116	C1571649
EDH	T123	C0082428
responses	T033	C1704632
reported	T170	C0684224
Ca(2+) influx	T043	C3158761
endothelial transient receptor potential vanilloid type 4 channel	T116	C1563722
TRPV4	T116	C1563722
prerequisite	T078	C0679209
activation	T052	C1879547
SKCa	T116	C1571638
IKCa	T116	C1571649
endothelial cells	T025	C0225336
attempted	T051	C1516084
impairment	T169	C0221099
EDH	T123	C0082428
hypertension	T047	C0020538
dysfunction	T077	C3887504
TRPV4	T116	C1563722
S	T116	C1571638
IKCa	T116	C1571649
superior mesenteric arteries	T023	C0162861
stroke-prone spontaneously hypertensive rats	T015	C0034705
SHRSP	T015	C0034705
Wistar-Kyoto (WKY) rats	T015	C0034709
WKY	T015	C0034709
arteries	T023	C0003842
EDH	T123	C0082428
responses	T033	C1704632
reduced	T080	C0392756
combination	T080	C0205195
SKCa	T116	C1571638
IKCa	T116	C1571649
blockers	T121	C0870261
apamin	T116	C0003521
TRAM-34	T109	C0916207
1-[(2-chlorophenyl)diphenylmethl]-1H-pyrazole	T109	C0916207
blockade	T169	C0332206
TRPV4	T116	C1563722
antagonist	T120	C0243076
RN-1734	T109	C2744078
HC-067047	T109	C3493142
SHRSP	T015	C0034705
arteries	T023	C0003842
EDH-mediated hyperpolarization	T123	C0082428
relaxation	T052	C0035028
significantly	T078	C0750502
impaired	T169	C0221099
WKY	T015	C0034709
GSK1016790A	T109	C2604031
TRPV4	T116	C1563722
activator	T121	C0243192
hyperpolarization	T043	C2262820
relaxation	T052	C0035028
WKY	T015	C0034709
arteries	T023	C0003842
SHRSP	T015	C0034705
arteries	T023	C0003842
GSK1016790A	T109	C2604031
hyperpolarization	T043	C2262820
relaxation	T052	C0035028
absent	T169	C0332197
Hyperpolarization	T043	C2262820
relaxation	T052	C0035028
cyclohexyl-[2-(3,5-dimethyl-pyrazol-1-yl)-6-methyl-pyrimidin-4-yl]-amine	T109	C2976731
SKCa	T116	C1571638
activator	T121	C0243192
marginally	T080	C1947914
decreased	T081	C0205216
SHRSP	T015	C0034705
arteries	T023	C0003842
WKY	T015	C0034709
arteries	T023	C0003842
expression	T045	C1171362
endothelial TRPV4	T116	C1563722
SKCa	T116	C1571638
significantly decreased	T081	C4055638
SHRSP	T015	C0034705
mesenteric arteries	T023	C0162861
WKY	T015	C0034709
function	T169	C0542341
expression	T045	C1171362
IKCa	T116	C1571649
SHRSP	T015	C0034705
arteries	T023	C0003842
findings	T033	C0243095
EDH	T123	C0082428
responses	T033	C1704632
impaired	T169	C0221099
superior mesenteric arteries	T023	C0162861
SHRSP	T015	C0034705
reduction	T061	C0441610
TRPV4	T116	C1563722
SKCa	T116	C1571638
input	T077	C1708517
EDH	T123	C0082428
Bioavailability	T062	C1706947
health risk assessment	T061	C0679809
potentially	T080	C3245505
toxic elements	T131	C0032346
Thriasio Plain, near Athens	T083	C0017446
Greece	T083	C0018226
concentrations	T081	C1446561
potentially	T080	C3245505
toxic elements	T131	C0032346
PTEs	T131	C0032346
areas of intense industrial activity	T033	C3846701
Thriasio Plain	T083	C0017446
plain near Athens	T083	C0017446
Greece	T083	C0018226
heavy industry	T090	C0524640
residential	T082	C0442506
horticultural	UnknownType	C4300640
area	T082	C0205146
PTEs	T131	C0032346
soils	T167	C0037592
soils	T167	C0037592
indigenous	T169	C0302891
plant species	T002	C0032098
assessing the health risk	T061	C0679809
associated with	T080	C0332281
soil	T167	C0037592
ingestion	T038	C0232478
Samples of soils	T167	C3687777
roadsides	T073	C0442650
plants	T002	C0032098
area	T082	C0205146
Concentrations	T081	C1446561
Al	T196	C0002367
As	T121	C0003818
Cd	T131	C0006632
Co	T123	C0009148
Cr	T131	C0008574
Cu	T121	C0009968
Fe	T121	C0302583
Mn	T123	C0024706
Mo	T123	C0026402
Ni	T123	C0028013
Pb	T131	C0023175
V	T131	C0042306
Zn	T121	C0043481
soils	T167	C0037592
plant tissues	T025	C1514137
As	T121	C0003818
Cd	T131	C0006632
Cr	T131	C0008574
Cu	T121	C0009968
Ni	T123	C0028013
Pb	T131	C0023175
Zn	T121	C0043481
regulatory	T089	C0220905
limits	T078	C1549649
Element	T196	C0013879
concentrations	T081	C1446561
plants	T002	C0032098
indigenous	T169	C0302891
plants	T002	C0032098
excluder	T169	C0332196
Copper	T121	C0009968
Zn	T121	C0043481
soil	T167	C0037592
plant	T002	C0032098
coefficients	T081	C1707429
elements	T196	C0013879
Cu	T121	C0009968
associated with	T080	C0332281
Cu	T121	C0009968
releasing	T169	C0391871
industrial	T057	C0021267
activity	T052	C0441655
Risk assessment analysis	T058	C0086930
As	T121	C0003818
element	T196	C0013879
health	T078	C0018684
risk	T078	C0035647
soil	T167	C0037592
ingestion	T038	C0232478
Cr	T131	C0008574
Pb	T131	C0023175
Mn	T123	C0024706
multi	T081	C0439064
element	T196	C0013879
contamination	T068	C0259846
PTEs	T131	C0032346
As	T121	C0003818
Cr	T131	C0008574
Pb	T131	C0023175
tolerance	T080	C1704410
limits	T169	C0439801
exposure to	T080	C0332157
toxic elements	T131	C0032346
Mn	T123	C0024706
Nutrients	T168	C0678695
thermal ecophysiology	T039	C1254359
intertidal	T082	C1254362
macroalga	T204	C0036500
multiple stressors	T078	C0597530
multiple drivers	T078	C1254370
Urbanization	T068	C0041938
coastlines	UnknownType	C0681784
nutrients	T168	C0678695
terrestrial environment	T082	C0014406
nearshore habitats	T082	C0871648
nutrient	T168	C0678695
coastal	UnknownType	C0681784
marine organisms	T001	C0599383
eutrophication	T067	C0015191
reduced	T080	C0392756
oxygen	T121	C0030054
positive effects	T080	C1280500
food	T168	C0016452
availability	T169	C0470187
species	T185	C1705920
nitrogen-limited	T123	C0028158
macroalgae	T204	C0036500
Nutrient	T168	C0678695
enrichment	T067	C1254366
environment	T082	C0014406
potential	T080	C3245505
negative impacts	T080	C4049986
increasing	T169	C0442808
temperatures	T081	C0039476
species	T185	C1705920
physiological response	T039	C1254359
organisms	T001	C0029235
simultaneous	T079	C0205420
changes	T169	C0392747
multiple drivers	T078	C1254370
global	T080	C2348867
climate change	T070	C2718051
ecological	T070	C0162358
responses	T032	C0871261
local levels	UnknownType	C0683925
nutrient	T168	C0678695
enrichment	T067	C1254366
nitrogen	T123	C0028158
availability	T169	C0470187
growth	T040	C0018270
Fucus vesiculosus	T002	C1083174
macroalgal	T204	C0036500
species	T204	C0036500
North Atlantic rocky intertidal zone	T083	C0004166
nutrient	T168	C0678695
algal blades	T185	C2698828
tissue growth	T042	C1621966
individuals	T078	C0441833
ambient	T080	C1879688
photosynthesis	T070	C0031764
nutrient	T168	C0678695
tissues	T025	C1514137
saturating irradiance	T070	C1282930
temperature	T081	C0039476
Respiration	T039	C0035203
nutrient	T168	C0678695
treatment	T169	C1522326
photosynthetic	T070	C0031764
oxygen	T121	C0030054
nutrient	T168	C0678695
tissue	T025	C1514137
ambient	T080	C1879688
elevated	T080	C3163633
temperatures	T081	C0039476
study	T062	C2603343
literature	T170	C0023866
responses to changes	T032	C0871261
multiple drivers	T078	C1254370
studying	T062	C2603343
impacts	T067	C0282165
global	T080	C2348867
climate change	T070	C2718051
environmental	T082	C0014406
conditions	T080	C0348080
trial	T062	C0008976
septic shock	T046	C0036983
reversal	T169	C0443290
quicker	T080	C0456962
pediatric	T080	C1521725
patients	T101	C0030705
randomized	T062	C0034656
early	T079	C1279919
goal-directed fluid-sparing strategy	T061	C1271494
usual care	T058	C0511425
SQUEEZE	T062	C0008976
study protocol	T170	C2348563
pilot randomized controlled trial	T062	C0206035
Current	T079	C0521116
pediatric	T080	C1521725
septic shock	T046	C0036983
resuscitation	T061	C0035273
guidelines	T170	C0162791
American College of Critical Care Medicine	T093	C1708333
early	T079	C1279919
goal-directed administration	T061	C1271494
intravascular	T082	C0442123
fluid	T031	C0005889
vasoactive	T080	C1980011
medication	T121	C0013227
infusions	T061	C0574032
persistent	T079	C0205322
fluid-refractory shock	T047	C0349412
accumulating	T033	C4055506
adult	T100	C0001675
pediatric	T080	C1521725
data	T078	C1511726
excessive	T080	C0442802
fluid administration	T061	C0522792
worse	T033	C1457868
patient	T101	C0030705
outcomes	T169	C1274040
increased risk of death	T033	C2749787
optimal amount	T081	C1265611
intravascular	T082	C0442123
fluid	T031	C0005889
early	T079	C1279919
pediatric	T080	C1521725
septic shock	T046	C0036983
resuscitation	T061	C0035273
initiation	T169	C1704686
vasoactive support	T080	C1980011
SQUEEZE Pilot Trial	T062	C0008976
pragmatic	T054	C0871858
two-arm	T062	C0242481
parallel-group	T062	C2826345
open-label	T062	C1709323
prospective pilot randomized controlled trial	T062	C0206035
Participants	T098	C0679646
children	T100	C0008059
aged	T032	C0001779
days	T079	C0439228
years	T079	C0439234
suspected	T078	C0750491
confirmed	T033	C0750484
septic shock	T046	C0036983
resuscitation	T061	C0035273
participants	T098	C0679646
enrolled	T058	C1516879
exception	T077	C1705847
consent	T169	C1511481
process	T067	C1522240
randomly	T080	C0439605
assigned	T169	C1516050
concealed	T080	C0443189
allocation	T052	C1706778
Usual Care	T058	C0511425
control	T096	C0009932
Fluid Sparing (intervention) resuscitation strategy	T061	C0035273
primary	T080	C0205225
objective	T170	C0018017
pilot trial	T062	C0008976
feasibility	T062	C0015730
enroll	T058	C1516879
participants	T098	C0679646
study protocol	T170	C2348563
primary outcome measure	T080	C3274433
success	T080	C0679864
participant	T098	C0679646
enrollment	T058	C1516879
rate	T081	C1521828
participants	T098	C0679646
site	T082	C0205145
month	T079	C0439231
enrollment	T058	C1516879
objectives	T170	C0018017
appropriateness	T080	C0814634
eligibility criteria	T080	C1516637
completeness	T080	C0439812
clinical outcomes	T169	C1274040
endpoints	T080	C2349179
planned	T169	C1301732
multisite trial	T062	C0206012
nested translational study	T062	C0008972
SQUEEZE-D	T062	C0008972
feasibility	T062	C0015730
cell-free DNA	T114	C4289789
procoagulant molecule	T116	C1292267
prognostic utility	T170	C0220901
blood samples	T031	C0178913
children	T100	C0008059
enrolled	T058	C1516879
SQUEEZE Pilot Trial	T062	C0008976
baseline	T081	C1442488
degree	T081	C0449286
fluid	T031	C0005889
resuscitation	T061	C0035273
timing	T079	C0449243
initiation	T169	C1704686
vasoactive support	T080	C1980011
therapeutic	T169	C0302350
targets	T169	C1521840
children	T100	C0008059
septic shock	T046	C0036983
prospective study	T062	C0033522
date	T079	C0011008
question	T170	C1522634
children	T100	C0008059
developed countries	T080	C0282613
Canada	T083	C0006823
Recruitment	T052	C2949735
SQUEEZE Pilot Trial	T062	C0008976
opened	T033	C3483819
Findings	T033	C0243095
feasibility	T062	C0015730
planned	T169	C1301732
multicenter trial	T062	C0206012
overall	T080	C1561607
research question	T078	C0681799
Entropy-driven reactions	T169	C0443286
living	T078	C0376558
cells	T025	C0007634
assay	T059	C1510438
let-7a microRNA	T114	C1101610
Imaging	T060	C0079595
microRNA	T114	C1101610
miRNA	T114	C1101610
living	T078	C0376558
cells	T025	C0007634
monitoring	T057	C0005517
expression	T045	C0017262
distribution	T169	C1704711
miRNA	T114	C1101610
research	T062	C0035168
miRNA	T114	C1101610
diseases	T047	C0012634
expression levels	T081	C3244092
down-regulation	T044	C0013081
cellular	T025	C0007634
miRNA	T114	C1101610
associated with	T080	C0332281
diseases	T047	C0012634
enzyme	T116	C0014442
free	T169	C0332296
amplification strategies	T063	C0887815
intracellular	T082	C0178719
miRNA	T114	C1101610
assay	T059	C1510438
entropy-driven reaction	T169	C0443286
amplification	T063	C0887815
assay	T059	C1510438
miRNA	T114	C1101610
detection limit	T081	C2718050
signal	T067	C1710082
amplification	T067	C1521871
signal	T067	C1710082
enhancement	T052	C2349975
specific	T080	C0205369
miRNA	T114	C1101610
living	T078	C0376558
cells	T025	C0007634
accurate	T080	C0443131
information	T078	C1533716
cellular	T025	C0007634
miRNA	T114	C1101610
biological events	T038	C3714634
highly sensitive	T080	C0439822
simultaneous	T079	C0521115
imaging	T060	C0079595
multiple	T081	C0439064
biomarkers	T201	C0005516
accuracy	T080	C0598285
early disease diagnosis	T060	C0596473
Iterative	T033	C1854293
Development	T169	C1527148
Evaluation	T058	C0220825
Pharmacogenomic	T091	C1138555
Clinical Decision Support System	T170	C0525070
Warfarin Dosing	T081	C0366686
Pharmacogenomic	T091	C1138555
dosing	T081	C0178602
patient	T101	C0030705
implementation	T052	C1708476
clinical	T080	C0205210
challenges	T058	C0805586
evaluate	T058	C0220825
clinical decision support system	T170	C0525070
CDSS	T170	C0525070
pharmacogenomic	T091	C1138555
warfarin dosing	T081	C0366686
designed	T052	C1707689
physicians	T097	C0031831
pharmacists	T097	C0031323
physicians	T097	C0031831
pharmacists	T097	C0031323
prescribing	T058	C0278329
tasks	T057	C3540678
simulated patient	T065	C3825675
scenarios	T169	C0683579
iterations	T033	C1854293
development	T169	C1527148
validation	T062	C1519941
phases	T079	C0205390
pharmacogenomic	T091	C1138555
CDSS	T170	C0525070
prototype	T080	C0205556
scenario	T169	C0683579
usability	T170	C1510648
measured	T080	C0444706
efficiency	T081	C0013682
recorded	T170	C0034869
time to task completion	T201	C1316026
participants	T098	C0679646
perceived	T041	C0030971
satisfaction	T041	C0242428
Kruskal-Wallis and Mann Whitney U tests	T170	C0282574
qualitatively analyzed	T059	C0022885
Usability	T170	C1510648
development	T169	C1527148
iteration	T033	C1854293
CDSS	T170	C0525070
design	T052	C1707689
second	T079	C0457385
validation	T062	C1519941
iteration	T033	C1854293
CDSS	T170	C0525070
validation	T062	C1519941
iteration	T033	C1854293
participants	T098	C0679646
time to complete tasks	T201	C1316026
median	T082	C0549183
seconds	T079	C0457385
seconds	T079	C0457385
development	T169	C1527148
iteration	T033	C1854293
increase	T169	C0442805
time on task	T079	C0871530
increase	T169	C0442805
time	T079	C0040223
CDSS	T170	C0525070
design	T052	C1707689
Efficiency	T081	C0013682
pharmacists	T097	C0031323
physicians	T097	C0031831
development	T169	C1527148
iteration	T033	C1854293
validation	T062	C1519941
iteration	T033	C1854293
increased	T081	C0205217
CDSS	T170	C0525070
CDSS	T170	C0525070
doses	T081	C0178602
validation	T062	C1519941
iteration	T033	C1854293
iteration	T033	C1854293
second	T079	C0457385
iteration	T033	C1854293
satisfaction	T041	C0242428
iterations	T033	C1854293
qualitative analysis	T059	C0022885
second	T079	C0457385
prototype	T080	C0205556
pharmacogenomic	T091	C1138555
CDSS	T170	C0525070
warfarin	T109	C0043031
drug	T121	C1254351
CDSS	T170	C0525070
prototype	T080	C0205556
increased	T081	C0205217
time	T079	C0040223
tool	T033	C0871532
doses	T081	C0178602
pharmacogenomics	T091	C1138555
CDSS	T170	C0525070
design	T052	C1707689
clinical testing	T062	C1516634
Pedicle Screw	T074	C1961768
Combined	T080	C0205195
Lateral Mass Screw	T074	C0005975
Fixation	T061	C0185023
Treatment	T061	C0087111
Basilar Invagination	T019	C3887851
Congenital C2-C3 Fusion	T019	C0022738
Clinical evaluation	T058	C4084924
surgical	T061	C0543467
fixation	T061	C0185023
technique	T169	C0449851
combined	T080	C0205195
pedicle screw	T074	C1961768
lateral mass screw	T074	C0005975
LMS	T074	C0005975
technique	T169	C0449851
treatment	T061	C0087111
congenital C2-C3 fusion	T019	C0022738
basilar invagination	T019	C3887851
BI	T019	C3887851
Posterior	T082	C0205095
occipitocervical	T029	C0027530
fixation	T061	C0185023
C2 pedicle screw	T074	C1961768
BI	T019	C3887851
cases	T169	C0868928
BI	T019	C3887851
concurrent	T079	C0205420
congenital C2-C3 fusion	T019	C0022738
C2 pedicles	T023	C0456605
thinner	T080	C0205168
normal	T080	C0205307
population	T098	C1257890
fail	T169	C0231175
issue	T033	C0033213
combining	T080	C0205195
pedicle screw	T074	C1961768
LMS	T074	C0005975
strengthen	T078	C0808080
fixation	T061	C0185023
patients	T101	C0030705
combined	T080	C0205195
pedicle screw	T074	C1961768
LMS	T074	C0005975
fixation	T061	C0185023
retrospectively studied	T062	C0035363
instrument	T074	C0348000
position	T082	C0733755
fusion	T169	C0699952
status	T080	C0449438
complications	T046	C0009566
analyzed	T062	C0936012
spinal cord	T037	C0037929
vertebral artery injury	T037	C0433912
follow-up	T058	C1522577
time	T079	C0040223
months	T079	C0439231
fusion	T169	C0699952
patients	T101	C0030705
radiologically	T060	C0043299
cases	T169	C0868928
recurred	T067	C0034897
BI	T019	C3887851
instrument	T074	C0348000
failure	T033	C0162643
fusion	T169	C0699952
occiput	T029	C0230005
C2	T023	C0456605
revision	T061	C0558347
patients	T101	C0030705
complications	T046	C0009566
instrument	T074	C0348000
failure	T033	C0162643
cerebrospinal fluid leakage	T047	C0023182
intracranial	T029	C0524466
infection	T046	C3714514
clinical	T080	C0205210
outcome	T169	C1274040
technique	T169	C0449851
treatment	T061	C0087111
BI	T019	C3887851
congenital C2-C3 fusion	T019	C0022738
Co-occurrence	T079	C2745955
clustering	T081	C0012641
health	T078	C0018684
conditions	T080	C0348080
age	T032	C0001779
cross-sectional	T062	C0010362
findings	T169	C2607943
Millennium Cohort Study	T081	C0009247
co-occurrence	T079	C2745955
clustering	T081	C0012641
adverse	T046	C0877248
health	T078	C0018684
conditions	T080	C0348080
year	T079	C1510829
children	T100	C0008059
differences	T080	C1705242
sociodemographic factors	T078	C0011292
prospective cohort study	T062	C1709709
Children	T100	C0008059
UK	T083	C0041700
year	T079	C1510829
singleton	T099	C1313913
children	T100	C0008059
data	T078	C1511726
health	T078	C0018684
conditions	T080	C0348080
sociodemographic information	T078	C1533716
complete	T080	C0205197
cases	T169	C0868928
Prevalence	T081	C0220900
co-occurrence	T079	C2745955
clustering	T081	C0012641
health	T078	C0018684
conditions	T080	C0348080
wheeze	T184	C0043144
eczema	T047	C0013595
long-standing illness	T184	C0221423
wheeze	T184	C0043144
eczema	T047	C0013595
injury	T037	C3263723
socioemotional difficulties	T048	C0013985
Strengths and Difficulties Questionnaire	T170	C3472494
unfavourable weight	T032	C0005910
thin	T033	C0041667
overweight	T184	C0497406
obese	T047	C0028754
normal	T032	C0005910
children	T100	C0008059
adverse	T046	C0877248
health	T078	C0018684
conditions	T080	C0348080
co-occurrence	T079	C2745955
Co-occurrence	T079	C2745955
boys	T100	C0870221
children	T100	C0008059
income	T081	C0021162
households	T099	C0020052
Latent class analysis	T062	C0936012
classes	T170	C0456387
normative	T080	C0205307
atopic	T046	C0392707
burdened	T078	C2828008
socioemotional burdened	T048	C0013985
unfavourable weight	T032	C0005910
injury	T037	C3263723
eczema	T047	C0013595
injury	T037	C3263723
eczema	T047	C0013595
unfavourable weight	T032	C0005910
co-occurrence	T079	C2745955
class	T170	C0456387
membership	T055	C0680038
sociodemographic factors	T078	C0011292
boys	T100	C0870221
children	T100	C0008059
mothers	T099	C0026591
educational attainment	T033	C0013658
children	T100	C0008059
income	T081	C0021162
households	T099	C0020052
socioemotional burdened	T048	C0013985
class	T170	C0456387
Children	T100	C0008059
mothers	T099	C0026591
educational attainment	T033	C0013658
normative	T080	C0205307
eczema	T047	C0013595
unfavourable weight	T032	C0005910
classes	T170	C0456387
Co-occurrence	T079	C2745955
adverse	T046	C0877248
health	T078	C0018684
conditions	T080	C0348080
age	T032	C0001779
associated with	T080	C0332281
adverse	T046	C0877248
socioeconomic	T077	C0748878
circumstances	T077	C1254372
Holistic	T078	C0019844
child	T100	C0008059
care	T052	C1947933
boys	T100	C0870221
income	T081	C0021162
groups	T078	C0441833
prevent	T080	C2700409
reduce	T080	C0392756
co-occurrence	T079	C2745955
later	T079	C0205087
childhood	T079	C0231335
adolescence	T079	C0001578
Genomic	T028	C0017428
characterization	T052	C1880022
wild-bird	T012	C0325328
origin	T033	C0243095
pigeon	T012	C0325912
paramyxovirus type 1	T005	C0027984
PPMV-1	T005	C0027984
isolated	T169	C0205409
northwest region of China	T083	C0008115
Pigeon	T012	C0325912
paramyxovirus type-1	T005	C0027984
PPMV-1	T005	C0027984
enzootic	T169	C0598394
pigeon	T012	C0325912
flocks	T096	C1633987
severe	T080	C0205082
economic losses	T081	C0681022
poultry	T012	C0032850
industry	T057	C0021267
countries	T083	C0454664
PPMV-1	T005	C0027984
isolate	T123	C1764827
PPMV-1/QL-01/CH/15	T005	C0027984
isolated	T169	C0205409
woodpecker	T012	C0326243
northwest region of China	T083	C0008115
genome	T028	C0017428
sequenced	T059	C3854164
results	T169	C1274040
virus	T005	C0042776
genome	T028	C0017428
length	T081	C1444754
gene arrangement 3'-NP-P-M-F-HN-L-5'	T044	C0887940
amino acid	T116	C0002520
mutations	T045	C0026882
identified	T080	C0205396
functional domains	T087	C1514562
F	T116	C0162768
HN proteins	T116	C0019822
pathogenicity index	T032	C1136169
isolate	T123	C1764827
evaluated	T058	C0220825
mean death time	T079	C1301931
MDT	T079	C1301931
intracerebral pathogenicity index	T032	C1136169
ICPI	T032	C1136169
isolate	T123	C1764827
mesogenic	T080	C0205556
Sequencing	T059	C1294197
results	T169	C1274040
virulent	T080	C1520022
Newcastle disease virus	T005	C0027984
cleavage motif (112)R-R-Q-K-R-F(117)	T087	C0002518
fusion protein	T116	C0162768
cleavage site	T087	C0002518
Morbidity	T081	C0026538
mortality	T081	C0205848
inoculation	T061	C2987620
pigeons	T012	C0325912
virus	T005	C0042776
nonpathogenic	T033	C0243095
chickens	T012	C0008051
immune responses	T042	C0301872
pigeons	T012	C0325912
chickens	T012	C0008051
induced	T169	C0205263
in vivo	T082	C1515655
HI serum antibody titers	T059	C2229730
results	T169	C1274040
phylogenetic	T062	C1519068
evolutionary distance analysis	T062	C0936012
PPMV-1	T005	C0027984
strain	T001	C1518614
sub-genotype VIa	T170	C0441756
class II	T170	C0441886
identification	T059	C0599616
analysis	T062	C0936012
PPMV-1	T005	C0027984
co-circulation	T033	C0237318
wild birds	T012	C0325328
domestic pigeon	T012	C0999232
flocks	T096	C1633987
China	T083	C0008115
data	T078	C1511726
study	T062	C2603343
wild birds	T012	C0325328
dissemination	T082	C0205221
PPMV-1	T005	C0027984
references	T170	C1514811
improving	T080	C1272745
distribution	T082	C0037775
evolution	T045	C0015219
PPMV-1	T005	C0027984
China	T083	C0008115
Memory consolidation	T041	C0679057
effects	T080	C1280500
memory stabilization	T041	C0025361
item integration	T041	C0025361
older adults	T098	C0001792
study	T062	C2603343
differential effects	T169	C1274040
aging	T040	C0001811
consolidation processes	T041	C0679057
memory traces	T041	C0870873
memory stabilization	T041	C0025361
consolidation processes	T041	C0679057
integrating	T041	C0025361
memory traces	T041	C0870873
knowledge	T170	C0376554
item integration	T041	C0025361
Older adults	T098	C0001792
learned	T041	C0023185
nonwords	T170	C0282574
memory	T041	C0025260
nonwords	T170	C0282574
nonwords	T170	C0282574
English	T171	C0376245
words	T170	C0282574
hours	T079	C0439227
Participants	T098	C0679646
nonwords	T170	C0282574
recognition	T041	C0524637
recall	T041	C0034770
nonwords	T170	C0282574
processing	T052	C1709694
similar-sounding words	T170	C0282574
delayed test	T170	C0451414
memory consolidation processes	T041	C0679057
item integration	T041	C0025361
memory stabilization processes	T041	C0025361
memories	T041	C0025260
older adults	T098	C0001792
Mucosa	T031	C0026727
associated	T080	C0332281
biohydrogenating microbes	T001	C0445623
colon	T204	C3888384
microbiome	T001	C1956108
stress	T033	C0038435
associated with	T080	C0332281
high concentrations	T081	C1446561
poly-unsaturated fat	T109	C2362518
Polyunsaturated fatty acids	T109	C0032615
PUFAs	T109	C0032615
colon	T204	C3888384
microbiome	T001	C1956108
homeostasis	T038	C0019868
exerting	T040	C0015264
specific	T080	C0205369
antimicrobial	T195	C0003232
effects	T080	C1280500
mucosal	T031	C0026727
biofilm	T167	C1561572
formation	T169	C1522492
gut mucosal interface	T023	C0836209
standardized batch incubations	T059	C1439852
Mucosal-Simulator of the Human Microbial Intestinal Ecosystem	T170	C0282574
M-SHIME	T170	C0282574
in vitro	T080	C1533691
luminal	T030	C0524461
mucosal	T031	C0026727
effects of	T080	C1704420
PUFA	T109	C0032615
Western diet	T061	C3849996
linoleic acid	T109	C0023749
LA	T109	C0023749
High concentrations	T081	C1446561
LA	T109	C0023749
decrease	T081	C0547047
butyrate	T109	C0006521
production	T169	C0205245
Faecalibacterium prausnitzii	T007	C0317558
LA	T109	C0023749
biohydrogenation	T070	C0020286
vaccenic acid	T109	C0301702
VA	T109	C0301702
stearic acid	T109	C0038229
SA	T109	C0038229
faecal	T031	C0015733
batch incubations	T059	C1439852
LA	T109	C0023749
biohydrogenation	T070	C0020286
butyrate	T109	C0006521
production	T169	C0205245
positively correlated	T080	C1707520
SA	T109	C0038229
inhibit	T052	C3463820
butyrate	T109	C0006521
production	T169	C0205245
M-SHIME	T170	C0282574
mucosal	T031	C0026727
environment	T082	C0014406
stimulated	T070	C1948023
biohydrogenation	T070	C0020286
SA	T109	C0038229
F. prausnitzii	T007	C0317558
inhibition	T052	C3463820
LA	T109	C0023749
preference	T078	C0558295
biohydrogenating	T070	C0020286
genera	T185	C1708235
Roseburia	T007	C0995401
Pseudobutyrivibrio	T007	C1012458
mucosal	T031	C0026727
Co-culture	T059	C0282547
batch incubations	T059	C1439852
Roseburia hominis	T007	C1667633
F. prausnitzii	T007	C0317558
validated	T062	C1519941
observations	T062	C0302523
Correlations	T080	C1707520
networks	T169	C1882071
Roseburia	T007	C0995401
Pseudobutyrivibrio	T007	C1012458
luminal	T030	C0524461
mucosal SHIME microbiota	T059	C3496041
LA	T109	C0023749
induced stress	T033	C0038435
results	T169	C1274040
cross-shielding interactions	T169	C1704675
microbiome	T001	C1956108
importance	T080	C3898777
biohydrogenating	T070	C0020286
mucosal	T031	C0026727
bacteria	T007	C0004611
recovery	T052	C0237820
LA	T109	C0023749
stress	T033	C0038435
Genetic	T169	C0314603
parameters	T033	C0449381
tick count	T081	C0750480
udder	T023	C0242386
health	T078	C0018684
commercial	T170	C0680536
indigenous	T102	C1512704
ewes	UnknownType	C0699762
South Africa	T083	C0037712
genetics	T169	C0314603
tick infestation	T047	C0040196
sheep	T015	C0036945
host resistance	T169	C4281815
pest control programs	T057	C0031249
udder	T023	C0242386
health scores	T170	C1550208
site-specific	T082	C0449604
tick count	T081	C0750480
mating	T040	C1260875
weight	T081	C0043100
reproduction	T040	C0035150
records	T170	C0034869
ewes	UnknownType	C0699762
indigenous	T102	C1512704
Namaqua Afrikaner	T015	C1269178
NA	T015	C1269178
fat-tailed breed	T185	C1704650
commercial	T170	C0680536
Dorper	T015	C1296152
SA Mutton Merino (SAMM) breeds	T015	C1269346
Udder	T023	C0242386
scored	T081	C0449820
udder	T023	C0242386
intact	T080	C0205266
udder	T023	C0242386
damaged severely	T037	C0010957
ticks	T047	C0040196
counted	T081	C0750480
three locations	T029	C1545955
body sites	T029	C1545955
counted	T081	C0750480
head and thoracic limb	T023	C0229962
HTLTC	T023	C0229962
udder-pelvic limb	T023	C1268092
UPLTC	T023	C1268092
perineum-breech-tail	T023	C0039259
PBTTC	T023	C0039259
counts	T081	C0750480
total tick count	T081	C0750480
TTC	T081	C0750480
Reproduction	T040	C0035150
traits	T032	C0599883
lambs	T015	C1123019
weaned	T033	C0043084
ewe lambed	T033	C0243095
lamb weaned	T033	C0043084
ewe lambed	T033	C0243095
Udder	T023	C0242386
health scores	T170	C1550208
NA	T015	C1269178
ewes	UnknownType	C0699762
Dorpers	T015	C1296152
SAMM	T015	C1269346
ewes	UnknownType	C0699762
NA	T015	C1269178
ewes	UnknownType	C0699762
HTLTC	T023	C0229962
UPLTC	T023	C1268092
TTC	T081	C0750480
commercial	T170	C0680536
breeds	T185	C1704650
PBTTC	T023	C0039259
Dorpers	T015	C1296152
Heritability	T033	C4062865
estimates	T081	C0750572
HTLTC	T023	C0229962
UPLTC	T023	C1268092
PBTTC	T023	C0039259
TTC	T081	C0750480
udder	T023	C0242386
health score	T170	C1550208
Animal permanent environment	T082	C0871648
PBTTC	T023	C0039259
Significant genetic correlations	UnknownType	C0678931
HTLTC	T023	C0229962
UPLTC	T023	C1268092
UPLTC	T023	C1268092
udder	T023	C0242386
health score	T170	C1550208
HTLTC	T023	C0229962
UPLTC	T023	C1268092
UPLTC	T023	C1268092
PBTTC	T023	C0039259
ewes	UnknownType	C0699762
UPLTC	T023	C1268092
TTC	T081	C0750480
impaired	T169	C0221099
udder	T023	C0242386
health	T078	C0018684
Udder	T023	C0242386
health score	T170	C1550208
tick counts	T081	C0750480
reproduction	T040	C0035150
traits	T032	C0599883
indigenous	T102	C1512704
NA	T015	C1269178
breed	T185	C1704650
commercial	T170	C0680536
breeds	T185	C1704650
HTLTC	T023	C0229962
UPLTC	T023	C1268092
TTC	T081	C0750480
udder	T023	C0242386
health score	T170	C1550208
NA	T015	C1269178
breed	T185	C1704650
pastoral conditions	T058	C0030643
tick	T047	C0040196
tolerance	T080	C1704410
breeds	T185	C1704650
Starvation	T033	C0038187
antibiotics	T195	C0003232
formation	T043	C0007613
persister cells	T007	C0563199
Pseudomonas aeruginosa	T007	C0033809
Planktonic	T007	C0032071
stationary and exponential cultures	T059	C0430402
Pseudomonas aeruginosa	T007	C0033809
highly resistant	T169	C0332325
killing	T033	C1306577
bactericidal antimicrobials	T195	C0003232
persisters	T007	C0563199
cells	T007	C0563199
multidrug tolerant	T033	C0013220
recalcitrance	T169	C0205245
biofilm	T007	C0081786
infections	T046	C3714514
study	T170	C0085973
investigate	T169	C1292732
formation	T043	C0007613
persister cells	T007	C0563199
P. aeruginosa	T007	C0033809
stationary	T059	C0430402
exponential cultures	T059	C0430402
different	T080	C1705242
class	T170	C0456387
antimicrobials	T195	C0003232
susceptibilities	T169	C1264642
P. aeruginosa PAO1 wild-type	T007	C0033809
mutant strains	T001	C1518614
antimicrobials	T195	C0003232
standard microtiter broth dilution method	T059	C2827874
persister	T007	C0563199
formation	T043	C0007613
dose	T081	C1512045
time	T079	C0040223
killing experiments	T059	C0022885
performed	T169	C0884358
antibiotics	T195	C0003232
Ceftazidime	T109	C0007559
Cephalosporin	T109	C3536856
efficacy	T080	C1280519
culture	T059	C0430402
Stationary-phase cells	T007	C0563199
tolerant	T033	C0013220
imipenem	T109	C0020933
Carbapenem	T109	C0006968
exponential cells	T007	C0563199
fraction of	T081	C1264633
persisters	T007	C0563199
high	T080	C0205250
imipenem	T109	C0020933
concentration	T081	C0392762
populations	T098	C1257890
Polymyxin B	T116	C0032535
Polymyxin	T116	C0032539
low concentrations	T081	C0392762
cell populations	T098	C1257890
polymyxin B	T116	C0032535
concentration	T081	C0392762
exponential cells	T007	C0563199
regrowth	T169	C0205245
stationary population	T098	C1257890
Stationary cells	T007	C0563199
tolerant	T033	C0013220
tobramycin	T109	C0040341
Aminoglycoside	T109	C0002556
exponential cells	T007	C0563199
higher concentration	T081	C0392762
tobramycin	T109	C0040341
eliminated	T080	C0849355
survivors	T078	C0441833
Ciprofloxacin	T109	C0008809
Fluoroquinolone	T109	C0949665
low concentration	T081	C0392762
killing	T033	C1306577
cultures	T059	C0430402
P. aeruginosa	T007	C0033809
persisters	T007	C0563199
killing	T033	C1306577
Stationary cells	T007	C0563199
tolerant	T033	C0013220
exponential cells	T007	C0563199
assays	T059	C0005507
nutrient	T168	C0678695
deprivation	T080	C0871712
serine	T116	C0036720
starvation	T033	C0038187
stringent and general stress response	T039	C0149784
increased tolerance	T033	C0151956
P. aeruginosa	T007	C0033809
exponential and stationary planktonic cells	T007	C0563199
production	T043	C0007613
persisters	T007	C0563199
Chaetomium thermophilum	T004	C1225414
formate dehydrogenase	T116	C0016570
reduction	T070	C0301630
hydrogen carbonate	T197	C0973231
HCO3 -	T197	C0973231
formate	T109	C0220832
formate dehydrogenases	T116	C0016570
FDHs	T116	C0016570
cofactor	T123	C0178555
recycling	T068	C0282114
chemoenzymatic synthesis	T044	C1511130
FDH	T116	C0016570
CO2	T123	C0007012
conversion	T169	C0439836
CO2	T123	C0007012
products	T071	C1514468
formate	T109	C0220832
HCOO(-)	T109	C0220832
investigated	T169	C1292732
reduction	T070	C0301630
CO2	T123	C0007012
hydrogen carbonate	T197	C0973231
HCO3(-)	T197	C0973231
formate	T109	C0220832
FDHs	T116	C0016570
Candida methylica	T004	C1011924
CmFDH	T116	C0016570
Chaetomium thermophilum	T004	C1225414
CtFDH	T116	C0016570
NADH	T114	C0027289
reaction	T169	C0443286
catalytic performance	T044	C0243102
HCO3(-)	T197	C0973231
substrate	T167	C3891814
measuring	T080	C0444706
kinetic rates	T079	C1254367
productivity assays	T059	C1510438
CtFDH	T116	C0016570
efficiency	T081	C0013682
converting	T169	C0439836
HCO3(-)	T197	C0973231
formate	T109	C0220832
CmFDH	T116	C0016570
CmFDH	T116	C0016570
oxidation	T044	C0030011
formate	T109	C0220832
pH	T081	C0020283
reduction	T070	C0301630
pH	T081	C0020283
high concentrations	T081	C1446561
HCO3(-)	T197	C0973231
reaction rate	T079	C0678608
CtFDH	T116	C0016570
HCO3(-)	T197	C0973231
active site	T169	C0205681
active site	T169	C0205681
hydride transfer	T044	C1148560
CO2	T123	C0007012
reduction	T070	C0301630
hydride donated	T044	C1148560
NADH	T114	C0027289
carbon atom	T196	C0007009
HCO3(-)	T197	C0973231
electrons	T196	C0013852
molecule	T167	C0567416
hydrogen carbonate	T197	C0973231
hydride	T196	C0003075
formate	T109	C0220832
hydroxide ions	T196	C0220853
Evaluation	T170	C0015196
international	T078	C1512888
educational programme	T065	C0150562
health care professionals	T097	C1704312
management	T057	C1273870
perinatal	T079	C0178795
death	T040	C0011065
IMproving Perinatal mortality Review and Outcomes Via Education	T065	C0150562
IMPROVE	T065	C0150562
Stillbirths	T033	C0595939
neonatal deaths	T033	C0410916
devastating events	T051	C0441471
parents	T099	C0030551
clinicians	T080	C0205210
global public health	T091	C1456573
concerns	T078	C2699424
clinical management	T058	C1516615
deaths	T040	C0011065
investigation	T058	C0220825
assessment	T058	C0220825
bereavement care	T058	C0085882
families	T099	C0015576
educational programme	T065	C0150562
health care professionals	T097	C1704312
maternal	T033	C1858460
child health	T058	C0008078
Perinatal Society of Australia and New Zealand Guideline for Perinatal Mortality	T170	C0162791
IMproving Perinatal mortality Review and Outcomes Via Education	T065	C0150562
IMPROVE	T065	C0150562
programme	T065	C0150562
stillbirth	T033	C0595939
interactive skills	T065	C0559197
stations	T073	C1883167
participants	T098	C0679646
pre-	T065	C0150562
post-programme	T065	C0150562
knowledge	T170	C0376554
confidence	T041	C1704726
management	T057	C1273870
perinatal	T079	C0178795
deaths	T040	C0011065
satisfaction	T041	C0242428
programme	T065	C0150562
international	T078	C1512888
IMPROVE programme	T065	C0150562
health professionals	T097	C1704312
maternity hospitals	T093	C0020010
Australian	T083	C0004340
states	T083	C1301808
territories	UnknownType	C0681784
internationally	T078	C1512888
Vietnam	T083	C0042658
Fiji	T083	C0016080
Netherlands	T083	C0027778
assistance	T058	C0010210
International Stillbirth Alliance	T093	C1708333
ISA	T093	C1708333
programme materials	T170	C0282574
consultation	T058	C0009818
translation	T170	C0040712
Vietnam programme	T065	C0150562
Participants	T098	C0679646
pre-	T065	C0150562
post-programme	T065	C0150562
evaluation	T170	C0015196
questionnaires	T170	C0034394
knowledge	T170	C0376554
confidence	T041	C1704726
perinatal	T079	C0178795
death	T040	C0011065
management	T057	C1273870
satisfaction questionnaire	T170	C0034394
IMPROVE	T065	C0150562
workshops	T065	C0242262
participants	T098	C0679646
Australia	T083	C0004340
participants	T098	C0679646
internationally	T078	C1512888
Evaluations	T170	C0015196
significant	T078	C0750502
improvement	T057	C2936612
pre-	T065	C0150562
post-programme	T065	C0150562
knowledge	T170	C0376554
confidence	T041	C1704726
stations	T073	C1883167
satisfaction	T041	C0242428
settings	T082	C0162579
IMPROVE programme	T065	C0150562
Australia	T083	C0004340
international	T078	C1512888
settings	T082	C0162579
ISA	T093	C1708333
research	T062	C0035168
improvements	T057	C2936612
knowledge	T170	C0376554
sustained	T169	C0443318
death	T040	C0011065
changes in clinical practice	T057	C0205897
improvement	T057	C2936612
parents'	T099	C0030551
care	T052	C1947933
programme	T065	C0150562
low-income	T033	C1331016
countries	T083	C0454664
personal	T032	C1519021
recovery	T040	C2004454
goals	T170	C0018017
collaborative	T062	C0681804
qualitative study	T062	C0949415
Recovery	T040	C2004454
subjective process	T067	C1522240
personal	T032	C1519021
expectations	T078	C0679138
goals	T170	C0018017
hopes	T041	C0392347
study	T062	C2603343
persons	T098	C0027361
Community Mental Health Centre	T073	C0475309
CMHC	T073	C0475309
expectations	T078	C0679138
treatment	T061	C0087111
goals	T170	C0018017
hopes	T041	C0392347
recovery	T040	C2004454
health professionals	T097	C1704312
treatment	T061	C0087111
hermeneutic	T078	C0870642
service users	T101	C0030705
expectations	T078	C0679138
treatment	T061	C0087111
goals	T170	C0018017
hopes	T041	C0392347
recovery	T040	C2004454
health professionals	T097	C1704312
CMHC	T073	C0475309
years	T079	C0439234
treatment	T061	C0087111
health professionals	T097	C1704312
goals	T170	C0018017
hopes	T041	C0392347
collaborative approach	T054	C0282116
co-researcher	T097	C0035173
study	T062	C2603343
Data	T078	C1511726
data	T078	C1511726
thematic analysis	T062	C0936012
participants	T098	C0679646
health professionals	T097	C1704312
CMHC	T073	C0475309
recovery	T040	C2004454
goals	T170	C0018017
developing an understanding of oneself	T080	C0205556
mental health problems	T033	C1446377
feelings	T041	C1527305
behaviours	T053	C0004927
being 'pushed' into social arenas	T033	C0243095
finding helpful medication	T033	C0243095
counselling	T058	C0010210
family	T033	C0851511
practical	T033	C0243095
financial issues	T033	C0243095
participants	T098	C0679646
expectations	T078	C0679138
counselling	T058	C0010210
family	T033	C0851511
practical	T033	C0243095
financial challenges	T033	C0243095
CMHC	T073	C0475309
service users	T101	C0030705
recovery	T040	C2004454
everyday life	T078	C0376558
professional	T097	C1704312
helpers	T097	C0341652
recovery	T040	C2004454
health professionals	T097	C1704312
service user's	T101	C0030705
personal	T032	C1519021
goals	T170	C0018017
hopes	T041	C0392347
needs	T080	C0027552
desires	T041	C0871633
recovery	T040	C2004454
goals	T170	C0018017
counselling	T058	C0010210
family	T033	C0851511
practical	T033	C0243095
financial issues	T033	C0243095
Pathogenesis	T046	C0699748
COPD	T047	C0024117
Asthma	T047	C0004096
Asthma	T047	C0004096
COPD	T047	C0024117
diseases of the respiratory tract	T047	C0035242
unmet	T052	C3274904
medical	T169	C0205476
needs	T080	C0027552
review	T170	C0282443
pathogenesis	T046	C0699748
chronic inflammatory diseases	T047	C1290886
lung	T023	C0024109
review	T170	C0282443
conditions	T080	C0348080
treatment	T061	C0087111
pharmacology	T091	C0031330
treatment	T061	C0087111
asthma	T047	C0004096
COPD	T047	C0024117
Antigen specificity	T044	C1536991
anti-red blood cell IgG-Fc alloantibody	T116	C0003241
glycosylation	T070	C0017982
severity	T080	C0439793
haemolytic disease of the fetus and newborn	T047	C0014761
Haemolytic disease of the fetus and newborn	T047	C0014761
HDFN	T047	C0014761
disease	T047	C0012634
fetal	T018	C0015965
red blood cells	T025	C0014792
RBC	T025	C0014792
destroyed	T052	C1948029
maternal anti-RBC IgG alloantibodies	T116	C0729663
HDFN	T047	C0014761
anti-D	T116	C0140430
due to	T169	C0678226
anti-K	T116	C0313239
-c	T116	C0432626
-E	T116	C0947659
N-linked glycosylation	T044	C1622430
anti-D	T116	C0140430
low	T080	C0205251
fucosylation	T044	C3271553
increasing	T169	C0442808
affinity	T044	C0003255
IgG-Fc receptor IIIa	T116	C1521898
IIIb	T116	C0966831
correlated	T080	C1707520
HDFN	T047	C0014761
disease	T047	C0012634
severity	T080	C0439793
pregnant women	T098	C0033011
anti-c	T116	C0432626
-E	T116	C0947659
-K	T116	C0313239
alloantibodies	T129	C0022144
screening cohort	T058	C0422390
investigated	T169	C1292732
Fc-tail glycosylation	T044	C0376322
antibodies	T116	C0003241
trigger	T080	C1444748
immunisation	T061	C0020971
pregnancy outcome	T033	C0032972
Anti-c	T116	C0432626
-E	T116	C0947659
-K	T116	C0313239
independent of	T169	C0332291
event	T051	C0441471
immunisation	T061	C0020971
different	T080	C1705242
Fc-glycosylation	T044	C0376322
IgG	T116	C0020852
IgG fraction	T116	C0020852
anti-D	T116	C0140430
Fc-galactosylation	T044	C1159287
sialylation	T043	C4235385
anti-c	T116	C0432626
HDFN	T047	C0014761
disease	T047	C0012634
severity	T080	C0439793
anti-K	T116	C0313239
Fc-fucosylation	T044	C1159287
correlated	T080	C1707520
severe	T080	C0205082
fetal anaemia	T047	C2349595
IgG-Fc glycosylation	T044	C0376322
anti-RBC antibodies	T116	C0003241
antigen	T129	C0003320
features	T080	C2348519
clinical potency	T080	C3850123
predict	T078	C0681842
severity	T080	C0439793
treatment	T169	C0039798
poor pay	T081	C0871051
NHS	T058	C0027462
pay	T081	C0871051
campaign	UnknownType	C0680899
NHS	T058	C0027462
public	T098	C0683971
SARS	T047	C1175175
CoV	T005	C0010076
peptides	T116	C0030956
membrane	T026	C0596901
surface	T082	C0205148
ordering	T082	C1254362
curvature	T082	C1254362
Viral membrane fusion	T038	C1721020
membrane-anchored	T026	C1622010
viral fusion glycoproteins	T116	C0042716
S2	T116	C3658241
subunit	T116	C0599220
spike glycoprotein	T116	C3658241
severe acute respiratory syndrome	T047	C1175175
SARS	T047	C1175175
coronavirus	T005	C0010076
CoV	T005	C0010076
internal domains	T087	C1514562
fusion peptides	T116	C0030956
FP	T116	C0030956
virus entry	T038	C1537068
membrane fusion	T044	C0025246
studied	T062	C2603343
molecular	T080	C1521991
lipid	T109	C0023779
rearrangements	T067	C0596965
bilayer	T026	C0023768
fusion peptide	T116	C0030956
membrane	T026	C0596901
interactions	T169	C1704675
differential scanning calorimetry	T059	C0006780
DSC	T059	C0006780
electron spin resonance	T059	C0013845
ESR	T059	C0013845
membrane fusion	T044	C0025246
mechanism	T169	C0441712
promoted	T052	C0033414
SARS	T047	C1175175
FPs	T116	C0030956
DSC	T059	C0006780
data	T078	C1511726
peptides	T116	C0030956
structural	T082	C0678594
integrity	T080	C0205266
anionic vesicles	T026	C1622418
hypothesis	T078	C1512571
peptides	T116	C0030956
curvature	T082	C1254362
phosphatidylethanolamine	T109	C0031618
membranes	T026	C0596901
ESR	T059	C0013845
FPs	T116	C0030956
lipid	T109	C0023779
packing	T052	C2828395
ordering	T082	C1254362
intramembrane	T026	C0596901
water content	T081	C0392762
anionic membranes	T026	C0596901
bilayer	T026	C0023768
curvature	T082	C1254362
significance	T078	C0750502
ordering effect	T080	C1280500
membrane	T026	C0596901
dehydration	T033	C1963090
curvature	T082	C1254362
phospholipids	T109	C0031676
SARS	T047	C1175175
CoV	T005	C0010076
membrane fusion	T044	C0025246
defense mechanism	T040	C1154988
Antarctic	T083	C0920736
sponges	T204	C0032699
computational study	T059	C4297010
secondary metabolite	T123	C0870883
erebusinone	T123	C0870883
Ereb	T123	C0870883
Antarctic	T083	C0920736
sea sponge	T204	C4102027
Isodictya erinacea	T204	C4102027
bioactivity	T070	C0005520
Ereb	T123	C0870883
inhibit	T052	C3463820
molting	T040	C0282576
arthropod species	T204	C0003903
Orchomene plebs	T204	C3780008
Xanthurenic acid	T109	C0078610
XA	T109	C0078610
endogenous	T169	C0205227
molt regulator	T077	C1704735
arthropods	T204	C0003903
XA	T109	C0078610
inhibits	T052	C3463820
molting	T040	C0282576
binding	T044	C1167622
P450 enzymes	T116	C0010762
CYP315a1	T116	C0010762
CYP314a1	T116	C0010762
hydroxylations	T070	C0020365
molt-inducing hormone	T125	C0019932
20-hydroxyecdysone	T109	C0013495
20E	T109	C0013495
crystal structures	T104	C0444626
biochemical assays	T059	C0430027
CYP315a1	T116	C0010762
CYP314a1	T116	C0010762
exploration	T062	C0936012
XA	T109	C0078610
Ereb's	T123	C0870883
molt	T040	C0282576
inhibition	T052	C3463820
mechanisms	T169	C0441712
computational techniques	T062	C1516769
homology modeling	T063	C1512489
molecular dynamics simulations	T066	C2717775
binding site	T044	C1149343
bioinformatics	T091	C1140694
flexible receptor-flexible ligand docking	T044	C1522290
Born surface area calculations	T170	C0002045
structure-function relationships	T080	C0038477
P450s	T116	C0010762
inhibitors	T120	C0243077
Ereb	T123	C0870883
XA	T109	C0078610
Ereb	T123	C0870883
CYP315a1	T116	C0010762
aromatic residues	T104	C1254350
binding site	T044	C1149343
XA	T109	C0078610
CYP315a1	T116	C0010762
CYP314a1	T116	C0010762
aromatic	T104	C1254350
charged nature	T196	C0022023
anatomical mummies	T015	C0026779
Mombello	UnknownType	C0681784
detection	T033	C0442726
cocaine	T109	C0009170
nicotine	T109	C0028040
caffeine	T109	C0006644
hair	T023	C0018494
psychiatric patients	T101	C0748064
Mombello Psychiatric Hospital	T073	C0020021
Limbiate	UnknownType	C0681784
Milan	UnknownType	C0681784
Senavra Hospital	T073	C0019994
Psychiatric Hospital	T073	C0020021
Province of Milan	UnknownType	C0681784
bodies	T016	C0242821
Mombello patients	T101	C0748064
dissected	T169	C0205239
preserved	T059	C0033085
Giuseppe Paravicini	T016	C0086418
anatomist	T097	C0334865
asylum	T073	C0870166
aim	T078	C1947946
study	T062	C0008972
assemblage	T062	C0010995
sample	T077	C2347026
head hair	T023	C1261040
preparations	T052	C1521827
toxicological	T169	C0205472
analysis	T062	C0936012
high performance liquid chromatography	T059	C0008562
cocaine	T109	C0009170
metabolite	T123	C0870883
benzoylecgonine	T109	C0053258
detected	T033	C0442726
hair samples	T077	C2347026
concentrations	T081	C1446561
cocaine	T109	C0009170
benzoylecgonine	T109	C0053258
cocaine	T109	C0009170
medicine	T121	C0013227
patients	T073	C0020021
ingested	T038	C0232478
drug	T121	C0013227
detection	T033	C0442726
cocaine	T109	C0009170
analyses	T062	C0936012
nicotine	T109	C0028040
caffeine	T109	C0006644
intake	T169	C1512806
Terahertz identification	T059	C2350265
quantification	T081	C1709793
neurotransmitter	T123	C0027908
neurotrophy mixture	T116	C0027754
Terahertz spectroscopy	T059	C2350265
investigating	T169	C1292732
fingerprint spectrum	T059	C0016128
substances	T167	C0439861
cancerous	T191	C0006826
tissues	T024	C0040300
absorption	T067	C2825050
substances	T167	C0439861
tissues	T024	C0040300
overlap	T079	C1948020
quantitative	T081	C0392762
analyze	T062	C0936012
cancer cell	T025	C0334227
diagnose	T033	C0011900
accurately	T080	C0443131
neurotransmitters	T123	C0027908
γ-aminobutyric acid	T116	C0016904
L-glutamic acid	T116	C0061472
dopamine hydrochloride	T109	C0282151
metabolites	T123	C0870883
inositol	T109	C0021547
creatine	T116	C0010286
neurons	T025	C0027882
terahertz spectra	T059	C2350265
mixture ratios	T081	C0456603
characteristic	T080	C1521970
absorption	T067	C2825050
baseline	T081	C1442488
least square method	T081	C0023189
proportions	T081	C1709707
goodness of fit	T080	C0870608
nerve substances	T123	C0027908
quantitative	T081	C0392762
analysis	T062	C0936012
calcium hydroxyapatite	T121	C0115137
Deflux	T109	C0299556
injection	T061	C0021485
bladder neck	T023	C0227716
improvement	T077	C2986411
urinary incontinence	T046	C0042024
bladder exstrophy-epispadias complex	T047	C1838703
study	T062	C2603343
efficacy	T080	C1280519
endoscopic injection	T061	C3522839
calcium hydroxyapatite	T121	C0115137
CaHA	T121	C0115137
bladder neck	T023	C0227716
BN	T023	C0227716
patients	T101	C0030705
urinary incontinence	T046	C0042024
bladder exstrophy-epispadias complex	T047	C1838703
BEEC	T047	C1838703
retrospective cohort study	T062	C2985505
retrospectively studied	T062	C0035363
medical charts	UnknownType	C0184826
female	T032	C0086287
male	T032	C0086582
patients	T101	C0030705
BEEC	T047	C1838703
CaHA	T121	C0115137
Deflux	T109	C0299556
injection	T061	C0021485
continence improvement	T061	C1536613
incontinent	T047	C0021167
patients	T101	C0030705
endoscopic submucosal injection	T061	C3522839
CaHA	T121	C0115137
autologous	T080	C0439859
plasma	T031	C0032105
Patients	T101	C0030705
control group	T096	C0009932
Deflux	T109	C0299556
injection	T061	C0021485
follow-up	T058	C1522577
injection	T061	C0021485
post-injection complication	T046	C0274425
detected	T033	C0442726
patients	T101	C0030705
follow-up	T058	C1522577
patients	T101	C0030705
dry	T080	C1512080
injections	T061	C0021485
incontinence	T047	C0021167
patients	T101	C0030705
no change	T033	C0442739
patient	T101	C0030705
Deflux	T109	C0299556
injection	T061	C0021485
complete dryness	T080	C1512080
improvement	T077	C2986411
incontinence	T047	C0021167
no change	T033	C0442739
patients	T101	C0030705
no significant difference	T033	C3842396
continence achievement	T061	C0442964
CaHA	T121	C0115137
Deflux	T109	C0299556
statistical analysis	T062	C0871424
not significantly different	T033	C3842396
bladder capacity	T033	C0429807
preliminary results	T078	C1548161
study	T062	C2603343
revealed	T080	C0443289
CaHA	T121	C0115137
bulking agent	T121	C1320234
treatment	T061	C0087111
urinary incontinence	T046	C0042024
BEEC	T047	C1838703
Opportunities	T062	C0683937
genomic	T028	C0017428
prediction	T078	C0681842
fertility	T040	C0015895
endocrine	T022	C0014136
classical	T169	C0443177
fertility	T040	C0015895
traits	T032	C0599883
dairy cattle	T015	C0007452
Endocrine	T022	C0014136
fertility	T040	C0015895
traits	T032	C0599883
progesterone	T109	C0033308
concentration	T081	C1446561
levels	T080	C0441889
milk	T031	C0026131
alternative	T077	C1523987
indicators	T169	C1522602
fertility	T040	C0015895
dairy cows	T015	C0007452
farm	T082	C0557759
management	T057	C1273870
decisions	T041	C0679006
cow	T015	C0007452
reproductive	T040	C0035150
physiology	T039	C0031843
classical	T169	C0443177
traits	T032	C0599883
insemination	T042	C0021586
data	T078	C1511726
use of	T169	C1524063
endocrine	T022	C0014136
fertility	T040	C0015895
traits	T032	C0599883
genomic	T028	C0017428
evaluations	T062	C0015195
improvement	T077	C2986411
accuracy	T080	C0443131
endocrine	T022	C0014136
fertility	T040	C0015895
traits	T032	C0599883
concurrent	T079	C0205420
classical	T169	C0443177
traits	T032	C0599883
genomic	T028	C0017428
prediction	T078	C0681842
fertility	T040	C0015895
quantified	T081	C1709793
impact	T080	C4049986
traits	T032	C0599883
animals	T008	C0003062
investigated	T169	C1292732
Endocrine	T022	C0014136
classical	T169	C0443177
fertility	T040	C0015895
lactations	T042	C0022925
Holstein cows	T015	C0324069
Ireland	T083	C0022067
Netherlands	T083	C0027778
Sweden	T083	C0038995
United Kingdom	T083	C0041700
endocrine	T022	C0014136
traits	T032	C0599883
commencement of luteal activity	T042	C1254358
C-LA	T042	C1254358
proportion	T081	C1709707
samples	T167	C0370003
luteal activity	T042	C1254358
PLA	T167	C0370003
classical	T169	C0443177
trait	T032	C0599883
interval	T079	C1272706
interval	T079	C1272706
C-LA	T042	C1254358
endocrine	T022	C0014136
trait	T032	C0599883
classical	T169	C0443177
trait	T032	C0599883
investigated	T169	C1292732
target	T169	C1521840
breeding goal	T169	C1521840
trait	T032	C0599883
fertility	T040	C0015895
C-LA	T042	C1254358
PLA	T167	C0370003
predictor	T078	C2698872
traits	T032	C0599883
Genomic EBV	T028	C0017428
GEBV	T028	C0017428
fertility	T040	C0015895
genomic BLUP	T062	C1710191
bivariate models	T075	C0026336
SNP	T086	C0752046
fertility	T040	C0015895
traits	T032	C0599883
univariate models	T075	C0026336
accuracy	T080	C0443131
GEBV	T028	C0017428
cross-validation	T062	C0681935
accuracy	T080	C0443131
GEBV	T028	C0017428
bivariate	UnknownType	C0681927
predictions	T078	C0681842
endocrine	T022	C0014136
fertility	T040	C0015895
trait	T032	C0599883
classical	T169	C0443177
fertility	T040	C0015895
trait	T032	C0599883
Accuracy	T080	C0443131
GEBV	T028	C0017428
predicting	T078	C0681842
phenotypes	T032	C0031437
univariate model	T075	C0026336
predicting	T078	C0681842
bivariate model	T075	C0026336
C-LA	T042	C1254358
accuracy	T080	C0443131
increased	T081	C0205217
training animals	T008	C0003062
phenotyped	T032	C0031437
C-LA	T042	C1254358
phenotyping	T032	C0031437
training animals	T008	C0003062
C-LA	T042	C1254358
accuracy	T080	C0443131
increased	T081	C0205217
validation	T062	C1519941
animals	T008	C0003062
phenotyped	T032	C0031437
C-LA	T042	C1254358
no	T033	C1513916
substantial increase	T169	C0442805
accuracy	T080	C0443131
predicting	T078	C0681842
bivariate analysis	UnknownType	C0681927
PLA	T167	C0370003
accuracy	T080	C0443131
study	T062	C2603343
genomic	T028	C0017428
predictions	T078	C0681842
fertility	T040	C0015895
endocrine	T022	C0014136
traits	T032	C0599883
improvement	T077	C2986411
accuracy	T080	C0443131
prediction	T078	C0681842
classical	T169	C0443177
traits	T032	C0599883
studies	T062	C2603343
larger	T081	C0549177
training populations	T098	C1257890
greater	T081	C1704243
improvements	T077	C2986411
Microfluidic	T090	C1257867
design	T052	C1707689
crosslinked Hyaluronic Acid Nanoparticles	T073	C1450054
cHANPs	T073	C1450054
enhanced MRI	T060	C1707501
Recent	T079	C0332185
advancements	T079	C3854260
imaging diagnostics	T060	C0011923
nanostructures	T073	C1450053
Magnetic Resonance Imaging	T060	C0024485
MRI	T060	C0024485
Contrast Agents	T130	C0009924
CAs	T130	C0009924
chemically	T103	C0220806
modify	T169	C0392747
clinically	T080	C0205210
approved	T080	C0205540
compounds	T103	C1706082
microfluidic platforms	T090	C1257867
controlled	T169	C2587213
continuous	T078	C0549178
production	T052	C1883254
microfluidic platform	T090	C1257867
synthesize	T052	C1883254
crosslinked Hyaluronic Acid NanoParticles	T073	C1450054
cHANPs	T073	C1450054
clinically	T080	C0205210
relevant	T080	C2347946
MRI	T060	C0024485
CAs	T130	C0009924
gadolinium diethylenetriamine penta-acetic acid	T109	C0060933
Gd-DTPA	T109	C0060933
microfluidic	T090	C1257867
process	T067	C1522240
degree	T080	C0441889
control	T169	C2587213
particle	T073	C1450054
synthesis	T052	C1883254
production	T052	C1883254
monodisperse particles	T073	C1450054
interference	T169	C0521102
Gd-DTPA	T109	C0060933
polymer	T104	C0032521
precipitation	T070	C0032931
process	T067	C1522240
parameters	T077	C0549193
hydrophilic-lipophilic balance	T081	C0392762
HLB	T081	C0392762
surfactants	T120	C0038891
pH	T081	C0020283
conditions	T080	C0348080
production	T052	C1883254
design	T052	C1707689
Gd	T109	C0060933
cHANPs	T073	C1450054
relaxation rate T1	T081	C2697937
T1	T081	C2697937
Gd	T109	C0060933
cHANPs	T073	C1450054
value	T081	C1522609
relevant	T080	C2347946
clinical	T080	C0205210
Gd-DTPA	T109	C0060933
solution	T167	C0037633
microfluidic	T090	C1257867
intravascularly	T082	C0442123
injectable	T122	C1272883
biocompatible hydrogel	T109	C0063083
nanoparticles	T073	C1450054
clinically	T080	C0205210
approved	T080	C0205540
CAs	T130	C0009924
implementation	T052	C1708476
diagnostics	T080	C1704338
therapy	T061	C0087111
applications	T169	C4048755
Arthrobacter ginkgonis sp. nov.	T007	C0003876
actinomycete	T007	C0600148
isolated	T169	C0205409
rhizosphere	T070	C2936389
Ginkgo biloba L	T002	C0330206
Gram-stain-positive	T034	C0855278
aerobic	T080	C1510824
actinobacterial strain	T007	C0600148
SYP-A7299T	T007	C0003876
rod-coccus growth lifecycle	T007	C0562679
isolated	T169	C0205409
rhizosphere	T070	C2936389
Ginkgo biloba L	T002	C0330206
Phylogenetic analyses	T062	C1519068
16S rRNA gene sequences	T028	C0035899
strain SYP-A7299T	T007	C0003876
genus	T185	C1708235
Arthrobacter	T007	C0003876
Arthrobacter halodurans JSM 078085T	T007	C2762206
16S rRNA gene sequence	T028	C0035899
similarity	T080	C2348205
DNA	T114	C0012854
DNA	T114	C0012854
relatedness value	T081	C0392762
strain SYP-A7299T	T007	C0003876
A. halodurans JSM 078085T	T007	C2762206
cell-wall	T026	C0007623
peptidoglycan	T109	C0030958
A4α	T109	C0030958
glucose	T109	C0017725
galactose	T109	C0016945
whole-cell sugars	T109	C0242209
polar lipids	T109	C0023779
diphosphatidylglycerol	T123	C0574031
phosphatidylglycerol	T109	C0031614
phosphatidylinositol	T109	C0031621
glycolipids	T109	C0017950
polar lipid	T109	C0023779
menaquinone	T109	C0086605
MK-8(H2)	T109	C0084980
MK-9(H2)	T109	C0127520
cellular fatty acids	T109	C0015684
anteiso-C15: 0	T109	C0646611
iso-C15: 0	T109	C0044840
anteiso-C17: 0	T109	C0044862
DNA	T114	C0012854
G+C content	T081	C1135899
morphological	T082	C0543482
physiological	T169	C0205463
biochemical	T169	C0205474
chemotaxonomic characters	T169	C0205245
strain SYP-A7299T	T007	C0003876
species	T185	C1705920
genus	T185	C1708235
Arthrobacter	T007	C0003876
Arthrobacter ginkgonis sp. nov.	T007	C0003876
type strain	T001	C1518614
SYP-A7299T	T007	C0003876
=DSM 100491T=KCTC 39 592T	T007	C0003876
Decoding	T041	C0870395
Interactions	T043	C1373094
Regulating	T080	C0243148
Active State	T033	C0679217
Mechanics	T070	C0376706
Eukaryotic	T204	C0684063
Protein Kinases	T116	C0033640
Eukaryotic	T204	C0684063
protein kinases	T116	C0033640
regulate	T080	C0243148
cellular functions	T043	C0007613
phosphorylating	T044	C1158886
targeted	T169	C1521840
protein	T116	C0033684
substrates	T167	C3891814
through	T169	C0332273
highly	T080	C0205250
conserved	T169	C0443318
catalytic core	T026	C0243092
active state	T033	C0679217
catalytic core	T026	C0243092
oscillates	T061	C0695434
open	T082	C0175566
intermediate	T082	C0205103
closed	T082	C0677512
conformations	T082	C0033625
Currently	T079	C0521116
intramolecular interactions	T043	C1373094
regulate	T080	C0243148
active state	T033	C0679217
mechanics	T070	C0376706
not well understood	T080	C0205556
cAMP-dependent protein kinase	T116	C0010531
representative	T052	C1882932
model	T075	C0026336
coupled	T169	C1948027
biochemical	T169	C0205474
biophysical	T038	C1511162
computational techniques	T062	C1516769
highly	T080	C0205250
conserved	T080	C2347858
electrostatic	UnknownType	C0683119
hydrophobic interactions	T044	C0678607
harmoniously	T054	C0699798
regulate	T080	C0243148
mechanics	T070	C0376706
include	T169	C0332257
previously	T079	C0205156
identified	T080	C0205396
salt bridge	T044	C0023745
lysine	T116	C0024337
β3-strand	T082	C0600383
glutamate	T116	C0220839
αC-helix	T082	C0162805
electrostatic interaction	UnknownType	C0683119
phosphorylated	T044	C0031715
activation	T052	C1879547
loop	T082	C0445022
αC-helix	T082	C0162805
ensemble	T081	C0444667
hydrophobic	T080	C0598629
residues	T077	C1709915
decades	T081	C2981279
highly	T080	C0205250
conserved	T169	C0443318
β3	T082	C0600383
β3 -lysine	T116	C0024337
essential	T080	C0205224
phosphoryl transfer	T044	C1148560
findings	T169	C2607943
β3	T082	C0600383
β3 -lysine	T116	C0024337
phosphoryl transfer	T044	C1148560
essential	T080	C0205224
active state	T033	C0679217
mechanics	T070	C0376706
Acute	T079	C0205178
clinical	T080	C0205210
adverse radiation effects	T037	C0392615
Gamma Knife surgery	T061	C2960266
vestibular schwannomas	T191	C0027859
Vestibular schwannomas	T191	C0027859
VSs	T191	C0027859
Gamma Knife surgery	T061	C2960266
GKS	T061	C2960266
studies	T062	C2603343
long-term	T079	C0443252
morbidity	T081	C0178685
adverse radiation effects	T037	C0392615
AREs	T037	C0392615
acute	T079	C0205178
clinical	T080	C0205210
AREs	T037	C0392615
short-term	T079	C0443303
investigated	T169	C1292732
incidence	T081	C0021149
type	T080	C0332307
outcomes	T062	C0086750
reported	T170	C0684224
patients	T101	C0030705
treated	T169	C1522326
months	T079	C0439231
follow-up	T058	C1522577
disabling	T047	C0596452
symptom	T184	C1457887
months	T079	C0439231
GKS	T061	C2960266
affected	T169	C0392760
quality of life	T078	C0034380
symptom	T184	C1457887
outcome	T062	C0086750
prescribed	T058	C0278329
dose	T081	C0178602
patients	T101	C0030705
inclusion	T080	C1512693
acute	T079	C0205178
clinical	T080	C0205210
AREs	T037	C0392615
mean	T081	C0444504
followup	T058	C1522577
months	T079	C0439231
range	T081	C1514721
months	T079	C0439231
mean	T081	C0444504
days	T079	C0439228
median	T081	C0876920
days	T079	C0439228
range	T081	C1514721
days	T079	C0439228
patients	T101	C0030705
de novo	T078	C1515568
symptoms	T184	C1457887
symptoms	T184	C1457887
vertigo	T184	C0042571
gait disturbance	T033	C0575081
exacerbation	T033	C0235874
symptom	T184	C1457887
hearing loss	T033	C3887873
gait disturbance	T033	C0575081
vertigo	T184	C0042571
univariate	T062	C0683962
logistic regression analysis	UnknownType	C0681925
factors	T169	C1521761
statistically significant	T081	C0237881
age	T032	C0001779
odds ratio	T081	C0028873
OR	T081	C0028873
baseline	T081	C1442488
Gardner-Robertson	T170	C0451213
GR	T170	C0451213
OR	T081	C0028873
pure tone average	T081	C0392762
baseline	T081	C1442488
OR	T081	C0028873
Koos grade	T170	C0349674
baseline	T081	C1442488
Koos Grade I	T170	C0349674
Koos Grade II	T170	C0349674
OR	T081	C0028873
Koos Grade III	T170	C0349674
OR	T081	C0028873
statistically significant	T081	C0237881
isocenters	T082	C1881275
OR	T081	C0028873
maximal	T081	C0806909
dose	T081	C0178602
cochlea	T047	C0009197
OR	T081	C0028873
Fractional polynomial regression analysis	T170	C0034980
outcome	T062	C0086750
radiation dose rate	T081	C0560131
maximal	T081	C0806909
vestibular	T030	C0042606
dose	T081	C0178602
sample size	T081	C0242618
precludes	T169	C0332206
analysis	T062	C0936012
clinical	T080	C0205210
acute	T079	C0205178
AREs	T037	C0392615
patients	T101	C0030705
months	T079	C0439231
disabling	T047	C0596452
morbidity	T081	C0178685
cases	T077	C1706256
complete hearing loss	T033	C0581883
GR Class I	T170	C0451213
V	T170	C0451213
hemifacial spasm	T033	C0278152
persistent	T079	C0205322
dysgeusia	T033	C0013378
Acute	T079	C0205178
effects	T080	C1280500
radiosurgery	T061	C0085203
VS	T191	C0027859
de novo	T078	C1515568
vertigo	T184	C0042571
gait disturbance	T033	C0575081
exacerbation	T033	C0235874
hearing loss	T033	C3887873
de novo	T078	C1515568
vestibular	T030	C0042606
symptom	T184	C1457887
vestibular	T030	C0042606
dose	T081	C0178602
cases	T077	C1706256
effects	T080	C1280500
steroid therapy	T061	C0149783
AREs	T037	C0392615
rare	T080	C0522498
Long-chain n-3 PUFA	T109	C0015689
supplied	T052	C1999230
usual	T080	C3538928
diet	T168	C0012155
decrease	T081	C0547047
plasma stearoyl-CoA desaturase	T116	C0038233
index	T170	C0918012
non-hypertriglyceridemic	T033	C0243095
older adults	T098	C0001792
vascular	T023	C0005847
risk	T078	C0035647
activity	T044	C0243102
stearoyl-CoA desaturase-1	T116	C2002916
SCD1	T116	C2002916
central enzyme	T116	C0014442
synthesis	T052	C1883254
monounsaturated fatty acids	T109	C0015687
MUFA	T109	C0015687
associated with	T080	C0332281
de novo	T078	C1515568
lipogenesis	T040	C1563744
experimental models	T170	C0086272
SCD1	T116	C2002916
down-regulated	T044	C0013081
polyunsaturated fatty acids	T109	C0032615
PUFA	T109	C0032615
clinical studies	T062	C0008972
effect	T080	C1280500
long-chain n-3 PUFA	T109	C0015689
LCn-3PUFA	T109	C0015689
supplied	T052	C1999230
regular diet	T168	C0012155
absence	T169	C0332197
fatty fish	T168	C0453017
fish oil	T168	C0556145
supplementation,	T168	C0242295
related	T080	C0439849
changes	T169	C0392747
plasma SCD1	T116	C2002916
index	T170	C0918012
assessed	T052	C1516048
C16:1n-7	T109	C0069966
C16:0	T109	C0030234
ratio	T081	C0456603
adiposity	T032	C1563743
traits	T032	C0599883
nutrient intake	T033	C1287879
changes	T169	C0392747
sub-cohort	T098	C0599755
non-hypertriglyceridemic	T033	C0243095
subjects	T098	C0080105
PREDIMED (PREvención con DIeta MEDiterranea) trial	T062	C0008976
changes	T169	C0392747
fasting	T033	C0015663
triglycerides	T109	C0041004
plasma SCD1	T116	C2002916
index	T170	C0918012
increased	T081	C0205217
body weight	T032	C0005910
confidence interval	T081	C0009667
BMI	T201	C1305855
dietary	T168	C0012155
LCn-3PUFA	T109	C0015689
MUFA	T109	C0015687
plant-derived PUFA	T109	C1318902
associated with	T080	C0332281
decreased	T081	C0205216
plasma SCD1	T116	C2002916
index	T170	C0918012
increase	T169	C0442805
LCn-3PUFA	T109	C0015689
associations	T080	C0439849
food	T168	C0016452
groups	T078	C0441833
fatty fish	T168	C0453017
intake	T169	C1512806
increase	T169	C0442805
data	T078	C1511726
clinical	T080	C0205210
evidence	T078	C3887511
down-regulation	T044	C0013081
plasma SCD1	T116	C2002916
index	T170	C0918012
LCn-3PUFA	T109	C0015689
context	T078	C0449255
changes	T169	C0392747
fish	T013	C0016163
consumption	T052	C2983605
customary	T080	C3538928
non-supplemented	T033	C0243095
diet	T168	C0012155
Distinct cortical and sub-cortical neurogenic domains	T025	C2333134
GABAergic	T043	C1816494
interneuron	T025	C0021792
precursor	T078	C1709634
transcription factors	T116	C0040648
NKX2.1	T116	C1452466
OLIG2	T116	C2347389
COUP-TFII	T116	C1506576
fetal	T169	C0521457
human	T016	C0086418
telencephalon	T018	C0231028
similarities	T080	C2348205
differences	T080	C1705242
cortical GABAergic interneuron generation	T043	C1818464
rodent	T015	C0035804
primate	T015	C0033147
telencephalon	T018	C0231028
expression	T045	C1171362
interneuron	T025	C0021792
precursor	T078	C1709634
transcription factors	T116	C0040648
markers	T201	C0005516
immunohistochemistry	T060	C0021044
post-conceptional weeks	T032	C3827345
PCW	T032	C3827345
human	T016	C0086418
telencephalon	T018	C0231028
NKX2.1	T116	C1452466
OLIG2	T116	C2347389
COUP-TFII	T116	C1506576
expression	T045	C1171362
neurogenic domains	T025	C0027882
cortex	T023	C0007776
CGE compartments	T018	C1268212
lateral	T082	C0205093
medial	T082	C0205098
ventral	T082	C1704448
NKX2.1	T116	C1452466
expression	T045	C1171362
MGE	T018	C1268212
medial	T082	C0205098
CGE	T018	C1268212
ventral	T082	C1704448
septum	T023	C0936188
developmental stage	T079	C0870411
interneuron	T025	C0021792
NKX2.1	T116	C1452466
precursor	T078	C1709634
rodents	T015	C0035804
OLIG2	T116	C2347389
immunoreactivity	T044	C0597879
GABAergic cells	T025	C0815002
proliferative	T043	C0596290
zones	T082	C1710706
MGE	T018	C1268212
septum	T023	C0936188
NKX2.1	T116	C1452466
OLIG2	T116	C2347389
expression	T045	C1171362
LGE	T018	C1268212
CGE	T018	C1268212
cortex	T023	C0007776
PCW	T032	C3827345
OLIG2	T116	C2347389
cells	T025	C0815002
medial	T082	C0205098
anterior	T082	C0205094
cortical wall	T023	C0007776
migratory	T169	C0232901
pathway	T077	C1705987
interneuron	T025	C0021792
precursor	T078	C1709634
septum	T023	C0936188
medial	T082	C0205098
cortex	T023	C0007776
PCW	T032	C3827345
OLIG2	T116	C2347389
cells	T025	C0815002
cortex	T023	C0007776
dividing	T169	C0332849
cortical	T023	C0007776
progenitor	T025	C0038250
markers	T201	C0005516
COUP-TFII	T116	C1506576
progenitor cells	T025	C0038250
localized	T082	C0392752
ventral	T082	C1704448
CGE	T018	C1268212
ventral	T082	C1704448
cortex	T023	C0007776
COUP-TFII	T116	C1506576
PAX6	T116	C4308210
proliferative	T043	C0596290
zones	T082	C1710706
TBR1	T116	C3501502
calretinin	T116	C0054544
mitotic	T080	C1513354
cortical neurons	T025	C2333134
COUP-TFII	T116	C1506576
progenitors	T025	C0038250
pyramidal cells	T025	C0206441
interneurons	T025	C0021792
migrated	T169	C0232902
cortex	T023	C0007776
ventral	T082	C1704448
CGE	T018	C1268212
anteriorly	T082	C0205094
LGE	T018	C1268212
Primary neuroendocrine carcinoma	T191	C0206695
breast	T023	C0006141
single Center experience	T041	C0596545
review of the literature	T170	C0282441
Neuroendocrine carcinoma	T191	C0206695
breast	T023	C0006141
extremely	T080	C0205403
rare	T080	C0522498
tumor	T191	C0027651
standard	T080	C1442989
treatment	T061	C0087111
established	T080	C0443211
cases	T077	C1706256
literature	T170	C0023866
authors	T097	C3812881
cases	T077	C1706256
January	T080	C3829466
December	T080	C3830550
review of literature	T170	C0282441
patients	T101	C0030705
quadrantectomy	T061	C0337354
cases	T077	C1706256
axillary nodal dissection	T061	C0024203
mastectomy	T061	C0024881
axillary nodal dissection	T061	C0024203
Tumor size	T082	C0475440
T1	T033	C0475372
T2	T033	C0475373
N0	T033	C0441959
N1	T033	C0441962
TNM classification	T185	C0809869
Pathological specimens	T031	C0444061
stained	T080	C2986582
hematoxylin	T109	C0018964
eosin	T130	C0021212
immunohistochemical	T059	C1441616
panel	T078	C0441833
antibodies	T130	C0813154
Neuron-specific enolase	T129	C0003320
Chromogranin	T116	C0486578
Synaptophysin	T116	C0487636
Estrogen	T116	C1545287
Progesterone receptors	T116	C1545448
c-erb	T129	C0003320
Ki-67	T116	C0208804
cases	T077	C1706256
markers	T080	C0162490
Neuron-specific enolase	T129	C0003320
Chromogranin	T116	C0486578
Synaptophysin	T116	C0487636
Estrogen	T116	C1545287
Progesterone receptors	T116	C1545448
Ki-67	T116	C0208804
patients	T101	C0030705
Adjuvant chemotherapy	T061	C0085533
administrated	T061	C1533734
patients	T101	C0030705
Ki-67	T116	C0208804
patients	T101	C0030705
treated	T169	C1522326
radiotherapy	T061	C1522449
hormonal therapy	T061	C0279025
Neuroendocrine breast tumor	T191	C3544078
entity	T071	C1551338
treatment	T061	C0087111
correlate	T080	C1707520
size of tumor	T082	C0475440
lymph node	T023	C0024204
status	T080	C0449438
Ki-67	T116	C0208804
index	T170	C0600653
breast cancer	T191	C0678222
Diagnosis	T033	C0011900
Neuroendocrine breast carcinoma	T191	C0206695
parametric model	T170	C3161035
assess	T052	C1516048
delay	T079	C0205421
compression	T080	C0392756
mortality	T081	C0205848
decrease	T081	C0547047
mortality	T081	C0205848
ages	T032	C0001779
age	T032	C0001779
pattern	T082	C0449774
mortality	T081	C0205848
mortality	T081	C0205848
delay	T079	C0205421
differences	T080	C1705242
rate	T081	C1521828
decrease	T081	C0547047
ages	T032	C0001779
shape	T082	C0332479
age-at-death	T033	C1546180
distribution	T169	C1704711
mortality	T081	C0205848
compression	T080	C0392756
expansion	T169	C0442805
Evidence	T078	C3887511
compression	T080	C0392756
delay	T079	C0205421
mortality	T081	C0205848
parametric models	T170	C3161035
age	T032	C0001779
pattern	T082	C0449774
mortality	T081	C0205848
mortality	T081	C0205848
delay	T079	C0205421
mortality	T081	C0205848
compression	T080	C0392756
models	T170	C3161035
delay	T079	C0205421
compression	T080	C0392756
adult	T100	C0001675
old ages	T098	C1999167
mortality	T081	C0205848
compression	T080	C0392756
modal age	T032	C0001779
death	T033	C1306577
different	T080	C1705242
mechanisms	T169	C0441712
paper	T170	C1706852
parametric model	T170	C3161035
age	T032	C0001779
pattern	T082	C0449774
mortality	T081	C0205848
compression	T080	C0392756
different	T080	C1705242
stages of life	T079	C0680083
delay	T079	C0205421
mortality	T081	C0205848
CoDe model	T170	C3161035
model	T170	C3161035
parameters	T077	C0549193
constant	T080	C1948059
time	T079	C0040223
time	T079	C0040223
parameters	T077	C0549193
delay	T079	C0205421
mortality	T081	C0205848
compression	T080	C0392756
mortality	T081	C0205848
infancy	T079	C0231330
adolescence	T079	C0001578
young adulthood	T100	C0680085
late adulthood	T079	C0700597
old age	T098	C1999167
model	T170	C3161035
infant	T100	C0021270
mortality	T081	C0205848
functions	T169	C0542341
mixed logistic model	T081	C0023965
different	T080	C1705242
slopes	T081	C0807955
adult	T100	C0001675
middle	T079	C0026062
old age	T098	C1999167
modal age	T032	C0001779
death	T033	C1306577
parameter	T077	C0549193
delay	T079	C0205421
mortality	T081	C0205848
CoDe model	T170	C3161035
age	T032	C0001779
specific	T080	C0205369
probabilities	T081	C0033204
death	T033	C1306577
Japanese	T098	C1556094
French	T098	C1556084
American	T098	C0596070
Danish	T098	C1257890
men	T098	C0025266
women	T098	C0043210
age	T032	C0001779
pattern	T082	C0449774
mortality	T081	C0205848
Delay	T079	C0205421
mortality	T081	C0205848
increase	T169	C0442805
life expectancy	T102	C0023671
birth	T040	C0005615
compression	T080	C0392756
mortality	T081	C0205848
mortality declines	T081	C0282251
young age	T033	C4061789
compression	T080	C0392756
mortality	T081	C0205848
late adulthood age	T079	C0700597
Mortality	T081	C0205848
compression	T080	C0392756
old age	T098	C1999167
life expectancy	T102	C0023671
CoDe model	T170	C3161035
age	T032	C0001779
pattern	T082	C0449774
mortality	T081	C0205848
mortality	T081	C0205848
delay	T079	C0205421
compression	T080	C0392756
different	T080	C1705242
stages of life	T079	C0680083
increase	T169	C0442805
life expectancy	T102	C0023671
Prevalence	T081	C0033105
Hypothyroidism	T047	C0020676
Andalusia, Spain,	T083	C0037747
Thyroid Hormone	T116	C0040135
Comsumption	UnknownType	C0678263
Hypothyroidism	T047	C0020676
hormone deficiency	T047	C0599750
prevalence	T081	C0033105
Spain	T083	C0037747
prevalence	T081	C0033105
registration	T058	C1514821
patients	T101	C0030705
thyroid hormones	T116	C0040135
Andalusia (South Spain)	T083	C0037747
patients	T101	C0030705
levothyroxine	T109	C1881373
Andalusian Health Service	T058	C0018747
Prevalence	T081	C0033105
confidence intervals	T081	C0009667
management area	UnknownType	C0683738
sex	T032	C1522384
age groups	T100	C0027362
evaluated	T058	C0220825
people	T098	C0027361
female	T032	C0086287
levothyroxine	T109	C1881373
prevalence	T081	C0033105
hypothyroidism	T047	C0020676
CI	T081	C0009667
population	T098	C1257890
females	T032	C0086287
CI	T081	C0009667
males	T032	C0086582
CI	T081	C0009667
4.5-fold	T079	C1254367
population	T098	C1257890
women	T098	C0043210
CI	T081	C0009667
CI	T081	C0009667
prevalence	T081	C0033105
adult	T100	C0001675
women	T098	C0043210
western provinces	T083	C1514578
CI	T081	C0009667
eastern provinces	T083	C1514578
CI	T081	C0009667
coastal areas	T083	C0017446
CI	T081	C0009667
mountainous ones	T098	C1257890
CI	T081	C0009667
high prevalence	T081	C1512456
hypothyroidism	T047	C0020676
adult	T100	C0001675
population	T098	C1257890
Andalusia	T083	C0037747
countries	T083	C0454664
associated with	T080	C0332281
females	T032	C0086287
age	T032	C0001779
prevalence	T081	C0033105
illness	T184	C0221423
geographically-related	UnknownType	C0681784
variability	T077	C2827666
Disease Activity	T047	C1384960
Increased Risk of	T033	C0332167
Cardiovascular Death	T046	C0376297
Patients	T101	C0030705
Psoriatic Arthritis	T047	C0003872
cardiovascular (CV) morbidity	T047	C1301700
mortality	T046	C0376297
patients	T101	C0030705
psoriatic arthritis	T047	C0003872
PsA	T047	C0003872
mortality rate	T081	C0205848
cause of death	T033	C0007465
CV events	T033	C1320716
patients	T101	C0030705
northern	T082	C1709269
Sweden	T083	C0038995
PsA	T047	C0003872
Patients	T101	C0030705
PsA	T047	C0003872
standardized mortality ratio	T081	C1710186
SMR	T081	C1710186
standardized incidence ratio	T081	C2828391
SIR	T081	C2828391
CV events	T033	C1320716
National Causes of Death Register	T170	C0282574
National Inpatient Care Register	T170	C0282574
Sweden	T083	C0038995
general population	T098	C0683971
inflammatory	T169	C0333348
disease activity index	T060	C4065474
DAI	T060	C4065474
SMR	T081	C1710186
overall mortality	T081	C0026565
diseases of the circulatory system	T047	C0728936
International Classification of Diseases	T170	C0870733
regression analysis	T170	C0034980
DAI	T060	C4065474
death	T033	C1306577
stratifying	T080	C0205363
patients	T101	C0030705
causes of death	T033	C0007465
diseases of the circulatory system	T047	C0728936
malignant neoplasms	T191	C0006826
Peripheral	T047	C1704436
axial disease	T033	C3805913
death	T033	C1306577
peripheral disease	T047	C1704436
SIR	T081	C2828391
CV event	T033	C1320716
myocardial infarction	T047	C0027051
stroke	T037	C0018843
men	T098	C0025266
Patients	T101	C0030705
PsA	T047	C0003872
SMR	T081	C1710186
death	T033	C1306577
diseases of the circulatory system	T047	C0728936
general population	T098	C0683971
patients	T101	C0030705
death	T033	C1306577
DAI	T060	C4065474
axial involvement	T033	C3805913
peripheral disease	T047	C1704436
disease phenotypes	T032	C4086242
Histomorphometric	T059	C0200760
transcriptome	T086	C3178810
evaluation	T058	C0220825
healing bone	T033	C1321023
treated with	T061	C0332293
novel	T080	C0205314
human particulate dentin	T031	C0011429
powder	T122	C0032861
Human particulate dentin	T031	C0011429
HPD	T031	C0011429
potential	T080	C3245505
alternative	T077	C1523987
bone grafting	T061	C0005976
material	T122	C0181074
mechanism	T169	C0441712
bone healing	T033	C1321023
molecular	T080	C1521991
level	T080	C0441889
grafting	T061	C1961139
HPD	T031	C0011429
study	T062	C2603343
assessed	T052	C1516048
histological	T169	C0205462
global	T080	C2348867
gene expression	T045	C0017262
bone tissues	T024	C0391978
grafted	T169	C0700106
HPD	T031	C0011429
HPD	T031	C0011429
prepared	T033	C4082130
X-ray diffraction	T059	C0043301
XRD	T059	C0043301
energy dispersive x-ray spectroscopy	T059	C2699997
EDX	T059	C2699997
performed	T169	C0884358
confirm	T080	C1456348
crystal structure	T104	C0444626
organic compound	T109	C0029224
residues	T077	C1709915
surface morphology	T080	C0332437
Bony	T169	C0443157
defects	T169	C1457869
created	T052	C1706214
heads	T029	C0018670
New Zealand White rabbits	T015	C0324547
Sterilized	T080	C0205556
HPD	T031	C0011429
grafting material	T122	C0181074
quality	T080	C0332306
quantity	T081	C1265611
new bone formation	T042	C0029433
evaluated	T058	C0220825
micro-CT	T060	C2350281
histologic	T169	C0205462
analyses	T062	C0936012
during	T079	C0347984
experimental	T080	C1517586
periods	T079	C1948053
microarray assay	T059	C0022885
bone tissue	T024	C0391978
blood samples	T031	C0178913
post-implantation	T079	C1254367
results	T034	C0456984
XRD	T059	C0043301
EDX	T059	C2699997
HPD	T031	C0011429
physical	T070	C0597237
chemical properties	T070	C0243178
similar	T080	C2348205
natural	T169	C0205296
hydroxyapatite	T197	C0020326
New bone formation	T042	C0029433
observed	T169	C1441672
HPD	T031	C0011429
implantation	T061	C0021107
compared	T052	C1707455
controls	T096	C0009932
hematoxylin and eosin staining	T059	C0523207
micro-CT	T060	C2350281
bone volume	T032	C1317149
HPD	T031	C0011429
treated	T169	C1522326
animals	T008	C0003062
higher	T080	C0205250
control group	T096	C0009932
observation	T062	C0302523
times	T081	C1632851
Microarray analysis	T059	C1449575
vascular development	T042	C1621270
immune	T169	C0439662
inflammatory	T169	C0333348
genes	T028	C0017337
expressed	T045	C0017262
early	T079	C2363430
healing	T040	C0043240
stage	T079	C0205390
gene coding	T028	C3839127
IL-1 antagonist	T121	C3536785
IL1RN	T028	C1416402
expressed	T045	C0017262
inhibit	T044	C0021469
inflammatory response	T046	C1155266
CCL2 gene	T028	C1337092
activated	T052	C1879547
normal	T080	C0205307
level	T080	C0441889
BMP2	T028	C1332424
RUNX2	T028	C1419771
COL1A	T028	C0017337
OPN	T028	C1420369
expression	T045	C0017262
up-regulated	T044	C0041904
CCL2	T028	C1337092
predominated	T080	C0332251
osteoblastogenesis	T043	C1159974
HPD	T031	C0011429
treated	T169	C1522326
bony	T169	C0443157
defect	T169	C1457869
early stage	T079	C2363430
healing	T040	C0043240
HPD	T031	C0011429
accelerated	T169	C0521110
bone regeneration	T042	C0005972
augmentation	T033	C0332509
results	T034	C0456984
suggested	T078	C1705535
HPD	T031	C0011429
provided	T052	C1999230
potential	T080	C3245505
bone graft	T061	C0005976
resource	T078	C0178514
during	T079	C0347984
bone	T023	C0262950
healing process	T040	C2004454
person	T098	C0027361
docto	T097	C0031831
work-life balance	T056	C4277700
doctors	T097	C0031831
training	T065	C0220931
qualitative study	T062	C0949415
Investigate	T169	C1292732
work-life balance	T056	C4277700
doctors	T097	C0031831
training	T065	C0220931
UK	T083	C0041700
trainers	T073	C0453962
Qualitative	T080	C0205556
interviews	T052	C0021822
trainers	T073	C0453962
Postgraduate medical training	T065	C0871106
London	T083	C0023973
Yorkshire	T083	C0017446
Humber	T083	C0017446
Kent	T083	C0454861
Surrey	T083	C0454877
Sussex	T083	C0017446
Wales	T083	C0043015
junior doctor	T097	C0031831
contract	T170	C0332522
dispute	T054	C0680226
General Medical Council	T092	C0029246
study	T062	C2603343
postgraduate medical training	T065	C0871106
trainers	T073	C0453962
UK	T083	C0041700
graduates	T098	C0588053
International Medical Graduates	T097	C0016553
training	T065	C0220931
specialties	T091	C0037778
General Practice	T091	C0086343
Medicine	T091	C0025118
Obstetrics and Gynaecology	T091	C1274104
Psychiatry	T091	C0033873
Radiology	T091	C0034599
Surgery	T091	C0038894
Foundation	T092	C0016617
Postgraduate training	T065	C0871106
work-life imbalance	T056	C4277572
Long	T080	C0205166
hours	T079	C0439227
work	T057	C0043227
revision	T079	C0439617
completion	T080	C1554962
e-portfolio	T080	C0205556
workplaces	T082	C0162579
disrupt	T080	C0332454
personal lives	UnknownType	C0682273
separation	T068	C0599245
friends	T098	C0079382
family	T099	C0015576
cope	T055	C0009967
stresses	T048	C0038443
learning	T041	C0023185
training	T065	C0220931
leaving	T052	C1706081
lack	T080	C0332268
social support	T054	C0037438
stresses	T048	C0038443
training	T065	C0220931
Low	T080	C0205251
morale	T033	C0438698
harm	T033	C0438698
well-being	T033	C1821407
feeling	T041	C1527305
dehumanised	T054	C1135946
Work-life imbalance	T056	C4277572
severe	T080	C0205082
children	T100	C0008059
women	T098	C0043210
lack	T080	C0332268
less-than	T081	C0439092
full-time positions	T056	C2584323
discriminatory	T041	C0012632
attitudes	T041	C0004271
Female	T032	C0086287
talked	T056	C0234856
choose	T052	C1707391
specialty	T091	C0037778
work-life balance	T056	C4277700
General Practice	T091	C0086343
junior doctor	T097	C0031831
contract	T170	C0332522
exacerbate	T033	C0436331
existing	T080	C0205556
problems	T033	C0033213
lack	T080	C0332268
work-life balance	T056	C4277700
postgraduate medical training	T065	C0871106
negatively	T080	C3853545
impacted	T169	C0333125
learning	T041	C0023185
well-being	T033	C1821407
Women	T098	C0043210
children	T100	C0008059
affected	T169	C0392760
group	T078	C0441833
benefit	T081	C0814225
greatest	T081	C0205393
changes	T169	C0392747
improve	T033	C0184511
work-life balance	T056	C4277700
Reappraisal	T058	C1254363
Attentional Bias	T041	C4277667
Angry	T041	C0002957
Angry Faces	T033	C0015457
attentional bias	T041	C4277667
emotional	T033	C0849912
information	T078	C1533716
disorders	T047	C0012634
emotion	T041	C0013987
dysregulation	T048	C0004936
anxiety	T048	C0003469
depression	T048	C0011570
substance abuse	T048	C0740858
reappraisal	T058	C1254363
emotion regulation	T041	C2370884
strategy	T041	C0679199
subjective experience	T041	C0596545
emotions	T041	C0013987
reappraisal	T058	C1254363
attentional biases	T041	C4277667
emotional	T033	C0849912
information	T078	C1533716
research	T062	C0035168
investigated	T169	C1292732
instruction-induced state reappraisal	T058	C1254363
Study 1	T062	C2603343
trait reappraisal	T058	C1254363
Study 2	T062	C2603343
attentional biases	T041	C4277667
happy	T033	C3280055
angry	T041	C0002957
angry faces	T033	C0015457
Study 1	T062	C2603343
healthy	T080	C3898900
young women	T098	C0043210
groups	T078	C0441833
up	T078	C0441833
down	T078	C0441833
no-regulation	T078	C0441833
Participants	T098	C0679646
reappraise	T058	C1254363
emotions	T041	C0013987
emotional	T033	C0849912
experience	T041	C0596545
emotionally negative film clip	T170	C0282574
Attentional bias	T041	C4277667
dot-probe task	T061	C0039333
pictures	T073	C0441469
angry	T041	C0002957
happy	T041	C0018592
facial expressions	T033	C0015457
Study 2	T062	C2603343
group	T078	C0441833
healthy	T080	C3898900
young men	T098	C0025266
women	T098	C0043210
Participants	T098	C0679646
trait reappraisal	T058	C1254363
suppression	T041	C0728721
state	T048	C0700613
trait anxiety	T033	C0003467
dot-probe task	T061	C0039333
participants	T098	C0679646
Statistical tests	T170	C0237913
Study 1	T062	C2603343
participants	T098	C0679646
reappraised	T058	C1254363
negative emotions	T041	C0013987
emotionally negative film clip	T170	C0282574
attentional bias	T041	C4277667
angry	T041	C0002957
angry faces	T033	C0015457
compared	T052	C1707455
participants	T098	C0679646
reappraised	T058	C1254363
negative emotions	T041	C0013987
Multiple regression analyses	T170	C0034980
Study 2	T062	C2603343
trait reappraisal	T058	C1254363
angry	T041	C0002957
angry faces	T033	C0015457
state anxiety	T048	C0700613
disengagement	T052	C0441655
angry	T041	C0002957
angry faces	T033	C0015457
trait suppression	T041	C0728721
disengagement	T052	C0441655
happy faces	T033	C3280055
instruction-induced state reappraisal	T058	C1254363
trait reappraisal	T058	C1254363
attentional bias	T041	C4277667
negative	T033	C0205160
information	T078	C1533716
emotion regulation	T041	C2370884
emotional	T033	C0849912
information	T078	C1533716
Graded Structure	T185	C0008902
Sexual	T053	C0036864
Definitions	T170	C1704788
Categorizations	T185	C0008902
Had Sex	T033	C0243095
Virginity	T055	C0282349
Loss	T169	C0745777
Homosexual	T098	C0019898
Heterosexual	T098	C1527360
Men	T098	C0025266
Women	T098	C0043210
Definitions	T170	C1704788
sexual behavior	T053	C0036864
hierarchy	T080	C0019523
acts	T052	C0441655
sex	T040	C0009253
virginity	T055	C0282349
loss	T169	C0745777
research	T062	C0035168
theoretical	T078	C0871935
explanation	T170	C0681841
hierarchy	T080	C0019523
sexual	T053	C0036864
definitions	T170	C1704788
graded categorical structure	T185	C0008902
membership	T055	C0680038
judgments	T041	C0022423
Moderation	T080	C1881878
graded structure	T185	C0008902
sexual orientation	T032	C0205949
identity	T041	C0424215
sexual	T053	C0036864
definitions	T170	C1704788
year	T079	C1510829
participants	T098	C0679646
online survey	T170	C0038951
rating	T052	C0871208
behaviors	T053	C0004927
had sex	T033	C0243095
virginity	T055	C0282349
loss	T169	C0745777
Participants	T098	C0679646
groups	UnknownType	C0681860
heterosexual	T098	C1527360
male	T098	C0025266
female	T098	C0043210
gay male	T098	C0242657
lesbian	T098	C1533642
ratings	T052	C0871208
hierarchy	T080	C0019523
bidirectional genital acts	T053	C0036864
rated	T052	C0871208
higher	T080	C0205250
unidirectional	T053	C0036864
nonpenetrative contact	T033	C0563018
rated	T052	C0871208
higher	T080	C0205250
acts	T052	C0441655
no genital contact	T033	C0243095
Moderation	T080	C1881878
graded structure	T185	C0008902
predictions	T078	C0681842
groups	UnknownType	C0681860
lesbian group	UnknownType	C0681860
ratings	T052	C0871208
genital contact	T053	C0036864
unidirectional	T053	C0036864
nonpenetrative	T033	C0563018
evidence	T078	C3887511
gay male	T098	C0242657
anal intercourse	T054	C0556628
ratings	T052	C0871208
effects	T080	C1280500
group	UnknownType	C0681860
variation	T080	C0205419
experience	T041	C0596545
contextual perspective	T041	C0004271
identity	T041	C0424215
implications	T078	C3146298
findings	T033	C0243095
research	T062	C0035168
graded structure	T185	C0008902
benefit	T081	C0814225
research	T062	C0035168
sexual	T053	C0036864
definitions	T170	C1704788
definitions	T170	C1704788
soybean isoflavone	T109	C4076257
intestinal	T023	C0021853
antioxidant capacity	T044	C1148564
cytokines	T116	C0079189
piglets	T015	C0039005
fed	T052	C2987508
oxidized	T044	C0030011
fish oil	T109	C0016157
glycitein	T109	C0253391
synthetic	T052	C1883254
soybean isoflavone	T109	C4076257
ISF	T109	C4076257
intestinal	T023	C0021853
antioxidant capacity	T044	C1148564
morphology	T080	C0332437
cytokine	T116	C0079189
piglets	T015	C0039005
fed	T052	C2987508
oxidized	T044	C0030011
fish oil	T109	C0016157
piglets	T015	C0039005
treatments	T061	C0001563
control group	T096	C0009932
fed	T052	C2987508
basal diet	T168	C2983588
fresh	T080	C0443224
fish oil	T109	C0016157
dosage	T081	C0178602
oxidized	T044	C0030011
fish oil	T109	C0016157
ISF	T109	C4076257
oxidized	T044	C0030011
fish oil	T109	C0016157
ISF	T109	C4076257
feeding	T052	C2987508
supplementation	T061	C0242297
oxidized	T044	C0030011
fish oil	T109	C0016157
malondialdehyde	T109	C0024643
MDA	T109	C0024643
oxidized glutathione	T116	C0061516
GSSG	T116	C0061516
interleukin-1β	T116	C0021753
IL-1β	T116	C0021753
tumor necrosis factor-α	T116	C1456820
TNF-α	T116	C1456820
interleukin-2	T116	C0021756
IL-2	T116	C0021756
nuclear factor κ B	T116	C0079904
(NF-κB	T116	C0079904
inducible nitric oxide synthase	T116	C0132555
iNOS	T116	C0132555
NO	T121	C0028128
Caspase-3	T116	C0291573
jejunal mucosa	T023	C0227308
villous	T023	C0227266
height	T032	C0489786
duodenum	T023	C0013303
secretory immunoglobulin A	T116	C0020838
(sIgA	T116	C0020838
IL-4	T116	C0021758
jejunal mucosa	T023	C0227308
supplementation	T061	C0242297
fresh	T080	C0443224
oil	T109	C0016157
oxidized	T044	C0030011
fish oil	T109	C0016157
ISF	T109	C4076257
oxidized	T044	C0030011
fish oil	T109	C0016157
ISF	T109	C4076257
villous	T023	C0227266
height	T032	C0489786
sIgA	T116	C0020838
IL-4	T116	C0021758
jejunal mucosa	T023	C0227308
IL-1β	T116	C0021753
IL-2	T116	C0021756
jejunal mucosa	T023	C0227308
oxidized	T044	C0030011
fish oil	T109	C0016157
dietary supplementation	T061	C0242297
ISF	T109	C4076257
oxidized	T044	C0030011
fish oil	T109	C0016157
intestinal morphology	T023	C0021853
antioxidant capacity	T044	C1148564
immune function	T042	C1817756
piglets	T015	C0039005
piglets	T015	C0039005
Evolution	T045	C3825184
Enhanced	T052	C2349975
Footing	T169	C1527178
Snake	T014	C0037382
Limb Development	T042	C1517884
loss	T081	C1517945
limbs	T023	C0015385
snake	T014	C0037382
evolution	T045	C3825184
long-distance	T033	C0456966
cis-acting enhancer	T086	C1516561
Sonic Hedgehog	T028	C1335824
progressive	T169	C0205329
degeneration	T169	C1880269
binding sites	T087	C1514535
transcription factors	T116	C0040648
progressive	T169	C0205329
limblessness	T080	C0205556
occurring	T052	C1709305
reptiles	T014	C0035161
Dynamin-related protein 1	T116	C0669938
mediates	T169	C0205245
low glucose	T109	C0017725
induced	T169	C0205263
endothelial dysfunction	T047	C0856169
human	T016	C0086418
arterioles	T023	C0003847
glycemic regulation	T038	C1327622
increased	T081	C0205217
incidence	T081	C0021149
hypoglycemia	T047	C0020615
Hypoglycemic	T047	C0020615
burden	T078	C2828008
adverse	T169	C0001688
cardiovascular complications	T046	C0161816
acutely	T079	C0205178
chronically	T079	C0205191
endothelial dysfunction	T047	C0856169
data	T078	C1511726
mitochondrial dysfunction	T033	C4021734
hypoglycemia	T047	C0020615
induced	T169	C0205263
endothelial dysfunction	T047	C0856169
mechanisms	T169	C0441712
linkage	T169	C0205245
unknown	T080	C0439673
clinically	T080	C0205210
relevant	T080	C2347946
low-glucose	T109	C0017725
LG	T109	C0017725
exposures	T080	C0332157
acutely	T079	C0205178
induce	T169	C0205263
endothelial dysfunction	T047	C0856169
activation	T052	C1879547
mitochondrial fission process	T043	C0230871
Characterization	T052	C1880022
mitochondrial morphology	T033	C0243095
cultured	T169	C0205245
endothelial cells	T025	C0225336
confocal microscopy	T059	C0242842
Isolated	T169	C0205409
human	T016	C0086418
arterioles	T023	C0003847
effect	T080	C1280500
LG	T109	C0017725
induced	T169	C0205263
mitochondrial fission	T043	C0230871
formation	T169	C1522492
detrimental reactive oxygen species	T123	C1537052
ROS	T123	C1537052
bioavailability	T081	C0005508
nitric oxide	T121	C0028128
NO	T121	C0028128
endothelial-dependent vascular relaxation	T042	C1258036
Fluorescence microscopy	T059	C0026022
changes	T169	C0392747
mitochondrial	T026	C0026237
ROS	T123	C1537052
NO	T121	C0028128
levels	T080	C0441889
videomicroscopy	T059	C0242940
measure	T081	C0079809
vasodilation	T042	C0042401
response	T169	C0205245
Pharmacological	T169	C0205464
disruption	T169	C0332453
profission protein	T116	C0033684
Drp1	T116	C0669938
Mdivi-1	T109	C2933581
LG	T109	C0017725
exposure	T080	C0332157
reduced	T080	C0392756
mitochondrial fragmentation	T043	C0230871
vascular endothelial cells	T025	C1257792
LG	T109	C0017725
LG	T109	C0017725
Mdivi-1	T109	C2933581
prevented	T169	C1292733
formation	T169	C1522492
vascular	T023	C0005847
ROS	T123	C1537052
LG	T109	C0017725
LG	T109	C0017725
Mdivi-1	T109	C2933581
increased	T081	C0205217
presence	T033	C0150312
NO	T121	C0028128
LG	T109	C0017725
LG	T109	C0017725
Mdivi-1	T109	C2933581
improved	T033	C0184511
vascular dilation	T042	C0042401
response	T169	C0205245
acetylcholine	T109	C0001041
LG	T109	C0017725
LG	T109	C0017725
Mdivi-1	T109	C2933581
maximum	T081	C0806909
dose	T081	C0178602
decreased	T081	C0205216
expression	T045	C1171362
Drp1	T116	C0669938
siRNA	T114	C1099354
knockdown	T063	C2350567
LG	T109	C0017725
conditions	T080	C0348080
improved	T033	C0184511
vascular relaxation	T042	C1258036
Exposure to	T080	C0332157
LG	T109	C0017725
endothelial dysfunction	T047	C0856169
coupled	T169	C1948027
altered	T169	C0392747
mitochondrial	T026	C0026237
phenotypes	T032	C0031437
isolated	T169	C0205409
human	T016	C0086418
arterioles	T023	C0003847
Disruption	T169	C0332453
Drp1	T116	C0669938
subsequent	T079	C0332282
mitochondrial fragmentation	T043	C0230871
prevents	T169	C1292733
impaired	T169	C0221099
vascular dilation	T042	C0042401
restores	T169	C0205245
mitochondrial	T026	C0026237
phenotype	T032	C0031437
mitochondrial fission	T043	C0230871
primary	T080	C0205225
mediator	T080	C0205556
LG	T109	C0017725
induced	T169	C0205263
endothelial dysfunction	T047	C0856169
Acute	T079	C0205178
low-glucose	T109	C0017725
exposure	T080	C0332157
induces	T169	C0205263
mitochondrial fragmentation	T043	C0230871
endothelial cells	T025	C0225336
Drp1	T116	C0669938
associated with	T080	C0332281
impaired	T169	C0221099
endothelial	T025	C0225336
function	T043	C0007613
human	T016	C0086418
arterioles	T023	C0003847
Targeting	T043	C0599894
Drp1	T116	C0669938
prevents	T169	C1292733
fragmentation	T043	C0230871
vasofunction	T042	C1254358
therapeutic	T169	C0302350
target	T169	C1521840
cardiovascular complications	T046	C0161816
diabetics	T033	C0241863
http://ajpheart.podbean.com/e/mitochondrial-dynamics-impact-endothelial-function/	T170	C1704666
Yin Yang	T028	C0017337
gene expression	T045	C0017262
ratio	T081	C0456603
signature	T169	C1708225
ER+	T191	C2938924
node- breast cancer	T191	C3160889
Breast cancer	T191	C0006142
causes	T169	C0015127
cancer	T191	C0006826
death	T040	C0011065
women	T098	C0043210
complex	T080	C0439855
heterogeneous	T080	C0019409
disease	T047	C0012634
clinical	T080	C0205210
outcomes	T080	C0085415
Stratifying	T080	C0205363
patients	T101	C0030705
subgroups	T185	C1515021
outcomes	T080	C0085415
clinical decision making	T060	C4042877
study	T062	C0008972
groups	T078	C0441833
genes	T028	C0017337
Yin and Yang	T028	C0017337
prognostic	T201	C1511294
expression	T045	C0017262
ratio	T081	C0456603
signature	T169	C1708225
METABRIC	T170	C0242356
cohort	T062	C0086027
gene signature	T169	C1708225
stratifying	T080	C0205363
breast cancer	T191	C0006142
patients	T101	C0030705
risk levels	T080	C3166291
low-risk	T081	C3538919
patients	T101	C0030705
adjuvant	T169	C1522673
systemic therapy	T061	C1515119
intermediate	T082	C0205103
low-risk	T081	C3538919
patients	T101	C0030705
treated with	T061	C0332293
hormonal therapy	T061	C0279025
intermediate	T082	C0205103
high-risk groups	T098	C0684030
treated	T061	C0332293
chemotherapy	T061	C3665472
hormonal therapy	T061	C0279025
gene signature	T169	C1708225
risk level	T080	C3166291
stratifications	T185	C0008902
breast cancer	T191	C0006142
patients	T101	C0030705
validated	T062	C1519941
datasets	T170	C0150098
low-risk	T081	C3538919
group	T098	C1257890
estrogen receptor-positive	T191	C2938924
node negative	T191	C3160889
ER+	T191	C2938924
node-	T191	C3160889
patients	T101	C0030705
datasets	T170	C0150098
adjuvant therapy	T061	C0677850
year	T079	C0439234
disease-specific survival rate	T081	C2986538
Concordance Index	T170	C0918012
YMR	T060	C2698560
ER+	T191	C2938924
node negative	T191	C3160889
patients	T101	C0030705
commercially	T170	C0680536
signatures	T169	C1708225
YMR	T060	C2698560
significance	T078	C0750502
HR	T081	C2985465
stratifying	T080	C0205363
ER+	T191	C2938924
node-	T191	C3160889
subgroup	T185	C1515021
OncotypeDx	T060	C2698560
HR	T081	C2985465
MammaPrint	T059	C2827401
HR	T081	C2985465
rorS	T060	C2698560
HR	T081	C2985465
NPI	T060	C2698560
HR	T081	C2985465
YMR	T060	C2698560
signature	T169	C1708225
clinical	T080	C0205210
tool	T170	C0037589
subgroup	T185	C1515021
low-risk	T081	C3538919
ER+	T191	C2938924
node-	T191	C3160889
patients	T101	C0030705
adjuvant	T169	C1522673
hormonal therapy	T061	C0279025
AHT	T061	C0279025
Risk Factors	T033	C0035648
Associated With	T080	C0332281
Repeated	T169	C0205341
HIV Testing	T059	C0459958
Internet	T073	C0282111
Men Who Have Sex With Men	T098	C2827413
Men who have sex with men	T098	C2827413
MSM	T098	C2827413
represent	T052	C1882932
disproportionately	T080	C0205350
impacted	T169	C0333125
risk group	T098	C0684030
HIV	T005	C0019682
incidence	T081	C0021149
at-risk	T080	C1444641
U.S	T083	C0041703
studies	T062	C2603343
identified	T080	C0205396
risk factors	T033	C0035648
associated with	T080	C0332281
HIV testing	T059	C0459958
frequency	T081	C0871396
within	T082	C0332285
outside	T082	C0205101
health care settings	T058	C0086388
MSM	T098	C2827413
prospective cohort	T062	C1709709
mailed	T073	C0024492
at-home specimen collection kits	T074	C0025080
followed	T079	C1254367
year	T079	C0439234
Incidence density rate ratios	T081	C0456603
IDRR	T081	C0456603
testing	T169	C0039593
calculated	T052	C1441506
generalized	T082	C0205246
estimating	T081	C0750572
equations	T077	C0552449
association	T080	C0439849
HIV testing	T059	C0459958
behavioral	T053	C0004927
factors	T169	C1521761
incidence rate	T081	C1708485
testing	T169	C0039593
higher	T080	C0205250
Black	T098	C0005680
MSM	T098	C2827413
White	T098	C0007457
MSM	T098	C2827413
IDRR	T081	C0456603
confidence interval	T081	C0009667
CI	T081	C0009667
higher	T080	C0205250
MSM	T098	C2827413
condomless	T033	C0848723
condomless anal intercourse partners	T098	C0036911
anal	T023	C0003461
CAI	T098	C0036911
MSM	T098	C2827413
no	T033	C0205160
CAI	T098	C0036911
IDRR	T081	C0456603
CI	T081	C0009667
Increasing	T169	C0442808
availability of	T169	C0470187
HIV testing	T059	C0459958
outside	T082	C0205101
health care settings	T058	C0086388
at-home testing kits	T074	C0973155
conjunction	T078	C2699427
targeted	T169	C1521840
behavioral	T053	C0004927
interventions	T169	C1314939
biomedical	T091	C1879848
treatment preventions	T061	C0087111
nursingstandard.com	T170	C2349146
Nurse	T097	C0028661
suspended	T169	C1705537
months	T079	C0439231
Nursing and Midwifery Council	T094	C0033282
NMC	T094	C0033282
concealing	T080	C0443189
high temperature	T184	C0015967
colleague	T097	C0028661
Ebola	T047	C0282687
rcni.com/donna-wood	T170	C2349146
Theory of Mind	T078	C0935573
Adolescents	T100	C0205653
Bipolar Disorder	T048	C0005586
Euthymic Phase	T048	C0233475
Strange Stories Test	T170	C0282574
evaluated	T058	C0220825
theory of mind	T078	C0935573
ToM	T078	C0935573
adolescents	T100	C0205653
diagnosed	T033	C0011900
bipolar disorder	T048	C0005586
BD	T048	C0005586
euthymic period	T048	C0233475
typically developing (TD) group	T078	C0441833
BD	T048	C0005586
group	T078	C0441833
inpatients	T101	C0021562
euthymic phase	T048	C0233475
TD ‎group	T078	C0441833
age	T032	C0001779
gender	T032	C0079399
IQ	T032	C0456149
students	T098	C0038492
diagnosis	T033	C0011900
‎comorbid disorders	T047	C0012634
semi-structured interview	UnknownType	C0681913
Kiddie Schedule for Affective Disorders ‎and Schizophrenia-Present and Lifetime Version	UnknownType	C0681913
K-SADS-PL	UnknownType	C0681913
BD	T048	C0005586
adolescents	T100	C0205653
‎evaluate	T058	C0220825
attention deficit hyperactivity disorder	T048	C1263846
ADHD	T048	C1263846
mania	T048	C0338831
Conner's ‎Parent Rating Scale-Revised version (CPRS-R)	T081	C0681889
Young Mania Rating Scale	T170	C4087288
YMRS	T170	C4087288
Ravens Progressive Matrices	T170	C0451407
evaluate	T058	C0220825
intellectual ability	T033	C0423898
groups	T078	C0441833
Happe Strange Stories test	T170	C0282574
ToM	T078	C0935573
participants	T098	C0679646
Data	T078	C1511726
t-test	T170	C0871472
analysis of covariance	T081	C0814908
Pearson Correlation analysis	T062	C0010101
groups	T078	C0441833
BD	T048	C0005586
group's	T078	C0441833
mentalizing scores	T053	C2959458
TD group	T078	C0441833
ToM	T078	C0935573
impairments	T169	C0221099
adolescents	T100	C0205653
BD	T048	C0005586
trait marker	T045	C0017393
social problems	T033	C0037431
remission‏	T046	C0597370
TYW3	T116	C0033684
Taw3	T116	C0033684
SAM-dependent methyltransferases	T116	C0969403
S-adenosylmethionine (SAM)-dependent methyltransferases	T116	C0969403
regulate	T038	C1327622
biological processes	T038	C3714634
modification	T044	C2752381
proteins	T116	C0033684
nucleic acids	T114	C0028606
polysaccharides	T109	C0032594
metabolites	T123	C0870883
TYW3	T116	C0033684
Taw3	T116	C0033684
SAM-dependent methyltransferase	T116	C0969403
tRNA modification	T045	C1158758
wybutosine	T114	C1171957
decoding	T045	C1519614
protein synthesis	T044	C0597295
crystal structure	T026	C0230587
Taw3	T116	C0033684
TYW3	T116	C0033684
Sulfolobus solfataricus	T194	C0995927
α/β fold	T044	C0162847
S/T)xSSCxGR	T087	C0002518
aspartate	T116	C0085845
histidine	T116	C0019602
TYW3	T116	C0033684
Taw3	T116	C0033684
cluster	T081	C1704332
catalytic	T067	C0175921
structural	T116	C1510464
sequence	T087	C0002518
TYW3	T116	C0033684
Taw3	T116	C0033684
SAM-dependent methyltransferases	T116	C0969403
site-directed mutagenesis	T045	C0079870
in vivo complementation assays	T059	C0017381
mass spectrometry	T059	C0037813
ligand docking	T044	C1522290
cofactor binding	T044	C1323251
assays	T059	C1510438
active site	T169	C0205681
TYW3	T116	C0033684
cofactor binding	T044	C1323251
methyltransferase activity	T044	C1152247
Developmental	T080	C0458003
Profile	T059	C1979963
Diagnoses	T062	C1704656
Children	T100	C0008059
Motor Stereotypies	T033	C3898226
Motor stereotypies	T033	C3898226
difficulty	T080	C0332218
non-clinical behaviors	T053	C0004927
physiological	T039	C0031843
transient	T079	C0205374
symptoms	T184	C1457887
disorders	T047	C0012634
primary stereotypies	T048	C4302136
associated with	T080	C0332281
autistic spectrum disorder	T048	C1510586
ASD	T048	C1510586
intellectual disabilities	T048	C3714756
genetic syndromes	T047	C0567439
sensory impairment	T033	C4062750
study	T062	C2603343
obtain	T169	C1301820
assessment	T058	C0220825
relationship	T080	C0439849
stereotypies	T048	C0038273
neurodevelopmental disorders	T048	C1535926
studied	T062	C2603343
children	T100	C0008059
girls	T100	C0870604
aged	T032	C0001779
months	T079	C0439231
consultation	T058	C0009818
persistence	T033	C0518691
increased	T081	C0205217
severity	T080	C0392364
motor stereotypies	T033	C3898226
patients	T101	C0030705
diagnosis	T062	C1704656
ASD	T048	C1510586
assessment	T058	C0220825
Motor Severity Stereotypy Scale	T170	C0349674
MSSS	T170	C0349674
Repetitive Behavior Scale-Revised	T170	C0475483
RBS-R	T170	C0475483
Raven's Colored Progressive Matrices	T033	C4305179
Child Behavior CheckList	T060	C0870266
ages	T032	C0001779
CBCL	T060	C0870266
Social Responsiveness Scale	T170	C0349674
(SRS)	T170	C0349674
Autism Diagnostic Observation Schedule-second edition	T170	C0282574
ADOS 2	T170	C0282574
patients	T101	C0030705
motor stereotypies	T033	C3898226
periods of time	T079	C1948053
months	T079	C0439231
MSSS	T170	C0349674
child	T100	C0870604
limited	T169	C0439801
number	T081	C0237753
stereotypies	T048	C0038273
frequency	T081	C0871396
intensity	T080	C0522510
mild	T080	C2945599
interference	T169	C0521102
stereotypies	T048	C0038273
variable	T080	C0439828
impairment	T169	C0221099
life	T078	C0376558
mild	T080	C2945599
RBS-R	T170	C0475483
scores	T081	C0449820
stereotypic behaviors	T048	C0038271
children	T100	C0008059
children	T100	C0008059
repetitive behaviors	T033	C1827547
ritualistic behavior	T184	C2266670
sameness behavior	T033	C1827547
patients	T101	C0030705
normal cognitive level	T033	C4231661
CBCL	T060	C0870266
evidenced	T078	C3887511
behavioral problems	T048	C0233514
children	T100	C0008059
internalizing problems	T184	C1457887
attention	T041	C0004268
withdrawn	T048	C2825032
SRS	T170	C0349674
tested	T169	C0039593
patients	T101	C0030705
obtained	T169	C1301820
clinical scores	T033	C3533165
clinical	T080	C0205210
range	T081	C1514721
ADOS 2	T170	C0282574
patients	T101	C0030705
obtained	T169	C1301820
scores	T081	C0449820
moderate	T080	C0205081
level	T080	C0441889
ASD	T048	C1510586
symptoms	T184	C1457887
mild	T080	C2945599
level	T080	C0441889
signs	T184	C0037088
ASD	T048	C1510586
Motor stereotypies	T033	C3898226
children	T100	C0008059
normal cognitive level	T033	C4231661
diagnostic	T169	C0348026
issue	T033	C0033213
tailored	T170	C0870097
assessment	T058	C0220825
developmental	T080	C0458003
profile	T169	C2003903
standardized tests	T170	C0237892
misdiagnosis	T033	C0679838
motor stereotypies	T033	C3898226
movement disorder	T047	C0026650
Left ventricular	T023	C0225897
rotational	T082	C0445237
mechanics	T070	C0376706
infants	T100	C0021270
hypoxic ischemic encephalopathy	T047	C0752304
preterm infants	T100	C4048294
weeks	T079	C0439230
postmenstrual age	T032	C3828508
comparison	T052	C1707455
healthy	T080	C3898900
term controls	T096	C0009932
data	T078	C1511726
left ventricle	T023	C0225897
LV	T023	C0225897
rotational physiology	T091	C0031842
neonates	T100	C0021289
rotational	T082	C0445237
mechanics	T070	C0376706
infants	T100	C0021270
hypoxic ischemic encephalopathy	T047	C0752304
HIE	T047	C0752304
premature infants	T100	C4048294
weeks	T079	C0439230
weeks	T079	C0439230
postmenstrual age	T032	C3828508
PMA	T032	C3828508
preterm group	T098	C1257890
compare	T052	C1707455
healthy	T080	C3898900
term controls	T096	C0009932
term controls	T096	C0009932
compared	T052	C1707455
parameters	T077	C0549193
preterm infants	T100	C4048294
chronic lung disease	T047	C0746102
CLD	T047	C0746102
Echocardiography	T060	C0013516
hours	T079	C0439227
birth	T040	C0005615
weeks	T079	C0439230
PMA	T032	C3828508
LV	T023	C0225897
basal	T082	C0205112
rotation	T169	C0035868
twist	T082	C0231467
twist	T082	C0231467
LV length	T081	C1444754
twist rate	T081	C1521828
LVTR	T081	C1521828
untwist rate	T081	C1521828
LVUTR	T081	C1521828
One-way ANOVA	T081	C1709320
compare	T052	C1707455
values	T080	C0042295
gestation	T040	C0032961
birthweight	T032	C0005612
HIE	T047	C0752304
group	T098	C1257890
term controls	T096	C0009932
preterm group	T098	C1257890
gestation	T040	C0032961
weight	T081	C0043100
weeks	T079	C0439230
HIE	T047	C0752304
twist	T082	C0231467
LVTR	T081	C1521828
LVUTR	T081	C1521828
preterm group	T098	C1257890
clockwise	T169	C3831073
basal	T082	C0205112
rotation	T169	C0035868
term group	T098	C1257890
counterclockwise	T169	C3830994
apical	T082	C0205111
rotation	T169	C0035868
Preterm infants	T100	C4048294
CLD	T047	C0746102
apical	T082	C0205111
rotation	T169	C0035868
twist	T082	C0231467
compared	T052	C1707455
infants	T100	C0021270
CLD	T047	C0746102
Infants	T100	C0021270
HIE	T047	C0752304
rotational	T082	C0445237
mechanics	T070	C0376706
Preterm infants	T100	C4048294
weeks	T079	C0439230
PMA	T032	C3828508
comparable	T052	C1707455
measurements	T169	C0242485
twist	T082	C0231467
term infants	T100	C0456128
basal	T082	C0205112
basal	T082	C0205112
apical	T082	C0205111
rotation	T169	C0035868
Infants	T100	C0021270
CLD	T047	C0746102
apical	T082	C0205111
rotation	T169	C0035868
Comparing	T052	C1707455
effects of	T080	C1704420
different	T080	C1705242
dynamic sitting strategies	T061	C0454281
wheelchair seating	T074	C0438917
lumbar-pelvic angle	T029	C0024090
Prolonged	T079	C0439590
static sitting	T033	C4270719
wheelchair	T074	C0043143
associated with	T080	C0332281
increased	T081	C0205217
risk	T078	C0035647
lower back pain	T184	C0024031
wheelchair seating system	T074	C0438917
key factor	T169	C1521761
risk	T078	C0035647
spinal	T082	C0521329
loading	T169	C0205245
sitting position	T033	C0277814
study	T062	C2603343
dynamic sitting strategies	T061	C0454281
DSSs	T061	C0454281
examined	T033	C0332128
lumbar prominent dynamic sitting	T061	C0454281
LPDS	T061	C0454281
back reclined dynamic sitting	T061	C0454281
BRDS	T061	C0454281
femur upward dynamic sitting	T061	C0454281
FUDS	T061	C0454281
lumbar prominent with back reclined dynamic sitting	T061	C0454281
LBDS	T061	C0454281
lumbar prominent with femur upward dynamic sitting	T061	C0454281
LFDS	T061	C0454281
back reclined with femur upward dynamic sitting	T061	C0454281
BFDS	T061	C0454281
lumbar prominent with back reclined with femur upward dynamic sitting	T061	C0454281
LBFDS	T061	C0454281
objective	T170	C0018017
study	T062	C2603343
analyze	T062	C0936012
biomechanical	T070	C3658372
effects of	T080	C1704420
sitting strategies	T061	C0454281
lumbar-pelvic angles	T029	C0024090
able-bodied	T033	C0424576
participants	T098	C0679646
recruited	T169	C0205245
study	T062	C2603343
participants	T098	C0679646
performed	T169	C0884358
LPDS	T061	C0454281
BRDS	T061	C0454281
FUDS	T061	C0454281
LBDS	T061	C0454281
LFDS	T061	C0454281
BFDS	T061	C0454281
LBFDS	T061	C0454281
random	T080	C0439605
order	T080	C1705176
lumbar-pelvic angle	T029	C0024090
parameters	T077	C0549193
static	T080	C0441463
lumbar angle	T029	C0024090
static	T080	C0441463
pelvic angle	T023	C0030797
lumbar range of motion	T033	C0575375
pelvic range of motion	T033	C0243095
measured	T080	C0444706
compared	T052	C1707455
Results	T169	C1274040
LBDS	T061	C0454281
LBFDS	T061	C0454281
enabled	T041	C1171285
beneficial	T080	C0205556
lumbar movements	T201	C1286136
difference	T080	C1705242
strategies	T041	C0679199
nonsignificant	T033	C1273937
BRDS	T061	C0454281
BFDS	T061	C0454281
enabled	T041	C1171285
beneficial	T080	C0205556
pelvic movements	T061	C0454470
difference	T080	C1705242
strategies	T041	C0679199
nonsignificant	T033	C1273937
DSSs	T061	C0454281
LPDS	T061	C0454281
LFDS	T061	C0454281
enabled	T041	C1171285
beneficial	T080	C0205556
lumbar	T201	C1286136
pelvic movements	T061	C0454470
no significant	T033	C1273937
difference	T080	C1705242
observed	T169	C1441672
strategies	T041	C0679199
identified	T080	C0205396
effects	T080	C1280500
differences	T080	C1705242
DSSs	T061	C0454281
lumbar-pelvic angles	T029	C0024090
Wheelchair users	T101	C0853966
choose	T052	C1707391
suitable	T080	C3900053
DSS	T061	C0454281
meets	T067	C1550543
needs	T080	C0027552
findings	T033	C0243095
reference	T077	C1706462
practicing physicians	T097	C0017319
wheelchair users	T101	C0853966
choose	T052	C1707391
appropriate	T080	C1548787
wheelchair seating	T074	C0438917
heavy metal	T196	C0347988
health risk	T061	C0679809
HMHR	T061	C0679809
quantification	T081	C1709793
sources	T033	C0449416
southern	T082	C1710133
city	T083	C0008848
China	T083	C0008115
ME2	T073	C0037585
HMHR	T061	C0679809
model	T170	C0596657
Heavy metals	T196	C0347988
Cr	T131	C0008574
Co	T123	C0009148
Ni	T123	C0028013
As	T121	C0003818
Cd	T131	C0006632
Pb	T131	C0023175
PM	T167	C1720884
adversely affecting	T046	C0879626
human	T016	C0086418
health	T078	C0018684
source	T033	C0449416
heavy metals	T196	C0347988
source	T033	C0449416
specific	T080	C0205369
heavy metal	T196	C0347988
health risk	T061	C0679809
HMHR	T061	C0679809
effective	T080	C1704419
risks	T078	C0035647
exposure to	T080	C0332157
heavy metals	T196	C0347988
PM2.5	T167	C1720884
particulate matter	T167	C1720884
PM	T167	C1720884
aerodynamic diameter	T081	C1301886
Multilinear Engine 2	T073	C0037585
ME2	T073	C0037585
risk assessment	T058	C0086930
model	T170	C0596657
quantify	T081	C1709793
source	T033	C0449416
contributions	T052	C1880177
HMHR	T061	C0679809
heavy metal	T196	C0347988
non-cancer risk	T033	C1513916
non-HMCR	T033	C1513916
cancer risk	T081	C0596244
HMCR	T081	C0596244
model	T170	C0596657
ME2-HMHR	T170	C0596657
source	T033	C0449416
contributions	T052	C1880177
heavy metals	T196	C0347988
ME2	T073	C0037585
model	T170	C0596657
source	T033	C0449416
contributions	T052	C1880177
risk assessment	T058	C0086930
model	T170	C0596657
source	T033	C0449416
contributions	T052	C1880177
HMHR	T061	C0679809
Huzou	T083	C0008115
China	T083	C0008115
sources	T033	C0449416
Soil	T167	C0037592
dust	T167	C0013330
source	T033	C0449416
non-HMCR	T033	C1513916
HMCR	T081	C0596244
source	T033	C0449416
contributions	T052	C1880177
soil	T167	C0037592
dust	T167	C0013330
coal	T109	C0009131
combustion	T073	C0681531
cement dust	T033	C2220339
dust	T167	C0013330
vehicle	T131	C0004380
sources	T033	C0449416
soil	T167	C0037592
dust	T167	C0013330
contributor	T052	C1880177
HMCR	T081	C0596244
impact	T080	C4049986
soil	T167	C0037592
dust	T167	C0013330
PM2.5	T167	C1720884
abundance	T080	C2346714
heavy metals	T196	C0347988
soil	T167	C0037592
dust	T167	C0013330
Aspirin	T109	C0004057
Suppresses	T169	C1260953
Growth	T040	C0018270
PI3K	T028	C1335212
Mutant	T028	C0678941
Breast Cancer	T191	C0678222
Activating	T045	C0599177
AMPK	T116	C2350345
Inhibiting	T052	C3463820
mTORC1	T116	C2975458
incidence	T081	C0021149
oncogenic	T028	C0029016
mutations	T045	C0026882
PIK3CA	T028	C1335212
gene encoding	T028	C3839127
catalytic subunit	T087	C0600499
PI3K	T116	C0044602
PI3K	T116	C0044602
inhibitors	T121	C0014432
clinical benefit	T033	C1333602
breast cancer	T191	C0678222
patients	T101	C0030705
Recent	T079	C0332185
epidemiologic studies	T062	C0002783
suggested	T078	C1705535
therapeutic	T169	C0302350
benefit	T081	C0814225
aspirin	T109	C0004057
cancers	T191	C0006826
oncogenic PIK3CA	T116	C0044602
mutant	T028	C0678941
PIK3CA	T116	C0044602
expressing	T045	C0017262
breast cancer cells	T025	C1512505
sensitivity	T169	C0332324
aspirin	T109	C0004057
growth	T043	C0007595
suppression	T043	C0007613
wild-type	T028	C1883559
Aspirin	T109	C0004057
decreased	T081	C0205216
viability	T043	C0007620
anchorage-independent growth	T059	C1515979
mutant	T028	C0678941
PIK3CA	T116	C0044602
breast cancer cells	T025	C1512505
independently	T033	C1299583
effects	T080	C1280500
COX-2	T116	C0387583
NF-κB	T116	C0079904
effects of	T080	C1704420
aspirin	T109	C0004057
AMP-activated protein kinase	T116	C2350345
AMPK	T116	C2350345
activation	T045	C0599177
mTORC1	T116	C2975459
inhibition	T043	C1519312
autophagy	T043	C0004391
oncogenic	T028	C0029016
PIK3CA	T116	C0044602
mouse	T015	C0025929
mammary tumors	T191	C1458155
treated	T169	C1522326
aspirin	T109	C0004057
decreased	T081	C0205216
tumor growth	T191	C0598934
kinetics	T070	C0022702
combination	T080	C0205195
therapy	T061	C0087111
aspirin	T109	C0004057
PI3K	T116	C0044602
inhibitor	T080	C1999216
attenuated	T052	C0599946
tumor growth	T191	C0598934
evaluation	T058	C0220825
aspirin	T109	C0004057
PI3K	T116	C0044602
inhibitors	T121	C1254351
combination	T080	C0205195
therapy	T061	C0087111
targeting	T169	C1521840
breast cancer	T191	C0678222
Prevalence	T081	C0683919
Psychiatric Disorders	T048	C3841734
Female	T032	C0086287
Juvenile Offenders	T098	C0022443
Inmates	T098	C0033167
Juvenile Developmental Centers	T093	C1708333
special	T080	C0205555
group	T098	C1257890
youth	T100	C0087178
population	T098	C1257890
conflict	T055	C0009671
law	T089	C0728724
vulnerable	T169	C0332324
psychiatric illness	T048	C1404970
objective	T170	C0018017
study	T062	C2603343
prevalence	T081	C0683919
type	T080	C0332307
psychiatric disorders	T048	C3841734
institutionalized	T033	C0562359
female	T032	C0086287
juvenile offenders	T098	C0022443
non-offenders	T098	C1257890
same	T080	C0445247
age	T032	C0001779
sex	T032	C1522384
socioeconomic group	T080	C0086996
community	T096	C0009462
association	T041	C0004083
mental disorders	T048	C0004936
examined	T033	C0332128
female	T032	C0086287
inmates	T098	C0033167
Juvenile Development Centers	T093	C1708333
randomly	T080	C0439605
selected	T052	C1707391
comparison	T052	C1707455
subjects	T096	C0681850
community	T096	C0009462
One stage-structured assessment	T058	C1254363
psychopathology	T091	C0033927
structured	T169	C1300196
valid	T080	C2349099
Bangla	T171	C0023008
version	T170	C0333052
Development and Well-Being Assessment	T058	C1254363
DAWBA	T058	C1254363
Development and Well-Being Assessment	T058	C1254363
psychiatric	T169	C0205487
diagnosis	T033	C0011900
ICD-10	T170	C1137110
diagnostic criteria	T170	C0679228
research	T062	C0035168
result	T033	C0683954
revealed	T080	C0443289
conflict	T055	C0009671
law	T089	C0728724
mental disorder	T048	C0004936
non-offenders	T098	C1257890
psychiatric disorder	T048	C3841734
offenders	T098	C0699726
psychiatric disorders	T048	C3841734
Major Depressive Disorder	T048	C1269683
MDD	T048	C1269683
combined	T080	C0205195
MDD	T048	C1269683
Post Traumatic Stress Disorder	T048	C0038436
PTSD	T048	C0038436
non-offenders	T098	C1257890
psychiatric disorder	T048	C3841734
MDD	T048	C1269683
concluded	T078	C1707478
considerable	T080	C4288581
psychiatric disorders	T048	C3841734
prevalent	T081	C0683919
female	T032	C0086287
juvenile offenders	T098	C0022443
comparison	T052	C1707455
non-offenders	T098	C1257890
Broad	T082	C0332464
replication study	UnknownType	C0681825
confirm	T080	C1456348
findings	T033	C0243095
Association	T080	C0439849
neutrophil	T025	C0027950
lymphocyte	T025	C0024264
ratio	T081	C0456603
differentiated thyroid cancer	T191	C1337013
meta-analysis	T062	C0920317
association	T080	C0439849
neutrophil	T025	C0027950
lymphocyte	T025	C0024264
ratio	T081	C0456603
NLR	T081	C0456603
differentiated thyroid cancer	T191	C1337013
DTC	T191	C1337013
conducted	T169	C0884358
systematic	T169	C0220922
meta-analysis	T062	C0920317
prospective cohort studies	T062	C0033522
published	T170	C1704324
patients	T101	C0030705
cohorts	T098	C0599755
pretreatment	T052	C3539076
baseline	T081	C1442488
NLR	T081	C0456603
data	T078	C1511726
patients	T101	C0030705
thyroid nodules	T191	C0040137
meta-analysis	T062	C0920317
cohorts	T098	C0599755
NLR	T081	C0456603
patients	T101	C0030705
DTC	T191	C1337013
cases	T077	C1706256
statistically	T081	C0237881
patients	T101	C0030705
benign nodules	T191	C0749467
cases	T077	C1706256
CI	T081	C0009667
P	T081	C1709380
NLR	T081	C0456603
patients	T101	C0030705
DTC	T191	C1337013
patients	T101	C0030705
benign nodules	T191	C0749467
studies	T059	C0947630
association	T080	C0439849
NLR	T081	C0456603
papillary thyroid carcinoma	T191	C0238463
patients	T101	C0030705
stratified	T080	C0205363
age	T032	C0001779
years	T079	C1510829
cases	T077	C1706256
CI	T081	C0009667
P	T081	C1709380
elevated	T080	C3163633
NLR	T081	C0456603
reliable	T170	C3858758
indicator	T169	C1522602
progressing	T169	C0205329
DTC	T191	C1337013
patients	T101	C0030705
goiters	T046	C0018021
NLR	T081	C0456603
patients	T101	C0030705
aged	T032	C0001779
years	T079	C1510829
aged	T032	C0001779
years	T079	C1510829
investigations	T058	C0220825
NLR	T081	C0456603
prognosis	T033	C0011900
DTC	T191	C1337013
Transcriptomic	T086	C3178810
allelopathic	T070	C3658358
effects of	T080	C1704420
garlic	T168	C0993630
allelochemical	T103	C0220806
diallyl disulfide	T109	C0057693
tomato	T168	C0242772
roots	T002	C0242726
Garlic	T168	C0993630
allelopathic	T070	C3658358
crop	T002	C0242775
continuous	T078	C0549178
cropping	T090	C4042899
vegetable crops	T002	C0242775
Diallyl disulfide	T109	C0057693
DADS	T109	C0057693
allelochemicals	T103	C0220806
garlic	T168	C0993630
promotes	T052	C0033414
tomato	T168	C0242772
root growth	T040	C1524120
global	T080	C2348867
transcriptome	T086	C3178810
profiles	T081	C1956267
DADS	T109	C0057693
treated	T169	C1522326
tomato	T168	C0242772
roots	T002	C0242726
investigated	T169	C1292732
potential	T080	C3245505
growth-promoting mechanisms	UnknownType	C0682777
detected	T033	C0442726
differentially expressed	T045	C0017262
genes	T028	C0017337
DEGs	T028	C0017337
DEGs	T028	C0017337
assimilatory sulfate reduction	T044	C2612332
glutathione metabolism	T044	C1158188
up-regulated	T044	C0041904
short-term	T079	C0443303
DADS	T109	C0057693
treatment	T169	C1522326
increased activity of defensive enzymes	T033	C3267013
up-regulation	T044	C0041904
peroxidase genes	T028	C0017337
observed	T169	C1441672
DADS	T109	C0057693
induce	T169	C0205263
tomato	T168	C0242772
resistance	T169	C4281815
plant-pathogen interactions	T040	C1752856
DEGs	T028	C0017337
calcium signaling	T043	C0600431
inhibited	T080	C0311403
encoding	T052	C2700640
pathogenesis-related proteins	T116	C0070140
up-regulated	T044	C0041904
plant	T002	C0032098
hormone synthesis	T044	C0596715
signal transduction	T043	C0037083
significantly affected	T169	C0392760
DADS	T109	C0057693
expression	T045	C0017262
trends	T079	C1521798
genes	T028	C0017337
pathways	T044	C1704259
research	T062	C0035168
comprehensive	T080	C1880156
information	T078	C1533716
changes	T169	C0392747
tomato	T168	C0242772
root	T002	C0242726
transcriptome	T086	C3178810
affected	T169	C0392760
DADS	T109	C0057693
studies	T062	C2603343
DADS	T109	C0057693
responsive	T169	C0205342
genes	T028	C0017337
enhance	T052	C2349975
current	T079	C0521116
mechanisms	T044	C0678659
DADS	T109	C0057693
continuous	T078	C0549178
cropping	T090	C4042899
Mitotic	T080	C1513354
phosphotyrosine	T116	C0070948
network analysis	T170	C0868995
tyrosine phosphorylation	T044	C1519726
Polo-like kinase 1	T116	C0290178
PLK1	T116	C0290178
Tyrosine phosphorylation	T044	C1519726
associated with	T080	C0332281
cell proliferation	T043	C0596290
cell cycle	T043	C0007586
serine and threonine phosphorylation	T044	C1519253
phosphorylation	T044	C0031715
dynamic	T169	C0729333
mitotic phase	T043	C3893712
cell cycle	T043	C0007586
mitotic	T080	C1513354
phosphotyrosine	T116	C0070948
functionally	T169	C0542341
relevant	T080	C2347946
mitotic	T080	C1513354
phosphotyrosine	T116	C0070948
sites	T082	C0205145
characterized	T052	C1880022
modification	T169	C0392747
prevalent	T081	C0220900
examined	T033	C0332128
tyrosine phosphorylation	T044	C1519726
mitotic human cells	T025	C0230518
spindle-associated proteins	T116	C0033684
Database mining	T066	C1328866
mitotic	T080	C1513354
phosphotyrosine	T116	C0070948
sites	T082	C0205145
network analysis	T170	C0868995
tyrosine-phosphorylated proteins	T116	C0033684
kinetochore	T026	C0242609
spindle	T026	C1166795
SRC family kinases	T116	C0282625
Polo-like kinase 1	T116	C0290178
PLK1	T116	C0290178
signaling	T038	C3537152
spindle	T026	C1166795
subnetwork	T169	C1882071
phosphorylated	T116	C1519061
Tyr(217)	T116	C0041485
kinase domain	T087	C1519724
Substitution	T045	C0525038
Tyr(217)	T116	C0041485
phosphomimetic residue	T104	C1254350
PLK1	T116	C0290178
activity	T044	C1537044
in vitro	T080	C1533691
cells	T025	C0007634
analysis	T062	C0936012
Tyr(217)	T116	C0041485
phosphorylation	T044	C0031715
phosphorylation of Thr(210)	T044	C1158892
activation loop	T082	C0445022
phosphorylation	T044	C0031715
PLK1	T116	C0290178
activity	T044	C1537044
mitotic	T080	C1513354
tyrosine phosphorylation	T044	C1519726
serine/threonine kinase	T116	C0072402
mitotic cells	T025	C0230518
tyrosine phosphorylation	T044	C1519726
unrecognized	T080	C4288068
regulatory events	T169	C1514829
complexes	T080	C0439855
structures	T026	C0243092
cell cycle	T043	C0007586
Divided	T169	C0332849
Sliding	T169	C0332246
Superficial Temporal Artery	T023	C0226130
Flap	T023	C0038925
Primary	T080	C0205225
Donor-site	T029	C1444716
Closure	T061	C0185003
Superficial temporal artery	T023	C0226130
STA	T023	C0226130
flaps	T023	C0038925
reconstruction	T061	C0524865
hair-bearing areas	T029	C0005898
primary closure	T061	C0441503
donor site	T029	C1444716
size	T082	C0456389
skin island	T022	C1123023
large	T081	C0549177
skin grafts	T023	C0040748
donor site	T029	C1444716
baldness	T047	C0002170
divided	T169	C0332849
sliding	T169	C0332246
flap	T023	C0038925
technique	T169	C0449851
primary donor-site closure	T061	C0441503
latissimus dorsi musculocutaneous	T023	C0224362
flap	T023	C0038925
technique	T169	C0449851
hair-bearing STA	T023	C0226130
flap	T023	C0038925
primary donor-site closure	T061	C0441503
preventing	T080	C2700409
baldness	T047	C0002170
skin grafting	T061	C0037297
STA	T023	C0226130
flap	T023	C0038925
divided	T169	C0332849
creation	T052	C1706214
flap	T023	C0038925
divided	T169	C0332849
sliding	T169	C0332246
STA	T023	C0226130
flap	T023	C0038925
donor-site	T029	C1444716
problem	T033	C0033213
investigation	T058	C0220825
validate	T062	C1519941
maximum	T081	C0806909
possible	T033	C0332149
flap	T023	C0038925
size	T082	C0456389
technique	T169	C0449851
small	T081	C0700321
defects	T169	C0243067
skin cancer	T191	C0007114
ablation	T061	C0547070
trauma	T037	C3714660
Influence	T077	C4054723
Surface Properties	T070	C0038884
Adhesion Forces	T067	C0441722
Attachment	T052	C1947904
Streptococcus mutans	T007	C0038409
Zirconia	T121	C0078814
In Vitro	T080	C1533691
Zirconia	T121	C0078814
prevalent material	T167	C0520510
dentistry	T091	C0011438
foreign bodies	T037	C0016542
inserted	T058	C0441587
bacteria	T007	C0004611
oral cavity	T030	C0226896
effect	T080	C1280500
surface properties	T070	C0038884
surface roughness	T033	C4313424
hydrophobicity	T080	C0598629
adhesion	T070	C0175633
biofilm formation	T043	C1325881
Streptococcus mutans	T007	C0038409
S. mutans	T007	C0038409
zirconia	T121	C0078814
Atomic force microscopy	T059	C0242849
zirconia	T121	C0078814
surface	T082	C0205148
morphology	T080	C0332437
adhesion forces	T067	C0441722
S. mutans	T007	C0038409
zirconia	T121	C0078814
results	T169	C1274040
surface roughness	T033	C4313424
nanoscale	T081	C0392762
different	T080	C1705242
tested groups	T078	C0441833
Coarse	T080	C0205194
Medium	T081	C0439536
Fine	T080	C0205232
contact angles	T082	C0205143
Coarse group	T078	C0441833
Medium	T081	C0439536
Fine groups	T078	C0441833
surface roughness	T033	C4313424
hydrophobicity	T080	C0598629
adhesion forces	T067	C0441722
attachment	T052	C1947904
S. mutans	T007	C0038409
zirconia	T121	C0078814
influence	T077	C4054723
development	T169	C1527148
biofilm	T007	C0081786
surface roughness	T033	C4313424
nanoscale	T081	C0392762
hydrophobicity	T080	C0598629
zirconia	T121	C0078814
influence	T077	C4054723
S. mutans	T007	C0038409
adhesion force	T067	C0441722
attachment	T052	C1947904
biofilm formation	T043	C1325881
thiamine	T109	C0039840
symbioses	T070	C0039029
Root nodule	T002	C1720942
symbiosis	T070	C0039029
arbuscular mycorrhiza	T004	C1138420
Lotus japonicus	T002	C1940771
THIC	T028	C0017337
expressed	T045	C0017262
organs	T002	C0032098
encoded protein	T116	C0033684
catalyzes	T070	C0007382
thiamine biosynthesis	T044	C1157735
Loss of function	T033	C0243095
chlorosis	T047	C0008272
thiamine	T109	C0039840
phenotype	T032	C0031437
mortality	T081	C0205848
thiamine's	T109	C0039840
symbiosis	T070	C0039029
THI1	T028	C0017337
thiamine-biosynthesis gene	T028	C0017337
expressed	T045	C0017262
roots	T002	C0242726
nodules	T002	C1720942
seeds	T002	C0036563
thi1 mutant	T028	C0678941
green leaves	T002	C0242724
small	T081	C0700321
nodules	T002	C1720942
immature	T080	C0205252
seeds	T002	C0036563
phenotypes	T032	C0031437
THI1	T028	C0017337
complementation	T045	C0178654
exogenous	T169	C0205228
thiamine	T109	C0039840
THI1	T028	C0017337
nodule	T002	C1720942
enlargement	T169	C0542341
seed maturation	T039	C2265562
colonization	T033	C4289767
arbuscular mycorrhiza	T004	C1138420
AM	T004	C1138420
fungus	T004	C0016832
Rhizophagus irregularis	T004	C2664655
thi1 mutant	T028	C0678941
exogenous	T169	C0205228
thiamine	T109	C0039840
spores	T004	C0038029
R. irregularis	T004	C2664655
thiamine	T109	C0039840
host plants	UnknownType	C0868970
thiamine biosynthesis genes	T028	C0017337
thiamine	T109	C0039840
progeny	T099	C0680063
phenotypes	T032	C0031437
spore formation	T043	C1159442
hyphal growth	T043	C1156247
thiamine's	T109	C0039840
AM	T004	C1138420
Bilateral	T082	C0238767
sternal	T023	C0038293
infusion	T061	C0574032
ropivacaine	T109	C0073571
length of stay	T079	C0023303
ICU	T073	C0021708
cardiac surgery	T061	C0018821
increased	T081	C0205217
respiratory risk	UnknownType	C0548981
randomised controlled trial	T062	C0206035
bilateral	T082	C0238767
infusion	T061	C0574032
local anaesthetic	T109	C0002934
solution	T122	C0525069
sternotomy	T061	C0185792
wound	T037	C0043250
bilateral	T082	C0238767
sternal	T023	C0038293
technique	T169	C0449851
reducing	T080	C0392756
pain	T184	C0030193
sternotomy	T061	C0185792
effects	T080	C1280500
technique	T169	C0449851
intensive care	T058	C0085559
cardiac patients	T101	C0741926
increased	T081	C0205217
risk	T078	C0035647
respiratory complications	T046	C0161818
Randomised, observer-blind controlled trial	T062	C0206035
French University Hospital	T073	C0020028
adults	T100	C0001675
open-heart surgery	T061	C0189745
age	T032	C0001779
years	T079	C0439234
BMI	T201	C1305855
chronic obstructive pulmonary disease	T047	C0024117
active smoking habit	T169	C1266863
bilateral	T082	C0238767
sternal	T023	C0038293
infusion	T061	C0574032
ropivacaine	T109	C0073571
catheter	T074	C0085590
'intervention' group	T098	C2986530
standardised care	T052	C1947933
'control' group	T096	C0009932
Analgesia	T061	C3202977
paracetamol	T109	C0000970
self-administered	T169	C1519231
intravenous	T169	C1522726
morphine	T109	C0026549
length of time	T079	C1254367
readiness	T033	C1318963
discharge	T058	C0030685
ICU	T073	C0021708
assessed	T052	C1516048
committee	T096	C2699414
experts	T097	C0009817
No effect	T080	C1301751
groups	T078	C0441833
primary outcome	T080	C3274433
intention to treat	T062	C2718028
median values	T080	C0042295
control	T096	C0009932
intervention groups	T098	C2986530
postoperative	T033	C0241311
delays	T079	C0205421
effects	T080	C1280500
intervention	T061	C0184661
dynamic pain	T184	C0030193
patient satisfaction	T080	C0030702
occurrence of nausea	T184	C2219665
vomiting	T184	C0042963
occurrence	T079	C2745955
delirium	T048	C0011206
mental confusion	T048	C0009676
occurrence	T079	C2745955
pulmonary complications	T046	C0281169
patients	T101	C0030705
symptoms	T184	C1457887
neurological symptoms	T184	C0235031
healthy volunteers	T098	C1708335
small size effect	T081	C0814843
analgesic effects	T033	C0948482
time	T079	C0040223
ICU	T073	C0021708
EudraCT	T077	C4289562
ClinicalTrials.gov	T170	C4086204
Pupil Sizes	T201	C0517965
Scale	T170	C0349674
Attentional Load	T170	C0589051
Task	T057	C3540678
Experience	T041	C0596545
Multiple	T081	C0439064
Object	T072	C0347997
Tracking	T082	C0546881
Task	T057	C3540678
changes	T169	C0392747
attentional load	T170	C0589051
pupil size	T201	C0517965
modulations	T082	C0443264
changes	T169	C0392747
attentional load	T170	C0589051
task	T057	C3540678
experience	T041	C0596545
scale	T170	C0349674
pupil size	T201	C0517965
modulations	T082	C0443264
investigated	T169	C1292732
changes	T169	C0392747
affect	T041	C0001721
pupil sizes	T201	C0517965
manipulate	T053	C0018578
attentional load	T170	C0589051
participants	T098	C0679646
tracked	T082	C0546881
zero	T081	C0919414
five	T081	C0205451
objects	T072	C0347997
randomly	T080	C0439605
objects	T072	C0347997
computer	T073	C0009622
screen	T073	C1705053
investigate	T169	C1292732
effects of	T080	C1704420
task	T057	C3540678
experience	T041	C0596545
three	T081	C0205449
consecutive	T080	C1707491
days	T079	C0439228
pupil sizes	T201	C0517965
increment	T081	C1705117
attentional load	T170	C0589051
days	T079	C0439228
systematic	T169	C0220922
pupil size	T201	C0517965
reductions	T080	C0392756
model fit	T080	C0870608
pupil size	T201	C0517965
modulations	T082	C0443264
attentional load	T170	C0589051
task	T057	C3540678
experience	T041	C0596545
task performance	T061	C0039333
predictors	T078	C2698872
model	T170	C3161035
attentional load	T170	C0589051
task	T057	C3540678
experience	T041	C0596545
predictors	T078	C2698872
model fit	T080	C0870608
performance	T061	C0039333
predictor	T078	C2698872
model	T170	C3161035
model fit	T080	C0870608
results	T169	C1274040
pupillometry	T060	C0260180
viable	T080	C0443348
metric	T081	C0025867
attentional load	T170	C0589051
task	T057	C3540678
experience	T041	C0596545
visuospatial	T041	C0814069
tasks	T057	C3540678
Evolutionary	T038	C0282688
History	T169	C0019665
ADP-Ribosylation	T067	C0596043
DNA	T114	C0012854
Targeting	T169	C1521840
Toxin	T123	C0040549
Antitoxin	T121	C0003445
Module DarTG	T077	C1709061
Molecular Cell	T091	C1513407
DarTG	T077	C1709061
toxin	T123	C0040549
antitoxin	T121	C0003445
module	T077	C1709061
DarT	T116	C0014442
toxin	T123	C0040549
ADP-ribosylates	T067	C0596043
single-stranded DNA	T114	C0012935
DarG	T116	C0033684
antitoxin	T121	C0003445
counteracts	T169	C0443286
DarT	T116	C0014442
binding	T044	C1167622
enzymatic	T116	C0014442
remova	T052	C1883720
ADP-ribosylation	T067	C0596043
Growth differentiation factor 15	T116	C0668195
myomitokine	T123	C0574031
governing systemic energy homeostasis	T039	C3157768
Reduced	T080	C0392756
mitochondrial electron transport chain	T026	C1325653
activity	T052	C0441655
promotes	T052	C0033414
longevity	T079	C0023980
improves	T033	C0184511
energy homeostasis	T038	C3157043
cell-autonomous	T043	C0007613
non-autonomous factors	T043	C0007613
multiple model systems	T075	C0026339
mitohormetic	T040	C3178757
effect	T080	C1280500
mitochondrial unfolded protein response	T044	C2612628
UPR(mt)	T044	C2612628
adaptive stress-response	T039	C0149784
pathway	T077	C1705987
activated	T052	C1879547
mitochondrial	T026	C0026237
proteotoxic stress	T046	C0449430
mice	T015	C0025929
skeletal muscle-specific	T024	C0242692
deficiency	T169	C0011155
Crif1	T116	C2352141
muscle-specific	T024	C0026845
knockout	T015	C0206745
MKO	T015	C0206745
integral protein	T116	C0033684
large mitoribosomal subunit	T026	C1166894
39S	T026	C2611782
growth differentiation factor 15	T116	C0668195
GDF15	T116	C0668195
UPR(mt)	T044	C2612628
cell-non-autonomous	T043	C0007613
myomitokine	T123	C0574031
regulates systemic energy homeostasis	T039	C3157768
MKO mice	T015	C0206745
protected	T033	C1545588
obesity	T047	C0028754
sensitized	T040	C1325847
insulin	T116	C0021641
associated with	T080	C0332281
elevated	T080	C3163633
GDF15	T116	C0668195
secretion	T043	C1159339
UPR(mt)	T044	C2612628
activation	T052	C1879547
ob/ob mice	T015	C0206745
recombinant	T116	C0034861
GDF15	T116	C0668195
decreased	T081	C0205216
body weight	T032	C0005910
improved	T033	C0184511
insulin sensitivity	T046	C0920563
elevated	T080	C3163633
oxidative metabolism	T043	C0282636
lipid mobilization	T042	C0023773
liver	T023	C0023884
muscle	T024	C0026845
adipose tissue	T024	C0001527
GDF15	T116	C0668195
potent	T080	C3245505
mitohormetic	T040	C3178757
signal	T038	C3537152
onset of obesity	T033	C0243095
insulin resistance	T046	C0021655
Synthesis	T052	C1883254
characterization	T052	C1880022
acetylated amylose	T109	C0002732
development	T169	C1527148
inclusion complexes	T104	C1254350
rifampicin	T109	C0035608
Amylose	T109	C0002732
AM	T109	C0002732
inclusion complexes	T104	C1254350
agents	T120	C0450442
complexes	T104	C1704241
considered	T078	C0750591
biomaterial	T122	C0005479
guest molecules	T167	C0567416
released	T169	C0391871
later	T079	C0205087
applications	T169	C0205245
pharmaceutical industry	T093	C0013185
Rifampicin	T109	C0035608
RIF	T109	C0035608
active	T169	C0205177
drug	T121	C1254351
Mycobacterium tuberculosis	T007	C0026926
administration	T061	C1533734
RIF	T109	C0035608
dosages	T081	C0178602
side-effects	T169	C0001688
native	T169	C0302891
amylose	T109	C0002732
AM	T109	C0002732
formation	T169	C1522492
complexes	T104	C1704241
water solubility	T081	C0597682
degree	T081	C0449286
substitution	T052	C1706204
DS	T052	C1706204
solubilizing	T080	C0037628
acetylated amylose	T109	C0002732
AMA	T109	C0002732
water	T121	C0043047
neutral pH	T080	C1882074
observed	T169	C1441672
native	T169	C0302891
amylose	T109	C0002732
trace	T081	C0442822
solubility	T080	C0037628
acetylated amylose	T109	C0002732
characterized	T052	C1880022
Fourier Transform Infrared (FT-IR) spectroscopy	T062	C0206055
Scanning Electron Microscopy	T059	C0026020
SEM	T059	C0026020
FT-IR	T062	C0206055
results	T169	C1274040
indicated	T033	C1444656
acetylation	T044	C0001038
anhydroglucose	T109	C0017725
units	T081	C0439148
amylose	T109	C0002732
low	T080	C0205251
DS	T052	C1706204
SEM	T059	C0026020
results	T169	C1274040
smooth surfaces	T082	C0205148
amylose	T109	C0002732
granules	T167	C3853628
changed	T169	C0392747
surfaces	T082	C0205148
acetylation	T044	C0001038
Ultraviolet absorption spectroscopy	T059	C0260250
UV-vis	T059	C0260250
analysis	T062	C0936012
confirmed	T080	C0521093
formation	T169	C1522492
quantification	T081	C1709793
native	T169	C0302891
AM	T109	C0002732
RIF	T109	C0035608
AMA	T109	C0002732
RIF	T109	C0035608
amylose	T109	C0002732
inclusion complexes	T104	C1254350
characterization	T052	C1880022
solution	T167	C0037633
performed	T169	C0884358
dynamic light scattering	T059	C1882368
DLS	T059	C1882368
zeta potential	T067	C0597697
ZP	T067	C0597697
measurements	T169	C0242485
average size	T082	C0456389
inclusion complexes	T104	C1254350
determined by	T080	C0521095
DLS	T059	C1882368
ranged	T081	C1514721
ZP	T067	C0597697
analysis	T062	C0936012
complexes	T104	C1704241
stable	T080	C0205360
presence	T033	C0150312
RIF	T109	C0035608
development	T169	C1527148
effective	T080	C1704419
preparation	T052	C1521827
amylose	T109	C0002732
inclusion complexes	T104	C1254350
further	T082	C1517331
application	T169	C0205245
drug delivery systems	T074	C0085104
Selective	T052	C1707391
reaching	T040	C2584321
macaques	T015	C0024398
evidence	T078	C3887511
action	T052	C3266814
attention	T041	C0004268
monkey	T015	C0026447
selects	T052	C1707391
food	T168	C0016452
other	T080	C0205394
viable	T080	C0443348
objects	T072	C0347997
near	T080	C1706276
vicinity	T082	C0205146
desired	T041	C0871633
item	T168	C0016452
governs	T080	C0243148
pattern	T082	C0449774
direction	T082	C0449738
animal's	T008	C0003062
reaching	T040	C2584321
action	T052	C3266814
selection	T052	C1707391
important	T080	C3898777
component	T078	C1552020
controlling	T169	C2587213
animal's	T008	C0003062
action	T052	C3266814
selection	T052	C1707391
process	T067	C1522240
cases	T169	C0868928
presence	T080	C3854307
other	T080	C0205394
objects	T072	C0347997
constitute	T169	C1522492
potential	T080	C3245505
obstacles	T072	C0347997
constraints	T169	C0443288
movement	T040	C0026649
execution	T052	C1705848
pervious	T169	C0205326
other	T080	C0205394
objects	T072	C0347997
direct	T080	C1947931
influence	T077	C4054723
organization	T039	C0029237
response	T032	C0871261
kinematics	T091	C0600169
macaques	T015	C0024398
reaching	T040	C2584321
movements	T040	C0026649
examined	T033	C0332128
current	T079	C0521116
study	T062	C2603343
analysed	T062	C0936012
selectively	T052	C1707391
reached	T040	C2584321
grasp	T040	C0220843
food item	T168	C0016452
absence	T169	C0332197
presence	T080	C3854307
potential	T080	C3245505
obstacles	T072	C0347997
stones	T072	C0347997
affect	T041	C0001721
arm	T029	C0446516
trajectory	T082	C0449738
Changes	T169	C0392747
movement	T040	C0026649
parameterization	UnknownType	C0681933
noted	T080	C4288581
temporal	T079	C2362314
measures	T081	C0079809
movement	T040	C0026649
time	T079	C0040223
spatial ones	T082	C1254362
trajectory	T082	C0449738
presence	T080	C3854307
stones	T072	C0347997
vicinity	T082	C0205146
acting	T055	C0001241
hand	T023	C0018563
stalled	T052	C1947925
reaching	T040	C2584321
movement	T040	C0026649
affected	T041	C0001721
arm	T029	C0446516
trajectory	T082	C0449738
hand	T023	C0018563
veered away	T033	C1277225
stone	T072	C0347997
not	T169	C1518422
physical	T169	C0205485
obstacle	T072	C0347997
nearby	T080	C1706276
objects	T072	C0347997
motor response	T201	C1285623
macaques	T015	C0024398
attentional	T041	C0004268
mechanisms	T169	C0441712
successful	T080	C1272703
action	T052	C3266814
selection	T052	C1707391
revealed	T080	C0443289
reaching	T040	C2584321
path	T082	C0449738
data	T078	C1511726
human	T016	C0086418
studies	T062	C2603343
indicating	T078	C0392360
potential	T080	C3245505
obstacles	T072	C0347997
internally	T082	C0205102
represented	T052	C1882932
finding	T033	C0243095
basic	T169	C1527178
cognitive	T169	C1516691
operations	T052	C3241922
action	T052	C3266814
selection	T052	C1707391
macaques	T015	C0024398
novel	T080	C0205314
method	T170	C0025663
interactive	T169	C1704675
multi-objective	T080	C1571702
dose-guided patient positioning	T058	C1561964
intensity-modulated radiation therapy	T061	C1512814
IMRT	T061	C1512814
imaging	T060	C0011923
data	T078	C1511726
accurate	T080	C0443131
patient alignment	UnknownType	C0548501
anatomical landmarks	T029	C0504075
anatomical changes	T169	C0392747
patient position	T033	C0449850
dose	T081	C0178602
patient alignment	UnknownType	C0548501
imaging	T060	C0011923
data	T078	C1511726
dose	T081	C0178602
calculation	T052	C1441506
finding	T033	C0243095
optimal	T080	C2698651
dose	T081	C0178602
distribution	T169	C1704711
dose	T081	C0178602
patient alignment	UnknownType	C0548501
clinical	T080	C0205210
objectives	T170	C0018017
multi-objective	T080	C1571702
dose	T081	C0178602
distributions	T169	C1704711
patient shifts	T058	C0086388
dose	T081	C0178602
interpolation	T062	C3494285
Pareto-efficient patient shifts	T058	C0086388
interactive	T169	C1704675
dose	T081	C0178602
Dose	T081	C0178602
interpolation	T062	C3494285
accuracy	T080	C0443131
multi-objective	T080	C1571702
dose-guided positioning	T058	C1561964
head and neck	T191	C0278996
H&N	T191	C0278996
prostate cancer	T191	C0600139
patients	T101	C0030705
Dose-guided positioning	T058	C1561964
compared	T052	C1707455
CT	T060	C0040405
imaging	T060	C0011923
data	T078	C1511726
Dose	T081	C0178602
interpolation	T062	C3494285
accuracy	T080	C0443131
high	T080	C0205250
dose	T081	C0178602
H&N	T191	C0278996
prostate cases	T191	C0600139
comparison	T052	C1707455
dose	T081	C0178602
calculations	T052	C1441506
patients	T101	C0030705
dose-guided positioning	T058	C1561964
dose	T081	C0178602
distribution	T169	C1704711
compared	T052	C1707455
bony anatomy based alignment	T081	C1706765
H&N	T191	C0278996
dose	T081	C0178602
parotid glands	T023	C0030580
bony alignment	T081	C1706765
clinical target volume	T081	C0454198
CTV	T081	C0454198
compared	T052	C1707455
prostate	T191	C0600139
patients	T101	C0030705
CTV	T081	C0454198
compared	T052	C1707455
compared	T052	C1707455
H&N	T191	C0278996
prostate cases	T191	C0600139
dose-guided positioning	T058	C1561964
Clinical	T033	C2985631
radiological	T060	C0043299
outcome	T169	C1274040
pneumothorax	T047	C0032326
endoscopic lung volume reduction	T061	C0375931
valves	T074	C0042296
Valve	T074	C0042296
implantation	T061	C0021107
therapy	T061	C0087111
patients	T101	C0030705
advanced	T080	C0205179
emphysema	T047	C0034067
minimally invasive treatmen	T061	C0282624
associated with	T080	C0332281
complications	T046	C0009566
common	T081	C0205214
pneumothorax	T047	C0032326
Pneumothorax	T047	C0032326
rapid	T080	C0456962
target	T169	C1521840
lobe	T023	C0225752
volume reduction	T061	C0524689
predictor	T078	C2698872
clinical	T080	C0205210
benefit	T081	C0814225
complication	T046	C0009566
objective	T170	C0018017
study	T062	C2603343
exploratory data analysis	T080	C3899452
patients	T101	C0030705
pneumothorax	T047	C0032326
endoscopic valve therapy	T061	C0087111
emphysema	T047	C0034067
study	T062	C2603343
performed	T169	C0884358
retrospective evaluation	T062	C0035363
pneumothorax	T047	C0032326
management	T058	C0376636
impact	T080	C4049986
pneumothorax	T047	C0032326
clinical outcomes	T033	C2985631
patients	T101	C0030705
valve therapy	T061	C0087111
consecutive	T080	C1707491
patients	T101	C0030705
Pneumothorax	T047	C0032326
rate	T081	C0026538
valve therapy	T061	C0087111
Pneumothorax	T047	C0032326
management	T058	C0376636
chest tube insertion	T061	C0189476
valve	T074	C0042296
removal	T061	C0015252
surgical intervention	T033	C0549433
patients	T101	C0030705
pneumothorax	T047	C0032326
patients	T101	C0030705
modest	T080	C0205081
significant	T078	C0750502
improvements	T077	C2986411
lung function	T042	C0231921
parameters	T077	C0549193
forced expiratory volume	T042	C0016529
residual volume	T201	C0035190
total lung capacity	T033	C0040509
Persistent	T079	C0205322
lobar atelectasis	T046	C0004144
recovering	T077	C1709864
pneumothorax	T047	C0032326
associated with	T080	C0332281
relevant	T080	C2347946
clinical	T080	C0205210
improvement	T077	C2986411
observed	T169	C1441672
patients	T101	C0030705
Pneumothorax	T047	C0032326
frequent	T079	C0332183
severe	T080	C0205082
complication	T046	C0009566
valve therapy	T061	C0087111
intervention	T061	C0184661
pneumothorax	T047	C0032326
impair	T169	C0221099
clinical status	T080	C0449440
patients	T101	C0030705
Patients	T101	C0030705
lobar atelectasis	T046	C0004144
benefit	T081	C0814225
recovering	T077	C1709864
pneumothorax	T047	C0032326
lung function	T042	C0231921
parameters	T077	C0549193
3Mo	T075	C0026336
Model	T075	C0026336
Music	T170	C0026867
Based	T169	C1527178
Biofeedback	T061	C0005491
domain	T169	C1880389
sports	T056	C0038039
motor	T038	C0234130
rehabilitation	T169	C0034992
major	T080	C0205164
importance	T080	C3898777
regulate	T038	C1327622
control	T169	C2587213
physiological processes	T039	C0031845
physical motion	T070	C0026597
most	T081	C0205393
optimal	T080	C2698651
purpose	T169	C1285529
real-time	T079	C1550177
auditory feedback	T041	C0596134
physiological	T169	C0205463
physical	T169	C0205485
information	T078	C1533716
based	T169	C1527178
sound signals	T070	C0037709
sonification	T169	C0449851
proven	T080	C0456369
useful	T080	C3827682
use	T169	C0457083
music	T170	C0026867
biofeedback	T061	C0005491
systems	T169	C0449913
less	T081	C0439092
explored	T061	C1280903
current	T079	C0521116
article	T170	C1706852
use	T169	C0457083
music	T170	C0026867
musical	T170	C0026867
principles	T078	C0178566
major	T080	C0205164
value	T170	C1554112
mere	T080	C0547040
sound signals	T070	C0037709
benefit	T081	C0814225
psychological	T169	C0205486
physical	T169	C0205485
optimization	T052	C2698650
sports	T056	C0038039
motor	T038	C0234130
rehabilitation	T169	C0034992
tasks	T057	C3540678
article	T170	C1706852
present	T078	C0449450
3Mo model	T075	C0026336
main	T080	C1542147
functions	T169	C0542341
music	T170	C0026867
contribute	T052	C1880177
benefits	T081	C0814225
functions	T169	C0542341
power	T078	C0808080
music	T170	C0026867
Motivate	T041	C0026605
Monitor	T058	C1283169
Modify	T169	C0392747
physiological	T169	C0205463
physical	T169	C0205485
processes	T067	C1522240
model	T075	C0026336
concepts	T078	C0178566
theories	T078	C0871935
human	T016	C0086418
sensorimotor interaction	T040	C0237434
music	T170	C0026867
specifies	T080	C1521902
psychological	T169	C0205486
physiological	T169	C0205463
principles	T078	C0178566
3Mo model	T075	C0026336
intended	T080	C1283828
provide	T052	C1999230
conceptual framework	T077	C1254372
guides	T170	C0681464
future	T079	C0016884
research	T062	C0035168
musical	T170	C0026867
biofeedback	T061	C0005491
systems	T169	C0449913
domain	T169	C1880389
sports	T056	C0038039
motor	T038	C0234130
rehabilitation	T169	C0034992
Analysis	T059	C0002778
tilianin	T109	C0966451
acacetin	T109	C0100994
Agastache rugosa	T002	C1008095
high-performance liquid chromatography	T059	C0008562
ionic liquids	T103	C1720867
ultrasound	T169	C0220934
extraction	T059	C0684295
Ionic liquid	T103	C1720867
1-butyl-3-methylimidazolium bromide	T109	C1956443
methanol	T109	C0001963
ultrasonic	T169	C0220934
extraction	T059	C0684295
ILUAE	T059	C0684295
extract	T059	C0684295
tilianin	T109	C0966451
acacetin	T109	C0100994
aerial parts	T002	C1136056
Agastache rugose	T002	C1008095
A. rugose	T002	C1008095
reversed phase high performance liquid chromatographic	T059	C2717789
RP-HPLC	T059	C2717789
ultraviolet detection	T170	C0449335
RP-HPLC-UV)	T170	C0449335
InertSustain RP-C18 column	T075	C1705246
mobile phase	T130	C3469601
methanol	T109	C0001963
acetic acid	T109	C0000983
gradient	T081	C0812409
elution	T059	C1441565
detection wavelength	T081	C0449819
flow rate	T081	C2826285
column	T075	C1705246
temperature	T081	C0039476
optimized	T052	C2698650
conditions	T080	C0348080
tilianin	T109	C0966451
acacetin	T109	C0100994
method	T169	C0449851
ILUAE	T059	C0684295
traditional methods	T169	C0449851
higher	T080	C0205250
efficiency	T081	C0013682
higher	T080	C0205250
reproducibility	T080	C1514863
environmental friendly	T082	C0014406
active	T169	C0205177
compounds	T103	C1706082
traditional Chinese medicines	T091	C0025124
TCMs	T091	C0025124
Evaluation	T058	C0220825
MIF -173 G/C	T028	C1334507
Polymorphism	T045	C0678951
Turkish	T098	C0549217
Patients	T101	C0030705
Ankylosing Spondylitis	T047	C0038013
Ankylosing spondylitis	T047	C0038013
AS	T047	C0038013
chronic inflammatory disease	T047	C1290886
spine	T023	C0037949
sacroiliac joints	T030	C0036036
Macrophage migration inhibitory (MIF) factor	T116	C0024429
regulatory	T077	C1704735
cytokine	T116	C0079189
inhibits	T052	C3463820
immune cell migration	T043	C1326500
MIF gene	T028	C1334507
promoter	T028	C0314621
polymorphisms	T045	C0678951
progression	T046	C0242656
inflammatory disorders	T047	C1290884
investigate	T169	C1292732
MIF gene -173 G/C	T028	C1334507
single-nucleotide polymorphism	T086	C0752046
SNP	T086	C0752046
AS	T047	C0038013
Cross-sectional study	T062	C0010362
study	T062	C2603343
AS	T047	C0038013
normal	T080	C3898900
controls	T096	C0009932
MIF gene -173 G/C	T028	C1334507
SNP	T086	C0752046
analyzed	T062	C0936012
polymerase chain reaction	T063	C0032520
restriction fragment length polymorphism method	T059	C3714764
significant	T078	C0750502
groups	T098	C1257890
genotype	T032	C0017431
wild-type	T028	C1883559
G/G	T032	C0017431
G/C+C/C genotypes	T032	C0017431
clinical characteristics	T201	C0683325
significant	T078	C0750502
age	T032	C0001779
duration of disease	T079	C0872146
AS	T047	C0038013
patients	T101	C0030705
significant	T078	C0750502
AS	T047	C0038013
disease	T047	C0012634
MIF -173 G/C	T028	C1334507
polymorphism	T045	C0678951
MIF -173 G/C	T028	C1334507
polymorphism	T045	C0678951
C allele	T028	C0002085
duration of disease	T079	C0872146
AS	T047	C0038013
patients	T101	C0030705
Global	T080	C2348867
Cerebral Edema	T046	C0006114
Aneurysmal Subarachnoid Hemorrhage	T046	C0751530
clinical	T080	C0205210
literature	T170	C0023866
cerebral edema	T046	C0006114
early brain injury	T037	C0270611
aneurysmal subarachnoid hemorrhage	T046	C0751530
aSAH	T046	C0751530
Aneurysm rupture	T047	C0162869
global	T080	C2348867
cerebral edema	T046	C0006114
cerebral edema	T046	C0006114
aSAH	T046	C0751530
clinical course	T079	C0449259
quantitative analysis	T081	C0034384
cerebral edema	T046	C0006114
poor outcome	T033	C3806166
global	T080	C2348867
cerebral edema	T046	C0006114
global	T080	C2348867
ischemia	T046	C0022116
aneurysm rupture	T047	C0162869
dysfunction	T077	C3887504
autoregulation	T038	C0019868
blood breakdown	T043	C2937287
products	T071	C1514468
neuroinflammation	T046	C1408627
hyponatremia	T047	C0020625
endocrine abnormalities	T190	C4025823
molecular	T080	C1521991
level	T080	C0441889
aquaporin-4	T116	C0292777
matrix metalloproteinase-9	T116	C0165519
SUR1	T116	C3711621
TRPM4 cation channels	T116	C1384655
vascular endothelial growth factor	T116	C1171892
bradykinin	T116	C0006100
cellular	T025	C0007634
molecular	T080	C1521991
global	T080	C2348867
cerebral edema	T046	C0006114
aSAH	T046	C0751530
edema	T184	C0013604
patients	T101	C0030705
aSAH	T046	C0751530
status	T080	C0449438
pathological process	T046	C0030660
cerebral edema	T046	C0006114
aSAH	T046	C0751530
medical therapies	T061	C0418981
devastating	T169	C0332663
disease	T047	C0012634
Biliary	T023	C0005423
Phospholipids	T109	C0031676
Sustain	T169	C0443318
Enterocyte	T025	C0682610
Proliferation	T043	C0596290
Intestinal Tumor	T191	C0021841
Progression	T191	C0178874
Nuclear Receptor	T116	C0206588
Lrh1	T116	C1448055
mice	T015	C0025929
crypt compartment	T023	C3686613
intestinal epithelium	T024	C0226890
phospholipids	T109	C0031676
accumulation	T033	C4055506
phospholipids	T109	C0031676
colorectal tumors	T191	C0009404
biliary	T023	C0005423
phospholipid	T109	C0031676
flow	T070	C0806140
proliferative power	T169	C1514485
normal	T025	C0682610
dysplastic enterocytes	T025	C1512101
Abcb4	T028	C1412071
mice	T015	C0025929
biliary	T023	C0005423
phospholipid	T109	C0031676
secretion	T038	C0036536
Abcb4	T028	C1412071
mice	T015	C0025929
protected	T033	C1545588
intestinal	T023	C0021853
tumorigenesis	T191	C0007621
molecular	T080	C1521991
level	T080	C0441889
transcriptional activity	T045	C1148759
nuclear receptor	T116	C0206588
Liver Receptor Homolog-1	T116	C1448055
Lrh1	T116	C1448055
reduced	T080	C0392756
Abcb4	T028	C1412071
mice	T015	C0025929
re-activation	T052	C4086768
tumor	T191	C0027651
burden	T078	C2828008
control	T096	C0009932
mice	T015	C0025929
Feeding	T052	C2987508
Abcb4	T028	C1412071
mice	T015	C0025929
diet supplemented	T168	C0242295
phospholipids	T109	C0031676
overcomes	T052	C2983310
intestinal tumor	T191	C0021841
phenotype	T032	C0031437
absence	T169	C0332197
biliary	T023	C0005423
phospholipids	T109	C0031676
Abcb4 gene	T028	C1412071
protection	T033	C1545588
phospholipids	T109	C0031676
intestinal	T023	C0021853
tumorigenesis	T191	C0007621
Abcb4	T028	C1412071
mice	T015	C0025929
mice	T015	C0025929
intestinal	T023	C0021853
specific	T080	C0205369
ablation	T061	C0547070
Lrh1	T116	C1448055
nuclear hormone receptor	T116	C0887829
activates	T052	C1879547
phospholipids	T109	C0031676
data	T078	C1511726
biliary	T023	C0005423
phospholipids	T109	C0031676
intestinal mucosa	T024	C0021839
proliferation	T169	C1514485
tumor progression	T191	C0178874
activation	T052	C1879547
nuclear receptor	T116	C0206588
Lrh1	T116	C1448055
Metalloproteinase	T116	C0025543
meprin α	T116	C1622778
migration	T043	C1622501
invasion	T033	C1269955
human	T016	C0086418
hepatocarcinoma	T191	C2239176
cells	T025	C0334227
oncoprotein	T116	C0029005
Reptin	T116	C1120857
Hepatocellular carcinoma	T191	C2239176
associated with	T080	C0332281
high	T080	C0205250
rate	T081	C1521828
intra-hepatic	T029	C0205054
invasion	T033	C1269955
poor prognosis	T033	C0278252
Meprin alpha	T116	C1622778
Mep1A	T116	C1622778
secreted	T043	C1327616
metalloproteinase	T116	C0025543
cancer invasion	T033	C1269955
Mep1A	T116	C1622778
target	T169	C1521840
Reptin	T116	C1120857
protein that is oncogenic	T116	C0029005
HCC	T191	C2239176
Mep1A	T116	C1622778
regulation	T038	C1327622
Reptin	T116	C1120857
HCC	T191	C2239176
Reptin	T116	C1120857
oncogenic	T131	C0007090
effects	T080	C1280500
MepA	T116	C1622778
Reptin	T116	C1120857
expression	T045	C1171362
human	T016	C0086418
HCC	T191	C2239176
qRT-PCR	T063	C1514628
cultured cells	T025	C0007635
PCR	T063	C0032520
western blot	T059	C0949466
enzymatic activity measurements	T062	C0681902
Cell growth	T043	C0007595
assessed	T052	C1516048
counting	T059	C0007584
MTS assay	T062	C2986858
Cell migration	T043	C1622501
Boyden chambers	T074	C3874231
wound healing	T040	C0043240
assays	T059	C0005507
cell invasion	T033	C1269955
Boyden chambers	T074	C3874231
Silencing	T045	C0598496
Reptin	T028	C1419774
decreased	T081	C0205216
Mep1A	T116	C1622778
expression	T045	C1171362
activity	T052	C0441655
meprin β	T116	C1451346
Mep1A	T116	C1622778
meprin β	T116	C1451346
overexpressed	T045	C1514559
human	T016	C0086418
HCC	T191	C2239176
high	T080	C0205250
expression	T045	C1171362
correlated	T080	C1707520
poor prognosis	T033	C0278252
Mep1A	T116	C1622778
Reptin	T116	C1120857
expressions	T045	C1171362
correlated	T080	C1707520
Silencing	T045	C0598496
Mep1A	T028	C1417113
cell proliferation	T043	C0596290
decreased	T081	C0205216
cell migration	T043	C1622501
invasion	T033	C1269955
HuH7	T025	C0007601
Hep3B cells	T025	C0007601
overexpression	T045	C1514559
Mep1A	T116	C1622778
recombinant	T001	C1514798
Mep1A	T116	C1622778
increased	T081	C0205217
migration	T043	C1622501
invasion	T033	C1269955
overexpression	T045	C1514559
Mep1A	T116	C1622778
normal	T080	C0205307
cell migration	T043	C1622501
cells	T025	C0334227
Reptin	T116	C1120857
depleted	T169	C0333668
Mep1A	T116	C1622778
overexpressed	T045	C1514559
HCC	T191	C2239176
induces	T169	C0205263
HCC	T191	C2239176
cell migration	T043	C1622501
invasion	T033	C1269955
Mep1A	T116	C1622778
expression	T045	C1171362
Reptin	T116	C1120857
Mep1A	T116	C1622778
Reptin	T116	C1120857
induced	T169	C0205263
migration	T043	C1622501
Mep1A	T116	C1622778
target	T169	C1521840
HCC	T191	C2239176
Psychosocial impact	T080	C0033963
families	T099	C0015576
infant	T100	C0021270
hypoplastic left heart syndrome	T047	C0152101
during and after the interstage monitoring period	T079	C1254367
prospective mixed-method study	T062	C0033522
parents' experiences	T041	C0596545
coping ability	T055	C0009967
quality of life	T078	C0034380
monitoring	T058	C0030695
sick child	T101	C0260101
hypoplastic left heart syndrome	T047	C0152101
home	T082	C0442519
Interstage home monitoring	T058	C0030695
children	T100	C0008059
hypoplastic left heart syndrome	T047	C0152101
mortality	T081	C0008083
Norwood stages I and II	T061	C2242650
psychosocial impact	T080	C0033963
interstage home monitoring	T058	C0030695
Prospective mixed-method study	T062	C0033522
psychosocial impact	T080	C0033963
parents	T099	C0030551
interstage home monitoring	T058	C0030695
quantitative assessment	T081	C0034384
Short Form Health Survey questionnaire	T170	C1714475
Family Scale administered	T033	C0243095
discharge	T058	C0030685
before and after stage II	T079	C1254367
qualitative assessment	T080	C0034375
semi-structured interviews	UnknownType	C0681913
postdischarge	T033	C1320368
coping strategies	T061	C0474179
after hospital discharge	T033	C1320368
before and after stage II	T079	C1254367
infants	T100	C0021270
males	T032	C0086582
hypoplastic left heart syndrome	T047	C0152101
univentricular heart malformations	T019	C0018798
parents	T099	C0030551
mother/father	T099	C0030551
parent	T099	C0030551
households	T099	C0020052
single mother	T099	C0337491
no interstage deaths	T033	C0243095
Mental Health	T041	C0025353
Composite Summary scores	T081	C4055211
parents	T099	C0030551
mothers	T099	C0026591
fathers	T099	C0015671
vitality	T033	C0424589
mothers	T099	C0026591
fathers	T099	C0015671
before and after stage II	T079	C1254367
Family Scale values	T033	C0243095
social burdens	T078	C2828008
mothers	T099	C0026591
coping strategy	T061	C0474179
fragile emotional balance	T048	C0233459
parents	T099	C0030551
interstage home monitoring	T058	C0030695
protective intervention	T061	C0184661
psychosocial burden	T080	C0033963
before and after stage II	T079	C1254367
family	T099	C0015576
parents	T099	C0030551
parenthood	T054	C0337469
Healthcare professionals	T097	C0018724
parents	T099	C0030551
vulnerable interstage period	T079	C1254367
psychosocial	T169	C0542298
nursing support	T061	C0028678
Rates	T081	C1521828
predictors	T078	C2698872
injury	T037	C0178314
population	T081	C0032659
based	T169	C1527178
cohort	T098	C0599755
people	T098	C0027361
living	T078	C0376558
HIV	T047	C0019693
Injuries	T037	C0178314
global	T080	C2348867
burden	T078	C2828008
disease	T047	C0012634
epidemiology	T169	C0014508
injury	T037	C0178314
people living with HIV	T047	C0019693
PLHIV	T047	C0019693
not been well	T033	C3841798
elucidated	T052	C2986669
study	T062	C2603343
characterize	T052	C1880022
rates	T081	C1521828
predictors	T078	C2698872
injury	T037	C0178314
PLHIV	T047	C0019693
compared	T052	C1707455
general population	T098	C0683971
British Columbia	T083	C0006193
BC	T083	C0006193
Canada	T083	C0006823
population	T081	C0032659
based	T169	C1527178
dataset	T170	C0150098
created	T080	C1707531
linkage	T062	C0242239
between	T082	C0205103
BC Centre for Excellence in HIV/AIDS	T093	C1708333
PopulationDataBC	T078	C1511726
PLHIV	T047	C0019693
aged	T032	C0001779
20 years	T079	C0439234
older	T079	C0580836
compared	T052	C1707455
random	T080	C0439605
sample	T167	C0370003
adult	T100	C0001675
general population	T098	C0683971
International	T078	C1512888
Classification	T185	C0008902
Diseases	T047	C0012634
used	T169	C1524063
classify	T185	C0008902
unintentional	T037	C0151736
intentional injuries	T037	C0151737
based	T169	C1527178
external cause	T033	C1407879
injury	T037	C0178314
Generalized estimating equation	T081	C0026348
GEE	T081	C0026348
Poisson regression models	T081	C0023962
estimate	T081	C0750572
effect	T080	C1280500
HIV	T047	C0019693
status	T080	C0449438
rates	T081	C1521828
unintentional	T037	C0151736
intentional injury	T037	C0151737
identify	T080	C0205396
correlates	T080	C1707520
injury	T037	C0178314
PLHIV	T047	C0019693
incidence rate	T081	C1708485
unintentional injury	T037	C0151736
person	T098	C0027361
years	T079	C0439234
confidence interval	T081	C0009667
CI	T081	C0009667
PLHIV	T047	C0019693
person	T098	C0027361
years	T079	C0439234
CI	T081	C0009667
general population	T098	C0683971
PLHIV	T047	C0019693
deaths	T033	C1306577
due to	T169	C0678226
injury	T037	C0178314
compared	T052	C1707455
deaths	T033	C1306577
general population	T098	C0683971
models	T081	C0026348
PLHIV	T047	C0019693
report	T058	C0700287
unintentional	T037	C0151736
incidence rate	T081	C1708485
ratio	T081	C0456603
CI	T081	C0009667
intentional injury	T037	C0151737
incidence rate	T081	C1708485
ratio	T081	C0456603
CI	T081	C0009667
compared	T052	C1707455
general population	T098	C0683971
identified	T080	C0205396
elevated	T080	C3163633
rates	T081	C1521828
intentional	T037	C0151737
unintentional injury	T037	C0151736
PLHIV	T047	C0019693
Injuries	T037	C0178314
largely	T081	C0549177
preventable	T170	C1547273
targeted	T169	C1521840
needed	T080	C0027552
decrease	T081	C0547047
burden	T078	C2828008
injury	T037	C0178314
related	T080	C0439849
disability	T033	C0231170
death	T033	C1306577
PLHIV	T047	C0019693
TREK-1 (K2P2.1) K(+) channels	T116	C0754471
suppressed	T169	C1260953
patients	T101	C0030705
atrial fibrillation	T047	C0004238
heart failure	T047	C0018801
provide	T052	C1999230
therapeutic targets	T169	C0302350
rhythm control	T080	C0243148
Atrial fibrillation	T047	C0004238
AF	T047	C0004238
cardiac arrhythmia	T033	C0003811
Concomitant heart failure	T047	C0018801
HF	T047	C0018801
therapeutic	T169	C0302350
challenge	T059	C1315011
prolonged	T079	C0439590
atrial electrical refractoriness	T040	C0034954
non-failing hearts	T023	C0018787
downregulation	T044	C0013081
atrial repolarizing	T042	C1371280
TREK-1 (K2P2.1) K(+) channels	T116	C0754471
contributes	T052	C1880177
electrical remodeling	T046	C3658220
AF	T047	C0004238
HF	T047	C0018801
TREK-1 gene transfer	T063	C1517499
rhythm control	T080	C0243148
normalization	T062	C1882115
atrial effective refractory periods	T033	C0428938
AF	T047	C0004238
subset	T062	C2986480
patients	T101	C0030705
chronic AF	T047	C0694539
HF	T047	C0018801
atrial TREK-1	T116	C0754471
mRNA	T114	C0035696
levels	T080	C0441889
left atrium	T023	C0225860
right atrium	T023	C0225844
sinus rhythm	T033	C0232201
SR	T033	C0232201
subjects	T098	C0080105
Human	T016	C0086418
findings	T033	C0243095
porcine model	T075	C0026336
atrial tachypacing-induced AF	T047	C0004238
reduced	T080	C0392756
left ventricular function	T042	C0080310
TREK-1	T116	C0754471
mRNA	T114	C0035696
protein	T116	C0754471
suppressed	T169	C1260953
AF	T047	C0004238
animals	T008	C0003062
compared	T052	C1707455
SR	T033	C0232201
Downregulation	T044	C0013081
repolarizing	T042	C1371280
TREK-1 channels	T116	C0754471
prolongation	T079	C0439590
atrial effective refractory periods	T033	C0428938
baseline	T081	C1442488
consistent with	T078	C0332290
prior	T079	C0332152
observations	T062	C0302523
humans	T016	C0086418
HF	T047	C0018801
preclinical	T080	C1709630
therapeutic approach	T169	C0302350
pigs	T015	C0039005
randomized	T062	C0034656
atrial Ad-TREK-1 gene therapy	T061	C0017296
sham treatment	T061	C0032042
Gene transfer	T063	C1517499
effectively	T080	C1280519
increased	T081	C0205217
TREK-1 protein	T116	C0754471
levels	T080	C0441889
attenuated	T052	C0599946
atrial effective refractory period	T033	C0428938
prolongation	T079	C0439590
porcine AF model	T075	C0026336
Ad-TREK-1	T116	C0754471
SR	T033	C0232201
prevalence	T081	C0033105
AF	T047	C0004238
animals	T008	C0003062
compared	T052	C1707455
AF	T047	C0004238
conclusion	T078	C1707478
TREK-1	T116	C0754471
downregulation	T044	C0013081
rhythm control	T080	C0243148
Ad-TREK-1 transfer	T063	C1517499
suggest	T078	C1705535
mechanistic and potential therapeutic	T061	C0087111
significance	T078	C0750502
TREK-1 channels	T116	C0754471
subgroup	T185	C1515021
AF	T047	C0004238
patients	T101	C0030705
HF	T047	C0018801
prolonged	T079	C0439590
atrial effective refractory periods	T033	C0428938
Functional correction	T169	C0205245
TREK-1 gene therapy	T061	C0017296
novel	T080	C0205314
paradigm	T062	C0681797
AF	T047	C0004238
Rasch Rating Scale	T062	C0871207
Analysis	T062	C0936012
Presence	T033	C0150312
Nursing	T091	C0028677
Scale	T081	C0681889
RN	T097	C0687673
phenomenon	T067	C1882365
nursing	T091	C0028677
presence	T033	C0150312
emotional	T033	C0849912
connection	T082	C0449379
nurse	T097	C0028661
patient	T101	C0030705
technical skills	T169	C0449851
performed	T169	C0884358
nurse	T097	C0028661
Presence	T033	C0150312
Nursing	T091	C0028677
Scale	T081	C0681889
RN	T097	C0687673
version	T170	C0333052
PONS	T081	C0681889
RN	T097	C0687673
developed	T169	C1527148
measure	T081	C0079809
nurses'	T097	C0028661
perceptions	T041	C0030971
ability	T032	C0085732
present	T033	C0150312
patients	T101	C0030705
study	T062	C2603343
summarizes	T170	C1706244
process	T067	C1522240
re-evaluation	T062	C0681840
psychometric properties	T060	C0033920
PONS	T081	C0681889
RN	T097	C0687673
sample	T098	C1257890
registered nurses	T097	C0687673
providing	T052	C1999230
direct	T080	C1947931
patient care	T058	C0017313
responded	T041	C2911692
item	T071	C1551338
questionnaire	T170	C0034394
Rasch rating scale model	T062	C0871207
assessing	T058	C0184514
construct validity	T080	C0681897
PONS	T081	C0681889
RN	T097	C0687673
data	T078	C1511726
principal component analysis	T081	C0429865
PCA	T081	C0429865
residuals	T080	C1609982
supported	T077	C1521721
appropriateness	T080	C0814634
subscales	T081	C0459443
2-dimensional	T082	C1705052
structure	T082	C0678594
results	T033	C0683954
item	T071	C1551338
person	T098	C0027361
fit	T052	C2349186
analysis	T062	C0936012
rating scale	T081	C0681889
functioning	T169	C0205245
analysis	T062	C0936012
reliability analysis	UnknownType	C0814892
demonstrated	T080	C0443289
item	T071	C1551338
Presence	T033	C0150312
Nursing	T091	C0028677
Scale	T081	C0681889
RN	T097	C0687673
measures	T081	C0079809
high	T080	C0205250
validity and reliability	UnknownType	C0814892
sub-scales	T081	C0459443
rn	T097	C0687673
Elastin	T116	C0013765
Differentially Regulated	T045	C2755857
Pressure Therapy	T061	C1956078
Porcine	T015	C3665571
Model	T008	C0599779
Hypertrophic Scar	T020	C0162810
Beneficial effects	T080	C1280500
pressure therapy	T061	C1956078
hypertrophic scars	T020	C0162810
mechanisms	T169	C0441712
study	T062	C2603343
elastin	T116	C0013765
scar	T020	C0162810
pliability	T080	C0242808
relationship	T080	C0439849
Vancouver Scar Scale	T170	C0349674
VSS	T170	C0349674
scores	T081	C0449820
pressure-treated	T061	C1956078
scars	T020	C0162810
elastin	T116	C0013765
Hypertrophic scars	T020	C0162810
weekly	T079	C0332174
VSS	T170	C0349674
biopsy	T060	C0005558
procurement	T033	C0243095
Pressure treatment	T061	C1956078
day	T079	C0439228
postinjury	T079	C1254367
Treated	T061	C0087111
scars	T020	C0162810
compared	T052	C1707455
shams	T061	C0032042
Treatment	T061	C0087111
weeks	T079	C0439230
day	T079	C0439228
scars	T020	C0162810
weekly	T079	C0332174
day	T079	C0439228
Transcript	T114	C1519595
protein levels	T034	C0428479
elastin	T116	C0013765
quantified	T081	C1709793
Pressure treatment	T061	C1956078
VSS	T170	C0349674
scores	T081	C0449820
compared	T052	C1707455
sham-treated	T061	C0032042
scars	T020	C0162810
Pliability	T080	C0242808
VSSP	T080	C0242808
day	T079	C0439228
pretreatment	T052	C3539076
VSSP	T080	C0242808
Without treatment	T061	C0032042
sham-treated	T061	C0032042
scars	T020	C0162810
pliable	T080	C0242808
pressure-treated	T061	C1956078
scars	T020	C0162810
pliable	T080	C0242808
elastin	T116	C0013765
scars	T020	C0162810
day	T079	C0439228
uninjured skin	T022	C1123023
treatment	T061	C0087111
elastin	T116	C0013765
increased	T081	C0205217
increase	T169	C0442805
day	T079	C0439228
sham	T061	C0032042
scars	T020	C0162810
increase	T169	C0442805
Quantification	T081	C1709793
Verhoeff-Van Gieson staining	T059	C1294321
findings	T033	C0243095
immunofluorescence	T059	C0079603
alignment	T081	C1706765
elastin fibers	T116	C0013765
Pressure treatment	T061	C1956078
increased	T081	C0205217
protein level expression	T045	C1171362
elastin	T116	C0013765
compared	T052	C1707455
sham	T061	C0032042
scars	T020	C0162810
findings	T033	C0243095
extracellular matrix's	T024	C0015350
pressure	T067	C0033095
scar	T020	C0162810
treatment	T061	C0087111
rehabilitation	T169	C0034992
improvements	T077	C2986411
functional	T169	C0205245
psychosocial	T169	C0542298
outcomes	T169	C1274040
patients	T101	C0030705
Epigenome-wide analysis	T063	C2350277
SMAD3	T028	C0919432
methylation	T044	C0376452
birth	T040	C0005615
asthma in children	T047	C0264408
asthmatic	T047	C0004096
mothers	T099	C0026591
mechanisms	T169	C0441712
asthma	T047	C0004096
inception	T169	C1522492
epigenetic	T045	C1516924
mechanisms	T169	C0441712
asthma	T047	C0004096
pathogenesis	T046	C0699748
asthma	T047	C0004096
inception	T169	C1522492
assess	T058	C0184514
asthma	T047	C0004096
birth	T040	C0005615
epigenetic	T045	C1516924
mechanisms	T169	C0441712
DNA methylation	T044	C0376452
asthma	T047	C0004096
inception	T169	C1522492
Methylated CpG Island Recovery Assay chip	T059	C1328856
survey	T170	C0038951
DNA methylation	T044	C0376452
cord blood	T031	C0162371
mononuclear cells	T025	C0806987
children	T100	C0008059
nonasthmatic	T098	C0080105
asthmatic	T047	C0004096
subjects	T098	C0080105
age	T032	C0001779
years	T079	C0439234
Infant	T100	C0021270
Immune	T169	C0439662
Study	T062	C2603343
IIS	T062	C2603343
birth	T040	C0005615
cohort	T098	C0599755
asthma	T047	C0004096
SMAD3	T028	C0919432
methylation	T044	C0376452
IIS	T062	C2603343
replication	T045	C0598312
cohorts	T098	C0599755
Manchester	UnknownType	C0681784
Asthma	T047	C0004096
Allergy Study	T059	C0945823
Childhood Origins of Asthma	T047	C0264408
Study	T062	C2603343
analyzed	T062	C0936012
bisulfite sequencing	T063	C3831347
Illumina 450K arrays	T059	C0022885
Cord blood	T031	C0162371
mononuclear cell	T025	C0806987
IL-1β	T116	C1702300
levels	T080	C0441889
measured	T080	C0444706
ELISA	T059	C0014441
Neonatal	T100	C0021289
immune	T169	C0439662
cells	T025	C0007634
methylated regions	T086	C0004793
IIS	T062	C2603343
children	T098	C1257890
asthma	T047	C0004096
age	T032	C0001779
years	T079	C0439234
cohorts	T098	C0599755
methylation	T044	C0376452
SMAD3	T028	C0919432
asthma	T047	C0004096
associated	T080	C0332281
methylated regions	T086	C0004793
increased	T081	C0205217
asthmatic	T047	C0264408
children	T100	C0008059
asthmatic	T047	C0004096
mothers	T099	C0026591
associated with	T080	C0332281
childhood asthma	T047	C0264408
risk	T078	C0035647
SMAD3	T028	C0919432
methylation	T044	C0376452
IIS	T062	C2603343
neonates	T100	C0021289
maternal	T099	C0026591
asthma	T047	C0004096
associated with	T080	C0332281
neonatal	T100	C0021289
IL-1β	T116	C1702300
innate inflammatory mediator	T121	C0243042
childhood asthma	T047	C0264408
birth	T040	C0005615
epigenetic	T045	C1516924
modifications	T169	C0392747
immunoregulatory	T040	C0678889
proinflammatory	T169	C0333348
pathways	T044	C1704259
Maternal	T099	C0026591
asthma	T047	C0004096
epigenetic	T045	C1516924
mechanisms	T169	C0441712
inception	T169	C1522492
Clinical	T080	C0205210
correlates	T080	C1707520
faecal incontinence	T047	C0015732
systemic sclerosis	T047	C0036421
therapeutic avenues	UnknownType	C0679624
prevalence	T081	C0683921
severity	T080	C0392364
faecal incontinence	T047	C0015732
FI	T047	C0015732
SSc	T047	C0036421
association	T080	C0439849
intestinal	T023	C0021853
manifestations	T169	C0205319
potential	T080	C3245505
predictors	T078	C2698872
FI	T047	C0015732
impact	T080	C4049986
quality of life	T078	C0034380
cross-sectional study	T062	C0010362
SSc	T047	C0036421
subjects	T101	C0030705
Canadian Scleroderma Research Group	T093	C1708333
cohort	T098	C0599755
questionnaires	T170	C0034394
Jorge-Wexner score	T170	C0349674
FI	T047	C0015732
severity scale	T170	C0681887
Bristol stool scale	T170	C4084861
stool consistency	T033	C0426740
FI	T047	C0015732
Quality-of-Life scale	T170	C0451401
Constipation	T184	C0009806
Rome III criteria	T170	C0679228
Associations	T080	C0439849
Jorge-Wexner score	T170	C0349674
clinical variables	T033	C1836458
multivariate regression analyses	T170	C0034980
subjects	T101	C0030705
FI	T047	C0015732
mild	T080	C2945599
moderate to severe	T080	C1299393
patients	T101	C0030705
stools	T031	C0015733
constipation	T184	C0009806
previously	T079	C0205156
treated	T169	C1522326
small intestinal bacterial overgrowth	T047	C3160854
SIBO	T047	C3160854
Variables	T080	C0439828
independently	T078	C0085862
associated with	T080	C0332281
FI	T047	C0015732
loose	T184	C2129214
stools	T031	C0015733
odds ratio	T081	C0028873
OR	T081	C0028873
CI	T081	C0009667
constipation	T184	C0009806
OR	T081	C0028873
CI	T081	C0009667
P	T081	C1709380
history	T033	C0683519
SIBO	T047	C3160854
OR	T081	C0028873
CI	T081	C0009667
urinary incontinence	T046	C0042024
OR	T081	C0028873
CI	T081	C0009667
Quality of life	T078	C0034380
measured	T080	C0444706
FI	T047	C0015732
Quality-of-Life scale	T170	C0451401
inversely	T080	C0439850
correlated	T080	C1707520
FI	T047	C0015732
severity	T080	C0521117
correlation	T080	C1707520
coefficients	T081	C1707429
P	T081	C1709380
FI	T047	C0015732
common	T081	C0205214
severe	T080	C0205082
SSc	T047	C0036421
Loose stools	T184	C2129214
SIBO	T047	C3160854
constipation	T184	C0009806
urinary incontinence	T046	C0042024
strongly	T080	C0442821
associated with	T080	C0332281
FI	T047	C0015732
targeting	T169	C1521840
anorectal	T030	C3870603
dysfunction	T046	C0277785
concomitant	T079	C0521115
treatment	T061	C0087111
clinical	T080	C0205210
correlates	T080	C1707520
improvement	T077	C2986411
FI	T047	C0015732
quality of life	T078	C0034380
SSc	T047	C0036421
training	T065	C0220931
practice	T057	C0033284
impact	T080	C4049986
ENGAGE	T093	C1708333
Ireland's	T083	C0022067
national men's health training programme	T065	C0040607
Ireland's	T083	C0022067
National Men's Health Policy	T170	C0027458
recommended	T078	C0034866
training programmes	T065	C0040607
tailored	T058	C2986593
needs	T080	C0027552
working	T057	C0043227
health	T097	C1704312
allied health professionals	T097	C0002122
ENGAGE	T093	C1708333
recommendation	T078	C0034866
study	T062	C2603343
evaluated	T058	C0220825
impact	T080	C4049986
ENGAGE	T093	C1708333
frontline service providers'	T058	C0679886
self-reported knowledge	T033	C1948177
skills	T055	C0678856
capacity	T081	C1516240
practice	T057	C0033284
post	T079	C0687676
training	T065	C0220931
ENGAGE	T093	C1708333
Trainers	T073	C0453962
training programmes	T065	C0040607
participants	T098	C0679646
study	T062	C2603343
subset	T185	C1515021
training	T065	C0220931
participants	T098	C0679646
Quantitative	T081	C0392762
methodologies	T062	C0038949
post	T079	C0687676
post	T079	C0687676
training	T065	C0220931
questionnaire	T170	C0034394
Overall	T080	C1561607
participants	T098	C0679646
satisfied	T170	C4084799
training	T065	C0220931
immediately	T079	C0205253
post	T079	C0687676
training	T065	C0220931
follow up	T033	C0589120
Participants'	T098	C0679646
self-reported level of knowledge	T033	C1948177
skill	T055	C0678856
capacity	T081	C1516240
priorities	T079	C0439607
men	T098	C0025266
influencing	T077	C4054723
practice	T057	C0033284
organisation	T057	C0029236
increased	T081	C0205217
immediately	T079	C0205253
training	T065	C0220931
exception	T077	C1705847
improving	T080	C1272745
capacity	T081	C1516240
men	T098	C0025266
influencing	T077	C4054723
practice	T057	C0033284
organisation	T057	C0029236
improvements	T057	C2936612
sustained	T169	C0443318
post	T079	C0687676
training	T065	C0220931
majority	T054	C0680220
service providers	T058	C0679886
reported	T058	C0700287
ENGAGE	T093	C1708333
impacted	T080	C4049986
work	T057	C0043227
practice	T057	C0033284
post	T079	C0687676
training	T065	C0220931
findings	T033	C0243095
suggest	T078	C1705535
ENGAGE	T093	C1708333
succeeded	T033	C0243095
improving	T080	C1272745
service providers'	T058	C0679886
capacity	T081	C1516240
work	T057	C0043227
men	T098	C0025266
improving	T080	C1272745
gender	T032	C0079399
competency	T080	C0086035
health	T078	C0018684
health related services	T058	C0018747
increase	T081	C0205217
utilisation	T058	C0042155
services	T058	C0018747
men	T098	C0025266
improve	T033	C0184511
health outcomes	T057	C0085565
men	T098	C0025266
Double strand break	T049	C1511667
induction	T169	C0205263
kinetics	T070	C0022702
hypersensitivity	T046	C0020517
keratinocytes	T025	C0022567
subtherapeutic	T169	C0302350
doses	T081	C0178602
weeks	T079	C0439230
radiotherapy	T061	C1522449
hyper-radiosensitivity	T032	C0034537
HRS	T032	C0034537
quantifying	T081	C1709793
DNA double strand break (DSB) foci	T026	C3159064
epidermis	T024	C0014520
biopsies	T060	C0005558
radiotherapeutic	T170	C0034619
dose fractions	T081	C0178602
aim	T078	C1947946
study	T062	C2603343
HRS	T032	C0034537
week	T079	C0439230
radiotherapy	T061	C1522449
treatment	T061	C0087111
foci	T026	C3159064
foci	T026	C3159064
dose fractions	T081	C0178602
patients	T101	C0030705
prostate cancer	T191	C0600139
week	T079	C0439230
radiotherapy treatment	T061	C1522449
RT	T061	C1522449
dose fractions	T081	C0178602
skin	T022	C1123023
RT	T061	C1522449
treatment	T061	C0087111
skin biopsies	T060	C0150866
dose fractions	T081	C0178602
DSB-foci	T026	C3159064
markers	T086	C0012872
γH2AX	T028	C1415406
53BP1	T028	C1420865
epidermal	T024	C0014520
keratinocytes	T025	C0022567
immunofluorescence	T059	C0016318
immunohistochemical staining	T059	C1508788
digital image analysis	T060	C2348290
HRS	T032	C0034537
keratinocytes	T025	C0022567
dose-response relationships	T038	C0678790
DSB foci	T026	C3159064
treatment course	T079	C0454268
independent of	T169	C0332291
sampling	T060	C0441621
time	T079	C0040223
quantification	T081	C1709793
method	T170	C0025663
Foci	T026	C3159064
dose fractions	T081	C0178602
DSB	T049	C1511667
foci	T026	C3159064
dose fractions	T081	C0178602
doses	T081	C0178602
foci	T026	C3159064
damage	T049	C0012860
induction	T169	C0205263
comparison	T052	C1707455
γH2AX	T028	C1415406
53BP1	T028	C1420865
quantifications	T081	C1709793
double-staine	T080	C2986582
biopsies	T060	C0005558
HRS	T032	C0034537
dose-response relationships	T038	C0678790
evidence	T078	C3887511
HRS	T032	C0034537
assessed	T052	C1516048
γH2AX	T028	C1415406
53BP1	T028	C1420865
DSB foci	T026	C3159064
week	T079	C0439230
treatment course	T079	C0454268
daily	T079	C0332173
subtherapeutic	T169	C0302350
dose fractions	T081	C0178602
CT angiography	T060	C1536105
planning	T169	C1301732
transcatheter aortic valve replacement	T061	C3509486
automated tube voltage selection	T081	C0392762
Image quality	T080	C0806487
radiation	T070	C0851346
exposure	T080	C0332157
assess	T058	C0184514
image quality	T080	C0806487
accuracy	T080	C0598285
CT angiography	T060	C1536105
CTA	T060	C1536105
transcatheter aortic valve replacement	T061	C3509486
TAVR	T061	C3509486
planning	T169	C1301732
3rd generation dual-source CT	T060	C0040405
DSCT	T060	C0040405
patients	T101	C0030705
TAVR	T061	C3509486
planning	T169	C1301732
CTA	T060	C1536105
3rd generation DSCT	T060	C0040405
two-part protocol	T061	C0008971
retrospectively	T080	C1514923
ECG-gated coronary CTA	T060	C1634617
CCTA	T060	C1634617
prospectively	T080	C0205556
ECG-triggered aortoiliac CTA	T060	C1536105
contrast medium	T130	C0009924
Automated tube voltage selection	T081	C0392762
advanced iterative reconstruction	T060	C2986769
Effective dose	T081	C4019308
ED	T081	C4019308
signal-to-noise	T081	C2986823
SNR	T081	C2986823
contrast-to-noise ratios	T081	C0392762
CNR	T081	C0392762
Five-point scales	T170	C0282574
subjective	T080	C0439655
image quality analysis	T060	C1297895
patients	T101	C0030705
TAVR	T061	C3509486
sizing parameters	T033	C0449381
Image quality	T080	C0806487
CCTA	T060	C1634617
aortoiliac CTAs	T060	C1536105
CTA	T060	C1536105
studies	T062	C0008972
decreased	T081	C0205216
objective	T080	C1571702
image quality	T080	C0806487
SNR	T081	C2986823
CNR	T081	C0392762
Mean	T081	C0444504
ED	T081	C4019308
increased	T081	C0205217
CCTA	T060	C1634617
aortoiliac CTA	T060	C1536105
patients	T101	C0030705
TAVR	T061	C3509486
annulus	T023	C0225957
diameter	T081	C1301886
patients	T101	C0030705
No	T033	C1513916
severe	T080	C0205082
cardiac	T046	C0161816
vascular complications	T046	C0009566
3rd generation DSCT	T060	C0040405
diagnostic	T169	C0348026
image quality	T080	C0806487
TAVR	T061	C3509486
planning	T169	C1301732
CTA	T060	C1536105
assessment	T058	C0220825
TAVR	T061	C3509486
device	T074	C0025080
delivery	T169	C1705822
reducing	T080	C0392756
radiation dose	T081	C4019308
Giant	T025	C0017526
Aneurysmal Bone Cyst	T047	C0152244
Mandibular Condyle	T023	C0024688
Aneurysmal bone cyst	T047	C0152244
ABC	T047	C0152244
rare	T080	C0522498
rapidly	T080	C0456962
expanding	T082	C0205229
locally	T082	C1517927
destructive	T052	C1948029
easily	T033	C0332219
misdiagnosed	T033	C0679838
lesion	T033	C0221198
ABC	T047	C0152244
condyle	T023	C0024688
rare	T080	C0522498
year	T079	C0439234
old	T079	C0580836
female	T032	C0086287
giant	T025	C0017526
ABC	T047	C0152244
left mandibular condyle	T082	C0205091
mandibular condyle	T023	C0024688
patient	T101	C0030705
treated with	T061	C0332293
surgical resection	T061	C0015252
affected	T169	C0392760
bone	T023	C0262950
mandibular reconstruction	T061	C2242551
autologous	T080	C0439859
bone	T023	C0262950
Follow-up to date	T058	C3694716
signs	T033	C0311392
recurrence	T067	C0034897
clinical	T080	C0205210
feature	T080	C2348519
imaging finding	T034	C1287399
pathogenesis	T046	C0699748
treatment methods	T061	C0087111
ABCs	T047	C0152244
Association	T080	C0439849
postpartum depression	T048	C0221074
practice	T041	C0032893
exclusive breastfeeding	T055	C0242205
months	T079	C0439231
life	T078	C0376558
investigate	T169	C1292732
association	T080	C0439849
postpartum depression	T048	C0221074
occurrence	T079	C2745955
exclusive breastfeeding	T055	C0242205
cross-sectional study	T062	C0010362
states	T083	C1301808
Northeast region	T083	C0017446
vaccination campaign	T058	C4279933
mother	T099	C0026591
child	T100	C0008059
pairs	T080	C1709450
children	T100	C0008059
aged	T032	C0001779
days	T079	C0439228
months	T079	C0439231
Edinburgh Postnatal Depression Scale	T170	C0451144
screen	T058	C0220908
postpartum depression	T048	C0221074
outcome	T169	C1274040
lack	T080	C0332268
exclusive breastfeeding	T055	C0242205
occurrence	T079	C2745955
practice	T078	C1254370
preceding	T079	C0332152
interview	T052	C0021822
Postpartum depression	T048	C0221074
explanatory variable	UnknownType	C0681885
covariates	UnknownType	C0814913
socioeconomic	T102	C0037464
demographic conditions	T078	C0011292
maternal health care	T058	C0024922
prenatal	T058	C0033052
delivery	T061	C0011209
postnatal care	T058	C0032782
child's biological factors	T080	C0205556
Multivariate logistic regression analysis	T081	C0026777
confounding factors	T169	C0009673
Exclusive breastfeeding	T055	C0242205
observed	T169	C1441672
infants	T100	C0021270
women	T098	C0043210
symptoms	T184	C1457887
postpartum depression	T048	C0221074
multivariate logistic regression analysis	T081	C0026777
exclusive breastfeeding	T055	C0242205
absence	T169	C0332197
mothers	T099	C0026591
symptoms	T184	C1457887
postpartum depression	T048	C0221074
younger subjects	T098	C2349001
benefits	T081	C0814225
Bolsa Família Program	UnknownType	C0681136
antenatal care	T058	C0033052
pregnancy	T040	C0032961
Postpartum depression	T048	C0221074
reducing	T080	C0392756
practice	T078	C1254370
exclusive breastfeeding	T055	C0242205
disorder	T047	C0012634
prenatal	T058	C0033052
early postpartum	T079	C0233066
support guidelines	T170	C0282451
breastfeeding	T040	C0006147
low socioeconomic status	T081	C1328812
women	T098	C0043210
Evidence of	T169	C0332120
toothpick	T073	C3273359
groove	T030	C1184482
formation	T169	C1522492
Neandertal	T015	C3178755
anterior	T082	C0205094
posterior	T082	C0205095
teeth	T023	C0040426
microscopic examination	T059	C0026018
Neandertal	T015	C3178755
dentitions	T023	C0011443
El Sidrón	T083	C0017446
Spain	T083	C0037747
Hortus	T083	C0017446
France	T083	C0016674
unusual	T080	C2700116
microstriations	T070	C1254365
mesial	T029	C1708982
distal sides	T082	C0205108
tooth	T023	C0040426
cervix	T029	C0446455
similar	T080	C2348205
toothpick	T073	C3273359
grooves	T030	C1184482
Homo species	T015	C1300203
early stages	T079	C2363430
formation	T169	C1522492
experimental replication	T062	C0237832
groove	T030	C1184482
grass	T002	C0018210
stalks	T002	C2700372
Comparisons	T052	C1707455
isolated	T169	C0205409
Neandertal	T015	C3178755
teeth	T023	C0040426
experimental	T080	C1517586
dental	T080	C0226984
specimens	T167	C0370003
marks	T184	C0037088
initial stages	T079	C2363430
toothpick	T073	C3273359
groove	T030	C1184482
formation	T169	C1522492
five-grade recording scale	T170	C0349674
groove	T030	C1184482
formation process	T169	C1522492
Hortus	T083	C0017446
individuals	T098	C0027361
incidence	T081	C0021149
individuals	T098	C0027361
El Sidrón	T083	C0017446
individuals	T098	C0027361
Toothpick	T073	C3273359
grooves	T030	C1184482
El Sidrón	T083	C0017446
earliest stages	T079	C2363430
development	T169	C1527148
grooves	T030	C1184482
Hortus	T083	C0017446
Neandertals	T015	C3178755
well-developed	T080	C0205556
Toothpick	T073	C3273359
grooves	T030	C1184482
incisors	T023	C0021156
canines	T023	C0010482
differences	T080	C1705242
occlusal	T029	C0447303
dental wear	T037	C2717979
Hortus	T083	C0017446
individuals	T098	C0027361
age	T032	C0001779
meat	T168	C0025017
diet	T168	C0012155
food	T168	C0016452
debris	T167	C0440266
probing	T169	C0449851
cleaning methodology	T052	C1947930
identification	T080	C0205396
characterization	T052	C1880022
incipient	T079	C0205256
toothpick	T073	C3273359
grooves	T030	C1184482
human	T016	C0086418
fossil	T167	C0016614
record	T170	C0034869
contribute	T052	C1880177
increase	T169	C0442805
knowledge	T170	C0376554
Neandertals	T015	C3178755
behavioral	T055	C0018464
oral care habits	T033	C0424439
THSD7A	T116	C2745341
expression	T045	C1171362
human	T016	C0086418
cancer	T191	C0006826
Thrombospondin Type-1 Domain containing 7A	T116	C2745341
THSD7A	T116	C2745341
membranous nephropathy	T047	C4054536
female patient	T032	C0150905
synchronously	T079	C0439580
suffering	T184	C0751408
THSD7A	T116	C2745341
positive	T033	C1514241
malignancy	T080	C0205282
THSD7A	T116	C2745341
tumor antigen	T116	C0041361
tissue spots	T024	C2316370
tumor entities	T033	C1276705
immunohistochemistry	T060	C0021044
tissue microarrays	T075	C1519522
THSD7A	T116	C2745341
expression	T045	C1171362
different neoplasias	T191	C0027651
staining patterns	T082	C0449778
gain and loss	T033	C0243095
THSD7A	T116	C2745341
expression	T045	C1171362
expression status	T045	C1171362
non-tumor tissue	T024	C0040300
tumor-specific markers	T123	C0041365
tumor entities	T033	C1276705
prognostic value	T081	C0449821
THSD7A	T116	C2745341
tumor development	T033	C1850355
therapy	T061	C4087167
Civil Society	UnknownType	C0680324
Drug Policy Reform	UnknownType	C0815220
Health	T078	C0018684
Human Welfare	T095	C0037440
India	T083	C0021201
lack	T080	C0332268
adequate	T080	C0205411
opioids	T109	C0242402
India	T083	C0021201
analgesics	T109	C0002771
agonist	T121	C2987634
therapies	T061	C0087111
severe	T080	C0205082
unalleviated pain	T184	C0030193
languish	T080	C1762617
suffering	T048	C0683278
drug dependence	T048	C1510472
India	T083	C0021201
opium	T109	C0029112
exporter	T097	C0402574
prohibitive	T054	C0683610
narcotics law	T089	C0027413
control	T080	C0243148
harmful use of drugs	T048	C0013146
availability	T169	C0470187
access	T082	C0444454
opioids	T109	C0242402
medical	UnknownType	C0678312
scientific	T062	C0683933
purposes	T169	C1285529
Amendment	T170	C0680532
law	T170	C1947938
national regulatory framework	T089	C0220868
access	T082	C0444454
essential	T080	C0205224
opioid analgesics	T109	C0002772
achievement	T053	C0001072
policy reforms	UnknownType	C0815220
law enforcement	T064	C0162469
drug policy	UnknownType	C0683727
mitigate	T067	C1553901
human suffering,	T048	C0683278
multilayered complexities	T033	C0037431
policy framework	T170	C0242456
adverse	T080	C0205169
impact	UnknownType	C0814716
reform	T064	C0206597
civil society movement	T054	C0680411
health care professionals	T097	C1704312
lawyers	T097	C0086530
media	T097	C4054555
policy analysts	T097	C0870132
government officials	T097	C0242304
public	T098	C0034035
challenges	T058	C0805586
reform	UnknownType	C0680438
success	T054	C0597535
access	T080	C0018748
opioid	T109	C0242402
medications	T058	C0150270
executive arm of the government	T097	C0335161
interim	T079	C2827738
measures	T170	C0033107
judicial intervention	T064	C0178362
public	T098	C0034035
interest	T098	C0021729
litigation	T068	C0079706
crafting a viable policy document	T064	C0242440
legislative approval	T064	C0680796
implementation	T052	C1708476
drug policy reforms	UnknownType	C0683727
global	T080	C2348867
policy	T170	C0242456
mandates	UnknownType	C0814715
humanitarian	T095	C0037440
healthcare	T058	C0086388
quality-of-life	T078	C0034380
considerations	T033	C0518609
Efficacy	T080	C1280519
Synbiotics	T168	C2936470
Treatment	T061	C0087111
Bacillary Dysentery	T047	C1527298
Children	T100	C0008059
Double-Blind	T062	C0013072
Randomized	T062	C0206035
Placebo-Controlled Study	T062	C0599724
Bacillary dysentery	T047	C1527298
children's	T100	C0008059
admission to hospitals	T058	C0184666
assess	T058	C0184514
probiotic	T007	C0525033
prebiotic	T109	C2717875
synbiotics	T168	C2936470
effects	T080	C1280500
children	T100	C0008059
dysentery	T047	C0013369
randomized clinical trial	T062	C0206034
children	T100	C0008059
dysentery	T047	C0013369
groups	T078	C0441833
synbiotic	T168	C2936470
group	T078	C0441833
tablet	T122	C0039225
/day	T079	C0439505
synbiotic	T168	C2936470
days	T079	C0439228
placebo	T122	C1696465
group	T078	C0441833
placebo	T122	C1696465
tablets	T122	C0039225
tablet	T122	C0039225
probiotics	T007	C0525033
standard	T080	C1442989
treatment	T061	C0087111
administered	T169	C1521801
patients	T101	C0030705
Duration	T079	C0449238
hospitalization	T058	C0019993
dysentery	T047	C0013369
fever	T184	C0015967
weight loss	T033	C1262477
assessed	T052	C1516048
group	T078	C0441833
no significant difference	T033	C3842396
groups	T078	C0441833
baseline	T081	C1442488
characteristics	T080	C1521970
mean duration	T079	C0449238
dysentery	T047	C0013369
reduced	T080	C0392756
mean duration	T079	C0449238
fever	T184	C0015967
reduced	T080	C0392756
synbiotic	T168	C2936470
group	T078	C0441833
days	T079	C0439228
comparison	T052	C1707455
placebo	T122	C1696465
group	T078	C0441833
days	T079	C0439228
Average amount	T081	C1265611
weight loss	T033	C1262477
synbiotic	T168	C2936470
group	T078	C0441833
comparison	T052	C1707455
placebo	T122	C1696465
group	T078	C0441833
no significant difference	T033	C3842396
mean duration	T079	C0449238
hospitalization	T058	C0019993
groups	T078	C0441833
synbiotics	T168	C2936470
adjuvant therapy	T061	C0677850
standard	T080	C1442989
treatment	T061	C0087111
dysentery	T047	C0013369
reduces	T080	C0392756
duration	T079	C0449238
dysentery	T047	C0013369
fever	T184	C0015967
rate of weight losses	T033	C1262477
trial	T062	C0008976
registered	T058	C1514821
Effect	T080	C1280500
type 2 diabetes mellitus	T047	C0011860
pharmacokinetics	T169	C0031328
transplacental transfer	UnknownType	C0678748
nifedipine	T109	C0028066
hypertensive	T047	C0020538
pregnant women	T098	C0033011
Diabetes mellitus	T047	C0011849
inhibit	T052	C3463820
cytochrome P450 3A4	T116	C1142644
enzyme	T116	C0014442
metabolism	T044	C0683140
nifedipine	T109	C0028066
treatment	T061	C0087111
hypertension	T047	C0020538
pregnant women	T098	C0033011
aimed	T078	C1947946
assess	T058	C0184514
effect	T080	C1280500
type 2 diabetes mellitus	T047	C0011860
T2DM	T047	C0011860
pharmacokinetics	T169	C0031328
placental transfer	UnknownType	C0678748
nifedipine	T109	C0028066
amniotic fluid	T031	C0002638
hypertensive	T047	C0020538
pregnant women	T098	C0033011
study	T062	C2603343
hypertensive	T047	C0020538
pregnant women	T098	C0033011
control group	T096	C0009932
CG	T096	C0009932
hypertensive	T047	C0020538
pregnant women	T098	C0033011
T2DM	T047	C0011860
nifedipine	T109	C0028066
week	T079	C0439230
gestation	T040	C0032961
blood samples	T031	C0178913
administration	T061	C1533734
medication	T121	C0013227
At delivery	T079	C3263555
samples	T031	C0178913
maternal	T099	C0026591
fetal blood	T031	C0015925
amniotic fluid	T031	C0002638
determination	T059	C1148554
nifedipine	T109	C0028066
median	T081	C0876920
pharmacokinetic	T169	C0031328
parameters	T077	C0549193
CG	T096	C0009932
peak plasma concentration	T081	C0683150
Cmax	T081	C0683150
time to reach Cmax	T081	C2348796
tmax	T081	C2348796
area under the plasma concentration	T081	C0376690
time curve	T081	C2986848
AUC	T081	C0376690
half-life	T079	C0018517
volume of distribution	T081	C0683148
bioavailability	T081	C0005508
Vd	T081	C0683148
F	T081	C0005508
ClT	UnknownType	C0683152
F	T081	C0005508
parameters	T077	C0549193
T2DM	T047	C0011860
group	T098	C1257890
Cmax	T081	C0683150
tmax	T081	C2348796
AUC	T081	C0376690
Vd	T081	C0683148
F	T081	C0005508
total clearance	UnknownType	C0683152
ClT	UnknownType	C0683152
F	T081	C0005508
ratios	T081	C0456603
plasma concentrations	T081	C0683150
nifedipine	T109	C0028066
umbilical vein	T018	C0041637
intervillous space	T030	C0230968
amniotic fluid	T031	C0002638
maternal	T099	C0026591
CG	T096	C0009932
T2DM	T047	C0011860
amniotic fluid	T031	C0002638
maternal	T099	C0026591
plasma	T031	C0032105
ratio	T081	C0456603
groups	T098	C1257890
ratios	T081	C0456603
plasma concentrations	T081	C0683150
umbilical artery	T018	C0041632
umbilical vein	T018	C0041637
CG	T096	C0009932
T2DM	T047	C0011860
influence	T077	C4054723
T2DM	T047	C0011860
pharmacokinetics	T169	C0031328
placental transfer	UnknownType	C0678748
nifedipine	T109	C0028066
hypertensive	T047	C0020538
women	T098	C0043210
controlled	T033	C2911690
diabetes	T047	C0011847
Results	T169	C1274040
International Postmarketing Surveillance Study	T062	C0033267
pl-VEGF165	T121	C1254351
Safety	T068	C0036043
Efficacy	T080	C1280519
Patients	T101	C0030705
Peripheral Arterial Disease	T047	C1704436
treatment	T061	C0087111
chronic	T079	C0205191
lower limb	T023	C0023216
ischemia	T046	C0022116
vascular surgeons	T097	C0586909
pharmacological	T169	C0205464
therapies	T061	C0087111
disease progression	T046	C0242656
treatment methods	T061	C0087111
pl-VEGF165	T121	C1254351
gene therapy	T061	C0017296
drug	T121	C1254351
Russia	T083	C0035970
treatment	T061	C0087111
atherosclerotic	T169	C0333482
peripheral arterial disease	T047	C1704436
PAD	T047	C1704436
clinical studies	T062	C0008972
study	T062	C2603343
drug	T121	C1254351
gene construction	T114	C0012931
pl-VEGF165	T121	C1254351
active substance	T123	C0574031
postmarketing surveillance study	T062	C0033267
safety	T068	C0036043
side effects	T046	C0879626
efficacy	T080	C1280519
gene therapy	T061	C0017296
patients	T101	C0030705
clinical practice	T057	C0205897
patients	T101	C0030705
stage II-III	T079	C1306673
chronic	T079	C0205191
limb	T023	C0015385
ischemia	T046	C0022116
Fontaine classification	T170	C0282574
healthcare facilities	T073	C0018704
Russia	T083	C0035970
Ukraine	T083	C0041580
study	T062	C2603343
control group	T096	C0009932
conservative therapy	T061	C0459914
prostaglandins	T109	C0033554
prostacyclins	T109	C0205911
treatment group	T098	C1257890
treatment	T061	C0087111
pl-VEGF165	T121	C1254351
intramuscular injections	T169	C0021492
dose	T081	C0178602
Pain-free walking distance	T033	C0243095
PWD	T033	C0243095
efficacy	T080	C1280519
Fontaine	T170	C0282574
stages II-III	T079	C1306673
blood flow linear velocity	T033	C0243095
BFLV	T033	C0243095
ankle-brachial index	T201	C1328319
ABI	T201	C1328319
months	T079	C0439231
safety	T068	C0036043
pl-VEGF165	T121	C1254351
gene transfer	T063	C1517499
trial protocol	T062	C4255259
months	T079	C0439231
adverse events	T046	C0877248
AEs	T046	C0877248
serious adverse events	T046	C0877248
SAEs	T046	C0877248
visits	T058	C0008952
medical care	T058	C3825410
PWD	T033	C0243095
treatment group	T098	C1257890
mean	T081	C0444504
control group	T096	C0009932
BFLV	T033	C0243095
ABI values	T201	C1328319
treatment group	T098	C1257890
control group	T096	C0009932
therapeutic effect	T201	C1527144
stage III	T080	C0205578
disease	T047	C0012634
PWD	T033	C0243095
No	T033	C1513916
angiogenic therapy	T061	C0087111
AEs	T046	C0877248
side effects	T046	C0879626
limb salvage	T061	C0949591
treatment	T098	C1257890
control groups	T096	C0009932
results	T169	C1274040
study	T062	C2603343
phase IIb	T062	C1706096
III	T062	C0282461
clinical study	T062	C0008972
pl-VEGF165	T121	C1254351
intramuscular	T082	C0442117
gene transfer	T063	C1517499
treatment	T061	C0087111
claudication	T047	C1456822
chronic	T079	C0205191
lower limb	T023	C0023216
ischemia	T046	C0022116
clinical practice	T057	C0205897
Psychological factors	T041	C0033898
associated with	T080	C0332281
NAFLD	T047	C0400966
NASH	T047	C3241937
systematic review	T170	C1955832
Nonalcoholic fatty liver disease	T047	C0400966
NAFLD	T047	C0400966
chronic liver diseases	T047	C0341439
pathogenesis	T046	C0699748
NAFLD	T047	C0400966
severe	T080	C0205082
nonalcoholic steatohepatitis	T047	C3241937
NASH	T047	C3241937
mechanisms	T169	C0441712
review	T078	C1552617
psychological factors	T041	C0033898
associated with	T080	C0332281
NAFLD	T047	C0400966
NASH	T047	C3241937
factors	T169	C1521761
investigated	T169	C1292732
emotional	T033	C0849912
cognitive	T169	C1516691
behavioral	T053	C0004927
electronic databases	T170	C3841595
English language	T171	C0376245
period	T079	C1948053
PubMed	T170	C1138432
Thomson ISI - Web of Science	T170	C0242356
Scopus	T170	C0242356
ProQuest	T170	C0242356
ScienceDirect	T170	C0242356
emotional	T033	C0849912
factors	T169	C1521761
depression	T048	C0011570
anxiety	T033	C0003467
investigation	T169	C1292732
cognitive functioning	T041	C0392335
contents	T077	C0456205
processes	T067	C1522240
initiate	T169	C1704686
lifestyle changes	T054	C0870811
behavioral	T053	C0004927
factors	T169	C1521761
physical activity	T056	C0026606
nutrition	T040	C1442959
food intake	T040	C0013470
substance	T167	C0439861
consumption	T039	C1947907
coffee	T168	C0009237
alcohol	T168	C0001967
cigarettes	T073	C0677453
factors	T169	C1521761
protective factors	T055	C0679688
vulnerability factors	T033	C0035648
NAFLD	T047	C0400966
NASH	T047	C3241937
cognitive-behavioral disease	T048	C0556006
management	T058	C0376636
lifestyle changes	T054	C0870811
diet	T168	C0012155
exercise	T056	C0015259
clustering	T169	C1522242
protein universe	T116	C0033684
Active site profile-based clustering	T169	C1522242
protein structures	T116	C1510464
sequences	T087	C0002518
Protein function	T044	C1527118
molecular functional level	T080	C0935587
amino acids	T116	C0002520
functional families	T078	C1254370
superfamily	T078	C1254370
Active site profiling	T062	C0242481
DASP	T170	C2348167
DASP2	T170	C2348167
sequence databases	T170	C0950141
active site profiling	T062	C0242481
TuLIP	T170	C0025663
Two-Level Iterative clustering Process	T170	C0025663
clustering process	T169	C1522242
active site profiling	T062	C0242481
superfamily	T078	C1254370
clusters	T081	C1704332
TuLIP	T170	C0025663
functionally relevant families	T078	C1254370
Structure-Function Linkage Database	T170	C0242356
SFLD	T170	C0242356
DASP2	T170	C2348167
clusters	T081	C1704332
multiple functional families	T078	C1254370
TuLIP	T170	C0025663
clusters	T081	C1704332
DASP2	T170	C2348167
functionally relevant group	T078	C1254370
clustering	T169	C1522242
functionally relevant group	T078	C1254370
TuLIP	T170	C0025663
enolase	T116	C0031691
glutathione transferase	T116	C0017837
structures	T116	C0596527
superfamilies	T078	C1254370
SFLD	T170	C0242356
Correlation	T080	C1707520
structures	T082	C0678594
statistically significant analysis	T062	C0871424
TuLIP	T170	C0025663
enolase	T116	C0031691
clusters	T081	C1704332
DASP2 GenBank	T170	C0598211
sequences	T087	C0002518
F-measure	T081	C0079809
performance analysis	T062	C0936012
enolase	T116	C0031691
GEMMA	T170	C0025663
SCI-PHY	T170	C0025663
TuLIP	T170	C0025663
enolase families	T116	C0031691
literature	T170	C0023866
Early	T079	C1279919
high school engagement	T065	C2584312
students	T098	C0038492
attention/deficit hyperactivity disorder	T048	C1263846
Students	T098	C0038492
attention/deficit hyperactivity disorder	T048	C1263846
ADHD	T048	C1263846
peers	T098	C0679739
academic achievement	T055	C0700132
education attainment	T033	C0013658
School engagement	T065	C2584312
engagement	T065	C2584312
education	T065	C0013621
outcomes	T169	C1274040
school engagement	T065	C2584312
students	T098	C0038492
ADHD	T048	C1263846
high school transition	T078	C0871305
period	T079	C1948053
low school engagement	T033	C0243095
Participants	T098	C0679646
adolescents	T100	C0205653
years	T079	C0439234
year	T079	C0439234
high school	T073	C0599395
diagnosed	T062	C1704656
ADHD	T048	C1263846
Participants	T098	C0679646
paediatric	T091	C0030755
practices	T057	C0205897
Cross-sectional study	T062	C0010362
school engagement	T065	C2584312
Data	T078	C1511726
assessment	T058	C0220825
child	T100	C0008059
parent	T099	C0030551
teacher	T097	C0221457
surveys	T170	C0038951
School engagement	T065	C2584312
student attitudes	T041	C0871447
school	T073	C0036375
cognitive	T041	C0009240
emotional	T041	C0013987
suspension	T033	C4272256
rates	T081	C1521828
behavioural	T053	C0004927
Multivariable regression analyses	T170	C0034980
student	T098	C0038492
family	T099	C0015576
school factors	UnknownType	C0814325
engagement	T065	C2584312
students	T098	C0038492
ADHD	T048	C1263846
year	T079	C0439234
high school	T073	C0599395
peers	T098	C0679739
year	T079	C0439234
attitudes	T041	C0004271
high rates of suspension	T033	C0243095
years	T079	C0439234
suspensions	T033	C4272256
attitudes	T041	C0004271
adolescent	T100	C0205653
depression	T048	C0011570
adolescent	T100	C0205653
supervision	T061	C0038842
devaluing	T041	C0564495
education	T065	C0013621
Conduct problems	UnknownType	C0684326
hyperactivity	T048	C0424295
increased likelihood of being suspended	T033	C0243095
cognitive ability	T041	C0392334
family	T099	C0015576
socio-economic status	T080	C0086996
schools	T073	C0036375
risk	T078	C0035647
individual	T098	C0237401
family	T099	C0015576
factors	T033	C4035944
adolescent	T100	C0205653
depression	T048	C0011570
behavioural problems	T048	C0233514
education	T065	C0013621
values	T080	C0042295
family	T099	C0015576
supervision	T061	C0038842
high school transition	T078	C0871305
students	T098	C0038492
ADHD	T048	C1263846
Proliferation	T043	C0596290
Endothelial Cells	T025	C0225336
Enhanced	T052	C2349975
Plasma	T104	C0017110
Nonthermal plasma	T058	C0752188
medical treatment technique	UnknownType	C0679624
reactive chemical species	T123	C0162772
ROS	T123	C0162772
living body	T016	C0242821
plasma	T104	C0017110
plasma	T104	C0017110
gas	T104	C0017110
liquid	T167	C0302908
interface	T082	C1254362
biomedical application	T058	C0752188
gas	T104	C0017110
liquid	T167	C0302908
plasma	T104	C0017110
living cells	T025	C0007634
plasma	T104	C0017110
gas	T104	C0017110
liquid	T167	C0302908
interface	T082	C1254362
plasma	T104	C0017110
enhancement	T052	C2349975
proliferation	T043	C0596290
endothelial cells	T025	C0225336
plasma	T104	C0017110
H2O2	T121	C0020281
HNO2	T197	C0028214
HNO3	T131	C0068808
phosphate buffered	T121	C0991865
saline	T167	C0036082
Mg(++)	T123	C0024467
Ca(++)	T121	C0006675
PBS	T121	C0991865
concentration	T081	C1446561
600-second discharge	T079	C3864299
pH	T081	C0020283
PBS	T121	C0991865
plasma	T104	C0017110
discharge time	T079	C3864299
Temperature	T081	C0039476
PBS	T121	C0991865
cell-cultured	T025	C0007635
plasma	T104	C0017110
discharge for 600 s	T079	C3864299
treatment	T169	C1522326
treatment	T169	C1522326
plasma	T104	C0017110
enhanced	T052	C2349975
proliferation	T043	C0596290
endothelial cells	T025	C0225336
treatment	T169	C1522326
H2O2	T121	C0020281
cell proliferation	T043	C0596290
ROS	T123	C0162772
plasma	T104	C0017110
treatment	T169	C1522326
enhancement	T052	C2349975
cell proliferation	T043	C0596290
biomedical applications	T058	C0752188
gas	T104	C0017110
liquid	T167	C0302908
plasma	T104	C0017110
pH	T081	C0020283
Transmembrane Activity	T044	C1148560
Peptide	T116	C0030956
Gold Nanostars	T121	C0018026
Computed Tomography	T060	C0040405
Photoacoustic Imaging	T060	C3897929
Photothermal Therapy	T061	C0454527
Progress	T169	C1280477
multifunctional nanomaterials	T073	C1450053
tumor therapy	T061	C0920425
development	T169	C1527148
tumor	T191	C0027651
targeting	T169	C1521840
delivery strategies	T061	C0087111
approach	T169	C1292724
pH	T081	C0020283
strategy	T169	C0449851
target	T169	C1521840
acidic solid tumor microenvironment	T070	C2936626
pH (low) insertion peptides	T116	C2606266
pHLIPs	T116	C2606266
pH	T081	C0020283
transmembrane activity	T044	C1148560
fold	T082	C0332462
insert	T169	C0205245
lipid bilayer	T026	C0023768
tumor cells	T025	C0597032
acidity	T070	C1254365
cellular internalization	T067	C1254366
nanomaterials	T073	C1450053
synchronously	T079	C0439580
gold nanostars	T121	C0018026
GNSs	T121	C0018026
pHLIPs	T116	C2606266
GNS	T121	C0018026
pHLIP	T116	C2606266
targeting	T169	C1521840
photothermal therapeutic	T061	C0454527
PTT	T061	C0454527
efficiency	T081	C0013682
GNS	T121	C0018026
pHLIP	T116	C2606266
characteristics	T080	C1521970
size	T082	C0456389
biocompatibility	T044	C0596177
GNS	T121	C0018026
mPEG	T109	C0066763
cellular internalization	T067	C1254366
GNS	T121	C0018026
pHLIP	T116	C2606266
cells	T025	C0007634
media	T167	C1705217
pH	T081	C0020283
pH	T081	C0020283
tumor	T191	C0027651
accumulation	T033	C4055506
GNS	T121	C0018026
pHLIP	T116	C2606266
GNS	T121	C0018026
mPEG	T109	C0066763
intravenous injection	T169	C0021494
MCF-7	T025	C0596890
breast tumor	T191	C1458155
animal models	T050	C0012644
GNS	T121	C0018026
pHLIP	T116	C2606266
signals	T067	C1710082
GNS	T121	C0018026
mPEG	T109	C0066763
computed tomography	T060	C0040405
CT	T060	C0040405
photoacoustic (PA) imaging	T060	C3897929
targeting	T169	C1521840
efficiency	T081	C0013682
PTT	T061	C0454527
efficacy	T080	C1280519
tumors	T191	C0027651
side effects	T046	C0879626
tissues	T024	C0040300
GNS	T121	C0018026
pHLIP	T116	C2606266
tumor	T191	C0027651
targeting	T169	C1521840
pHLIPs	T116	C2606266
characteristics	T080	C1521970
GNS	T121	C0018026
GNS s	T121	C0018026
tumor	T191	C0027651
imaging	T060	C0011923
therapy	T061	C0087111
cyclopropanation	T044	C1511131
polycyclopropanated polyketide	T109	C3179052
jawsamycin	T109	C0003240
biosynthesis	T169	C0005572
Jawsamycin	T109	C0003240
polyketide	T109	C3179052
nucleoside	T114	C0028621
polycyclopropane	T109	C0010587
polyketide chain	T109	C3179052
cyclopropane	T109	C0010587
jawsamycin	T109	C0003240
cyclopropanation	T044	C1511131
mechanism	T169	C0441712
enzymatic	T116	C0014442
synthesis	T169	C0005572
polyketide	T109	C3179052
cyclopropanation	T044	C1511131
reaction rates	T079	C0678608
condensation	T067	C0596312
cyclopropanation reactions	T044	C1511131
laparoscopic radical antegrade modular pancreatosplenectomy	T061	C0519801
left-sided pancreatic cancer	T191	C0346647
institution	T093	C2607850
oncological outcomes	T033	C0679250
Laparoscopic surgery	T061	C0751429
pancreatic cancer	T191	C0346647
technical difficulties	T067	C1710348
oncological	T191	C0027651
safety	T068	C0036043
Radical antegrade modular pancreatosplenectomy	T061	C0842939
RAMPS	T061	C0842939
negative margin	T033	C1709157
radical lymph node dissection	T061	C0184919
favorable	T080	C3640814
laparoscopic application	T082	C0393360
laparoscopic	T060	C0031150
RAMPS	T061	C0842939
patients	T101	C0030705
left-sided pancreatic cancer	T191	C0346647
trocars	T074	C0041158
operative procedures	T061	C0543467
range of dissection	T061	C0242382
RAMPS	T061	C0842939
Strasberg	T170	C0805191
follow-up data	T170	C1704685
patients	T101	C0030705
pancreatic ductal adenocarcinoma	T191	C1335302
operative time	T079	C3494201
estimated blood loss	T033	C1443559
length of postoperative hospital stay	T079	C0023303
postoperative	T046	C0032787
morbidities	T081	C0026538
patients	T101	C0030705
urinary retention	T033	C0080274
lymph nodes	T023	C0024204
negative margins	T033	C1709157
follow-up	T058	C1522577
disease free survival	T081	C0242793
overall survival rates	T081	C0038954
laparoscopic	T060	C0031150
RAMPS	T061	C0842939
perioperative	T079	C1518988
survival outcomes	T081	C0038954
Laparoscopic	T060	C0031150
RAMPS	T061	C0842939
oncologically	T191	C0027651
feasible procedure	T080	C3831015
patients	T101	C0030705
left-sided pancreatic cancer	T191	C0346647
Individual	T098	C0237401
classification	T185	C0008902
strong	T080	C0442821
risk	T078	C0035647
attitudes	T041	C0004271
lottery	T081	C0392762
types	T080	C0332307
age groups	T100	C0027362
Empirical	T080	C1880496
evaluations	T169	C1292732
risk	T078	C0035647
attitudes	T041	C0004271
weak	T080	C1762617
definition	T170	C1704788
risk	T078	C0035647
risky	T078	C0035647
riskless options	T169	C1518601
lottery	T081	C0392762
outcome	T169	C1274040
individuals	T098	C0237401
weak	T080	C1762617
risk	T078	C0035647
choice	T052	C1707391
contexts	T078	C0449255
risky	T078	C0035647
riskless gains	T081	C1517378
weak	T080	C1762617
risk	T078	C0035647
contexts	T078	C0449255
losses	T081	C1517945
phenomenon	T067	C1882365
reflection effect	T067	C1882365
age differences	T100	C0699810
risk	T078	C0035647
attitudes	T041	C0004271
weak	T080	C1762617
definition	T170	C1704788
reflection effect	T067	C1882365
increases	T169	C0442805
diminishes	T081	C0205216
older	T079	C1254367
weak	T080	C1762617
risk	T078	C0035647
attitudes	T041	C0004271
generalizability	T080	C0205556
use of	T169	C1524063
strong	T080	C0442821
strong	T080	C0442821
definition	T170	C1704788
risk	T078	C0035647
options	T169	C1518601
value	T081	C1522609
different	T080	C1705242
degrees	T081	C0449286
risk	T078	C0035647
outcome	T169	C1274040
variance	T080	C1711260
reanalysis	T062	C0936012
data	T078	C1511726
results	T169	C1274040
individuals	T098	C0237401
manifests	T169	C0205319
reflection effect	T067	C1882365
strong	T080	C0442821
definition	T170	C1704788
risk	T078	C0035647
lottery	T081	C0392762
pair types	T080	C0332307
older adults	T098	C0001792
risk	T078	C0035647
younger	T079	C0332239
adults	T100	C0001675
Treating	T169	C1522326
binge	T048	C0596170
(fat) body	T023	C0015665
Representations	T052	C1882932
fatness	T033	C4024583
gold standard	T080	C0150110
psychological	T169	C0205486
treatment manual	UnknownType	C0814280
binge eating disorder	T048	C0596170
reports	T058	C0700287
results	T034	C0456984
Foucauldian	T016	C0086418
discourse analysis	T062	C0870428
representations	T052	C1882932
fatness	T033	C4024583
empirically	T080	C1880496
psychological	T169	C0205486
treatment manual	UnknownType	C0814280
binge eating disorder	T048	C0596170
condition	T080	C0348080
characterized	T052	C1880022
weight	T032	C0005910
shape	T080	C0348078
Analyses	T062	C0936012
indicate	T033	C1444656
manual	T073	C0024763
weight loss	T033	C1262477
relatively	T080	C0205345
treating	T169	C1522326
diagnostic	T169	C0348026
symptoms	T184	C1457887
mechanisms	T169	C0441712
binge eating disorder	T048	C0596170
critical concerns	T033	C3869780
observations	T062	C0302523
findings	T033	C0243095
psychology's	T091	C0033909
medical framing	T080	C0205556
fatness	T033	C4024583
obesity	T047	C0028754
gold standard	T080	C0150110
intervention	T058	C1273869
psychology	T091	C0033909
discipline	T058	C0237070
weight loss	T033	C1262477
associated with	T080	C0332281
binge eating disorder	T048	C0596170
fat bodies	T023	C0015665
practitioners	T097	C0017319
problem	T033	C0033213
fat shame	T041	C0036938
society	T092	C0037455
individual	T098	C0237401
body	T016	C0242821
provide	T052	C1999230
individuals	T098	C0237401
fat stigma	T033	C0277787
oppression	T054	C0235132
provide	T052	C1999230
bodies	T016	C0242821
Diversity	T080	C1880371
Planctomycetes	T007	C1222577
Soils	T167	C0037592
Lichen	T002	C0023657
Sub-Arctic	T083	C0003740
Ecosystems	T070	C0162358
Northwestern	T082	C1709274
Siberia	T083	C0037045
terrestrial	T082	C0562020
ecosystems	T070	C0162358
tundra	T083	C3850151
lichens	T002	C0023657
genera	T185	C1708235
Cladonia	T004	C1080962
Cetraria	T004	C1094116
microbial	T001	C0599840
lichen	T002	C0023657
ecosystems	T070	C0162358
sub-arctic zone	T083	C0003740
northwestern	T082	C1709274
Siberia	T083	C0037045
forested	T070	C0086312
tundra	T083	C3850151
soil	T167	C0037592
shallow acidic peatland	T083	C0017446
study	T062	C2603343
soil	T167	C0037592
peat	T167	C0030739
lichen	T002	C0023657
colonized	T033	C4289767
bacteria	T007	C0004611
phylum	T185	C1709533
Planctomycetes	T007	C1222577
planctomycetes	T007	C1222577
fluorescence	T070	C0016315
in situ hybridization	T063	C0162788
cells per gram of wet weight	T081	C0392762
16S rRNA	T114	C3537372
gene fragments	T028	C0017337
Planctomycetes	T007	C1222577
16S rRNA	T114	C3537372
gene	T028	C0017337
Illumina pair-end sequencing	T170	C1553778
soil	T167	C0037592
peat samples	T167	C0030739
Lichen	T002	C0023657
planctomycetes	T007	C1222577
diversity	T080	C1880371
operational taxonomic units	T062	C0683955
sequence identity	T081	C1710052
soil	T167	C0037592
tundra	T083	C3850151
family	T077	C1704727
Planctomycetaceae	T007	C0995267
Planctomycetes	T007	C1222577
sequences	T086	C0162326
Phycisphaera-related group WD2101	T007	C2791840
order	T185	C1705177
Tepidisphaerales	T007	C4087581
peat	T167	C0030739
Isosphaera	T007	C0995268
Singulisphaera group	T007	C2291815
lineages	T077	C1881379
genera	T185	C1708235
Gemmata	T007	C0995258
Planctopirus	T007	C4103516
Rubinisphaera	T007	C4103506
habitats	T082	C0871648
Singulisphaera-like bacteria	T007	C0004611
soil	T167	C0037592
peat samples	T167	C0030739
planctomycetes	T007	C1222577
low temperatures	T070	C0009264
growth	T040	C0018270
polysaccharides	T109	C0032594
lichenan	T109	C0064959
lichen	T002	C0023657
phytomass	T081	C0005535
Relationship	T080	C0439849
polycythemia	T047	C0032461
in-hospital mortality	T080	C0085556
chronic obstructive pulmonary disease	T047	C0024117
patients	T101	C0030705
low-risk	T081	C3538919
pulmonary embolism	T047	C0034065
Pulmonary embolism	T047	C0034065
PE	T047	C0034065
frequent	T079	C0332183
subjects	T098	C0080105
chronic obstructive pulmonary disease	T047	C0024117
COPD	T047	C0024117
associated with	T080	C0332281
mortality	T081	C0079320
multi-center retrospective study	T062	C0035363
investigate	T169	C1292732
polycythemia	T047	C0032461
associated with	T080	C0332281
in-hospital mortality	T080	C0085556
COPD	T047	C0024117
patients	T101	C0030705
low-risk	T081	C3538919
PE	T047	C0034065
COPD	T047	C0024117
patients	T101	C0030705
PE	T047	C0034065
Patients	T101	C0030705
PESI score	T033	C0243095
demographic	T090	C0011298
clinical	T080	C0205210
laboratory information	UnknownType	C0677075
time of admission	T079	C3854259
medical records	T170	C0025102
subjects	T098	C0080105
hospital discharge	T058	C0586003
mortality	T081	C0079320
patients	T101	C0030705
COPD	T047	C0024117
PE	T047	C0034065
low risk	T081	C3538919
polycythemia	T047	C0032461
polycythemia	T047	C0032461
polycythemia	T047	C0032461
significantly lower	T081	C4055638
forced expiratory volume in one second (FEV1) level	T060	C2238302
lower PaO2	T033	C2363807
SpO2	T042	C2317096
higher PaCO2	T034	C0391839
COPD	T047	C0024117
patients	T101	C0030705
polycythemia	T047	C0032461
higher	T080	C0205250
proportion	T081	C1709707
arrhythmia	T033	C0003811
electrocardiogram	T033	C0013798
ECG	T033	C0013798
hospital duration time	T081	C0392762
higher	T080	C0205250
mechanical ventilation rate	T061	C2223989
noninvasive	T185	C2986496
invasive	T080	C0205281
higher	T080	C0205250
in-hospital mortality	T080	C0085556
Multivariate logistic regression analysis	UnknownType	C0681925
polycythemia	T047	C0032461
associated with	T080	C0332281
mortality	T081	C0079320
COPD	T047	C0024117
patients	T101	C0030705
low-risk	T081	C3538919
PE	T047	C0034065
Polycythemia	T047	C0032461
risk factor	T033	C0035648
in-hospital mortality	T080	C0085556
COPD	T047	C0024117
patients	T101	C0030705
PE	T047	C0034065
low risk	T081	C3538919
Masitinib	T109	C2351398
treatment	T061	C0087111
severely	T080	C0205082
symptomatic	T169	C0231220
indolent systemic mastocytosis	T047	C0272203
randomised	T062	C0034656
placebo-controlled	T062	C1706408
phase 3 study	T062	C0282461
Indolent systemic mastocytosis	T047	C0272203
subvariant	T080	C0205556
smouldering systemic mastocytosis	T191	C3897042
lifelong	T079	C4274169
associated with	T080	C0332281
reduced quality of life	T033	C1963786
Masitinib	T109	C2351398
inhibits	T052	C3463820
KIT	T116	C0033640
LYN kinases	T116	C1442804
indolent systemic mastocytosis	T047	C0272203
pathogenesis	T046	C0699748
safety	T062	C1705187
efficacy	T062	C1707887
masitinib	T109	C2351398
placebo	T122	C1696465
severely symptomatic	T033	C0436345
patients	T101	C0030705
unresponsive	T169	C0205269
optimal	T080	C2698651
symptomatic	T169	C0231220
treatments	T061	C0087111
randomised	T062	C0034656
double-blind	T062	C0013072
placebo-controlled	T062	C1706408
phase 3 study	T062	C0282461
adults	T100	C0001675
aged	T032	C0001779
indolent	T047	C0272203
smouldering systemic mastocytosis	T191	C3897042
WHO	T093	C0043237
classification	T185	C0008902
documented	T170	C0920316
mastocytosis	T047	C0024899
histological criteria	T201	C0449574
countries	T083	C0454664
patients	T101	C0030705
cutaneous	T082	C0221912
systemic mastocytosis	T047	C0221013
protocol amendment	T170	C1507394
Patients	T101	C0030705
randomised	T062	C0034656
oral	T169	C1527415
masitinib	T109	C2351398
placebo	T122	C1696465
severe symptoms	T033	C0436345
primary endpoint	T130	C2986535
response	T201	C0521982
improvement	T077	C2986411
baseline	T081	C1442488
severe baseline symptom	T033	C0436345
pruritus	T184	C0033774
score	T081	C0449820
Hamilton Rating Scale for Depression	T170	C0451203
Fatigue Impact Scale	T170	C2733557
treatment effect	T080	C0087113
methodology	T062	C0086912
rare diseases	T047	C0678236
generalised estimating equation model	T170	C0282574
intention-to-treat	T062	C2718028
population	T098	C1257890
participants	T098	C0679646
treatment	T061	C0087111
non-treatment-related cause	T033	C0243095
safety	T062	C1705187
patients	T101	C0030705
dose	T081	C0870450
study drug	T062	C0013175
trial	T062	C0008976
ClinicalTrials.gov, number NCT00814073	T062	C0008976
Feb	T080	C3830166
July	T080	C3829447
patients	T101	C0030705
randomly assigned	UnknownType	C0814868
masitinib	T109	C2351398
placebo	T122	C1696465
weeks	T079	C0439230
masitinib	T109	C2351398
associated with	T080	C0332281
response	T201	C0521982
primary endpoint	T130	C2986535
responses	T201	C0521982
responses	T201	C0521982
weighted generalised estimating equation	T080	C0205556
placebo	T122	C1696465
odds ratio	T081	C0028873
Frequent	T079	C0332183
severe adverse events	T033	C1519255
placebo	T122	C1696465
diarrhoea	T184	C0011991
masitinib	T109	C2351398
group	T078	C0441833
placebo	T122	C1696465
group	T078	C0441833
asthenia	T184	C0004093
frequent	T079	C0332183
serious adverse events	T033	C1519255
diarrhoea	T184	C0011991
patients	T101	C0030705
urticaria	T047	C0042109
life-threatening	T033	C2826244
toxicities	T037	C0600688
patient	T101	C0030705
placebo	T122	C1696465
group	T078	C0441833
died	T033	C1546956
unrelated	T080	C1704623
study treatment	T062	C3161471
study findings	T033	C0683954
masitinib	T109	C2351398
effective	T080	C1704419
tolerated agent	T121	C1254351
treatment	T061	C0087111
severely symptomatic	T033	C0436345
indolent	T047	C0272203
smouldering systemic mastocytosis	T191	C3897042
Attributable risk	T080	C0814766
ambient	T080	C1879688
PM10	T167	C1720884
mortality	T081	C0205848
years of life lost	T081	C2713320
Chengdu	UnknownType	C0681784
China	T083	C0008115
Attributable risk	T080	C0814766
planning	T058	C0018727
evaluating public health interventions	T058	C0557980
attributable risk	T080	C0814766
air pollutants	T131	C0001869
temporal relationships	T079	C0449235
exposure	T080	C0332157
risk	T078	C0035647
attributable risk	T080	C0814766
ambient	T080	C1879688
air pollutants	T131	C0001869
basin regions	UnknownType	C0681784
Sichuan Basin	UnknownType	C0681784
China	T083	C0008115
PM10	T167	C1720884
deaths	T033	C1306577
Basin region	UnknownType	C0681784
distributed lag non-linear model	T081	C0392762
attributable risk	T080	C0814766
Chengdu	UnknownType	C0681784
China	T083	C0008115
association	T080	C0439849
PM10	T167	C1720884
years of life lost	T081	C2713320
YLL	T081	C2713320
analysis	T062	C0936012
population-attributable fractions	T081	C1264633
non-accidental	T169	C0521130
respiratory	T169	C0521346
cardiovascular mortality	T081	C0205848
PM10	T167	C1720884
cumulative increases	T169	C0442805
YLL	T081	C2713320
non-accidental	T169	C0521130
respiratory	T169	C0521346
cardiovascular mortality	T081	C0205848
inverse U-shaped pattern	T082	C0449774
cumulative risk	T078	C0035647
PM10	T167	C1720884
YLL	T081	C2713320
mortality	T081	C0205848
PM10	T167	C1720884
effects	T080	C1280500
YLL	T081	C2713320
men	T098	C0025266
elderly	T098	C0001792
Far-infrared	T070	C1289903
protects	T033	C1545588
vascular endothelial cells	T025	C1257792
advanced glycation end products	T109	C0162574
induced	T169	C0205263
injury	T037	C0178314
PLZF	T116	C1674035
autophagy	T043	C0004391
diabetic mice	T015	C0085243
advanced glycation end products	T109	C0162574
AGEs	T109	C0162574
diabetic	T047	C0011847
patients	T101	C0030705
induces	T169	C0205263
vascular endothelial	T024	C0014261
injury	T037	C0178314
Promyelocytic leukemia zinc finger protein	T116	C1674035
PLZF	T116	C1674035
transcription factor	T116	C0040648
activated	T039	C2253861
low-temperature	T070	C0009264
far-infrared	T070	C1289903
FIR	T070	C1289903
irradiation	T070	C1282930
exert beneficial effects	T038	C3714634
vascular endothelium	T024	C0014261
study	T062	C2603343
investigated	T169	C1292732
influence	T077	C4054723
FIR	T070	C1289903
induced	T169	C0205263
PLZF	T116	C1674035
activation	T039	C2253861
AGE	T109	C0162574
induced	T169	C0205263
endothelial	T024	C0014261
injury	T037	C0178314
both	T080	C1706086
in vitro	T062	C0681828
in vivo	T062	C0681829
FIR	T070	C1289903
irradiation	T070	C1282930
inhibited	T080	C0311403
AGE	T109	C0162574
induced	T169	C0205263
apoptosis	T043	C0162638
human umbilical vein endothelial cells	T025	C3179121
HUVECs	T025	C3179121
PLZF	T116	C1674035
activation	T039	C2253861
increased	T081	C0205217
expression	T045	C1171362
phosphatidylinositol-3 kinases	T116	C2936824
PI3K	T116	C2936824
important	T080	C3898777
kinases	T116	C0031727
autophagic	T043	C0004391
signaling pathway	T044	C0037080
FIR	T070	C1289903
induced	T169	C0205263
PLZF	T116	C1674035
activation	T039	C2253861
autophagy	T043	C0004391
HUVEC	T025	C3179121
through	T169	C0332273
upregulation	T044	C0041904
PI3K	T116	C2936824
Immunofluorescence	T059	C0016318
staining	T059	C0487602
AGEs	T109	C0162574
HUVECs	T025	C3179121
localized	T082	C0392752
lysosomes	T026	C0024369
FIR	T070	C1289903
induced	T169	C0205263
autophagy	T043	C0004391
promoted	T052	C0033414
AGEs	T109	C0162574
degradation	T169	C0243125
HUVECs	T025	C3179121
nicotinamide	T109	C0028027
streptozotocin	T109	C0038432
induced	T169	C0205263
diabetic mice	T015	C0085243
FIR	T070	C1289903
therapy	T061	C0087111
reduced	T080	C0392756
serum AGEs	T116	C0217068
AGEs	T109	C0162574
deposition	T169	C0333562
vascular endothelium	T024	C0014261
FIR	T070	C1289903
therapy	T061	C0087111
reduced	T080	C0392756
diabetes	T047	C0011847
induced	T169	C0205263
inflammatory markers	T033	C4087233
vascular endothelium	T024	C0014261
improved	T033	C0184511
vascular endothelial	T024	C0014261
function	T042	C1254358
protective effects	T039	C3179279
FIR	T070	C1289903
therapy	T061	C0087111
not found	T033	C0442737
PLZF	T116	C1674035
knockout mice	T015	C0206745
data	T078	C1511726
suggest	T078	C1705535
FIR	T070	C1289903
induced	T169	C0205263
PLZF	T116	C1674035
activation	T039	C2253861
vascular endothelial cells	T025	C1257792
vascular endothelium	T024	C0014261
diabetic mice	T015	C0085243
AGE	T109	C0162574
induced	T169	C0205263
injury	T037	C0178314
Ultrasonic computed tomography imaging	T060	C0729619
iron oxide nanoparticles	T130	C3652446
Iron oxide nanoparticles	T130	C3652446
IONPs	T130	C3652446
increasingly	T169	C0442805
intensively investigated	T169	C1292732
field	T077	C1521738
medical imaging	T060	C0025086
currently	T079	C0521116
FDA	T093	C0041714
approved	T080	C0205540
magnetic resonance imaging	T060	C0024485
MRI	T060	C0024485
highly	T080	C0205250
visualize	T169	C0234621
ultrasound	T070	C1456803
Previous	T079	C0205156
reports	T170	C0684224
conventional	T080	C0439858
ultrasound B-scan (pulse-echo) imaging technique	T060	C0203325
limited	T169	C0439801
detectability	T201	C3830527
particles	T104	C0597177
aim	T078	C1947946
study	T062	C0681814
feasibility	T080	C3827682
imaging	T060	C0011923
IONPs	T130	C3652446
through-transmission ultrasound methodology	T078	C3266812
ultrasonic computed tomography	T060	C0430022
UCT	T060	C0430022
IONPs	T130	C3652446
acoustically	T070	C0001166
analysed	T062	C0936012
quantify	T081	C1709793
effect	T080	C1280500
speed	T081	C0678536
sound	T070	C0037709
SOS	T070	C0037709
acoustic	T070	C0001166
attenuation	T052	C0599946
function	T169	C0542341
concentration	T081	C1446561
through-transmission projection	T060	C0430022
UCT imaging	T060	C0729619
performed	T169	C0884358
breast	T023	C0006141
breast mimicking phantom	T170	C0597204
ex vivo	T169	C2348480
ex vivo tissue model	T050	C1519523
IONPs	T130	C3652446
MRI scan	T060	C0024485
performed	T169	C0884358
verify	T169	C1711411
particles	T104	C0597177
examined	T033	C0332128
ultrasound	T070	C1456803
experiment	T062	C0681814
imaged	T170	C1704254
magnetic resonance	T070	C0917874
clinically relevant	T080	C2347946
concentrations	T081	C1446561
results	T033	C0683954
consistent	T078	C0332290
concentration	T081	C1446561
dependent	T169	C3244310
speed	T081	C0678536
sound	T070	C0037709
increase	T169	C0442805
IONPs	T130	C3652446
Imaging	T060	C0011923
based	T169	C1527178
property	T080	C0871161
substantial contrast-to-noise ratio	T081	C0392762
improvement	T077	C2986411
SOS	T070	C0037709
effect	T080	C1280500
discernible	T080	C0205396
image	T170	C1704254
contrast	T080	C1979874
detection	T033	C0442726
particles	T104	C0597177
existence	T081	C1547035
location	T082	C0450429
both	T080	C1706086
raster-scan projection	T060	C0430022
UCT imaging	T060	C0729619
significant	T078	C0750502
change	T169	C0392747
acoustic	T070	C0001166
attenuation coefficient	T081	C2986722
noted	T080	C4288581
Based	T169	C1527178
findings	T033	C0243095
concluded	T078	C1707478
IONPs	T130	C3652446
effective	T080	C1704419
SOS	T070	C0037709
based	T169	C1527178
contrast agent	T130	C0009924
potentially useful	T080	C3827682
ultrasonic	T070	C1456803
breast	T023	C0006141
imaging	T060	C0011923
particle	T104	C0597177
capacity	T081	C1516240
significantly enhancing	T052	C2349975
diagnosis accuracy	T080	C0598285
multimodal	T060	C1513743
MRI	T060	C0024485
ultrasound imaging	T060	C0041618
capabilities	T080	C2698977
Genetically	T169	C0314603
encoded	T052	C2700640
calcium indicators	T130	C0596234
long-term	T079	C0443252
calcium	T121	C0006675
dynamics	T044	C0596957
apoptosis	T043	C0162638
Intracellular calcium release	T044	C1820193
essential	T080	C0205224
regulating	T043	C0596286
cellular functions	T043	C0007613
Specific	T080	C0205369
spatio-temporal	T062	C3494293
patterns	T082	C0449774
cytosolic	T026	C1383501
calcium	T121	C0006675
elevations	T080	C3163633
critical	T080	C1511545
determinants	T169	C1521761
cell fate	T043	C1540661
pro-apoptotic	T080	C1516044
cellular	T025	C0007634
stressors	T078	C0597530
apoptotic program	T043	C1159821
hours	T079	C0439227
days	T079	C0439228
measurement	T169	C0242485
long-term	T079	C0443252
calcium	T121	C0006675
dynamics	T044	C0596957
essential	T080	C0205224
understanding	T041	C0162340
mechanistic	T169	C0441712
role	T077	C1705810
calcium	T121	C0006675
apoptotic cell death	T043	C0162638
technical	T169	C0449851
limitations	T169	C0449295
calcium	T121	C0006675
sensitive	T169	C0332324
dyes	T130	C0013343
measure	T081	C0079809
cytosolic	T026	C1383501
calcium	T121	C0006675
long-term	T079	C0443252
calcium	T121	C0006675
dynamics	T044	C0596957
living cells	T025	C0007634
treatment	T061	C0087111
apoptosis	T043	C0162638
inducing	T169	C0205263
drugs	T121	C0013227
Genetically	T169	C0314603
encoded	T052	C2700640
calcium indicators	T130	C0596234
overcome	T052	C2983310
limitations	T169	C0449295
calcium	T121	C0006675
sensitive	T169	C0332324
dyes	T130	C0013343
performance	T052	C1882330
genetically	T169	C0314603
encoded	T052	C2700640
calcium	T121	C0006675
indicators	T130	C0021212
GCaMP6s	T130	C0596234
GCaMP6f	T130	C0596234
ratiometric dye	T130	C0016320
Fura-2	T109	C0079389
GCaMP6s	T130	C0596234
Fura-2	T109	C0079389
agonist	T121	C2987634
induced	T169	C0205263
calcium	T121	C0006675
transients	T079	C0205374
utility	T169	C0457083
GCaMP6s	T130	C0596234
continuously	T078	C0549178
measuring	T080	C0444706
apoptotic	T080	C1516044
calcium release	T059	C0201925
course	T079	C0750729
hours	T079	C0439227
treatment	T061	C0087111
staurosporine	T109	C0075193
GCaMP6s	T130	C0596234
measuring	T080	C0444706
apoptotic	T080	C1516044
calcium release	T059	C0201925
courses	T079	C0750729
significant	T078	C0750502
heterogeneity	T080	C0019409
calcium release	T059	C0201925
dynamics	T044	C0596957
cells	T025	C0007634
staurosporine	T109	C0075193
GCaMP6s	T130	C0596234
excellent	T080	C1961136
indicator	T130	C0021212
monitoring	T058	C1283169
long-term	T079	C0443252
changes	T169	C0392747
cytosolic	T026	C1383501
calcium	T121	C0006675
apoptosis	T043	C0162638
Staphylococcus pseudintermedius	T007	C1680786
Human	T016	C0086418
Infection	T046	C3714514
Cases	T169	C0868928
Spain	T083	C0037747
Dog	T015	C0012984
Human	T016	C0086418
Transmission	T046	C0242781
Staphylococcus pseudintermedius	T007	C1680786
opportunistic pathogen	T001	C0450254
identified	T080	C0205396
infectious agent	T001	C0314732
colonizer	T033	C2747813
dogs	T015	C0012984
S. pseudintermedius	T007	C1680786
detected	T033	C0442726
humans	T016	C0086418
people	T098	C0027361
contact with	T169	C0332158
dogs	T015	C0012984
study	T062	C0681814
possible	T033	C0332149
S. pseudintermedius	T007	C1680786
pet	T008	C0031268
human	T016	C0086418
transmission	T046	C0242781
analyzed	T062	C0936012
clinical	T080	C0205210
human	T016	C0086418
cases	T169	C0868928
patients	T101	C0030705
dog	T015	C0012984
owners	T098	C1704784
S. pseudintermedius	T007	C1680786
detected	T033	C0442726
colonizer	T033	C2747813
healthy	T080	C3898900
animals	T008	C0003062
S. pseudintermedius	T007	C1680786
isolates	T123	C1764827
patients	T101	C0030705
dogs	T015	C0012984
household	T099	C0020052
identical	T080	C0205280
pulsed-field gel electrophoresis	T059	C0085117
patterns	T082	C0449774
sequence types	T033	C2359784
STs	T033	C2359784
antimicrobial resistance	T201	C1456627
phenotypes and genotypes	T032	C0678920
methicillin susceptible	T032	C0079830
Resistance	T169	C4281815
erythromycin	T109	C0014806
clindamycin	T109	C0008947
tetracycline	T109	C0039644
trimetoprim-sulfamethoxazole	T121	C0041044
ciprofloxacin	T109	C0008809
identified	T080	C0205396
S. pseudintermedius	T007	C1680786
strains	T001	C1518614
lineages	T077	C1881379
ST241	T033	C2359784
ST521	T033	C2359784
detected	T033	C0442726
strains	T001	C1518614
dog	T015	C0012984
owner	T098	C1704784
patients	T101	C0030705
strains	T001	C1518614
other	T080	C0205394
patients	T101	C0030705
presented	T078	C0449450
STs	T033	C2359784
ST719	T033	C2359784
ST720	T033	C2359784
knowledge	T170	C0376554
description	T170	C0678257
human	T016	C0086418
infections	T046	C3714514
S. pseudintermedius	T007	C1680786
Spain	T083	C0037747
TANGO	T170	C0282574
screening tool	T058	C0220908
comorbidities	T078	C0009488
causal pathway	T170	C0282654
nocturia	T047	C0028734
robust screening metric	T058	C1710032
urinary tract	T023	C0042027
comorbidities	T078	C0009488
multidisciplinary assessment	T060	C0729737
patients	T101	C0030705
nocturia	T047	C0028734
Variables	T080	C0439828
association with	T080	C0332281
nocturia	T047	C0028734
night	T079	C0240526
Discriminating	T080	C0205235
tools	T058	C0220908
comorbidities	T078	C0009488
questionnaire	T170	C0034394
medical	T169	C0205476
checklist	T170	C1707357
clinical measures	T033	C3266594
Short-Form	T170	C2964478
SF	T170	C2964478
screening tool	T058	C0220908
tool	T058	C0220908
individuals	T098	C0237401
nocturia	T047	C0028734
Sleep	T040	C0037313
Continence	T061	C0442964
Falls	T033	C0085639
Rehabilitation service	T058	C0587660
routine care	T058	C0262500
Data collected	T033	C4019276
descriptive analysis	T170	C0678257
nocturia	T047	C0028734
screening metric	T058	C1710032
TANGO	T170	C0282574
TANGO	T170	C0282574
Targeting	T169	C1521840
individual's Aetiology	T169	C0015127
Nocturia	T047	C0028734
demographic characteristics	T102	C0683970
statistical	T062	C0871424
structural framework	T073	C0026349
TANGO	T170	C0282574
SF	T170	C2964478
TANGO	T170	C0282574
SF	T170	C2964478
patient	T101	C0030705
nocturia	T047	C0028734
screening tool	T058	C0220908
diagnostic	T169	C0348026
morbidities	T081	C0026538
clinical relevance	T201	C0683325
nocturia	T047	C0028734
patients	T101	C0030705
disciplines	T058	C0237070
medical specialties	T091	C0037778
TANGO	T170	C0282574
smooth inequalities	T080	C0242503
associated with	T080	C0332281
assessment	T058	C0220825
care	T052	C1947933
patients	T101	C0030705
nocturia	T047	C0028734
Probabilistic	T081	C0033204
acute	T079	C0205178
risk assessment	T058	C0086930
cumulative exposure	T067	C2986588
organophosphorus	T109	C0360429
carbamate pesticides	T109	C0360422
dietary vegetables	T168	C0042440
fruits	T168	C0016767
Shanghai	UnknownType	C0681784
populations	T098	C1257890
Organophosphorus pesticides	T109	C0360429
OPs	T109	C0360429
carbamate pesticides	T109	C0360422
CPs	T109	C0360422
pesticides	T131	C0031253
China	T083	C0008115
protecting	T033	C1545588
agricultural commodities	T002	C0242775
determined	T080	C0521095
cumulative acute exposure	T067	C2986588
OPs	T109	C0360429
CPs	T109	C0360422
Shanghai	UnknownType	C0681784
residents	T098	C2347958
vegetables	T168	C0042440
fruits	T168	C0016767
VFs	T168	C0016452
food consumption	T052	C2983605
data	T078	C1511726
obtained	T169	C1301820
Shanghai Food Consumption Survey	T170	C0038951
SHFCS	T170	C0038951
participants	T098	C0679646
aged	T032	C0001779
years	T079	C0439234
pesticide residue	T131	C0031251
data	T078	C1511726
obtained	T169	C1301820
Shanghai	UnknownType	C0681784
monitoring	T058	C1283169
programme	T169	C3484370
organophosphates	T109	C0360429
carbamates	T109	C0360422
samples	T167	C0444315
VFs	T168	C0016452
probabilistic	T081	C0033204
performed	T169	C0884358
recommended	T078	C0034866
EFSA	T170	C0282574
optimistic model	T170	C3161035
zero	T081	C0919414
processing	T057	C0016487
factors	T169	C1521761
PFs	T169	C1521761
pessimistic model	T170	C3161035
replaced by	T169	C1299987
limit of detection	T081	C2718050
LOD	T081	C2718050
without	T080	C0332288
PFs	T169	C1521761
relative potency factor (RPF) method	T170	C0025663
pesticides	T131	C0031253
index compound	T103	C1706082
IC	T103	C1706082
methamidophos	T109	C0066080
chlorpyrifos	T109	C0013328
separately	T080	C0443299
pessimistic model	T170	C3161035
methamidophos	T109	C0066080
IC	T103	C1706082
risk	T078	C0035647
exposure	T080	C0332157
ARfD	T081	C0454255
day	T079	C0439228
populations	T098	C1257890
preschool children	T100	C0008100
school-age children	T100	C2827631
adults	T100	C0001675
no risk	T033	C4036089
exposure	T080	C0332157
ARfD	T081	C0454255
methamidophos	T109	C0066080
optimistic model	T170	C3161035
chlorpyrifos	T109	C0013328
day	T079	C0439228
optimistic	T033	C0564470
pessimistic models	T170	C3161035
populations	T098	C1257890
Chinese habits	T033	C2242848
eating	T040	C0013470
processed food	T168	C0344355
vegetables	T168	C0042440
cooked	T056	C0335326
fruits	T168	C0016767
washed	T078	C1548982
peeled	T169	C0441602
acute	T079	C0205178
risk	T078	C0035647
exposure to	T080	C0332157
VF	T168	C0016452
sourced	T033	C0449416
OPs	T109	C0360429
CPs	T109	C0360422
Shanghai	UnknownType	C0681784
MODEM	T062	C0700032
comprehensive	T080	C1880156
approach	T082	C0449445
modelling	T062	C0870071
outcome	T080	C0085415
costs	T081	C0010186
impacts	T080	C4049986
interventions	T061	C0184661
dementia	T048	C0497327
Protocol	T170	C0442711
paper	T073	C0030351
MODEM project	T062	C0700032
comprehensive	T080	C1880156
approach	T082	C0449445
MODelling	T062	C0870071
outcome	T080	C0085415
costs	T081	C0010186
impacts	T080	C4049986
interventions	T061	C0184661
DEMentia	T048	C0497327
changes	T169	C0392747
future	T079	C0016884
treatment	T061	C0087111
care	T052	C1947933
people	T098	C0027361
dementia	T048	C0497327
support	T061	C0344211
family	T099	C0015576
unpaid	T033	C0557361
carers	T097	C1305660
result	T169	C1274040
outcomes	T080	C0085415
efficient	T080	C0442799
use of	T169	C1524063
resources	T078	C0035201
MODEM	T062	C0700032
systematic	T169	C0220922
mapping	T052	C1283195
literature	T170	C0023866
effective	T080	C1704419
cost	T081	C0010186
effective	T080	C1704419
interventions	T061	C0184661
dementia	T048	C0497327
care	T052	C1947933
findings	T169	C2607943
data	T078	C1511726
cohort	T098	C0599755
model	T170	C3161035
quality of life	T078	C0034380
cost	T081	C0010186
impacts	T080	C4049986
evidence	T078	C3887511
interventions	T061	C0184661
available	T169	C0470187
England	T083	C0014282
period	T079	C1948053
Modelling	T062	C0870071
models	T170	C3161035
combining	T080	C0205195
microsimulation	UnknownType	C0869023
macrosimulation methods	UnknownType	C0869023
modelling	T062	C0870071
costs	T081	C0010186
outcomes	T080	C0085415
care	T052	C1947933
individual	T098	C0027361
life-course	T079	C1510618
dementia diagnosis	T048	C0497327
individuals	T098	C0027361
England	T083	C0014282
whole	T081	C0444667
Project	T062	C0700032
online	UnknownType	C0683828
Dementia Evidence Toolkit	T170	C0282574
evidence	T078	C3887511
summaries	T170	C1706244
literature	T170	C0023866
database	T170	C0242356
available	T169	C0470187
papers	T073	C0030351
academic journals	T073	C0162443
MODEM Legacy Model	T170	C3161035
local commissioners	T097	C0679924
services	T057	C0557854
model	T170	C3161035
populations	T098	C1257890
Modelling	T062	C0870071
effects of	T080	C1704420
evidence	T078	C3887511
cost	T081	C0010186
effective	T080	C1704419
interventions	T061	C0184661
information	T078	C1533716
available	T169	C0470187
potential	T080	C3245505
improve	T033	C0184511
health	T078	C0018684
quality of life	T078	C0034380
people	T098	C0027361
dementia	T048	C0497327
carers	T097	C1305660
resources	T078	C0035201
Assessment	T062	C0936012
neuroanatomical	T080	C0220784
behavioural effects	UnknownType	C0815123
in ovo	T169	C2827729
methylmercury	T109	C0025794
exposure	T080	C0332157
zebra finches	T012	C0326833
Taeniopygia guttata	T012	C0326833
Methylmercury	T109	C0025794
MeHg	T109	C0025794
crosses	T077	C2828360
blood brain barrier	T023	C0005854
known	T080	C0205309
neuro	T080	C0205494
toxicant	T131	C0599787
MeHg	T109	C0025794
accumulation	T033	C4055506
brain	T023	C0006104
causes	T169	C0015127
histopathological	T169	C0243140
alterations	T169	C0392747
neurobehavioral	T080	C2986478
changes	T169	C0392747
impairments	T169	C0221099
cognitive	T169	C1516691
motor functions	T038	C0234130
mammalian	T015	C0024660
models	T050	C0012644
birds	T012	C0005595
neurotoxic effects	T037	C0235032
MeHg	T109	C0025794
pre	T079	C0332152
hatching	T040	C0598016
brain	T023	C0006104
consequent	T033	C3845876
behavioral alterations	T055	C0542299
adult	T100	C0001675
birds	T012	C0005595
not	T169	C1518422
received	T080	C1514756
attention	T041	C0004268
passerine birds	T012	C0600537
poorly	T080	C0205169
represented	T052	C1882932
MeHg	T109	C0025794
neurotoxicology	T040	C0597059
studies	T062	C2603343
comparison	T052	C1707455
avian	T012	C0005595
orders	T185	C3858829
study	T062	C2603343
used	T169	C1524063
egg	T168	C0013710
injection method	T170	C0456651
investigate	T169	C1292732
long term effects	T067	C0023983
in ovo	T169	C2827729
MeHg	T109	C0025794
exposure	T080	C0332157
brain	T023	C0006104
histopathology	T169	C0243140
courtship behavior	T054	C0237550
model	T050	C0012644
songbird	T012	C0600538
species	T185	C1705920
zebra finch	T012	C0326833
Taeniopygia guttata	T012	C0326833
Egg	T168	C0013710
treatment	T169	C1522326
groups	UnknownType	C0681860
included	T169	C0332257
low	T080	C0205251
MeHg	T109	C0025794
dose	T081	C0178602
Hg	T131	C0025424
egg	T168	C0013710
high	T080	C0205250
MeHg	T109	C0025794
dose	T081	C0178602
Hg	T131	C0025424
egg	T168	C0013710
vehicle control	T122	C0042444
water	T121	C0043047
No adverse effects	T184	C0853204
in ovo	T169	C2827729
MeHg	T109	C0025794
treatment	T169	C1522326
detected	T033	C0442726
courtship	T054	C0237548
courtship song quality	T080	C0332306
mating behavior	T040	C1154349
experimental	T080	C1517586
males	T032	C0086582
sexually maturity	T033	C0233891
suggest	T078	C1705535
observable	T201	C1285601
neurobehavioral effects	UnknownType	C0815123
MeHg	T109	C0025794
exposure	T080	C0332157
timing	T079	C0040223
exposure	T080	C0332157
during	T079	C0347984
offspring	T099	C0680063
development	T039	C0243107
neuroanatomical	T080	C0220784
analysis	T062	C0936012
indicated	T033	C1444656
increase	T169	C0442805
telencephalon	T023	C0039452
volume	T081	C0449468
increased	T081	C0205217
MeHg	T109	C0025794
concentrations	T081	C1446561
suggest	T078	C1705535
prolonged	T079	C0439590
inflammatory response	T046	C1155266
region of the brain	T029	C1273723
Evaluation	T058	C0220825
Condom Barriers Scale	T170	C0349674
Young	T100	C0238598
Black Men Who Have Sex With Men	T098	C2827413
Reliability and Validity	T080	C0035036
Subscales	T170	C0349674
Reliable	T080	C0035037
valid	T080	C2349099
scale	T170	C0349674
measures	T081	C0086749
barriers	T061	C0004764
condom use	T055	C0679782
young	T100	C0238598
black men who have sex with men	T098	C2827413
YBMSM	T098	C2827413
Condom Barriers Scales	T170	C0349674
YBMSM	T098	C2827413
clinic-based	T080	C0205210
sample	T077	C2347026
YBMSM	T098	C2827413
computer-assisted	T059	C2362103
self-interview	T052	C0021822
measure	T081	C0086749
abbreviated version	T170	C0282574
Condom Barriers Scale	T170	C0349674
Reliability	T080	C0035037
criterion validity	T081	C2699472
subscales	T170	C0349674
reliable	T080	C0035037
partner	T098	C0036911
barriers	T061	C0004764
Cronbach α	T081	C0392762
sensation	T042	C0036658
barriers	T061	C0004764
motivation	T041	C0026605
barriers	T061	C0004764
complete absence of barriers	T033	C0517435
partner	T098	C0036911
sensation	T042	C0036658
motivation	T041	C0026605
subscales	T170	C0349674
significantly	T081	C0237881
associated with	T080	C0332281
condomless	T033	C0420844
insertive	T054	C0233979
anal sex	T055	C0282347
Ps	T081	C0392762
condomless	T033	C0420844
receptive	T042	C0544683
anal sex	T055	C0282347
Ps	T081	C0392762
subscales	T170	C0349674
significantly	T081	C0237881
associated with	T080	C0332281
measures	T081	C0086749
condomless	T033	C0420844
sex	T040	C0009253
continuous	T078	C0549178
level	T080	C0441889
Ps	T081	C0392762
sensation	T042	C0036658
barriers	T061	C0004764
associated with	T080	C0332281
condomless	T033	C0420844
anal sex	T055	C0282347
subscales	T170	C0349674
significantly	T081	C0237881
associated with	T080	C0332281
condom use	T055	C0679782
problems	T078	C1546466
Ps	T081	C0392762
measure	T081	C0086749
condomless	T033	C0420844
oral sex	T055	C0282348
Ps	T081	C0392762
partner	T098	C0036911
barriers	T061	C0004764
sensation	T042	C0036658
barriers	T061	C0004764
subscale	T170	C0349674
significantly	T081	C0237881
associated with	T080	C0332281
positive	T033	C1514241
Chlamydia	T007	C0008148
gonorrhea	T047	C0018081
subscales	T170	C0349674
reliability	T080	C0035037
validity	T080	C0042284
measures	T081	C0086749
observational	T062	C1518527
experimental research	T062	C0681814
YBMSM	T098	C2827413
Variation	T070	C0042333
Intensity	T080	C0522510
Selection	T045	C0036576
Codon	T086	C0009221
Bias	T078	C0242568
Time	T079	C0040223
Contrasting Patterns	T082	C0449774
Base Composition	T081	C0004790
Evolution	T045	C0015219
Drosophila	T204	C0013138
degenerate	T169	C1880269
coding sites	T028	C0079941
genome	T028	C0017428
selection	T045	C0036576
demography	T078	C0011292
evolution	T045	C0015219
base composition	T081	C0004790
changes	T169	C0392747
sites	T028	C0079941
Drosophila	T204	C0013138
issue	T033	C0033213
whole-genome polymorphism data set	T170	C3242346
D. simulans	T204	C0998507
analyzed	T062	C0936012
samples	T026	C0444241
D. simulans	T204	C0998507
polymorphism data set	T170	C3242346
D. melanogaster	T204	C0013139
D. yakuba	T204	C0998511
outgroup	T098	C0871022
evidence	T078	C3887511
selection	T045	C0036576
sites	T028	C0079941
lineages	T078	C0282637
substantial period	T079	C1948053
intensity	T080	C0522510
selection	T045	C0036576
GC content	T081	C1135899
model	T075	C0026339
base composition	T081	C0004790
evolution	T045	C0015219
observed	T169	C1441672
biased	T078	C0242568
substitution pattern	T082	C0449774
lineages	T078	C0282637
ancestral reduction	T080	C0392756
selection	T045	C0036576
intensity	T080	C0522510
result	T034	C0456984
increase	T169	C0442805
mutational	T045	C0026882
bias	T078	C0242568
polymorphism-based methods	T060	C0796451
estimating	T081	C0750572
selection	T045	C0036576
coefficients	T081	C1707429
selection	T045	C0036576
intensity	T080	C0522510
codon	T086	C0009221
stable	T080	C0205360
D. simulans	T204	C0998507
long-term	T079	C0443252
estimates	T081	C0750572
D. melanogaster	T204	C0013139
higher	T080	C0205250
short-term	T079	C0443303
continuing	T078	C0549178
decline	T081	C0282251
selection	T045	C0036576
intensity	T080	C0522510
extent	T082	C0439792
short-term	T079	C0443303
estimates	T081	C0750572
selection	T045	C0036576
active	T169	C0205177
GC	T081	C1135899
genome	T028	C0017428
evidence	T078	C3887511
complex	T080	C0439855
evolutionary patterns	T082	C0449774
neutral short introns	T114	C0021920
standard	T081	C0034925
GC	T081	C1135899
biased	T078	C0242568
gene conversion	T045	C0017259
model	T075	C0026339
results	T034	C0456984
dynamic	T169	C0729333
base composition	T081	C0004790
evolution	T045	C0015219
Case	T169	C0868928
Koch's Spine	T047	C0041330
Treated	T169	C1522326
Modified	T169	C0392747
Transpedicular Vertebral Curettage	T061	C0010468
Posterior	T082	C0205095
Fixation	T061	C0185023
Technique	T169	C0449851
Tuberculosis	T047	C0041296
TB	T047	C0041296
chronic	T079	C0205191
granulomatous infection	T047	C1610637
acid-fast mycobacterium tuberculosis bacilli	T007	C0026926
Spinal involvement	T029	C0444534
TB	T047	C0041296
Spinal TB	T047	C0041330
Pott's disease	T047	C0041330
skeletal TB	UnknownType	C0041329
thoracolumbar junction	T030	C0224591
level	T080	C0441889
spine	T023	C0037949
diagnosis	T033	C0011900
treatment	T061	C0087111
neurological complications	T046	C0235029
spinal deformity	T190	C0575157
report	T170	C0684224
case	T169	C0868928
young	T079	C0332239
female	T032	C0086287
tuberculosis	T047	C0041330
D12-L1	T030	C0507384
treated	T169	C1522326
posterior	T082	C0205095
decompression	T061	C1829459
modified	T169	C0392747
transpedicular approach	T061	C0010468
posterior	T082	C0205095
instrumentation	T061	C0356967
outcome	T169	C1274040
comparison	T052	C1707455
comorbidity indices	T081	C1516737
predicting	T078	C0681842
inpatient	T101	C0021562
rehabilitation	T061	C0034991
outcomes	T080	C0085415
Comorbid conditions	T033	C1275743
health care	T058	C0086388
comorbidity index	T081	C1516737
predicting	T078	C0681842
impact	T080	C4049986
comorbidities	T078	C0009488
rehabilitation	T061	C0034991
outcomes	T080	C0085415
determined	T080	C0521095
Compare	T052	C1707455
associations	T080	C0439849
comorbidity	T078	C0009488
measured	T080	C0444706
Charlson Comorbidity Index	T081	C1516737
CCI	T081	C1516737
Cumulative Index Rating Scale	T081	C0681889
CIRS	T081	C0681889
rehabilitation	T061	C0034991
outcomes	T080	C0085415
determine	T080	C0521095
comorbidity indices	T081	C1516737
variation	T080	C0205419
rehabilitation	T061	C0034991
outcomes	T080	C0085415
Prospective open-cohort study	T062	C1709709
Inpatient	T101	C0021562
rehabilitation	T061	C0034991
ward	T073	C1305702
Melbourne	T083	C0004340
Australia	T083	C0004340
Adults	T100	C0001675
admitted	T058	C0184666
inpatient	T101	C0021562
rehabilitation	T061	C0034991
outcomes	T080	C0085415
demographic	T078	C0011292
age	T032	C0001779
gender	T032	C0079399
discharge	T058	C0030685
destination	T082	C0079220
clinical	T080	C0205210
outcomes	T080	C0085415
reason	T033	C0566251
rehabilitation	T061	C0034991
length of stay	T079	C0023303
Functional Independence Measure	T170	C0451172
CCI	T081	C1516737
CIRS	T081	C0681889
regression analyses	T170	C0034980
performed	T169	C0884358
determine	T080	C0521095
influence	T077	C4054723
comorbidity	T078	C0009488
dependent variables	T169	C0871711
LOS	T079	C0023303
rehabilitation	T061	C0034991
change	T081	C0443172
Functional Independence Measure-motor	T170	C0451172
score	T081	C0449820
rehabilitation	T061	C0034991
discharge	T058	C0030685
admission	T058	C0184666
discharge	T058	C0030685
destination	T082	C0079220
home	T082	C0442519
mean	T081	C0444504
age	T032	C0001779
years	T079	C0439234
females	T032	C0086287
patients	T101	C0030705
previously	T079	C0205156
lived at home	T033	C0425078
family	T099	C0015576
relatives	T099	C0080103
reason	T033	C0566251
rehabilitation	T061	C0034991
orthopaedic	T061	C1136201
conditions	T080	C0348080
people	T098	C0027361
discharged	T058	C0030685
home	T082	C0442519
LOS	T079	C0023303
days	T079	C0439228
patients	T101	C0030705
comorbidity	T078	C0009488
recorded	T170	C0034869
CCI	T081	C1516737
patients	T101	C0030705
comorbidity	T078	C0009488
recorded	T170	C0034869
CIRS	T081	C0681889
comorbidities	T078	C0009488
difference	T080	C1705242
CCI	T081	C1516737
CIRS	T081	C0681889
ability	T032	C0085732
variance	T080	C1711260
LOS	T079	C0023303
R2	T081	C2827748
comorbidities	T078	C0009488
change	T081	C0443172
disability	T033	C0231170
rehabilitation	T061	C0034991
R2	T081	C2827748
comorbidities	T078	C0009488
discharge	T058	C0030685
destination	T082	C0079220
comorbidities	T078	C0009488
comorbidities	T078	C0009488
demographic	T078	C0011292
clinical information	T170	C2708733
CIRS	T081	C0681889
CCI	T081	C1516737
patient	T101	C0030705
sample	T167	C0370003
provide	T052	C1999230
information	T078	C1533716
impact	T080	C4049986
comorbidities	T078	C0009488
rehabilitation	T061	C0034991
outcomes	T080	C0085415
research	T062	C0035168
determine	T080	C0521095
appropriate	T080	C1548787
measure	T081	C0079809
comorbidity	T078	C0009488
relevance	T080	C2347946
inpatient	T101	C0021562
rehabilitation	T061	C0034991
outcomes	T080	C0085415
Internet Gaming	T056	C3842705
Disorder	T048	C0004936
Unique Variance	T080	C1711260
Psychological Distress	T048	C0815107
Disability	T033	C0231170
Comorbid	T033	C1275743
Depression	T048	C0011570
OCD	T048	C0028768
ADHD	T048	C1263846
Anxiety	T033	C0003467
study	T062	C2603343
knowledge	T170	C0376554
relationship	T080	C0439849
Internet Gaming Disorder	T048	C0004936
IGD	T048	C0004936
mental disorders	T048	C0004936
comorbidities	T078	C0009488
anxiety	T033	C0003467
depression	T048	C0011570
Attention Deficit Hyperactivity Disorder	T048	C1263846
ADHD	T048	C1263846
obsessive compulsive disorder	T048	C0028768
OCD	T048	C0028768
assessing	T058	C0184514
IGD	T048	C0004936
unique variance	T080	C1711260
distress	T033	C0231303
disability	T033	C0231170
online survey	T170	C0038951
convenience sample	T062	C0150095
Internet gaming	T056	C3842705
Participants	T098	C0679646
meeting criteria	T077	C1254372
IGD	T048	C0004936
Personal Internet Gaming Disorder Evaluation-9	T062	C0242481
PIE-9	T062	C0242481
higher comorbidity	T078	C0009488
depression	T048	C0011570
OCD	T048	C0028768
ADHD	T048	C1263846
anxiety	T033	C0003467
IGD	T048	C0004936
criteria	T078	C0243161
IGD	T048	C0004936
proportion	T081	C1709707
unique variance	T080	C1711260
distress	T033	C0231303
disability	T033	C0231170
IGD	T048	C0004936
larger proportion	T081	C1709707
unique variance	T080	C1711260
disability	T033	C0231170
anxiety	T033	C0003467
ADHD	T048	C1263846
proportion	T081	C1709707
depression	T048	C0011570
Replications	T080	C1883725
clinical samples	T098	C2349001
longitudinal designs	T052	C1707689
structured diagnostic interviews	UnknownType	C0681913
Real	T080	C0237400
Impact	T080	C4049986
Urinary Incontinence	T046	C0042024
Female Sexual Dysfunction	T048	C1112442
Case Control Study	T062	C0007328
Urinary incontinence	T046	C0042024
UI	T046	C0042024
associated with	T080	C0332281
negative	T033	C0205160
effects	T080	C1280500
women's	T098	C0043210
sexuality	T053	C0036915
Women's	T098	C0043210
sexuality	T053	C0036915
sexual function	T040	C0278092
complex	T080	C0439855
issue	T033	C0033213
role	T077	C1705810
UI	T046	C0042024
not completely	T080	C0205257
assess	T052	C1516048
impact	T080	C4049986
UI	T046	C0042024
female sexual function	T040	C0278098
comparing	T052	C1707455
population	T098	C1257890
control group	T096	C0009932
continent	T080	C0443192
women	T098	C0043210
case-control study	T062	C0007328
evaluated	T058	C0220825
continent	T080	C0443192
incontinent	T169	C0231238
women	T098	C0043210
age	T032	C0001779
range	T081	C1514721
sexuality	T053	C0036915
patients	T101	C0030705
evaluated	T058	C0220825
anamnesis	T042	C0021055
physical examination	T058	C0031809
self-report	T062	C2700446
quality-of-life questionnaires	T170	C0451149
incontinent	T169	C0231238
women	T098	C0043210
pad test	T060	C0430973
Patients	T101	C0030705
sexual activity	T053	C0036864
evaluated	T058	C0220825
role	T077	C1705810
UI	T046	C0042024
sexual abstinence	T055	C0036899
Sexual abstinence	T055	C0036899
absence of sexual activity	T033	C3840693
sexually active	T033	C0241028
women	T098	C0043210
self-report	T062	C2700446
Sexuality	T053	C0036915
Quotient	T081	C2347741
Female	T032	C0086287
Version	T170	C0333052
questionnaire	T170	C0034394
women	T098	C0043210
study	T062	C2603343
incontinent	T169	C0231238
continent	T080	C0443192
Sexual abstinence	T055	C0036899
women	T098	C0043210
Incontinent	T169	C0231238
women	T098	C0043210
higher prevalence	T081	C1512456
sexual abstinence	T055	C0036899
counterparts	T099	C0682323
Age	T032	C0001779
marital status	T102	C0024819
UI	T046	C0042024
isolated	T169	C0205409
predictive factors	T170	C0683956
sexual abstinence	T055	C0036899
incontinent	T169	C0231238
women	T098	C0043210
Sexually active	T033	C0241028
women	T098	C0043210
incontinent	T169	C0231238
continent	T080	C0443192
demographic	T090	C0011298
data	T078	C1511726
frequency	T079	C0439603
sexual activity	T053	C0036864
incontinent	T169	C0231238
women	T098	C0043210
sexual desire	T048	C1409687
foreplay	T033	C0558138
harmony	T054	C0699798
partner	T098	C3887537
sexual comfort	T041	C1331418
sexual satisfaction	T041	C0871356
Women	T098	C0043210
greater	T081	C1704243
urinary leakage	T033	C3897214
pad test	T060	C0430973
weight	T081	C0043100
sexual function	T040	C0278092
score	T081	C0449820
Women	T098	C0043210
UI	T046	C0042024
sexual abstinent	T055	C0036899
continent	T080	C0443192
women	T098	C0043210
women	T098	C0043210
UI	T046	C0042024
sexual desire	T048	C1409687
sexual comfort	T041	C1331418
sexual satisfaction	T041	C0871356
counterparts	T099	C0682323
frequency	T079	C0439603
sexual activity	T053	C0036864
Salvianolic Acids	T109	C3252265
Injection	T122	C1272883
SAFI	T122	C1272883
suppresses	T169	C1260953
inflammatory responses	T046	C1155266
activated	T052	C1879547
microglia	T025	C0206116
attenuate	T052	C0599946
brain damage	T037	C0270611
focal cerebral ischemia	T047	C0917798
Inflammatory reactions	T046	C0021368
microglia	T025	C0206116
brain	T023	C0006104
roles	T077	C1705810
ischemia	T047	C0007786
reperfusion (I/R) cerebral injuries	T037	C3854511
Microglia	T025	C0206116
activation	T052	C1879547
TLR4	T044	C2247725
NF-κB signal pathways	T045	C1513838
Salvianolic acids	T109	C3252265
injection	T122	C1272883
SAFI	T122	C1272883
clinical practice	T057	C0205897
treat	T169	C1522326
ischemic stroke	T047	C0948008
reported	T058	C0700287
neuroprotective effects	T169	C0815279
mechanisms	T169	C0441712
studied	T062	C2603343
effect	T080	C1280500
SAFI	T122	C1272883
inflammatory responses	T046	C1155266
LPS	T109	C0023810
stimulated	T070	C1948023
BV-2	T007	C4075604
microglia	T025	C0206116
discover	T052	C1880355
beneficial	T081	C0814225
in vitro	T062	C0681828
effects	T080	C1280500
SAFI	T122	C1272883
in vivo	T062	C0681829
therapeutic effect	T201	C1527144
MCAO	T020	C0740391
Middle cerebral artery occlusion	T020	C0740391
rat	T015	C0034721
model	T050	C0012644
employed	T033	C0557351
mechanism	T169	C0441712
SAFI	T122	C1272883
treating	T169	C1522326
ischemic stroke	T047	C0948008
Rats	T015	C0034721
SAFI	T122	C1272883
group	T078	C0441833
SAFI	T122	C1272883
I	T047	C0917798
R injury	T037	C3854511
results	T169	C1274040
SAFI	T122	C1272883
treatment	T169	C1522326
significantly decreased	T081	C4055638
neuroinflammation	T046	C0021368
infarction	T046	C0021308
volume	T081	C0449468
vehicle	T122	C0042444
group	T078	C0441833
Activation	T052	C1879547
microglia cells	T025	C0206116
reduced	T080	C0392756
TLR4	T044	C2247725
NF-κB signals	T045	C1513838
inhibited	T080	C0311403
SAFI	T122	C1272883
treatment	T169	C1522326
ischemic	T169	C0475224
hemisphere	T023	C0228174
reduced	T080	C0392756
expression	T045	C1171362
release	T058	C0680255
cytokines	T116	C0079189
IL-1β	T116	C0021753
IL-6	T116	C0021760
study	T062	C2603343
evidence	T078	C3887511
SAFI	T122	C1272883
effectively	T080	C1704419
brain	T023	C0006104
cerebral ischemia	T047	C0917798
attenuating	T052	C0599946
inflammation	T046	C0021368
microglia	T025	C0206116
Dynamics	T070	C3826426
bacterial	T080	C0521009
class Bacilli	T007	C1040746
deepest valley lake	T083	C0337049
Kashmir	UnknownType	C0681784
Manasbal Lake	T083	C0337049
bacteria	T007	C0004611
ecological indicators	T130	C0021212
aquatic systems	T070	C0162358
comprehensive and systematic analysis	T062	C0936012
Manasbal Lake	T083	C0337049
deepest spring fed valley lake	T083	C0337049
Kashmir	UnknownType	C0681784
analyze	T062	C0936012
bacterial community composition	T080	C2936393
BCC	T080	C2936393
systematic	T081	C1710275
regular sampling of waters	T057	C0597681
waters	T121	C0043047
sampling stations	T082	C0449705
Lake	T083	C0337049
degree of human interference	T080	C0205556
zones	T082	C1710706
ecological interests	T078	C1254370
isolated	T169	C0205409
species	T185	C1705920
identified	T080	C0205396
Bergey's Manual specification	T170	C0282574
micro and macro morphological characteristics	T080	C1521970
biochemical characteristics	T080	C1521970
culture media	T130	C0010454
confirmation	T033	C0750484
sequencing	T169	C1561491
16s rRNA gene	T028	C0035899
universal bacterial primers	T114	C0073429
27F	T114	C0073429
1429R	T114	C0073429
sampling stations	T082	C0449705
class Bacilli	T007	C1040746
maximum	T081	C0806909
relative abundance	T080	C2346714
contribution	T052	C1880177
bacterial species	T185	C1705920
process	T067	C1522240
identification	T080	C0205396
Bacillus aerius	T007	C2617064
Bacillus altitudinis	T007	C2617063
Bacillus anthracis	T007	C0004589
Bacillus cereus	T007	C0004590
Bacillus ginsengisoli	T007	C3717612
Bacillus pumilus	T007	C0314874
Bacillus safensis	T007	C2654376
Bacillus stratosphericus	T007	C2617062
Bacillus subtilis	T007	C0004595
Bacillus tequilensis	T007	C1462983
Bacillus thermocopriae	T007	C3721500
Bacillus thuringiensis	T007	C0004597
Brevibacillus agri strain	T007	C1015757
Lysinibacillus boronitolerans	T007	C1664577
Lysinibacillus pakistanensis	T007	C3557569
Lysinibacillus sphaericus	T007	C0314884
angle	T082	C0205143
fixation failure	T046	C0410837
femoral neck fractures	T037	C0015806
cannulated compression screws	T074	C0005975
angle	T082	C0205143
deformity	T190	C0302142
affected	T169	C0392760
lower extremity	T023	C0023216
measurement	T169	C0242485
orientation	T082	C1704322
femoral neck fracture	T037	C0015806
retrospective study	T062	C0035363
reproducibility	T080	C1514863
short-term prognosis	T058	C0033325
treated	T169	C1522326
cannulated compression screws	T074	C0005975
measurement	T169	C0242485
treatment	T061	C0087111
femoral neck fractures	T037	C0015806
patients	T101	C0030705
femoral neck fractures	T037	C0015806
cannulated compression screws	T074	C0005975
retrospectively analyzed	T062	C0936012
angle	T082	C0205143
fracture line	T082	C1254362
vertical	T082	C0205128
neck axis	T082	C1522496
ICC	T081	C1707429
reproducibility	T080	C1514863
angles	T082	C0205143
pre-operative	T079	C0445204
post-operative	T079	C0032790
radiographs	T060	C1306645
angles	T082	C0205143
fractures	T037	C0016658
groups	T078	C0441833
months	T079	C0439231
fixation	T061	C0016641
radiographs	T060	C1306645
fractures	T037	C0016658
ICC	T081	C1707429
pre-operative	T079	C0445204
radiographs	T060	C1306645
confidence interval	T081	C0009667
CI	T081	C0009667
CI	T081	C0009667
angles	T082	C0205143
inter-rater reproducibility	T080	C1514863
pre-operative	T079	C0445204
post-operative	T079	C0032790
radiographs	T060	C1306645
fixation failure	T046	C0410837
rate	T081	C1521828
screw loosening	T046	C0410830
fracture displacement	T037	C0585059
femoral neck	T023	C0015815
CI	T081	C0009667
CI	T081	C0009667
CI	T081	C0009667
failure rates	T081	C1521828
fractures	T037	C0016658
post-operative	T079	C0032790
CI	T081	C0009667
CI	T081	C0009667
inter-rater reproducibility	T080	C1514863
short-term prognosis	T058	C0033325
femoral neck fractures	T037	C0015806
cannulated compression screws	T074	C0005975
Retirement	T033	C0035345
crisis	T033	C0231224
warnings	T080	C1550014
reality	T078	C0871222
figures	T081	C0237753
startling	T033	C0243095
NHS	T064	C0027461
staff	T097	C0028698
retire	T033	C0035345
surged	T169	C0442805
consequences	T169	C0686907
alarming	T080	C0205404
shortage	T081	C0392762
nurses	T097	C0028661
healthcare professionals	T097	C1704312
inevitable	T080	C0205423
Burden	T081	C0162698
Mental Disorders	T048	C0004936
Eastern Mediterranean Region	T083	C0282645
Eastern Mediterranean Region	T083	C0282645
EMR	T083	C0282645
increase	T169	C0442805
chronic disorders	T047	C0008679
mental illness	T048	C0004936
study	T062	C0008972
burden	T081	C0162698
mental disorders	T048	C0004936
EMR	T083	C0282645
data	T078	C1511726
Global Burden of Disease study	T170	C4277729
GBD	T170	C4277729
DALYs	UnknownType	C4300518
disability-adjusted life years	UnknownType	C4300518
assessment	T058	C0220825
premature mortality	T033	C1855073
years of life lost	T081	C2713320
YLLs	T081	C2713320
years lived with disability	T079	C1254367
YLDs	T079	C1254367
DALYs	UnknownType	C4300518
YLLs	T081	C2713320
YLDs	T079	C1254367
mental disorders	T048	C0004936
total disease burden	T081	C0162698
EMR	T083	C0282645
DALYS	UnknownType	C4300518
population	T098	C1257890
DALYS	UnknownType	C4300518
males	T032	C0086582
females	T032	C0086287
high-income	T033	C0948433
high-income countries	T083	C0454664
DALYS	UnknownType	C4300518
males	T032	C0086582
females	T032	C0086287
middle-income	T080	C0870890
countries	T083	C0454664
DALYS	UnknownType	C4300518
males	T032	C0086582
females	T032	C0086287
low-income	T033	C1331016
countries	T083	C0454664
Females	T032	C0086287
burden	T081	C0162698
mental disorders	T048	C0004936
males	T032	C0086582
ages	T032	C0001779
years of age	T079	C1510829
DALYs	UnknownType	C4300518
age group	T100	C0027362
age group	T100	C0027362
DALYs	UnknownType	C4300518
burden	T081	C0162698
mental disorders	T048	C0004936
EMR	T083	C0282645
DALYs	UnknownType	C4300518
DALYs	UnknownType	C4300518
mental disorders group	T098	C1257890
EMR	T083	C0282645
depressive disorders	T048	C0011581
DALYs	UnknownType	C4300518
anxiety disorders	T048	C0003469
EMR	T083	C0282645
Palestine	UnknownType	C0681784
burden of mental disorders	T081	C0162698
mental disorders	T048	C0004936
EMR countries	T083	C0454664
mental disorder burden	T081	C0162698
EMR ministries	UnknownType	C0683710
provision	T033	C1821241
mental health services	T058	C0025355
stigma of mental illness	T033	C3825632
accelerating	T169	C0442808
burden of mental health	T081	C0162698
instability	T033	C1444783
mental health problems	T033	C1446377
increased	T081	C0205217
burden of diseases	T081	C0162698
region	T083	C0017446
Father	T099	C0015671
Daughter	T099	C0011011
inherited	T169	C0439660
cutis aplasia	T019	C0282160
family	T099	C0015576
Marfan syndrome	T047	C0024796
case report	T170	C0085973
case	T169	C0868928
newborn	T100	C0021289
co-occurrence	T079	C2745955
Marfan syndrome	T047	C0024796
aplasia cutis congenita	T019	C0282160
ACC	T019	C0282160
family history	T033	C0241889
significant	T078	C0750502
Marfan syndrome	T047	C0024796
ACC	T019	C0282160
father	T099	C0015671
case	T169	C0868928
details	T080	C1522508
mutation	T045	C0026882
Marfan syndrome	T047	C0024796
coinheritance	T169	C0728826
Marfan syndrome	T047	C0024796
ACC	T019	C0282160
Hyperandrogenemia	T033	C1299574
women	T098	C0043210
polycystic ovary syndrome	T047	C0032460
prevalence	T081	C0220900
characteristics	T080	C1521970
association with	T080	C0332281
body mass index	T201	C1305855
Hyperandrogenemia	T033	C1299574
diagnostic	T169	C0348026
diagnosis	T033	C0011900
polycystic ovary syndrome	T047	C0032460
PCOS	T047	C0032460
estimate	T081	C0750572
prevalence	T081	C0220900
characteristics	T080	C1521970
hyperandrogenemia	T033	C1299574
women	T098	C0043210
PCOS	T047	C0032460
investigate	T169	C1292732
clinical	T080	C0205210
biochemical	T169	C0205474
characteristics	T080	C1521970
body mass index	T201	C1305855
BMI	T201	C1305855
presence	T033	C0150312
hyperandrogenemia	T033	C1299574
women	T098	C0043210
diagnosed	T033	C0011900
PCOS	T047	C0032460
Hyperandrogenemia	T033	C1299574
testosterone	T109	C0039601
T	T109	C0039601
free testosterone	T109	C0443483
FT	T109	C0443483
∆4 androstenedione	T109	C4284099
Δ4-A	T109	C4284099
hormone	T125	C0019932
Patients	T101	C0030705
stratified	T080	C0205363
groups	T098	C1257890
BMI	T201	C1305855
threshold	T080	C0449864
Hyperandrogenemia	T033	C1299574
present	T033	C0150312
patients	T101	C0030705
Elevated	T080	C3163633
T	T109	C0039601
elevated	T080	C3163633
FT	T109	C0443483
Δ4-A	T109	C4284099
patients	T101	C0030705
normal weight	T033	C2712185
women	T098	C0043210
BMI	T201	C1305855
hyperandrogenemia	T033	C1299574
hip circumference	T201	C0562350
HOMA-IR	T059	C3639411
increased	T081	C0205217
T	T109	C0039601
FT	T109	C0443483
Δ4-A	T109	C4284099
17-hydroxyprogesterone	T109	C0045010
17-OHP	T109	C0045010
dehydroepiandrosterone sulfate	T109	C0057277
DHEAS	T109	C0057277
white blood cells	T025	C0023516
WBC	T025	C0023516
neutrophils	T025	C0027950
women	T098	C0043210
hyperandrogenemia	T033	C1299574
overweight	T184	C0497406
women	T098	C0043210
T	T109	C0039601
FT	T109	C0443483
Δ4-A	T109	C4284099
17-OHP	T109	C0045010
DHEAS	T109	C0057277
cortisol	T109	C0020268
measured	T080	C0444706
thyroid-stimulating hormone (TSH) levels	T059	C0202230
women	T098	C0043210
hyperandrogenemia	T033	C1299574
prevalence	T081	C0220900
hyperandrogenemia	T033	C1299574
PCOS	T047	C0032460
women	T098	C0043210
Women	T098	C0043210
BMI	T201	C1305855
significant	T078	C0750502
androgens	T121	C0002844
WBC	T025	C0023516
neutrophils	T025	C0027950
HOMA-IR	T059	C3639411
women	T098	C0043210
BMI	T201	C1305855
androgens	T121	C0002844
TSH	T121	C2825077
cortisol	T109	C0020268
presence	T033	C0150312
hyperandrogenemia	T033	C1299574
Course	T079	C0750729
Approach	T082	C0449445
Doctor	T097	C0031831
Nursing Practice Project	T062	C0008967
Student	T098	C0038492
Concept	T078	C0178566
Completion	T080	C0205197
course	T079	C0750729
approach	T082	C0449445
doctor	T097	C0031831
nursing practice project	T062	C0008967
students	T098	C0038492
work	T057	C0043227
groups	T078	C0441833
faculty member	T097	C0015535
complete	T080	C0205197
projects	T077	C1709701
minimum	T080	C1524031
practicum	T065	C0032929
hours	T079	C0439227
semester	T079	C2348178
courses	T079	C0750729
Project teams	T096	C0871489
agency	T092	C0237463
community	T096	C0009462
mentors	T098	C0025369
Project findings	T033	C0243095
disseminated	T082	C0205221
written	T170	C0684224
oral reports	T170	C0684224
approach	T082	C0449445
faculty	T097	C0015535
resources	T169	C0024752
students	T098	C0038492
mentoring	T065	C4255266
opportunities	T078	C1254370
reflection	T054	C0037397
time	T079	C0040223
project development	T169	C1527148
Clinical	T080	C0205210
angiographic	T060	C0002978
correlation	T080	C1707520
high-sensitivity C-reactive protein	T116	C0006560
acute ST elevation myocardial infarction	T047	C1303258
Vascular inflammation	T047	C0947751
inflammatory responses	T046	C1155266
pathogenesis	T046	C0699748
acute	T079	C0205178
atherothrombotic	T020	C1963943
events	T051	C0441471
acute coronary syndrome	T047	C0948089
ACS	T047	C0948089
myocardial infarction	T047	C0027051
MI	T047	C0027051
ST segment elevation myocardial infarction	T047	C1536220
STEMI	T047	C1536220
clinical	T080	C0205210
forms	T080	C0348078
ACS	T047	C0948089
C-reactive protein	T116	C0006560
CRP	T116	C0006560
acute phase prsotein	T116	C0001347
high-sensitivity methods	T059	C3839560
hs-CRP	T059	C3839560
elevated	T080	C3163633
level	T034	C0428528
body fluids	T031	C0005889
chronic inflammatory	T046	C0021376
status	T080	C0449438
hs-CRP	T059	C3839560
level	T034	C0428528
inflammatory	T046	C0021368
marker	T201	C0005516
coronary artery disease	T047	C0010054
CAD	T047	C0010054
study	T062	C2603343
investigated	T169	C1292732
correlation	T080	C1707520
hs-CRP	T059	C3839560
level	T034	C0428528
clinical	T080	C0205210
angiographic	T060	C0002978
features	T080	C2348519
STEMI	T047	C1536220
risk factors	T033	C0035648
complications	T046	C0009566
myocardial infarction	T047	C0027051
angiographically significant	T078	C0750502
CAD	T047	C0010054
patients	T101	C0030705
STEMI	T047	C1536220
analyzed	T062	C0936012
interval	T079	C1272706
symptom onset	T079	C4086878
reperfusion therapy	T061	C0035124
window period	T079	C1948053
h	T079	C0439227
hs-CRP	T059	C3839560
non-diabetic patients	T101	C0030705
compared	T052	C1707455
diabetic	T047	C0011847
patients	T101	C0030705
correlation	T080	C1707520
hs-CRP	T059	C3839560
hs-troponin T	T059	C3827339
hs-CRP	T059	C3839560
values	T080	C0042295
patients	T101	C0030705
mortality	T081	C0205848
study	T062	C2603343
atherosclerosis	T047	C0004153
clinical applications	T058	C1254363
therapy	T061	C0087111
disease	T047	C0012634
Bioelectrochemical	T059	C2350499
anaerobic	T080	C3641081
sewage treatment	T057	C0597443
technology	T090	C0039421
Arctic	T083	C0003740
communities	T096	C0009462
study	T062	C2603343
wastewater	T083	C0450237
treatment	T169	C1522326
technology	T090	C0039421
remote	T082	C0205157
northern	T082	C1709269
communities	T096	C0009462
technology	T090	C0039421
based	T169	C1527178
enhanced	T052	C2349975
biodegradation	T070	C0005482
organic carbon	T104	C0302333
anaerobic	T080	C3641081
methanogenic	T194	C0025621
microbial	T001	C0599840
electrochemical	T059	C2350499
bioelectrochemical	T059	C2350499
degradation processes	T169	C0243125
biomethane	T109	C0029224
production	T169	C1522492
microbial	T001	C0599840
electrochemical	T059	C2350499
degradation	T169	C0243125
membraneless flow	T033	C0243095
bioanode	T073	C0003103
biocathode	T073	C0007441
operating	T169	C3242339
applied	T169	C4048755
voltage	T081	C0598352
water	T121	C0043047
electrolysis	T061	C0013829
threshold	T080	C0449864
Laboratory	T073	C0022877
wastewater	T083	C0450237
treatment	T169	C1522326
tests	T170	C0392366
broad range	T082	C0332464
mesophilic	T080	C0205081
psychrophilic temperatures	T070	C0009264
synthetic	T080	C2004457
wastewater	T083	C0450237
biochemical oxygen demand	T059	C3826658
BOD5	T059	C3826658
removal	T052	C1883720
efficiency	T081	C0013682
effluent	T170	C1546612
BOD5	T059	C3826658
concentration	T081	C1446561
electricity	T070	C0013790
consumption	T169	C0457083
chemical oxygen demand	T038	C2936287
COD	T038	C2936287
removed	T080	C0849355
observed	T169	C1441672
Low	T080	C0205251
energy	T081	C1442080
consumption	T169	C0457083
enhanced	T052	C2349975
methane	T109	C0025617
production	T169	C1522492
positive	T033	C1446409
energy	T081	C1442080
balance	T169	C0205415
bioelectrochemical	T059	C2350499
treatment	T169	C1522326
system	T169	C0449913
Impact	T080	C4049986
femoral artery	T023	C0015801
puncture	T058	C0034117
digital subtraction angiography	T060	C0002979
road mapping	T052	C1283195
vascular	T047	C1393529
bleeding	T046	C0019080
complications	T046	C0009566
transcatheter aortic valve implantation	T061	C3509486
large	T081	C0549177
diameter	T081	C1301886
risk	T078	C0035647
vascular	T047	C1393529
bleeding	T046	C0019080
complications	T046	C0009566
transcatheter aortic valve implantation	T061	C3509486
TAVI	T061	C3509486
analysis	T062	C0936012
assess	T058	C0184514
impact	T080	C4049986
femoral artery	T023	C0015801
puncture	T058	C0034117
technique	T169	C0449851
digital subtraction angiography	T060	C0002979
DSA	T060	C0002979
road mapping	T052	C1283195
TAVI	T061	C3509486
periprocedural	T046	C1141861
vascular	T023	C0005847
bleeding	T046	C0019080
analysis	T062	C0936012
TAVI	T061	C3509486
patients	T101	C0030705
prospective institutional database	T170	C0242356
femoral artery	T023	C0015801
puncture	T058	C0034117
technique	T169	C0449851
DSA	T060	C0002979
road mapping	T052	C1283195
technique	T169	C0449851
vascular	T023	C0005847
puncture	T058	C0034117
angiographic	T060	C0002978
data	T078	C1511726
bony	T169	C0443157
iliofemoral	T023	C1279169
landmarks	T029	C0504075
radiopaque object	T074	C0181739
patients	T101	C0030705
TAVI	T061	C3509486
road mapping	T052	C1283195
technique	T169	C0449851
RM group	T078	C0441833
patients	T101	C0030705
TAVI	T061	C3509486
road mapping	T052	C1283195
control group	T096	C0009932
periprocedural anticoagulation	T061	C0003281
groups	T078	C0441833
single suture-based closure device	T074	C0025080
endpoints	T080	C2349179
VARC-2 criteria	T170	C0282574
RM group	T078	C0441833
years	T079	C0439234
years	T079	C0439234
control group	T096	C0009932
females	T032	C0086287
groups	T078	C0441833
baseline logistic EuroSCORE	T170	C3164744
RM	T078	C0441833
control group	T096	C0009932
sheath size	T082	C0456389
RM	T078	C0441833
control group	T096	C0009932
associated with	T080	C0332281
implantation	T061	C0021107
RM group	T078	C0441833
vascular complications	T047	C1393529
bleeding	T046	C0019080
days	T079	C0439228
lower	T080	C0205251
RM group	T078	C0441833
control group	T096	C0009932
analysis	T062	C0936012
complications	T046	C0009566
road map group	T078	C0441833
statistical significance	T081	C0237881
vascular	T047	C1393529
bleeding	T046	C0019080
complications	T046	C0009566
all-cause mortality	T081	C0178686
groups	T078	C0441833
femoral artery	T023	C0015801
puncture	T058	C0034117
technique	T169	C0449851
DSA	T060	C0002979
road mapping	T052	C1283195
associated with	T080	C0332281
vascular	T047	C1393529
bleeding	T046	C0019080
complications	T046	C0009566
TAVI	T061	C3509486
simple	T080	C0205352
effective	T080	C1704419
patient outcomes	T170	C2987124
Differential	T080	C1705242
Roles	T078	C1552020
AXIN1	T116	C1438871
AXIN2	T116	C1454580
Tankyrase	T116	C0963182
Inhibitor-Induced	T121	C0014432
Formation	T169	C1522492
Degradasomes	T116	C1180347
β-Catenin	T116	C0105770
Degradation	T169	C0243125
Inhibition	T039	C1524081
tankyrase enzymes	T116	C0963182
TNKS1	T116	C1504783
TNKS2	T116	C1448153
highly	T080	C0205250
dynamic	T169	C0729333
assemblies	T044	C0872376
β-catenin	T116	C0105770
destruction complex	T104	C1704241
components	T116	C1179435
degradasomes	T116	C1180347
promote	T052	C0033414
degradation	T169	C0243125
β-catenin	T116	C0105770
reduced	T080	C0392756
Wnt signaling	T044	C1520113
activity	T169	C0205177
colorectal cancer	T191	C1527249
cells	T025	C0007634
AXIN1	T116	C1438871
AXIN2	T116	C1454580
Conductin	T116	C1454580
rate-limiting	T169	C0489879
factors	T169	C1521761
stability	T080	C0205360
function	T169	C0542341
endogenous	T169	C0205227
destruction complexes	T104	C1704241
stabilized	T033	C0184512
TNKS	T116	C0963182
inhibition	T039	C1524081
degradation	T169	C0243125
AXIN	T116	C3178961
proteasome	T116	C1180347
role	T078	C1552020
AXIN1	T116	C1438871
AXIN2	T116	C1454580
scaffolding proteins	T116	C0033684
Wnt signaling pathway	T044	C1520113
remains	T080	C1527428
incompletely	T080	C0205257
understood	T041	C0162340
relative	T080	C0205345
contribution	T052	C1880177
formation	T169	C1522492
degradasomes	T116	C1180347
protein	T116	C0033684
assemblies	T044	C0872376
morphological	T082	C0543482
functional	T169	C0205245
correlates	T080	C1707520
endogenous	T169	C0205227
β-catenin	T116	C0105770
destruction complexes	T104	C1704241
SW480	T025	C0007634
colorectal cancer	T191	C1527249
cells	T025	C0007634
treated	T169	C1522326
tankyrase inhibitor	T121	C0014432
TNKSi	T121	C0014432
G007-LK	T109	C3658785
found	T033	C0150312
AXIN1	T116	C1438871
degradasome	T116	C1180347
formation	T169	C1522492
formation	T169	C1522492
degradasomes	T116	C1180347
capacity	T081	C1516240
degrade	T169	C0243125
β-catenin	T116	C0105770
considerably	T078	C0750591
impaired	T169	C0221099
G007-LK-treated	T109	C3658785
cells	T025	C0007634
AXIN2	T116	C1454580
findings	T033	C0243095
novel	T080	C0205314
insights	T041	C0233820
differential	T080	C1705242
functional roles	T077	C1705810
AXIN1	T116	C1438871
AXIN2	T116	C1454580
β-catenin	T116	C0105770
destruction complex	T104	C1704241
MRI	T060	C0024485
prostate cancer	T191	C0376358
detection	T033	C0011900
high-level representation	UnknownType	C0683878
hierarchical	T169	C0699032
classification	T185	C0008902
high-level feature representation	UnknownType	C0683878
deep neural networks	T170	C0870951
detection	T033	C0011900
prostate cancer	T191	C0376358
high-level feature representation	UnknownType	C0683878
hierarchical	T169	C0699032
classification	T185	C0008902
detection	T033	C0011900
results	T169	C1274040
High-level feature representation	UnknownType	C0683878
deep learning network	T170	C0870951
multiparametric MR	T060	C4304904
images	T170	C1704922
data	T078	C1511726
high-level features	T080	C2346469
hierarchical	T169	C0699032
classification	T185	C0008902
method	T170	C0025663
multiple random forest classifiers	T170	C0282574
iteratively constructed	T052	C1707689
detection	T033	C0011900
results	T169	C1274040
prostate cancer	T191	C0376358
experiments	T062	C0681814
patient	T101	C0030705
method	T170	C0025663
section-based evaluation	T058	C0220825
SBE	T058	C0220825
sensitivity	T169	C0332324
specificity	T081	C0037791
high-level features	T080	C2346469
method	T170	C0025663
performance	T052	C1882330
conventional	T081	C0205214
handcrafted features	T080	C2346469
LBP	T080	C2346469
Haar-like features	T080	C2346469
detecting	T033	C0011900
prostate cancer	T191	C0376358
regions	T029	C0005898
context	T078	C0449255
features	T080	C2348519
hierarchical	T169	C0699032
classification	T185	C0008902
effective	T080	C1704419
cancer	T191	C0006826
detection	T033	C0011900
result	T169	C1274040
Quantitative Susceptibility Mapping	T060	C0006117
Structural Feature based Collaborative Reconstruction	T066	C0020912
SFCR	T066	C0020912
Human	T016	C0086418
Brain	T023	C0006104
reconstruction	T066	C0020912
MR	T070	C0917874
quantitative susceptibility mapping	T060	C0006117
QSM	T060	C0006117
local phase	T079	C0205390
measurements	T169	C0242485
regularization strategies	T169	C0205245
priori	T079	C0332152
information	T078	C1533716
magnitude	T081	C1704240
phase images	T170	C1704922
proposed	T080	C1553874
anatomy	T017	C0700276
magnitude	T081	C1704240
phase images	T170	C1704922
susceptibility maps	T073	C0024779
erroneous	T078	C1547323
estimation	T081	C0750572
reconstructed susceptibility map	T073	C0024779
structural feature based collaborative reconstruction	T066	C0020912
SFCR	T066	C0020912
QSM	T060	C0006117
magnitude	T081	C1704240
susceptibility	T081	C1547045
information	T078	C1533716
SFCR	T066	C0020912
algorithm	T170	C0002045
consecutive steps	T077	C1261552
reconstruction models	T170	C3161035
structural feature	T082	C0678594
norm constraint	T169	C0443288
norm constraint	T169	C0443288
structure	T082	C0678594
features	T080	C2348519
noise	T067	C0028263
artifacts	T068	C0085089
M-step	T077	C1261552
susceptibility map	T073	C0024779
reconstructed	T066	C0020912
compressed sensing model	T170	C3161035
magnitude	T081	C1704240
S-step	T077	C1261552
susceptibility map	T073	C0024779
spatial domain	T082	C1254362
constraints	T169	C0443288
susceptibility map	T073	C0024779
M-step	T077	C1261552
Simulations	T062	C0679083
in vivo	T082	C1515655
human	T016	C0086418
experiments	T062	C0681814
MRI	T060	C0024485
SFCR	T066	C0020912
quality	T080	C0332306
susceptibility maps	T073	C0024779
RMSE	T081	C0871425
MSSIM	T081	C0871425
susceptibility	T081	C1547045
gray matter	T024	C0018220
multiple head positions	T082	C0582540
supine position	T082	C0038846
COSMOS	T169	C0449913
result	T169	C1274040
High	T080	C0205250
HbA1c	T116	C0019018
onset	T080	C0332162
predictor	T078	C2698872
metabolic control	T044	C1513158
individual	T098	C0237401
child	T100	C0008059
type 1 diabetes mellitus	T047	C0011854
metabolic control	T044	C1513158
onset	T080	C0332162
type 1 diabetes	T047	C0011854
metabolic control	T044	C1513158
clinical	T080	C0205210
parameters	T033	C0449381
childhood	T079	C0231335
transition	T052	C2700061
pediatric care	T061	C3839839
adult	T100	C0001675
diabetes care	T061	C0150544
Data	T078	C1511726
onset	T080	C0332162
months	T079	C0439231
years	T079	C0439234
diagnosis	T033	C0011900
transition	T052	C2700061
HbA1c	T116	C0019018
clinical	T080	C0205210
parameters	T033	C0449381
patients	T101	C0030705
Swedish pediatric quality registry, SWEDIABKIDS	T170	C0282574
patients	T101	C0030705
adult	T100	C0001675
diabetes care	T061	C0150544
Children	T100	C0008059
HbA1c	T116	C0019018
patients	T101	C0030705
low	T080	C0205251
group	T098	C1257890
diagnosis	T033	C0011900
metabolic control	T044	C1513158
childhood	T079	C0231335
children	T100	C0008059
HbA1c	T116	C0019018
patients	T101	C0030705
high	T080	C0205250
group	T098	C1257890
diagnosis	T033	C0011900
high	T080	C0205250
HbA1c	T116	C0019018
follow-up	T058	C1522577
individual	T098	C0237401
no significant	T033	C1273937
correlation	T080	C1707520
high	T080	C0205250
HbA1c	T116	C0019018
onset	T080	C0332162
follow-up	T058	C1522577
follow-up	T058	C1522577
children	T100	C0008059
high	T080	C0205250
group	T098	C1257890
smokers	T033	C0337664
physically active	T033	C0556453
retinopathy	T047	C0035309
children	T100	C0008059
low	T080	C0205251
group	T098	C1257890
High	T080	C0205250
HbA1c	T116	C0019018
onset	T080	C0332162
associated with	T080	C0332281
high	T080	C0205250
HbA1c	T116	C0019018
follow-up	T058	C1522577
group	T098	C1257890
predictor	T078	C2698872
metabolic control	T044	C1513158
individual	T098	C0237401
diabetes	T047	C0011847
team	T096	C0871489
diagnosis	T033	C0011900
high	T080	C0205250
goals	T170	C0018017
achievement	T053	C0001072
metabolic control	T044	C1513158
decrease	T081	C0547047
risk	T078	C0035647
microvascular complications	T047	C3837959
Photosensitizer	T121	C0162713
Decorated	T067	C1254366
Red Blood Cells	T025	C0014792
Ultra-Sensitive Light-Responsive Drug Delivery System	T074	C0085104
Red blood cells	T025	C0014792
RBCs	T025	C0014792
abundant	T080	C2346714
cells	T025	C0007634
blood	T031	C0005767
natural drug delivery system	T070	C1254365
DDS	T070	C1254365
biocompatibility	T044	C0596177
photosensitizer	T121	C0162713
chlorin e6	T109	C0055367
Ce6	T109	C0055367
decorated	T067	C1254366
membrane	T026	C0596901
RBCs	T025	C0014792
mixing	T080	C1720722
membrane	T026	C0596901
integrity	T080	C1947912
stability	T080	C0205360
light	T070	C0023693
irradiation	T070	C1282930
density	T081	C0178587
generated	T052	C3146294
singlet oxygen	T123	C0074565
Ce6	T109	C0055367
result of photodynamic effect	UnknownType	C0940920
disruption	T169	C0332453
RBC	T025	C0014792
membrane	T026	C0596901
doxorubicin	T109	C0013089
DOX	T109	C0013089
DOX	T109	C0013089
chemotherapy	T061	C3665472
drug	T121	C0013227
model	T170	C3161035
light-responsive RBC-based DDS	T074	C0085104
decorating	T067	C1254366
Ce6	T109	C0055367
cell membrane	T026	C0007603
DOX	T109	C0013089
cells	T025	C0007634
light	T070	C0023693
triggered	T080	C1444748
cell membrane	T026	C0007603
trigger	T080	C1444748
DOX	T109	C0013089
light-controlled chemotherapy	T061	C3665472
specificity	T081	C0037791
RBC	T025	C0014792
biomolecules	T167	C0567416
enzymes	T116	C0014442
catalytic	T070	C0007382
function	T169	C0542341
light	T070	C0023693
work	T057	C0043227
biocompatible cell-based DDS	T074	C0085104
stimuli	T067	C0234402
cancer therapy	T061	C0920425
applications	T169	C4048755
biotechnologies	T091	C0005574
Validation	T062	C1519941
Neogen® Fentanyl	T109	C0015846
ELISA	T059	C0014441
Blood	T031	C0005767
Urine	T031	C0042036
Neogen® Fentanyl	T109	C0015846
enzyme-linked immunosorbent assay	T059	C0014441
Scientific Working Group	T098	C1257890
Forensic Toxicology	T090	C1721026
Standard Practices	T091	C0086343
Validation	T062	C1519941
Forensic Toxicology	T090	C1721026
Laboratory Guidelines.	T170	C4291774
whole blood	T031	C0370231
urine	T031	C0042036
validation	T062	C1519941
evaluation	T058	C0220825
sensitivity	T081	C1511883
precision	T080	C1706245
specificity	T081	C0037791
carryover	T080	C0205556
plate drift	T080	C0205556
evaluation	T058	C0220825
limit of detection	T081	C2718050
blood	T031	C0005767
urine	T031	C0042036
Precision	T080	C1706245
concentrations	T081	C1446561
replicates	T080	C1883725
whole blood	T031	C0370231
coefficient of variation	T081	C0681921
CV	T081	C0681921
urine	T031	C0042036
CV	T081	C0681921
concentrations	T081	C1446561
replicates	T080	C1883725
Cross-reactivity	T044	C0010357
evaluated	T058	C0220825
norfentanyl	T109	C0214194
acetyl fentanyl	T109	C3700366
4-anilino-N-phenethylpiperidine	T109	C2713534
beta-hydroxythiofentanyl	T121	C4305828
butyryl fentanyl	T121	C4305826
furanyl fentanyl	T109	C0015846
Everolimus	T109	C0541315
Treatment	T061	C0087111
Pseudomyogenic Hemangioendothelioma	T191	C0018915
Pseudomyogenic hemangioendothelioma	T191	C0018915
PMH	T191	C0018915
vascular neoplasm	T191	C0282607
soft tissue	T024	C0225317
young adults	T100	C0238598
Metastatic	T169	C1522484
PMH	T191	C0018915
fatal	T080	C1302234
effective	T080	C1704419
medications	T121	C0013227
case	T077	C1706256
boy	T100	C0870221
metastatic	T169	C1522484
PMH	T191	C0018915
responded to treatment	T201	C0521982
everolimus	T109	C0541315
mammalian target of rapamycin inhibitor	T121	C2746052
Immunohistochemistry	T060	C0021044
mammalian target of rapamycin	T116	C1307407
expressed	T045	C1171362
PMH	T191	C0018915
biopsy specimens	T024	C0677862
reduction	T080	C0392756
PMH	T191	C0018915
tumor size	T082	C0475440
treatment	T061	C0087111
Roles	T080	C1521970
Acetylation	T044	C0001038
Phosphorylation	T044	C0031715
LIFR	T116	C0125607
Dependent	T169	C3244310
Self-Renewal	T043	C1155711
Growth	T040	C0018270
Signaling	T044	C0037080
Mouse Embryonic Stem Cells	T025	C4042879
LIF	T116	C0125606
self-renewal	T043	C1155711
mouse embryonic stem cells	T025	C4042879
mESCs	T025	C4042879
absence	T080	C0332268
cells	T025	C0007634
differentiate	T169	C2945687
LIF	T116	C0125606
LIF receptor	T116	C0125607
LIFR	T116	C0125607
activates	T052	C1879547
JAK-STAT3 pathway	T044	C0037080
remains unknown	T080	C0439673
receptor complex	T026	C1523873
triggers	T080	C1444748
differentiation	T169	C2945687
self-renewal	T043	C1155711
LIFR	T116	C0125607
cytoplasmic domain	T026	C1511625
self-renewal	T043	C1155711
domain	T169	C1880389
juxtamembrane region	T026	C1622525
differentiation	T169	C2945687
domain	T169	C1880389
C-terminal region	T087	C1707271
differentiation	T169	C2945687
domain	T169	C1880389
SPXX repeats	T116	C0030956
phosphorylated	T044	C0031715
MAPK	T116	C0752312
restrict	T169	C0443288
STAT3 activation	T043	C2248236
self-renewal	T043	C1155711
domain	T169	C1880389
3K motif	T116	C0660452
acetylated	T044	C0001038
mESCs	T025	C4042879
LIFR	T116	C0125607
homodimerization	T044	C1512485
STAT3	T116	C0253050
hypo- or hyper-activation	T052	C1879547
depending	T169	C3244310
presence	T033	C0150312
absence	T169	C0332197
gp130	T116	C0082758
LIFR	T116	C0125607
activated	T052	C1879547
STAT3	T116	C0253050
restricts	T169	C0443288
differentiation	T169	C2945687
cytokine	T116	C0079189
induction	T169	C0205263
LIFR	T116	C0125607
acetylation	T044	C0001038
serine phosphorylation	T044	C1519253
differentially	T169	C2945687
stem cell	T025	C0038250
self-renewal	T043	C1155711
differentiation	T169	C2945687
Interprofessional	T054	C0021799
primary care	T058	C0033137
team meetings	T058	C0589031
qualitative	T080	C0205556
approach	T082	C0449445
observations	T062	C0302523
personal	T032	C1519021
opinions	UnknownType	C0683292
people	T098	C0027361
multiple chronic conditions	T047	C3266262
primary care services	T058	C0018747
increases	T169	C0442805
Professionals	T097	C0679924
disciplines	T057	C0013996
collaborate	T054	C0282116
coordinate	T169	C0700114
care	T052	C1947933
health care needs	T058	C0086388
lack	T080	C0332268
information	T078	C1533716
interprofessional	T054	C0021799
team (IPT) meetings	T058	C0589031
study	T062	C2603343
interprofessional	T054	C0021799
collaboration	T054	C0282116
primary care	T058	C0033137
team meetings	T058	C0589031
Netherlands	T083	C0027778
current practice	T057	C0033284
personal	T032	C1519021
opinions	UnknownType	C0683292
Qualitative study	T062	C0949415
observations	T062	C0302523
team meeting	T058	C0589031
interviews	T058	C0683518
participants	T098	C0679646
IPT meetings	T058	C0589031
primary care practices	T058	C0033137
video recordings	T073	C0042650
Experiences	T041	C0596545
semi-structured interviews	UnknownType	C0681913
participants	T098	C0679646
health care professionals	T097	C0018724
disciplines	T057	C0013996
team meetings	T058	C0589031
data	T078	C1511726
analysed	T062	C0936012
content analysis	T062	C0681915
participants	T098	C0679646
opinions	UnknownType	C0683292
team meetings	T058	C0589031
observations	T062	C0302523
team meetings	T058	C0589031
lacked	T080	C0332268
team coordinator	T097	C1711307
leader	T097	C0401960
discrepancy	T033	C1290905
findings	T033	C0243095
observations	T062	C0302523
interviews	T052	C0021822
interviews	T052	C0021822
Team structure and composition	T098	C1257890
Patient-centredness	T058	C0243024
Interaction	T054	C0021797
Attitude	T041	C0004271
motivation	T041	C0026605
IPT meetings	T058	C0589031
improvements	T077	C2986411
patient-centredness	T058	C0243024
leadership	T054	C0023181
chairpersons	T097	C1524106
discrepancy	T033	C1290905
observations	T062	C0302523
interviews	T052	C0021822
improve	T077	C2986411
team members	T096	C1551024
awareness	T041	C0004448
aspects	T080	C1879746
improved	T077	C2986411
training	T065	C0220931
challenges	T058	C0805586
Urachal carcinoma	T047	C2931202
Report	T170	C0684224
cases	T077	C1706256
review of	T169	C0699752
literature	T170	C0023866
Urachal carcinoma	T047	C2931202
rare	T080	C0522498
tumor	T191	C0027651
ovaries	T023	C0029939
less often	T033	C3843156
adnexal	T023	C0001575
region	T029	C0005898
urinary system	T022	C1508753
present	T078	C0449450
cases	T077	C1706256
urachal carcinoma	T047	C2931202
case	T077	C1706256
male	T098	C0025266
patient	T101	C0030705
presented	T078	C0449450
painless hematuria	T184	C0473235
blood clots	T046	C0302148
month	T079	C0439231
case	T077	C1706256
woman	T098	C0043210
presented	T078	C0449450
gross hematuria	T033	C0473237
mild	T080	C2945599
dysuria	T184	C0013428
urgency and frequent urination	T047	C0085606
year	T079	C0439234
surgical resection	T061	C0728940
patients	T101	C0030705
diagnosed	T033	C0011900
urachal adenocarcinoma	T047	C2931201
mixed	T169	C0205430
type	T080	C0332307
urachal mucinous adenocarcinoma	T047	C2931201
histopathological	T169	C0243140
examination	T058	C0582103
review of	T169	C0699752
published	T057	C0034037
cases	T077	C1706256
relevant	T080	C2347946
literature	T170	C0023866
presented	T078	C0449450
aim	T078	C1947946
present	T033	C0150312
study	T062	C0008972
understand	T041	C0162340
disease	T191	C0027651
better	T080	C0332272
reduce	T080	C0392756
rate	T081	C1521828
clinical	T080	C0205210
pathological	T169	C1521733
misdiagnosis	T033	C0679838
Recombinant	T063	C0017387
Human	T016	C0086418
Anti-Platelet scFv Antibody	T116	C0370058
scFv	T129	C1883036
Pichia pastoris	T004	C0997362
Atheroma	T046	C0264956
Cells	T025	C0007634
immune system	T022	C0020962
progression	T046	C0242656
atherosclerotic plaque	T031	C2936350
plaque	T033	C0332461
instability	T033	C1444783
rupture	T037	C3203359
acute	T079	C0205178
atherothrombotic	T020	C1963943
coronary artery disease	T047	C0010054
cerebrovascular disease	T047	C0007820
peripheral arterial disease	T047	C0085096
cloning	T062	C0525050
expression	T045	C1171362
purification	T169	C1998793
immunoreactivity	T044	C0597879
assessment	T058	C0220825
recombinant	T001	C1514798
single-chain variable fragment	T129	C1883036
scFv	T129	C1883036
human	T016	C0086418
anti-αIIbβ3 antibody	T116	C0016011
HuAb	T116	C0016011
atheromatous	T046	C0264956
lesions	T033	C0221198
presence	T033	C0150312
platelets	T025	C0005821
platelets	T025	C0005821
atheroma plaques	T031	C2936350
inflammation	T046	C0021368
platelet	T025	C0005821
leucocyte	T025	C0023516
aggregates	T080	C0205418
thrombi	T046	C0087086
formation	T169	C1522492
relevant	T080	C2347946
biomarkers	T201	C0005516
atherosclerotic	T169	C0333482
progression	T046	C0242656
DNA sequence	T086	C0162326
encodes	T052	C2700640
anti-αIIbβ3 TEG4 scFv	T129	C1883036
phage-display selection	T063	C3494191
activated	T052	C1879547
platelets	T025	C0005821
inserted	T045	C1512796
eukaryote	T204	C0684063
vector	T114	C1514152
pPICZαA	T114	C1514152
tag sequence	T086	C0162326
encoding	T052	C2700640
cysteines	T116	C0010654
specific	T080	C0205369
grafting experiments	T059	C0022885
recombinant protein	T116	C0034861
expressed	T045	C1171362
high	T080	C0205250
Pichia pastoris	T004	C0997362
culture	T130	C0010454
P. pastoris	T004	C0997362
expression	T045	C1171362
system	T169	C0449913
secretion	T038	C0036536
recombinant proteins	T116	C0034861
supernatant	T031	C1550101
scFv	T129	C1883036
cytoplasm	T026	C0010834
bacteria	T007	C0004611
low	T080	C0205251
yield	T081	C0392762
low	T080	C0205251
solubility	T080	C0037628
reduced	T080	C0392756
affinity	T044	C0003255
improved	T033	C0184511
recovery	T052	C0237820
highly	T080	C0205250
purified	T169	C1998793
biologically active scFv fragments	T123	C0574031
scFv	T129	C1883036
grafted	T169	C0700106
site	T082	C0205145
nanoparticles	T073	C1450054
imaging	T060	C0011923
atherosclerotic plaques	T031	C2936350
inflammatory	T169	C0333348
processes	T067	C1522240
high risk of	T033	C0332167
instability	T033	C1444783
Identification	T080	C0205396
MiR-21-5p	T114	C1101610
Functional Regulator	T028	C0017362
Mesothelin	T028	C1334533
Expression	T045	C0017262
MicroRNA	T114	C1101610
Affinity	T070	C1510827
Coupled	T169	C1948027
Next Generation Sequencing	T063	C2936622
MicroRNAs	T114	C1101610
miRNAs	T114	C1101610
small non-coding RNAs	T114	C0887909
regulate	T045	C0017263
mRNA expression	T045	C1515670
silencing	T045	C0598496
target	T169	C1521840
transcripts	T114	C1519595
binding	T044	C1167622
miRNA recognition elements (MREs)	T086	C0314659
3'untranslated region	T086	C0600600
3'UTR	T086	C0600600
identification	T080	C0205396
bona fide	T082	C2323869
targets	T169	C1521840
researchers working	T033	C0243095
functional aspect	T169	C0205245
miRNAs	T114	C1101610
method (miR-CATCH)	T169	C0449851
biotinylated	T044	C1159274
DNA	T114	C0012854
antisense oligonucleotides	T114	C0079925
mRNA	T114	C0035696
miRNAs::mRNA interactions	T045	C1523523
physiological cellular	T043	C1325880
miR-CATCH technique	T169	C0449851
mesothelin (MSLN) gene	T028	C1334533
coupled	T169	C1948027
next generation sequencing	T063	C2936622
NGS	T063	C2936622
miRNAs	T114	C1101610
regulate	T045	C0017263
MSLN mRNA	T028	C1334533
protein levels	T034	C0428479
malignant pleural mesothelioma	T191	C0812413
MPM	T191	C0812413
Biotinylated	T044	C1159274
MSLN oligos	T028	C1334533
miRNA::MSLN mRNA complexes	T114	C1099355
cell line (Met-5A)	T025	C0007600
expresses	T045	C1171362
MSLN	T116	C0380162
MiRNAs	T114	C1101610
targeting	T169	C1521840
MSLN mRNA	T028	C1334533
NGS	T063	C2936622
miR-21-5p	T114	C1101610
miR-100-5p	T114	C1101610
validation analyses	T062	C0936012
MiR-21-5p	T114	C1101610
modulate	T082	C0443264
MSLN	T028	C1334533
expression	T045	C0017262
miRNA	T114	C1101610
mimic	T061	C0393040
experiments	T062	C0681814
malignant	T025	C0334227
cell lines	T025	C0007600
miRNA	T114	C1101610
inhibitor	T080	C1999216
experiments	T062	C0681814
luciferase	T116	C0024075
assays	T059	C0005507
Mero-14 cells	T025	C0007634
miR-21-5p	T114	C1101610
regulator	T028	C0017362
MSLN	T028	C1334533
in vitro experiments	T062	C0681828
treatment	T061	C0087111
miR-21-5p	T114	C1101610
mimic	T061	C0393040
proliferation	T169	C1514485
MPM	T191	C0812413
cell lines	T025	C0007600
miR-CATCH technique	T169	C0449851
coupled	T169	C1948027
NGS	T063	C2936622
in vitro	T080	C1533691
validation	T062	C1519941
method	T169	C0449851
miRNA::mRNA interactions	T045	C1523523
MiR-21-5p	T114	C1101610
regulator	T028	C0017362
MSLN	T028	C1334533
functional role	T169	C0205245
cellular growth	T043	C0007595
Zoonotic	T001	C1628327
Non-zoonotic	T033	C0243095
Parasites	T204	C0030498
Wild	T170	C0445392
Rodents	T015	C0035804
Turkman Sahra, Northeastern Iran	T083	C0022065
study	T062	C2603343
collect informative data	T062	C0010995
parasitic infection	T047	C0747256
wild	T170	C0445392
rodents	T015	C0035804
finding	T033	C0243095
parasites	T204	C0030498
medical	T169	C0205476
importance	T080	C3898777
human	T016	C0086418
total number	T081	C4288115
wild	T170	C0445392
rodents	T015	C0035804
captured	T169	C0205245
rural areas	T082	C0178837
Turkmen Sahra, Golestan Province	T083	C0022065
handmade traps	T073	C0699733
Animals	T008	C0003062
anesthetized	T033	C1720436
surveyed	T170	C0038951
ectoparasite	T204	C0562634
carcasses	T021	C0229961
dissected	T169	C0205239
examination	T033	C0332128
endoparsites	T204	C0320225
species	T185	C1705920
rodents	T015	C0035804
including	T169	C0332257
Mus musculus	T015	C0025914
Rattus norvegicus	T015	C0034693
Rhombomys opimus	T015	C1646173
Meriones libycus	T015	C1681293
captured	T169	C0205245
Parasitic infestation	T047	C1384353
detected	T033	C0442726
sampled	T078	C0870078
rodents	T015	C0035804
Parasite infestation	T047	C1384353
rates	T081	C1521828
sampled	T078	C0870078
rodents	T015	C0035804
Hymenolepis diminuta	T204	C0322197
Cryptosporidium spp	T204	C1744526
Trichuris spp	T204	C0684063
Cysticercus fasciolaris	T204	C0322189
Angiostrongylus spp	T204	C1641848
Capillaria sp	T204	C0006896
Rhipicephalus spp	T204	C0323464
Nosopsyllus fasciatus	T204	C0323233
Laelaps nuttalli	T204	C3012304
genera	T185	C1708235
species	T185	C1705920
identified	T080	C0205396
parasites	T204	C0030498
zoonotic	T001	C1628327
public health	T170	C3244304
importance	T080	C3898777
L. nuttalli	T204	C3012304
N. fasciatus	T204	C0323233
non-zoonotic	T033	C0243095
detected	T033	C0442726
parasites	T204	C0030498
survey	T170	C0038951
Harboring	T169	C0332257
wide	T082	C0332464
zoonotic	T001	C1628327
parasites	T204	C0030498
sampled	T078	C0870078
wild	T170	C0445392
rodents	T015	C0035804
particularly	T080	C0205369
nearby	T080	C1706276
villages	T083	C0562518
potential	T080	C3245505
risk	T078	C0035647
native inhabitants	T098	C0079891
controlling	T169	C2587213
rodents	T015	C0035804
population	T098	C1257890
residential regions	T082	C0442506
improving	T033	C0184511
awareness	T041	C0004448
local	T082	C0205276
people	T098	C0027361
risk	T078	C0035647
disease transmission	T046	C0242781
rodents	T015	C0035804
necessary	T080	C3898777
successful	T080	C1272703
aging	T040	C0001811
pilot study	T062	C0031928
intergenerational	T079	C0598500
health promotion program	T058	C0043113
evaluate	T058	C0220825
effectiveness	T080	C1280519
intergenerational	T079	C0598500
health promotion program	T058	C0043113
research project	T062	C0700032
total	T080	C0439810
participants	T098	C0679646
week	T079	C0439230
program	T058	C0043113
completed	T080	C0205197
pre-test and post-test	T170	C0032919
middle-aged	T100	C0205847
older adults	T098	C0001792
recruited	T052	C2949735
Taipei	T083	C0017446
young adults	T100	C0238598
recruited	T052	C2949735
principal investigator's	T097	C1521895
university	T073	C0041740
Attitudes toward Aging Scale	T170	C0282574
Spiritual Health Scale	T170	C0282574
assessment	T058	C0220825
instruments	T170	C0282574
study	T062	C2603343
results	T033	C0683954
significant	T078	C0750502
improvements	T077	C2986411
Attitudes toward Aging Scale	T170	C0282574
young adult	T100	C0238598
group	T078	C0441833
years	T079	C1510829
Spiritual Health Scale	T170	C0282574
older adult	T098	C0001792
group	T078	C0441833
aged	T032	C0001779
years	T079	C1510829
evaluation	T058	C0220825
participants	T098	C0679646
satisfied	T041	C0242428
program	T058	C0043113
results	T033	C0683954
successful	T080	C1272703
aging	T040	C0001811
intergenerational	T079	C0598500
learning	T065	C0013621
Signs	T184	C0037088
dysarthria	T048	C0013362
adults	T100	C0001675
22q11.2 deletion syndrome	T047	C0012236
study	T062	C2603343
adults	T100	C0001675
22q11.2 deletion syndrome	T047	C0012236
22q11DS	T047	C0012236
dysarthria	T048	C0013362
intelligibility	T041	C0589416
tests	T060	C0683443
compared	T052	C1707455
control group	T096	C0009932
participants	T098	C0679646
22q11.2 deletion	T049	C2910370
males	T032	C0086582
females	T032	C0086287
age	T032	C0001779
years	T079	C0439234
compared	T052	C1707455
control group	T096	C0009932
gender	T032	C0079399
age	T032	C0001779
males	T032	C0086582
females	T032	C0086287
age	T032	C0001779
years	T079	C0439234
Assessment	T052	C1516048
non-verbal and verbal tasks	T060	C0430022
respiration	T039	C0035203
phonation	T042	C0031577
oral motor function	T042	C0563145
velopharyngeal function	T059	C4027435
articulation	T042	C0234830
prosody	T033	C0233743
Swedish Test of Intelligibility	T170	C0451496
STI	T170	C0451496
assessments	T052	C1516048
inter-rater	T081	C0870740
intra-rater reliability	T081	C0392762
participants	T098	C0679646
22q11DS	T047	C0012236
problems	T033	C0033213
control group	T096	C0009932
STI	T170	C0451496
speech deviation	T033	C0243095
rated	T052	C0871208
speech	T040	C0037817
respiration	T039	C0035203
phonation	T042	C0031577
oral motor function	T042	C0563145
velopharyngeal function	T059	C4027435
study	T062	C2603343
neurological etiology	T169	C1314792
structural etiology	T169	C1314792
speech difficulties	T033	C0233715
22q11DS	T047	C0012236
Signs	T184	C0037088
speech motor planning	T041	C0025361
speech motor programming	T041	C0025361
studies	T062	C2603343
results	T169	C1274040
studies	T062	C2603343
structural brain abnormalities	T033	C1866933
neurological speech symptoms	T184	C1457887
clinical purposes	T169	C1285529
clinicians	T097	C0871685
speech symptoms	T184	C0478143
individuals	T098	C0237401
22q11DS	T047	C0012236
etiology	T169	C1314792
speech symptoms	T184	C0478143
Sulfur	T121	C0038774
Zinc	T121	C0043481
Availability	T169	C0470187
Co-granulated	T167	C3853628
Zn	T121	C0043481
Elemental Sulfur	T121	C0038774
Fertilizers	T073	C0015919
Acidification	T067	C2987513
oxidation	T044	C0030011
elemental sulfur	T121	C0038774
ES	T121	C0038774
ZnO	T121	C0043491
slow	T080	C0439834
release	T169	C1283071
sulfur	T121	C0038774
S	T121	C0038774
zinc	T121	C0043481
Zn	T121	C0043481
granular	T167	C3853628
fertilizer	T073	C0015919
ES	T121	C0038774
ZnO	T121	C0043491
evaluated	T052	C1516048
effect	T080	C1280500
microorganisms	T001	C0445623
carbon	T196	C0007009
source	T033	C0449416
granule	T167	C3853628
evaluated	T052	C1516048
granulated	T167	C3853628
ES-Zn fertilizers	T167	C1289929
without	T080	C0332288
S-oxidizing microorganisms	T001	C0445623
ZnSO4	T121	C0078794
ZnO	T121	C0043491
center	T082	C0205099
Petri dishes	T074	C1322960
contrasting	T080	C1979874
pH	T081	C0020283
soils	T167	C0037592
Soil	T167	C0037592
pH	T081	C0020283
CaCl2	T121	C0006686
S	T121	C0038774
Zn	T121	C0043481
ES	T121	C0038774
evaluated	T052	C1516048
soil sections	T167	C0037592
fertilizer	T073	C0015919
application site	T082	C0205145
visualization test	T059	C0022885
Zn	T121	C0043481
diffusion	T070	C0012222
significant	T078	C0750502
pH decrease	T033	C0728725
observed	T169	C1441672
acidic	T103	C0001128
soil	T167	C0037592
ES-Zn fertilizer	T167	C1289929
treatments	T169	C1522326
alkaline	T080	C1979842
soil	T167	C0037592
Acidithiobacillus thiooxidans	T007	C0039878
inoculated treatment	T034	C0427946
Zn	T121	C0043481
visualization tests	T059	C0022885
Zn	T121	C0043481
concentrations	T081	C1446561
higher	T080	C0205250
acidic	T103	C0001128
alkaline	T080	C1979842
soil	T167	C0037592
Elemental S oxidation	T044	C1159425
greater	T081	C1704243
acidic	T103	C0001128
soil	T167	C0037592
alkaline	T080	C1979842
soil	T167	C0037592
ES-Zn granular fertilizers	T167	C1289929
increased	T081	C0205217
S	T121	C0038774
Zn	T121	C0043481
concentrations	T081	C1446561
soil	T167	C0037592
slow	T080	C0439834
release	T169	C1283071
nutrients	T168	C0678695
soil	T167	C0037592
Impact	T080	C4049986
Blood Transfusions	T061	C0005841
Survival	T052	C0038952
Locally	T082	C1517927
Advanced	T080	C0205179
Cervical Cancer	T191	C4048328
Patients	T101	C0030705
Neoadjuvant Chemotherapy	T061	C4272610
Radical Surgery	T061	C0543467
Transfusions	T061	C0005841
progresses	T169	C1272688
modern medicine	T079	C0242324
evidence	T078	C3887511
transfusions	T061	C0005841
survival	T052	C0038952
outcomes	T080	C0085415
patients	T101	C0030705
affected	T169	C0392760
solid cancers	T191	C0006826
study	T062	C0008972
aimed	T078	C1947946
investigate	T169	C1292732
perioperative	T079	C1518988
blood transfusion	T061	C0005841
locally	T082	C1517927
advanced	T080	C0205179
cervical cancer	T191	C4048328
patients	T101	C0030705
affected	T169	C0392760
locally	T082	C1517927
advanced	T080	C0205179
cervical cancer	T191	C4048328
neoadjuvant chemotherapy	T061	C4272610
radical surgery	T061	C0543467
retrospectively	T062	C0035363
searched	T052	C1706202
test	T169	C0039593
impact	T080	C4049986
perioperative	T079	C1518988
transfusions	T061	C0005841
survival	T052	C0038952
outcomes	T080	C0085415
year	T079	C0439234
survival	T052	C0038952
outcomes	T080	C0085415
Kaplan-Meier	T062	C2827659
Cox models	T081	C0010234
study	T062	C0008972
patients	T101	C0030705
patients	T101	C0030705
blood transfusion	T061	C0005841
univariate analysis	T062	C0683962
observed	T169	C1441672
transfusion	T061	C0005841
risk	T078	C0035647
developing	T169	C0332253
recurrence	T191	C1458156
hazard ratio	T081	C2985465
HR	T081	C2985465
confidence interval	T081	C0009667
CI	T081	C0009667
P	T081	C0033204
year	T079	C0439234
disease-free survival	T081	C0242793
noncomplete	T033	C3272974
clinical response	T033	C4055223
neoadjuvant chemotherapy	T061	C4272610
HR	T081	C2985465
CI	T081	C0009667
P	T081	C0033204
pathological	T033	C4050242
P	T081	C0033204
response	T033	C4050242
neoadjuvant chemotherapy	T061	C4272610
parametrial	T029	C1518890
P	T081	C0033204
vaginal	T023	C0042232
P	T081	C0033204
lymph node	T023	C0024204
P	T081	C0033204
multivariate analysis	T081	C0026777
vaginal	T023	C0042232
HR	T081	C2985465
CI	T081	C0009667
P	T081	C0033204
lymph node	T023	C0024204
HR	T081	C2985465
CI	T081	C0009667
P	T081	C0033204
P	T081	C0033204
disease-free survival	T081	C0242793
outcomes	T080	C0085415
observed	T169	C1441672
patients	T101	C0030705
blood transfusion	T061	C0005841
HR	T081	C2985465
CI	T081	C0009667
P	T081	C0033204
overall survival	T081	C4086681
observed	T169	C1441672
lymph node	T023	C0024204
P	T081	C0033204
vaginal	T023	C0042232
P	T081	C0033204
survival	T052	C0038952
blood transfusions	T061	C0005841
risk	T078	C0035647
developing	T169	C0332253
recurrence	T191	C1458156
LAAC	T191	C4048328
patients	T101	C0030705
treated	T061	C0332293
neoadjuvant chemotherapy	T061	C4272610
radical surgery	T061	C0543467
unclear	T033	C3845108
prospective studies	T062	C0033522
Tissue	T024	C0040300
antiviral	T033	C0243095
T cell immunity	T040	C1817907
human	T016	C0086418
CMV infection	T047	C0010823
T cell	T025	C0039194
responses	T042	C0301872
viruses	T005	C0042776
tissue	T024	C0040300
human	T016	C0086418
antiviral	T033	C0243095
T cells	T025	C0039194
blood	T031	C0005767
Cytomegalovirus	T005	C0010825
CMV	T005	C0010825
humans	T016	C0086418
T cell immunity	T040	C1817907
tissue	T024	C0040300
immune responses	T042	C0301872
human	T016	C0086418
CMV	T005	C0010825
CMV	T005	C0010825
T cells	T025	C0039194
virus	T005	C0042776
persistence	T081	C1547035
CMV	T005	C0010825
T cell	T025	C0039194
homeostasis	T038	C0019868
blood	T031	C0005767
lymphoid	T024	C0024296
mucosa	T024	C0026724
secretory tissues	T024	C0040300
CMV	T005	C0010825
seropositive	T080	C0521143
seronegative	T034	C0521144
donors	T098	C0013018
CMV	T005	C0010825
T cells	T025	C0039194
distribution patterns	T082	C0449775
blood	T031	C0005767
bone marrow	T024	C0005953
BM	T024	C0005953
lymph nodes	T023	C0024204
LN	T023	C0024204
frequency	T080	C1561548
function	T169	C0542341
blood	T031	C0005767
tissues	T024	C0040300
CMV	T005	C0010825
genomes	T028	C0017428
detected	T033	C0442726
lung	T023	C0024109
spleen	T023	C0037993
BM	T024	C0005953
blood	T031	C0005767
LN	T023	C0024204
CMV	T005	C0010825
T cells	T025	C0039194
blood	T031	C0005767
BM	T024	C0005953
samples	T167	C0370003
virus detection	T043	C1154657
lung	T023	C0024109
CMV	T005	C0010825
T cells	T025	C0039194
virus	T005	C0042776
LNs	T023	C0024204
CMV	T005	C0010825
T cells	T025	C0039194
phenotypes	T032	C0031437
virus	T005	C0042776
T cell	T025	C0039194
differentiation	T043	C0007589
enhanced	T052	C2349975
viral	T169	C0521026
persistence	T081	C1547035
tissue	T024	C0040300
T cell	T025	C0039194
CMV	T005	C0010825
control	T058	C0085557
viral	T169	C0521026
tissue	T024	C0040300
intrinsic factors	T116	C0021918
homeostasis	T038	C0019868
tissue	T024	C0040300
T cells	T025	C0039194
lifespan	T102	C0870809
Lipid levels	T059	C0523744
risk	T078	C0035647
recurrent venous thrombosis	T046	C1735901
results	T169	C1274040
MEGA follow-up study	T062	C0016441
lipid levels	T059	C0523744
risk	T078	C0035647
recurrent venous thrombosis	T046	C1735901
unclear	T033	C3845108
Lipids	T109	C0023779
assessed	T052	C1516048
patients	T101	C0030705
venous thrombosis	T046	C0042487
followed	T079	C0332283
years	T079	C0439234
Lipids	T109	C0023779
associated with	T080	C0332281
recurrence	T067	C0034897
patients	T101	C0030705
events	T051	C0441471
Testing lipid levels	T059	C0523744
useful	T080	C3827682
identify	T080	C0205396
patients	T101	C0030705
increased	T081	C0205217
risk	T078	C0035647
recurrence	T067	C0034897
risk factors	T033	C0035648
recurrent venous thrombosis	T046	C1735901
duration	T079	C0449238
anticoagulation	T061	C0003281
association	T080	C0439849
lipid levels	T059	C0523744
venous thrombosis	T046	C0042487
data	T078	C1511726
lipids	T109	C0023779
risk	T078	C0035647
recurrence	T067	C0034897
assess	T052	C1516048
association	T080	C0439849
lipid levels	T059	C0523744
recurrent venous thrombosis	T046	C1735901
Patients	T101	C0030705
Patients	T101	C0030705
venous thrombosis	T046	C0042487
MEGA study	T062	C0016441
included	T169	C0332257
Follow-up	T058	C1522577
started	T080	C1272689
date	T079	C0011008
end	T082	C0444930
anticoagulant treatment	T061	C0150457
Percentile	T081	C1264641
categories	T170	C0683312
total	T109	C0543421
low-density lipoprotein	T109	C0023824
high-density lipoprotein cholesterol	T109	C0023822
triglycerides	T109	C0041004
apolipoproteins B	T116	C0003593
A1	T116	C0085201
established	T080	C0443211
reference	T081	C0034925
percentile	T081	C1264641
Lipids	T109	C0023779
measured	T080	C0444706
months	T079	C0439231
discontinuing	T033	C1444662
anticoagulation	T061	C0003281
Results	T169	C1274040
patients	T101	C0030705
years	T079	C0439234
recurrence	T067	C0034897
incidence rate	T081	C1708485
patient	T101	C0030705
years	T079	C0439234
confidence interval	T081	C0009667
CI	T081	C0009667
hazard ratios	T081	C2985465
ranging	T081	C1514721
CI	T081	C0009667
CI	T081	C0009667
percentile	T081	C1264641
category	T170	C0683312
reference	T081	C0034925
association	T080	C0439849
percentile	T081	C1264641
categories	T170	C0683312
recurrence	T067	C0034897
lipid levels	T059	C0523744
age-	T032	C0001779
sex	T032	C0079399
models	T075	C0026339
further	T082	C1517331
adjustments	T169	C0456081
body mass index	T201	C1305855
diabetes	T047	C0011847
estrogen	T109	C0014939
statin	T109	C0360714
use	T169	C0457083
duration	T079	C0449238
anticoagulation	T061	C0003281
Subgroup	T185	C1515021
analyses	T062	C0936012
stratified	T080	C0205363
provoked	T080	C1444748
events	T051	C0441471
location	T082	C0450429
deep vein thrombosis	T047	C0149871
pulmonary embolism	T047	C0034065
sex	T032	C0079399
reveal	T080	C0443289
association	T080	C0439849
lipid levels	T059	C0523744
Testing lipid levels	T059	C0523744
identify	T080	C0205396
patients	T101	C0030705
increased	T081	C0205217
risk	T078	C0035647
recurrent venous thrombosis	T046	C1735901
study	T062	C2603343
events	T051	C0441471
influence	T077	C4054723
duration	T079	C0449238
anticoagulation	T061	C0003281
Insecticidal effects	T038	C0596781
deltamethrin	T109	C0057233
laboratory	T073	C0022877
field	T077	C1521738
populations	T081	C0032659
Culicoides species	T204	C0010446
host	T001	C1167395
contact	T067	C0392367
reduction	T080	C0392756
methods	T062	C0242481
India	T083	C0021201
Bluetongue virus	T005	C0005867
BTV	T005	C0005867
transmitted	T046	C0242781
Culicoides	T204	C0010446
biting midges	T204	C0007747
bluetongue	T047	C0005866
BT	T047	C0005866
clinical disease	T047	C0012634
sheep	T015	C0036945
BT	T047	C0005866
detrimental effect	T046	C0879626
farmers	T097	C0221460
India	T083	C0021201
hyperendemic outbreaks	T047	C0277550
southern states	T083	C1301808
country	T083	C0454664
method	T062	C0242481
toxic effects	T037	C0600688
deltamethrin	T109	C0057233
Culicoides	T204	C0010446
deltamethrin	T109	C0057233
traditional control methods	T062	C3824729
farmers	T097	C0221460
India	T083	C0021201
deltamethrin	T109	C0057233
colonised strain	T080	C0456178
Culicoides nubeculosus Meigen	T204	C0322767
World Health Organisation	T093	C0043237
exposure assay	T059	C0005507
method	T062	C0242481
field	T077	C1521738
populations	T081	C0032659
Culicoides spp.	T204	C0010446
India	T083	C0021201
field	T077	C1521738
population	T081	C0032659
C. oxystoma	T204	C0322770
India	T083	C0021201
deltamethrin	T109	C0057233
laboratory-reared	T059	C0022885
C.nubeculosus	T204	C0322767
C. nubeculosus	T204	C0322767
deltamethrin	T109	C0057233
ambient temperatures	T070	C0428692
mortality rate	T081	C0205848
Behavioural assays	T059	C0005507
C. nubeculosus	T204	C0322767
WHO	T093	C0043237
tubes	T077	C1561954
deltamethrin	T109	C0057233
field	T077	C1521738
experiments	T062	C0681814
India	T083	C0021201
repellent	T131	C0544309
toxic effects	T037	C0600688
deltamethrin	T109	C0057233
Traditional methods	T062	C0242481
application	T169	C4048755
neem oil	T109	C0068484
burning	T067	C1254366
neem	T002	C1060234
leaves	T002	C0242724
no	T033	C1513916
protection	T033	C1545588
field	T077	C1521738
Culicoides	T204	C0010446
India	T083	C0021201
deltamethrin	T109	C0057233
laboratory-bred	T059	C0022885
C. nubeculosus	T204	C0322767
traditional methods	T062	C0242481
insect control	T068	C0021569
protection	T033	C1545588
sheep	T015	C0036945
susceptibility	T038	C1326888
deltamethrin	T109	C0057233
field	T077	C1521738
populations	T081	C0032659
Culicoides	T204	C0010446
resistance	T032	C0021575
synthetic pyrethrioids	T121	C1254351
insect control	T068	C0021569
methods	T062	C0242481
vaccination	T061	C0042196
Indian	T083	C0021201
livestock	T008	C2936506
BTV	T005	C0005867
transmission	T046	C0242781
Correlation	T080	C1707520
Lipid	T109	C0023779
Profile	T059	C1979963
BMI	T201	C1305855
Bone Mineral Density	T201	C0005938
Postmenopausal	T040	C0206159
Women	T098	C0043210
reduction	T080	C0392756
bone density	T201	C0005938
osteoporosis	T047	C0029456
postmenopausal	T040	C0206159
women	T098	C0043210
elevated	T080	C3163633
lipid	T109	C0023779
parameters	T033	C0449381
Body Mass Index	T201	C1305855
BMI	T201	C1305855
study	T062	C2603343
correlation	T080	C1707520
lipid	T109	C0023779
parameters	T033	C0449381
BMI	T201	C1305855
osteoporosis	T047	C0029456
postmenopausal	T040	C0206159
women	T098	C0043210
study	T062	C2603343
matched	T080	C1708943
type	T080	C0332307
experimental	T080	C1517586
group	T078	C0441833
controls	T096	C0009932
experimental	T080	C1517586
group	T078	C0441833
females	T098	C0043210
postmenopausal	T040	C0206159
age	T032	C0001779
DEXA method	T060	C1510486
diagnosed	T033	C0011900
osteoporosis	T047	C0029456
University Medical Center of RS	T073	C0000872
control group	T096	C0009932
females	T098	C0043210
postmenopausal	T040	C0206159
age	T032	C0001779
diagnosed	T033	C0011900
osteoporosis	T047	C0029456
groups	T078	C0441833
matched	T080	C1708943
age	T032	C0001779
years	T079	C1510829
participants	T098	C0679646
study	T062	C2603343
biochemical analysis of blood	T059	C0005774
analysis	T062	C0936012
lipid	T109	C0023779
profile	T059	C1979963
total cholesterol	T109	C0543421
LDL cholesterol	T109	C0023824
triglycerides	T109	C0041004
TG	T109	C0041004
HDL cholesterol	T109	C0023822
values	T080	C0042295
BMI	T201	C1305855
waist circumference	T201	C0455829
WC	T201	C0455829
Analysis	T062	C0936012
data	T078	C1511726
research	T062	C0035168
univariate logistic regression	T062	C0206031
values	T080	C0042295
lipid	T109	C0023779
parameters	T033	C0449381
total cholesterol	T109	C0543421
LDL	T109	C0023824
TG	T109	C0041004
significantly	T078	C0750502
associated with	T080	C0332281
osteoporosis	T047	C0029456
multivariate logistic model	T081	C0023965
total cholesterol	T109	C0543421
independent	T078	C0085862
risk factor	T033	C0035648
osteoporosis	T047	C0029456
postmenopausal	T040	C0206159
women	T098	C0043210
BMI	T201	C1305855
values	T080	C0042295
not	T033	C1513916
statistically significantly	T081	C0237881
associated with	T080	C0332281
osteoporosis	T047	C0029456
decrease	T081	C0547047
bone mineral density	T201	C0005938
osteoporosis	T047	C0029456
postmenopausal	T040	C0206159
women	T098	C0043210
risk factors	T033	C0035648
identification	T080	C0205396
effective	T080	C1704419
prevention	T080	C2700409
disease	T047	C0029456
elderly	T098	C0001792
Heterotopic ossification	T046	C0029396
recombinant human bone morphogenetic protein-7	T116	C1445625
incidence	T081	C0021149
heterotopic ossification	T046	C0029396
recombinant human bone morphogenetic protein-7	T116	C1445625
rhBMP-7	T116	C1445625
treatment	T061	C0087111
nonunions	T033	C3897107
Bone morphogenetic proteins	T116	C0053932
BMPs	T116	C0053932
bone formation	T042	C0029433
auto-induction	T044	C1148560
Recombinant human BMP-7	T116	C1445625
bone grafts	T122	C0181075
patients	T101	C0030705
treatment	T061	C0087111
long bone nonunions	T033	C3897107
patients	T101	C0030705
evaluated	T058	C0220825
radiographicaly	T060	C0841672
development	T169	C1527148
heterotopic ossification	T046	C0029396
standard	T080	C1442989
assessment	T058	C0220825
nonunion	T033	C3897107
healing	T040	C0043240
patients	T101	C0030705
radiographic	T070	C0444708
signs	T184	C0037088
heterotopic ossification	T046	C0029396
CT scan	T060	C0040405
Nonunion	T033	C3897107
site	T082	C0205145
palpation	T060	C0030247
ROM evaluation	T059	C1562926
adjacent	T082	C0205117
joints	T030	C0022417
Factors	T169	C1521761
patient	T101	C0030705
age	T032	C0001779
gender	T032	C0079399
nonunion	T033	C3897107
location	T082	C0450429
size	T082	C0456389
chronicity	T079	C0547045
number of previous procedures	T169	C2700391
infection	T046	C3714514
surrounding	T082	C1282914
tissues	T024	C0040300
condition	T080	C0348080
surgical procedure	T061	C0543467
graft	T122	C0181074
fixation	T061	C0185023
type	T080	C0332307
amount	T081	C1265611
rhBMP-7	T116	C1445625
correlated	T080	C1707520
development	T169	C1527148
heterotopic ossification	T046	C0029396
statistical analysis	T062	C0871424
Pearsons χ (2) test	T170	C0237913
nonunions	T033	C3897107
treated	T169	C1522326
rhBMP-7	T116	C1445625
healed	T169	C0205249
procedures	T169	C2700391
Heterotopic bone formation	T046	C0029396
patients	T101	C0030705
radiological evaluation	T058	C0220825
nonunion	T033	C3897107
mean time	T079	C0040223
rhBMP-7	T116	C1445625
application	T169	C4048755
heterotopic ossification	T046	C0029396
femur	T023	C0015811
cases	T077	C1706256
tibia	T023	C1279118
humerus	T023	C0020164
patient	T101	C0030705
patients	T101	C0030705
palpable mass	T033	C0746412
patient	T101	C0030705
para-articular knee nonunion	T033	C3897107
treated	T169	C1522326
rhBMP-7	T116	C1445625
size	T082	C0456389
heterotopic ossification	T046	C0029396
knee range of motion	T033	C0576094
patients	T101	C0030705
heterotopic ossification	T046	C0029396
male	T032	C0086582
Statistical analysis	T062	C0871424
patient's	T101	C0030705
gender	T032	C0079399
factor	T169	C1521761
development	T169	C1527148
heterotopic ossification	T046	C0029396
Heterotopic ossification	T046	C0029396
rhBMP-7	T116	C1445625
nonunions	T033	C3897107
clinical outcome	T169	C1274040
cases	T077	C1706256
male	T032	C0086582
patients	T101	C0030705
Hypocretin/Orexin Peptides	T116	C1113688
Excite	T052	C0549255
Rat	T015	C0034693
Neuroendocrine	T022	C0027912
Dopamine Neurons	T025	C1512035
Orexin 2 Receptor	T116	C0671880
Activation	T052	C1879547
Mixed	T169	C0205430
Cation	T104	C0007447
Current	T043	C0162585
Hypocretin/Orexin	T116	C1113688
H/O	T116	C1113688
neurons	T025	C0027882
lateral hypothalamus	T029	C0020654
compelling	UnknownType	C0815217
modulator candidates	T098	C0027361
chronobiology	T091	C0008716
neuroendocrine	T022	C0027912
output	T077	C1709366
consequence	T169	C0686907
hormone release	T125	C0815016
anterior pituitary	T023	C0032008
effects	T080	C1280500
H/O peptides	T116	C1113688
tuberoinfundibular dopamine (TIDA) neurons	T025	C1512035
cells	T025	C0007634
control	T080	C0243148
inhibition	T052	C3463820
pituitary	T023	C0032005
secretion of prolactin	T043	C2611224
whole cell recordings	T062	C0242624
performed	T169	C0884358
male	T032	C0086582
rat	T015	C0034693
hypothalamic slices	T082	C0449445
H/O-A	T116	C0671870
H/O-B	T116	C0671872
excited	T052	C0549255
TIDA neurons	T025	C1512035
inducing	T169	C0205263
reversible	T169	C0205343
depolarising	T046	C1395184
phasic to tonic discharge	T082	C1254362
H/O	T116	C1113688
induced	T169	C0205263
inward	T082	C0439786
current	T043	C0162585
underpinning	T077	C1521721
effect	T080	C1280500
post-synaptic	T026	C1167384
presence	T033	C0150312
tetrodotoxin	T109	C0039705
appeared	T080	C0700364
Na(+)	T116	C0037492
dependent	T080	C0851827
transient receptor potential-like channel	T116	C1563722
blocked	T169	C0332206
2-APB	T109	C0669933
diminished	T081	C0205216
removal	T052	C1883720
extracellular	T026	C0521119
Na(+)	T116	C0037492
consequence of	T169	C0686907
OX2R receptor	T116	C0671880
activation	T052	C1879547
blocked	T169	C0332206
OX2R receptor	T116	C0671880
antagonist	T120	C0243076
TCS OX2 29	T109	C3492123
OX1R receptor	T116	C0597357
antagonist	T120	C0243076
SB 334867	T109	C1097132
Application	T058	C0185125
hormone	T125	C0019932
melatonin	T109	C0025219
failed	T169	C0231175
alter	T169	C0392747
TIDA	T025	C1512035
membrane potential	T043	C0025251
oscillatory activity	T061	C0695434
description	T170	C0678257
electrophysiological effects	T060	C0850293
H/Os	T116	C1113688
TIDA network	T025	C1512035
identifies	T080	C0205396
cellular mechanisms	T044	C3537153
contribute	T052	C1880177
circadian rhythmicity	T040	C0008810
prolactin secretion	T043	C2611224
Improving	T080	C1272745
consumers	T098	C1707496
mental health organizations	T093	C0178740
mental ill health	T048	C0004936
Stigmatizing	T033	C0277787
consumers	T098	C1707496
working	T057	C0043227
mental health organizations	T093	C0178740
mental health policies	T170	C3244237
organizations	T093	C0920545
work	T057	C0043227
collaboratively	T054	C0282116
consumers	T098	C1707496
producing	T169	C0678227
delivering	T058	C0011211
services	T057	C0557854
social exchange theory	UnknownType	C0683615
mutual	T080	C1709100
exchange	T054	C0678640
maximise	T081	C0806909
benefits	T081	C0814225
partnership	T054	C0680453
current	T079	C0521116
study	T062	C2603343
perspectives	UnknownType	C0678958
working	T057	C0043227
organizations	T093	C0920545
level	T080	C0441889
consumer	T098	C1707496
leadership	T054	C0023181
Interviews	T052	C0021822
participants	T098	C0679646
range	T081	C1514721
mental health organizations	T093	C0178740
Data	T078	C1511726
analyzed	T062	C0936012
thematic analytic	T062	C0936012
discursive	T033	C4068735
psychological techniques	T060	C0033903
Findings	T033	C0243095
stigma	T033	C0277787
organizations	T093	C0920545
consumers	T098	C1707496
leadership positions	T054	C0023181
consumers	T098	C1707496
perceived	T041	C0030971
work	T057	C0043227
mental health organizations	T093	C0178740
discourses	T054	C2584313
consumers	T098	C1707496
mental health organizations	T093	C0178740
mental health system	T093	C0178740
ability	T032	C0085732
safety	T058	C0150755
support	T054	C0037438
consumers	T098	C1707496
social exchange theory	UnknownType	C0683615
authors	T097	C3812881
organizations	T093	C0920545
stigma	T033	C0277787
promote	T052	C0033414
consumers	T098	C1707496
maximize	T081	C0806909
mutual	T080	C1709100
benefits	T081	C0814225
sex	T032	C1522384
intraspecies	T185	C1705920
variation	T080	C0205419
ocean	T083	C0028814
acidification	T067	C2987513
responses	T032	C0871261
Ocean	T083	C0028814
acidification	T067	C2987513
OA	T067	C2987513
major threat	T078	C0749385
ecosystems	T070	C0162358
globally	T080	C2348867
significant	T078	C0750502
ecological	T070	C0162358
economic	T169	C0013557
importance	T080	C3898777
number	T081	C0237753
complexity	T169	C0237523
experiments	T062	C0681814
examining	T033	C0332128
effects of	T080	C1704420
OA	T067	C2987513
substantially	T078	C0750502
increased	T081	C0205217
past	T079	C1444637
decade	T081	C2981279
attempt	T051	C1516084
address	T078	C1547607
multi-stressor	T078	C0597530
interactions	T169	C1704675
long-term	T079	C0443252
responses	T032	C0871261
increasing	T169	C0442808
range	T081	C1514721
aquatic organisms	T001	C0596121
differences	T080	C1705242
response	T032	C0871261
males	T032	C0086582
females	T032	C0086287
elevated pCO2	T033	C0858343
investigated	T169	C1292732
fewer	T081	C0205388
date	T079	C0011008
difficulty	T080	C0332218
sex	T032	C1522384
non-destructively	T078	C1254370
early life stages	T079	C0680083
sex	T032	C1522384
significantly	T078	C0750502
impact	T080	C4049986
organism	T001	C0029235
responses	T032	C0871261
OA	T067	C2987513
affecting	T169	C0392760
physiology	T039	C0031843
reproduction	T040	C0035150
biochemistry	T169	C0205474
ultimately survival	T169	C0220921
impacts	T080	C4049986
ecological theory	T078	C0871935
differential	T080	C0443199
resource allocation	T081	C0086914
reproduction	T040	C0035150
predict	T078	C0681842
females	T032	C0086287
sensitive	T169	C0332324
OA	T067	C2987513
production cost	T169	C0220812
eggs	T025	C0029974
compared	T052	C1707455
sperm	T025	C0037868
sex	T032	C1522384
specific studies	T062	C2603343
significant	T078	C0750502
differences	T080	C1705242
responses	T032	C0871261
males	T032	C0086582
females	T032	C0086287
OA	T067	C2987513
consequences	T169	C0686907
forecasting	T079	C0220831
natural	T169	C0205296
populations	T098	C1257890
near-future	T079	C0016884
ocean	T083	C0028814
Computational analysis	T059	C4297010
conserved coil	T082	C0444764
functional residues	T077	C1709915
mitochondrial genomic sequences	T059	C3863348
dermatophytes	T004	C0011635
Dermatophyte	T004	C0011635
fungi	T004	C0016832
invade	T080	C1517574
keratinized	T169	C0232387
tissue	T024	C0040300
humans	T016	C0086418
animals	T008	C0003062
infection	T046	C3714514
dermatophytosis	T047	C0011636
genera	T185	C1708235
Microsporum	T004	C0026033
Trichophyton	T004	C0040933
Epidermophyton	T004	C0014529
infection	T046	C3714514
groin	T029	C0018246
tinea cruris	T047	C1384589
beard	T023	C0221982
tinea barbae	T047	C2349994
scalp	T023	C0036270
tinea capitis	T047	C0040250
feet	T023	C0016504
tinea pedis	T047	C0040259
glabrous skin	T023	C1180283
tinea corporis	T047	C0040252
nail	T023	C0027342
tinea unguium	T047	C0040261
hand	T023	C0018563
tinea manuum	T047	C0153246
evolutionary	T045	C0015219
relationship	T080	C0439849
three genera	T185	C1708235
dermatophyte	T004	C0011635
epidemiologically important	T169	C1516907
pathogenicity	T032	C1136169
Mitochondrial DNA	T114	C0012929
evolves	T038	C0282688
more rapidly	T080	C0456962
nuclear DNA	T114	C1179920
rate of mutation	T080	C3178846
less affected	T169	C0392760
genetic recombination	T045	C0034865
important tool	T073	C2827396
phylogenetic studies	T062	C1519068
conserved coil	T082	C0444764
functional residues	T077	C1709915
Trichophyton rubrum	T004	C0040935
Trichophyton mentagrophytes	T004	C0040934
Epidermophyton floccosum	T004	C0014530
Microsporum canis	T004	C0319950
Protein coding sequences	T028	C0079941
mitochondrial genome	T028	C1819716
similar sequences	T086	C0162326
homology modelling	T063	C1512489
structure	T116	C1510464
pocket	T087	C0599218
identification	T062	C0936012
comparative analysis	T062	C0683941
protein sequences	T087	C0002518
active sites	T169	C0205681
genera	T185	C1708235
Trichophyton	T004	C0040933
Microsporum	T004	C0026033
Epidermophyton floccosum	T004	C0014530
protein sequences	T087	C0002518
conserved coil	T082	C0444764
functional residues	T077	C1709915
E. floccusum	T004	C0014530
lesser infectivity	T080	C0030657
organism	T001	C0029235
functional residues	T077	C1709915
disease	T047	C0012634
putative target sites	T169	C1521840
drug designing	T090	C0013171
Non-intubated	T061	C0087111
subxiphoid	T082	C4039027
uniportal video-assisted thoracoscopic thymectomy	T061	C4304660
thymectomy	T061	C0040071
glasses-free	T033	C0243095
3D	T082	C0450363
vision	T040	C0042789
Trans-sternal thymectomy	T061	C0405560
accepted	T080	C1272684
standard	T080	C1442989
surgical procedure	T061	C0543467
thymic masses	T023	C0040113
Recently	T079	C0332185
minimally	T080	C0547040
invasive	T169	C0038895
methods	T170	C0025663
video-assisted thoracoscopic surgery	T061	C4304660
(VATS)	T061	C4304660
non-intubated	T061	C0087111
anesthesia	T061	C0002903
emerged	T080	C0700364
methods	T170	C0025663
advantages	T081	C0814225
including	T169	C0332257
reductions	T080	C0392756
surgical trauma	T033	C4060629
postoperative associated pain	T184	C0030201
VATS	T061	C4304660
cosmetic	T061	C0442965
benefits	T081	C0814225
Considering	T078	C0750591
advantages	T081	C0814225
subxiphoid	T082	C4039027
uniportal VATS	T061	C4304660
thymic mass	T024	C1515430
glasses-free	T033	C0243095
3D	T082	C0450363
thoracoscopic	T082	C0442425
display system	T170	C0871584
Trends	T079	C0040833
dietary intake	T040	C1286104
adults	T100	C0001675
type 2 diabetes	T047	C0011860
NHANES	T062	C0376344
Dietary	T168	C0012155
recommendations	T078	C0034866
adults	T100	C0001675
diabetes	T047	C0011860
healthy diet	T061	C0452415
portion sizes	T081	C3658326
trends	T079	C0040833
energy	T081	C0006777
nutrient intakes	T081	C0006777
US	T083	C0041703
adults	T100	C0001675
type 2 diabetes	T047	C0011860
Participants	T098	C0679646
adults	T100	C0001675
aged	T032	C0001779
years	T079	C0439234
cross-sectional National Health and Nutrition Examination Surveys	T062	C0376344
Diabetes	T047	C0011860
self-report	T062	C2700446
physician's	T097	C0031831
diagnosis	T033	C0011900
Intake of energy	T081	C0006777
nutrients	T168	C0678695
h	T079	C0439227
participants	T098	C0679646
food	T168	C0016452
Linear regression	T081	C0023733
test	T169	C0039593
trends	T079	C0040833
intake	T040	C1286104
time	T079	C0040223
participants	T098	C0679646
demographic characteristics	T102	C0683970
adults	T100	C0001675
diabetes	T047	C0011860
energy intake	T081	C0006777
increased	T081	C0205217
1689 kcal	T081	C0439259
1895 kcal	T081	C0439259
plateau	T081	C2964353
energy intake	T081	C0006777
younger	T100	C0238598
older adults	T098	C0001792
men	T098	C0025266
women	T098	C0043210
non-Hispanic whites	T098	C0221786
non-Hispanic blacks	T098	C0085756
percentage	T081	C0439165
calories	T081	C1556156
carbohydrate	T168	C0453802
total fat	T109	C0012171
protein	T168	C0453858
Percentage	T081	C0439165
calories	T081	C1556156
saturated fat	UnknownType	C0682953
study	T062	C2603343
periods	T079	C1948053
recommendations	T078	C0034866
Fibre intake	T033	C0474451
recommendations	T078	C0034866
Sodium	T168	C0037570
cholesterol	T109	C0008395
calcium	T197	C0006726
intakes	T040	C1286104
increased	T081	C0205217
energy intake	T081	C0006777
adults	T100	C0001675
diabetes	T047	C0011860
dietary	T168	C0012155
trends	T079	C0040833
diabetes	T047	C0011860
data	T078	C1511726
plateau	T081	C2964353
energy intake	T081	C0006777
adults	T100	C0001675
diabetes	T047	C0011860
increase	T169	C0442805
fibre	T168	C0012173
reduce	T081	C0547047
saturated fat	UnknownType	C0682953
Clonal	T024	C1522642
serotype	T170	C0449943
dynamics	T070	C3826426
serogroup 6	T007	C1532752
isolates	T123	C1764827
invasive pneumococcal disease	T047	C1320214
Portugal	T083	C0032729
serogroup 6	T007	C1532752
Streptococcus pneumoniae	T007	C0038410
serotypes	T170	C0449943
identified	T080	C0205396
introduction	T169	C0579004
pneumococcal conjugate vaccines	T121	C0206515
PCVs	T121	C0206515
decrease	T081	C0547047
6B-2 variant	T080	C0205419
invasive pneumococcal disease	T047	C1320214
IPD	T047	C1320214
6B-1	T080	C0205419
post	T079	C0687676
conjugate vaccine	T121	C0206515
introduction	T169	C0579004
decrease	T081	C0547047
CC273 isolates	T123	C1764827
Serotype 6C	T007	C3697188
associated with	T080	C0332281
adult	T100	C0001675
IPD	T047	C1320214
increased	T081	C0205217
age group	T100	C0027362
lineages	T078	C0282637
CC315	T078	C0282637
CC395	T078	C0282637
lineages	T078	C0282637
expressed	T045	C1171362
serogroup 6	T007	C1532752
serotypes	T170	C0449943
children	T100	C0008059
findings	T169	C2607943
cross-protection	T044	C2717886
PCVs	T121	C0206515
serotype 6C	T007	C3697188
IPD	T047	C1320214
vaccinated	T033	C1519885
children	T100	C0008059
adults	T100	C0001675
Serotype 6A	T007	C2732283
serogroup 6	T007	C1532752
serotype	T170	C0449943
children	T100	C0008059
decreased	T081	C0205216
adult	T100	C0001675
IPD	T047	C1320214
serogroup 6	T007	C1532752
serotypes	T170	C0449943
detected	T033	C0442726
phenotypic	T032	C0031437
genotypic	T032	C0017431
assays	T059	C1510438
adequate	T080	C0205411
serotypes	T170	C0449943
serogroup 6	T007	C1532752
isolates	T123	C1764827
Minimally invasive	T169	C2711297
percutaneous nephrolithotomy	T061	C0162428
impacted	T169	C0333125
proximal	T082	C0205107
ureteral stones	T047	C0041952
systematic review	T170	C1955832
meta-analysis	T062	C0920317
Urinary stones	T047	C0451641
medical	T169	C0205476
disorders	T047	C0012634
treatment	T169	C1522326
impacted proximal ureteral stones	T047	C0041952
proximal	T082	C0205107
IPUS	T047	C0041952
urologists	T097	C0260314
aim	T078	C1947946
study	T062	C2603343
compare the efficacy	T062	C1707887
safety	T062	C1705187
minimally invasive	T169	C2711297
percutaneous nephrolithotomy	T061	C0162428
MI	T169	C2711297
PCNL	T061	C0162428
ureteroscopic lithotripsy	T061	C0558630
URL	T061	C0558630
treatment	T169	C1522326
IPUS	T047	C0041952
meta-analysis	T062	C0920317
studies	T062	C0008972
PubMed	T170	C1138432
Embase	T170	C0242356
Cochrane Library	T170	C0242356
1978 to November 2016	T079	C0585341
analyzed	T062	C0936012
Stata 12.0	T170	C0037589
RevMan 5.3	T170	C0037589
Odds ratios	T081	C0028873
OR	T081	C0028873
standard mean difference	T081	C0444504
SMD	T081	C0444504
binary	T080	C1706942
continuous variables	T081	C3242610
confidence intervals	T081	C0009667
CIs	T081	C0009667
study	T062	C2603343
PRISMA guidelines	T170	C0282458
prospective studies	T062	C0033522
included	T169	C0332257
meta-analysis	T062	C0920317
MI	T169	C2711297
PCNL	T061	C0162428
URL	T061	C0558630
MI	T169	C2711297
PCNL	T061	C0162428
associated with	T080	C0332281
longer postoperative	T079	C0032790
hospital stay	T079	C3489408
URL	T061	C0558630
SMD	T081	C0444504
CI	T081	C0009667
difference	T080	C1705242
observed	T169	C1441672
operative time	T079	C3494201
SMD	T081	C0444504
CI	T081	C0009667
MI	T169	C2711297
PCNL	T061	C0162428
OR	T081	C0028873
CI	T081	C0009667
OR	T081	C0028873
CI	T081	C0009667
URL	T061	C0558630
surgical conversion	T061	C3494226
OR	T081	C0028873
CI	T081	C0009667
postoperative	T079	C0032790
shock wave lithotripsy	T061	C0015359
OR	T081	C0028873
CI	T081	C0009667
complications	T046	C0009566
differences	T080	C1705242
observed	T169	C1441672
between	T082	C0205103
MI	T169	C2711297
PCNL	T061	C0162428
URL	T061	C0558630
OR	T081	C0028873
CI	T081	C0009667
hematuria	T047	C0018965
OR	T081	C0028873
CI	T081	C0009667
MI	T169	C2711297
PCNL	T061	C0162428
optimal	T080	C2698651
considered	T078	C0750591
preferred	T078	C0558295
treatment method	T061	C0087111
IPUS	T047	C0041952
better efficacy	T080	C1280519
safety	T062	C1705187
URL	T061	C0558630
required	T169	C1514873
future	T079	C0016884
Predictive Factors	T170	C0683956
Long-term	T079	C0443252
Outcome	T169	C1274040
Subthalamic Nucleus	T023	C0152355
Deep Brain Stimulation	T061	C0394162
Parkinson's Disease	T047	C0030567
usefulness	T080	C3827682
subthalamic nucleus	T023	C0152355
deep brain stimulation	T061	C0394162
STN	T023	C0152355
DBS	T061	C0394162
treatment	T169	C1522326
Parkinson's disease	T047	C0030567
PD	T047	C0030567
preoperative	T079	C0445204
predictive factors	T170	C0683956
long-term	T079	C0443252
outcome	T169	C1274040
STN	T023	C0152355
DBS	T061	C0394162
not	T169	C1518422
sufficiently	T080	C0205410
established	T080	C0443211
study	T062	C2603343
predictive factors	T170	C0683956
subjects	T096	C0681850
patients	T101	C0030705
classified	T185	C0008902
two	T081	C0205448
groups	UnknownType	C0681860
basis	T169	C1527178
activities of daily living	T056	C0001288
ADL	T056	C0001288
five years	T079	C0439234
after	T079	C0687676
STN	T023	C0152355
DBS	T061	C0394162
surgery	T061	C0543467
patients	T101	C0030705
assigned	T169	C1516050
independent	T169	C0332291
ADL	T056	C0001288
group	UnknownType	C0681860
group I	UnknownType	C0681860
patients	T101	C0030705
dependent	T169	C3244310
ADL	T056	C0001288
group	UnknownType	C0681860
group D	UnknownType	C0681860
Group I	UnknownType	C0681860
patients	T101	C0030705
Schwab and England (S&E) scale	T170	C4034311
S&E	T170	C4034311
score	T081	C0449820
during	T079	C0347984
off-period	T079	C1948053
patients	T101	C0030705
independent	T169	C0332291
ADL	T056	C0001288
all the time	T079	C2003902
Group D	UnknownType	C0681860
patients	T101	C0030705
score	T081	C0449820
lower	T080	C0205251
during	T079	C0347984
off-period	T079	C1948053
patients	T101	C0030705
independent	T169	C0332291
ADL	T056	C0001288
entire	T081	C0439751
day	T079	C0439228
studied	T062	C2603343
differences	T080	C1705242
preoperative state	T033	C0178808
two	T081	C0205448
groups	UnknownType	C0681860
Statistically significant	T081	C0237881
differences	T080	C1705242
PD	T047	C0030567
onset age	T081	C0206132
age	T032	C0001779
surgery	T061	C0543467
preoperative	T079	C0445204
unified Parkinson's disease rating scale	T170	C4034309
UPDRS	T170	C4034309
part I	T082	C0449719
score	T081	C0449820
part II	T082	C0449719
score	T081	C0449820
total	T080	C0439810
subscore	T081	C0449820
axial symptoms	T033	C4314351
part III	T082	C0449719
mini-mental state examination (MMSE) score	T033	C2960235
S&E	T170	C4034311
score	T081	C0449820
logistic regression analysis	UnknownType	C0681925
significant	T078	C0750502
independent	T169	C0332291
variables	T080	C0439828
long-term	T079	C0443252
independent	T169	C0332291
ADL	T056	C0001288
age	T032	C0001779
surgery	T061	C0543467
MMSE score	T033	C2960235
preoperative	T079	C0445204
S&E scale	T170	C4034311
score	T081	C0449820
during	T079	C0347984
off-period	T079	C1948053
PD	T047	C0030567
onset age	T081	C0206132
age	T032	C0001779
surgery	T061	C0543467
preoperative	T079	C0445204
high	T080	C0205250
level	T080	C0441889
ADL	T056	C0001288
cognitive function	T041	C0392335
axial symptoms	T033	C4314351
important	T080	C3898777
predictive factors	T170	C0683956
long-term	T079	C0443252
outcome	T169	C1274040
STN	T023	C0152355
DBS	T061	C0394162
Persuades	T078	C3825845
Analysis	T062	C0936012
Persuasion	T078	C3825845
Choices	T055	C0008300
Antibiotic	T195	C0003232
Free	T080	C1996904
Food	T168	C0016452
Personal communication	T054	C0086792
person	T098	C0027361
persuades	T078	C3825845
behavior	T053	C0004927
behaviors	T053	C0004927
spread	T080	C0332261
understand	T041	C0162340
personal communication	T054	C0086792
spreads	T080	C0332261
behavior	T053	C0004927
investigated	T169	C1292732
adults'	T100	C0001675
likelihood	T081	C0033204
persuading	T078	C3825845
social network	T098	C0150775
buy	T052	C0870238
antibiotic	T195	C0003232
free	T080	C1996904
food	T168	C0016452
attempted	T051	C1516084
persuade	T078	C3825845
behavioral	T053	C0004927
determinants	T169	C1521761
homophily	T080	C0205556
superdiffuser	T080	C0205556
traits	T055	C0037401
potential	T080	C3245505
consumers	T098	C1707496
findings	T033	C0243095
behavioral	T053	C0004927
determinants	T169	C1521761
behavioral	T053	C0004927
intentions	T041	C0162425
mavenism	T080	C0205556
predicted	T078	C0681842
intentions	T041	C0162425
persuade	T078	C3825845
Homophily	T080	C0205556
mavenism	T080	C0205556
connectivity	T169	C0205245
predicted	T078	C0681842
patterns	T082	C0449774
interpersonal	T054	C0021797
persuasion	T078	C3825845
vegetarians	T098	C0042441
homophily	T080	C0205556
action	T052	C3266814
behavioral	T053	C0004927
determinants	T169	C1521761
mavenism	T080	C0205556
predicted	T078	C0681842
persuasion	T078	C3825845
intentions	T041	C0162425
Persuasiveness	T078	C3825845
associated with	T080	C0332281
targeting	T169	C1521840
network	T098	C0150775
members	T098	C0680022
mavenism	T080	C0205556
associated with	T080	C0332281
structurally	T082	C0678594
central	T082	C0205099
members	T098	C0680022
Modeling	T062	C0870071
flux	T070	C2348693
metabolites	T123	C0870883
juvenile hormone	T125	C0022439
biosynthesis	T038	C0220781
pathway	T044	C1704259
generalized additive models	T075	C0026336
ordinary differential equations	T170	C0282574
Juvenile hormone	T125	C0022439
JH	T125	C0022439
development	T169	C1527148
reproductive maturation	T040	C0036887
insects	T204	C0021585
corpora allata	T023	C0010085
CA	T023	C0010085
female	T032	C0086287
adult mosquitoes	T204	C0026584
fluctuating	T079	C0231241
levels	T080	C0441889
JH	T125	C0022439
ovarian development	T042	C1160265
nutritional	T080	C1521739
signals	T043	C0037083
rate	T081	C1521828
JH	T125	C0022439
biosynthesis	T038	C0220781
rate	T081	C1521828
flux	T070	C2348693
isoprenoids	T109	C0682996
pathway	T044	C1704259
changes	T169	C0392747
precursor	T167	C3891814
enzyme	T116	C0014442
levels	T080	C0441889
comprehensive	T080	C1880156
study	T062	C2603343
changes	T169	C0392747
enzymatic activities	T044	C0243102
precursor	T167	C3891814
mosquito	T204	C0026584
Aedes aegypti	T204	C0322859
JH	T125	C0022439
biosynthesis	T038	C0220781
pathway	T044	C1704259
studies	T062	C2603343
quantitative approaches	UnknownType	C0681919
changes	T169	C0392747
metabolic	T169	C0311400
reactions	T169	C0443286
pathway	T044	C1704259
JH	T125	C0022439
synthesis	T038	C0220781
generalized additive models	T075	C0026336
GAMs	T075	C0026336
changes	T169	C0392747
metabolite	T123	C0870883
concentrations	T081	C0457929
changes	T169	C0392747
enzymatic activities	T044	C0243102
substrate	T167	C3891814
concentrations	T081	C0457929
Changes	T169	C0392747
substrate	T167	C3891814
concentrations	T081	C0457929
model	T075	C0026336
metabolic	T169	C0311400
steps	T077	C1261552
analyzed	T062	C0936012
enzymatic activities	T044	C0243102
fitness	T052	C2349186
GAMs	T075	C0026336
substrate	T167	C3891814
concentrations	T081	C0457929
GAMs	T075	C0026336
experimental	T080	C1517586
data	T078	C1511726
ordinary differential equations	T170	C0282574
ODE	T170	C0282574
changes	T169	C0392747
metabolites	T123	C0870883
function	T169	C0542341
levels	T080	C0441889
enzymatic catalytic activities	T044	C0243102
results	T169	C1274040
models	T075	C0026336
changes	T169	C0392747
flux	T070	C2348693
metabolites	T123	C0870883
JH	T125	C0022439
pathway	T044	C1704259
design	T052	C1707689
validate	T062	C1519941
experimental	T080	C1517586
manipulations	T169	C0205245
JH	T125	C0022439
synthesis	T038	C0220781
Associations	T080	C0439849
human breast milk	T109	C0885503
hormones	T125	C0019932
adipocytokines	T116	C1955907
infant growth	T039	C0205714
body composition	T032	C0005885
first 6 months of life	T033	C3280927
human breast milk	T109	C0885503
HBM	T109	C0885503
HBM	T109	C0885503
maternal	T033	C1858460
body mass index	T201	C1305855
BMI	T201	C1305855
sex	T032	C0079399
stage of lactation	T042	C0022925
HBM	T109	C0885503
insulin	T116	C0021641
glucose	T109	C0017725
leptin	T116	C0299583
IL-6	T116	C0021760
TNF-α	T116	C1456820
associations	T080	C0439849
infant	T100	C0021270
body composition	T032	C0005885
breastfeeding infants	T033	C1623041
mothers	T033	C1623040
lactation	T042	C0022925
Infants	T100	C0021270
body composition measured	T201	C1285593
dual-energy X-ray absorptiometry	T060	C1510486
HBM	T109	C0885503
interaction	T169	C1704675
maternal	T033	C1858460
BMI	T201	C1305855
infant sex	T032	C0079399
insulin levels	T059	C0202098
insulin was 229% higher	T034	C0428405
obese	T047	C0028754
mothers	T099	C0026591
female infants	T033	C2222300
normal weight	T033	C2712185
mothers	T099	C0026591
nursing	T040	C0006147
nursing	T040	C0006147
female infants	T033	C2222300
obese	T047	C0028754
mothers	T099	C0026591
male infants	T033	C2216472
leptin	T116	C0299583
association	T080	C0439849
BMI	T201	C1305855
overweight	T184	C0497406
obese	T047	C0028754
mothers	T099	C0026591
higher leptin levels	T033	C2747815
normal weight	T033	C2712185
mothers	T099	C0026591
Leptin	T116	C0299583
BMI	T201	C1305855
sex	T032	C0079399
inverse	T080	C0439850
relationship	T080	C0439849
leptin	T116	C0299583
levels	T080	C0441889
infant length	T033	C0455806
percent fat	T033	C0518026
total fat mass	T032	C3656665
trunk fat mass	T032	C3656665
associations	T080	C0439849
interactions	T169	C1704675
glucose	T109	C0017725
TNF-α	T116	C1456820
IL-6	T116	C0021760
maternal	T033	C1858460
BMI	T201	C1305855
infant	T100	C0021270
sex	T032	C0079399
stage of lactation	T042	C0022925
insulin	T116	C0021641
leptin	T116	C0299583
Aryl hydrocarbon receptor (AhR) rs2066853	T028	C0596123
gene polymorphism	T045	C0678951
infertile	T046	C0021359
oligoasthenoteratozoospermic	T047	C0028960
men	T098	C0025266
seminal	T201	C1519232
oxidative stress	T049	C0242606
aryl hydrocarbon receptor (AhR) rs2066853	T028	C0596123
gene polymorphism	T045	C0678951
infertile	T046	C0021359
oligoasthenoteratozoospermic	T047	C0028960
OAT	T047	C0028960
men	T098	C0025266
seminal	T201	C1519232
oxidative stress	T049	C0242606
OS	T049	C0242606
Egyptian men	T098	C0025266
semen analysis	T059	C0202533
fertile	T040	C0015895
normozoospermic controls	T033	C4231237
infertile	T046	C0021359
OAT	T047	C0028960
men	T098	C0025266
history taking	T058	C0199182
clinical examination	T201	C1274016
semen analysis	T059	C0202533
estimation	T081	C0750572
seminal	T201	C1519232
glutathione peroxidase	T116	C0017822
GPx	T116	C0017822
malondialdehyde	T109	C0024643
MDA	T109	C0024643
AhR rs2066853	T028	C0596123
gene polymorphism	T045	C0678951
blood	T031	C0005767
PCR	T063	C0032520
RFLP	T049	C0035268
infertile	T046	C0021359
OAT	T047	C0028960
men	T098	C0025266
fertile	T040	C0015895
controls	T096	C0009932
AhR rs2066853	T028	C0596123
genotypes	T032	C0017431
decreased	T081	C0205216
prevalence	T081	C0033105
wild	T028	C1883559
homozygous genotype GG	T032	C0019904
heterozygous genotype GA	T032	C0019425
increased	T081	C0205217
prevalence	T081	C0033105
homozygous genotype AA	T032	C0019904
alleles	T028	C0002085
AhR rs2066853	T028	C0596123
OAT	T047	C0028960
men	T098	C0025266
fertile	T040	C0015895
men	T098	C0025266
decreased	T081	C0205216
prevalence	T081	C0033105
G allele	T028	C0002085
increased	T081	C0205217
prevalence	T081	C0033105
A allele	T028	C0002085
Seminal	T201	C1519232
MDA	T109	C0024643
increase	T081	C0205217
seminal	T201	C1519232
GPx	T116	C0017822
decrease	T081	C0205216
AA	T032	C0019904
GA	T032	C0019425
AA genotypes	T032	C0019904
GG genotype	T032	C0019904
AhR rs2066853	T028	C0596123
genotype	T032	C0017431
polymorphism	T045	C0678951
decreased	T081	C0205216
sperm	T025	C0037868
increased	T081	C0205217
seminal	T201	C1519232
oxidative stress	T049	C0242606
infertile	T046	C0021359
OAT	T047	C0028960
men	T098	C0025266
Associations	T080	C0439849
gender	T032	C0079399
proxy	T096	C0600420
female	T032	C0086287
menopausal status	T201	C1513126
histological	T169	C0205462
features	T080	C2348519
drug-induced liver injury	T047	C0860207
Gender	T032	C0079399
menopause	T039	C0025320
type	T080	C0332307
severity	T080	C0439793
drug-induced liver injury	T047	C0860207
DILI	T047	C0860207
influencing	T077	C4054723
host	T001	C1167395
responses	T033	C1704632
injury	T037	C3263723
aim	T078	C1947946
study	T062	C2603343
assess	T052	C1516048
associations	T080	C0439849
gender	T032	C0079399
female	T032	C0086287
age	T032	C0001779
proxy	T096	C0600420
menopause	T039	C0025320
histological	T169	C0205462
features	T080	C2348519
liver injury	T037	C0160390
adults	T100	C0001675
Drug-Induced Liver Injury	T047	C0860207
Network	T169	C1882071
DILIN	T169	C1882071
registry	T170	C0034975
participants	T098	C0679646
causality	T169	C0015127
score	T081	C0449820
probable	T033	C0332148
liver biopsy	T060	C0193388
DILI	T047	C0860207
chronic liver disease	T047	C0341439
Biochemical	T169	C0205474
histological	T169	C0205462
injury	T037	C3263723
types	T080	C0332307
hepatocellular	T046	C0151763
cholestatic/mixed injury	T047	C1737228
cohort	T098	C0599755
divided	T169	C0332849
gender	T032	C0079399
age	T032	C0001779
categories	T170	C0683312
men	T098	C0025266
women	T098	C0043210
women	T098	C0043210
age	T032	C0001779
Interaction	T169	C1704675
gender	T032	C0079399
age	T032	C0001779
category	T170	C0683312
assessed	T052	C1516048
Hepatocellular injury	T046	C0151763
women	T098	C0043210
biochemical	T169	C0205474
injury	T037	C3263723
types	T080	C0332307
black race	T098	C0005680
possible	T033	C0332149
ageing	T040	C0001811
effects	T080	C1280500
severe	T080	C0205082
hepatitis	T047	C0019158
biopsies	T060	C0005558
women	T098	C0043210
compared	T052	C1707455
men	T098	C0025266
women	T098	C0043210
Compared	T052	C1707455
men	T098	C0025266
biopsies	T060	C0005558
women	T098	C0043210
greater	T081	C1704243
plasma cell infiltration	T047	C0391861
hepatocyte apoptosis	T043	C3269241
hepatocyte	T025	C0227525
rosettes	T033	C0035863
lobular	T080	C0205417
iron	T121	C0302583
positive	T033	C1514241
hepatocytes	T025	C0227525
histological	T169	C0205462
cholestasis	T047	C0008370
associations	T080	C0439849
cases	T169	C0868928
amoxicillin/clavulanic acid	T121	C0054066
anabolic steroids	T109	C0002744
nitrofurantoin	T109	C0028156
DILI	T047	C0860207
gender	T032	C0079399
distributions	T169	C1704711
Gender	T032	C0079399
proxy	T096	C0600420
menopause	T039	C0025320
associated with	T080	C0332281
features	T080	C2348519
inflammation	T046	C0021368
injury	T037	C3263723
DILI	T047	C0860207
Anticancer Compound	T109	C0003392
Natural	T169	C0205296
Oridonin	T109	C0069639
Apoptosis	T043	C0162638
Cell Cycle Arrest	T043	C1155873
Mitochondrial Pathway	T045	C1513340
cytotoxicity	T049	C0596402
natural	T169	C0205296
ent-kaurene diterpenoid	T121	C1254351
oridonin	T109	C0069639
oridonin	T109	C0069639
cancer therapy	T061	C0920425
moderate potency	T038	C0678792
oridonin	T109	C0069639
A-ring modified analogues, and their derivatives	T104	C0002776
substituents on 14-OH position	T104	C1254350
synthesized	T052	C1883254
evaluated	T058	C0220825
anticancer	T109	C0003392
efficacy	T080	C1280519
derivatives	T104	C0243072
oridonin	T109	C0069639
drug	T121	C1254351
sensitive	T169	C0332324
drug-resistant	T038	C0013203
cancer cells	T025	C0334227
compound, 13p	T109	C0003392
200-fold	T079	C1254367
efficacious	T080	C1280519
oridonin	T109	C0069639
MCF-7 cancer cells	T025	C0596890
13p	T109	C0003392
apoptosis	T043	C0162638
cell cycle arrest	T043	C1155873
G2/M phase	T043	C1517347
mitochondrial membrane potential	T043	C1720920
Bax/Bcl-2	T116	C0219474
activated caspase-3	T116	C4290004
cleavage	T044	C0597304
MCF-7 cells	T025	C0596890
treatment	T061	C0087111
13p	T109	C0003392
mitochondrial pathway	T045	C1513340
13p	T109	C0003392
apoptosis	T043	C0162638
13p	T109	C0003392
tumor growth	T191	C0598934
mouse	T015	C0025929
xenograft models	T050	C1520166
no observable toxic effect	T184	C0857329
Stromal alterations	T033	C1336512
ovarian cancers	T191	C0029925
wavelength	T081	C0449819
dependent	T080	C0851827
Second Harmonic Generation microscopy	T059	C0026018
optical scattering	T067	C0596837
Ovarian cancer	T191	C0029925
gynecological	T091	C0018417
cancer	T191	C0006826
survival rate	T081	C0038954
specific rates	T081	C2986538
dependent	T080	C0851827
disease	T047	C0012634
diagnosis	T033	C0011900
screening	T058	C0220908
imaging tools	T074	C1512629
early lesions	T033	C0221198
subtypes	T185	C0872379
ovarian cancer	T191	C0029925
treatments	T061	C0087111
screening	T058	C0220908
imaging tools	T074	C1512629
wavelength	T081	C0449819
dependent	T080	C0851827
collagen	T116	C0009325
Second Harmonic Generation (SHG) imaging microscopy	T059	C0026018
optical scattering measurements	T059	C0027692
structural	T116	C1510464
differences	T080	C1705242
extracellular matrix	T024	C0015350
ECM	T024	C0015350
stroma	T023	C0927195
benign tumors	T191	C0086692
endometrioid tumors	T191	C0474809
low	T191	C3839184
high-grade serous tumors	T191	C3839280
SHG	T059	C0026018
signatures	T169	C1704864
conversion	T169	C0439836
efficiency	T081	C0013682
optical scattering	T067	C0596837
organization	T169	C1300196
collagen	T116	C0009325
sub-micron	T081	C0439201
size scale	T170	C0282574
structural	T116	C1510464
information	T078	C1533716
wavelength	T081	C0449819
dependence	T080	C0851827
size	T082	C0456389
distribution	T169	C1704711
collagen fibrils	T024	C1179626
fibers	T024	C0225325
wavelengths	T081	C0449819
wavelength	T081	C0449819
dependence	T080	C0851827
metrics	T024	C0015350
structural	T116	C1510464
differences	T080	C1705242
collagen	T116	C0009325
organization	T169	C1300196
classification	T185	C0008902
type I and II serous tumors	T191	C0476122
type I endometrioid tumors	T191	C0474809
ECM	T024	C0015350
serous malignancies	T191	C0476122
SHG	T059	C0026018
metrics	T024	C0015350
optical scattering measurements	T059	C0027692
linear discriminant model	T170	C3161035
tissues	T024	C0040300
high-grade serous tumors	T191	C3839280
tissue types	T024	C2713035
High-grade serous tumors	T191	C3839280
ovarian cancers	T191	C0029925
histological analysis	UnknownType	C0679557
etiology	T169	C1314792
in vivo	T062	C0681829
screening tool	T058	C0220908
SHG	T059	C0026018
optical scattering measurements	T059	C0027692
information	T078	C1533716
superior diagnostic power	T060	C0430022
clinical imaging	T060	C0011923
modalities	T169	C1275506
measurements	T169	C0242485
subtypes	T185	C0872379
ovarian cancer	T191	C0029925
treatment protocols	T061	C0040808
altered	T078	C1515926
collagen	T116	C0009325
histological analysis	UnknownType	C0679557
etiology	T169	C1314792
in vivo	T062	C0681829
screening tool	T058	C0220908
ovarian malignancies	T191	C1140680
metastasize	T191	C0027627
clinical imaging	T060	C0011923
Metal-on-Metal Bearings	T074	C3494213
Total Hip Arthroplasty	T061	C0040508
Hip Resurfacing	T061	C1719285
Review Article	T170	C0282443
metal-on-metal (MoM) bearings	T074	C3494213
hip arthroplasty	T061	C0186193
MoM bearings	T074	C3494213
metal-on-polyethylene	T074	C3880938
lower risk of	T081	C3538919
dislocation	T037	C0012691
larger head sizes	T080	C0205556
trend	T079	C1521798
re-introduction	T061	C0376495
MoM bearing	T074	C3494213
evidence	T078	C3887511
MoM bearing	T074	C3494213
successful	T080	C1272703
MoM bearings	T074	C3494213
reintroduction	T061	C0376495
metal-on-metal bearings	T074	C3494213
total hip arthroplasty	T061	C0040508
metal-on-metal bearings	T074	C3494213
stemmed total hip arthroplasty	T061	C0040508
metal-on-metal hip resurfacing	T061	C1955625
orthopaedics	T091	C0029355
metal-on-metal hip resurfacing	T061	C1955625
total hip arthroplasty	T061	C0040508
literature	T170	C0023866
strategy	T041	C0679199
MEDLINE	T170	C0025141
Embase	T170	C0242356
quality articles	T170	C1706852
inclusion criteria	T080	C1512693
review	T170	C0282443
metal-on-metal	T074	C3494213
total hip arthroplasty	T061	C0040508
hip resurfacing	T061	C1719285
articles	T170	C1706852
articles	T170	C1706852
review	T170	C0282443
Metal-on-metal hip resurfacing	T074	C3881498
treatment	T061	C0087111
specific	T080	C0205369
patient populations	T081	C2361270
appropriate	T080	C1548787
implant design	T061	C0021107
metal-on-metal total hip arthroplasty	T074	C3881498
all patient populations	T081	C2361270
follow-up	T058	C1522577
patients	T101	C0030705
metal-on-metal hip resurfacing	T061	C1955625
critical	T080	C1511545
long-term	T079	C0443252
outcomes	T080	C0085415
patients	T101	C0030705
complications	T046	C0009566
Morphogenetic	T040	C0026559
Alterations	T078	C1515926
Alternaria alternata	T004	C0320062
Exposed to	T080	C0332157
Dicarboximide Fungicide	T131	C0392419
Iprodione	T109	C0123904
Fungicide-resistant	T169	C0332325
Alternaria alternata	T004	C0320062
control	T169	C2587213
Alternaria diseases	T047	C0026946
crop	T002	C0242775
fields	T090	C0001829
investigate	T169	C1292732
cytological	T169	C0205471
fungicide	T131	C0392419
resistance	T039	C1514892
mechanisms	T169	C0441712
A. alternata	T004	C0320062
dicarboximide fungicide	T131	C0392419
iprodione	T109	C0123904
A. alternata	T004	C0320062
isolated	T169	C0205409
cactus	T002	C0330340
brown spot	T077	C1705203
cultured	T059	C0200954
potato-dextrose agar	T130	C1254353
PDA	T130	C1254353
without	T080	C0332288
iprodione	T109	C0123904
fungal cultures	T059	C0200954
different	T080	C1705242
growth	T040	C0018270
characteristics	T080	C1521970
no	T034	C3686837
initial	T079	C0205265
full	T080	C0443225
growth	T040	C0018270
observed	T169	C1441672
light	T059	C0430389
electron microscopy	T059	C0026019
Mycelia	T004	C0949695
grow	T040	C0018270
one day after incubation	T079	C1649476
DAI	T079	C1649476
continued	T078	C0549178
full	T080	C0443225
growth	T040	C0018270
control-growth	T040	C0018270
Con-G	T040	C0018270
PDA	T130	C1254353
fungicide	T131	C0392419
PDA	T130	C1254353
iprodione	T109	C0123904
no fungal growth	T034	C3686837
iprodione-no growth	T034	C3686837
Ipr-N	T034	C3686837
DAI	T079	C1649476
initial	T079	C0205265
growth	T040	C0018270
iprodione-initial growth	T040	C0018270
Ipr-I	T040	C0018270
DAI	T079	C1254367
colonies	T025	C1947989
expanded	T082	C0205229
continuously	T078	C0549178
full	T080	C0443225
growth	T040	C0018270
iprodione-growth	T040	C0018270
Ipr-G	T040	C0018270
Ipr-I	T040	C0018270
morphogenetic	T040	C0026559
changes	T169	C0392747
resisting	T039	C1514892
fungicidal	T044	C1321381
toxicity	T080	C0040539
Con-G	T040	C0018270
multicellular conidia	T004	C0038029
cell walls	T026	C3826300
septa	T026	C0243092
intact	T080	C0205266
dense	T080	C0439794
cytoplasm	T026	C0010834
Ipr-N	T034	C3686837
fungal	T004	C0016832
sporulation	T043	C2613267
inhibited	T080	C0311403
undeveloped	T033	C0243095
unicellular conidia	T004	C0038029
degraded	T033	C0243095
necrotic	T042	C0027540
cytoplasm	T026	C0010834
Ipr-I	T040	C0018270
conspicuous cellular changes	T049	C1265925
sporulation	T043	C2613267
multicellular conidia	T004	C0038029
double layered	T033	C0205400
thickened	T033	C0205400
cell walls	T026	C3826300
accumulation	T033	C4055506
proliferated	T169	C1514485
lipid bodies	T026	C0230704
conidial	T004	C0038029
cytoplasm	T026	C0010834
inhibit	T080	C0311403
penetration	T169	C0205321
fungicide	T131	C0392419
conidial	T004	C0038029
cells	T025	C0007634
fungicide	T131	C0392419
associated	T080	C0332281
toxicity	T080	C0040539
energy	T081	C1442080
nutritional	T080	C1521739
sources	T033	C0449416
fungal	T004	C0016832
growth	T040	C0018270
mature	T079	C0205286
colonies	T025	C1947989
Ipr-G	T040	C0018270
multicellular conidia	T004	C0038029
cell walls	T026	C3826300
intact	T080	C0205266
cytoplasm	T026	C0010834
lipid bodies	T026	C0230704
Con-G	T040	C0018270
diagnostic image	T078	C1551337
quality	T080	C0806487
coronary angiography	T060	C0085532
third-generation dual-source CT	T060	C0040405
usage	T169	C0457083
coronary CT angiography	T060	C1634617
CTA	T060	C1634617
patients	T101	C0030705
acute	T184	C0522051
chronic chest pain	T184	C1740831
diagnostic accuracy	T080	C0598285
Agatston score	T081	C0449820
AS	T081	C0449820
heart rate	T201	C0018810
arrhythmia	T033	C0003811
severe obesity	T047	C0028756
third-generation dual-source CT	T060	C0040405
DSCT	T060	C0040405
CTA	T060	C1634617
clinical setting	T082	C3176918
patients	T101	C0030705
BMI	T201	C1305855
male	T098	C0025266
CTA	T060	C1634617
DSCT	T060	C0040405
retrospective single-center analysis	T062	C0936012
contrast-enhanced volume dataset	T170	C0150098
sequential	T060	C0441633
SSM	T060	C0441633
helical scan mode	T060	C0441633
HSM	T060	C0441633
Coronary segments	T023	C1283333
diagnostic	T080	C0806487
non-diagnostic image quality	T080	C0806487
invasive angiography	T060	C0002971
diagnostic accuracy	T080	C0598285
CTA	T060	C1634617
SSM	T060	C0441633
HSM	T060	C0441633
diagnostic image	T078	C1551337
quality	T080	C0806487
AS	T081	C0449820
influence	T077	C4054723
diagnostic image	T078	C1551337
quality	T080	C0806487
SSM	T060	C0441633
HSM	T060	C0441633
Diagnostic image	T078	C1551337
quality	T080	C0806487
SSM	T060	C0441633
patients	T101	C0030705
AS	T081	C0449820
SSM	T060	C0441633
sensitivity	T081	C1511883
specificity	T081	C0037791
PPV	T081	C1514243
NPV	T081	C1513918
HSM	T060	C0441633
sensitivity	T081	C1511883
specificity	T081	C0037791
PPV	T081	C1514243
NPV	T081	C1513918
diagnostic accuracy	T080	C0598285
SSM	T060	C0441633
radiation doses	T081	C4019308
HSM	T060	C0441633
age	T098	C0599755
BMI	T201	C1305855
cohorts	T098	C0599755
SSM	T060	C0441633
third-generation DSCT	T060	C0040405
dose	T081	C0178602
diagnostic image	T078	C1551337
quality	T080	C0806487
patients	T101	C0030705
AS	T081	C0449820
heart rate	T201	C0018810
heart rhythm	T042	C0232187
obesity	T047	C0028754
Antagonistic	T044	C1148560
Self-Organizing Patterning	T045	C0376678
Control	T169	C2587213
Maintenance	T039	C2371947
Regeneration	T042	C0034963
Anteroposterior	T082	C0442212
Axis	T082	C1522496
Planarians	T204	C0032068
Planarian	T204	C0032068
flatworms	T204	C0032211
maintain	T039	C2371947
body	T017	C1268086
regenerate	T169	C0334213
arbitrary	T080	C1264693
tissue	T024	C0040300
fragments	T031	C0486805
phenomena	T067	C1882365
self-maintaining	T052	C0024501
self-organizing patterning	T045	C0376678
mechanisms	T169	C0441712
molecular	T080	C1521991
mechanisms	T169	C0441712
morphogenic	T044	C1152630
gradient	T081	C0812409
canonical Wnt signaling	T044	C3178960
gene expression	T045	C0017262
planarian	T204	C0032068
anteroposterior	T082	C0442212
A/P	T082	C0442212
axis	T082	C1522496
results	T033	C0683954
gradient	T081	C0812409
formation	T169	C1522492
autonomously	T169	C0332291
tail	T023	C0039259
autoregulatory	T038	C0019868
Wnt	T116	C0753137
Wnt	T028	C0935995
expression	T045	C1171362
gradient	T081	C0812409
steady state	T070	C0678587
regeneration	T042	C0034963
Functional	T169	C0205245
antagonism	T044	C1148560
tail	T023	C0039259
Wnt	T116	C0753137
gradient	T081	C0812409
unknown	T080	C0439673
head	T029	C0018670
patterning	T045	C0376678
spatial	T082	C0037775
proportions	T081	C1709707
planarian	T204	C0032068
A/P	T082	C0442212
axis	T082	C1522496
mutually	T080	C1709100
exclusive	T078	C1548966
molecular fate	T044	C1148560
during	T079	C0347984
regeneration	T042	C0034963
results	T033	C0683954
planarian	T204	C0032068
A/P	T082	C0442212
axis	T082	C1522496
self-organizing patterning	T045	C0376678
deployed	T052	C2825812
functionally	T169	C0205245
coupled	T169	C1948027
mutual	T080	C1709100
antagonism	T044	C1148560
Characterization	T052	C1880022
Ectopic Expression	T045	C1512167
CoWRI1	T028	C1517488
AP2/EREBP	T028	C1517488
Transcription Factor	T116	C0040648
Coconut	T002	C0009210
Cocos nucifera L	T002	C0009210
Endosperm	T002	C2717855
Seeds	T002	C0036563
Oil	T109	C0032085
Transgenic	T002	C0085245
Arabidopsis thaliana	T002	C0162740
Rice	T002	C1140671
Oryza sativa L	T002	C1140671
Coconut	T002	C0009210
Cocos nucifera L.	T002	C0009210
tropical	T070	C0041183
crop	T002	C0242775
monocotyledonous family	T077	C1704727
Arecaceae	T002	C0682477
Palmaceae	T002	C0682477
genes	T028	C0017337
metabolic processes	T040	C0025519
coconut	T002	C0009210
endosperm	T002	C2717855
investigated	T169	C1292732
study	T062	C2603343
WRI1	T028	C1517488
gene family	T028	C1517488
coconut	T002	C0009210
endosperm	T002	C2717855
CoWRI1	T028	C1517488
transcriptional	T045	C0040649
activities	T052	C0441655
interactions	T169	C1704675
acetyl-CoA carboxylase	T116	C0001022
BCCP2	T116	C0213275
promoter	T114	C0086860
CoWRI1	T028	C1517488
yeast two-hybrid	T063	C0599647
yeast one-hybrid	T063	C0599647
characterization	T052	C1880022
seed	T002	C0036563
expression	T045	C0017262
Arabidopsis	T002	C0162741
endosperm	T002	C2717855
expression	T045	C0017262
rice	T002	C1140671
transgenic	T002	C0085245
Arabidopsis	T002	C0162741
over-expressions	T045	C0017262
CoWRI1	T028	C1517488
T2	T002	C0085245
lines	T002	C1140671
quantitative real-time PCR	T063	C3179034
mRNA	T114	C0035696
genes	T028	C0017337
encoding	T052	C2700640
enzymes	T116	C0014442
fatty acid biosynthesis	T044	C0596562
triacylglycerols	T109	C0041004
BCCP2	T028	C0017337
KASI	T028	C0017337
MAT	T028	C0017337
ENR	T028	C0017337
FATA	T028	C0017337
GPDH	T028	C0017337
assayed	T059	C0005507
seeds	T002	C0036563
lipid	T109	C0023779
fatty acids	T109	C0015684
C16:0	T109	C0030234
C18:0	T109	C0038228
homozygous	T032	C0019904
T2	T002	C0085245
transgenic	T002	C0085245
rice lines	T002	C1140671
G5	T002	C1140671
G2	T002	C1140671
CoWRI1	T028	C1517488
expression	T045	C0017262
CoWRI1	T028	C1517488
transcripts	T114	C1519595
wild type	T028	C1883559
Analyses	T062	C0936012
seed	T002	C0036563
oil	T109	C0032085
starch	T109	C0038179
protein	T116	C0033684
T2	T002	C0085245
transgenic lines	T002	C0085245
seed	T002	C0036563
oil	T109	C0032085
transgenic lines	T002	C0085245
starch	T109	C0038179
protein	T116	C0033684
analysis	T062	C0936012
fatty acid	T109	C0015684
palmitic acid	T109	C0030234
C16:0	T109	C0030234
linolenic acid	T109	C0125903
C18:3	T109	C0125903
seeds	T002	C0036563
transgenic	T002	C0085245
rice lines	T002	C1140671
oleic acid	T109	C0028928
C18:1	T109	C0028928
Tooth Discoloration	T033	C0040434
Resulting	T169	C0678226
Nano	T081	C1553036
Zinc Oxide-Eugenol	T122	C0043492
Sealer	T122	C0676273
quality	T080	C0332306
endodontic sealer	T122	C0676273
tooth color	T033	C0475833
friendly	T080	C2700214
study	T062	C2603343
tooth discoloration	T033	C0040434
potential	T080	C3245505
nano	T081	C1553036
zinc oxide-eugenol	T122	C0043492
NZOE	T122	C0043492
sealer	T122	C0676273
tooth discoloration	T033	C0040434
pulp chamber	T030	C0034099
human	T016	C0086418
maxillary central	T023	C0021156
lateral incisors	T023	C0021156
filled	T052	C1708059
sealers	T122	C0676273
AH-26	T104	C0051001
resin-based sealer	T104	C0051001
Pulpdent	T122	C0072601
sealer	T122	C0676273
ZOE	T122	C0043492
NZOE	T122	C0043492
sealer	T122	C0676273
Color	T080	C0009393
measurements	T169	C0242485
baseline	T081	C1442488
before placement	T080	C1524072
sealers	T122	C0676273
h	T079	C0439227
h	T079	C0439227
h	T079	C0439227
week	T079	C0439230
month	T079	C0439231
sealers	T122	C0676273
Easy Shade spectrophotometer	T074	C0183400
Data	T078	C1511726
analyzed	T062	C0936012
SPSS software	T073	C0037585
one-way ANOVA	T081	C1709320
ANOVA	T081	C0002780
observed	T169	C1441672
paired comparison test	T170	C0282574
NZOE	T122	C0043492
sealer	T122	C0676273
tooth discoloration	T033	C0040434
potential	T080	C3245505
comparison	T052	C1707455
AH-26	T104	C0051001
ZOE	T122	C0043492
sealer	T122	C0676273
identity	T078	C0017390
Palearctic	UnknownType	C0681784
species	T185	C1705920
wolf spider	T204	C0323749
genus	T185	C1708235
Trebacosa	T204	C3409647
Araneae	T204	C0037913
Lycosidae	T204	C0323749
paper	T170	C1706852
Trebacosa brunhesi	T204	C3409647
synonym	T077	C0871468
Trebacosa europaea	T204	C3409647
examination	T169	C1292732
specimens	T167	C0370003
localities	T083	C0017446
species	T185	C1705920
type	T080	C0332307
species	T185	C1705920
genus	T185	C1708235
Trebacosa marxi	T204	C3409648
specimens	T167	C0370003
localities	T083	C0017446
T. europaea	T204	C3409647
inter-	T080	C0205369
intraspecific differences	T080	C1705242
genus	T185	C1708235
Scanning electron micrographs	T059	C0026020
structure	T082	C0678594
female's genitalia	T023	C0017421
numerical	T081	C0237753
study	T062	C2603343
functionally graded materials	T073	C3273359
stent	T074	C0038257
design	T052	C1707689
Undesirable	T080	C1883420
deformation	T080	C2919017
stent	T074	C0038257
significant	T037	C0178324
injure	T037	C3263723
blood vessel	T023	C0005847
plaque	T033	C0332461
reduce/minimize	T033	C0243095
undesirable	T080	C1883420
deformations	T080	C2919017
Functionally Graded Materials	T073	C3273359
FGM	T073	C3273359
Finite Element (FE) method	T170	C3826344
employed	T033	C0557351
simulate	T062	C0679083
expansion	T169	C0442805
stent	T074	C0038257
displacement	T067	C2347509
stenosis	T046	C1261287
plaque	T033	C0332461
hyperelastic	T073	C0450146
plaque	T033	C0332461
elastoplastic stents	T074	C0441289
Dogboning	T169	C0001688
foreshortening	T033	C0243095
maximum	T081	C0806909
stress	T033	C0038435
plaque	T033	C0332461
pressure	T067	C0033095
expand	T082	C0205229
stent	T074	C0038257
stent	T074	C0038257
materials	T167	C0520510
FGMs	T073	C3273359
lower	T080	C0547044
dogboning	T169	C0001688
stents	T074	C0038257
uniform	T080	C0205375
materials	T167	C0520510
stent	T074	C0038257
lowest	T080	C1708760
heterogeneous index	T170	C0918012
lowest	T080	C1708760
dogboning	T169	C0001688
Steel	T122	C0038239
stent	T074	C0038257
lowest	T080	C1708760
foreshortening	T033	C0243095
expansion pressure	T081	C4049814
difference	T081	C1705241
lower	T080	C0547044
dogboning	T169	C0001688
FGM	T073	C3273359
heterogeneous index	T170	C0918012
suitable	T080	C3900053
results	T169	C1274040
results	T169	C1274040
material	T167	C0520510
parameters	T077	C0549193
crucial	T080	C1511545
effects	T080	C1280500
deformation	T080	C2919017
stent	T074	C0038257
result	T169	C1274040
design	T052	C1707689
FGM	T073	C3273359
parameters	T077	C0549193
biomechanical	T081	C0009563
optimization	T052	C2698650
Women's	T098	C0043210
human papillomavirus	T005	C0021344
self-sampling	T060	C0080142
UK	T083	C0041700
cervical	T023	C0007874
screening programme	T058	C1254363
Testing	T169	C0039593
human papillomavirus	T005	C0021344
HPV	T005	C0021344
cervical	T023	C0007874
screening programme	T058	C1254363
HPV	T005	C0021344
HPV	T005	C0021344
self-sampling	T060	C0080142
policy	T170	C0242456
practice	T041	C0237607
potential	T080	C3245505
barriers	T033	C4296486
HPV	T005	C0021344
self-sampling	T060	C0080142
cross-sectional survey	T062	C0010362
women	T098	C0043210
Logistic regression analysis	UnknownType	C0681925
determinants	T169	C1521761
self-sampling	T060	C0080142
women	T098	C0043210
self-sampling	T060	C0080142
Interviews	T052	C0021822
survey	T170	C0038951
participants	T098	C0679646
HPV	T005	C0021344
Lower	T080	C0205556
intention	T041	C0162425
associated with	T080	C0332281
lower	T080	C0205556
lower	T080	C0205556
education	T065	C0013621
lower	T080	C0205556
perceived	T041	C0030971
HPV	T005	C0021344
cervical cancer	T191	C0302592
Interviews	T052	C0021822
personal	T032	C1519021
barriers	T033	C4296486
Personal	T032	C1519021
barriers	T033	C4296486
knowledge	T170	C0376554
HPV	T005	C0021344
self-sampling	T060	C0080142
women's	T098	C0043210
low confidence	T033	C0558092
low confidence	T033	C0558092
lack of confidence	T033	C0558092
cervical	T023	C0007874
screening programme	T058	C1254363
sample	T167	C0370003
contamination	T078	C2349974
identity theft	T054	C3658363
research	T062	C0035168
HPV	T005	C0021344
self-sampling	T060	C0080142
policy	T170	C0242456
practice	T041	C0237607
Personal	T032	C1519021
system-related barriers	T033	C0243095
low confidence	T033	C0558092
cervical	T023	C0007874
screening	T058	C1710032
HPV	T005	C0021344
self-sampling	T060	C0080142
cervical	T023	C0007874
screening programme	T058	C1254363
N-Terminal	T087	C1706793
Hypothesis	T078	C1512571
Alzheimer's Disease	T047	C0002395
amyloid	T116	C0002716
abeta peptide	T116	C0078939
Aβ	T116	C0078939
hypothesis	T078	C1512571
years	T079	C0439234
dominant	T169	C1527180
model	T170	C3161035
Alzheimer's disease	T047	C0002395
AD	T047	C0002395
pathogenesis	T046	C0699748
development	T169	C1527148
treatments	T061	C0087111
controversial	T054	C0680243
lack	T080	C0332268
mechanistic path	T169	C0441712
cleavage products	T167	C0439861
amyloid precursor protein	T116	C0085151
APP	T116	C0085151
soluble	T080	C1948047
Aβ monomer	T116	C3484390
molecular	T080	C1521991
fragments	T169	C0332255
deleterious effects	T080	C1280500
synaptic form	T042	C0597545
function	T169	C0542341
review of	T169	C0699752
literature	T170	C0023866
published work	T073	C0034036
aggregation kinetics	T070	C0022702
structural	T082	C0678594
morphology	T080	C0332437
Aβ	T116	C0078939
clearance	T080	C0449297
molecular	T080	C1521991
simulations	T062	C0679083
long-term potentiation	T042	C0206249
measurements	T169	C0242485
inhibition binding	T044	C2259198
binding	T044	C1167622
monoclonal antibody	T116	C0003250
aducanumab	T129	C4043101
hypothesize	T078	C1512571
N-terminal domains	T087	C1706793
neurotoxic	T131	C0260049
Aβ oligomers	T116	C0078939
causing	T169	C0678227
disease	T047	C0012634
Generation	T052	C3146294
High-Quality	T080	C0332306
SWATH(®)	T170	C0282574
Acquisition	T052	C1706701
Data	T078	C1511726
Label-free	T033	C0243095
Quantitative	T081	C0392762
Proteomics Studies	T091	C0872252
TripleTOF(®) Mass Spectrometers	T074	C0183396
Data	T078	C1511726
independent	T169	C0332291
acquisition	T052	C1706701
mass spectrometry technique	T059	C0037813
MS	T059	C0037813
MS/MS	T063	C0599748
analysis	T062	C0936012
detectable	T201	C3830527
species	T071	C1551338
information	T078	C1533716
data	T078	C1511726
mined	T066	C1328866
acquire	T052	C1706701
high-quality	T080	C0332306
SWATH(®)	T170	C0282574
Acquisition	T052	C1706701
data	T078	C1511726
large	T081	C0549177
quantitative	T081	C0392762
proteomic studies	T091	C0872252
variable	T080	C0439828
sized	T082	C0456389
Q1 windows	T170	C0282574
acquisition	T052	C1706701
MS/MS	T063	C0599748
data	T078	C1511726
generating	T052	C3146294
specificity	T081	C0037791
quantitative	T081	C0392762
data	T078	C1511726
Alkaptonuria	T047	C0002066
Fourier-transform infrared microscopy	T059	C0596777
FTIRM	T059	C0596777
low energy X-ray fluorescence microscopy	T059	C0026022
LEXRF	T059	C0026022
correlative study	T062	C1511524
rare disease	T047	C0678236
Alkaptonuria	T047	C0002066
AKU	T047	C0002066
ultra-rare disease	T047	C0678236
associated	T080	C0332281
lack	T080	C0332268
enzyme	T116	C0014442
tyrosine catabolism	T044	C1156678
deficiency	T169	C0011155
accumulation	T033	C4055506
homogentisic acid	T109	C0019881
HGA	T109	C0019881
ochronotic pigment	UnknownType	C0028818
joint	T030	C0022417
cartilage	T024	C0007301
severe	T080	C0205082
arthropathy	T047	C0022408
Secondary amyloidosis	T047	C0002726
unequivocally	T080	C4053896
assessed	T052	C1516048
comorbidity	T078	C0009488
AKU	T047	C0002066
arthropathy	T047	C0022408
ochronotic pigment	UnknownType	C0028818
structurally	T082	C0678594
amyloid	T116	C0002716
Synchrotron Radiation	T067	C0599746
Infrared	T059	C0596777
X-Ray Fluorescence microscopies	T059	C0026022
bio-assays	T059	C0005507
analytical	T062	C0936012
chemical composition	T070	C0243176
morphology	T080	C0332437
AKU	T047	C0002066
cartilage	T024	C0007301
evinced	T169	C0205319
AKU	T047	C0002066
cartilage	T024	C0007301
proteoglycans	T116	C0033692
depletion	T169	C0333668
increased Sodium levels	T033	C0595879
accumulation	T033	C4055506
lipids	T109	C0023779
peri-lacunar regions	T030	C0229984
amyloid	T116	C0002716
formation	T169	C1522492
increase	T169	C0442805
aromatic compounds	T109	C1510940
oxygen-containing species	T197	C0684299
depletion	T169	C0333668
Magnesium	T123	C0024467
content	T081	C1264655
localized	T082	C0392752
peri-lacunar region	T030	C0229984
presence	T033	C0150312
calcium carbonate	T121	C0006681
proximity	T082	C1514583
cartilage lacunae	T030	C0225370
common	T081	C0205214
AKU	T047	C0002066
arthropathy	T047	C0022408
disease	T047	C0012634
presence	T033	C0150312
amyloids	T116	C0002716
peculiar	T033	C0205161
calcifications	T042	C1533591
analyses	T062	C0936012
AKU	T047	C0002066
cartilage	T024	C0007301
disease	T047	C0012634
new	T080	C0205314
Ochronotic pigment	UnknownType	C0028818
AKU	T047	C0002066
tissue degeneration	T042	C1623047
bio-assays	T059	C0005507
composition	T070	C0243176
structural	T082	C0678594
relationship	T080	C0439849
amyloids	T116	C0002716
present	T079	C0521116
work	T062	C0035168
integration	T169	C0243126
analytical	T062	C0936012
standardized	T080	C1442989
analyses	T062	C0936012
Unbiased estimates	T062	C1711255
cerebrospinal fluid	T031	C0007806
β-amyloid 1-42	T116	C0169424
cutoffs	T169	C1442160
memory clinic	T073	C0442592
population	T098	C1257890
cutoff	T169	C1442160
β-amyloid 1-42	T116	C0169424
cerebrospinal fluid	T031	C0007806
CSF	T031	C0007806
marker	T201	C0005516
Alzheimer's disease	T047	C0002395
AD	T047	C0002395
data-driven	T080	C3899452
Gaussian mixture modeling	T081	C0026348
memory clinic	T073	C0442592
population	T098	C1257890
cross-sectional	T062	C0010362
prospective cohort study	T062	C1709709
subjects	T098	C2349001
subjective cognitive decline	T046	C0234985
mild cognitive impairment	T048	C1270972
AD	T047	C0002395
dementia	T048	C0497327
dementia	T048	C0497327
AD	T047	C0002395
Amsterdam	UnknownType	C0681784
Dementia	T048	C0497327
Cohort	T098	C0599755
CSF	T031	C0007806
β-amyloid 1-42	T116	C0169424
cutoffs	T169	C1442160
data-driven	T080	C3899452
Gaussian mixture modeling	T081	C0026348
total population	T081	C3258257
subgroups	T185	C1515021
clinical diagnosis	T060	C0332140
age	T032	C0001779
apolipoprotein E (APOE) genotype	T059	C1446118
investigated	T169	C1292732
abnormal	T033	C0205161
β-amyloid 1-42	T116	C0169424
data-driven	T080	C3899452
cutoff	T169	C1442160
predict	T078	C0681842
progression	T169	C0449258
AD	T047	C0002395
dementia	T048	C0497327
abnormal	T033	C0205161
β-amyloid 1-42	T116	C0169424
clinical diagnosis	T060	C0332140
cutoff	T169	C1442160
Cox proportional hazards regression	T081	C0010235
group	T078	C0441833
patients	T101	C0030705
cutoff	T169	C1442160
abnormal	T033	C0205161
CSF	T031	C0007806
β-amyloid 1-42	T116	C0169424
CI	T081	C0009667
cutoffs	T169	C1442160
diagnostic	T033	C0011900
APOE genotype	T059	C1446118
subgroups	T185	C1515021
cutoff	T169	C1442160
higher	T080	C0205250
elderly	T098	C0001792
subjects	T098	C2349001
subjects	T098	C2349001
data-driven	T080	C3899452
cutoff	T169	C1442160
higher	T080	C0205250
clinical diagnosis	T060	C0332140
cutoff	T169	C1442160
predictive	T080	C0681890
accuracy	T080	C0443131
progression	T169	C0449258
AD	T047	C0002395
dementia	T048	C0497327
subjects	T098	C2349001
HR	T081	C2985465
p	T081	C1709380
Mixture modeling	T081	C0026348
robust	T080	C2986815
method	T170	C0025663
cutoffs	T169	C1442160
CSF	T031	C0007806
β-amyloid 1-42	T116	C0169424
biological	T080	C0205460
changes	T169	C0392747
AD	T047	C0002395
cutoffs	T169	C1442160
clinical diagnosis	T060	C0332140
Identification	T080	C0205396
anti-mycobacterial	T121	C0360390
functional	T169	C0205245
properties	T080	C0871161
piperidinol derivatives	T121	C1254351
Tuberculosis	T047	C0041296
TB	T047	C0041296
global	T080	C2348867
health	T078	C0018684
threat	T078	C0749385
cause of death	T033	C0007465
infectious agent	T001	C0314732
worldwide	T080	C2348867
TB	T047	C0041296
drug	T121	C0013227
regimen	T061	C0040808
inadequate	T080	C0205412
anti-tubercular agents	T121	C1254351
prevalence	T081	C0220900
drug-resistant TB	T047	C0206525
study	T062	C2603343
investigate	T169	C1292732
piperidinol compound derivative	T121	C1254351
active	T169	C0205177
Mycobacterium tuberculosis	T007	C0026926
bacillus	T007	C0004587
antibacterial	T195	C0279516
properties	T080	C0871161
piperidinol compound	T121	C1254351
bis-Mannich base	T109	C0024728
analogue	T104	C0243071
evaluated	T058	C0220825
M. smegmatis	T007	C0317761
Gram-negative organisms	T007	C0018150
Cytotoxicity	T049	C0596402
studies	T062	C2603343
selectivity index	T170	C0918012
compounds	T121	C1254351
resistant	T169	C0332325
mutants	T049	C0596988
M. smegmatis	T007	C0317761
piperidinol	T121	C1254351
bis-Mannich base lead derivatives	T121	C1254351
genome sequencing	T063	C1328887
genetic modifications	T063	C4277689
compounds	T121	C1254351
piperidinol	T121	C1254351
bis-Mannich base analogue	T121	C1254351
mycobacteria	T007	C0026912
organism	T001	C0029235
cytotoxicity	T049	C0596402
selectivity index	T170	C0918012
mycobacteria	T007	C0026912
genome sequencing	T063	C1328887
M. smegmatis	T007	C0317761
strains	T001	C1518614
resistant	T169	C0332325
lead compounds	T121	C1254351
identification	T080	C0205396
single nucleotide polymorphisms	T086	C0752046
results	T033	C0683954
piperidinol moiety	T121	C1254351
compound class	T121	C1254351
anti-tubercular agents	T121	C1254351
Metatranscriptomics	T059	C0752248
Bacterial	T007	C0004611
Eukaryotic Fibrolytic Communities	T007	C0004611
Rumen	T023	C0035946
Dairy Cow	T015	C3687529
Mixed	T169	C0205430
Diet	T168	C0012155
Ruminants	T015	C0035950
energy	T081	C1442080
degradation	T169	C0243125
plant	T002	C0032098
polysaccharides	T109	C0032594
activity	T052	C0441655
rumen	T023	C0035946
microbiota	T002	C1000792
process	T067	C1522240
in vitro	T080	C1533691
microbiota members	T002	C1000792
enzymes	T116	C0014442
in vivo	T082	C1515655
RNA-sequencing	T059	C0917793
expression	T045	C0017262
genes	T028	C0017337
carbohydrate-active enzymes	T116	C0014442
CAZymes	T116	C0014442
rumen	T023	C0035946
microbiota	T002	C1000792
lactating dairy cow	T015	C3687529
microorganisms	T001	C0445623
fiber	T002	C1260603
community	T096	C0009462
Functional analysis	T062	C0936012
CAZymes	T116	C0014442
transcripts	T114	C1519595
CAZyme	T116	C0014442
GH94	T116	C0055033
cellobiose-phosphorylase	T116	C0055033
GH13	T116	C0002712
amylase	T116	C0002712
GH43	T116	C0062220
GH10	T116	C0062220
hemicellulases	T116	C0062220
GH9	T116	C1260229
GH48	T116	C1260229
cellulases	T116	C1260229
PL11	T116	C0032491
pectinase	T116	C0032491
GH2	T116	C0014442
GH3	T116	C0014442
oligosaccharidases	T116	C0014442
fibrolytic bacteria	T007	C0004611
Prevotella	T007	C0242946
Ruminocccus	T007	C0318074
Fibrobacter	T007	C0995400
contribution	T052	C1880177
fungi	T004	C0016832
ciliate protozoa	T204	C0008781
polysaccharide	T109	C0032594
degradation	T169	C0243125
protozoa	T204	C0033739
rumen	T023	C0035946
fibrolytic bacterial community	T007	C0004611
CAZyme	T116	C0014442
transcripts	T114	C1519595
strains	T007	C0004611
metatranscriptomics	T059	C0752248
rumen	T023	C0035946
microbial community	T001	C0445623
Fine Mapping	T052	C1283195
Carbon Assimilation Rate 8	T028	C0017337
Quantitative Trait Locus	T028	C0597336
Flag Leaf	T002	C0242724
Nitrogen	T123	C0028158
Content	T077	C0456205
Stomatal	T002	C1955855
Conductance	T081	C0392762
Photosynthesis	T070	C0031764
Rice	T002	C1140671
Increasing	T169	C0442808
rate	T081	C1521828
leaf photosynthesis	T070	C0031764
grain yield	T081	C0392762
rice	T002	C1140671
Oryza sativa	T002	C1140671
variation	T080	C0205419
CO2 assimilation rate	T081	C1521828
rice cultivars	T002	C1140671
quantitative genetics	T090	C1514626
genes	T028	C0017337
photosynthesis	T070	C0031764
location	T082	C0450429
Carbon Assimilation Rate 8	T028	C0017337
CAR8	T028	C0017337
crossing	T045	C0010366
indica cultivar	T002	C1659274
Japanese	T083	C0022341
commercial	T170	C0680536
cultivar	T002	C0032098
Fine mapping	T052	C1283195
CAR8	T028	C0017337
encodes	T052	C2700640
putative Heme Activator Protein 3	T116	C0033684
OsHAP3	T116	C0033684
CCAAT-box-binding transcription factor	T116	C0526260
OsHAP3H	T028	C0017337
Sequencing analysis	T063	C1328887
indica	T002	C1659274
allele	T028	C0002085
CAR8	T028	C0017337
1-bp deletion	T049	C0162773
bp	T044	C0600436
start codon	T086	C0242610
truncated protein	T116	C1144558
amino acids	T116	C0002520
CAR8	T028	C0017337
identical	T080	C0205280
DTH8	T028	C0017337
Ghd8	T028	C0017337
LHD1	T028	C0017337
rice	T002	C1140671
flowering	T040	C1820370
date	T079	C0011008
increase	T169	C0442805
A	T081	C1521828
increase	T169	C0442805
RuBP regeneration rate	T081	C1521828
increased	T081	C0205217
leaf	T002	C0242724
nitrogen	T123	C0028158
content	T077	C0456205
reduced	T080	C0392756
stomatal	T002	C1955855
limitation	T169	C0449295
increased	T081	C0205217
stomatal	T002	C1955855
conductance	T081	C0392762
A	T081	C1521828
allele	T028	C0002085
hydraulic conductivity	T080	C0205556
promote	T052	C0033414
stomatal	T002	C1955855
conductance	T081	C0392762
CAR8	T028	C0017337
physiological aspects	T039	C0031843
photosynthesis	T070	C0031764
analysis	T062	C0936012
molecular functions	T044	C1148560
CAR8	T028	C0017337
association	T080	C0439849
photosynthesis	T070	C0031764
flowering	T040	C1820370
genetic	T169	C0314603
mechanisms	T169	C0441712
improve	T033	C0184511
photosynthesis	T070	C0031764
rice	T002	C1140671
crops	UnknownType	C0868961
Allogeneic stem cell transplantation	T061	C2242529
adult	T100	C0001675
patients	T101	C0030705
acute lymphoblastic leukemia	T191	C0023449
central nervous system involvement	T033	C4050309
study	T062	C2603343
Adult	T100	C0001675
ALL	T191	C0023449
Working Group	T098	C1883562
Japan	T083	C0022341
Society	T092	C0037455
Hematopoietic Cell Transplantation	T061	C1705576
prognosis	T058	C0033325
adult	T100	C0001675
acute lymphoblastic leukemia	T191	C0023449
ALL	T191	C0023449
patients	T101	C0030705
central nervous system (CNS) involvement	T033	C4050309
CNS+	T033	C4050309
allogeneic hematopoietic stem cell transplantation	T061	C1705576
allo-SCT	T061	C1705576
retrospectively	T080	C1514923
outcomes	T080	C0085415
allo-SCT	T061	C1705576
patients	T101	C0030705
CNS involvement	T033	C4050309
patients	T101	C0030705
without	T080	C0332288
CNS involvement	T033	C4050309
CNS-	T033	C4050309
database	T170	C0242356
Japan	T083	C0022341
criteria	T078	C0243161
study	T062	C2603343
diagnosis	T062	C1704656
ALL	T191	C0023449
years	T079	C1510829
allo-SCT	T061	C1705576
first	T081	C0205435
SCT	T061	C1705576
Data	T078	C1511726
patients	T101	C0030705
CNS+ patients	T101	C0030705
CNS- patients	T101	C0030705
analyses	T062	C0936012
CNS- patients	T101	C0030705
CNS+ patients	T101	C0030705
younger	T079	C0332239
worse	T033	C1457868
disease	T047	C0012634
status	T080	C0449438
SCT	T061	C1705576
performance status	T201	C1518965
PS	T201	C1518965
SCT	T061	C1705576
Incidence	T081	C0021149
relapse	T067	C0035020
CNS+ patients	T101	C0030705
incidence	T081	C0021149
CNS	T022	C3714787
relapse	T067	C0035020
probability	T081	C0033204
year	T079	C0439234
overall survival	T081	C4086681
OS	T081	C4086681
CNS- patients	T101	C0030705
univariate analysis	T062	C0683962
patients	T101	C0030705
received	T080	C1514756
SCT	T061	C1705576
CR	T033	C0677874
no difference	T033	C3842396
probability	T081	C0033204
OS	T081	C4086681
CNS+	T033	C4050309
CNS-	T033	C4050309
patients	T101	C0030705
CNS involvement	T033	C4050309
unfavorable	T080	C3640815
effect	T080	C1280500
OS	T081	C4086681
multivariate analysis	T081	C0026777
CNS+ patients	T101	C0030705
CR	T033	C0677874
OS	T081	C4086681
CNS- patients	T101	C0030705
Silent strain of caregiving	T054	C1328742
best predictors	T033	C0035648
distress	T033	C0231303
family carers	T099	C0086279
geriatric patients	T101	C0870602
best predictors	T033	C0035648
distress suffered	T033	C0231303
family carers	T099	C0086279
FCs	T099	C0086279
geriatric patients	T101	C0870602
cross-sectional study	T062	C0010362
FC	T099	C0086279
geriatric patient	T101	C0870602
dyads	T098	C0870454
negative impact of care	T033	C0243095
NIoC	T033	C0243095
subscale	T081	C0459443
COPE index	T081	C0392762
lower stress	T033	C4075362
higher stress	T033	C4075362
FCs	T099	C0086279
process of providing care	T058	C2735110
explanatory	T170	C0681841
variables	T033	C2673413
sociodemographic	T078	C0011292
care-related attributes	T058	C0086388
patient-related results	T033	C0243095
geriatric assessments	T058	C0017463
disease	T047	C0012634
profiles	T058	C0747306
explanatory	T170	C0681841
variables	T033	C2673413
highest predictive powe	T080	C0681890
distress	T033	C0231303
FCs	T099	C0086279
multiple logistic regression (LR) model	UnknownType	C0681925
LR	UnknownType	C0681925
statistical information criteria	T081	C0237881
statistical robustness	T081	C0237881
discriminative power	T169	C2945687
model	T075	C0026336
cross-validation method	T062	C0681935
age	T032	C0001779
FCs	T099	C0086279
geriatric patients	T101	C0870602
explanatory	T170	C0681841
variables	T033	C2673413
predictors	T033	C0035648
statistical model	T081	C0026348
distress	T033	C0231303
lower self-evaluation of health	T058	C0175637
self-appraisal	T041	C2936632
coping	T055	C0009967
caregiver	T099	C0086279
lower	T080	C0205251
general support	T058	C1276367
care	T052	C1947933
motor retardation	T033	C0424230
cared	T052	C1947933
Timed Up and Go (TUG) test	T060	C3161512
TUG test	T060	C3161512
patient	T101	C0030705
predictor	T033	C0035648
distress	T033	C0231303
variables	T033	C2673413
NIoC	T033	C0243095
mobility of geriatric patients	T061	C2094221
kinesitherapeutic methods	T061	C0087111
hospital stay	T079	C3489408
FCs	T099	C0086279
Microbiological	T170	C0025953
Clinical Characteristics	T201	C0683325
Hypermucoviscous Klebsiella pneumoniae	T007	C0001699
Isolates	T123	C1764827
Associated with	T080	C0332281
Invasive Infections	T047	C4285937
China	T083	C0008115
distinctive syndrome	T047	C0039082
caused by	T169	C0015127
hypermucoviscous Klebsiella pneumoniae	T007	C0001699
HMKP	T007	C0001699
pyogenic liver abscess	T047	C0267830
PLA	T047	C0267830
globally emerging disease	T047	C0872315
study	T062	C2603343
K. pneumoniae	T007	C0001699
isolates	T123	C1764827
associated with	T080	C0332281
various types	T080	C0332307
invasive infections	T047	C4285937
HMKP	T007	C0001699
associated with	T080	C0332281
PLA	T047	C0267830
Multivariate regression analysis	T081	C0026777
male patients	T032	C0150904
years	T079	C0439234
PLA	T047	C0267830
diabetes mellitus	T047	C0011849
hypertension	T047	C0020538
independent	T078	C0085862
risk factors	T033	C0035648
HMKP infections	T047	C0948802
K2	T170	C0449547
capsular	T082	C0205151
serotype	T170	C0449943
HMKP	T007	C0001699
isolates	T123	C1764827
K1	T170	C0449547
Seventy-five percentage	T081	C0439165
K1	T170	C0449547
HMKP	T007	C0001699
isolates	T123	C1764827
associated with	T080	C0332281
PLA	T047	C0267830
K2	T170	C0449547
HMKP	T007	C0001699
isolates	T123	C1764827
accounted	T078	C0750591
more types	T080	C0332307
invasive infections	T047	C4285937
positive	T033	C1446409
rates	T081	C1521828
iutA	T028	C0017337
mrkD	T028	C0017337
aerobactin	T028	C0017337
iroN	T028	C0017337
rmpA	T028	C0017337
HMKP	T007	C0001699
isolates	T123	C1764827
significantly higher	T081	C4055637
non-HMKP	T007	C0001699
isolates	T123	C1764827
correlation	T080	C1707520
magA	T028	C0017337
ybtS	T028	C0017337
alls	T028	C0017337
wcaG	T028	C0017337
K1	T170	C0449547
isolates	T123	C1764827
mrkD	T028	C0017337
exclusively detected	T033	C0442726
HMKP	T007	C0001699
K2	T170	C0449547
isolates	T123	C1764827
K1	T170	C0449547
K2	T170	C0449547
HMKP	T007	C0001699
non-HMKP	T007	C0001699
isolates	T123	C1764827
positive	T033	C1446409
rmpA	T028	C0017337
Aerobactin	T028	C0017337
found	T033	C0150312
K1	T170	C0449547
K2	T170	C0449547
isolates	T123	C1764827
ST23	T170	C0449943
found	T033	C0150312
most prevalent	T079	C0332183
ST	T170	C0449943
HMKP	T007	C0001699
isolates	T123	C1764827
K1	T170	C0449547
K2	T170	C0449547
K5	T170	C0449547
K20	T170	C0449547
K57	T170	C0449547
found	T033	C0150312
K1	T170	C0449547
isolates	T123	C1764827
ST65	T170	C0449943
most prevalent	T079	C0332183
ST	T170	C0449943
found	T033	C0150312
K2	T170	C0449547
isolates	T123	C1764827
ST23-K1	T170	C0449547
HMKP	T007	C0001699
isolates	T123	C1764827
associated with	T080	C0332281
PLA	T047	C0267830
ST65-K2	T170	C0449547
isolates	T123	C1764827
correlated	T080	C1707520
types of infections	T185	C0457463
ST23-K1	T170	C0449547
isolates	T123	C1764827
PFGE	T059	C0085117
results	T169	C1274040
homology	T080	C2697616
HMKP	T007	C0001699
isolates	T123	C1764827
diverse	T080	C1880371
five	T081	C0205451
PFGE	T059	C0085117
clusters	T081	C1704332
similarity	T080	C2348205
accounted	T078	C0750591
three	T081	C0205449
isolates	T123	C1764827
five	T081	C0205451
PFGE	T059	C0085117
clusters	T081	C1704332
accounted	T078	C0750591
isolates	T123	C1764827
study	T062	C2603343
found	T033	C0150312
hypertension	T047	C0020538
male patients	T032	C0150904
years	T079	C0439234
old	T079	C0580836
independent	T078	C0085862
risk factors	T033	C0035648
composition	T201	C0486616
ST types	T170	C0449943
PFGE	T059	C0085117
clusters	T081	C1704332
K. pneumoniae	T007	C0001699
K2	T170	C0449547
isolates	T123	C1764827
diverse	T080	C1880371
K1	T170	C0449547
isolates	T123	C1764827
K1	T170	C0449547
K2	T170	C0449547
HMKP	T007	C0001699
isolates	T123	C1764827
specific profiles	T169	C2003903
virulence	T038	C0042765
associated	T078	C0750490
genes	T028	C0017337
Haemoglobinopathies	T047	C0019045
β-Thalassaemia	T047	C0005283
Tribals	T098	C0040881
Working	T057	C0043227
Tea	T168	C0039400
Gardens	T080	C4019428
Assam	UnknownType	C0681784
India	T083	C0021201
Prevalence	T081	C0220900
haemoglobinopathies	T047	C0019045
β-thalassaemia	T047	C0005283
very high	T080	C0205250
India	T083	C0021201
information	T078	C1533716
tribals	T098	C0040881
working	T057	C0043227
tea	T168	C0039400
gardens	T080	C4019428
Assam	UnknownType	C0681784
very less	T080	C0205251
study	T062	C2603343
prevalence	T081	C0220900
haemoglobinopathies	T047	C0019045
β-thalassaemia	T047	C0005283
tribals	T098	C0040881
working	T057	C0043227
tea	T168	C0039400
gardens	T080	C4019428
Assam	UnknownType	C0681784
tribals	T098	C0040881
working	T057	C0043227
tea	T168	C0039400
gardens	T080	C4019428
Assam	UnknownType	C0681784
analysed	T062	C0936012
Complete Blood Count	T059	C0009555
CBC	T059	C0009555
High Pressure Liquid Chromatography	T059	C0008562
HPLC	T059	C0008562
detection	T061	C1511790
haemoglobinopathies	T047	C0019045
β-thalassaemia	T047	C0005283
study	T062	C2603343
prevalence	T081	C0220900
sickle cell anaemia	T047	C0002895
β-thalassaemia	T047	C0005283
very high	T080	C0205250
population	T098	C1257890
results	T169	C1274040
indicated	T033	C1444656
prevalence	T081	C0220900
β-thalassaemia	T047	C0005283
Munda ethnic group	T098	C0015031
prevalence	T081	C0220900
sickle cell anaemia	T047	C0002895
Lohar ethnic group	T098	C0015031
study	T062	C2603343
presence	T033	C0150312
HbE	T116	C0019024
tribals	T098	C0040881
working	T057	C0043227
tea	T168	C0039400
gardens	T080	C4019428
Assam	UnknownType	C0681784
findings	T033	C0243095
sickle cell anaemia	T047	C0002895
β-thalassaemia	T047	C0005283
health	T078	C0018684
problem	T033	C0033213
tribals	T098	C0040881
working	T057	C0043227
tea	T168	C0039400
gardens	T080	C4019428
Assam	UnknownType	C0681784
diagnostic facilities	T058	C0011929
haemoglobinopathy	T047	C0019045
thalassaemia	T047	C0039730
established	T080	C0443211
areas	T082	C0205146
haemoglobinopathy	T047	C0019045
thalassaemia	T047	C0039730
database	T170	C0242356
collection	T169	C1516698
haematological analysis laboratories	T073	C0022877
genetic counselling clinics	T073	C0442592
prenatal diagnosis centres	T073	C0565990
neonatal screening centres	T073	C0565990
Long Term	T079	C0443252
Outcome	T169	C1274040
Patients	T101	C0030705
Esophageal Stenting	T061	C1654920
Cancer Esophagus	T191	C0152018
Rural Hospital	T093	C0020023
Punjab	UnknownType	C0681784
India	T083	C0021201
Cancer of the esophagus	T191	C0152018
cause	T078	C0085978
cancer deaths	T081	C1516192
Punjab	UnknownType	C0681784
India	T083	C0021201
Patients	T101	C0030705
present	T033	C0150312
dysphagia	T047	C0011168
symptom	T184	C1457887
advanced disease	UnknownType	C0679246
time	T079	C0040223
presentation	T078	C0449450
tertiary care centre	T073	C0587437
Palliative procedures	T061	C1285158
important	T080	C3898777
Stenting	T061	C2348535
option	T169	C1518601
palliate	T080	C1285530
symptoms	T184	C1457887
dysphagia	T047	C0011168
patient	T101	C0030705
suffering the most	T033	C0518881
success	T080	C0679864
rate	T081	C1521828
early	T184	C0231243
long term	T079	C0443252
complications	T046	C0009566
mortality	T081	C0205848
esophageal stenting	T061	C1654920
malignant esophageal stricture	T047	C0341129
patients	T101	C0030705
One hundred	T081	C1704407
patients	T101	C0030705
esophageal stenting	T061	C1654920
January	T080	C3829466
January	T080	C3829466
included	T169	C0332257
study	T062	C2603343
retrospectively analysed	T062	C0035363
data	T078	C1511726
patient	T101	C0030705
characteristics	T080	C1521970
causes	T169	C1314792
non-operability	T080	C0205187
early	T184	C0231243
long term	T079	C0443252
complications	T046	C0009566
re-interventions	T061	C0184661
efficacy	T080	C1280519
mortality	T081	C0205848
patients	T101	C0030705
indications	T078	C3146298
stenting	T061	C2348535
advanced disease	UnknownType	C0679246
amenable	T080	C3900053
surgery	T061	C0543467
metastatic disease	T191	C2939420
CVA	T047	C0038454
cardiac	T033	C0262402
respiratory problem	T184	C1659989
surgery	T061	C0543467
patients	T101	C0030705
patients	T101	C0030705
squamous cell carcinoma	T191	C0007137
adenocarcinoma	T191	C0001418
patients	T101	C0030705
presented	T078	C0449450
dysphagia	T047	C0011168
chest pain	T184	C0008031
recurrent cough	T033	C3553459
recurrent vomiting	T184	C0750325
dysphagia	T047	C0011168
liquids	T167	C0302908
solids	T167	C0302909
complete dysphagia	T047	C0011168
stenting	T061	C2348535
significant	T078	C0750502
improvement	T077	C2986411
dysphagia	T047	C0011168
score	T081	C0449820
Post procedure	T079	C3272301
stay	T079	C0023303
days	T079	C0439228
patient	T101	C0030705
procedure	T061	C0184661
complication	T046	C0009566
post procedural bleed	T037	C0919874
days	T079	C0439228
stenting	T061	C2348535
death	T033	C1306577
patient	T101	C0030705
Minor	T041	C0558080
complications	T046	C0009566
present	T033	C0150312
patients	T101	C0030705
treated	T169	C1522326
affecting	T169	C0392760
efficacy	T080	C1280519
procedure	T061	C0184661
include	T052	C2700399
pain	T184	C0030193
stenting	T061	C2348535
stent obstruction	T046	C0028778
stent migration	T046	C4087543
minor	T041	C0558080
complications	T046	C0009566
treated	T169	C1522326
except	T169	C0332300
patients	T101	C0030705
re-stenting	T061	C2348535
Esophageal stenting	T061	C1654920
procedure	T061	C0184661
stay	T079	C0023303
patient	T101	C0030705
hospital	T073	C0019994
patients	T101	C0030705
morbidity	T081	C0026538
effectively	T080	C1704419
technical glitches	T067	C1710348
patient	T101	C0030705
counseled	T061	C0600047
procedure	T061	C0184661
prevent	T169	C1292733
manage	T169	C2587213
post procedure	T079	C3272301
complications	T046	C0009566
Treatment	T169	C0039798
Carcinoma In Situ of the Glans Penis	T191	C0686217
Topical Imiquimod	T200	C3215046
Carbon Dioxide Laser	T074	C0392251
Excision	T061	C0728940
Different	T080	C1705242
approaches	T169	C1292724
described	T078	C1552738
carcinoma in situ (CIS) of the glans penis	T191	C0686217
erythroplasia of Queyrat	T191	C0154089
including	T169	C0332257
topical chemotherapy	T061	C1519552
immunotherapy	T061	C0021083
laser	UnknownType	C0441543
surgical excision	T061	C0728940
evaluated	T061	C0728940
efficacy	T080	C1280519
topical imiquimod	T200	C3215046
IQ	T200	C3215046
carbon dioxide laser	T074	C0392251
ablation	T061	C0348007
lesion	T033	C0221198
patients affected	T080	C0522476
CIS	T191	C0686217
glans	T023	C1550261
treated	T061	C0332293
IQ	T200	C3215046
carbon dioxide laser	T074	C0392251
ablation	T061	C0348007
patient	T101	C0030705
performed	T169	C0884358
histologic examination	T059	C0019637
before	T079	C0332152
after	T079	C0687676
IQ	T200	C3215046
toxicity	T037	C0013221
adverse effects	T046	C0879626
After treatment	T079	C2709088
histologic examination	T059	C0019637
no residual tumor	T034	C0332652
patients	T101	C0030705
complete response	T033	C4050307
CR	T033	C4050307
stable disease	T033	C0677946
patients	T101	C0030705
progressive disease	T047	C1335499
patients	T101	C0030705
CR	T033	C4050307
human papillomavirus	T005	C0021344
related	T080	C0439849
lesions	T033	C0221198
no	T033	C1513916
relapses	T067	C0035020
after	T079	C0687676
follow-up	T058	C1522577
months	T079	C0439231
patients	T101	C0030705
progressive disease	T047	C1335499
penectomy	T061	C0194708
patients	T101	C0030705
alive	T033	C2584946
follow-up examination	T033	C0260832
patients	T101	C0030705
mild	T080	C2945599
toxicity	T037	C0013221
burning erythema	T184	C0085624
no	T033	C1513916
major	T080	C0205164
adverse effects	T046	C0879626
treatment	T169	C0039798
IQ	T200	C3215046
glans	T023	C1550261
CIS	T191	C0686217
effective	T080	C1704419
human papillomavirus	T005	C0021344
related	T080	C0439849
lesions	T033	C0221198
histologic examination	T059	C0019637
before	T079	C0332152
after	T079	C0687676
IQ	T200	C3215046
treatment	T169	C0039798
patients	T101	C0030705
rarity	T080	C0522498
disease	T047	C0012634
limitation	T169	C0449295
IQ	T200	C3215046
follow-up	T058	C1522577
protocol	T170	C0442711
mandatory	T061	C0683517
lack	T080	C0332268
long-term	T079	C0443252
efficacy	T080	C1280519
Progressive	T169	C0205329
subcortical	T029	C0815275
calcifications	T042	C1533591
venous hypertension	T047	C0340766
intracranial	T029	C0524466
dural arteriovenous fistula	T190	C0752156
Intracranial	T029	C0524466
dural arteriovenous fistulas	T190	C0752156
dAVF	T190	C0752156
acquired lesions	T033	C1711164
reported	T058	C0700287
findings	T033	C0243095
CT	T060	C0040405
haemorrhage	T046	C0019080
focal oedema	T046	C0006114
progressive	T169	C0205329
subcortical	T029	C0815275
calcification	T042	C1533591
CT	T060	C0040405
venous hypertension	T047	C0340766
dAVF	T190	C0752156
Static Cold Storage	T059	C0010405
Hypothermic Machine Perfusion	T061	C0193410
Oxidative Stress Factors	T059	C0696141
Adhesion Molecules	T116	C1720822
Zinc Finger Transcription Factor Proteins	T116	C2700330
Liver Transplantation	T061	C0023911
static cold storage	T059	C0010405
SCS	T059	C0010405
hypothermic machine perfusion	T061	C0193410
HMP	T061	C0193410
oxidative stress factors	T059	C0696141
OSF	T059	C0696141
adhesion molecules	T116	C1720822
AM	T116	C1720822
zinc finger transcription factor	T116	C2700330
Snail	T116	C2700330
liver transplantation	T061	C0023911
dogs	T015	C0012984
donor	T058	C0262458
group	T078	C0441833
SCS	T059	C0010405
group	T078	C0441833
HMP	T061	C0193410
group	T078	C0441833
groups	T078	C0441833
Livers retrieved	T061	C0023911
group	T078	C0441833
transplanted	T061	C0023911
group	T078	C0441833
SCS	T059	C0010405
livers	T023	C0023884
group	T078	C0441833
transplanted	T061	C0023911
group	T078	C0441833
HMP	T061	C0193410
group	T078	C0441833
euthanized	T058	C3686530
livers	T023	C0023884
group	T078	C0441833
dogs	T015	C0012984
liver transplants	T061	C0023911
groups	T078	C0441833
liver	T023	C0023884
sampling process	T062	C0036150
OSF	T059	C0696141
AM	T116	C1720822
groups	T078	C0441833
no significant differences	T033	C3842396
transplantation	T061	C0040732
chemokine CXCL14	T116	C3180772
Snail	T116	C2700330
groups	T078	C0441833
no significant differences	T033	C3842396
group	T078	C0441833
P-selectin	T116	C0134835
group	T078	C0441833
transplantation	T061	C0040732
HIF-1α	T116	C1528324
chemokine CXCL14	T116	C3180772
P-selectin	T116	C0134835
Snail	T116	C2700330
group	T078	C0441833
group	T078	C0441833
HMP	T061	C0193410
OSF	T059	C0696141
inflammatory factors	T169	C0333348
conducive	T033	C0243095
liver transplantation	T061	C0023911
Physiology	T039	C0031843
respiratory disturbances	T033	C4314646
muscular dystrophies	T047	C0026850
Muscular dystrophy	T047	C0026850
myopathies	T047	C0026848
progressive	T169	C0205329
skeletal muscle wasting	T046	C0541794
respiratory muscles	T023	C0035231
Respiratory failure	T047	C1145670
respiratory system	T022	C0035237
fails	T169	C0231175
gas exchange functions	UnknownType	C0678852
feature	T080	C2348519
muscular dystrophy	T047	C0026850
death	T033	C1306577
consequence of	T169	C0686907
lung	T023	C0024109
failure	T047	C1145670
pump failure	T047	C1145670
recurrent	T079	C2945760
aspiration	T046	C0700198
progressive	T169	C0205329
weakness of respiratory muscles	T033	C1836141
increase	T169	C0442805
contract	UnknownType	C0678852
resistive and elastic components	T080	C0205556
breathing	T039	C0035203
increase	T169	C0442805
airway obstruction	T047	C0001883
chest wall	T023	C0205076
lung	T023	C0024109
stiffening	T184	C0427008
respiratory disturbances	T033	C4314646
muscular dystrophy	T047	C0026850
restrictive pulmonary function	T033	C3806472
hypoventilation	T046	C3203358
thoracoabdominal	T082	C0444467
hypercapnia	T033	C0020440
dyspnoea	T184	C0013404
impaired regulation of breathing	UnknownType	C0548979
inefficient cough	T033	C0455777
sleep disordered breathing	T047	C0037315
muscular dystrophy	T047	C0026850
progression	T046	C0242656
symptom	T184	C1457887
prognosis	T058	C0033325
degree of respiratory involvement	T033	C0243095
feature	T080	C2348519
muscular dystrophy	T047	C0026850
respiratory failure	T047	C1145670
respiratory system	T022	C0035237
oxygenation	T042	C0597398
carbon dioxide elimination	T039	C0221102
lung	T023	C0024109
respiratory failure	T047	C1145670
recurrent	T079	C2945760
aspiration	T046	C0700198
hypoxaemia	T033	C0700292
hypercarbia	T033	C0020440
Ventilatory failure	T046	C0398353
muscular dystrophy	T047	C0026850
increased	T081	C0205217
respiratory load	T033	C0243095
respiratory muscles weakness	T033	C1836141
Respiratory load	T033	C0243095
increases	T169	C0442805
muscular dystrophy	T047	C0026850
scoliosis	T190	C0036439
chest wall compliance	T034	C0429679
decrease	T081	C0547047
atelectasis	T046	C0004144
fibrosis	T046	C0016059
lung compliance	T042	C0024112
decrease	T081	C0547047
airway obstruction	T047	C0001883
airway resistance	T042	C4048282
increase	T169	C0442805
consequences of	T169	C0686907
respiratory pump failure	T047	C1145670
restrictive pulmonary function	T033	C3806472
hypoventilation	T046	C3203358
thoracoabdominal	T082	C0444467
hypercapnia	T033	C0020440
dyspnoea	T184	C0013404
impaired regulation of breathing	UnknownType	C0548979
inefficient cough	T033	C0455777
sleep disordered breathing	T047	C0037315
mechanisms	T033	C0457994
respiratory disturbances	T033	C4314646
patients	T101	C0030705
muscular dystrophy	T047	C0026850
respiratory disturbances	T033	C4314646
patients	T101	C0030705
muscular dystrophy	T047	C0026850
description	T170	C3259023
muscular dystrophy	T047	C0026850
respiratory implications	T033	C0243095
Significance	T078	C0750502
uterine corpus tumor	T191	C0153574
invasion	T033	C1269955
early-stage	T185	C1517886
cervical cancer	T191	C0007847
characteristics	T080	C1521970
survival	T052	C0038952
outcomes	T169	C1274040
women	T098	C0043210
surgically-treated	T061	C0543467
cervical cancer	T191	C0007847
uterine corpus tumor	T191	C0153574
invasion	T033	C1269955
Surveillance, Epidemiology, and End Results Program	T093	C0242638
cervical cancer	T191	C0007847
patients	T101	C0030705
hysterectomy	T061	C0020699
Logistic regression models	UnknownType	C0681925
risk factors	T033	C0035648
uterine corpus tumor	T191	C0153574
invasion	T033	C1269955
multivariable analysis	T081	C0026777
Association	T080	C0439849
uterine corpus tumor	T191	C0153574
invasion	T033	C1269955
cause-specific survival	T081	C1707318
CSS	T081	C1707318
cervical cancer	T191	C0007847
Cox proportional hazard regression models	T170	C0034980
multivariable analysis	T081	C0026777
uterine corpus	T191	C0153574
invasion	T033	C1269955
non-invasion	T169	C0205303
Median	T081	C0876920
follow-up	T058	C1522577
time	T079	C0040223
deaths	T040	C0011065
cervical cancer	T191	C0007847
Uterine corpus	T191	C0153574
invasion	T033	C1269955
independently	T078	C0085862
associated with	T080	C0332281
older age	T032	C0001779
non-squamous histology	T169	C4048239
high-grade tumors	T191	C1334017
large tumor size	T082	C0475440
nodal	T082	C0443268
metastasis	T191	C0027627
multivariable analysis	T081	C0026777
univariable analysis	T062	C0683962
uterine corpus tumor	T191	C0153574
invasion	T033	C1269955
associated with	T080	C0332281
decreased	T081	C0205216
CSS	T081	C1707318
non-invasion	T169	C0205303
controlling	T067	C2239193
significant	T078	C0750502
prognostic factors	T201	C1514474
uterine corpus tumor	T191	C0153574
invasion	T033	C1269955
independent	T078	C0085862
prognostic factor	T201	C1514474
decreased	T081	C0205216
CSS	T081	C1707318
adjusted-hazard ratio	T081	C2985465
confidence interval	T081	C0009667
stage T1b	T185	C0475385
uterine corpus tumor	T191	C0153574
invasion	T033	C1269955
independent	T078	C0085862
prognostic factor	T201	C1514474
decreased	T081	C0205216
CSS	T081	C1707318
adjusted-hazard ratio	T081	C2985465
Uterine corpus tumor	T191	C0153574
invasion	T033	C1269955
associated with	T080	C0332281
decreased	T081	C0205216
CSS	T081	C1707318
stage T1b1	T170	C0730458
disease	T191	C0153574
stage T1b2	T170	C0730459
disease	T191	C0153574
Uterine corpus tumor	T191	C0153574
invasion	T033	C1269955
independent	T078	C0085862
prognostic factor	T201	C1514474
decreased	T081	C0205216
survival	T052	C0038952
women	T098	C0043210
early-stage	T185	C1517886
cervical cancer	T191	C0007847
gene targeting	T063	C0242613
non-homologous end-joining	T169	C2984257
Lipomyces starkeyi	T004	C1002871
strains	T001	C1518614
Microbial	T001	C0599840
lipids	T109	C0023779
production	T057	C0033268
oleochemicals	T103	C0220806
biodiesel	T109	C2717894
Oleaginous yeasts	T004	C0043393
alternative	T077	C1523987
lipid	T109	C0023779
producers	T004	C0043393
plants	T002	C0032098
animals	T008	C0003062
chemical	T092	C0007983
fuel industries	T057	C0021267
oleaginous yeast	T004	C0043393
Lipomyces starkeyi	T004	C1002871
lipid	T109	C0023779
producer	T004	C0043393
lipid	T109	C0023779
productivity	T052	C0441655
cost-effective production	T057	C0033268
oleochemicals	T103	C0220806
fuels	T073	C0556991
Genetic	T063	C0017387
metabolic engineering	T063	C3179022
L. starkeyi	T004	C1002871
lipid	T109	C0023779
production	T057	C0033268
mechanisms	T169	C0441712
lipid	T109	C0023779
biosynthesis pathways	T169	C0005572
integrative transformation system	T169	C0205245
drug	T121	C1254351
marker	T045	C0017393
L. starkeyi	T004	C1002871
gene-targeting	T063	C0242613
frequencies	T081	C0017270
non-homologous recombination	T045	C0034865
L. starkeyi	T004	C1002871
Genetic engineering tools	T063	C0017387
L. starkeyi	T004	C1002871
genetic tool	T063	C0017387
application	T169	C0205245
L. starkeyi	T004	C1002871
gene-targeting system	T063	C0242613
L. starkeyi	T004	C1002871
mutants	T028	C0678941
disrupting	T080	C0332454
genes	T028	C0017337
LsKu70p	T116	C0033684
LsKu80p	T116	C0033684
LsLig4p	T116	C0033684
homology	T080	C2697616
yeasts	T004	C0043393
Ku70p	T116	C0033684
Ku80p	T116	C0033684
Lig4p	T116	C0033684
non-homologous end-joining pathway	T169	C2984257
Deletion	T045	C0017260
LsLIG4 gene	T028	C0017337
homologous recombination	T045	C0034865
efficiency	T081	C0013682
LsURA3	T028	C0017337
locus	T082	C1708726
wild-type	T028	C1883559
strain	T001	C1518614
2000-bp homologous flanking regions	T086	C0004793
homologous recombination	T045	C0034865
efficiencies	T081	C0013682
mutant	T028	C0678941
∆l sku70∆lslig4	T028	C0678941
mutant	T028	C0678941
∆lsku70∆lsku80∆lslig4	T028	C0678941
L. starkeyi	T004	C1002871
∆lslig4	T028	C0678941
strains	T001	C1518614
recipient strains	T001	C1518614
genetic	T063	C0017387
metabolic engineering	T063	C3179022
approaches	T169	C1292724
yeast	T004	C0043393
clinical	T080	C0205210
dietary	T168	C0012155
psychological	T169	C0205486
risk factors	T033	C0035648
relapse	T067	C0035020
ulcerative colitis	T047	C0009324
clinical	T080	C0205210
endoscopic	T082	C0442418
histological	T169	C0205462
remission	T046	C0597370
relapse	T067	C0035020
patients	T101	C0030705
ulcerative colitis	T047	C0009324
UC	T047	C0009324
clinical	T080	C0205210
endoscopic	T082	C0442418
histological	T169	C0205462
remission	T046	C0597370
follow up	T058	C1522577
relapse	T067	C0035020
patients	T101	C0030705
UC	T047	C0009324
clinical	T080	C0205210
endoscopic	T082	C0442418
histological	T169	C0205462
remission	T046	C0597370
risk	T078	C0035647
relapse	T067	C0035020
Patients	T101	C0030705
UC	T047	C0009324
clinical	T080	C0205210
endoscopic	T082	C0442418
histological	T169	C0205462
remission	T046	C0597370
followed up	T058	C1522577
year	T079	C0439234
clinical	T080	C0205210
dietary	T168	C0012155
psychological	T169	C0205486
factors	T033	C0035648
relapse	T067	C0035020
relapse	T067	C0035020
infection	T046	C3714514
antibiotic	T195	C0003232
NSAIDs	T121	C0003211
patient	T101	C0030705
compliance	T055	C1321605
medications	T058	C2081612
patients	T101	C0030705
males	T098	C0025266
age	T032	C0001779
years	T079	C0439234
followed up	T058	C1522577
months	T079	C0439231
relapsed	T067	C0035020
relapse	T067	C0035020
months	T079	C0439231
univariate analysis	T062	C0683962
NSAIDs	T121	C0003211
days	T079	C0439228
relapse	T067	C0035020
respiratory tract infection	T047	C0035243
weeks	T079	C0439230
steroids	T109	C0038317
consumption	T039	C1947907
calcium	T121	C0006675
riboflavin	T109	C0035527
vitamin A	T109	C0042839
consumption	T039	C1947907
sugars	T109	C0242209
multivariate analysis	T081	C0026777
NSAIDs	T121	C0003211
intake	T169	C1512806
Vitamin A	T109	C0042839
predictors	T078	C2698872
relapse	T067	C0035020
relapse	T067	C0035020
follow up	T058	C1522577
months	T079	C0439231
patients	T101	C0030705
UC	T047	C0009324
clinical	T080	C0205210
endoscopic	T082	C0442418
histological	T169	C0205462
remission	T046	C0597370
predictors	T078	C2698872
relapse	T067	C0035020
NSAIDs	T121	C0003211
days	T079	C0439228
relapse	T067	C0035020
Vitamin A	T109	C0042839
Reduction	T070	C0301630
H2O2	T121	C0020281
Electron Transport	T044	C0013846
Decaheme Cytochrome	T116	C0010749
ITO	T197	C0669925
Electrode	T073	C1705652
decaheme cytochrome MtrC	T116	C0010749
Shewanella oneidensis MR-1	T007	C1028266
immobilized	T116	C0014444
ITO	T197	C0669925
electrode	T073	C1705652
H2O2	T121	C0020281
reduction	T070	C0301630
MtrC	T116	C0010749
peroxidase activity	T044	C1151518
horseradish peroxidase	T116	C0019941
heme	T109	C0018966
cofactors	T109	C0009235
electronic communication	T170	C0683826
electrode	T073	C1705652
ITO	T197	C0669925
electrode	T073	C1705652
immobilization	T067	C1254366
MtrC	T116	C0010749
current density	T081	C2349035
SHE	T073	C1705652
UV-visible	T070	C1883416
Resonance Raman spectroelectrochemical studies	T059	C0037815
catalytic	T070	C0007382
potential	T080	C3245505
multiheme cytochromes	T116	C0010749
catalyze	T070	C0007382
technologically	UnknownType	C0681539
MtrC	T116	C0010749
biotechnological	T091	C0005574
H2O2	T121	C0020281
reduction	T070	C0301630
fuel cells	T073	C3273359
biosensors	T075	C0600364
Ophthalmic Manifestations	T184	C0015411
Facial	T029	C0015450
Dog Bites	T037	C0259797
Children	T100	C0008059
ophthalmic manifestations	T184	C0015411
periocular injuries	T037	C4290297
pediatric	T080	C1521725
facial	T029	C0015450
dog bites	T037	C0259797
retrospective	T080	C1514923
review	T170	C0282443
children	T100	C0008059
younger	T079	C0332239
years	T079	C0439234
medical	T169	C0205476
attention	T041	C0004268
dog bite	T037	C0259797
face	T029	C0015450
January	T080	C3829466
May	T079	C3812381
performed	T169	C0884358
large tertiary	T081	C0205372
pediatric hospital	T093	C0020017
Data	T078	C1511726
type	T080	C0332307
location of injury	T033	C0552513
surgical intervention	T033	C0549433
complications	T046	C1264516
collected	T169	C1516698
total	T080	C0439810
children	T100	C0008059
aged	T032	C0001779
years	T079	C0439234
identified	T080	C0205396
dog bite	T037	C0259797
dog bite s	T037	C0259797
Dog bite	T037	C0259797
Dog bite s	T037	C0259797
face	T029	C0015450
occurred	T079	C2745955
most	T081	C0205393
patients	T101	C0030705
children	T100	C0008059
facial	T029	C0015450
dog bite injuries	T037	C0259797
suffered	T048	C0683278
ophthalmic manifestations	T184	C0015411
average	T081	C1510992
age	T032	C0001779
years	T079	C0439234
Eyelid injuries	T037	C0339089
occurred	T079	C2745955
children	T100	C0008059
sustained	T169	C0443318
canalicular system	T022	C0460002
injuries	T037	C0005658
suffered	T048	C0683278
corneal abrasions	T037	C0010032
patients	T101	C0030705
sustained	T169	C0443318
facial	T029	C0015450
nerve injury	T037	C0161479
resulting in	T169	C0332294
lagophthalmos	T047	C0152226
patients	T101	C0030705
suffered	T048	C0683278
vision loss	T033	C0456909
Complications	T046	C1264516
occurred	T079	C2745955
patients	T101	C0030705
most	T081	C0205393
common	T169	C1522138
epiphora	T204	C1024522
patients	T101	C0030705
upper eyelid ptosis	UnknownType	C0748090
prominent	T080	C0205402
scar formation	T033	C1822291
patients	T101	C0030705
children	T100	C0008059
needed	T080	C0027552
secondary procedure	T061	C0445275
correct	T080	C2349182
complications	T046	C1264516
authors	T097	C3812881
report	T170	C0684224
clinical features	T080	C2348519
management	T090	C3273539
largest series	T081	C0205549
ophthalmic	T037	C0015408
periocular injuries	T037	C4290297
associated with	T080	C0332281
pediatric	T080	C1521725
facial	T029	C0015450
dog bite	T037	C0259797
dog bite s	T037	C0259797
injuries	T037	C0005658
occur	T079	C2745955
dog bite	T037	C0259797
dog bite s	T037	C0259797
face	T029	C0015450
ocular adnexa	T023	C0229243
early	T079	C1279919
appropriate	T080	C1548787
surgical management	T058	C1515089
complications	T046	C1264516
need	T080	C0027552
revision surgery	T061	C0035110
common	T169	C1522138
Blastocystis subtyping	T204	C3106936
intestinal parasites	T047	C0021832
children	T100	C0008059
geographical regions of Colombia	T083	C3245499
Blastocystis	T204	C0005707
enteric protist colonizing	T033	C4289767
people	T098	C0027361
non-human hosts	T001	C1167395
genetic diversity	T070	C0042333
subdivision of the genus	T185	C1708235
multiple subtypes	T185	C0449560
ST	T185	C0449560
non-human hosts	T001	C1167395
Blastocystis STs	T204	C3106936
18S alleles	T028	C0002085
symptomatic	T169	C0231220
abdominal pain	T184	C0000737
anal pruritus	T184	C0033775
diarrhea	T184	C0011991
headache	T184	C0018681
nauseas	T184	C0027497
vomit	T184	C0042963
asymptomatic	T033	C0231221
children	T100	C0008059
geographical regions of Colombia	T083	C3245499
fecal samples	T058	C0455051
national survey	T062	C0681817
intestinal parasites	T047	C0021832
children	T100	C0008059
Blastocystis positive	T204	C0005707
DNA extraction	T063	C3839098
Real Time PCR	T063	C1709846
sequencing	T059	C1294197
Blastocystis	T047	C3687300
primers	T114	C0206415
small subunit	T026	C1167012
rRNA gene	T028	C0035899
ST identification	T059	C1261145
DNA	T114	C0012854
Ascaris lumbricoides	T204	C0003955
Trichuris trichiura	T204	C0040913
hookworms	T204	C1265425
Necator americanus	T204	C0002826
Ancylostoma duodenale	T204	C0162314
Giardia duodenalis	T204	C0017535
Entamoeba complex	T204	C1285568
Entamoeba coli	T204	C0320420
Hymenolepis nana	T204	C0322196
Endolimax nana	T204	C0320452
Neobalantidium coli	T204	C0004694
Blastocystis	T204	C0005707
positive samples	T033	C1514241
ST1	T204	C3106801
ST2	T204	C3106925
ST3	T204	C3106933
ST4	T204	C3961358
ST6	T204	C3106938
ST7	T204	C3106936
alleles	T028	C0002085
ST1	T204	C3106801
alleles	T028	C0002085
ST2	T204	C3106925
alleles	T028	C0002085
ST3	T204	C3106933
allele	T028	C0002085
ST4	T204	C3961358
allele	T028	C0002085
ST6	T204	C3106938
allele	T028	C0002085
ST7	T204	C3106936
high-resolution	T059	C1719039
molecular markers	T201	C0005516
Blastocystis	T204	C0005707
transmission	T070	C1521797
Stramenopila	T204	C1004618
health and disease	T070	C0679215
municipal solid waste	T167	C1550151
landfill	T083	C0599634
influence	T077	C4054723
polychlorinated dibenzo-p-dioxins	T109	C4277576
polychlorinated dibenzofurans	T109	C4277574
PCDD	T109	C4277576
Fs	T109	C4277574
ambient air	T167	C0001861
case study	T170	C0085973
East China	T083	C0008115
Municipal solid waste	T167	C1550151
MSW	T167	C1550151
landfill	T083	C0599634
disposal	T052	C1707797
MSW	T167	C1550151
MSW	T167	C1550151
disposed	T052	C1707797
landfills	T083	C0599634
world	T098	C2700280
influence	T077	C4054723
MSW	T167	C1550151
landfill	T083	C0599634
polychlorinated dibenzo-p-dioxins	T109	C4277576
polychlorinated dibenzofurans	T109	C4277574
PCDD	T109	C4277576
Fs	T109	C4277574
surrounding atmosphere	T070	C0935443
ambient air	T167	C0001861
analyzed	T062	C0936012
surrounding sites	T082	C0205145
background site	T082	C0205145
upwind site	T082	C0205145
downwind site	T082	C0205145
MSW	T167	C1550151
landfill	T083	C0599634
East China	T083	C0008115
study	T062	C2603343
concentrations	T081	C1446561
PCDD	T109	C4277576
Fs	T109	C4277574
PCDD	T109	C4277576
Fs	T109	C4277574
ambient air	T167	C0001861
surrounding sites	T082	C0205145
background site	T082	C0205145
upwind site	T082	C0205145
downwind site	T082	C0205145
toxic equivalent concentrations	T081	C1446561
TEQ	T081	C1446561
PCDD	T109	C4277576
Fs	T109	C4277574
ambient air	T167	C0001861
surrounding sites	T082	C0205145
background site	T082	C0205145
upwind site	T082	C0205145
downwind site	T082	C0205145
congener profiles	T059	C1979963
PCDD	T109	C4277576
Fs	T109	C4277574
TEQ	T081	C1446561
background atmosphere	T070	C0935443
surrounding atmosphere	T070	C0935443
landfill	T083	C0599634
statistically significant	T081	C0237881
PCDD	T109	C4277576
Fs	T109	C4277574
TEQ	T081	C1446561
ambient air	T167	C0001861
downwind site	T082	C0205145
upwind site	T082	C0205145
landfill	T083	C0599634
influence	T077	C4054723
PCDD	T109	C4277576
Fs	T109	C4277574
ambient air	T167	C0001861
downwind site	T082	C0205145
percentile	T081	C1264641
carcinogenic risk	T081	C0596244
CR	T081	C0596244
PCDD	T109	C4277576
Fs	T109	C4277574
ambient air	T167	C0001861
urrounding sites	T082	C0205145
background site	T082	C0205145
upwind site	T082	C0205145
downwind site	T082	C0205145
much lower than the threshold value	T080	C0443151
CR	T081	C0596244
landfill	T083	C0599634
influence	T077	C4054723
CR	T081	C0596244
PCDD	T109	C4277576
Fs	T109	C4277574
surrounding atmosphere	T070	C0935443
cancer risk	T081	C0596244
non-carcinogenic risk	T033	C4036089
non-CR	T033	C4036089
analysis	T062	C0936012
landfill	T083	C0599634
influence	T077	C4054723
non-CR	T033	C4036089
PCDD	T109	C4277576
Fs	T109	C4277574
surrounding atmosphere	T070	C0935443
non-carcinogenic effects	T080	C1301751
Methodological considerations	T080	C1879746
community	T096	C0009462
water fluoridation	T069	C0016323
cessation	T052	C1880019
study	T062	C2603343
High-quality	T062	C0814847
research	T062	C0242481
community	T096	C0009462
water fluoridation	T069	C0016323
CWF	T069	C0016323
CWF	T069	C0016323
cessation	T052	C1880019
dental health	T058	C0011365
CWF	T069	C0016323
cessation	T052	C1880019
studies	T062	C2603343
methodological complexity	T169	C0237523
study	T062	C2603343
systematic review	T170	C1955832
cessation	T052	C1880019
studies	T062	C2603343
methodological considerations	T080	C1879746
CWF	T069	C0016323
cessation	T052	C1880019
studies	T062	C2603343
future	T079	C0016884
methodological aspects	T080	C1879746
study design	T062	C0035171
comparison community	T096	C0009462
target population	T098	C0039309
time frame	T079	C0872291
sampling strategy	T170	C0449370
clinical indicators	T169	C1522602
assessment criteria	T170	C0935549
biomarkers	T201	C0005516
recommendations	T078	C2936699
planning	T058	C0018727
future	T079	C0016884
CWF	T069	C0016323
cessation	T052	C1880019
studies	T062	C2603343
dental caries	T047	C0011334
study design	T062	C0035171
research question	T078	C0681799
recommendations	T078	C0034866
methodological aspects	T080	C1879746
epidemiological study	T062	C0002783
CWF	T069	C0016323
cessation	T052	C1880019
dental caries	T047	C0011334
researchers	T097	C0035173
optimize	T052	C2698650
resources	T078	C0035201
study	T062	C2603343
Central Myxoma	T191	C0027149
Myxofibroma	T191	C0205766
Jaws	T023	C0022359
Clinico	T073	C0442592
Epidemiologic	T169	C0014508
Review	T170	C0282443
Myxomas	T191	C0027149
benign	T080	C0205183
rare tumors	T047	C4054123
connective-tissue	T024	C0009780
origin	T079	C0439659
hard (central)	T024	C0040300
soft tissues	T024	C0225317
body	T016	C0242821
aim	T078	C1947946
study	T062	C0008972
central myxoma of the jaw	T191	C1404550
clinic	T073	C0442592
epidemiologic	T169	C0014508
environment	T082	C0014406
patients	T101	C0030705
central myxoma of the jaw	T191	C1404550
Oral and Maxillofacial Surgery department	T092	C1704729
regional University Teaching Hospital	T073	C0020027
retrospectively studied	T062	C0035363
age	T032	C0001779
sex	T032	C1522384
site of tumor	T082	C0475445
duration	T079	C0449238
signs/symptoms	T033	C3540840
treatment given	T033	C0580351
complications	T046	C0009566
Data	T078	C1511726
analyzed	T062	C0936012
Statistical Package for Social Sciences (SPSS) version 16	T073	C0037585
SPSS Inc	T073	C0683757
Chicago	T083	C0008044
IL	T083	C0020898
USA	T083	C0041703
Microsoft Excel 2007	T073	C0037585
Microsoft	T073	C0683757
Redmond	T083	C0008848
WA	T083	C0043038
USA	T083	C0041703
Results	T169	C1274040
descriptive statistics	T081	C2828391
tables	T170	C1706074
charts	T170	C0684240
test for significance	T170	C0392366
Pearson Chi-square	T170	C0008041
patients	T101	C0030705
period	T079	C1948053
reviewed	T080	C1709940
females	T032	C0086287
males	T032	C0086582
male-to-female ratio	UnknownType	C0682069
ages	T032	C0001779
patients	T101	C0030705
ranged	T081	C1514721
years	T079	C1510829
years	T079	C1510829
mandible	T023	C0024687
cases	T169	C0868928
maxilla	T023	C0024947
cases	T169	C0868928
combination	T080	C0205195
maxilla	T023	C0024947
zygoma	T023	C1269549
case	T169	C0868928
Bucco-lingual	T023	C0229962
bucco-palatal	T023	C0229962
expansion	T082	C0205229
cases	T169	C0868928
Histological	T169	C0205462
assessment	T058	C0220825
tissue specimens	T024	C1292533
fibromyxoma	T191	C0205766
accounted	T078	C0085978
cases	T169	C0868928
cases	T169	C0868928
diagnosed	T033	C0011900
myxoma	T191	C0027149
patients	T101	C0030705
jaw resections	T061	C2090639
mandibulectomies	T061	C0185566
patients	T101	C0030705
maxillectomies	T061	C0407722
patients	T101	C0030705
duration of hospital stay	T079	C4019086
ranged	T081	C1514721
days	T079	C0439228
days	T079	C0439228
Complications	T046	C0009566
patients	T101	C0030705
surgical wound infections	T046	C0038941
patients	T101	C0030705
environment	T082	C0014406
large tumors	T080	C0475278
follow-up	T058	C1522577
review	T078	C1552617
radical	T080	C0439807
patients	T101	C0030705
Pediatric	T080	C1521725
Hypovitaminosis D	T047	C0042870
Perspectives	T080	C1879746
Clinical	T201	C0683325
Implications	T078	C1707478
Vitamin D	T109	C0042866
secosteroid	T109	C0036532
essential	T080	C0205224
development	T040	C0678723
maintenance	T052	C0024501
healthy	T080	C3898900
bone	T023	C0262950
adult	T100	C0001675
pediatric	T080	C1521725
populations	T098	C1257890
Low level	T081	C1611820
25-hydroxy vitamin D	T121	C0006657
25-(OH)-D	T121	C0006657
children	T100	C0008059
adverse	T046	C0879626
health outcomes	T170	C1550208
rickets	T047	C0035579
osteomalacia	T047	C0029442
osteomalacic myopathy	T047	C0410213
sarcopenia	T047	C0872084
weakness	T184	C3714552
growth retardation	T046	C0151686
hypocalcemia	T047	C0020598
seizure	T184	C0036572
tetany	T047	C0039621
autism	T048	C0004352
cardiovascular diseases	T047	C0007222
diabetes mellitus	T047	C0011849
cancers	T191	C0006826
prostate	T191	C0376358
colon	T191	C0009375
breast	T191	C0006142
infectious diseases	T047	C0009450
viral	T047	C0042769
tuberculosis	T047	C0041296
autoimmune diseases,	T047	C0004364
multiple sclerosis	T047	C0026769
Hashimoto's thyroiditis	T047	C0677607
Risk factors	T033	C0035648
hypovitaminosis D	T047	C0042870
people	T098	C0027361
darker skin pigmentation	T042	C0037290
use	T169	C1524063
sunscreen	T167	C0038818
insufficient	T080	C0205412
ultraviolet B	T070	C0564461
exposure	T080	C0332157
prematurity	T047	C0021294
living in northern latitudes	T082	C0337646
malnutrition	T047	C0162429
obesity	T047	C0028754
exclusive breastfeeding	T055	C0242205
low maternal vitamin D level	T033	C0243095
medications	T121	C0013227
drinking	T040	C0684271
unfortified cow's milk	T168	C0349374
liver failure	T047	C0085605
chronic renal insufficiency	T047	C0403447
cystic fibrosis	T047	C0010674
asthma	T047	C0004096
sickle cell hemoglobinopathy	T047	C1399386
review	T170	C0282443
vitamin D deficiency	T047	C0042870
adverse	T046	C0879626
health outcomes	T170	C1550208
pediatric	T080	C1521725
age groups	T100	C0027362
recommended treatment regimen	T033	C0516913
review	T170	C0282443
ecological	T082	C0565987
gradients	T081	C0812409
leaf	T002	C0242724
margin	T082	C0205284
entirety	T081	C0439751
Evaluating	T170	C0015196
roles	T077	C1705810
biomechanics	T091	C0005537
hydraulics	T090	C1518533
vein geometry	T090	C0449829
bud	T002	C2700462
packing	T052	C2828395
recent	T079	C0332185
commentary	T170	C0282411
proposed	T080	C1553874
constraints	T169	C0443288
packing	T052	C2828395
young	T079	C0332239
leaves	T002	C0242724
buds	T002	C2700462
positive	T033	C1446409
association	T078	C0750490
non-entire	T080	C0205556
leaf	T002	C0242724
margins	T082	C0205284
latitude	T081	C1627936
consider	T078	C0750591
alternative	T077	C1523987
explanations	T170	C0681841
review	T078	C1552617
logic	T078	C0023963
evidence	T078	C3887511
major	T080	C0205164
hypotheses	T078	C1512571
functional	T169	C0205245
significance	T078	C0750502
marginal	T082	C0205284
teeth	T002	C0242724
putative	T078	C0750591
effects	T080	C1280500
leaf	T002	C0242724
cooling	T070	C0678568
optimal	T080	C2698651
areas	T082	C0205146
major	T080	C0205164
veins	T023	C0042449
enhanced	T081	C0205217
leaf	T002	C0242724
margin	T082	C0205284
photosynthesis	T070	C0031764
hydathodal function	T043	C0007613
defense	T077	C1880266
against	T080	C0521124
herbivores	T008	C0562691
bud	T002	C2700462
packing	T052	C2828395
Theoretical	T078	C0871935
empirical	T080	C1880496
problems	T033	C0033213
hypotheses	T078	C1512571
except	T169	C0332300
support-supply hypothesis	T078	C1512571
thinner	T080	C0205168
leaves	T002	C0242724
non-entire	T080	C0205556
margins	T082	C0205284
Phylogenetically	T078	C0871077
structured analyses	T062	C0936012
angiosperms	T002	C0330208
El Yunque	UnknownType	C0681784
flora	T033	C0314761
genus	T185	C1708235
Viburnum	T002	C0969714
non-entire	T080	C0205556
margins	T082	C0205284
indeed	T080	C2984081
common	T081	C0205214
thinner	T080	C0205168
leaves	T002	C0242724
angiosperms	T002	C0330208
association	T078	C0750490
leaf	T002	C0242724
thickness	T080	C1280412
non-entire	T080	C0205556
leaf	T002	C0242724
margins	T082	C0205284
stronger	T080	C0442821
latitude	T081	C1627936
outline	T170	C0600661
synthetic model	T170	C3161035
biomechanics	T091	C0005537
hydraulics	T090	C1518533
vein	T023	C0042449
geometry	T090	C0449829
rates	T079	C0449249
leaf	T002	C0242724
expansion	T043	C0007595
development	T169	C1527148
resting	T033	C0679218
buds	T002	C2700462
leaf	T002	C0242724
thickness	T080	C1280412
drive	T033	C1287104
patterns	T082	C0449774
distribution	T082	C0037775
entire	T081	C0439751
non-entire	T080	C0205556
leaf	T002	C0242724
margins	T082	C0205284
model	T170	C3161035
dominance	T078	C0870441
entire	T081	C0439751
margins	T082	C0205284
tropics	UnknownType	C0681784
Mediterranean scrub	T083	C0282645
tundra	T083	C3850151
non-entire	T080	C0205556
margins	T082	C0205284
cold temperate	T070	C0009264
deciduous forests	T070	C0086312
tropical	UnknownType	C0681784
vines	T002	C0330100
early-successional trees	T002	C0040811
entire	T081	C0439751
leaf	T002	C0242724
margins	T082	C0205284
monocots	T002	C0331451
Spinose-toothed leaves	T002	C0242724
short-statured	T033	C0349588
evergreen trees	T002	C0040811
shrubs	T002	C0446286
Mediterranean scrub	T083	C0282645
semiarid habitats	T082	C0871648
Viral Vector	T121	C1520007
Biosafety	T170	C1443933
Laboratory Animal Research	T062	C0003048
Viral vector	T121	C1520007
research	T062	C0035168
presents	T078	C0449450
unique	T080	C1710548
occupational health	T091	C0079920
safety	T068	C0036043
challenges	T058	C0805586
institutions	T093	C2607850
rapid	T080	C0456962
development	T169	C1527148
in vivo	T082	C1515655
in vitro	T080	C1533691
gene-editing technologies	T063	C4277689
Risks	T078	C0035647
human	T016	C0086418
animal	T008	C0003062
health	T078	C0018684
incumbent	T080	C3898777
institutions	T093	C2607850
appropriately	T080	C1548787
evaluate	T058	C0220825
viral vector	T121	C1520007
usage	T169	C0457083
research	T062	C0035168
basis	T169	C1527178
available	T169	C0470187
information	T078	C1533716
governmental regulations	T064	C0034982
guidelines	T170	C0162791
review	T078	C1552617
factors	T169	C1521761
risk assessment	T058	C0086930
viral vector	T121	C1520007
usage	T169	C0457083
animals	T008	C0003062
relevant	T080	C2347946
regulatory documents	T170	C1301746
associated with	T080	C0332281
research	T062	C0035168
most	T081	C0205393
commonly	T081	C0205214
viral vectors	T121	C1520007
research	T062	C0035168
review	T078	C1552617
particularly	T080	C0205369
focused	T169	C1285542
background	T077	C1706907
research	T062	C0035168
associated	T080	C0332281
health	T078	C0018684
environmental risks	T080	C0686732
related	T080	C0439849
adenoviral	T005	C0001483
adeno-associated viral	T005	C1564874
lentiviral	T005	C0079679
herpesviral	T005	C0019369
vectors	T121	C1520007
Liver Inflammation	T047	C0019158
Decreased	T081	C0205216
Canalicular	T023	C0005393
Bile Transporter	T116	C0618375
Expression	T045	C1171362
Pediatric	T080	C1521725
Onset	T081	C0206132
Intestinal Failure	T047	C0012634
liver disease	T047	C0023895
complication	T046	C0009566
parenteral nutrition	T061	C0030547
PN	T061	C0030547
intestinal failure	T047	C0012634
IF	T047	C0012634
pathogenesis	T046	C0699748
investigated	T169	C1292732
molecular	T080	C1521991
mechanisms	T169	C0441712
liver injury	T037	C0160390
pediatric	T080	C1521725
onset	T081	C0206132
IF	T047	C0012634
Liver	T023	C0023884
expression	T045	C1171362
canalicular	T023	C0005393
phospholipid	T109	C0031676
ABCB4	T116	C1260069
bile acid	T109	C0005390
ABCB11	T116	C1313221
sterol	T109	C0038323
ABCG5/8	T116	C0971221
transporters	T116	C0007292
upstream regulators	T116	C0033684
LXR	T116	C4277606
FXR	T116	C1173940
pro-inflammatory cytokines	T116	C0079189
interleukin-6	T116	C0021760
IL6	T116	C0021760
tumor necrosis factor	T116	C0041368
TNF	T116	C0041368
investigated	T169	C1292732
patients	T101	C0030705
IF	T047	C0012634
age	T032	C0001779
IQR	T081	C1711350
biochemical	T169	C0205474
histologic	T169	C0205462
liver injury	T037	C0160390
PN	T061	C0030547
serum	T031	C0229671
plant sterols	T109	C0031866
fibroblast growth factor 19	T116	C1431711
α-tocopherol	T109	C0969677
Patients	T101	C0030705
PN	T061	C0030547
liver injury	T037	C0160390
patients	T101	C0030705
weaning	T033	C0043084
PN	T061	C0030547
Histologic	T169	C0205462
portal inflammation	T033	C2748698
PN	T061	C0030547
dependent	T169	C3244310
weaned	T033	C0043084
patients	T101	C0030705
progression	T046	C0242656
cholestasis	T047	C0008370
liver fibrosis	T047	C0239946
Patients	T101	C0030705
portal inflammation	T033	C2748698
liver	T023	C0023884
RNA expression	T045	C0040649
IL6	T028	C1334122
TNF	T028	C0812246
repression	T045	C0920533
FXR	T116	C1173940
canalicular	T023	C0005393
bile transporter	T116	C0618375
gene	T028	C0017337
RNA expression	T045	C0040649
ABCB4	T028	C1412071
ABCB11	T028	C1412070
decreased	T081	C0205216
protein expression	T045	C1171362
ABCB11	T116	C1313221
ABCB4	T116	C1260069
upregulation	T044	C0041904
LXR	T116	C4277606
ABCG5/8	T028	C1422255
RNA expression	T045	C0040649
suppressed	T169	C1260953
patients	T101	C0030705
portal inflammation	T033	C2748698
PN	T061	C0030547
increased	T081	C0205217
serum	T031	C0229671
levels	T080	C0441889
plant sterols	T109	C0031866
stigmasterol	T109	C0038329
avenasterol	T109	C0031866
sitosterol	T109	C0220914
serum	T031	C0229671
citrulline	T116	C0008864
marker	T201	C0005516
enterocyte mass	T025	C0682610
portal inflammation	T033	C2748698
pediatric	T080	C1521725
onset	T081	C0206132
IF	T047	C0012634
PN	T061	C0030547
intestinal	T023	C0021853
compromise	T033	C2945640
liver inflammation	T047	C0019158
associates	T080	C0332281
progression	T046	C0242656
biochemical	T169	C0205474
histologic	T169	C0205462
liver injury	T037	C0160390
reducing	T080	C0392756
expression	T045	C1171362
canalicular	T023	C0005393
bile transporters	T116	C0618375
Impaired mobility	T033	C0518456
depressed mood	T033	C0344315
cognitive impairment	T048	C0338656
polypharmacy	T033	C2922974
disability	T033	C0231170
cancer	T191	C0006826
outpatients	T101	C0029921
Physical Frailty	T033	C0424594
Elderly	T098	C0001792
Cancer patients	T101	C1516213
PF	T033	C0424594
EC	T101	C1516213
cohort study	T081	C0009247
disability	T033	C0231170
oncologic factors	T033	C4294904
disability	T033	C0231170
outpatients	T101	C0029921
cancer	T191	C0006826
Physical Frailty	T033	C0424594
Elderly	T098	C0001792
Cancer patients	T101	C1516213
PF	T033	C0424594
EC	T101	C1516213
France	T083	C0016674
prospective bicentric observational cohort study	T062	C1709709
outpatients	T101	C0029921
cancer	T191	C0006826
cross-sectional analysis	T062	C0010362
oncologic factors	T033	C4294904
geriatric	T080	C1704440
variables	T080	C0439828
disability	T033	C0231170
comprehensive	T080	C1880156
geriatric assessment	T058	C0017463
CGA	T058	C0017463
Disability	T033	C0231170
impairment	T169	C0221099
activities of daily living	T056	C0001288
ADL	T056	C0001288
instrumental activities of daily living	T033	C1290928
(IADL	T033	C1290928
Univariate	T062	C0683962
multivariate	T081	C0026777
logistic models	T081	C0023965
disabled patients	T101	C0018576
multivariate	T081	C0026777
models	T081	C0023965
receiver operating characteristic curve	T081	C0035787
AUC	T081	C0376690
ROC	T081	C0035787
logistic model	T081	C0023965
women	T098	C0043210
cancer	T191	C0006826
disability	T033	C0231170
oncologic factors	T033	C4294904
cancer site	T082	C0872338
cancer extension	T191	C1704231
disability	T033	C0231170
Impaired mobility	T033	C0518456
poor functional status	T033	C0598463
depressive mood	T033	C0344315
cognitive impairment	T048	C0338656
polypharmacy	T033	C2922974
disability	T033	C0231170
Disability	T033	C0231170
cancer	T191	C0006826
outpatients	T101	C0029921
cancer treatment	T061	C0920425
oncologic factors	T033	C4294904
Impaired mobility	T033	C0518456
depressed mood	T033	C0344315
cognitive impairment	T048	C0338656
polypharmacy	T033	C2922974
disability	T033	C0231170
cancer treatment	T061	C0920425
corrective actions	T169	C1947976
patient	T101	C1516213
autonomy	T041	C0598368
treatment	T061	C0920425
follow-up	T058	C1522577
Synthesis	T070	C0007987
SAR	T080	C0038477
molecular docking	T063	C3494273
study	T062	C2603343
non-β-lactam inhibitors	T121	C0014432
TEM type β-lactamase	T116	C0597979
acylated phenoxyanilide	T121	C1254351
thiourea compounds	T121	C1254351
investigated	T169	C1292732
inhibit	T039	C1524081
TEM type β-lactamase enzyme	T116	C0597979
compounds 4g	T121	C1254351
5c	T121	C1254351
inhibition	T039	C1524081
potency	T081	C1710560
micromolar	T081	C0439194
action	T052	C3266814
non-covalent binding	T044	C1167622
TEM-171	T116	C0597979
active site	T169	C0205681
structure activity relationship	T080	C0038477
carbon chain length	T081	C0596310
substituents in ortho- and para-positions	UnknownType	C0680963
acylated phenoxyanilide	T121	C1254351
molecular modelling	T062	C0600115
study	T062	C2603343
Metabolic responses	T033	C4054530
Daphnia similis	T204	C1005664
chronic	T079	C0205191
AgNPs	T073	C1721060
GC-Q-TOF/MS	T059	C0599827
LC-Q-TOF/MS	T059	C0599827
Silver	T196	C0037125
nanoparticles	T073	C1721060
AgNPs	T073	C1721060
nanomaterials	T073	C1450053
fast-growing	T033	C4086299
increased	T081	C0205217
AgNPs	T073	C1721060
environment	T082	C0014406
health and ecological risks	T078	C0035647
chronic toxicity tests	T060	C1136118
metabolic	T123	C0870883
changes	T169	C0392747
Daphna similis	T204	C1005664
exposure to	T080	C0332157
AgNPs	T073	C1721060
non-targeted mass spectrometry	T059	C0037813
metabolomics	T091	C1328813
baseline	T081	C1442488
metabolite	T123	C0870883
change	T169	C0392747
aquatic organism	T001	C0596121
Daphnia crustacean	T204	C0010979
life-cycle	T079	C0023675
dynamic kinetic pattern	T033	C0243095
Daphnia's	T204	C0010979
metabolome	T070	C2350399
cycle	T079	C0023675
day	T079	C0439228
day	T079	C0439228
level	T080	C0441889
metabolites	T123	C0870883
increasing	T169	C0442808
day	T079	C0439228
day	T079	C0439228
baseline	T081	C1442488
level	T080	C0441889
day	T079	C0439228
day	T079	C0439228
samples	T167	C0370003
exposed to	T080	C0332157
environmental concentrations	T081	C0392762
AgNPs	T073	C1721060
morphological or structural changes	T033	C0243095
metabolite	T123	C0870883
changes	T169	C0392747
days	T079	C0439228
changes	T169	C0392747
steady state	T070	C0678587
day	T079	C0439228
changes	T169	C0392747
metabolites	T123	C0870883
amino acids	T116	C0002520
serine	T116	C0036720
threonine	T116	C0040005
tyrosine	T116	C0041485
sugars	T109	C0242209
d-allose	T109	C0894158
fatty acids	T109	C0015684
arachidonic acid	T109	C0003695
metabolites	T123	C0870883
Daphnia	T204	C0010979
chronic	T079	C0205191
AgNPs	T073	C1721060
stress	T070	C0038442
findings	T169	C2607943
capability	T080	C2698977
metabolomics	T091	C1328813
metabolic responses	T033	C4054530
environmental	T082	C0014406
silver	T196	C0037125
nanoparticles	T073	C1721060
relative effectiveness	T081	C0035023
high-intensity	T185	C4081854
low-intensity models	T081	C0392762
behaviour change	T055	C0542299
communication interventions	T061	C1274143
abortion	T033	C0156543
care-seeking	T055	C0018695
Bihar	UnknownType	C0681784
Jharkhand	UnknownType	C0681784
India	T083	C0021201
cross-sectional study	T062	C0010362
effectiveness	T080	C1280519
high-intensity model	T185	C4081854
HIM	T185	C4081854
low-intensity model	T081	C0392762
LIM	T081	C0392762
behaviour change	T055	C0542299
communication interventions	T061	C1274143
Bihar	UnknownType	C0681784
Jharkhand	UnknownType	C0681784
India	T083	C0021201
women's	T098	C0043210
knowledge	T033	C1948177
safe abortion	T033	C0156543
dose effect	UnknownType	C0683160
intervention	T061	C0184661
cross-sectional household surveys	T062	C0010362
married	T033	C0555047
women	T098	C0043210
aged	T032	C0001779
intervention	T061	C0184661
districts	UnknownType	C0681784
Difference-in-difference models	T081	C0392762
efficacy	T080	C1280519
intervention	T061	C0184661
sociodemographic characteristics	T033	C0243095
intervention	T061	C0184661
abortion	T033	C0156543
knowledge	T170	C0376554
HIM	T185	C4081854
intervention	T061	C0184661
comprehensive knowledge	T170	C0376554
abortion	T033	C0156543
knowledge	T170	C0376554
legality of abortion	T061	C0000812
safe abortion care	T058	C3697217
knowledge	T170	C0376554
abortion	T033	C0156543
intervention	T061	C0184661
abortion	T033	C0156543
care-seeking	T055	C0018695
behaviour	T053	C0004927
women	T098	C0043210
safe abortion	T033	C0156543
postabortion complications	T046	C0851640
Tissue	T024	C0040300
MicroRNA	T114	C1101610
diagnostic	T201	C1511876
prognostic biomarkers	T080	C1514475
patients	T101	C0030705
resectable	T061	C0015252
pancreatic ductal adenocarcinoma	T191	C1335302
periampullary cancers	T191	C1335377
aim	T078	C1947946
study	T062	C2603343
diagnostic	T169	C0348026
prognostic	T170	C0220901
microRNA	T114	C1101610
expression profiles	T081	C1956267
tissue	T024	C0040300
patients	T101	C0030705
pancreatic cancer	T191	C0235974
periampullary cancers	T191	C1335377
Expression	T045	C0017262
microRNAs	T114	C1101610
formalin	T109	C0949307
paraffin-embedded tissue	T024	C1519524
patients	T101	C0030705
resected	T061	C0015252
pancreatic ductal adenocarcinoma	T191	C1335302
ampullary cancer	T191	C0262401
duodenal cancer	T191	C0541912
distal	T082	C0205108
common bile duct cancer	T191	C0740277
gastric cancer	T191	C0024623
chronic pancreatitis	T047	C0149521
normal pancreas	T033	C0940731
microRNAs	T114	C1101610
PCR	T063	C0032520
Fluidigm platform	T170	C0282574
microRNAs	T114	C1101610
expressed	T045	C0017262
patients	T101	C0030705
pancreatic cancer	T191	C0235974
healthy controls	T080	C2986479
chronic pancreatitis	T047	C0149521
patients	T101	C0030705
miRNAs	T114	C1101610
upregulated	T044	C0041904
miR-21-5p	T028	C1537719
23a-3p	T028	C1842758
31-5p	T028	C1537742
34c-5p	T028	C1537747
93-3p	T028	C1537750
135b-3p	T028	C1537788
155-5p	T028	C1537811
186-5p	T028	C1537820
196b-5p,	T028	C1537832
203	T028	C1537841
205-5p	T114	C4284346
210	T028	C1537846
222-3p	T028	C1537860
451	T028	C1826031
492	T028	C1826046
614	T028	C1826193
miR-622	T028	C1826201
downregulated	T044	C0013081
miR-122-5p	T028	C1865068
130b-3p	T028	C1537780
216b	T028	C2239687
217	T028	C1537853
miR-375	T028	C1537896
MicroRNAs	T114	C1101610
diagnostic	T169	C0348026
complexity	T080	C0439855
microRNAs	T114	C1101610
associated with	T080	C0332281
prognosis	T058	C0033325
let-7 g	T114	C1621390
miR-29a-5p	T028	C1835841
34a-5p	T028	C1537745
125a-3p	T028	C1537770
146a-5p	T028	C1826002
187	T028	C1537821
205-5p	T114	C4284346
212-3p	T028	C1537848
222-5p	T028	C1537860
miR-450b-5p	T028	C2239697
Prognostic indices	T081	C0033326
expression	T045	C0017262
microRNAs	T114	C1101610
pancreatic	T191	C0235974
ampullary cancer	T191	C0262401
study	T062	C2603343
pancreatic cancer	T191	C0235974
tissue	T024	C0040300
microRNA	T114	C1101610
expression profile	T081	C1956267
periampullary cancers	T191	C1335377
chronic pancreatitis	T047	C0149521
normal pancreas	T033	C0940731
prognostic	T170	C0220901
microRNAs	T114	C1101610
microRNA	T114	C1101610
associated with	T080	C0332281
overall survival	T081	C4086681
patients	T101	C0030705
resected	T061	C0015252
pancreatic cancer	T191	C0235974
Effectiveness	T080	C1280519
workers	T098	C1527116
general health examination	T060	C0420142
Korea	T083	C0022771
health examination period	T058	C1254363
compliance	T033	C3714738
retrospective cohort study	T062	C2985505
evaluated	T058	C0220825
effectiveness	T080	C1280519
Workers	T098	C1527116
General Health Examination	T060	C0420142
health examination period	T058	C1254363
compliance	T033	C3714738
retrospective cohort	T062	C2985505
health examination	T058	C1254363
participants	T098	C0679646
cardio	T047	C0007222
cerebrovascular disease	T047	C0007820
stratification	T062	C1514983
age	T032	C0001779
sex	T032	C1522384
national health insurance type	T058	C0027452
cumulative	T080	C1511559
incidence	T081	C0021149
cardio	T047	C0007222
cerebrovascular disease	T047	C0007820
health examination	T058	C1254363
compliance	T033	C3714738
health examination period	T058	C1254363
compliance	T033	C3714738
compliant group	T098	C1257890
cumulative	T080	C1511559
incidence	T081	C0021149
cardio	T047	C0007222
cerebrovascular disease	T047	C0007820
non-compliant group	T098	C1257890
sex	T032	C1522384
working	T057	C0043227
age	T032	C0001779
workplace	T082	C0162579
policyholder	T078	C1551367
cardio	T047	C0007222
cerebrovascular disease	T047	C0007820
health examination period	T058	C1254363
statistically significant	T081	C0237881
ischemic heart disease	T047	C0151744
participants	T098	C0679646
men	T098	C0025266
office workers	T033	C2230102
higher relative risk of	T033	C0332167
ischemic heart disease	T047	C0151744
non-office workers	T098	C1527116
confidence interval	T081	C0009667
ischemic	T169	C0475224
cerebrovascular disease	T047	C0007820
hemorrhagic	T080	C0333275
cerebrovascular disease	T047	C0007820
men	T098	C0025266
cardio	T047	C0007222
cerebrovascular disease	T047	C0007820
women	T098	C0043210
Workers	T098	C1527116
General Health Examinations	T060	C0420142
non-office workers	T098	C1527116
prevention	T061	C0199176
ischemic heart disease	T047	C0151744
office workers	T033	C2230102
age	T032	C0001779
men	T098	C0025266
prevention	T061	C0199176
cardio	T047	C0007222
cerebrovascular disease	T047	C0007820
occupational characteristics	T169	C0521127
health examination period	T058	C1254363
Calibration	T081	C0006751
Self-Report	T062	C2700446
Measures	T081	C0079809
Physical Activity	T056	C0026606
Sedentary Behavior	T033	C3824706
Calibration	T081	C0006751
equations	T077	C0552449
potential	T080	C3245505
improve	T080	C1272747
accuracy	T080	C4035952
self-report	T062	C2700446
measures	T081	C0079809
physical activity	T056	C0026606
PA	T056	C0026606
sedentary behavior	T033	C3824706
SB	T033	C3824706
re-scaling	T052	C1947916
potentially	T080	C3245505
estimates	T081	C0750572
calibration	T081	C0006751
models	T081	C0026348
estimate	T081	C0750572
PA	T056	C0026606
SB	T033	C3824706
representative	T081	C1299385
adults	T100	C0001675
Physical Activity	T056	C0026606
Measurement Survey	T062	C0376688
PAMS	T062	C0376688
Participants	T098	C0679646
PAMS	T062	C0376688
trials	T062	C0681815
Sensewear armband (SWA)	T073	C1301852
monitor	T074	C0596972
24 hours	T079	C0439584
telephone	T062	C0021823
administered	T169	C1519231
physical activity recall	T058	C1254363
PAR	T058	C1254363
statistical model	T081	C0026348
validation	T169	C2984648
procedures	T169	C2700391
calibration	T081	C0006751
models	T081	C0026348
predict	UnknownType	C0681843
objectively	T062	C0683957
measured	T081	C0079809
SB	T033	C3824706
moderate to vigorous PA	T056	C0026606
MVPA	T056	C0026606
self-reported	T062	C2700446
PAR	T058	C1254363
Equivalence	UnknownType	C0814870
equivalence	UnknownType	C0814870
predicted	UnknownType	C0681843
objective	T062	C0683957
measures	T081	C0079809
SB	T033	C3824706
MVPA	T056	C0026606
SB	T033	C3824706
MVPA	T056	C0026606
sex	T032	C1522384
age	T033	C3172266
education	T033	C0424927
BMI	T201	C1305855
Cross-validation	T062	C0681935
analyses	T081	C0002780
SB	T033	C3824706
MVPA	T056	C0026606
Equivalence	UnknownType	C0814870
predicted	UnknownType	C0681843
statistically	T081	C0237881
objective	T062	C0683957
SB	T033	C3824706
MVPA	T056	C0026606
regression	T170	C0034980
models	T081	C0026348
statistically	T081	C0237881
self-report	T062	C2700446
measures	T081	C0079809
population	T098	C1257890
models	T081	C0026348
estimates	T081	C0750572
PAR	T058	C1254363
statistically	T081	C0237881
SB	T033	C3824706
MVPA	T056	C0026606
SWA	T073	C1301852
monitor	T074	C0596972
estimates	T081	C0750572
individual behavior	T055	C0946284
Human	T016	C0086418
amnion	T018	C1305379
epithelial cells	T025	C0014597
cell death	T043	C0007587
immunomodulation	T061	C1963758
microglia	T025	C0206116
mouse model	T050	C2986594
perinatal brain injury	T037	C2347482
Human	T016	C0086418
amnion	T018	C1305379
epithelial cells	T025	C0014597
hAECs	T025	C0014597
clonogenic	T081	C0392762
reduce	T081	C0205216
inflammatory	T046	C0021368
induced	T169	C0205263
tissue injury	T037	C0037578
Perturbation	T169	C0332453
immune response	T042	C0301872
pathogenesis	T046	C0699748
perinatal brain injury	T037	C2347482
modulating	T082	C0443264
response	T042	C0301872
novel	T080	C0205314
therapy	T061	C0087111
treating	T169	C1522326
injury	T037	C2347482
immunomodulatory	T061	C1963758
hAECs	T025	C0014597
animal models	T008	C0599779
investigation	T058	C0220825
effects	T080	C1280500
brain	T023	C0006104
immune	T169	C0439662
cells	T025	C0007634
injury	T037	C2347482
investigate	T058	C0220825
effects	T080	C1280500
hAECs	T025	C0014597
microglia	T025	C0206116
immune responders	T042	C0301872
injury	T037	C2347482
brain	T023	C0006104
mouse model	T050	C2986594
neonatal	T079	C2939425
inflammation	T046	C0021368
perinatal	T079	C0178795
hyperoxia	T184	C0242706
risk factors	T033	C0035648
perinatal brain injury	T037	C2347482
embryonic	T042	C0013936
day	T079	C0439228
administered	T061	C1533734
lipopolysaccharide	T109	C0023810
LPS	T109	C0023810
saline	T167	C0036082
control	T167	C1550141
intra-amniotically	T169	C1512912
C57Bl/6 J mouse pups	T015	C1521751
postnatal	T079	C0443281
day	T079	C0439228
LPS	T109	C0023810
pups	T015	C1521751
hyperoxia	T184	C0242706
oxygen	T121	C0030054
control pups	T096	C0009932
normoxia	T070	C0311411
days	T079	C0439228
Pups	T015	C1521751
hAECs	T025	C0014597
saline	T167	C0036082
intravenously	T061	C1737200
controls	T096	C0009932
LPS	T109	C0023810
hyperoxia	T184	C0242706
pups	T015	C1521751
reduced	T081	C0205216
body weight	T032	C0005910
increased	T081	C0205217
density	T081	C0178587
apoptotic	T080	C1516044
cells	T025	C0007634
TUNEL	T063	C1515232
cortex	T023	C0007776
striatum	T023	C0010097
white matter	T024	C0682708
astrocytes	T025	C0004112
GFAP	T116	C0017626
white matter	T024	C0682708
activated	T169	C1515877
microglia	T025	C0206116
CD68	T116	C0215872
cortex	T023	C0007776
striatum	T023	C0010097
microglia	T025	C0206116
density	T081	C0178587
Iba1	T116	C0312586
hAEC	T025	C0014597
administration	T061	C1533734
decreased	T081	C0205216
body weight	T032	C0005910
reduced	T081	C0205216
apoptosis	T043	C0162638
astrocyte	T025	C0004112
areal coverage	T169	C1999244
white matter	T024	C0682708
increased	T081	C0205217
density	T081	C0178587
activated	T169	C1515877
microglia	T025	C0206116
primary	T080	C0205225
microglia	T025	C0206116
CD45	T116	C1435882
CD11b	T116	C1136310
LPS	T109	C0023810
co-culture	T059	C0282547
hAEC	T025	C0014597
conditioned medium	T130	C0162518
hAEC	T025	C0014597
conditioned medium	T130	C0162518
increased	T081	C0205217
microglial	T025	C0206116
phagocytic activity	T043	C0031308
decreased	T081	C0205216
microglia	T025	C0206116
apoptosis	T043	C0162638
decreased	T081	C0205216
M1 activation markers	T043	C0024426
CD86	T116	C1528561
hAECs	T025	C0014597
LPS	T109	C0023810
release	T061	C1963578
cytokines	T116	C0079189
modulate	T082	C0443264
microglia	T025	C0206116
activity	T052	C0441655
data	T078	C1511726
hAECs	T025	C0014597
immunomodulate	T061	C1963758
brain	T023	C0006104
microglia	T025	C0206116
release	T061	C1963578
trophic factors	T116	C1579754
observation	T062	C0302523
hAECs	T025	C0014597
therapeutic utility	T061	C0087111
management	T058	C0376636
perinatal brain injury	T037	C2347482
Identification	T080	C0205396
DNA Methylation	T044	C0376452
Biomarkers	T123	C0041366
Chemotherapy	T061	C3665472
Response	T201	C0521982
Colorectal Cancer	T191	C1527249
Resistance	T038	C0013203
5-Fluorouracil	T114	C0016360
5-FU	T114	C0016360
treatment	T169	C1522326
colorectal cancer	T191	C1527249
CRC	T191	C1527249
risk of recurrence	T081	C2986492
DNA methylation	T044	C0376452
mechanisms	T046	C0920474
recurrent disease	T047	C0277556
contribution	T052	C1880177
drug resistance	T038	C0013203
clarified	T052	C2986669
study	T062	C0008972
methylation	T044	C0376452
phenotype	T032	C0031437
CRC	T191	C1527249
identification	T080	C0205396
markers	T123	C0041366
chemotherapy	T061	C3665472
response	T201	C0521982
DNA methylation	T044	C0376452
profiling	T169	C2003903
non-recurrent	T079	C0439597
recurrent	T079	C2945760
CRC	T191	C1527249
patients	T101	C0030705
Illumina Infinium HumanMethylation450 Beadchip assay	T063	C1880239
CRC	T191	C1527249
cells	T025	C0334227
genetic backgrounds	T032	C4042916
response	T201	C0521982
5-FU	T114	C0016360
global methylation	T044	C0376452
levels	T080	C0441889
HT29	T025	C0282639
SW48	T025	C0085983
treated	T169	C1522326
5-FU	T114	C0016360
DNA methylation	T044	C0376452
inhibitor	T080	C1999216
5-aza-2'-deoxycytidine	T114	C0049065
5-azadC	T114	C0049065
effects	T080	C1280500
drug	T121	C1254351
classes	T170	C0456387
cell viability	T043	C0007620
global methylation	T044	C0376452
profiles	T059	C1979963
genome-wide methylation study	T063	C2350277
clinical	T080	C0205210
specimens	T167	C0370003
recurrent	T079	C2945760
CRCs	T191	C1527249
methylation	T044	C0376452
levels	T080	C0441889
non-recurrent	T079	C0439597
CRCs	T191	C1527249
identified	T080	C0205396
methylated genes	T028	C0017337
genes	T028	C0017337
hyper	T033	C0243095
genes	T028	C0017337
hypomethylated	T033	C0243095
recurrent	T079	C2945760
group	T078	C0441833
non-recurrent	T079	C0439597
hypermethylated and hypomethylated genes	T028	C0017337
recurrent	T079	C2945760
non-recurrent	T079	C0439597
methylation	T044	C0376452
hypermethylated genes	T028	C0017337
MAPK signaling pathway	T043	C1518102
regulator	T077	C1704735
apoptosis	T043	C0162638
hypomethylated genes	T028	C0017337
PI3K-AKT signaling pathway	T044	C0037080
proliferation process	T169	C1514485
5-azadC	T114	C0049065
treatment	T169	C1522326
response	T201	C0521982
5-FU	T114	C0016360
growth inhibition	T043	C1512773
5-FU	T114	C0016360
hypermethylated cell lines SW48	T025	C0085983
genes	T028	C0017337
recurrent	T079	C2945760
CRCs	T191	C1527249
therapeutic	T061	C0087111
targets	T169	C1521840
patients	T101	C0030705
chemoresistance	T038	C0013203
aberrant	T080	C0443127
methylation	T044	C0376452
CCNEI	T028	C0017337
CCNDBP1	T028	C1413177
PON3	T028	C1418756
DDX43	T028	C1425700
CHL1	T028	C1413393
CRC	T191	C1527249
associated with	T080	C0332281
recurrence	T067	C0034897
CRC	T191	C1527249
5-azadC	T114	C0049065
5-FU	T114	C0016360
MAPK signaling pathway	T043	C1518102
Effect	T080	C1280500
Successive Administration	T061	C1533734
Vancomycin	T116	C0042313
Amikacin	T109	C0002499
Auditory Function	T039	C0018767
Immature Animals	T032	C0596750
Effect	T080	C1280500
successive administration	T061	C1533734
vancomycin	T116	C0042313
amikacin	T109	C0002499
therapeutic	T169	C0302350
doses	T081	C0178602
immature	T080	C0205252
auditory organ	T022	C0587901
compared	T052	C1707455
single	T081	C0205171
administration	T058	C3469597
same	T080	C0445247
drugs	T121	C1254351
chronic	T079	C0205191
experiments	T062	C0205664
immature	T080	C0205252
rabbits	T015	C3887509
recording	T080	C2355580
short-latency	T079	C0242465
auditory brainstem response	T201	C0085854
ABR	T201	C0085854
distortion product otoacoustic emission	T060	C0430676
DPOAE	T060	C0430676
Drug administration	T058	C3469597
increased	T081	C0205217
ABR	T201	C0085854
threshold	T081	C0004312
Ototoxic	T037	C0235280
antibiotics	T195	C0003232
DPOAE	T060	C0430676
affected	T169	C0392760
activity	T033	C3668946
outer hair cells	T025	C1518683
No	T033	C1513916
enhancement	T052	C2349975
ototoxic effects	T037	C0235280
observed	T169	C1441672
successive administration	T061	C1533734
antibiotics	T195	C0003232
Water	T121	C0043047
safety	T068	C0036043
healthcare facilities	T073	C0018704
Vieste Charter	T170	C0282574
Study Group	T097	C0035173
Hospital	T073	C0019994
Hygiene	T091	C0020405
Italian Society of Hygiene, Preventive Medicine and Public Health	T093	C1274109
GISIO-SItI	T093	C1274109
Local Health Authority	T093	C1274109
Foggia	T083	C0017446
Apulia	T083	C0017446
Italy	T083	C0022277
National Convention	T068	C0086047
water	T121	C0043047
healthcare facilities	T073	C0018704
Vieste-Pugnochiuso	T083	C0017446
Vieste Charter	T170	C0282574
collaboration	T054	C0282116
experts	T097	C0009817
National Institute of Health	T093	C0920537
the Ministry of Health	UnknownType	C0683710
risk factors	T033	C0035648
affect	T058	C2237113
water	T121	C0043047
safety	T068	C0036043
healthcare facilities	T073	C0018704
regulatory frameworks	T170	C0282574
management of installations	T058	C1254363
quality	T080	C0332306
water	T121	C0043047
risks	T078	C0035647
health facilities	T073	C0018704
water safety plans	T089	C0871600
treatments	T169	C1522326
healthcare facilities	T073	C0018704
responsibility	T055	C0678341
maintenance	T052	C0024501
facilities	T073	C0018704
multidisciplinary approach	T082	C0449445
education	T065	C0013621
research	T062	C0035168
regional and national coordination	T169	C0700114
communication	T054	C0009452
In Vivo	T082	C1515655
Three-Dimensional	T082	C0450363
Patellar	T023	C0030647
Mechanics	T070	C0376706
Normal	T080	C0205307
Knees	T023	C0022742
Compared	T052	C1707455
Domed	T082	C0444914
Anatomic	T080	C0220784
Patellar	T023	C0030647
Components	T073	C1708963
Patellofemoral	T030	C0447801
complications	T169	C1171258
revision surgery	T061	C0035110
following	T079	C0332282
total knee arthroplasty	T061	C0086511
TKA	T061	C0086511
High	T080	C0205250
forces	T067	C0441722
patellofemoral articulation	T030	C0447801
coupled	T169	C1948027
small	T081	C0700321
patellofemoral	T030	C0447801
contact area	T082	C0205146
design	T052	C1707689
study	T062	C2603343
three-dimensional	T082	C0450363
3D	T082	C0450363
in vivo	T082	C1515655
mechanics	T070	C0376706
domed	T082	C0444914
anatomically	T080	C0220784
shaped	T082	C0332479
patellar	T023	C0030647
components	T073	C1708963
compared	T052	C1707455
native	T169	C0302891
patellae	T023	C0030647
normal	T080	C0205307
knees	T023	C0022742
treated with	T061	C0332293
LCS-PS (low contact stress-posterior stabilized) TKA	T061	C0086511
anatomically	T080	C0220784
shaped	T082	C0332479
patellar	T023	C0030647
component	T073	C1708963
treated with	T061	C0332293
PFC Sigma RP-PS (press-fit condylar Sigma rotating platform-posterior stabilized) TKA	T061	C0086511
domed	T082	C0444914
patellar	T023	C0030647
component	T073	C1708963
analyzed	T062	C0936012
fluoroscopic	T060	C0016356
surveillance	T169	C0220920
patient	T101	C0030705
performed	T169	C0884358
weight-bearing	T033	C0085086
deep	T082	C0205125
knee bend	T033	C0243095
full	T080	C0443225
knee extension	T033	C2237139
maximum	T081	C0806909
knee flexion	T033	C0240114
segmented	T082	C0441635
computed tomography	T060	C0412645
CT	T060	C0412645
scans	T060	C0441633
computer-assisted-design	T066	C0162517
CAD	T066	C0162517
models	T170	C3161035
implanted	T074	C0021102
components	T073	C1708963
Three-dimensional	T082	C0450363
patellofemoral	T030	C0447801
kinematics	T091	C0600169
3D	T082	C0450363
2D	T082	C1705052
Contact mechanics	T070	C0376706
calculated	T052	C1441506
distance map	T073	C0024779
articulating patellar	T023	C0030647
femoral surfaces	T029	C0828554
patellar	T023	C0030647
component	T073	C1708963
good	T080	C0205170
rotational kinematics	T091	C0600169
femoral trochlea	T023	C0223886
compared	T052	C1707455
normal	T080	C0205307
patella	T023	C0030647
contact areas	T082	C0205146
TKA	T061	C0086511
groups	T078	C0441833
knee flexion	T033	C0240114
mean	T081	C0444504
standard deviation	T081	C0871420
LCS-PS group	T078	C0441833
Sigma RP-PS group	T078	C0441833
areas	T082	C0205146
smaller	T080	C0547044
reported	T170	C0684224
normal	T080	C0205307
patella	T023	C0030647
Contact points	T082	C3714763
TKA	T061	C0086511
groups	T078	C0441833
center	T082	C0205099
patellar	T023	C0030647
components	T073	C1708963
designs	T052	C1707689
performed	T169	C0884358
satisfactorily	T080	C0205410
patellofemoral	T030	C0447801
contact areas	T082	C0205146
reduced	T080	C0392756
comparison	T052	C1707455
native	T169	C0302891
patella	T023	C0030647
Assessment	T052	C1516048
Extravascular Implantable Defibrillator	T074	C0162589
Feasibility	T080	C0443348
Substernal Ventricular Pacing	T061	C1285520
objective	T170	C0018017
study	T062	C0681814
assess	T052	C1516048
feasibility	T080	C0443348
ventricular pacing	T061	C1285520
thresholds	T080	C0449864
within	T082	C0332285
substernal space	T029	C0230145
new	T080	C0205314
extravascular ICD	T074	C0162589
configuration	T082	C0449830
pacing	T061	C1285520
capabilities	T080	C2698977
patients	T101	C0030705
midline sternotomy	T061	C1282959
duodecapolar diagnostic pacing catheter	T074	C0085590
positioned	T082	C0733755
substernal space	T029	C0230145
anterior	T082	C0205094
pericardium	T023	C0031050
cutaneous patch	T033	C0241148
left lateral position	T082	C0450414
Different	T080	C1705242
unipolar	T082	C0443340
bipolar	T082	C0443156
pacing	T061	C1285520
configurations	T082	C0449830
assessed	T052	C1516048
Strength-duration curves	T059	C0022885
performed	T169	C0884358
optimal	T080	C2698651
output	T060	C0204709
mA	T081	C0450172
pulse width	T081	C0487742
milliseconds	T079	C0439223
patients	T101	C0030705
mean	T081	C0444504
age	T032	C0001779
years	T079	C0439234
included	T169	C0332257
ventricular	T082	C1522565
configuration	T082	C0449830
mean	T081	C0444504
bipolar	T082	C0443156
pacing	T061	C1285520
thresholds	T080	C0449864
milliseconds	T079	C0439223
mA	T081	C0450172
patients	T101	C0030705
mA	T081	C0450172
patients	T101	C0030705
mA	T081	C0450172
patients	T101	C0030705
mA	T081	C0450172
patients	T101	C0030705
electrode	T074	C0013812
spacing	T081	C1710137
successful	T080	C1272703
bipolar	T082	C0443156
configuration	T082	C0449830
Unipolar	T082	C0443340
pacing	T061	C1285520
successful	T080	C1272703
patients	T101	C0030705
mean	T081	C0444504
thresholds	T080	C0449864
mA	T081	C0450172
milliseconds	T079	C0439223
patients	T101	C0030705
mA	T081	C0450172
milliseconds	T079	C0439223
patients	T101	C0030705
mA	T081	C0450172
milliseconds	T079	C0439223
patients	T101	C0030705
mA	T081	C0450172
milliseconds	T079	C0439223
patients	T101	C0030705
Ventricular pacing	T061	C1285520
pacing	T061	C1285520
substernal space	T029	C0230145
patients	T101	C0030705
midline sternotomy	T061	C1282959
feasible	T080	C0443348
Closed	T169	C0587267
sternum	T023	C0038293
studies	T062	C2603343
needed	T080	C0027552
pacing	T061	C1285520
thresholds	T080	C0449864
accurately	T080	C0443131
Effects	T080	C1280500
specific blend	T167	C0439861
essential oils	T109	C0028910
apparent	T078	C0750489
nutrient	T168	C0678695
digestion	T040	C0012238
rumen	T023	C0035946
fermentation	T044	C0015852
rumen	T023	C0035946
microbial populations	T001	C0599840
sheep	T015	C0036945
alfalfa hay	T002	C2827434
concentrate diet	T168	C0012155
experiment	T062	C0205664
investigate	T169	C1292732
effects	T080	C1280500
mixture	T167	C0439962
essential oils	T109	C0028910
MEO	T109	C0028910
thyme	T109	C0304119
clove	T109	C0028906
cinnamon EO	T109	C0301249
rumen	T023	C0035946
microbial fermentation	T044	C0015852
nutrient	T168	C0678695
apparent	T078	C0750489
digestibility	T033	C0243095
blood	T031	C0005767
metabolites	T123	C0870883
fistulated sheep	T015	C0036945
sheep	T015	C0036945
ruminal fistulas	T190	C0302142
repeated measurement design	T170	C0282574
periods	T079	C0439531
effect	T080	C1280500
MEO	T109	C0028910
apparent	T078	C0750489
nutrient	T168	C0678695
digestibility	T033	C0243095
rumen	T023	C0035946
fermentation	T044	C0015852
characteristics	T080	C1521970
rumen	T023	C0035946
microbial population	T001	C0599840
blood	T031	C0005767
chemical metabolites	T123	C0870883
Animals	T008	C0003062
alfalfa hay	T002	C2827434
concentrate diet	T168	C0012155
Ruminal pH	T081	C0020283
volatile fatty acids	T109	C0015691
VFA	T109	C0015691
concentration	T081	C0392762
molar proportion of individual	T081	C0392762
VFA	T109	C0015691
acetate: propionate ratio	T081	C0392762
methane production	T040	C1855163
MEO	T109	C0028910
control	T096	C0009932
Small peptides	T116	C0030956
Small peptides plus amino acid nitrogen	T081	C0392762
large peptides	T116	C0030956
large peptides nitrogen concentration	T081	C0392762
rumen fluid	T031	C0227245
MEO	T109	C0028910
supplementation	T061	C0242297
rumen fluid	T031	C0227245
ammonia	T121	C0002607
concentration	T081	C0392762
morning feeding	T052	C2987508
sheep	T015	C0036945
MEO	T109	C0028910
control	T096	C0009932
MEO	T109	C0028910
morning feeding	T052	C2987508
ammonia	T121	C0002607
nitrogen concentration	T081	C0392762
sheep	T015	C0036945
MEO	T109	C0028910
control	T096	C0009932
diet	T168	C0012155
Ruminal protozoa	T204	C0033739
hyper ammonia producing (HAP) bacteria	T007	C0004611
counts	T059	C0004618
MEO	T109	C0028910
diet	T168	C0012155
control	T096	C0009932
red	T059	C0014772
white blood cells	T034	C0427512
hemoglobin	T059	C0518015
hematocrit	T033	C0518014
glucose	T059	C0337438
beta-hydroxybutyric acid	T109	C0047456
cholesterol	T059	C0201950
total protein	T059	C0555903
albumin	T059	C0201838
blood urea nitrogen	T059	C0005845
aspartate aminotransferase	T059	C0201899
alanine aminotransferase	T059	C0201836
concentration	T081	C0392762
Apparent	T078	C0750489
total tract digestibility	T033	C0243095
dry matter	T167	C0439861
crude proten	T116	C0033684
organic matter	T167	C0439861
neutral detergent fiber	T167	C0439861
MEO	T109	C0028910
supplementation	T061	C0242297
supplementation	T061	C0242297
MEO	T109	C0028910
limited effects	T080	C1280500
apparent	T078	C0750489
nutrient	T168	C0678695
digestibility	T033	C0243095
ruminal fermentation	T044	C0015852
protozoa	T204	C0033739
HAP bacteria	T007	C0004611
count	T059	C0004618
blood cells	T025	C0005773
metabolites	T123	C0870883
High throughput	T060	C0872186
selection	T052	C1707391
antibiotic-resistant	T032	C0949285
transgenic	T002	C0085245
Arabidopsis plants	T002	C0162741
Kanamycin	T109	C0022487
resistance	T032	C0949285
most	T081	C0205393
frequently	T079	C0332183
antibiotic-resistance	T032	C0949285
marker	T201	C0005516
Arabidopsis	T002	C0162741
transformations	T039	C3714584
method	T170	C0025663
frequently	T079	C0332183
escape	T055	C0014832
untransformed plants	T002	C0032098
high	T080	C0205250
seedling	T002	C0242437
density	T081	C0178587
selection	T052	C1707391
developed	T169	C1527148
robust	T080	C2986815
high	T080	C0205250
density	T081	C0178587
selection	T052	C1707391
method	T170	C0025663
top	T082	C1704458
agar	T109	C0001771
Arabidopsis thaliana	T002	C0162740
Top	T082	C1704458
agar	T109	C0001771
effectively	T080	C1704419
suppressed	T080	C0443189
growth	T039	C0220844
untransformed wild-type plants	T002	C0330098
selection	T052	C1707391
media	T130	C0010454
high	T080	C0205250
density	T081	C0178587
Survival	T052	C0038952
transformed	T039	C3714584
plants	T002	C0032098
selection	T052	C1707391
confirmed	T033	C0750484
green	T080	C0332583
true	T080	C0205238
leaves	T002	C0242724
expression	T045	C0017262
firefly luciferase	T116	C0311727
reporter gene	T028	C0206414
Top	T082	C1704458
agar	T109	C0001771
method	T170	C0025663
selection	T052	C1707391
large	T081	C0549177
amount	T081	C1265611
seeds	T002	C0036563
Arabidopsis	T002	C0162741
transformation	T039	C3714584
Limb	T023	C0015385
remote ischaemic postconditioning	T061	C2936234
induced	T169	C0205263
elevation	T081	C0205217
fibulin-5	T116	C1452861
neuroprotection	T043	C0598958
rats	T015	C0034721
cerebral ischaemia	T047	C0917798
reperfusion injury	T037	C0035126
Activation	T052	C1879547
AKT pathway	T044	C1515844
Limb	T023	C0015385
remote ischaemic postconditioning	T061	C2936234
RIPostC	T061	C2936234
treatment	T061	C0087111
brain ischaemia injury	T037	C2945681
study	T062	C2603343
fibulin-5	T116	C1452861
neuroprotection	T043	C0598958
RIPostC	T061	C2936234
cerebral ischaemia	T047	C0917798
reperfusion (I/R) injury	T037	C0035126
rats	T015	C0034721
middle cerebral artery occlusion	T020	C0740391
MCAO	T020	C0740391
model	T075	C0026339
rats	T015	C0034721
RIPostC	T061	C2936234
minutes	T079	C0439232
occlusion	T020	C0740391
minutes	T079	C0439232
bilateral	T082	C0238767
femoral artery	T023	C0015801
reperfusion	T061	C0035124
downregulate	T044	C0013081
fibulin-5	T116	C1452861
level	T080	C0441889
fibulin-5 siRNA	T114	C1099354
injected	T061	C1533685
lateral ventricle	T030	C0152279
hours	T079	C0439227
MCAO	T020	C0740391
study	T062	C2603343
RIPostC	T061	C2936234
attenuated	T052	C0599946
cerebral I	T047	C0917798
R injury	T037	C0035126
decreasing	T033	C0442797
infarct	T046	C0021308
volume	T081	C0449468
neurobehavioral score	T081	C0449820
suppressing	T169	C1260953
blood brain barrier	T023	C0005854
BBB	T023	C0005854
leakage	T046	C0015376
mRNA	T114	C0035696
protein levels	T034	C0428479
fibulin-5	T116	C1452861
upregulated	T044	C0041904
RIPostC	T061	C2936234
hours	T079	C0439227
hours	T079	C0439227
reperfusion	T061	C0035124
Downregulation	T044	C0013081
fibulin-5	T116	C1452861
attenuated	T052	C0599946
neuroprotection	T043	C0598958
RIPostC	T061	C2936234
fibulin-5	T116	C1452861
upregulated	T044	C0041904
RIPostC	T061	C2936234
activation	T052	C1879547
PI3K/AKT pathway	T044	C1515844
results	T169	C1274040
evidence	T078	C3887511
upregulation	T044	C0041904
fibulin-5	T116	C1452861
RIPostC	T061	C2936234
cerebral I	T047	C0917798
R injury	T037	C0035126
Optomechanical Control	T169	C0443254
Quantum Yield	T081	C0392762
Trans-Cis Ultrafast Photoisomerization	T044	C0596342
Retinal	T109	C0035331
Chromophore	T120	C0596335
Model	T075	C0026336
quantum yield	T081	C0392762
photochemical reaction	T070	C2350502
fundamental quantities	T081	C1265611
photochemistry	T090	C0031739
transduction of light energy into chemical energy	T043	C0376451
Nature	T078	C0349590
photoreceptors	T025	C0031760
reactivity	UnknownType	C0678596
chromophore	T120	C0596335
molecular environment	T082	C0014406
quantum yields	T081	C0392762
retinal	T109	C0035331
chromophore	T120	C0596335
rhodopsin proteins	T116	C0035499
mechanical forces	T067	C0563538
molecular system	T080	C1521991
reactivity	UnknownType	C0678596
tensile forces	T081	C0039526
retinal	T109	C0035331
chromophore	T120	C0596335
model	T075	C0026336
substantial and regular increase	T080	C0205556
trans-to-cis photoisomerization	T044	C0596342
quantum yield	T081	C0392762
cis photoisomer	T104	C1254350
rationale	T078	C2699007
mechanochemical effect	T070	C2350457
photoisomerization mechanism	T070	C2350502
Quality	T080	C0332306
nursing intensity data	T073	C0028694
inter-rater reliability	T081	C0870740
patient	T101	C0030705
classification	T185	C0008902
two decades	T081	C2981279
clinical	T080	C0205210
use	T169	C0457083
study	T062	C2603343
measure	T081	C0079809
inter-rater reliability	T081	C0870740
Oulu Patient Classification	T185	C0008902
methods	T169	C0025664
reliability testing	T081	C0237829
Oulu Patient Classification	T185	C0008902
RAFAELA(®) System	T170	C0282574
assist	T080	C1269765
nursing managers	T097	C0454680
allocation	T052	C1706778
nursing	T058	C0028682
resources	T078	C0018741
increased	T081	C0205217
intensity	T080	C0522510
inpatient care	T058	C0019993
years	T079	C0439234
reliability testing	T081	C0237829
classification	T185	C0008902
clinical	T080	C0205210
use	T169	C0457083
years	T079	C0439234
Retrospective	T080	C1514923
statistical study	T170	C0038208
test	T081	C0237829
inter-rater reliability	T081	C0870740
nurses	T097	C0028661
classified	T185	C0008902
patients	T101	C0030705
ratings	T052	C0871208
annually	T079	C0332181
standardization	T062	C0038136
Data	T078	C1511726
parallel classifications	T185	C0008902
obtained	T169	C1301820
inpatient	T101	C0021562
different	T080	C1705242
specialties	T091	C0037778
university hospital	T073	C0020028
Finland	T083	C0016132
Parallel classification	T185	C0008902
practices	T091	C4035713
reliability	T081	C2347947
classification	T185	C0008902
calculated	T052	C1441506
statistical coefficients	T081	C1707429
Inter-rater reliability	T081	C0870740
coefficients	T081	C1707429
nursing	T058	C0028682
intensity	T080	C0522510
category	T170	C0683312
practices	T091	C4035713
detectable	T033	C0442726
differences	T080	C1705242
agreement	T080	C0205556
levels	T080	C0441889
occurred	T052	C1709305
Planning and Coordination of Nursing Care	T058	C3863893
Guiding of Care	T058	C1254363
Continued Care	T058	C0009853
Emotional Support	T058	C0600015
descriptions	T170	C0678257
clarify	T052	C2986669
concepts	T078	C0178566
nursing documentation	T058	C0184600
promote	T052	C0033414
level	T080	C0441889
agreement	T080	C0205556
results	T169	C1274040
agreement	T080	C0205556
kappa coefficients	T081	C1707429
Water pipe	T073	C4302493
Smoking	T055	C0037369
Secondhand Tobacco Smoke	T037	C0375734
Effects	T080	C1280500
CYP1A2	T116	C1620185
CYP2A6	T116	C3884187
Phenotypes	T032	C0031437
Caffeine Urine Test	T059	C0042014
Public policies	T097	C0085098
cigarette smoking	T055	C0700219
exposure	T080	C0332157
secondhand smoke	T037	C0375734
associated diseases	T046	C0243083
tobacco consumption	T055	C0543414
water pipe	T073	C4302493
smoking	T055	C0037369
water pipe	T073	C4302493
smoking	T055	C0037369
cytochrome P450 (CYP450) activities	T044	C1149063
drug interaction	T044	C0687133
potential	T080	C3245505
humans	T016	C0086418
secondhand smoke	T037	C0375734
drug metabolism	T044	C0683140
healthy volunteers	T098	C1708335
water pipe smokers	T055	C3697029
secondhand tobacco smoke	T037	C0375734
persons	T098	C0027361
controls	T096	C0009932
systematically compared	T052	C1707455
CYP1A2	T116	C1620185
CYP2A6	T116	C3884187
enzyme activities	T044	C0243102
in vivo	T082	C1515655
caffeine urine test	T059	C0042014
self-reported	T062	C2700446
duration	T079	C0449238
water pipe	T073	C4302493
smoking	T055	C0037369
h	T079	C0439227
week	T079	C0439230
years	T079	C0439234
exposure	T080	C0332157
secondhand smoke	T037	C0375734
group	T098	C1257890
h	T079	C0439227
self-reported	T062	C2700446
weekly	T079	C0332174
exposure	T080	C0332157
tobacco smoke	T131	C0439994
cigarettes	T073	C0677453
smoked	T131	C0239059
hour	T079	C0439227
years	T079	C0439234
Analysis	T062	C0936012
variance	T080	C1711260
CYP1A2	T116	C1620185
CYP2A6	T116	C3884187
activities	T044	C0243102
study	T062	C2603343
groups	T098	C1257890
water pipe	T073	C4302493
secondhand smoke	T037	C0375734
exposure	T080	C0332157
CYP1A2	T116	C1620185
CYP2A6	T116	C3884187
activities	T044	C0243102
analysis	T062	C0936012
exposure	T080	C0332157
controls	T096	C0009932
water pipe	T073	C4302493
secondhand smoke	T037	C0375734
in vivo	T082	C1515655
activities	T044	C0243102
drug metabolism	T044	C0683140
pathways	T044	C1704259
constituents	T167	C0729650
tobacco consumption	T055	C0543414
water pipe	T073	C4302493
drug metabolism	T044	C0683140
cigarette smoke	T131	C0239059
studies	T062	C2603343
water pipe	T073	C4302493
secondhand tobacco smoke	T037	C0375734
CYP450	T116	C0010762
smoke	T131	C0439994
exposure	T080	C0332157
wettability	T080	C0162598
zeta potential	T067	C0597697
hydroxylation	T070	C0020365
hydroxylation degree	T033	C0243095
biological response	T033	C0243095
biomaterials	T122	C0005479
composition	T080	C0205556
electric charge	T070	C0563548
wettability	T080	C0162598
roughness	T080	C0205556
implant	T074	C0021102
surfaces	T082	C0205148
influence	T077	C4054723
interaction	T169	C1704675
biological fluids	T031	C0005889
tissues	T024	C0040300
systematic studies	T062	C0242481
materials	T167	C0520510
experimental conditions	T080	C0348080
lacking	T080	C0332268
scientific literature	T170	C0023866
research	T062	C0035168
investigate	T169	C1292732
correlations	T080	C1707520
surface characteristics	T080	C0449588
wettability	T080	C0162598
zeta potential	T067	C0597697
hydroxylation	T070	C0020365
hydroxylation degree	T033	C0243095
biological response	T033	C0243095
protein	T116	C0033684
protein adsorption	T033	C0243095
blood	T031	C0005767
wettability	T080	C0162598
cell	T043	C0007577
bacterial adhesion	T040	C0004614
biomaterials	T122	C0005479
surfaces	T082	C0205148
implantable biomaterials	T122	C0005479
Roughness	T080	C0205556
smooth surfaces	T082	C0205148
controlled protocol	T170	C2348563
roughness effects	T080	C0205556
oxides	T197	C0030015
ZrO2	T197	C0021521
Al2O3	T122	C0002374
SiO2	T122	C0037098
metals	T197	C0025552
316LSS steel	T122	C0038239
Ti	T196	C0040302
Nb	T196	C0028101
polymers	T104	C0032521
corona treated polystyrene	T109	C0032604
cell culture	T059	C1331092
untreated polystyrene	T109	C0032604
bacteria culture	T059	C0430402
biomedical applications	T073	C3273359
surfaces	T082	C0205148
characterized	T052	C1880022
contact profilometry	T062	C0242481
SEM	T059	C0026020
EDS	T059	C2699997
XPS	T059	C2700282
FTIR	T062	C0206055
zeta potential	T067	C0597697
wettability	T080	C0162598
fluids	T167	C0302908
Protein	T116	C0033684
Protein adsorption	T033	C0243095
blood	T031	C0005767
wettability	T080	C0162598
bacterial	T040	C0004614
cell adhesion	T043	C0007577
investigate	T169	C1292732
correlations	T080	C1707520
surface physiochemical properties	T070	C0038884
biological responses	T033	C0243095
XPS	T059	C2700282
electrokinetic measurements	T081	C0392762
techniques	T169	C0449851
hydroxylation	T070	C0020365
hydroxylation degree	T033	C0243095
surface charge	T081	C0392762
isoelectric point	T081	C0022171
wettability	T080	C0162598
blood	T031	C0005767
test	T170	C0392366
tests	T170	C0392366
Hydroxylation	T070	C0020365
Hydroxylation degree	T033	C0243095
wettability	T080	C0162598
water	T121	C0043047
surface charge	T081	C0392762
Wetting tests	T062	C0242481
media	T167	C1705217
materials	T167	C0520510
protein	T116	C0033684
protein absorption	T033	C0243095
hydroxylation	T070	C0020365
hydroxylation degree	T033	C0243095
charge	T081	C0392762
wettability	T080	C0162598
maximum	T081	C0806909
surfaces	T082	C0205148
wettability	T080	C0162598
water	T121	C0043047
protein	T116	C0033684
media	T167	C1705217
surface charge	T081	C0392762
bacterial adhesion	T040	C0004614
no effect	T080	C1301751
surface charge	T081	C0392762
protein	T116	C0033684
protein adsorption	T033	C0243095
acid component	T080	C0205556
surface energy	T081	C1442080
hydroxylation	T070	C0020365
hydroxylation degree	T033	C0243095
wettability	T080	C0162598
surface charge	T081	C0392762
energy	T081	C1442080
polar component	T080	C0205556
cell adhesion	T043	C0007577
viability	T043	C0007620
Persistent	T079	C0205322
effects	T080	C1280500
pre-Columbian	T081	C0032659
plant	T002	C0032098
domestication	T078	C0175819
Amazonian forest	T070	C0086312
composition	T201	C0486616
pre-Columbian	T081	C0032659
societies	T092	C0037455
Amazonian	T070	C0086312
landscapes	T082	C0870781
basin-wide analysis	T062	C0936012
pre-Columbian	T081	C0032659
impacts	T080	C4049986
Amazonian forests	T070	C0086312
archaeological sites	T082	C0205145
Amazonia	UnknownType	C0681784
abundances	T080	C2346714
woody	T002	C0040811
species	T185	C1705920
domesticated	T078	C0175819
pre-Columbian	T081	C0032659
peoples	T098	C0027361
Domesticated	T078	C0175819
species	T185	C1705920
nondomesticated species	T185	C1705920
hyperdominant	T169	C1527180
abundance	T080	C2346714
richness	T080	C0205556
domesticated	T078	C0175819
species	T185	C1705920
forests	T070	C0086312
archaeological sites	T082	C0205145
southwestern and eastern Amazonia	UnknownType	C0681784
archaeological sites	T082	C0205145
abundance	T080	C2346714
domesticated	T078	C0175819
species	T185	C1705920
analyses	T062	C0936012
tree	T002	C0040811
communities	T096	C0009462
Amazonia	UnknownType	C0681784
history	T169	C0019665
plant	T002	C0032098
domestication	T078	C0175819
Amazonian	T070	C0086312
peoples	T098	C0027361
Halogenated phenolic compounds	T109	C1959882
wild fish	T013	C0016163
Canadian Areas	T083	C0006823
Concern	T078	C2699424
halogenated phenolic compounds	T109	C1959882
plasma	T031	C0032105
brown bullhead	T013	C0328325
Ameiurus nebulosus	T013	C0328325
Canadian Areas	T083	C0006823
Concern	T078	C2699424
AOCs	T083	C0006823
thyroid	T023	C0040132
disrupting chemicals	T131	C1568245
Hydroxylated polychlorinated biphenyls	T109	C0032447
OH-PCBs	T109	C0032447
AOCs	T083	C0006823
detection	T061	C1511790
frequency	T079	C0439603
Detroit River	T070	C0337050
AOC	T083	C0006823
OH-PCBs	T109	C0032447
pentachloro, hexachloro, and heptachloro congeners	T104	C0678518
thyroid hormones	T116	C0040135
Pentachlorophenol	T109	C0030855
PCP	T109	C0030855
fish	T013	C0016163
Prince Edward Bay	T083	C3203003
Bay of Quinte Lake reference site	T083	C3203003
Hillman Marsh	T073	C0475311
the Wheatley Harbour reference site	T073	C0475311
sources of contamination	T057	C2728510
Elevated PCP concentrations	T059	C0524230
plasma	T031	C0032105
brown bullhead	T013	C0328325
Toronto and Region AOC	T083	C0006823
Triclosan	T109	C0040958
Toronto and Region AOC	T083	C0006823
wastewater	T083	C0450237
plasma	T031	C0032105
brown bullhead	T013	C0328325
Bay of Quinte	T083	C3203003
AOC	T083	C0006823
polybrominated diphenyl ethers	T109	C2350562
Toronto and Region AOC	T083	C0006823
Bay of Quinte	T083	C3203003
AOC	T083	C0006823
Trenton and Belleville	T083	C0006823
Distribution patterns	T082	C0449775
properties	T070	C0243178
usage	T169	C0457083
investigation	T062	C0683933
characteristics	T080	C1521970
AOC	T083	C0006823
genetic	T169	C0314603
variation	T070	C0042333
resistance	T039	C1514892
infection	T046	C3714514
Drosophila melanogaster genetic reference panel	T204	C0013139
Individuals	T098	C0027361
disease	T047	C0012634
genetic	T169	C0314603
variation	T070	C0042333
individual	T098	C0027361
variation	T070	C0042333
resistance	T039	C1514892
tolerance	T080	C1704410
fungal pathogen Metarhizium anisopliae Ma549	T004	C0997672
Drosophila melanogaster Genetic Reference Panel	T204	C0013139
DGRP	T204	C0013139
host defense	T042	C0520990
Ma549	T004	C0997672
defense	T077	C1880266
bacterium	T007	C0004611
Pseudomonas aeruginosa Pa14	T007	C0033809
DGRP	T204	C0013139
phenotypes	T032	C0031437
oxidative stress	T049	C0242606
sensitivity	T169	C0332324
starvation	T033	C0038187
stress resistance	UnknownType	C0678683
hemolymph	T031	C0019051
glucose levels	T059	C0337438
sleep	T040	C0037313
indices	T170	C0918012
polymorphisms	T045	C0032529
associated with	T080	C0332281
differences	T080	C1705242
mean survival times	T081	C0086595
microenvironmental	T082	C4072789
plasticity	T070	C0678558
differ	T080	C1705242
ability	T032	C0085732
adapt	T038	C0392673
variable	T080	C0439828
pathogen	T001	C0450254
exposures	T080	C0332157
polymorphisms	T045	C0032529
increasing	T169	C0442808
resistance	T039	C1514892
Ma549	T004	C0997672
sex biased	T078	C0242568
non-coding regions	T114	C0021920
effect	T080	C1280500
defense	T077	C1880266
host defense	T042	C0520990
correlated	T080	C1707520
longevity	T079	C0023980
fecundity	T040	C0015895
Ma549	T004	C0997672
minor alleles	T028	C0002085
Pa14	T007	C0033809
susceptible	T169	C0231204
Pa14	T007	C0033809
resistant	T039	C1514892
pathway	T077	C1705987
analysis	T062	C0936012
Pa14	T007	C0033809
Ma549	T004	C0997672
resistance	T039	C1514892
genes	T028	C0017337
functionally	T169	C0205245
processes	T067	C1522240
phagocytosis	T043	C0031308
engulfment	T043	C1159764
cell mobility	T043	C1516353
intermediary metabolism	T040	C0025519
protein phosphorylation	T044	C1158886
axon guidance	T043	C2984268
response to DNA damage	T043	C1155291
drug metabolism	T044	C0683140
Functional	T169	C0205245
testing	T169	C0039593
insertional mutagenesis	T045	C0079868
candidate genes	T028	C0017337
tested	T169	C0039593
influence	T077	C4054723
susceptibility	T169	C0231204
Ma549	T004	C0997672
candidate genes	T028	C0017337
homologs	T085	C0162774
studies	T062	C0008972
human	T016	C0086418
disease	T047	C0012634
genes	T028	C0017337
variation	T070	C0042333
susceptibility	T169	C0231204
species	T185	C1705920
Surrogate	T099	C4053457
inaccuracy	T080	C0443236
older adults'	T098	C0001792
desire	T041	C0871633
life-sustaining interventions	T061	C0871803
decisional	T041	C0679006
incapacity	T201	C3176592
erroneous	T078	C1547323
quality-of-life assessments	T060	C0281588
Family members	T099	C0086282
decisions	T041	C0679006
relative	T099	C0080103
desire	T041	C0871633
treatments	T061	C0087111
quality-of-life assessments	T060	C0281588
data	T078	C1511726
community-dwelling	T056	C4045975
adults	T100	C0001675
years	T079	C0439234
quality of life	T078	C0034380
desire	T041	C0871633
interventions	T061	C0184661
health states	T033	C0683314
current state	T033	C0683314
mild	T080	C2945599
moderate	T080	C0205081
stroke	T047	C0038454
brain cancer	T191	C0006118
severe	T080	C0205082
dementia	T048	C0497327
ratings	T052	C0871208
Likert-type scales	T170	C0451267
rating scales	T081	C0681889
surrogate	T099	C4053457
older adult	T098	C0001792
quality-of-life	T078	C0034380
ratings	T052	C0871208
older adult	T098	C0001792
surrogate	T099	C4053457
surrogates'	T099	C4053457
inaccuracy	T080	C0443236
desire	T041	C0871633
treatment	T061	C0087111
quality-of-life	T078	C0034380
ratings	T052	C0871208
predictor	T078	C2698872
inaccuracy	T080	C0443236
health states	T033	C0683314
current health state	T033	C0683314
regression coefficients	T081	C1707429
negative	T033	C0205160
surrogate	T099	C4053457
quality of life	T078	C0034380
older adult	T098	C0001792
older adult	T098	C0001792
desire	T041	C0871633
quality-of-life	T078	C0034380
ratings	T052	C0871208
surrogates'	T099	C4053457
desire	T041	C0871633
life-sustaining interventions	T061	C0871803
quality of life	T078	C0034380
cognitive decline	T046	C0234985
family members	T099	C0086282
decisions	T041	C0679006
Gain-of-function mutation	T045	C0026882
SCN5A	T028	C1419864
ventricular arrhythmias	T047	C0085612
early onset	T033	C1833334
atrial fibrillation	T047	C0004238
Mutations	T045	C0026882
SCN5A	T028	C1419864
gene	T028	C0017337
encoding	T052	C2700640
cardiac	T023	C0018787
sodium channel (NaV1.5)	T116	C0037492
spectrum	T077	C2827424
inherited	T169	C0439660
cardiac arrhythmia disorders	T033	C0003811
study	T062	C2603343
genetic	T169	C0314603
functional determinants	T169	C1521761
Dutch	T098	C0013331
family	T099	C0015576
phenotype	T032	C0031437
ventricular arrhythmias	T047	C0085612
adrenergic	T169	C0599756
component	T077	C1705248
isolation	T169	C0205409
combination	T080	C0205195
heart function	T042	C0232164
early onset	T033	C1833334
years	T079	C0439234
atrial fibrillation	T047	C0004238
generation	T079	C0079411
sequencing	T086	C0162326
proband	T099	C1948021
generation	T079	C0079411
Dutch	T098	C0013331
family	T099	C0015576
missense mutation	T045	C0599155
SCN5A-(p.M1851V)	T028	C1419864
clinical	T080	C0205210
phenotype	T032	C0031437
family	T099	C0015576
functionally	T169	C0205245
genetic	T169	C0314603
defect	T169	C1457869
patch clamp	T062	C0920630
electrophysiological studies	T060	C0850293
human embryonic	T018	C0868971
kidney cells	T025	C0553257
transfected	T063	C0040669
mutant	T049	C0596988
wild-type Nav1.5	T028	C1419864
current	T070	C1705970
inactivation	T169	C0544461
inactivation	T169	C0544461
SCN5A-M1851V channels	T116	C0037492
voltage	T081	C0598352
dependence	T169	C3244310
inactivation	T169	C0544461
positive	T033	C1446409
potentials	T080	C3245505
TTX	T109	C0039705
sensitive	T169	C0332324
window current	T070	C1705970
SCN5A-M1851V channels	T116	C0037492
upstroke velocity	T081	C0439830
SCN5A-M1851V channels	T116	C0037492
depolarization voltage	T081	C0598352
negative	T033	C0205160
mutation	T045	C0026882
gain-of-function mechanism	T169	C0441712
channel	T116	C0037492
window current	T070	C1705970
clinical	T080	C0205210
phenotype	T032	C0031437
ventricular arrhythmias	T047	C0085612
atrial fibrillation	T047	C0004238
findings	T033	C0243095
cardiac arrhythmias	T033	C0003811
mutations	T045	C0026882
SCN5A	T028	C1419864
cancer	T191	C0006826
Warburg effect	T049	C1520120
testable	T169	C0332265
example	T077	C1707959
minimum	T080	C1524031
entropy	T067	C0376522
production rate	T081	C0392762
principle	T078	C0178566
Cancer cells	T025	C0334227
consume	T169	C0205245
glucose	T109	C0017725
glycolytic fermentation	T044	C1158288
lactate	T109	C0376261
respiration	T039	C0035203
characteristic	T080	C1521970
Warburg effect	T049	C1520120
moles	T081	C0439189
ATP	T114	C0001480
respiration	T039	C0035203
fermentation	T044	C0015852
moles	T081	C0439189
ATP	T114	C0001480
mole	T081	C0439189
glucose	T109	C0017725
consumed	T169	C0205245
function	T169	C0542341
Warburg effect	T049	C1520120
Productions	T169	C0205245
free energy	T070	C0678591
ΔG	T070	C1637382
enthalpy	T081	C0599530
ΔH	T081	C1710184
entropy	T067	C0376522
ΔS	T080	C1710185
mole	T081	C0439189
linearly	T082	C0205132
fraction (x) of	T081	C1264633
glucose	T109	C0017725
consumed	T169	C0205245
fermentation	T044	C0015852
frequently	T079	C0332183
estimated	T081	C0750572
calculation	T052	C1441506
pure	T080	C0237400
respiration	T039	C0035203
fermentative	T044	C0015852
metabolism	T040	C0025519
decreases	T081	C0547047
production	T169	C0205245
entropy	T067	C0376522
mole	T081	C0439189
glucose	T109	C0017725
consumed	T169	C0205245
cancer cells	T025	C0334227
hypothesize	T078	C1512571
increased	T081	C0205217
fermentation	T044	C0015852
cancer cells	T025	C0334227
accomplish	T080	C0205556
Prigogine theorem	T170	C0282574
trend	T079	C1521798
minimize	T081	C0392762
rate	T081	C1521828
production	T169	C0205245
entropy	T067	C0376522
theorem	T170	C0282574
open cellular systems	T025	C0007634
steady state	T070	C0678587
evolve	T169	C1280477
minimize	T081	C0392762
rates	T081	C1521828
entropy	T067	C0376522
production	T169	C0205245
modified	T033	C0184511
replicating	T080	C1883725
cells	T025	C0007634
entropy	T067	C0376522
rate	T081	C1521828
CO2	T123	C0007012
concentrations	T081	C1446561
ppm	T081	C0439187
glucose	T109	C0017725
respiration	T039	C0035203
entropy	T067	C0376522
fermentation	T044	C0015852
experimental	T080	C1517586
tests	T059	C0022885
validate	T080	C1456348
hypothesis	T078	C1512571
minimization	T081	C0392762
rate	T081	C1521828
entropy	T067	C0376522
production	T169	C0205245
Warburg effect	T049	C1520120
Potential	T080	C3245505
drug-drug interactions	T044	C0687133
prescriptions	T058	C0033080
elderly	T098	C0001792
patients	T101	C0030705
primary health care	T058	C0033137
Elderly	T098	C0001792
patients	T101	C0030705
high risk	T033	C0332167
drug-drug interactions	T044	C0687133
DDIs	T044	C0687133
study	T062	C2603343
evaluates	T058	C0220825
potential	T080	C3245505
DDIs	T044	C0687133
elderly	T098	C0001792
patients	T101	C0030705
primary health care	T058	C0033137
outpatient clinic	T073	C0029916
Online database systems	T170	C0242356
DDIs	T044	C0687133
prescriptions	T058	C0033080
patients	T101	C0030705
clinical severity	T033	C1836458
DDIs	T044	C0687133
Lexi-Interact Online database	T170	C0242356
prescriptions	T058	C0033080
DDIs	T044	C0687133
detected	T033	C0442726
DDIs	T044	C0687133
prescriptions	T058	C0033080
Prescriptions	T058	C0033080
patients	T101	C0030705
patients	T101	C0030705
significantly higher	T081	C4055637
DDIs	T044	C0687133
frequency	T079	C0205212
DDIs	T044	C0687133
increased	T081	C0205217
drugs	T121	C1254351
prescription	T058	C0033080
Acetylsalicylic acid	T109	C0004057
salbutamol	T109	C0001927
frequently	T079	C0332183
prescribed	T058	C0278329
drugs	T121	C1254351
clinically important	T033	C0243095
DDIs	T044	C0687133
acetylsalicylic acid	T109	C0004057
escitalopram	T109	C1099456
interact	T169	C1704675
Beers criteria	T080	C4042847
predicted clinical outcomes	T033	C1333602
DDIs	T044	C0687133
therapeutic efficacy	T080	C2348767
adverse	T046	C0559546
toxic reactions	T033	C0542243
Prediction	T078	C0681842
DDIs	T044	C0687133
elderly	T098	C0001792
patients	T101	C0030705
prescribing	T058	C0033080
drug safety	T080	C0678800
nonsteroidal anti-inflammatory agents	T121	C0003211
selective serotonin reuptake inhibitors	T121	C0360105
beta-2 adrenergic receptor agonists	T121	C2936789
Discontinued	T033	C1444662
Splenogonadal Fusion	T019	C0266636
Bilateral Empty Scrotum	T019	C1261504
Month	T032	C1510828
Boy	T100	C0870221
Splenogonadal fusion	T019	C0266636
rare	T080	C0522498
congenital anomaly	T019	C0000768
splenic tissue	T024	C0771377
adherent	T169	C0334154
gonads	T023	C0018067
Bostroem	T016	C0086418
German	T098	C1556085
pathologist	T097	C0334866
case	T077	C1706256
month	T032	C1510828
boy	T100	C0870221
case	T077	C1706256
bilateral empty scrotum	T019	C1261504
routine	T080	C0205547
laparoscopic	T060	C0521291
exploration	T061	C1280903
right vas deferens	T023	C0228039
testicular vessels	T023	C4266473
right internal inguinal ring	T023	C0932530
right inguinal	T029	C0230318
exploration	T061	C1280903
blind ending	T033	C0243095
vas deferens	T023	C0042360
testicular vessels	T023	C4266473
left testis	T023	C0227998
intra-abdominally	T082	C1512910
internal ring	T030	C1512866
mass	T184	C0577573
upper pole	T023	C0227991
Wedge biopsy	T060	C0192152
upper pole of the testicle	T023	C0227991
site	T029	C1515974
mass	T184	C0577573
tissue diagnosis	T185	C1546905
orchidopexy	T061	C0194907
Histology	T059	C0344441
splenic tissue	T024	C0771377
splenogonadal fusion	T019	C0266636
rare	T080	C0522498
condition	T047	C0012634
surgeons	T097	C0582175
rare disease	T047	C0678236
unnecessary	T058	C0376708
interventions	T061	C0808232
orchiectomy	T061	C0029189
Real-world impact	T080	C4049986
non-breast cancer-specific death	T033	C1408354
overall survival	T081	C4086681
resectable	T080	C1514888
breast cancer	T191	C0006142
occurrence rate	T081	C1521828
non-breast cancer-specific death	T033	C1408354
non-BCSD	T033	C1408354
impact	T080	C4049986
patients	T101	C0030705
breast cancer	T191	C0006142
Women	T098	C0043210
resectable	T080	C1514888
breast cancer	T191	C0006142
Surveillance, Epidemiology, and End Results database	T093	C0242638
analyzed	T062	C0936012
outcome	T169	C1274040
events	T051	C0441471
breast cancer	T191	C0006142
breast cancer-specific death	T081	C1516192
BCSD	T081	C1516192
non-BCSD	T033	C1408354
survival	T052	C0038952
Binary logistics	T062	C0206031
estimate	T081	C0750572
occurrence rates	T081	C1521828
non-BCSD	T033	C1408354
BCSD	T081	C1516192
clinicopathological factors	T169	C1521761
Gray method	T170	C0282574
measure	T081	C0079809
cumulative incidence	T081	C0021149
non-BCSD	T033	C1408354
BCSD	T081	C1516192
ratio	T081	C0456603
non-BCSDs	T033	C1408354
causes of death	T033	C0007465
stacked	T082	C3272897
cumulative incidence	T081	C0021149
function plots	T170	C0681493
impact	T080	C4049986
non-BCSD	T033	C1408354
overall survival	T081	C4086681
OS	T081	C4086681
Models of Cox proportional hazards regression	T081	C0010235
competing risk regression	T170	C0034980
suitable model	T170	C3161035
non-BCSDs	T033	C1408354
BCSDs	T081	C1516192
oldest age group	T100	C0027362
black race	T098	C0005680
single or divorced marital status	T033	C4060922
associated with	T080	C0332281
non-BCSDs	T033	C1408354
age	T032	C0001779
hormone receptor-positive (HoR+) status	T191	C1562029
increased	T081	C0205217
non-BCSD	T033	C1408354
patients	T101	C0030705
grade 1, stage I disease	T047	C0012634
HoR+ status	T191	C1562029
non-BCSD	T033	C1408354
causes of death	T033	C0007465
incorrect interpretations	T033	C3845771
inaccuracy	T080	C0443236
Cox proportional hazards model	T081	C0010235
competing risk model	T170	C0034980
OS	T081	C4086681
impaired	T169	C0221099
non-BCSD	T033	C1408354
breast cancer	T191	C0006142
clinical trial	T062	C0008976
planning	T058	C1254363
oldest	T100	C0001795
patients	T101	C0030705
HoR+	T191	C1562029
breast cancer	T191	C0006142
non-BCSD	T033	C1408354
competing risk event	UnknownType	C0814316
American Cancer Society	T094	C0002455
Hip	T023	C0019552
segmentation	T066	C2697664
MRI	T060	C0024485
infants	T100	C0021270
DDH	T019	C0019555
diagnosis	T033	C0011900
treatment planning	T170	C0599880
Diagnosis	T033	C0011900
surgical management	T058	C1515089
Developmental Dysplasia of the Hip	T019	C0019555
DDH	T019	C0019555
physical examination	T058	C0031809
ultrasound scanning	T060	C0041618
Magnetic Resonance Imaging	T060	C0024485
MRI	T060	C0024485
techniques	T169	C0449851
treatment planning	T170	C0599880
semi-automatic	T169	C0205554
method	T170	C0025663
segment surface models	T170	C3161035
acetabulum	T023	C0000962
MRI	T060	C0024485
images	T078	C1551337
method	T170	C0025663
clinical	T080	C0205210
knowledge	T170	C0376554
intensity priors	T170	C0876936
Random Walker (RW) formulation	T170	C0002045
modified	T169	C0392747
RW	T170	C0002045
compensates	T080	C0205432
incomplete	T080	C0205257
blurred	T080	C0205556
boundaries	T185	C2828371
image	T078	C1551337
information	T078	C1533716
neighboring slices	T082	C1254362
sequence	T169	C1519249
node weights	T081	C0392762
pilot study	T062	C0031928
evaluate	T058	C0220825
segmentation	T066	C2697664
infant	T100	C0021270
hip	T023	C0019552
MRI	T060	C0024485
sequences	T169	C1519249
MR scanner	T074	C0183115
Contours	T082	C0876954
semi-automated	T169	C0205554
segmentation	T066	C2697664
compared	T052	C1707455
manually	T033	C3842330
segmented	T066	C2697664
hip	T023	C0019552
contours	T082	C0876954
Dice Ratio	T081	C0456603
DR	T081	C0456603
Hausdorff Distance	T081	C0012751
HD	T081	C0012751
Root Mean Square	T081	C2347976
RMS	T081	C2347976
method	T170	C0025663
DR	T081	C0456603
HD	T081	C0012751
RMS	T081	C2347976
DR	T081	C0456603
HD	T081	C0012751
RMS	T081	C2347976
right	T029	C0834313
left acetabular contours	T029	C0834314
higher	T080	C0205250
conventional	T080	C0439858
RW	T170	C0002045
segmentation	T066	C2697664
execution	T052	C1705848
time	T079	C0040223
segmentation	T066	C2697664
algorithm	T170	C0002045
seconds	T079	C0457385
CPU	T073	C1707144
basal cell carcinoma	T191	C0007117
high-definition optical coherence tomography	T060	C0920367
Basal cell carcinoma	T191	C0007117
BCC	T191	C0007117
non-melanoma skin cancer	T191	C0699893
BCC	T191	C0007117
invasive	T080	C0205281
biopsies	T060	C0005558
high-definition optical coherence tomography	T060	C0920367
HD-OCT	T060	C0920367
non-invasive	T169	C0205303
in vivo imaging method	T059	C1708481
skin	T022	C1123023
BCC	T191	C0007117
HD-OCT	T060	C0920367
images	T078	C1551337
histopathological architecture	T169	C0243140
BCC	T191	C0007117
HD-OCT	T060	C0920367
BCC	T191	C0007117
detection method	T060	C0430022
skin surface	T029	C1180212
segmentation	T058	C0700381
surface flattening	T169	C0016203
BCC	T191	C0007117
effectiveness	T080	C1280519
BCC	T191	C0007117
Fall	T033	C0085639
risk factors	T033	C0035648
analysis	T062	C0936012
sample entropy	T067	C0376522
plantar	T029	C0230463
kinematic	T070	C1254365
signal	T067	C1710082
stance phase	T033	C2019827
Falls	T033	C0085639
multi-causal phenomenon	T067	C1882365
complex	T080	C0439855
interaction	T169	C1704675
research	T062	C0035168
study	T062	C2603343
effect	T080	C1280500
multiple	T081	C0439064
variables	T080	C0439828
potential	T080	C3245505
risk of falls	T033	C1268740
construct	T185	C2827421
elderly fall risk assessment model	T170	C3161035
demographics	T090	C0011298
data	T078	C1511726
gait characteristics	T033	C2045693
subjects	T098	C2349001
Malianwa Street	T073	C0442658
aged	T032	C0001779
years old	T079	C1510829
participated	T169	C0679823
questionnaire	T170	C0034394
survey	T170	C0038951
Participants	T098	C0679646
groups	T078	C0441833
high	T098	C0684030
medium	T098	C2348561
low risk	T081	C3538919
group	T078	C0441833
score	T081	C0449820
elderly fall risk assessment scale	T170	C0349674
data	T078	C1511726
ground reaction force	T070	C0336996
GRF	T070	C0336996
ground reaction moment	T070	C1254365
GRM	T070	C1254365
record	T080	C2355580
performed	T169	C0884358
walking	T056	C0080331
comfortable state	T033	C1822395
demographic	T102	C0683970
variables	T080	C0439828
sample entropy	T067	C0376522
GRF	T070	C0336996
GRM	T070	C1254365
impulse difference	T081	C1705241
bilateral foot	T023	C4299794
potential	T080	C3245505
explanatory	T170	C0681841
variables	T080	C0439828
risk assessment	T058	C0086930
model	T170	C3161035
investigated	T169	C1292732
groups	T078	C0441833
difference	T081	C1705241
variable	T080	C0439828
Statistical differences	T081	C1705241
found	T033	C0150312
variables	T080	C0439828
age	T032	C0001779
impulse difference	T081	C1705241
sample entropy	T067	C0376522
GRF	T070	C0336996
vertical	T082	C0205128
direction	T082	C0449738
sample entropy	T067	C0376522
GRM	T070	C1254365
anterior-posterior	T082	C1999039
direction	T082	C0449738
multiple	T081	C0439064
regression analysis	T170	C0034980
results	T169	C1274040
indicated	T033	C1444656
age	T032	C0001779
impulse difference	T081	C1705241
sample entropy	T067	C0376522
GRM	T070	C1254365
individuals	T098	C0237401
levels of fall risk	T058	C1532976
results	T169	C1274040
potentially	T080	C3245505
useful	T080	C3827682
fall risk assessment	T058	C1532976
monitor	T058	C0150369
state	T169	C1442792
physical function	T033	C0516981
elderly population	T098	C0001792
Endurance	T033	C0518031
personalized fitness planner	T170	C0282574
Endurance	T033	C0518031
important	T080	C3898777
factor	T169	C1521761
cardiovascular fitness	T040	C2981722
capacity	T081	C1516240
individual	T098	C0237401
perform	T169	C0884358
exercise	T056	C0015259
longer duration	T079	C0449238
increased	T081	C0205217
intensity	T080	C0522510
subject specific	T080	C0205369
exercise	T056	C0015259
parameters	T077	C0549193
endurance	T033	C0518031
individual	T098	C0237401
statistical technique	T062	C1710191
model	T170	C3161035
endurance	T033	C0518031
factors	T169	C1521761
observations	T062	C0302523
individuals	T098	C0237401
over time	T079	C0040223
proposed	T080	C1553874
model	T170	C3161035
device	T074	C0025080
endurance	T033	C0518031
subject	T096	C0681850
exercise regime	T061	C0454291
test user	T078	C1548600
fitness planner	T170	C0282574
exercise regimes	T061	C0454291
fitness	T056	C1456706
goal	T170	C0018017
Heart rate	T201	C0018810
variability	T077	C2827666
biomarker	T201	C0005516
sedation depth	T033	C0235195
estimation	T081	C0750572
ICU	T073	C0021708
patients	T101	C0030705
automated patient-specific system	T170	C0596139
level of sedation	T033	C2226609
ICU	T073	C0021708
patients	T101	C0030705
heart rate	T201	C0018810
variability	T077	C2827666
signal	T067	C1710082
presented	T078	C0449450
paper	T170	C0282420
ECG	T033	C0013798
mechanically ventilated	T061	C0199470
adult	T100	C0001675
patients	T101	C0030705
administered	T169	C1521801
sedatives	T121	C0036557
ICU setting	T073	C0021708
support vector machine	T081	C2699740
sedation depth	T033	C0235195
monitoring	T058	C1283169
heart rate	T201	C0018810
variability	T077	C2827666
measures	T081	C0079809
leave-one-subject-out cross validation	T062	C0681935
classifier	T169	C4291659
training	T065	C0040607
performance	T052	C1882330
evaluations	T058	C0220825
patient-specific system	T170	C0596139
provided	T052	C1999230
sensitivity	T081	C0036667
specificity	T081	C0037791
AUC	T081	C0376690
physiological	T169	C0205463
signals	T067	C1710082
patient	T101	C0030705
specific	T080	C0205369
sedation level	T033	C2226609
prediction	T078	C0681842
system	T169	C0449913
automated multimodal system	T170	C0596139
clinical	T080	C0205210
staff	T097	C0851286
ICUs	T073	C0021708
interpret	T169	C1285553
sedation level	T033	C2226609
patient	T101	C0030705
RELIABILITY AND VALIDITY	T080	C0035036
DIABETES EATING PROBLEM SURVEY-REVISED	T058	C0012158
TURKISH	T098	C0549217
CHILDREN	T100	C0008059
ADOLESCENTS	T100	C0205653
TYPE 1 DIABETES MELLITUS	T047	C0011854
study	T062	C2603343
examine	T169	C1292732
reliability and validity	T080	C0035036
Turkish	T098	C0549217
version	T170	C0333052
Diabetes Eating Problem Survey-Revised	T058	C0012158
DEPS-R	T058	C0012158
children	T100	C0008059
adolescent	T100	C0205653
Type 1 Diabetes Mellitus	T047	C0011854
children	T100	C0008059
adolescents	T100	C0205653
type 1 diabetes	T047	C0011854
ages	T032	C0001779
years	T079	C0439234
DEPS-R	T058	C0012158
Turkish	T098	C0549217
version	T170	C0333052
tests	T169	C0039593
validity	T081	C2349101
confirmatory factor analysis	T080	C0870334
investigate	T169	C1292732
factor structure	T081	C0870541
Turkish	T098	C0549217
version	T170	C0333052
DEPS-R	T058	C0012158
Turkish	T098	C0549217
version	T170	C0333052
DEPS-R	T058	C0012158
satisfactory	T080	C0205410
Cronbach's	T081	C0870731
correlated	T080	C1707520
ag	T032	C0001779
hemoglobin A1c levels	T034	C1261236
BMI	T201	C1305855
SDS	T081	C0449820
criterion validity	T081	C2699472
DEPS-R	T058	C0012158
scores	T081	C0449820
Turkish	T098	C0549217
version	T170	C0333052
samples	T098	C1257890
females	T032	C0086287
males	T032	C0086582
Disturbed eating behaviors	T048	C4062871
insulin	T116	C0021641
restriction	T169	C0443288
metabolic control	T044	C1513158
self-administered	T169	C1519231
diabetes	T047	C0011854
screening	T058	C1710032
disordered eating behavior	T048	C4062871
clinical	T080	C0205210
care	T058	C0086388
adolescents	T100	C0205653
type 1 diabetes	T047	C0011854
Turkish	T098	C0549217
version	T170	C0333052
DEPS-R	T058	C0012158
screening	T058	C1710032
disordered eating behaviors	T048	C4062871
type 1 diabetes	T047	C0011854
disordered eating behaviors	T048	C4062871
comparison	T052	C1707455
localization	T169	C0475264
rectal carcinomas	T191	C0007113
general	T082	C0205246
rules	T170	C0870077
Japanese classification of colorectal carcinoma	T185	C0008902
JCCRC	T185	C0008902
Western	T082	C1705493
guidelines	T170	C0162791
aim	T078	C1947946
compare	T052	C1707455
localization	T169	C0475264
rectal cancers	T191	C0007113
classified	T185	C0008902
general	T082	C0205246
rules	T170	C0870077
Japanese classification of colorectal carcinoma	T185	C0008902
JCCRC	T185	C0008902
European Society for Medical Oncology	T093	C1708333
ESMO	T093	C1708333
National Comprehensive Cancer Network	T093	C1513893
NCCN	T093	C1513893
guidelines	T170	C0162791
rigid endoscopic	T060	C0014245
measurements	T169	C0242485
medical records	T170	C0025102
patients	T101	C0030705
scheduled	T080	C0205539
receive	T080	C1514756
curative surgery	T061	C1511562
histologically	T169	C0205462
rectal adenocarcinoma	T191	C0149978
during	T079	C0347984
investigated	T169	C1292732
Rigid proctoscopy	T060	C0033251
performed	T169	C0884358
patients	T101	C0030705
rectal cancer	T191	C0007113
located in	T082	C0332285
upper	T082	C1282910
Ra	T082	C1282910
lower	T082	C0441994
Rb	T082	C0441994
division	T061	C1293097
double-contrast barium enema	T060	C0412118
median	T081	C0876920
height	T032	C0489786
anal verge	T023	C0227423
range	T081	C1514721
rigid proctoscopy	T060	C0033251
cancers	T191	C0006826
assigned	T169	C1516050
Ra	T082	C1282910
Rb	T082	C0441994
cancers	T191	C0006826
Ra	T082	C1282910
Rb	T082	C0441994
located	T082	C0332285
within	T082	C0332285
anal verge	T023	C0227423
rigid proctoscopy	T060	C0033251
Ra	T082	C1282910
Rb	T082	C0441994
cancers	T191	C0006826
located in	T082	C0332285
mid	T082	C0444598
low	T080	C0205251
rectum	T023	C0034896
Ra	T082	C1282910
Rb	T082	C0441994
cancers	T191	C0006826
rectal cancers	T191	C0007113
NCCN	T093	C1513893
guidelines	T170	C0162791
classifications	T185	C0008902
mid-	T082	C0444598
low	T080	C0205251
rectal cancers	T191	C0007113
ESMO	T093	C1708333
guidelines	T170	C0162791
Natural orifice transluminal endoscopic surgery	T061	C2936208
snake-mechanism	T169	C0441712
movable pulley	T074	C1709769
Natural orifice transluminal endoscopic surgery	T061	C2936208
technique	T169	C0449851
develop	T169	C1527148
advanced	T080	C0205179
surgical robot	T074	C3204163
mechanism	T169	C0441712
natural orifice surgery	T061	C2936206
active-controlled overtube-type platform	T075	C1710360
channels	T082	C0439799
endoscopic camera	T074	C0179535
surgical	T061	C0543467
tools	T073	C0336791
platform	T075	C1710360
suggest	T078	C1705535
advanced	T080	C0205179
snake mechanism	T169	C0441712
movable pulleys	T074	C1709769
snake mechanism	T169	C0441712
degrees of freedom	T169	C0205245
stiffness	T080	C0205556
maneuverability	T080	C0205556
active-controlled platform	T075	C1710360
satisfactory	T080	C0205410
prototypes	T170	C3161035
ex vivo	T169	C2348480
experiments	T062	C0681814
mechanism	T169	C0441712
snake-like robotic	T073	C0336537
platform	T075	C1710360
natural orifice surgery	T061	C2936206
suggested	T078	C1705535
snake mechanism	T169	C0441712
movable pulleys	T074	C1709769
stiffness	T080	C0205556
maneuverability	T080	C0205556
mechanism	T169	C0441712
alternative	T077	C1523987
platform	T075	C1710360
natural orifice surgery	T061	C2936206
β-blockers	T121	C0001645
regression	T046	C0597370
left ventricular mass	T033	C0455825
hypertension	T047	C0020538
patients	T101	C0030705
Bayesian network	T081	C0026348
meta-analysis	T062	C0920317
Left ventricular hypertrophy	T047	C0149721
LVH	T047	C0149721
patients	T101	C0030705
hypertension	T047	C0020538
HT	T047	C0020538
expert consensus document	T170	C1301746
American	T098	C0596070
angiotensin-converting enzyme inhibitor	T121	C0003015
ACEI	T121	C0003015
angiotensin receptor blockers	T121	C0815017
ARBs	T121	C0815017
therapeutic drugs	T121	C0013227
efficacy	T080	C1280519
fat-soluble and selective β1-receptor blockers	T121	C0304516
FS-β-B	T121	C0304516
β-blockers	T121	C0001645
regression	T046	C0597370
LVH	T047	C0149721
analysis	T062	C0920317
compare	T052	C1707455
efficacy	T080	C1280519
FS-β-B	T121	C0304516
antihypertensive drugs	T121	C0003364
ACEI	T121	C0003015
ARBs	T121	C0815017
calcium channel blockers	T121	C0006684
CCBs	T121	C0006684
diuretics	T121	C0012798
regression	T046	C0597370
LVH	T047	C0149721
Relative	T080	C0205345
trials	T062	C0008976
PubMed	T170	C1138432
Web of Science	T170	C2349146
OVID EBM Reviews	T170	C0282443
Cochrane databases	T170	C0242356
papers	T170	C1706852
examined	T169	C1292732
Bayesian	T081	C0026348
meta-analysis	T062	C0920317
randomized controlled trials	T062	C0206035
RCTs	T062	C0206035
regression	T046	C0597370
LVH	T047	C0149721
Sensitivity analysis	T062	C0936012
regression analysis	T170	C0034980
heterogeneity	T080	C0019409
Inconsistency analysis	T062	C0936012
analysis	T062	C0920317
trials	T062	C0008976
network	T081	C0026348
consistent	T078	C0332290
RCTs	T062	C0206035
patients	T101	C0030705
HT	T047	C0020538
LVH	T047	C0149721
analysis	T062	C0920317
Bayesian network	T081	C0026348
meta-analysis	T062	C0920317
statistically significant	T081	C0237881
groups	T078	C0441833
FS-β-B	T121	C0304516
ACEI	T121	C0003015
CI	T081	C0009667
FS-β-B	T121	C0304516
ARB	T121	C0815017
Cl	T081	C0009667
FS-β-B	T121	C0304516
efficacy	T080	C1280519
compared	T052	C1707455
diuretic	T121	C0012798
CI	T081	C0009667
CCB	T121	C0006684
CI	T081	C0009667
probabilities	T081	C0033204
efficacious	T080	C1280519
treatments	T061	C0087111
FS-β-B	T121	C0304516
ARB	T121	C0815017
ACEI	T121	C0003015
CCB	T121	C0006684
diuretic	T121	C0012798
analysis	T062	C0920317
FS-β-B	T121	C0304516
therapeutic drugs	T121	C0013227
HT	T047	C0020538
LVH	T047	C0149721
patients	T101	C0030705
efficacy	T080	C1280519
FS-β-B	T121	C0304516
regression	T046	C0597370
LVH	T047	C0149721
quality	T080	C0332306
trials	T062	C0008976
Improved	T033	C0184511
risk	T078	C0035647
stratification	T062	C1514983
patients	T101	C0030705
urothelial carcinoma	T191	C2145472
Paris	T083	C0030561
System	T169	C0449913
Reporting	T058	C0700287
Urinary Cytology	T059	C2979983
Paris	T083	C0030561
System	T169	C0449913
Reporting	T058	C0700287
Urinary Cytology	T059	C2979983
TPS	T059	C2979983
cytomorphologic	T026	C0243092
criteria	T078	C0243161
diagnosis	T033	C0011900
high-grade urothelial carcinoma	T191	C2145472
HGUC	T191	C2145472
urinary tract cytology	T059	C2979983
UTC	T059	C2979983
specimens	T167	C0370003
elevated	T080	C3163633
nuclear-to-cytoplasmic (N/C) ratio	T049	C0333907
atypical	T080	C0205182
nuclear	T026	C0007610
borders	T082	C0205284
moderate	T080	C0205081
severe	T080	C0205082
hyperchromasia	T033	C0333910
coarse chromatin	T033	C1868540
malignant	T080	C0205282
UTC	T059	C2979983
specimens	T167	C0370003
degenerative	T169	C1880269
changes	T169	C0392747
malignant cells	T025	C0334227
TPS	T059	C2979983
cytomorphologic	T026	C0243092
criteria	T078	C0243161
UTC	T059	C2979983
specimens	T167	C0370003
patients	T101	C0030705
diagnosis	T033	C0011900
HGUC	T191	C2145472
reviewed	T080	C1709940
reclassified	T080	C0205542
TPS	T059	C2979983
criteria	T078	C0243161
presence	T033	C0150312
TPS	T059	C2979983
cytomorphologic	T026	C0243092
criteria	T078	C0243161
HGUC	T191	C2145472
specimen	T167	C0370003
atypical	T080	C0205182
cells	T025	C0007634
criteria	T078	C0243161
specimens	T167	C0370003
diagnosed	T033	C0011900
HGUC	T191	C2145472
significantly	T078	C0750502
change	T169	C0392747
reclassification	T185	C0008902
approximately	T080	C0332232
indeterminate	T078	C0205258
specimens	T167	C0370003
reclassified	T080	C0205542
risk	T078	C0035647
category	T170	C0683312
cytomorphologic	T026	C0243092
N/C ratio	T049	C0333907
specimens	T167	C0370003
approximately	T080	C0332232
specimens	T167	C0370003
specimens	T167	C0370003
cytomorphologic	T026	C0243092
criteria	T078	C0243161
TPS	T059	C2979983
HGUC	T191	C2145472
malignant cells	T025	C0334227
specimens	T167	C0370003
HGUC	T191	C2145472
TPS	T059	C2979983
fraction of	T081	C1264633
atypical	T080	C0205182
cells	T025	C0007634
criteria	T078	C0243161
malignant	T080	C0205282
UTC	T059	C2979983
specimens	T167	C0370003
TPS	T059	C2979983
criteria	T078	C0243161
improved	T033	C0184511
specimen	T167	C0370003
risk	T078	C0035647
stratification	T062	C1514983
approximately	T080	C0332232
indeterminate	T078	C0205258
specimens	T167	C0370003
risk	T078	C0035647
categories	T170	C0683312
significantly	T078	C0750502
changing	T169	C0392747
frequency	T079	C0376249
HGUC	T191	C2145472
diagnoses	T033	C0011900
Cancer	T191	C0006826
American Cancer Society	T094	C0002455
diagnostic	T169	C0348026
benefit	T081	C0814225
bee venom	T116	C0004920
components	T077	C1705248
years	T079	C0439234
allergen	T129	C0002092
rApi m 1	T129	C0002092
ImmunoCAP system	T170	C0282574
diagnosis	T033	C0011900
bee venom (BV) allergy	T046	C1828283
components	T077	C1705248
sensitivity	T081	C1511883
specificity	T081	C1511884
rApi m 1	T129	C0002092
2	T129	C0002092
3	T129	C0002092
5	T129	C0002092
10	T129	C0002092
BV-allergic	T046	C1828283
patients	T101	C0030705
sensitivity	T081	C1511883
rApi m 1	T129	C0002092
2	T129	C0002092
investigated	T169	C1292732
sensitization	T040	C1325847
monosensitization	T040	C1325847
double sensitization	T040	C1325847
Analysis	T062	C0936012
BV	T116	C0004920
allergens	T129	C0002092
CAP system	T170	C0282574
sensitivity	T081	C1511883
analysis	T062	C0936012
rApi m 1	T129	C0002092
2	T129	C0002092
Immulite	T073	C3829562
Sensitization	T040	C1325847
rate	T081	C1521828
rApi m 5	T129	C0002092
double-sensitized	T040	C1325847
patients	T101	C0030705
rApi m 2	T129	C0002092
benefit	T081	C0814225
BV	T116	C0004920
components	T077	C1705248
insufficient	T080	C0231180
sensitivity	T081	C1511883
cross-reacting	T044	C0010357
allergens	T129	C0002092
Orai1	T116	C4255013
Antimicrobial	T121	C1136254
Secretion	T031	C0036537
Pancreatic Acini	T023	C0227578
Gut Microbiome	T001	C4018878
Regulates	T040	C1155268
Gut	T023	C0699819
Innate Immunity	T032	C0020969
gut microbiome	T001	C4018878
physiologic functions	T039	C1254359
communicates	T033	C0566001
host	T001	C1167395
immune system	T022	C0020962
Antimicrobial peptides	T116	C4084937
critica	T080	C1511545
components	T116	C1179435
intestinal	T023	C0021853
innate immunity	T032	C0020969
prominent	T080	C0205402
antimicrobials secreted	T043	C1819788
pancreatic acini	T023	C0227578
gut microbiome	T001	C4018878
intestinal	T023	C0021853
innate immunity	T032	C0020969
barrier function	T042	C1254358
survival	T169	C0220921
Deletion	T052	C1880274
Ca(2+) channel Orai1	T028	C1823405
pancreatic acini	T023	C0227578
mice	T015	C0026809
mortality	T081	C0026565
activation of the intestinal innate immune response	T040	C1817386
mice	T015	C0026809
acinar	T082	C0332207
Orai1	T028	C1823405
intestinal	T023	C0021853
bacterial	T080	C0521009
outgrowth	T043	C0007613
dysbiosis	T184	C4287543
systemic	T169	C0205373
translocation	T043	C0599718
inflammation	T046	C0021368
death	T040	C0011065
digestive enzyme	T116	C0544420
supplementation	T061	C0948571
ineffective	T078	C3242229
treatments	T061	C0087111
bacterial	T080	C0521009
outgrowth	T043	C0007613
purified	T169	C1998793
liquid diet	T061	C0301571
broad-spectrum antibiotics	T195	C0003232
survival	T169	C0220921
feeding	T052	C2987508
weight gain	T033	C0043094
Pancreatic levels	T034	C1306845
cathelicidin	T116	C0671062
antimicrobial peptide	T116	C4084937
CRAMP	T116	C4084937
reduced	T080	C0392756
supplement	T169	C2348609
CRAMP	T116	C4084937
intestinal disease	T047	C0021831
findings	T033	C0243095
critical	T080	C1511545
antimicrobial	T121	C1136254
pancreatic secretion	T042	C0232787
gut	T023	C0699819
innate immunity	T032	C0020969
Palliative Care	T091	C0030231
Attachment	T052	C1947904
Hybrid Removable Prosthesis	T061	C3642532
Abutment	T023	C0545406
injury	T037	C0178314
unsatisfactory	T080	C0439856
aesthetics	T090	C0014901
retention	T061	C0011397
cast partial denture	UnknownType	C0545391
Removable Partial Denture	T074	C0011463
RPD	T074	C0011463
design	T058	C0011395
fabrication	T067	C1254366
economics	T169	C0013557
patient comfort	T058	C4277744
clinical report	T170	C1299495
RPD	T074	C0011463
technique	T169	C0449851
coronal	T082	C0205123
attachment	T052	C1947904
reduces	T080	C0392756
comfort	T041	C1331418
patient	T101	C0030705
CXCL5	T116	C1955899
Osteosarcoma	T191	C0029463
Cell Migration and Invasion	T191	C0027627
Autocrine	T042	C0596138
Paracrine	T039	C0597170
CXCL5	T116	C1955899
CXC-type chemokine	T116	C0282553
granulocytic immune cells	T025	C0018183
binding to its receptor CXCR2	T044	C1149468
CXCL5	T116	C1955899
CXCR2	T116	C0527994
oncogenic	T116	C0029005
human	T016	C0086418
cancers	T191	C0006826
CXCL5	T116	C1955899
osteosarcoma	T191	C0029463
cell migration and invasion	T191	C0027627
protein expression	T045	C1171362
CXCL5	T116	C1955899
increased	T081	C0205217
osteosarcoma	T191	C0029463
tissues	T024	C0040300
matched adjacent nontumor tissues	T024	C0040300
expression	T045	C1171362
CXCL5	T116	C1435946
advanced clinical stage	T079	C0205563
metastasis	T046	C4255448
CXCL5	T116	C1955899
expression levels	T081	C3244092
increased	T081	C0205217
osteosarcoma	T191	C0029463
cell lines	T025	C0085983
Saos-2	T025	C0085983
MG63	T025	C0085983
U2OS	T025	C0085983
SW1353	T025	C0085983
normal osteoblast	T025	C0029418
hFoB1.19 cells	T025	C0029418
U2OS cells	T025	C0085983
transfected	T045	C0314641
CXCL5	T028	C1332819
specific siRNA	T114	C1099354
overexpression	T045	C1514559
plasmid	T114	C0032136
Knockdown	T063	C2350567
CXCL5	T028	C1332819
suppressed	T169	C1260953
U2OS	T025	C0085983
cell migration and invasion	T191	C0027627
overexpression	T045	C1514559
CXLC5	T116	C1955899
migration and invasion	T191	C0027627
U2OS cells	T025	C0085983
exogenous	T169	C0205228
CXCL5	T116	C1955899
treatment	T169	C0039798
CXCL5	T116	C1955899
overexpressing	T045	C1514559
hFoB1.19 cells	T025	C0029418
migration and invasion	T191	C0027627
U2OS cells	T025	C0085983
CXCL5	T116	C1955899
U2OS	T025	C0085983
cell migration and invasion	T191	C0027627
paracrine	T039	C0597170
CXCL5	T116	C1955899
osteosarcoma	T191	C0029463
oncogenic	T116	C0029005
osteosarcoma	T191	C0029463
metastasis	T046	C4255448
CXCL5	T116	C1955899
potential	T080	C3245505
therapeutic target	T169	C0205245
osteosarcoma	T191	C0029463
treatment	T169	C0039798
Integrating	T052	C1881786
molecular	T080	C1521991
QTL	T028	C0597336
data	T078	C1511726
genome-wide genetic association analysis	T063	C2350277
Probabilistic	T081	C0033204
assessment	T169	C1292732
enrichment	T077	C2986411
colocalization	T169	C0475264
statistical framework	T081	C0026348
integrating	T052	C1881786
result	T169	C1274040
molecular	T080	C1521991
quantitative trait loci	T028	C0597336
QTL	T028	C0597336
mapping	T052	C1283195
genome-wide genetic association analysis	T063	C2350277
complex	T080	C0439855
traits	T032	C0599883
quantitatively	T081	C0392762
assessing	T169	C1292732
enrichment	T077	C2986411
molecular	T080	C1521991
QTLs	T028	C0597336
complex	T080	C0439855
trait	T032	C0599883
associated	T080	C0332281
genetic variants	T028	C0678941
colocalizations	T169	C0475264
types	T080	C0332307
association	T080	C0439849
signals	T067	C1710082
natural Bayesian hierarchical model	T081	C0242198
association	T080	C0439849
molecular	T080	C1521991
QTLs	T028	C0597336
SNP	T086	C0752046
level	T080	C0441889
SNPs	T086	C0752046
complex	T080	C0439855
traits	T032	C0599883
computational	T052	C1880157
procedure	T169	C2700391
enrichment	T077	C2986411
fine-mapping	T052	C1283195
colocalization	T169	C0475264
analyses	T062	C0936012
distinct feature	T080	C2348519
compared	T052	C1707455
colocalization	T169	C0475264
analysis	T062	C0936012
procedures	T169	C2700391
literature	T170	C0023866
approach	T082	C0449445
computationally	T052	C1880157
efficient	T080	C0442799
summary	T170	C1706244
level	T080	C0441889
statistics	T081	C2828391
evaluate	T169	C1292732
computational	T052	C1880157
approach	T082	C0449445
extensive	T080	C0205231
simulation	T066	C0009609
studies	T062	C2603343
analyses	T062	C0936012
blood lipid	T109	C0596192
data	T078	C1511726
whole blood	T031	C0370231
eQTL	T028	C0597336
data	T078	C1511726
GTEx project	T062	C4289040
utility	T170	C0025663
method	T170	C0025663
computation	T052	C1880157
colocalization	T169	C0475264
signals	T067	C1710082
characteristics	T080	C1521970
association	T080	C0439849
data	T078	C1511726
utility	T170	C0025663
enrichment	T077	C2986411
analysis	T062	C0936012
colocalized	T169	C0475264
signals	T067	C1710082
potential	T080	C3245505
limitations	T169	C0449295
molecular	T080	C1521991
QTL	T028	C0597336
data	T078	C1511726
software	T073	C0037585
computation	T052	C1880157
procedures	T169	C2700391
enloc	T170	C0242356
https://github.com/xqwen/integrative	T170	C2349146
Engineering	T063	C0017387
ribosomal DNA	T114	C0012933
megabase synthetic chromosome	T075	C0872017
976,067-base pair linear chromosome	T075	C0872017
synXII	T075	C0872017
chromosome XII	T026	C0008642
Saccharomyces cerevisiae	T004	C0036025
SynXII	T075	C0872017
two-step method	T169	C0449851
megachunk integration	T063	C0017387
meiotic recombination-mediated assembly	T063	C0017387
functional	T169	C0205245
chromosome	T026	C0008642
S. cerevisiae	T004	C0036025
Minor growth defect	T169	C1457869
bugs	T169	C1457869
detected	T033	C0442726
synXII	T075	C0872017
deletion	T045	C0017260
tRNA	T114	C0035711
genes	T028	C0017337
ectopic copy	T028	C0017337
single tRNA	T114	C0035711
gene	T028	C0017337
ribosomal gene cluster	T028	C0017258
rDNA	T028	C0017258
synXII	T075	C0872017
assembly process	T063	C0017387
modified	T169	C0392747
rDNA	T028	C0017258
regenerate	T169	C0334213
rDNA	T028	C0017258
chromosomal locations	T026	C0008633
sequences	T086	C0004793
rDNA	T028	C0017258
species	T185	C1705920
identity	T033	C0243095
Saccharomyces	T004	C0036024
synXII	T075	C0872017
strain	T001	C1518614
identified	T080	C0205396
Saccharomyces bayanus	T004	C1504647
standard	T080	C1442989
Humidity	T070	C0020167
Sensitive	T169	C0332324
Clothing	T073	C0009072
Personal Thermoregulation	T061	C0262758
humidity	T070	C0020167
induced	T169	C0205263
smart clothing	T073	C0009072
designed to reversibly adapt	T062	C3274373
thermal insulation functionality	T073	C1708520
pores	T023	C0221956
human skin	T022	C1123023
pores	T023	C0221956
Nafion	T109	C0068361
sheets	T073	C0039717
humidity	T070	C0020167
human sweating	T033	C0038990
air flow	T067	C0042491
humidity	T070	C0020167
apparent temperature	T081	C0039476
human sweating pores	T023	C0221956
perspiration	T033	C0038990
wearer warm	T073	C0009072
thickness	T080	C1280412
adjustable clothes	T073	C0009072
bent polymer sheets	T073	C0039717
fabrics	T073	C0039717
humidity	T070	C0020167
sheets	T073	C0039717
fabrics	T073	C0039717
thermal insulation	T169	C0205245
insulation layer	T073	C1708520
thickness	T080	C1280412
humidity	T070	C0020167
warmth-preservation	T039	C0392197
humidity	T070	C0020167
sensitive	T169	C0332324
polymer materials	T073	C0039717
personal comfort	T041	C1331418
reducing energy consumption	T033	C0243095
heating or cooling	T169	C0205245
smart design	T052	C1707689
Development	T039	C0243107
automaton model	T075	C0026336
rotational activity	T052	C0441655
atrial fibrillation	T047	C0004238
Atrial fibrillation	T047	C0004238
AF	T047	C0004238
treat	T061	C0087111
effectively	T080	C1704419
uncertainty	T033	C0087130
ablate	T061	C0162563
eliminate	T052	C0441655
arrhythmogenic	T046	C0085611
substrate	T167	C3891814
model	T075	C0026336
electrical	T169	C0442828
activation	T052	C1879547
events	T051	C0441471
catheter ablation strategy	T061	C0162559
two-dimensional	T082	C1705052
576×576 node automaton	T073	C0336537
simulate	T052	C0441655
atrial	T023	C0018792
atrial electrical activity	T042	C0596673
substrate	T167	C3891814
differing	T080	C1705242
refractory period	T043	C0678839
locations	T082	C0450429
Fibrosis	T046	C0016059
conduction	T042	C0232217
block	T047	C0018794
Larger	T081	C0549177
areas	T082	C0205146
block	T046	C0028778
simulate	T052	C0441655
ablation lesions	T033	C0221198
Anisotropy	T070	C0085406
ratio	T081	C0456603
premature	T079	C1254367
electrical impulse	T043	C1720744
initiate	T078	C1548602
activation	T052	C1879547
Rotational activity	T052	C0441655
refractory patch dimensions	T081	C0439534
larger	T081	C0549177
refractory regions	T082	C1254362
premature	T079	C1254367
stimulus	T067	C0234402
inducing	T169	C0205263
average	T081	C1510992
rotors	T074	C0025080
patch edges	T082	C1254362
maximum	T081	C0806909
rotors	T074	C0025080
refractory patch dimensions	T081	C0439534
size	T082	C0456389
left atrial	T023	C0225860
virtual field	T082	C1254362
Rotors	T074	C0025080
refractory patch edge	T082	C1254362
wavefront arrival was delayed	T033	C0243095
fiber	T024	C1304649
cluster	T081	C1704332
size	T082	C0456389
rotational activity	T052	C0441655
large	T081	C0549177
fiber	T024	C1304649
cluster	T081	C1704332
spatially variable refractoriness	T080	C0205556
obstacles	T080	C4045969
conduction	T042	C0232217
lacking	T080	C0332268
size	T082	C0456389
nascent rotors	T074	C0025080
stabilized	T033	C0184512
anchoring	T044	C1624581
large	T081	C0549177
fiber	T024	C1304649
cluster	T081	C1704332
Transient	T079	C0205374
rotors	T074	C0025080
traversing	T052	C0441655
region	T082	C0205147
refractory periods	T043	C0678839
obstacle	T080	C4045969
conduction	T042	C0232217
delay wavefront arrival	T033	C0243095
longest	T080	C1522425
refractory period	T043	C0678839
rotors	T074	C0025080
rotor	T074	C0025080
spin rate	T081	C0392762
activation pathway	T044	C1148560
Elimination	T052	C0441655
anchors	T061	C1293132
removal	T061	C0015252
ablation	T061	C0162563
region	T082	C0205147
rotor	T074	C0025080
onset	T080	C0332162
location	T029	C1515974
obstacles	T080	C4045969
conduction	T042	C0232217
spatial differences	T033	C0243095
refractory period	T043	C0678839
parameters	T078	C0237767
maintaining	T169	C1314677
rotational activity	T052	C0441655
simulation	T062	C0679083
atrial	T023	C0018792
substrate	T167	C3891814
Multimodal brain imaging	T060	C1513743
magnetoencephalography	T060	C0024489
method	T060	C0430022
measuring	T169	C0242485
blood pressure	T040	C0005823
cardiorespiratory oscillations	T040	C0871665
Studies	T062	C2603343
magnetoencephalography	T060	C0024489
MEG	T060	C0024489
methods	T060	C0430022
metabolic dimension	T169	C0025520
MEG	T060	C0024489
investigation	T058	C0220825
blood pressure measurements	T058	C3826646
MEG	T060	C0024489
methods	T060	C0430022
neurovascular status	T058	C1828265
low frequency	T079	C0205213
fluctuations	T184	C0231239
functional connectivity	T169	C1707489
brain networks	T023	C2951780
multimodal brain imaging	T060	C1513743
non-invasively	T169	C0205303
cerebral	T023	C0006104
hemodynamic	T042	C0019010
cardiorespiratory	T060	C0846599
blood pressure	T040	C0005823
oscillations	T040	C0871665
MEG	T060	C0024489
methods	T060	C0430022
MEG	T060	C0024489
fibre optics	T090	C0015979
method	T060	C0430022
measuring	T169	C0242485
blood pressure	T040	C0005823
cardiorespiratory oscillations	T040	C0871665
MEG	T060	C0024489
potential	T080	C3245505
multimodal	T060	C1513743
brain research	T062	C0035168
human	T016	C0086418
effects of	T080	C1704420
mild hypercapnia	T033	C0020440
modalities	T169	C1275506
Effect of	T080	C1704420
peritoneal lavage	T058	C0031148
solution	T167	C0037633
temperature	T081	C0039476
body temperature	T032	C0005903
anaesthetised	T033	C1720436
cats	T015	C0007450
dogs	T015	C0012984
prospective	T062	C0033522
randomised	T062	C0206034
non-blinded	T062	C0242481
clinical study	T062	C0008972
effect of	T080	C1704420
peritoneal lavage	T058	C0031148
warmed	T070	C0687712
fluid	T167	C0302908
body temperature	T032	C0005903
anesthetised	T033	C1720436
cats	T015	C0007450
dogs	T015	C0012984
body mass	T033	C0518010
coeliotomy	T061	C0023038
standardised anaesthetic protocol	T170	C0442711
Oesophageal	T058	C3161742
rectal temperatures	T033	C0489749
measured	T080	C0444706
various time points	T079	C1552717
surgery	T061	C0543467
group 1 patients	T101	C0030705
lavaged	T061	C0022100
sterile	T080	C0232920
isotonic saline	T121	C0445115
group	T096	C1642385
Groups	T096	C1642385
age	T100	C0596090
mass	T081	C1306372
body condition	T033	C3687361
surgical incision	T061	C0184898
Duration	T079	C0449238
anaesthesia	T061	C0002921
surgical procedures	T061	C0543467
peritoneal lavage	T058	C0031148
groups	T096	C1642385
Linear regression	T081	C0023733
no significant change	T033	C0243095
oesophageal temperature	T058	C3161742
lavage	T061	C0022100
period	T079	C1948053
group	T096	C1642385
group 2 patients	T101	C0030705
mean	T081	C0444504
temperature changes	T080	C0450031
results	T033	C0459422
rectal temperature	T033	C0489749
mean	T081	C0444504
isotonic	T121	C0022260
crystalloid solution	T121	C0056562
peritoneal lavage	T058	C0031148
temperature	T081	C0039476
warms	T070	C0687712
small animal patients	T101	C0030705
clinical setting	T082	C3176918
lavage	T061	C0022100
Bioengineered	T090	C2717958
3D	T082	C0450363
Models	T075	C0026339
Studying	T062	C2603343
Human	T016	C0086418
Cell	T025	C0007634
Tuberculosis	T007	C0026926
Interactions	T169	C1704675
In vivo	T082	C1515655
animal models	T008	C0599779
studying	T062	C2603343
relationships	T080	C0439849
tuberculosis	T007	C0026926
host	T001	C1167395
in vitro	T080	C1533691
cellular models	T075	C0026339
microsphere	T074	C0026032
3D	T082	C0450363
in vitro	T080	C1533691
culture system	T063	C1516329
Mycobacterium tuberculosis	T007	C0026926
human	T016	C0086418
blood	T031	C0005767
mononuclear cells	T025	C0806987
host	T001	C1167395
pathogen	T001	C0450254
interactions	T169	C1704675
Perspectives	T078	C1254370
cardiovascular	T022	C0007226
effects of	T080	C1704420
incretin	T116	C1562292
drugs	T121	C1254351
cardiovascular	T022	C0007226
outcome	T169	C1274040
trials	T062	C0008976
glucose	T109	C0017725
drugs	T121	C1254351
type 2 diabetes mellitus	T047	C0011860
glucagon-like peptide-1 receptor	T192	C0378073
agonists	T121	C0243192
GLP-1RA	T121	C0243192
liraglutide	T116	C1456408
semaglutide	T116	C3885068
reduction	T081	C0547047
cardiovascular events	T033	C1320716
trials	T062	C0008976
incretin	T116	C1562292
drugs	T121	C1254351
lixisenatide	T116	C2973895
dipeptidyl peptidase-4 inhibitors	T121	C1827106
DPP4i	T121	C1827106
Mechanisms	T169	C0441712
cardiovascular	T022	C0007226
differences	T080	C1705242
DPP4i	T121	C1827106
GLP1-RA	T121	C0243192
GLP1-RA	T121	C0243192
review	T170	C0282443
evidence	T078	C3887511
experimental	T062	C0681814
mechanistic studies	T062	C0681814
action	T052	C3266814
GLP1-RA	T121	C0243192
DPP4i	T121	C1827106
cardiovascular system	T022	C0007226
clinical	T081	C0011001
pre-clinical sources	T081	C0011001
results	T169	C1274040
cardiovascular	T022	C0007226
outcome	T169	C1274040
trials	T062	C0008976
experimental	T062	C0681814
preclinical data	T170	C1516606
heart failure	T047	C0018801
results	T169	C1274040
hypotheses	T078	C1512571
findings	T169	C2607943
cardioprotection	T169	C0205245
incretin	T116	C1562292
drugs	T121	C1254351
incretin	T116	C1562292
cardiovascular	T022	C0007226
effects of	T080	C1704420
cardiac	T023	C0018787
action	T052	C3266814
GLP-1	T116	C0061355
metabolites	T123	C0870883
GLP-1 receptor	T192	C0378073
pathways	T044	C1704259
DPP4	T116	C0081937
substrates	T167	C3891814
GLP-1	T116	C0061355
breast magnetic resonance imaging	T060	C0344104
predicting	T078	C0681842
residual	T080	C1609982
lobular carcinoma in situ	T191	C0279563
initial	T079	C0205265
excision	T061	C0728940
Breast magnetic resonance (MR) imaging	T060	C0344104
screening	T060	C0199230
modality	T078	C0695347
detecting	T061	C1511790
suspicious	T033	C4050405
lesions	T033	C0221198
patients	T101	C0030705
history	T033	C0262926
lobular carcinoma in situ	T191	C0279563
LCIS	T191	C0279563
study	T062	C2603343
aimed	T078	C1947946
evaluate	T058	C0220825
effectiveness	T080	C1280519
breast MR imaging	T060	C0344104
detecting	T061	C1511790
remnant	T018	C3272697
LCIS	T191	C0279563
lesions	T033	C0221198
after	T079	C0687676
initial	T079	C0205265
excision	T061	C0728940
patients	T101	C0030705
LCIS	T191	C0279563
underwent	T033	C2586066
initial	T079	C0205265
excision	T061	C0728940
Breast ultrasonography	T060	C0080264
breast MR imaging	T060	C0344104
after	T079	C0687676
initial	T079	C0205265
excision	T061	C0728940
Imaging findings	T034	C1287399
compared	T052	C1707455
pathologic	T046	C0030660
results	T169	C1274040
cases	T077	C1706256
positive margins	T033	C1709603
after	T079	C0687676
initial	T079	C0205265
excision	T061	C0728940
LCIS	T191	C0279563
atypical lobular hyperplasia	T046	C1368920
Residual	T080	C1609982
lesions	T033	C0221198
identified	T080	C0205396
cases	T077	C1706256
invasive lobular carcinoma	T191	C0279565
LCIS	T191	C0279563
atypical lobular hyperplasia	T046	C1368920
papillary carcinoma in situ	T191	C0334242
Prior	T079	C0332152
second	T081	C0205436
operation	T061	C0543467
lesions	T033	C0221198
cases	T077	C1706256
ultrasonography	T060	C0080264
sensitivity	T081	C1511883
specificity	T081	C1511884
cases	T077	C1706256
breast MR imaging	T060	C0344104
sensitivity	T081	C1511883
specificity	T081	C1511884
Breast MR imaging	T060	C0344104
higher	T080	C0205250
sensitivity	T081	C1511883
breast ultrasonography	T060	C0080264
detecting	T061	C1511790
remnant	T018	C3272697
LCIS	T191	C0279563
lesions	T033	C0221198
suspicious	T033	C4050405
lesion	T033	C0221198
breast MR imaging	T060	C0344104
second	T081	C0205436
operation	T061	C0543467
considered	T078	C0750591
possibility	T033	C0332149
multifocality	T033	C2986663
LCIS	T191	C0279563
confirmed	T033	C0750484
initial	T079	C0205265
operation	T061	C0543467
Construction	T070	C0007987
Fused Polyheterocycles	T104	C1254350
Sequential	T080	C1705294
[4 + 2] and [3 + 2] Cycloadditions	T067	C0598128
Pd	T196	C0030230
catalyzed	T070	C0007382
aerobic	T080	C1510824
oxidative reaction	T044	C0030011
quinazolinones	T109	C1720912
alkynes	T109	C0002078
sequential	T080	C1705294
[4 + 2] and [3 + 2] cycloadditions	T067	C0598128
assemble	T052	C1706853
novel	T080	C0205314
fused-polycyclic system	T104	C1254350
tetrahydropyridine	T109	C0044607
dihydrofuran rings	T109	C0029224
reaction process	T067	C0596319
C-H and N-H bond	T044	C0813982
formation	T169	C1522492
tetrahydropyridine	T109	C0044607
oxygen radical	T121	C0030054
cyclization	T070	C0010546
dihydrofuran ring	T109	C0029224
atom	T196	C0567415
economical synthesis	T090	C0013556
substrate	T167	C3891814
tolerance	T080	C1704410
construction	T070	C0007987
polycyclic molecules	T104	C1254350
pharmaceutical interest.	T091	C0008003
Biological	T080	C0205460
basis	T121	C1874451
radiation protection	T061	C0034533
rejuvenation	T061	C0035016
Human beings	T016	C0086418
radiation	T070	C0851346
proximity	T082	C1514583
radioactive waste	T069	C0034552
sites	T082	C0205145
participation	T169	C0679823
medical procedures	T058	C0199171
X-rays	T070	C0043309
radiation exposures	T037	C0015333
legally regulated	T064	C0851285
radiation protection	T061	C0034533
policy	T170	C0242456
biological	T080	C0205460
cellular	T059	C0178539
molecular	T080	C1521991
effects of	T080	C1704420
low doses	T081	C0445550
dose rates	T081	C1512044
radiation	T070	C0851346
high dose	T081	C0444956
radiation exposures	T037	C0015333
technical developments	T169	C1527148
biology	T091	C0005532
medicine	T091	C0025118
single cell techniques	T059	C0597452
big data computational research	T059	C4297010
approaches	T169	C1292724
study	T062	C2603343
biology	T091	C0005532
low doses	T081	C0445550
radiation	T070	C0851346
support	T077	C1521721
idea	T078	C1947946
low doses	T081	C0445550
radiation	T070	C0851346
associated with	T080	C0332281
high dose	T081	C0444956
exposures	T037	C0014412
sufficient	T080	C0205410
development	T169	C1527148
theoretical framework	T170	C0282574
low dose	T081	C0445550
radiation exposures	T037	C0015333
radiation effects	T067	C4281532
low doses	T081	C0445550
radiation protection	T061	C0034533
policy	T170	C0242456
Gleason grade grouping	T185	C0332326
prostate cancer	T191	C0600139
prognostic value	T201	C1514474
Asian	T098	C0078988
men	T098	C0025266
International Society of Urological Pathology	T093	C1708333
Grade Groups	T185	C0332326
GG	T185	C0332326
Epstein	T170	C1547383
colleagues	T098	C0681088
Gleason score	T033	C3203027
GS	T033	C3203027
adopted	T033	C0425382
WHO classification	T185	C4267671
studies	T062	C2603343
revision	T079	C0439617
Caucasian populations	T098	C0043157
GG system	T185	C0332326
biochemical disease-free survival	T081	C0242793
mixed-ethnicity	T098	C0015031
cohort	T098	C0599755
Asian	T098	C0078988
men	T098	C0025266
radical prostatectomies	T061	C0194810
RPs	T061	C0194810
GS	T033	C3203027
biopsy	T060	C0005558
RP	T061	C0194810
cases	T169	C0868928
GG	T185	C0332326
GS	T033	C3203027
GS	T033	C3203027
GS	T033	C3203027
GS	T033	C3203027
GS	T033	C3203027
Biochemical recurrence	T033	C2985506
RP	T061	C0194810
prostate-specific antigen	T116	C0138741
PSA	T116	C0138741
RP	T061	C0194810
PSA	T116	C0138741
nadir	T080	C1708760
data	T078	C1511726
Kaplan-Meier analysis	T081	C1720943
biochemical recurrence	T033	C2985506
Gleason GG	T185	C0332326
biopsy	T060	C0005558
prostatectomy	T061	C0033573
scoring	T081	C0449820
Multivariate analysis	T081	C0026777
GG	T185	C0332326
risk	T078	C0035647
biochemical recurrence	T033	C2985506
GG system	T185	C0332326
prognostic	T081	C0449821
discrimination	T169	C2945687
biopsy	T060	C0005558
RP	T061	C0194810
GS	T033	C3203027
study	T062	C2603343
validates	T062	C1519941
revised	T079	C0439617
updated	T079	C1519814
GG system	T185	C0332326
mixed-ethnicity population	T098	C0015031
Asian	T098	C0078988
men	T098	C0025266
GG	T185	C0332326
risk	T078	C0035647
biochemical recurrence	T033	C2985506
clinical management	T058	C1516615
patients	T101	C0030705
prostate cancer	T191	C0600139
Membrane	T026	C3161472
nanoclusters	T081	C1704332
FcγRI	T116	C0123263
inhibitory	T052	C3463820
SIRPα	T116	C0671702
activation of human macrophages	T043	C2248379
Signal integration	T043	C0037083
activating	T052	C1879547
Fc receptors	T116	C0034805
inhibitory	T052	C3463820
signal regulatory protein α	T116	C0671702
SIRPα	T116	C0671702
macrophage	T025	C0024432
phagocytosis	T043	C0031308
dual-color direct stochastic optical reconstruction microscopy	T059	C0430389
Fcγ receptor I	T116	C0123263
FcγRI	T116	C0123263
FcγRII	T116	C0796385
SIRPα	T116	C0671702
homogeneously	T080	C1881065
macrophage	T025	C0024432
surfaces	T026	C0699040
discrete	T080	C0443299
nanoclusters	T081	C1704332
Nanoclusters	T081	C1704332
FcγRI	T116	C0123263
FcγRII	T116	C0796385
associated with	T080	C0332281
nanoclusters	T081	C1704332
SIRPα	T116	C0671702
actin cytoskeleton	T026	C0025979
Fc receptor	T116	C0034805
activation	T043	C1514758
Src-family kinase	T116	C0282625
signaling	T043	C1154413
FcγRI	T116	C0123263
SIRPα	T116	C0671702
nanoclusters	T081	C1704332
Co-ligation	T044	C0314675
SIRPα	T116	C0671702
CD47	T116	C1506697
nanocluster	T081	C1704332
signals	T043	C0037083
activation	T052	C1879547
FcγRI	T116	C0123263
nanoclusters	T081	C1704332
reorganize	T078	C0680829
periodically	T079	C0332182
concentric rings	T082	C1254362
nanometer	T081	C0439202
micron-scale	T081	C0439201
reorganization	T078	C0680829
activating	T052	C1879547
inhibitory	T052	C3463820
receptors	T116	C0597357
human macrophages	T025	C0024432
concurrent	T079	C0205420
signal integration	T043	C0037083
Firecracker	T073	C0336696
eye exposure	T033	C3544170
experimental study	T062	C0681814
simulation	T062	C0679083
mechanisms	T169	C0441712
traumatic	T169	C0332663
ocular injury	T037	C0015408
accurate	T080	C0443131
diagnoses	T033	C0011900
symptoms	T184	C1457887
eye protection	T073	C3826373
comprehension	T041	C0162340
dynamics	T070	C3826426
primary	T080	C0205225
blast injury	T037	C0005700
mechanisms	T169	C0441712
issue	T033	C0033213
pressure	T067	C0033095
wave	T070	C0678544
propagation	T067	C1254366
reflection	T081	C4054089
cause	T078	C0085978
ocular damage	T033	C4061128
dissenting	T054	C0012742
opinions	T041	C0871010
conclusive	T080	C2828146
evidence	T078	C3887511
numerical investigation	T058	C0220825
blast	T070	C0337026
trauma	T037	C3714660
dynamic	T169	C0729333
effect	T080	C1280500
pressure	T067	C0033095
propagation	T067	C1254366
amplification	T067	C1521871
geometry	T090	C0449829
bony orbit	T023	C1266926
inducing	T169	C0205263
resonance	T070	C0459800
cavity	T030	C0029180
effect	T080	C1280500
standing wave	T070	C0678544
hazardous	T080	C0337044
eye	T023	C0015392
tissues	T024	C0040300
experimental	T080	C1517586
evidence	T078	C3887511
numerically	T081	C0243174
identified	T080	C0205396
phenomenon	T067	C1882365
tests	T170	C0392366
evaluating	T058	C0220825
response	T032	C0871261
porcine	T015	C3665571
eyes	T023	C0015392
blast	T070	C0337026
overpressure	T067	C0033095
firecrackers	T073	C0336696
explosion	T067	C0015329
performed	T169	C0884358
orbital cavity	T030	C0029180
effect	T080	C1280500
enucleated eyes	T037	C1396718
orbit	T030	C0029180
experimental	T080	C1517586
measurements	T169	C0242485
obtained	T169	C1301820
explosion	T067	C0015329
tests	T170	C0392366
paper	T170	C0282420
corroborate	T080	C1456348
numerical evidence	T078	C3887511
high-frequency	T079	C0205212
pressure	T067	C0033095
amplification	T067	C1521871
enhancing	T052	C2349975
ocular	T023	C0015392
tissues	T024	C0040300
attributable	T041	C0596130
orbital bony walls	T029	C4243627
eye	T023	C0015392
platelet-activating receptor	T116	C0071234
C-type lectin receptor-2	T116	C2354438
role	T077	C1705810
liver regeneration	T042	C0023907
partial hepatectomy	T061	C0193398
mice	T015	C0025929
Regeneration	T042	C0023907
role	T077	C1705810
C-type lectin receptor-2	T116	C2354438
CLEC-2	T116	C2354438
70% hepatectomy	T061	C0193398
HPx	T061	C0193398
Wild-type	T028	C1883559
CLEC-2	T028	C0017337
deleted	T045	C0017260
platelets	T025	C0005821
chimeric mice	T015	C0025929
flKO	T015	C0025929
HPx	T061	C0193398
liver/body weight ratio	T081	C2983636
flKO	T015	C0025929
wild-type	T015	C1520150
CLEC-2	T116	C2354438
role	T077	C1705810
liver regeneration	T042	C0023907
HPx	T061	C0193398
role	T077	C1705810
C-type lectin receptor (CLEC)-2	T116	C2354438
liver regeneration	T042	C0023907
partial liver resection	T061	C0193398
mice	T015	C0025929
chimeric mice	T015	C0025929
transplanted	T169	C0700106
fetal	T169	C0521457
liver cells	T025	C0227525
wild-type (WT) mice	T015	C1520150
CLEC-2	T028	C0017337
deleted	T045	C0017260
mice	T015	C0025929
mice	T015	C0025929
CLEC-2	T028	C0017337
deleted	T045	C0017260
platelets	T025	C0005821
generated	T052	C3146294
Mice	T015	C0025929
70% partial hepatectomy	T061	C0193398
PH	T061	C0193398
Immunohistochemical staining	T059	C0487602
expression	T045	C1171362
endogenous	T169	C0205227
ligand	T103	C0023688
CLEC-2	T116	C2354438
podoplanin	T116	C3537357
accumulation	T043	C0007613
platelets	T025	C0005821
liver	T023	C0023884
quantified	T081	C1709793
hepatic	T029	C0205054
expression	T045	C1171362
IL-6	T116	C0021760
gp130	T116	C0017968
STAT3	T116	C0253050
Akt	T116	C0164786
ERK1/2	T116	C0600388
liver/body weight ratio	T081	C2983636
expression	T045	C1171362
cell proliferation	T043	C0596290
markers	T059	C1611701
flKO group	T015	C0025929
WT group	T015	C1520150
expression	T045	C1171362
phosphorylated (p) Akt	T116	C0164786
pERK1	T116	C0600388
WT	T015	C1520150
flKO groups	T015	C0025929
expression	T045	C1171362
pSTAT3	T116	C0253050
IL-6	T116	C0021760
WT group	T015	C1520150
flKO group	T015	C0025929
expression	T045	C1171362
podoplanin	T116	C3537357
hepatic sinusoids	T023	C0227523
groups	T078	C0441833
platelets	T025	C0005821
hepatic sinusoids	T023	C0227523
flKO group	T015	C0025929
WT group	T015	C1520150
CLEC-2	T116	C2354438
hepatic regeneration	T042	C0023907
liver resection	T061	C0019144
CLEC-2	T116	C2354438
liver regeneration	T042	C0023907
platelets	T025	C0005821
sinusoidal	T030	C0682624
endothelial cells	T025	C0225336
Temporal	T079	C1254367
Stability	T080	C0205360
Heavy Drinking	T033	C0556345
Drinking	T055	C0001948
Reductions	T061	C0441610
Heavy Drinkers	T055	C0337678
COMBINE Study	T062	C2603343
Food and Drug Administration	T093	C0041714
FDA	T093	C0041714
expand	T082	C0205229
primary	T080	C0205225
end points	T080	C2349179
development	T169	C1527148
medications	T058	C2081612
alcohol use disorder	T048	C0001956
abstinence	T061	C3843422
alcohol	T168	C0001967
nonabstinent	T033	C0243095
outcome	T169	C1274040
heavy drinking	T033	C0556345
heavy drinking	T033	C0556345
defined	T170	C1704788
drinks	T168	C0001967
women	T098	C0043210
drinks	T168	C0001967
men	T098	C0025266
cutoff	T169	C1442160
FDA	T093	C0041714
suggested	T078	C1705535
months	T079	C0439231
appropriate	T080	C1548787
length for a clinical trial	T062	C1706316
stability	T080	C0205360
nonabstinent	T033	C0243095
drinking	T055	C0001948
outcome	T169	C1274040
clinical trials	T062	C0008976
examined	T033	C0332128
stability	T080	C0205360
nonheavy drinking	T033	C0556344
during	T079	C0347984
after treatment	T058	C0001758
secondary analysis	UnknownType	C0683944
COMBINE study	T062	C2603343
data	T078	C1511726
examined	T033	C0332128
transitions	T052	C2700061
heavy drinking	T033	C0556345
during the course of treatment	T079	C0454268
months	T079	C0439231
during	T079	C0347984
transition	T052	C2700061
treatment	T061	C0087111
months	T079	C0439231
months	T079	C0439231
months	T079	C0439231
latent variable mixture models	UnknownType	C0681946
Heavy drinking	T033	C0556345
nonheavy drinking	T033	C0556344
stable	T080	C0205360
consecutive	T080	C1707491
months	T079	C0439231
minimum	T080	C1524031
months	T079	C0439231
individuals	T098	C0237401
stable	T080	C0205360
low-risk	T081	C3538919
drinkers	T033	C0556338
abstainers	UnknownType	C0682156
heavy drinkers	T055	C0337678
treatment	T061	C0087111
characterized	T052	C1880022
probability	T081	C0033204
transitioning	T052	C2700061
heavy drinking	T033	C0556345
state	T169	C1442792
heavy drinking	T033	C0556345
state	T169	C1442792
heavy drinkers	T055	C0337678
heavy drinking	T033	C0556345
threshold	T080	C0449864
during treatment	T079	C2709058
reported	T058	C0700287
average	T081	C1510992
reduction	T061	C0441610
drinking frequency	T033	C0556327
reduction	T061	C0441610
drinking	T055	C0001948
pretreatment	T052	C3539076
drinking	T055	C0001948
levels	T080	C0441889
results	T034	C0456984
stability	T080	C0205360
heavy drinking	T033	C0556345
outcome	T169	C1274040
months	T079	C0439231
treatment	T061	C0087111
drink	T168	C0001967
cutoff	T169	C1442160
reductions	T061	C0441610
alcohol consumption	T055	C0001948
patients	T101	C0030705
studies	T062	C2603343
clinical	T080	C0205210
reduction	T061	C0441610
end points	T080	C2349179
Oral health	T058	C0029162
transition	T052	C2700061
Hadza foragers	T098	C1257890
Tanzania	T083	C0039298
Conventional	T080	C0439858
decline	T081	C0547047
oral health	T058	C0029162
transition	T052	C2700061
hunting	T056	C4255216
gathering	T056	C2371489
agriculture	T090	C0001829
increased	T081	C0205217
consumption	T039	C1947907
carbohydrates	T109	C0012170
example	T077	C1707959
mismatch	T080	C1881865
biology	T091	C0005532
modern lifestyle	T054	C0023676
bioarchaeological record	T170	C0034869
Neolithic Revolution	T109	C2948499
New World	T098	C2700280
studies	T062	C2603343
populations	T081	C0032659
assertion	T080	C1301625
comprehensive	T080	C1880156
study	T062	C2603343
oral health	T058	C0029162
living population	T098	C1257890
transition	T052	C2700061
bush	T002	C0330099
village life	T054	C0023676
Hadza	T098	C1257890
hunter	T097	C0239971
gatherers	T098	C1257890
Tanzania	T083	C0039298
hypothesis	T078	C1512571
shift	T052	C2700061
foraging	T055	C2752984
farming	T090	C0001829
agricultural intensification	T090	C0001827
increased	T081	C0205217
periodontal disease	T047	C0031090
caries	T047	C0011334
orthodontic	T169	C0332276
disorders	T047	C0012634
results	T169	C1274040
women	T098	C0043210
living	T080	C0337645
villages	T083	C0562518
consuming	T039	C1947907
agricultural	T002	C0242775
diet	T168	C0012155
caries	T047	C0011334
periodontal disease	T047	C0031090
living	T080	C0337645
bush	T002	C0330099
consuming	T039	C1947907
wild-food diet	T168	C0012155
men	T098	C0025266
living	T080	C0337645
bush	T002	C0330099
consuming	T039	C1947907
wild-food diet	T168	C0012155
living	T080	C0337645
village	T083	C0562518
consuming	T039	C1947907
agricultural	T002	C0242775
diet	T168	C0012155
findings	T033	C0243095
high	T080	C0205250
incidence	T081	C0021149
maize	T168	C1138842
consumption	T039	C1947907
village	T083	C0562518
variation	T080	C0205419
rate	T081	C1521828
caries	T047	C0011334
men	T098	C0025266
women	T098	C0043210
high	T080	C0205250
caries	T047	C0011334
incidences	T081	C0021149
men	T098	C0025266
bush	T002	C0330099
honey	T168	C0019906
tobacco	T167	C0008038
marijuana.	T109	C0024808
data	T078	C1511726
mechanisms	T169	C0441712
cariogenesis	T047	C0011334
multifactorial	T033	C1837655
relationships	T080	C0439849
oral health	T058	C0029162
shift	T052	C2700061
wild-food diet	T168	C0012155
cultigens	T002	C0242775
R2R3MYB	T116	C0040648
VvMYBPA1	T116	C0040648
grape	T002	C0682492
phenylpropanoid pathway	T044	C1156966
tobacco	T002	C0740009
flowers	T002	C0330090
tobacco	T002	C0740009
ectopic expression	T045	C1512167
VvMYBPA1	T116	C0040648
grape	T002	C0682492
regulator	T077	C1704735
proanthocyanidin	T109	C0072018
up- or down-regulates	T043	C1157519
phenylproanoid pathway	T044	C1156966
Proanthocyanidins	T109	C0072018
flavonoids	T109	C0596577
animal	T168	C3668949
human diet	T168	C0012155
Research	T062	C0035168
crops	T002	C0242775
health	T078	C0018684
compounds	T080	C0205198
Flavonoids	T109	C0596577
synthesis	T052	C1883254
MBW	T026	C1167128
transcriptional complex	T026	C1167128
R2R3MYB	T116	C0040648
bHLH	T116	C0288972
WD40 proteins	T116	C0040648
MYB	T116	C0040648
channeling	T082	C0439799
complex	T104	C1704241
pathway	T044	C1704259
tobacco	T002	C0740009
model	T075	C0026336
tested	T169	C0039593
ectopic expression	T045	C1512167
proanthocyanidin	T109	C0072018
regulator	T077	C1704735
VvMYBPA1	T116	C0040648
grape	T002	C0682492
induces	T169	C0205263
biosynthesis	T169	C0005572
compounds	T080	C0205198
committed cells	T025	C0301868
transcriptomic	T045	C0040649
metabolic	T169	C0311400
analyses	T062	C0936012
transgenic lines	T002	C0085245
progeny	T099	C0680063
VvMYBPA1	T116	C0040648
phenylpropanoid pathway	T044	C1156966
tobacco	T002	C0740009
floral organs	T002	C0330090
VvMYBPA1	T116	C0040648
expression	T045	C1171362
expression	T045	C1171362
proanthocyanidin	T109	C0072018
early genes	T028	C0017337
phenylpropanoid pathway	T044	C1156966
proanthocyanidins	T109	C0072018
chlorogenic acids	T109	C0008240
de novo	T078	C1515568
floral limbs, tubes	T002	C0330090
stamens	T002	C1136236
phenylpropanoid branches	T044	C1156966
depleted	T169	C0333668
floral structure	T002	C0330090
novel	T080	C0205314
VvMYBPA1	T116	C0040648
MYBs	T116	C0040648
proanthocyanidins	T109	C0072018
findings	T169	C2607943
designing strategies	T041	C0679199
crops	T002	C0242775
health	T078	C0018684
compounds	T080	C0205198
Genome-wide association mapping	T063	C2350277
winter barley	T002	C0004755
grain	T002	C0086369
yield	T081	C0392762
culm	T002	C0242767
cell wall	T026	C0007623
polymer	UnknownType	C0683005
content	T081	C1264655
CoMPP technique	T059	C0022885
collection	T169	C1516698
winter barley varieties	T002	C0004755
Hordeum vulgare L.	T002	C0331554
grown	T040	C0597252
field	T082	C1254362
years	T079	C0439234
northern	T082	C1709269
Italy	T083	C0022277
grain	T002	C0086369
straw	T109	C4047917
yields	T081	C0392762
year	T079	C0439234
barley yellow mosaic virus	T005	C1000417
BaYMV	T005	C1000417
influenced	T077	C4054723
performances	T052	C1882330
average	T081	C1510992
reduction	T080	C0392756
grain	T002	C0086369
straw	T109	C4047917
harvested	T169	C0205245
comparison	T052	C1707455
second	T081	C0205436
year	T079	C0439234
genetic determination	T059	C1285573
GD	T059	C1285573
grain	T002	C0086369
yield	T081	C0392762
years	T079	C0439234
straw	T109	C4047917
yield	T081	C0392762
GD	T059	C1285573
Cell wall	T026	C0007623
polymers	UnknownType	C0683005
culms	T002	C0242767
culms	T002	C0242767
quantified	T081	C1709793
monoclonal antibodies	T116	C0003250
LM6	T129	C1449622
LM11	T129	C1449622
JIM13	T129	C1449622
BS-400-3	T129	C1449622
carbohydrate-binding module CBM3a	T129	C1449622
CoMPP technique	T059	C0022885
LM6	T129	C1449622
detects	T033	C0442726
arabinan	T109	C0052274
components	T077	C1705248
GD	T059	C1285573
years	T079	C0439234
significantly	T078	C0750502
negative	T033	C0205160
correlation	T080	C1707520
grain	T002	C0086369
yield	T081	C0392762
GYLD	T081	C0392762
heritability	T081	C0392762
H2	T081	C0392762
calculated	T052	C1441506
GYLD	T081	C0392762
LM6	T129	C1449622
JIM	T129	C1449622
total	T080	C0439810
SNPs	T086	C0752046
study	T062	C2603343
population structure	T090	C0597254
linkage disequilibrium	T081	C0023746
LD	T081	C0023746
genome-wide association study	T063	C2350277
GWAS	T063	C2350277
Marker-trait associations	T090	C1328885
MTA	T090	C1328885
grain	T002	C0086369
yield	T081	C0392762
cell wall	T026	C0007623
LM6	T129	C1449622
JIM13	T129	C1449622
significant	T078	C0750502
correlations	T080	C1707520
years	T079	C0439234
single QTL	T028	C0597336
GYLD	T081	C0392762
MTAs	T090	C1328885
chromosome 3H	T026	C0008633
Hv-eIF4E gene	T028	C1414351
resistance	T169	C4281815
BaYMV	T005	C1000417
QTL	T028	C0597336
rym4	T028	C0017337
locus	T082	C1708726
resistance	T169	C4281815
virus	T005	C0042776
GWAs	T063	C2350277
arabinans	T109	C0052274
quantified	T081	C1709793
LM6	T129	C1449622
identification	T080	C0205396
major	T080	C0205164
QTLs	T028	C0597336
3H	T026	C0008633
putative candidate genes	T028	C0017337
study	T062	C2603343
gene expression	T045	C0017262
levels	T081	C3244092
bioinformatics	T091	C1140694
Prevalence	T081	C0220900
Clinical	T080	C0205210
Relevance	T080	C2347946
ASA	T109	C0004057
Nonresponse	T033	C4282382
Cardiac Surgery	T061	C0018821
prevalence	T081	C0220900
acetylsalicylic acid	T109	C0004057
ASA	T109	C0004057
nonresponse	T033	C4282382
patients	T101	C0030705
coronary artery bypass graft (CABG) surgery	T061	C0010055
consequences	T169	C0686907
cardiovascular events	T033	C1320716
prospective	T062	C0033522
observational	T062	C1518527
bicentric cohort study	T081	C0009247
German University hospitals	T073	C0019994
patients	T101	C0030705
elective	T061	C0206058
CABG surgery	T061	C0010055
Platelet function	T043	C1254881
postoperatively	T079	C0032790
arachidonic acid	T109	C0003695
ASPItest	T059	C0032184
thrombin receptor-activating peptide 6	T116	C0219419
TRAPtest	T059	C0032184
multiple electrode aggregometry	T059	C0032184
Multiplate	T059	C0032184
ASPItest	T059	C0032184
ASA	T109	C0004057
nonresponders	T033	C0919875
follow-up	T058	C1522577
cardiovascular events	T033	C1320716
hospital admissions	T058	C0184666
deaths	T033	C1306577
cardiovascular disease	T047	C0007222
prevalence	T081	C0220900
ASA	T109	C0004057
nonresponse	T033	C4282382
significantly	T078	C0750502
increased	T081	C0205217
aggregation curve	T059	C3828533
TRAPtest	T059	C0032184
platelet count	T059	C0032181
cardiopulmonary bypass time	T033	C0429123
ASA	T109	C0004057
nonresponse	T033	C4282382
follow-up	T058	C1522577
end point	T080	C2349179
ASA	T109	C0004057
responders	T033	C0919876
nonresponders	T033	C0919875
study	T062	C0008972
perioperative	T079	C1518988
ASA	T109	C0004057
nonresponse	T033	C4282382
patients	T101	C0030705
CABG	T061	C0010055
cardiovascular events	T033	C1320716
follow-up	T058	C1522577
randomized dosage adjustment trial	T062	C0206034
ASA	T109	C0004057
treatment	T061	C1533734
CABG surgery	T061	C0010055
Genome Sequences	T085	C2348746
Mycobacteriophages Jane and Sneeze	T005	C0026911
isolated	T169	C0205409
phages	T005	C0004651
Mycobacterium smegmatis mc(2)155	T007	C0317761
Hillsborough	T083	C3812217
NJ	T083	C0027971
Palo Verde	T083	C0017446
Costa Rica	T083	C0010182
mycobacteriophages	T005	C0026911
nucleotide	T114	C0028630
differences	T080	C1705242
genomes	T028	C0017428
mycobacteriophage	T005	C0026911
mobile element 1	T114	C1257903
Effect	T080	C1280500
Punica granatum	T002	C1001173
fruit peel	T168	C0016767
glucose-6-phosphate dehydrogenase	T116	C0017757
malate dehydrogenase	T116	C0024544
amphistome	T204	C0684063
Gastrothylax indicus	T204	C3006520
Increasing	T169	C0442808
anthelmintic	T121	C0003158
resistance	T038	C0013203
impact	T080	C4049986
anthelmintics	T121	C0003158
environment	T082	C0014406
helminth parasite	T204	C0018893
sheep	T015	C0036945
lipogenic enzymes	T116	C0014442
glucose-6-phosphate dehydrogenase	T116	C0017757
G-6-PDH	T116	C0017757
malate dehydrogenase	T116	C0024544
MDH	T116	C0024544
subcellular	T026	C3893246
distribution pattern	T082	C0449775
Activity	T044	C0243102
G-6-PDH	T116	C0017757
cytosolic fraction	T026	C1511625
MDH	T116	C0024544
cytosolic	T026	C1511625
mitochondrial fraction	T026	C0026237
Gastrothylax indicus	T204	C3006520
in vitro	T080	C1533691
treatment	T169	C1522326
ethanolic	T109	C0001962
aqueous extracts	T167	C2828366
Punica granatum	T002	C1001173
fruit peel	T168	C0016767
anthelmintic	T121	C0003158
albendazole	T109	C0001911
G-6-PDH	T116	C0017757
activity	T044	C0243102
decreased	T080	C0392756
MDH	T116	C0024544
suppressed	T169	C1260953
control	T167	C1550141
Albendazole	T109	C0001911
effective	T080	C1704419
negative control	T077	C1947986
extracts	T167	C2828366
results	T169	C1274040
phytochemicals	T109	C0577749
plant	T002	C0032098
potential	T080	C3245505
vermifuge	T121	C0003158
vermicide	T131	C1254354
Remitting Seronegative Symmetrical Synovitis With Pitting Edema	T047	C2919482
FDG PET/CT	T060	C4271885
Remitting seronegative symmetrical synovitis with pitting edema	T047	C2919482
RS3PE	T047	C2919482
rare condition	T047	C0678236
elderly	T098	C0001792
types	T080	C0332307
rheumatic	T047	C0035435
malignant diseases	T047	C0442867
year	T079	C0439234
man	T098	C0025266
diagnosis	T033	C0011900
RS3PE	T047	C2919482
clinical sign	T184	C0037088
laboratory data	T078	C1705214
malignancies	T191	C0006826
RS3PE	T047	C2919482
FDG PET/CT	T060	C4271885
occult tumors	T191	C0027667
images	T170	C1704254
multiple	T081	C0439064
symmetrically	T033	C0332516
diffusely	T082	C0205219
increased	T081	C0205217
F-FDG	T109	C0046056
uptake	T039	C0243144
soft tissue	T024	C0225317
joints	T030	C0022417
bones	T023	C0262950
shoulders	T029	C0037004
hips	T023	C0019552
knees	T023	C0022742
ankles	T029	C0003086
Parks	T073	C0562547
Social	T169	C0728831
Cultural	T169	C0220814
Spaces	T082	C1883067
U.S	T083	C0041703
Foreign	T080	C1517294
Born	T040	C0005615
Latinas	T098	C0949335
Parks	T073	C0562547
opportunities	UnknownType	C0814559
people	T098	C0027361
activities	T052	C0441655
promote	T052	C0033414
physical	T169	C0205485
emotional	T033	C0849912
well-being	T078	C0018684
focus groups	T096	C0016400
personal	T032	C1519021
interviews	T052	C0021822
Northeastern	T082	C1709272
city	T083	C0008848
high	T080	C0205250
rate	T081	C1521828
obesity	T047	C0028754
examined	T033	C0332128
perceptions	T041	C0030971
barriers	T078	C1254370
facilitators	T080	C0205556
use of	T169	C1524063
parks	T073	C0562547
park	T073	C0562547
features	T080	C2348519
promote	T052	C0033414
physical activity	T056	C0026606
Latina	T098	C0949335
women	T098	C0043210
Foreign	T080	C1517294
born	T040	C0005615
Latinas	T098	C0949335
environmental	T082	C0014406
characteristics	T080	C1521970
parks	T073	C0562547
types	T080	C0332307
amenities	T073	C1547538
cultural	T052	C0441655
social activities	T054	C2371613
U.S.	T083	C0041703
born	T040	C0005615
Latinas	T098	C0949335
parks	T073	C0562547
physical activity	T056	C0026606
weight	T032	C0005910
management	T052	C0441655
foreign	T080	C1517294
born	T040	C0005615
participants	T098	C0679646
conceptualized	T041	C0589138
parks	T073	C0562547
sociocultural family centers	T082	C1254362
common	T081	C0205214
conceptualizations	T041	C0589138
exercise	T056	C0015259
individual	T098	C0027361
health	T078	C0018684
gain	T081	C1517378
findings	T169	C2607943
new	T080	C0205314
policies	T170	C0242456
culturally	T169	C0220814
specific	T080	C0205369
park	T073	C0562547
programming	T077	C1704769
promote	T052	C0033414
goals	T170	C0018017
increasing	T169	C0442808
levels	T080	C0441889
physical activity	T056	C0026606
health	T078	C0018684
impact	T080	C4049986
childhood maltreatment	T048	C0008060
differential	T080	C0443199
efficacy	T080	C1280519
CBASP	T061	C0033968
escitalopram	T109	C1099456
patients	T101	C0030705
chronic depression	T048	C0581391
secondary analysis	UnknownType	C0683944
Childhood maltreatment	T048	C0008060
CM	T048	C0008060
indicated	T033	C1444656
predictor	T078	C2698872
differential	T080	C0443199
response	T032	C0871261
antidepressant treatment	T061	C1096649
psychotherapy	T061	C0033968
compared	T052	C1707455
medication	T121	C0013227
secondary analysis	UnknownType	C0683944
investigated	T169	C1292732
presence	T080	C3854307
CM	T048	C0008060
results	T169	C1274040
differential	T080	C0443199
indication	T078	C3146298
Cognitive Behavioral Analysis System of Psychotherapy	T061	C0033968
CBASP	T061	C0033968
escitalopram	T109	C1099456
clinical management	T058	C1516615
ESC	T109	C1099456
patients	T101	C0030705
chronic depression	T048	C0581391
randomized	T062	C0034656
sessions	T077	C1883017
CBASP	T061	C0033968
ESC	T109	C1099456
course	T079	C0750729
8 weeks	T079	C0439230
acute	T079	C0205178
20 weeks	T079	C0439230
extended	T169	C0231448
treatment	T061	C0087111
German	T083	C0017480
treatment sites	T082	C0337950
CM	T048	C0008060
assessed	T052	C1516048
Childhood	T079	C0231335
Trauma	T080	C1510467
Questionnaire	T170	C0034394
clinician	T097	C0871685
rated	T052	C0871208
Early Trauma Inventory	T170	C0282574
Intention-to-treat analyses	T062	C2718028
impact	T080	C4049986
CM	T048	C0008060
depression	T048	C0011570
global functioning	T060	C0017644
quality of life	T078	C0034380
presence	T080	C3854307
CM	T048	C0008060
result	T169	C1274040
significant	T078	C0750502
differences	T080	C1705242
treatment response	T201	C0521982
CBASP	T061	C0033968
ESC	T109	C1099456
outcome measure	T081	C0086749
28 weeks	T079	C0439230
treatment	T061	C0087111
independent of	T169	C0332291
CM	T048	C0008060
assessment	T058	C0220825
8 weeks	T079	C0439230
significant	T078	C0750502
CM	T048	C0008060
treatment	T061	C0087111
interaction	T169	C1704675
found	T033	C0150312
scores	T081	C0449820
Montgomery-Asberg Depression Rating Scale	T170	C4054475
Patients	T101	C0030705
history	T033	C0262926
CM	T048	C0008060
receiving	T080	C1514756
CBASP	T061	C0033968
significantly lower	T081	C4055638
response rate	T079	C0237629
compared	T052	C1707455
patients	T101	C0030705
CM	T048	C0008060
receiving	T080	C1514756
ESC	T109	C1099456
8 weeks	T079	C0439230
Conclusively	T080	C2828146
CBASP	T061	C0033968
ESC	T109	C1099456
effective	T080	C1704419
treatment	T061	C0087111
difficult	T080	C0332218
treat	T169	C1522326
subgroup	T185	C1515021
patients	T101	C0030705
chronic depression	T048	C0581391
history	T033	C0262926
CM	T048	C0008060
CM	T048	C0008060
predictor	T078	C2698872
longer	T080	C0205166
latency	T079	C0023103
treatment response	T201	C0521982
case	T169	C0868928
psychotherapy	T061	C0033968
CBASP	T061	C0033968
escitalopram	T109	C1099456
effective	T080	C1704419
treatment	T061	C0087111
chronic depression	T048	C0581391
treatments	T061	C0087111
effective	T080	C1704419
difficult	T080	C0332218
treat	T169	C1522326
subgroup	T185	C1515021
patients	T101	C0030705
chronic depression	T048	C0581391
history	T033	C0262926
childhood maltreatment	T048	C0008060
Childhood maltreatment	T048	C0008060
result	T169	C1274040
longer	T080	C0205166
latency	T079	C0023103
treatment response	T201	C0521982
case	T169	C0868928
psychotherapy	T061	C0033968
locus coeruleus	T023	C0023951
analgesic efficacy	T033	C0948482
N-acetylaspartylglutamate peptidase	T116	C0067685
GCPII	T116	C0067685
inhibitors	T121	C0014432
ZJ43	T109	C1451894
2-PMPA	T109	C0910831
N-acetylaspartylglutamate	T116	C0130693
NAAG	T116	C0130693
neurotransmitter	T123	C0027908
mammalian	T015	C0024660
nervous system	T022	C0027763
NAAG	T116	C0130693
activates	T052	C1879547
group II metabotropic glutamate receptor	T116	C0532371
mGluR3	T116	C0532371
extracellular enzyme, glutamate carboxypeptidase II	T116	C0067685
GCPII	T116	C0067685
in vivo	T082	C1515655
Inhibitors of this enzyme	T121	C0014432
analgesic	T109	C0002771
animal models	T008	C0599779
inflammatory	T184	C0234251
neuropathic	T033	C3714625
bone cancer	T191	C0279530
pain	T184	C0030193
NAAG	T116	C0130693
GCPII	T116	C0067685
locus coeruleus	T023	C0023951
noradrenergic	T044	C0599861
inhibitory	T052	C3463820
formalin	T109	C0949307
footpad	T023	C2985236
model	T050	C0012644
systemic	T169	C0205373
treatment	T169	C0039798
GCPII inhibitors	T121	C0014432
inflammatory pain	T184	C0234251
response	T032	C0871261
spinal	T082	C0521329
noradrenaline	T109	C0028351
analgesic efficacy	T033	C0948482
blocked	T169	C0332206
systemic	T169	C0205373
injection	T061	C0021485
group II mGluR	T116	C0532371
antagonist	T121	C1254351
intrathecal (spinal) injection	T061	C0021896
alpha 2 adrenergic receptor antagonist	T121	C0304513
microinjection	T061	C0025991
α-amino-3-hydroxy-5-methylisoxazole-4-propionic acid (AMPA) receptor antagonist	T121	C1254351
contralateral	T082	C0441988
locus coeruleus	T023	C0023951
Footpad	T023	C2985236
inflammation	T046	C0021368
glutamate	T116	C0017789
contralateral	T082	C0441988
locus coeruleu	T023	C0023951
systemic	T169	C0205373
treatment	T169	C0039798
GCPII inhibitor	T121	C0014432
blocks	T169	C0332206
Direct	T080	C1947931
injection	T061	C0021485
GCPII inhibitors	T121	C0014432
contralateral	T082	C0441988
ipsilatera	T082	C0441989
locus coeruleus	T023	C0023951
inflammatory pain	T184	C0234251
response	T032	C0871261
dose-dependent	T081	C1512045
contralateral	T082	C0441988
effect	T080	C1280500
blocked	T169	C0332206
intrathecal injection	T061	C0021896
alpha 2 adrenergic receptor antagonist	T121	C0304513
hypothesis	T078	C1512571
analgesic efficacy	T033	C0948482
GCPII inhibitors	T121	C0014432
contralatera	T082	C0441988
locus coeruleus	T023	C0023951
group II mGluR	T116	C0532371
AMPA	T116	C1528634
alpha 2 adrenergic receptors	T116	C0001639
Association	T080	C0439849
physical activity	T056	C0026606
body composition	T032	C0005885
cardiometabolic risk factors	T033	C0035648
prevalence	T081	C0220900
cardiovascular disease	T047	C0007222
Korean population	T098	C1556095
Korea	T083	C0022771
national health and nutrition examination survey	T062	C0376344
Data	T078	C1511726
associations	T080	C0439849
physical activity	T056	C0026606
PA	T056	C0026606
level	T080	C0441889
body composition	T032	C0005885
prevalence	T081	C0220900
cardiovascular diseases	T047	C0007222
Asian populations	T081	C0032659
rare	T080	C0522498
International Physical Activity Questionnaire	T170	C0034394
IPAQ	T170	C0034394
estimate	T081	C0750572
PA	T056	C0026606
levels	T080	C0441889
analyze	T062	C0936012
association	T080	C0439849
PA	T056	C0026606
level	T080	C0441889
body composition	T032	C0005885
parameters	T077	C0549193
prevalence	T081	C0220900
cardiovascular diseases	T047	C0007222
data	T078	C1511726
Korean	T083	C0022771
National Health and Nutrition Examination Survey	T062	C0376344
Moderate	T080	C0205081
high	T080	C0205250
PA	T056	C0026606
levels	T080	C0441889
associated	T080	C0439849
lower prevalence	T081	C1518029
hypertension	T047	C0020538
diabetes mellitus	T047	C0011849
lower	T080	C0205251
concentrations	T081	C1446561
serum ferritin	T033	C4076066
parathyroid hormone	T033	C4314193
alkaline phosphatase	T033	C1860130
Sarcopenia	T047	C0872084
low	T080	C0205251
moderate	T080	C0205081
high	T080	C0205250
PA	T056	C0026606
group	T078	C0441833
p	T081	C1709380
underweight	T033	C0041667
central obesity	T033	C0311277
observed	T169	C1441672
low	T080	C0205251
PA	T056	C0026606
group	T078	C0441833
prevalence	T081	C0220900
rates	T081	C1521828
cardiovascular diseases	T047	C0007222
lower	T080	C0205251
moderate	T080	C0205081
odds ratio	T081	C0028873
OR	T081	C0028873
confidence interval	T081	C0009667
CI	T081	C0009667
p	T081	C1709380
high	T080	C0205250
activity	T056	C0026606
groups	T078	C0441833
OR	T081	C0028873
CI	T081	C0009667
p	T081	C1709380
low	T080	C0205251
activity	T056	C0026606
group	T078	C0441833
age	T032	C0001779
sex	T032	C0079399
smoking	T055	C0037369
underlying disease	T047	C0012634
general	T047	C0028754
abdominal obesity	T033	C0311277
muscle mass	T033	C0240417
Regular physical activity	UnknownType	C0815170
associated	T080	C0439849
low prevalence	T081	C1518029
cardiovascular diseases	T047	C0007222
stroke	T037	C0018843
myocardial infarction	T047	C0027051
stable angina	T047	C0340288
chronic renal disease	T047	C1561643
independent of	T169	C0332291
body composition	T032	C0005885
risk factors	T033	C0035648
Korean population	T098	C1556095
positive	T033	C1446409
dose-response relationship	T038	C0678790
Treated	T061	C0087111
Prevalence	T081	C0033105
Attention-Deficit/Hyperactivity Disorder	T048	C1263846
Increased	T081	C0205217
School-Aged Children	T100	C2827631
Adolescents	T100	C0205653
United States	T083	C0041703
purpose	T169	C1285529
describe	T078	C1552738
changes	T169	C0392747
treated	T061	C0087111
prevalence	T081	C0033105
medically	T169	C0205476
managed	T058	C0184516
attention-deficit/hyperactivity disorder	T048	C1263846
ADHD	T048	C1263846
insured	T170	C1548605
school-aged children	T100	C2827631
adolescents	T100	C0205653
United States	T083	C0041703
examine	T033	C0332128
differences	T081	C1705241
employer-sponsored insurance	T081	C3824871
ESI	T081	C3824871
Medicaid insurance	T058	C0021682
longitudinal	T082	C0205127
administrative datasets	T170	C0150098
medical	T169	C0205476
drug	T121	C0013227
claims	T058	C3824919
data	T078	C1511726
individuals	T098	C0237401
ESI	T081	C3824871
Medicaid insurance	T058	C0021682
Truven Health MarketScan(®) Administrative Claims Databases	T170	C0242356
Treated	T061	C0087111
prevalence	T081	C0033105
measured	T080	C0444706
percentage	T081	C0439165
school-aged children	T100	C2827631
adolescents	T100	C0205653
calendar year	T079	C0456586
criteria	T078	C0243161
medically	T169	C0205476
managed	T058	C0184516
ADHD	T048	C1263846
calendar year	T079	C0456586
Subjects	T098	C0080105
eligible	T080	C1548635
inclusion	T080	C1512693
aged	T032	C0001779
years	T079	C0439234
continuously	T078	C0549178
calendar year	T079	C0456586
annual	T079	C0332181
prevalence	T081	C0033105
treated	T061	C0087111
ADHD	T048	C1263846
school-aged children	T100	C2827631
adolescents	T100	C0205653
ESI	T081	C3824871
increased	T081	C0205217
Medicaid	T058	C0021682
increased	T081	C0205217
steady	T080	C0205361
Treated	T061	C0087111
prevalence	T081	C0033105
ADHD	T048	C1263846
increased	T081	C0205217
continuously	T078	C0549178
time	T079	C0040223
school-aged children	T100	C2827631
adolescents	T100	C0205653
ESI	T081	C3824871
declined	T081	C0205216
Medicaid sample	T058	C0021682
Acute	T079	C0205178
macular edema	T047	C0271051
peripapillary	T082	C0442163
soft	T080	C0205358
exudate	T031	C0015388
pancreas transplantation	T061	C0030275
accelerated	T169	C0521110
progression	T046	C0242656
diabetic retinopathy	T047	C0011884
pancreas transplantation	T061	C0030275
diabetic retinopathy	T047	C0011884
inconclusive	T080	C1629507
patients	T101	C0030705
type 1 diabetes mellitus	T047	C0011854
DM	T047	C0011854
pancreas transplantation	T061	C0030275
acute	T079	C0205178
macular edema	T047	C0271051
peripapillary	T082	C0442163
soft	T080	C0205358
exudate	T031	C0015388
rapid	T080	C0456962
progression	T046	C0242656
proliferative diabetic retinopathy	T047	C0154830
retrospective observational study	T062	C0035363
diabetic	T047	C0011847
patients	T101	C0030705
pancreas transplantation	T061	C0030275
single	T081	C0205171
medical center	T073	C0565990
symptomatic	T169	C0231220
acute	T079	C0205178
macular edema	T047	C0271051
peripapillary	T082	C0442163
soft	T080	C0205358
exudate	T031	C0015388
within	T082	C0332285
3 months	T079	C1442461
after	T079	C0687676
operation	T061	C0543467
complete	T080	C0205197
ophthalmic course	T079	C0449259
medical records	T170	C0025102
patients	T101	C0030705
retrospectively	T080	C1514923
reviewed	T080	C1709940
Diabetic retinopathy	T047	C0011884
progression	T046	C0242656
following	T079	C0332282
treatment	T061	C0087111
pancreas transplantation	T061	C0030275
measured	T080	C0444706
Chinese	T098	C0152035
women	T098	C0043210
type 1 DM	T047	C0011854
study	T062	C2603343
hemoglobin (Hb) A1c	T116	C0019018
transplantation	T061	C0030275
decreased	T081	C0205216
rapidly	T080	C0456962
within	T082	C0332285
2 months	T079	C1442456
postsurgery	T079	C0032790
patients	T101	C0030705
no	T169	C1518422
mild	T080	C2945599
pretransplant	T169	C0040733
diabetic retinopathy	T047	C0011884
acute	T079	C0205178
symptomatic	T169	C0231220
macular edema	T047	C0271051
peripapillary	T082	C0442163
soft	T080	C0205358
exudate	T031	C0015388
both eyes	T023	C0229118
pancreas transplantation	T061	C0030275
macular edema	T047	C0271051
resolved	T033	C3714811
without	T080	C0332288
treatment	T061	C0087111
cases	T169	C0868928
progressed	T046	C0242656
proliferative diabetic retinopathy	T047	C0154830
received	T080	C1709850
panretinal photocoagulation	T061	C0730064
Diabetic retinopathy	T047	C0011884
stable	T080	C0205360
all	T081	C0444868
eyes	T023	C0015392
after	T079	C0687676
treatment	T061	C0087111
visual	T169	C0234621
prognosis was good	T033	C0278250
except	T169	C0332300
one	T081	C0205447
eye	T023	C0015392
macular	T082	C0332574
branch retinal artery occlusion	T047	C0006123
foveal	T023	C0016622
involvement	T169	C1314939
Acute	T079	C0205178
macular edema	T047	C0271051
pancreas transplantation	T061	C0030275
favorable	T080	C3640814
treatment outcome	T080	C0085415
progression	T046	C0242656
proliferative diabetic retinopathy	T047	C0154830
High	T080	C0205250
pretransplant	T169	C0040733
HbA1c	T116	C0019018
abrupt	T080	C1276802
blood sugar	T109	C0005802
normalization	T169	C0205245
disease course	T046	C0242656
Anger	T041	C0002957
aggression	T055	C0001807
borderline personality disorder	T048	C0006012
attention deficit hyperactivity disorder	T048	C1263846
stress	T033	C0038435
impact	T080	C4049986
stress	T033	C0038435
anger	T041	C0002957
aggression	T055	C0001807
Borderline Personality Disorder	T048	C0006012
BPD	T048	C0006012
Attention Deficit Hyperactivity Disorder	T048	C1263846
ADHD	T048	C1263846
investigated	T169	C1292732
study	T062	C2603343
investigate	T169	C1292732
anger	T041	C0002957
aggression	T055	C0001807
patients	T101	C0030705
disorders	T047	C0012634
unmedicated	T033	C0243095
female	T032	C0086287
BPD	T048	C0006012
patients	T101	C0030705
ADHD	T048	C1263846
patients	T101	C0030705
healthy controls	T080	C2986479
HC	T080	C2986479
self-reports	T062	C2700446
measuring	T080	C0444706
trait	T032	C0599883
anger	T041	C0002957
aggression	T055	C0001807
emotion regulation	T041	C2370884
Point Subtraction Aggression Paradigm	T062	C0681797
state anger measurement	T062	C0242481
resting	T080	C0348080
stress conditions	T080	C0348080
Stress	T033	C0038435
induced	T169	C0205263
Mannheim Multicomponent Stress Test	T060	C3494508
MMST	T060	C3494508
patient	T101	C0030705
scored	T081	C0449820
self-report	T062	C2700446
measures	T080	C0444706
compared	T052	C1707455
HCs	T080	C2986479
Compared	T052	C1707455
ADHD	T048	C1263846
patients	T101	C0030705
BPD	T048	C0006012
patients	T101	C0030705
trait	T032	C0599883
aggression	T055	C0001807
hostility	T041	C0020039
anger	T041	C0002957
anger	T041	C0002957
BPD	T048	C0006012
patients	T101	C0030705
anger	T041	C0002957
HCs	T080	C2986479
ADHD	T048	C1263846
patients	T101	C0030705
stress-dependent	T169	C0205245
anger	T041	C0002957
behavioral level	T053	C0004927
BPD	T048	C0006012
patients	T101	C0030705
aggression	T055	C0001807
anger	T041	C0002957
emotion regulation	T041	C2370884
deficits	T080	C2987487
findings	T033	C0243095
impact	T080	C4049986
stress	T033	C0038435
anger	T041	C0002957
BPD	T048	C0006012
patients	T101	C0030705
aggressive behavior	T055	C0001807
females	T032	C0086287
BPD	T048	C0006012
ADHD	T048	C1263846
anger	T041	C0002957
clinical	T080	C0205210
importance	T080	C3898777
BPD	T048	C0006012
patients	T101	C0030705
Interferon gamma	T028	C1334085
interleukin 10	T028	C1334098
polymorphisms	T045	C0678951
Chinese	T098	C0152035
children	T100	C0008059
hemophagocytic lymphohistiocytosis	T047	C0024291
study	T062	C2603343
investigate	T169	C1292732
interferon gamma	T028	C1334085
IFN-γ	T028	C1334085
interleukin-10	T028	C1334098
IL-10	T028	C1334098
gene	T028	C0017337
single nucleotide polymorphisms	T086	C0752046
susceptibility	T201	C0012655
hemophagocytic lymphohistiocytosis	T047	C0024291
HLH	T047	C0024291
Chinese	T098	C0152035
children	T100	C0008059
without known family history of	T033	C0332123
HLH	T047	C0024291
children	T100	C0008059
HLH	T047	C0024291
age	T032	C0001779
gender	T032	C0079399
healthy controls	T080	C2986479
Xuzhou Children's Hospital	T073	C0019994
study	T062	C2603343
Serum	T031	C0229671
IFN-γ	T116	C3539881
IL-10	T116	C0085295
measured	T080	C0444706
enzyme linked-immunosorbent assay	T059	C0014441
Polymorphisms	T045	C0678951
IFN-γ gene	T028	C1334085
IL-10	T028	C1334098
analyzed	T033	C2963401
allele	T028	C0002085
specific	T080	C0205369
PCR	T063	C0032520
Median serum	T031	C0229671
concentrations	T081	C1446561
IFN -γ	T116	C3539881
IL-10	T116	C0085295
significantly higher	T081	C4055637
children	T100	C0008059
HLH	T047	C0024291
compared	T052	C1707455
healthy controls	T080	C2986479
frequencies	T079	C0439603
IFN-γ	T028	C1334085
T/A and T/T genotypes	T032	C0017431
T allele	T028	C0002085
significantly higher	T081	C4055637
HLH	T047	C0024291
compared	T052	C1707455
control group	T096	C0009932
frequencies	T079	C0439603
IL-10	T028	C1334098
G/A genotype	T032	C0017431
G allele	T028	C0002085
significantly increased	T081	C4055637
HLH	T047	C0024291
patients	T101	C0030705
compared	T052	C1707455
healthy controls	T080	C2986479
No significant	T033	C1273937
difference	T033	C3842396
distribution	T169	C1704711
IFN-γ	T028	C1334085
G/A genotypes	T032	C0017431
children	T100	C0008059
HLH	T047	C0024291
controls	T080	C0243148
study	T062	C2603343
presents	T033	C0150312
preliminary	T079	C0439611
evidence	T078	C3887511
IFN	T028	C1334085
T/A, T/T	T032	C0017431
IL-10	T028	C1334098
A/G genotypes	T032	C0017431
HLH	T047	C0024291
susceptibility	T201	C0012655
Chinese	T098	C0152035
children	T100	C0008059
HLH	T047	C0024291
Data	T078	C1511726
Implementation	T052	C1708476
Alarm	T074	C0336648
Reduction	T080	C0392756
Interventions	T061	C0184661
Cardiovascular Surgical ICU	T073	C0587446
Alarm fatigue	T033	C4035921
ICU	T073	C0021708
setting	T082	C3176918
documented	T058	C1301725
literature	T170	C0023866
ICU's	T073	C0021708
high-intensity	T185	C4081854
environment	T082	C0014406
staff's	T097	C0851286
vigilant	T041	C0043012
attention	T041	C0004268
distraction	T053	C4060717
false	T080	C0205237
alarms	T074	C0336648
staff	T097	C0851286
tasks	T057	C3540678
dissatisfaction	T041	C0870433
patient safety	T058	C1113679
risk	T078	C0035647
alarms	T074	C0336648
missed	T080	C1705492
ignored	T078	C1554079
patient safety	T058	C1113679
alarm	T074	C0336648
systems	T169	C0449913
cardiovascular surgical intensive care unit	T073	C0587446
CVSICU	T073	C0587446
examine	T033	C0332128
nurses	T097	C0028661
attitudes	T041	C0004271
clinical	T080	C0205210
alarm	T074	C0336648
signals	T067	C1710082
nurses	T097	C0028661
audible alarm	T073	C1706857
signals	T067	C1710082
implement	T052	C1708476
best practices	T078	C3179154
monitor alarm	T033	C2091666
reduction	T080	C0392756
patient safety	T058	C1113679
CVSICU	T073	C0587446
nurses	T097	C0028661
alarm	T074	C0336648
perception survey	T170	C0038951
alarm	T074	C0336648
discriminability testing	T169	C0039593
Nurse survey data	T170	C2361339
baseline	T081	C1442488
alarm	T074	C0336648
data	T078	C1511726
targeted	T169	C1521840
alarm	T074	C0336648
reduction	T080	C0392756
interventions	T061	C0184661
alarm	T074	C0336648
data	T078	C1511726
cardiorespiratory event	T033	C1320716
data	T078	C1511726
year	T079	C0439234
CVSICU	T073	C0587446
monitor alarm	T033	C2091666
pulse oximetry	T060	C0034108
heart rate	T201	C0018810
systolic	T033	C0277882
diastolic blood pressure	T047	C0235222
pulse oximetry	T060	C0034108
sensor	T073	C0183210
ventricular tachycardia	T047	C0042514
targeted	T169	C1521840
implementation	T052	C1708476
reduction	T080	C0392756
alarms	T074	C0336648
bed	T073	C0004916
cardiorespiratory events	T033	C1320716
reduce	T080	C0392756
alarm fatigue	T033	C4035921
decrease	T081	C0547047
alarm	T074	C0336648
burden	T078	C2828008
targeted	T169	C1521840
interventions	T061	C0184661
alarms	T074	C0336648
delays	T079	C0205421
alarm	T074	C0336648
self-correction	T169	C1947976
alarm	T074	C0336648
threshold	T080	C0449864
limits	T169	C0439801
alarm	T074	C0336648
notification	T058	C0422202
secondary device	T074	C0025080
teaching	T065	C0220924
staff	T097	C0851286
alarm	T074	C0336648
individual	T098	C0237401
patients	T101	C0030705
NCAM1 gene set	T028	C1334863
depressive symptoms	T184	C0086132
brain structural	T023	C0006104
correlates	T039	C0871083
healthy individuals	T098	C0237401
Depressive symptoms	T184	C0086132
depressive disorders	T048	C0011581
continuous spectrum	T059	C0037812
depressive symptoms	T184	C0086132
biological underpinnings	T033	C0243095
depression	T048	C0011570
Gene set enrichment analysis	T059	C0796344
GSEA	T059	C0796344
gene groups	T028	C0017337
complex traits	T032	C0678922
genome-wide association study	T063	C2350277
GWAS	T063	C2350277
data of depression scores	T033	C3483981
brain-level structural	T023	C0006104
correlates	T039	C0871083
healthy young individuals	T098	C0237401
symptom level	T033	C1319166
depression scores	T033	C3483981
robust	T080	C2986815
gene sets	T028	C0017337
NCAM1	T028	C1334863
Interactions	T045	C0596610
Collagen Formation	T044	C2246343
Depression scores	T033	C3483981
associated with	T080	C0332281
decreased	T081	C0205216
fractional anisotropy	T070	C0085406
FA	T070	C0085406
brain white matter property	T023	C0152381
within the forceps minor	T023	C0152325
left superior temporal longitudinal fasciculus	T023	C2337627
mean FA	T070	C0085406
depression score	T033	C3483981
associated voxels	T077	C2700259
phenotype	T032	C0031437
GSEA	T059	C0796344
NCAM1	T028	C1334863
Interactions	T045	C0596610
gene set	T028	C0017337
NCAM1	T028	C1334863
Interactions	T045	C0596610
gene set	T028	C0017337
depression scores	T033	C3483981
structural brain	T023	C0006104
correlates	T039	C0871083
healthy participants	T098	C1708335
molecular underpinnings	T033	C0243095
depressive symptomatology	T184	C0086132
HPV	T005	C0021344
diseases	T047	C0012634
Italy	T083	C0022277
Human papillomavirus (HPV) infection	T047	C0343641
cervical cancer	T191	C0007847
development	T169	C1527148
genital warts	T047	C1398518
cancer	T191	C0006826
penis	T023	C0030851
anus	T023	C0003461
head	T029	C0018670
neck	T029	C0027530
oropharynx	T029	C0521367
genitourinary system	T022	C0042066
study	T062	C2603343
evaluation	T169	C1292732
hospitalizations	T058	C0019993
HPV-related pathologies	T047	C0343641
Italy	T083	C0022277
national hospital discharge	T058	C0586003
forms	T073	C0376315
Ministry of Health	T093	C1274109
HPV	T005	C0021344
hospitalizations	T058	C0019993
diagnostic	T169	C0348026
codes	T170	C0805701
ICD-9-CM	T170	C1137112
coding system	T185	C2347818
hospitalizations	T058	C0019993
HPV-related pathologies	T047	C0343641
literature	T170	C0023866
evaluated	T169	C1292732
hospitalization rates	T081	C1521828
hr	T081	C1521828
trend	T079	C1521798
time	T079	C0040223
Uterine cervical cancer	T191	C0007847
CIN III	T191	C0851140
hospitalizations	T058	C0019993
hr	T081	C1521828
Head	T029	C0018670
neck	T029	C0027530
oropharynx	T029	C0521367
pathologies	T169	C1521733
cases	T169	C0868928
hr	T081	C1521828
males	T032	C0086582
females	T032	C0086287
genital warts	T047	C1398518
hospitalizations	T058	C0019993
hr	T081	C1521828
males	T032	C0086582
females	T032	C0086287
anal	T191	C0153446
hospitalizations	T058	C0019993
genitourinary	T191	C0751569
penis cancers	T191	C0153601
study	T062	C2603343
evaluation	T169	C1292732
hospitalizations	T058	C0019993
HPV-related pathologies	T047	C0343641
public health	T078	C0018684
issue	T033	C0033213
Italy	T083	C0022277
impact	T080	C4049986
population	T098	C1257890
discovery	T052	C1880355
potent	T080	C0205556
selective	T080	C0205556
kynurenine 3-monooxygenase	T116	C0064449
inhibitors	T121	C0014432
treatment	T061	C0087111
acute pancreatitis	T047	C0001339
series	T081	C0205549
potent	T080	C0205556
competitive	T080	C0205556
highly	T080	C0205250
selective	T080	C0205556
kynurenine monooxygenase	T116	C0064449
inhibitors	T121	C0014432
discovered	T052	C1880355
substrate	T167	C3891814
approach	T082	C0449445
treatment	T061	C0087111
acute pancreatitis	T047	C0001339
lead	T169	C1522538
compound	T103	C1706082
good	T080	C0205170
cellular	T025	C0007634
potency	T080	C0205556
pharmacodynamic	T038	C0851347
activity	T052	C0441655
in vivo	T082	C1515655
Draft Genome	T028	C0017428
Sequence	T086	C0314659
Providencia stuartii PS71	T007	C0315286
Multidrug-Resistant	T032	C0242640
Strain	T001	C1518614
Associated with	T080	C0332281
Nosocomial Infections	T047	C0205721
Greece	T083	C0018226
Providencia stuartii	T007	C0315286
frequently	T079	C0332183
associated with	T080	C0332281
nosocomial outbreaks	T047	C0205721
intrinsic	T082	C0205102
resistance	T169	C4281815
commonly	T081	C0205214
antimicrobials	T121	C1136254
draft genome	T028	C0017428
sequence	T086	C0314659
P. stuartii strain	T007	C0315286
acquired	T080	C0439661
resistance genes	T028	C2945710
panresistance	T169	C4281815
cephalosporins	T109	C3536856
blaSHV-5	T028	C0017337
blaVEB-1	T028	C0017337
carbapenems	T109	C0006968
blaVIM-1	T028	C0017337
aminoglycosides	T109	C0002556
rmtB	T028	C0017337
outbreak	T067	C0012652
Greek	T083	C0018226
hospitals	T073	C0019994
Impact	T080	C4049986
diabetic ketoacidosis	T047	C0011880
management	T058	C0376636
medical intensive care unit	T073	C2711734
order set	T170	C0282574
implementation	T052	C1708476
rate	T081	C1521828
compliance	T058	C0525058
ADA DKA guidelines	T170	C0162791
medical intensive care unit	T073	C2711734
MICU	T073	C2711734
academic medical centre	T073	C0000872
implementation	T052	C1708476
computerised DKA order set	T170	C0282574
protocol	T061	C0008971
Retrospective	T080	C1514923
chart review	T170	C0282443
adult patients	T101	C0030705
DKA	T047	C0011880
admitted	T058	C0809949
MICU	T073	C2711734
pre-order set	T170	C0282574
PRE	T170	C0282574
post-order set	T170	C0282574
POST	T170	C0282574
primary outcome	T169	C1274040
administration	T061	C1533734
intravenous fluid resuscitation	T061	C2317423
insulin	T116	C0021641
bolus	T061	C1511237
initial	T079	C0205265
insulin	T116	C0021641
infusion rate	T079	C2964135
patients	T101	C0030705
PRE group	UnknownType	C0681860
treatment	T061	C0087111
compliant	T080	C0566588
guidelines	T170	C0162791
patients	T101	C0030705
POST group	UnknownType	C0681860
OR	T081	C0028873
CI	T081	C0009667
Compliance	T058	C0525058
guidelines	T170	C0162791
significantly higher	T081	C4055637
POST group	UnknownType	C0681860
OR	T081	C0028873
CI	T081	C0009667
Compliance	T058	C0525058
fluid resuscitation	T061	C0150238
insulin	T116	C0021641
bolus	T061	C1511237
initial	T079	C0205265
insulin	T116	C0021641
infusion rate	T079	C2964135
Time	T079	C0040223
DKA	T047	C0011880
resolution	T077	C2699488
decreased	T081	C0205216
hypoglycaemia	T047	C0020615
increased	T081	C0205217
Implementation	T052	C1708476
computerised DKA order set	T170	C0282574
protocol	T061	C0008971
associated with	T080	C0332281
improved	T033	C0184511
compliance	T058	C0525058
ADA DKA guidelines	T170	C0162791
fluid resuscitation	T061	C0150238
initial	T079	C0205265
insulin	T116	C0021641
infusion rate	T079	C2964135
time	T079	C0040223
DKA	T047	C0011880
resolution	T077	C2699488
transition	T052	C2700061
subcutaneous	T082	C0443315
insulin	T116	C0021641
patients	T101	C0030705
POST implementation group	UnknownType	C0681860
hypoglycaemia	T047	C0020615
Acetylcholinesterase	T116	C0001044
Sensor	T075	C0600364
Synthesized Paramagnetic Nanoparticles	T130	C2713587
Neurotoxic Compounds	T131	C0260049
Assay	T059	C1510438
Magnetic particles	T130	C2713587
MPs	T130	C2713587
biological applications	T169	C0205245
molecules	T167	C0567416
immobilized	T067	C1254366
molecules	T167	C0567416
enzymes	T116	C0014442
Acetylcholinesterase	T116	C0001044
AChE	T116	C0001044
enzyme	T116	C0014442
neurotransmission	T043	C0027793
enzyme	T116	C0014442
targeted	T169	C1521840
molecules	T167	C0567416
Alzheimer's	T047	C0002395
drugs	T121	C1254351
pesticides	T131	C0031253
warfare agents	T109	C1113670
electrochemical biosensor	T075	C0600364
AChE	T116	C0001044
immobilized	T116	C0014444
MPs	T130	C2713587
stabilized	T033	C0184512
glutaraldehyde (GA) molecule	T109	C0017814
assay	T059	C1510438
neurotoxic compounds	T131	C0260049
prepared nanoparticles	T073	C1450054
modified by	T080	C0205349
pure AChE	T116	C0001044
measurement	T169	C0242485
anti-Alzheimer's	T033	C0243095
drug	T121	C1254351
galantamine	T109	C0016967
carbamate pesticide	T109	C0360422
carbofuran	T109	C0006995
limit	T078	C1549649
detection	T033	C0442726
measurements	T169	C0242485
screen-printed sensor	T075	C0600364
carbon	T196	C0007009
working	T074	C0013812
silver	T196	C0037125
reference	T074	C4067887
carbon	T196	C0007009
auxiliary electrode	T074	C0013812
Standard Ellman's assay	T059	C1510438
validation	T062	C1519941
measurement	T169	C0242485
inhibitors	T120	C0243077
elimination	T052	C1883720
reversible	T169	C0205343
inhibitors	T120	C0243077
galantamine	T109	C0016967
active site	T169	C0205681
AChE	T116	C0001044
lower	T052	C2003888
pH	T081	C0020283
original	T078	C0205313
activity	T052	C0441655
AChE	T116	C0001044
inhibition	T052	C3463820
galantamine	T109	C0016967
observed	T169	C1441672
decarbamylation	T067	C1254366
AChE	T116	C0001044
carbofuran	T109	C0006995
adduct	T104	C0596040
organic solvents	T109	C0360100
AChE	T116	C0001044
measurement	T169	C0242485
MPs	T130	C2713587
AChE	T116	C0001044
Alanine Aminotransferase	T116	C0001899
Marker	T201	C0005516
Lipotoxicity	T047	C0039082
Consequences	T169	C0686907
Hyperandrogenemia	T033	C1299574
Women	T098	C0043210
Polycystic Ovary Syndrome	T047	C0032460
studies	T062	C2603343
Alanine aminotransferase	T116	C0001899
ALT	T116	C0001899
women	T098	C0043210
polycystic ovary syndrome	T047	C0032460
PCOS	T047	C0032460
control subjects	T096	C0009932
Plasma ALT levels	T059	C1272112
marker	T201	C0005516
hepatic	T029	C0205054
lipotoxicity	T047	C0039082
hepatic	T029	C0205054
hepatic steatosis	T047	C0015695
hepatic	T029	C0205054
insulin resistance	T046	C0021655
Retrospective chart	T170	C0282574
PCOS	T047	C0032460
women	T098	C0043210
ALT levels	T059	C1272112
lipotoxicity	T047	C0039082
consequences	T169	C0686907
fasting	T059	C0428568
oral glucose tolerance test	T060	C0029161
Women	T098	C0043210
PCOS	T047	C0032460
years	T079	C0439234
age	T032	C0001779
body mass index	T201	C1305855
metabolic syndrome	T047	C0039082
MetS	T047	C0039082
ALT levels	T059	C1272112
homeostatic model assessment for insulin resistance	T059	C3639411
HDL-C	T109	C0023822
Matsuda index	T170	C0918012
insulin secretion-sensitivity index-2	T060	C0430022
free testosterone	T109	C0443483
fasting glucose	T034	C1261430
triglyceride levels	T034	C0428475
ALT	T116	C0001899
fasting glucose	T034	C1261430
triglyceride levels	T034	C0428475
women	T098	C0043210
MetS	T047	C0039082
whole-body insulin resistance	T046	C0021655
Matsuda index	T170	C0918012
Plasma ALT levels	T059	C1272112
predictor	T078	C2698872
liver	T023	C0023884
lipotoxicity	T047	C0039082
systemic lipotoxic	T047	C0039082
consequences	T169	C0686907
hyperandrogenemia	T033	C1299574
women	T098	C0043210
PCOS	T047	C0032460
validation	T062	C1519941
study	T062	C2603343
ALT	T116	C0001899
clinicians	T097	C0871685
women	T098	C0043210
metabolic risks	T201	C2321263
Opioid	T109	C0242402
Chronic Pain	T184	C0150055
Patients	T101	C0030705
Chronic Kidney Disease	T047	C1561643
Systematic Review	T170	C1955832
prevalence	T081	C0220900
chronic pain	T184	C0150055
opioid	T109	C0242402
management	T058	C1611232
patients	T101	C0030705
chronic kidney disease	T047	C1561643
CKD	T047	C1561643
Systematic review	T170	C1955832
methodological quality assessment	UnknownType	C0815254
studies	T170	C0085973
prevalence	T081	C0220900
pain	T184	C0030193
type	T080	C0332307
dose	T081	C0678766
opioid	T109	C0242402
effectiveness	T080	C1280519
pain control	T061	C1304888
adverse effects	T046	C0879626
opioids	T109	C0242402
CKD	T047	C1561643
patients	T101	C0030705
inclusion criteria	T080	C1512693
randomized controlled trials	T062	C0282440
RCT	T062	C0282440
observational studies	T170	C3658316
studies	T170	C0085973
high	T080	C0205250
quality	T080	C0332306
moderate	T081	C0439536
quality	T080	C0332306
low	T080	C0205251
quality	T080	C0332306
studies	T170	C0085973
studies	T170	C0085973
countries	T083	C0454664
sample size	T081	C0242618
studies	T170	C0085973
prevalence	T081	C0220900
chronic	T079	C0205191
uncontrolled pain	T184	C0747149
opioids	T109	C0242402
dose	T081	C0678766
duration	T081	C0920470
prescribed	T058	C0278329
opioids	T109	C0242402
studies	T170	C0085973
systematic review	T170	C1955832
prevalence	T081	C0220900
chronic pain	T184	C0150055
patients	T101	C0030705
CKD	T047	C1561643
underprescription	UnknownType	C0679863
analgesics	T109	C0002771
opioids	T109	C0242402
CKD	T047	C1561643
population	T081	C2361270
Clinicians	T097	C0871685
randomized control trials	T062	C0282440
opioid	T109	C0242402
therapy	T061	C0087111
opioid	T109	C0242402
doses	T081	C0678766
dosing	T081	C0678766
intervals	T079	C0031084
adequacy	T080	C0814633
symptom control	T061	C1274136
adverse side effects	T046	C0879626
Cognitive impairment	T048	C0338656
first-episode	T079	C0439615
drug-naïve patients	T101	C0030705
schizophrenia	T048	C0036341
Relationships	T080	C0439849
serum concentrations	T081	C0683149
brain-derived neurotrophic factor	T116	C0107103
glial cell line-derived neurotrophic factor	T116	C0207072
brain-derived neurotrophic factor	T116	C0107103
BDNF	T116	C0107103
glial cell line -derived neurotrophic factor	T116	C0207072
GDNF	T116	C0207072
regulation of synaptic plasticity	T042	C1326639
cognitive processes	T041	C0871689
psychiatric disorders	T048	C0004936
associations	T080	C0439849
serum	T031	C0229671
BDNF	T116	C0107103
GDNF	T116	C0207072
cognitive functions	T041	C0392335
first-episode drug-naïve (FEDN) patients	T101	C0030705
schizophrenia	T048	C0036341
BDNF	T116	C0107103
GDNF	T116	C0207072
FEDN patients	T101	C0030705
age	T032	C0001779
sex	T032	C1522384
healthy controls	T080	C2986479
test subjects	T096	C0681850
neurocognitive tests	T060	C0872227
verbal fluency test	T060	C0033905
VFT	T060	C0033905
trail making test	T170	C0040604
TMT	T170	C0040604
digit span test	T170	C0451577
DST	T170	C0451577
Stroop test	T060	C2718024
Patients	T101	C0030705
controls	T096	C0009932
neurocognitive performances	T060	C0872227
DST	T170	C0451577
BDNF	T116	C0107103
levels	T080	C0441889
TMT-part B scores	T080	C0237855
VFT-action	T060	C0033905
GDNF	T116	C0207072
levels	T080	C0441889
VFT-action scores	T080	C0237855
TMT-part B scores	T080	C0237855
patients	T101	C0030705
cognitive dysfunction	T048	C0338656
early stages	T079	C2363430
schizophrenia	T048	C0036341
BDNF	T116	C0107103
GDNF	T116	C0207072
pathological	T169	C1521733
mechanisms	T169	C0441712
cognitive impairment	T048	C0338656
FEDN patients	T101	C0030705
schizophrenia	T048	C0036341
Comprehensive	T080	C1880156
functional analysis	T062	C0936012
genes	T028	C0017337
proteins	T116	C0033684
interpretation	T170	C0459471
high dimensional datasets	T170	C0150098
genomic	T062	C0681814
proteomic experiments	T062	C0681814
ClueGO software	T073	C0037585
Cytoscape App	T170	C3658280
biological	T080	C0205460
information	T078	C1533716
genes	T028	C0017337
proteins	T116	C0033684
functional enrichment analysis	T062	C0936012
data	T078	C1511726
annotation	T170	C1706814
ontology	T090	C1518584
resources	T078	C0035201
automatically	T169	C0205554
accessed	T082	C0444454
ClueGO	T073	C0037585
Predefined settings	T170	C4281677
selection	T052	C1707391
terms	T078	C1705313
analysis	T062	C0936012
Results	T169	C1274040
networks	T169	C1882071
Gene Ontology	T170	C1138831
GO	T170	C1138831
pathways	T077	C1705987
species	T185	C1705920
ClueGO	T073	C0037585
organisms	T001	C0029235
ClueGO	T073	C0037585
CluePedia App	T170	C3658280
protein-protein interactions	T044	C0872079
pathways	T077	C1705987
Management	T061	C1536570
precipitated opiate withdrawal syndrome	T048	C3274502
induced	T169	C0205263
nalmefene	T109	C0068377
prescribed	T058	C0278329
opiate	T121	C0376196
dependent patients	T169	C0581116
review	T170	C0282443
clinicians	T097	C0871685
Nalmefene	T109	C0068377
long-acting µ-opioid antagonist	T121	C3536879
approved	T080	C0205540
treat	T169	C1522326
alcohol use disorder	T048	C0001956
occasionally	T079	C1998882
prescribed	T058	C0278329
opiate	T121	C0376196
dependent	T169	C0581116
opioid	T109	C0242402
treated	T169	C1522326
patients	T101	C0030705
review	T078	C1552617
literature	T170	C0023866
drug-drug interactions	T044	C0687133
nalmefene	T109	C0068377
opioids	T109	C0242402
precipitated opioid withdrawal	T048	C0029104
management	T061	C1536570
planning	T169	C1301732
care	T058	C0017313
discharge	T058	C0030685
comprehensive review	T058	C3494708
precipitated opioid withdrawal syndrome	T048	C3274502
nalmefene	T109	C0068377
associated with	T080	C0332281
opioid	T109	C0242402
misused	T033	C1997897
legally	T169	C1301860
prescribed	T058	C0278329
Expert opinion	T077	C0600219
treating	T169	C1522326
opiate	T121	C0376196
dependent patient	T169	C0581116
alcohol use disorder	T048	C0001956
conditions	T080	C0348080
clinical attention	T080	C0205210
New	T080	C0205314
drugs	T121	C0013227
alcohol use disorder	T048	C0001956
approved	T080	C0205540
potential	T080	C3245505
drug-drug interactions	T044	C0687133
opioid	T109	C0242402
medications	T170	C4284232
Opiate	T121	C0376196
dependent patients	T169	C0581116
risk factors	T033	C0035648
alcohol use disorder	T048	C0001956
treatment maintenance	T061	C0814469
nalmefene	T109	C0068377
administered	T058	C0806914
opiate	T121	C0376196
dependent patients	T169	C0581116
acute	T079	C0205178
opioid withdrawal syndrome	T048	C3274502
occur	T052	C1709305
Management	T061	C1536570
acute	T079	C0205178
opioid withdrawal	T048	C0029104
include	T052	C2700399
long-acting µ-opioid agonists	T044	C1373059
hospitalization	T058	C0019993
supportive treatment	T061	C0344211
management	T058	C1610129
polydrug abusers	T033	C0556390
multidisciplinary approach	T060	C0729737
improved	T033	C0184511
through	T169	C0332273
continuing medical education	T078	C1553904
residues	T077	C1709915
dengue virus	T005	C0011315
NS2b-NS3-protease	T116	C1612175
binding sites	T192	C0005456
antiviral inhibitors	UnknownType	C0042771
NS2B-NS3 protease	T116	C1612175
Dengue Virus	T005	C0011315
DENV	T005	C0011315
replication process	T045	C1514849
complex	T026	C1167179
target	T169	C1521840
antiviral	T121	C0003451
discovery	T052	C1880355
drug	T121	C1254351
viral polyprotein processing	T043	C1159314
protease	T116	C1947941
conserved	T086	C0009802
Dengue virus	T005	C0011315
serotypes	T170	C0449943
drug	T121	C1254351
influential	T078	C0021399
residues	T077	C1709915
Dengue	T005	C0011315
NS2b-NS3 Protease	T116	C1612175
protein	T116	C0033684
influential	T078	C0021399
residues	T077	C1709915
non-competitive inhibitor	UnknownType	C0815027
development	T169	C1527148
computational	T091	C0376528
alanine	T116	C0001898
scanning mutagenesis	T063	C1517890
sequence	T086	C0314659
structure conservation	T086	C0009802
structure	T082	C0678594
characteristics	T080	C1521970
multilayer perceptron model	T170	C0870951
groups	T078	C0441833
residues	T077	C1709915
binding sites	T192	C0005456
DENV	T005	C0011315
protease	T116	C1947941
residues	T077	C1709915
amino acids	T116	C0002520
beta sheet	T082	C0162806
beta sheet	T082	C0162806
closed conformation	T082	C0033625
NS2b	T116	C1612175
residues	T077	C1709915
active site	T169	C0205681
residues	T077	C1709915
NS2b-NS3	T116	C1612175
residues	T077	C1709915
stability	T080	C0205360
protease	T116	C1947941
residues	T077	C1709915
amino acids	T116	C0002520
peptide	T116	C0030956
vaccine development	T062	C0597634
Association	T080	C0439849
Toll-Like Receptor 4	T116	C1411976
Human	T016	C0086418
Monocyte	T025	C0026473
Subsets	T185	C1515021
Vulnerability	T033	C1821973
Characteristics	T080	C1521970
Coronary	T023	C0018787
Plaque	T033	C0332461
Assessed	T052	C1516048
64-Slice Multidetector Computed Tomography	T060	C3179130
Toll-like receptor 4	T116	C1411976
TLR-4	T116	C1411976
monocyte activation	T043	C1155075
patients	T101	C0030705
accelerated	T169	C0521110
atherosclerosis	T047	C0004153
relationship	T080	C0439849
expression	T045	C0597360
TLR-4	T116	C1411976
circulating	T169	C0175630
monocyte	T025	C0026473
coronary	T023	C0018787
plaque	T033	C0332461
vulnerability	T033	C1821973
evaluated	T058	C0220825
relationship	T080	C0439849
64-slice multidetector computed tomography	T060	C3179130
MDCT	T060	C3179130
patients	T101	C0030705
stable angina pectoris	T047	C0340288
SAP	T047	C0340288
patients	T101	C0030705
SAP	T047	C0340288
MDCT	T060	C3179130
monocyte	T025	C0026473
subsets	T185	C1515021
CD14(++)CD16(-)	T025	C0026473
CD14(++)CD16(+)	T025	C0026473
CD14(+)CD16(+)	T025	C0026473
expression	T045	C0597360
TLR-4	T116	C1411976
flow cytometry	T059	C0016263
Intracoronary	T023	C0018787
plaques	T033	C0332461
assessed	T052	C1516048
64-slice MDCT	T060	C3179130
vulnerability	T033	C1821973
intracoronary	T023	C0018787
plaques	T033	C0332461
positive remodeling	T046	C3854505
remodeling index	T033	C0243095
CT	T060	C0040405
attenuation	T081	C2986722
circulating	T169	C0175630
CD14(++)CD16(+)monocytes	T025	C0026473
expressed	T045	C0597360
TLR-4	T116	C1411976
CD14(++)CD16(-)	T025	C0026473
CD14(+)CD16(+)monocytes	T025	C0026473
expression	T045	C0597360
TLR-4	T116	C1411976
CD14(++)CD16(+)monocytes	T025	C0026473
patients	T101	C0030705
vulnerable plaque	T033	C0332461
TLR-4	T116	C1411976
expression	T045	C0597360
CD14(++)CD16(+)monocytes	T025	C0026473
correlated	T080	C1707520
remodeling index	T033	C0243095
correlated	T080	C1707520
CT	T060	C0040405
attenuation value	T081	C2986722
Upregulation	T044	C0949479
TLR-4	T116	C1411976
CD14(++)CD16(+)monocytes	T025	C0026473
associated with	T080	C0332281
coronary	T023	C0018787
plaque	T033	C0332461
vulnerability	T033	C1821973
patients	T101	C0030705
SAP	T047	C0340288
Delta-frequency	T033	C0429299
stimulation	T070	C1948023
cerebellar	T023	C0007765
projections	T082	C0348018
compensate	T080	C0205432
schizophrenia	T048	C0036341
medial frontal dysfunction	T048	C4062322
Schizophrenia	T048	C0036341
abnormalities	T033	C1704258
medial frontal cortex	T023	C0016733
cognitive deficits	T048	C0009241
investigate	T169	C1292732
novel	T080	C0205314
strategy	T041	C0679199
normalize	T062	C1882115
medial frontal brain	T024	C2951740
activity	T039	C0443158
stimulating	T070	C1948023
cerebellar	T023	C0007765
projections	T082	C0348018
interval timing	T079	C0872291
study	T062	C2603343
cognitive processing	T041	C0025361
frontal	T023	C0016733
cerebellar networks	T023	C2953133
disrupted	T080	C0332454
patients	T101	C0030705
schizophrenia	T048	C0036341
novel	T080	C0205314
findings	T033	C0243095
patients	T101	C0030705
schizophrenia	T048	C0036341
delta rhythms	T042	C0011227
medial frontal cortex	T023	C0016733
cerebellar	T023	C0007765
frontal	T023	C0016733
interactions	T169	C1704675
animal models	T008	C0599779
frontal	T023	C0016733
cerebellar neurons	T025	C0682702
modulated	T082	C0443264
interval timing	T079	C0872291
delta-frequency	T033	C0429299
interactions	T169	C1704675
delta-frequency	T033	C0429299
optogenetic	T063	C3494301
stimulation	T070	C1948023
thalamic	T023	C0039729
synaptic terminals	T026	C0206181
lateral	T082	C0205093
cerebellar	T023	C0007765
projection	T082	C0348018
neurons	T025	C0027882
medial frontal	T024	C2951740
activity	T039	C0443158
rodent model	T050	C1519106
schizophrenia-related	T048	C0036341
frontal dysfunction	T048	C4062322
data	T078	C1511726
cerebellum	T023	C0007765
influences	T077	C4054723
medial frontal networks	T029	C4248854
cerebellum	T023	C0007765
cognitive processing	T041	C0025361
Variables	T080	C0439828
associated with	T080	C0332281
unplanned	T080	C0205556
general adult	T100	C0001675
ICU admission	T058	C0583239
hospitalised patients	T101	C0870668
protocol	T170	C0442711
systematic	T169	C0220922
review	T078	C1552617
Failure	T169	C0231175
identify	T080	C0205396
deterioration	T067	C0868945
hospitalised patients	T101	C0870668
associated with	T080	C0332281
delayed	T079	C0205421
admission to intensive care units	T058	C0583239
ICUs	T073	C0021708
poor	T080	C2700379
outcomes	T080	C0085415
Existing	T077	C2987476
vital sign	T201	C0518766
Early Warning Score	T081	C0449820
(EWS)	T081	C0449820
algorithms	T170	C0002045
sufficiently	T080	C0205410
high	T080	C0205250
positive	T077	C3812269
predictive value	T080	C1514307
automated	T169	C0205554
activation	T052	C1879547
ICU	T073	C0021708
outreach team	T097	C0586969
Incorporating	T169	C0332257
patient data	T170	C2707520
improve	T033	C0184511
predictive	T080	C0681890
power	T081	C3854080
EWS	T081	C0449820
algorithms	T170	C0002045
currently	T079	C0521116
patient data	T170	C2707520
variables	T080	C0439828
predictive	T080	C0681890
ICU admission	T058	C0583239
protocol	T170	C0442711
systematic	T169	C0220922
review	T078	C1552617
variables	T080	C0439828
associated with	T080	C0332281
ICU admission	T058	C0583239
MEDLINE	T170	C0242356
EMBASE	T170	C0242356
CINAHL	T170	C0242356
Cochrane Library	T170	C0242356
including	T169	C0332257
Cochrane Database of Systematic Reviews	T170	C0242356
Cochrane Central Register of Controlled Trials	T170	C0282574
(CENTRAL)	T170	C0282574
searched	T052	C1706202
studies	T062	C2603343
assess	T058	C0184514
association	T080	C0439849
routinely	T080	C0205547
recorded	T170	C0034869
variables	T080	C0439828
associated with	T080	C0332281
subsequent	T079	C0332282
unplanned	T080	C0205556
ICU admission	T058	C0583239
studies	T062	C2603343
involving	T169	C1314939
adult	T100	C0001675
patients	T101	C0030705
admitted to	T058	C0184666
general	T082	C0205246
ICUs	T073	C0021708
included	T169	C0332257
extract	T080	C0849355
data	T078	C1511726
relating to	T080	C0332281
statistical association	T062	C0010101
ICU admission	T058	C0583239
predictor	T078	C0681842
variables	T080	C0439828
quality	T080	C0332306
studies	T062	C2603343
generalisability	T082	C0205246
findings	T033	C0243095
results	T169	C1274040
review	T078	C1552617
aid	T080	C1269765
development	T169	C1527148
models	T170	C3161035
predict	T078	C0681842
risk	T078	C0035647
unplanned	T080	C0205556
ICU admission	T058	C0583239
Diagnosis	T033	C0011900
retinal	T023	C0035298
health	T078	C0018684
digital fundus images	T060	C0200189
continuous wavelet transform	T062	C2936326
CWT	T062	C2936326
entropies	T067	C0376522
Vision	T040	C0042789
humans	T016	C0086418
personal	T032	C1519021
professional life	T090	C2698884
prevalence	T081	C0220900
ocular diseases	T047	C0015397
diseases	T047	C0012634
glaucoma	T047	C0017601
Diabetic Retinopathy	T047	C0011884
DR	T047	C0011884
Age-related Macular Degeneration	T047	C0242383
AMD	T047	C0242383
leading	T169	C1522538
causes	T169	C0015127
blindness	T033	C0456909
developed countries	T080	C0282613
diseases	T047	C0012634
mass screening programmes	T058	C0024870
time-consuming	T080	C3827829
labor	T057	C0043227
diagnosis	T033	C0011900
subjective	T080	C0439655
automated computer aided diagnosis system	T060	C0011905
analysis	T062	C0936012
inter-observer subjective variabilities	T081	C0021713
image interpretation	T060	C0020910
automatic	T169	C0205554
classification	T185	C0008902
normal	T080	C0205307
abnormal	T033	C0205161
DR	T047	C0011884
AMD	T047	C0242383
glaucoma	T047	C0017601
images	T070	C0237660
normal	T080	C0205307
abnormal	T033	C0205161
fundus images	T060	C0200189
database	T170	C0242356
2D-Continuous Wavelet Transform	T062	C2936326
CWT	T062	C2936326
fundus images	T060	C0200189
energy	T081	C1442080
entropies	T067	C0376522
images	T070	C0237660
sampling approach	T170	C0449370
normal	T080	C0205307
abnormal	T033	C0205161
datasets	T170	C0150098
Particle Swarm Optimization	T170	C0282574
PSO	T170	C0282574
stratified	T080	C0205363
cross validation	T062	C0681935
performance rate	T081	C3533080
sensitivity	T081	C0036667
specificity	T081	C0037791
abnormal	T033	C0205161
fundus images	T060	C0200189
eye	T023	C0015392
health	T078	C0018684
screening tool	T058	C0220908
polyclinics	T073	C0442592
workload	T081	C0085122
specialists	T097	C1611835
hospitals	T073	C0019994
epigenetic landscape	T045	C1516924
age	T032	C0001779
related	T169	C1552599
diseases	T047	C0012634
geroscience	T090	C1518533
perspective	T078	C1254370
review	T170	C0282443
epigenetics	T045	C1516924
age	T032	C0001779
related	T169	C1552599
diseases	T047	C0012634
studies	T062	C0008972
DNA methylation landscape	T044	C0376452
cardio-vascular diseases	T047	C0007222
musculoskeletal function	T042	C0026861
frailty	T033	C0424594
conceptual framework	T077	C1254372
geroscience	T090	C1518533
advanced	T098	C0001792
age	T032	C0001779
risk factor	T033	C0035648
pathologies	T169	C0205469
aims	T078	C1947946
mechanistic links	T080	C0439849
aging	T040	C0001811
age	T032	C0001779
related	T169	C1552599
diseases	T047	C0012634
DNA methylation	T044	C0376452
remodeling	UnknownType	C0678692
aging	T040	C0001811
global hypomethylation	T045	C2613367
genome	T028	C0017428
hypermethylation	T045	C1512554
specific	T080	C0205369
loci	T028	C0678933
increase	T169	C0442805
inter-individual variation	T070	C0042333
stochastic	T081	C0038347
changes	T169	C0392747
DNA methylation	T044	C0376452
values	T080	C0042295
epigenetic	T045	C1516924
modifications	T033	C3840684
development	T169	C1527148
age	T032	C0001779
related	T169	C1552599
diseases	T047	C0012634
complex	T080	C0439855
relationship	T080	C0439849
epigenetic signatures	T045	C1516924
aging	T040	C0001811
age	T032	C0001779
related	T169	C1552599
disease	T047	C0012634
relevant	T080	C2347946
results	T033	C2825142
epigenetics clocks	T045	C1516924
cohorts	T098	C0599755
subjects	T098	C0080105
affected	T169	C0392760
age	T032	C0001779
related	T169	C1552599
diseases	T047	C0012634
studies	T062	C0008972
review	T170	C0282443
Beneficial Effects	T080	C1280500
Phyllanthus amarus	T002	C0950041
High Fructose Diet	T168	C0012155
Insulin Resistance	T046	C0021655
Hepatic Oxidative Stress	T049	C0242606
Male	T032	C0086582
Wistar Rats	T015	C0034716
Insulin resistance	T046	C0021655
IR	T046	C0021655
obesity	T047	C0028754
type 2 diabetes mellitus	T047	C0011860
cardiovascular diseases	T047	C0007222
high-fructose	T109	C0016745
consumption	T039	C1947907
potential	T080	C3245505
factor	T169	C1521761
rising incidence	T169	C0220888
IR	T046	C0021655
study	T062	C2603343
investigates	T169	C1292732
beneficial effects	T080	C1280500
aqueous extract	T167	C2828366
Phyllanthus amaru	T002	C0950041
PAAE	T167	C2828366
IR	T046	C0021655
oxidative stress	T049	C0242606
high-fructose	T109	C0016745
HF	T109	C0016745
male	T032	C0086582
Wistar rats	T015	C0034716
HF diet	T168	C0012155
PAAE	T167	C2828366
concurrently	T079	C0205420
rats	T015	C0034716
Fructose-fed	T080	C0205556
rats	T015	C0034716
weight gain	T033	C0043094
hyperglycemia	T047	C0020456
hyperinsulinemia	T047	C0020459
impaired glucose tolerance	T047	C0271650
impaired insulin sensitivity	T046	C0920563
dyslipidemia	T047	C0242339
hyperleptinemia	T047	C0012634
hypoadiponectinemia	T047	C2675519
Co-administration	T061	C1533734
PAAE	T167	C2828366
HF diet	T168	C0012155
alterations	T078	C1515926
hepatic	T029	C0205054
antioxidant status	T044	C1148564
lipid peroxidation	T044	C0023775
protein oxidation	T044	C1159301
reduced glutathione	T034	C0034917
lower activities	T038	C3890174
enzymatic antioxidants	T121	C0003402
histopathological changes	T169	C0243140
distortion	T080	C2919017
liver sinusoids	T023	C0227523
HF diet	T168	C0012155
rats	T015	C0034716
PAAE	T167	C2828366
treatment	T061	C0087111
PAAE	T167	C2828366
insulin sensitivity	T046	C0920563
metabolic syndrome	T047	C0025517
hepatic oxidative stress	T049	C0242606
fructose-fed	T080	C0205556
rats	T015	C0034716
Environmental factors	T169	C1516998
hypertension	T047	C0020538
Environmental factors	T169	C1516998
poor health	T033	C0683321
worldwide	T098	C2700280
evidence	T078	C3887511
air pollution	T069	C0001873
disability-adjusted life years	UnknownType	C4300518
Outdoor	UnknownType	C0680182
temperature	T081	C0039476
seasonal	T079	C0036497
climate changes	T070	C2718051
cardiovascular	T029	C3887460
health	T078	C0018684
air pollution	T069	C0001873
evidence	T078	C3887511
environmental exposure	T037	C0014412
noise	T067	C0028263
poor cardiovascular outcome	T033	C0243095
hypertension	T047	C0020538
evidence	T078	C3887511
environmental factors	T169	C1516998
cardiovascular disease	T047	C0007222
hypertension	T047	C0020538
impact	T080	C4049986
air pollution	T069	C0001873
short-term	T079	C0443303
long-term effects	T067	C0023983
outdoor	UnknownType	C0680182
temperature	T081	C0039476
noise pollution	T069	C0686918
People	T098	C0027361
low	T080	C0205251
social classes	T080	C0037402
children	T100	C0008059
women	T098	C0043210
older people	T098	C3826770
cardiovascular diseases	T047	C0007222
susceptibility	T169	C1264642
effects	T080	C1280500
environmental stressors	T033	C0596519
concept	T078	C0178566
environmental justice	T078	C1254370
evidence	T078	C3887511
public health policies	T064	C0680811
social inequalities	T080	C0680381
cardiovascular	T029	C3887460
health	T078	C0018684
effects of	T080	C1704420
probiotic	T007	C0525033
synbiotic	T168	C2936470
supplementation	T061	C0242296
metabolic syndrome	T047	C0524620
indices	T078	C0010439
adults	T100	C0001675
risk	T078	C0035647
type 2 diabetes	T047	C0011860
study protocol	T170	C1507394
randomized controlled trial	T062	C0206035
incidence	T081	C0021149
type 2 diabetes	T047	C0011860
cardiovascular diseases	T047	C0007222
obesity	T047	C0028754
rising	T169	C0442805
pathogenesis	T046	C0699748
intriguing	T041	C0543488
dysbiosis	T046	C3658208
intestinal microbiota	T001	C2985398
new	T080	C0205314
candidate	T078	C0392360
metabolic diseases	T047	C0025517
intestinal microbiota	T001	C2985398
probiotic	T007	C0525033
synbiotic	T168	C2936470
supplementation	T061	C0242296
may improve	T080	C1272747
metabolic dysfunction	T047	C0025517
prevent	T080	C0392756
diabetes	T047	C0011847
prediabetics	T047	C0362046
study	T062	C2603343
synthesis	T052	C1883254
study	T062	C2603343
synbiotics	T168	C2936470
carried	T052	C0206243
Iran	T083	C0022065
randomized triple-blind controlled clinical trial	T062	C0206035
adults	T100	C0001675
impaired glucose tolerance	T047	C0271650
inclusion criteria	T080	C1512693
selected	T052	C1707391
random	T080	C0439605
sampling method	T170	C0449370
randomly	T080	C0439605
allocated	T052	C1706778
months	T079	C0439231
probiotic	T007	C0525033
synbiotic	T168	C2936470
placebo	T122	C1696465
fecal	T031	C0015733
abundance	T080	C2346714
bacteria	T007	C0004611
blood pressure	T040	C0005823
height	T032	C0489786
weight	T032	C0005910
waist	T201	C0455829
hip circumferences	T201	C0562350
measured	T080	C0444706
baseline	T081	C1442488
following	T079	C0332282
treatment	T061	C0087111
plasma lipid profiles	T059	C0850354
HbA1C	T116	C0019018
fasting plasma glucose	T059	C0583513
insulin	T116	C0021641
levels	T080	C0441889
measured	T080	C0444706
insulin resistance	T059	C4049994
HOMA-IR	T059	C4049994
beta-cell function	T059	C4055385
HOMA-B	T059	C4055385
calculated	T052	C1441506
baseline	T081	C1442488
repeated	T169	C0205341
months	T079	C0439231
data	T078	C1511726
compared	T052	C1707455
groups	UnknownType	C0681860
using	T169	C1524063
statistical methods	T062	C1710191
results	T169	C1274040
trial	T062	C0206035
contribute	T052	C1880177
evidence-based clinical guidelines	T170	C0282451
gut microbiota	T001	C2985398
manipulation	T061	C0087111
maximize	T169	C0442805
health benefits	T081	C0086387
prevention	T061	C0199176
management	T058	C0376636
metabolic syndrome	T047	C0524620
prediabetes	T047	C0362046
Iranian Registry	T170	C0034975
Clinical Trials	T062	C0008976
IRCT201511032321N2	T170	C0282574
Evaluation	T052	C1516048
relationship	T080	C0439849
static	T080	C0441463
measurement	T169	C0242485
transverse arch	T029	C0230467
flexibility	T080	C0242808
forefoot	T023	C1510667
gait	T033	C0016928
parameters	T077	C0549193
healthy subjects	T098	C1708335
Purpose	UnknownType	C0681832
investigate	T169	C1292732
relationship	T080	C0439849
static	T080	C0441463
measurement	T169	C0242485
transverse arch	T029	C0230467
forefoot	T023	C1510667
3-dimensional	T082	C0450363
3D	T082	C0450363
foot scanner	T074	C4052629
kinetics	T070	C0022702
kinematics	T091	C0600169
gait	T033	C0016928
parameters	T077	C0549193
sagittal plane	T029	C0935598
Subjects	T098	C0080105
Methods	T170	C0025663
healthy subjects	T098	C1708335
study	T062	C0681814
transverse arch	T029	C0230467
forefoot	T023	C1510667
measured	T080	C0444706
conditions	T080	C0348080
condition	T080	C0348080
sitting	T033	C0277814
condition	T080	C0348080
standing	T082	C0231472
condition	T080	C0348080
foot	T023	C0016504
forward	T082	C0439780
lower leg	T023	C1140621
tilting	T080	C1711426
anteriorly	T082	C0205094
maximum	T081	C0806909
position	T082	C0733755
heel	T029	C0018870
contact	T169	C0332158
Gait	T033	C0016928
parameters	T077	C0549193
recorded	T081	C3853788
3D motion analysis system	T073	C1704459
force plate	T074	C0492768
Correlation	T080	C1707520
coefficients	T081	C1707429
TAF	T080	C0242808
comparison	T052	C1707455
conditions	T080	C0348080
gait	T033	C0016928
parameters	T077	C0549193
calculated	T052	C1441506
Spearman correlation analysis	T062	C0010101
Results	T169	C1274040
Rates	T081	C1521828
transverse arch	T029	C0230467
forefoot	T023	C1510667
width	T081	C0487742
height	T032	C0489786
condition	T080	C0348080
condition	T080	C0348080
significantly correlated	T080	C1707520
anterior	T082	C0205094
posterior	T082	C0205095
component	T077	C1705248
ground reaction forces	T067	C0441722
hip joint	T030	C0019558
extension	T169	C0231448
angle	T082	C0205143
ankle	T029	C0003086
plantar flexion moment	T042	C0231784
Conclusion	T078	C1707478
study's	T062	C0681814
findings	T033	C0243095
indicated	T033	C1444656
increased	T081	C0205217
stiffness	T184	C0427008
transverse arch	T029	C0230467
forefoot	T023	C1510667
related	T080	C0439849
increase	T169	C0442805
ankle	T029	C0003086
plantar moment	T042	C0231784
decreased	T081	C0205216
stiffness	T184	C0427008
transverse arch	T029	C0230467
forefoot	T023	C1510667
related	T080	C0439849
increase	T169	C0442805
hip joint	T030	C0019558
extension	T169	C0231448
angle	T082	C0205143
gait	T033	C0016928
Management	T058	C0376636
Case Outcome	T062	C0543472
Gastric Impaction	T020	C0267223
Raptors	T012	C0600536
Case Series	T062	C0150093
raptors	T012	C0600536
American kestrel	T012	C0325583
Falco sparverius	T012	C0325583
peregrine falcon	T012	C0325581
Falco peregrinus	T012	C0325581
golden eagle	T012	C0325569
Aquila chrysaetos	T012	C0325569
barn owl	T012	C0326063
Tyto alba	T012	C0326063
diagnosed	T033	C0011900
ventricular	T023	C2355627
proventricular	T023	C0033745
foreign material	T037	C0232481
impactions	T046	C0333124
artificial turf substrate	T167	C3891814
paper	T073	C0030351
plastic substrate	T073	C0032162
grass	T002	C0018210
newspaper	T073	C0027989
Partial or total anorexia	T047	C0003123
birds	T012	C0600536
decreased	T081	C0205216
casting	T061	C3519992
birds	T012	C0600536
Survey	T170	C0038951
radiographs	T060	C1306645
gastric	T023	C0038351
enlargement	T061	C1293134
birds	T012	C0600536
kestrel	T012	C0325582
eagle	T012	C0325569
treated	T169	C1522326
gastroscopy	T060	C0017195
gastric lavage	T061	C0017134
surgical intervention	T033	C0549433
ventricular	T023	C2355627
impactions	T046	C0333124
birds	T012	C0600536
died of undetermined causes	T033	C2826209
after surgery	T079	C0032790
peregrine falcon	T012	C0325581
died	T033	C1306577
before medical	T061	C3179131
surgical intervention	T033	C0549433
owl	T012	C0326063
oral mineral oil	T200	C1250025
liquid diet	T061	C0301571
facilitate egestion of the foreign material	T037	C0232481
pellet	T081	C1706128
Lead poisoning	T037	C0023176
predisposing cause	T079	C0032946
foreign body ingestion	T037	C0232481
eagle	T012	C0325569
underlying causes	T169	C0015127
pica	T048	C0031873
birds	T012	C0600536
not determined	T080	C0521096
Radiographs	T060	C1306645
diagnostic information	T058	C0811871
sick	T184	C0221423
raptors	T012	C0600536
exhibit vomiting	T184	C0042963
changes in appetite	T033	C0426587
casting frequency	T061	C3519992
treatment decisions	T061	C0087111
impacted	T169	C0333125
birds	T012	C0600536
consideration	T033	C0518609
substrate	T167	C3891814
enrichment items	T073	C3273359
potential	T080	C3245505
foreign material that could be ingested	T037	C0232481
management strategy	T058	C0376636
raptors	T012	C0600536
Anti-inflammatory	T033	C0243095
activity	T052	C0441655
Elaeagnus angustifolia	T002	C1006436
fruit extract	T109	C0772257
rat	T015	C0034693
paw	T023	C0687080
edema	T184	C0013604
Elaeagnus angustifolia	T002	C1006436
fruit	T168	C0016767
Iranian	T083	C0022065
herbal medicine	T121	C2240391
treat	T169	C1522326
diarrhea	T184	C0011991
rheumatoid arthritis	T047	C0003873
effects	T080	C1280500
E. angustifolia	T002	C1006436
fruit extract	T109	C0772257
acute	T079	C0205178
chronic phases	T079	C0457343
formalin	T109	C0949307
induced	T169	C0205263
rat	T015	C0034693
paw	T023	C0687080
edema	T184	C0013604
examined	T033	C0332128
acute	T079	C0205178
chronic	T079	C0457343
anti-inflammatory effects	T033	C0243095
E. angustifolia	T002	C1006436
fruit extract	T109	C0772257
investigated	T169	C1292732
subcutaneous injection	T169	C0021499
formalin	T109	C0949307
rat's	T015	C0034693
paw	T023	C0687080
Thirty minutes	T079	C1442458
procedure	T169	C2700391
experimental	T080	C1517586
groups	T078	C0441833
treated	T169	C1522326
intraperitoneally	T082	C0442120
hydroalcoholic fruit extracts	T109	C0772257
E. angustifolia	T002	C1006436
concentrations	T081	C1264643
sodium salicylate	T109	C0037549
SS	T109	C0037549
distilled water	T121	C0790233
positive	T033	C1446409
negative	T033	C0205160
control groups	T096	C0009932
Treatment	T169	C1522326
SS	T109	C0037549
fruit extracts	T109	C0772257
performed	T169	C0884358
daily	T079	C0332173
days	T079	C0439228
degree	T081	C0449286
edema	T184	C0013604
measured	T080	C0444706
mercury plethysmometer	T074	C0025080
digital caliper	T074	C0175720
acute	T079	C0205178
anti-inflammatory	T033	C0243095
study	T062	C2603343
extract	T167	C2828366
anti-inflammatory effect	T080	C1515999
dose-dependent	T081	C1512045
results	T169	C1274040
extract	T167	C2828366
different	T080	C1705242
compared with	T052	C1707455
negative	T033	C0205160
control group	T096	C0009932
sodium salicylate	T109	C0037549
Results	T169	C1274040
chronic	T079	C0457343
study	T062	C2603343
suggested	T078	C1705535
E. angustifolia	T002	C1006436
extract	T167	C2828366
reduced	T080	C0392756
paw	T023	C0687080
edema	T184	C0013604
inflammation	T046	C0021368
dose-dependent	T081	C1512045
results	T169	C1274040
measurement	T169	C0242485
digital caliper	T074	C0175720
mercury plethysmometer	T074	C0025080
Phytochemical tests	T059	C0022885
hydroalcoholic fruit extract	T109	C0772257
E. angustifolia	T002	C1006436
positive	T033	C1446409
cardiac glycosides	T109	C0007158
flavonoids	T109	C0596577
terpenoids	T109	C0039561
saponins	T109	C0036189
findings	T033	C0243095
E. angustifolia	T002	C1006436
fruit extract	T109	C0772257
acute	T079	C0205178
chronic	T079	C0457343
anti-inflammatory	T033	C0243095
activities	T052	C0441655
folk medicine	T061	C0016419
Increased	T081	C0205217
cerebral blood volume	T032	C4277714
pulsatility	T080	C0577317
head-down tilt	T082	C0242683
elevated carbon dioxide	T033	C0020440
elevated carbon dioxide	T033	C0020440
SPACECOT Study	T062	C2603343
Astronauts	T097	C0242688
hyperopic shifts	T047	C0020490
posterior	T082	C0205095
eye globe	T023	C0015392
flattening	T169	C0016203
dilated	T033	C0700124
optic nerve sheaths	T023	C0228673
optic disc swelling	T047	C0030353
spaceflight	T057	C0037741
Elevated intracranial pressure	T047	C0151740
ICP	T047	C0151740
cephalad	T082	C0205096
fluid shifts	T039	C0242705
hypothesized	T078	C1512571
ocular changes	T033	C0429568
Head-down tilt	T082	C0242683
HDT	T082	C0242683
Earth	T083	C0242744
similar	T080	C2348205
fluid shifts	T039	C0242705
Sealed environments	T082	C0014406
elevated	T080	C3163633
carbon dioxide	T123	C0007012
CO2	T123	C0007012
potent	T080	C3245505
arteriolar vasodilator	T121	C2267010
cerebral blood volume	T032	C4277714
flow	T033	C0428714
intracranial	T029	C0524466
compliance	T033	C3714738
ICP	T047	C0151740
collaborative pilot study	T062	C0031928
National Space Biomedical Research Institute	T093	C1708333
German Aerospace Center	T092	C1561598
hypotheses	T078	C1512571
HDT	T082	C0242683
elevated	T080	C3163633
CO2	T123	C0007012
physiologically	T169	C0205463
interact	T169	C1704675
cerebrovascular	T080	C1880018
pulsatility	T080	C0577317
HDT	T082	C0242683
elevated	T080	C3163633
CO2	T123	C0007012
double-blind	T062	C0013072
crossover study	T062	C0150097
cerebral blood volume	T032	C4277714
CBV	T032	C4277714
pulsatility	T080	C0577317
near-infrared spectroscopy	T059	C0376519
non-invasive	T169	C0205303
ICP	T047	C0151740
intraocular pressure	T042	C0021888
IOP	T042	C0021888
HDT	T082	C0242683
nominal	T081	C1264625
elevated	T080	C3163633
ambient	T080	C1879688
CO2	T123	C0007012
cohort	T098	C0599755
CBV	T032	C4277714
pulsatility	T080	C0577317
increased significantly	T081	C0205217
cardiac	T082	C1522601
frequencies	T079	C0439603
increase	T169	C0442805
pulsatility	T080	C0577317
amplitude	T082	C2346753
Mayer wave frequencies	T079	C0439603
increase	T169	C0442805
HDT	T082	C0242683
CO2	T123	C0007012
interaction	T169	C1704675
pulsatility	T080	C0577317
individual	T098	C0027361
differences	T080	C1705242
atmospheres	T070	C0004178
not detected	T033	C0442737
ICP	T047	C0151740
IOP	T042	C0021888
cohort	T098	C0599755
"water hammer" effect	T033	C0232123
cerebral	T023	C0006104
pulsatility	T080	C0577317
spaceflight	T057	C0037741
associated with	T080	C0332281
ocular changes	T033	C0429568
astronauts	T097	C0242688
Shift Work	T090	C1658633
Associated with	T080	C0332281
Metabolic Syndrome	T047	C0524620
Young	T079	C0332239
Female	T032	C0086287
Korean	T098	C1556095
Workers	T090	C1306056
Shift work	T090	C1658633
associated with	T080	C0332281
health problems	T078	C0021788
metabolic syndrome	T047	C0524620
study	T062	C2603343
association	T080	C0439849
shift work	T090	C1658633
metabolic syndrome	T047	C0524620
young	T079	C0332239
workers	T090	C1306056
subjects	T098	C0080105
Korean	T098	C1556095
National Health and Nutrition Examination Survey	T062	C0376344
shift	T033	C0425104
day workers	T033	C4316562
cross-sectional study	T062	C0010362
calculated	T169	C0444686
odds ratios	T081	C0028873
multivariate	T081	C0026777
logistic regression analysis	UnknownType	C0681925
examine	T033	C0332128
association	T080	C0439849
shift work	T090	C1658633
metabolic syndrome	T047	C0524620
prevalence	T081	C0033105
metabolic syndrome	T047	C0524620
male	T032	C0086582
female	T032	C0086287
shift workers	T033	C0425104
confounding factors	T169	C0009673
shift work	T090	C1658633
associated with	T080	C0332281
metabolic syndrome	T047	C0524620
female	T032	C0086287
workers	T090	C1306056
odds ratio	T081	C0028873
confidence interval	T081	C0009667
Shift work	T090	C1658633
associated with	T080	C0332281
metabolic syndrome	T047	C0524620
young	T079	C0332239
women	T098	C0043210
manage	T058	C0184516
metabolic syndrome	T047	C0524620
workplace	T082	C0162579
In Vitro	T080	C1533691
Differentiation	T043	C0007589
Human	T016	C0086418
Pluripotent Stem Cells	T025	C0872076
Trophoblastic Cells	T025	C1519658
placenta	T018	C0032043
organ	T023	C0178784
embryogenesis	T042	C0013936
survival	T052	C0038952
embryo	T018	C0013935
placenta	T018	C0032043
trophoblastic cells	T025	C1519658
differentiate	T043	C0007589
extra-embryonic trophectoderm cells	T043	C1326118
preimplantation	T039	C1446949
blastocyst	T018	C1281743
differentiation events	T043	C0007589
human	T016	C0086418
placenta	T018	C0032043
isolation	T061	C0204727
manipulation	T061	C0947647
human	T016	C0086418
embryogenesis	T042	C0013936
Human pluripotent stem cells	T025	C0872076
hPSCs	T025	C0872076
model system	T170	C3161035
human development	T039	C0020119
differentiated	T043	C0007589
in vitro	T080	C1533691
trophoblastic cells	T025	C1519658
trophoblast	T025	C1519658
cell types	T025	C0007634
differentiating	T043	C0007589
hPSCs	T025	C0872076
trophoblastic cells	T025	C1519658
bone morphogenic protein 4	T116	C0033684
inhibitors	T080	C1999216
Activin	T116	C0050668
Nodal signaling pathways	T044	C3271798
trophoblast	T025	C1519658
cell types	T025	C0007634
transfected	T063	C0040669
siRNAs	T114	C1099354
phenotypes	T032	C0031437
infected	T033	C0439663
pathogens	T001	C0450254
hPSCs	T025	C0872076
differentiated	T043	C0007589
trophoblast	T018	C0041178
progenitors	T025	C0038250
in vitro	T080	C1533691
differentiation method	T043	C0007589
human	T016	C0086418
trophoblasts	T018	C0041178
hPSCs	T025	C0872076
restrictions	T169	C0443288
human	T016	C0086418
embryos	T018	C0013935
drug discovery	T062	C0920472
stem cell research	T062	C1514966
Metabolomics	T123	C0870883
analysis	T062	C0936012
anaphylactoid reaction	T046	C0340865
reveals	T080	C0443289
mechanism	T169	C0441712
rat	T015	C0034721
model	T008	C0599779
Anaphylactoid reactions	T046	C0340865
immune-mediated immediate hypersensitivity reactions	T047	C0301918
serious	T080	C0205404
threat	T078	C0749385
public health	T058	C0699943
effect	T080	C1280500
mechanism	T169	C0441712
not clear	T033	C3845108
diagnostic tests	T060	C0086143
limited	T169	C0439801
Comprehensive	T080	C1880156
metabolite	T123	C0870883
analysis	T062	C0936012
reveal	T080	C0443289
anaphylactoid	T080	C1706805
effect	T080	C1280500
mechanism	T169	C0441712
systematically	T169	C0220922
provide	T052	C1999230
reference	T081	C0034925
future	T079	C0016884
diagnostic	T169	C0348026
purposes	T169	C1285529
Plasma	T031	C0032105
Brown Norway rats	T015	C0034700
intravenous injection	T169	C0021494
saline	T167	C0036082
compound 48/80	T109	C0009574
ovalbumin	T116	C0029923
used	T169	C1524063
study	T062	C2603343
effect	T080	C1280500
mechanism	T169	C0441712
anaphylactoid reactions	T046	C0340865
metabolomics	T123	C0870883
UPLC-qTOF-MS/MS	T063	C0599748
Metabolomics	T123	C0870883
proteomics data	T170	C0242356
used	T169	C1524063
analyze	T062	C0936012
anaphylactoid	T080	C1706805
pathways	T044	C1704259
MetaboAnalyst	T170	C0037589
followed by	T079	C0332283
pathway analysis	T170	C0868995
metabolites	T123	C0870883
identified	T080	C0205396
METLIN database	T170	C0242356
MS/MS	T063	C0599748
confirmed by	T080	C0521093
authentic standards	T081	C0034925
results	T169	C1274040
adenosine	T114	C0001443
histamine	T109	C0019588
N-acetylhistamine	T109	C0067730
N(α)-γ-glutamylhistamine	T109	C0061063
malate	T109	C0220873
xanthine	T114	C0043314
important	T080	C3898777
anaphylactoid reactions	T046	C0340865
effect	T080	C1280500
mechanism	T169	C0441712
histidine metabolism	T044	C1156823
arachidonic acid metabolism	T044	C1158360
energy metabolism	T039	C0014272
purine metabolism	T169	C0920640
other	T080	C0205394
small	T081	C0700321
molecules	T167	C0567416
through	T169	C0332273
metabolites	T123	C0870883
Multiple linear regression analysis	UnknownType	C0681925
indicated	T033	C1444656
not	T169	C1518422
only	T081	C0205171
histamine	T109	C0019588
N(α)-γ-glutamylhistamine	T109	C0061063
arachidonic acid	T109	C0003695
used	T169	C1524063
anaphylactoid	T080	C1706805
symptoms	T184	C1457887
animals	T008	C0003062
citrate cycle	T044	C1516586
histidine metabolism	T044	C1156823
arachidonic acid metabolism	T044	C1158360
main	T080	C1542147
pathways	T044	C1704259
anaphylactoid reactions	T046	C0340865
determined by	T080	C0521095
MetaboAnalyst	T170	C0037589
results	T169	C1274040
provide	T052	C1999230
reference	T170	C1514811
improve	T033	C0184511
diagnostic accuracy	T080	C0598285
predict	T078	C0681842
treatment efficacy	T080	C0087113
anaphylactoid reactions	T046	C0340865
clinical setting	T082	C3176918
Prevalence	T081	C0683921
Sleep Apnea	T047	C0037315
Type B Aortic Dissection	T190	C0340647
False	T080	C0205237
Lumen	T030	C0524461
Thrombosis	T046	C0040053
Obstructive sleep apnea	T047	C0520679
OSA	T047	C0520679
aortic dissection	T047	C0340643
Thrombosis	T046	C0040053
false	T080	C0205237
lumen	T030	C0524461
associated with	T080	C0332281
prognosis	T058	C0033325
type B aortic dissection	T190	C0340647
AoD	T190	C0340647
partial thrombosis	T020	C0333204
predictor	T170	C0683956
mortality	T081	C0178686
study	T062	C2603343
severity	T080	C0392364
OSA	T047	C0520679
associated with	T080	C0332281
false	T080	C0205237
lumen	T030	C0524461
thrombosis	T046	C0040053
observational study	T062	C1518527
type B AoD	T190	C0340647
patients	T101	C0030705
false	T080	C0205237
lumen	T030	C0524461
partially	T081	C0728938
thrombosed	T046	C0040053
thrombosed	T046	C0040053
computer tomography angiography	T060	C1536105
image	T078	C1551337
Patients	T101	C0030705
non-OSA group	UnknownType	C0681860
apnea-hypopnea index	T170	C4083070
AHI	T170	C4083070
mild	UnknownType	C0681860
AHI	T170	C4083070
moderate	UnknownType	C0681860
AHI	T170	C4083070
severe OSA groups	UnknownType	C0681860
AHI	T170	C4083070
AHI	T170	C4083070
prevalence	T081	C0683921
OSA	T047	C0520679
type B dissection	T190	C0340647
cases	T077	C1706256
patients	T101	C0030705
non-OSA group	UnknownType	C0681860
mild group	UnknownType	C0681860
moderate group	UnknownType	C0681860
severe group	UnknownType	C0681860
partially	T081	C0728938
thrombosed	T046	C0040053
false	T080	C0205237
lumen	T030	C0524461
patients	T101	C0030705
Multivariable analysis	T081	C0026777
OSA	T047	C0520679
severity	T080	C0392364
positively	T033	C1446409
associated with	T080	C0332281
partial	T081	C0728938
thrombosis	T046	C0040053
odds ratio	T081	C0028873
confidence interval	T081	C0009667
confounding factors	T169	C0009673
OSA	T047	C0520679
patients	T101	C0030705
type B AoD	T190	C0340647
severity	T080	C0392364
OSA	T047	C0520679
associated with	T080	C0332281
increased	T081	C0205217
risk	T078	C0035647
partial	T081	C0728938
false	T080	C0205237
lumen	T030	C0524461
thrombosis	T046	C0040053
OSA	T047	C0520679
etiology	T169	C1314792
prognosis	T058	C0033325
AoD	T190	C0340647
Contextual Factors	T041	C0542559
Stunting	T046	C0018273
Children	T100	C0008059
Age	T032	C0001779
Months	T079	C0439231
Under-Privileged Community	T096	C0009462
Dhaka	T083	C0004732
Bangladesh	T083	C0004732
factors	T169	C1521761
associated with	T080	C0332281
stunting	T046	C0018273
children	T100	C0008059
aged	T032	C0001779
months	T079	C0439231
slum	T080	C0037345
Dhaka	T083	C0004732
Bangladesh	T083	C0004732
case control study	T062	C0007328
Children	T100	C0008059
length-for-age Z-score	T081	C0871421
LAZ	T081	C0871421
control	T096	C0009932
LAZ	T081	C0871421
logistic regression model	UnknownType	C0681925
factors	T169	C1521761
associated with	T080	C0332281
stunting	T046	C0018273
risk factors	T033	C0035648
stunting	T046	C0018273
child's	T100	C0008059
age	T032	C0001779
months	T079	C0439231
maternal	T099	C0026591
undernutrition	T047	C0162429
mother's education	T033	C2924476
years	T079	C0439234
consumption	T040	C0684271
untreated drinking water	T167	C0599638
monthly	T079	C0332177
family	T099	C0015576
income	T081	C0021162
USD	T081	C1555442
findings	T033	C0243095
study	T062	C0007328
maternal	T099	C0026591
undernutrition	T047	C0162429
less education	T033	C0013658
consumption	T040	C0684271
untreated drinking water	T167	C0599638
family	T099	C0015576
income	T081	C0021162
associated	T080	C0332281
factors	T169	C1521761
childhood	T079	C0231335
stunting	T046	C0018273
Americans	T098	C0596070
Good Health	T080	C3898900
Unmet Need	T033	C4061640
Health Care Expenses	T081	C3242647
health care expenditures	T081	C3242647
concentrated	T081	C0392762
Americans	T098	C0596070
health care resources	T078	C0018741
out-of-pocket spending	T054	C0680969
low spenders	T098	C1257890
population	T098	C1257890
received	T080	C1514756
care	T058	C0086388
timely	T080	C3827828
spending	T054	C0680969
population	T098	C1257890
year	T079	C0439234
period	T079	C1948053
examined	T033	C0332128
Penile Erosion	T020	C1536126
Paraplegic	T047	C0030486
Man	T098	C0025266
Indwelling Urinary Catheter	T074	C0521197
Scrotal Edema	T033	C0151609
chronic	T079	C0205191
use of	T169	C1524063
urinary indwelling catheters	T074	C0521197
long-term	T079	C0443252
patient care	T058	C0017313
complications	T046	C0009566
awareness	T041	C0004448
urogenital	T022	C0042066
trauma	T037	C3714660
urinary catheterization	T061	C0042019
symptomatic	T169	C0231220
urinary tract infections	T047	C0042029
preventable measures	T080	C2700409
decrease	T081	C0547047
risk	T078	C0035647
mechanical trauma	T037	C3714660
urethra	T023	C0041967
glans penis	T023	C0227948
chronic	T079	C0205191
catheterization	T061	C0007430
year	T079	C0439234
old	T079	C0580836
paraplegic	T047	C0030486
male	T032	C0086582
chronic	T079	C0205191
indwelling catheter	T074	C0007439
acquired	T080	C0439661
ventral	T082	C1704448
penile erosion	T020	C1536126
cared	T052	C1947933
ICU setting	T073	C0021708
Modified	T169	C0392747
anastomotic technique	T061	C0677554
thoracolaparoscopic Ivor-Lewis esophagectomy	T061	C0472889
early	T079	C1279919
outcomes	T080	C0085415
technical details	T080	C1522508
Thoracoscopic intrathoracic esophagogastrostomy	T061	C0192353
technical requirements	UnknownType	C0681521
application of	T169	C1524063
minimally	T080	C0547040
invasive	T080	C0205281
Ivor-Lewis esophagectomy	T061	C0472889
reduce	T081	C0547047
surgical procedure	T061	C0543467
modified	T169	C0392747
anastomotic technique	T061	C0677554
thoracolaparoscopic Ivor-Lewis esophagectomy	T061	C0472889
modified	T169	C0392747
approach	T169	C1292724
operations	T061	C0543467
intrathoracic suturing	T061	C0009068
knotting	T061	C0087111
instruments	T074	C0348000
OrVil system	T074	C0025080
reverse-puncture head	T074	C0025080
consecutive	T080	C1707491
patients	T101	C0030705
cancer	T191	C0006826
distal third of the esophagus	T029	C0227191
gastric cardia	T029	C0007144
modified	T169	C0392747
surgical procedure	T061	C0543467
short-term	T079	C0443303
outcomes	T080	C0085415
modified	T169	C0392747
anastomotic technique	T061	C0677554
thoracolaparoscopic Ivor-Lewis esophagectomy	T061	C0472889
Quantitative analysis	UnknownType	C0681919
cell proliferation	T043	C0596290
dye dilution assay	T060	C0013341
Application	T169	C4048755
cell lines	T025	C0682523
cocultures	T059	C0282547
Cell proliferation	T043	C0596290
processes in biological systems	T038	C3714634
quantitative analysis	UnknownType	C0681919
cell proliferation	T043	C0596290
biological	T091	C0005532
applications	T169	C4048755
drug screening	T059	C0373483
biologics	T121	C0005522
assessment	T058	C0220825
cytotoxicity	T049	C0596402
Conventional	T080	C0439858
proliferation assays	T062	C3899698
cell number	T059	C0007584
calibration curve	T081	C0006751
homogeneous	T080	C1881065
cell population	T025	C0007634
analysis	T062	C0936012
cocultured cells	T025	C0007635
assays	T059	C0005507
measure	T169	C0242485
cell proliferation	T043	C0596290
cellular metabolic activity	T043	C1524026
DNA content	T081	C0032246
overcome	T052	C2983310
dye dilution assay	T060	C0013341
fluorescent cell tracking dyes	T130	C0016320
retained	T169	C0333118
cells	T025	C0007634
diluted	T169	C1948037
proportionally	T080	C0205351
cell divisions	T043	C0007590
assay	T059	C1510438
quantitatively analyze	UnknownType	C0681919
cell proliferation	T043	C0596290
cell lines	T025	C0682523
concurrently	T079	C0205420
analyze	T062	C0936012
proliferation	T169	C1514485
cell lines	T025	C0682523
coculture	T059	C0282547
cell tracking	T062	C2936595
dyes	T130	C0016320
spectral	T081	C1883073
characteristics	T080	C1521970
mean division time	T081	C0392762
estimated	T081	C0750572
dye dilution assay	T060	C0013341
population doubling time	T079	C2986483
conventional	T080	C0439858
methods	T170	C0025663
values	UnknownType	C0456580
literature	T170	C0023866
dye	T130	C0016320
cocultured cells	T025	C0007635
investigated	T169	C1292732
characteristic	T080	C1521970
cells	T025	C0007634
characteristic	T080	C1521970
dye	T130	C0016320
flow cytometric analyses	T059	C0016263
cellular	T025	C0007634
properties	T080	C0871161
valuable	T080	C0205556
information	T078	C1533716
cell status	T080	C0449438
diverse	T080	C1880371
conditions	T080	C0348080
Engineering	T063	C0017387
In Vivo	T082	C1515655
Applications	T169	C4048755
Riboswitches	T114	C2936590
Riboswitches	T114	C2936590
common	T081	C0205214
gene regulatory units	T028	C0017362
bacteria	T007	C0004611
capable	T080	C2698977
altering	T078	C1515926
gene expression	T045	C0017262
response	T032	C0871261
small molecule	T109	C1328819
structured RNA elements	T114	C0035668
modular	T077	C1709061
subunits	T081	C1711351
aptamer domain	T114	C0599013
binds	T044	C1167622
high	T080	C0205250
specificity	T081	C0037791
affinity	T070	C1510827
target	T169	C1521840
ligand	T103	C0023688
expression	T045	C0017262
transduces	T043	C0037083
ligand binding	T044	C1517880
gene expression	T045	C0017262
Significant	T078	C0750502
progress	T169	C1280477
engineering	T063	C0017387
novel	T080	C0205314
aptamer domains	T114	C0599013
new	T080	C0205314
small molecule	T109	C1328819
inducers	T167	C3898767
gene expression	T045	C0017262
Modified	T169	C0392747
expression	T045	C0017262
optimized	T052	C2698650
function	T169	C0542341
fused	T169	C0699952
natural	T169	C0205296
synthetic	T080	C2004457
aptamer domains	T114	C0599013
field	T077	C2346620
privileged	T078	C1547898
scaffolds	T073	C0337143
development	T169	C1527148
tools	T073	C2827396
RNA	T114	C0035668
fluorescent	T070	C0016315
biosensors	T075	C0600364
review	T170	C0282443
summarize	T170	C1552616
methods	T170	C0025663
engineer	T057	C0578393
riboswitches	T114	C2936590
applications	T169	C4048755
natural	T169	C0205296
synthetic	T080	C2004457
riboswitches	T114	C2936590
enzyme	T059	C0033629
strain engineering	T091	C1879848
gene expression	T045	C0017262
cellular physiology	T043	C0007613
real-time imaging	T060	C0079595
cellular metabolites	T123	C0870883
signals	T044	C0037080
novel	T080	C0205314
assay	T059	C1510438
measure	T081	C0079809
tertiary	T197	C0597565
quaternary amines	T109	C0578399
wastewater	T069	C3494254
indicator	T169	C1522602
NDMA	T109	C0012431
wastewater	T069	C3494254
precursors	T078	C1709634
study	T059	C0947630
examined	T033	C0332128
potential	T080	C3245505
novel	T080	C0205314
bulk amine assay	T059	C1510438
approximation	T080	C0332232
tertiary	T197	C0597565
quaternary amine	T109	C0578399
wastewaters	T069	C3494254
surface	T082	C0205148
water samples	T197	C1550678
approximation	T080	C0332232
compared	T052	C1707455
N-nitrosodimethylamine	T109	C0012431
NDMA	T109	C0012431
formation	T169	C1522492
potential	T080	C3245505
chloramines	T109	C0008164
colorimetric method	T059	C0009407
examined	T033	C0332128
detection	T033	C0442726
amines	T109	C0002508
environmental	T082	C0014406
water samples	T197	C1550678
method	T059	C0871511
liquid-liquid extraction	T059	C3178840
catalyzed	T169	C0205245
reaction	T067	C0596319
undefined	T078	C0750600
product	T071	C1514468
strong	T080	C0442821
chromophore	T120	C0596335
fluorophore	T121	C0598447
reaction	T067	C0596319
catalyzed	T169	C0205245
number	T081	C0237753
compounds	T080	C0205198
tertiary	T197	C0597565
quaternary amine	T109	C0578399
moieties	T077	C3641152
tertiary	T197	C0597565
quaternary compounds	T109	C0578399
efficient	T080	C0442799
producers	T169	C0205245
NDMA	T109	C0012431
chloramination	T070	C0002505
conditions	T080	C0348080
linear correlation	T080	C1707520
consequently	T033	C3845876
bulk amine signals	T067	C1710082
NDMA	T109	C0012431
formation	T169	C1522492
potential	T080	C3245505
wastewater	T069	C3494254
samples	T167	C0370003
evidence	T078	C3887511
approximately	T080	C0332232
tertiary	T197	C0597565
measured	T080	C0444706
NDMA	T109	C0012431
estimated	T081	C0750572
nitrogen	T123	C0028158
dissolved organic nitrogen originates	T109	C0002508
bulk amines	T109	C0002508
normalization	T062	C1882115
NDMA	T109	C0012431
concentration	T081	C1446561
amine	T109	C0002508
measurement	T169	C0242485
ozone	T103	C0030106
effectively	T080	C1704419
destroyed	T052	C1948029
tertiary	T197	C0597565
quaternary amine	T109	C0578399
structures	T082	C0678594
NDMA	T109	C0012431
treated	T169	C1522326
wastewater	T069	C3494254
samples	T167	C0370003
bulk amine assay	T059	C1510438
measurements	T169	C0242485
tertiary	T197	C0597565
quaternary amines	T109	C0578399
NDMA	T109	C0012431
formation	T169	C1522492
potential	T080	C3245505
sample	T167	C0370003
useful	T080	C3827682
characterizing	T052	C1880022
tool	T169	C0449851
NDMA	T109	C0012431
precursors	T078	C1709634
wastewater	T069	C3494254
Chlamydia pneumoniae	T007	C0085504
infection	T046	C3714514
promotes	T052	C0033414
vascular endothelial cell	T025	C1257792
angiogenesis	T042	C0302600
IQGAP1	T116	C0529338
signaling pathway	T044	C0037080
Chlamydia pneumoniae	T007	C0085504
C. pneumoniae	T007	C0085504
infection	T046	C3714514
potential role	T077	C1705810
angiogenesis	T042	C0302600
C. pneumoniae	T007	C0085504
involved	T169	C1314939
process	T067	C1522240
investigated	T169	C1292732
effect	T080	C1280500
C. pneumoniae	T007	C0085504
infection	T046	C3714514
angiogenesis	T042	C0302600
roles	T077	C1705810
IQGAP1	T116	C0529338
signaling	T044	C0037080
C. pneumoniae	T007	C0085504
infection	T046	C3714514
induced	T169	C0205263
angiogenesis	T042	C0302600
C. pneumoniae	T007	C0085504
infection	T046	C3714514
significantly enhanced	T052	C2349975
angiogenesis	T042	C0302600
assessed	T052	C1516048
tube formation assay	T059	C1510438
possibly	T033	C0332149
inducing	T169	C0205263
vascular endothelial cell	T025	C1257792
VEC	T025	C1257792
migration	T052	C0013975
wound healing	T040	C0043240
Transwell migration assays	T059	C1510438
Subsequently	T079	C0332282
immunoprecipitation	T059	C0021069
Western blot	T059	C0949466
tube formation assay	T059	C1510438
results	T034	C1254595
phosphorylation	T044	C1158886
IQGAP1	T116	C0529338
N-WASP	T116	C0531254
required	T169	C1514873
angiogenesis	T042	C0302600
induced	T169	C0205263
C. pneumoniae	T007	C0085504
infection	T046	C3714514
co-immunoprecipitation	T059	C1449705
study	T059	C0681827
revealed	T080	C0443289
IQGAP1	T116	C0529338
associated with	T080	C0332281
N-WASP	T116	C0531254
C. pneumoniae	T007	C0085504
infection	T046	C3714514
VECs	T025	C1257792
Actin polymerization	T043	C1155982
assay	T059	C1510438
C. pneumoniae	T007	C0085504
infected	T033	C0439663
VECs	T025	C1257792
IQGAP1	T116	C0529338
N-WASP	T116	C0531254
filamentous actin	T116	C1180307
common	T081	C0205214
localized	T082	C0392752
leading edge	T026	C1621433
lamellipodia	T026	C0230628
impaired	T169	C0221099
depletion	T169	C0333668
IQGAP1	T116	C0529338
small interference RNA	T114	C1099354
knockdown	T063	C2350567
IQGAP1	T028	C1416471
significantly decreased	T081	C0205216
N-WASP	T116	C0531254
phosphorylation	T044	C1158886
Tyr256	T116	C0041485
induced	T169	C0205263
C. pneumoniae	T007	C0085504
infection	T046	C3714514
conclude	T078	C1707478
C. pneumoniae	T007	C0085504
infection	T046	C3714514
promotes	T052	C0033414
VEC	T025	C1257792
migration	T052	C0013975
angiogenesis	T042	C0302600
IQGAP1	T116	C0529338
signaling pathway	T044	C0037080
Four-Dimensional	T082	C2347299
Graded	T185	C0441800
Consciousness	T041	C0234421
multidimensional	T082	C2347299
phenomenon	T067	C1882365
polysemous notion	T080	C0205556
consciousness	T041	C0234421
resistant	T169	C0332325
consistent	T078	C0332290
measurement	T169	C0242485
unambiguous definition	T170	C1704788
no agreement	T033	C0243095
issues	T033	C0033213
disagreements	T054	C0012742
debate	T052	C0870392
consciousness	T041	C0234421
gradational	T185	C0441800
nature	T078	C0349590
article	T170	C1706852
consciousness	T041	C0234421
graded	T185	C0441800
multidimensional	T082	C2347299
time	T079	C0040223
question	T170	C1522634
graded	T185	C0441800
cases	T169	C0868928
consciousness	T041	C0234421
measure	T081	C0079809
gradable	T185	C0441800
aspects	T080	C1879746
consciousness	T041	C0234421
quality	T080	C0332306
abstractness	T170	C0679195
complexity	T041	C0237521
usefulness	T080	C3827682
dimensions	T081	C0439534
phenomenal	T080	C3898065
semantic	T078	C0036612
physiological	T169	C0205463
functional	T169	C0542341
consciousness	T041	C0234421
phenomenal	T080	C3898065
quality	T080	C0332306
semantic	T078	C0036612
abstraction	T170	C0679195
physiological	T169	C0205463
complexity	T041	C0237521
functional	T169	C0542341
usefulness	T080	C3827682
four-dimensional	T082	C2347299
hierarchical nature	T078	C0349590
consciousness	T041	C0234421
approach	T082	C0449445
advantageous	T080	C3898777
attention	T041	C0004268
important	T080	C3898777
differences	T080	C1705242
subjective	T080	C0205556
measures	T081	C0079809
awareness	T041	C0004448
creature	T008	C0003062
ranked	T170	C0699794
higher	T080	C0205250
consciousness	T041	C0234421
innovative explanations	T170	C0681841
phenomena	T067	C1882365
interpretations	T170	C0459471
blindsight	T080	C0205556
locked-in syndrome	T047	C0023944
4D	T082	C2347299
predictions	T078	C0681842
hypotheses	T078	C1512571
experimentally	T062	C0681814
tested	T169	C0039593
interdimensional dependencies	T169	C3244310
Synthesis	T052	C1883254
Carbamate	T109	C0006948
Derivatives	T104	C0002776
2-Furoyl-1-piperazine	T123	C0566267
Therapeutic Agents	T121	C1611640
aim	T078	C1947946
research work	T062	C0242481
biologically active	T123	C0566267
carbamate	T109	C0006948
derivatives	T104	C0002776
2-furoyl-1-piperazine	T123	C0566267
toxicity	T037	C0600688
synthesis	T052	C1883254
multiple sequence	T169	C1519249
structural	T082	C0678594
confirmation	T033	C0750484
EI-MS	T059	C4054904
IR	T059	C0037807
1H-NMR	T060	C3850001
enzyme inhibition	T039	C1524081
antibacterial potential	T033	C0243095
synthesized compounds	T123	C0566267
evaluated	T058	C0220825
compounds	T123	C0566267
therapeutic agents	T121	C1611640
cytotoxicity	T049	C0596402
compounds	T123	C0566267
active	T169	C0205177
acetylcholinesterase enzyme	T116	C0001044
12	T123	C0566267
14	T123	C0566267
good	T080	C0205170
inhibitory potential	T042	C0234122
Eserine	T109	C1314787
reference standard	T081	C0034925
compounds	T123	C0566267
Gram-positive	T007	C0018154
Gram-negative bacterial strains	T007	C0018150
Epidemiology	T091	C0014507
outcomes	T057	C0085565
injuries	T037	C0178314
Kenya	T083	C0022558
multisite surveillance study	T057	C0681625
Injury	T037	C0178314
disability	T033	C0231170
death	T033	C1306577
deaths	T033	C1306577
year	T079	C0439234
injury	T037	C0178314
burden	T078	C2828008
low- and middle-income countries	T083	C0454664
injury	T037	C0178314
injury -related deaths	T033	C1306577
burden	T078	C2828008
trauma	T037	C3714660
registries	T170	C0920465
injury	T037	C0178314
epidemiology	T091	C0014507
outcomes	T057	C0085565
low- and middle-income countries	T083	C0454664
Kenya	T083	C0022558
data	T078	C1511726
injury	T037	C0178314
epidemiology	T091	C0014507
care	T052	C1947933
objective	T170	C0018017
study	T062	C0002783
investigate	T169	C1292732
epidemiology	T091	C0014507
outcomes	T057	C0085565
injuries	T037	C0178314
referral hospitals	T073	C0019994
Kenya	T083	C0022558
hospital	T073	C0019994
trauma	T037	C3714660
registries	T170	C0920465
January	T080	C3829466
May	T079	C3812381
injured patients	T101	C0030705
casualty departments	T073	C0562508
Kenyatta National	T073	C0019994
Thika Level 5	T073	C0019994
Machakos Level 5	T073	C0019994
Meru Level 5 Hospitals	T073	C0019994
Data collected	T062	C0010995
demographic characteristics	T102	C0683970
type	T080	C0332307
prehospital care	T058	C2735050
received	T080	C1514756
prehospital time	T079	C0040223
injury pattern	T037	C0178314
outcomes	T057	C0085565
patients	T101	C0030705
Patients	T101	C0030705
male	T032	C0086582
young	T079	C0332239
mean age	T032	C0001779
years	T079	C0439234
mechanisms of injury	T169	C0449413
road	T073	C0442650
traffic injuries	T037	C0178314
falls	T037	C0000921
struck/hit by	T169	C0332159
person	T098	C0027361
object	T072	C0347997
Burn	T037	C0006434
mechanism of injury	T169	C0449413
age	T032	C0001779
category	T170	C0683312
years	T079	C0439234
Body regions	T029	C0005898
injured	T169	C0332664
lower extremity	T023	C0023216
upper extremity	T023	C1140618
head	T029	C0018670
mortality rate	T081	C0205848
Significant predictors	T078	C2698872
mortality	T081	C0205848
multivariate analysis	T081	C0026777
Glasgow Coma Scale ≤12	T033	C0278173
injury severity score	T170	C0021504
burns	T037	C0006434
gunshot injuries	T037	C0043252
Hospital	T073	C0019994
trauma	T037	C3714660
registries	T170	C0920465
sources of data	T081	C0011001
study the epidemiology	T062	C0002783
injuries	T037	C0178314
low- and middle-income countries	T083	C0454664
Data	T078	C1511726
trauma	T037	C3714660
registries	T170	C0920465
public	T092	C0678367
health	T078	C0018684
interventions	T061	C0184661
quality-of-care improvement programs	T058	C1254363
child	T100	C0008059
phenylketonuria	T047	C0031485
focal segmental glomerulosclerosis	T047	C0333497
proteinuria	T033	C0033687
Phenylketonuria	T047	C0031485
PKU	T047	C0031485
common	T081	C0205214
inborn error of amino acid metabolism	T047	C0002514
Phenylalanine hydroxylase	T116	C0031456
deficient	T169	C0011155
enzyme	T116	C0014442
untreated	T033	C0332155
growth failure	T047	C0878787
microcephaly	T019	C0025958
global developmental delay	T048	C0557874
seizures	T184	C0036572
severe intellectual impairment	T048	C4294877
characterize	T052	C1880022
clinical picture	T201	C0683325
PKU	T047	C0031485
protein	T116	C0033684
homeostasis	T038	C0019868
nephrotic syndrome	T047	C0027726
quantitative	T081	C0392762
defect	T169	C1457869
significant	T078	C0750502
proteinuria	T033	C0033687
Focal segmental glomerulosclerosis	T047	C0333497
FSGS	T047	C0333497
special	T080	C0205555
congenital	T080	C1744681
variant	T080	C0205419
affecting	T169	C0392760
children	T100	C0008059
adults	T100	C0001675
male	T032	C0086582
child	T100	C0008059
presented	T033	C0150312
generalized edema	T033	C1850534
global developmental delay	T048	C0557874
Investigations	T058	C1261322
revealed	T080	C0443289
PKU	T047	C0031485
FSGS	T047	C0333497
congenital nephrosis	T047	C3501848
ameliorated	T033	C0184511
PKU	T047	C0031485
salutary effect	T080	C0205556
growth and development	T040	C0018271
PKU	T047	C0031485
FSGS	T047	C0333497
Gastrointestinal disorders	T047	C0017178
Curry-Jones syndrome	T047	C0795915
Clinical	T080	C0205210
molecular	T080	C1521991
insights	T041	C0233820
affected	T169	C0392760
newborn	T100	C0021289
Curry-Jones syndrome	T047	C0795915
CJS	T047	C0795915
pattern	T082	C0449774
malformation	T190	C0302142
craniosynostosis	T047	C0010278
pre-axial polysyndactyly	T033	C2751914
agenesis of the corpus callosum	T019	C0175754
cutaneous	T033	C1704258
gastrointestinal	T082	C0521362
gastrointestinal abnormalities	T019	C3824760
recurrent	T079	C2945760
mosaic mutation	T045	C0026882
SMO (c.1234 C>T; p.Leu412Phe)	T049	C4086836
causes	T169	C0015127
CJS	T047	C0795915
report	T170	C0684224
gastrointestinal	T082	C0521362
surgical findings	T033	C0243095
baby	T100	C0021270
CJS	T047	C0795915
abdominal obstruction	T047	C0848160
reviews	T169	C0699752
spectrum of gastrointestinal malformations	T033	C0243095
gastrointestinal	T082	C0521362
rare disorder	T047	C0678236
week	T079	C0439230
female	T032	C0086287
craniosynostosis	T047	C0010278
pre-axial polysyndactyly	T033	C2751914
cutaneous findings	T033	C0243095
clinical diagnosis	T060	C0332140
CJS	T047	C0795915
infant	T100	C0021270
abdominal distension	T033	C0000731
beginning	T079	C0439659
second	T081	C0205436
day	T079	C0439228
life	T078	C0376558
Surgical exploration	T060	C0184899
revealed	T080	C0443289
intestinal malrotation	T019	C0221210
Ladd procedure	T061	C3665975
Multiple small nodules	T033	C0243095
found	T033	C0243095
surface of the small and large bowel	T029	C0735973
in addition to	T169	C0332287
apparent	T078	C0750489
intestinal duplication	T019	C0221210
posterior	T082	C0205095
pancreas	T023	C0030274
Histopathology	T169	C0243140
serosal	T029	C0521344
nodules	T020	C0028259
revealed	T080	C0443289
bundles of smooth muscle	T024	C1267092
with associated	T080	C0332281
ganglion cells	T025	C0228071
Molecular analysis	T063	C1513380
SMO c.1234 C>T mutation	T049	C4086836
affected	T169	C0392760
skin	T022	C1123023
intestinal hamartoma	T191	C0345896
Gastrointestinal	T082	C0521362
features	T033	C0243095
structural malformations	T033	C1704258
malformations	T190	C0302142
motility disorders	T046	C0679316
upper GI bleeding	T046	C0041909
causes	T169	C0015127
morbidity	T081	C0026538
CJS	T047	C0795915
Smooth muscle	T024	C1267092
Smooth muscle hamartomas	T191	C0018552
recognized feature	T033	C0243095
children	T100	C0008059
CJS	T047	C0795915
abdominal obstruction	T047	C0848160
requiring surgical intervention	T033	C0549433
somatic mutation	T049	C0544886
SMO	T028	C1364142
structural malformations	T033	C1704258
malformations	T190	C0302142
predisposition	T032	C0220898
bowel hamartomas	T191	C0345896
myofibromas	T191	C1266121
mutation	T045	C0026882
burden	T078	C2828008
involved	T169	C1314939
tissues	T024	C0040300
variable manifestations	T033	C3150238
Sella turcica bridging	T190	C1866959
dental anomalies	T033	C0262444
association	T080	C0439849
Sella turcica bridging	T190	C1866959
STB	T190	C1866959
calcification	T042	C0006660
interclinoid ligament	T024	C0023685
sella turcica	T023	C0036609
associated with	T080	C0332281
dental anomalies	T033	C0262444
palatal canine	T033	C2749981
impaction	T190	C0040456
transposition	T190	C1319068
study	T062	C2603343
association	T080	C0439849
canine	T033	C2749981
impaction	T190	C0040456
hyperdontia	T033	C0040457
hypodontia	T019	C0020608
sellar	T023	C0036609
dimensions	T081	C0439534
bridging	T190	C1866959
Lateral	T082	C0205093
cephalometric	T060	C0007723
radiographs	T060	C1306645
patients	T101	C0030705
impacted	T190	C0040456
canines	T033	C2749981
dental agenesis	T019	C0399352
hyperdontia	T033	C0040457
Linear	T082	C0205132
dimensions	T081	C0439534
sella turcica	T023	C0036609
control group	T096	C0009932
individuals	T098	C0237401
standardize scoring scale	T170	C0349674
STB	T190	C1866959
radiographs	T060	C1306645
frequency	T079	C0439603
partial	T081	C0728938
complete	T080	C0205197
calcifications	T042	C0006660
sella	T023	C0036609
patients	T101	C0030705
dental anomalies	T033	C0262444
increased	T081	C0205217
controls	T096	C0009932
STB	T190	C1866959
interclinoid distance	T081	C0012751
linear	T082	C0205132
dimensions	T081	C0439534
sella	T023	C0036609
statistically significant	T081	C0237881
sellar	T023	C0036609
dimensions	T081	C0439534
STB	T190	C1866959
radiographs	T060	C1306645
ages	T032	C0001779
STB	T190	C1866959
patients	T101	C0030705
dental abnormalities	T033	C0262444
Coxiella burnetii	T007	C0010240
isolates	T123	C1764827
infected cattle	T015	C0007452
induce	T169	C0205263
proinflammatory cytokine response	T043	C2247677
isolates	T123	C1764827
infected goats	T015	C1510458
sheep	T015	C0036945
Coxiella burnetii	T007	C0010240
causative agent	T033	C0449411
Q fever	T047	C0034362
prevalence	T081	C0220900
C. burnetii	T007	C0010240
cattle	T015	C0007452
goats	T015	C1510458
sheep	T015	C0036945
infected cattle	T015	C0007452
associated with	T080	C0332281
human	T016	C0086418
outbreaks	T067	C0012652
investigated	T169	C1292732
immune response	T042	C0301872
humans	T016	C0086418
C. burnetii	T007	C0010240
isolates	T123	C1764827
host origins	T001	C1167395
multilocus variable number of tandem repeat analysis	T059	C1443925
MLVA	T059	C1443925
genotypes	T032	C0017431
Cytokine responses	T043	C2247677
human	T016	C0086418
peripheral blood mononuclear cells	T025	C1321301
PBMCs	T025	C1321301
stimulated	T070	C1948023
C. burnetii	T007	C0010240
isolates	T123	C1764827
MLVA	T059	C1443925
genotype	T032	C0017431
goats	T015	C1510458
sheep	T015	C0036945
cattle	T015	C0007452
acute	T047	C0519066
chronic Q fever	T047	C1443892
patients	T101	C0030705
Coxiella burnetii	T007	C0010240
isolates	T123	C1764827
cattle	T015	C0007452
induce	T169	C0205263
IL-1β	T116	C0021753
TNF-α	T116	C0041368
IL-22	T116	C0961814
isolates	T123	C1764827
goats	T015	C1510458
sheep	T015	C0036945
chronic Q fever	T047	C1443892
patients	T101	C0030705
cytokine	T116	C0079189
induction	T169	C0205263
isolates	T123	C1764827
MVLA	T059	C1443925
genotype	T032	C0017431
response	T043	C2247677
MLVA	T059	C1443925
genotypes	T032	C0017431
proinflammatory cytokine response	T043	C2247677
induced	T169	C0205263
human	T016	C0086418
PBMCs	T025	C1321301
C. burnetii	T007	C0010240
isolates	T123	C1764827
cattle	T015	C0007452
incidence	T081	C0021149
human	T016	C0086418
Q fever	T047	C0034362
outbreaks	T067	C0012652
cattle	T015	C0007452
cytokine	T116	C0079189
cytokine profile	T081	C0392762
PBMCs	T025	C1321301
stimulated	T070	C1948023
C. burnetii	T007	C0010240
isolates	T123	C1764827
chronic Q fever	T047	C1443892
patients	T101	C0030705
isolates	T123	C1764827
goats	T015	C1510458
cytokine responses	T043	C2247677
host origin	T001	C1167395
MLVA	T059	C1443925
genotype	T032	C0017431
BRCA1-Associated Protein-1	T116	C1368335
Isoform	T116	C0597298
Affects	T077	C4054723
Response	T032	C0871261
Mesothelioma Cells	T191	C0025500
Drugs	T121	C0013227
Impairing	T169	C0221099
BRCA1	T116	C1528558
DNA Repair	T045	C0012899
BRCA1 associated protein1	T116	C1368335
BAP1	T116	C1368335
tumor suppressor	T116	C0597611
multiple	T081	C0439064
cellular processes	T043	C0007613
transcriptional regulation	T045	C1158770
chromatin modification	T045	C1156197
deubiquitinating	T044	C1157996
histone 2A	T116	C0147579
DNA repair	T045	C0012899
BAP1	T116	C1368335
mutations	T045	C0026882
frequent	T079	C0332183
malignant pleural mesothelioma	T191	C0812413
MPM	T191	C0812413
aim	T078	C1947946
functionally	T169	C0205245
characterize	T080	C1521970
identified	T080	C0205396
isoform	T116	C0597298
of BAP1	T116	C1368335
investigate	T169	C1292732
effects	T080	C1280500
expression	T045	C0017262
drug sensitivity	T032	C0237865
MPM	T191	C0812413
Expression	T045	C0017262
BAP1	T116	C1368335
detected	T033	C0442726
quantitative polymerase chain reaction	T059	C2733022
MPM	T191	C0812413
normal	T080	C0205307
mesothelium	T024	C0086610
cell lines	T025	C0007600
tumor	T024	C0475358
nontumor samples	T024	C1292533
Histone H2A	T116	C0019646
ubiquitination	T044	C1156207
levels	T080	C0441889
analyzed	T062	C0936012
Western blot	T059	C0949466
acidic extraction	T059	C0684295
core histones	T116	C2987130
Subcellular	T026	C3893246
localization	T169	C0475264
BAP1	T116	C1368335
isoforms	T116	C0597298
examined	T033	C0332128
immunofluorescence	T059	C0079603
MPM	T191	C0812413
cell survival	T043	C0007620
response	T032	C0871261
poly(adenosine diphosphate-ribose) polymerase	T116	C0032405
PARP	T116	C0032405
phosphoinositide 3-kinase	T116	C0044602
PI3K	T116	C0044602
mammalian target of rapamycin	T116	C1307407
mTOR	T116	C1307407
inhibitors	T121	C0014432
analyzed	T062	C0936012
in vitro assays	T062	C1515653
identified	T080	C0205396
alternative splice isoform	T116	C1720834
BAP1	T116	C1368335
BAP1Δ	T028	C1332380
catalytic domain	T087	C0600499
Cells	T025	C0007634
transfected	T063	C0040669
BAP1Δ	T028	C1332380
reduced	T080	C0392756
deubiquitinating activity	T044	C1157996
compared	T052	C1707455
BAP1	T116	C1368335
expression	T045	C0017262
BAP1Δ	T028	C1332380
transcript	T114	C1519595
abundant	T080	C2346714
nontumor	T024	C1292533
MPM	T191	C0812413
cell lines	T025	C0085983
expressing	T045	C0017262
BAP1Δ	T028	C1332380
sensitive	T169	C0332324
olaparib	T109	C2316164
PARP1	T116	C1567710
inhibitor	T121	C0014432
cytotoxicity	T049	C0596402
sensitivity	T169	C0332324
enhanced	T052	C2349975
olaparib	T109	C2316164
treatment	T058	C3887704
combined	T080	C0205195
GDC0980	T121	C2984520
PI3K	T116	C0044602
mTOR	T116	C1307407
inhibitor	T121	C0014432
induces	T169	C0205263
downregulation	T044	C0013081
BRCA1	T116	C1528558
observations	T062	C0302523
BAP1Δ	T028	C1332380
regulate DNA damage response	T043	C3270705
influences	T077	C4054723
drug sensitivity	T032	C0237865
relevant	T080	C2347946
investigate	T169	C1292732
patients	T101	C0030705
high	T080	C0205250
expression	T045	C0017262
BAP1Δ	T028	C1332380
responsive	T201	C0521982
PARP	T116	C0032405
PI3K	T116	C0044602
mTOR	T116	C1307407
inhibitors	T121	C0014432
Cucurbitacin B	T109	C0056580
Pressure	T184	C0497233
Overload	UnknownType	C0684338
Cardiac Hypertrophy	T046	C1383860
anti-cardiac hypertrophy drugs	T121	C1254351
cause	T169	C0015127
prevalence	T081	C0033105
heart failure	T047	C0018801
anti-hypertrophy	T033	C0243095
anti-fibrosis	T033	C0243095
potential	T080	C3245505
natural plant	T002	C0032098
triterpenoid	T109	C1519655
Cucurbitacin B	T109	C0056580
in vitro	T062	C0681828
in vivo	T062	C0681829
Aortic banding	T061	C0185014
AB	T061	C0185014
cardiac hypertrophy	T046	C1383860
surgery	T061	C0543467
mice	T015	C0025929
cucurbitacin B	T109	C0056580
treatment	T061	C0087111
Gavage	T169	C2698653
body weight	T032	C0005910
AB	T061	C0185014
cucurbitacin B	T109	C0056580
anti-hypertrophy	T033	C0243095
-fibrosis	T033	C0243095
heart	T023	C0018787
weight	T081	C0043100
myocardial cell	T025	C0225828
cross-sectional area	T201	C2923394
interstitial fibrosis	T046	C0240035
systolic	T079	C0039155
diastolic	T201	C0012000
abnormalities	T033	C0205161
gene expression	T045	C0017262
hypertrophic	T046	C0020564
fibrotic	T169	C0334129
markers	T201	C0005516
microvascular density	T080	C3272839
pressure	T184	C0497233
overload	UnknownType	C0684338
hypertrophic	T046	C0020564
mice	T015	C0025929
Cucurbitacin B	T109	C0056580
hypertrophy	T046	C0020564
inhibitory effect	T033	C0243095
phenylephrine	T109	C0031469
stimulated	T070	C1948023
cardiomyocytes	T025	C0225828
Cucurbitacin B	T109	C0056580
mitigated	T067	C1553901
cardiac hypertrophy	T046	C1383860
autophagy	T043	C0004391
associated with	T080	C0332281
blockade	T169	C0332206
Akt	T116	C0164786
mTOR	T116	C1453984
FoxO3a	T116	C1506134
signal pathway	T044	C0037080
SC79	T109	C4307495
MK2206	T109	C2933427
3-MA	T114	C0047569
Akt	T116	C0164786
agonist	T121	C2987634
inhibitor	T120	C0243077
autophagy	T043	C0004391
inhibitor	T120	C0243077
in vitro	T062	C0681828
overexpression	T045	C1514559
Akt	T116	C0164786
Cucurbitacin B	T109	C0056580
cardiac hypertrophy	T046	C1383860
human	T016	C0086418
cardiomyocytes AC16	T025	C0225828
cucurbitacin B	T109	C0056580
cardiac hypertrophy	T046	C1383860
autophagy	T043	C0004391
cardiomyocytes	T025	C0225828
associated with	T080	C0332281
inhibition	T043	C1519312
Akt	T116	C0164786
mTOR	T116	C1453984
FoxO3a	T116	C1506134
signal axis	T044	C0037080
Inflammatory	T169	C0333348
Oxidative Stress	T049	C0242606
Markers	T201	C0005516
Experimental	T080	C1517586
Allergic Asthma	T047	C0155877
Ovalbumin	T116	C0029923
induced	T169	C0205263
allergic lung inflammation	T047	C0002390
ALI	T047	C0002390
condition	T080	C0348080
cytokines	T116	C0079189
extracellular matrix	T024	C0015350
remodeling	T038	C1820201
redox	T044	C0030012
imbalance	T184	C1397014
study	T062	C2603343
evaluated	T058	C0220825
pulmonary function	T042	C0231921
inflammatory	T169	C0333348
markers	T201	C0005516
interleukin-4	T116	C0021758
IL-4	T116	C0021758
myeloperoxidase	T116	C0027021
MPO	T116	C0027021
eosinophil cells	T025	C0014467
redox	T044	C0030012
markers	T201	C0005516
lungs	T023	C0024109
BALB/c mice	T015	C0025919
ovalbumin	T116	C0029923
OVA	T116	C0029923
sensitization	T040	C1325847
challenge	T059	C0022885
results	T169	C1274040
increase	T169	C0442805
bronchial hyperresponsiveness	T047	C0085129
stimulated	T070	C1948023
methacholine	T109	C0600370
Mch	T109	C0600370
inflammatory	T169	C0333348
cell influx	T043	C0007613
eosinophils	T025	C0014467
increase	T169	C0442805
high mobility group box 1	T116	C0019796
HMGB1	T116	C0019796
lipid peroxidation	T044	C0023775
LP	T044	C0023775
antioxidant	T121	C0003402
defenses	T077	C1880266
OVA	T116	C0029923
group	UnknownType	C0681860
control group	T096	C0009932
OVA	T116	C0029923
induced	T169	C0205263
ALI	T047	C0002390
redox	T044	C0030012
concomitantly	T079	C0521115
impaired	T169	C0221099
lung function	T039	C0035245
associated with	T080	C0332281
HMGB1	T116	C0019796
expression	T045	C1171362
proteolytic	T044	C0597304
remodeling	T038	C1820201
results	T169	C1274040
HMGB1	T116	C0019796
important	T080	C3898777
therapeutic	T169	C0302350
target	T169	C1521840
asthma	T047	C0004096
orchestrates	T080	C0205556
redox	T044	C0030012
signaling	T038	C3537152
inflammation	T046	C0021368
remodeling	T038	C3714634
disease	T047	C0012634
development	T169	C1527148
Association	T080	C0439849
prematurity	T047	C0021294
<30 weeks' gestational age	T032	C0017504
blood pressure	T040	C0005823
urinary	T080	C1524119
albumin	T116	C2362049
calcium	T121	C0006675
phosphate	T121	C0031603
early childhood	T079	C0599196
data	T078	C1511726
blood pressures	T040	C0005823
BP	T040	C0005823
urinary	T080	C1524119
albumin	T116	C2362049
mineral	T197	C0026162
excretion	T039	C0221102
early childhood	T079	C0599196
contemporary	T079	C1254367
cohorts	T098	C0599755
extremely	T080	C0205403
low	T080	C0205251
gestational age	T032	C0017504
GA	T032	C0017504
neonates	T100	C0021289
compare	T052	C1707455
BPs	T040	C0005823
urinary	T080	C1524119
excretion	T039	C0221102
albumin	T116	C2362049
calcium	T121	C0006675
phosphate	T121	C0031603
preterm	T079	C2964377
term-born	T040	C0233324
cohorts	T098	C0599755
early childhood	T079	C0599196
prospective observational study	T062	C0033522
single	T081	C0205171
center	T073	C0475309
involving	T169	C1314939
children	T100	C0008059
<5 years age	T032	C0001779
born preterm	T033	C0151526
GA <30 weeks	T033	C0460089
at term	T040	C0233324
≥37 weeks' GA	T033	C3536634
Urinary albumin	T034	C0587185
calcium	T034	C0428302
phosphate levels	T034	C0428304
indexed	T170	C0918012
creatinine	T109	C0010294
BP	T040	C0005823
measured	T080	C0444706
median	T082	C2939193
IQR	T081	C1711350
follow-up	T058	C1522577
age	T032	C0001779
cohort	T098	C0599755
months	T079	C0439231
Preterm-born children	T100	C4048294
significantly lower	T081	C4055638
mean	T081	C0444504
GA	T032	C0017504
birth weight	T032	C0005612
higher	T080	C0205250
mean	T081	C0444504
systolic	T201	C0871470
diastolic	T201	C0428883
mean BPs	T033	C0428886
compared	T052	C1707455
term	T040	C0233324
controls	T096	C0009932
significantly higher	T081	C4055637
proportion	T081	C1709707
preterm-born children	T100	C4048294
weighed	T032	C0005910
<10th centile	T033	C3276033
systolic BP	T201	C0871470
>95th centile	T033	C0243095
follow-up	T058	C1522577
Albumin	T116	C2362049
calcium	T121	C0006675
excretion	T039	C0221102
not differ	T033	C3842396
groups	UnknownType	C0681860
median	T081	C0876920
urine-phosphate creatinine ratios	T201	C2735243
higher	T080	C0205250
preterm group	T100	C4048294
logistic regression	T062	C0206031
lower	T080	C0205251
GA	T032	C0017504
younger	T079	C0332239
age	T032	C0001779
follow-up	T058	C1522577
significantly	T078	C0750502
associated with	T080	C0332281
increased	T081	C0205217
risk	T078	C0035647
systolic	T201	C0871470
diastolic BP	T201	C0428883
95th centile	T033	C0243095
male gender	T032	C0086582
associated with	T080	C0332281
decreased	T081	C0205216
risk	T078	C0035647
diastolic hypertension	T047	C0235222
early childhood	T079	C0599196
children born preterm	T100	C4048294
significantly	T078	C0750502
elevated	T080	C3163633
BP	T040	C0005823
compared	T052	C1707455
term-born	T040	C0233324
counterparts	T096	C0009932
monitoring	T058	C1283169
BPs	T040	C0005823
population	T098	C1257890
Recombinant	T116	C0034861
protein transduction domain	T087	C1514562
Cu/Zn superoxide dismutase	T116	C0010461
alleviates	T080	C0392756
bone cancer	T191	C0279530
pain	T184	C0596240
peroxiredoxin 4	T116	C0914290
modulation	T044	C1148560
antioxidation	T044	C1148560
Bone cancer	T191	C0279530
pain	T184	C0596240
BCP	T184	C0596240
serious	T080	C0205404
chronic	T079	C0205191
clinical condition	T080	C0348080
reactive oxygen species	T123	C0162772
ROS	T123	C0162772
considered	T078	C0750591
involved	T169	C1314939
development	T169	C1527148
persistency	T079	C0205322
Normally	T080	C0205307
superoxide dismutase	T116	C0038838
SOD	T116	C0038838
superoxide anions	T196	C0038836
hydrogen peroxide	T121	C0020281
H2O2	T121	C0020281
H2O2	T121	C0020281
water	T121	C0043047
peroxiredoxin 4	T116	C0914290
reported	T170	C0684224
recombinant	T116	C0034861
protein transduction domain	T087	C1514562
PTD	T087	C1514562
Cu/Zn SOD	T116	C0010461
effectively	T080	C1704419
scavenged	T044	C1148560
excessive	T080	C0442802
ROS	T123	C0162772
prevented	T169	C1292733
cardiomyocytes	T025	C0225828
hypoxia-reoxygenation	T169	C0542341
damage	T169	C1883709
PTD	T087	C1514562
Cu/Zn SOD	T116	C0010461
prevent	T169	C1292733
BCP	T184	C0596240
development	T169	C1527148
unknown	T080	C0439673
current	T079	C0521116
study	T062	C0681814
found	T033	C0150312
implanted	T074	C0021102
carcinoma	T191	C0007097
rat	T015	C0034721
tibia	T023	C0040184
induced	T169	C0205263
hyperalgesia	T184	C0020429
increased	T081	C0205217
H2O2	T121	C0020281
levels	T080	C0441889
decreased	T081	C0205216
SOD	T116	C0038838
peroxiredoxin 4	T116	C0914290
levels	T080	C0441889
administration	T169	C1521801
recombinant	T116	C0034861
PTD	T087	C1514562
Cu/Zn SOD	T116	C0010461
tumor-burden	T081	C1516167
rats	T015	C0034721
hyperalgesia	T184	C0020429
significantly	T078	C0750502
attenuated	T052	C0599946
peroxiredoxin 4	T116	C0914290
expression	T045	C1171362
significantly increased	T081	C4055637
In addition	T169	C0332287
increased	T081	C0205217
expression	T045	C0597360
N-methyl-d-aspartic acid (NMDA) receptors	T116	C0080093
decreased	T081	C0205216
expression	T045	C0597360
γ-aminobutyric acid (GABA) receptors	T116	C0206518
cancer pain	T184	C0596240
prevented	T169	C1292733
PTD	T087	C1514562
Cu/Zn SOD	T116	C0010461
administration	T169	C1521801
peroxiredoxin 4	T116	C0914290
overexpression	T045	C1514559
data	T078	C1511726
suggested	T078	C1705535
reactive oxygen species	T123	C0162772
role	T077	C1705810
cancer metastatic	T191	C0027627
pain	T184	C0596240
development	T169	C1527148
persistency	T079	C0205322
attenuated by	T080	C0332161
adminstration	T169	C1521801
recombinant PTD	T116	C0034861
Cu/Zn SOD	T116	C0010461
peroxiredoxin 4	T116	C0914290
modulation	T044	C1148560
oxidative stress	T049	C0242606
Immune dysregulation	T033	C1844666
offspring	T099	C0680063
bipolar	T048	C0005586
parent	T099	C0030551
serum	T031	C0229671
levels	T080	C0441889
immune	T169	C0439662
growth factors	T116	C0018284
adolescent age	T100	C0205653
Immune dysregulation	T033	C1844666
vulnerability	T033	C1821973
mood disorders	T048	C0525045
Immune	T169	C0439662
growth factors	T116	C0018284
Stem Cell Factor	T116	C0143630
SCF	T116	C0143630
Insulin-like Growth Factor-Binding Protein-2	T116	C0123257
IGF-BP2	T116	C0123257
Epidermal Growth Factor	T116	C0242275
EGF	T116	C0242275
IL-7	T116	C0021761
sCD25	T116	C0487019
altered	T169	C0392747
patients	T101	C0030705
mood disorders	T048	C0525045
study	T062	C2603343
investigate	T169	C1292732
levels	T080	C0441889
factors	T116	C0018284
serum	T031	C0229671
adolescent	T100	C0205653
bipolar	T048	C0005586
offspring	T099	C0680063
heightened	T080	C0442803
risk	T078	C0035647
mood disorder	T048	C0525045
development	T169	C1527148
analyze	T062	C0936012
data	T078	C1511726
published data	T170	C1704324
Growth factors	T116	C0018284
assessed	T052	C1516048
CBA	T059	C0005507
ELISA	T059	C0014441
adolescent	T100	C0205653
bipolar	T048	C0005586
offspring	T099	C0680063
mean	T081	C0444504
age	T032	C0001779
years	T079	C0439234
age	T032	C0001779
gender	T032	C0079399
matched	T080	C1708943
healthy	T080	C3898900
controls	T096	C0009932
EGF	T116	C0242275
correlating	T080	C1707520
cluster	T081	C1704332
neurotrophic compounds	T116	C0132298
S100B	T116	C3711149
BDNF	T116	C3486709
decreased	T081	C0205216
serum	T031	C0229671
IL-7	T116	C0021761
SCF	T116	C0143630
IGF-BP2	T116	C0123257
sCD25	T116	C0487019
correlating	T080	C1707520
cluster	T081	C1704332
immune	T169	C0439662
growth factors	T116	C0018284
increased	T081	C0205217
IGF-BP2	T116	C0123257
significantly	T078	C0750502
serum	T031	C0229671
offspring	T099	C0680063
mood disorder	T048	C0525045
IL-7	T116	C0021761
SCF	T116	C0143630
serum	T031	C0229671
offspring	T099	C0680063
expirienced	T041	C0596545
mood episode	T048	C0525045
pattern	T082	C0449774
de	T081	C0547047
increases	T169	C0442805
bipolar	T048	C0005586
offspring	T099	C0680063
mood disorder	T048	C0525045
time	T079	C0040223
IGF-BP2	T116	C0123257
level	T080	C0441889
significantly	T078	C0750502
offspring	T099	C0680063
mood disorder	T048	C0525045
Correlations	T080	C1707520
published	T170	C1704324
immune-cellular abnormalities	T190	C4023612
conclusion	T078	C1707478
adolescents	T100	C0205653
familial	T169	C0241888
mood disorder	T048	C0525045
development	T169	C1527148
risk	T078	C0035647
characterized	T052	C1880022
pattern	T082	C0449774
compounds	T116	C0018284
network	T169	C1882071
hematopoiesis	T042	C0018951
neurogenesis	T040	C0814002
inflammation	T046	C0021368
eNOS	T116	C0132555
S-nitrosylates	T044	C1159123
β-actin	T116	C0005186
Cys374	T116	C0010654
regulates	T044	C1327623
PKC-θ	T116	C0171420
immune synapse	T026	C1171348
impairing	T169	C0221099
actin binding	T044	C1149245
profilin-1	T116	C0525216
actin cytoskeleton coordinates the organization	T043	C1155966
signaling microclusters	T129	C0021054
immune synapse	T026	C1171348
IS	T026	C1171348
mechanisms	T044	C3537153
nitric oxide	T121	C0028128
NO	T121	C0028128
endothelial nitric oxide synthase	T116	C0132555
eNOS	T116	C0132555
protein kinase C-θ	T116	C0171420
PKC-θ	T116	C0171420
central supramolecular activation cluster	T026	C1171348
c-SMAC	T026	C1171348
IS	T026	C1171348
eNOS	T116	C0132555
translocated	T043	C0599893
Golgi	T026	C0018042
IS	T026	C1171348
colocalized	T082	C0392752
F-actin	T116	C1180307
c-SMAC	T026	C1171348
actin polymerization	T043	C1155982
retrograde flow	T067	C1709934
β-actin	T116	C0005186
PKC-θ	T116	C0171420
lamellipodium-like	T026	C0230628
distal	T082	C0205108
(d)-SMAC	T026	C1171348
promoting	T052	C0033414
PKC-θ	T116	C0171420
activation	T044	C0014429
eNOS	T116	C0132555
NO	T121	C0028128
S-nitrosylated	T044	C1159123
β-actin	T116	C0005186
Cys374	T116	C0010654
impaired	T169	C0221099
actin binding	T044	C1149245
profilin-1	T116	C0525216
PFN1	T116	C0525216
transnitrosylating	T044	C3158785
S-nitroso-L-cysteine	T109	C0073896
Cys-NO	T109	C0073896
NO	T121	C0028128
PFN1-actin complexes	T116	C1180347
regulation	T044	C1327623
PKC-θ	T116	C0171420
overexpression	T045	C1514559
PFN1	T028	C1456390
actin-binding	T044	C1149245
mutants	T049	C0596988
β-actin (C374S)	T028	C1384510
PFN1 (H119E)	T028	C1456390
PKC-θ	T116	C0171420
c-SMAC	T026	C1171348
NO	T121	C0028128
mechanism	T044	C3537153
actin cytoskeleton controls the organization	T043	C1155966
activation	T052	C1879547
signaling microclusters	T129	C0021054
IS	T026	C1171348
Dobutamine Stress Echocardiography	T060	C0949700
Impact	T080	C4049986
Abnormal	T033	C0205161
Blood Potassium Levels	T034	C1261540
Cardiac Arrhythmias	T033	C0003811
Guidelines	T170	C0162791
abnormal	T033	C0205161
blood potassium level	T034	C1261540
contraindication	T080	C0522473
performing	T169	C0884358
dobutamine stress echocardiography	T060	C0949700
DSE	T060	C0949700
reviewed	T080	C1709940
consecutive series of patients	T062	C2985408
potassium	T123	C0032821
testing	T169	C0039593
hours	T079	C0439227
DSE	T060	C0949700
evaluation	T058	C0220825
myocardial ischemia	T047	C0151744
year	T079	C0439234
period	T079	C1948053
potassium	T123	C0032821
range	T081	C1514721
laboratory	T073	C0022877
Hemolyzed samples	T033	C0475880
association	T080	C0439849
potassium levels	T033	C0428289
development	T169	C1527148
supraventricular	T046	C0428974
ventricular arrhythmias	T047	C0085612
assessed	T052	C1516048
arrhythmias	T033	C0003811
low	T080	C0205251
supraventricular tachycardia	T047	C0039240
atrial fibrillation	T047	C0004238
nonsustained ventricular tachycardia	T046	C2919575
sustained ventricular tachycardia	T047	C0750197
ventricular fibrillation	T047	C0042510
overall safety	T068	C0036043
DSE	T060	C0949700
arrhythmias	T033	C0003811
patients	T101	C0030705
potassium levels	T033	C0428289
arrhythmia	T033	C0003811
rates	T081	C1521828
low	T080	C0205251
patients	T101	C0030705
potassium	T123	C0032821
abnormalities	T033	C1704258
Patients	T101	C0030705
hyperkalemia	T033	C0020461
risk	T078	C0035647
mild	T080	C2945599
odds ratio	T081	C0028873
OR	T081	C0028873
CI	T081	C0009667
severe	T080	C0205082
OR	T081	C0028873
CI	T081	C0009667
supraventricular arrhythmias	T046	C0428974
mild	T080	C2945599
ventricular arrhythmias	T047	C0085612
OR	T081	C0028873
CI	T081	C0009667
rare	T080	C0522498
patients	T101	C0030705
severe	T080	C0205082
hypokalemia	T033	C0020621
potassium levels	T033	C0428289
increased	T081	C0205217
risk	T078	C0035647
supraventricular arrhythmia	T046	C0428974
ventricular ectopy	T047	C0012634
DSE	T060	C0949700
abnormalities	T033	C1704258
blood potassium concentrations	T034	C1261540
DSE	T060	C0949700
patients	T101	C0030705
potassium	T123	C0032821
abnormalities	T033	C1704258
Elevated	T080	C3163633
potassium levels	T033	C0428289
associated with	T080	C0332281
supraventricular	T046	C0428974
ventricular arrhythmias	T047	C0085612
low	T080	C0205251
risk	T078	C0035647
patients	T101	C0030705
low	T080	C0205251
potassium levels	T033	C0428289
DSE	T060	C0949700
increased	T081	C0205217
risk	T078	C0035647
arrhythmia	T033	C0003811
severe	T080	C0205082
hypokalemia	T033	C0020621
prior	T079	C0332152
DSE	T060	C0949700
Anatomical	T080	C0220784
subgroup	T185	C1515021
analysis	T062	C0936012
MERIDIAN	UnknownType	C0681784
cohort	T098	C0599755
Posterior fossa abnormalities	T033	C3280768
assess	T058	C0184514
diagnostic	T169	C0348026
clinical	T080	C0205210
contribution	T052	C1880177
in utero magnetic resonance (iuMR) imaging	T060	C0024485
fetuses	T018	C0015965
diagnosed	T033	C0011900
abnormalities of the posterior fossa	T033	C3280768
intracranial abnormality	T033	C3809358
antenatal ultrasonography	T060	C0080265
USS	T060	C0080265
report	T170	C0684224
sub-group	T185	C1515021
analysis	T062	C0936012
fetuses	T018	C0015965
abnormalities of the posterior fossa	T033	C3280768
diagnosed	T033	C0011900
antenatal USS	T060	C0080265
ventriculomegaly	UnknownType	C0743968
MERIDIAN	UnknownType	C0681784
cohort	T098	C0599755
iuMR imaging	T060	C0024485
USS	T060	C0080265
outcome	T080	C0085415
reference data	T078	C1554143
available	T169	C0470187
diagnostic accuracy	T080	C0598285
USS	T060	C0080265
iuMR	T060	C0024485
reported	T170	C0684224
indicators	T130	C0021212
diagnostic confidence	T080	C0598285
effects	T080	C1280500
prognosis	T058	C0033325
clinical management	T058	C1516615
Abnormalities confined to the posterior fossa	T033	C3280768
USS	T060	C0080265
fetuses	T018	C0015965
parenchymal	T025	C0682552
CSF	T031	C0007806
lesions	T033	C0221198
diagnostic accuracy	T080	C0598285
detecting	T033	C0442726
isolated	T169	C0205409
posterior fossa abnormality	T033	C3280768
USS	T060	C0080265
iuMR	T060	C0024485
difference	T081	C1705241
improvement	T077	C2986411
appropriate	T080	C1548787
diagnostic confidence	T080	C0598285
assessed	T058	C0184514
score	T081	C0449820
based	T169	C1527178
weighted	T081	C0043100
average	T081	C1510992
method	T170	C0025663
reduction	T061	C0441610
'high	T080	C0205250
incorrect	T080	C3827420
diagnoses	T033	C0011900
iuMR imaging	T060	C0024485
prognostic information	T058	C0033325
women	T098	C0043210
iuMR imaging	T060	C0024485
cases	T077	C1706256
overall	T080	C1561607
effect	T080	C1280500
iuMR	T060	C0024485
clinical management	T058	C1516615
significant	T078	C0750502
major	T080	C0205164
decisive	T033	C0564585
cases	T077	C1706256
data	T078	C1511726
woman	T098	C0043210
fetus	T018	C0015965
posterior fossa abnormality	T033	C3280768
intracranial finding	T033	C3809358
USS	T060	C0080265
iuMR imaging	T060	C0024485
evaluation	T058	C0220825
basis	T169	C1527178
improved	T033	C0184511
diagnostic accuracy	T080	C0598285
confidence	T080	C0598285
substantial	T080	C0205082
effects	T080	C1280500
prognostic information	T058	C0033325
women	T098	C0043210
clinical management	T058	C1516615
Design	T052	C1707689
synthesis	T052	C1883254
evaluation	T058	C0220825
curcumin	T109	C0010467
derivatives	T104	C0243072
Nrf2	T116	C0289507
activators	T045	C0599177
cytoprotectors	T039	C0524828
oxidative death	T043	C3893307
Activation	T045	C0599177
nuclear factor erythroid-2-related factor 2	T116	C0289507
Nrf2	T116	C0289507
cancer	T191	C0006826
curcumin	T109	C0010467
Nrf2	T116	C0289507
activator	T045	C0599177
cancer	T191	C0006826
chemopreventive agent	T121	C1516463
study	T062	C2603343
curcumin	T109	C0010467
analogs	T104	C0243071
geminal dimethyl substituents on the active methylene group	T104	C1254350
Nrf2	T116	C0289507
activators	T045	C0599177
cytoprotectors	T039	C0524828
oxidative death	T043	C3893307
geminally dimethylated	T104	C1254350
catechol	T109	C0054858
curcumin	T109	C0010467
analog	T104	C0243071
compound 3	T121	C1254351
lead molecule	T121	C1254351
stability	T044	C0314668
cytoprotective	T039	C0524828
activity	T052	C0441655
tert-butyl hydroperoxide	T109	C0076150
t-BHP	T109	C0076150
death	T043	C0007587
HepG2 cells	T025	C2717940
Mechanism	T169	C0441712
studies	T062	C2603343
cytoprotective	T039	C0524828
effects	T080	C1280500
activating	T052	C1879547
Nrf2	T116	C0289507
signaling pathway	T044	C0037080
Michael acceptor	T121	C1254351
catechol	T109	C0054858
copper	T121	C0009968
iron	T121	C0302583
ion	T196	C0022023
chelators	T121	C0007974
metal	T197	C0025552
ion	T196	C0022023
oxidations	T044	C0030011
compound 3	T121	C1254351
o-quinone	T109	C0034435
Nrf2	T116	C0289507
cytoprotection	T039	C0524828
designing	T052	C1707689
natural	T169	C0205296
curcumin	T109	C0010467
Nrf2	T116	C0289507
activators	T045	C0599177
stability	T044	C0314668
proelectrophilic	T070	C1254365
Safe	T068	C0036043
Self-Injury	T037	C0424366
Practical Guide	T170	C0681464
Understanding	T041	C0162340
Responding	T053	C0004927
Harm-reduction	T061	C0679771
Inckle Kay	T170	C0805191
Safe	T068	C0036043
Self-Injury	T037	C0424366
Practical Guide	T170	C0681464
Understanding	T041	C0162340
Responding	T053	C0004927
Harm-reduction	T061	C0679771
author	T097	C3812881
book	T170	C0006002
concise	T081	C1806781
exploration	T169	C1292732
stereotypes	T041	C0038272
truths	T080	C0205238
self-harm	T037	C0424366
chapters	T170	C0005990
grounded	T170	C1510611
challenging view	T082	C0449911
self-harm	T037	C0424366
understood	T041	C0162340
perspectives	T041	C0030971
Pre-hospital	T079	C1254367
policies	T170	C0242456
care of patients	T058	C0017313
acute coronary syndromes	T047	C0948089
India	T083	C0021201
policy	T170	C0242456
document	T170	C1301746
analysis	T062	C0936012
Ischemic heart disease	T184	C0002962
leading	T169	C1522538
cause of death	T033	C0007465
India	T083	C0021201
high-income	T033	C0948433
countries	T083	C0454664
pre-hospital systems of care	T058	C1444165
manage	T058	C0184516
acute	T079	C0205178
manifestations of	T080	C1280464
ischemic heart disease	T184	C0002962
acute coronary syndrome	T047	C0948089
ACS	T047	C0948089
unknown	T080	C0439673
guidelines	T170	C0162791
policies	T170	C0242456
regulations	T064	C0851285
laws	T089	C0023150
exist	T077	C2987476
pre-hospital	T079	C1254367
ACS	T047	C0948089
care	T058	C0086388
India	T083	C0021201
nation-wide	T082	C1254362
document	T170	C1301746
analysis	T062	C0936012
knowledge	T170	C0376554
November	T079	C3828767
May	T079	C3812381
searched	T052	C1706202
publicly	T080	C0205556
available	T169	C0470187
emergency care	T061	C1527398
guidelines	T170	C0162791
legislation	T170	C0600657
pre-hospital	T079	C1254367
ACS	T047	C0948089
care	T058	C0086388
Indian	T083	C0021201
states	T083	C1301808
Union Territories	T083	C0017446
Internet	T073	C0282111
search	T052	C1706202
direct	T080	C1947931
correspondence	T170	C0282413
found	T033	C0150312
documents	T170	C1301746
pre-hospital	T079	C1254367
ACS	T047	C0948089
care	T058	C0086388
India	T083	C0021201
legislation mandating	UnknownType	C0814715
acute care	T058	C0679878
emergencies	T067	C0013956
trauma	T037	C3714660
regulations	T064	C0851285
laws	T089	C0023150
pre-hospital	T079	C1254367
ACS	T047	C0948089
care	T058	C0086388
absent	T169	C0332197
Policy makers	T097	C0242170
urgently	T079	C0439609
need	T080	C0027552
comprehensive	T080	C1880156
multi-stakeholder	T080	C0205556
policies	T170	C0242456
pre-hospital	T079	C1254367
emergency	T067	C0013956
cardiovascular care	T058	C4273565
India	T083	C0021201
Lack	T080	C0332268
antimicrobial	T034	C1271650
efficacy	T080	C1280519
mecetronium etilsulfate	T109	C0771499
propanol	T109	C0175804
hand rubs	T121	C1330330
surgical	T061	C0543467
hand disinfection	T058	C0018570
aim	T078	C1947946
study	T062	C2603343
mecetronium etilsulfate	T109	C0771499
MES	T109	C0771499
efficacy	T080	C1280519
surgical	T061	C0543467
hand disinfection	T058	C0018570
hand rubs	T121	C1330330
iso-propanol	T109	C0022237
n-propanol	T109	C0001964
applied	T169	C4048755
compared	T052	C1707455
EN 12791	T121	C1254351
procedure	T169	C2700391
crossover design	T062	C0242817
commercial	T170	C0680536
hand rub	T121	C1330330
MES	T109	C0771499
hand rubs	T121	C1330330
identical	T080	C0205280
MES	T109	C0771499
formulations	T077	C1705957
log10	T081	C1690986
reduction	T080	C0392756
better	T080	C0332272
compared	T052	C1707455
procedure	T169	C2700391
mean	T081	C0444504
standard deviation	T081	C0871420
antimicrobial	T034	C1271650
contribution	T052	C1880177
MES	T109	C0771499
hand rubs	T121	C1330330
Skin Conductance	T042	C0814024
Responses	T032	C0871261
Neural	T169	C3714606
Activations	T052	C1879547
Fear	T041	C0015726
Conditioning	T041	C0009647
Extinction	T041	C0015347
Recall	T041	C0034770
Anxiety Disorders	T048	C0003469
fear	T041	C0015726
conditioning	T041	C0009647
extinction	T041	C0015347
neurocircuitry	T062	C0596723
extensively	T080	C0205231
studied	T062	C2603343
healthy	T080	C3898900
clinical	T080	C0205210
populations	T098	C1257890
particular focus	T082	C0205234
posttraumatic stress disorder	T048	C0038436
significant	T078	C0750502
overlap	T079	C1948020
symptoms	T184	C1457887
posttraumatic stress disorder	T048	C0038436
anxiety disorders	T048	C0003469
received	T080	C1514756
less	T081	C0439092
attention	T041	C0004268
fear	T041	C0015726
levels	T080	C0441889
characterize	T052	C1880022
anxiety disorders	T048	C0003469
examining	T058	C0582103
neural	T169	C3714606
correlates	T080	C1707520
fear	T041	C0015726
extinction	T041	C0015347
learning	T041	C0023185
pathogenesis	T046	C0699748
anxiety disorders	T048	C0003469
investigate	T169	C1292732
psychophysiological	T041	C0018467
neural	T169	C3714606
correlates	T080	C1707520
fear	T041	C0015726
conditioning	T041	C0009647
extinction	T041	C0015347
recall	T041	C0034770
anxiety disorders	T048	C0003469
document	T170	C1301746
features	T080	C2348519
function	T169	C0542341
multiple	T081	C0439064
diagnoses	T033	C0011900
anxiety	T033	C0003467
severity	T080	C0439793
investigation	T058	C0220825
cross-sectional	T062	C0010362
case-control	T058	C0872128
functional magnetic resonance imaging	T060	C0376335
study	T062	C2603343
academic medical center	T073	C0000872
Participants	T098	C0679646
healthy	T080	C3898900
controls	T096	C0009932
individuals	T098	C0237401
following	T079	C0332282
anxiety disorders	T048	C0003469
generalized anxiety disorder	T048	C0270549
social anxiety disorder	T048	C4237417
specific phobia	T048	C0236801
panic disorder	T048	C0030319
study	T062	C2603343
dates	T079	C0011008
fear	T041	C0015726
conditioning	T041	C0009647
extinction	T041	C0015347
paradigm	T062	C0681797
Skin conductance	T042	C0814024
responses	T032	C0871261
blood oxygenation level-dependent	T042	C1655730
responses	T032	C0871261
trait	T032	C0599883
anxiety scores	T033	C3483978
State Trait Anxiety Inventory	T060	C0683457
Trait	T032	C0599883
Form	T080	C0348078
functiona	T169	C0542341
connectivity	T169	C1707489
study	T062	C2603343
included	T052	C2700399
healthy	T080	C3898900
controls	T096	C0009932
women	T098	C0043210
individuals	T098	C0237401
anxiety disorders	T048	C0003469
women	T098	C0043210
P values	T081	C1709380
reported	T058	C0700287
neuroimaging	T060	C0679575
results	T034	C0456984
familywise	T099	C0015576
error	T080	C0743559
corrected	T080	C0205202
Skin conductance	T042	C0814024
responses	T032	C0871261
extinction	T041	C0015347
recall	T041	C0034770
individuals	T098	C0237401
anxiety disorders	T048	C0003469
healthy	T080	C3898900
controls	T096	C0009932
ηp2	T081	C0392762
ηp2	T081	C0392762
partial eta squared	T081	C0392762
anxiety	T033	C0003467
group	T098	C1257890
lower	T080	C0205251
activation	T052	C1879547
ventromedial prefrontal cortex	T023	C3850122
vmPFC	T023	C3850122
extinction	T041	C0015347
recall	T041	C0034770
ηp2	T081	C0392762
hypoactive	T033	C0086439
pattern	T082	C0449774
early	T079	C1279919
conditioning	T041	C0009647
ηp2	T081	C0392762
vmPFC	T023	C3850122
hypoactivation	T052	C1879547
associated with	T080	C0332281
anxiety symptom	T033	C0860603
severity	T080	C0439793
conditioning	T041	C0009647
extinction	T041	C0015347
recall	T041	C0034770
number	T081	C0237753
co-occuring	T052	C1709305
anxiety disorders	T048	C0003469
diagnosed	T033	C0011900
ηp2	T081	C0392762
conditioning	T041	C0009647
ηp2	T081	C0392762
extinction	T041	C0015347
recall	T041	C0034770
Psychophysiological	T041	C0018467
interaction analyses	T081	C0237688
revealed	T080	C0443289
fear	T041	C0015726
network connectivity	T040	C0598941
healthy	T080	C3898900
controls	T096	C0009932
anxiety	T033	C0003467
group	T098	C1257890
fear	T041	C0015726
learning	T041	C0023185
ηp2	T081	C0392762
range	T081	C1514721
P	T081	C1709380
range	T081	C1514721
extinction	T041	C0015347
recall	T041	C0034770
ηp2	T081	C0392762
range	T081	C1514721
P	T081	C1709380
range	T081	C1514721
skin conductance	T042	C0814024
response	T032	C0871261
group	T098	C1257890
differences	T081	C1705241
extinction	T041	C0015347
recall	T041	C0034770
brain	T023	C0006104
activation	T052	C1879547
patterns	T082	C0449774
anxious	T048	C0849801
healthy	T080	C3898900
individuals	T098	C0237401
findings	T033	C0243095
future	T079	C0016884
studies	T062	C2603343
examine	T058	C0582103
conditions	T080	C0348080
longitudinally	T062	C0023981
context	T078	C0449255
treatment trials	T062	C0008976
improve	T033	C0184511
guide therapeutics	T061	C1562629
advanced	T080	C0205179
neurobiological	T091	C0027817
understanding	T041	C0162340
disorder	T047	C0012634
Extracellular vesicles	T026	C3894683
bone marrow	T024	C0005953
mesenchymal stem cells	T025	C1257975
protect	T033	C1545588
murine	T015	C0026809
hepatic ischemia	T046	C0920569
hepatic ischemia - reperfusion injury	T037	C4303160
reperfusion injury	T037	C0035126
Hepatic ischemia-reperfusion injury	T037	C4303160
IRI	T037	C4303160
associated inflammation	T046	C0021368
liver dysfunction	T046	C0086565
complications	T046	C0009566
liver surgery	T061	C0193373
transplantation	T061	C0040732
Mesenchymal stem cells	T025	C1257975
MSC	T025	C1257975
reduce	T080	C0392756
hepatic IRI	T037	C4303160
reparative	T058	C1254363
immunomodulatory	T121	C1527392
immunomodulatory effects	T080	C1280500
injured	T169	C0332664
tissues	T024	C0040300
beneficial effects	T080	C1280500
extracellular vesicles	T026	C3894683
MSCs	T025	C1257975
MSC	T025	C1257975
EV	T026	C3894683
tissue injury	T033	C2136639
systemically administered	UnknownType	C0678812
mouse bone marrow	T024	C1511243
MSC	T025	C1257975
EV	T026	C3894683
evaluated	T062	C0178628
experimental murine model	T008	C0887965
hepatic IRI	T037	C4303160
induced	T169	C0205263
cross clamping	T169	C1883710
hepatic artery	T023	C0019145
portal vein	T023	C0032718
minutes	T079	C0439232
reperfusion	T061	C0035124
periods	T079	C1948053
hours	T079	C0439227
controls, intravenous administration	T082	C0013125
MSC	T025	C1257975
EV	T026	C3894683
minutes	T079	C0439232
IRI	T037	C4303160
dramatically reduced	T080	C0392756
tissue necrosis	T042	C0027540
decreased	T081	C0205216
caspase-3 positive	T116	C0291573
apoptotic cells	T026	C3269134
reduced	T080	C0392756
aminotransferase	T116	C0002594
MSC	T025	C1257975
EV	T026	C3894683
increased	T081	C0205217
hepatic	T029	C0205054
mRNA expression	T045	C1515670
NACHT, LRR and PYD domains-containing protein 12	T028	C1864814
Nlrp12	T028	C1864814
chemokine (C-X-C motif) ligand 1	T028	C0812445
CXCL1	T028	C0812445
reduced	T080	C0392756
mRNA expression	T045	C1515670
inflammatory	T169	C0333348
cytokines	T116	C0079189
IL-6	T116	C0021760
IRI	T037	C4303160
MSC	T025	C1257975
EV	T026	C3894683
increased	T081	C0205217
cell viability	T043	C0007620
suppressed	T169	C1260953
oxidative	T169	C0311404
injury	T080	C1510467
NF-κB	T116	C0961340
activity	T052	C0441655
AML12 murine hepatocytes	T025	C0227525
in vitro	T080	C1533691
administration	T061	C1533734
EV	T026	C3894683
bone marrow	T024	C0005953
MSCs	T025	C1257975
ameliorate	T033	C0243095
hepatic IRI	T037	C4303160
reducing	T080	C0392756
hepatic injury	T037	C0160390
modulation	T082	C0443264
inflammatory response	T046	C1155266
Nucleic acid detection	T059	C0872232
CRISPR	T114	C3658200
Cas13a	T116	C0599560
C2c2	T116	C0599560
Rapid	T080	C0456962
sensitive	T169	C0332324
nucleic acid detection	T059	C0872232
aid	T080	C1269765
point-of-care	T078	C1547702
pathogen	T001	C0450254
detection	T061	C1511790
genotyping	T059	C1285573
disease	T047	C0012634
monitoring	T058	C1283169
RNA	T114	C0035668
RNA	T114	C0035668
targeting	T169	C1521840
clustered regularly interspaced short palindromic repeats	T114	C3658200
CRISPR	T114	C3658200
effector	T116	C0599560
Cas13a	T116	C0599560
C2c2	T116	C0599560
collateral	T082	C1948058
effect	T080	C1280500
ribonuclease activity	T045	C1148840
target	T169	C1521840
recognition	T044	C0599844
combine	T080	C0205195
collateral	T082	C1948058
effect	T080	C1280500
Cas13a	T116	C0599560
isothermal amplification	T059	C3539922
establish	T080	C0443211
CRISPR	T114	C3658200
diagnostic	T169	C0348026
CRISPR	T114	C3658200
Dx	T169	C0348026
rapid	T080	C0456962
DNA	T114	C0012854
RNA	T114	C0035668
detection	T061	C1511790
attomolar sensitivity	T081	C1511883
single-base	T114	C1704464
mismatch	T080	C1881865
specificity	T081	C0037791
Cas13a	T116	C0599560
molecular	T080	C1521991
detection	T061	C1511790
platform	T075	C1710360
Specific High-Sensitivity Enzymatic Reporter UnLOCKing	T075	C1710360
SHERLOCK	T075	C1710360
detect	T033	C0442726
specific	T080	C0205369
strains	T001	C1518614
Zika	T005	C0318793
Dengue virus	T005	C0011315
pathogenic	T001	C0450254
bacteria	T007	C0004611
genotype	T032	C0017431
human	T016	C0086418
DNA	T114	C0012854
identify	T080	C0205396
mutations	T045	C0026882
cell-free	T026	C0007625
tumor DNA	T114	C0012930
SHERLOCK	T075	C1710360
reaction	T169	C0443286
reagents	T130	C0034760
lyophilized	T059	C0016698
cold-chain	T066	C0282332
long-term	T079	C0443252
storage	T169	C1698986
field applications	UnknownType	C0869019
thoracoscopic	T058	C0039989
resection	T061	C0015252
solitary pulmonary nodule	T191	C2350019
cancer	T191	C0006826
patients	T101	C0030705
Solitary pulmonary nodules	T191	C2350019
SPN	T191	C2350019
detected	T033	C0442726
cancer	T191	C0006826
patients	T101	C0030705
lesions	T033	C0577916
pulmonary metastases	T191	C0153676
increasingly	T169	C0442808
treated	T169	C1522326
non-surgical techniques	T061	C0087111
histological	T169	C0205462
confirmation	T033	C0750484
histological	T169	C0205462
nature	T169	C1262865
SPN	T191	C2350019
resected	T080	C1521996
thoracoscopy	T058	C0039989
risk factors	T033	C0035648
malignancy	T191	C4282132
Single-institution retrospective analysis	T062	C0035363
consecutive	T080	C1707491
patients	T101	C0030705
malignancies	T191	C4282132
thoracoscopic	T058	C0039989
resection	T061	C0015252
SPN	T191	C2350019
unknown	T080	C0439673
diagnosis	T033	C0011900
cancer	T191	C0006826
patients	T101	C0030705
thoracoscopic	T058	C0039989
resection	T061	C0015252
SPN	T191	C2350019
resected	T080	C1521996
SPN	T191	C2350019
benign	T080	C0205183
patients	T101	C0030705
malignant	T080	C0205282
patients	T101	C0030705
metastasis	T191	C0027627
patients	T101	C0030705
primary	T080	C0205225
lung cancer	T191	C0242379
patients	T101	C0030705
univariate analysis	T062	C0683962
malignancy	T191	C4282132
associated with	T080	C0332281
age	T032	C0001779
years	T079	C1510829
disease	T047	C0012634
interval	T079	C1272706
months	T079	C0439231
SPN	T191	C2350019
size	T082	C0475440
upper lobe	T023	C0225756
localization	T169	C0475264
SUVmax	T081	C2986846
PET-CT	T060	C1699633
multivariate analysis	T081	C0026777
upper lobe	T023	C0225756
localization	T169	C0475264
SUVmax	T081	C2986846
associated with	T080	C0332281
malignancy	T191	C4282132
Smoking	T055	C0037369
associated with	T080	C0332281
SPN	T191	C2350019
primary	T080	C0205225
lung cancer	T191	C0242379
series	T081	C0205549
SPN	T191	C2350019
patients	T101	C0030705
malignant disease	T047	C0442867
pulmonary metastases	T191	C0153676
newly diagnosed	T080	C1518321
NSCLC	T191	C0007131
Smoking	T055	C0037369
associated with	T080	C0332281
primary	T080	C0205225
lung cancer	T191	C0242379
no	T033	C1513916
predictor	T078	C2698872
pulmonary metastasis	T191	C0153676
lung cancer	T191	C0242379
histological	T169	C0205462
confirmation	T033	C0750484
SPN	T191	C2350019
patients	T101	C0030705
previous	T079	C0205156
malignancies	T191	C4282132
diagnostic	T169	C0348026
uncertainty	T033	C0087130
suboptimal	T080	C2984009
treatments	T061	C0087111
Reliability	T080	C0205556
Fear Assessment	T058	C4040543
Growing	T033	C3687568
Pigs	T015	C0039005
Exposed to	T080	C0332157
Novel	T080	C0205314
Object	T072	C0347997
Test	T169	C0039593
Commercial	T170	C0680536
Conditions	T080	C0348080
objective	T170	C0018017
assess	T052	C1516048
reliability	T080	C0205556
feasibility	T062	C0015730
novel	T080	C0205314
object	T072	C0347997
test	T169	C0039593
assessing fear	T058	C2364227
pigs	T015	C0039005
commercial	T170	C0680536
conditions	T080	C0348080
commercial	T170	C0680536
farms	T082	C0557759
pens housing	T073	C0020057
growing	T033	C3687568
pigs	T015	C0039005
assessed	T052	C1516048
balloons	T073	C3273359
novel	T015	C0039005
stimulus	T067	C0234402
Measures	T081	C0079809
time	T079	C0040223
pig	T015	C0039005
contact	T067	C0392367
balloons	T073	C3273359
nonhuman	T015	C0237798
animals	T008	C0003062
watching	T041	C2371283
balloons	T073	C3273359
animals	T008	C0003062
touching	T169	C2584295
balloons	T073	C3273359
periods	T079	C1948053
time	T079	C0040223
pig	T015	C0039005
contact	T067	C0392367
balloons	T073	C3273359
ranged	T081	C1514721
effect	T080	C1280500
farm	T082	C0557759
contact	T067	C0392367
latency	T079	C0242465
ranging	T081	C1514721
difference	T080	C1705242
intrafarm	T082	C0557759
variability	T077	C2827666
Interobserver repeatability	T170	C0870736
high	T080	C0205250
measure	T081	C0079809
ranging	T081	C1514721
contact	T067	C0392367
latency	T079	C0242465
measure	T081	C0079809
assess	T052	C1516048
fear	T041	C0015726
stimulus	T067	C0234402
commercial	T170	C0680536
farms	T082	C0557759
prediction	T078	C0681842
activators	T121	C0751968
human	T016	C0086418
constitutive androstane receptor	T116	C0914906
structure	T085	C0026383
three-dimensional quantitative structure-activity relationship	T081	C0887820
methods	T170	C0025663
constitutive androstane receptor	T116	C0914906
CAR	T116	C0914906
NR1I3)	T116	C0663285
regulates the expression	T045	C2755857
numerous	T081	C0439064
drug-metabolizing	T044	C0683140
enzymes	T116	C0014442
transporters	T116	C0007292
upregulation	T044	C0041904
enzymes	T116	C0014442
CYP2B6	T116	C0534137
CAR	T116	C0914906
activators	T121	C0751968
severe	T080	C0205082
drug-drug interactions	T044	C0687133
DDIs	T044	C0687133
effective	T080	C1704419
computational approaches	T062	C1516769
CAR	T116	C0914906
three-dimensional quantitative structure-activity relationship	T081	C0887820
3D-QSAR	T081	C0887820
models	T170	C3161035
CAR	T116	C0914906
activating	T043	C1514758
potency	T080	C3245505
compounds	T121	C1254351
drug-discovery	T062	C0920472
process	T067	C1522240
Models	T170	C3161035
comparative molecular field analysis	T063	C1513380
CoMFA	T063	C1513380
molecular	T167	C0567416
alignments	T081	C1706765
ligands binding	T044	C1517880
CAR	T116	C0914906
ligand-docking	T044	C1522290
28 compounds	T121	C1254351
CoMFA	T063	C1513380
model	T170	C3161035
modified by	T080	C0205349
lipophilic	T081	C0598631
parameter	T081	C0598631
predictive ability	T080	C1514307
predictability	T081	C0237793
3D-QSAR	T081	C0887820
model	T170	C3161035
CAR	T116	C0914906
activation	T043	C1514758
compounds	T121	C1254351
external validation	T062	C1519941
results	T169	C1274040
3D-QSAR	T081	C0887820
model	T170	C3161035
precise	T080	C2828393
prediction	T078	C0681842
CAR	T116	C0914906
activating	T043	C1514758
potency	T080	C3245505
drug candidates	T121	C1254351
minimized	T080	C1524031
DDI	T044	C0687133
risk	T078	C0035647
enzyme-induction	T045	C0014431
early	T079	C1279919
drug-discovery	T062	C0920472
stage	T079	C1306673
Effects of	T080	C1704420
siRNA	T114	C1099354
suppression	T045	C0038855
HPV-11 L1	T028	C0017376
expression	T045	C0017262
proliferation	T043	C0596290
apoptosis	T043	C0162638
vaginal epithelial cells	T025	C1987256
aim	T078	C1947946
study	T062	C2603343
investigate	T169	C1292732
effects of	T080	C1704420
human papillomavirus (HPV) infection	T047	C0343641
gynecological disease	T047	C1384956
vaginitis	T047	C0042267
small interfering RNA	T114	C1099354
siRNA	T114	C1099354
HPV	T005	C0021344
prevention	T061	C0199176
clinic	T073	C0442592
Human	T016	C0086418
vaginal epithelial cells	T025	C1987256
transfected	T063	C0040669
HPV-11 L1	T028	C0017376
expression vector	T114	C0599566
siRNA	T114	C1099354
HPV-11 L1	T028	C0017376
vectors	T114	C0017397
control group	T096	C0009932
transfected	T063	C0040669
siRNA	T114	C1099354
Cell proliferation	T043	C0596290
MTT assay	T059	C1510438
expression	T045	C1171362
apoptosis	T043	C0162638
proteins	T116	C0033684
measured	T080	C0444706
western blot analysis	T059	C2121086
Compared	T052	C1707455
control group	T096	C0009932
HPV-11 L1	T028	C0017376
mRNA	T114	C0035696
protein levels	T034	C0428479
increased	T081	C0205217
transfection	T063	C0040669
HPV-11 L1	T028	C0017376
expression vector	T114	C0599566
cells	T025	C0007634
silencing	T045	C0598496
HPV-11 L1	T028	C0017376
cell proliferation	T043	C0596290
HPV-11 group	T078	C0441833
lower	T080	C0205251
control group	T096	C0009932
cell proliferation	T043	C0596290
increased	T081	C0205217
cells	T025	C0007634
transfected	T063	C0040669
silenced	T045	C0598496
L1	T028	C0017376
control group	T096	C0009932
silencing	T045	C0598496
HPV-11 L1	T028	C0017376
decreased	T081	C0205216
caspase-3	T028	C1413132
caspase-9	T028	C1332668
expressions	T045	C0017262
cells	T025	C0007634
expression	T045	C0017262
increased	T081	C0205217
HPV-11 L1	T028	C0017376
study	T062	C2603343
siRNA	T114	C1099354
silencing	T045	C0598496
HPV-11 L1	T028	C0017376
therapeutic applications	T061	C0278296
gynecological diseases	T047	C1384956
associated with	T080	C0332281
HPV-11	T005	C1093046
infection	T046	C3714514
evaluation	T058	C0220825
neuroendocrine	T022	C0027912
dysfunction	T077	C3887504
acute	T079	C0205178
aneurysmal subarachnoid hemorrhage	T046	C0751530
prospective study	T062	C0033522
aim	T078	C1947946
investigate	T169	C1292732
pattern	T082	C0449774
neuroendocrine	T022	C0027912
cases	T101	C0030705
acute	T079	C0205178
aneurysmal subarachnoid hemorrhage	T046	C0751530
SAH	T046	C0751530
Endocrine	T022	C0014136
assessment	T058	C0220825
cases	T101	C0030705
acute	T079	C0205178
aneurysmal SAH	T046	C0751530
days	T079	C0439228
ictus	T047	C0038454
gonadotropic	T116	C0018061
somatotrophic	T116	C0037663
thyrotropic	T116	C0040160
corticotrophic	T116	C0001655
evaluated	T058	C0220825
dysfunction	T077	C3887504
cases	T101	C0030705
males	T032	C0086582
females	T032	C0086287
age	T032	C0001779
range	T081	C1514721
years	T079	C1510829
mean	T081	C0444504
age	T032	C0001779
years	T079	C1510829
acute	T079	C0205178
SAH	T046	C0751530
studied	T062	C0008972
aneurysms	T047	C0002940
anterior circulation	T042	C0007818
posterior circulation	T042	C0007818
hormone deficiency	T047	C0599750
growth hormone	T116	C0037663
gonadotrophin	T116	C0018061
corticotrophin	T116	C0001655
thyrotrophin	T116	C0040160
Hyperprolactinemia	T047	C0020514
cases	T101	C0030705
One-pituitary hormone axis deficiency	T033	C0857439
cases	T101	C0030705
cases	T101	C0030705
pituitary hormone	T116	C0032015
dysfunction	T077	C3887504
cases	T101	C0030705
hormonal	T125	C0019932
dysfunction	T077	C3887504
pituitary hormone axes	T116	C0032015
cases	T101	C0030705
hormonal	T125	C0019932
dysfunction	T077	C3887504
Endocrine dysfunction	T047	C1397856
cases	T101	C0030705
acute	T079	C0205178
SAH	T046	C0751530
pituitary hormone axes	T116	C0032015
dysfunction	T077	C3887504
cases	T101	C0030705
hormonal	T125	C0019932
evaluation	T058	C0220825
acute	T079	C0205178
SAH	T046	C0751530
Validity	T081	C2349101
reliability	T081	C2347947
fluoroscopy	T060	C0016356
digital radiography	T060	C0012249
evaluate	T058	C0220825
diaphragmatic	T023	C0011980
mobility	T070	C0026597
Fluoroscopy	T060	C0016356
method	T062	C2911685
evaluate	T058	C0220825
diaphragm	T023	C0011980
methods	T062	C2911685
diaphragmatic	T023	C0011980
mobility	T070	C0026597
fluoroscopy	T060	C0016356
validity	T081	C2349101
reliability	T081	C2347947
evaluation method	T062	C2911685
diaphragmatic	T023	C0011980
motion	T070	C0026597
fluoroscopy	T060	C0016356
digital radiography	T060	C0012249
healthy	T080	C3898900
adults	T100	C0001675
adults	T100	C0001675
evaluated	T058	C0220825
anthropometry	T062	C0003188
pulmonary function test	T060	C0024119
evaluation	T058	C0220825
diaphragm	T023	C0011980
mobility	T070	C0026597
fluoroscopy	T060	C0016356
digital radiography	T060	C0012249
method	T062	C2911685
Pearson correlation coefficient	T081	C0871052
intraclass correlation coefficient	T081	C0392762
ICC	T081	C0392762
validity	T081	C2349101
reliability	T081	C2347947
measurement	T169	C0242485
diaphragmatic	T023	C0011980
motion	T070	C0026597
ICC	T081	C0392762
relationship	T080	C0439849
assessment	T058	C0220825
validity	T081	C2349101
reliability	T081	C2347947
hemidiaphragm	T023	C1269845
mobility	T070	C0026597
reliability	T081	C2347947
left hemidiaphragm	T023	C0929194
assessment	T058	C0220825
assessment	T058	C0220825
reliability	T081	C2347947
mobility	T070	C0026597
hemidiaphragms	T023	C1269845
reliability	T081	C2347947
mobility	T070	C0026597
hemidiaphragms	T023	C1269845
evaluation	T058	C0220825
diaphragmatic	T023	C0011980
motion	T070	C0026597
fluoroscopy	T060	C0016356
digital radiography	T060	C0012249
valid	T080	C2349099
reliable	T080	C0205556
method	T062	C2911685
healthy	T080	C3898900
adults	T100	C0001675
Loss of control	T080	C0243148
alcohol seeking	UnknownType	C0813934
rats	T015	C0086893
individual	T098	C0237401
vulnerability	T033	C1821973
alcohol consumption	T055	C0001948
Alcohol use disorder	T048	C0001956
AUD	T048	C0001956
excessive alcohol use	T033	C0560219
persistent	T079	C0205322
alcohol seeking	UnknownType	C0813934
AUD	T048	C0001956
chronic	T079	C0205191
excessive alcohol use	T033	C0560219
subgroup	T185	C1515021
individuals	T098	C0237401
drink alcohol	T033	C3842894
AUD	T048	C0001956
interaction	T169	C1704675
individual	T098	C0237401
vulnerability	T033	C1821973
prolonged alcohol exposure	T051	C4038778
study	T062	C2603343
assessed	T052	C1516048
prolonged exposure to alcohol	T051	C4038778
individual levels of alcohol intake	T055	C0001948
development	T169	C1527148
loss of control	T080	C0243148
alcohol seeking	UnknownType	C0813934
conditioned suppression model	T170	C3161035
investigate	T169	C1292732
prolonged alcohol exposure	T051	C4038778
conditioned suppression	T169	C1260953
alcohol seeking	UnknownType	C0813934
assessed	T052	C1516048
intermittent alcohol access	T079	C1254367
IAA	T079	C1254367
subgroup	T185	C1515021
rats	T015	C0086893
suppression	T169	C1260953
alcohol seeking	UnknownType	C0813934
IAA	T079	C1254367
influence	T077	C4054723
alcohol intake	T055	C0001948
loss of control	T080	C0243148
alcohol seeking	UnknownType	C0813934
determined by	T080	C0521095
assessing	T052	C1516048
conditioned suppression	T169	C1260953
subgroups	T185	C1515021
low and high alcohol drinking	T080	C0205556
rats	T015	C0086893
low alcohol drinking	T080	C0205556
rats	T015	C0086893
high alcohol drinking	T080	C0205556
rats	T015	C0086893
aversion-resistant	T169	C0332325
alcohol seeking	UnknownType	C0813934
IAA	T079	C1254367
groups	T078	C0441833
loss of control	T080	C0243148
alcohol seeking	UnknownType	C0813934
AUD	T048	C0001956
humans	T016	C0086418
alcohol exposure	T051	C4038778
individual's	T098	C0237401
Neural	T169	C3714606
correlates	T041	C0871178
experimental	T080	C1517586
trauma	T037	C3714660
memory retrieval	T041	C0679061
Traumatic	T169	C0332663
memories	T041	C0025260
intrusions	T185	C4049623
flashbacks	T033	C1821940
development	T169	C1527148
maintenance	T052	C0024501
post-traumatic stress disorder	T048	C0038436
PTSD	T048	C0038436
neural	T169	C3714606
mechanisms	T169	C0441712
traumatic	T169	C0332663
memories	T041	C0025260
diagnosis	T033	C0011900
personalized	T080	C1709510
treatment	T061	C0087111
prevention	T061	C0199176
identification	T080	C0205396
neural	T169	C3714606
predictor variables	T170	C0683956
intrusion	T185	C4049623
development	T169	C1527148
trauma	T037	C3714660
exposure	T080	C0332157
investigation	T058	C0220825
examined	T033	C0332128
neural correlates	T041	C0871178
experimental	T080	C1517586
trauma	T037	C3714660
memory retrieval	T041	C0679061
traumatic film paradigm	T062	C0681797
healthy	T080	C3898900
females	T032	C0086287
implicit	T033	C0561768
explicit	T041	C0561766
retrieval tasks	T041	C0679061
implicit	T033	C0561768
experimental	T080	C1517586
trauma	T037	C3714660
retrieval	T041	C0679061
retrosplenial cortex	T023	C4085586
anterior cingulate cortex	T023	C0175190
ACC	T023	C0175190
retrieval tasks	T041	C0679061
trauma-related	T033	C1144879
activity	T052	C0441655
posterior cingulate cortex	T023	C0175191
PCC	T023	C0175191
precuneus	T023	C1281018
neural	T169	C3714606
activity	T052	C0441655
experimental	T080	C1517586
trauma	T037	C3714660
exposure	T080	C0332157
predicted	T078	C0681842
intrusion	T185	C4049623
development	T169	C1527148
independent	T078	C0085862
contributions	T052	C1880177
activity	T052	C0441655
retrosplenial cortex	T023	C4085586
implicit	T033	C0561768
retrieval	T041	C0679061
PCC	T023	C0175191
explicit	T041	C0561766
retrieval	T041	C0679061
Additional	T169	C1524062
analyses	T062	C0936012
revealed	T080	C0443289
connectivity	T169	C1707489
bilateral amygdala	T023	C0002708
supplementary motor area	T029	C3496173
precentral	T023	C0921005
paracentral lobule	T023	C0228203
control group	T096	C0009932
experimental	T080	C1517586
trauma	T037	C3714660
group	T078	C0441833
study	T062	C0008972
neural	T169	C3714606
correlates	T041	C0871178
experimental	T080	C1517586
trauma	T037	C3714660
memory retrieval	T041	C0679061
predictive value	T080	C1514307
subsequent	T079	C0332282
symptom	T184	C1457887
development	T169	C1527148
results	T169	C1274040
personalized	T080	C1709510
early treatment	UnknownType	C0814494
prevention	T080	C2700409
PTSD	T048	C0038436
Targeting	T044	C1159372
Nrf2	T116	C0289507
Amyloid-Beta Liaison	T044	C1149161
Alzheimer's Disease	T047	C0002395
Rational Approach	T081	C0010998
Amyloid	T116	C0002716
prominent	T080	C0205402
feature	T080	C2348519
Alzheimer's disease	T047	C0002395
AD	T047	C0002395
linear	T082	C0205132
linkage	T080	C0439849
amyloid-β peptide	T116	C0078939
Aβ	T116	C0078939
disease onset	T079	C0277793
progression	T046	C0242656
context	T078	C0449255
partnership	T080	C0439849
Aβ	T044	C1510880
Nrf2 pathways	T044	C1518762
acquiring	T080	C0439661
paramount	T080	C0205250
importance	T080	C3898777
deciphering	T169	C1285553
Aβ	T116	C0078939
disease	T047	C0012634
network	T169	C1882071
new	T080	C0205314
antiaggregating agents	T121	C0085826
simultaneously	T079	C0521115
activate transcription	T045	C0162493
antioxidant	T121	C0003402
responses	T040	C0683154
lead 1	T121	C1254351
properties	T080	C0871161
preliminary	T079	C0439611
requirements	T033	C0556043
Aβ	T116	C0078939
recognition	T044	C0599844
identified	T080	C0205396
catechol derivative 12	T121	C1254351
SH-SY5Y neuroblastoma cells	UnknownType	C0815000
12	T121	C1254351
combined	T080	C0205195
free radical scavenger	T120	C0079381
properties	T080	C0871161
trigger	T080	C1444748
Nrf2 pathway	T044	C1518762
induce	T045	C0017391
Nrf2	T116	C0289507
dependent	T169	C3244310
defensive	T033	C2164680
gene NQO1	T028	C0919428
electrophilic activation	T070	C1254365
transcriptional response	T045	C0040649
formation	T169	C1522492
cytotoxic	T169	C1511636
stable	T080	C0205360
oligomeric intermediates	T121	C1254351
significantly	T078	C0750502
more	T081	C0205172
effective	T080	C1704419
less toxic	T037	C0013221
prototype 1	T121	C1254351
different	T080	C1705242
chemical features	T070	C0243178
regulate Nrf2	T045	C1523114
Aβ	T116	C0078939
activities	T044	C1148560
pathways	T044	C1704259
compound 12	T121	C1254351
derivatives	T121	C1254351
therapeutic	T169	C0302350
potential	T080	C3245505
Nrf2	T116	C0289507
Aβ	T116	C0078939
cellular	T025	C0007634
network	T169	C1882071
generating	T052	C3146294
drug leads	T121	C1254351
AD	T047	C0002395
Young	T079	C0332239
people	T098	C0027361
mental health	T041	C0025353
practitioners	T097	C1306754
researchers	T097	C0035173
Transition Preparation Programme	T170	C0282574
outcomes	T169	C1274040
experience	T041	C0596545
young	T079	C0332239
people	T098	C0027361
Child and Adolescent Mental Health Services	T058	C0025355
CAMHS	T058	C0025355
UK	T083	C0041700
young	T079	C0332239
people	T098	C0027361
child and adolescent mental health services	T058	C0025355
CAMHS	T058	C0025355
discharge	T079	C1548175
referral to	T058	C2585021
adult service	T058	C0025355
age	T032	C0001779
period	T079	C1948053
increased	T081	C0205217
risk	T078	C0035647
onset of	T080	C0332162
mental health problems	T033	C1446377
complex	T080	C0439855
psychosocial	T169	C0542298
physical	T169	C0205485
changes	T169	C0392747
CAMHS	T058	C0025355
transitions	T052	C2700061
negative	T033	C0205160
outcomes	T169	C1274040
young	T079	C0332239
people	T098	C0027361
preparation	T052	C1521827
outcomes	T169	C1274040
experience	T041	C0596545
study	T062	C0008972
young	T079	C0332239
people	T098	C0027361
transitioned	T052	C2700061
transition	T052	C2700061
CAMHS	T058	C0025355
CAMHS	T058	C0025355
Transition Preparation Programme	T170	C0282574
TPP	T170	C0282574
routine	T080	C0205547
NHS	T058	C0027462
young	T079	C0332239
people	T098	C0027361
UK	T083	C0041700
National Health Service	T058	C0027462
NHS	T058	C0027462
participatory research workshops	T065	C0242262
parents	T099	C0030551
questionnaires	T170	C0034394
clinical staff	T097	C0025106
workshops	T065	C0242262
young	T079	C0332239
people's	T098	C0027361
ideas	T078	C1254370
Young	T079	C0332239
people	T098	C0027361
co-research opportunities	T062	C0683937
young	T079	C0332239
people	T098	C0027361
anxious	T033	C0003467
fearful	T041	C0015726
CAMHS	T058	C0025355
perceived	T041	C0030971
mental health services	T058	C0025355
Participants	T098	C0679646
transition	T052	C2700061
procedures	T169	C2700391
preparation activities	T052	C0441655
Transition	T052	C2700061
Peer Support	T061	C0679740
transition	T052	C2700061
booklet	T073	C0030258
CAMHS	T058	C0025355
leavers	T098	C1257890
discharge	T079	C1548175
transfer	T078	C3244299
adult service	T058	C0025355
Preparation	T052	C1521827
confidence	T041	C1704726
young	T079	C0332239
people	T098	C0027361
responsibility	T055	C0678341
adult	T100	C0001675
world	T098	C2700280
clinicians	T097	C0871685
anxious	T033	C0003467
transition	T052	C2700061
impact	T080	C4049986
young	T079	C0332239
people	T098	C0027361
communication	T054	C0009452
lack	T080	C0332268
services	T058	C0025355
Parents	T099	C0030551
support	T054	C0037438
offspring	T099	C0680063
transition	T052	C2700061
period	T079	C1948053
Clinicians	T097	C0871685
lack	T080	C0332268
NHS	T058	C0027462
procedures	T169	C2700391
policies	T170	C0242456
barriers	T080	C0205556
implementation	T052	C1708476
young	T079	C0332239
people's	T098	C0027361
ideas	T078	C1254370
young	T079	C0332239
people	T098	C0027361
co-research opportunities	T062	C0683937
Mental health services	T058	C0025355
anxiety	T033	C0003467
CAMHS	T058	C0025355
leavers	T098	C1257890
Young	T079	C0332239
people	T098	C0027361
ideas	T078	C1254370
preparation	T052	C1521827
CAMHS	T058	C0025355
confidence	T041	C1704726
responsibility	T055	C0678341
health care	T058	C0086388
collaboration	T054	C0282116
NHS	T058	C0027462
staff	T097	C0851286
researchers	T097	C0035173
implementation	T052	C1708476
research	T062	C0035168
findings	T169	C2607943
Histone Acetyltransferase Gcn5	T116	C1571486
Positively Regulates T Cell Activation	T043	C1326165
Histone acetyltransferases	T116	C0062773
HATs	T116	C0062773
regulate inducible transcription	T045	C1158770
multiple	T081	C0439064
cellular processes	T043	C1325880
inflammatory	T046	C1155266
immune response	T042	C0301872
functions	T044	C1527118
general control nonrepressed-protein 5	T116	C1571486
Gcn5	T116	C1571486
HAT	T116	C0062773
yeast	T004	C0043393
human	T016	C0086418
immune regulation	T040	C1327458
study	T062	C0008972
deleted	T045	C0017260
Gcn5	T116	C1571486
encoded	T052	C2700640
Kat2a gene	T028	C1415020
T lymphocytes	T025	C0039194
crossing	T045	C0010366
floxed Gcn5	T028	C1415020
Lck-Cre	T028	C0919477
mice	T015	C0025929
Gcn5	T116	C1571486
important roles	T077	C1705810
stages	T079	C1306673
T cell functions	T043	C0007613
development	T043	C0815089
clonal expansion	T046	C1516670
differentiation	T043	C0007589
Loss of	T033	C0243095
Gcn5	T116	C1571486
impaired T cell proliferation	T049	C4022557
IL-2 production	T040	C1819447
Th1	T025	C0242632
Th17	T025	C2936411
Th2	T025	C0242633
regulatory T cell differentiation	T043	C1155041
Gcn5	T116	C1571486
il-2	T028	C0879590
promoter	T114	C0086860
interacting	T169	C1704675
NFAT	T116	C0288011
T cells	T025	C0039194
TCR	T116	C0034790
TCR stimulation	T044	C2259054
acetylating	T044	C0001038
NFAT	T116	C0288011
Gcn5	T116	C1571486
catalyzes	T070	C0007382
histone H3 lysine H9 acetylation	T044	C2613321
promote	T052	C0033414
IL-2 production	T040	C1819447
T cell	T025	C0039194
suppression	T169	C1260953
Gcn5	T116	C1571486
mice	T015	C0025929
myelin oligodendrocyte glycoprotein	T116	C0069428
induced	T169	C0205263
experimental autoimmune encephalomyelitis	T050	C0014072
experimental model	T170	C0086272
human	T016	C0086418
multiple sclerosis	T047	C0026769
reveals	T080	C0443289
physiological functions	T039	C1254359
Gcn5	T116	C1571486
molecular mechanism	T044	C3537153
functions	T044	C1527118
regulating T cell immunity	T038	C1818823
Gcn5	T116	C1571486
autoimmune disease	T047	C0004364
therapy	T061	C0087111
Minor physical anomalies	T019	C0000768
dermatoglyphic	T029	C0221916
affective disorders	T048	C0525045
systematic review	T170	C1955832
increased	T081	C0205217
prevalence	T081	C0220900
minor physical anomalies	T019	C0000768
MPAs	T019	C0000768
abnormalities of dermatoglyphic patterns	T019	C0432333
physical	T169	C0205485
manifestations	T169	C0205319
neurodevelopmental disruption	UnknownType	C0679378
affective disorders	T048	C0525045
review	T170	C1955832
frequency	T079	C0439603
MPAs	T019	C0000768
dermatoglyphic abnormalities	T019	C0432333
mood disorders	T048	C0525045
MEDLINE	T170	C0025141
PsychInfo	T170	C0242356
Web of Science search	T170	C0242356
publications	T073	C0034036
frequency	T079	C0439603
MPAs	T019	C0000768
dermatoglyphic traits	T190	C4025116
bipolar disorder	T048	C0005586
unipolar depression	T048	C0041696
studies	T062	C2603343
MPAs	T019	C0000768
dermatoglyphics	T059	C0011624
discrepant	T033	C1290905
findings	T169	C2607943
relative	T080	C0205345
contribution	T052	C1880177
neurodevelopmental retardation	UnknownType	C0679378
aetiology	T169	C1314792
affective disorders	T048	C0525045
research	T062	C0035168
Increased	T169	C0442805
recognition	T041	C0524637
neurodevelopmental	T042	C0599855
processes	T067	C1522240
origin	T079	C0439659
affective disorders	T048	C0525045
effective	T080	C1704419
intervention	T061	C0184661
prevention	T061	C0199176
Novel Strategy	T062	C0035171
Super-Charged NK Cells	T025	C0022688
Significant Potential	T080	C3245505
Lyse	T046	C0024348
Differentiate	T080	C0205615
Cancer Stem Cells	T025	C1956422
Differences	T081	C1705241
NK Expansion	T043	C0007595
Function	T169	C0542341
Healthy	T098	C1708335
Cancer Patients	T101	C1516213
Natural killer (NK) cells	T025	C0022688
cancer stem cells	T025	C1956422
undifferentiated tumors	T191	C0205698
novel strategy	T062	C0035171
super-charged NK cells	T025	C0022688
significant potential	T080	C3245505
lyse	T046	C0024348
differentiate	T080	C0205615
cancer stem cells	T025	C1956422
differences	T081	C1705241
dynamics	T070	C3826426
NK cell	T025	C0022688
expansion	T043	C0007595
healthy donors	T098	C0013018
cancer patients	T101	C1516213
Decline in cytotoxicity	T033	C1849420
lower	T082	C0441994
interferon (IFN)-γ secretion	T043	C3156720
osteoclast	T025	C0029431
OC	T025	C0029431
NK cells	T025	C0022688
cancer patients	T101	C1516213
faster	T080	C0456962
expansion	T043	C0007595
contaminating	T169	C0205279
T cells	T025	C0039194
purified	T169	C1998793
NK cells	T025	C0022688
healthy donors	T098	C0013018
OCs	T025	C0029431
super-charged NK cells	T025	C0022688
T cell	T025	C0039194
expansion	T043	C0007595
days	T079	C0439228
patient	T101	C0030705
NK cells	T025	C0022688
NK cells	T025	C0022688
tumor	T191	C0027651
BLT-humanized mice	T050	C2986594
faster	T080	C0456962
expansion	T043	C0007595
T cells resulting in decreased numbers	T033	C2673541
function	T169	C0542341
NK cells	T025	C0022688
NK cells	T025	C0022688
mice	T015	C0025929
no	T033	C1513916
tumor	T191	C0027651
expanding	T043	C0007595
NK cells	T025	C0022688
cytotoxicity	T049	C0596402
dendritic cells	T025	C0011306
DCs	T025	C0011306
OCs	T025	C0029431
faster	T080	C0456962
expansion	T043	C0007595
T cells	T025	C0039194
purified	T169	C1998793
NK cells	T025	C0022688
decline in NK cell numbers	T033	C2363838
healthy individuals	T098	C1708335
anti-CD3 mAb	T116	C3831520
T cell proliferation	T043	C1155046
enhancing	T052	C2349975
NK cell	T025	C0022688
expansion	T043	C0007595
expanding	T043	C0007595
NK cells	T025	C0022688
lower	T082	C0441994
cytotoxicity	T049	C0596402
higher	T080	C0205250
secretion of IFN-γ	T043	C3156720
Expansion	T043	C0007595
functional	T169	C0205245
activation	T052	C1879547
super-charged NK cells	T025	C0022688
OCs	T025	C0029431
dependent	T080	C0851827
interleukin (IL)-12	T116	C0123759
IL-15	T116	C0254610
novel strategy	T062	C0035171
expand	T043	C0007595
super-charged NK cells	T025	C0022688
rapid and sustained expansion	T043	C0007595
T cells	T025	C0039194
purified	T169	C1998793
NK cells	T025	C0022688
expansion	T043	C0007595
DCs	T025	C0011306
OCs	T025	C0029431
potential	T080	C3245505
mechanism	T169	C0441712
numbers	T081	C0237753
function	T169	C0542341
NK cells decline	T033	C2363838
cancer patients	T101	C1516213
BLT-humanized mice	T050	C2986594
Extremely	T080	C0205403
Giant Liver Hemangioma	T191	C0238246
Kasabach-Merritt Syndrome	T047	C0221025
year	T079	C0439234
old	T079	C0580836
male	T032	C0086582
found	T033	C0150312
giant liver hemangioma	T191	C0238246
initial	T079	C0205265
size	T082	C0475440
years	T079	C0439234
received	T080	C1514756
arterial embolization	T061	C3163695
twice	T081	C1948050
shrink	T082	C0205230
tumor	T191	C0027651
no effect	T080	C1301751
obtained	T169	C1301820
tumor	T191	C0027651
rapidly	T080	C0456962
grown	T067	C2911660
abnormalities	T033	C1704258
hematological	T022	C0279810
coagulative	T042	C0005778
systems	T169	C0449913
Preoperative	T079	C0445204
computed tomography	T060	C0040405
revealed	T080	C0443289
right	T082	C0205090
hepatic vein	T023	C0019155
right	T082	C0205090
hepatic artery	T023	C0019145
right	T082	C0205090
portal vein	T023	C0032718
not involved	T033	C4296884
hemangioma	T191	C0018916
Resection	T061	C0728940
giant liver hemangioma	T191	C0238246
successfully	T080	C1272703
performed	T169	C0884358
intraoperative	T079	C0456904
intentional	T080	C1283828
bloodletting	T061	C0005857
concurrent	T079	C0205420
blood salvage	T061	C0200591
hematological	T022	C0279810
coagulative	T042	C0005778
abnormalities	T033	C1704258
returned	T080	C0332156
normal	T080	C0205307
procedure	T061	C0087111
Role	T077	C1705810
cysteine	T116	C0010654
residues	T077	C1709915
regulation	T169	C0518894
peptidyl-prolyl cis-trans isomerase activity	T044	C1150301
wheat	T168	C0043137
cyclophilin	T116	C0917877
TaCYPA-1	T028	C1418793
Oxidative	T169	C0311404
conditions	T080	C0348080
inhibition	T052	C3463820
peptidyl-prolyl cis-trans isomerase (PPIase) activity	T044	C1150301
cyclophilins	T116	C0917877
Thiol	T109	C0038734
redox	T044	C0030012
regulation	T169	C0518894
proteins	T116	C0033684
activity	T044	C0243102
wheat	T168	C0043137
cyclophilin	T116	C0917877
TaCYPA-1	T028	C1418793
modulated	T082	C0443264
mechanism	T169	C0441712
redox	T044	C0030012
regulation	T169	C0518894
regulation	T169	C0518894
PPIase activity	T044	C1150301
TaCYPA-1	T028	C1418793
mutants	T049	C0596988
TaCYPA-1	T028	C1418793
substituting	T052	C1706204
cysteine	T116	C0010654
residues	T077	C1709915
positions	T082	C0733755
serine	T116	C0036720
proline	T116	C0033382
Comparative analysis	T062	C0683941
PPIase activity	T044	C1150301
catalytic	T070	C0007382
efficiencies	T081	C0013682
TaCYPA-1C40S	T116	C0136073
TaCYPA-1C122S	T116	C0136073
significantly lower	T081	C4055638
TaCYPA-1	T116	C0136073
mutant	T049	C0596988
TaCYPA-1C40S/C122S	T116	C0136073
significantly higher	T081	C4055637
wild-type	T028	C1883559
TaCYPA-1	T028	C1418793
mutants	T049	C0596988
differential	T080	C0443199
sensitivity	T169	C0332324
Cu2+	T121	C1177210
results	T169	C1274040
study	T062	C2603343
revealed	T080	C0443289
lacking	T080	C0332268
PPIase activity	T044	C1150301
mutant	T049	C0596988
TaCYPA-1C126P	T028	C1418793
partial	T081	C0728938
protection	T033	C1545588
heat stress	T039	C0282498
observations	T062	C0302523
mechanism	T169	C0441712
TaCYPA-1	T028	C1418793
thermotolerance	T039	C3544386
activities	T052	C0441655
cis to trans isomerisation	T044	C0596342
identified	T080	C0205396
Association	T080	C0439849
Exclusive Breastfeeding	T055	C0242205
Duration	T079	C0449238
Systemic Inflammation	T047	C3646020
Markers	T201	C0005516
Adolescents	T100	C0205653
Cross-Sectional Study	T062	C0010362
Breastfeeding duration	T033	C2136514
associated with	T080	C0332281
less	T081	C0439092
low-grade	T080	C1282907
inflammation	T046	C0021368
healthy	T080	C3898900
adolescents	T100	C0205653
scarce	T080	C0231180
information	T078	C1533716
obese	T047	C0028754
exclusive breastfeeding	T055	C0242205
serum concentrations	T081	C0683149
inflammatory	T169	C0333348
markers	T201	C0005516
population	T098	C1257890
Spanish	T098	C0086409
adolescents	T100	C0205653
cross-sectional study	T062	C0010362
performed	T169	C0884358
adolescents	T100	C0205653
schools	T073	C0036375
southeast	T082	C1711190
Spain	T083	C0037747
Data	T078	C1511726
breastfeeding duration	T033	C2136514
collected	T169	C1516698
parental questionnaire	T170	C0034394
Interleukin-6	T116	C0021760
IL-6	T116	C0021760
tumor necrosis factor-alpha	T116	C1456820
TNF-α	T116	C1456820
determined by	T080	C0521095
enzyme-linked immunosorbent assay	T059	C0014441
C-reactive protein	T116	C0006560
CRP	T116	C0006560
determined by	T080	C0521095
solid-phase chemiluminescent immunometric assay	T059	C0020980
multivariate	T081	C0026777
correlation analyses	T062	C0010101
confirmed	T080	C1456348
strong	T080	C0442821
association	T080	C0439849
confidence interval	T081	C0009667
markers	T201	C0005516
inflammation	T046	C0021368
exclusive breastfeeding	T055	C0242205
duration	T079	C0449238
No significant	T033	C1273937
differences	T080	C1705242
observed	T169	C1441672
IL-6	T116	C0021760
TNF-α	T116	C1456820
CRP	T116	C0006560
serum concentrations	T081	C0683149
normal weight	T201	C1285592
overweight	T184	C0497406
obese	T047	C0028754
adolescents	T100	C0205653
except for	T169	C0332300
IL-6	T116	C0021760
normal weight	T201	C1285592
obese	T047	C0028754
subjects	T100	C0205653
no significant	T033	C1273937
association	T080	C0439849
found	T033	C0150312
markers	T201	C0005516
inflammation	T046	C0021368
body mass index	T201	C1305855
BMI	T201	C1305855
z-score	T081	C0871421
found	T033	C0150312
possible	T033	C0332149
association	T080	C0439849
inflammatory	T169	C0333348
markers	T201	C0005516
exclusive breastfeeding	T055	C0242205
duration	T079	C0449238
adolescents	T100	C0205653
regardless	T080	C3641650
BMI	T201	C1305855
finding	T033	C0243095
suggests	T078	C1705535
increased	T081	C0205217
body weight	T032	C0005910
obesity	T047	C0028754
association	T080	C0439849
breastfeeding	T040	C0006147
inflammation	T046	C0021368
results	T169	C1274040
understanding	T041	C0162340
relationship	T080	C0439849
breastfeeding	T040	C0006147
inflammatory	T169	C0333348
markers	T201	C0005516
adolescents	T100	C0205653
Effect	T080	C1280500
ultrasound	T070	C1456803
enzymatic	T116	C0014442
pre-treatment	T052	C3539076
yield	T081	C0392762
properties	T080	C0871161
banana	T168	C0004722
juice	T168	C1268568
Effect	T080	C1280500
ultrasound	T070	C1456803
enzymatic	T116	C0014442
pre-treatments	T052	C3539076
cellulase	T116	C0007641
pectinase	T116	C0032491
yield	T081	C0392762
properties	T080	C0871161
banana	T168	C0004722
juice	T168	C1268568
investigated	T169	C1292732
two-level full factorial design	UnknownType	C0681865
ultrasonication time	T079	C0040223
min	T079	C0439232
cellulase	T116	C0007641
concentration	T081	C0392762
pectinase	T116	C0032491
concentration	T081	C0392762
yield	T081	C0392762
viscosity	T070	C0042784
clarity	T059	C3272888
total soluble solids	T081	C0392762
TSS	T081	C0392762
pH	T081	C0020283
pectinase	T116	C0032491
effective	T080	C1704419
increasing	T169	C0442808
yield	T081	C0392762
juice	T168	C1268568
cellulase	T116	C0007641
Ultrasonic pre-treatment	T052	C3539076
not	T033	C1513916
significantly increase	T169	C0442805
yield	T081	C0392762
juice	T168	C1268568
ultrasound	T070	C1456803
pre-treatment	T052	C3539076
enzymes	T116	C0014442
maximum yield	T081	C0392762
control	T096	C0009932
viscosity	T070	C0042784
juice	T168	C1268568
decreased	T081	C0205216
enzymes	T116	C0014442
ultrasound	T070	C1456803
clarity	T080	C2963144
juice	T168	C1268568
cellulase	T116	C0007641
treatment	T169	C1522326
improved	T033	C0184511
pectinase	T116	C0032491
treatment	T169	C1522326
Ultrasonication	T070	C1456803
effective	T080	C1704419
pectinase	T116	C0032491
cellulase	T116	C0007641
treatment	T169	C1522326
improving	T080	C1272745
clarity	T201	C0486588
juice	T168	C1268568
TSS	T081	C0392762
increased	T081	C0205217
enzymatic	T116	C0014442
treatment	T169	C1522326
ultrasonication	T070	C1456803
pH	T081	C0020283
treatment	T169	C1522326
treated	T169	C1522326
juices	T168	C1268568
Significant correlations	T080	C1707520
Electrocardiographic appearance	T034	C0428946
aortic stenosis	T047	C0003507
aortic valve replacement	T061	C0003506
QRS complex	T033	C0429097
ST-segment	T033	C0429029
T wave	T033	C0239242
observed	T169	C1441672
aortic stenosis	T047	C0003507
AS	T047	C0003507
S-wave	T033	C0429094
dynamic	T169	C0729333
change	T169	C0392747
leads V1	T029	C0441907
V3	T029	C0449218
AS	T047	C0003507
prospective study	T062	C0033522
patients	T101	C0030705
surgical	T061	C0543467
aortic valve replacement	T061	C0003506
AVR	T061	C0003506
patients	T101	C0030705
symptomatic	T169	C0231220
asymptomatic	T033	C0231221
AS	T047	C0003507
hemodynamic stability	T039	C0489528
EFLV	T201	C0428772
AVA	T032	C0428817
PG	T201	C0232117
mm Hg	T081	C0439475
mm Hg	T081	C0439475
end-diastolic LV dimension	T033	C2059470
evaluated	T058	C0220825
impact	T080	C4049986
S-wave	T033	C0429094
magnitude	T081	C1704240
right precordial	T184	C2729494
AVR	T061	C0003506
patients	T101	C0030705
S-wave	T033	C0429094
changes	T169	C0392747
electrocardiogram	T033	C0013798
hemodynamic measurements	T061	C0204901
echocardiography	T060	C0013516
Analysis	T062	C0936012
echocardiographic	T060	C0013516
parameters	T033	C0449381
measured	T080	C0444706
patients	T101	C0030705
surgery	T061	C0543467
statistical significance	T081	C0237881
asymptomatic	T033	C0231221
symptomatic	T169	C0231220
statistical significance	T081	C0237881
observed	T169	C1441672
change	T169	C0392747
S-wave	T033	C0429094
magnitude	T081	C1704240
right precordial	T184	C2729494
patients	T101	C0030705
AVR	T061	C0003506
statistically significant	T081	C0237881
predictive value	T080	C1514307
S-wave	T033	C0429094
magnitude	T081	C1704240
leads V2	T029	C0441908
V3	T029	C0449218
dependent variables	T169	C0871711
PG	T201	C0232117
end-diastolic LV dimension	T033	C2059470
S-wave	T033	C0429094
right precordial	T184	C2729494
increase	T169	C0442805
PG	T201	C0232117
AVA	T032	C0428817
suggestive of	T169	C0332299
referral for	T058	C2585524
AVR	T061	C0003506
Anemia	T047	C0002871
complicating	T169	C1522701
type 2 diabetes	T047	C0011860
Prevalence	T081	C0220900
risk factors	T033	C0035648
prognosis	T058	C0033325
prevalence	T081	C0220900
risk factors	T033	C0035648
prognosis	T058	C0033325
anemia	T047	C0002871
representative	T097	C0030701
patients	T101	C0030705
type 2 diabetes	T047	C0011860
Fremantle Diabetes Study Phase II	T062	C2603343
FDS2	T062	C2603343
males	T032	C0086582
Busselton Diabetes Study	T062	C2603343
BDS	T062	C2603343
males	T032	C0086582
cohorts	T098	C0599755
BDS	T062	C2603343
participants	T098	C0679646
diabetes	T047	C0011847
analyzed	T062	C0936012
prevalence	T081	C0220900
anemia	T047	C0002871
hemoglobin	T116	C0019046
males	T032	C0086582
females	T032	C0086287
determined	T080	C0521095
sample	T031	C0178913
FDS2	T062	C2603343
anemia	T047	C0002871
assessed	T052	C1516048
logistic regression	T062	C0206031
Cox proportional hazards modeling	T081	C0010235
predictors	T033	C0035648
death	T040	C0011065
prevalence	T081	C0220900
anemia	T047	C0002871
FDS2	T062	C2603343
participants	T098	C0679646
BDS	T062	C2603343
patients	T101	C0030705
BDS	T062	C2603343
participants	T098	C0679646
diabetes	T047	C0011847
FDS2	T062	C2603343
patients	T101	C0030705
anemia	T047	C0002871
risk factor	T033	C0035648
serum vitamin B12	T059	C0427408
serum ferritin	T033	C0241012
transferrin saturation	T059	C1277709
serum testosterone	T059	C0428413
males	T032	C0086582
glitazone	T109	C1257987
therapy	T061	C0087111
estimated glomerular filtration rate	T059	C3811844
eGFR	T059	C3811844
malignancy	T191	C4282132
hemoglobinopathy	T047	C0019045
anemic	T033	C0857322
non-anemic	T033	C0857322
FDS2	T062	C2603343
patients	T101	C0030705
predictors	T033	C0035648
Aboriginality	T033	C1704258
marital status	T102	C0024819
smoking	T055	C0037369
eGFR	T059	C3811844
anemia	T047	C0002871
associated with	T080	C0332281
increase	T169	C0442805
Type 2 diabetes	T047	C0011860
anemia	T047	C0002871
risk factors	T033	C0035648
present	T033	C0150312
Anemia	T047	C0002871
associated with	T080	C0332281
increased risk of death	T033	C2749787
predictors	T033	C0035648
Succinic acid	T109	C0075429
production	T052	C1883254
immobilized	T025	C0282542
cultures	T059	C0007585
spent sulphite liquor	T167	C0302908
fermentation	T044	C0015852
medium	T167	C1705217
Spent sulphite liquor	T130	C0010454
SSL	T130	C0010454
carbon	T196	C0007009
source	T033	C0449416
production	T052	C1883254
succinic acid	T109	C0075429
immobilized	T025	C0282542
cultures	T059	C0007585
Actinobacillus succinogenes	T007	C1026661
Basfia succiniciproducens	T007	C3716734
supports	T167	C0439861
delignified cellulosic material	T121	C3256315
DCM	T121	C3256315
alginate	T109	C0102137
beads	T167	C0439861
Fed-batch immobilized cultures	T059	C3179109
A. succinogenes	T007	C1026661
alginates	T109	C0102137
higher	T080	C0205250
sugar	T109	C0242209
succinic acid	T109	C0075429
conversion yield	T081	C0392762
yield	T081	C0392762
DCM	T121	C3256315
immobilized	T025	C0282542
cultures	T059	C0007585
succinic acid	T109	C0075429
concentration	T081	C1446561
yield	T081	C0392762
fed-batch	T059	C3179109
immobilized	T025	C0282542
cultures	T059	C0007585
B. succiniciproducens	T007	C3716734
alginates	T109	C0102137
higher	T080	C0205250
A. succinogenes	T007	C1026661
immobilized	T025	C0282542
cultures	T059	C0007585
nano	T081	C1553036
filtrated SSL	T167	C0302908
fermentation	T044	C0015852
medium	T167	C1705217
Immobilized	T025	C0282542
cultures	T059	C0007585
B. succiniciproducens	T007	C3716734
alginate	T109	C0102137
beads	T167	C0439861
sequential fed-batch	T059	C3179109
fermentations	T044	C0015852
nano	T081	C1553036
filtrated SSL	T130	C0010454
production	T052	C1883254
succinic acid	T109	C0075429
yield	T081	C0392762
productivity	T081	C0033269
immobilized	T025	C0282542
cultures	T059	C0007585
efficiency	T081	C0013682
succinic acid	T109	C0075429
production	T052	C1883254
compared	T052	C1707455
free cell cultures	T059	C0007585
Interventions	T058	C1273869
Improve	T033	C0184511
Grandparent	T099	C0337471
Caregivers'	T099	C0086279
Mental	T041	C0025353
Physical Health	T033	C0517226
Integrative Review	T170	C0282443
aim	T078	C1947946
integrative review	T170	C0282443
grandparent	T099	C0337471
caregiver	T099	C0086279
interventions	T058	C1273869
improve	T033	C0184511
physical	T033	C0517226
mental health	T041	C0025353
database	T170	C0242356
search	T052	C1706202
relevant	T080	C2347946
studies	T062	C2603343
published	T057	C0034037
publications	T073	C0034036
studies	T062	C2603343
inclusion	T080	C1512693
exclusion criteria	T169	C0680251
studies	T062	C2603343
grandparent	T099	C0337471
mental health	T041	C0025353
outcomes	T169	C1274040
physical health	T033	C0517226
social relations	T098	C0337609
Improvements	T077	C2986411
areas	T082	C0205146
improvements	T077	C2986411
physical health	T033	C0517226
small effect sizes	T081	C0814843
measures	T169	C1879489
outcomes	T169	C1274040
interventions	T058	C1273869
grandparent	T099	C0337471
caregiver	T099	C0086279
studies	T062	C2603343
limited	T169	C0439801
design	T052	C1707689
randomized controlled trial	T062	C0206035
interventions	T058	C1273869
variations	T080	C0205419
grandchild's	T099	C0337548
parent's	T099	C0030551
ages	T032	C0001779
grandparent	T099	C0337471
primary	T080	C0205225
shared	T054	C0237876
care	T052	C1947933
future	T079	C0016884
research	T062	C0035168
attenuated	T052	C0599946
Mycobacterium tuberculosis	T007	C0026926
clinical	T080	C0205210
strain	T001	C1518614
defect	T169	C1457869
ESX-1	T116	C1744314
secretion	T038	C0036536
minimal	T080	C0547040
host	T001	C1167395
immune responses	T042	C0301872
pathology	T091	C0030664
Mycobacterium tuberculosis (M.tb) DK9897	T007	C0026926
attenuated	T052	C0599946
strain	T001	C1518614
isolated	T169	C0205409
patient	T101	C0030705
extrapulmonary tuberculosis	T047	C0679362
vaccination	T061	C0042196
subunit vaccine	T121	C0887892
H56	T121	C0887892
induced	T169	C0205263
poor	T080	C0542537
protection	T033	C1545588
attenuation	T052	C0599946
lack	T080	C0332268
protection	T033	C1545588
M.tb DK9897	T007	C0026926
secrete	T038	C0036536
EsxA	T116	C1744314
virulence factor	T109	C1136170
host response	T042	C0301872
Genome sequencing	T063	C1328887
frameshift mutation	T049	C0079380
eccCa1 gene	T028	C0017337
encoded	T052	C2700640
EccCa1 protein	T116	C1254349
energy	T081	C1442080
ESX-1	T116	C1744314
secretion	T038	C0036536
defect	T169	C1457869
ESX-1	T116	C1744314
type VII secretion system	T043	C3159197
Genetic complementation	T045	C0178654
plasmid	T114	C0032136
M.tb H37Rv	T007	C0026926
eccCa1-eccCb1-pe35	T114	C0012931
EsxA	T116	C1744314
secretion	T038	C0036536
host	T001	C1167395
EsxA	T116	C1744314
T-cell	T025	C0039194
responses	T042	C0301872
increased	T081	C0205217
strain	T001	C1518614
virulence	T038	C0042765
ESX-1	T116	C1744314
secretion	T038	C0036536
defect	T169	C1457869
prevents	T169	C1292733
virulence factors	T109	C1136170
infection	T046	C3714514
attenuates	T052	C0599946
M.tb	T007	C0026926
T-cell	T025	C0039194
responses	T042	C0301872
antigens	T129	C0003320
in vivo	T082	C1515655
cytokine production	T040	C1327413
gross pathology	T034	C0428094
granuloma formation	T038	C1817882
lungs	T023	C0024109
M.tb DK9897	T007	C0026926
infected animals	T033	C0237158
M.tb DK9897	T007	C0026926
phagosome membrane	T026	C1166752
cytosol	T026	C1383501
Results	T033	C0683954
patients	T101	C0030705
sarcoma	T191	C1261473
not otherwise specified	T080	C1518425
diagnoses	T033	C0011900
Ewing sarcoma	T191	C0553580
treated	T033	C0332154
Euro-EWING 99 trial	T062	C0008976
Euro-EWING 99 trial	T062	C0008976
European	T098	C1535514
Ewing tumor	T191	C0553580
Working	T057	C0043227
Initiative	T033	C1287154
National	T092	C0015737
Groups	T078	C0441833
EE99	T170	C1507394
international	T078	C1512888
phase III study	T062	C0282461
patients	T101	C0030705
Ewing sarcoma	T191	C0553580
German Society of Pediatric Oncology and Hematology (GPOH) data center	T093	C1708333
registered	T058	C1514821
patients	T101	C0030705
diagnoses	T033	C0011900
Ewing sarcoma	T191	C0553580
treated	T033	C0332154
EE99 protocol	T170	C1507394
non-Ewing database	T170	C0242356
Data	T078	C1511726
patients	T101	C0030705
diagnoses	T033	C0011900
Ewing sarcoma	T191	C0553580
treated	T033	C0332154
EE99 protocol	T170	C1507394
analyzed	T062	C0936012
Patients	T101	C0030705
miscellaneous	T080	C0205395
histologic	T169	C0205462
diagnoses	T033	C0011900
majority	T081	C0205393
diagnosed	T033	C0011900
sarcoma	T191	C1261473
not otherwise specified	T080	C1518425
NOS	T080	C1518425
bone	T024	C0391978
soft tissue	T024	C0225317
median	T081	C0876920
age	T032	C0001779
diagnosis	T033	C0011900
Localized disease	T047	C0277565
diagnosed	T033	C0011900
patients	T101	C0030705
distant metastases	T191	C0027627
primary	T080	C0205225
diagnosis	T033	C0011900
median	T081	C0876920
follow-up	T058	C1522577
time	T079	C0040223
Patients	T101	C0030705
localized disease	T047	C0277565
event-free survival	T081	C0242793
EFS	T081	C0242793
EFS	T081	C0242793
patients	T101	C0030705
metastases	T191	C0027627
EFS	T081	C0242793
patients	T101	C0030705
sarcoma	T191	C1261473
NOS	T080	C1518425
patients	T101	C0030705
localized	T047	C0277565
metastatic disease	T191	C0027627
EFS	T081	C0242793
EFS	T081	C0242793
patients	T101	C0030705
diagnoses	T033	C0011900
Ewing sarcoma	T191	C0553580
treated	T033	C0332154
EE99	T170	C1507394
significantly	T078	C0750502
patients	T101	C0030705
localized	T047	C0277565
metastatic disease	T191	C0027627
Sarcomas	T191	C1261473
soft tissue	T024	C0225317
bone	T024	C0391978
classified	T185	C0008902
current	T079	C0521116
diagnostic categories	T185	C1550395
therapeutic	T169	C0302350
challenge	T058	C0805586
Capsular Polysaccharide	T109	C0032595
Types	T080	C0332307
Virulence-Related	T038	C0042765
Traits	T032	C0599883
Epidemic	T067	C0014499
KPC	T047	C1855645
Producing	T169	C0678227
Klebsiella pneumoniae	T007	C0001699
Isolates	T123	C1764827
Chinese	T083	C0008115
University Hospital	T073	C0020028
Klebsiella pneumoniae	T007	C0001699
important	T080	C3898777
human	T016	C0086418
pathogen	T001	C0450254
associated with	T080	C0332281
variety	T077	C2346866
diseases	T047	C0012634
prevalence	T081	C0220900
blaKPC	T028	C0017337
K. pneumoniae	T007	C0001699
KPC-Kp	T007	C0001699
rapidly increasing	T169	C0442808
Capsule	T116	C0085229
important	T080	C3898777
virulence factor	T109	C1136170
K. pneumoniae	T007	C0001699
study	T062	C2603343
systematically	T169	C0220922
characterize	T052	C1880022
capsular polysaccharide	T109	C0032595
CPS	T109	C0032595
virulence	T038	C0042765
traits	T032	C0599883
KPC-Kp	T007	C0001699
strains	T001	C1518614
KPC-Kp	T007	C0001699
isolates	T123	C1764827
recovered	T080	C0521108
clinical samples	T167	C0370003
Chinese hospital	T073	C0020028
assigned	T169	C1516050
clonal lineages	T078	C0282637
multilocus sequence typing	T062	C2936544
MLST	T062	C2936544
Capsule	T116	C0085229
typing	T058	C0441704
wzi sequencing	T059	C1294197
wzc polymerase chain reaction	T063	C0032520
PCR	T063	C0032520
virulence	T038	C0042765
genes	T028	C0017337
characterized	T052	C1880022
molecular approaches	T059	C0200924
virulence	T038	C0042765
strains	T001	C1518614
biofilm formation	T043	C1325881
serum	T031	C0229671
killing	T043	C0599733
resistance	T169	C4281815
phagocytosis	T043	C0031308
infection	T046	C3714514
models	T170	C3161035
STs	T033	C2359784
found	T033	C0150312
KPC-Kp	T007	C0001699
isolates	T123	C1764827
isolates	T123	C1764827
ST11	T033	C2359784
6	T033	C2359784
isolates	T123	C1764827
ST147	T033	C2359784
isolates	T123	C1764827
ST15	T033	C2359784
ST1456	T033	C2359784
ST65	T033	C2359784
ST23	T033	C2359784
wzi gene DNA sequences	T059	C3708993
wzc PCR	T063	C0032520
strains	T001	C1518614
capsular	T116	C0085229
type	T080	C0332307
wzi47-K47	T116	C0085229
wzi64-K64	T116	C0085229
wzi8-K8	T116	C0085229
wzi37-K37	T116	C0085229
wzi53-K53	T116	C0085229
wzi125-K2	T116	C0085229
wzi1-K1	T116	C0085229
Heterogeneity	T032	C0242960
detected	T033	C0442726
biofilm formation	T043	C1325881
phagocytosis	T043	C0031308
CPS	T109	C0032595
types	T080	C0332307
ST11	T033	C2359784
strains	T001	C1518614
virulent	T080	C1520022
ST	T033	C2359784
strains	T001	C1518614
KPC-Kp	T007	C0001699
strains	T001	C1518614
variability	T077	C2827666
virulence-associated	T038	C0042765
traits	T032	C0599883
ST	T033	C2359784
types	T080	C0332307
CPS	T109	C0032595
Interaction-driven	T169	C1704675
electronic states	T082	C0449830
artificial atoms	T196	C0567415
ZnO	T121	C0043491
interface	T080	C0205556
investigated	T169	C1292732
electronic states	T082	C0449830
planar quantum dots	T073	C1258084
ZnO	T121	C0043491
interface	T080	C0205556
interacting	T169	C1704675
electrons	T196	C0013852
externally applied	T169	C4048755
magnetic field	T070	C0563533
electron-electron	T196	C0013852
interaction	T169	C1704675
effects	T080	C1280500
much stronger	T080	C0442821
case	T169	C0868928
traditional semiconductor quantum systems	T169	C0449913
GaAs	T197	C0061005
InAs	T197	C0172463
quantum dots	T073	C1258084
stronger	T080	C0442821
Coulomb effects	T080	C1280500
ZnO	T121	C0043491
quantum dots	T073	C1258084
compared	T052	C1707455
energy spectra	T067	C1254366
magnetization	T070	C0563532
system	T169	C0449913
InAs	T197	C0172463
quantum dots	T073	C1258084
ZnO	T121	C0043491
quantum dots	T073	C1258084
stronger	T080	C0442821
Coulomb interaction	T169	C1704675
manifests	T169	C0205319
unique	T080	C1710548
ground state	T082	C0449830
different	T080	C1705242
properties	T077	C1882134
InAs	T197	C0172463
dot	T073	C1258084
results	T169	C1274040
magnetization	T070	C0563532
exhibits behaviors	T080	C0205556
never	T079	C2003901
before	T079	C0332152
observed	T169	C1441672
quantum dot	T073	C1258084
realistic set of parameters	T081	C0392762
stronger	T080	C0442821
temperature	T081	C0039476
dependence	T080	C0851827
unexpected features	T080	C2348519
paramagnetic-like behavior	T070	C1254365
high temperatures	T081	C0039476
quantum-dot	T073	C1258084
helium	T121	C0018880
Evaluation	T058	C0220825
Tobacco Control Policies	T064	C0680803
San Francisco	T083	C0036152
Homeless	T098	C0019863
Housing Programs	UnknownType	C0687761
Surgeon General's Report	T170	C0684224
noted	T080	C4288581
high	T080	C0205250
smoking rates	T033	C1822491
vulnerable populations	T098	C0949366
homeless	T098	C0019863
persistent	T079	C0205322
public	T092	C0678367
health problem	T033	C1398682
smoking	T055	C0037369
prevalence	T081	C0683919
individuals	T098	C0237401
experiencing	T055	C0683573
homelessness	T033	C0237154
service providers	T058	C0679886
homeless	T098	C0019863
comprehensive	T080	C1880156
tobacco control policies	T064	C0680803
conducted	T169	C1300196
qualitative study	T062	C0949415
homeless	T098	C0019863
housing programs	UnknownType	C0687761
San Francisco	T083	C0036152
Administrators	T097	C0085751
representing	T052	C1882932
homeless service agencies	T092	C0586395
interviewed	T052	C0021822
assess	T058	C0184514
institutional	T078	C0015003
smoking	T055	C0037369
policies	T170	C0242456
cessation	T055	C0085134
programs	T169	C3484370
perceived	T041	C0030971
barriers	T080	C0679881
receptivity	T169	C0205342
instituting	T078	C1272753
tobacco	T109	C0040329
control	T169	C2587213
interventions	T061	C0184661
Respondents	T098	C0282122
indicated	T033	C1444656
programs	T169	C3484370
adopted	T080	C1272684
smoke	T131	C0037366
free	T169	C0332296
grounds	T082	C1254362
eliminated	T080	C0849355
evidence	T078	C3887511
staff	T097	C0851286
smoking	T055	C0037369
smoking	T055	C0037369
status	T080	C0449438
clients	T096	C0008942
assessed	T052	C1516048
required	T169	C1514873
programs	T169	C3484370
offered	T033	C1444648
smoking cessation	T055	C0085134
interventions	T061	C0184661
administrators	T097	C0085751
receptive	T169	C0205342
adopting	T080	C1272684
policies	T170	C0242456
promote	T052	C0033414
tobacco	T109	C0040329
free	T169	C0332296
culture	T092	C0037455
noted	T080	C4288581
clients	T096	C0008942
unique	T080	C1710548
challenges	T058	C0805586
traditional	T169	C0443324
smoking cessation	T055	C0085134
programs	T169	C3484370
Homeless	T098	C0019863
housing programs	UnknownType	C0687761
San Francisco	T083	C0036152
adopted	T080	C1272684
tobacco	T109	C0040329
free	T169	C0332296
culture	T092	C0037455
Existing	T077	C2987476
policies	T170	C0242456
created	T052	C1706214
response	T032	C0871261
external	T082	C0205101
mandates	T170	C1442085
smoking cessation	T055	C0085134
programs	T169	C3484370
modified	T169	C0392747
effectively	T080	C1704419
clients	T096	C0008942
micromolar	T081	C0439300
inhibitors	T121	C0014432
aldose reductase	T116	C0002003
ALR2	T116	C0002003
poly (ADP-ribose) polymerase	T116	C0032405
PARP-1	T116	C0032405
structure	T082	C0678594
design	T052	C1707689
Clinical studies	T062	C0008972
diabetic retinopathy	T047	C0011884
disorder	T047	C0012634
ALR2	T116	C0002003
PARP-1	T116	C0032405
retinal	T023	C0035298
cells	T025	C0007634
targets	T169	C1521840
treatment	T061	C0087111
diabetic retinopathy	T047	C0011884
inhibitors	T121	C0014432
ALR2	T116	C0002003
PARP-1	T116	C0032405
structure	T082	C0678594
design	T052	C1707689
target	T169	C1521840
proteins	T116	C0033684
thiazolidine-2,4-dione	T109	C1568506
TZD	T109	C1568506
derivatives	T169	C1527240
designed	T052	C1707689
synthesized	T052	C1883254
in vitro	T080	C1533691
inhibitory activities	T044	C1152555
ALR2	T116	C0002003
PARP-1	T116	C0032405
experimental results	T033	C2825142
compounds 5b	T121	C1254351
5f	T121	C1254351
biochemical	T169	C0205474
activities	T052	C0441655
micromolar	T081	C0439300
submicromolar	T081	C0439300
range	T081	C1514721
IC50	T081	C0600495
targeted	T169	C1521840
enzymes	T116	C0014442
structure-activity relationship	T080	C0038477
inhibitors	T121	C0014432
enzymes	T116	C0014442
binding	T044	C1167622
mode	T169	C1513371
inhibitors	T121	C0014432
active sites	T169	C0205681
enzymes	T116	C0014442
positive	T033	C1446409
results	T033	C0683954
biochemical	T169	C0205474
assay	T059	C0005507
compounds	T121	C1254351
optimized	T052	C2698650
utilized	T169	C0042153
treatment	T061	C0087111
diabetic retinopathy	T047	C0011884
Microbiology	T059	C0085672
Upper	T030	C0225377
Lower Airways	T039	C0231989
Pediatric	T080	C1521725
Cystic Fibrosis	T047	C0010674
Patients	T101	C0030705
pediatric	T080	C1521725
cystic fibrosis	T047	C0010674
CF	T047	C0010674
patients	T101	C0030705
sinus surgery	T061	C0748725
Retrospective	T062	C0035363
Tertiary care	T073	C0337954
children's hospital	T093	C0020017
sinus	T059	C2237356
pulmonary cultures	T059	C2020984
CF	T047	C0010674
patients	T101	C0030705
Demographics	T062	C0011289
culture	T059	C0430400
results	T169	C1274040
analyzed	UnknownType	C0681874
Results	T169	C1274040
patients	T101	C0030705
female	T098	C0043210
Methicillin	T109	C0025643
sensitive	T169	C0332324
Staphylococcus aureus	T007	C0038172
pathogen	T001	C4267729
prevalence	T081	C0683921
Pseudomonas aeruginosa	T007	C0033809
pulmonary	T059	C2020984
sinus cultures	T059	C2237356
older	T098	C1999167
patients	T101	C0030705
younger	T100	C0238598
patients	T101	C0030705
P	T081	C0033105
moderate	T080	C1881878
agreement	T080	C1707520
sinus	T059	C2237356
pulmonary cultures	T059	C2020984
Kappa	T170	C0439099
statistic range	T081	C0220900
prevalence	T081	C0220900
methicillin-resistant S aureus	T007	C1265292
MRSA	T007	C1265292
significantly	T081	C0237881
lower respiratory tract culture	T059	C2199769
sinus culture	T059	C2237356
P	T081	C0033105
P	T081	C0033105
prevalence	T081	C0220900
positive	T033	C1514241
sinus cultures	T059	C2237356
P	T081	C0033105
Patients	T101	C0030705
pulmonary	T080	C2709248
MRSA	T007	C1265292
coinfected	T047	C0275524
pulmonary	T080	C2709248
P aeruginosa	T007	C0033809
risk ratio	T081	C0242492
CI	T081	C0009667
Aspergillus fumigatus	T004	C0004037
risk ratio	T081	C0242492
CI	T081	C0009667
moderate	T080	C1881878
correlation	T080	C1707520
pulmonary	T080	C2709248
sinus	T030	C0030471
pathogens	T001	C4267729
CF	T047	C0010674
patients	T101	C0030705
treating	T061	C0087111
infections	T046	C3714514
prevalence	T081	C0220900
MRSA	T007	C1265292
sinus cultures	T059	C2237356
investigation	T058	C0220825
miR-451	T114	C2603907
proliferation	T169	C1514485
migration	T039	C1533574
malignant glioma	T191	C0555198
cells	T025	C0007634
AMPK	T116	C0252214
signaling	T038	C3537152
mTOR	T116	C1307407
modulation	T082	C0443264
Rac1	T116	C0139880
activation	T045	C0599177
Glioblastoma multiforme	T191	C1621958
GBM	T191	C1621958
WHO grade IV astrocytoma	T191	C0017636
primary neoplasm	T191	C0677930
central nervous system	T022	C3714787
CNS	T022	C3714787
malignancy	T191	C4282132
mortality rates	T081	C0205848
invasive nature	T080	C0205281
GBM	T191	C1621958
surgical resection	T061	C0728940
chemotherapeutic access	T061	C0870057
patient	T101	C0030705
prognosis	T058	C0033325
migration	T039	C1533574
tumor cells	T025	C0597032
tumor cell	T025	C0597032
proliferation	T169	C1514485
acquisition	T052	C1706701
migratory	T169	C0232901
capability	T080	C2698977
intracellular	T082	C0178719
factors	T169	C1521761
crucial mechanism	T169	C0441712
progression	T169	C0449258
invasion	T033	C1269955
qRT-PCR	T063	C1514628
analysis	T062	C0936012
expression	T045	C0017262
miR-451	T028	C1826031
glioma	T191	C0017638
tissue	T024	C0040300
control brain tissue	T023	C0459385
central	T082	C0205099
portions	T082	C0449719
tumor	T191	C0027651
glioma	T191	C0017638
cell lines	T025	C0085983
decreased	T081	C0205216
miR-451	T028	C1826031
expression	T045	C0017262
suppressed	T169	C1260953
tumor cell	T025	C0597032
proliferation	T169	C1514485
migration	T039	C1533574
concomitant	T079	C0521115
CAB39	T116	C2715759
AMPK	T116	C0252214
mTOR	T116	C1307407
pathway activation	T169	C1514528
Rac1	T116	C0139880
cofilin	T116	C0056080
pathway activation	T169	C1514528
miR-451	T114	C2603907
cytological behavior	T169	C0205471
activation	T045	C0599177
mTOR	T116	C1307407
Rac1	T116	C0139880
AMPKα1	T116	C1739697
expression	T045	C1171362
synthetic	T052	C1883254
shRNA	T114	C2930586
glioma	T191	C0017638
microenvironment	T070	C2936626
heterogeneity	T080	C0019409
miR-451	T028	C1826031
expression	T045	C0017262
miR-451	T114	C2603907
upregulating	T044	C0041904
AMPK	T116	C0252214
signaling	T038	C3537152
modulating	T082	C0443264
activation	T045	C0599177
mTOR	T116	C1307407
Rac1	T116	C0139880
cofilin	T116	C0056080
glioma	T191	C0017638
proliferation	T169	C1514485
migration	T039	C1533574
therapeutic	T169	C0302350
suppressing	T169	C1260953
tumor cell	T025	C0597032
proliferation	T169	C1514485
cell	T025	C0007634
infiltration	T046	C0332448
Comparison	T052	C1707455
Gasoline Direct-Injection	T073	C3273359
GDI	T073	C3273359
Port Fuel Injection	T073	C3273359
PFI	T073	C3273359
Vehicle Emissions	T131	C0004380
Emission	T131	C0004380
Certification	T064	C0007836
Standards	T170	C0038137
Cold-Start	T033	C0243095
Organic	T080	C0747055
Aerosol	T073	C0001712
Formation	T169	C1522492
Potential	T080	C3245505
Potential	T080	C3245505
Climate	T070	C0008946
Impacts	T080	C4049986
increases	T081	C0205217
Corporate	T080	C0205556
Average Fuel Economy	T081	C0870462
standards	T170	C0038137
widespread	T082	C0205391
vehicles	T073	C0175845
gasoline direct-injection	T073	C3273359
GDI	T073	C3273359
engines	T073	C3273359
engine	T073	C3273359
technologies	T090	C0039421
emissions	T131	C0004380
quantify	T081	C1709793
effects	T080	C1280500
measured	T080	C0444706
gas-	T104	C0017110
particle-phase	T104	C1254350
emissions	T131	C0004380
light-duty	T080	C0205556
gasoline	T073	C0017113
vehicles	T073	C0175845
California	T083	C0006754
tested	T170	C0392366
chassis	T073	C1707356
dynamometer	T073	C3273359
cold-start	T033	C0243095
GDI	T073	C3273359
vehicles	T073	C0175845
GDIs	T073	C3273359
certified	T064	C0007836
emissions	T131	C0004380
standard	T170	C0038137
superultra-low-emission vehicles	T185	C0008902
SULEV	T185	C0008902
quantified	T081	C1709793
effects of	T080	C1704420
engine	T073	C3273359
technology	T090	C0039421
emission	T131	C0004380
certification	T064	C0007836
standards	T170	C0038137
cold-start	T033	C0243095
emissions	T131	C0004380
vehicles	T073	C0175845
certified	T064	C0007836
emissions	T131	C0004380
standard	T170	C0038137
statistical	T090	C0038215
difference	T081	C1705241
gas-phase	T104	C1254350
pollutant	T131	C0599786
emissions	T131	C0004380
PFIs	T073	C3273359
GDIs	T073	C3273359
GDIs	T073	C3273359
average	T081	C1510992
factor	T169	C1521761
particulate matter	T167	C1720884
PM	T167	C1720884
emissions	T131	C0004380
PFIs	T073	C3273359
elemental carbon	T196	C0007009
EC	T196	C0007009
emissions	T131	C0004380
SULEV	T185	C0008902
certified	T064	C0007836
GDIs	T073	C3273359
factor	T169	C1521761
PM	T167	C1720884
emissions	T131	C0004380
GDIs	T073	C3273359
certified	T064	C0007836
ultralow-emission vehicles	T185	C0008902
improvements	T077	C2986411
engine	T073	C3273359
design	T052	C1707689
calibration	T081	C0006751
Comprehensive	T080	C1880156
organic	T080	C0747055
revealed	T080	C0443289
statistically significant	T081	C0237881
differences	T081	C1705241
composition	T070	C0243176
volatile	T080	C1963547
organic compounds	T109	C0029224
emissions	T131	C0004380
PFI	T073	C3273359
GDIs	T073	C3273359
benzene	T109	C0005036
toluene	T109	C0040383
ethylbenzene	T109	C0059792
xylenes	T109	C0043368
BTEX	T109	C0029224
organic	T080	C0747055
aerosol	T073	C0001712
ozone	T103	C0030106
formation	T169	C1522492
potential	T080	C3245505
exhaust	T131	C0178629
engine	T073	C3273359
technology	T090	C0039421
Cold-start	T033	C0243095
contributes	T052	C1880177
larger	T081	C0549177
fraction of	T081	C1264633
emissions	T131	C0004380
vehicles	T073	C0175845
emission	T131	C0004380
standards	T170	C0038137
Organic	T080	C0747055
gas	T104	C0017110
emissions	T131	C0004380
sensitive	T169	C0332324
cold-start	T033	C0243095
compared	T052	C1707455
pollutants	T131	C0599786
tested	T170	C0392366
statistically significant	T081	C0237881
differences	T081	C1705241
effects of	T080	C1704420
cold-start	T033	C0243095
GDIs	T073	C3273359
PFIs	T073	C3273359
measured	T080	C0444706
decrease	T081	C0205216
CO2	T123	C0007012
emissions	T131	C0004380
GDIs	T073	C3273359
greater	T081	C1704243
potential	T080	C3245505
climate	T070	C0008946
associated with	T080	C0332281
black carbon	T121	C0007010
emissions	T131	C0004380
PFI	T073	C3273359
GDI	T073	C3273359
vehicles	T073	C0175845
reduction	T080	C0392756
global warming	T069	C0206217
TRIB3	T116	C1259051
downregulation	T044	C0013081
enhances	T052	C2349975
doxorubicin	T109	C0013089
induced	T169	C0458082
cytotoxicity	T049	C0596402
gastric cancer	T191	C0024623
cells	T025	C0334227
TRIB3	T116	C1259051
pseudokinase	T116	C0033684
regulate multiple pro-survival pathways	T038	C1327622
therapeutic	T061	C0087111
target	T169	C1521840
treatment	T061	C0920425
human	T016	C0086418
tumors	T191	C0027651
cancer	T191	C0006826
TRIB3	T116	C1259051
protein levels	T034	C0428479
good	T033	C0278250
poor prognosis	T033	C0278252
cancer patients	T101	C1516213
TRIB3	T116	C1259051
expression	T045	C1171362
survival	T043	C0007620
gastric cancer	T191	C0024623
cells	T025	C0334227
anticancer drugs	T109	C0003392
tested	T169	C0039593
anticancer drug	T109	C0003392
doxorubicin	T109	C0013089
induced	T169	C0458082
cytotoxicity	T049	C0596402
TRIB3	T028	C1540055
transcription	T045	C0040649
apoptotic cell death	T043	C0162638
TRIB3 siRNA	T114	C1099354
knockdown	T063	C2350567
enhance	T052	C2349975
doxorubicin	T109	C0013089
induced	T169	C0458082
apoptosis	T043	C0162638
gastric cancer	T191	C0024623
cells	T025	C0334227
expression	T045	C1171362
downstream	T082	C0522506
apoptotic factors	T116	C0763396
overexpression	T045	C1514559
TRIB3	T116	C1259051
protected cells	T025	C0007634
doxorubicin	T109	C0013089
induced	T169	C0458082
apoptosis	T043	C0162638
downregulation	T044	C0013081
TRIB3	T116	C1259051
promote	T052	C0033414
cell death	T043	C0007587
enhance	T052	C2349975
doxorubicin	T109	C0013089
induced	T169	C0458082
apoptosis	T043	C0162638
anti-apoptotic	T120	C2986514
TRIB3	T116	C1259051
inductions	T045	C0017391
MAPKs	T116	C0752312
doxorubicin	T109	C0013089
TRIB3	T116	C1259051
downregulation	T044	C0013081
TRIB3	T116	C1259051
overexpression	T045	C1514559
doxorubicin	T109	C0013089
induced	T169	C0458082
MAPK activation	T044	C1155551
findings	T033	C2825141
TRIB3	T116	C1259051
anti-apoptotic	T120	C2986514
doxorubicin	T109	C0013089
gastric cancer	T191	C0024623
cell lines	T025	C0334227
TRIB3	T116	C1259051
expression	T045	C1171362
anticancer drugs	T109	C0003392
doxorubicin	T109	C0013089
irinotecan	T109	C0123931
oxaliplatin	T109	C0069717
cancer therapy	T061	C0920425
Digital	T023	C0016129
Myopericytoma	T191	C1302808
Case Report	T170	C0007320
Systematic Literature Review	T170	C1955832
myopericytoma	T191	C1302808
MP	T191	C1302808
perivascular tumor	T191	C1335392
unknown etiology	T033	C0743626
potential	T080	C3245505
mimicry	T044	C0242943
malignancy	T191	C4282132
MP tumors	T191	C1302808
surgeons	T097	C0582175
differential diagnosis	T060	C0011906
case report	T170	C0007320
healthy	T080	C3898900
right-hand dominant	T032	C0344333
male	T098	C0025266
outpatient clinic	T073	C0029916
painless	T169	C0234226
swelling	T033	C0038999
erythema of the pulp of his left index finger	T033	C2071552
plain film X-ray	T060	C1306645
near-complete	T080	C0205197
bony destruction	T033	C3810196
distal phalanx	T023	C0223821
Pathological	T046	C0030660
evaluation	T058	C0220825
incisional biopsy	T060	C0184922
benign variant	T191	C0086692
MP	T191	C1302808
lesion	T033	C0221198
excision	T061	C0728940
tumor	T191	C0027651
shelling	T061	C1283248
no evidence of	T080	C0332125
recurrence	T067	C0034897
postoperatively	T079	C0032790
management	T058	C0376636
outcome	T080	C0085415
cases	T170	C0085973
hand and wrist	T029	C0869996
MP	T191	C1302808
Gene expression	T045	C0017262
evidence	T078	C3887511
EGFR	T116	C0034802
proximal-distal limb	T023	C0015385
patterning	T045	C0376678
myriapod	T204	C0597910
Evolution	T045	C0015219
segmented limbs	T023	C0015385
Arthropoda	T204	C0003903
head	T029	C0018670
trunk	T029	C0460005
appendages	T023	C0598782
Proximodistal limb	T023	C0015385
patterning	T045	C0376678
regulatory networks	T044	C1720950
vinegar fly	T204	C0598324
Drosophila melanogaster	T204	C0013139
insects	T204	C0021585
morphogens	T123	C0566267
Wingless	T116	C0168282
Wg	T116	C0168282
Decapentaplegic	T116	C0082344
Dpp	T116	C0082344
EGFR-signaling cascade	T044	C1155379
Wg	T116	C0168282
Dpp	T116	C0082344
studied	T062	C2603343
arthropods	T204	C0003903
Pancrustacea	T204	C1218615
Hexapoda	T204	C1095852
Crustacea	T204	C0010395
Myriapoda	T204	C0597910
Chelicerata	T204	C0998333
investigation	T169	C1292732
EGFR-signaling	T044	C1155379
insects	T204	C0021585
Hexapoda	T204	C1095852
Gene expression analysis	T063	C1880945
Egfr	T116	C0034802
potential	T080	C3245505
ligands	T103	C0023688
putative downstream factors	T116	C0033684
pill millipede	T204	C0323823
Glomeris marginata	T204	C1023180
Myriapoda	T204	C0597910
Diplopoda	T204	C0323823
mandibulate	T204	C1218616
arthropods	T204	C0003903
EGFR-signaling	T044	C1155379
regulatory mechanism	T033	C0243095
proximodistal limb	T023	C0015385
patterning	T045	C0376678
Pirfenidone	T109	C0298067
normalizes	T169	C0599112
tumor microenvironment	T070	C2936626
chemotherapy	T061	C3665472
Normalization	T061	C0556530
tumor microenvironment	T070	C2936626
targeting	T169	C1521840
components	T026	C0932050
tumor	T191	C0027651
extracellular matrix	T024	C0015350
potential	T080	C3245505
decompress	T169	C1965697
tumor	T191	C0027651
blood vessels	T023	C0005847
increase	T169	C0442805
vessel	T023	C0005847
perfusion	T042	C0599705
drug delivery	T061	C0087111
efficacy	T080	C0598333
cancer therapy	T061	C0920425
identify	T080	C0205396
tolerated	T033	C0243095
pharmaceutical agents	T121	C1254351
microenvironment	T070	C2936626
solid tumors	T191	C0280100
enhance	T052	C2349975
chemotherapy	T061	C3665472
study	T062	C2603343
Pirfenidone	T109	C0298067
clinically	T080	C0205210
approved	T080	C0205540
anti-fibrotic drug	T121	C4031950
treatment	T061	C0087111
idiopathic pulmonary fibrosis	T047	C1800706
investigate	T169	C1292732
tumor microenvironment	T070	C2936626
normalization	T061	C0556530
orthotopic	T082	C0574893
mammary	T023	C0006141
tumor models	T170	C1710493
Pirfenidone	T109	C0298067
reduces	T081	C0547047
collagen	T116	C0009325
hyaluronan	T109	C0813622
levels	T080	C0441889
result	T169	C1274040
significantly	T078	C0750502
increases	T169	C0442805
blood vessel	T023	C0005847
functionality	T169	C0542341
perfusion	T042	C0599705
anti-tumor efficacy	T080	C0598333
doxorubicin	T109	C0013089
Reduction	T080	C0392756
extracellular matrix components	T026	C0932050
TGFβ signaling pathway	T169	C2984328
inhibition	T052	C3463820
downregulation	T044	C0013081
TGFβ1	T028	C1366557
COL1A1	T028	C1332772
COL3A1	T028	C1413581
HAS2	T028	C1415475
HAS3	T028	C1415476
expression	T045	C0017262
levels	T080	C0441889
findings	T033	C0243095
evidence	T078	C3887511
Pirfenidone	T109	C0298067
strategy	T062	C0035171
enhance	T052	C2349975
drug delivery	T061	C0087111
solid tumors	T191	C0280100
normalizing	T061	C0556530
tumor microenvironment	T070	C2936626
Serum	T031	C0229671
vascular endothelial growth factor receptor-3	T116	C0169539
levels	T081	C1446561
patients	T101	C0030705
esophageal squamous cell cancer	T191	C0279626
Esophageal cancer	T191	C0014859
tumors of the gastrointestinal tract	T191	C0017185
serum	T031	C0229671
vascular endothelial growth factor-3	T116	C0169539
VEGFR-3	T116	C0169539
expression	T045	C1171362
patients	T101	C0030705
esophageal squamous cell carcinoma	T191	C0279626
ESCC	T191	C0279626
VEGFR-3	T116	C0169539
ESCC	T191	C0279626
patients	T101	C0030705
ESCC	T191	C0279626
Pre-therapy	T079	C1882440
preoperative	T079	C0445204
samples	T031	C1550100
ELISA	T059	C0014441
VEGFR-3	T116	C0169539
serum values	T081	C0683149
VEGFR-3	T116	C0169539
patients	T101	C0030705
ESCC	T191	C0279626
healthy	T080	C3898900
donors	T098	C0013018
sensitivity	T081	C1511883
VEGFR-3	T116	C0169539
ESCC	T191	C0279626
VEGFR-3	T116	C0169539
diagnostic	T169	C0348026
biomarker	T201	C0005516
ESCC	T191	C0279626
Biomarker	T201	C0005516
ESCC	T191	C0279626
VEGFR-3	T116	C0169539
Zinc	T121	C0043481
Wound Healing	T040	C0043240
Review of	T169	C0699752
Zinc	T121	C0043481
Physiology	T039	C0031843
Clinical Applications	T169	C4048755
understanding	T041	C0233820
zinc	T121	C0043481
human	T016	C0086418
physiology	T039	C0031843
constantly	T080	C1948059
gaps	T082	C3887622
function	T169	C0542341
zinc	T121	C0043481
wound healing	T040	C0043240
review	T170	C0282443
aims	T078	C1947946
clinician	T097	C0871685
sufficient	T080	C0205410
zinc	T121	C0043481
biology	T091	C0005532
zinc	T121	C0043481
wound healing	T040	C0043240
Zinc	T121	C0043481
ion	T196	C0022023
physiology	T039	C0031843
zinc deficiency	T047	C0235950
manifestations	T169	C0205319
delayed	T079	C0205421
wound healing	T040	C0043240
immune dysfunction	T047	C0021053
impairment	T169	C0221099
multiple	T081	C0439064
sensory systems	T022	C0682647
consensus	T054	C0376298
detrimental effects	T080	C1280500
zinc deficiency	T047	C0235950
wound healing	T040	C0043240
discord	T054	C0680238
literature	T170	C0023866
optimal methods	T170	C0025663
true benefits	T081	C0814225
zinc	T121	C0043481
thyroid hormone deficiency	T047	C0020676
treatment	T061	C0087111
risk	T078	C0035647
herpes zoster	T047	C0019360
Thyroid hormone	T116	C0040135
TH	T116	C0040135
herpes virus	T005	C0019369
gene expression	T045	C0017262
replication	T045	C0598312
neurons	T025	C0027882
epigenetics	T045	C1516924
nuclear receptors	T116	C0206588
patients	T101	C0030705
hypothyroidism	T047	C0020676
herpes zoster	T047	C0019360
HZ	T047	C0019360
TH deficiency	T047	C0020676
risk factor	T033	C0035648
varicella zoster virus	T005	C0042338
VZV	T005	C0042338
reactivation	T052	C4086768
aim	T078	C1947946
study	T062	C2603343
hypothesis	T078	C1512571
TH treatment	T061	C2986608
complication	T046	C0009566
HZ	T047	C0019360
study	T062	C2603343
investigated	T169	C1292732
hypothesis	T078	C1512571
comprehensive medical database	T170	C0242356
Kaiser Permanente Southern California	T093	C1708333
KPSC	T093	C1708333
patients	T101	C0030705
TH	T116	C0040135
medication	T058	C2081612
HZ	T047	C0019360
Kaplan-Meier analysis	T081	C1720943
hypothyroidism	T047	C0020676
patients	T101	C0030705
TH	T116	C0040135
medicines	T121	C0013227
risk	T078	C0035647
HZ	T047	C0019360
analysis	T062	C0936012
patients	T101	C0030705
medication	T058	C2081612
treatment	T061	C0087111
TH deficiency	T047	C0020676
risk	T078	C0035647
HZ	T047	C0019360
hazard ratio	T081	C2985465
confidence interval	T081	C0009667
risk	T078	C0035647
HZ	T047	C0019360
age groups	T100	C0027362
years	T079	C0439234
cohort	T098	C0599755
female	T032	C0086287
patients	T101	C0030705
TH treatment	T061	C2986608
risk	T078	C0035647
male	T032	C0086582
findings	T033	C0243095
hypothesis	T078	C1512571
TH	T116	C0040135
HZ	T047	C0019360
studies	T062	C2603343
evaluate the laboratory data	T058	C0262707
analysis	T062	C0936012
hormonal	T080	C0458083
effects	T080	C1280500
individuals	T098	C0027361
Peer	T098	C0679739
Exclusion	T052	C2828389
Pubertal	T033	C1627769
Transition	T052	C2700061
Social Competence	T054	C0683256
youth	T100	C0087178
early puberty	T047	C0034013
peer	T098	C0679739
exclusion	T052	C2828389
early	T079	C1279919
developers	T098	C1257890
experience	T041	C0596545
peer	T098	C0679739
exclusion	T052	C2828389
social competence	T054	C0683256
bolster	T169	C1511253
develop	T169	C1527148
maintain	T052	C0024501
positive	T033	C1446409
relationships	T080	C0439849
peers	T098	C0679739
present	T033	C0150312
study	T062	C2603343
pubertal	T033	C1627769
timing	T079	C0449243
tempo	T079	C0876945
predicts	T078	C0681842
decrements	T080	C0392756
children's	T100	C0008059
social competence	T054	C0683256
decrements	T080	C0392756
social competence	T054	C0683256
associations	T080	C0332281
puberty	T039	C0034011
timing	T079	C0449243
tempo	T079	C0876945
peer	T098	C0679739
exclusion	T052	C2828389
time	T079	C0040223
Longitudinal	T062	C0023981
data	T078	C1511726
families	T099	C0015576
female	T098	C0043210
White	T098	C0007457
years	T079	C0439234
participated	T169	C0679823
Phase III	T062	C0282461
NICHD	T093	C1513896
SECCYD	T062	C0023981
results	T169	C1274040
latent growth curve models	UnknownType	C0814921
earlier	T079	C1279919
pubertal	T033	C1627769
timing	T079	C0449243
rapid	T080	C0456962
pubertal	T033	C1627769
tempo	T079	C0876945
girls	T100	C0870604
associated with	T080	C0332281
high	T080	C0205250
initial	T079	C0205265
levels	T080	C0441889
peer	T098	C0679739
exclusion	T052	C2828389
mediation analyses	UnknownType	C0814912
early	T079	C1279919
developers'	T098	C1257890
susceptibility	T169	C1264642
peer	T098	C0679739
exclusion	T052	C2828389
associated with	T080	C0332281
initial	T079	C0205265
level	T080	C0441889
social competence	T054	C0683256
boys	T100	C0870221
pubertal	T033	C1627769
timing	T079	C0449243
tempo	T079	C0876945
associated with	T080	C0332281
peer	T098	C0679739
exclusion	T052	C2828389
effects of	T080	C1704420
pubertal	T033	C1627769
timing	T079	C0449243
peer	T098	C0679739
exclusion	T052	C2828389
intercept	T081	C3146232
slope	T081	C0807955
initial	T079	C0205265
levels	T080	C0441889
social competence	T054	C0683256
average	T081	C1510992
early	T079	C1279919
developers'	T098	C1257890
low	T080	C0205251
levels	T080	C0441889
social competence	T054	C0683256
high	T080	C0205250
initial	T079	C0205265
levels	T080	C0441889
peer	T098	C0679739
exclusion	T052	C2828389
experienced	T041	C0596545
decrements	T080	C0392756
peer	T098	C0679739
exclusion	T052	C2828389
association	T080	C0332281
intercepts	T081	C3146232
puberty	T039	C0034011
peer	T098	C0679739
exclusion	T052	C2828389
slopes	T081	C0807955
social competence	T054	C0683256
peer	T098	C0679739
exclusion	T052	C2828389
stronger	T080	C0442821
boys	T100	C0870221
girls	T100	C0870604
findings	T033	C0243095
early	T079	C1279919
developers'	T098	C1257890
susceptibility	T169	C1264642
experiences	T041	C0596545
peer	T098	C0679739
exclusion	T052	C2828389
associated with	T080	C0332281
development	T169	C1527148
social competence	T054	C0683256
Air pollution	T069	C0001873
characteristics	T080	C1521970
health risks	T061	C0679809
Henan Province	T083	C1514578
China	T083	C0008115
severe	T080	C0205082
air pollution	T069	C0001873
China	T083	C0008115
air pollution	T069	C0001873
characteristics	T080	C1521970
health	T078	C0018684
risks	T078	C0035647
dataset	T170	C0150098
daily	T079	C0332173
concentrations	T081	C1446561
pollutants	T131	C0001869
PM2.5	T167	C1720884
PM10	T167	C1720884
CO	T131	C0007018
SO2	T131	C0038777
NO2	T131	C0028160
O3	T103	C0030106
Henan province	T083	C1514578
air pollution	T069	C0001873
status	T080	C0449438
Henan province	T083	C1514578
northern part	T082	C1709269
Zhengzhou	T083	C0008848
city	T083	C0008848
worst	T080	C1522166
air quality	T080	C2371710
PM2.5	T167	C1720884
concentrations	T081	C1446561
Chinese Ambient Air Quality Standard	T081	C0034925
PM2.5	T167	C1720884
pollutant	T131	C0599786
ozone	T103	C0030106
pollution	T069	C0001873
summer	T079	C0241301
air quality index	T170	C0918012
AQI	T170	C0918012
health	T078	C0018684
pollutants	T131	C0599786
aggregate air quality index	T170	C0918012
AAQI	T170	C0918012
health-risk based air quality index	T170	C0918012
HAQI	T170	C0918012
evaluate the health risks	T061	C0679809
HAQI	T170	C0918012
AQI	T170	C0918012
health	T078	C0018684
risks	T078	C0035647
air pollution	T069	C0001873
general public	T098	C0683971
health protection measures	T058	C1254363
population	T081	C0032659
HAQI	T170	C0918012
population	T081	C0032659
cities	T083	C0008848
Henan province	T083	C1514578
polluted air	T069	C0001873
population	T081	C0032659
exposed to	T080	C0332157
air	T167	C0001861
unhealthy	T033	C0243095
sensitive	T169	C0332324
people	T098	C0027361
people	T098	C0027361
exposed to	T080	C0332157
air	T167	C0001861
healthy	T080	C3898900
people	T098	C0027361
health	T078	C0018684
risks	T078	C0035647
winter	T079	C0241737
seasons	T079	C0036497
HAQI	T170	C0918012
algorithm	T170	C0002045
clinical	T170	C1516606
epidemiologic	T169	C0014508
data	T170	C0150098
HAQI	T170	C0918012
Increased	T081	C0205217
risk	T078	C0035647
PTLD	T191	C0432487
lung transplant recipients	T033	C2063401
cystic fibrosis	T047	C0010674
Post-transplant lymphoproliferative disease	T191	C0432487
PTLD	T191	C0432487
morbidity	T081	C0026538
mortality	T081	C0026566
lung transplantation	T061	C0024128
Recipients	T101	C0376387
cystic fibrosis	T047	C0010674
CF	T047	C0010674
increased	T081	C0205217
risk	T078	C0035647
PTLD	T191	C0432487
literature	T170	C0023866
single center cohorts	T098	C0599755
PTLD	T191	C0432487
adult	T100	C0001675
lung transplant	T061	C0024128
population	T098	C1257890
International Society for Heart and Lung Transplantation Registry	T170	C0282574
studied	T062	C2603343
adult	T100	C0001675
recipients	T098	C1709854
lung transplants	T061	C0024128
outcome	T169	C1274040
development	T169	C1527148
time	T079	C0040223
PTLD	T191	C0432487
transplant	T061	C0040732
predictors	T078	C2698872
Epstein-Barr virus	T005	C0014644
EBV	T005	C0014644
cytomegalovirus	T005	C0010825
CMV	T005	C0010825
serostatus	T201	C1300950
gender	T032	C0079399
age	T032	C0001779
Outcomes	T169	C1274040
assessed	T052	C1516048
univariable	T062	C0683962
multivariable Cox proportional hazard models	T081	C0010235
hazard ratios	T081	C2985465
HR	T081	C2985465
cohort	T098	C0599755
diagnosis	T033	C0011900
CF	T047	C0010674
PTLD	T191	C0432487
CF	T047	C0010674
recipients	T101	C0376387
non-CF recipients	T033	C2063401
non-CF recipients	T033	C2063401
CF	T047	C0010674
recipients	T101	C0376387
higher prevalence	T081	C0220900
EBV	T005	C0014644
CMV seronegativity	T034	C2919629
higher prevalences	T081	C0220900
high risk	T078	C0035647
EBV	T005	C0014644
CMV	T005	C0010825
CF	T047	C0010674
development	T169	C1527148
PTLD	T191	C0432487
HR	T081	C2985465
Stratified multivariable analysis	T081	C0026777
age	T032	C0001779
EBV	T005	C0014644
negative	T033	C1513916
non-CF recipients	T033	C2063401
increased	T081	C0205217
risk	T078	C0035647
PTLD	T191	C0432487
EBV	T005	C0014644
CF	T047	C0010674
recipients	T101	C0376387
increased	T081	C0205217
risk	T078	C0035647
CF	T047	C0010674
recipients	T101	C0376387
risk	T078	C0035647
PTLD	T191	C0432487
non-CF recipients	T033	C2063401
studies	T062	C2603343
risk factors	T033	C0035648
management	T058	C0035649
population post-transplant	T033	C2063401
Methods	T170	C0025663
tools	UnknownType	C0541506
current	T079	C0521116
perspectives	T078	C1254370
proteogenomics	T091	C3897816
technological advancements	UnknownType	C0681519
high-throughput next-generation sequencing	T063	C2936625
deep mass spectrometry	T059	C0037813
proteomics	T091	C0872252
proteogenomics	T091	C3897816
integrative analysis	T062	C0936012
proteomic and genomic data	T078	C1511726
research field	UnknownType	C0683945
field	UnknownType	C0683945
protein	T116	C0033684
identification	T080	C0205396
sample-specific genomic	T170	C0282574
transcriptomic sequencing data	T170	C0026382
integrative analysis	T062	C0936012
quantitative	T081	C0392762
measurements	T169	C0242485
genomic and proteomic studies	T062	C0681814
identified	T080	C0205396
gene expression regulation	T045	C0017263
cell signaling	T043	C0037083
disease	T047	C0012634
methods	T170	C0025663
tools	UnknownType	C0541506
array	T082	C1510941
integrative proteogenomic approaches	T169	C1292724
article	T170	C1706852
systematically	T169	C0220922
classify	T185	C0008902
published	T057	C0034037
methods	T170	C0025663
tools	UnknownType	C0541506
major categories	T185	C1550395
Sequence	T086	C0004793
Sequence -centric proteogenomics	T091	C3897816
Analysis	T062	C0936012
proteogenomic relationships	T080	C0439849
Integrative modeling	T062	C0870071
proteogenomic data	T078	C1511726
Data sharing	T054	C2713450
visualization	T041	C0175631
comprehensive	T080	C1880156
review of	T169	C0699752
methods	T170	C0025663
available	T169	C0470187
tools	UnknownType	C0541506
category	T170	C0683312
typical	T080	C3538928
applications	T169	C0205245
Plasma	T031	C0032105
DNA	T114	C0012854
RNA	T114	C0035668
differentially	T080	C1705242
impact	T080	C4049986
coagulation	T042	C0005778
abdominal sepsis	T047	C1141926
explorative study	T062	C2603343
Cell-free DNA	T114	C4289789
cfDNA	T114	C4289789
extracellular	T026	C0521119
RNA	T114	C0035668
exRNA	T114	C0035668
suspected	T078	C0750491
activate	T169	C1515877
coagulation cascades	T047	C0005779
sepsis	T047	C0243026
study	T062	C2603343
investigated	T169	C1292732
influence	T077	C4054723
plasmatic	T031	C0032105
nucleic acids	T114	C0028606
coagulation	T042	C0005778
septic	T169	C0333534
patients	T101	C0030705
comparison	T052	C1707455
patients	T101	C0030705
abdominal surgery	T061	C0198482
patients	T101	C0030705
sepsis	T047	C0243026
postoperative	T079	C0032790
patients	T101	C0030705
healthy volunteers	T098	C1708335
included	T169	C0332257
longitudinal study	T062	C0023981
Blood	T031	C0005767
collected	T078	C1516695
sepsis	T047	C0243026
onset	T079	C0277793
surgery	T061	C0543467
Levels	T080	C0441889
cfDNA	T114	C4289789
exRNA	T114	C0035668
measured	T080	C0444706
quantitative	T081	C0392762
probe-based	T074	C0182400
polymerase chain reaction	T063	C0032520
thromboelastography	T059	C0040017
coagulation	T042	C0005778
thromboaggregometry	T059	C0022885
platelet function	T043	C1254881
cfDNA	T114	C4289789
exRNA	T114	C0035668
elevated	T080	C3163633
patients	T101	C0030705
sepsis	T047	C0243026
compared	T052	C1707455
postoperative	T079	C0032790
patients	T101	C0030705
healthy volunteers	T098	C1708335
higher	T080	C0205250
exRNA	T114	C0035668
levels	T080	C0441889
correlated	T080	C1707520
faster clotting time	T034	C2266672
stable clots	T046	C0302148
cfDNA	T114	C4289789
correlated	T080	C1707520
shorter clotting time	T034	C2266672
fibrinolysis	T039	C0016017
higher	T080	C0205250
cfDNA	T114	C4289789
associated with	T080	C0332281
kidney dysfunction	T046	C0151746
markers	T201	C0005516
cell damage	T049	C0599732
lactate dehydrogenase	T116	C0022917
lactate	T109	C0376261
nucleic acid	T114	C0028606
associated with	T080	C0332281
different	T080	C1705242
effects	T080	C1280500
coagulation	T042	C0005778
sepsis	T047	C0243026
overall	T080	C1561607
procoagulatory	T042	C2917275
influence	T077	C4054723
individualized	T080	C1881197
therapeutic approaches	T061	C0087111
patients	T101	C0030705
suffering	T184	C0751408
coagulation	T042	C0005778
associated	T033	C0449380
organ dysfunction	T047	C0342953
Association	T080	C0439849
Fat Mass	T032	C3656665
Obesity	T047	C0028754
associated	T080	C0332281
Gene Variant	T028	C0678941
Lifestyle	T054	C0023676
Factors	T169	C1521761
Body Fat	T201	C0344335
Indian	T098	C1524069
Children	T100	C0008059
intronic variants	T028	C0678941
fat mass	T032	C3656665
obesity	T047	C0028754
associated	T080	C0332281
(FTO) gene	T028	C1970415
associated with	T080	C0332281
obesity	T047	C0028754
traits	T032	C0599883
humans	T016	C0086418
study	T062	C2603343
study	T062	C2603343
FTO gene	T028	C1970415
variants	T028	C0678941
body mass index	T201	C1305855
BMI	T201	C1305855
association	T080	C0439849
FTO gene	T028	C1970415
variants	T028	C0678941
lifestyle	T054	C0023676
factors	T169	C1521761
obese	T047	C0028754
normal weight	T033	C2712185
Indian	T098	C1524069
children	T100	C0008059
children	T100	C0008059
boys	T100	C0870221
age	T032	C0001779
years	T079	C0439234
studied	T062	C2603343
Height	T032	C0005890
weight	T032	C0005910
waist	T201	C0455829
hip circumference	T201	C0562350
measured	T080	C0444706
Physical activity	T056	C0026606
questionnaire	T170	C4264334
food	T168	C0016452
intake	T169	C1512806
food frequency questionnaire	T170	C2986698
assessed	T052	C1516048
Body fat percentage	T201	C1632383
%BF	T201	C1632383
dual-energy X-ray absorptiometry	T060	C1510486
FTO allelic variants	T028	C0678941
rs9939609 site	T082	C1517493
SYBR Green Amplification Refractory Mutation System real-time polymerase chain reaction	T063	C1709846
allele	T028	C0002085
specific	T080	C0205369
primers	T114	C0206415
Generalized linear model	T081	C0023732
investigate	T169	C1292732
simultaneous	T079	C0521115
influence	T077	C4054723
genetic	T169	C0314603
lifestyle	T054	C0023676
factors	T169	C1521761
%BF	T201	C1632383
height	T032	C0005890
weight	T032	C0005910
BMI	T201	C1305855
normal	T080	C0205307
obese	T047	C0028754
children	T100	C0008059
AA allele	T028	C0002085
obese	T047	C0028754
children	T100	C0008059
normal weight	T033	C2712185
children	T100	C0008059
Children	T100	C0008059
AA allele	T028	C0002085
obese	T047	C0028754
physical activity	T056	C0026606
children	T100	C0008059
AT allele	T028	C0002085
obesity	T047	C0028754
highest	T080	C1522410
intake of calories	T081	C4281687
compared	T052	C1707455
children	T100	C0008059
AT allele	T028	C0002085
normal	T080	C0205307
%BF	T201	C1632383
associated with	T080	C0332281
AA alleles	T028	C0002085
junk food	T168	C0681578
intake	T169	C1512806
healthy	T080	C3898900
food	T168	C0016452
intake	T169	C1512806
physical activity	T056	C0026606
Healthy lifestyle	T055	C4277664
physical activity	T056	C0026606
diet	T168	C0012155
low	T080	C0205251
calories	T081	C1556156
fat	T109	C0012171
modifying	T169	C0392747
risk	T078	C0035647
FTO variants	T028	C0678941
children	T100	C0008059
Museum	T073	C0026863
specimen	T167	C0370003
data	T078	C1511726
plant disease	T047	C0032080
increases	T169	C0442805
insect vector	T204	C0021573
insect vector population	T098	C1257890
emergence rate	T081	C1521828
plant diseases	T047	C0032080
increasing	T169	C0442808
climate change	T070	C2718051
changes	T169	C0392747
vector populations	T098	C1257890
risks	T078	C0035647
agricultural	T090	C0001829
agricultural sustainability	T169	C0205245
Assessing and managing	T052	C0441655
disease	T047	C0012634
risks	T078	C0035647
contemporary and historical emergence events	T051	C0441471
potato growers	T097	C0027363
western United States	T083	C0041703
Mexico	T083	C0025885
Central America	T083	C0007674
yield loss	T081	C0392762
Zebra Chip disease	T047	C0012634
insecticide	T131	C0021576
populations	T098	C1257890
insect vector	T204	C0021573
potato psyllid	T204	C1502411
Bactericera cockerelli	T204	C1502411
Hemiptera	T204	C0018992
Triozidae	T204	C1007295
Zebra Chip	T047	C0012634
outbreaks	T067	C0012652
hypotheses	T078	C1512571
B. cockerelli	T204	C1502411
occupancy	T080	C2827063
increased	T081	C0205217
century	T121	C0719214
California	T083	C0006754
climate change	T070	C2718051
warmer winters	T079	C0241737
dataset	T170	C0150098
museum	T073	C0026863
specimen	T167	C0370003
records	T170	C0034869
Hemiptera	T204	C0018992
analyzed	T062	C0936012
B. cockerelli	T204	C1502411
hierarchical occupancy model	T170	C3161035
species	T185	C1705920
species lists	T170	C0745732
evidence	T078	C3887511
B. cockerelli	T204	C1502411
occupancy	T080	C2827063
increased	T081	C0205217
century	T121	C0719214
climate changes	T070	C2718051
analysis	T062	C0936012
species	T185	C1705920
occupancy	T080	C2827063
analysis	T062	C0936012
hypothesis	T078	C1512571
B. cockerelli	T204	C1502411
population	T098	C1257890
increased	T081	C0205217
B. cockerelli	T204	C1502411
population	T098	C1257890
dynamics	T070	C3826426
Zebra Chip	T047	C0012634
Zebra Chip epidemics	T047	C0277548
historical macro-ecological approach	T082	C0449445
comparative risk assessment	T058	C0086930
pest	T204	C0684063
insect vector	T204	C0021573
outbreaks	T067	C0012652
Effect	T080	C1280500
halotolerant rhizobacteria	T007	C0004611
isolated	T169	C0205409
halophytes	T002	C2350261
growth	T040	C0018270
sugar beet	T002	C0330391
Beta vulgaris L	T002	C0330391
salt stress	T043	C1154956
Utilization	T169	C0042153
rhizobacteria	T007	C0004611
associated with	T080	C0332281
plant roots	T002	C0242726
harsh	T033	C4068826
environments	T082	C0014406
feasible strategy	T062	C0035171
agricultural production	T090	C0001827
soil	T167	C0037592
salinity	T034	C1956027
Halophytes	T002	C2350261
high	T080	C0205250
salt environments	T082	C0178838
roots	T002	C0242726
associated with	T080	C0332281
microbial candidates	T001	C0599840
promoting	T052	C0033414
growth	T040	C0018270
salt tolerance	T043	C1752460
crops	T002	C0242775
study	T062	C2603343
isolate	T169	C0205409
halotolerant plant	T002	C2350260
growth	T040	C0597252
promoting	T052	C0033414
rhizobacterial	T080	C0521009
strains	T001	C1518614
halophytes	T002	C2350261
evaluate	T052	C1516048
activity	T052	C0441655
effects	T080	C1280500
sugar beet	T002	C0330391
Beta vulgaris L	T002	C0330391
growth	T040	C0018270
salinity stress	T043	C1154956
isolates	T123	C1764827
ability	T032	C0085732
1-aminocyclopropane-1-carboxylate deaminase	T116	C0044278
ACD	T116	C0044278
plant-growth	T040	C0597252
promoting	T052	C0033414
characteristics	T080	C1521970
identified	T080	C0205396
sequencing	T169	C1561491
16S rRNA	T114	C3537372
gene	T028	C0017337
isolates	T123	C1764827
Micrococcus yunnanensis	T007	C2766719
Planococcus rifietoensis	T007	C1483193
Variovorax paradoxus	T007	C0314842
enhanced	T052	C2349975
salt stress	T043	C1154956
tolerance	T080	C1704410
sugar beet	T002	C0330391
resulting in	T169	C0332294
greater	T081	C1704243
seed germination	T040	C1160189
plant	T002	C0032098
biomass	T081	C0005535
higher	T080	C0205250
photosynthetic	T070	C0031764
capacity	T081	C1516240
lower	T080	C0205251
stress	T033	C0038435
induced	T169	C0205263
ethylene	T109	C0015075
production	T169	C0005572
different	T080	C1705242
NaCl	T121	C0037494
concentrations	T081	C1446561
results	T169	C1274040
salinity	T034	C1956027
adapted	T038	C0392673
ACD	T116	C0044278
bacteria	T007	C0004611
isolated	T169	C0205409
halophytes	T002	C2350261
promote	T052	C0033414
sugar beet	T002	C0330391
growth	T040	C0018270
saline stress conditions	T043	C1154956
Potential	T080	C3245505
Sunitinib	T109	C1176020
Induced	T169	C0205263
Coronary Artery	T023	C0205042
Aortic Dissections	T047	C0340643
Small-molecule multitargeted tyrosine kinase inhibitor (TKI) therapy	T061	C0879484
cancer	T191	C0006826
drugs	T121	C0013227
associated with	T080	C0332281
cardiovascular toxicity	T037	C0876994
aortic dissection	T047	C0340643
knowledge	T170	C0376554
first time	T079	C0040223
coronary dissection	T047	C0340643
potentially	T080	C3245505
associated with	T080	C0332281
TKI treatment	T061	C0879484
Recovery of	T052	C0237820
orthographic	T090	C0871846
processing	T041	C0025361
stroke	T047	C0038454
longitudinal	T062	C0023981
fMRI	T060	C0376335
orthographic	T090	C0871846
processing	T041	C0025361
normal reading and spelling	T048	C1404290
neural changes	T169	C3714606
impairment	T169	C0221099
recovery	T052	C0237820
orthographic	T090	C0871846
lexical processing	T041	C0871801
ischemic	T046	C0022116
left posterior cerebral artery (PCA) stroke	T047	C2062605
longitudinal case study	T062	C0023981
MMY	T016	C0086418
impairments	T169	C0221099
orthographic	T090	C0871846
lexical processing	T041	C0871801
reading and spelling	T048	C1404290
stroke	T047	C0038454
onset	T079	C0277793
stroke	T047	C0038454
hypothesis	T078	C1512571
acute	T079	C0205178
impairment	T169	C0221099
reading and spelling	T048	C1404290
loss of	T081	C1517945
neural activation	T169	C3714606
left fusiform gyrus	T023	C2337131
FG	T023	C2337131
gain of	T081	C1517378
neural activation	T169	C3714606
MMY's	T016	C0086418
neural changes	T169	C3714606
behavioral	T053	C0004927
recovery of naming as well	T040	C2004454
neural recovery	T169	C3714606
reading and spelling	T048	C1404290
neural changes	T169	C3714606
orthographic	T090	C0871846
processing	T041	C0025361
longitudinal behavioral	T062	C0004939
functional magnetic resonance imaging	T060	C0376335
fMRI	T060	C0376335
reading	T041	C0586739
spelling	UnknownType	C0869025
visual object naming	T170	C0451342
stroke	T047	C0038454
hypothesis	T078	C1512571
orthographic	T090	C0871846
lexical processing	T041	C0871801
up-regulation	T044	C0041904
neural activation	T169	C3714606
orthographic	T090	C0871846
lexical processing	T041	C0871801
left mid-FG	T029	C2953769
inferior frontal junction	T023	C0152298
IFJ	T023	C0152298
neural changes	T169	C3714606
orthographic	T090	C0871846
processing	T041	C0025361
reading	T041	C0586739
spelling	UnknownType	C0869025
visual object naming	T170	C0451342
left mid-FG	T029	C2953769
left PCA stroke	T047	C2062605
orthographic	T090	C0871846
lexical processing	T041	C0871801
posterior region	T082	C1254362
adjacent	T082	C0205117
stroke	T047	C0038454
distant frontal	T082	C1254362
orthographic	T090	C0871846
processing	T041	C0025361
Nodal	T082	C0443268
skip	T033	C0560435
metastasis	T191	C0596869
thoracic esophageal squamous cell carcinoma	T191	C0861674
cohort study	T081	C0009247
Nodal	T082	C0443268
skip	T033	C0560435
metastasis	T191	C0596869
prognostic factor	T201	C1514474
malignancies	T191	C4282132
esophageal cancer	T191	C0014859
unclear	T033	C3845108
investigate	T169	C1292732
effect	T080	C1280500
nodal	T082	C0443268
skip	T033	C0560435
thoracic esophageal squamous cell carcinoma	T191	C0861674
patients	T101	C0030705
esophagectomy	T061	C0085198
thoracic esophageal squamous cell carcinoma	T191	C0861674
Center for Esophageal Diseases	T093	C1708333
Padova	UnknownType	C0681784
January	T080	C3829466
December	T080	C3830550
retrospectively evaluated	T062	C0035363
Selection criteria	T080	C0242801
R0 resection	T033	C0677874
pathological	T169	C1521733
M0 stage	T033	C0445034
pathological	T169	C1521733
lymph node involvement	T033	C0806692
Patients	T101	C1516213
neoadjuvant therapy	T061	C0600558
patients	T101	C0030705
lymph node involvement	T033	C0806692
pathological	T169	C1521733
evaluation	T058	C0220825
patients	T101	C1516213
nodal	T082	C0443268
skip	T033	C0560435
metastasis	T191	C0596869
lymph node metastases	T191	C0596869
patient	T101	C1516213
nodal	T082	C0443268
skip	T033	C0560435
metastasis	T191	C0596869
overall survival	T081	C4086681
disease free survival	T081	C0242793
patients	T101	C0030705
peritumoral	T082	C3897941
distant	T082	C0443203
lymph node metastases	T191	C0596869
nodal	T082	C0443268
skip	T033	C0560435
metastasis	T191	C0596869
C.I	T081	C0009667
patients	T101	C0030705
lymph node metastasis	T191	C0596869
lymph node metastasis	T191	C0596869
C.I	T081	C0009667
middle	T082	C0444598
thoracic esophagus	T023	C0227188
C.I	T081	C0009667
lower	T082	C0441994
thoracic esophagus	T023	C0227188
upper	T082	C1282910
thoracic esophagus	T023	C0227188
C.I.	T081	C0009667
clinical	T080	C0205210
N0 stage	T033	C0441959
clinical	T080	C0205210
N+ stage	T033	C1272457
Nodal	T082	C0443268
skip	T033	C0560435
metastasis	T191	C0596869
metastatic lymph involvement	T033	C0806692
thoracic esophageal squamous cell carcinoma	T191	C0861674
neither	T080	C4284892
overall survival	T081	C4086681
disease free survival	T081	C0242793
associated with	T080	C0332281
nodal	T082	C0443268
skip	T033	C0560435
metastasis	T191	C0596869
Association	T080	C0439849
leukemia inhibitory factor gene	T028	C1366463
polymorphism	T045	C0678951
in vitro	T080	C1533691
fertilization	T040	C0015914
outcome	T169	C1274040
population	T098	C1257890
northern Iran	T083	C0022065
studies	T062	C2603343
endometrial	T082	C0227843
leukemia inhibitory factor	T116	C0125606
LIF	T116	C0125606
embryo implantation	T040	C0029976
LIF	T116	C0125606
glycoprotein	T116	C0017968
biological functions	T038	C3714634
stimulation	T070	C1948023
cell proliferation	T043	C0596290
differentiation	T043	C0007589
survival	T043	C0007620
essential	T080	C0205224
blastocyete	T018	C0005705
development	T169	C1527148
implantation	T040	C0029976
LIF receptor	T116	C0125607
activates	T052	C1879547
signaling pathways	T044	C0037080
diverse cell types	T170	C0449475
Jak/STAT	T169	C2984327
MAPK	T116	C0752312
PI3-kinase	T116	C0044602
pathways	T044	C0037080
endometrium	T023	C0014180
fertile	T040	C0015895
woman	T098	C0043210
expression	T045	C1171362
LIF	T116	C0125606
proliferative	T046	C0334094
phase	T079	C0205390
failure	T169	C0231174
implantation	T061	C0021107
study	T062	C2603343
association	T080	C0439849
maternal	T033	C1858460
genotype	T032	C0017431
SNP 3951C/T	T086	C0752046
LIF	T116	C0125606
in vitro fertilization	T061	C0015915
embryo transfer	T061	C0013938
IVF	T061	C0015915
ET	T061	C0013938
outcome	T080	C0085415
infertile	T046	C0021359
women	T098	C0043210
case-control study	T062	C0007328
infertile	T046	C0021359
patients	T101	C0030705
women	T098	C0043210
healthy child	T033	C0686744
controls	T096	C0009932
Genotyping	T059	C1285573
SNP-3951C/T	T086	C0752046
PCR/RFLP	T059	C3714764
Allele	T028	C0002085
genotype	T032	C0017431
distribution	T169	C1704711
patients	T101	C0030705
controls	T096	C0009932
LIF	T116	C0125606
genotype	T032	C0017431
frequencies	T081	C0017270
cases	T169	C0868928
C/C	T086	C0004793
C/T	T086	C0004793
T/T	T086	C0004793
allele	T028	C0002085
frequencies	T081	C0017270
LIF	T116	C0125606
genotype	T032	C0017431
frequencies	T081	C0017270
controls	T096	C0009932
C/C	T086	C0004793
C/T	T086	C0004793
T/T	T086	C0004793
allele	T028	C0002085
frequencies	T081	C0017270
results	T169	C1274040
SNP 3951C/T	T086	C0752046
LIF	T116	C0125606
associated with	T080	C0332281
IVF	T061	C0015915
ET	T061	C0013938
outcome	T080	C0085415
population	T098	C1257890
studies	T062	C2603343
patients	T101	C0030705
control subjects	T096	C0009932
confirm	T080	C1456348
results	T169	C1274040
ANTI ANGIOGENIC EFFECT	T033	C0243095
CHEBULAGIC ACID	T109	C0653267
INHIBITION	T052	C3463820
VEGFR2	T044	C3549205
GSK3β DEPENDENT SIGNALING PATHWAYS	T044	C0037080
Inhibition	T052	C3463820
angiogenesis	T042	C0302600
strategy	T170	C0679716
prevent	T080	C2700409
cancer growth	T191	C1516170
targets	T169	C1521840
vessels	T023	C0005847
proliferating	T169	C1514485
tumor cells	T025	C0597032
Endothelial cells	T025	C0225336
pathways	T044	C0037080
angiogenesis	T042	C0302600
pathways	T044	C0037080
targeted	T169	C1521840
multi targeted drugs	T121	C1254351
anti angiogenic effect	T033	C0243095
Chebulagic acid	T109	C0653267
benzopyran	T109	C0005078
tannin	T109	C1456509
fruits	T168	C0016767
Terminalia chebula	T002	C1193061
molecular mechanism	T044	C3537153
anti angiogenic effect	T033	C0243095
chebulagic acid	T109	C0653267
molecular docking studies	T170	C3494274
HUVECs	T025	C3179121
culture	T059	C0007585
Chebulagic acid	T109	C0653267
inhibited	T052	C3463820
GSK-3β	T116	C0244988
dependent	T169	C3244310
β-catenin	T116	C0105770
phosphorylation	T044	C1158886
VE-cadherin	T116	C0300423
β-catenin	T116	C0105770
signaling	T044	C0037080
VEGFR2	T116	C3849882
phosphorylation	T044	C1158886
VEGF signaling	T044	C3271788
Chebulagic acid	T109	C0653267
inhibits	T052	C3463820
angiogenesis	T042	C0302600
blocking	T169	C0332206
VEGF	T116	C1256770
VEGFR2	T116	C3849882
cell-cell contact dependent downstream signaling pathway	T044	C0037080
B-cell epitopes	T129	C0282581
malaria vaccine	T121	C0206255
P. falciparum Schizont Egress Antigen-1	T116	C3849939
Naturally	T169	C0205296
antibodies	T116	C0003241
PfSEA-1A	T116	C3849939
malaria	T047	C0024530
children	T100	C0008059
Vaccination	T061	C0042196
mice	T015	C0025929
PbSEA-1A	T129	C4040232
parasitemia	T047	C0242723
Plasmodium berghei ANKA	T204	C0032149
immunogenicity	T038	C4277607
PfSEA-1A	T116	C3849939
B-cell epitopes	T129	C0282581
peptide	T116	C0030956
microarrays	T075	C1136348
anti-sera	T116	C0020960
rPfSEA-1A	T116	C3849939
vaccinated	T033	C1519885
primates	T015	C0033147
evaluated	T058	C0220825
epitope	T129	C0003316
antibody	T116	C0003241
parasitemia	T047	C0242723
treatment	T061	C0087111
reinfection	T169	C0205339
cohort	T098	C0599755
Western Kenya	T083	C0022558
Antibodies	T116	C0003241
epitopes	T129	C0003316
parasitemia	T047	C0242723
week	T079	C0439230
transmission	T070	C1521797
immunogens	T116	C0042213
antibody responses	T038	C0003261
epitopes	T129	C0003316
Estrogen	T109	C0014939
deficiency	T169	C0011155
accelerates	T169	C0521110
lumbar facet joints	T030	C0507372
arthritis	T047	C0003864
increase	T169	C0442805
prevalence	T081	C0220900
lumbar facet joint	T030	C0507372
LFJ	T030	C0507372
arthritis	T047	C0003864
women	T098	C0043210
age	T032	C0001779
menopause	T039	C0025320
protective role	T078	C0086939
estrogen	T109	C0014939
LFJ	T030	C0507372
arthritis	T047	C0003864
no evidence	T080	C0332125
indication	T078	C3146298
mechanism	T169	C0441712
effect	T080	C1280500
study	T062	C2603343
ovariectomized (OVX) mice	T015	C0025929
estrogen	T109	C0014939
deficient	T169	C0011155
status	T080	C0449438
post-menopausal	T040	C0206159
women	T098	C0043210
Micro-CT	T060	C2350281
immunohistochemistry	T060	C0021044
assess	T058	C0184514
morphological	T082	C0543482
molecular	T080	C1521991
changes	T169	C0392747
ovariectomy	T061	C0029936
induced	T169	C0205263
LFJ	T030	C0507372
arthritis	T047	C0003864
results	T169	C1274040
LFJ	T030	C0507372
subchondral bone mass	T201	C0005938
decreased	T081	C0205216
OVX mice	T015	C0025929
increased	T081	C0205217
cavities	T030	C0229984
interface	T082	C1254362
subchondral bone	T023	C0262950
Severe	T080	C0205082
cartilage	T024	C0007301
degradation	T169	C0243125
ovariectomy	T061	C0029936
induced	T169	C0205263
LFJ	T030	C0507372
arthritis	T047	C0003864
Increased	T081	C0205217
blood vessels	T023	C0005847
innervations	T080	C1619351
degenerated	T046	C0011164
LFJ	T030	C0507372
subchondral bone	T023	C0262950
area	T029	C0005898
17β-Estradiol	T109	C0014912
treatment	T061	C0087111
suppressed	T169	C1260953
LFJ	T030	C0507372
subchondral bone turnover	T033	C0231544
inhibited	T080	C0311403
cartilage	T024	C0007301
degradation	T169	C0243125
increased	T081	C0205217
blood vessel	T023	C0005847
nerve ending	T026	C0027747
growth	T040	C0018270
degenerated	T046	C0011164
LFJ	T030	C0507372
OVX mice	T015	C0025929
study	T062	C2603343
estrogen	T109	C0014939
factor	T169	C1521761
regulating LFJ metabolism	T169	C0518894
Severe	T080	C0205082
LFJ	T030	C0507372
degeneration	T046	C0011164
estrogen	T109	C0014939
absent	T169	C0332197
in vivo	T082	C1515655
Collapsed	T169	C0392748
subchondral bone	T023	C0262950
initiation	T169	C1704686
process	T067	C1522240
estrogen replacement therapy	T061	C0014935
degeneration	T046	C0011164
LFJ	T030	C0507372
estrogen	T109	C0014939
deficient	T169	C0011155
conditions	T080	C0348080
Dexmedetomidine	T109	C0113293
Effect	T080	C1280500
Emergence Agitation	T048	C0920253
Delirium	T048	C0011206
Children	T100	C0008059
Laparoscopic Hernia Repair	T061	C2111384
Preliminary	T079	C0439611
Study	T062	C2603343
safety	T080	C0678800
efficacy	T080	C1280519
dexmedetomidine	T109	C0113293
Dex	T109	C0113293
emergence agitation	T048	C0920253
EA	T048	C0920253
delirium	T048	C0011206
ED	T048	C0011206
children	T100	C0008059
laparoscopic hernia repair	T061	C2111384
general anesthesia	T061	C0002915
children	T100	C0008059
years	T079	C0439234
randomized	T062	C0034656
groups	T078	C0441833
controls	T096	C0009932
saline	T167	C0036082
intravenous	T082	C0348016
Dex	T109	C0113293
D1	T081	C0178602
D2	T081	C0178602
D3	T081	C0178602
Dex	T109	C0113293
saline	T167	C0036082
infusion	T061	C0574032
anesthesia	T121	C4049933
EA	T048	C0920253
ED	T048	C0011206
5-point scale	T170	C0282574
C	T096	C0009932
D1	T081	C0178602
D2	T081	C0178602
D3	T081	C0178602
groups	T078	C0441833
EA	T048	C0920253
frequencies	T079	C0439603
ED	T048	C0011206
frequencies	T079	C0439603
CHIPPS	T170	C1504479
scores	T081	C0449820
sevoflurane	T109	C0074414
doses	T081	C0178602
controls	T096	C0009932
D3	T081	C0178602
Intervals	T079	C1272706
mask	T074	C0024861
removal	T052	C1883720
spontaneous eye opening	T082	C1882151
longer	T080	C0205166
D2	T081	C0178602
D3	T081	C0178602
controls	T096	C0009932
PACU	T073	C0034871
stay	T079	C3489408
longer	T080	C0205166
D3	T081	C0178602
postoperative	T079	C0032790
EA	T048	C0920253
pain	T184	C0030201
sevoflurane	T109	C0074414
Dex	T109	C0113293
Farnesylthiosalicylic acid	T109	C0297002
lipid-polyethylene glycol-polymer hybrid nanoparticles	T121	C1254351
treatment	T061	C0087111
glioblastoma	T191	C0017636
lipid-polyethylene glycol (PEG)-polymer hybrid nanoparticles	T121	C1254351
tumour tissue	T024	C0475358
active ingredient	T120	C1372955
generation	T079	C0079411
antineoplastic drug	T109	C0003392
farnesylthiosalicylic acid	T109	C0297002
FTA	T109	C0297002
treatment	T061	C0087111
glioblastoma	T191	C0017636
Farnesylthiosalicylic acid	T109	C0297002
poly(lactic-co-glycolic acid)-1,2 distearoyl-glycerol-3-phospho-ethanolamine-N [methoxy (PEG)-2000] ammonium salt	T121	C1254351
PLGA-DSPE-PEG	T121	C1254351
1,2-dioleoyl-3-trimethylammonium-propane (DOTAP) hybrid nanoparticles	T121	C1254351
prepared	T033	C4082130
evaluated	T058	C0220825
in-vitro characterization	T062	C0681828
Cytotoxicity	T049	C0596402
FTA-loaded nanoparticles	T109	C0297002
efficacy	T081	C0013682
rat glioma-2 (RG2) cells	T025	C0007634
evaluated	T058	C0220825
in vitro	T062	C0681828
non-malignant cell line, L929	T025	C0007600
in vivo	T062	C0681829
Scanning electron microscopy studies	T059	C0523160
formulations prepared	T077	C1705957
smooth surface	T201	C1182795
spherical in shape	T082	C0332501
FTA	T109	C0297002
FTA-loaded nanoparticles	T109	C0297002
cytotoxic activity	T049	C0596402
RG2 glioma cell lines	T025	C0007600
cell culture studies	UnknownType	C0681854
DOTAP	T121	C1254351
Magnetic resonance imaging	T060	C0024485
histopathologic	T091	C0677043
evaluation	T058	C0220825
RG2 tumour cells	T025	C0431085
rat glioma model	T050	C0012644
Wistar rats	T015	C0034716
intravenous	T169	C0021494
intratumoral injections	T169	C1517565
drug	T121	C1254351
FTA-loaded nanoparticles	T109	C0297002
tumour size	T082	C0475440
in-vivo studies	T062	C0681829
efficiency	T081	C0013682
intratumoral administration	T169	C1517565
intravenous route	T169	C1522726
Farnesylthiosalicylic acid	T109	C0297002
PLGA-DSPE-PEG-DOTAP hybrid nanoparticles	T121	C1254351
effective	T080	C1704419
glioblastoma	T191	C0017636
in-vitro	T062	C0681828
in-vivo experiments	T062	C0681829
Map learning	T041	C0582587
working memory	T041	C0025265
learning strategies	T065	C0237896
research	T062	C0035168
learning spatial	T041	C0582587
information	T078	C1533716
map	T073	C0024779
different modalities	T169	C1275506
working memory	T041	C0025265
participants	T098	C0679646
simultaneous	T079	C0521115
interference task	T041	C0025361
cognitive load	T081	C0870301
without interference	T041	C0025361
cognitive load	T081	C0870301
modality	T078	C0695347
interference	T041	C0679066
tapping task	T041	C0025361
visuospatial	T041	C0814069
backwards counting task	T041	C0025361
verbal	T080	C0439824
articulatory	T048	C0003910
suppression task	T059	C0201782
verbal	T080	C0439824
n-back task	T041	C0025361
central executive	T041	C0025361
Spatial recall	T033	C0243095
assessed	T052	C1516048
directional judgements	T041	C0022423
map drawing	UnknownType	C0699866
Cognitive load	T081	C0870301
spatial recall	T033	C0243095
regardless	T080	C3641650
interference	T041	C0679066
modality	T078	C0695347
learning maps	T041	C0582587
learning strategy	T065	C0237896
resources	T078	C0035201
working memory	T041	C0025265
4-Anilino-2-pyridylquinazolines	T109	C0034407
pyrimidines	T114	C0034289
Potent	T080	C0442821
Nontoxic	T080	C1518413
Inhibitors	T120	C0243077
Breast Cancer Resistance Protein	T116	C0761993
ABCG2	T116	C0761993
Multidrug resistance	T032	C0242640
MDR	T032	C0242640
ATP-binding cassette (ABC) transport proteins	T116	C0242738
chemotherapeutic treatment	T061	C3665472
cancer	T191	C0027651
overcome	T052	C2983310
inhibition	T052	C3463820
transporter	T116	C0596902
mechanisms	T169	C0441712
transport process	T044	C1519628
breast cancer resistance protein	T116	C0761993
BCRP	T116	C0761993
ABCG2	T116	C0761993
inhibitors	T120	C0243077
ABCG2	T116	C0761993
investigated	T169	C1292732
4-substituted-2-pyridylquinazolines	T109	C0034407
inhibitory	T052	C3463820
potency	T080	C3245505
selectivity	T081	C0037791
ABCG2	T116	C0761993
quinazoline scaffold	T109	C0034407
4-methylpyrimidine	T114	C0034289
cytotoxicity	T049	C0596402
reverse	T169	C1555029
MDR	T032	C0242640
chemotherapeutic agents	T121	C0729502
SN-38	T109	C0142710
mitoxantrone	T109	C0026259
MX	T109	C0026259
Interaction	T169	C1704675
compounds	T103	C1706082
ABCG2	T116	C0761993
investigated	T169	C1292732
colorimetric	T059	C1531834
ATPase	T116	C0001473
assay	T059	C2717977
Enzyme kinetic studies	T090	C1516893
Hoechst 33342	T121	C0062907
fluorescent dye	T130	C0016320
substrate	T167	C3891814
ABCG2	T116	C0761993
compounds	T103	C1706082
binding modes	T052	C1145667
Biosamples	T077	C1706958
Smoking Cessation	T055	C0085134
Trials	T062	C0008976
Genetic	T034	C0730319
Metabolomic	T091	C1328813
Epigenetic	T045	C1516924
Findings	T033	C0243095
genotypes	T032	C0017431
biomarkers	T201	C0005516
smoking cessation	T055	C0085134
smoking cessation treatments	T061	C1095963
smoking cessation treatment	T061	C1095963
individual's	T098	C0237401
genetic	T059	C2986505
metabolic profile	T039	C3853758
incentive	T080	C0021147
smoking cessation	T055	C0085134
researchers	T097	C0687734
biosamples	T077	C1706958
genotyping	T059	C1285573
research studies	T062	C0681814
clinical trials	T062	C0008976
ACR	T094	C1515941
Appropriateness Criteria	T078	C0243161
Radiologic	T169	C0205483
Management	T058	C0376636
Mesenteric Ischemia	T047	C1412000
Mesenteric vascular insufficiency	T047	C1412000
medical condition	T033	C3843040
bowel infarction	T047	C0241950
morbidity	T081	C0026538
mortality	T081	C0178686
approach	T082	C0449445
therapy	T061	C0087111
acute mesenteric ischemia	T047	C0001363
aspiration	T061	C0349707
embolectomy	T061	C0162575
transcatheter	T061	C0203005
thrombolysis	T061	C0040044
angioplasty	T061	C0162577
stenting	T061	C2348535
treatment	T061	C0087111
arterial stenosis	T190	C0238397
Nonocclusive mesenteric ischemia	T047	C3852986
transarterial infusion	T061	C0021439
vasodilators	T121	C0042402
nitroglycerin	T109	C0017887
papaverine	T109	C0030350
glucagon	T116	C0017687
prostaglandin E1	T109	C0002335
therapy	T061	C0087111
chronic mesenteric ischemia	T047	C0311262
angioplasty	T061	C0162577
stent placement	T061	C0522776
endovascular approach	T061	C1997114
surgical bypass	T061	C1536078
endarterectomy	T061	C0014098
diagnosis	T033	C0011900
median arcuate ligament syndrome	T047	C1861783
surgical	T061	C0543467
clinical situation	T080	C0018759
Venous	T082	C0348013
mesenteric ischemia	T047	C1412000
systemic	T169	C0205373
anticoagulation	T061	C0003281
Transhepatic	T082	C0589464
transjugular	T082	C1254362
superior mesenteric vein	T023	C0226742
catheterization and thrombolytic infusion	T060	C2025545
symptoms	T184	C1457887
condition of the patient	T033	C0683521
response	T032	C0871261
systemic	T169	C0205373
anticoagulation	T061	C0003281
Adjunct	T169	C1719882
transjugular intrahepatic portosystemic shunt creation	T061	C0339897
improvement	T077	C2986411
American College of Radiology	T094	C1515941
Appropriateness Criteria	T078	C0243161
evidence-based	T169	C1510541
guidelines	T170	C0162791
clinical conditions	T033	C0683521
reviewed	T080	C1709940
annually	T079	C0332181
multidisciplinary expert panel	T097	C1319406
guideline	T170	C0162791
development	T169	C1527148
revision	T079	C0439617
extensive analysis	T062	C0936012
medical literature	T078	C0025120
peer-reviewed journals	T170	C2985503
methodologies	T062	C0086912
RAND	T170	C3826892
UCLA	T170	C4285296
Appropriateness	T080	C0814634
Grading of Recommendations Assessment, Development, and Evaluation	T170	C0282574
GRADE	T170	C0282574
appropriateness	T080	C0814634
imaging	T060	C0079595
treatment procedures	T061	C0087111
clinical	T080	C0205210
scenarios	T169	C0683579
instances	T078	C1550608
evidence	T078	C3887511
lacking	T080	C0332268
equivocal	T080	C0332241
expert opinion	T077	C0600219
supplement	T169	C2348609
evidence	T078	C3887511
imaging	T060	C0079595
treatment	T061	C0087111
Blur	T080	C1511231
perception	T041	C0030971
visual field	T082	C0042826
myopia	T047	C0027092
emmetropia	T033	C0234622
evaluated	T058	C0220825
ability	T032	C0085732
emmetropic	T033	C0234622
myopic	T047	C0027092
observers	T096	C0870992
detect	T033	C0442726
discriminate	T080	C0205235
blur	T080	C1511231
retina	T023	C0035298
monocular	T042	C0042797
binocular viewing	T041	C0042794
conditions	T080	C0348080
recruited	T052	C2949735
young	T079	C0332239
healthy adults	T033	C0686750
myopes	T047	C0027092
best-corrected	T080	C4072794
visual acuity	T201	C0042812
LogMAR (20/20)	T074	C0007963
better	T080	C0332272
eye	T023	C0015392
no binocular	T033	C0243095
accommodative dysfunction	T033	C0042790
Monocular	T042	C0042797
binocular	T041	C0042794
blur	T080	C1511231
discrimination	T080	C0205235
thresholds	T080	C0449864
measured	T080	C0444706
function	T170	C1705273
pedestal blur	T080	C1511231
naturalistic	T169	C0205296
stimuli	T067	C0234402
adaptive 4AFC procedure	T060	C0430872
Stimuli	T067	C0234402
presented	T078	C0449450
diameter	T081	C1301886
Gaussian blur pedestals	T080	C1511231
confined	T169	C0443288
annulus	T073	C3273359
eccentricity	T042	C0871265
blur	T080	C1511231
increment	T081	C1705117
applied	T169	C4048755
one quadrant	T082	C1631280
image	T170	C1704922
adaptive procedure	T060	C0430872
efficiently	T080	C0442799
estimated	T081	C0750572
dipper shaped	T033	C0243095
blur	T080	C1511231
discrimination	T080	C0205235
threshold	T080	C0449864
function	T170	C1705273
two	T081	C0205448
parameters	T077	C0549193
intrinsic	T082	C0205102
blur	T080	C1511231
blur	T080	C1511231
sensitivity	T169	C0332324
amount	T081	C1265611
intrinsic	T082	C0205102
blur	T080	C1511231
increased	T081	C0205217
retinal eccentricities	T042	C0871265
lower	T052	C2003888
binocular	T041	C0042794
monocular	T042	C0042797
conditions	T080	C0348080
similar	T080	C2348205
refractive	T042	C0870812
groups	T078	C0441833
Blur	T080	C1511231
sensitivity	T169	C0332324
decreased	T081	C0205216
retinal eccentricity	T042	C0871265
highest	T080	C1522410
binocular	T041	C0042794
central vision	T042	C0678899
Myopes	T047	C0027092
worse	T033	C1457868
blur	T080	C1511231
sensitivity	T169	C0332324
emmetropes	T033	C0234622
monocularly	T042	C0042797
binocularly	T041	C0042794
blur	T080	C1511231
perception	T041	C0030971
worsens	T033	C1457868
visual periphery	T041	C0234628
binocular	T041	C0042794
summation	T042	C0234108
evident	T078	C0750489
central vision	T042	C0678899
myopes	T047	C0027092
monocular	T042	C0042797
impairment	T169	C0221099
blur	T080	C1511231
sensitivity	T169	C0332324
improves	T033	C0184511
binocular	T041	C0042794
conditions	T080	C0348080
Implications	T041	C0679201
development	T169	C1527148
myopia	T047	C0027092
Risk Factors	T033	C0035648
Neurological Deterioration	T184	C1536136
Patients	T101	C0030705
Cerebral Infarction	T047	C0007785
Large-Artery Atherosclerosis	T047	C2711237
patients	T101	C0030705
acute	T079	C0205178
ischemic stroke	T047	C0948008
neurological deterioration	T184	C1536136
ND	T184	C1536136
observed	T169	C1441672
difficult	T080	C0332218
predict	T078	C0681842
time of admission	T079	C3854259
patients	T101	C0030705
large-artery atherosclerosis	T047	C2711237
LAA	T047	C2711237
aggressive	T079	C0580822
medical treatments	T058	C0237726
surgical interventions	T058	C4035998
helpful	T080	C3898897
ND	T184	C1536136
investigated	T169	C1292732
factors	T169	C0014501
associated with	T080	C0332281
ND	T184	C1536136
patients	T101	C0030705
LAA	T047	C2711237
studied	T062	C2603343
patients	T101	C0030705
LAA	T047	C2711237
admitted to our hospital	T058	C0184666
divided	T169	C0332849
groups	T078	C0441833
group	T078	C0441833
deterioration	T046	C0234985
group	T078	C0441833
evaluated	T058	C0220825
medical records	T170	C0025102
risk factors	T033	C0035648
radiological	T077	C0929225
findings	T033	C0243095
diffusion	T070	C0012222
positive	T033	C1514241
lesion	T033	C0221198
degree of stenosis	T201	C4034225
study population	T098	C2348561
patients	T101	C0030705
suffer	T048	C0683278
deterioration	T046	C0234985
univariate analysis	T062	C0683962
blood pressure	T040	C0005823
BP	T040	C0005823
heart rate	T201	C0018810
National Institutes of Health Stroke Scale (NIHSS) score	T033	C4269147
diffusion	T070	C0012222
positive	T033	C1514241
lesion	T033	C0221198
count of red blood cell	T059	C0014772
high-density lipoprotein	T116	C0023821
degree of stenosis	T201	C4034225
significantly	T078	C0750502
groups	T078	C0441833
multivariate analysis	T081	C0026777
systolic BP	T201	C0871470
odds ratio	T081	C0028873
associated with	T080	C0332281
ND	T184	C1536136
diffusion-weighted image	T060	C0598801
DWI	T060	C0598801
positive	T033	C1514241
lesion	T033	C0221198
degree of stenosis	T201	C4034225
NIHSS score	T033	C4269147
independent	T078	C0085862
factors	T169	C0014501
associated with	T080	C0332281
ND	T184	C1536136
High BP	T047	C0020538
severity	T080	C0439793
neurological deficit	T033	C0521654
time of admission	T079	C3854259
radiological	T077	C0929225
findings	T033	C0243095
degree of stenosis	T201	C4034225
DWI	T060	C0598801
positive	T033	C1514241
lesion	T033	C0221198
independently	T033	C0243095
associated with	T080	C0332281
ND	T184	C1536136
patients	T101	C0030705
LAA	T047	C2711237
Development	T169	C1527148
validation	T062	C1519941
risk assessment tool	T058	C0086930
low back	T023	C0230102
loading	T032	C1318107
Lifting Fatigue Failure Tool	T122	C0005479
LiFFT	T122	C0005479
musculoskeletal disorders	T047	C0026857
MSDs	T047	C0026857
fatigue	T184	C0015672
failure process	T169	C0231174
affected	T169	C0392760
tissues	T024	C0040300
low back exposure	T032	C1318107
assessment tool	T122	C0005479
Lifting Fatigue Failure Tool	T122	C0005479
LiFFT	T122	C0005479
daily dose	T081	C2348070
cumulative	T080	C1511559
loading	T032	C1318107
low back	T023	C0230102
fatigue	T184	C0015672
failure	T169	C0231174
principles	T078	C0178566
variables	T080	C0439828
cumulative	T080	C1511559
load	T032	C1318107
associated with	T080	C0332281
lifting	T052	C0206244
task	T057	C3540678
weight of the load	T081	C0043100
horizontal distance	T081	C0012751
spine	T023	C0037949
to the load	T032	C1318107
repetitions	T169	C0205341
tasks performed	T061	C0039333
workday	T079	C0680192
new tool	T122	C0005479
validated	T062	C1519941
epidemiological	T169	C1516907
databases	T170	C0242356
Lumbar Motion	T033	C0575375
Lumbar Motion Monitor	T033	C0575375
LMM	T033	C0575375
database	T170	C0242356
database	T170	C0242356
U.S	T083	C0041703
automotive manufacturer	T090	C3641679
LiFFT	T122	C0005479
cumulative damage metric	T058	C0558029
low back disorders	T184	C0024031
LBDs	T184	C0024031
LMM database	UnknownType	C0677336
low back outcomes	T080	C0085415
automotive database	T073	C0589476
outcome measure	T081	C0086749
LiFFT	T122	C0005479
practitioner friendly	T080	C0205556
cumulative	T080	C1511559
damage metric	T058	C0558029
low back outcomes	T080	C0085415
Genetic Diversity	T070	C0042333
Accessions	T170	C1510755
Pineapple	T002	C0946573
Ananas comosus (L.) Merr.	T002	C0946573
ISSR	T114	C0039290
SSR	T114	C1519302
Markers	T086	C0012872
Inter simple sequence repeat	T114	C0039290
ISSR	T114	C0039290
simple sequence repeat	T114	C1519302
SSR	T114	C1519302
markers	T086	C0012872
genetic diversity	T070	C0042333
pineapple	T002	C0946573
accessions	T170	C1510755
countries	T083	C0454664
regions	T083	C0017446
ISSR	T114	C0039290
primers	T114	C0206415
amplified	T059	C1441475
polymorphic	T080	C1882417
SSR	T114	C1519302
primers	T114	C0206415
amplified	T059	C1441475
polymorphic	T080	C1882417
Nei's gene diversity	T170	C0282574
h	T170	C0282574
Shannon's information index	T170	C0918012
I	T170	C0918012
polymorphism information content	T170	C0282574
PIC	T170	C0282574
SSR	T114	C1519302
primers	T114	C0206415
ISSR	T114	C0039290
primers	T114	C0206415
h	T170	C0282574
I	T170	C0918012
PIC	T170	C0282574
SSR system	T114	C1519302
ISSR system	T114	C0039290
genetic diversity	T070	C0042333
pineapple	T002	C0946573
accessions	T170	C1510755
genetic	T169	C0314603
similarities	T080	C2348205
ISSR	T114	C0039290
SSR	T114	C1519302
ISSR	T114	C0039290
SSR	T114	C1519302
genetic diversity	T070	C0042333
pineapple	T002	C0946573
accessions	T170	C1510755
clustered	T062	C1881045
pineapple	T002	C0946573
accessions	T170	C1510755
phylogenetic trees	T080	C1519069
ISSR	T114	C0039290
SSR	T114	C1519302
ISSR	T114	C0039290
SSR	T114	C1519302
analyses	T062	C0936012
unweighted pair-group with arithmetic averaging (UPGMA) method	T170	C0025663
principal components analysis	T081	C0429865
PCA	T081	C0429865
UPGMA	T170	C0025663
clustering	T062	C1881045
pineapple	T002	C0946573
germplasm	T002	C4046074
pineapple	T002	C0946573
breeding strategies	T040	C4042898
Advanced age	T098	C1999167
barrier	T169	C0443288
functional	T169	C0205245
arteriovenous fistula	T020	C1541850
retrospective study	T062	C0035363
Arteriovenous fistulas	T020	C1541850
AVFs	T020	C1541850
vascular access	T074	C0750138
hemodialysis	T061	C0019004
controversy	T054	C0680243
AVFs	T020	C1541850
elderly	T098	C0001792
patients	T101	C0030705
Single-center retrospective review	T062	C0035363
investigate	T169	C1292732
impact	T080	C4049986
age	T032	C0001779
AVF	T020	C1541850
outcomes	T169	C1274040
patients	T101	C0030705
AVF	T020	C1541850
creation	T052	C1706214
stratified	T080	C0205363
age	T032	C0001779
<65	T100	C0027362
65-75	T100	C0027362
>75	T100	C0027362
years	T079	C0439234
AVF	T020	C1541850
outcomes	T169	C1274040
primary	T080	C0205225
failure	T169	C0231174
AVF	T020	C1541850
patency	T042	C0042377
primary	T080	C0205225
secondary	T080	C0175668
functional	T169	C0205245
AVF	T020	C1541850
complications	T046	C0009566
years	T079	C0439234
AVF	T020	C1541850
creation	T052	C1706214
cohort	T098	C0599755
male	T098	C0025266
Caucasian	T098	C0043157
diabetes	T047	C0011847
cardiovascular disease	T047	C0007222
aged	T032	C0001779
<65	T100	C0027362
years	T079	C0439234
65-75	T100	C0027362
years	T079	C0439234
aged	T032	C0001779
>75	T100	C0027362
years	T079	C0439234
primary	T080	C0205225
failure	T169	C0231174
primary	T080	C0205225
patency	T042	C0042377
complications	T046	C0009566
intervention	T061	C0184661
age groups	T100	C0027362
association	T080	C0439849
age	T032	C0001779
secondary	T080	C0175668
patency	T042	C0042377
functional	T169	C0205245
patency	T042	C0042377
age	T032	C0001779
>75	T100	C0027362
risk factor	T033	C0035648
shortened	T080	C1282927
lifespan	T079	C1254367
patients	T101	C0030705
aged	T032	C0001779
>75	T100	C0027362
years	T079	C0439234
secondary	T080	C0175668
patency	T042	C0042377
years	T079	C0439234
younger	T079	C0332239
patients	T101	C0030705
Functional	T169	C0205245
patency	T042	C0042377
years	T079	C0439234
aged	T032	C0001779
>75	T100	C0027362
years	T079	C0439234
younger	T079	C0332239
patients	T101	C0030705
AVF	T020	C1541850
maturation	T039	C1254042
primary	T080	C0205225
patency	T042	C0042377
complications	T046	C0009566
interventions	T061	C0184661
age	T032	C0001779
75	T100	C0027362
younger	T079	C0332239
secondary	T080	C0175668
functional	T169	C0205245
patency	T042	C0042377
rates	T081	C1521828
aged	T032	C0001779
>75	T100	C0027362
years	T079	C0439234
advanced age	T098	C1999167
patients	T101	C0030705
AVF	T020	C1541850
creation	T052	C1706214
modified	T169	C0392747
ESBL	T116	C0486433
ESBL Nordmann/Dortet/Poirel-based protocol	T059	C0022885
optimize	T052	C2698650
early	T079	C1279919
sepsis	T047	C0243026
management	T058	C0376636
evaluated	T169	C1292732
modification	T169	C0392747
colorimetric test	T059	C1531834
detection	T061	C1511790
ESBL	T116	C0486433
Enterobacteriaceae	T007	C0014346
positive	T033	C1446409
blood cultures	T059	C0200949
manipulation	T059	C0022885
materials	T167	C0520510
time	T079	C0040223
protocol	T059	C0022885
sensitivity	T169	C0332324
specificity	T081	C0037791
development	T169	C1527148
robust viromics	T028	C0042720
examinations	T062	C0242481
Metagenomics	T090	C2717799
microbial communities	T001	C0599840
maintaining life on this planet	T058	C0184640
Sequencing	T063	C0487717
genetic content	T028	C0017272
phage communities	T005	C0004651
sequences	T059	C0162801
sequence	T059	C0162801
data repositories	T073	C3847505
small fraction	T081	C1264633
BLAST	T170	C2698333
representative	T052	C1882932
viral taxon	T170	C0597651
Homology	T080	C2697616
classification	T185	C0008902
sequence repositories	T170	C0026382
small fraction	T081	C1264633
phage diversity	T005	C0004651
lateral	T082	C0205093
gene transfer	T063	C1517499
pervasive	T082	C0205391
phage communities	T005	C0004651
particular gene	T028	C0017337
particular viral species	T005	C0042776
indication	T078	C3146298
specific gene	T028	C0017337
limitation	T169	C0449295
analysis of viral metagenomic datasets	T059	C3854164
BLAST	T170	C2698333
integrating the sequence identity	T170	C2359783
length of alignments	T063	C0080143
taxonomic signal	T169	C0008903
each gene	T028	C0017337
information content	T078	C1533716
quantifiable metric	T081	C0025867
predictions	T078	C0681842
viral community	T001	C1956108
proof-of-concept	T078	C1254370
implemented	T052	C1708476
freshwater viral metagenomes	T028	C2717745
robust method	T080	C2986815
viral metagenomic data	T090	C2717799
tool	T170	C0037589
versatile	T080	C0205556
customized	T052	C1880202
investigations	T058	C1261322
environment	T082	C0014406
biome	T001	C1956108
PRESENCE OF	T033	C0150312
CITRININ	T109	C0008861
GRAINS	T168	C0007757
POSSIBLE	T033	C0332149
HEALTH	T078	C0018684
EFFECTS	T080	C1280500
Citrinin	T109	C0008861
mycotoxin	T109	C0026955
produced	T169	C0205245
species	T185	C1705920
genera Aspergillus	T004	C0004034
Penicillium	T004	C0030843
Monascus	T004	C0997448
occurs	T052	C1709305
stored grain	T168	C0007757
Citrinin	T109	C0008861
formed	T169	C0205431
harvest	T169	C0205245
occurs	T052	C1709305
stored grains	T168	C0007757
occurs	T052	C1709305
other plant products	UnknownType	C0541488
co-occurrence	T079	C2745955
mycotoxins	T109	C0026955
observed	T169	C1441672
ochratoxin A	T109	C0069299
associated with	T080	C0332281
endemic nephropathy	T047	C0004698
European Union	T092	C0015179
level	T080	C0441889
systematic	T169	C0220922
monitoring	T058	C1283169
Citrinin	T109	C0008861
grains	T168	C0007757
aim	T078	C1947946
determining	T080	C0205556
permissible amount	T081	C1265611
food	T168	C0016452
systematic	T169	C0220922
monitoring	T058	C1283169
above mentioned mycotoxin	T109	C0008861
Croatia	T083	C0010343
begin	T079	C0439659
main goal	T170	C0018017
study	T062	C2603343
determine	T080	C0205556
presence of	T033	C0150312
Citrinin	T109	C0008861
grains	T168	C0007757
sampled	T078	C0870078
area	T082	C0205146
Međimurje	T083	C0079170
Osijek-Baranja	T083	C0079170
Vukovar-Srijem	T083	C0079170
Brod-Posavina County	T083	C0079170
purpose	T169	C1285529
identification	T080	C0205396
quantification	T081	C1709793
citrinin	T109	C0008861
high performance liquid chromatograph (HPLC) with fluorescence	T059	C4054775
used	T033	C1273517
Calibration curve	T081	C0006751
Intra assay CV	T170	C3176771
Inter assay CV	T170	C3176771
LOQ	T081	C1709793
area	T082	C0205146
Međimurje County	T083	C0079170
samples	T167	C0370003
corn	T168	C1138842
samples	T167	C0370003
wheat	T168	C0043137
analyzed	T062	C0936012
samples	T167	C0370003
contained	T052	C2700400
Citrinin	T109	C0008861
area	T082	C0205146
Osijek-Baranja	T083	C0079170
Vukovar-Srijem County	T083	C0079170
samples	T167	C0370003
County	T083	C0079170
analyzed	T062	C0936012
mean value	T081	C0444504
samples	T167	C0370003
Osijek-Baranja County	T083	C0079170
median	T081	C2348144
Vukovar-Srijem County	T083	C0079170
mean value	T081	C0444504
citrinin	T109	C0008861
median	T081	C2348144
analyzed	T062	C0936012
samples	T167	C0370003
Brod-Posavina County	T083	C0079170
samples	T167	C0370003
contained	T052	C2700400
citrinin	T109	C0008861
amount	T081	C1265611
registered	T058	C1514821
amount	T081	C1265611
samples	T167	C0370003
results	T169	C1274040
grains	T168	C0007757
several	T081	C0439064
Counties	T083	C0079170
contain	T052	C2700400
amounts	T081	C1265611
Citrinin	T109	C0008861
indicating	T033	C1444656
significant	T078	C0750502
intake	T169	C1512806
citrinin	T109	C0008861
humans	T016	C0086418
grains	T168	C0007757
grain-based products	T168	C0016452
everyday	T079	C0332173
diet	T168	C0012155
age groups	T100	C0027362
small children	T100	C0008059
higher	T080	C0205250
intake	T169	C1512806
citrinin	T109	C0008861
occur	T052	C1709305
emphasize	T080	C0205556
systematic	T169	C0220922
analysis	T062	C0936012
larger amount	T081	C1265611
samples	T167	C0370003
large grains	T168	C0007757
small grains	T168	C0007757
area	T082	C0205146
Brod-Posavina County	T083	C0079170
citrinin	T109	C0008861
contamination	T078	C2349974
grains	T168	C0007757
asses	T052	C1516048
health	T078	C0018684
risk	T078	C0035647
humans	T016	C0086418
Recurrent noncoding regulatory mutations	T045	C0026882
pancreatic ductal adenocarcinoma	T191	C1335302
contributions	T052	C1880177
coding mutations	T045	C0026882
tumorigenesis	T191	C0007621
somatic alterations	T049	C0544886
noncoding DNA	T114	C0021920
somatic noncoding alterations	T049	C0544886
pancreatic ductal adenocarcinomas	T191	C1335302
PDAs	T191	C1335302
mutated regulatory regions	T086	C0004793
recurrent noncoding mutations	T045	C0026882
PDA	T191	C1335302
pathways	T044	C1704259
axon guidance	T043	C2984268
cell adhesion	T043	C0007577
identified	T080	C0205396
processes	T067	C1522240
transcription	T045	C0040649
homeobox genes	T028	C0017347
identified	T080	C0205396
mutations	T045	C0026882
protein binding sites	T087	C1514535
differential	T080	C0443199
expression	T045	C0017262
proximal	T082	C0205107
genes	T028	C0017337
effects of	T080	C1704420
mutations	T045	C0026882
expression	T045	C0017262
expression modulation score	T081	C0392762
quantifies	T081	C1709793
strength	T078	C0808080
gene regulation	T045	C0017263
regulatory elements	T028	C0017362
elements	T028	C0017362
single-cancer analysis	T059	C0022885
noncoding alterations	T045	C0026882
regulatory mutations	T045	C0026882
candidates	T080	C0205556
diagnostic	T201	C1511876
prognostic markers	T080	C1514475
mechanisms	T169	C0441712
tumor evolution	T191	C0007621
Distal	T082	C0205108
posterior cerebral artery	T023	C0149576
revascularization	T061	C0007794
fusiform	T077	C0332493
PCA	T023	C0149576
aneurysm	T047	C0002940
revascularization	T061	C0007794
proximal	T082	C0205107
posterior cerebral artery	T023	C0149576
occlusion	T020	C0028790
treatment	T169	C1522326
giant	T047	C0751004
fusiform aneurysms	T190	C0333099
infarction	T046	C0021308
posterior cerebral artery	T023	C0149576
occlusion	T020	C0028790
authors	T097	C3812881
bypass	T061	C0741847
vessel	T023	C0005847
fusiform aneurysm	T190	C0333099
posterior cerebral artery	T023	C0149576
P2-P3 junction	UnknownType	C0682580
clinically failed	T033	C3640841
balloon test occlusion	T058	C3697458
preoperatively	T079	C0445204
occipital artery	T023	C0226117
distal	T082	C0205108
posterior cerebral artery	T023	C0149576
bypass	T061	C0741847
endovascular occlusion of the parent vessel	T061	C2223520
aneurysm	T047	C0002940
follow up	T058	C1522577
cerebral angiography	T060	C0007767
bypass	T061	C0741847
patient	T101	C0030705
posterior cerebral artery	T023	C0149576
territory stroke	T047	C0038454
distal	T082	C0205108
revascularization	T061	C0007794
proximal	T082	C0205107
posterior cerebral artery	T023	C0149576
occlusion	T020	C0028790
cerebral ischemia	T047	C0917798
infarction	T046	C0021308
patients	T101	C0030705
test occlusion	T058	C3697458
Test Score	T080	C0237855
Fair	T080	C2911689
Individual	T098	C0237401
Tested	T170	C0392366
Effects of	T080	C1704420
Scoring Procedures	T062	C0036449
Multiple	T081	C0439064
Attempts	T051	C1516084
Testing	T169	C0039593
Motor Skill	T040	C0026612
Task	T057	C3540678
Tests	T170	C0392366
test batteries	T170	C0392366
assessing	T052	C1516048
motor skills	T040	C0026612
research studies	T062	C0681814
clinical settings	T062	C0008976
procedures	T169	C0025664
scoring	T062	C0036449
performances	T055	C0597198
attempts	T051	C1516084
scored	T081	C0449820
average	T081	C1510992
computed	T059	C1441526
scoring	T062	C0036449
procedures	T169	C0025664
attempts	T051	C1516084
research	T062	C0035168
procedures	T169	C0025664
individual's	T098	C0237401
skill	T040	C0026612
level	T080	C0441889
tests	T170	C0392366
study	T062	C2603343
tested	T170	C0392366
female	T098	C0043210
soccer	T056	C0037393
players	T097	C0335104
juggling	T056	C0034872
soccer ball	T073	C0336986
attempts	T051	C1516084
trials	T062	C0681815
scored	T081	C0449820
procedures	T169	C0025664
best of	T080	C1522427
mean of	T081	C0444504
attempts	T051	C1516084
Individual	T098	C0237401
raw scores	T081	C0449820
trials	T062	C0681815
no general effect	T080	C1301751
trials	T062	C0681815
mean (SD) percentage difference	T081	C0392762
lowest	T080	C1708760
highest	T080	C1522410
scores	T081	C0449820
players	T097	C0335104
significant	T078	C0750502
lowest	T080	C1708760
highest	T080	C1522410
score	T081	C0449820
Correlations	T080	C1707520
raw scores	T081	C0449820
low	T080	C0205251
trials	T062	C0681815
higher	T080	C0205250
scoring	T062	C0036449
procedures	T169	C0025664
trial	T062	C0681815
significantly	T078	C0750502
different	T080	C1705242
raw score	T081	C0449820
scoring	T062	C0036449
procedure	T169	C0025664
mean percentage difference	T081	C0392762
best-of-two	T081	C0449820
best-of-ten scores	T081	C0449820
players	T097	C0335104
significant	T078	C0750502
difference	T080	C1705242
scoring	T062	C0036449
procedures	T169	C0025664
No significant differences	T033	C3842396
mean-of-rule scorings	T081	C0449820
Best-of-rule	T081	C0449820
mean-of-rule scorings	T081	C0449820
significantly	T078	C0750502
different	T080	C1705242
best-of-two	T081	C0449820
mean-of-two	T081	C0449820
mean difference	T081	C0392762
highest	T080	C1522410
lowest	T080	C1708760
rank	T170	C0699794
players	T097	C0335104
individual	T098	C0237401
rankings	T170	C0699794
group	T098	C1257890
procedures	T169	C0025664
procedural	T169	C0025664
differences	T080	C1705242
scoring	T062	C0036449
procedures	T169	C0025664
results	T034	C0456984
test outcomes	T034	C0456984
test results	T034	C0456984
diagnosing	T033	C0011900
intervention	T061	C0184661
groups	T078	C0441833
research	T062	C0035168
scoring	T062	C0036449
procedures	T169	C0025664
tests	T170	C0392366
Fast Peak-Searching Algorithm	T170	C0002045
Ultrasonic Elastography	T060	C3163956
Tissue axial strain estimation with ultrasound elastography	T060	C2316047
tracking-based elastography algorithms	T170	C0002045
locating	T033	C0243095
extrema	T080	C0205556
ultrasonic	T169	C0220934
radiofrequency	T070	C2347883
signals	T067	C1710082
problem	T033	C0033213
proposed	T080	C1553874
locate	T033	C0243095
maxima	T081	C0806909
minima	T080	C1524031
RF	T070	C2347883
signals	T067	C1710082
derivation	T080	C1441547
operation	T052	C3241922
algorithm	T170	C0002045
locate	T033	C0243095
extrema	T080	C0205556
peaks	T080	C0444505
noise	T067	C0028263
algorithm	T170	C0002045
implementation	T052	C1708476
compared	T052	C1707455
standard cross-correlation method	T062	C0242481
computing	T052	C1880157
signal-to-noise ratio	T081	C2986823
contrast-to-noise ratio	T081	C0392762
Audiovisual	T039	C1254359
integration	T040	C0679019
face	T029	C0015450
name	T170	C1547383
associative	T041	C0679045
memory formation	T041	C0025260
multisensory	T080	C0445254
experience	T041	C0596545
environment	T082	C0014406
memories	T041	C0025260
retrieval	T041	C0679061
study	T062	C2603343
audiovisual	T039	C1254359
AV	T039	C1254359
integration	T040	C0679019
associative	T041	C0679045
memory formation	T041	C0025260
magnetic resonance imaging	T060	C0024485
neural	T025	C0027882
mechanisms	T169	C0441712
AV	T039	C1254359
integration	T040	C0679019
associative	T041	C0679045
memory	T041	C0025260
overlap	T079	C1948020
activity	T052	C0441655
anterior superior temporal sulcus	T030	C3499005
STS	T030	C1281074
AV	T039	C1254359
integration	T040	C0679019
AV	T039	C1254359
face	T029	C0015450
name	T170	C1547383
Dynamic causal modeling	UnknownType	C0681944
anterior STS	T030	C3499005
associative	T041	C0679045
memory system	T041	C0025260
memory formation	T041	C0025260
AV	T039	C1254359
face	T029	C0015450
name	T170	C1547383
associations	T041	C0679045
fusiform gyrus	T023	C0228243
anterior STS	T030	C3499005
participants	T098	C0679646
remembered	T041	C0034770
face	T029	C0015450
name	T170	C1547383
multisensory	T080	C0445254
associative	T041	C0679045
memories	T041	C0025260
retrieval	T041	C0679061
Liquid chromatography-tandem mass spectrometry	T059	C4049918
quantification	T081	C1709793
acetamiprid	T109	C1142891
thiacloprid	T109	C0962702
residues	T131	C1254354
butterbur	T002	C1019150
regulated conditions	T082	C0014406
analytical method	T170	C0178476
quantify	T081	C1709793
residual	T131	C1254354
levels	T080	C0441889
neonicotinoid insecticides	T131	C1997222
acetamiprid	T109	C1142891
thiacloprid	T109	C0962702
field-incurred	T169	C0443318
butterbur	T002	C1019150
samples	T167	C0370003
liquid chromatography-tandem mass spectrometry	T059	C4049918
LC-MS/MS	T059	C4049918
Samples	T167	C0370003
extracted	T059	C0684295
acetonitrile	T109	C0050456
dichloromethane	T109	C0025748
purification	T169	C1998793
Florisil(®) cartridge	T074	C1504285
Linearity	T082	C0205132
matrix-matched calibration curve	T081	C0006751
compounds	T131	C1254354
concentration	T081	C1446561
range	T081	C1514721
determination coefficients	T081	C2827748
R(2)	T081	C2827748
limits of detection	T081	C2718050
LOD	T081	C2718050
quantitation	T081	C1709793
LOQ	T081	C1709793
acetamiprid	T109	C1142891
thiacloprid	T109	C0962702
acetamiprid	T109	C1142891
thiacloprid	T109	C0962702
spiking levels	T080	C0441889
LOQ	T081	C1709793
LOQ	T081	C1709793
relative standard deviations	T081	C0871420
RSDs	T081	C0871420
method	T170	C0178476
field-incurred	T169	C0443318
samples	T167	C0370003
treated	T169	C1522326
commercial	T170	C0680536
pesticide product	T131	C0031253
days	T079	C0439228
harvest	T169	C0205245
days	T079	C0439228
harvest	T169	C0205245
residues	T131	C1254354
days	T079	C0439228
treatment	T169	C1522326
days	T079	C0439228
treatment	T169	C1522326
method	T170	C0178476
accurate	T080	C0443131
leafy vegetables	T168	C0042440
Percentile	T081	C1264641
categorization	T185	C0008902
QT interval	T033	C1287082
approach	T082	C0449445
identifying	T058	C0557971
adult	T100	C0001675
patients	T101	C0030705
risk	T078	C0035647
cardiovascular death	T201	C2926098
QT prolongation	T033	C0151878
cardiovascular death	T201	C2926098
CVD	T201	C2926098
inconsistent	T080	C0442809
purpose of this study	UnknownType	C0681832
compare	T052	C1707455
correction formulas	T081	C0392762
percentile values	T081	C1532337
QT	T081	C0860814
heart rate	T201	C0018810
ranges	T081	C1514721
ability	T032	C0085732
remove	T052	C1883720
relationship	T080	C0439849
QT	T081	C0860814
heart rate	T201	C0018810
CVD	T201	C2926098
Participants	T098	C0679646
veterans	T098	C0042610
ECG	T033	C0013798
Veterans Affairs Medical Center	T170	C0282574
Palo Alto	T083	C3827373
March	T079	C3829202
December	T080	C3830550
CVD	T201	C2926098
correction formulas	T081	C0392762
Bazett	T081	C1882512
Fridericia	T081	C1882513
Framingham	T081	C0392762
Hodges	T081	C0392762
QT interval	T033	C1287082
percentiles	T081	C1264641
heart rate	T201	C0018810
ranges	T081	C1514721
Schwartz	T016	C0086418
median	T082	C2939193
years	T079	C1510829
CVD	T201	C2926098
equations	T077	C0552449
heart rate	T201	C0018810
hazard ratio	T081	C2985465
confidence interval	T081	C0009667
CVD	T201	C2926098
percentile	T081	C1264641
QT interval	T033	C1287082
heart rate	T201	C0018810
ranges	T081	C1514721
QTc Bazett	T081	C1882512
QTc Hodges	T081	C0392762
QTc Framingham	T081	C0392762
QTc Bazett	T081	C1882512
significantly higher	T081	C4055637
formulas	T170	C0489829
percentile	T081	C1264641
Framingham	T081	C0392762
Hodges	T081	C0392762
Fridericia equations	T081	C0392762
remove	T052	C1883720
effect	T080	C1280500
heart rate	T201	C0018810
QT interval	T033	C1287082
Bazett equation	T081	C0392762
QT-interval	T033	C1287082
percentiles	T081	C1264641
heart rate	T201	C0018810
approach	T082	C0449445
QT intervals	T033	C1287082
drugs	T061	C3687832
stressors	T078	C0597530
CVD	T201	C2926098
risk	T078	C0035647
Exam	UnknownType	C0681376
Self-Regulated Learning	T041	C1510634
Strategies	T065	C0237896
Achievement	T065	C0237912
Introductory Biology	T091	C0005532
college	T073	C0557806
introductory science	T090	C0036397
courses	T065	C0013652
students	T098	C0038492
disciplinary content	T080	C0205556
autonomous	UnknownType	C0815096
effective	T080	C1704419
learners	T098	C0038492
Self-regulated learning	T041	C1510634
SRL	T041	C1510634
learning goals	T078	C2010704
progress	T169	C1280477
study strategies	T065	C0237896
SRL	T041	C1510634
learners	T098	C0038492
undergraduate	T170	C0683865
introductory biology	T091	C0005532
course	T065	C0013652
SRL	T041	C1510634
strategies	T065	C0237896
students	T098	C0038492
exams	UnknownType	C0681376
strategies	T065	C0237896
achievement	T053	C0001072
grade	T185	C0441800
improvement	T033	C0184511
exams	UnknownType	C0681376
students	T098	C0038492
exams	UnknownType	C0681376
Higher	T080	C0205250
achieving	T053	C0001072
students	T098	C0038492
students	T098	C0038492
exam	UnknownType	C0681376
grades	T185	C0441800
improved	T033	C0184511
first half	T033	C3843058
semester	T079	C2348178
cognitive	T041	C0009240
metacognitive strategies	T041	C0870885
frequently	T079	C0332183
lower	T052	C2003888
achieving	T053	C0001072
peers	T098	C0679739
Lower	T052	C2003888
achieving	T053	C0001072
students	T098	C0038492
frequently	T079	C0332183
strategies	T065	C0237896
outcomes	T169	C1274040
students	T098	C0038492
introductory biology	T091	C0005532
limited	T169	C0439801
knowledge	T065	C0013621
SRL	T041	C1510634
strategies	T065	C0237896
limited	T169	C0439801
impact	T080	C4049986
achievement	T065	C0237912
Course	T065	C0013652
interventions	T058	C0242687
SRL	T041	C1510634
pedagogical tools	T090	C1510624
fostering	T056	C0242298
students	T098	C0038492
lifelong	T079	C4274169
learning skills	T041	C0871370
Characterising	T052	C1880022
bias	T078	C0242568
regulatory risk	T078	C0035647
decision analysis	T090	C0011108
analysis	T062	C0936012
heuristics	T170	C0597916
health technology	T058	C0752189
appraisal	T058	C1254363
chemicals	T103	C0220806
regulation	T064	C0851285
climate change	T070	C2718051
governance	T052	C0441655
environmental	T185	C0237095
public health domains	T170	C3244304
heuristic methods	T170	C0597916
risk	T078	C0035647
decision analysis	T090	C0011108
problem structures	T033	C0033213
data	T078	C1511726
lacking	T080	C0332268
decisions	T041	C0679006
source	T033	C0449416
uncertainty	T033	C0087130
model	T170	C3161035
measurement error	T081	C0681899
uncertainty	T033	C0087130
inference rules	T170	C0870077
identify	T169	C0205245
analyse	T169	C1524024
heuristics	T170	C0597916
risk	T078	C0035647
objects	T077	C1518526
discriminate	T080	C0205235
signal	T067	C1710082
noise	T067	C0028263
weight	T081	C0043100
evidence	T078	C3887511
models	T170	C3161035
datasets	T170	C0150098
policy	T170	C0242456
heuristics	T170	C0597916
generalisations	T080	C0205556
relationships	T080	C0439849
surrogates	T099	C4053457
clinical trials	T062	C0008976
conventions	T080	C0205556
stability	T080	C0205360
decision analysis	T090	C0011108
error	T080	C0743559
significance testing	T169	C0039593
heuristics	T170	C0597916
justifications	T078	C0392360
assumptions	T078	C1254370
practical applications	T169	C0205245
Heuristic	T170	C0597916
decision rules	T170	C0870077
feasibility rules	T170	C0870077
surrogates	T099	C4053457
utility maximisation	T080	C0205556
distributional	T169	C1704711
concerns	T078	C2699424
practice	T077	C1254372
costs and benefits	T081	C0010187
arbitrary	T080	C1264693
thresholds	T080	C0449864
problem	T033	C0033213
rule-entrenchment	T067	C1254366
analytical choices	T052	C1707391
practice	T077	C1254372
uncertainty	T033	C0087130
bias	T078	C0242568
Strategies	T041	C0679199
risk	T078	C0035647
decision analysis	T090	C0011108
assumptions	T078	C1254370
scope	T077	C1710028
conditions	T078	C1254370
heuristics	T170	C0597916
testing	T169	C0039593
empirical	T078	C0392360
theoretical justifications	T078	C0392360
sensitivity	T081	C0036667
analysis	T062	C0936012
simulations	T062	C0679083
multiple bias analysis	T062	C0242481
deductive systems of inference	T170	C0282574
directed acyclic graphs	T170	C1706232
rule	T170	C0870077
uncertainty	T033	C0087130
heuristics	T170	C0597916
recovery schemes	T170	C1519193
biases;	T078	C0242568
decision rules	T170	C0870077
values	T080	C0042295
evidence	T078	C3887511
convention	T080	C0205556
Multicentric Castleman disease	T191	C1334815
hyaline	T031	C0020191
vascular	T023	C0005847
variant	T080	C0205419
unusual	T080	C2700116
systemic	T169	C0205373
manifestations	T080	C1280464
case report	T170	C0007320
Castleman disease	T191	C1334815
rare	T080	C0522498
lymphoproliferative disorder	T191	C0024314
localized	T082	C0392752
disseminated	T082	C0205221
lymphadenopathy	T047	C0497156
systemic	T169	C0205373
manifestations	T080	C1280464
categorized	T185	C0008902
numerous	T081	C0439064
unicentric	T047	C0017531
multicentric	T191	C1334815
histopathological	T169	C0243140
variants	T080	C0205419
hyaline	T031	C0020191
vascular	T023	C0005847
plasma cell	T025	C0032112
mixed	T080	C0205419
subtypes	T185	C0872379
causative	T033	C0449411
viral infections	T047	C0042769
human immunodeficiency virus	T005	C0019682
human herpesvirus-8	T005	C0376526
Kaposi sarcoma herpesvirus	T005	C0376526
asymptomatic	T033	C0231221
symptoms	T184	C1457887
multiple	T081	C0439064
organs	T023	C0178784
mechanism	T169	C0441712
pathogenesis	T046	C0699748
treatment	T169	C1522326
directed	T080	C1879741
etiologies	T169	C0015127
interleukin-6	T116	C0021760
cluster of differentiation 20	T116	C0054946
viral agents	T169	C0521026
year	T079	C0439234
Sri Lankan	T098	C1553327
woman	T098	C0043210
body swelling	T184	C0577596
foamy urine	T184	C2188715
weeks	T079	C0439230
duration	T079	C0449238
Examination	T058	C0582103
pallor	T033	C0030232
generalized edema	T033	C1850534
axillary	T029	C0004454
cervical	T082	C0205064
inguinal lymphadenopathy	T047	C0578736
hypertension	T047	C0020538
hepatomegaly	T033	C0019209
Investigations	T058	C1261322
bicytopenia	T034	C1142446
nephrotic range proteinuria	T033	C0445118
hypoalbuminemia	T047	C0239981
hypogammaglobulinemia	T047	C0086438
features	T080	C2348519
hyaline	T031	C0020191
vascular	T023	C0005847
type	T080	C0332307
Castleman disease	T191	C1334815
lymph node biopsy	T060	C0193842
managed	T058	C0086583
rituximab	T116	C0393022
clinical	T080	C0205210
improvement	T077	C2986411
Castleman disease	T191	C1334815
broad	T082	C0332464
spectrum	T077	C2827424
clinical	T080	C0205210
manifestations	T080	C1280464
disease	T047	C0012634
pathogeneses	T046	C0699748
associations	T080	C0205556
complications	T046	C0009566
Medical	T169	C0205476
professionals	T097	C1704312
spectrum	T077	C2827424
diagnosis	T033	C0011900
aggressive targeted therapy	T061	C2985566
patients	T101	C0030705
AGES-Reykjavik study atlases	T073	C0004171
Non-linear	T077	C0206165
multi-spectral template	T078	C1705542
atlases	T073	C0004171
studies	T062	C2603343
ageing	T040	C0001811
brain	T023	C0006104
Quantitative analyses	T081	C0034384
brain	T023	C0006104
structures	T082	C0678594
Magnetic Resonance	T060	C0024485
MR	T060	C0024485
image	T060	C0024485
data	T078	C1511726
automatic	T169	C0205554
segmentation	T066	C2697664
algorithms	T170	C0002045
algorithms	T170	C0002045
templates	T078	C1705542
atlases	T073	C0004171
coordinate space	T170	C1183514
freely	T080	C1996904
available	T169	C0470187
brain	T023	C0006104
atlases	T073	C0004171
young	T079	C0332239
individuals	T098	C0027361
cohort studies	T081	C0009247
publicly	T092	C0678367
available	T169	C0470187
multi-spectral template	T078	C1705542
tissue	T024	C0040300
probability	T081	C0033204
atlases	T073	C0004171
regional	T082	C0205147
atlases	T073	C0004171
optimised	T052	C2698650
studies	T062	C2603343
ageing	T040	C0001811
cohorts	T098	C0599755
validation	T062	C1519941
data	T078	C1511726
regional	T082	C0205147
segmentation	T066	C2697664
integrity	T080	C1947912
dataset	T170	C0150098
Comparative	T062	C0683941
evolutionary analysis	T062	C0936012
adapter molecule MyD88	T028	C1417530
invertebrate	T204	C0021948
metazoans	T204	C2713498
myeloid differentiation factor 88	T028	C1417530
MyD88	T028	C1417530
Toll-like receptor	T116	C0670896
TLR	T116	C0670896
signalling pathways	T043	C0037083
TLR	T116	C0670896
pattern-recognition receptor	T116	C1564907
PRR	T116	C1564907
Drosophila	T204	C0013138
study	T062	C2603343
MyD88 gene	T028	C1417530
identified	T080	C0205396
characterized	T052	C1880022
shellfish	T204	C1304606
Scapharca subcrenata	T204	C3346701
DEATH domain	T087	C1511738
TIR domain	T082	C1956034
molluscs	T204	C0026391
comparative genomic evidence	T063	C0796358
MyD88	T028	C1417530
different	T080	C1705242
lengths	T081	C1444754
quantitative	T081	C0392762
exon	T114	C0015295
intron regions	T114	C0021920
specific mechanisms	T169	C0441712
phylogenetic relationships	T062	C1519068
invertebrate	T204	C0021948
metazoan	T204	C2713498
MyD88	T028	C1417530
MrBayes and PhyML software	T170	C0037589
construct	T185	C2827421
phylogenetic trees	T080	C1519069
Bayesian	T081	C0242196
maximum likelihood approaches	T081	C0024970
MyD88	T028	C1417530
Arthropoda	T204	C0003903
lower	T080	C0205251
invertebrates	T204	C0021948
contrast	T080	C1979874
morphological	T082	C0543482
taxonomy	T090	C0087066
investigated	T169	C1292732
evolutionary patterns	T045	C0015219
positive selection sites	T028	C0678933
PSSs	T028	C0678933
MyD88 gene	T028	C1417530
Arthropoda	T204	C0003903
Mollusca	T204	C0026391
Insecta	T204	C0021585
PAML software	T170	C0037589
maximum likelihood method	T170	C0025663
data	T078	C1511726
positive selection sites	T028	C0678933
detected	T033	C0442726
groups	T098	C1257890
partial sites	T087	C0002518
TIR domain	T082	C1956034
not found	T033	C0442737
DEATH domain	T087	C1511738
study	T062	C2603343
diversification	T057	C0680948
MyD88	T028	C1417530
invertebrate	T204	C0021948
metazoans	T204	C2713498
specific	T080	C0205369
evolutionary position	T045	C0015219
Arthropoda	T204	C0003903
MyD88	T028	C1417530
positive	T033	C1446409
selection pressures	T045	C0036576
MyD88	T028	C1417530
Arthropoda	T204	C0003903
Mollusca	T204	C0026391
Insecta	T204	C0021585
results	T169	C1274040
valuable contribution	T052	C1880177
clarify	T052	C2986669
evolutionary pattern	T045	C0015219
TLR	T116	C0670896
MyD88	T028	C1417530
signalling pathways	T043	C0037083
invertebrate	T204	C0021948
vertebrate taxa	T010	C0042567
Rubinstein-Taybi Syndrome	T047	C0035934
Associated with	T080	C0332281
Pituitary Macroadenoma	T191	C0346308
Case Report	T170	C0085973
Rubinstein-Taybi Syndrome	T047	C0035934
RSTS	T047	C0035934
autosomal dominant disorder	T047	C3899989
characterized	T052	C1880022
prenatal	T079	C2828394
postnatal	T079	C0443281
growth restriction	T046	C0151686
microcephaly	T019	C0025958
dysmorphic craniofacial features	T019	C0432072
broad thumbs	T033	C0426891
toes	T033	C1865038
intellectual disability	T048	C3714756
pituitary macroadenoma	T191	C0346308
associated with	T080	C0332281
RSTS	T047	C0035934
Caucasian	T098	C0043157
female	T098	C0043210
past medical history	T033	C0455458
RSTS	T047	C0035934
diagnosed	T033	C0011900
age	T032	C0001779
gadolinium	T130	C0016911
pituitary mass	T190	C0342419
magnetic resonance imaging	T060	C0024485
MRI	T060	C0024485
brain	T023	C0006104
years	T079	C0439234
migraine-like headaches	T184	C0018681
imaging	T060	C0011923
radiographic evidence	T078	C3887511
growth	T040	C0018270
size	T082	C0456389
pituitary	T023	C0032005
sellar lesion	T033	C0221198
resected	T061	C0015252
endoscopic	T082	C0442418
transnasal	T082	C3897344
transsphenoidal approach	T082	C0205508
thyrotroph adenoma	T191	C0346303
RSTS	T047	C0035934
rare	T080	C0522498
neurodevelopmental	T048	C1535926
genetic disease	T047	C0019247
patients with disabilities	T101	C0018576
survive	T052	C0038952
adulthood	T079	C0700597
disorder	T047	C0012634
associated with	T080	C0332281
increased	T081	C0205217
predisposition	T032	C0220898
development	T169	C1527148
nervous system tumors	T191	C0027766
pituitary adenomas	T191	C0032000
radiological	T091	C0039431
paradox	T033	C0221733
cognitive function	T041	C0392335
MRI	T060	C0024485
burden	T078	C2828008
white matter	T024	C0682708
lesions	T033	C0221198
people	T098	C0027361
multiple sclerosis	T047	C0026769
systematic review	T170	C1955832
meta-analysis	T170	C0282458
Moderate	T080	C0205081
correlation	T080	C1707520
imaging quantification	T052	C2984008
brain	T023	C0006104
white matter	T024	C0682708
lesions	T033	C0221198
cognitive	T169	C1516691
performance	T055	C0597198
people	T098	C0027361
multiple sclerosis	T047	C0026769
MS	T047	C0026769
features	T080	C2348519
pathology	T091	C0030664
methodological	T078	C3266812
limitations	T169	C0449295
primary	T080	C0205225
literature	T170	C0023866
cognitive	T169	C1516691
radiological	T091	C0039431
paradox	T033	C0221733
potential	T080	C3245505
methodological	T078	C3266812
factors	T169	C1521761
assessment	T052	C1516048
relationship	T080	C0439849
Systematic review	T170	C1955832
meta-analysis	T170	C0282458
primary	T080	C0205225
research	T062	C0035168
cognitive function	T041	C0392335
white matter	T024	C0682708
lesion	T033	C0221198
burden	T078	C2828008
papers	T073	C0030351
eligibility criteria	T080	C1512693
review	T170	C0282443
meta-analysis	T170	C0282458
results	T169	C1274040
participants	T098	C0679646
Aggregate	T080	C0205418
correlation	T080	C1707520
cognition	T041	C0009240
T2	T033	C0475373
lesion	T033	C0221198
burden	T078	C2828008
confidence interval	T081	C0009667
methodological	T078	C3266812
variability	T077	C2827666
factors	T169	C1521761
cognitive	T169	C1516691
data	T078	C1511726
image analysis techniques	T059	C0200765
radiological	T091	C0039431
paradox	T033	C0221733
evaluation	T058	C0220825
multiple	T081	C0439064
components	T077	C1705248
complex	T080	C0439855
pathology	T091	C0030664
optimum	T080	C2698651
measurement	T169	C0242485
techniques	T169	C0449851
cognitive	T169	C1516691
MRI	T060	C0024485
feature	T080	C2348519
quantification	T081	C1709793
consensus	T054	C0376298
standards	T080	C1442989
image analysis	T059	C0200765
MS	T047	C0026769
benchmarking	T081	C0525063
innovation	T170	C0683888
Long Non-Coding RNA	T114	C3494264
SNHG6	T028	C1822801
Biomarker	T123	C0041365
Hepatocellular Carcinoma	T191	C2239176
Long Non-coding RNAs	T114	C3494264
lncRNAs	T114	C3494264
non-protein coding	T114	C0887909
transcripts	T114	C1519595
nucleotides	T114	C0028630
biological	T080	C0205460
pathways	T077	C1705987
expression	T045	C0017262
lncRNAs	T114	C3494264
cancer initiation	T191	C0598935
progression	T191	C0178874
patients	T101	C0030705
hepatocellular carcinoma	T191	C2239176
HCC	T191	C2239176
diagnosed	T033	C0011900
late stages	T079	C1279941
diagnostic methods	T060	C0920688
study	T062	C2603343
expression	T045	C0017262
lncRNAs	T114	C3494264
analysed	T062	C0936012
genomic	T170	C0150098
transcriptome datasets	T170	C0150098
analyses	T062	C0936012
SNHG6	T028	C1822801
lncRNAs	T114	C3494264
dysregulation	T045	C0017263
expression	T045	C0017262
HCC tumors	T191	C2239176
normal tissues	T024	C0040300
dysregulation	T045	C0017263
SNHG6	T028	C1822801
cancer	T191	C0006826
analyses	T062	C0936012
SNHG6	T028	C1822801
co-expressed	T045	C0017262
genes	T028	C0017337
8q	T086	C1515445
structural	T082	C0678594
integrity	T080	C1947912
ribosome	T026	C0035553
translation	T045	C1519614
comprehensive	T080	C1880156
in silico	T066	C3489666
analysis	T062	C0936012
investigating	T169	C1292732
SNHG6	T028	C1822801
hepatocellular carcinoma	T191	C2239176
researches	T062	C0035168
Expressional	T045	C0017262
divergence	T082	C0443204
insect	T204	C0021585
GOX genes	T028	C1415468
glucose oxidase	T116	C0017735
Insect herbivores	T204	C0021585
secrete	T043	C1327616
glucose oxidase	T116	C0017735
GOX	T116	C0017735
plants	T002	C0032098
counteract	T053	C1947978
plant	T002	C0032098
defenses	T077	C1880266
potential	T080	C3245505
pathogens	T001	C0450254
herbivores	T204	C0021585
significantly higher	T081	C4055637
GOX	T116	C0017735
activities	T052	C0441655
counterparts	T053	C1947978
larvae	T204	C0023047
species	T185	C1705920
Helicoverpa armigera	T204	C1002429
counterpart	T053	C1947978
Helicoverpa assulta	T204	C1093556
protein	T116	C0033684
digestible	T040	C0012238
carbohydrate	T168	C0453802
allelochemical	T123	C1135843
host plant	UnknownType	C0868970
treatments	T169	C1522326
GOX	T028	C1415468
transcripts	T114	C1519595
activities	T052	C0441655
labial glands	T023	C0226928
GOX	T028	C1415468
activity	T052	C0441655
transcripts	T114	C1519595
upregulated	T044	C0041904
food	T168	C0016452
ingestion	T038	C0232478
body growth	T040	C0231256
downregulated	T044	C0013081
ingestion	T038	C0232478
wandering	T053	C0233569
pupation	T040	C1326578
species	T185	C1705920
host plants	UnknownType	C0868970
upregulated	T044	C0041904
GOX	T028	C1415468
transcripts	T114	C1519595
GOX	T028	C1415468
activity	T052	C0441655
species	T185	C1705920
GOX	T028	C1415468
transcripts	T114	C1519595
activity	T052	C0441655
allelochemicals	T123	C1135843
GOX	T028	C1415468
transcripts	T114	C1519595
species	T185	C1705920
GOX	T116	C0017735
activities	T052	C0441655
H. armigera	T204	C1002429
H. assulta	T204	C1093556
GOX	T028	C1415468
transcripts	T114	C1519595
significantly higher	T081	C4055637
developmental stages	T079	C0870411
host plants	UnknownType	C0868970
allelochemicals	T123	C1135843
encounter	T053	C1947978
data	T078	C1511726
greater	T081	C1704243
GOX	T116	C0017735
activity	T052	C0441655
herbivores	T204	C0021585
greater	T081	C1704243
transcription	T045	C0040649
transcript	T114	C1519595
translation	T045	C1519614
better enzyme stability	T044	C0014439
Propranolol	T109	C0033497
Decompression Sickness	T047	C0011119
DISSUB	T073	C0221094
Rescue	T057	C0242857
Swine	T015	C1135183
Disabled submarine	T073	C0221094
DISSUB	T073	C0221094
survivors	T096	C1171334
elevated CO2 levels	T033	C0020440
inert gas saturation	UnknownType	C0545273
CO2	T123	C0007012
toxicity	T080	C0040539
decompression sickness	T047	C0011119
DCS	T047	C0011119
Propranolol	T109	C0033497
reduce CO2 production	T059	C0201930
DISSUB	T073	C0221094
model	T075	C0026336
humans	T016	C0086418
DCS	T047	C0011119
DISSUB	T073	C0221094
rescue scenario	T057	C0242857
oxygen prebreathe	T039	C0035203
OPB	T039	C0035203
DCS	T047	C0011119
DISSUB	T073	C0221094
rescue protocols	T057	C0242857
swine model	T015	C1135183
DISSUB	T073	C0221094
rescue	T057	C0242857
propranolol	T109	C0033497
DCS	T047	C0011119
mortality	T081	C0205848
OPB	T039	C0035203
male	T032	C0086582
Yorkshire Swine	T015	C0324292
pressurized	T067	C0033095
Propranolol	T109	C0033497
administered at	T169	C1521801
animal	T008	C0003062
rapidly decompressed	T169	C1965697
DCS	T047	C0011119
onset time	T079	C0449244
mortality	T081	C0205848
animals	T008	C0003062
PROP1.0	T109	C0033497
PROP1.0	T109	C0033497
OPB45	T039	C0035203
dive	T032	C0178599
OPB	T039	C0035203
decompression	T169	C1965697
methodology	T078	C3266812
swine	T015	C1135183
pressurized	T067	C0033095
PROP0.5	T109	C0033497
propranolol	T109	C0033497
administered at	T169	C1521801
Control animals	T008	C1511501
normal saline	T121	C0445115
OPB	T039	C0035203
reduced mortality	T081	C0205848
PROP1.0	T109	C0033497
OBP45	T039	C0035203
PROP1.0	T109	C0033497
PROP0.5	T109	C0033497
increased mortality	T081	C0205848
beta blockers	T121	C0001645
saturation decompression	T169	C1965697
DCS	T047	C0011119
worsen mortality	T081	C0205848
swine	T015	C1135183
model	T075	C0026336
bounce diving	T032	C0178599
Gut microbiota	T001	C4018878
protection	T033	C1545588
diarrheal	T184	C0011991
infections	T046	C3714514
mammalian	T015	C0024660
gut microbiota	T001	C4018878
microbial	T001	C0445623
community	T096	C0009462
resides	T052	C2982691
gastrointestinal tract	T022	C0017189
gut microbiota	T001	C4018878
host	T001	C1167395
colonization	T033	C4289767
resistance	T169	C4281815
prevent	T169	C0205245
colonization	T033	C4289767
foreign microbes	T001	C0445623
diarrheal	T184	C0011991
pathogens	T001	C0450254
Clostridium difficile	T007	C0079134
Salmonella enterica serovar Typhimurium	T007	C0036126
diarrheagenic Escherichia coli	T007	C1264842
literature review	T170	C0282441
effects of	T080	C1704420
gut microbiota	T001	C4018878
infection	T046	C3714514
diarrheal	T184	C0011991
pathogens	T001	C0450254
PubMed	T170	C1138432
articles	T170	C1706852
data	T078	C1511726
laboratory	T073	C0022877
gut microbiota	T001	C4018878
protection	T033	C1545588
diarrheal	T184	C0011991
infections	T046	C3714514
direct	T080	C1947931
inhibition	T052	C3463820
pathogens	T001	C0450254
indirect	T080	C0439852
effects	T080	C1280500
host	T001	C1167395
functions	T169	C0542341
Direct	T080	C1947931
effects of	T080	C1704420
microbiota	T001	C4018878
diarrheal	T184	C0011991
pathogens	T001	C0450254
nutrients	T168	C0678695
metabolites	T123	C0870883
inhibit	T169	C0205245
pathogen	T001	C0450254
growth	T040	C0018270
virulence	T038	C0042765
Indirect	T080	C0439852
effects of	T080	C1704420
gut microbiota	T001	C4018878
maintenance	T052	C0024501
gut mucosal barrier	T042	C0232577
innate	T032	C0020969
adaptive immunity	T039	C0678209
Human	T016	C0086418
epidemiological studies	T062	C0002783
experimental	T080	C1517586
infections	T046	C3714514
laboratory animals	T008	C0003064
antibiotic treatment	T061	C0338237
gut microbial	T001	C4018878
community	T096	C0009462
colonization	T033	C4289767
resistance	T169	C4281815
diarrheal	T184	C0011991
pathogens	T001	C0450254
research	T062	C0035168
development	T169	C1527148
next-generation probiotics	T007	C0525033
colonization	T033	C4289767
resistance	T169	C4281815
prevent	T169	C0205245
travellers' diarrheal	T047	C0277528
Ecotoxicity	T037	C0600688
testing	T169	C0039593
environmental risk assessment	T058	C4076706
iron	T121	C0302583
nanomaterials	T073	C1450053
remediation	T069	C3853059
Recommendations	T078	C0034866
FP7 project NanoRem	T062	C0700032
Nanoremediation	T069	C3853059
iron	T121	C0302583
Fe	T121	C0302583
nanomaterials	T073	C1450053
treating	T169	C1522326
contaminated	T169	C0205279
soil	T167	C0037592
groundwater	T121	C0043047
potential risks	T078	C0035647
engineered nanomaterials	T073	C1450053
environment	T082	C0014406
study	T062	C2603343
assessed	T052	C1516048
ecotoxicity	T037	C0600688
Fe	T121	C0302583
nanomaterials	T073	C1450053
Nano-Goethite	T197	C0300269
Trap-Ox Fe-zeolites	T121	C0302583
Carbo-Iron	T121	C0302583
FerMEG12	T121	C0302583
European FP7 project NanoRem	T062	C0700032
remediation	T069	C3853059
test battery	T059	C0022885
ecotoxicity	T037	C0600688
tests	T059	C0022885
bacteria	T007	C0004611
V. fisheri	T007	C0318276
E. coli	T007	C0014834
algae	T204	C0002028
P. subcapitata	T002	C1089415
Chlamydomonas sp.	T002	C0008155
crustaceans	T204	C0010395
D. magna	T204	C1081963
worms	T204	C0018893
E. fetida	T204	C0524676
L. variegatus	T204	C0998692
plants	T002	C0032098
R. sativus	T002	C0996771
L. multiflorum	T002	C0331557
Fe oxide	T121	C0060240
nanoscale zero valent iron	T121	C0302583
nZVI	T121	C0302583
Fe	T121	C0302583
matrix	T082	C1704640
material	T167	C0520510
ball milled nZVI	T121	C0302583
FerMEG12	T121	C0302583
no toxicity	T033	C1513916
test battery	T059	C0022885
concentrations	T081	C1446561
cutoff	T169	C1442160
hazard	T080	C0598697
labeling	T064	C2827499
chemicals regulation	T064	C0851285
Europe	T083	C0015176
Fe	T121	C0302583
nanomaterials	T073	C1450053
turbidity	T080	C0301633
aggregation	T169	C0332621
sedimentation behavior	T070	C1384604
aqueous	T080	C0599956
media	T167	C1705217
recommendations	T078	C0034866
future testing	T169	C0039593
Fe	T121	C0302583
nanomaterials	T073	C1450053
environmental risk assessment	T058	C4076706
Grade Group	T185	C0008902
Underestimation	T033	C0243095
Prostate Biopsy	T060	C0194804
Predictive Factors	T170	C0683956
Outcomes	T033	C1518681
Candidates	T098	C1257890
Active Surveillance	T058	C1827061
outcomes	T033	C1518681
predictive factors	T170	C0683956
prostate cancer	T191	C0376358
PCa	T191	C0376358
grade group	T185	C0008902
GG	T185	C0008902
prostate biopsies	T060	C0194804
monocentric cohort	T098	C0599755
patients	T101	C0030705
treated	T169	C1522326
minimally invasive radical prostatectomy	T061	C0194810
RP	T061	C0194810
monocentric prospectively maintained database	T170	C0242356
patients	T101	C0030705
minimally invasive RP	T061	C0194810
outcomes	T033	C1518681
associated with	T080	C0332281
GG	T185	C0008902
biopsy	T060	C0005558
RP	T061	C0194810
Multivariate logistic regression	T062	C0206031
nomogram	T170	C1450294
GG1	T185	C0008902
Biopsy	T060	C0005558
GG	T185	C0008902
RP	T061	C0194810
Patients	T101	C0030705
GG1	T185	C0008902
GG2	T185	C0008902
GG3	T185	C0008902
RP	T061	C0194810
longer time	T079	C0040223
biochemical recurrence	T033	C2985506
GG2	T185	C0008902
GG3	T185	C0008902
biopsy	T060	C0005558
RP	T061	C0194810
shorter time	T079	C0040223
biochemical recurrence	T033	C2985506
GG1	T185	C0008902
multivariate analyses	T081	C0026777
variables	T081	C1705098
GG1	T185	C0008902
PCa	T191	C0376358
age	T032	C0001779
abnormal digital rectal examination	T060	C1384593
prostate	T023	C0033572
prostate -specific antigen density	T033	C0243095
percentage of positive cores	T033	C0243095
body mass index	T170	C4055400
nomogram	T170	C1450294
Biopsy	T060	C0005558
grading system	T058	C1273712
GG	T185	C0008902
biopsy	T060	C0005558
RP	T061	C0194810
clinical outcomes	T033	C1518681
nomogram	T170	C1450294
probability	T081	C0033204
GG1	T185	C0008902
patients	T101	C0030705
evaluation	T058	C0220825
Characterization	T052	C1880022
electrocorticogram	T060	C0430797
high	T080	C0205250
gamma	T070	C0017011
signal	T067	C1710082
response	T032	C0871261
varying	T080	C1705242
upper extremity	T023	C1140618
movement	T040	C0026649
velocity	T081	C0439830
mechanism	T169	C0441712
human	T016	C0086418
primary motor cortex	T029	C3495441
M1	T029	C3495441
encodes	T052	C2700640
upper extremity	T023	C1140618
movement	T040	C0026649
kinematics	T091	C0600169
human	T016	C0086418
electrocorticogram	T060	C0430797
ECoG	T060	C0430797
signals	T067	C1710082
modulate	T082	C0443264
upper extremity	T023	C1140618
movement	T040	C0026649
relationship	T080	C0439849
explicitly	T080	C2963144
characterized	T052	C1880022
issue	T033	C0033213
recorded	T081	C3853788
high	T080	C0205250
density	T081	C0178587
ECoG	T060	C0430797
signals	T067	C1710082
patients	T101	C0030705
epilepsy	T047	C0014544
surgery	T061	C0543467
evaluation	T058	C0220825
performed	T169	C0884358
elementary	T167	C0013878
upper extremity	T023	C1140618
movements	T040	C0026649
systematically	T169	C0220922
varying	T080	C1705242
movement	T040	C0026649
speed	T081	C0678536
duration	T079	C0449238
Specifically	T080	C0205369
subjects	T096	C0681850
performed	T169	C0884358
intermittent	T079	C0205267
pincer grasp	T033	C0429273
release	T169	C0391871
elbow flexion	T033	C2215879
extension	T169	C0231448
shoulder flexion	T033	C0575546
extension	T169	C0231448
slow	T080	C0439834
moderate	T080	C0205081
fast	T080	C0456962
speeds	T081	C0678536
movements	T040	C0026649
bursts	T081	C4296482
power	T081	C3854080
high	T080	C0205250
observed	T169	C1441672
M1	T029	C3495441
addition	T169	C0332287
amplitude	T082	C2346753
power	T081	C3854080
bursts	T081	C4296482
area	T082	C0205146
M1	T029	C3495441
elevated	T080	C3163633
high	T080	C0205250
activity	T052	C0441655
directly	T080	C1947931
proportional	T080	C0205351
movement	T040	C0026649
speed	T081	C0678536
duration	T079	C0449238
elevated	T080	C3163633
high	T080	C0205250
activity	T052	C0441655
increased	T081	C0205217
movement	T040	C0026649
duration	T079	C0449238
Based	T169	C1527178
linear regression	T081	C0023733
M1	T029	C3495441
high	T080	C0205250
power	T081	C3854080
amplitude	T082	C2346753
duration	T079	C0449238
covaried	T080	C0205419
movement	T040	C0026649
speed	T081	C0678536
duration	T079	C0449238
average	T081	C1510992
findings	T033	C0243095
indicate	T078	C3146298
encoding	T052	C2700640
upper extremity	T023	C1140618
movement	T040	C0026649
speed	T081	C0678536
M1	T029	C3495441
high	T080	C0205250
activity	T052	C0441655
primarily	T080	C0205225
linear	T082	C0205132
activity	T052	C0441655
elevated	T080	C3163633
movement	T040	C0026649
M1	T029	C3495441
transient	T079	C0205374
instructions	T170	C1442085
specific	T080	C0205369
movement	T040	C0026649
duration	T079	C0449238
entirety	T081	C0444667
movement	T040	C0026649
spatial distribution	T082	C0037775
high	T080	C0205250
activity	T052	C0441655
presence	T033	C0150312
recruitment	T052	C2949735
phenomenon	T067	C1882365
higher	T080	C0205250
speeds	T081	C0678536
increased	T081	C0205217
muscle	T024	C0026845
activity	T052	C0441655
activation	T052	C1879547
M1	T029	C3495441
area	T082	C0205146
Fatty Acids	T109	C0015684
Different	T080	C1705242
Adipogenic Differentiation	T044	C0596843
Potentials	T080	C3245505
Stromal Vascular Cells	T025	C0162597
Isolated	T169	C0205409
Abdominal Fat	T024	C1563742
Laying	T040	C1622979
Hens	T012	C0008051
study	T062	C2603343
effects of	T080	C1704420
fatty acids	T109	C0015684
FA	T109	C0015684
chicken serum	T129	C1440440
CS	T129	C1440440
expression	T045	C0017262
adipogenic	T044	C0596843
transcripts	T114	C1519595
adipogenesis	T044	C0596843
chicken	T012	C0008051
stromal vascular cells	T025	C0162597
SVC	T025	C0162597
SVC	T025	C0162597
DMEM	T121	C1665363
FBS	T130	C3812213
Control	T096	C0009932
treated	T169	C1522326
oleic acid	T109	C0028928
OLA	T109	C0028928
FBS	T130	C3812213
linoleic acid	T109	C0023749
LNA	T109	C0023749
FBS	T130	C3812213
palmitic acid	T109	C0030234
PAM	T109	C0030234
FBS	T130	C3812213
stearic acid	T109	C0038229
STA	T109	C0038229
FBS	T130	C3812213
cells	T025	C0007634
DMEM	T121	C1665363
CS	T129	C1440440
treated	T169	C1522326
OLA	T109	C0028928
CS	T129	C1440440
OLA	T109	C0028928
PAM	T109	C0030234
CS	T129	C1440440
PAM	T109	C0030234
STA	T109	C0038229
CS	T129	C1440440
STA	T109	C0038229
LNA	T109	C0023749
CS	T129	C1440440
LNA	T109	C0023749
Adipogenesis	T044	C0596843
Oil Red O staining	T059	C1294000
glycerol-3-phosphate dehydrogenase (GPDH) activity	T044	C1151278
OLA	T109	C0028928
PAM	T109	C0030234
STA	T109	C0038229
increased	T081	C0205217
SVC	T025	C0162597
FBS	T130	C3812213
CS	T129	C1440440
OLA	T109	C0028928
PAM	T109	C0030234
STA	T109	C0038229
Adipogenesis	T044	C0596843
induced	T169	C0205263
FBS	T130	C3812213
OLA	T109	C0028928
FBS	T130	C3812213
LNA	T109	C0023749
FBS	T130	C3812213
PAM	T109	C0030234
FBS	T130	C3812213
STA	T109	C0038229
CS	T129	C1440440
OLA	T109	C0028928
CS	T129	C1440440
LNA	T109	C0023749
CS	T129	C1440440
PAM	T109	C0030234
CS	T129	C1440440
STA	T109	C0038229
FBS	T130	C3812213
GPDH activity	T044	C1151278
significantly higher	T081	C4055637
FBS	T130	C3812213
OLA	T109	C0028928
FBS	T130	C3812213
LNA	T109	C0023749
FBS	T130	C3812213
FBS	T130	C3812213
expression	T045	C0017262
FABP4	T028	C1333527
mRNA	T114	C0035696
increased	T081	C0205217
FBS	T130	C3812213
OLA	T109	C0028928
FBS	T130	C3812213
LNA	T109	C0023749
FBS	T130	C3812213
PAM	T109	C0030234
C/EBPα	T028	C1413322
C/EBPβ	T028	C1413323
ATGL	T028	C1538686
increased	T081	C0205217
FBS	T130	C3812213
OLA	T109	C0028928
FBS	T130	C3812213
LNA	T109	C0023749
cells	T025	C0007634
Expression	T045	C0017262
FABP4	T028	C1333527
C/EBPβ	T028	C1413323
mRNA	T114	C0035696
higher	T080	C0205250
CS	T129	C1440440
CS	T129	C1440440
OLA	T109	C0028928
CS	T129	C1440440
LNA	T109	C0023749
CS	T129	C1440440
PAM	T109	C0030234
CS	T129	C1440440
STA	T109	C0038229
compared	T052	C1707455
FBS	T130	C3812213
expression	T045	C0017262
ATGL	T028	C1538686
C/EBPα	T028	C1413322
higher	T080	C0205250
CS	T129	C1440440
CS	T129	C1440440
OLA	T109	C0028928
CS	T129	C1440440
LNA	T109	C0023749
FBS	T130	C3812213
cells	T025	C0007634
results	T033	C2825142
FA	T109	C0015684
different	T080	C1705242
potentials	T080	C3245505
induce	T169	C0205263
adipogenesis	T044	C0596843
LNA	T109	C0023749
potent	T080	C3245505
FA	T109	C0015684
potentials	T080	C3245505
presence	T033	C0150312
CS	T129	C1440440
novel	T080	C0205314
rapid	T080	C0456962
analysis	T062	C0936012
mass spectrometry	T059	C0037813
downstream	T082	C0522506
refolding	T044	C0162847
recombinant human insulin-like growth factor-1	T116	C0904505
mecasermin	T116	C0904505
Mecasermin	T116	C0904505
elevated blood sugar	T047	C0020456
growth hormone	T116	C0037663
resistant	T169	C0332325
Laron-type dwarfism	T047	C0271568
Mecasermin	T116	C0904505
inclusion bodies	T026	C0007637
E.coli	T007	C0014834
rapid	T080	C0456962
analytical method	T170	C0178476
refolding	T044	C0162847
purification	T059	C0597301
mecasermin	T116	C0904505
drug product	T121	C0013227
samples	T167	C0370003
oxidation	T044	C0030011
mecasermin	T116	C0904505
mecasermin	T116	C0904505
mecasermin	T116	C0904505
reduction	T070	C0301630
mecasermin	T116	C0904505
samples	T167	C0370003
MALDI-ISD	T059	C0282597
peak intensity ratio	T081	C0392762
charge state distribution	T080	C0205556
CSD	T080	C0205556
mecasermin	T116	C0904505
ESI-MS	T059	C0596495
HPLC	T059	C0008562
drift time	T081	C0392762
collision cross-sectional areas	T081	C0392762
CCS	T081	C0392762
mecasermin	T116	C0904505
ESI-IMS-MS	T059	C0022885
coupled	T169	C1948027
HPLC	T059	C0008562
MALDI-ISD	T059	C0282597
CSD values	T081	C0392762
ESI-MS	T059	C0596495
CCS	T081	C0392762
ESI-IMS-MS	T059	C0022885
relationship	T080	C0439849
folded	T082	C0332462
unfolded	T082	C1254362
proteoforms	T116	C1510464
mecasermin	T116	C0904505
mecasermin	T116	C0904505
free-SH: protein ratio	T081	C0392762
mecasermin	T116	C0904505
drug product	T121	C0013227
collision cross-sectional area	T081	C0392762
ESI-IMS-MS	T059	C0022885
proteoform	T116	C1510464
rapid	T080	C0456962
samples	T167	C0370003
mecasermin	T116	C0904505
ESI-IMS-MS	T059	C0022885
HPLC	T059	C0008562
rapid	T080	C0456962
robust	T080	C2986815
free-SH: protein ratio	T081	C0392762
mecasermin	T116	C0904505
proteoform	T116	C1510464
oxidation	T044	C0030011
mecasermin	T116	C0904505
ESI-IMS-MS	T059	C0022885
critical	T080	C1511545
quality	T080	C0332306
attributes	T080	C1882133
quality	T080	C0332306
design	T052	C1707689
mecasermin	T116	C0904505
Regulated	T045	C0017263
Intron	T114	C0021920
Removal	T052	C1883720
Motivational State	T041	C3825945
Experience	T041	C0596545
experiences	T041	C0596545
transient memory	T041	C0025265
internal state	T041	C0025361
organism	T001	C0029235
experience	T041	C0596545
memories	T041	C0025260
time	T079	C0040223
experience	T041	C0596545
internal state	T041	C0025361
influence	T077	C4054723
duration	T079	C0449238
memory	T041	C0025260
self-assembled aggregated	T080	C0205418
Drosophila Orb2A protein	T116	C0949989
long-lasting memory	T041	C0423909
adult fly	T204	C1440070
brain	T023	C0006104
mRNA	T114	C0035696
encoding	T052	C2700640
Orb2A protein	T116	C0949989
unspliced non-protein-coding form	T114	C0026661
convergence	T052	C2700387
experience	T041	C0596545
internal drive	T041	C0013126
increases	T169	C0442805
spliced protein-coding Orb2A mRNA	T114	C0035696
pasilla	T116	C1100909
fly	T204	C1440070
mammalian	T015	C0024660
Nova-1	T116	C0033684
2	T116	C0033684
mediator	T116	C1363844
Orb2A mRNA	T114	C0035696
processing	T045	C0314627
single-nucleotide	T114	C0028630
substitution	T044	C0596324
intronic	T114	C0021920
reduces	T080	C0392756
Pasilla	T116	C1100909
binding	T044	C0033618
intron	T114	C0021920
removal	T052	C1883720
impairs	T169	C0221099
long-term memory	T041	C0423909
pasilla	T116	C1100909
processing	T045	C0314627
unspliced Orb2A mRNA	T114	C0035696
experience	T041	C0596545
internal state	T041	C0025361
Orb2A protein	T116	C0949989
abundance	T080	C2346714
long-term memory	T041	C0423909
formation	T169	C1522492
FLASHE Study	T170	C0038951
Survey	T170	C0038951
Development	T169	C1527148
Dyadic	T098	C0870454
Participant	T098	C0679646
Characteristics	T080	C1521970
National Cancer Institute	T093	C1513882
Family Life	T054	C0015608
Activity	T052	C0441655
Sun	T070	C0038817
Health	T078	C0018684
Eating	T040	C0013470
FLASHE	T170	C0038951
Study	T170	C0038951
cancer preventive	T061	C0281206
behaviors	T055	C0018687
parent	T099	C0030551
adolescent	T100	C0205653
dyads	T098	C0870454
FLASHE	T170	C0038951
physical activity	T056	C0026606
diet	T168	C0012155
cancer preventive behaviors	T061	C0281206
parent	T099	C0030551
adolescent	T100	C0205653
dyads	T098	C0870454
FLASHE surveys	T170	C0038951
literature reviews	T170	C0282441
scientific	T090	C0036397
input	T077	C1708517
experts	T097	C0009817
cognitive testing	T060	C0204471
cross-sectional	T062	C0010362
web-based study	T062	C2603343
parents	T099	C0030551
adolescent	T100	C0205653
children	T099	C0680063
administered	T169	C1621583
April	T079	C3715024
October	T079	C3828732
parent	T099	C0030551
adolescent	T100	C0205653
dyads	T098	C0870454
parents	T099	C0030551
adolescents	T100	C0205653
FLASHE surveys	T170	C0038951
FLASHE	T170	C0038951
parent	T099	C0030551
adolescent	T100	C0205653
interpersonal	T080	C3476070
psychosocial variables	T080	C0033963
parenting	T054	C0085092
community	T080	C0563116
home environments	T082	C0442519
FLASHE	T170	C0038951
responses	T078	C1547656
parents	T099	C0030551
adolescents	T100	C0205653
dyads	T098	C0870454
correlated	T081	C0010100
FLASHE	T170	C0038951
research questions	T078	C0681799
individuals	T098	C0027361
dyads	T098	C0870454
ability	T032	C0085732
similarity	T080	C2348205
parents	T099	C0030551
adolescents	T100	C0205653
cancer preventive behaviors	T061	C0281206
FLASHE	T170	C0038951
researchers	T097	C0035173
practitioners	T097	C0017319
research	T062	C0035168
cancer preventive	T061	C0281206
health behaviors	T055	C0018687
Sex differences	T032	C0036866
effect of	T080	C1704420
chronic mild stress	UnknownType	C1510527
mouse	T015	C0025929
prefrontal cortical	T023	C0162783
BDNF	T116	C0107103
ovarian hormones	T109	C0729511
Depression	T048	C0011570
induced	T169	C0205263
stress	T033	C0038435
sex	T032	C1522384
age	T032	C0001779
hormonal	T080	C0458083
animal	T008	C0003062
duration	T079	C0449238
stressors	T078	C0597530
depression	T048	C0011570
comorbidities	T078	C0009488
women	T098	C0043210
men	T098	C0025266
sex	T032	C1522384
animal models	T008	C0599779
depression	T048	C0011570
effect of	T080	C1704420
sex	T032	C1522384
ovarian hormones	T109	C0729511
depression	T048	C0011570
phenotypes	T032	C0031437
mice	T015	C0025929
Chronic Variable Mild Stress	UnknownType	C1510527
CVMS	UnknownType	C1510527
paradigm	T062	C0242481
Adult	T100	C0001675
male	T032	C0086582
intact female	T033	C3687560
ovariectomized (OVX) female	T033	C3687559
mice	T015	C0025929
CVMS	UnknownType	C1510527
behavior	T053	C0004927
depression	T048	C0011570
phenotype	T032	C0031437
intact females	T033	C3687560
males	T032	C0086582
OVX females	T033	C3687559
anhedonia	T048	C0178417
depression	T048	C0011570
phenotype	T032	C0031437
molecular level	T081	C0596958
expression	T045	C1171362
Brain-Derived Neurotrophic Factor	T116	C0107103
BDNF	T116	C0107103
neuropeptide	T116	C0027895
associated with	T080	C0332281
depression	T048	C0011570
stress	T033	C0038435
genes	T028	C0017337
CRH	T028	C1366488
NR3C1	T028	C1334899
CART	T028	C1824528
NPY	T028	C1417815
Prefrontal Cortex	T023	C0162783
PFC	T023	C0162783
BDNF	T116	C0107103
protein expression	T045	C1171362
mRNA expression	T045	C1515670
CRH	T028	C1366488
NR3C1	T028	C1334899
CART	T028	C1824528
NPY	T028	C1417815
intact females	T033	C3687560
mice	T015	C0025929
OVX females	T033	C3687559
males	T032	C0086582
behavioral	T033	C0243095
molecular responses	T033	C4054479
CVMS	UnknownType	C1510527
17β-Estradiol	T109	C0014912
E2	T109	C0014912
administration	T061	C1533734
Progesterone	T109	C0033308
P4	T109	C0033308
OVX female	T033	C3687559
stress	T033	C0038435
mice	T015	C0025929
expression	T045	C1171362
BDNF	T116	C0107103
PFC	T023	C0162783
effects of	T080	C1704420
E2	T109	C0014912
administration	T061	C1533734
stress	T033	C0038435
Development	T169	C1527148
Evaluation	T062	C0015194
ADHD	T048	C1263846
ADHD Cognitions Scale	T170	C0451081
Adults	T100	C0001675
clinical literature	T170	C0023866
ADHD	T048	C1263846
adults	T100	C0001675
overly positive	T041	C0009240
optimistic cognitions	T041	C0563183
impairment	T169	C0221099
failure	T055	C0680095
self-regulation skills	T055	C0678856
population	T098	C1257890
research	T062	C0035168
literature	T170	C0023866
ADHD	T048	C1263846
ADHD Cognitions Scale	T170	C0451081
ACS	T170	C0451081
self-report	T062	C2700446
measure	T081	C0079809
ADHD	T048	C1263846
thoughts	T041	C0039869
psychometric properties	T080	C0871161
self-report	T062	C2700446
measures	T081	C0079809
ACS	T170	C0451081
community samples	T096	C0009462
one-factor solution	T081	C0392762
replicated	T169	C0205173
sample	T096	C0009462
internal consistency	T081	C0870731
convergent	T080	C1510594
divergent validity	T080	C1510603
samples	T096	C0009462
Scores	T081	C0449820
ACS	T170	C0451081
functional impairment	T033	C4062321
time management problems	T033	C0033213
avoidant coping	T033	C0231426
strategies	T041	C0679199
study	T062	C2603343
ACS	T170	C0451081
maladaptive	T033	C0562443
ADHD	T048	C1263846
cognitions	T041	C0009240
cognitive-behavioral treatment	T061	C0009244
study	T062	C2603343
thoughts	T041	C0039869
ADHD	T048	C1263846
ADHD -related impairment	T033	C4062321
Visual	T169	C0234621
Confidence	T041	C1704726
Visual	T169	C0234621
confidence	T041	C1704726
observer's	T096	C0870992
ability	T032	C0085732
judge	T041	C0022423
accuracy	T080	C0443131
perceptual decisions	T041	C0679006
confidence	T041	C1704726
judgments	T041	C0022423
psychophysics	T091	C0033930
visual perception	T041	C0042830
visual	T169	C0234621
confidence	T041	C1704726
experimental evidence	T078	C3887511
metacognitive abilities	T041	C0589513
perceptual sensitivity	T041	C0312418
experimental paradigms	T062	C0681797
study	T062	C2603343
visual	T169	C0234621
confidence	T041	C1704726
humans	T016	C0086418
nonhuman animals	T008	C0003062
origins	T079	C0439659
confidence	T041	C1704726
judgments	T041	C0022423
investigators	T097	C0035173
signal decision theory	T170	C0011114
fails	T169	C0231175
response times	T079	C0034746
evidence	T078	C3887511
models	T170	C3161035
dynamics	T070	C3826426
perceptual decisions	T041	C0679006
models	T170	C3161035
results	T169	C1274040
paradoxical	T080	C0205310
dissociation	T048	C0086168
performance	T055	C0597198
confidence	T041	C1704726
Grapevine	T002	C0682492
Subtilase Family	T116	C0767764
Sequences	T086	C0004793
Nomenclature Proposal	T170	C0600281
grapevine	T002	C0682492
serine peptidases	T116	C2717971
subtilase family	T116	C0767764
Plasmopara viticola	T002	C1091290
resistance	T169	C4281815
grapevine	T002	C0682492
re-analyzed	T062	C0936012
subtilase	T116	C0767764
genes	T028	C0017337
National Center for Biotechnology Information	T092	C1705803
database	T170	C0242356
NCBI	T092	C1705803
grapevine	T002	C0682492
genome annotation	T063	C2936606
sequencing data	T170	C0026382
prediction	T078	C0681842
algorithms	T170	C0002045
consequence	T169	C0686907
gene annotations	T063	C2936606
grapevine	T002	C0682492
subtilase	T116	C0767764
gene family	T028	C1517488
sequences	T086	C0004793
SBT	T116	C0767764
sequence identifiers	T170	C0600091
bioinformatic	T091	C1140694
predictions	T078	C0681842
nomenclature	T170	C0600281
grapevine	T002	C0682492
SBT	T116	C0767764
genes	T028	C0017337
results	T034	C0456984
grapevine	T002	C0682492
subtilase	T116	C0767764
gene family	T028	C1517488
subtilase	T116	C0767764
genes	T028	C0017337
encoding	T052	C2700640
subtilase proteins	T116	C0767764
alterations	T045	C0596611
expression	T045	C0017262
data	T078	C1511726
subtilases	T116	C0767764
grapevine	T002	C0682492
resistance	T169	C4281815
P. viticola	T002	C1091290
pathosystem	T001	C0450254
alteration	T045	C0596611
Shared Decision Making	T041	C3179495
promise	T078	C1555307
healthcare system	T093	C0018696
Peru	T083	C0031238
Peru	T083	C0031238
sustained development	T070	C0282113
decades	T081	C2981279
improvements	T057	C2936612
quality of education	T080	C0870471
health	T058	C0034379
sectors	T078	C0009433
region	T083	C0017446
gaps	T033	C4277599
infrastructure	T058	C1254363
poor literacy level	T033	C1401894
population	T098	C1257890
health	T078	C0018684
model	T170	C3161035
patient care	T058	C0017313
systems	T093	C0018696
cooperate	T054	C0392337
communicate	T054	C0009452
communication	T054	C0009452
system	T093	C0018696
referral of patients	T058	C0034927
basic level	T033	C1547668
complex level	T033	C1547668
care	T058	C0017313
development	T169	C1527148
person-centered clinical practice	T058	C1254363
economic	T169	C0013557
social	T169	C0728831
educational	T065	C0013652
clinical practice	T058	C1254363
medical training	T065	C0220931
development	T169	C1527148
humanism	T078	C0020156
patient	T101	C0030705
medical act	T062	C0079816
doctors'	T097	C0031831
humanistic care approach	T052	C1947933
person	T098	C0027361
health care	T058	C0086388
caring	T055	C0150499
respectful	T054	C0679133
model	T170	C3161035
clinical practice	T058	C1254363
markers	T201	C0005516
quiescent	T080	C3686820
pancreatic stellate cells	T025	C2936598
normal	T080	C0205307
human	T016	C0086418
pancreas	T023	C0030274
Pancreatic stellate cells	T025	C2936598
PSCs	T025	C2936598
fibrogenic cells	T025	C0007634
pancreatic cancer	T191	C0235974
chronic pancreatitis	T047	C0149521
quiescent	T080	C3686820
hepatic stellate cells	T025	C2340138
qHSCs	T025	C2340138
marker	T201	C0005516
quiescent	T080	C3686820
PSCs	T025	C2936598
qPSCs	T025	C2936598
formalin-fixed and paraffin embedded (FFPE) normal human pancreatic tissue	T024	C2711483
qPSCs	T025	C2936598
normal	T080	C0205307
human	T016	C0086418
FFPE pancreatic tissue	T024	C2711483
Immunohistochemical	T059	C1441616
IHC	T059	C1441616
double-IHC	T059	C1441616
immunofluorescence	T059	C0079603
IF	T059	C0079603
double-IF analyses	T059	C0079603
tissue microarray	T075	C1519522
normal	T080	C0205307
human	T016	C0086418
pancreatic tissue	T024	C0587009
normal	T080	C0205307
human	T016	C0086418
liver	T023	C0023884
control	T096	C0009932
Antibodies	T116	C0003241
adipophilin	T116	C1505480
α-SMA	T116	C2716282
CD146	T116	C0386212
CRBP-1	T116	C1872428
cytoglobin	T116	C1450216
desmin	T116	C0011696
GFAP	T116	C0017626
nestin	T116	C3711758
S100A4	T116	C0287850
vinculin	T116	C1454484
periacinar	T082	C0442156
cells	T025	C0007634
normal	T080	C0205307
human	T016	C0086418
pancreas	T023	C0030274
perisinusoidal cells	T025	C0227531
normal	T080	C0205307
human	T016	C0086418
liver	T023	C0023884
immunolabelling	T059	C0079609
capacity	T081	C1516240
semiquantitative scoring system	T057	C2986822
Double-IF	T059	C0079603
markers	T201	C0005516
markers	T201	C0005516
periacinar	T082	C0442156
cells	T025	C0007634
histochemical stains	T059	C1508788
human	T016	C0086418
qPSCs	T025	C2936598
ultrastructure	T078	C0041623
electron microscopy	T059	C0013842
Adipophilin	T116	C1505480
CRBP-1	T116	C1872428
cytoglobin	T116	C1450216
vinculin	T116	C1454484
qHSCs	T025	C2340138
liver	T023	C0023884
cytoglobin	T116	C1450216
adipophilin	T116	C1505480
qPSCs	T025	C2936598
pancreas	T023	C0030274
Adipophilin	T116	C1505480
immunohistochemistry	T060	C0021044
preanalytical time interval	T079	C0872291
PATI	T079	C0872291
tissue	T024	C0040300
formalin fixation	T059	C3536615
Cytoglobin	T116	C1450216
S100A4	T116	C0287850
vinculin	T116	C1454484
periacinar	T082	C0442156
fibroblasts	T025	C0016030
FBs	T025	C0016030
markers	T201	C0005516
human	T016	C0086418
qPSCs	T025	C2936598
cytoglobin	T116	C1450216
adipophilin	T116	C1505480
markers	T201	C0005516
qPSCs	T025	C2936598
normal	T080	C0205307
human	T016	C0086418
pancreas	T023	C0030274
adipophilin	T116	C1505480
qPSC	T025	C2936598
PATI	T079	C0872291
Cytoglobin	T116	C1450216
marker	T201	C0005516
qPSCs	T025	C2936598
FBs	T025	C0016030
Biomagnetic monitoring	T059	C0596176
atmospheric pollution	UnknownType	C0683932
review of	T169	C0699752
magnetic	T070	C0563532
biological sensors	T075	C0600364
Biomagnetic monitoring	T059	C0596176
atmospheric pollution	UnknownType	C0683932
environmental	T082	C0014406
magnetism	T070	C0563532
Particulate matter	T167	C1720884
PM	T167	C1720884
atmospheric pollution	UnknownType	C0683932
measurable	T169	C1513040
magnetic minerals	T197	C0439876
Biological	T080	C0205460
surfaces	T082	C0205148
atmospheric pollution	UnknownType	C0683932
magnetic	T070	C0563532
particles	T104	C0597177
location	T082	C0450429
specific	T080	C0205369
time-integrated	T033	C1961029
air quality	T080	C2371710
information	T078	C1533716
review	T170	C0282443
biological material	T075	C0600364
sensors	T075	C0600364
biomagnetic monitoring	T059	C0596176
magnetic properties	T070	C0563532
lichens	T002	C0023657
mosses	T002	C0282635
leaves	T002	C0242724
bark	T002	C0949119
trunk wood	T002	C2700369
insects	T204	C0021585
crustaceans	T204	C1704306
mammal	T015	C0024660
human tissues	T024	C0440744
atmospheric pollutant species	T131	C0001869
PM	T167	C1720884
NOx	T197	C0028167
trace elements	T123	C0040577
PAHs	T109	C0032458
pros and cons	T033	C0243095
biomagnetic monitoring	T059	C0596176
atmospheric pollution	UnknownType	C0683932
large-scale implementation	UnknownType	C0814860
biomagnetic monitoring	T059	C0596176
future	T079	C0016884
researchers	T097	C0035173
policy makers	T097	C0242170
biological sensor	T075	C0600364
biomagnetic monitoring	T059	C0596176
infrared spectroscopy	T059	C0260249
imaging	T060	C0079595
cancer	T191	C0006826
diagnosis	T033	C0011900
FTIR	T062	C0206055
imaging	T060	C0079595
diagnose	T033	C0011900
differentiate	T080	C0205615
molecular	T080	C1521991
differences	T080	C1705242
normal	T024	C0040300
diseased	T047	C0012634
tissues	T024	C0040300
differences	T080	C1705242
distribution	T169	C1704711
structure	T082	C0678594
lipids	T109	C0023779
proteins	T116	C0033684
nucleic acids	T114	C0028606
metabolites	T123	C0870883
differences	T080	C1705242
type	T033	C0872066
cancer	T191	C0006826
sensitivity	T169	C0332324
chemotherapy	T061	C3665472
drugs	T121	C1254351
individual	T098	C0237401
FTIR spectroscopy	T062	C0206055
imaging	T060	C0079595
technique	T169	C0449851
detection	T061	C1511790
dreadful disease	T047	C0012634
high sensitivity	T059	C1441604
accuracy	T080	C4035952
technique	T169	C0449851
medical community	T073	C1562642
technique	T169	C0449851
early stage	T079	C2363430
cancer	T191	C0006826
detection	T061	C1511790
technique	T169	C0449851
challenges	T058	C0805586
diagnosis	T033	C0011900
cancer	T191	C0006826
sample preparations	T059	C3824791
data interpretation	T058	C0262707
data analysis	T057	C0010992
research	T062	C0035168
morphology	T080	C0332437
biology	T091	C0005532
spectroscopy	T062	C0206055
imaging	T060	C0079595
invaluable	T080	C1511545
information	T078	C1533716
CLASP2	T116	C1566863
Protein Interaction Network	T169	C3178902
Adipocytes	T025	C0206131
CLIP2	T116	C2350719
AGAP3	T116	C0061928
CLASP2	T116	C1566863
G2L1	T116	C0033684
MARK2	T116	C0299851
SOGA1	T116	C0026045
SOGA1	T116	C0026045
Microtubule-Associated Protein	T116	C0026045
CLASP2	T116	C1566863
microtubule-associated protein	T116	C0026045
insulin	T116	C0021641
stimulated	T045	C0599177
phosphorylation	T044	C1158886
co-localization	T169	C0475264
reorganized	T078	C0680829
actin	T116	C0001271
GLUT4	T116	C0166441
plasma membrane	T026	C0007603
gain	T081	C1517378
insight	T041	C0233820
role	T077	C1705810
CLASP2	T116	C1566863
system	T043	C0597714
developed	T169	C1527148
successfully	T080	C1272703
executed	T052	C1705848
streamlined	T080	C0205357
interactome	T044	C0872079
approach	T082	C0444454
CLASP2	T116	C1566863
protein network	T169	C3178902
3T3-L1 adipocytes	T025	C1257743
different	T080	C1705242
commercially	T170	C0680536
available	T169	C0470187
antibodies	T116	C0003241
CLASP2	T116	C1566863
antibody	T116	C0003241
epitope	T129	C0003316
overexpressed	T045	C1171362
CLASP2	T116	C1566863
performed	T169	C0884358
multiple	T081	C0439064
affinity purification	T059	C0008551
coupled	T169	C1948027
mass spectrometry	T059	C0037813
AP	T059	C0008551
MS	T059	C0037813
experiments	T062	C0681814
combination	T080	C0205195
label-free	T033	C0475878
quantitative	T081	C0392762
proteomics	T091	C0872252
analyzed	T062	C0936012
data	T078	C1511726
bioinformatics	T091	C1140694
tool	T170	C0037589
Significance Analysis of Interactome	T170	C3203917
SAINT	T170	C3203917
discovered	T052	C1880355
CLASP2	T116	C1566863
co-immunoprecipitates	T129	C0301871
co-IPs	T129	C0301871
protein	T116	C0033684
SOGA1	T116	C0026045
microtubule-associated protein kinase	T116	C3542416
MARK2	T116	C0299851
microtubule	T026	C0026046
actin	T116	C0001271
regulating	T038	C1327622
protein	T116	C0033684
G2L1	T116	C0033684
GTPase-activating proteins	T116	C0061928
AGAP1	T116	C1173678
AGAP3	T116	C0061928
CLASP2	T116	C1566863
interactome	T044	C0872079
subsequent	T079	C0332282
AGAP3	T116	C0061928
CLIP2	T116	C2350719
interactome	T044	C0872079
analysis	T062	C0936012
preference	T078	C0558295
AGAP3	T116	C0061928
CLIP2	T116	C2350719
MARK2	T116	C0299851
interactome	T044	C0872079
analysis	T062	C0936012
confirmed	T033	C0750484
reciprocal	T080	C1882911
co-IP	T129	C0301871
CLASP2	T116	C1566863
MARK2	T116	C0299851
co-IP	T129	C0301871
SOGA1	T116	C0026045
glycogen synthase	T116	C0017932
glycogenin	T116	C1612135
Investigating	T169	C1292732
SOGA1	T116	C0026045
interactome	T044	C0872079
confirmed	T033	C0750484
SOGA1	T116	C0026045
reciprocal	T080	C1882911
co-IP	T129	C0301871
CLASP2	T116	C1566863
MARK2	T116	C0299851
glycogen synthase	T116	C0017932
glycogenin	T116	C1612135
SOGA1	T116	C0026045
confirmed	T033	C0750484
colocalize	T082	C0392752
CLASP2	T116	C1566863
tubulin	T116	C0041348
SOGA1	T116	C0026045
microtubule-associated protein	T116	C0026045
results	T033	C0683954
metabolic function	T044	C0597299
proposed	T080	C1553874
protein networks	T169	C3178902
relationship	T080	C0439849
microtubules	T026	C0026046
cytoskeleton	T026	C0010853
associated	T080	C0332281
protein biology	T091	C0026376
